-- MySQL dump 10.13  Distrib 5.5.38, for debian-linux-gnu (x86_64)
--
-- Host: localhost    Database: pgi
-- ------------------------------------------------------
-- Server version	5.5.38-0ubuntu0.14.04.1

/*!40101 SET @OLD_CHARACTER_SET_CLIENT=@@CHARACTER_SET_CLIENT */;
/*!40101 SET @OLD_CHARACTER_SET_RESULTS=@@CHARACTER_SET_RESULTS */;
/*!40101 SET @OLD_COLLATION_CONNECTION=@@COLLATION_CONNECTION */;
/*!40101 SET NAMES utf8 */;
/*!40103 SET @OLD_TIME_ZONE=@@TIME_ZONE */;
/*!40103 SET TIME_ZONE='+00:00' */;
/*!40014 SET @OLD_UNIQUE_CHECKS=@@UNIQUE_CHECKS, UNIQUE_CHECKS=0 */;
/*!40014 SET @OLD_FOREIGN_KEY_CHECKS=@@FOREIGN_KEY_CHECKS, FOREIGN_KEY_CHECKS=0 */;
/*!40101 SET @OLD_SQL_MODE=@@SQL_MODE, SQL_MODE='NO_AUTO_VALUE_ON_ZERO' */;
/*!40111 SET @OLD_SQL_NOTES=@@SQL_NOTES, SQL_NOTES=0 */;

--
-- Table structure for table `2015_4_24_statistics`
--

DROP TABLE IF EXISTS `2015_4_24_statistics`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `2015_4_24_statistics` (
  `RSID` varchar(255) DEFAULT NULL,
  `Drug` varchar(255) DEFAULT NULL,
  `Genotype` varchar(255) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8 ROW_FORMAT=COMPACT;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `2015_4_24_statistics`
--

LOCK TABLES `2015_4_24_statistics` WRITE;
/*!40000 ALTER TABLE `2015_4_24_statistics` DISABLE KEYS */;
INSERT INTO `2015_4_24_statistics` VALUES ('rs2016848','Ace Inhibitors, Plain--PA164712308','AG'),('rs2016848','Ace Inhibitors, Plain--PA164712308','AA'),('rs1799722','Ace Inhibitors, Plain--PA164712308','CT'),('rs1799722','Ace Inhibitors, Plain--PA164712308','TT'),('rs9934438','acenocoumarol--PA452632','AG'),('rs9934438','acenocoumarol--PA452632','AA'),('rs2108622','acenocoumarol--PA452632','CT'),('rs2108622','acenocoumarol--PA452632','TT'),('rs1057910','acenocoumarol--PA452632','AC'),('rs1057910','acenocoumarol--PA452632','CC'),('rs4086116','acenocoumarol--PA452632','CT'),('rs4086116','acenocoumarol--PA452632','TT'),('rs1800629','adalimumab--PA10004','AG'),('rs1800629','adalimumab--PA10004','AA'),('rs712829','Alkylating Agents--PA164712331','GT'),('rs712829','Alkylating Agents--PA164712331','TT'),('rs9263827','allopurinol--PA448320','CT'),('rs9263827','allopurinol--PA448320','TT'),('rs9263726','allopurinol--PA448320','AG'),('rs9263726','allopurinol--PA448320','AA'),('rs9263733','allopurinol--PA448320','CT'),('rs9263733','allopurinol--PA448320','TT'),('rs9263745','allopurinol--PA448320','AG'),('rs9263745','allopurinol--PA448320','AA'),('rs9263781','allopurinol--PA448320','CT'),('rs9263781','allopurinol--PA448320','CC'),('rs9263785','allopurinol--PA448320','GT'),('rs9263785','allopurinol--PA448320','GG'),('rs9263794','allopurinol--PA448320','AG'),('rs9263794','allopurinol--PA448320','GG'),('rs9263796','allopurinol--PA448320','CT'),('rs9263796','allopurinol--PA448320','TT'),('rs9263800','allopurinol--PA448320','AG'),('rs9263800','allopurinol--PA448320','AA'),('rs12720441','amiodarone--PA448383','AG'),('rs12720441','amiodarone--PA448383','AA'),('rs5065','amlodipine--PA448388','AG'),('rs5065','amlodipine--PA448388','GG'),('rs10509681','amodiaquine--PA448404','CT'),('rs10509681','amodiaquine--PA448404','CC'),('rs11572080','amodiaquine--PA448404','CT'),('rs11572080','amodiaquine--PA448404','TT'),('rs2070995','Analgesics--PA164712362','CT'),('rs2070995','Analgesics--PA164712362','CC'),('rs9514091','anthracyclines and related substances--PA130620651','AG'),('rs9514091','anthracyclines and related substances--PA130620651','AA'),('rs9024','anthracyclines and related substances--PA130620651','AG'),('rs9024','anthracyclines and related substances--PA130620651','AA'),('rs10836235','anthracyclines and related substances--PA130620651','CT'),('rs10836235','anthracyclines and related substances--PA130620651','TT'),('rs1045642','anthracyclines and related substances--PA130620651','AG'),('rs1045642','anthracyclines and related substances--PA130620651','GG'),('rs2032582','anthracyclines and related substances--PA130620651','AC'),('rs2032582','anthracyclines and related substances--PA130620651','CC'),('rs2227631','antidepressants--PA452229','AG'),('rs2227631','antidepressants--PA452229','GG'),('rs1799889','antidepressants--PA452229','AG'),('rs1799889','antidepressants--PA452229','GG'),('rs6295','antidepressants--PA452229','CG'),('rs6295','antidepressants--PA452229','GG'),('rs7569963','antidepressants--PA452229','AG'),('rs7569963','antidepressants--PA452229','AA'),('rs61888800','antidepressants--PA452229','GT'),('rs61888800','antidepressants--PA452229','TT'),('rs2032583','antidepressants--PA452229','AG'),('rs2032583','antidepressants--PA452229','GG'),('rs2235015','antidepressants--PA452229','AC'),('rs2235015','antidepressants--PA452229','AA'),('rs2273697','antiepileptics--PA143485705','AG'),('rs2273697','antiepileptics--PA143485705','AA'),('rs3740066','antiepileptics--PA143485705','CT'),('rs3740066','antiepileptics--PA143485705','TT'),('rs717620','antiepileptics--PA143485705','CT'),('rs717620','antiepileptics--PA143485705','TT'),('rs1045642','antiepileptics--PA143485705','AG'),('rs1045642','antiepileptics--PA143485705','GG'),('rs2070744','Antihypertensives And Diuretics In Combination--PA164712446','CT'),('rs2070744','Antihypertensives And Diuretics In Combination--PA164712446','TT'),('rs2070744','Antihypertensives--PA164712445','CT'),('rs2070744','Antihypertensives--PA164712445','TT'),('rs1801252','Antihypertensives--PA164712445','AG'),('rs1801252','Antihypertensives--PA164712445','GG'),('rs1057910','Antiinflammatory agents, non-steroids--PA164712462','AC'),('rs1057910','Antiinflammatory agents, non-steroids--PA164712462','CC'),('rs1042522','antineoplastic agents--PA452621','CG'),('rs1042522','antineoplastic agents--PA452621','CC'),('rs951439','antipsychotics--PA452233','CT'),('rs951439','antipsychotics--PA452233','TT'),('rs1079598','antipsychotics--PA452233','AG'),('rs1079598','antipsychotics--PA452233','GG'),('rs2069514','antipsychotics--PA452233','AG'),('rs2069514','antipsychotics--PA452233','AA'),('rs4680','antipsychotics--PA452233','AG'),('rs4680','antipsychotics--PA452233','AA'),('rs1801133','antipsychotics--PA452233','AG'),('rs1801133','antipsychotics--PA452233','AA'),('rs1800497','antipsychotics--PA452233','AA'),('rs1800497','antipsychotics--PA452233','AG'),('rs7412','Antivirals for treatment of HIV infections, combinations--PA','CT'),('rs7412','Antivirals for treatment of HIV infections, combinations--PA','TT'),('rs429358','Antivirals for treatment of HIV infections, combinations--PA','CT'),('rs429358','Antivirals for treatment of HIV infections, combinations--PA','CC'),('rs1799732','aripiprazole--PA10026','GG'),('rs1799732','aripiprazole--PA10026','G/del'),('rs1050828','artesunate--PA165111697','CT'),('rs1050828','artesunate--PA165111697','TT'),('rs20417','aspirin--PA448497','CG'),('rs20417','aspirin--PA448497','GG'),('rs730012','aspirin--PA448497','AC'),('rs730012','aspirin--PA448497','CC'),('rs1801253','atenolol--PA448499','CG'),('rs1801253','atenolol--PA448499','CC'),('rs1935349','atorvastatin--PA448500','CT'),('rs1935349','atorvastatin--PA448500','TT'),('rs2276307','atorvastatin--PA448500','AG'),('rs2276307','atorvastatin--PA448500','GG'),('rs17238540','atorvastatin--PA448500','GT'),('rs17238540','atorvastatin--PA448500','GG'),('rs5443','atorvastatin--PA448500','CT'),('rs5443','atorvastatin--PA448500','TT'),('rs1142345','azathioprine--PA448515','CT'),('rs1142345','azathioprine--PA448515','CC'),('rs1800460','azathioprine--PA448515','CT'),('rs1800460','azathioprine--PA448515','TT'),('rs1800462','azathioprine--PA448515','CG'),('rs1800462','azathioprine--PA448515','GG'),('rs1127354','azathioprine--PA448515','AC'),('rs1127354','azathioprine--PA448515','AA'),('rs4253778','Beta Blocking Agents--PA164712535','CG'),('rs4253778','Beta Blocking Agents--PA164712535','CC'),('rs17098707','Beta Blocking Agents--PA164712535','AT'),('rs17098707','Beta Blocking Agents--PA164712535','TT'),('rs1801253','Beta Blocking Agents--PA164712535','CG'),('rs1801253','Beta Blocking Agents--PA164712535','CC'),('rs16944','Bisphosphonates--PA164712563','AG'),('rs16944','Bisphosphonates--PA164712563','GG'),('rs2297480','Bisphosphonates--PA164712563','GT'),('rs2297480','Bisphosphonates--PA164712563','GG'),('rs1934951','Bisphosphonates--PA164712563','CT'),('rs1934951','Bisphosphonates--PA164712563','TT'),('rs1801253','bucindolol--PA165945764','CG'),('rs1801253','bucindolol--PA165945764','CC'),('rs165599','bupropion--PA448687','AG'),('rs165599','bupropion--PA448687','AA'),('rs1800497','bupropion--PA448687','AG'),('rs1800497','bupropion--PA448687','AA'),('rs2298383','caffeine--PA448710','CT'),('rs2298383','caffeine--PA448710','TT'),('rs5751876','caffeine--PA448710','CT'),('rs5751876','caffeine--PA448710','CC'),('rs1801131','capecitabine--PA448771','GT'),('rs1801131','capecitabine--PA448771','GG'),('rs2297595','capecitabine--PA448771','CT'),('rs2297595','capecitabine--PA448771','CC'),('rs1045642','capecitabine--PA448771','AG'),('rs1045642','capecitabine--PA448771','GG'),('rs3812718','carbamazepine--PA448785','CT'),('rs3812718','carbamazepine--PA448785','TT'),('rs1051740','carbamazepine--PA448785','CT'),('rs1051740','carbamazepine--PA448785','CC'),('rs2234922','carbamazepine--PA448785','AG'),('rs2234922','carbamazepine--PA448785','GG'),('rs2273697','carbamazepine--PA448785','AG'),('rs2273697','carbamazepine--PA448785','AA'),('rs1045642','carbamazepine--PA448785','AG'),('rs1045642','carbamazepine--PA448785','GG'),('rs11615','carboplatin--PA448803','AG'),('rs11615','carboplatin--PA448803','GG'),('rs9981861','carboplatin--PA448803','CT'),('rs9981861','carboplatin--PA448803','CC'),('rs1801253','carvedilol--PA448817','CG'),('rs1801253','carvedilol--PA448817','CC'),('rs1057910','celecoxib--PA448871','AC'),('rs1057910','celecoxib--PA448871','CC'),('rs1799853','celecoxib--PA448871','CT'),('rs1799853','celecoxib--PA448871','TT'),('rs4149056','cerivastatin--PA448897','CC'),('rs4149056','cerivastatin--PA448897','CT'),('rs2227983','cetuximab--PA10040','AG'),('rs2227983','cetuximab--PA10040','AA'),('rs1799732','chlorpromazine--PA448964','GG'),('rs1799732','chlorpromazine--PA448964','G/del'),('rs5065','chlorthalidone--PA448970','AG'),('rs5065','chlorthalidone--PA448970','GG'),('rs1142345','cisplatin--PA449014','CT'),('rs1142345','cisplatin--PA449014','CC'),('rs12201199','cisplatin--PA449014','AT'),('rs12201199','cisplatin--PA449014','TT'),('rs1800460','cisplatin--PA449014','CT'),('rs1800460','cisplatin--PA449014','TT'),('rs1042522','cisplatin--PA449014','CG'),('rs1042522','cisplatin--PA449014','CC'),('rs1695','cisplatin--PA449014','AG'),('rs1695','cisplatin--PA449014','GG'),('rs1799793','cisplatin--PA449014','CT'),('rs1799793','cisplatin--PA449014','TT'),('rs11615','cisplatin--PA449014','AG'),('rs11615','cisplatin--PA449014','GG'),('rs9332377','cisplatin--PA449014','CT'),('rs9332377','cisplatin--PA449014','TT'),('rs9597','cisplatin--PA449014','CG'),('rs9597','cisplatin--PA449014','GG'),('rs1045642','cisplatin--PA449014','GG'),('rs1045642','cisplatin--PA449014','AG'),('rs2227631','citalopram--PA449015','AG'),('rs2227631','citalopram--PA449015','GG'),('rs1799889','citalopram--PA449015','AG'),('rs1799889','citalopram--PA449015','GG'),('rs1954787','citalopram--PA449015','CT'),('rs1954787','citalopram--PA449015','CC'),('rs7569963','citalopram--PA449015','AG'),('rs7569963','citalopram--PA449015','AA'),('rs4244285','clopidogrel--PA449053','AG'),('rs4244285','clopidogrel--PA449053','AA'),('rs742105','clozapine--PA449061','CT'),('rs742105','clozapine--PA449061','TT'),('rs1079598','clozapine--PA449061','AG'),('rs1079598','clozapine--PA449061','GG'),('rs1799732','clozapine--PA449061','GG'),('rs1799732','clozapine--PA449061','G/del'),('rs1800497','clozapine--PA449061','AG'),('rs1800497','clozapine--PA449061','AA'),('rs9282861','conjugated estrogens--PA164754789','CT'),('rs9282861','conjugated estrogens--PA164754789','TT'),('rs9340799','conjugated estrogens--PA164754789','AG'),('rs9340799','conjugated estrogens--PA164754789','GG'),('rs1042522','cyclophosphamide--PA449165','CG'),('rs1042522','cyclophosphamide--PA449165','CC'),('rs1799983','cyclophosphamide--PA449165','GT'),('rs1799983','cyclophosphamide--PA449165','GG'),('rs1695','cyclophosphamide--PA449165','AG'),('rs1695','cyclophosphamide--PA449165','GG'),('rs1799793','cyclophosphamide--PA449165','CT'),('rs1799793','cyclophosphamide--PA449165','TT'),('rs4244285','cyclophosphamide--PA449165','AG'),('rs4244285','cyclophosphamide--PA449165','AA'),('rs3745274','cyclophosphamide--PA449165','GT'),('rs3745274','cyclophosphamide--PA449165','TT'),('rs8192709','cyclophosphamide--PA449165','CT'),('rs8192709','cyclophosphamide--PA449165','TT'),('rs2279343','cyclophosphamide--PA449165','AG'),('rs2279343','cyclophosphamide--PA449165','GG'),('rs9561778','cyclophosphamide--PA449165','GT'),('rs9561778','cyclophosphamide--PA449165','TT'),('rs776746','cyclosporine--PA449167','CT'),('rs776746','cyclosporine--PA449167','TT'),('rs1045642','cyclosporine--PA449167','AG'),('rs1045642','cyclosporine--PA449167','GG'),('rs2072671','cytarabine--PA449177','AC'),('rs2072671','cytarabine--PA449177','CC'),('rs532545','cytarabine--PA449177','CT'),('rs532545','cytarabine--PA449177','TT'),('rs602950','cytarabine--PA449177','AG'),('rs602950','cytarabine--PA449177','GG'),('rs1045642','cytarabine--PA449177','AG'),('rs1045642','cytarabine--PA449177','GG'),('rs61888800','desipramine--PA449233','GT'),('rs61888800','desipramine--PA449233','TT'),('rs1057910','diclofenac--PA449293','AC'),('rs1057910','diclofenac--PA449293','CC'),('rs2070744','diuretics--PA151249535','CT'),('rs2070744','diuretics--PA151249535','TT'),('rs4961','diuretics--PA151249535','GT'),('rs4961','diuretics--PA151249535','TT'),('rs1382368','docetaxel--PA449383','CT'),('rs1382368','docetaxel--PA449383','TT'),('rs1402467','docetaxel--PA449383','CG'),('rs1402467','docetaxel--PA449383','GG'),('rs11045585','docetaxel--PA449383','AG'),('rs11045585','docetaxel--PA449383','GG'),('rs2301159','docetaxel--PA449383','AG'),('rs2301159','docetaxel--PA449383','AA'),('rs518329','docetaxel--PA449383','CT'),('rs518329','docetaxel--PA449383','CC'),('rs3734254','docetaxel--PA449383','CT'),('rs3734254','docetaxel--PA449383','TT'),('rs6922548','docetaxel--PA449383','AG'),('rs6922548','docetaxel--PA449383','GG'),('rs2234922','docetaxel--PA449383','AG'),('rs2234922','docetaxel--PA449383','GG'),('rs4646487','docetaxel--PA449383','CT'),('rs4646487','docetaxel--PA449383','TT'),('rs12418','docetaxel--PA449383','AG'),('rs12418','docetaxel--PA449383','AA'),('rs4148950','docetaxel--PA449383','AG'),('rs4148950','docetaxel--PA449383','AA'),('rs1799983','doxorubicin--PA449412','GT'),('rs1799983','doxorubicin--PA449412','GG'),('rs2070744','doxorubicin--PA449412','CT'),('rs2070744','doxorubicin--PA449412','TT'),('rs8133052','doxorubicin--PA449412','AG'),('rs8133052','doxorubicin--PA449412','AA'),('rs9561778','doxorubicin--PA449412','GT'),('rs9561778','doxorubicin--PA449412','TT'),('rs17222723','doxorubicin--PA449412','AT'),('rs17222723','doxorubicin--PA449412','AA'),('rs8187710','doxorubicin--PA449412','AG'),('rs8187710','doxorubicin--PA449412','AA'),('rs45511401','doxorubicin--PA449412','GT'),('rs45511401','doxorubicin--PA449412','TT'),('rs1045642','doxorubicin--PA449412','AG'),('rs1045642','doxorubicin--PA449412','GG'),('rs16969968','Drugs used in nicotine dependence--PA164712720','AG'),('rs16969968','Drugs used in nicotine dependence--PA164712720','AA'),('rs1800497','Drugs used in nicotine dependence--PA164712720','AG'),('rs1800497','Drugs used in nicotine dependence--PA164712720','AA'),('rs963468','duloxetine--PA10066','AG'),('rs963468','duloxetine--PA10066','AA'),('rs3745274','efavirenz--PA449441','TT'),('rs3745274','efavirenz--PA449441','GT'),('rs2227983','egfr inhibitors--PA153561371','AG'),('rs2227983','egfr inhibitors--PA153561371','AA'),('rs1695','epirubicin--PA449476','AG'),('rs1695','epirubicin--PA449476','GG'),('rs1045642','epirubicin--PA449476','AG'),('rs1045642','epirubicin--PA449476','GG'),('rs2227983','erlotinib--PA134687924','AG'),('rs2227983','erlotinib--PA134687924','AA'),('rs712829','erlotinib--PA134687924','GT'),('rs712829','erlotinib--PA134687924','TT'),('rs1800629','etanercept--PA449515','AG'),('rs1800629','etanercept--PA449515','AA'),('rs1799971','ethanol--PA448073','AG'),('rs1799971','ethanol--PA448073','GG'),('rs1800497','ethanol--PA448073','AG'),('rs1800497','ethanol--PA448073','AA'),('rs16944','etidronic acid--PA449548','AG'),('rs16944','etidronic acid--PA449548','GG'),('rs2784917','etoposide--PA449552','AG'),('rs2784917','etoposide--PA449552','GG'),('rs1045642','fexofenadine--PA449621','AG'),('rs1045642','fexofenadine--PA449621','GG'),('rs1042522','fluorouracil--PA128406956','CG'),('rs1042522','fluorouracil--PA128406956','CC'),('rs1799983','fluorouracil--PA128406956','GT'),('rs1799983','fluorouracil--PA128406956','GG'),('rs2070744','fluorouracil--PA128406956','CT'),('rs2070744','fluorouracil--PA128406956','TT'),('rs1801131','fluorouracil--PA128406956','GT'),('rs1801131','fluorouracil--PA128406956','GG'),('rs1801133','fluorouracil--PA128406956','AG'),('rs1801133','fluorouracil--PA128406956','AA'),('rs1695','fluorouracil--PA128406956','GG'),('rs1695','fluorouracil--PA128406956','AG'),('rs13181','fluorouracil--PA128406956','GT'),('rs13181','fluorouracil--PA128406956','GG'),('rs1801158','fluorouracil--PA128406956','CT'),('rs1801158','fluorouracil--PA128406956','TT'),('rs1801159','fluorouracil--PA128406956','CT'),('rs1801159','fluorouracil--PA128406956','CC'),('rs2297595','fluorouracil--PA128406956','CT'),('rs2297595','fluorouracil--PA128406956','CC'),('rs67376798','fluorouracil--PA128406956','AT'),('rs67376798','fluorouracil--PA128406956','AA'),('rs9561778','fluorouracil--PA128406956','GT'),('rs9561778','fluorouracil--PA128406956','TT'),('rs1045642','fluorouracil--PA128406956','AG'),('rs1045642','fluorouracil--PA128406956','GG'),('rs25531','fluoxetine--PA449673','CT'),('rs25531','fluoxetine--PA449673','CC'),('rs2227631','fluoxetine--PA449673','AG'),('rs2227631','fluoxetine--PA449673','GG'),('rs1799889','fluoxetine--PA449673','AG'),('rs1799889','fluoxetine--PA449673','GG'),('rs61888800','fluoxetine--PA449673','GT'),('rs61888800','fluoxetine--PA449673','TT'),('rs11045819','fluvastatin--PA449688','AC'),('rs11045819','fluvastatin--PA449688','AA'),('rs17238540','fluvastatin--PA449688','GT'),('rs17238540','fluvastatin--PA449688','GG'),('rs5443','fluvastatin--PA449688','CT'),('rs5443','fluvastatin--PA449688','TT'),('rs10042486','fluvoxamine--PA449690','CT'),('rs10042486','fluvoxamine--PA449690','TT'),('rs6295','fluvoxamine--PA449690','CG'),('rs6295','fluvoxamine--PA449690','GG'),('rs4961','furosemide--PA449719','GT'),('rs4961','furosemide--PA449719','TT'),('rs712829','gefitinib--PA131301952','GT'),('rs712829','gefitinib--PA131301952','TT'),('rs712829','geldanamycin--PA152031327','GT'),('rs712829','geldanamycin--PA152031327','TT'),('rs9937','gemcitabine--PA449748','AG'),('rs9937','gemcitabine--PA449748','GG'),('rs2072671','gemcitabine--PA449748','AC'),('rs2072671','gemcitabine--PA449748','CC'),('rs60369023','gemcitabine--PA449748','AG'),('rs60369023','gemcitabine--PA449748','AA'),('rs4149056','hmg coa reductase inhibitors--PA133950441','CT'),('rs4149056','hmg coa reductase inhibitors--PA133950441','CC'),('rs1935349','hmg coa reductase inhibitors--PA133950441','CT'),('rs1935349','hmg coa reductase inhibitors--PA133950441','TT'),('rs17238540','hmg coa reductase inhibitors--PA133950441','GT'),('rs17238540','hmg coa reductase inhibitors--PA133950441','GG'),('rs5443','hmg coa reductase inhibitors--PA133950441','CT'),('rs5443','hmg coa reductase inhibitors--PA133950441','TT'),('rs7297610','hydrochlorothiazide--PA449899','CT'),('rs7297610','hydrochlorothiazide--PA449899','TT'),('rs4961','hydrochlorothiazide--PA449899','GT'),('rs4961','hydrochlorothiazide--PA449899','TT'),('rs20417','ibuprofen--PA449957','CG'),('rs20417','ibuprofen--PA449957','GG'),('rs1045642','idarubicin--PA449961','AG'),('rs1045642','idarubicin--PA449961','GG'),('rs7142881','iloperidone--PA161199368','AG'),('rs7142881','iloperidone--PA161199368','AA'),('rs4799915','iloperidone--PA161199368','CT'),('rs4799915','iloperidone--PA161199368','TT'),('rs1800629','infliximab--PA452639','AG'),('rs1800629','infliximab--PA452639','AA'),('rs9657182','interferon alfa-2a, recombinant--PA164779048','CT'),('rs9657182','interferon alfa-2a, recombinant--PA164779048','TT'),('rs1127354','interferon alfa-2b, recombinant--PA164783990','AC'),('rs1127354','interferon alfa-2b, recombinant--PA164783990','AA'),('rs4124874','irinotecan--PA450085','GT'),('rs4124874','irinotecan--PA450085','GG'),('rs9597','irinotecan--PA450085','CG'),('rs9597','irinotecan--PA450085','GG'),('rs762551','leflunomide--PA450192','AC'),('rs762551','leflunomide--PA450192','AA'),('rs1051266','leucovorin--PA450198','CC'),('rs1051266','leucovorin--PA450198','CT'),('rs13181','leucovorin--PA450198','GT'),('rs13181','leucovorin--PA450198','GG'),('rs67376798','leucovorin--PA450198','AT'),('rs67376798','leucovorin--PA450198','AA'),('rs2284017','lithium--PA450243','CT'),('rs2284017','lithium--PA450243','CC'),('rs7439366','lorazepam--PA450267','CT'),('rs7439366','lorazepam--PA450267','CC'),('rs1057910','losartan--PA450268','AC'),('rs1057910','losartan--PA450268','CC'),('rs17238540','lovastatin--PA450272','GT'),('rs17238540','lovastatin--PA450272','GG'),('rs5443','lovastatin--PA450272','CT'),('rs5443','lovastatin--PA450272','TT'),('rs9340799','medroxyprogesterone--PA450344','AG'),('rs9340799','medroxyprogesterone--PA450344','GG'),('rs1142345','mercaptopurine--PA450379','CT'),('rs1142345','mercaptopurine--PA450379','CC'),('rs1800460','mercaptopurine--PA450379','CT'),('rs1800460','mercaptopurine--PA450379','TT'),('rs1800462','mercaptopurine--PA450379','CG'),('rs1800462','mercaptopurine--PA450379','GG'),('rs1800584','mercaptopurine--PA450379','CT'),('rs1800584','mercaptopurine--PA450379','TT'),('rs1051266','mercaptopurine--PA450379','CC'),('rs1051266','mercaptopurine--PA450379','CT'),('rs1801133','mercaptopurine--PA450379','AG'),('rs1801133','mercaptopurine--PA450379','AA'),('rs2853539','methotrexate--PA450428','AG'),('rs2853539','methotrexate--PA450428','GG'),('rs1051266','methotrexate--PA450428','CC'),('rs1051266','methotrexate--PA450428','CT'),('rs1799983','methotrexate--PA450428','GT'),('rs1799983','methotrexate--PA450428','GG'),('rs2070744','methotrexate--PA450428','CT'),('rs2070744','methotrexate--PA450428','TT'),('rs1801394','methotrexate--PA450428','AG'),('rs1801394','methotrexate--PA450428','GG'),('rs1801131','methotrexate--PA450428','GG'),('rs1801131','methotrexate--PA450428','GT'),('rs1801133','methotrexate--PA450428','AA'),('rs1801133','methotrexate--PA450428','AG'),('rs2236225','methotrexate--PA450428','AG'),('rs2236225','methotrexate--PA450428','AA'),('rs1127354','methotrexate--PA450428','AC'),('rs1127354','methotrexate--PA450428','AA'),('rs11545078','methotrexate--PA450428','AG'),('rs11545078','methotrexate--PA450428','AA'),('rs1800909','methotrexate--PA450428','AG'),('rs1800909','methotrexate--PA450428','GG'),('rs1544105','methotrexate--PA450428','CT'),('rs1544105','methotrexate--PA450428','TT'),('rs2372536','methotrexate--PA450428','CG'),('rs2372536','methotrexate--PA450428','GG'),('rs4673993','methotrexate--PA450428','CT'),('rs4673993','methotrexate--PA450428','CC'),('rs17602729','methotrexate--PA450428','AG'),('rs17602729','methotrexate--PA450428','AA'),('rs2298383','methotrexate--PA450428','CT'),('rs2298383','methotrexate--PA450428','TT'),('rs9895420','methotrexate--PA450428','AT'),('rs9895420','methotrexate--PA450428','AA'),('rs2238476','methotrexate--PA450428','AG'),('rs2238476','methotrexate--PA450428','AA'),('rs246240','methotrexate--PA450428','AG'),('rs246240','methotrexate--PA450428','GG'),('rs35592','methotrexate--PA450428','CT'),('rs35592','methotrexate--PA450428','CC'),('rs4888024','methotrexate--PA450428','AG'),('rs4888024','methotrexate--PA450428','GG'),('rs9345389','methotrexate--PA450428','AG'),('rs9345389','methotrexate--PA450428','GG'),('rs3892097','metoprolol--PA450480','CT'),('rs3892097','metoprolol--PA450480','TT'),('rs1801253','metoprolol--PA450480','CG'),('rs1801253','metoprolol--PA450480','CC'),('rs10042486','milnacipran--PA164752812','CT'),('rs10042486','milnacipran--PA164752812','TT'),('rs730012','montelukast--PA450546','AC'),('rs730012','montelukast--PA450546','CC'),('rs2660845','montelukast--PA450546','AG'),('rs2660845','montelukast--PA450546','AA'),('rs2115819','montelukast--PA450546','AG'),('rs2115819','montelukast--PA450546','GG'),('rs119774','montelukast--PA450546','CT'),('rs119774','montelukast--PA450546','TT'),('rs1799971','morphine--PA450550','AG'),('rs1799971','morphine--PA450550','GG'),('rs2368564','muraglitazar--PA162356187','CT'),('rs2368564','muraglitazar--PA162356187','TT'),('rs5370','muraglitazar--PA162356187','GT'),('rs5370','muraglitazar--PA162356187','TT'),('rs4149117','mycophenolate mofetil--PA450566','GT'),('rs4149117','mycophenolate mofetil--PA450566','GG'),('rs2278294','mycophenolate mofetil--PA450566','CT'),('rs2278294','mycophenolate mofetil--PA450566','TT'),('rs1799971','naloxone--PA450586','AG'),('rs1799971','naloxone--PA450586','GG'),('rs1799971','naltrexone--PA450588','AG'),('rs1799971','naltrexone--PA450588','GG'),('rs1799732','nemonapride--PA151186253','GG'),('rs1799732','nemonapride--PA151186253','G/del'),('rs1800497','nemonapride--PA151186253','AG'),('rs1800497','nemonapride--PA151186253','AA'),('rs16969968','nicotine--PA450626','AG'),('rs16969968','nicotine--PA450626','AA'),('rs1800497','nicotine--PA450626','AG'),('rs1800497','nicotine--PA450626','AA'),('rs1801133','nitrous oxide--PA450645','AG'),('rs1801133','nitrous oxide--PA450645','AA'),('rs1045642','nortriptyline--PA450657','AG'),('rs1045642','nortriptyline--PA450657','GG'),('rs951439','olanzapine--PA450688','CT'),('rs951439','olanzapine--PA450688','TT'),('rs4731426','olanzapine--PA450688','CG'),('rs4731426','olanzapine--PA450688','CC'),('rs3813929','olanzapine--PA450688','CT'),('rs3813929','olanzapine--PA450688','TT'),('rs6318','olanzapine--PA450688','CG'),('rs6318','olanzapine--PA450688','CC'),('rs6313','olanzapine--PA450688','AG'),('rs6313','olanzapine--PA450688','AA'),('rs7997012','olanzapine--PA450688','AG'),('rs7997012','olanzapine--PA450688','GG'),('rs5443','olanzapine--PA450688','CT'),('rs5443','olanzapine--PA450688','TT'),('rs6280','olanzapine--PA450688','CT'),('rs6280','olanzapine--PA450688','TT'),('rs1079598','olanzapine--PA450688','AG'),('rs1079598','olanzapine--PA450688','GG'),('rs1799732','olanzapine--PA450688','GG'),('rs1799732','olanzapine--PA450688','G/del'),('rs1800497','olanzapine--PA450688','AG'),('rs1800497','olanzapine--PA450688','AA'),('rs2032583','Other antidepressants--PA164713016','AG'),('rs2032583','Other antidepressants--PA164713016','GG'),('rs2235015','Other antidepressants--PA164713016','AC'),('rs2235015','Other antidepressants--PA164713016','AA'),('rs1695','oxaliplatin--PA131285527','GG'),('rs1695','oxaliplatin--PA131285527','AG'),('rs13181','oxaliplatin--PA131285527','GT'),('rs13181','oxaliplatin--PA131285527','GG'),('rs11615','oxaliplatin--PA131285527','AG'),('rs11615','oxaliplatin--PA131285527','GG'),('rs1042522','paclitaxel--PA450761','CG'),('rs1042522','paclitaxel--PA450761','CC'),('rs9981861','paclitaxel--PA450761','CT'),('rs9981861','paclitaxel--PA450761','CC'),('rs12721627','paclitaxel--PA450761','CG'),('rs12721627','paclitaxel--PA450761','CC'),('rs11572080','paclitaxel--PA450761','CT'),('rs11572080','paclitaxel--PA450761','TT'),('rs11572103','paclitaxel--PA450761','AT'),('rs11572103','paclitaxel--PA450761','AA'),('rs11188072','pantoprazole--PA450774','CT'),('rs11188072','pantoprazole--PA450774','TT'),('rs10042486','paroxetine--PA450801','CT'),('rs10042486','paroxetine--PA450801','TT'),('rs11042725','paroxetine--PA450801','AC'),('rs11042725','paroxetine--PA450801','AA'),('rs12979860','peginterferon alfa-2a--PA164749390','CT'),('rs12979860','peginterferon alfa-2a--PA164749390','TT'),('rs8099917','peginterferon alfa-2a--PA164749390','GT'),('rs8099917','peginterferon alfa-2a--PA164749390','GG'),('rs12979860','peginterferon alfa-2b--PA164784024','CT'),('rs12979860','peginterferon alfa-2b--PA164784024','TT'),('rs8099917','peginterferon alfa-2b--PA164784024','GT'),('rs8099917','peginterferon alfa-2b--PA164784024','GG'),('rs9657182','peginterferon alfa-2b--PA164784024','CT'),('rs9657182','peginterferon alfa-2b--PA164784024','TT'),('rs12050217','perindopril--PA450877','AG'),('rs12050217','perindopril--PA450877','GG'),('rs275651','perindopril--PA450877','AT'),('rs275651','perindopril--PA450877','AA'),('rs951439','perphenazine--PA450882','CT'),('rs951439','perphenazine--PA450882','TT'),('rs2108622','phenprocoumon--PA450921','CT'),('rs2108622','phenprocoumon--PA450921','TT'),('rs3812718','phenytoin--PA450947','CT'),('rs3812718','phenytoin--PA450947','TT'),('rs2234922','phenytoin--PA450947','AG'),('rs2234922','phenytoin--PA450947','GG'),('rs1057910','phenytoin--PA450947','AC'),('rs1057910','phenytoin--PA450947','CC'),('rs1799853','phenytoin--PA450947','CT'),('rs1799853','phenytoin--PA450947','TT'),('rs1045642','phenytoin--PA450947','AG'),('rs1045642','phenytoin--PA450947','GG'),('rs1695','Platinum compounds--PA164713176','AG'),('rs1695','Platinum compounds--PA164713176','GG'),('rs3212986','Platinum compounds--PA164713176','AA'),('rs11615','Platinum compounds--PA164713176','AG'),('rs11615','Platinum compounds--PA164713176','GG'),('rs3212986','Platinum compounds--PA164713176','AC'),('rs11615','platinum--PA150595617','AG'),('rs11615','platinum--PA150595617','GG'),('rs2306283','pravastatin--PA451089','AG'),('rs2306283','pravastatin--PA451089','GG'),('rs4149015','pravastatin--PA451089','AG'),('rs4149015','pravastatin--PA451089','AA'),('rs20455','pravastatin--PA451089','AG'),('rs20455','pravastatin--PA451089','GG'),('rs1935349','pravastatin--PA451089','CT'),('rs1935349','pravastatin--PA451089','TT'),('rs2276307','pravastatin--PA451089','AG'),('rs2276307','pravastatin--PA451089','GG'),('rs17238540','pravastatin--PA451089','GT'),('rs17238540','pravastatin--PA451089','GG'),('rs5443','pravastatin--PA451089','CT'),('rs5443','pravastatin--PA451089','TT'),('rs1050828','primaquine--PA451103','CT'),('rs1050828','primaquine--PA451103','TT'),('rs58597806','propofol--PA451141','AG'),('rs58597806','propofol--PA451141','AA'),('rs1142345','purine analogues--PA452634','CT'),('rs1142345','purine analogues--PA452634','CC'),('rs1800460','purine analogues--PA452634','CT'),('rs1800460','purine analogues--PA452634','TT'),('rs1800462','purine analogues--PA452634','CG'),('rs1800462','purine analogues--PA452634','GG'),('rs1050828','pyrimethamine--PA451193','CT'),('rs1050828','pyrimethamine--PA451193','TT'),('rs951439','quetiapine--PA451201','CT'),('rs951439','quetiapine--PA451201','TT'),('rs1127354','ribavirin--PA451241','AC'),('rs1127354','ribavirin--PA451241','AA'),('rs12979860','ribavirin--PA451241','CT'),('rs12979860','ribavirin--PA451241','TT'),('rs8099917','ribavirin--PA451241','GT'),('rs8099917','ribavirin--PA451241','GG'),('rs16944','risedronate--PA451255','AG'),('rs16944','risedronate--PA451255','GG'),('rs2842030','risperidone--PA451257','GT'),('rs2842030','risperidone--PA451257','TT'),('rs7799039','risperidone--PA451257','AG'),('rs7799039','risperidone--PA451257','AA'),('rs3813928','risperidone--PA451257','AG'),('rs3813928','risperidone--PA451257','AA'),('rs6311','risperidone--PA451257','CT'),('rs6311','risperidone--PA451257','TT'),('rs6313','risperidone--PA451257','AG'),('rs6313','risperidone--PA451257','AA'),('rs724226','risperidone--PA451257','AG'),('rs724226','risperidone--PA451257','GG'),('rs6280','risperidone--PA451257','CT'),('rs6280','risperidone--PA451257','TT'),('rs1799978','risperidone--PA451257','CC'),('rs1799978','risperidone--PA451257','CT'),('rs165599','risperidone--PA451257','AG'),('rs165599','risperidone--PA451257','AA'),('rs1800497','risperidone--PA451257','AG'),('rs1800497','risperidone--PA451257','AA'),('rs2494732','risperidone--PA451257','CT'),('rs2494732','risperidone--PA451257','CC'),('rs1128503','risperidone--PA451257','AG'),('rs1128503','risperidone--PA451257','GG'),('rs7412','ritonavir--PA451260','CT'),('rs7412','ritonavir--PA451260','TT'),('rs429358','ritonavir--PA451260','CT'),('rs429358','ritonavir--PA451260','CC'),('rs396991','rituximab--PA451261','AC'),('rs396991','rituximab--PA451261','CC'),('rs20417','rofecoxib--PA451268','CG'),('rs20417','rofecoxib--PA451268','GG'),('rs10192566','rosiglitazone--PA451283','CG'),('rs10192566','rosiglitazone--PA451283','GG'),('rs10509681','rosiglitazone--PA451283','CC'),('rs10509681','rosiglitazone--PA451283','CT'),('rs5443','rosuvastatin--PA134308647','CT'),('rs5443','rosuvastatin--PA134308647','TT'),('rs2231142','rosuvastatin--PA134308647','GT'),('rs2231142','rosuvastatin--PA134308647','TT'),('rs6295','Selective serotonin reuptake inhibitors--PA164713257','CG'),('rs6295','Selective serotonin reuptake inhibitors--PA164713257','GG'),('rs4343','sildenafil--PA451346','AG'),('rs4343','sildenafil--PA451346','AA'),('rs4149056','simvastatin--PA451363','CT'),('rs4149056','simvastatin--PA451363','CC'),('rs1935349','simvastatin--PA451363','CT'),('rs1935349','simvastatin--PA451363','TT'),('rs2276307','simvastatin--PA451363','AG'),('rs2276307','simvastatin--PA451363','GG'),('rs17238540','simvastatin--PA451363','GT'),('rs17238540','simvastatin--PA451363','GG'),('rs5443','simvastatin--PA451363','CT'),('rs5443','simvastatin--PA451363','TT'),('rs776746','sirolimus--PA451365','CT'),('rs776746','sirolimus--PA451365','TT'),('rs4961','spironolactone--PA451483','GT'),('rs4961','spironolactone--PA451483','TT'),('rs4343','spironolactone--PA451483','AG'),('rs4343','spironolactone--PA451483','AA'),('rs1050828','sulfadoxine--PA451540','CT'),('rs1050828','sulfadoxine--PA451540','TT'),('rs12255372','sulfonamides, urea derivatives--PA10390','GT'),('rs12255372','sulfonamides, urea derivatives--PA10390','TT'),('rs5443','sumatriptan--PA451566','CT'),('rs5443','sumatriptan--PA451566','TT'),('rs776746','tacrolimus--PA451578','CT'),('rs776746','tacrolimus--PA451578','TT'),('rs2032582','tacrolimus--PA451578','AC'),('rs2032582','tacrolimus--PA451578','CC'),('rs4986938','tamoxifen--PA451581','CT'),('rs4986938','tamoxifen--PA451581','TT'),('rs17222723','tenofovir--PA10204','AT'),('rs17222723','tenofovir--PA10204','AA'),('rs2273697','tenofovir--PA10204','AG'),('rs2273697','tenofovir--PA10204','AA'),('rs717620','tenofovir--PA10204','CT'),('rs717620','tenofovir--PA10204','TT'),('rs1402467','thalidomide--PA451644','CG'),('rs1402467','thalidomide--PA451644','GG'),('rs2301159','thalidomide--PA451644','AG'),('rs2301159','thalidomide--PA451644','AA'),('rs3734254','thalidomide--PA451644','CT'),('rs3734254','thalidomide--PA451644','TT'),('rs6922548','thalidomide--PA451644','AG'),('rs6922548','thalidomide--PA451644','GG'),('rs4646487','thalidomide--PA451644','CT'),('rs4646487','thalidomide--PA451644','TT'),('rs12418','thalidomide--PA451644','AG'),('rs12418','thalidomide--PA451644','AA'),('rs1871450','thalidomide--PA451644','AG'),('rs1871450','thalidomide--PA451644','AA'),('rs4148950','thalidomide--PA451644','AG'),('rs4148950','thalidomide--PA451644','AA'),('rs1142345','thioguanine--PA451663','CT'),('rs1142345','thioguanine--PA451663','CC'),('rs1800460','thioguanine--PA451663','CT'),('rs1800460','thioguanine--PA451663','TT'),('rs1800462','thioguanine--PA451663','CG'),('rs1800462','thioguanine--PA451663','GG'),('rs712829','topoisomerase I inhibitors--PA150481186','GT'),('rs712829','topoisomerase I inhibitors--PA150481186','TT'),('rs10811661','troglitazone--PA451799','CT'),('rs10811661','troglitazone--PA451799','CC'),('rs854547','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','AG'),('rs854547','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','AA'),('rs2814707','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','CT'),('rs2814707','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','TT'),('rs928655','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','AG'),('rs928655','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','AA'),('rs774359','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','CT'),('rs774359','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','CC'),('rs983332','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','TT'),('rs437943','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','CT'),('rs437943','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','CC'),('rs6028945','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','GT'),('rs6028945','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','TT'),('rs6071980','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','CT'),('rs6071980','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','CC'),('rs983332','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','GT'),('rs7439366','valproic acid--PA451846','CT'),('rs7439366','valproic acid--PA451846','CC'),('rs1105879','valproic acid--PA451846','AC'),('rs1105879','valproic acid--PA451846','CC'),('rs2070959','valproic acid--PA451846','AG'),('rs2070959','valproic acid--PA451846','GG'),('rs6759892','valproic acid--PA451846','GT'),('rs6759892','valproic acid--PA451846','GG'),('rs1057910','valproic acid--PA451846','AC'),('rs1057910','valproic acid--PA451846','CC'),('rs1487278','venlafaxine--PA451866','CT'),('rs1487278','venlafaxine--PA451866','CC'),('rs3892097','venlafaxine--PA451866','CT'),('rs3892097','venlafaxine--PA451866','TT'),('rs10918594','verapamil--PA451868','CG'),('rs10918594','verapamil--PA451868','GG'),('rs11739136','verapamil--PA451868','CT'),('rs11739136','verapamil--PA451868','TT'),('rs17708472','warfarin--PA451906','AG'),('rs17708472','warfarin--PA451906','AA'),('rs7294','warfarin--PA451906','CT'),('rs7294','warfarin--PA451906','TT'),('rs9934438','warfarin--PA451906','AG'),('rs9934438','warfarin--PA451906','AA'),('rs10871454','warfarin--PA451906','CT'),('rs10871454','warfarin--PA451906','TT'),('rs8050894','warfarin--PA451906','CG'),('rs8050894','warfarin--PA451906','GG'),('rs2292566','warfarin--PA451906','AG'),('rs2292566','warfarin--PA451906','AA'),('rs2108622','warfarin--PA451906','CT'),('rs2108622','warfarin--PA451906','TT'),('rs1799853','warfarin--PA451906','CT'),('rs1799853','warfarin--PA451906','TT'),('rs28371685','warfarin--PA451906','CT'),('rs28371685','warfarin--PA451906','TT'),('rs28371686','warfarin--PA451906','CG'),('rs28371686','warfarin--PA451906','GG'),('rs7900194','warfarin--PA451906','AG'),('rs7900194','warfarin--PA451906','AA'),('rs1057910','warfarin--PA451906','AC'),('rs1057910','warfarin--PA451906','CC'),('rs339097','warfarin--PA451906','AG'),('rs339097','warfarin--PA451906','GG'),('rs951439','ziprasidone--PA451974','CT'),('rs951439','ziprasidone--PA451974','TT');
/*!40000 ALTER TABLE `2015_4_24_statistics` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `66asbykulujf`
--

DROP TABLE IF EXISTS `66asbykulujf`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `66asbykulujf` (
  `RSID` varchar(20) DEFAULT NULL,
  `Alleles` varchar(7) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `Drug` varchar(60) DEFAULT NULL,
  `System` varchar(60) DEFAULT NULL,
  `subSystem` text,
  `drugID` varchar(60) DEFAULT NULL,
  `info` text,
  `Level` varchar(10) DEFAULT NULL,
  `Efficacy` varchar(20) DEFAULT NULL,
  `Dosage` varchar(20) DEFAULT NULL,
  `Toxicity` varchar(20) DEFAULT NULL,
  `Genotype` varchar(10) DEFAULT NULL,
  `Sentence` text
) ENGINE=InnoDB DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `66asbykulujf`
--

LOCK TABLES `66asbykulujf` WRITE;
/*!40000 ALTER TABLE `66asbykulujf` DISABLE KEYS */;
INSERT INTO `66asbykulujf` VALUES ('rs2016848','G > A','MME','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','increased','AA','                Patients with the AA genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cough with ACE inhibitor treatment.'),('rs7569963','G > A','CREB1','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','AA','                Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1801133','G > A','CLCN6','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','increased','AG','                Patients with the AG genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs16944','A > G','IL1B','Bisphosphonates','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs2297480','T > G','FDPS','Bisphosphonates','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 2B','increased','-','-','GT','                Patients with the GT genotype may have an increased chance of response to bisphosphonate treatment as compared to patients with the GG genotype. Patients with the GT genotype may still be at risk for non-response to bisphosphonate treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1801131','T > G','MTHFR','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','GT','                Patients with the GT genotype may have increased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to capecitabine.'),('rs2297595','T > C','DPYD','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1051740','T > C','EPHX1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 2B','-','increased','-','CC','                Patients with the CC genotype and Epilepsy who are treated with carbamazepine may have an increased dose of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to carbamazepine.'),('rs2016848','G > A','MME','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','increased','AA','                Patients with the AA genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cough with ACE inhibitor treatment.'),('rs1799722','C > T','BDKRB2','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','increased','CT','                Patients with the CT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for cough.'),('rs2228001','G > T','XPC','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','decreased','TT','                Patients with the TT genotype may have a decreased but not non-existent risk for toxicity with cisplatin treatment as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs712829','G > T','EGFR','Alkylating Agents','VARIOUS','','','An alkylating antineoplastic agent is an alkylating agent used in cancer treatment that attaches an alkyl group to DNA.','Level 4','decreased','-','-','GT','                Cancer cells with the GT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.'),('rs7569963','G > A','CREB1','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','decreased','-','-','AA','                Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs16944','A > G','IL1B','clodronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00720 ','A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs2070995','T > C','KCNJ6','Analgesics','NERVOUS SYSTEM','ANALGESICS','','An analgesic, or painkiller, is any member of the group of drugs used to achieve analgesia  relief from pain.','Level 3','increased','-','-','CC','                Patients with the CC genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance for requiring a rescue analgesic.'),('rs1402467','C > G','SULT1C4','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs1045642','A > G','ABCB1','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs4646487','C > T','CYP4B1','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs1056836','C > G','CYP1B1','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with taxanes may have longer disease-free progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs2227631','A > G','SERPINE1','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs7997012','A > G','HTR2A','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs6295','C > G','HTR1A','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','increased','-','-','GG','                Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs1360780','T > C','FKBP5','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','CC','                Patients with the CC genotype may 1) have decreased response to antidepressants 2) have decreased suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs3800373','C > A','FKBP5','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 2B','decreased','-','-','AA','                Patients with the AA genotype and depression who are treated with antidepressants may be less likely to have improvement in symptoms as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs963468','G > A','DRD3','duloxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00476 ','Duloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is a drug which primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), pain related to diabetic peripheral neuropathy and in some countries stress urinary incontinence (SUI). It is manufactured and marketed by Eli Lilly and Company.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to duloxetine treatment.'),('rs7569963','G > A','CREB1','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','AA','                Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs2032583','A > G','ABCB1','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','increased','-','-','AG','                Patients with the AG genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs2235015','C > A','ABCB1','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','AC','                Patients with the AC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs16944','A > G','IL1B','etidronic acid','VARIOUS','','Etidronic acid is a chelating ','Etidronic acid is a chelating agent and may be added to bind or, to some extent, counter the effects of substances, such as calcium, iron or other metal ions, which may be discharged as a component of grey wastewater and could conceivably contaminate groundwater supplies. As a phosphonate it has corrosion inhibiting properties on unnalloyed steel. Etidronic acid also acts to retard rancidification and oxidation of fatty acids.','Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs3740066','C > T','ABCC2','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','decreased','-','-','TT','                Patients with the TT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. This association was not found in all studies. Other genetic and clinical factors may also influence a patients response to antiepileptics.'),('rs1045642','A > G','ABCB1','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','increased','-','-','AG','                Genotype AG may be associated with increased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype GG. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. Theres also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patients response to antiepileptics.'),('rs1801131','T > G','MTHFR','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GT','                Patients with the GT genotype may have decreased risk of Drug Toxicity when treated with fluorouracil and radiotherapy in people with Rectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1801133','G > A','MTHFR','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','AG','                Patients with the AG genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1801159','T > C','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased likelihood of middle-severe nausea,  vomiting and white blood cell decreases in cancer patients treated with fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk of fluorouracil  related adverse events.'),('rs2297595','T > C','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1042522','C > G','TP53','antineoplastic agents','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','','Inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1079598','A > G','DRD2','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1801133','G > A','CLCN6','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','increased','AG','                Patients with the AG genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1800497','G > A','ANKK1','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1801133','G > A','MTHFR','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 3','-','-','-','AG','                Patients with the AG genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patients risk for toxicity to mercaptopurine.'),('rs1801131','T > G','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','GT','                Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of clinical response but may have a decreased response base on Disease Activity Score in 44 joints improvement at 6 months as compared to patients with the TT genotype. This association has been contradicted in other studies including a larger meta-analysis that found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs1801131','T > G','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','-','GT','                Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype or may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype.  This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Rheumatoid Arthritis may be more at risk of alopecia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of alopecia.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse events as compared to patients with the AA genotype (though this association has not been found in all studies). There does not seem to be an association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','AG','                Patients with the AG genotype with non-hodgkin lymphoma who are treated with methotrexate may be less likely to have event free survival at 5 years as compared to patients with the GG genotype. This genotype was not associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the GG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','decreased','increased','AG','                Patients with the AG genotype and Leukemia who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate as compared to patients with the GG genotype or may be at decreased risk of toxicity as compared to patients with the AA genotype. This association has been contradicted or not found in several studies. Other genetic and clinical factors may also influence a patients risk for toxicity and response with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk Graft vs Host disease and efficacy of methotrexate treatment.'),('rs1801253','G > C','ADRB1','atenolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00335','A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. [DrugBank]','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs4846051','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','AA','                Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients level of methotrexate induced toxicity.'),('rs1801253','G > C','ADRB1','atenolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00335','A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. [DrugBank]','Level 3','decreased','-','increased','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs2372536','C > G','ATIC','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','CG','                Patients with the CG genotype and rheumatoid arthritis who are treated with methotrexate may be less likely to have symptom improvement as compared to patients with the GG genotype.'),('rs1801133','G > A','MTHFR','nitrous oxide','VARIOUS','','','Nitrous oxide, commonly known as laughing gas, nitrous, nitro, or NOS[1] is a chemical compound','Level 3','-','-','-','AG','                Patients with the GA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients homocysteine levels after nitrous oxide anesthesia.'),('rs2842030','G > T','RGS4','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients response to perphanazine.'),('rs1801253','G > C','ADRB1','Beta Blocking Agents','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','','Beta blockers are a class of drugs that target the beta receptor. Beta receptors are found on cells of the heart muscles, smooth muscles, airways, arteries, kidneys, and other tissues that are part of the sympathetic nervous system and lead to stress responses, especially when they are stimulated by epinephrine (adrenaline).','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','Beta Blocking Agents','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','','Beta blockers are a class of drugs that target the beta receptor. Beta receptors are found on cells of the heart muscles, smooth muscles, airways, arteries, kidneys, and other tissues that are part of the sympathetic nervous system and lead to stress responses, especially when they are stimulated by epinephrine (adrenaline).','Level 3','decreased','-','increased','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs6280','C > T','DRD3','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','decreased','-','-','CT','                Patients with the CT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patients response to olanzapine.'),('rs16944','A > G','IL1B','Bisphosphonates','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs2297480','T > G','FDPS','Bisphosphonates','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 2B','increased','-','-','GT','                Patients with the GT genotype may have an increased chance of response to bisphosphonate treatment as compared to patients with the GG genotype. Patients with the GT genotype may still be at risk for non-response to bisphosphonate treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1801253','G > C','ADRB1','bucindolol','VARIOUS','','','Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity.[1][2] It was under review by the FDA in the United States for the treatment of heart failure in 2009 ','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','bucindolol','VARIOUS','','','Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity.[1][2] It was under review by the FDA in the United States for the treatment of heart failure in 2009 ','Level 3','decreased','-','increased','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1056836','C > G','CYP1B1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with taxanes may have longer disease-free progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs165599','G > A','ARVCF','bupropion','NERVOUS SYSTEM','','','Bupropion is a drug primarily used as an atypical antidepressant and smoking cessation aid. Marketed as Wellbutrin, Budeprion, Prexaton, Elontril, Aplenzin, or other trade names, it is one of the most frequently prescribed antidepressants in the United States. Marketed in lower-dose formulations as Zyban, Voxra, or other names, it is also widely used to reduce nicotine cravings by people who are trying to quit smoking. It is taken in the form of pills, and in the United States is available only by prescription.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AG genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1800497','G > A','ANKK1','bupropion','NERVOUS SYSTEM','','','Bupropion is a drug primarily used as an atypical antidepressant and smoking cessation aid. Marketed as Wellbutrin, Budeprion, Prexaton, Elontril, Aplenzin, or other trade names, it is one of the most frequently prescribed antidepressants in the United States. Marketed in lower-dose formulations as Zyban, Voxra, or other names, it is also widely used to reduce nicotine cravings by people who are trying to quit smoking. It is taken in the form of pills, and in the United States is available only by prescription.','Level 1B','decreased','-','-','AG','                Patients with the AG genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients chance for quitting smoking.'),('rs2842030','G > T','RGS4','perphenazine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00850 ','An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. [PubChem]','Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients response to perphanazine.'),('rs1051740','T > C','EPHX1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','decreased','CC','                Patients with the CC genotype who use phenytoin during the first trimester of pregnancy may be less likely to have a child with a craniofacial abnormality as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk of having a child with a craniofacial abnormality.'),('rs1801131','T > G','MTHFR','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','GT','                Patients with the GT genotype may have increased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to capecitabine.'),('rs2297595','T > C','DPYD','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1045642','A > G','ABCB1','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 3','-','-','increased','AG','                Patients with AG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.'),('rs2227956','G > A','HSPA1A','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 3','-','-','increased','AA','                Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients chance of adverse response.'),('rs1051740','T > C','EPHX1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 2B','-','increased','-','CC','                Patients with the CC genotype and Epilepsy who are treated with carbamazepine may have an increased dose of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to carbamazepine.'),('rs16944','A > G','IL1B','risedronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00884 ','Risedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis','Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs2661319','T > C','RGS4','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs750332','C > T','BAT2','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 3','-','-','decreased','TT','                Patients with the TT genotype who are treated with carbamazepine may have a decreased, but not absent, risk of Stevens-Johnson syndrome as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients risk for Stevens-Johnson syndrome with carbamazepine treatment.'),('rs2842030','G > T','RGS4','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 4','decreased','-','-','TT','                Patients with the TT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs6280','C > T','DRD3','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patients response.'),('rs1045642','A > G','ABCB1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 4','-','increased','-','AG','                Patient with genotype AG may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine.'),('rs10192566','C > G','LPIN1','rosiglitazone','ALIMENTARY TRACT AND METABOLISM','DRUGS USED IN DIABETES','DB00412 ','Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl).','Level 3','-','-','-','CG','                Patients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to rosiglitazone.'),('rs9981861','T > C','DSCAM','carboplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00958 ','An organoplatinum compound that possesses antineoplastic activity.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.'),('rs1801253','G > C','ADRB1','carvedilol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB01136','Carvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-2 adrenergic receptors.','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','carvedilol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB01136','Carvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-4 adrenergic receptors.','Level 3','decreased','-','increased','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1056836','C > G','CYP1B1','taxanes','VARIOUS','','','Taxanes are diterpenes produced by the plants of the genus Taxus (yews), and are widely used as chemotherapy agents.[1] Taxane agents include paclitaxel (Taxol) and docetaxel (Taxotere).Taxanes present difficulties in formulation as medicines because they are poorly soluble in water.','Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with taxanes may have longer disease-free progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs1402467','C > G','SULT1C4','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs4646487','C > T','CYP4B1','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs16944','A > G','IL1B','tiludronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB01133','Tiludronate is a bisphosphonate characterized by a (4-chlorophenylthio) group on the carbon atom of the basic P-C-P structure common to all bisphosphonates.','Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs1105879','A > C','UGT1A6','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','AC','                Patients with the AC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs6759892','T > G','UGT1A10','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','GT','                Patients with the GT genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients valproic acid dose requirement.'),('rs10494366','G > T','NOS1AP','verapamil','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 3','-','-','decreased','TT','                Patients with the TT genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients QTc prolongation risk.'),('rs2228001','G > T','XPC','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','decreased','TT','                Patients with the TT genotype may have a decreased but not non-existent risk for toxicity with cisplatin treatment as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1042522','C > G','TP53','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs316019','A > C','SLC22A2','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1045642','A > G','ABCB1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have better response (decreased risk of lymph node metastases and increased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs2227631','A > G','SERPINE1','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs7997012','A > G','HTR2A','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1954787','T > C','GRIK4','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 1B','increased','-','-','CT','                Patients with the CT genotype may have an increased chance of response to citalopram treatment as compared to patients with the TT genotype. Patients with the CT genotype may still be at risk for non-response to citalopram treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs7569963','G > A','CREB1','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','decreased','-','-','AA','                Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs16944','A > G','IL1B','clodronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00720 ','A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs1360780','T > C','FKBP5','clomipramine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01242 ','Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. ','Level 3','-','-','decreased','CC','                Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to paroxetine, venlafaxine, clomipramine or nefazodone.'),('rs1079598','A > G','DRD2','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1800497','G > A','ANKK1','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1042522','C > G','TP53','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs4880','A > G','SOD2','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients survival when treated with cyclophosphamide.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2A','increased','-','-','AG','                Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs2740574','C > T','CYP3A4','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','TT','                Premenopausal patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have a shorter period of time before chemotherapy-induced ovarian failure compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.'),('rs2279343','A > G','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','increased','AG','                Patients with the AG genotype who have received a  hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for oral mucositis.'),('rs1045642','A > G','ABCB1','cyclosporine','VARIOUS','','','Cyclosporine is available in its original form and as another product that has been modified (changed) so that the medication can be better absorbed in the body. Original cyclosporine and cyclosporine (modified) are absorbed by the body in different amounts, so they cannot be substituted for one another. Take only the type of cyclosporine that was prescribed by your doctor. When your doctor gives you a written prescription, check to be sure that he or she has specified the type of cyclosporine you should receive. Each time you have your prescription filled, look at the brand name printed on your prescription label to be sure that you have received the same type of cyclosporine. Talk to your pharmacist if the brand name is unfamiliar or you are not sure you have received the right type of cyclosporine.','Level 3','-','increased','-','AG','                Patients with genotype AG may have increased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.'),('rs1045642','A > G','ABCB1','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1402467','C > G','SULT1C4','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs2301159','G > A','SLC10A2','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs1883322','C > T','PPARD','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2016520','C > T','PPARD','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs3734254','C > T','PPARD','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','TT','                Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs6922548','A > G','PPARD','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4646487','C > T','CYP4B1','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2740574','C > T','CYP3A','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','-','TT','                Patients with the TT genotype may have decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of docetaxel.'),('rs1056836','C > G','CYP1B1','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with taxanes may have longer disease-free progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs12418','G > A','CHST3','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs4148950','G > A','CHST3','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','increased','AG','                Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs8133052','G > A','CBR3','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','increased','-','-','AG','                Patients with the AG genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype, or 1) may have increased metabolism of doxorubicin 2) may have less tumor reduction 3) may have decreased severity of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to doxorubicin treatment and risk of toxicity.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs16969968','G > A','CHRNA3','Drugs used in nicotine dependence','NERVOUS SYSTEM','','','','Level 3','increased','-','-','AG','                Patients with AG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the AG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Finding are based on haplotype analysis of rs16969968 and rs680244. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs1800497','G > A','ANKK1','Drugs used in nicotine dependence','NERVOUS SYSTEM','','','','Level 3','increased','-','-','AG','                Patients with AG genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs963468','G > A','DRD3','duloxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00476 ','Duloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is a drug which primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), pain related to diabetic peripheral neuropathy and in some countries stress urinary incontinence (SUI). It is manufactured and marketed by Eli Lilly and Company.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to duloxetine treatment.'),('rs1695','A > G','GSTP1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 2A','increased','-','-','AG','                Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1045642','A > G','ABCB1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs712829','G > T','EGFR','erlotinib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00530 ','Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.','Level 3','-','-','decreased','GT','                Patients with the GT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.'),('rs712829','G > T','EGFR','erlotinib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00530 ','Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.','Level 4','increased','-','-','GT','                Patients with the GT genotype may be more sensitive to treatment with erlotinib  compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.'),('rs1800497','G > A','ANKK1','ethanol','VARIOUS','','','Ethanol is a psychoactive drug and is one of the oldest recreational drugs still used by humans. Ethanol can cause alcohol intoxication when consumed. Best known as the type of alcohol found in alcoholic beverages, it is also used in thermometers, as a solvent, and as a fuel. In common usage, it is often referred to simply as alcohol or spirits.','Level 2B','-','-','increased','AG','                Patients with AG genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patients risk for alcohol dependency.'),('rs16944','A > G','IL1B','etidronic acid','VARIOUS','','Etidronic acid is a chelating ','Etidronic acid is a chelating agent and may be added to bind or, to some extent, counter the effects of substances, such as calcium, iron or other metal ions, which may be discharged as a component of grey wastewater and could conceivably contaminate groundwater supplies. As a phosphonate it has corrosion inhibiting properties on unnalloyed steel. Etidronic acid also acts to retard rancidification and oxidation of fatty acids.','Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs1045642','A > G','ABCB1','fexofenadine','RESPIRATORY SYSTEM','ANTIHISTAMINES FOR SYSTEMIC USE','DB00950','Fexofenadine hydrochloride (Allegra) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine.','Level 3','-','-','-','AG','                Healthy individuals with the AG genotype who are treated with fexofenadine may have higher plasma drug levels as compared to healthy individuals with the AA genotype.  Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.'),('rs1042522','C > G','TP53','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1801131','T > G','MTHFR','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GT','                Patients with the GT genotype may have decreased risk of Drug Toxicity when treated with fluorouracil and radiotherapy in people with Rectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1801133','G > A','MTHFR','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','AG','                Patients with the AG genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','AG','                Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for hematological toxicity when exposed to fluorouracil.'),('rs1801159','T > C','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased likelihood of middle-severe nausea,  vomiting and white blood cell decreases in cancer patients treated with fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk of fluorouracil  related adverse events.'),('rs2297595','T > C','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','AG','                Patients with the AG genotype may have better response (decreased risk of lymph node metastases and increased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs25531','T > C','SLC6A4','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 4','decreased','-','-','CC','                Patients with the CC genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT.  Other genetic and clinical factors may also influence a patients response.'),('rs2227631','A > G','SERPINE1','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs10042486','C > T','HTR1A','fluvoxamine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00176 ','Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.','Level 3','decreased','-','-','TT','                Patients with the TT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment  as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs6295','C > G','HTR1A','fluvoxamine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00176 ','Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.','Level 3','increased','-','-','GG','                Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs712829','G > T','EGFR','gefitinib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00317 ','Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells.','Level 3','increased','-','-','GT','                Patients with the GT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs712829','G > T','EGFR','geldanamycin','VARIOUS','','','Geldanamycin is a benzoquinone ansamycin antibiotic that inhibits the function of Hsp90 (Heat Shock Protein 90) by binding to the unusual ADP/ATP-binding pocket of the protein.[1] HSP90 client proteins play important roles in the regulation of the cell cycle, cell growth, cell survival, apoptosis, angiogenesis and oncogenesis.','Level 4','decreased','-','-','GT','                Patients with the genotype GT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patients response.'),('rs9937','A > G','RRM1','gemcitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00441 ','Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar? by Eli Lilly and Company. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication.','Level 4','-','-','decreased','GG','                Patients with the GG genotype and the A allele of rs1042858 with advanced breast cancer who are treated with gemcitabine 1) may be less likely to experience toxicity such as neutropenia 2) may have a tendency, though not a statistically significant one, towards poorer progression-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of toxicity and response to gemcitabine.'),('rs1045642','A > G','ABCB1','idarubicin','GENITO URINARY SYSTEM AND SEX HORMONES','OTHER GYNECOLOGICALS','DB01050','Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs7142881','G > A','NUBPL','iloperidone','VARIOUS','','','Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.','Level 3','-','-','increased','AG','                Patients with the AG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs4799915','C > T','CELF4','iloperidone','VARIOUS','','','Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.','Level 3','-','-','increased','CT','                Patients with the CT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs762551','C > A','CYP1A2','leflunomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00762 ','Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I.','Level 3','-','-','decreased','AA','                Patients with the AA genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity with leflunomide treatment.'),('rs1051266','T > C','SLC19A1','leucovorin','VARIOUS','','','Folinic acid (INN) or leucovorin (USAN), generally administered as calcium or sodium folinate (or leucovorin calcium/sodium), is an adjuvant used in cancer chemotherapy involving the drug methotrexate.[1] It is also used in synergistic combination with the chemotherapy agent 5-fluorouracil.','Level 3','increased','-','-','CC','                Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) increased likelihood of Toxic liver disease 2) decreased, but not absent, risk of Drug Toxicity 3) decreased likelihood of treatment interruptions as compared to patients with the CT and TT genotype. Further, patients with the CC genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patients response to leucovorin, mercaptopurine and methotrexate.'),('rs2284017','T > C','CACNG2','lithium','VARIOUS','','','Lithium and its compounds have several industrial applications, including heat-resistant glass and ceramics, high strength-to-weight alloys used in aircraft, lithium batteries and lithium-ion batteries. These uses consume more than half of lithium production.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs1051266','T > C','SLC19A1','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 3','increased','-','-','CC','                Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) increased likelihood of Toxic liver disease 2) decreased, but not absent, risk of Drug Toxicity 3) decreased likelihood of treatment interruptions as compared to patients with the CT and TT genotype. Further, patients with the CC genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patients response to leucovorin, mercaptopurine and methotrexate.'),('rs1801133','G > A','MTHFR','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 3','-','-','-','AG','                Patients with the AG genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patients risk for toxicity to mercaptopurine.'),('rs2076369','T > G','PICK1','methamphetamine','VARIOUS','','','In low doses, methamphetamine can cause an elevated mood and increase alertness, concentration, and energy in fatigued individuals. At higher doses, it can induce psychosis, rhabdomyolysis and cerebral hemorrhage. Methamphetamine is known to have a high potential for abuse and addiction. Recreational use of methamphetamine may result in psychosis or lead to post-withdrawal syndrome, a withdrawal syndrome that can persist for months beyond the typical withdrawal period. Unlike amphetamine and cocaine, methamphetamine is neurotoxic to humans, damaging both dopamine and serotonin neurons in the CNS. Entirely opposite to the long-term use of amphetamine, there is evidence that methamphetamine causes brain damage from long-term use in humans; this damage includes adverse changes in brain structure and function, such as reductions in gray matter volume in several brain regions and adverse changes in markers of metabolic integrity.','Level 3','-','-','decreased','GG','                Patients with the GG genotype who are methamphetamine abusers may have a decreased, but not absent, risk for spontaneous relapse of psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for spontaneous relapse of psychosis with methamphetamine abuse.'),('rs1051266','T > C','SLC19A1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','CC','                Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) increased likelihood of Toxic liver disease 2) decreased, but not absent, risk of Drug Toxicity 3) decreased likelihood of treatment interruptions as compared to patients with the CT and TT genotype. Further, patients with the CC genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patients response to leucovorin, mercaptopurine and methotrexate.'),('rs1051266','T > C','SLC19A1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk of hepatotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for hepatoxicity.'),('rs1051266','T > C','SLC19A1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','CC','                Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have less symptom improvement as compared to patients with the TT genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patients response to methotrexate therapy.'),('rs1801394','A > G','MTRR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 2B','-','-','increased','AG','                Pediatric ALL patients with AG genotypes may have increased likelihood of methotrexate induced toxicity (oral mucositis), increased speed of platelet recovery and increased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the AA genotype. Allele G is not associated with decreased IQ in pediatric ALL patients treated with methotrexate. Other genetic and clinical factors may also influence response to methotrexate.'),('rs1801131','T > G','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','GT','                Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of clinical response but may have a decreased response base on Disease Activity Score in 44 joints improvement at 6 months as compared to patients with the TT genotype. This association has been contradicted in other studies including a larger meta-analysis that found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs1801131','T > G','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','-','GT','                Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype or may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype.  This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Rheumatoid Arthritis may be more at risk of alopecia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of alopecia.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse events as compared to patients with the AA genotype (though this association has not been found in all studies). There does not seem to be an association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','AG','                Patients with the AG genotype with non-hodgkin lymphoma who are treated with methotrexate may be less likely to have event free survival at 5 years as compared to patients with the GG genotype. This genotype was not associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the GG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','decreased','increased','AG','                Patients with the AG genotype and Leukemia who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate as compared to patients with the GG genotype or may be at decreased risk of toxicity as compared to patients with the AA genotype. This association has been contradicted or not found in several studies. Other genetic and clinical factors may also influence a patients risk for toxicity and response with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk Graft vs Host disease and efficacy of methotrexate treatment.'),('rs4846051','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','AA','                Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients level of methotrexate induced toxicity.'),('rs1544105','C > T','FPGS','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','CT','                Patients with the TC genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs2372536','C > G','ATIC','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','CG','                Patients with the CG genotype and rheumatoid arthritis who are treated with methotrexate may be less likely to have symptom improvement as compared to patients with the GG genotype.'),('rs2236624','T > C','ADORA2A','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for an adverse event as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for an adverse event.'),('rs246240','A > G','ABCC1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity to methotrexate.'),('rs1045642','A > G','ABCB1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 4','-','-','increased','AG','                Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have an increased risk of adverse drug events (please note this association was not significant after correcting for multiple variables) 2) may have an increased risk of not responding to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse drug events and responsiveness when treated with methotrexate.'),('rs1045642','A > G','ABCB1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 4','decreased','-','-','AG','                Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have an increased risk of adverse drug events (please note this association was not significant after correcting for multiple variables) 2) may have an increased risk of not responding to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse drug events and responsiveness when treated with methotrexate.'),('rs4888024','A > G','Not available','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','-','AG','                Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.'),('rs1801253','G > C','ADRB1','metoprolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','metoprolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','metoprolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','decreased','-','increased','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs10042486','C > T','HTR1A','milnacipran','VARIOUS','','','Milnacipran (Ixel, Savella, Dalcipran, Toledomin) is a serotonin','Level 3','decreased','-','-','TT','                Patients with the TT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment  as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs2660845','G > A','LTA4H','montelukast','RESPIRATORY SYSTEM','DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES','DB00471 ','Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it.','Level 3','-','-','increased','AG','                Patients with the AG genotype and asthma who are treated with montelukast  may have an increased risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of asthma exacerbations with montelukast treatment.'),('rs2115819','A > G','ALOX5','montelukast','RESPIRATORY SYSTEM','DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES','DB00471 ','Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it.','Level 3','increased','-','-','AG','                Patients with the AG genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to montelukast.'),('rs4149117','T > G','SLCO1B3','mycophenolate mofetil','VARIOUS','','DB00688 ','Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent, inosine monophosphate dehydrogenase (IMPDH) inhibitor.','Level 4','-','-','-','GG','                Patients with the GG genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity and exposure to mycophenolic acid.'),('rs2278294','C > T','IMPDH1','mycophenolate mofetil','VARIOUS','','DB00688 ','Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent, inosine monophosphate dehydrogenase (IMPDH) inhibitor.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1360780','T > C','FKBP5','nefazodone','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01149 ','Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to paroxetine, venlafaxine, clomipramine or nefazodone.'),('rs1800497','G > A','ANKK1','nemonapride','VARIOUS','','','Nemonapride (Emilace) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in 1991. ','Level 3','-','-','increased','AG','                Female patients with the AG genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patients response to nemonapride.'),('rs16969968','G > A','CHRNA5','nicotine','NERVOUS SYSTEM','OTHER NERVOUS SYSTEM DRUGS','DB00184','Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. [PubChem]','Level 3','-','-','increased','AG','                Patients with AG genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype. Findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patients risk for nicotine dependency.'),('rs1800497','G > A','ANKK1','nicotine','NERVOUS SYSTEM','OTHER NERVOUS SYSTEM DRUGS','DB00184','Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. [PubChem]','Level 3','increased','-','-','AG','                Patients with AG genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs1801133','G > A','MTHFR','nitrous oxide','VARIOUS','','','Nitrous oxide, commonly known as laughing gas, nitrous, nitro, or NOS[1] is a chemical compound','Level 3','-','-','-','AG','                Patients with the GA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients homocysteine levels after nitrous oxide anesthesia.'),('rs1045642','A > G','ABCB1','nortriptyline','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00540 ','Nortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for postural hypotension with nortriptyline treatment.'),('rs2842030','G > T','RGS4','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients response to perphanazine.'),('rs7997012','A > G','HTR2A','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for side effects with olanzapine treatment.'),('rs6280','C > T','DRD3','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','decreased','-','-','CT','                Patients with the CT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patients response to olanzapine.'),('rs1079598','A > G','DRD2','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs762551','C > A','CYP1A2','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','decreased','-','-','AA','                Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have decreased response to olanzapine based on decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patients response to olanzapine.'),('rs1800497','G > A','ANKK1','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs2032583','A > G','ABCB1','Other antidepressants','NERVOUS SYSTEM','','','','Level 3','increased','-','-','AG','                Patients with the AG genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs2235015','C > A','ABCB1','Other antidepressants','NERVOUS SYSTEM','','','','Level 3','decreased','-','-','AC','                Patients with the AC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 3','-','-','increased','AG','                Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1042522','C > G','TP53','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs9981861','T > C','DSCAM','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.'),('rs1056836','C > G','CYP1B1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with taxanes may have longer disease-free progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs11188072','C > T','CYP2C19','pantoprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00213 ','Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.','Level 3','-','increased','-','CT','                Patients with the CT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs10042486','C > T','HTR1A','paroxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00726 ','Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]','Level 3','decreased','-','-','TT','                Patients with the TT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment  as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs6295','C > G','HTR1A','paroxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00726 ','Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs1360780','T > C','FKBP5','paroxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00726 ','Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]','Level 3','-','-','decreased','CC','                Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to paroxetine, venlafaxine, clomipramine or nefazodone.'),('rs12979860','C > T','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs12979860','C > T','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs2842030','G > T','RGS4','perphenazine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00850 ','An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. [PubChem]','Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients response to perphanazine.'),('rs1051740','T > C','EPHX1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','decreased','CC','                Patients with the CC genotype who use phenytoin during the first trimester of pregnancy may be less likely to have a child with a craniofacial abnormality as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk of having a child with a craniofacial abnormality.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','-','AG','                Patients with genotype AG may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patients dose of phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','decreased','-','-','AG','                Patients with genotype AG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians. Other genetic or clinical factors may influence a patients response to phenytoin.'),('rs1695','A > G','GSTP1','Platinum compounds','VARIOUS','','','','Level 3','-','-','increased','AG','                Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs12979860','C > T','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs16944','A > G','IL1B','risedronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00884 ','Risedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis','Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs2661319','T > C','RGS4','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs2842030','G > T','RGS4','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 4','decreased','-','-','TT','                Patients with the TT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs724226','A > G','GRM3','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','GG','                Patients with the GG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs6280','C > T','DRD3','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patients response.'),('rs165599','G > A','COMT','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs1800497','G > A','ANKK1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1800497','G > A','ANKK1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','AG','                Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the GG genotype or may have less improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs3803300','T > C','AKT1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 4','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the CT or GG genotype. Please note this did not reach statistical significance. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs1128503','A > G','ABCB1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patients response.'),('rs10192566','C > G','LPIN1','rosiglitazone','ALIMENTARY TRACT AND METABOLISM','DRUGS USED IN DIABETES','DB00412 ','Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl).','Level 3','-','-','-','CG','                Patients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to rosiglitazone.'),('rs7997012','A > G','HTR2A','Selective serotonin reuptake inhibitors','VARIOUS','','','Selective beta-2-adrenoreceptor agonists are a class of drugs that act on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation, resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin.They are primarily used to treat asthma and other pulmonary disorders.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs6295','C > G','HTR1A','Selective serotonin reuptake inhibitors','VARIOUS','','','Selective beta-2-adrenoreceptor agonists are a class of drugs that act on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation, resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin.They are primarily used to treat asthma and other pulmonary disorders.','Level 3','increased','-','-','GG','                Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs4343','G > A','ACE','sildenafil','GENITO URINARY SYSTEM AND SEX HORMONES','UROLOGICALS','DB00203 ','Sildenfail is a vasoactive agent used to treat erectile dysfunction and reduce symptoms in patients with pulmonary arterial hypertension (PAH). Sildenafil elevates levels of the second messenger, cGMP, by inhibiting its breakdown via phosphodiesterase type 5 (PDE5).','Level 3','decreased','-','-','AG','                Patients with the AG genotype and erectile dysfunction who are treated with sildenafil may have a decreased chance of positive erectile response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to sildenafil.'),('rs2740574','C > T','CYP3A','sirolimus','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00877 ','A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production.','Level 2A','-','decreased','-','TT','                Patients with the TT genotype may require a decreased dose of tacrolimus or sirolimus as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs4343','G > A','ACE','spironolactone','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','DIURETICS','DB00421 ','A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis.','Level 3','increased','-','-','AG','                Patients with the AG genotype is associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs12255372','G > T','TCF7L2','sulfonamides, urea derivatives','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','decreased','-','-','GT','                Patients with the GT genotype and type II diabetes who are treated with sulfonylureas may be less likely to achieve a target HbA1c level of <7% as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs2740574','C > T','CYP3A','tacrolimus','DERMATOLOGICALS','OTHER DERMATOLOGICAL PREPARATIONS','DB00864 ','Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient??s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. ','Level 2A','-','decreased','-','TT','                Patients with the TT genotype may require a decreased dose of tacrolimus or sirolimus as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs4986938','C > T','ESR2','tamoxifen','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ENDOCRINE THERAPY','DB00675','One of the selective estrogen receptor modulators (SERM) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer.','Level 3','-','-','-','CT','                Patients with the CT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the  CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.'),('rs1056836','C > G','CYP1B1','taxanes','VARIOUS','','','Taxanes are diterpenes produced by the plants of the genus Taxus (yews), and are widely used as chemotherapy agents.[1] Taxane agents include paclitaxel (Taxol) and docetaxel (Taxotere).Taxanes present difficulties in formulation as medicines because they are poorly soluble in water.','Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with taxanes may have longer disease-free progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs9349256','G > A','ABCC10','tenofovir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00300 ','Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased but not absent risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1402467','C > G','SULT1C4','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs2301159','G > A','SLC10A2','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs1883322','C > T','PPARD','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2016520','C > T','PPARD','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs3734254','C > T','PPARD','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','increased','-','-','TT','                Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs6922548','A > G','PPARD','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4646487','C > T','CYP4B1','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs12418','G > A','CHST3','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs1871450','G > A','CHST3','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','increased','-','-','AG','                Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs4148950','G > A','CHST3','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','increased','-','increased','AG','                Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs16944','A > G','IL1B','tiludronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB01133','Tiludronate is a bisphosphonate characterized by a (4-chlorophenylthio) group on the carbon atom of the basic P-C-P structure common to all bisphosphonates.','Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs712829','G > T','EGFR','topoisomerase I inhibitors','VARIOUS','','','Topoisomerase inhibitors are agents designed to interfere with the action of topoisomerase enzymes[1] (topoisomerase I and II), which are enzymes that control the changes in DNA structure[2] by catalyzing the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle.','Level 4','decreased','-','-','GT','                Cancer patients with genotype GT may be less likely to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patients response.'),('rs1105879','A > C','UGT1A6','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','AC','                Patients with the AC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs6759892','T > G','UGT1A10','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','GT','                Patients with the GT genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients valproic acid dose requirement.'),('rs1487278','T > C','TPH2','venlafaxine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','increased','-','-','CT','                Patients with the CT genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to antidepressant.'),('rs1360780','T > C','FKBP5','venlafaxine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to paroxetine, venlafaxine, clomipramine or nefazodone.'),('rs10494366','G > T','NOS1AP','verapamil','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 3','-','-','decreased','TT','                Patients with the TT genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients QTc prolongation risk.'),('rs7294','C > T','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.'),('rs2359612','A > G','PRSS53','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTSANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','increased','-','GG','                Patients with the GG genotype who are treated with warfarin may require a higher dose as compared to patients with the AG or AA genotype.');
/*!40000 ALTER TABLE `66asbykulujf` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `common_diseases`
--

DROP TABLE IF EXISTS `common_diseases`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `common_diseases` (
  `Disease` varchar(20) DEFAULT NULL,
  `RSID` varchar(20) DEFAULT NULL,
  `Allele` varchar(7) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `frequency` varchar(20) DEFAULT NULL,
  `Odds_Ratio` varchar(20) DEFAULT NULL
) ENGINE=MyISAM DEFAULT CHARSET=utf8;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `common_diseases`
--

LOCK TABLES `common_diseases` WRITE;
/*!40000 ALTER TABLE `common_diseases` DISABLE KEYS */;
INSERT INTO `common_diseases` VALUES ('Diseases','RSID','Alleles','Gene','Frequency','Odds_Ratio'),('Esophageal cancer','rs2274223','G','PLCE1','0.21','1.34'),('Esophageal cancer','rs11066015','A','ACAD10','0.19','1.38'),('Esophageal cancer','rs11066280','A','C12orf51','0.21','1.3'),('Esophageal cancer','rs2074356','T','C12orf51','0.13','1.56'),('Esophageal cancer','rs8030672','A','CORO2B - ANP32A','0.03','1.56'),('Esophageal cancer','rs2014300','G','RUNX1','0.83','1.43'),('Esophageal cancer','rs9868873','G','SEMA5B','0.82','1.19'),('Esophageal cancer','rs6772209','G','UBE2V1P2 - TBL1XR1','0.97','1.49'),('Esophageal cancer','rs10052657','C','PDE4D','0.78','1.49'),('Esophageal cancer','rs10058728','T','CSNK1A1','0.98','2.04'),('Esophageal cancer','rs10484761','G','LRFN2 - UNC5CL','0.09','1.33'),('Systemic lupus eryth','rs7329174','G','ELF1','0.22','1.26'),('Systemic lupus eryth','rs1913517','A','WDFY4;LRRC18','0.29','1.24'),('Systemic lupus eryth','rs4639966','G','TREH - DDX6','0.3','1.29'),('Systemic lupus eryth','rs6590330','A','NCRNA00288 - ETS1','0.34','1.37'),('Systemic lupus eryth','rs1385374','A','SLC15A4','0.2','1.26'),('Systemic lupus eryth','rs7197475','A','ZNF689 - PRR14','0.08','1.31'),('Systemic lupus eryth','rs7186852','A','ZNF689 - PRR14','0.08','1.29'),('Systemic lupus eryth','rs2205960','A','TNFSF4 - RPL26P11','0.27','1.46'),('Systemic lupus eryth','rs131654','A','RIMBP3C - UBE2L3','0.48','1.28'),('Systemic lupus eryth','rs13385731','A','RASGRP3','0.85','1.43'),('Systemic lupus eryth','rs7574865','A','STAT4','0.33','1.51'),('Systemic lupus eryth','rs10036748','A','TNIP1','0.76','1.23'),('Systemic lupus eryth','rs548234','G','LOC100287304','0.26','1.25'),('Systemic lupus eryth','rs2230926','C','TNFAIP3','0.04','1.72'),('Systemic lupus eryth','rs4917014','A','C7orf72 - IKZF1','0.68','1.39'),('Systemic lupus eryth','rs1167796','G','HIP1','0.71','1.2'),('Systemic lupus eryth','rs4728142','A','KCP - IRF5','0.13','1.43'),('Systemic lupus eryth','rs7812879','G','FAM167A - BLK','0.76','1.45'),('Type 2 diabetes','rs163182','C','KCNQ1','0.34','1.28'),('Type 2 diabetes','rs1436953','G','C2CD4A - C2CD4B','0.64','1.14'),('Type 2 diabetes','rs10906115','A','CDC123 - CAMK1D','0.57','1.13'),('Type 2 diabetes','rs5015480','C','HHEX - EXOC6','0.17','1.17'),('Type 2 diabetes','rs1359790','G','NDFIP2 - SPRY2','0.71','1.15'),('Type 2 diabetes','rs1436955','C','C2CD4A - C2CD4B','0.73','1.13');
/*!40000 ALTER TABLE `common_diseases` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `copy_of_statistics_report`
--

DROP TABLE IF EXISTS `copy_of_statistics_report`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `copy_of_statistics_report` (
  `RSID` varchar(255) DEFAULT NULL,
  `Genotype` varchar(255) DEFAULT NULL,
  `Drug` varchar(255) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8 ROW_FORMAT=COMPACT;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `copy_of_statistics_report`
--

LOCK TABLES `copy_of_statistics_report` WRITE;
/*!40000 ALTER TABLE `copy_of_statistics_report` DISABLE KEYS */;
INSERT INTO `copy_of_statistics_report` VALUES ('rs9263800','AA','allopurinol--PA448320'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs688','TT','atenolol--PA448499'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs9679162','TT','cisplatin--PA449014'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs9679162','TT','fluorouracil--PA128406956'),('rs1045642','GG','fluorouracil--PA128406956'),('rs1045642','GG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs4888024','AG','methotrexate--PA450428'),('rs9679162','TT','mitoxantrone--PA450526'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs1045642','GG','paclitaxel--PA450761'),('rs275651','AT','perindopril--PA450877'),('rs1045642','GG','phenytoin--PA450947'),('rs6759892','GG','valproic acid--PA451846'),('rs1045642','GG','vincristine--PA451879'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs4888024','GG','methotrexate--PA450428'),('rs2368564','TT','muraglitazar--PA162356187'),('rs4731426','CC','olanzapine--PA450688'),('rs10811661','CT','troglitazone--PA451799'),('rs6759892','GT','valproic acid--PA451846'),('rs1045642','AG','anthracyclines and related substances--PA130620651'),('rs1045642','AG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','AG','capecitabine--PA448771'),('rs1045642','AG','carbamazepine--PA448785'),('rs1045642','AG','cisplatin--PA449014'),('rs1045642','AG','cyclosporine--PA449167'),('rs1045642','AG','cytarabine--PA449177'),('rs1045642','AG','doxorubicin--PA449412'),('rs1045642','AG','epirubicin--PA449476'),('rs1045642','AG','fexofenadine--PA449621'),('rs1045642','AG','fluorouracil--PA128406956'),('rs11045819','AC','fluvastatin--PA449688'),('rs7297610','CT','hydrochlorothiazide--PA449899'),('rs1045642','AG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs1045642','AG','methotrexate--PA450428'),('rs4888024','GG','methotrexate--PA450428'),('rs2368564','CT','muraglitazar--PA162356187'),('rs1045642','AG','nortriptyline--PA450657'),('rs4731426','CC','olanzapine--PA450688'),('rs6313','AA','olanzapine--PA450688'),('rs1045642','AG','phenytoin--PA450947'),('rs6313','AA','risperidone--PA451257'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs4253778','CG','Beta Blocking Agents--PA164712535'),('rs1934951','TT','Bisphosphonates--PA164712563'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs1045642','GG','fluorouracil--PA128406956'),('rs1045642','GG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs4888024','GG','methotrexate--PA450428'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs4731426','CC','olanzapine--PA450688'),('rs6313','AA','olanzapine--PA450688'),('rs1045642','GG','paclitaxel--PA450761'),('rs1934951','TT','pamidronate--PA450767'),('rs1045642','GG','phenytoin--PA450947'),('rs6313','AA','risperidone--PA451257'),('rs10811661','CT','troglitazone--PA451799'),('rs6759892','GG','valproic acid--PA451846'),('rs1045642','GG','vincristine--PA451879'),('rs1934951','TT','zoledronate--PA10235'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs9679162','TT','cisplatin--PA449014'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs9679162','TT','fluorouracil--PA128406956'),('rs1045642','GG','fluorouracil--PA128406956'),('rs11045819','AC','fluvastatin--PA449688'),('rs1045642','GG','idarubicin--PA449961'),('rs4888024','GG','methotrexate--PA450428'),('rs9679162','TT','mitoxantrone--PA450526'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs1045642','GG','paclitaxel--PA450761'),('rs275651','AA','perindopril--PA450877'),('rs1045642','GG','phenytoin--PA450947'),('rs1045642','GG','vincristine--PA451879'),('rs9263800','AA','allopurinol--PA448320'),('rs1045642','AG','anthracyclines and related substances--PA130620651'),('rs1045642','AG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','AG','capecitabine--PA448771'),('rs1045642','AG','carbamazepine--PA448785'),('rs1045642','AG','cisplatin--PA449014'),('rs1045642','AG','cyclosporine--PA449167'),('rs1045642','AG','cytarabine--PA449177'),('rs1045642','AG','doxorubicin--PA449412'),('rs1045642','AG','epirubicin--PA449476'),('rs1045642','AG','fexofenadine--PA449621'),('rs1045642','AG','fluorouracil--PA128406956'),('rs1045642','AG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs1045642','AG','methotrexate--PA450428'),('rs4888024','AG','methotrexate--PA450428'),('rs1045642','AG','nortriptyline--PA450657'),('rs4731426','CG','olanzapine--PA450688'),('rs275651','AT','perindopril--PA450877'),('rs1045642','AG','phenytoin--PA450947'),('rs10811661','CT','troglitazone--PA451799'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs1045642','GG','fluorouracil--PA128406956'),('rs1045642','GG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs4888024','AG','methotrexate--PA450428'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs4731426','CG','olanzapine--PA450688'),('rs1045642','GG','paclitaxel--PA450761'),('rs275651','AT','perindopril--PA450877'),('rs1045642','GG','phenytoin--PA450947'),('rs6759892','GG','valproic acid--PA451846'),('rs1045642','GG','vincristine--PA451879'),('rs9263800','AA','allopurinol--PA448320'),('rs1045642','AG','anthracyclines and related substances--PA130620651'),('rs1045642','AG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','AG','capecitabine--PA448771'),('rs1045642','AG','carbamazepine--PA448785'),('rs1045642','AG','cisplatin--PA449014'),('rs1045642','AG','cyclosporine--PA449167'),('rs1045642','AG','cytarabine--PA449177'),('rs1045642','AG','doxorubicin--PA449412'),('rs1045642','AG','epirubicin--PA449476'),('rs1045642','AG','fexofenadine--PA449621'),('rs1045642','AG','fluorouracil--PA128406956'),('rs1045642','AG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs1045642','AG','methotrexate--PA450428'),('rs4888024','GG','methotrexate--PA450428'),('rs1045642','AG','nortriptyline--PA450657'),('rs4731426','CG','olanzapine--PA450688'),('rs275651','AT','perindopril--PA450877'),('rs1045642','AG','phenytoin--PA450947'),('rs10811661','CT','troglitazone--PA451799'),('rs9263800','AG','allopurinol--PA448320'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1934951','CT','Bisphosphonates--PA164712563'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs1805087','GG','cisplatin--PA449014'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs1045642','GG','fluorouracil--PA128406956'),('rs11045819','AC','fluvastatin--PA449688'),('rs1045642','GG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs1805087','GG','methotrexate--PA450428'),('rs4888024','GG','methotrexate--PA450428'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs4731426','CG','olanzapine--PA450688'),('rs6313','AG','olanzapine--PA450688'),('rs1045642','GG','paclitaxel--PA450761'),('rs275651','AA','perindopril--PA450877'),('rs1045642','GG','phenytoin--PA450947'),('rs6313','AG','risperidone--PA451257'),('rs6759892','GT','valproic acid--PA451846'),('rs1045642','GG','vincristine--PA451879'),('rs9263800','AG','allopurinol--PA448320'),('rs1045642','AG','anthracyclines and related substances--PA130620651'),('rs1045642','AG','antiepileptics--PA143485705'),('rs688','TT','atenolol--PA448499'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1934951','CT','Bisphosphonates--PA164712563'),('rs1045642','AG','capecitabine--PA448771'),('rs1045642','AG','carbamazepine--PA448785'),('rs1045642','AG','cisplatin--PA449014'),('rs1045642','AG','cyclosporine--PA449167'),('rs1045642','AG','cytarabine--PA449177'),('rs1045642','AG','doxorubicin--PA449412'),('rs1045642','AG','epirubicin--PA449476'),('rs1045642','AG','fexofenadine--PA449621'),('rs1045642','AG','fluorouracil--PA128406956'),('rs1045642','AG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs1045642','AG','methotrexate--PA450428'),('rs4888024','AG','methotrexate--PA450428'),('rs2368564','CT','muraglitazar--PA162356187'),('rs1045642','AG','nortriptyline--PA450657'),('rs4731426','CC','olanzapine--PA450688'),('rs6313','AG','olanzapine--PA450688'),('rs275651','AT','perindopril--PA450877'),('rs1045642','AG','phenytoin--PA450947'),('rs6313','AG','risperidone--PA451257'),('rs6759892','GT','valproic acid--PA451846'),('rs688','TT','atenolol--PA448499'),('rs4253778','CG','Beta Blocking Agents--PA164712535'),('rs4933824','GG','iloperidone--PA161199368'),('rs4888024','AG','methotrexate--PA450428'),('rs2368564','CT','muraglitazar--PA162356187'),('rs4731426','CC','olanzapine--PA450688'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs2368564','CT','muraglitazar--PA162356187'),('rs6313','AA','olanzapine--PA450688'),('rs6313','AA','risperidone--PA451257'),('rs1045642','AG','anthracyclines and related substances--PA130620651'),('rs1045642','AG','antiepileptics--PA143485705'),('rs4253778','CG','Beta Blocking Agents--PA164712535'),('rs1045642','AG','capecitabine--PA448771'),('rs1045642','AG','carbamazepine--PA448785'),('rs1045642','AG','cisplatin--PA449014'),('rs1045642','AG','cyclosporine--PA449167'),('rs1045642','AG','cytarabine--PA449177'),('rs1045642','AG','doxorubicin--PA449412'),('rs1045642','AG','epirubicin--PA449476'),('rs1045642','AG','fexofenadine--PA449621'),('rs1045642','AG','fluorouracil--PA128406956'),('rs1045642','AG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs1045642','AG','methotrexate--PA450428'),('rs2368564','CT','muraglitazar--PA162356187'),('rs1045642','AG','nortriptyline--PA450657'),('rs4731426','CC','olanzapine--PA450688'),('rs12050217','AG','perindopril--PA450877'),('rs1045642','AG','phenytoin--PA450947'),('rs6759892','GG','valproic acid--PA451846'),('rs1045642','AG','anthracyclines and related substances--PA130620651'),('rs1045642','AG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','AG','capecitabine--PA448771'),('rs1045642','AG','carbamazepine--PA448785'),('rs1045642','AG','cisplatin--PA449014'),('rs1045642','AG','cyclosporine--PA449167'),('rs1045642','AG','cytarabine--PA449177'),('rs1045642','AG','doxorubicin--PA449412'),('rs1045642','AG','epirubicin--PA449476'),('rs1045642','AG','fexofenadine--PA449621'),('rs1045642','AG','fluorouracil--PA128406956'),('rs1045642','AG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs1045642','AG','methotrexate--PA450428'),('rs1045642','AG','nortriptyline--PA450657'),('rs4731426','CC','olanzapine--PA450688'),('rs12050217','GG','perindopril--PA450877'),('rs1045642','AG','phenytoin--PA450947'),('rs6759892','GT','valproic acid--PA451846'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1934951','CT','Bisphosphonates--PA164712563'),('rs7297610','CT','hydrochlorothiazide--PA449899'),('rs4933824','GG','iloperidone--PA161199368'),('rs4888024','GG','methotrexate--PA450428'),('rs2368564','TT','muraglitazar--PA162356187'),('rs6313','AA','olanzapine--PA450688'),('rs12050217','AG','perindopril--PA450877'),('rs6313','AA','risperidone--PA451257'),('rs10811661','CC','troglitazone--PA451799'),('rs9263800','AG','allopurinol--PA448320'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs9679162','TT','cisplatin--PA449014'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs9679162','TT','fluorouracil--PA128406956'),('rs1045642','GG','fluorouracil--PA128406956'),('rs1045642','GG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs9679162','TT','mitoxantrone--PA450526'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs4731426','CC','olanzapine--PA450688'),('rs6313','AA','olanzapine--PA450688'),('rs1045642','GG','paclitaxel--PA450761'),('rs1045642','GG','phenytoin--PA450947'),('rs6313','AA','risperidone--PA451257'),('rs1045642','GG','vincristine--PA451879'),('rs1045642','AG','anthracyclines and related substances--PA130620651'),('rs1045642','AG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','AG','capecitabine--PA448771'),('rs1045642','AG','carbamazepine--PA448785'),('rs1045642','AG','cisplatin--PA449014'),('rs1045642','AG','cyclosporine--PA449167'),('rs1045642','AG','cytarabine--PA449177'),('rs1045642','AG','doxorubicin--PA449412'),('rs1045642','AG','epirubicin--PA449476'),('rs1045642','AG','fexofenadine--PA449621'),('rs1045642','AG','fluorouracil--PA128406956'),('rs1045642','AG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs1045642','AG','methotrexate--PA450428'),('rs1045642','AG','nortriptyline--PA450657'),('rs6313','AA','olanzapine--PA450688'),('rs1045642','AG','phenytoin--PA450947'),('rs6313','AA','risperidone--PA451257'),('rs6759892','GG','valproic acid--PA451846'),('rs1045642','AG','anthracyclines and related substances--PA130620651'),('rs1045642','AG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','AG','capecitabine--PA448771'),('rs1045642','AG','carbamazepine--PA448785'),('rs1045642','AG','cisplatin--PA449014'),('rs1045642','AG','cyclosporine--PA449167'),('rs1045642','AG','cytarabine--PA449177'),('rs1045642','AG','doxorubicin--PA449412'),('rs1045642','AG','epirubicin--PA449476'),('rs1045642','AG','fexofenadine--PA449621'),('rs1045642','AG','fluorouracil--PA128406956'),('rs11045819','AC','fluvastatin--PA449688'),('rs1045642','AG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs1045642','AG','methotrexate--PA450428'),('rs4888024','AG','methotrexate--PA450428'),('rs1045642','AG','nortriptyline--PA450657'),('rs4731426','CG','olanzapine--PA450688'),('rs6313','AG','olanzapine--PA450688'),('rs1045642','AG','phenytoin--PA450947'),('rs6313','AG','risperidone--PA451257'),('rs10811661','CC','troglitazone--PA451799'),('rs6759892','GG','valproic acid--PA451846'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs4253778','CG','Beta Blocking Agents--PA164712535'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs1805087','GG','cisplatin--PA449014'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs1045642','GG','fluorouracil--PA128406956'),('rs7297610','CT','hydrochlorothiazide--PA449899'),('rs1045642','GG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs1805087','GG','methotrexate--PA450428'),('rs4888024','GG','methotrexate--PA450428'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs6313','AA','olanzapine--PA450688'),('rs1045642','GG','paclitaxel--PA450761'),('rs1045642','GG','phenytoin--PA450947'),('rs6313','AA','risperidone--PA451257'),('rs1045642','GG','vincristine--PA451879'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs11045819','AC','fluvastatin--PA449688'),('rs7297610','CT','hydrochlorothiazide--PA449899'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs4731426','CC','olanzapine--PA450688'),('rs10811661','CT','troglitazone--PA451799'),('rs688','TT','atenolol--PA448499'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1934951','TT','Bisphosphonates--PA164712563'),('rs4933824','GG','iloperidone--PA161199368'),('rs4731426','CG','olanzapine--PA450688'),('rs1934951','TT','pamidronate--PA450767'),('rs6759892','GT','valproic acid--PA451846'),('rs1934951','TT','zoledronate--PA10235'),('rs9263800','AG','allopurinol--PA448320'),('rs1045642','AG','anthracyclines and related substances--PA130620651'),('rs1045642','AG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','AG','capecitabine--PA448771'),('rs1045642','AG','carbamazepine--PA448785'),('rs1045642','AG','cisplatin--PA449014'),('rs1045642','AG','cyclosporine--PA449167'),('rs1045642','AG','cytarabine--PA449177'),('rs1045642','AG','doxorubicin--PA449412'),('rs1045642','AG','epirubicin--PA449476'),('rs1045642','AG','fexofenadine--PA449621'),('rs1045642','AG','fluorouracil--PA128406956'),('rs1045642','AG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs1045642','AG','methotrexate--PA450428'),('rs4888024','GG','methotrexate--PA450428'),('rs1045642','AG','nortriptyline--PA450657'),('rs12050217','AG','perindopril--PA450877'),('rs1045642','AG','phenytoin--PA450947'),('rs6759892','GT','valproic acid--PA451846'),('rs1045642','AG','anthracyclines and related substances--PA130620651'),('rs1045642','AG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','AG','capecitabine--PA448771'),('rs1045642','AG','carbamazepine--PA448785'),('rs1045642','AG','cisplatin--PA449014'),('rs1045642','AG','cyclosporine--PA449167'),('rs1045642','AG','cytarabine--PA449177'),('rs1045642','AG','doxorubicin--PA449412'),('rs1045642','AG','epirubicin--PA449476'),('rs1045642','AG','fexofenadine--PA449621'),('rs1045642','AG','fluorouracil--PA128406956'),('rs7297610','CT','hydrochlorothiazide--PA449899'),('rs1045642','AG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs1045642','AG','methotrexate--PA450428'),('rs4888024','AG','methotrexate--PA450428'),('rs1045642','AG','nortriptyline--PA450657'),('rs4731426','CG','olanzapine--PA450688'),('rs6313','AG','olanzapine--PA450688'),('rs12050217','GG','perindopril--PA450877'),('rs275651','AT','perindopril--PA450877'),('rs1045642','AG','phenytoin--PA450947'),('rs6313','AG','risperidone--PA451257'),('rs6759892','GT','valproic acid--PA451846'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1934951','CT','Bisphosphonates--PA164712563'),('rs9679162','TT','cisplatin--PA449014'),('rs9679162','TT','fluorouracil--PA128406956'),('rs11045819','AA','fluvastatin--PA449688'),('rs4933824','GG','iloperidone--PA161199368'),('rs4888024','AG','methotrexate--PA450428'),('rs9679162','TT','mitoxantrone--PA450526'),('rs4731426','CC','olanzapine--PA450688'),('rs10811661','CC','troglitazone--PA451799'),('rs6759892','GT','valproic acid--PA451846'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs11045819','AC','fluvastatin--PA449688'),('rs4933824','GG','iloperidone--PA161199368'),('rs6313','AA','olanzapine--PA450688'),('rs6313','AA','risperidone--PA451257'),('rs10811661','CC','troglitazone--PA451799'),('rs6759892','GT','valproic acid--PA451846'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs11045819','AC','fluvastatin--PA449688'),('rs4933824','GG','iloperidone--PA161199368'),('rs6313','AA','olanzapine--PA450688'),('rs6313','AA','risperidone--PA451257'),('rs10811661','CC','troglitazone--PA451799'),('rs6759892','GT','valproic acid--PA451846'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs1805087','GG','cisplatin--PA449014'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs1045642','GG','fluorouracil--PA128406956'),('rs11045819','AC','fluvastatin--PA449688'),('rs1045642','GG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs1805087','GG','methotrexate--PA450428'),('rs4888024','AG','methotrexate--PA450428'),('rs2368564','TT','muraglitazar--PA162356187'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs4731426','CC','olanzapine--PA450688'),('rs6313','AA','olanzapine--PA450688'),('rs1045642','GG','paclitaxel--PA450761'),('rs12050217','AG','perindopril--PA450877'),('rs1045642','GG','phenytoin--PA450947'),('rs6313','AA','risperidone--PA451257'),('rs6759892','GT','valproic acid--PA451846'),('rs1045642','GG','vincristine--PA451879'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs4253778','CG','Beta Blocking Agents--PA164712535'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs1045642','GG','fluorouracil--PA128406956'),('rs1045642','GG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs4888024','AG','methotrexate--PA450428'),('rs2368564','TT','muraglitazar--PA162356187'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs1045642','GG','paclitaxel--PA450761'),('rs1045642','GG','phenytoin--PA450947'),('rs6759892','GG','valproic acid--PA451846'),('rs1045642','GG','vincristine--PA451879'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs4253778','CG','Beta Blocking Agents--PA164712535'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs1045642','GG','fluorouracil--PA128406956'),('rs11045819','AC','fluvastatin--PA449688'),('rs1045642','GG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs4888024','GG','methotrexate--PA450428'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs4731426','CG','olanzapine--PA450688'),('rs1045642','GG','paclitaxel--PA450761'),('rs275651','AT','perindopril--PA450877'),('rs1045642','GG','phenytoin--PA450947'),('rs10811661','CT','troglitazone--PA451799'),('rs6759892','GG','valproic acid--PA451846'),('rs1045642','GG','vincristine--PA451879'),('rs9263800','AG','allopurinol--PA448320'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs11045819','AC','fluvastatin--PA449688'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs4731426','CG','olanzapine--PA450688'),('rs12050217','AG','perindopril--PA450877'),('rs10811661','CC','troglitazone--PA451799'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs1045642','GG','fluorouracil--PA128406956'),('rs1045642','GG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs4888024','AG','methotrexate--PA450428'),('rs2368564','CT','muraglitazar--PA162356187'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs4731426','CC','olanzapine--PA450688'),('rs1045642','GG','paclitaxel--PA450761'),('rs1045642','GG','phenytoin--PA450947'),('rs10811661','CC','troglitazone--PA451799'),('rs1045642','GG','vincristine--PA451879'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs2368564','CT','muraglitazar--PA162356187'),('rs6313','AA','olanzapine--PA450688'),('rs6313','AA','risperidone--PA451257'),('rs1045642','AG','anthracyclines and related substances--PA130620651'),('rs1045642','AG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','AG','capecitabine--PA448771'),('rs1045642','AG','carbamazepine--PA448785'),('rs1045642','AG','cisplatin--PA449014'),('rs1045642','AG','cyclosporine--PA449167'),('rs1045642','AG','cytarabine--PA449177'),('rs1045642','AG','doxorubicin--PA449412'),('rs1045642','AG','epirubicin--PA449476'),('rs1045642','AG','fexofenadine--PA449621'),('rs1045642','AG','fluorouracil--PA128406956'),('rs1045642','AG','idarubicin--PA449961'),('rs622342','AA','metformin--PA450395'),('rs1045642','AG','methotrexate--PA450428'),('rs4888024','GG','methotrexate--PA450428'),('rs2368564','TT','muraglitazar--PA162356187'),('rs1045642','AG','nortriptyline--PA450657'),('rs4731426','CG','olanzapine--PA450688'),('rs12050217','AG','perindopril--PA450877'),('rs275651','AT','perindopril--PA450877'),('rs1045642','AG','phenytoin--PA450947'),('rs1045642','AG','anthracyclines and related substances--PA130620651'),('rs1045642','AG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','AG','capecitabine--PA448771'),('rs1045642','AG','carbamazepine--PA448785'),('rs1045642','AG','cisplatin--PA449014'),('rs1045642','AG','cyclosporine--PA449167'),('rs1045642','AG','cytarabine--PA449177'),('rs1045642','AG','doxorubicin--PA449412'),('rs1045642','AG','epirubicin--PA449476'),('rs1045642','AG','fexofenadine--PA449621'),('rs1045642','AG','fluorouracil--PA128406956'),('rs1045642','AG','idarubicin--PA449961'),('rs622342','AA','metformin--PA450395'),('rs1045642','AG','methotrexate--PA450428'),('rs4888024','GG','methotrexate--PA450428'),('rs2368564','TT','muraglitazar--PA162356187'),('rs1045642','AG','nortriptyline--PA450657'),('rs4731426','CG','olanzapine--PA450688'),('rs12050217','AG','perindopril--PA450877'),('rs275651','AT','perindopril--PA450877'),('rs1045642','AG','phenytoin--PA450947'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs9679162','TT','cisplatin--PA449014'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs9679162','TT','fluorouracil--PA128406956'),('rs1045642','GG','fluorouracil--PA128406956'),('rs11045819','AC','fluvastatin--PA449688'),('rs1045642','GG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs9679162','TT','mitoxantrone--PA450526'),('rs2368564','CT','muraglitazar--PA162356187'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs4731426','CC','olanzapine--PA450688'),('rs1045642','GG','paclitaxel--PA450761'),('rs1045642','GG','phenytoin--PA450947'),('rs6759892','GG','valproic acid--PA451846'),('rs1045642','GG','vincristine--PA451879'),('rs9263800','AG','allopurinol--PA448320'),('rs4933824','GG','iloperidone--PA161199368'),('rs4731426','CC','olanzapine--PA450688'),('rs10811661','CC','troglitazone--PA451799'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs2368564','CT','muraglitazar--PA162356187'),('rs4731426','CG','olanzapine--PA450688'),('rs6313','AA','olanzapine--PA450688'),('rs6313','AA','risperidone--PA451257'),('rs9263800','AG','allopurinol--PA448320'),('rs1045642','AG','anthracyclines and related substances--PA130620651'),('rs1045642','AG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','AG','capecitabine--PA448771'),('rs1045642','AG','carbamazepine--PA448785'),('rs1045642','AG','cisplatin--PA449014'),('rs1045642','AG','cyclosporine--PA449167'),('rs1045642','AG','cytarabine--PA449177'),('rs1045642','AG','doxorubicin--PA449412'),('rs1045642','AG','epirubicin--PA449476'),('rs1045642','AG','fexofenadine--PA449621'),('rs1045642','AG','fluorouracil--PA128406956'),('rs1045642','AG','idarubicin--PA449961'),('rs622342','AA','metformin--PA450395'),('rs1045642','AG','methotrexate--PA450428'),('rs4888024','AG','methotrexate--PA450428'),('rs1045642','AG','nortriptyline--PA450657'),('rs4731426','CC','olanzapine--PA450688'),('rs275651','AT','perindopril--PA450877'),('rs1045642','AG','phenytoin--PA450947'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs11045819','AA','fluvastatin--PA449688'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs2368564','TT','muraglitazar--PA162356187'),('rs4731426','CC','olanzapine--PA450688'),('rs6313','AA','olanzapine--PA450688'),('rs6313','AA','risperidone--PA451257'),('rs6759892','GT','valproic acid--PA451846'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs9679162','TT','cisplatin--PA449014'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs9679162','TT','fluorouracil--PA128406956'),('rs1045642','GG','fluorouracil--PA128406956'),('rs1045642','GG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs4888024','AG','methotrexate--PA450428'),('rs9679162','TT','mitoxantrone--PA450526'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs1045642','GG','paclitaxel--PA450761'),('rs1045642','GG','phenytoin--PA450947'),('rs6759892','GG','valproic acid--PA451846'),('rs1045642','GG','vincristine--PA451879'),('rs9263800','AA','allopurinol--PA448320'),('rs1045642','AG','anthracyclines and related substances--PA130620651'),('rs1045642','AG','antiepileptics--PA143485705'),('rs688','TT','atenolol--PA448499'),('rs1045642','AG','capecitabine--PA448771'),('rs1045642','AG','carbamazepine--PA448785'),('rs9679162','TT','cisplatin--PA449014'),('rs1045642','AG','cisplatin--PA449014'),('rs1045642','AG','cyclosporine--PA449167'),('rs1045642','AG','cytarabine--PA449177'),('rs1045642','AG','doxorubicin--PA449412'),('rs1045642','AG','epirubicin--PA449476'),('rs1045642','AG','fexofenadine--PA449621'),('rs9679162','TT','fluorouracil--PA128406956'),('rs1045642','AG','fluorouracil--PA128406956'),('rs1045642','AG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs1045642','AG','methotrexate--PA450428'),('rs4888024','AG','methotrexate--PA450428'),('rs9679162','TT','mitoxantrone--PA450526'),('rs1045642','AG','nortriptyline--PA450657'),('rs4731426','CC','olanzapine--PA450688'),('rs1045642','AG','phenytoin--PA450947'),('rs6759892','GG','valproic acid--PA451846'),('rs9263800','AA','allopurinol--PA448320'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs1045642','GG','fluorouracil--PA128406956'),('rs1045642','GG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs2368564','CT','muraglitazar--PA162356187'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs4731426','CC','olanzapine--PA450688'),('rs6313','AA','olanzapine--PA450688'),('rs1045642','GG','paclitaxel--PA450761'),('rs275651','AA','perindopril--PA450877'),('rs1045642','GG','phenytoin--PA450947'),('rs6313','AA','risperidone--PA451257'),('rs1045642','GG','vincristine--PA451879'),('rs9263800','AA','allopurinol--PA448320'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs11045819','AC','fluvastatin--PA449688'),('rs4933824','GG','iloperidone--PA161199368'),('rs4888024','AG','methotrexate--PA450428'),('rs2368564','TT','muraglitazar--PA162356187'),('rs4731426','CC','olanzapine--PA450688'),('rs6313','AG','olanzapine--PA450688'),('rs275651','AA','perindopril--PA450877'),('rs6313','AG','risperidone--PA451257'),('rs10811661','CC','troglitazone--PA451799'),('rs6759892','GG','valproic acid--PA451846'),('rs9263800','AG','allopurinol--PA448320'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1805087','GG','cisplatin--PA449014'),('rs11045819','AC','fluvastatin--PA449688'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs1805087','GG','methotrexate--PA450428'),('rs4731426','CC','olanzapine--PA450688'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs1045642','GG','fluorouracil--PA128406956'),('rs1045642','GG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs2368564','TT','muraglitazar--PA162356187'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs4731426','CC','olanzapine--PA450688'),('rs6313','AA','olanzapine--PA450688'),('rs1045642','GG','paclitaxel--PA450761'),('rs12050217','GG','perindopril--PA450877'),('rs1045642','GG','phenytoin--PA450947'),('rs6313','AA','risperidone--PA451257'),('rs1045642','GG','vincristine--PA451879'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs9679162','TT','cisplatin--PA449014'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs9679162','TT','fluorouracil--PA128406956'),('rs1045642','GG','fluorouracil--PA128406956'),('rs11045819','AC','fluvastatin--PA449688'),('rs1045642','GG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs4888024','GG','methotrexate--PA450428'),('rs9679162','TT','mitoxantrone--PA450526'),('rs2368564','CT','muraglitazar--PA162356187'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs4731426','CG','olanzapine--PA450688'),('rs6313','AG','olanzapine--PA450688'),('rs1045642','GG','paclitaxel--PA450761'),('rs12050217','AG','perindopril--PA450877'),('rs275651','AT','perindopril--PA450877'),('rs1045642','GG','phenytoin--PA450947'),('rs6313','AG','risperidone--PA451257'),('rs6759892','GG','valproic acid--PA451846'),('rs1045642','GG','vincristine--PA451879'),('rs1045642','AG','anthracyclines and related substances--PA130620651'),('rs1045642','AG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1045642','AG','capecitabine--PA448771'),('rs1045642','AG','carbamazepine--PA448785'),('rs1045642','AG','cisplatin--PA449014'),('rs1045642','AG','cyclosporine--PA449167'),('rs1045642','AG','cytarabine--PA449177'),('rs1045642','AG','doxorubicin--PA449412'),('rs1045642','AG','epirubicin--PA449476'),('rs1045642','AG','fexofenadine--PA449621'),('rs1045642','AG','fluorouracil--PA128406956'),('rs1045642','AG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs1045642','AG','methotrexate--PA450428'),('rs4888024','AG','methotrexate--PA450428'),('rs1045642','AG','nortriptyline--PA450657'),('rs4731426','CG','olanzapine--PA450688'),('rs1045642','AG','phenytoin--PA450947'),('rs6759892','GT','valproic acid--PA451846'),('rs9263800','AG','allopurinol--PA448320'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs4933824','GG','iloperidone--PA161199368'),('rs4888024','GG','methotrexate--PA450428'),('rs2368564','CT','muraglitazar--PA162356187'),('rs4731426','CG','olanzapine--PA450688'),('rs6313','AA','olanzapine--PA450688'),('rs12050217','GG','perindopril--PA450877'),('rs6313','AA','risperidone--PA451257'),('rs10811661','CT','troglitazone--PA451799'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs4253778','CC','Beta Blocking Agents--PA164712535'),('rs1934951','CT','Bisphosphonates--PA164712563'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs1045642','GG','fluorouracil--PA128406956'),('rs1045642','GG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs4888024','GG','methotrexate--PA450428'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs4731426','CC','olanzapine--PA450688'),('rs6313','AG','olanzapine--PA450688'),('rs1045642','GG','paclitaxel--PA450761'),('rs1045642','GG','phenytoin--PA450947'),('rs6313','AG','risperidone--PA451257'),('rs6759892','GT','valproic acid--PA451846'),('rs1045642','GG','vincristine--PA451879'),('rs1045642','GG','anthracyclines and related substances--PA130620651'),('rs1045642','GG','antiepileptics--PA143485705'),('rs1934951','TT','Bisphosphonates--PA164712563'),('rs1045642','GG','capecitabine--PA448771'),('rs1045642','GG','carbamazepine--PA448785'),('rs1805087','GG','cisplatin--PA449014'),('rs1045642','GG','cisplatin--PA449014'),('rs1045642','GG','clopidogrel--PA449053'),('rs1045642','GG','cyclosporine--PA449167'),('rs1045642','GG','cytarabine--PA449177'),('rs1045642','GG','dexamethasone--PA449247'),('rs1045642','GG','doxorubicin--PA449412'),('rs1045642','GG','efavirenz--PA449441'),('rs1045642','GG','epirubicin--PA449476'),('rs1045642','GG','fexofenadine--PA449621'),('rs1045642','GG','fluorouracil--PA128406956'),('rs11045819','AC','fluvastatin--PA449688'),('rs1045642','GG','idarubicin--PA449961'),('rs4933824','GG','iloperidone--PA161199368'),('rs622342','AA','metformin--PA450395'),('rs1805087','GG','methotrexate--PA450428'),('rs2368564','TT','muraglitazar--PA162356187'),('rs1045642','GG','nelfinavir--PA450606'),('rs1045642','GG','nevirapine--PA450616'),('rs1045642','GG','nortriptyline--PA450657'),('rs4731426','CG','olanzapine--PA450688'),('rs6313','AA','olanzapine--PA450688'),('rs1045642','GG','paclitaxel--PA450761'),('rs1934951','TT','pamidronate--PA450767'),('rs1045642','GG','phenytoin--PA450947'),('rs6313','AA','risperidone--PA451257'),('rs1045642','GG','vincristine--PA451879'),('rs1934951','TT','zoledronate--PA10235');
/*!40000 ALTER TABLE `copy_of_statistics_report` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `drug_hyperlink`
--

DROP TABLE IF EXISTS `drug_hyperlink`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `drug_hyperlink` (
  `Accession_Id` varchar(20) DEFAULT NULL,
  `Name` varchar(150) DEFAULT NULL,
  `Generic_Names` varchar(150) DEFAULT NULL,
  `Type` varchar(50) DEFAULT NULL,
  `Cross_references` text,
  `Smoles` text,
  `External_Vocabulary` text
) ENGINE=MyISAM DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `drug_hyperlink`
--

LOCK TABLES `drug_hyperlink` WRITE;
/*!40000 ALTER TABLE `drug_hyperlink` DISABLE KEYS */;
INSERT INTO `drug_hyperlink` VALUES ('PharmGKB Accession I','Name','Generic Names','Trade Names','Type','Cross-references','SMILES'),('PA1000','phenformin','Beta-Pebg,Beta-Phenethybiguanide,Beta-Phenethylbiguanide,Fenformin,Fenformina [INN-Spanish],N-Phenethylbiguanide Hydrochloride,PEDG,Phenethylbiguanide','Azucaps,Cronoformin,D Bretard,DB Comb,DB-Retard,DB','Drug/Small Molecule','TTD:DAP000206,bindingDb:50240908,chemSpider:7953,drugBank:DB00914,keggCompound:C07673,pubChemCompound:8249,pubChemSubstance:151385,pubChemSubstance:46505230,url:http://en.wikipedia.org/wiki/Phenformin','c1ccc(cc1)CCNC(=N)NC(=N)N'),('PA10004','adalimumab','Ig gamma-1 chain C region','Humira,Humira Pen','Drug/Small Molecule','DailyMed:608d4f0d-b19f-46d3-749a-7159aa5f933d,TTD:DAP000392,dpd:2258595,drugBank:DB00051,genBank:J00228,ndc:0074-3799-02,uniProtKb:P01857,url:http://en.wikipedia.org/wiki/Adalimumab',''),('PA10005','adefovir dipivoxil','ADV,Adefovir,Adefovir pivoxil,Adefovirdipivoxl,GS-840,PMEA,adefovir dipivoxil,bis-POM PMEA','Hepsera,Preveon','Drug/Small Molecule','DailyMed:a60adac4-57c2-4089-aefc-1a77a48676fc,TTD:DNC001135,bindingDb:50038612,chemSpider:54855,drugBank:DB00718,keggDrug:D01655,ndc:61958-0501-1,pubChemCompound:60871,pubChemSubstance:46507520,pubChemSubstance:7848718,url:http://en.wikipedia.org/wiki/Adefovir',''),('PA10015','aminolevulinic acid','5-aminolevulinic acid,ALA,Aminolevulinate,delta-Aminolevulinic acid','Aladerm,Kerastick,Levulan,Levulan Kerastick','Drug/Small Molecule','DailyMed:e45cc371-9ebc-4904-12bc-65cb4e2817ad,DailyMed:l51b031a0-bc40-4159-a434-d48c3eadd2ca,TTD:DAP000314,chebi:17549,chemSpider:134,drugBank:DB00855,keggCompound:C00430,ndc:67308-101-01,pubChemCompound:137,pubChemSubstance:3719,pubChemSubstance:46506856,url:http://en.wikipedia.org/wiki/Aminolevulinic_acid','CC(=O)CC(C(=O)O)N'),('PA10026','aripiprazole','OPC 31,OPC-14597,aripiprazole','Abilify,Abilitat','Drug/Small Molecule','DailyMed:c040bd1d-45b7-49f2-93ea-aed7220b30ac,TTD:DAP000076,chebi:31236,chemSpider:54790,drugBank:DB01238,iupharLigand:34,keggCompound:C12564,keggDrug:D01164,ndc:59148-013-15,pubChemCompound:60795,pubChemSubstance:46505745,pubChemSubstance:582954,url:http://en.wikipedia.org/wiki/Aripiprazole','c1cc(c(c(c1)Cl)Cl)N2CCN(CC2)CCCCOc3ccc4c(c3)NC(=O)CC4'),('PA10032','bivalirudin','Angiomax,bivalirudin','Angiomax,Angiox','Drug/Small Molecule','DailyMed:911cd48f-01ea-4dec-b30c-95e7e0ea9d2a,TTD:DAP000542,dpd:2246533,drugBank:DB00006,ndc:65293-001-01,pubChemCompound:16129704,pubChemSubstance:214065,url:http://en.wikipedia.org/wiki/Bivalirudin','[H]/N=C(N)/NCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@@H]5CCCN5C(=O)[C@@H](CC6=CC=CC=C6)N'),('PA10034','bosentan','Bosentan hydrate,bosentan','Tracleer','Drug/Small Molecule','DailyMed:749e42fb-2fe0-45dd-9268-b43bb3f4081c,TTD:DNC000341,chebi:51450,chemSpider:94651,dpd:2244982,drugBank:DB00559,keggDrug:D01227,ndc:66215-101-06,pubChemCompound:104865,pubChemSubstance:46507154,pubChemSubstance:682323,url:http://en.wikipedia.org/wiki/Bosentan',''),('PA10035','bromazepam','7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiaxepin-2(1H)-one,7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiazepin-2(1H)-one,Bromazepamum [inn-latin]','Apo-Bromazepam,Calmepam,Compedium,Compendium,Creos','Drug/Small Molecule','TTD:DAP001035,chemSpider:2347,dpd:518123,drugBank:DB01558,keggDrug:D01245,pubChemCompound:2441,pubChemSubstance:10476910,pubChemSubstance:46505694,url:http://en.wikipedia.org/wiki/Bromazepam','c1ccnc(c1)C2=NCC(=O)Nc3c2cc(cc3)Br'),('PA10040','cetuximab','Anti EGFR,IMC-C225,cetuximab','Erbitux','Drug/Small Molecule','DailyMed:8bc6397e-4bd8-4d37-a007-a327e4da34d9,TTD:DNC000788,drugBank:DB00002,genBank:J00228,ndc:66733-948-23,url:http://en.wikipedia.org/wiki/Cetuximab',''),('PA10049','cyproterone','Cyproterone acetate','Androcur,Apo-cyproterone,CyPat,Gen-Cyproterone,Nov','','',''),('PA10054','dexmethylphenidate','D-methylphenidate,Ritadex','Focalin','Drug/Small Molecule','',''),('PA10066','duloxetine','(+-)-duloxetine,Duloxetine HCl,Duloxetine Hydrochloride','Cymbalta,Yentreve','Drug/Small Molecule','DailyMed:81a06b90-50d3-40c1-98ca-0e344c76b2c4,TTD:DAP000494,chebi:36795,chemSpider:54822,drugBank:DB00476,iupharLigand:202,keggDrug:D01179,ndc:54868-5215-2,pubChemCompound:60835,pubChemSubstance:46507937,pubChemSubstance:704934,url:http://en.wikipedia.org/wiki/Duloxetine','CNCC[C@@H](c1cccs1)Oc2cccc3c2cccc3'),('PA10068','electrolytes','','','Drug/Small Molecule','',''),('PA10069','emtricitabine','emtricitabine','Coviracil,Emtriva,Racivir','','',''),('PA10072','epoetin alfa','Epoetin,Erythropoietin precursor','Epogen,Epogin,Epomax,Eprex,NeoRecormon,Procrit,Rec','Drug/Small Molecule','DailyMed:1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5,TTD:DAP000202,dpd:2243403,drugBank:DB00016,genBank:X02158,ndc:55513-126-10,uniProtKb:P01588,url:http://en.wikipedia.org/wiki/Epoetin_alfa',''),('PA10074','escitalopram','Cipralex,Escitalopram Oxalate,escitalopram','Lexapro','Drug/Small Molecule','DailyMed:13bb8267-1cab-43e5-acae-55a4d957630a,TTD:DAP000741,chebi:36791,chemSpider:129277,dpd:2263238,drugBank:DB01175,ndc:0456-2005-01,pubChemCompound:146570,pubChemSubstance:46507040,pubChemSubstance:724297,url:http://en.wikipedia.org/wiki/Escitalopram','CN(C)CCC[C@@]1(c2ccc(cc2CO1)C#N)c3ccc(cc3)F'),('PA10075','esomeprazole','(-)-omeprazole,(s)-omeprazole,Esomeprazole Sodium,Esomperazole,esomeprazole','Axagon,Esopral,Lucen,Nexiam,Nexium,Nexium IV','Drug/Small Molecule','DailyMed:c325bbfc-46f3-471e-7bbc-ed0d6965d13b,TTD:DCL000524,chebi:50275,dpd:2244521,drugBank:DB00736,keggDrug:D01984,ndc:0186-6020-01,pubChemCompound:4594,pubChemSubstance:3865629,url:http://en.wikipedia.org/wiki/Esomeprazole','Cc1cnc(c(c1OC)C)C[S@](=O)c2[nH]c3ccc(cc3n2)OC'),('PA10079','fenoterol','Fenoterolum [inn-latin],Phenoterol','Berotec','','',''),('PA10084','fosamprenavir','','Lexiva,Telzir','Drug/Small Molecule','DailyMed:4f5d4370-4833-412b-8699-1c66a8abeb08,TTD:DAP000707,chemSpider:116245,dpd:2261545,drugBank:DB01319,ndc:0173-0721-00,pubChemCompound:131536,pubChemSubstance:10242897,pubChemSubstance:46504901,url:http://en.wikipedia.org/wiki/Fosamprenavir',''),('PA10088','gemifloxacin','Gemifloxacin mesilate,gemifloxacin mesylate','Factive','Drug/Small Molecule','DailyMed:a51dc88f-c298-402e-b204-618609a4721c,TTD:DAP000851,chebi:101853,drugBank:DB01155,keggDrug:D02471,ndc:67707-320-05,pubChemCompound:5464436,pubChemSubstance:610685,url:http://en.wikipedia.org/wiki/Gemifloxacin',''),('PA10090','l-glutamine','(s)-2,5-diamino-5-oxopentanoic acid,2-Aminoglutaramic acid,AES-14,Glutamine,L-glutamine,l-(+)-glutamine,l-2-aminoglutaramic acid,l-glutamic acid gamma','Cebrogen,Earthlink Science Glutamine Chews Chocola','Drug/Small Molecule','HET:GLN,chebi:18050,chebi:28300,chemSpider:5746,drugBank:DB00130,iupharLigand:723,keggCompound:C00064,keggDrug:D00015,pdb:GLN,pubChemCompound:5961,pubChemSubstance:46505866,pubChemSubstance:8143908,url:http://en.wikipedia.org/wiki/L-Glutamine',''),('PA10116','iobenguane (131i)','','','Drug/Small Molecule','',''),('PA10136','melarsoprol','','','Drug/Small Molecule','',''),('PA10140','miglustat','','Miglustat, Hydrochloride,Zavesca','Drug/Small Molecule','TTD:DAP000609,bindingDb:18355,chebi:50381,chemSpider:46764,dpd:2250519,drugBank:DB00419,pubChemCompound:51634,pubChemSubstance:189803,pubChemSubstance:46506350,url:http://en.wikipedia.org/wiki/Miglustat',''),('PA10158','pipotiazine','Pipothiazine,Pipotiazina [inn-spanish],Pipotiazinum [inn-latin]','Piportil Depot,Piportil L4','Drug/Small Molecule','chemSpider:56598,dpd:1926667,drugBank:DB01621,keggDrug:D08385,pubChemCompound:62867,pubChemSubstance:14883233,pubChemSubstance:46508263','CN(C)S(=O)(=O)c1ccc2c(c1)N(c3ccccc3S2)CCCN4CCC(CC4)CCO'),('PA10159','pirenzepine','','Bisvanil,Gasteril,Gastrozepin,Leblon,Pirenzepin,Pi','Drug/Small Molecule','TTD:DAP000492,chebi:8247,chemSpider:4682,dpd:608998,drugBank:DB00670,iupharLigand:328,keggCompound:C07508,pubChemCompound:4848,pubChemSubstance:46509029,pubChemSubstance:9711,url:http://en.wikipedia.org/wiki/Pirenzepine',''),('PA10162','podophyllum','','Podocon-25,Podofin','Drug/Small Molecule','',''),('PA10176','rasburicase','Urate oxidase,Uricase,rasburicase','Elitek,Fasturtec','Drug/Small Molecule','DailyMed:0ae10bc4-6b65-402f-9db5-2d7753054922,dpd:2248416,drugBank:DB00049,genBank:X61766,ndc:0024-5150-10,uniProtKb:Q00511,url:http://en.wikipedia.org/wiki/Rasburicase',''),('PA10196','technetium (99mtc) mertiatide','','','Drug/Small Molecule','',''),('PA10202','telithromycin','telithromycin','Ketek','Drug/Small Molecule','DailyMed:4471223e-9023-457e-be2e-8e4e0c2d94d1,HET:TEL,TTD:DAP000109,dpd:2247520,drugBank:DB00976,keggCompound:C12009,keggDrug:D01078,ndc:0088-2225-41,pdb:TEL,pubChemCompound:5462516,pubChemSubstance:14168,url:http://en.wikipedia.org/wiki/Telithromycin',''),('PA10204','tenofovir','D,L-Tenofovir,PMPA,TDF,Tenofovir disoproxil,Tenofovir disoproxil fumarate','Apropovir,Viread','','',''),('PA10209','thioacetazone and isoniazid','','','Drug/Small Molecule','',''),('PA10211','thyrotropin','','','Drug Class','',''),('PA10226','valdecoxib','valdecoxib','Bextra','Drug/Small Molecule','DailyMed:caf64301-262c-45ca-acd1-a9d6696c584e,bindingDb:13063,chemSpider:106796,dpd:2246622,drugBank:DB00580,ndc:0025-1975-31,pdb:COX,pubChemCompound:119607,pubChemSubstance:46506229,pubChemSubstance:696308,url:http://en.wikipedia.org/wiki/Valdecoxib','Cc1c(c(no1)c2ccccc2)c3ccc(cc3)S(=O)(=O)N'),('PA10227','valganciclovir','Cymeval,L-valine, ester with ganciclovir,valganciclovir','Valcyt,Valcyte','Drug/Small Molecule','DailyMed:dc548ff9-e8ea-4d6e-b9b4-e31f53ac4078,TTD:DAP000646,chemSpider:57721,dpd:2245777,drugBank:DB01610,ndc:0004-0038-22,pubChemCompound:64147,pubChemSubstance:11068227,pubChemSubstance:46505524,url:http://en.wikipedia.org/wiki/Valganciclovir','CC(C)[C@@H](C(=O)OCC(CO)OCn1cnc2c1nc([nH]c2=O)N)N'),('PA10229','vardenafil','VDN','Levitra','Drug/Small Molecule','DailyMed:80971965-5c77-4950-b65d-7996b802d2cd,TTD:DAP000414,bindingDb:14776,chemSpider:99300,dpd:2250462,drugBank:DB00862,ndc:0085-1923-01,pubChemCompound:110634,pubChemSubstance:46506777,pubChemSubstance:687902,url:http://en.wikipedia.org/wiki/Vardenafil',''),('PA10231','vigabatrin','','4-Amino-5-hexenoic acid,4-Aminohexenoic acid,GVG,S','Drug/Small Molecule','DailyMed:a88ac1b4-e2c9-45c0-b321-4785902172e3,TTD:DAP000557,bindingDb:50118886,chemSpider:5463,dpd:2068036,drugBank:DB01080,keggCompound:C07500,keggDrug:D00535,ndc:67386-211-65,pubChemCompound:5665,pubChemSubstance:183802,pubChemSubstance:46507052,url:http://en.wikipedia.org/wiki/Vigabatrin','C=CC(CCC(=O)O)N'),('PA10232','vindesine','Desacetylvinblastine Amide Sulfate,Vindesine Sulfate','DAVA,Eldesine,Eldisine','Drug/Small Molecule','TTD:DAP000949,chebi:36373,chemSpider:37302,dpd:555665,drugBank:DB00309,keggDrug:D01769,pubChemCompound:40839,pubChemSubstance:181645,pubChemSubstance:46504548,url:http://en.wikipedia.org/wiki/Vindesine',''),('PA10233','voriconazole','VCZ,voriconazole','Vfend','Drug/Small Molecule','DailyMed:ce3ef5cf-3087-4d92-9d94-9eb8287228db,TTD:DAP001271,chebi:10023,chemSpider:64684,dpd:2256460,drugBank:DB00582,keggCompound:C07622,keggDrug:D00578,ndc:0049-3190-28,pubChemCompound:71616,pubChemSubstance:213886,pubChemSubstance:46506421,url:http://en.wikipedia.org/wiki/Voriconazole','C[C@@H](c1c(cncn1)F)[C@](Cn2cncn2)(c3ccc(cc3F)F)O'),('PA10235','zoledronate','ZOL,Zoledronic acid','Aclasta,Reclast,Zometa,Zometa Concentrate','Drug/Small Molecule','DailyMed:f0cdfa57-95e5-416b-bc2f-cde2491c2fd0,HET:ZOL,TTD:DAP001539,bindingDb:12578,chemSpider:61986,dpd:2242725,drugBank:DB00399,keggDrug:D01968,ndc:0078-0387-25,pdb:ZOL,pubChemCompound:68740,pubChemSubstance:46507310,pubChemSubstance:536160,url:http://en.wikipedia.org/wiki/Zoledronate',''),('PA10236','zopiclone','(+-)-zopiclone,Zopiclona [INN-Spanish],Zopiclone [Ban:Inn:Jan],Zopiclonum [INN-Latin]','Amoban,Amovane,Imovance,Imovane,Novo-zopiclone,Nu-','Drug/Small Molecule','TTD:DAP000427,bindingDb:50054136,chebi:32315,chemSpider:5533,dpd:2257580,drugBank:DB01198,keggDrug:D01372,pubChemCompound:5735,pubChemSubstance:46505233,url:http://en.wikipedia.org/wiki/Zopiclone','CN1CCN(CC1)C(=O)OC2c3c(nccn3)C(=O)N2c4ccc(cn4)Cl'),('PA10238','pancreozymin (cholecystokinin)','','','Drug/Small Molecule','',''),('PA10239','clodronate','clodronate','Acide Clodronique [INN-French],Acido Clodronico [I','Drug/Small Molecule','TTD:DAP000564,bindingDb:50216172,chebi:110423,chemSpider:23731,dpd:1984837,drugBank:DB00720,pubChemCompound:25419,pubChemSubstance:168153,pubChemSubstance:46508646,url:http://en.wikipedia.org/wiki/Clodronate',''),('PA10240','haemophilus b conjugate vaccine (prp-d-diphtheria toxoid conjugate)','','Prohibit','Drug/Small Molecule','',''),('PA10242','nitrazepam','1, 3-Dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one,1,3-Dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one,2,3-Dihydro-7-nitro-5-phenyl-1H-1,4-b','Alodorm,Apo-nitrazepam tablets BP,Apodorm,Atempol,','Drug/Small Molecule','TTD:DAP000691,bindingDb:50020856,chemSpider:4350,dpd:511528,drugBank:DB01595,keggCompound:C07487,keggDrug:D00531,pubChemCompound:4506,pubChemSubstance:10470563,pubChemSubstance:46505806,url:http://en.wikipedia.org/wiki/Nitrazepam','c1ccc(cc1)C2=NCC(=O)Nc3c2cc(cc3)N(=O)=O'),('PA10246','almotriptan','almotriptan','Almogran,Axert','Drug/Small Molecule','DailyMed:b13ba9bf-1661-456a-8eae-6d110ea08c94,TTD:DAP001345,chebi:520985,chemSpider:110198,dpd:2248128,drugBank:DB00918,ndc:0062-2080-06,pubChemCompound:123606,pubChemSubstance:46505165,pubChemSubstance:700325,url:http://en.wikipedia.org/wiki/Almotriptan','CN(C)CCc1c[nH]c2c1cc(cc2)CS(=O)(=O)N3CCCC3'),('PA10247','aminobenzoic acid','','','Drug/Small Molecule','','c1ccc(c(c1)C(=O)O)N'),('PA10251','atazanavir','ATV,ATZ,Atazanavir sulfate,BMS-232632,atazanavir','Latazanavir,Reyataz,Zrivada','Drug/Small Molecule','TTD:DNC000332,bindingDb:13934,chebi:37924,chemSpider:130642,dpd:2248610,drugBank:DB01072,keggDrug:D01276,pubChemCompound:148192,pubChemSubstance:46508504,pubChemSubstance:725881,url:http://en.wikipedia.org/wiki/Atazanavir',''),('PA10252','bortezomib','bortezomib','Velcade','Drug/Small Molecule','DailyMed:1521d321-e724-4ffc-adad-34bf4f44fac7,TTD:DAP001318,chebi:52717,dpd:2262452,drugBank:DB00188,ndc:63020-049-01,pubChemCompound:93860,pubChemSubstance:670916,url:http://en.wikipedia.org/wiki/Bortezomib',''),('PA10253','buserelin','','Cinnafact,Suprefact','Drug/Small Molecule','',''),('PA10268','flupenthixol','Flupenthixole','Depixol,Emergil,Fluanxol,Fluanxol Depot,Flupentixo','Drug/Small Molecule','TTD:DAP000026,chebi:5121,dpd:2156016,drugBank:DB00875,keggDrug:D01044,pubChemCompound:17012,url:http://en.wikipedia.org/wiki/Flupenthixol',''),('PA10270','ibandronate','Ibandronate sodium,Ibandronate sodium monohydrate,Ibandronic Acid,R484,ibandronate','Bondronat,Boniva,Bonviva','Drug/Small Molecule','HET:BFQ,TTD:DAP001022,bindingDb:12577,chemSpider:54839,dpd:2232770,drugBank:DB00710,ndc:0004-0185-23,pdb:BFQ,pubChemCompound:60852,pubChemSubstance:214304,pubChemSubstance:46508134,url:http://en.wikipedia.org/wiki/Ibandronate',''),('PA10284','oxprenolol','(+)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol,(+-)-oxprenolol,(1)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol,1-(Isopropylamino)','Coretal,Laracor,Slow-pren,Trasacor,Trasicor','Drug/Small Molecule','TTD:DAP000485,bindingDb:50240370,chemSpider:4470,dpd:402575,drugBank:DB01580,pubChemCompound:4631,pubChemSubstance:10354504,pubChemSubstance:46508996,url:http://en.wikipedia.org/wiki/Oxprenolol','CC(C)NCC(COc1ccccc1OCC=C)O'),('PA10292','suramin','Bayer 205,SVR,Sodium suramin,Suramin sodium,Suramine,Suramine sodium','Antrypol,Belganyl,Farma,Fourneau,Germanin,Moranyl,','Drug/Small Molecule','HET:SVR,TTD:DAP001031,chebi:45906,chemSpider:5168,drugBank:DB04786,iupharLigand:1728,keggCompound:C07974,pdb:SVR,pubChemCompound:5361,pubChemSubstance:46507013,pubChemSubstance:7890636,url:http://en.wikipedia.org/wiki/Suramin',''),('PA10305','lanthanum carbonate','','','Drug/Small Molecule','','C(=O)([O-])[O-].[La]'),('PA10308','alpha-1-proteinase inhibitor','Alpha 1-antitrypsin,Alpha-1 protease inhibitor,Alpha-1-antiproteinase,Alpha-1-antitrypsin precursor','Aralast,Prolastin','Drug/Small Molecule','DailyMed:f7f84d2a-d740-4414-9bfe-fccee9e73da0,TTD:DAP001102,dpd:2204606,drugBank:DB00058,genBank:K01396,ndc:0944-2802-01,uniProtKb:P01009,url:http://en.wikipedia.org/wiki/Alpha_1-antitrypsin',''),('PA10309','amsacrine','Acridinyl Anisidide,M-AMSA,MAMSA','AMSA P-D,Amsidine,Amsidyl,Amsine','Drug/Small Molecule','TTD:DAP000046,chebi:2687,chemSpider:2094,dpd:582212,drugBank:DB00276,keggCompound:C01553,keggDrug:D02321,pubChemCompound:2179,pubChemSubstance:46507539,pubChemSubstance:4711,url:http://en.wikipedia.org/wiki/Amsacrine',''),('PA10318','dornase alfa','DNase,DNase I,Deoxyribonuclease I,Deoxyribonuclease-1 precursor,Dornase alfa,rhDNase','Dilor,Dilor-400,Lufyllin,Lufyllin-400,Neothylline,','Drug/Small Molecule','TTD:DAP000981,dpd:2046733,drugBank:DB00003,genBank:M55983,uniProtKb:P24855,url:http://en.wikipedia.org/wiki/Dornase_alfa',''),('PA10323','l-tryptophan','(-)-Tryptophan,(S)-Tryptophan,(S)-a-Amino-1H-indole-3-propanoic acid,(S)-a-Amino-b-indolepropionic acid,(S)-a-Aminoindole-3-propionic acid,2-Amino-3-i','Alti-Tryptophan,Lyphan','Drug/Small Molecule','HET:TRP,TTD:DAP001316,bindingDb:21974,chebi:16828,chemSpider:6066,drugBank:DB00150,iupharLigand:717,keggCompound:C00078,keggDrug:D00020,pdb:TRP,pubChemCompound:6305,pubChemSubstance:46508329,pubChemSubstance:8144649',''),('PA10333','tadalafil','CIA,ICOS 351,Tadanafil,tadalafil','Cialis,Cialis/Tadalafil Hcl,Cialis/Taladafil','Drug/Small Molecule','DailyMed:bcd8f8ab-81a2-4891-83db-24a0b0e25895,HET:CIA,TTD:DAP000615,bindingDb:14777,chemSpider:99301,dpd:2248088,drugBank:DB00820,keggDrug:D02008,ndc:0002-4465-34,pdb:CIA,pubChemCompound:110635,pubChemSubstance:46507646,pubChemSubstance:687903,url:http://en.wikipedia.org/wiki/Tadalafil',''),('PA10335','technetium (99mtc) sulfur colloid','','','Drug/Small Molecule','',''),('PA10339','hemophilus influenzae b vaccines','','','Drug Class','',''),('PA10344','acamprosate','3-(Acetylamino)propanesulphonic acid,3-Acetamido-1-propanesulfonic acid,N-Acetylhomotaurine,acamprosate','Campral','Drug/Small Molecule','DailyMed:1c427b06-32d4-482f-bb83-71e386c1e203,TTD:DAP000857,chebi:51041,chemSpider:64300,drugBank:DB00659,keggDrug:D02780,ndc:0456-3330-01,pubChemCompound:71158,pubChemSubstance:213365,pubChemSubstance:46506657,url:http://en.wikipedia.org/wiki/Acamprosate',''),('PA10352','palonosetron','palonosetron','Aloxi,Onicit','Drug/Small Molecule','DailyMed:f4216772-6c37-4ff0-a575-f758390656e3,TTD:DAP000367,chemSpider:130656,drugBank:DB00377,ndc:58063-797-25,pubChemCompound:148211,pubChemSubstance:46508530,pubChemSubstance:725898,url:http://en.wikipedia.org/wiki/Palonosetron',''),('PA10364','memantine','DMAA,Memantina [INN-Spanish],Memantine HCL,Memantine Hydrochloride,Memantine [INN],Memantinum [INN-Latin],memantine','Ebixa,Namenda','Drug/Small Molecule','DailyMed:b9f27baf-aa2a-443a-9ef5-e002d23407ba,TTD:DAP000493,bindingDb:50062599,chemSpider:3914,dpd:2260638,drugBank:DB01043,keggCompound:C13736,ndc:0456-3205-60,pubChemCompound:4054,pubChemSubstance:46506702,pubChemSubstance:586325,url:http://en.wikipedia.org/wiki/Memantine','CC12CC3CC(C1)(CC(C3)(C2)N)C'),('PA10366','protamine','','','Drug/Small Molecule','',''),('PA10367','rabies immunoglobulin','','','Drug/Small Molecule','',''),('PA10373','calcium phosphate','','','Drug/Small Molecule','','[O-]P(=O)([O-])[O-].[Ca+2]'),('PA10381','androgens and estrogens','','','Drug Class','',''),('PA10384','antiinflammatory and antirheumatic products, non-steroids','','','Drug Class','',''),('PA10387','hydantoin derivatives','','','Drug Class','',''),('PA10389','non-selective monoamine reuptake inhibitors','','','Drug Class','',''),('PA10390','sulfonamides, urea derivatives','','','Drug Class','',''),('PA10393','antiglaucoma preparations and miotics','','','Drug Class','',''),('PA10402','benzodiazepine derivatives','','','Drug Class','',''),('PA10405','adrenergics, inhalants','','','Drug Class','',''),('PA10407','calcium channel blockers','','','Drug Class','',''),('PA10410','carbonic anhydrase inhibitors','','','Drug Class','',''),('PA10420','colony stimulating factors','','','Drug Class','',''),('PA10432','thiazide derivatives','','','Drug Class','',''),('PA10457','kaolin','','Kaopectate','Drug/Small Molecule','dpd:2233881,drugBank:DB01575,url:http://en.wikipedia.org/wiki/Kaolin',''),('PA10472','organic nitrates','','','Drug Class','',''),('PA10478','phenothiazines with aliphatic side-chain','','','Drug Class','',''),('PA10479','phosphates','','','Drug/Small Molecule','',''),('PA10481','pyrethrins and piperonyl butoxide','','A-200 Gel Concentrate,A-200 Shampoo Concentrate,Ba','Drug/Small Molecule','',''),('PA10489','selenium supplements','','','Drug/Small Molecule','',''),('PA10492','combinations of sulfonamides and trimethoprim, incl. derivatives','','','Drug Class','',''),('PA10499','thioxanthene derivatives','','','Drug Class','',''),('PA10500','thyroid hormones','','','Drug Class','',''),('PA10505','vitamin b-complex, plain','','','Drug Class','',''),('PA10715','sulfamethoxazole and trimethoprim','','','Drug/Small Molecule','','COc1cc(cc(c1OC)OC)Cc2cnc(nc2N)N.c1cnc(nc1)NS(=O)(=O)c2ccc(cc2)N'),('PA10733','androgens for topical use','','','Drug Class','',''),('PA10741','sulfonamides, plain','','','Drug Class','',''),('PA10772','sulfonamides','','','Drug Class','',''),('PA10799','anakinra','ICIL-1RA,IL-1RN,IL-1ra,IL1 inhibitor,IRAP,Interleukin-1 receptor antagonist protein precursor','Kineret','Drug/Small Molecule','TTD:DAP000095,dpd:2245913,drugBank:DB00026,genBank:M55646,keggDrug:D02934,uniProtKb:P18510,url:http://en.wikipedia.org/wiki/Anakinra',''),('PA10804','imatinib','Imatinib Mesylate,Imatinib Methansulfonate,sti-571','Gleevec,Glivec','Drug/Small Molecule','DailyMed:211ef2da-2868-4a77-8055-1cb2cd78e24b,HET:STI,TTD:DNC001383,bindingDb:13530,chebi:45783,chemSpider:5101,dpd:2253283,drugBank:DB00619,keggDrug:D01441,ndc:0078-0401-34,pdb:STI,pubChemCompound:5291,pubChemSubstance:46505055,pubChemSubstance:841977,url:http://en.wikipedia.org/wiki/Imatinib','Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C'),('PA10810','pemetrexed','LY231514,Pemetrexed Disodium','Alimta','Drug/Small Molecule','DailyMed:f5a860f3-37ec-429c-ae04-9c88d7c55c08,HET:LYA,TTD:DCL000320,chemSpider:54830,dpd:2253437,drugBank:DB00642,ndc:0002-7640-01,pdb:LYA,pubChemCompound:60843,pubChemSubstance:197081,pubChemSubstance:46505640,url:http://en.wikipedia.org/wiki/Pemetrexed',''),('PA10813','tinidazole','tinidazole','Fasigyn,Tindamax','Drug/Small Molecule','DailyMed:a0d01539-8413-4703-94cc-d221918630a1,chemSpider:5279,drugBank:DB00911,keggDrug:D01426,ndc:0178-8250-40,pubChemCompound:5479,pubChemSubstance:46506396,pubChemSubstance:7848489,url:http://en.wikipedia.org/wiki/Tinidazole','c1ccc2c(c1)[nH]c(n2)c3cscn3'),('PA10815','nadroparin','','','Drug/Small Molecule','',''),('PA10816','ezetimibe','SCH58235','Ezedoc,Ezetrol,Zetia','','',''),('PA10819','gamma hydroxybutyric acid','4-Hydroxy-butanoic acid,4-Hydroxybutyric acid,4-hydroxybutanoate,4-hydroxybutanoic acid,GHB,Juice,Liquid Ecstasy,Sodium oxybate,gamma-Hydroxybutyric a','Xyrem','Drug/Small Molecule','DailyMed:926eb076-a4a8-45e4-91ef-411f0aa4f3ca,TTD:DAP001522,chebi:16724,chemSpider:2300886,drugBank:DB01440,keggCompound:C00989,ndc:68727-100-01,pubChemCompound:3037032,pubChemSubstance:46507548,pubChemSubstance:8144929,url:http://en.wikipedia.org/wiki/Gamma-Hydroxybutyric_acid',''),('PA10827','barbiturates, plain','','','Drug Class','',''),('PA10832','corticosteroids','Corticosteroids','','Drug Class','',''),('PA10888','clobazam','clobazam','Chlorepin,Clorepin,Frisium,Mystan,Urbadan,Urbanyl','Drug/Small Molecule','TTD:DAP000672,chebi:31413,chemSpider:2687,dpd:2247230,drugBank:DB00349,keggDrug:D01253,pubChemCompound:2789,pubChemSubstance:46506115,url:http://en.wikipedia.org/wiki/Clobazam','CN1c2ccc(cc2N(C(=O)CC1=O)c3ccccc3)Cl'),('PA10892','gliclazide','1-(3-Azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea,1-(Hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea,Gliclazida [INN-Spanish],Gli','Diamicron,Diamicron MR,Glimicron,Mylan-Gliclazide,','Drug/Small Molecule','TTD:DAP000522,chebi:31654,chemSpider:3356,dpd:2248453,drugBank:DB01120,keggDrug:D01599,pubChemCompound:3475,pubChemSubstance:46505475,url:http://en.wikipedia.org/wiki/Gliclazide',''),('PA1102','qt-prolonging drugs','','','Drug Class','',''),('PA127840611','troleandomycin','Oleandocetine,Oleandomycin triacetate,Oleandomycin triacetyl ester,Oleandomycin, triacetate (ester),Triacetyloleandomycin','Cyclamycin,Evramicina,Matromicina,Tao,Treolmicina,','Drug/Small Molecule','HET:TAO,TTD:DAP000411,chemSpider:16707,drugBank:DB01361,keggCompound:C12753,keggDrug:D01322,pdb:TAO,pubChemCompound:202225,pubChemSubstance:46508062,pubChemSubstance:583142,url:http://en.wikipedia.org/wiki/Troleandomycin',''),('PA128406956','fluorouracil','','5 Fluorouracil,Adrucil,Arumel,Carac,Carzonal,Efflu','Drug/Small Molecule','DailyMed:e0794add-67a7-4308-93e9-f889472716cc,HET:URF,TTD:DAP000829,chebi:46345,chemSpider:3268,dpd:2182742,drugBank:DB00544,keggCompound:C07649,keggDrug:D00584,ndc:0703-3015-13,pdb:URF,pubChemCompound:3385,pubChemSubstance:46508557,pubChemSubstance:7847650,url:http://en.wikipedia.org/wiki/Fluorouracil','c1c(c(=O)[nH]c(=O)[nH]1)F'),('PA128406980','phencyclidine','1-(1-Phenylcyclohexyl)piperidine,1-(1-Phenylcyclohexyl)piperidine hydrochloride,Angel dust,Busy bee,CJS,Cadillac,DOA,DUST,Elephant tranquilizer,Fencic','','Drug/Small Molecule','chemSpider:6224,drugBank:DB03575,keggCompound:C07575,pdb:1PC,pubChemCompound:6468,pubChemSubstance:46508889,pubChemSubstance:9778,url:http://en.wikipedia.org/wiki/Phencyclidine','c1ccc(cc1)C2(CCCCC2)N3CCCCC3'),('PA128406983','pesticides','','','Drug Class','',''),('PA129945760','NG-monomethyl-l-arginine','','','Drug/Small Molecule','',''),('PA130150436','perhexiline','(+)-2-(2,2-Dicyclohexylethyl)piperidine,(-)-2-(2,2-Dicyclohexylethyl)piperidine,2-(2,2-Dicyclohexylethyl)piperidine,Perhexilene,Perhexilina [INN-Spani','','Drug/Small Molecule','TTD:DAP000957,chebi:35553,chemSpider:4584,drugBank:DB01074,pubChemCompound:4746,pubChemSubstance:165685,pubChemSubstance:46504471,url:http://en.wikipedia.org/wiki/Perhexiline','C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3'),('PA130230921','uridine','','','Drug/Small Molecule','chebi:16704,drugBank:DB02745,keggCompound:C00299,pdb:URI,pubChemCompound:453551,pubChemCompound:6029,pubChemSubstance:3593,pubChemSubstance:46507015,url:http://en.wikipedia.org/wiki/Uridine',''),('PA130230922','6-o-phosphoryl inosine monophosphate','','','Drug/Small Molecule','drugBank:DB03510,pdb:IMO,pubChemCompound:444818,pubChemCompound:46936701,pubChemSubstance:46506764,pubChemSubstance:7888380',''),('PA130231310','sulfaphenazole','phenylsulfapyrazole,sulfafenazol [inn-spanish],sulfafenazolo [italian],sulfaphenazol [inn-french],sulfaphenazolum [inn-latin],sulfaphenazon,sulfapheny','Eftolon,Sulfabid','Drug/Small Molecule','',''),('PA130232992','bevacizumab','Avastin,R-435,antiVEGF,bevacizumab','Avastin','Drug/Small Molecule','DailyMed:939b5d1f-9fb2-4499-80ef-0607aa6b114e,TTD:DAP000393,dpd:2270994,drugBank:DB00112,ndc:50242-060-01,url:http://en.wikipedia.org/wiki/Bevacizumab',''),('PA130413154','tegaserod','SDZ HTF 919,Tegaserod maleate,tegaserod','Zelmac,Zelnorm','Drug/Small Molecule','DailyMed:a274e3ea-bf67-4f81-aaa0-10475b20cd69,chebi:51043,chemSpider:4589305,dpd:2245566,drugBank:DB01079,ndc:0078-0355-80,pubChemCompound:5487301,pubChemSubstance:46506519,pubChemSubstance:707054,url:http://en.wikipedia.org/wiki/Tegaserod',''),('PA130619705','orbofiban','','','Drug/Small Molecule','',''),('PA130620649','granulocyte colony-stimulating factor','','','Drug/Small Molecule','',''),('PA130620651','anthracyclines and related substances','','','Drug Class','',''),('PA131053734','ketanserin','','','Drug/Small Molecule','',''),('PA131285527','oxaliplatin','Oxalatoplatin,Oxalatoplatinum,Oxaliplatin [Usan:Inn:Ban],Oxaliplatino [Spanish],Oxaliplatinum [Latin],Oxaloplatine [French],Oxaloplatino [Spanish],oxa','DACPLAT,Eloxatin,Elplat,Foloxatine,Transplatin','Drug/Small Molecule','DailyMed:9e51cc79-620c-48d7-b267-78e43c1ef6e4,TTD:DAP000062,chebi:31941,chemSpider:8062727,drugBank:DB00526,keggDrug:D01790,ndc:0703-3985-01,pubChemCompound:6857599,pubChemCompound:9887054,pubChemSubstance:184140,pubChemSubstance:46509083,url:http://en.wikipedia.org/wiki/Oxaliplatin',''),('PA131301952','gefitinib','ZD-1839,ZD1839','Iressa,Irressat','Drug/Small Molecule','DailyMed:827d60e8-7e07-41b7-c28b-49ef1c4a5a41,HET:IRE,TTD:DAP000657,bindingDb:5447,chebi:49668,chemSpider:110217,dpd:2248676,drugBank:DB00317,keggDrug:D01977,ndc:0310-0482-30,pdb:IRE,pubChemCompound:123631,pubChemSubstance:46508649,pubChemSubstance:7849039,url:http://en.wikipedia.org/wiki/Gefitinib','COc1cc2c(cc1OCCCN3CCOCC3)c(ncn2)Nc4ccc(c(c4)Cl)F'),('PA131548935','drotrecogin alfa','Anticoagulant protein C,Autoprothrombin IIA,Blood coagulation factor XIV,Vitamin K-dependent protein C precursor,drotrecogin alfa','Xigris','Drug/Small Molecule','DailyMed:14bc1219-c08d-41a1-a142-ec0767fb2f2b,TTD:DAP000151,dpd:2247130,drugBank:DB00055,genBank:M11228,ndc:0002-7559-01,uniProtKb:P04070,url:http://en.wikipedia.org/wiki/Drotrecogin_alfa',''),('PA131550706','echinacea','','','Drug/Small Molecule','',''),('PA131625240','raltitrexed','ZD-1694,ZD1694,raltitrexed','Tomudex','Drug/Small Molecule','HET:D16,TTD:DAP000759,bindingDb:18795,chemSpider:94568,dpd:2229566,drugBank:DB00293,keggCompound:C11372,keggDrug:D01064,pdb:D16,pubChemCompound:104758,pubChemSubstance:13546,pubChemSubstance:46504880,url:http://en.wikipedia.org/wiki/Raltitrexed','Cc1[nH]c(=O)c2cc(ccc2n1)CN(C)c3ccc(s3)C(=O)N[C@@H](CCC(=O)O)C(=O)O'),('PA131887008','3,4-methylenedioxymethamphetamine','Ecstasy,MDMA','','Drug/Small Molecule','chebi:1391,chemSpider:1556,drugBank:DB01454,keggCompound:C07577,pubChemCompound:1615,pubChemSubstance:46506404,pubChemSubstance:9780,url:http://en.wikipedia.org/wiki/3%2C4-Methylenedioxymethamphetamine',''),('PA131887911','semaxanib','','','Drug/Small Molecule','',''),('PA131889722','telcyta','','','Drug/Small Molecule','',''),('PA131890620','cannabinoids','','','Drug Class','',''),('PA131890625','tenoxicam','Tenoxicamum [INN-Latin]','Apo-Tenoxicam,Novo-Tenoxicam,Tilcotil','Drug/Small Molecule','TTD:DAP000736,chemSpider:4471584,dpd:2231120,drugBank:DB00469,keggDrug:D01767,pubChemCompound:5312154,pubChemSubstance:183540,pubChemSubstance:46507303','CN1C(=C(c2c(ccs2)S1(=O)=O)O)C(=O)Nc3ccccn3'),('PA131890628','tranilast','','','Drug/Small Molecule','',''),('PA132595336','calcein','','','Drug/Small Molecule','',''),('PA133822447','catecholamines','','','Drug Class','',''),('PA133888888','almokalant','','','Drug/Small Molecule','',''),('PA133888889','hydroquinidine','','','Drug/Small Molecule','','CC[C@@H]1CN2CCC1C[C@@H]2[C@H](c3ccnc4c3cc(cc4)OC)O'),('PA133888890','sematilide','','','Drug/Small Molecule','','CCN(CC)CCNC(=O)c1ccc(cc1)NS(=O)(=O)C'),('PA133950441','hmg coa reductase inhibitors','statin,statins','','Drug Class','',''),('PA134308647','rosuvastatin','ZD-4522,rosuvastatin calcium','Astende,Cirantan,Cresadex,Crestor,Provisacor,Razel','Drug/Small Molecule','DailyMed:bb0f3b5e-4bc6-41c9-66b9-6257e2513512,HET:FBI,TTD:DAP000555,bindingDb:50215703,chebi:38545,dpd:2247163,drugBank:DB01098,keggDrug:D01915,ndc:0310-0755-90,pdb:FBI,pubChemCompound:6439133,pubChemSubstance:706341,url:http://en.wikipedia.org/wiki/Rosuvastatin',''),('PA134521193','coumarin','','','Drug/Small Molecule','','c1ccc2c(c1)ccc(=O)o2'),('PA134653756','diflomotecan','','','Drug/Small Molecule','',''),('PA134687812','benzydamine','','','Drug/Small Molecule','',''),('PA134687887','selective beta-2-adrenoreceptor agonists','','','Drug Class','',''),('PA134687907','formoterol','Formoterol fumarate,Formoterolum [INN-Latin],formoterol','Foradil,Foradile,Oxeze Turbuhaler,Oxeze Turbuhaler','Drug/Small Molecule','DailyMed:7b9da867-04ad-4ace-a889-9f4ff8bec47b,TTD:DAP000247,chemSpider:3292,dpd:2237225,drugBank:DB00983,keggCompound:C07805,ndc:0085-1402-01,pubChemCompound:3410,pubChemSubstance:10007,pubChemSubstance:46507099,url:http://en.wikipedia.org/wiki/Formoterol',''),('PA134687923','GW2016','','','Drug/Small Molecule','',''),('PA134687924','erlotinib','OSI-774,erlotinib','Tarceva','Drug/Small Molecule','HET:AQ4,TTD:DAP001010,bindingDb:5446,chebi:114785,chemSpider:154044,dpd:2269023,drugBank:DB00530,pdb:AQ4,pubChemCompound:176870,pubChemSubstance:46508021,pubChemSubstance:7885946,url:http://en.wikipedia.org/wiki/Erlotinib','COCCOc1cc2c(cc1OCCOC)ncnc2Nc3cccc(c3)C#C'),('PA134687925','canertinib','','','Drug/Small Molecule','',''),('PA134687926','EKB-569','','','Drug/Small Molecule','',''),('PA134687937','mianserin','Mianserina [inn-spanish],Mianserine,Mianserine [inn-french],Mianserinum [inn-latin],Mianseryna [polish]','Bolvidon,Norval,Tolvan','Drug/Small Molecule','TTD:DAP000293,chebi:51137,chemSpider:4040,drugBank:DB06148,iupharLigand:135,pubChemCompound:4184,pubChemSubstance:14848151,pubChemSubstance:46508096,url:http://en.wikipedia.org/wiki/Mianserin','CN1CCN2c3ccccc3Cc4ccccc4C2C1'),('PA134687941','desmethylcitalopram','','','Drug/Small Molecule','',''),('PA134687942','levomepromazine','','','Drug/Small Molecule','',''),('PA134687947','eletriptan','eletriptan','Relpax','Drug/Small Molecule','DailyMed:85745375-fcb6-4edc-b6db-a77b4a5f3e8c,TTD:DAP000008,chebi:50922,chemSpider:70379,dpd:2256304,drugBank:DB00216,iupharLigand:118,iupharLigand:40,keggDrug:D01973,ndc:0049-2340-05,pubChemCompound:77993,pubChemSubstance:46506380,pubChemSubstance:655051,url:http://en.wikipedia.org/wiki/Eletriptan','CN1CCC[C@@H]1Cc2c[nH]c3c2cc(cc3)CCS(=O)(=O)c4ccccc4'),('PA134688071','atomoxetine','Tomoxetina [Spanish],Tomoxetine,Tomoxetine [INN],Tomoxetinum [Latin]','Strattera','Drug/Small Molecule','DailyMed:309de576-c318-404a-bc15-660c2b1876fb,TTD:DAP000721,bindingDb:50133749,chebi:127342,chemSpider:49516,dpd:2262800,drugBank:DB00289,keggDrug:D02574,ndc:0002-3227-30,pubChemCompound:54841,pubChemSubstance:214424,pubChemSubstance:46506160,url:http://en.wikipedia.org/wiki/Atomoxetine','Cc1ccccc1O[C@H](CCNC)c2ccccc2'),('PA134698661','pranlukast','ONO-RS 411','','Drug/Small Molecule','TTD:DAP000977,chemSpider:102999,drugBank:DB01411,pubChemCompound:115100,pubChemSubstance:46508129,pubChemSubstance:692058,url:http://en.wikipedia.org/wiki/Pranlukast','c1ccc(cc1)CCCCOc2ccc(cc2)C(=O)Nc3cccc4c3oc(cc4=O)c5[nH]nnn5'),('PA134711056','domperidone','','Domperidon,Lopac-D-122,Motilium,Nauzelin','Drug/Small Molecule','TTD:DAP001368,bindingDb:50241107,chebi:31515,chemSpider:3039,dpd:2238444,drugBank:DB01184,keggDrug:D01745,pubChemCompound:3151,pubChemSubstance:183089,pubChemSubstance:46508314,url:http://en.wikipedia.org/wiki/Domperidone','c1ccc2c(c1)[nH]c(=O)n2CCCN3CCC(CC3)n4c5ccc(cc5[nH]c4=O)Cl'),('PA134711723','aminohippurate','Aminohippurate Sodium,Aminohippuric acid,Aminohippuric acid Sodium salt,PAH,Sodium p-aminohippurate,Sodium para-Aminohippurate,para-Aminohippurate','','Drug/Small Molecule','DailyMed:a1975215-25f1-4c5a-878d-bcbf5326bb92,chemSpider:2063,dpd:140287,drugBank:DB00345,keggDrug:D01421,ndc:0006-3395-11,pubChemCompound:2148,pubChemSubstance:46507106,url:http://en.wikipedia.org/wiki/Para-Aminohippurate','c1ccc(c(c1)C(=O)NCC(=O)[O-])N'),('PA134711724','ochratoxin A','','','Drug/Small Molecule','',''),('PA134852920','benzbromarone','','','Drug/Small Molecule','',''),('PA134967247','2-methoxyestradiol','','','Drug/Small Molecule','',''),('PA135057240','bupivacaine','(+-)-Bupivacaine,Bloqueina,Bupivacaina [INN-Spanish],Bupivacaine HCL,Bupivacaine HCL KIT,Bupivacainum [INN-Latin],DL-Bupivacaine,DUR-843,LAC-43,bupiva','Anekain,Bupivan,Carbostesin,Chirocaine,DepoBupivac','','',''),('PA136437519','Lorenzo\'s oil','','','Drug/Small Molecule','',''),('PA137179528','nimesulide','','','Drug/Small Molecule','chebi:44445,chemSpider:4339,drugBank:DB04743,pdb:NIM,pubChemCompound:4495,pubChemSubstance:46507721,pubChemSubstance:7889413','CS(=O)(=O)Nc1ccc(cc1Oc2ccccc2)N(=O)=O'),('PA137867605','O6-(4-Bromothenyl)guanine','PaTrin-2,lomeguatrib','','Drug/Small Molecule','',''),('PA140222717','n-acetyl serotonin','','','Drug/Small Molecule','bindingDb:29612,drugBank:DB04275,pdb:ASE,pubChemCompound:903,pubChemSubstance:46507511,pubChemSubstance:7885978',''),('PA140222718','hydroxytryptamine','','','Drug/Small Molecule','','c1ccc2c(c1)c(cn2O)CCN'),('PA140222719','tetrabenazine','Tetra benazin,Tetrabenazina [inn-spanish],Tetrabenazinum [inn-latin],Tetrabenzaine,Tetrabenzine','Nitoman,Regulin,Rubigen,Xenazine','Drug/Small Molecule','DailyMed:ac768bab-8afa-4446-bc7f-caeeffec0cda,TTD:DAP000756,bindingDb:50017701,chemSpider:5796,dpd:2199270,drugBank:DB04844,keggCompound:C11168,ndc:67386-421-01,pubChemCompound:6018,pubChemSubstance:13350,pubChemSubstance:46506426,url:http://en.wikipedia.org/wiki/Tetrabenazine','CC(C)CC1CN2CCc3cc(c(cc3C2CC1=O)OC)OC'),('PA140222720','MPP+','1-methyl-4-phenylpyridinium (MPP+)','','Drug/Small Molecule','',''),('PA140222783','glycyl-sarcosine','','','Drug/Small Molecule','','CN(CC(=O)O)C(=O)CN'),('PA140222784','kyotorphin','','','Drug/Small Molecule','',''),('PA142320763','allopregnanolone','','','Drug/Small Molecule','',''),('PA142650384','pitavastatin','','Livalo','Drug/Small Molecule','',''),('PA142899133','hexoprenaline','','','Drug/Small Molecule','',''),('PA143414738','atrasentan','','','Drug/Small Molecule','',''),('PA143485261','artemisinin and derivatives','','','Drug Class','',''),('PA143485705','antiepileptics','Antiepileptics','','Drug Class','',''),('PA143487910','aliskiren','Rasilez,SPP 100,aliskiren','Tekturna','Drug/Small Molecule','DailyMed:833c7a0b-5f64-4363-94d5-9a179049113a,TTD:DAP001219,bindingDb:17950,chebi:601027,chemSpider:4591452,drugBank:DB01258,keggDrug:D03208,ndc:0078-0486-15,pubChemCompound:5493444,pubChemSubstance:17397362,pubChemSubstance:46507474,url:http://en.wikipedia.org/wiki/Aliskiren',''),('PA144614921','reboxetine','Reboxetine mesylate,reboxetine','Davedax,Edronax,Norebox,Prolift,Solvex,Vestra','Drug/Small Molecule','TTD:DAP000720,bindingDb:35226,chemSpider:59268,drugBank:DB00234,pubChemCompound:65856,pubChemSubstance:207897,pubChemSubstance:46504845,url:http://en.wikipedia.org/wiki/Reboxetine','CCOc1ccccc1O[C@@H](c2ccccc2)[C@@H]3CNCCO3'),('PA144614922','Opipramol','','','Drug/Small Molecule','','c1ccc2c(c1)C=Cc3ccccc3N2CCCN4CCN(CC4)CCO'),('PA144997862','retigabine','','','Drug/Small Molecule','','CCOC(=O)Nc1ccc(cc1N)NCc2ccc(cc2)F'),('PA145007158','torcetrapib','','','Drug/Small Molecule','',''),('PA146096020','nitrendipine','Nitrendipin,Nitrendipino [INN-Spanish],Nitrendipinum [INN-Latin]','Bayotensin,Baypress,Bylotensin,Deiten,Nidrel,Nitre','Drug/Small Molecule','TTD:DAP001263,bindingDb:50012016,chemSpider:4351,drugBank:DB01054,iupharLigand:2334,keggCompound:C07713,keggDrug:D00629,pubChemCompound:4507,pubChemSubstance:179531,pubChemSubstance:46508817,url:http://en.wikipedia.org/wiki/Nitrendipine','CCOC(=O)C1=C(NC(=C(C1c2cccc(c2)N(=O)=O)C(=O)OC)C)C'),('PA146096021','bisantrene','','','Drug/Small Molecule','',''),('PA146096022','forskolin','','','Drug/Small Molecule','chebi:42471,chemSpider:43607,drugBank:DB02587,pdb:FOK,pubChemCompound:47936,pubChemSubstance:11120323,pubChemSubstance:46509044,url:http://en.wikipedia.org/wiki/Forskolin',''),('PA146123005','talinolol','','','Drug/Small Molecule','',''),('PA147358765','alpha-methyl-para-tyrosine','','','Drug/Small Molecule','',''),('PA150047156','non-nucleoside reverse transcriptase inhibitors','','','Drug Class','',''),('PA150481186','topoisomerase I inhibitors','','','Drug Class','',''),('PA150481187','folic acid analogues','','','Drug Class','',''),('PA150481188','vinca alkaloids and analogues','','','Drug Class','',''),('PA150481189','taxanes','','','Drug Class','',''),('PA150595617','platinum','','','Drug/Small Molecule','','[Pt]'),('PA151070295','thyroxine','','','Drug/Small Molecule','','c1c(cc(c(c1I)Oc2cc(c(c(c2)I)O)I)I)CC(C(=O)O)N'),('PA151186253','nemonapride','','','Drug/Small Molecule','',''),('PA151249535','diuretics','','','Drug Class','',''),('PA151917011','valinomycin','','','Drug/Small Molecule','',''),('PA151917012','dactinomycin','AD,Antibiotic From Streptomyces Parvullus,Dactinomicina [INN-Spanish],Dactinomycine [INN-French],Dactinomycinum [INN-Latin],actd','ACT,ACT D,ACTINOMYCIN D,ACTO-D,Actactinomycin a Iv','Drug/Small Molecule','TTD:DNC000380,bindingDb:50023797,chebi:27666,dpd:213071,drugBank:DB00970,keggCompound:C06770,keggDrug:D00214,pubChemCompound:2019,pubChemSubstance:8990,url:http://en.wikipedia.org/wiki/Dactinomycin',''),('PA151929741','trichostatin A','','','Drug/Small Molecule','',''),('PA151958300','otamixaban','','','Drug/Small Molecule','',''),('PA151958355','grapefruit juice','','','Drug/Small Molecule','',''),('PA151958360','naringin','','','Drug/Small Molecule','',''),('PA151958361','naringenin','','','Drug/Small Molecule','bindingDb:23419,chebi:17846,chemSpider:388383,drugBank:DB03467,keggCompound:C00509,pdb:NAR,pubChemCompound:439246,pubChemSubstance:3792,pubChemSubstance:46508043','c1cc(ccc1C2CC(=O)c3c(cc(cc3O2)O)O)O'),('PA151958362','6,7-dihydroxybergamottin','','','Drug/Small Molecule','',''),('PA151958365','methyl-CCNU','','','Drug/Small Molecule','',''),('PA151958400','neuropsychiatric medications','','','Drug Class','',''),('PA151958426','nebivolol','nebivololum [latin]','Bystolic,Lobivon,Nebicard-5,Nebilet,Nebilong,Nebip','Drug/Small Molecule','DailyMed:673f5ad2-c09b-4a89-9407-efdadd007917',''),('PA151958574','posaconazole','posaconazole','Noxafil','Drug/Small Molecule','DailyMed:b073b082-7b57-4423-8c06-4fd4263d6f84,TTD:DAP001101,chemSpider:130409,drugBank:DB01263,keggDrug:D02555,ndc:0085-1328-01,pubChemCompound:147912,pubChemSubstance:17396726,pubChemSubstance:46508639,url:http://en.wikipedia.org/wiki/Posaconazole',''),('PA151958596','curcumin','','','Drug/Small Molecule','',''),('PA151958637','4-methylthioamphetamine','','','Drug/Small Molecule','','CC(Cc1ccc(cc1)SC)N'),('PA152031327','geldanamycin','','','Drug/Small Molecule','bindingDb:50227098,chemSpider:3342,drugBank:DB02424,keggCompound:C11222,pdb:GDM,pubChemCompound:46936377,pubChemCompound:5281885,pubChemSubstance:13401,pubChemSubstance:46505674,url:http://en.wikipedia.org/wiki/Geldanamycin',''),('PA152132897','Tilarginine Acetate','','','Drug/Small Molecule','',''),('PA152207466','farnesyltransferase inhibitors','','','Drug Class','',''),('PA152241907','lapatinib','FMM,GW 572016,GW572016,Lapatinib ditosylate,Lapatinib tosilate hydrate,lapatinib','Tycerb,Tykerb','Drug/Small Molecule','DailyMed:63319b01-cad6-4d0a-c39b-938fa951a808,HET:FMM,TTD:DCL000344,bindingDb:5445,chebi:49603,chemSpider:181006,drugBank:DB01259,keggDrug:D04024,ndc:0173-0752-00,pdb:FMM,pubChemCompound:208908,pubChemSubstance:14911387,pubChemSubstance:46507141,url:http://en.wikipedia.org/wiki/Lapatinib','CS(=O)(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F'),('PA152241908','PHA-665752','','','Drug/Small Molecule','',''),('PA152241909','PP2','','','Drug/Small Molecule','',''),('PA152407999','rimonabant','SR 141716,SR 141716A,SR141716,SR141716A,rimonabant','Acomplia,Rimoslim,Riobant,Slimona,Zimulti','Drug/Small Molecule','TTD:DNC001371,bindingDb:21278,chemSpider:94641,drugBank:DB06155,iupharLigand:743,iupharLigand:745,keggCompound:C14319,keggDrug:D05731,pubChemCompound:104850,pubChemSubstance:47207392,pubChemSubstance:99443236,url:http://en.wikipedia.org/wiki/Rimonabant',''),('PA152408000','SR144528','','','Drug/Small Molecule','',''),('PA152432579','xanomeline','','','Drug/Small Molecule','','CCCCCCOc1c(nsn1)C2=CCCN(C2)C'),('PA152432599','itopride','','','Drug/Small Molecule','','CN(C)CCOc1ccc(cc1)CNC(=O)c2ccc(c(c2)OC)OC'),('PA152530737','dilazep','','','Drug/Small Molecule','',''),('PA152530738','tubercidin','7-Deazadenosine,7-deazaadenosine,Antibiotic 155B2T,Antibiotic XK 101-1,Sparsomycin A,TBC,TBN,Toyocamycin,Tubercidine','','Drug/Small Molecule','chebi:48267,drugBank:DB03172,pdb:TBN,pubChemCompound:46936593,pubChemCompound:6245,pubChemSubstance:46505938,pubChemSubstance:7890700',''),('PA152530740','8-cyclopentyl-1,3-dipropylxanthine','8-cyclopentyl-1','','Drug/Small Molecule','',''),('PA153561371','egfr inhibitors','','','Drug Class','',''),('PA153590860','camptothecin','(+)-camptothecin,(+)-camptothecine,(s)-(+)-camptothecin,(s)-camptothecin,20(S)-Camptothecin,21,22-Secocamptothecin-21-oic acid lactone,CPT,Camptotheci','','Drug/Small Molecule','chebi:27656,chemSpider:22775,drugBank:DB04690,keggCompound:C01897,pdb:EHD,pubChemCompound:24360,pubChemSubstance:46507644,pubChemSubstance:7887296,url:http://en.wikipedia.org/wiki/Camptothecin',''),('PA153619853','dronedarone','','','Drug/Small Molecule','',''),('PA153627678','idraparinux','','','Drug/Small Molecule','',''),('PA153906323','rolipram','rolipram','','Drug/Small Molecule','chemSpider:394978,drugBank:DB03606,pdb:4SR,pubChemCompound:448055,pubChemSubstance:46507984,pubChemSubstance:7885374','COc1ccc(cc1OC2CCCC2)C3CC(=O)NC3'),('PA154081778','4-methylumbelliferone','','','Drug/Small Molecule','','Cc1cc(=O)oc2c1ccc(c2)O'),('PA154081779','naphthol','','','Drug/Small Molecule','',''),('PA154410481','prasugrel','cs-747','Effient,Efient,Prasita','Drug/Small Molecule','',''),('PA161199368','iloperidone','','','Drug/Small Molecule','','CC(=O)c1ccc(c(c1)OC)OCCCN2CCC(CC2)c3c4ccc(cc4on3)F'),('PA161660841','ebselen','','','Drug/Small Molecule','',''),('PA161660849','LY686017','','','Drug/Small Molecule','',''),('PA161748474','ximelagatran','H 376/95,ximelagatran','Exanta,Exarta','Drug/Small Molecule','TTD:DAP001218,chemSpider:7848559,drugBank:DB04898,pubChemCompound:9574101,pubChemSubstance:12015148,pubChemSubstance:46509040,url:http://en.wikipedia.org/wiki/Ximelagatran',''),('PA161925594','tropisetron','','','Drug/Small Molecule','',''),('PA161990676','tetrahydrobiopterin','5,6,7,8 Tetrahydrobiopterin,BH4,sapropterin','Dapropterin,Kuvan,Phenoptin,Sapropterin','Drug/Small Molecule','DailyMed:af38711e-8873-4790-a92d-4d583e23fb89,HET:THB,TTD:DNC000425,chebi:15372,chemSpider:1093,drugBank:DB00360,keggCompound:C00272,ndc:68135-300-01,pdb:THB,pubChemCompound:1125,pubChemSubstance:3570,pubChemSubstance:46508597,url:http://en.wikipedia.org/wiki/Tetrahydrobiopterin',''),('PA162168179','SJG-136','','','Drug/Small Molecule','',''),('PA162356187','muraglitazar','','','Drug/Small Molecule','',''),('PA162360980','meglitinides','','','Drug Class','',''),('PA162363968','lenalidomide','CC-5013,CDC 501,IMiD3,lenalidomide','Revimid,Revlimid','Drug/Small Molecule','DailyMed:5fa97bf5-28a2-48f1-8955-f56012d296be,TTD:DAP001255,bindingDb:50078323,chemSpider:187515,drugBank:DB00480,keggDrug:D04687,ndc:59572-410-00,pubChemCompound:216326,pubChemSubstance:46505725,pubChemSubstance:789509,url:http://en.wikipedia.org/wiki/Lenalidomide',''),('PA162364313','bezafibrate','Bezafibrat,Bezafibrato [inn-spanish],Bezafibratum [inn-latin]','Befizal,Bezalip,Bezalip retard,Bezatol,Bezatol SR,','','',''),('PA162370429','CBLB502','','','Drug/Small Molecule','',''),('PA162372840','sunitinib','SU11248,Sunitinib malate,Sutent','SU-11248,sunitinib','Drug/Small Molecule','DailyMed:43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c,HET:B49,TTD:DCL000646,bindingDb:4814,chebi:38940,chemSpider:4486264,dpd:2280795,drugBank:DB01268,keggDrug:D06402,ndc:0069-0550-38,pdb:B49,pubChemCompound:5329102,pubChemSubstance:14830382,pubChemSubstance:46507140,url:http://en.wikipedia.org/wiki/Sunitinib','CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C2/c3cc(ccc3NC2=O)F)C'),('PA162372878','dasatinib','BMS-354825,dasatinib','Sprycel','Drug/Small Molecule','DailyMed:4764f37b-c9e6-4ede-bcc2-8a03b7c521df,TTD:DAP000004,bindingDb:13216,chebi:49375,chemSpider:2323020,drugBank:DB01254,keggDrug:D03658,ndc:0003-0527-11,pubChemCompound:3062316,pubChemSubstance:10061134,pubChemSubstance:46505143,url:http://en.wikipedia.org/wiki/Dasatinib','Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl'),('PA162373091','panitumumab','ABX-EGF,panitumumab','Vectibix','Drug/Small Molecule','DailyMed:e0fa4bca-f245-4d92-ae29-b0c630a315c2,TTD:DNC000135,drugBank:DB01269,ndc:55513-954-01,uniProtKb:P01859,url:http://en.wikipedia.org/wiki/Panitumumab',''),('PA162565876','perazine','','','Drug/Small Molecule','','CN1CCN(CC1)CCCN2c3ccccc3Sc4c2cccc4'),('PA162565877','amisulpride','Aminosultopride,amisulpride','Deniban,Solian','Drug/Small Molecule','TTD:DAP000848,chemSpider:2074,drugBank:DB06288,pubChemCompound:2159,pubChemSubstance:99443244,url:http://en.wikipedia.org/wiki/Amisulpride','CCN1CCCC1CNC(=O)c2cc(c(cc2OC)N)S(=O)(=O)CC'),('PA162565878','fluspirilene','Fluspirileno [inn-spanish],Fluspirilenum [inn-latin]','Imap,Lopac-F-100,Redeptin','Drug/Small Molecule','TTD:DAP000980,bindingDb:26948,chemSpider:3279,drugBank:DB04842,iupharLigand:85,keggDrug:D02629,pubChemCompound:3396,pubChemSubstance:159093,pubChemSubstance:46508202,url:http://en.wikipedia.org/wiki/Fluspirilene','c1ccc(cc1)N2CNC(=O)C23CCN(CC3)CCCC(c4ccc(cc4)F)c5ccc(cc5)F'),('PA162630444','eszopiclone','Esopiclone','Estorra,Lunesta','Drug/Small Molecule','DailyMed:6f5724ab-6f5b-448d-ab7e-4f8bc24dab1a,TTD:DAP000933,bindingDb:26265,chebi:53760,chemSpider:839530,drugBank:DB00402,ndc:0339-4162-11,pubChemCompound:969472,pubChemSubstance:46505809,pubChemSubstance:734464,url:http://en.wikipedia.org/wiki/Eszopiclone',''),('PA163518919','paliperidone','9-Hydroxyrisperidone','Invega','Drug/Small Molecule','DailyMed:7b8e5b26-b9e4-4704-921b-3c3c0d159916,TTD:DAP000847,chemSpider:103109,drugBank:DB01267,keggDrug:D05339,ndc:50458-554-01,pubChemCompound:115237,pubChemSubstance:14905143,pubChemSubstance:46506296,url:http://en.wikipedia.org/wiki/Paliperidone',''),('PA163522137','oxatomide','','','Drug/Small Molecule','','c1ccc(cc1)C(c2ccccc2)N3CCN(CC3)CCCn4c5ccccc5[nH]c4=O'),('PA163522138','ouabain','G-Strophanthin,Ouabagenin L-Rhamnoside,Ouabain Octahydrate,Ouabain, Octahydrate,Ouabaine,Strophanthin G,Strophanthin-G','Acocantherin,Astrobain,G-Strophicor,Gratibain,Grat','Drug/Small Molecule','TTD:DAP000465,chebi:472805,chemSpider:388599,drugBank:DB01092,keggCompound:C01443,keggDrug:D00112,pubChemCompound:439501,pubChemSubstance:4621,pubChemSubstance:46505479,url:http://en.wikipedia.org/wiki/Ouabain',''),('PA163522472','darunavir','AIDS073035,Darunavirum [INN-latin],TMC-114,TMC114,UIC-94017','Prezista','Drug/Small Molecule','DailyMed:814301f9-c990-46a5-b481-2879a521a16f,TTD:DAP001086,bindingDb:8125,chebi:367163,chemSpider:184733,dpd:2284057,drugBank:DB01264,keggDrug:D03656,ndc:59676-563-01,pubChemCompound:213039,pubChemSubstance:17397753,pubChemSubstance:46506908,url:http://en.wikipedia.org/wiki/Darunavir',''),('PA163522473','tipranavir','TPV,tipranavir','Aptivus','Drug/Small Molecule','HET:TPV,TTD:DAP001085,bindingDb:558,chemSpider:58539,dpd:2273322,drugBank:DB00932,pdb:TPV,pubChemCompound:65027,pubChemSubstance:206974,pubChemSubstance:46506257,url:http://en.wikipedia.org/wiki/Tipranavir',''),('PA164712302','2-amino-1-phenylethanol derivatives','','','Drug Class','',''),('PA164712303','3-oxoandrosten (4) derivatives','','','Drug Class','',''),('PA164712304','5-androstanon (3) derivatives','','','Drug Class','',''),('PA164712305','ACE inhibitors and calcium channel blockers','','','Drug Class','',''),('PA164712306','ACE inhibitors and diuretics','','','Drug Class','',''),('PA164712307','Ace Inhibitors, Combinations','','','Drug Class','',''),('PA164712308','Ace Inhibitors, Plain','Ace Inhibitor','','Drug Class','',''),('PA164712309','Acetic acid derivatives and related substances','','','Drug Class','',''),('PA164712310','Acid preparations','','','Drug Class','',''),('PA164712311','Acidifiers','','','Drug Class','',''),('PA164712312','Acridine derivatives','','','Drug Class','',''),('PA164712313','Acth','','','Drug Class','',''),('PA164712314','Actinomycines','','','Drug Class','',''),('PA164712315','Adamantane derivatives','','','Drug Class','',''),('PA164712316','Adrenergic and dopaminergic agents','','','Drug Class','',''),('PA164712317','Adrenergics For Systemic Use','','','Drug Class','',''),('PA164712318','Adrenergics and other drugs for obstructive airway diseases','','','Drug Class','',''),('PA164712319','Adrenergics and other drugs for obstructive airway diseases','','','Drug Class','',''),('PA164712320','Agents Acting On The Renin-angiotensin System','RAAS acting drugs','','Drug Class','',''),('PA164712321','Agents Against Amoebiasis And Other Protozoal Diseases','','','Drug Class','',''),('PA164712322','Agents Against Leishmaniasis And Trypanosomiasis','','','Drug Class','',''),('PA164712323','Agents For Treatment Of Hemorrhoids And','','','Drug Class','',''),('PA164712324','Aldehydes and derivatives','','','Drug Class','',''),('PA164712325','Aldose reductase inhibitors','','','Drug Class','',''),('PA164712326','Aldosterone antagonists','','','Drug Class','',''),('PA164712327','Alimentary Tract And Metabolism','','','Drug Class','',''),('PA164712328','Alkaloids, excl. rauwolfia','','','Drug Class','',''),('PA164712329','Alkaloids, excl. rauwolfia, in combination with diuretics','','','Drug Class','',''),('PA164712330','Alkyl sulfonates','','','Drug Class','',''),('PA164712331','Alkylating Agents','','','Drug Class','',''),('PA164712332','All Other Non-therapeutic Products','All Other Non-therapeutic Products','','Drug Class','',''),('PA164712334','All Other Therapeutic Products','All Other Therapeutic Products','','Drug Class','',''),('PA164712336','Allergen extracts','','','Drug Class','',''),('PA164712337','Allergens','Allergens','','Drug Class','',''),('PA164712339','Alpha and beta blocking agents','','','Drug Class','',''),('PA164712340','Alpha and beta blocking agents and other diuretics','','','Drug Class','',''),('PA164712341','Alpha and beta blocking agents and thiazides','','','Drug Class','',''),('PA164712342','Alpha glucosidase inhibitors','','','Drug Class','',''),('PA164712343','Alpha- and beta-adrenoreceptor agonists','','','Drug Class','',''),('PA164712344','Alpha-adrenoreceptor antagonists','','','Drug Class','',''),('PA164712345','Alpha-adrenoreceptor antagonists','','','Drug Class','',''),('PA164712346','Alpha-adrenoreceptor antagonists and diuretics','','','Drug Class','',''),('PA164712347','Aluminium agents','','','Drug Class','',''),('PA164712348','Aluminium compounds','','','Drug Class','',''),('PA164712349','Amides','','','Drug Class','',''),('PA164712350','Amino acids','','','Drug Class','',''),('PA164712351','Amino acids and derivatives','','','Drug Class','',''),('PA164712352','Amino acids, incl. combinations with polypeptides','','','Drug Class','',''),('PA164712353','Amino acids/carbohydrates/minerals/vitamins, combinations','','','Drug Class','',''),('PA164712354','Aminoalkyl ethers','','','Drug Class','',''),('PA164712355','Aminoquinolines','','','Drug Class','',''),('PA164712356','Aminosalicylic acid and derivatives','','','Drug Class','',''),('PA164712357','Aminosalicylic acid and similar agents','','','Drug Class','',''),('PA164712358','Amphenicols','Amphenicols','','Drug Class','',''),('PA164712360','Anabolic Agents For Systemic Use','','','Drug Class','',''),('PA164712361','Anabolic Steroids','','','Drug Class','',''),('PA164712362','Analgesics','','','Drug Class','',''),('PA164712363','Analgesics and anesthetics','','','Drug Class','',''),('PA164712364','Androgen, progestogen and estrogen in combination','','','Drug Class','',''),('PA164712365','Androgens And Female Sex Hormones In Combination','','','Drug Class','',''),('PA164712366','Androgens and female sex hormones in combination with other drugs','','','Drug Class','',''),('PA164712367','Androstan derivatives','','','Drug Class','',''),('PA164712368','Angiotensin II antagonists and calcium channel blockers','','','Drug Class','',''),('PA164712369','Angiotensin II antagonists and diuretics','','','Drug Class','',''),('PA164712371','Angiotensin II Antagonists, Combinations','','','Drug Class','',''),('PA164712372','Angiotensin II Antagonists','Angiotensin II antagonists, plain','','Drug Class','',''),('PA164712373','Anilides','','','Drug Class','',''),('PA164712374','Antacids with antiflatulents','','','Drug Class','',''),('PA164712375','Antacids with antispasmodics','','','Drug Class','',''),('PA164712376','Antacids with sodium bicarbonate','','','Drug Class','',''),('PA164712377','Antacids, other combinations','','','Drug Class','',''),('PA164712378','Anterior Pituitary Lobe Hormones And Analogues','','','Drug Class','',''),('PA164712379','Anthelmintics','','','Drug Class','',''),('PA164712380','Anthrax vaccines','','','Drug Class','',''),('PA164712381','Anti-acne Preparations','','','Drug Class','',''),('PA164712382','Anti-acne Preparations For Systemic Use','','','Drug Class','',''),('PA164712383','Anti-acne Preparations For Topical Use','','','Drug Class','',''),('PA164712384','Anti-androgens','','','Drug Class','',''),('PA164712385','Anti-dementia Drugs','','','Drug Class','',''),('PA164712386','Anti-estrogens','','','Drug Class','',''),('PA164712387','Anti-gonadotropin-releasing hormones','','','Drug Class','',''),('PA164712388','Anti-parathyroid Agents','','','Drug Class','',''),('PA164712389','Anti-parkinson Drugs','','','Drug Class','',''),('PA164712390','Antiadrenal Preparations','','','Drug Class','',''),('PA164712391','Antiadrenergic Agents, Centrally Acting','','','Drug Class','',''),('PA164712392','Antiadrenergic Agents, Ganglion-blocking','','','Drug Class','',''),('PA164712393','Antiadrenergic Agents, Peripherally Acting','','','Drug Class','',''),('PA164712394','Antiallergic agents, excl. corticosteroids','','','Drug Class','',''),('PA164712395','Antiallergic agents, excl. corticosteroids','','','Drug Class','',''),('PA164712396','Antiallergic agents, excl. corticosteroids','','','Drug Class','',''),('PA164712397','Antiandrogens','','','Drug Class','',''),('PA164712398','Antiandrogens and estrogens','','','Drug Class','',''),('PA164712399','Antiandrogens, plain','','','Drug Class','',''),('PA164712400','Antianemic Preparations','','','Drug Class','',''),('PA164712401','Antiarrhythmics, class III','','','Drug Class','',''),('PA164712402','Antiarrhythmics, class Ia','','','Drug Class','',''),('PA164712403','Antiarrhythmics, class Ib','','','Drug Class','',''),('PA164712404','Antiarrhythmics, class Ic','','','Drug Class','',''),('PA164712405','Antibacterials For Systemic Use','','','Drug Class','',''),('PA164712406','Antibiotics','','','Drug Class','',''),('PA164712414','Antibiotics And Chemotherapeutics For Dermatological Use','','','Drug Class','',''),('PA164712415','Antibiotics And Chemotherapeutics, Combinations','','','Drug Class','',''),('PA164712416','Antibiotics For Topical Use','','','Drug Class','',''),('PA164712417','Antibiotics and corticosteroids','','','Drug Class','',''),('PA164712418','Anticestodals','','','Drug Class','',''),('PA164712419','Anticholinergic Agents','','','Drug Class','',''),('PA164712420','Anticholinergics','','','Drug Class','',''),('PA164712421','Anticholinergics','','','Drug Class','',''),('PA164712423','Anticholinesterases','Anticholinesterases','','Drug Class','',''),('PA164712424','Anticorticosteroids','','','Drug Class','',''),('PA164712425','Antidepressants in combination with psycholeptics','','','Drug Class','',''),('PA164712426','Antidiarrheal Microorganisms','Antidiarrheal microorganisms','','Drug Class','',''),('PA164712428','Antidiarrheals, Intestinal Antiinflammatory/antiinfective','','','Drug Class','',''),('PA164712429','Antidotes','','','Drug Class','',''),('PA164712431','Antiemetics And Antinauseants','Antiemetics And Antinauseants','','Drug Class','',''),('PA164712433','Antifibrinolytics','','','Drug Class','',''),('PA164712434','Antifungals For Dermatological Use','','','Drug Class','',''),('PA164712435','Antifungals For Systemic Use','Antifungals for systemic use','','Drug Class','',''),('PA164712436','Antifungals For Topical Use','','','Drug Class','',''),('PA164712438','Antigonadotropins and similar agents','','','Drug Class','',''),('PA164712440','Antigout Preparations','Antigout Preparations','','Drug Class','',''),('PA164712441','Antigrowth hormones','','','Drug Class','',''),('PA164712442','Antihemorrhagics','','','Drug Class','',''),('PA164712443','Antihidrotics','','','Drug Class','',''),('PA164712444','Antihistamines For Systemic Use','antihistamines for systemic use','','Drug Class','',''),('PA164712445','Antihypertensives','','','Drug Class','',''),('PA164712446','Antihypertensives And Diuretics In Combination','','','Drug Class','',''),('PA164712447','Antiinfectives','Antiinfectives','','Drug Class','',''),('PA164712450','Antiinfectives','','','Drug Class','',''),('PA164712451','Antiinfectives','','','Drug Class','',''),('PA164712452','Antiinfectives','Antiinfectives','','Drug Class','',''),('PA164712453','Antiinfectives And Antiseptics, Excl. Combinations','','','Drug Class','',''),('PA164712454','Antiinfectives For Systemic Use','','','Drug Class','',''),('PA164712455','Antiinfectives and antiseptics for local oral treatment','','','Drug Class','',''),('PA164712456','Antiinfectives for treatment of acne','','','Drug Class','',''),('PA164712457','Antiinfectives/antiseptics In Combination With Corticosteroids','','','Drug Class','',''),('PA164712458','Antiinflammatory Agents','','','Drug Class','',''),('PA164712459','Antiinflammatory Agents','','','Drug Class','',''),('PA164712460','Antiinflammatory Agents And Antiinfectives In Combination','','','Drug Class','',''),('PA164712461','Antiinflammatory And Antirheumatic Products','','','Drug Class','',''),('PA164712462','Antiinflammatory agents, non-steroids','NSAID,NSAIDs','','Drug Class','',''),('PA164712463','Antiinflammatory agents, non-steroids and antiinfectives in combination','','','Drug Class','',''),('PA164712464','Antiinflammatory preparations, non-steroids for topical use','','','Drug Class','',''),('PA164712465','Antiinflammatory products for vaginal administration','','','Drug Class','',''),('PA164712466','Antiinflammatory/antirheumatic Agents In Combination','','','Drug Class','',''),('PA164712467','Antiinflammatory/antirheumatic agents in combination with corticosteroids','','','Drug Class','',''),('PA164712468','Antimalarials','','','Drug Class','',''),('PA164712469','Antimigraine Preparations','','','Drug Class','',''),('PA164712470','Antimony compounds','','','Drug Class','',''),('PA164712471','Antimycobacterials','','','Drug Class','',''),('PA164712473','Antimycotics For Systemic Use','Antimycotics For Systemic Use','','Drug Class','',''),('PA164712474','Antinematodal Agents','','','Drug Class','',''),('PA164712475','Antineoplastic And Immunomodulating Agents','','','Drug Class','',''),('PA164712476','Antineovascularisation agents','','','Drug Class','',''),('PA164712478','Antiobesity Preparations, Excl. Diet Products','Antiobesity Preparations, Excl. Diet Products','','Drug Class','',''),('PA164712479','Antiparasitic Products, Insecticides And Repellents','','','Drug Class','',''),('PA164712480','Antiprogestogens','','','Drug Class','',''),('PA164712482','Antipropulsives','Antipropulsives','','Drug Class','',''),('PA164712483','Antiprotozoals','','','Drug Class','',''),('PA164712484','Antipruritics, Incl. Antihistamines, Anesthetics, Etc.','Antipruritics, Incl. Antihistamines, Anesthetics, Etc.','','Drug Class','',''),('PA164712486','Antipsoriatics','','','Drug Class','',''),('PA164712487','Antipsoriatics For Systemic Use','','','Drug Class','',''),('PA164712488','Antipsoriatics For Topical Use','','','Drug Class','',''),('PA164712489','Antiseptics','','','Drug Class','',''),('PA164712491','Antiseptics And Disinfectants','Antiseptics And Disinfectants','','Drug Class','',''),('PA164712492','Antiseptics and corticosteroids','','','Drug Class','',''),('PA164712493','Antispasmodics And Anticholinergics In Combination With Other Drugs','','','Drug Class','',''),('PA164712494','Antispasmodics In Combination With Analgesics','','','Drug Class','',''),('PA164712495','Antispasmodics In Combination With Psycholeptics','','','Drug Class','',''),('PA164712496','Antispasmodics in combination with other drugs','','','Drug Class','',''),('PA164712497','Antispasmodics, psycholeptics and analgesics in combination','','','Drug Class','',''),('PA164712499','Antithyroid Preparations','','','Drug Class','',''),('PA164712500','Antitrematodals','','','Drug Class','',''),('PA164712501','Antivaricose Therapy','','','Drug Class','',''),('PA164712502','Antivertigo Preparations','Antivertigo preparations','','Drug Class','',''),('PA164712504','Antivirals For Systemic Use','','','Drug Class','',''),('PA164712505','Antivirals for treatment of HIV infections, combinations','','','Drug Class','',''),('PA164712506','Antracen derivatives','','','Drug Class','',''),('PA164712507','Anxiolytics','','','Drug Class','',''),('PA164712508','Appetite Stimulants','','','Drug Class','',''),('PA164712509','Arsenic compounds','','','Drug Class','',''),('PA164712512','Arteriolar Smooth Muscle, Agents Acting On','','','Drug Class','',''),('PA164712513','Aryloxyacetic acid derivatives','','','Drug Class','',''),('PA164712514','Ascorbic Acid (vitamin C), Incl. Combinations','','','Drug Class','',''),('PA164712515','Ascorbic acid (vitamin C), combinations','','','Drug Class','',''),('PA164712516','Ascorbic acid (vitamin C), plain','','','Drug Class','',''),('PA164712517','Avermectines','','','Drug Class','',''),('PA164712518','Azaspirodecanedione derivatives','','','Drug Class','',''),('PA164712519','Bacterial And Viral Vaccines, Combined','Bacterial and viral vaccines, combined','','Drug Class','',''),('PA164712520','Bacterial Vaccines','','','Drug Class','',''),('PA164712522','Barbiturates in combination with other drugs','','','Drug Class','',''),('PA164712523','Barbiturates, combinations','','','Drug Class','',''),('PA164712524','Barium sulfate containing X-ray contrast media','','','Drug Class','',''),('PA164712525','Belladonna And Derivatives, Plain','','','Drug Class','',''),('PA164712526','Belladonna alkaloids, semisynthetic, quaternary ammonium compounds','','','Drug Class','',''),('PA164712527','Belladonna alkaloids, tertiary amines','','','Drug Class','',''),('PA164712528','Belladonna and derivatives in combination with analgesics','','','Drug Class','',''),('PA164712529','Belladonna and derivatives in combination with psycholeptics','','','Drug Class','',''),('PA164712530','Benzamides','','','Drug Class','',''),('PA164712531','Benzimidazole derivatives','','','Drug Class','',''),('PA164712532','Benzodiazepine related drugs','','','Drug Class','',''),('PA164712533','Benzomorphan derivatives','','','Drug Class','',''),('PA164712534','Benzothiazepine derivatives','','','Drug Class','',''),('PA164712535','Beta Blocking Agents','Beta adrenergic antagonists,beta blocking agents','','Drug Class','',''),('PA164712536','Beta Blocking Agents And Other Antihypertensives','','','Drug Class','',''),('PA164712537','Beta Blocking Agents And Other Diuretics','','','Drug Class','',''),('PA164712538','Beta Blocking Agents And Thiazides','','','Drug Class','',''),('PA164712539','Beta Blocking Agents And Vasodilators','','','Drug Class','',''),('PA164712540','Beta Blocking Agents, Thiazides And Other Diuretics','','','Drug Class','',''),('PA164712541','Beta blocking agents, non-selective','','','Drug Class','',''),('PA164712542','Beta blocking agents, non-selective, and other antihypertensives','','','Drug Class','',''),('PA164712543','Beta blocking agents, non-selective, and other diuretics','','','Drug Class','',''),('PA164712544','Beta blocking agents, non-selective, and thiazides','','','Drug Class','',''),('PA164712545','Beta blocking agents, non-selective, and vasodilators','','','Drug Class','',''),('PA164712546','Beta blocking agents, non-selective, thiazides and other diuretics','','','Drug Class','',''),('PA164712547','Beta blocking agents, selective','','','Drug Class','',''),('PA164712548','Beta blocking agents, selective, and other antihypertensives','','','Drug Class','',''),('PA164712549','Beta blocking agents, selective, and other diuretics','','','Drug Class','',''),('PA164712550','Beta blocking agents, selective, and thiazides','','','Drug Class','',''),('PA164712551','Beta blocking agents, selective, and vasodilators','','','Drug Class','',''),('PA164712552','Beta blocking agents, selective, thiazides and other diuretics','','','Drug Class','',''),('PA164712554','Beta-lactamase inhibitors','','','Drug Class','',''),('PA164712555','Beta-lactamase resistant penicillins','','','Drug Class','',''),('PA164712556','Beta-lactamase sensitive penicillins','','','Drug Class','',''),('PA164712557','Biguanides','','','Drug Class','',''),('PA164712558','Biguanides','','','Drug Class','',''),('PA164712559','Biguanides and amidines','','','Drug Class','',''),('PA164712560','Bile And Liver Therapy','','','Drug Class','',''),('PA164712561','Bioflavonoids','','','Drug Class','',''),('PA164712562','Bismuth preparations','','','Drug Class','',''),('PA164712563','Bisphosphonates','Bisphosphonate','','Drug Class','',''),('PA164712564','Bisphosphonates, combinations','','','Drug Class','',''),('PA164712565','Bisquaternary ammonium compounds','','','Drug Class','',''),('PA164712566','Blood And Blood Forming Organs','','','Drug Class','',''),('PA164712567','Blood And Related Products','','','Drug Class','',''),('PA164712568','Blood Glucose Lowering Drugs, Excl. Insulins','','','Drug Class','',''),('PA164712569','Blood Substitutes And Perfusion Solutions','','','Drug Class','',''),('PA164712570','Blood coagulation factors','','','Drug Class','',''),('PA164712571','Blood substitutes and plasma protein fractions','','','Drug Class','',''),('PA164712572','Blood tests, auxiliary products','','','Drug Class','',''),('PA164712573','Blood transfusion, auxiliary products','','','Drug Class','',''),('PA164712574','Bone morphogenetic proteins','','','Drug Class','',''),('PA164712575','Boric acid products','','','Drug Class','',''),('PA164712576','Brucellosis vaccines','','','Drug Class','',''),('PA164712577','Bulk producers','','','Drug Class','',''),('PA164712578','Butylpyrazolidines','','','Drug Class','',''),('PA164712579','Butyrophenone derivatives','','','Drug Class','',''),('PA164712580','Calcineurin inhibitors','','','Drug Class','',''),('PA164712581','Calcitonin preparations','','','Drug Class','',''),('PA164712582','Calcium','Calcium','','Drug Class','',''),('PA164712584','Calcium Channel Blockers And Diuretics','Calcium channel blockers and diuretics','','Drug Class','',''),('PA164712585','Calcium Homeostasis','','','Drug Class','',''),('PA164712587','Calcium compounds','','','Drug Class','',''),('PA164712588','Calcium, combinations with other drugs','','','Drug Class','',''),('PA164712589','Capillary Stabilizing Agents','','','Drug Class','',''),('PA164712590','Capsaicin and similar agents','','','Drug Class','',''),('PA164712591','Carbamates','','','Drug Class','',''),('PA164712592','Carbamic acid esters','','','Drug Class','',''),('PA164712593','Carbamide products','','','Drug Class','',''),('PA164712594','Carbapenems','','','Drug Class','',''),('PA164712595','Carbohydrates/proteins/minerals/vitamins, combinations','','','Drug Class','',''),('PA164712596','Carboxamide derivatives','','','Drug Class','',''),('PA164712597','Cardiac Glycosides','','','Drug Class','',''),('PA164712598','Cardiac Stimulants Excl. Cardiac Glycosides','','','Drug Class','',''),('PA164712599','Cardiac Therapy','','','Drug Class','',''),('PA164712600','Cardiovascular System','','','Drug Class','',''),('PA164712601','Cardiovascular System','','','Drug Class','',''),('PA164712602','Caries prophylactic agents','','','Drug Class','',''),('PA164712603','Central Nervous System','','','Drug Class','',''),('PA164712604','Centrally acting antiobesity products','','','Drug Class','',''),('PA164712605','Centrally acting sympathomimetics','','','Drug Class','',''),('PA164712606','Chemicals and reagents for analysis','','','Drug Class','',''),('PA164712607','Chemotherapeutics For Topical Use','','','Drug Class','',''),('PA164712608','Chlorine containing products','','','Drug Class','',''),('PA164712609','Cholera vaccines','','','Drug Class','',''),('PA164712610','Choline derivatives','','','Drug Class','',''),('PA164712611','Choline esters','','','Drug Class','',''),('PA164712612','Cicatrizants','','','Drug Class','',''),('PA164712613','Cod-liver oil ointments','','','Drug Class','',''),('PA164712614','Colchicine derivatives','','','Drug Class','',''),('PA164712615','Colouring agents','','','Drug Class','',''),('PA164712616','Combinations Of Antibacterials','Combinations of antibacterials','','Drug Class','',''),('PA164712617','Combinations Of Antihypertensives In Atc-gr. C02','','','Drug Class','',''),('PA164712618','Combinations and complexes of aluminium, calcium and magnesium compounds','','','Drug Class','',''),('PA164712619','Combinations for eradication of Helicobacter pylori','','','Drug Class','',''),('PA164712620','Combinations of adrenergics','','','Drug Class','',''),('PA164712622','Combinations of antihistamines','','','Drug Class','',''),('PA164712623','Combinations of antineoplastic agents','','','Drug Class','',''),('PA164712624','Combinations of drugs for treatment of tuberculosis','','','Drug Class','',''),('PA164712625','Combinations of oral blood glucose lowering drugs','','','Drug Class','',''),('PA164712626','Combinations of penicillins, incl. beta-lactamase inhibitors','','','Drug Class','',''),('PA164712627','Combinations of vitamins','','','Drug Class','',''),('PA164712628','Contact laxatives','','','Drug Class','',''),('PA164712629','Contraceptives For Topical Use','','','Drug Class','',''),('PA164712630','Contrast Media','','','Drug Class','',''),('PA164712631','Corticosteroid derivatives','','','Drug Class','',''),('PA164712634','Corticosteroids And Antiinfectives In Combination','Corticosteroids and antiinfectives in combination','','Drug Class','',''),('PA164712635','Corticosteroids And Antiinfectives In Combination','Corticosteroids and antiinfectives in combination','','Drug Class','',''),('PA164712636','Corticosteroids For Systemic Use','','','Drug Class','',''),('PA164712637','Corticosteroids For Systemic Use, Combinations','Corticosteroids for systemic use, combinations','','Drug Class','',''),('PA164712638','Corticosteroids and antiinfectives in combination','','','Drug Class','',''),('PA164712641','Corticosteroids and mydriatics in combination','','','Drug Class','',''),('PA164712643','Corticosteroids, Combinations With Antibiotics','','','Drug Class','',''),('PA164712644','Corticosteroids, Combinations With Antiseptics','','','Drug Class','',''),('PA164712645','Corticosteroids, Dermatological Preparations','','','Drug Class','',''),('PA164712646','Corticosteroids, Other Combinations','','','Drug Class','',''),('PA164712647','Corticosteroids, combinations for treatment of acne','','','Drug Class','',''),('PA164712648','Corticosteroids, moderately potent (group II)','','','Drug Class','',''),('PA164712649','Corticosteroids, moderately potent, combinations with antibiotics','','','Drug Class','',''),('PA164712650','Corticosteroids, moderately potent, combinations with antiseptics','','','Drug Class','',''),('PA164712651','Corticosteroids, moderately potent, other combinations','','','Drug Class','',''),('PA164712652','Corticosteroids, potent (group III)','','','Drug Class','',''),('PA164712653','Corticosteroids, potent, combinations with antibiotics','','','Drug Class','',''),('PA164712654','Corticosteroids, potent, combinations with antiseptics','','','Drug Class','',''),('PA164712655','Corticosteroids, potent, other combinations','','','Drug Class','',''),('PA164712656','Corticosteroids, very potent (group IV)','','','Drug Class','',''),('PA164712657','Corticosteroids, very potent, combinations with antibiotics','','','Drug Class','',''),('PA164712658','Corticosteroids, very potent, combinations with antiseptics','','','Drug Class','',''),('PA164712659','Corticosteroids, very potent, other combinations','','','Drug Class','',''),('PA164712660','Corticosteroids, weak (group I)','','','Drug Class','',''),('PA164712661','Corticosteroids, weak, combinations with antibiotics','','','Drug Class','',''),('PA164712662','Corticosteroids, weak, combinations with antiseptics','','','Drug Class','',''),('PA164712663','Corticosteroids, weak, other combinations','','','Drug Class','',''),('PA164712664','Corticosteroids/antiinfectives/mydriatics in combination','','','Drug Class','',''),('PA164712665','Cosmetics','','','Drug Class','',''),('PA164712666','Cough And Cold Preparations','','','Drug Class','',''),('PA164712667','Cough Suppressants And Expectorants, Combinations','','','Drug Class','',''),('PA164712668','Cough Suppressants, Excl. Combinations With Expectorants','','','Drug Class','',''),('PA164712669','Coxibs','','','Drug Class','',''),('PA164712670','Curare alkaloids','','','Drug Class','',''),('PA164712671','Cyclic amines','','','Drug Class','',''),('PA164712672','Cytotoxic Antibiotics And Related Substances','','','Drug Class','',''),('PA164712673','Dantrolene and derivatives','','','Drug Class','',''),('PA164712674','Decongestants And Antiallergics','','','Drug Class','',''),('PA164712675','Decongestants And Other Nasal Preparations For Topical Use','','','Drug Class','',''),('PA164712676','Dermatologicals','','','Drug Class','',''),('PA164712677','Detoxifying agents for antineoplastic treatment','','','Drug Class','',''),('PA164712678','Diagnostic Agents','','','Drug Class','',''),('PA164712679','Diagnostic Agents','','','Drug Class','',''),('PA164712680','Diagnostic Radiopharmaceuticals','','','Drug Class','',''),('PA164712681','Diaminopyrimidines','','','Drug Class','',''),('PA164712682','Diazepines, oxazepines and thiazepines','','','Drug Class','',''),('PA164712683','Dibenzo-bicyclo-octadiene derivatives','','','Drug Class','',''),('PA164712684','Dichloroacetamide derivatives','','','Drug Class','',''),('PA164712685','Diet Formulations For Treatment Of Obesity','','','Drug Class','',''),('PA164712687','Digestives, Incl. Enzymes','Digestives, Incl. Enzymes','','Drug Class','',''),('PA164712688','Dihydropyridine derivatives','','','Drug Class','',''),('PA164712689','Dipeptidyl peptidase 4 (DPP-4) inhibitors','','','Drug Class','',''),('PA164712690','Diphenylbutylpiperidine derivatives','','','Drug Class','',''),('PA164712691','Diphenylmethane derivatives','','','Drug Class','',''),('PA164712692','Diphenylpropylamine derivatives','','','Drug Class','',''),('PA164712693','Diphtheria vaccines','','','Drug Class','',''),('PA164712694','Direct thrombin inhibitors','','','Drug Class','',''),('PA164712695','Diuretics And Potassium-sparing Agents In Combination','','','Drug Class','',''),('PA164712696','Dopa and dopa derivatives','','','Drug Class','',''),('PA164712697','Dopamine agonists','','','Drug Class','',''),('PA164712698','Dopaminergic Agents','','','Drug Class','',''),('PA164712699','Drugs Affecting Bone Structure And Mineralization','','','Drug Class','',''),('PA164712700','Drugs For Acid Related Disorders','','','Drug Class','',''),('PA164712701','Drugs For Bile Therapy And Lipotropics In Combination','','','Drug Class','',''),('PA164712702','Drugs For Functional Bowel Disorders','','','Drug Class','',''),('PA164712703','Drugs For Functional Gastrointestinal Disorders','','','Drug Class','',''),('PA164712704','Drugs For Obstructive Airway Diseases','','','Drug Class','',''),('PA164712705','Drugs For Peptic Ulcer And Gastro-oesophageal Reflux Disease (gord)','','','Drug Class','',''),('PA164712706','Drugs For Treatment Of Bone Diseases','','','Drug Class','',''),('PA164712707','Drugs For Treatment Of Lepra','Drugs for treatment of lepra','','Drug Class','',''),('PA164712708','Drugs For Treatment Of Tuberculosis','','','Drug Class','',''),('PA164712709','Drugs Used In Addictive Disorders','','','Drug Class','',''),('PA164712710','Drugs Used In Benign Prostatic Hypertrophy','','','Drug Class','',''),('PA164712711','Drugs Used In Diabetes','','','Drug Class','',''),('PA164712712','Drugs acting on serotonin receptors','','','Drug Class','',''),('PA164712713','Drugs for embolisation','','','Drug Class','',''),('PA164712714','Drugs for treatment of hypercalcemia','','','Drug Class','',''),('PA164712715','Drugs for treatment of hyperkalemia and hyperphosphatemia','','','Drug Class','',''),('PA164712716','Drugs for treatment of hypoglycemia','','','Drug Class','',''),('PA164712718','Drugs used in alcohol dependence','','','Drug Class','',''),('PA164712719','Drugs used in erectile dysfunction','','','Drug Class','',''),('PA164712720','Drugs used in nicotine dependence','','','Drug Class','',''),('PA164712721','Drugs used in opioid dependence','','','Drug Class','',''),('PA164712722','Ectoparasiticides, Incl. Scabicides','','','Drug Class','',''),('PA164712723','Ectoparasiticides, Incl. Scabicides, Insecticides And Repellents','','','Drug Class','',''),('PA164712724','Electrolyte solutions','','','Drug Class','',''),('PA164712725','Electrolytes With Carbohydrates','','','Drug Class','',''),('PA164712727','Emollients And Protectives','Emollients And Protectives','','Drug Class','',''),('PA164712728','Encephalitis vaccines','','','Drug Class','',''),('PA164712729','Endocrine Therapy','','','Drug Class','',''),('PA164712730','Enemas','','','Drug Class','',''),('PA164712731','Enzyme and acid preparations, combinations','','','Drug Class','',''),('PA164712732','Enzyme inhibitors','','','Drug Class','',''),('PA164712733','Enzyme preparations','','','Drug Class','',''),('PA164712734','Enzymes','','','Drug Class','',''),('PA164712735','Enzymes','','','Drug Class','',''),('PA164712736','Enzymes','','','Drug Class','',''),('PA164712737','Enzymes','','','Drug Class','',''),('PA164712738','Enzymes','','','Drug Class','',''),('PA164712739','Enzymes','','','Drug Class','',''),('PA164712740','Epoxides','','','Drug Class','',''),('PA164712741','Ergot alkaloids','','','Drug Class','',''),('PA164712742','Ergot alkaloids','','','Drug Class','',''),('PA164712743','Ergot alkaloids','','','Drug Class','',''),('PA164712744','Ergot alkaloids and oxytocin incl. analogues, in combination','','','Drug Class','',''),('PA164712745','Esters of aminobenzoic acid','','','Drug Class','',''),('PA164712746','Esters of benzoic acid','','','Drug Class','',''),('PA164712747','Estren derivatives','','','Drug Class','',''),('PA164712748','Estren derivatives','','','Drug Class','',''),('PA164712749','Estrogens, combinations with other drugs','','','Drug Class','',''),('PA164712750','Ethers','','','Drug Class','',''),('PA164712751','Ethers chemically close to antihistamines','','','Drug Class','',''),('PA164712752','Ethers of tropine or tropine derivatives','','','Drug Class','',''),('PA164712753','Ethers, chemically close to antihistamines','','','Drug Class','',''),('PA164712754','Ethylene imines','','','Drug Class','',''),('PA164712755','Expectorants','','','Drug Class','',''),('PA164712756','Expectorants, Excl. Combinations With Cough Suppressants','','','Drug Class','',''),('PA164712757','Fat/carbohydrates/proteins/minerals/vitamins, combinations','','','Drug Class','',''),('PA164712758','Fatty acid derivatives','','','Drug Class','',''),('PA164712759','Fenamates','','','Drug Class','',''),('PA164712760','Fibrates','','','Drug Class','',''),('PA164712761','Fibrinogen','','','Drug Class','',''),('PA164712762','First-generation cephalosporins','','','Drug Class','',''),('PA164712763','Folic acid and derivatives','','','Drug Class','',''),('PA164712764','Fourth-generation cephalosporins','','','Drug Class','',''),('PA164712765','Gangliosides and ganglioside derivatives','','','Drug Class','',''),('PA164712766','General Nutrients','','','Drug Class','',''),('PA164712767','Genito Urinary System And Sex Hormones','','','Drug Class','',''),('PA164712768','Glycogenolytic Hormones','Glycogenolytic hormones','','Drug Class','',''),('PA164712770','Glycopeptide antibacterials','','','Drug Class','',''),('PA164712771','Gonadotropin releasing hormone analogues','','','Drug Class','',''),('PA164712772','Gonadotropin-releasing hormones','','','Drug Class','',''),('PA164712773','Gonadotropins','','','Drug Class','',''),('PA164712774','Gonadotropins And Other Ovulation Stimulants','','','Drug Class','',''),('PA164712775','Guanidine derivatives','','','Drug Class','',''),('PA164712776','Guanidine derivatives','','','Drug Class','',''),('PA164712777','Guanidine derivatives and diuretics','','','Drug Class','',''),('PA164712778','Gynecological Antiinfectives And Antiseptics','','','Drug Class','',''),('PA164712779','H2-receptor antagonists','','','Drug Class','',''),('PA164712780','HMG CoA reductase inhibitors in combination with other lipid modifying agents','','','Drug Class','',''),('PA164712781','HMG CoA reductase inhibitors, other combinations','','','Drug Class','',''),('PA164712782','Halogenated hydrocarbons','','','Drug Class','',''),('PA164712783','Hemodialytics And Hemofiltrates','','','Drug Class','',''),('PA164712784','Hemodialytics, concentrates','','','Drug Class','',''),('PA164712785','Hemofiltrates','','','Drug Class','',''),('PA164712786','Heparin group','','','Drug Class','',''),('PA164712787','Heparins or heparinoids for topical use','','','Drug Class','',''),('PA164712788','Hepatic And Reticulo Endothelial System','','','Drug Class','',''),('PA164712789','Hepatitis vaccines','','','Drug Class','',''),('PA164712790','High-ceiling Diuretics','','','Drug Class','',''),('PA164712791','High-ceiling diuretics and potassium-sparing agents','','','Drug Class','',''),('PA164712792','Hormone Antagonists And Related Agents','','','Drug Class','',''),('PA164712793','Hormones And Related Agents','','','Drug Class','',''),('PA164712794','Hydrazides','','','Drug Class','',''),('PA164712795','Hydrazinophthalazine derivatives','','','Drug Class','',''),('PA164712796','Hydrazinophthalazine derivatives and diuretics','','','Drug Class','',''),('PA164712797','Hydroxyquinoline derivatives','','','Drug Class','',''),('PA164712798','Hypertonic solutions','','','Drug Class','',''),('PA164712799','Hypnotics And Sedatives','','','Drug Class','',''),('PA164712800','Hypnotics and sedatives in combination, excl. barbiturates','','','Drug Class','',''),('PA164712801','Hypothalamic Hormones','','','Drug Class','',''),('PA164712802','I.v. Solution Additives','','','Drug Class','',''),('PA164712803','I.v. Solutions','','','Drug Class','',''),('PA164712804','Imidazole and triazole derivatives','','','Drug Class','',''),('PA164712807','Imidazole derivatives','Imidazole derivatives','','Drug Class','',''),('PA164712809','Imidazole derivatives and corticosteroids','','','Drug Class','',''),('PA164712810','Imidazoline derivatives','','','Drug Class','',''),('PA164712811','Imidazoline receptor agonists','','','Drug Class','',''),('PA164712812','Imidazoline receptor agonists in combination with diuretics','','','Drug Class','',''),('PA164712813','Imidazothiazole derivatives','','','Drug Class','',''),('PA164712814','Immune Sera','Immune sera','','Drug Class','',''),('PA164712815','Immune Sera And Immunoglobulins','','','Drug Class','',''),('PA164712817','Immunoglobulins','','','Drug Class','',''),('PA164712818','Immunoglobulins, normal human','','','Drug Class','',''),('PA164712819','Immunostimulants','Immunostimulants','','Drug Class','',''),('PA164712821','Immunosuppressants','Immunosuppressants','','Drug Class','',''),('PA164712823','Incontinence equipment','','','Drug Class','',''),('PA164712824','Indifferent preparations','','','Drug Class','',''),('PA164712825','Indium (111In) compounds','','','Drug Class','',''),('PA164712826','Indium (111In) compounds','','','Drug Class','',''),('PA164712827','Indole derivatives','','','Drug Class','',''),('PA164712828','Infant Formulas','','','Drug Class','',''),('PA164712829','Inflammation And Infection Detection','','','Drug Class','',''),('PA164712830','Influenza vaccines','','','Drug Class','',''),('PA164712831','Insecticides And Repellents','','','Drug Class','',''),('PA164712832','Insulins And Analogues','','','Drug Class','',''),('PA164712833','Insulins and analogues for inhalation','','','Drug Class','',''),('PA164712834','Insulins and analogues for injection, fast-acting','','','Drug Class','',''),('PA164712835','Insulins and analogues for injection, intermediate-acting','','','Drug Class','',''),('PA164712836','Insulins and analogues for injection, intermediate-acting combined with fast-acting','','','Drug Class','',''),('PA164712837','Insulins and analogues for injection, long-acting','','','Drug Class','',''),('PA164712838','Interleukin inhibitors','','','Drug Class','',''),('PA164712839','Interleukins','','','Drug Class','',''),('PA164712840','Intermediate-acting sulfonamides','','','Drug Class','',''),('PA164712841','Intestinal Adsorbents','','','Drug Class','',''),('PA164712842','Intestinal Antiinfectives','','','Drug Class','',''),('PA164712843','Intestinal Antiinflammatory Agents','','','Drug Class','',''),('PA164712844','Intrauterine contraceptives','','','Drug Class','',''),('PA164712845','Intravaginal contraceptives','','','Drug Class','',''),('PA164712846','Iodine (123I) compounds','','','Drug Class','',''),('PA164712847','Iodine (125I) compounds','','','Drug Class','',''),('PA164712848','Iodine (131I) compounds','','','Drug Class','',''),('PA164712849','Iodine (131I) compounds','','','Drug Class','',''),('PA164712850','Iodine Therapy','Iodine therapy','','Drug Class','',''),('PA164712851','Iodine products','','','Drug Class','',''),('PA164712853','Iron Preparations','','','Drug Class','',''),('PA164712854','Iron bivalent, oral preparations','','','Drug Class','',''),('PA164712855','Iron chelating agents','','','Drug Class','',''),('PA164712856','Iron in combination with folic acid','','','Drug Class','',''),('PA164712857','Iron in other combinations','','','Drug Class','',''),('PA164712858','Iron trivalent, oral preparations','','','Drug Class','',''),('PA164712859','Iron trivalent, parenteral preparations','','','Drug Class','',''),('PA164712860','Irrigating Solutions','','','Drug Class','',''),('PA164712861','Isotonic solutions','','','Drug Class','',''),('PA164712862','Laxatives','laxatives','','Drug Class','',''),('PA164712863','Leukotriene receptor antagonists','','','Drug Class','',''),('PA164712864','Lincosamides','','','Drug Class','',''),('PA164712865','Lipid Modifying Agents','','','Drug Class','',''),('PA164712866','Lipid Modifying Agents, Combinations','','','Drug Class','',''),('PA164712867','Lipid Modifying Agents, Plain','','','Drug Class','',''),('PA164712868','Liquid plasters','','','Drug Class','',''),('PA164712869','Lithium','','','Drug Class','',''),('PA164712870','Liver Therapy, Lipotropics','','','Drug Class','',''),('PA164712871','Liver therapy','','','Drug Class','',''),('PA164712872','Local Anesthetics','local anesthetics','','Drug Class','',''),('PA164712873','Local hemostatics','','','Drug Class','',''),('PA164712874','Long-acting sulfonamides','','','Drug Class','',''),('PA164712875','Low-ceiling Diuretics, Excl. Thiazides','','','Drug Class','',''),('PA164712876','Low-ceiling Diuretics, Thiazides','','','Drug Class','',''),('PA164712877','Low-ceiling diuretics and potassium-sparing agents','','','Drug Class','',''),('PA164712878','Low-energy diets','','','Drug Class','',''),('PA164712879','Lung surfactants','','','Drug Class','',''),('PA164712880','MAO inhibitors','','','Drug Class','',''),('PA164712881','MAO inhibitors and diuretics','','','Drug Class','',''),('PA164712882','Macrolides','','','Drug Class','',''),('PA164712883','Macrolides, Lincosamides And Streptogramins','','','Drug Class','',''),('PA164712884','Magnesium','','','Drug Class','',''),('PA164712885','Magnesium compounds','','','Drug Class','',''),('PA164712886','Magnetic Resonance Imaging Contrast Media','','','Drug Class','',''),('PA164712887','Measles vaccines','','','Drug Class','',''),('PA164712888','Medical gases','','','Drug Class','',''),('PA164712890','Medicated Dressings','Medicated Dressings','','Drug Class','',''),('PA164712891','Medicated dressings with antiinfectives','','','Drug Class','',''),('PA164712892','Medicated shampoos','','','Drug Class','',''),('PA164712893','Melatonin receptor agonists','','','Drug Class','',''),('PA164712894','Meningococcal vaccines','','','Drug Class','',''),('PA164712895','Mercurial diuretics','','','Drug Class','',''),('PA164712896','Mercurial products','','','Drug Class','',''),('PA164712897','Methanolquinolines','','','Drug Class','',''),('PA164712898','Methyldopa','','','Drug Class','',''),('PA164712899','Methyldopa and diuretics in combination','','','Drug Class','',''),('PA164712900','Methylhydrazines','','','Drug Class','',''),('PA164712901','Milk substitutes','','','Drug Class','',''),('PA164712902','Mineral Supplements','','','Drug Class','',''),('PA164712903','Mineralocorticoids','','','Drug Class','',''),('PA164712904','Monoamine oxidase A inhibitors','','','Drug Class','',''),('PA164712905','Monoamine oxidase B inhibitors','','','Drug Class','',''),('PA164712906','Monoamine oxidase inhibitors, non-selective','','','Drug Class','',''),('PA164712907','Monobactams','','','Drug Class','',''),('PA164712908','Monoclonal antibodies','','','Drug Class','',''),('PA164712909','Morphinan derivatives','','','Drug Class','',''),('PA164712910','Mucolytics','','','Drug Class','',''),('PA164712911','Multivitamins with minerals','','','Drug Class','',''),('PA164712912','Multivitamins, Combinations','','','Drug Class','',''),('PA164712913','Multivitamins, Plain','Multivitamins, plain','','Drug Class','',''),('PA164712914','Multivitamins, other combinations','','','Drug Class','',''),('PA164712916','Mumps vaccines','','','Drug Class','',''),('PA164712917','Muscle Relaxants','','','Drug Class','',''),('PA164712918','Muscle Relaxants, Centrally Acting Agents','','','Drug Class','',''),('PA164712919','Muscle Relaxants, Directly Acting Agents','','','Drug Class','',''),('PA164712920','Muscle relaxants','','','Drug Class','',''),('PA164712921','Musculo-skeletal System','','','Drug Class','',''),('PA164712922','Mydriatics And Cycloplegics','','','Drug Class','',''),('PA164712923','Nasal Decongestants For Systemic Use','','','Drug Class','',''),('PA164712924','Nasal Preparations','','','Drug Class','',''),('PA164712925','Natural and semisynthetic estrogens, plain','','','Drug Class','',''),('PA164712926','Natural opium alkaloids','','','Drug Class','',''),('PA164712927','Nerve depressants','','','Drug Class','',''),('PA164712928','Nervous System','','','Drug Class','',''),('PA164712929','Neuraminidase inhibitors','','','Drug Class','',''),('PA164712930','Nicotinic acid and derivatives','','','Drug Class','',''),('PA164712931','Nicotinic acid and derivatives','','','Drug Class','',''),('PA164712932','Nitroferricyanide derivatives','','','Drug Class','',''),('PA164712933','Nitrofuran derivatives','','','Drug Class','',''),('PA164712934','Nitrofuran derivatives','','','Drug Class','',''),('PA164712935','Nitrofuran derivatives','','','Drug Class','',''),('PA164712936','Nitrogen mustard analogues','','','Drug Class','',''),('PA164712937','Nitroimidazole derivatives','','','Drug Class','',''),('PA164712938','Nitroimidazole derivatives','','','Drug Class','',''),('PA164712939','Nitrosoureas','','','Drug Class','',''),('PA164712940','Non-selective Calcium Channel Blockers','','','Drug Class','',''),('PA164712941','Non-selective beta-adrenoreceptor agonists','','','Drug Class','',''),('PA164712942','Non-watersoluble X-ray contrast media','','','Drug Class','',''),('PA164712943','Nucleoside and nucleotide reverse transcriptase inhibitors','','','Drug Class','',''),('PA164712944','Nutrients without phenylalanine','','','Drug Class','',''),('PA164712945','Ocular Vascular Disorder Agents','','','Drug Class','',''),('PA164712946','Ophthalmological And Otological Preparations','','','Drug Class','',''),('PA164712947','Ophthalmologicals','','','Drug Class','',''),('PA164712948','Opioid anesthetics','','','Drug Class','',''),('PA164712949','Opioids in combination with antispasmodics','','','Drug Class','',''),('PA164712950','Opium alkaloids and derivatives','','','Drug Class','',''),('PA164712951','Opium derivatives and expectorants','','','Drug Class','',''),('PA164712952','Oral rehydration salt formulations','','','Drug Class','',''),('PA164712953','Organic acids','','','Drug Class','',''),('PA164712954','Organophosphorous compounds','','','Drug Class','',''),('PA164712955','Oripavine derivatives','','','Drug Class','',''),('PA164712956','Osmotically acting laxatives','','','Drug Class','',''),('PA164712957','Other Agents Acting On The Renin-angiotensin System','','','Drug Class','',''),('PA164712958','Other Alimentary Tract And Metabolism Products','Other Alimentary Tract And Metabolism Products','','Drug Class','',''),('PA164712960','Other Anabolic Agents','','','Drug Class','',''),('PA164712961','Other Analgesics And Antipyretics','Other analgesics and antipyretics','','Drug Class','',''),('PA164712962','Other Antianemic Preparations','Other antianemic preparations','','Drug Class','',''),('PA164712963','Other Antibacterials','Other antibacterials','','Drug Class','',''),('PA164712964','Other Antidiarrheals','Other antidiarrheals','','Drug Class','',''),('PA164712965','Other Antihypertensives','Other antihypertensives','','Drug Class','',''),('PA164712966','Other Antineoplastic Agents','Other antineoplastic agents','','Drug Class','',''),('PA164712967','Other Cardiac Preparations','Other cardiac preparations','','Drug Class','',''),('PA164712968','Other Cold Combination Preparations','','','Drug Class','',''),('PA164712969','Other Dermatological Preparations','Other Dermatological Preparations','','Drug Class','',''),('PA164712971','Other Diagnostic Agents','Other diagnostic agents','','Drug Class','',''),('PA164712972','Other Diagnostic Radiopharmaceuticals','','','Drug Class','',''),('PA164712973','Other Diuretics','','','Drug Class','',''),('PA164712974','Other Drugs For Acid Related Disorders','','','Drug Class','',''),('PA164712976','Other Drugs For Disorders Of The Musculo-skeletal System','Other Drugs For Disorders Of The Musculo-skeletal System,Other drugs for disorders of the musculo-skeletal system','','Drug Class','',''),('PA164712977','Other Drugs For Obstructive Airway Diseases, Inhalants','Other drugs for obstructive airway diseases, inhalants','','Drug Class','',''),('PA164712978','Other Drugs Used In Diabetes','','','Drug Class','',''),('PA164712980','Other Gynecologicals','Other Gynecologicals,Other gynecologicals','','Drug Class','',''),('PA164712981','Other Hematological Agents','Other Hematological Agents','','Drug Class','',''),('PA164712983','Other Mineral Supplements','','','Drug Class','',''),('PA164712984','Other Nervous System Drugs','Other Nervous System Drugs,Other nervous system drugs','','Drug Class','',''),('PA164712986','Other Nutrients','','','Drug Class','',''),('PA164712987','Other Ophthalmological And Otological Preparations','','','Drug Class','',''),('PA164712988','Other Ophthalmologicals','Other ophthalmologicals','','Drug Class','',''),('PA164712989','Other Otologicals','','','Drug Class','',''),('PA164712990','Other Plain Vitamin Preparations','Other plain vitamin preparations','','Drug Class','',''),('PA164712991','Other Respiratory System Products','Other Respiratory System Products,Other respiratory system products','','Drug Class','',''),('PA164712993','Other Sex Hormones And Modulators Of The Genital System','','','Drug Class','',''),('PA164712994','Other Systemic Drugs For Obstructive Airway Diseases','Other systemic drugs for obstructive airway diseases','','Drug Class','',''),('PA164712995','Other Therapeutic Radiopharmaceuticals','','','Drug Class','',''),('PA164712996','Other Urologicals, Incl. Antispasmodics','','','Drug Class','',''),('PA164712997','Other Vaccines','','','Drug Class','',''),('PA164712998','Other Vitamin Products, Combinations','','','Drug Class','',''),('PA164712999','Other agents against amoebiasis and other protozoal diseases','','','Drug Class','',''),('PA164713000','Other agents against leishmaniasis and trypanosomiasis','','','Drug Class','',''),('PA164713001','Other agents for local oral treatment','','','Drug Class','',''),('PA164713002','Other agents for treatment of hemorrhoids and anal fissures for topical use','','','Drug Class','',''),('PA164713003','Other alkylating agents','','','Drug Class','',''),('PA164713004','Other aminoglycosides','','','Drug Class','',''),('PA164713006','Other anterior pituitary lobe hormones and analogues','','','Drug Class','',''),('PA164713007','Other anti-acne preparations for systemic use','','','Drug Class','',''),('PA164713008','Other anti-acne preparations for topical use','','','Drug Class','',''),('PA164713009','Other anti-dementia drugs','','','Drug Class','',''),('PA164713010','Other anti-parathyroid agents','','','Drug Class','',''),('PA164713011','Other antiallergics','','','Drug Class','',''),('PA164713014','Other antibiotics for topical use','','','Drug Class','',''),('PA164713015','Other anticestodals','','','Drug Class','',''),('PA164713016','Other antidepressants','','','Drug Class','',''),('PA164713018','Other antiemetics','','','Drug Class','',''),('PA164713019','Other antiepileptics','','','Drug Class','',''),('PA164713020','Other antifungals for topical use','','','Drug Class','',''),('PA164713021','Other antiglaucoma preparations','','','Drug Class','',''),('PA164713022','Other antigout preparations','','','Drug Class','',''),('PA164713023','Other antihistamines for systemic use','','','Drug Class','',''),('PA164713025','Other antihypertensives and diuretics','','','Drug Class','',''),('PA164713026','Other antiinfectives','','','Drug Class','',''),('PA164713027','Other antiinfectives and antiseptics','','','Drug Class','',''),('PA164713028','Other antiinflammatory and antirheumatic agents, non-steroids','','','Drug Class','',''),('PA164713029','Other antiinflammatory therapeutic radiopharmaceuticals','','','Drug Class','',''),('PA164713030','Other antiinflammatory/antirheumatic agents in combination with other drugs','','','Drug Class','',''),('PA164713031','Other antimalarials','','','Drug Class','',''),('PA164713032','Other antimigraine preparations','','','Drug Class','',''),('PA164713033','Other antimycotics for systemic use','','','Drug Class','',''),('PA164713034','Other antinematodals','','','Drug Class','',''),('PA164713036','Other antiobesity drugs','','','Drug Class','',''),('PA164713037','Other antipruritics','','','Drug Class','',''),('PA164713038','Other antipsoriatics for systemic use','','','Drug Class','',''),('PA164713039','Other antipsoriatics for topical use','','','Drug Class','',''),('PA164713040','Other antipsychotics','','','Drug Class','',''),('PA164713041','Other antiseptics and disinfectants','','','Drug Class','',''),('PA164713042','Other antispasmodics in combination with analgesics','','','Drug Class','',''),('PA164713043','Other antispasmodics in combination with psycholeptics','','','Drug Class','',''),('PA164713044','Other antithrombotic agents','','','Drug Class','',''),('PA164713045','Other antithyroid preparations','','','Drug Class','',''),('PA164713046','Other antitrematodal agents','','','Drug Class','',''),('PA164713047','Other antivirals','','','Drug Class','',''),('PA164713048','Other anxiolytics','','','Drug Class','',''),('PA164713049','Other bacterial vaccines','','','Drug Class','',''),('PA164713050','Other blood glucose lowering drugs, excl. insulins','','','Drug Class','',''),('PA164713051','Other capillary stabilizing agents','','','Drug Class','',''),('PA164713052','Other cardiac combination products','','','Drug Class','',''),('PA164713053','Other cardiac glycosides','','','Drug Class','',''),('PA164713055','Other cardiac stimulants','','','Drug Class','',''),('PA164713056','Other cardiovascular system diagnostic radiopharmaceuticals','','','Drug Class','',''),('PA164713057','Other central nervous system diagnostic radiopharmaceuticals','','','Drug Class','',''),('PA164713058','Other centrally acting agents','','','Drug Class','',''),('PA164713059','Other cephalosporins','','','Drug Class','',''),('PA164713060','Other chemotherapeutics','','','Drug Class','',''),('PA164713061','Other cicatrizants','','','Drug Class','',''),('PA164713062','Other class I antiarrhythmics','','','Drug Class','',''),('PA164713063','Other combinations of nutrients','','','Drug Class','',''),('PA164713064','Other cough suppressants','','','Drug Class','',''),('PA164713065','Other cough suppressants and expectorants','','','Drug Class','',''),('PA164713066','Other cytotoxic antibiotics','','','Drug Class','',''),('PA164713067','Other dermatologicals','','','Drug Class','',''),('PA164713069','Other diagnostic radiopharmaceuticals for inflammation and infection detection','','','Drug Class','',''),('PA164713070','Other diagnostic radiopharmaceuticals for tumour detection','','','Drug Class','',''),('PA164713071','Other dopaminergic agents','','','Drug Class','',''),('PA164713072','Other drugs affecting bone structure and mineralization','','','Drug Class','',''),('PA164713073','Other drugs for bile therapy','','','Drug Class','',''),('PA164713075','Other drugs for functional bowel disorders','','','Drug Class','',''),('PA164713077','Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)','','','Drug Class','',''),('PA164713078','Other drugs for treatment of tuberculosis','','','Drug Class','',''),('PA164713079','Other drugs used in benign prostatic hypertrophy','','','Drug Class','',''),('PA164713080','Other ectoparasiticides, incl. scabicides','','','Drug Class','',''),('PA164713081','Other emollients and protectives','','','Drug Class','',''),('PA164713082','Other estrogens','','','Drug Class','',''),('PA164713083','Other general anesthetics','','','Drug Class','',''),('PA164713085','Other hem products','','','Drug Class','',''),('PA164713086','Other hepatic and reticulo endothelial system diagnostic radiopharmaceuticals','','','Drug Class','',''),('PA164713087','Other high-ceiling diuretics','','','Drug Class','',''),('PA164713088','Other hormone antagonists and related agents','','','Drug Class','',''),('PA164713089','Other hormones','','','Drug Class','',''),('PA164713090','Other hypnotics and sedatives','','','Drug Class','',''),('PA164713091','Other i.v. solution additives','','','Drug Class','',''),('PA164713092','Other immunoglobulins','','','Drug Class','',''),('PA164713093','Other immunostimulants','','','Drug Class','',''),('PA164713094','Other immunosuppressants','','','Drug Class','',''),('PA164713095','Other insecticides and repellents','','','Drug Class','',''),('PA164713096','Other intestinal adsorbents','','','Drug Class','',''),('PA164713097','Other intestinal antiinfectives','','','Drug Class','',''),('PA164713098','Other irrigating solutions','','','Drug Class','',''),('PA164713099','Other laxatives','','','Drug Class','',''),('PA164713100','Other lipid modifying agents','','','Drug Class','',''),('PA164713101','Other local anesthetics','','','Drug Class','',''),('PA164713102','Other low-ceiling diuretics','','','Drug Class','',''),('PA164713103','Other magnetic resonance imaging contrast media','','','Drug Class','',''),('PA164713104','Other mineral products','','','Drug Class','',''),('PA164713105','Other muscle relaxants, peripherally acting agents','','','Drug Class','',''),('PA164713106','Other nasal preparations','','','Drug Class','',''),('PA164713108','Other non-selective calcium channel blockers','','','Drug Class','',''),('PA164713109','Other non-therapeutic auxiliary products','','','Drug Class','',''),('PA164713110','Other ophthalmological diagnostic agents','','','Drug Class','',''),('PA164713112','Other opioids','','','Drug Class','',''),('PA164713113','Other oxytocics','','','Drug Class','',''),('PA164713114','Other parasympathomimetics','','','Drug Class','',''),('PA164713115','Other peripheral vasodilators','','','Drug Class','',''),('PA164713117','Other plant alkaloids and natural products','','','Drug Class','',''),('PA164713118','Other potassium-sparing agents','','','Drug Class','',''),('PA164713119','Other psychostimulants and nootropics','','','Drug Class','',''),('PA164713120','Other quaternary ammonium compounds','','','Drug Class','',''),('PA164713121','Other quinolones','','','Drug Class','',''),('PA164713122','Other renal system diagnostic radiopharmaceuticals','','','Drug Class','',''),('PA164713123','Other respiratory system diagnostic radiopharmaceuticals','','','Drug Class','',''),('PA164713125','Other sclerosing agents','','','Drug Class','',''),('PA164713126','Other selective calcium channel blockers with mainly vascular effects','','','Drug Class','',''),('PA164713127','Other specific antirheumatic agents','','','Drug Class','',''),('PA164713128','Other surgical aids','','','Drug Class','',''),('PA164713130','Other systemic hemostatics','','','Drug Class','',''),('PA164713131','Other therapeutic products','','','Drug Class','',''),('PA164713132','Other topical products for joint and muscular pain','','','Drug Class','',''),('PA164713133','Other urologicals','','','Drug Class','',''),('PA164713134','Other vasodilators used in cardiac diseases','','','Drug Class','',''),('PA164713135','Other viral vaccines','','','Drug Class','',''),('PA164713136','Otologicals','','','Drug Class','',''),('PA164713137','Ovulation stimulants, synthetic','','','Drug Class','',''),('PA164713138','Oxazol, thiazine, and triazine derivatives','','','Drug Class','',''),('PA164713139','Oxazolidine derivatives','','','Drug Class','',''),('PA164713140','Oxicams','','','Drug Class','',''),('PA164713141','Oxytocics','','','Drug Class','',''),('PA164713142','Oxytocin and analogues','','','Drug Class','',''),('PA164713143','Pain Palliation (bone Seeking Agents)','','','Drug Class','',''),('PA164713144','Pancreatic Hormones','','','Drug Class','',''),('PA164713145','Papaverine and derivatives','','','Drug Class','',''),('PA164713146','Papillomavirus vaccines','','','Drug Class','',''),('PA164713147','Paramagnetic contrast media','','','Drug Class','',''),('PA164713148','Parasympathomimetics','','','Drug Class','',''),('PA164713149','Parasympathomimetics','','','Drug Class','',''),('PA164713150','Parathyroid Hormones And Analogues','Parathyroid hormones and analogues','','Drug Class','',''),('PA164713152','Penicillamine and similar agents','','','Drug Class','',''),('PA164713153','Penicillins with extended spectrum','','','Drug Class','',''),('PA164713154','Perchlorates','','','Drug Class','',''),('PA164713156','Peripheral Vasodilators','Peripheral Vasodilators','','Drug Class','',''),('PA164713157','Peripherally acting antiobesity products','','','Drug Class','',''),('PA164713158','Peritoneal Dialytics','','','Drug Class','',''),('PA164713159','Peroxides','','','Drug Class','',''),('PA164713160','Pertussis vaccines','','','Drug Class','',''),('PA164713161','Phenol and derivatives','','','Drug Class','',''),('PA164713162','Phenothiazine derivatives','','','Drug Class','',''),('PA164713163','Phenylalkylamine derivatives','','','Drug Class','',''),('PA164713164','Phenylalkylamine derivatives','','','Drug Class','',''),('PA164713165','Phenylpiperidine derivatives','','','Drug Class','',''),('PA164713166','Phosphodiesterase inhibitors','','','Drug Class','',''),('PA164713167','Phosphonic acid derivatives','','','Drug Class','',''),('PA164713168','Piperazine and derivatives','','','Drug Class','',''),('PA164713169','Piperazine derivatives','','','Drug Class','',''),('PA164713170','Piperidinedione derivatives','','','Drug Class','',''),('PA164713171','Pituitary And Hypothalamic Hormones And Analogues','','','Drug Class','',''),('PA164713172','Plague vaccines','','','Drug Class','',''),('PA164713173','Plant Alkaloids And Other Natural Products','','','Drug Class','',''),('PA164713174','Plasters','','','Drug Class','',''),('PA164713175','Platelet aggregation inhibitors excl. heparin','','','Drug Class','',''),('PA164713176','Platinum compounds','','','Drug Class','',''),('PA164713177','Pneumococcal vaccines','','','Drug Class','',''),('PA164713178','Polymyxins','','','Drug Class','',''),('PA164713179','Posterior Pituitary Lobe Hormones','','','Drug Class','',''),('PA164713181','Potassium','Potassium','','Drug Class','',''),('PA164713182','Potassium-sparing Agents','','','Drug Class','',''),('PA164713183','Pregnadien derivatives','','','Drug Class','',''),('PA164713184','Pregnen (4) derivatives','','','Drug Class','',''),('PA164713185','Preparations For Treatment Of Wounds And Ulcers','','','Drug Class','',''),('PA164713186','Preparations containing sulfur','','','Drug Class','',''),('PA164713187','Preparations for biliary tract therapy','','','Drug Class','',''),('PA164713188','Preparations increasing uric acid excretion','uricosurics','','Drug Class','',''),('PA164713189','Preparations inhibiting uric acid production','','','Drug Class','',''),('PA164713190','Preparations with no effect on uric acid metabolism','','','Drug Class','',''),('PA164713191','Preparations with salicylic acid derivatives','','','Drug Class','',''),('PA164713192','Progestogens','','','Drug Class','',''),('PA164713193','Progestogens','','','Drug Class','',''),('PA164713194','Progestogens','','','Drug Class','',''),('PA164713195','Progestogens and estrogens, fixed combinations','','','Drug Class','',''),('PA164713196','Progestogens and estrogens, sequential preparations','','','Drug Class','',''),('PA164713197','Prolactine inhibitors','','','Drug Class','',''),('PA164713199','Propulsives','Propulsives','','Drug Class','',''),('PA164713200','Prostaglandin analogues','','','Drug Class','',''),('PA164713201','Protectives Against Uv-radiation','','','Drug Class','',''),('PA164713202','Protectives against UV-radiation for systemic use','','','Drug Class','',''),('PA164713203','Protectives against UV-radiation for topical use','','','Drug Class','',''),('PA164713204','Protein kinase inhibitors','','','Drug Class','',''),('PA164713205','Proteinase inhibitors','','','Drug Class','',''),('PA164713206','Proteolytic enzymes','','','Drug Class','',''),('PA164713207','Proton pump inhibitors','','','Drug Class','',''),('PA164713208','Psoralens for systemic use','','','Drug Class','',''),('PA164713209','Psoralens for topical use','','','Drug Class','',''),('PA164713210','Psychoanaleptics','','','Drug Class','',''),('PA164713211','Psycholeptics','','','Drug Class','',''),('PA164713212','Psycholeptics And Psychoanaleptics In Combination','','','Drug Class','',''),('PA164713213','Psychostimulants in combination with psycholeptics','','','Drug Class','',''),('PA164713214','Psychostimulants, Agents Used For Adhd And Nootropics','','','Drug Class','',''),('PA164713215','Purine derivatives','','','Drug Class','',''),('PA164713216','Pyrazolone derivatives','','','Drug Class','',''),('PA164713217','Pyrazolones','','','Drug Class','',''),('PA164713218','Pyrethrines','','','Drug Class','',''),('PA164713219','Pyrethrines, incl. synthetic compounds','','','Drug Class','',''),('PA164713220','Pyrimidine analogues','','','Drug Class','',''),('PA164713221','Pyrimidine derivatives','','','Drug Class','',''),('PA164713222','Quaternary ammonium compounds','','','Drug Class','',''),('PA164713223','Quinine and derivatives','','','Drug Class','',''),('PA164713224','Quinoline derivatives','','','Drug Class','',''),('PA164713225','Quinoline derivatives','','','Drug Class','',''),('PA164713226','Quinoline derivatives and corticosteroids','','','Drug Class','',''),('PA164713227','Quinoline derivatives and related substances','','','Drug Class','',''),('PA164713228','Quinolines','','','Drug Class','',''),('PA164713229','Quinolone Antibacterials','','','Drug Class','',''),('PA164713230','Quinolone vasodilators','','','Drug Class','',''),('PA164713231','Rauwolfia alkaloids','','','Drug Class','',''),('PA164713232','Rauwolfia alkaloids and diuretics in combination','','','Drug Class','',''),('PA164713233','Renal System','','','Drug Class','',''),('PA164713234','Renin-inhibitors','','','Drug Class','',''),('PA164713235','Respiratory System','','','Drug Class','',''),('PA164713236','Respiratory System','','','Drug Class','',''),('PA164713237','Respiratory stimulants','','','Drug Class','',''),('PA164713238','Retinoids for topical use in acne','','','Drug Class','',''),('PA164713239','Retinoids for treatment of acne','','','Drug Class','',''),('PA164713240','Retinoids for treatment of psoriasis','','','Drug Class','',''),('PA164713241','Rota virus diarrhea vaccines','','','Drug Class','',''),('PA164713242','Rubella vaccines','','','Drug Class','',''),('PA164713243','Salicylic acid and derivatives','','','Drug Class','',''),('PA164713244','Salicylic acid derivatives','','','Drug Class','',''),('PA164713245','Salicylic acid preparations','','','Drug Class','',''),('PA164713246','Salt solutions','','','Drug Class','',''),('PA164713247','Scilla glycosides','','','Drug Class','',''),('PA164713248','Sclerosing agents for local injection','','','Drug Class','',''),('PA164713249','Second-generation cephalosporins','','','Drug Class','',''),('PA164713250','Secondary and tertiary amines','','','Drug Class','',''),('PA164713251','Selective Calcium Channel Blockers With Direct Cardiac Effects','','','Drug Class','',''),('PA164713252','Selective Calcium Channel Blockers With Mainly Vascular Effects','','','Drug Class','',''),('PA164713253','Selective beta-2-adrenoreceptor agonists','','','Drug Class','',''),('PA164713254','Selective estrogen receptor modulators','','','Drug Class','',''),('PA164713255','Selective immunosuppressants','','','Drug Class','',''),('PA164713256','Selective serotonin (5HT1) agonists','','','Drug Class','',''),('PA164713257','Selective serotonin reuptake inhibitors','SSRI,SSRIs','','Drug Class','',''),('PA164713258','Sensitivity tests, discs and tablets','','','Drug Class','',''),('PA164713259','Sensitizers used in photodynamic/radiation therapy','','','Drug Class','',''),('PA164713260','Sensory Organs','','','Drug Class','',''),('PA164713261','Serotonin (5HT3) antagonists','','','Drug Class','',''),('PA164713262','Serotonin antagonists','','','Drug Class','',''),('PA164713263','Serotonin antagonists and diuretics','','','Drug Class','',''),('PA164713264','Sex Hormones And Modulators Of The Genital System','','','Drug Class','',''),('PA164713265','Short-acting sulfonamides','','','Drug Class','',''),('PA164713266','Silver compounds','','','Drug Class','',''),('PA164713267','Skeleton','','','Drug Class','',''),('PA164713268','Solutions affecting the electrolyte balance','','','Drug Class','',''),('PA164713269','Solutions for parenteral nutrition','','','Drug Class','',''),('PA164713270','Solutions producing osmotic diuresis','','','Drug Class','',''),('PA164713271','Solvents and diluting agents, incl. irrigating solutions','','','Drug Class','',''),('PA164713272','Somatropin and somatropin agonists','','','Drug Class','',''),('PA164713273','Specific Antirheumatic Agents','','','Drug Class','',''),('PA164713274','Specific immunoglobulins','','','Drug Class','',''),('PA164713275','Steroid antibacterials','','','Drug Class','',''),('PA164713276','Stomatological Preparations','Stomatological Preparations','','Drug Class','',''),('PA164713278','Stomi equipment','','','Drug Class','',''),('PA164713279','Streptogramins','','','Drug Class','',''),('PA164713280','Streptomycins','','','Drug Class','',''),('PA164713281','Strophantus glycosides','','','Drug Class','',''),('PA164713282','Substituted alkylamines','','','Drug Class','',''),('PA164713283','Substituted ethylene diamines','','','Drug Class','',''),('PA164713284','Succinimide derivatives','','','Drug Class','',''),('PA164713285','Sulfonamides','','','Drug Class','',''),('PA164713286','Sulfonamides','','','Drug Class','',''),('PA164713287','Sulfonamides','','','Drug Class','',''),('PA164713288','Sulfonamides (heterocyclic)','','','Drug Class','',''),('PA164713289','Sulfonamides And Trimethoprim','','','Drug Class','',''),('PA164713290','Sulfonamides and corticosteroids','','','Drug Class','',''),('PA164713291','Sulfonamides and potassium in combination','','','Drug Class','',''),('PA164713292','Sulfonamides and potassium in combination','','','Drug Class','',''),('PA164713293','Sulfonamides, combinations with other drugs','','','Drug Class','',''),('PA164713294','Sulfonamides, plain','','','Drug Class','',''),('PA164713295','Sulfonium derivatives','','','Drug Class','',''),('PA164713296','Sulfur containing products','','','Drug Class','',''),('PA164713297','Sulfur-containing imidazole derivatives','','','Drug Class','',''),('PA164713298','Superparamagnetic contrast media','','','Drug Class','',''),('PA164713299','Surgical Aids','','','Drug Class','',''),('PA164713300','Surgical Dressings','','','Drug Class','',''),('PA164713301','Sympathomimetics','','','Drug Class','',''),('PA164713302','Sympathomimetics excl. antiglaucoma preparations','','','Drug Class','',''),('PA164713303','Sympathomimetics in glaucoma therapy','','','Drug Class','',''),('PA164713304','Sympathomimetics used as decongestants','','','Drug Class','',''),('PA164713305','Sympathomimetics, combinations excl. corticosteroids','','','Drug Class','',''),('PA164713306','Sympathomimetics, labour repressants','','','Drug Class','',''),('PA164713307','Sympathomimetics, plain','','','Drug Class','',''),('PA164713308','Synthetic anticholinergic agents in combination with analgesics','','','Drug Class','',''),('PA164713309','Synthetic anticholinergic agents in combination with psycholeptics','','','Drug Class','',''),('PA164713310','Synthetic anticholinergics, esters with tertiary amino group','','','Drug Class','',''),('PA164713311','Synthetic anticholinergics, quaternary ammonium compounds','','','Drug Class','',''),('PA164713312','Synthetic antispasmodics, amides with tertiary amines','','','Drug Class','',''),('PA164713313','Synthetic estrogens, plain','','','Drug Class','',''),('PA164713314','Systemic Hormonal Preparations, Excl.','','','Drug Class','',''),('PA164713315','Tars','','','Drug Class','',''),('PA164713316','Technetium (99mTc) compounds','','','Drug Class','',''),('PA164713317','Technetium (99mTc) compounds','','','Drug Class','',''),('PA164713318','Technetium (99mTc) compounds','','','Drug Class','',''),('PA164713319','Technetium (99mTc) compounds','','','Drug Class','',''),('PA164713320','Technetium (99mTc) compounds','','','Drug Class','',''),('PA164713321','Technetium (99mTc) compounds','','','Drug Class','',''),('PA164713322','Technetium (99mTc) compounds','','','Drug Class','',''),('PA164713323','Technetium (99mTc), inhalants','','','Drug Class','',''),('PA164713324','Technetium (99mTc), particles and colloids','','','Drug Class','',''),('PA164713325','Technetium (99mTc), particles for injection','','','Drug Class','',''),('PA164713326','Technical disinfectants','','','Drug Class','',''),('PA164713327','Tertiary amines','','','Drug Class','',''),('PA164713328','Testosterone-5-alpha reductase inhibitors','','','Drug Class','',''),('PA164713329','Tests for allergic diseases','','','Drug Class','',''),('PA164713330','Tests for bile duct patency','','','Drug Class','',''),('PA164713331','Tests for diabetes','','','Drug Class','',''),('PA164713332','Tests for fat absorption','','','Drug Class','',''),('PA164713333','Tests for fertility disturbances','','','Drug Class','',''),('PA164713334','Tests for gastric secretion','','','Drug Class','',''),('PA164713335','Tests for liver functional capacity','','','Drug Class','',''),('PA164713336','Tests for pancreatic function','','','Drug Class','',''),('PA164713337','Tests for pituitary function','','','Drug Class','',''),('PA164713338','Tests for renal function','','','Drug Class','',''),('PA164713339','Tests for thyreoidea function','','','Drug Class','',''),('PA164713340','Tetracycline and derivatives','','','Drug Class','',''),('PA164713341','Tetracyclines','tetracyclines','','Drug Class','',''),('PA164713342','Tetrahydropyrimidine derivatives','','','Drug Class','',''),('PA164713343','Therapeutic Radiopharmaceuticals','','','Drug Class','',''),('PA164713344','Thiazides and potassium in combination','','','Drug Class','',''),('PA164713345','Thiazides, combinations with other drugs','','','Drug Class','',''),('PA164713346','Thiazides, combinations with psycholeptics and/or analgesics','','','Drug Class','',''),('PA164713347','Thiazides, plain','','','Drug Class','',''),('PA164713348','Thiocarbamide derivatives','','','Drug Class','',''),('PA164713349','Thiosemicarbazones','','','Drug Class','',''),('PA164713350','Thiouracils','','','Drug Class','',''),('PA164713351','Third-generation cephalosporins','','','Drug Class','',''),('PA164713353','Throat Preparations','Throat Preparations','','Drug Class','',''),('PA164713354','Thyroid','','','Drug Class','',''),('PA164713355','Thyroid Therapy','','','Drug Class','',''),('PA164713356','Tissue adhesives','','','Drug Class','',''),('PA164713357','Tonics','Tonics','','Drug Class','',''),('PA164713360','Topical Products For Joint And Muscular Pain','Topical Products For Joint And Muscular Pain','','Drug Class','',''),('PA164713361','Triazole derivatives','','','Drug Class','',''),('PA164713362','Triazole derivatives','','','Drug Class','',''),('PA164713363','Trimethoprim and derivatives','','','Drug Class','',''),('PA164713364','Tuberculosis diagnostics','','','Drug Class','',''),('PA164713365','Tuberculosis vaccines','','','Drug Class','',''),('PA164713366','Tumor necrosis factor alpha (TNF-alpha) inhibitors','','','Drug Class','',''),('PA164713367','Tumour Detection','','','Drug Class','',''),('PA164713368','Typhoid vaccines','','','Drug Class','',''),('PA164713369','Typhus (exanthematicus) vaccines','','','Drug Class','',''),('PA164713370','Tyrosine hydroxylase inhibitors','','','Drug Class','',''),('PA164713371','Ultrasound Contrast Media','Ultrasound contrast media','','Drug Class','',''),('PA164713373','Unclassified','','','Drug Class','',''),('PA164713374','Urinary antispasmodics','','','Drug Class','',''),('PA164713375','Urinary concrement solvents','','','Drug Class','',''),('PA164713376','Urine Tests','','','Drug Class','',''),('PA164713377','Urologicals','','','Drug Class','',''),('PA164713378','Vaccines','','','Drug Class','',''),('PA164713379','Varicella zoster vaccines','','','Drug Class','',''),('PA164713380','Various','','','Drug Class','',''),('PA164713381','Various alimentary tract and metabolism products','','','Drug Class','',''),('PA164713382','Various diagnostic radiopharmaceuticals','','','Drug Class','',''),('PA164713383','Various pain palliation radiopharmaceuticals','','','Drug Class','',''),('PA164713384','Various therapeutic radiopharmaceuticals','','','Drug Class','',''),('PA164713385','Various thyroid diagnostic radiopharmaceuticals','','','Drug Class','',''),('PA164713386','Vasodilators Used In Cardiac Diseases','','','Drug Class','',''),('PA164713387','Vasopressin and analogues','','','Drug Class','',''),('PA164713388','Vasopressin antagonists','','','Drug Class','',''),('PA164713389','Vasoprotectives','','','Drug Class','',''),('PA164713390','Viral Vaccines','','','Drug Class','',''),('PA164713391','Viscoelastic substances','','','Drug Class','',''),('PA164713392','Vitamin A And D, Incl. Combinations Of The Two','','','Drug Class','',''),('PA164713393','Vitamin A and D in combination','','','Drug Class','',''),('PA164713394','Vitamin A, plain','','','Drug Class','',''),('PA164713395','Vitamin B-complex with anabolic steroids','','','Drug Class','',''),('PA164713396','Vitamin B-complex with minerals','','','Drug Class','',''),('PA164713397','Vitamin B-complex with vitamin C','','','Drug Class','',''),('PA164713398','Vitamin B-complex, Incl. Combinations','','','Drug Class','',''),('PA164713399','Vitamin B-complex, other combinations','','','Drug Class','',''),('PA164713400','Vitamin B1 in combination with vitamin B6 and/or vitamin B12','','','Drug Class','',''),('PA164713401','Vitamin B1, Plain And In Combination With Vitamin B6 And B12','','','Drug Class','',''),('PA164713402','Vitamin B1, plain','','','Drug Class','',''),('PA164713403','Vitamin B12 (cyanocobalamin and analogues)','','','Drug Class','',''),('PA164713404','Vitamin K','','','Drug Class','',''),('PA164713405','Vitamin K And Other Hemostatics','','','Drug Class','',''),('PA164713406','Vitamin K antagonists','','','Drug Class','',''),('PA164713407','Vitamins','','','Drug Class','',''),('PA164713408','Vitamins','','','Drug Class','',''),('PA164713409','Vitamins with minerals','','','Drug Class','',''),('PA164713410','Vitamins, other combinations','','','Drug Class','',''),('PA164713411','Wart and anti-corn preparations','','','Drug Class','',''),('PA164713412','Washing agents etc.','','','Drug Class','',''),('PA164713413','Watersoluble, hepatotropic X-ray contrast media','','','Drug Class','',''),('PA164713414','Watersoluble, nephrotropic, high osmolar X-ray contrast media','','','Drug Class','',''),('PA164713415','Watersoluble, nephrotropic, low osmolar X-ray contrast media','','','Drug Class','',''),('PA164713416','X-ray Contrast Media, Iodinated','','','Drug Class','',''),('PA164713417','X-ray Contrast Media, Non-iodinated','','','Drug Class','',''),('PA164713418','Xanthine derivatives','','','Drug Class','',''),('PA164713419','Xanthine derivatives','','','Drug Class','',''),('PA164713420','Xanthines','','','Drug Class','',''),('PA164713421','Xanthines and adrenergics','','','Drug Class','',''),('PA164713422','Yellow fever vaccines','','','Drug Class','',''),('PA164713423','Yttrium (90Y) compounds','','','Drug Class','',''),('PA164713424','Zinc','','','Drug Class','',''),('PA164713425','Zinc bandages','','','Drug Class','',''),('PA164713426','Zinc products','','','Drug Class','',''),('PA164738432','AZD1152','','','Drug/Small Molecule','',''),('PA164740891','zanamivir','GANA,GNA,Modified sialic acid,ZMR,Zanamavir','Relenza','Drug/Small Molecule','DailyMed:d7c3bcc3-0c0d-4068-fd80-88cf54a376ef,HET:ZMR,TTD:DAP000715,bindingDb:4934,chebi:50663,chemSpider:54842,dpd:2240863,drugBank:DB00558,keggCompound:C08095,keggDrug:D00902,ndc:0173-0681-01,pdb:ZMR,pubChemCompound:60855,pubChemSubstance:197092,pubChemSubstance:46508581,url:http://en.wikipedia.org/wiki/Zanamivir','CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@@H]([C@@H](CO)O)O)C(=O)O)NC(=N)N'),('PA164742856','pefloxacin','','PFLX,Pefloxacin [INN-French],Pefloxacin mesylate,P','Drug/Small Molecule','TTD:DAP001001,chebi:50199,chemSpider:46291,drugBank:DB00487,keggDrug:D02306,pubChemCompound:51081,pubChemSubstance:189349,pubChemSubstance:46507338,url:http://en.wikipedia.org/wiki/Pefloxacin',''),('PA164742902','hesperetin','Cyanidanon 4\'-Methyl Ether 1626,Hesperitin,YSO2','Hesperin','Drug/Small Molecule','TTD:DAP001306,bindingDb:23418,chebi:28230,chemSpider:65234,drugBank:DB01094,keggCompound:C01709,pubChemCompound:72281,pubChemSubstance:46507998,pubChemSubstance:4847,url:http://en.wikipedia.org/wiki/Hesperetin','COc1ccc(cc1O)[C@@H]2CC(=O)c3c(cc(cc3O2)O)O'),('PA164742933','oxybenzone','(2-Hydroxy-4-methoxyphenyl)phenylmethanone,2-Benzoyl-5-methoxyphenol,2-Hydroxy-4-methoxybenzophenone,4-Methoxy-2-hydroxybenzophenone,4-Methoxy-2-hydro','','Drug/Small Molecule','bindingDb:50253134,chemSpider:4471,drugBank:DB01428,keggCompound:C14285,keggDrug:D05309,pubChemCompound:4632,pubChemSubstance:10421298,pubChemSubstance:46508419,url:http://en.wikipedia.org/wiki/Oxybenzone','COc1ccc(c(c1)O)C(=O)c2ccccc2'),('PA164742934','imiglucerase','Acid beta-glucosidase,Beta-glucocerebrosidase,D-glucosyl-N-acylsphingosine glucohydrolase,Glucosylceramidase precursor','Ceredase,Cerezyme','Drug/Small Molecule','DailyMed:df60f030-866b-4374-a31f-8ae3f6b45c38,dpd:2241751,drugBank:DB00053,genBank:M16328,keggDrug:D02810,ndc:58468-4663-1,uniProtKb:P04062,url:http://en.wikipedia.org/wiki/Imiglucerase',''),('PA164742936','metrizamide','','Amipaque','Drug/Small Molecule','chemSpider:391998,drugBank:DB01578,pubChemCompound:443944,pubChemSubstance:10299434,pubChemSubstance:46506223',''),('PA164742937','cyclizine','Ciclizina [INN-Spanish],Cyclizine Chloride,Cyclizine Hydrochloride,Cyclizinum [INN-Latin]','Emoquil,Marazine,Marezine,Marezine Hydrochloride,M','Drug/Small Molecule','TTD:DAP000337,chebi:3994,chemSpider:6470,dpd:4448,drugBank:DB01176,keggCompound:C06930,keggDrug:D03621,pubChemCompound:6726,pubChemSubstance:46506232,pubChemSubstance:9147,url:http://en.wikipedia.org/wiki/Cyclizine',''),('PA164742938','anidulafungin','anidulafungin','Eraxis','Drug/Small Molecule','DailyMed:a88d9010-55fb-4a02-baff-042cd27688ea,TTD:DAP000546,chebi:55346,chemSpider:145752,drugBank:DB00362,keggDrug:D03211,ndc:0049-0114-28,pubChemCompound:166548,pubChemSubstance:46505616,pubChemSubstance:743929,url:http://en.wikipedia.org/wiki/Anidulafungin',''),('PA164742939','conivaptan','Conivaptan hydrochloride,YM 087,YM-087,conivaptan','Vaprisol','Drug/Small Molecule','TTD:DNC001525,chebi:681850,chemSpider:133239,drugBank:DB00872,keggDrug:D01236,pubChemCompound:151171,pubChemSubstance:46504533,pubChemSubstance:728713,url:http://en.wikipedia.org/wiki/Conivaptan',''),('PA164742949','pramipexole','Furfuryl Acetate,Pramipexol,Pramipexol [Spanish],Pramipexole 2HCl Monohydrate,Pramipexole hydrochloride,Pramipexolum [Latin],pramipexole','Mirapex','Drug/Small Molecule','DailyMed:688fa4d7-de12-4930-8bc5-0169297c1da6,TTD:DAP000019,bindingDb:50226040,chebi:8356,dpd:2241594,drugBank:DB00413,keggDrug:D00559,ndc:0597-0183-90,pubChemCompound:59868,pubChemSubstance:196318,url:http://en.wikipedia.org/wiki/Pramipexole','CCCN[C@H]1CCc2c(sc(n2)N)C1'),('PA164742950','olmesartan','DE-092,Olmesartan medoximil,Olmesartan medoxomil,olmesartan','Benicar,Benicar HCT,Olmetec,Votum','Drug/Small Molecule','DailyMed:33770d80-754f-11de-8dba-0002a5d5c51b,TTD:DAP001412,chebi:48416,drugBank:DB00275,keggDrug:D01204,ndc:65597-101-30,pubChemCompound:130881,pubChemSubstance:707351,url:http://en.wikipedia.org/wiki/Olmesartan','CCCc1nc(c(n1Cc2ccc(cc2)c3ccccc3c4n[nH]nn4)C(=O)OCc5c(oc(=O)o5)C)C(C)(C)O'),('PA164742966','deserpidine','Deresperine,Desepridine,Deserpidin,Deserpidina [INN-Spanish],Deserpidinum [INN-Latin],Deserpine,Desmethoxyreserpine','Aescin,Canescin,Canescine,Enduronyl,Harmonyl,Rauno','Drug/Small Molecule','TTD:DAP000909,chebi:27478,chemSpider:8232,drugBank:DB01089,keggCompound:C06541,pubChemCompound:8550,pubChemSubstance:46505311,pubChemSubstance:8771',''),('PA164742970','carbimazole','Athyromazole,Carbethoxymethimazole,Carbimazol,Carbimazol [INN-Spanish, French],Carbimazolum [INN-Latin],Carbinazole','Atirozidina,Basolest,CG1,Carbimazol Spofa,Carbotir','Drug/Small Molecule','TTD:DAP000762,chebi:617099,chemSpider:28829,drugBank:DB00389,keggCompound:C07615,pubChemCompound:31072,pubChemSubstance:46506359,pubChemSubstance:9817,url:http://en.wikipedia.org/wiki/Carbimazole','CCOC(=O)n1ccn(c1=S)C'),('PA164742986','anagrelide','Anagrelide HCL,Anagrelide Hydrochloride,BL-4162A','Agrylin,Xagrid','Drug/Small Molecule','TTD:DAP000612,bindingDb:50000334,chebi:142290,dpd:2260107,drugBank:DB00261,keggDrug:D02933,ndc:0378-6868-01,pubChemCompound:2182,pubChemSubstance:660898,url:http://en.wikipedia.org/wiki/Anagrelide','c1cc(c(c2c1N=C3NC(=O)CN3C2)Cl)Cl'),('PA164742987','clavulanate','Clavulanic Acid','','','',''),('PA164742988','levocabastine','Levocabastin,Levocabastina [Spanish],Levocabastinum [Latin]','Livostin','Drug/Small Molecule','DailyMed:420b3f66-87f0-47d8-947c-541e84eb594a,TTD:DAP000335,chemSpider:49123,dpd:2131625,drugBank:DB01106,iupharLigand:1586,keggDrug:D01717,ndc:58768-610-10,pubChemCompound:54385,pubChemSubstance:46505909,pubChemSubstance:667972,url:http://en.wikipedia.org/wiki/Levocabastine','C[C@H]1[C@@](CCN(C1)[C@H]2CC[C@@](CC2)(c3ccc(cc3)F)C#N)(C(=O)O)c4ccccc4'),('PA164743013','caspofungin','Capsofungin,Caspofungin acetate','Cancidas','Drug/Small Molecule','DailyMed:3bad23a6-09a6-4194-9182-093ed61bc71c,TTD:DAP000547,chebi:474180,chemSpider:411774,dpd:2244266,drugBank:DB00520,ndc:0006-3822-10,pubChemCompound:2826718,pubChemCompound:468682,pubChemSubstance:46508288,pubChemSubstance:622847,url:http://en.wikipedia.org/wiki/Caspofungin',''),('PA164743014','nicergoline','','MNE,Nargoline,Nicergolin [German],Nicergolina [Dci','Drug/Small Molecule','TTD:DAP000902,chemSpider:31373,drugBank:DB00699,keggDrug:D01290,pubChemCompound:34040,pubChemSubstance:175827,pubChemSubstance:46508741,url:http://en.wikipedia.org/wiki/Nicergoline',''),('PA164743018','methdilazine','MD,Methdilazine Hcl,Methdilazine Monohydrochloride,Methdilazine hydrochloride,Methdilazinum [INN-Latin],Methilazine hydrochloride,Methodilazine,Metodi','Bristaline,Dilosyn,Disyncram,Disyncran,Tacaryl,Tac','Drug/Small Molecule','TTD:DAP001070,chemSpider:14009,drugBank:DB00902,keggCompound:C07175,keggDrug:D04979,pubChemCompound:14677,pubChemSubstance:46505472,pubChemSubstance:9384,url:http://en.wikipedia.org/wiki/Methdilazine',''),('PA164743019','cyclopentolate','Ciclopentolato [INN-Spanish],Cyclopentoiate,Cyclopentolate HCL,Cyclopentolatum [INN-Latin],Cyclopentylate,Diopentolate','AK-Pentolate,Akpentolate,Cyclogyl,Cylate,Minims Cy','Drug/Small Molecule','DailyMed:1d008c76-7210-4ace-90fa-7cd22762e12e,TTD:DAP001111,chebi:4024,chemSpider:2802,dpd:2148382,drugBank:DB00979,keggCompound:C06932,ndc:0065-0395-15,pubChemCompound:2905,pubChemSubstance:46504517,pubChemSubstance:9149,url:http://en.wikipedia.org/wiki/Cyclopentolate',''),('PA164743020','hexafluronium bromide','Hexafluorenium,Hexafluorenium bromide,hexafluronium bromide','Milaxen,Mylaxen','Drug/Small Molecule','TTD:DAP000963,drugBank:DB00941,keggDrug:D04435,pubChemCompound:9434,pubChemSubstance:152643,pubChemSubstance:46507171,url:http://en.wikipedia.org/wiki/Hexafluronium_bromide',''),('PA164743021','cefonicid','Cefonicido [inn-spanish],Cefonicidum [inn-latin]','Monocid,Praticef','Drug/Small Molecule','TTD:DAP001173,chebi:3491,drugBank:DB01328,keggCompound:C06882,pubChemCompound:43592,pubChemSubstance:183965','c1ccc(cc1)[C@H](C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSc4nnnn4CS(=O)(=O)O)C(=O)O)O'),('PA164743028','dihydroergotamine','9,10-dihydro-ergotamine,Dihidroergotamina [INN-Spanish],Dihydroergotamine mesylate,Dihydroergotamine methanesulfonate,Dihydroergotamine monomethanesul','Agit,Angionorm,D.H.E.,D.H.E. 45,DET MS,DHE-45,Derg','Drug/Small Molecule','DailyMed:111f628a-7e1e-4d47-8ac1-f898cbfc9b74,TTD:DAP000078,chebi:4562,chemSpider:10091,dpd:2241163,drugBank:DB00320,iupharLigand:121,keggCompound:C07798,ndc:0574-0850-05,pubChemCompound:10531,pubChemSubstance:153817,pubChemSubstance:46507711,url:http://en.wikipedia.org/wiki/Dihydroergotamine',''),('PA164743056','testolactone','Testolactona [INN-Spanish],Testolactonum [INN-Latin],Testolattone [Dcit]','Fludestrin,Teolit,Teslac,Teslak,Testolacton','Drug/Small Molecule','TTD:DAP000624,chebi:9460,chemSpider:13172,drugBank:DB00894,keggCompound:C02197,keggDrug:D00153,ndc:0003-0690-50,pubChemCompound:13769,pubChemSubstance:157104,pubChemSubstance:46508076','C[C@]12CC[C@H]3[C@H]([C@@H]1CCC(=O)O2)CCC4=CC(=O)C=C[C@]34C'),('PA164743057','cinalukast','','Cinalukast [Usan:Inn]','Drug/Small Molecule','TTD:DAP000976,bindingDb:50064086,chebi:126598,chemSpider:4940804,drugBank:DB00587,pubChemCompound:6436135,pubChemSubstance:213582,pubChemSubstance:46505799',''),('PA164743058','ospa lipoprotein','Outer surface protein A precursor','LYMErix','Drug/Small Molecule','TTD:DAP001334,drugBank:DB00045,genBank:X16467,uniProtKb:P14013',''),('PA164743086','carbetocin','Carbetocino [inn-spanish],Carbetocinum [inn-latin]','Duratocin','Drug/Small Molecule','TTD:DAP000269,chebi:59204,dpd:2231593,drugBank:DB01282,keggDrug:D07229,pubChemCompound:71715,pubChemSubstance:213985,url:http://en.wikipedia.org/wiki/Carbetocin',''),('PA164743096','icodextrin','Dextrine,icodextrin','Adept,Dextrin, Caloreen,Extraneal,Icodial','','',''),('PA164743097','muromonab','AntiCD3,Muromonab-CD3','Orthoclone OKT3','Drug/Small Molecule','DailyMed:2a1f1c18-fa95-45e6-bd00-ac53c73f4747,TTD:DAP001301,dpd:2015978,drugBank:DB00075,keggDrug:D05092,ndc:59676-101-01,url:http://en.wikipedia.org/wiki/Muromonab',''),('PA164743113','bambuterol','Bambuterol hydrochloride','Bambec,Oxeol','Drug/Small Molecule','TTD:DAP000250,chebi:553827,chemSpider:49466,drugBank:DB01408,pubChemCompound:54766,pubChemSubstance:11466389,pubChemSubstance:46505785,url:http://en.wikipedia.org/wiki/Bambuterol',''),('PA164743129','sodium stibogluconate','sodium stibogluconate','Lenocta,Myostibin,Pentostam,Stibanate,Stibanose,St','Drug/Small Molecule','TTD:DCL000001,chebi:28148,drugBank:DB05630,keggDrug:D00582,pubChemCompound:16685683,url:http://en.wikipedia.org/wiki/Sodium_stibogluconate','O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].OCC(O)C1O[Sb]2(O)(O[Sb]34([O-])OC(C(O)CO)C(O3)C(O4)C([O-])=O)OC1C(O2)C([O-])=O'),('PA164743136','altretamine','Altretaminum [INN-Latin],HEXAMETHYLMELAMINE,HMM,HTM,HXM','Hemel,Hexalen,Hexastat','Drug/Small Molecule','DailyMed:90a5e59a-bee8-404a-ad69-fabddeaf27f9,TTD:DAP000989,chemSpider:2038,dpd:2126230,drugBank:DB00488,ndc:58063-001-70,pubChemCompound:2123,pubChemSubstance:155900,pubChemSubstance:46505760,url:http://en.wikipedia.org/wiki/Altretamine','CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C'),('PA164743137','permethrin','permethrin','Acticin Cream,Elimite,Elimite Cream,Nix,Nix Cream ','Drug/Small Molecule','DailyMed:bdb796aa-a7d1-4476-988f-2b4a9519788f,TTD:DAP001235,chebi:34911,chemSpider:36845,dpd:771368,drugBank:DB04930,keggCompound:C14388,keggDrug:D05443,ndc:45802-269-37,pubChemCompound:40326,pubChemSubstance:10438901,pubChemSubstance:46505374,url:http://en.wikipedia.org/wiki/Permethrin',''),('PA164743138','darbepoetin alfa','Epoetin,Erythropoietin precursor','Aranesp','Drug/Small Molecule','TTD:DAP000800,dpd:2246360,drugBank:DB00012,genBank:X02158,uniProtKb:P01588,url:http://en.wikipedia.org/wiki/Darbepoetin_alfa',''),('PA164743139','echothiophate iodide','echothiophate iodide,phospholine','Echodide,Phospholine Iodide','','',''),('PA164743143','iophendylate','','Pantopaque','Drug/Small Molecule','chemSpider:2301035,drugBank:DB01187,pubChemCompound:3037234,pubChemSubstance:46508391,pubChemSubstance:750374',''),('PA164743144','latamoxef','moxalactam','','Drug/Small Molecule','TTD:DAP001181,chebi:599928,chemSpider:43215,drugBank:DB04570,keggDrug:D08109,pubChemCompound:47499,pubChemSubstance:46505546,url:http://en.wikipedia.org/wiki/Latamoxef',''),('PA164743145','methsuximide','(RS)-1,3-Dimethyl-3-phenyl-2,5-pyrrolidindion,1,3-Dimethyl-3-phenyl-2,5-dioxopyrrolidine,1,3-Dimethyl-3-phenyl-2,5-pyrrolidinedione,1,3-Dimethyl-3-phe','Celontin,Petinutin','Drug/Small Molecule','DailyMed:64a6ee88-c6b1-4e13-8208-b6772ef65a74,TTD:DAP001253,chemSpider:6231,dpd:22802,drugBank:DB05246,ndc:0071-0525-24,pubChemCompound:6476,pubChemSubstance:10394084,pubChemSubstance:46505339,url:http://en.wikipedia.org/wiki/Methsuximide',''),('PA164743146','vapreotide','RC-160,Vapreotida [INN-Spanish],Vapreotide acetate,Vapreotidum [inn-latin],bmy 41606,octastatin,vapreotide','Sanvar,Sanvar IR','Drug/Small Molecule','TTD:DAP001242,chemSpider:64425,drugBank:DB04894,iupharLigand:2054,keggDrug:D06281,pubChemCompound:23725064,pubChemCompound:71306,pubChemSubstance:46506923',''),('PA164743150','labetalol','Labetalol HCL,Labetalol hydrochloride,Labetalolum [INN-Latin],Labetolol','Albetol,Ibidomide,Normodyne,Presdate,Trandate','Drug/Small Molecule','DailyMed:fb7ddd5f-946b-4ceb-a59f-6c6b2e5679a8,TTD:DAP000038,bindingDb:25758,chebi:6343,chemSpider:3734,dpd:2243539,drugBank:DB00598,keggCompound:C07063,ndc:0172-4364-60,pubChemCompound:3869,pubChemSubstance:46505511,pubChemSubstance:9275,url:http://en.wikipedia.org/wiki/Labetalol','CC(CCc1ccccc1)NCC(c2ccc(c(c2)C(=O)N)O)O'),('PA164743181','framycetin','Framycetinum [INN-Latin],Neomycin B,Streptothricin B','Actilin,Actiline,Antibiotique,Dekamycin V,Enterfra','Drug/Small Molecule','TTD:DNC001005,bindingDb:19,chebi:7508,chemSpider:8075,dpd:2224887,drugBank:DB00452,iupharLigand:709,pubChemCompound:8378,pubChemSubstance:151525,pubChemSubstance:46508892',''),('PA164743233','glisoxepide','','','Drug/Small Molecule','TTD:DAP000925,chemSpider:30380,drugBank:DB01289,pubChemCompound:32778,pubChemSubstance:15478163,pubChemSubstance:46508780',''),('PA164743234','methotrimeprazine','Levomepromazine','Levoprome,Neozine,Neurocil,Nosinan,Nozinan','Drug/Small Molecule','chebi:6838,chemSpider:65239,dpd:1927655,drugBank:DB01403,keggCompound:C07192,keggDrug:D00403,pubChemCompound:72287,pubChemSubstance:46507223,pubChemSubstance:7847469,url:http://en.wikipedia.org/wiki/Levomepromazine',''),('PA164743235','bethanidine','Betanidin,Betanidine,Bethanidine sulfate','Esbatal,Regulin,Tenathan','Drug/Small Molecule','TTD:DAP000047,chebi:3079,chebi:37937,drugBank:DB00217,keggCompound:C08539,keggDrug:D01603,pubChemCompound:6324770,pubChemSubstance:10732','CNC(=NC)NCc1ccccc1'),('PA164743236','bevantolol','1-(3,4-Dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol,Bevantololum [inn-latin]','','Drug/Small Molecule','TTD:DAP000897,chebi:238698,chemSpider:2282,drugBank:DB01295,pubChemCompound:2372,pubChemSubstance:14952538,pubChemSubstance:46506014','Cc1cccc(c1)OCC(CNCCc2ccc(c(c2)OC)OC)O'),('PA164743249','gamma-homolinolenic acid','(8E,11E,14E)-8,11,14-Icosatrienoic acid,(Z,Z,Z)-8,11,14-Eicosatrienoic acid,8,11,14-Eicosatrienoic Acid,DGLA,Dihomo-gamma-linolenic acid,Homo-gamma-li','Star GLA,Tona-lean 1000 CLA','Drug/Small Molecule','HET:LAX,TTD:DAP000806,chebi:28661,chemSpider:4444199,drugBank:DB00154,keggCompound:C03242,pdb:LAX,pubChemCompound:5280581,pubChemSubstance:46508866,pubChemSubstance:8616330',''),('PA164743265','methysergide','Methyllysergic acid butanolamide,Methysergid,Methysergidum [INN-Latin],Metisergide [DCIT],Metisergido [INN-Spanish],N-(1-(Hydroxymethyl)propyl)-1-meth','Deseril,Desernil,Desernyl,Deseryl,Sansert','Drug/Small Molecule','DailyMed:3fae28ee-700e-4d4f-a040-02ef01a2aeb4,TTD:DAP000366,bindingDb:50031942,chebi:584020,dpd:27499,drugBank:DB00247,iupharLigand:134,keggCompound:C07199,keggDrug:D02357,ndc:0078-0058-05,pubChemCompound:9681,pubChemSubstance:7849416,url:http://en.wikipedia.org/wiki/Methysergide','CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2Cc3cn(c4c3c(ccc4)C2=C1)C)C'),('PA164743293','human serum albumin','Serum albumin precursor','Albutein','Drug/Small Molecule','DailyMed:4923eb2d-99bc-4e3d-8608-1f58adb83a8f,dpd:427675,drugBank:DB00062,genBank:M12523,ndc:0053-7670-06,uniProtKb:P02768',''),('PA164743456','cyclacillin','Aminocyclohexylpenicillin,Ciclacilina [INN-Spanish],Ciclacillin,Ciclacilline [INN-French],Ciclacillinum [INN-Latin],Ciclacillum','Bastcillin,Calthor,Citosarin,Cyclapen,Cyclapen-W,O','Drug/Small Molecule','TTD:DAP001159,chebi:31444,chemSpider:17941,drugBank:DB01000,keggCompound:C12766,keggDrug:D01334,pubChemCompound:19003,pubChemSubstance:46508073,pubChemSubstance:583155','CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3(CCCCC3)N)C(=O)O)C'),('PA164743463','butabarbital','Butabarbital Sodium,Butabarbitone,Butrate,Secbubarbital,Secbutabarbital,Secbutobarbital,Secbutobarbitone,Sodium Butabarbital','Butabarb,Butalan,Butatab,Butatal,Buticaps,Butisol,','Drug/Small Molecule','DailyMed:7883bbc0-0874-11dc-a818-0002a5d5c51b,TTD:DAP000667,chebi:3228,chemSpider:2385,dpd:581291,drugBank:DB00237,keggCompound:C07827,keggDrug:D03180,ndc:0037-0113-60,pubChemCompound:2479,pubChemSubstance:10029,pubChemSubstance:46505051,url:http://en.wikipedia.org/wiki/Butabarbital',''),('PA164743464','tamibarotene','Am 80,Tamibarotene,retinobenzoic acid','Amnoid,Tamibaro','Drug/Small Molecule','TTD:DAP000461,chebi:32181,chemSpider:97231,drugBank:DB04942,keggCompound:C12864,keggDrug:D01418,pubChemCompound:108143,pubChemSubstance:10234613,pubChemSubstance:46509039',''),('PA164743471','adenosine triphosphate','5\'-ATP,ATP,Adenosine 5\'-triphosphate,Adenosine 5\'-triphosphoric acid,Adenosine, 5\'-(tetrahydrogen triphosphate),Adenosine-5\'-triphosphate,Adenylpyroph','Adephos,Adetol,Adynol,Atipi,Atriphos,Cardenosine,F','Drug/Small Molecule','HET:ATP,TTD:DNC000262,bindingDb:2,chebi:15422,chemSpider:5742,drugBank:DB00171,iupharLigand:1713,keggCompound:C00002,pdb:ATP,pubChemCompound:5957,pubChemSubstance:3304,pubChemSubstance:46507614,url:http://en.wikipedia.org/wiki/Adenosine_triphosphate',''),('PA164743703','gadoversetamide','Gadoversetamide [USAN:INN:BAN],gadoversetamide','OptiMARK','Drug/Small Molecule','DailyMed:20372fd0-cd3c-47b2-bfc1-f5b8bc03ec0a,chemSpider:392041,dpd:2242986,drugBank:DB00538,keggDrug:D01646,ndc:0019-1177-02,pubChemCompound:444013,pubChemSubstance:46504481,pubChemSubstance:7848709,url:http://en.wikipedia.org/wiki/Gadoversetamide',''),('PA164743704','antithymocyte globulin','Thymoglobulin,rabbit atg,ratg','ATG-Fresenius,ATG-Fresenius S,Genzyme,Genzyme),Thy','Drug/Small Molecule','TTD:DAP001300,dpd:2246805,drugBank:DB00098',''),('PA164743726','tyloxapol','Macrocyclon','Alevaire,SuperVent','Drug/Small Molecule','TTD:DCL000254,chemSpider:11052515,drugBank:DB06439,keggDrug:D03261,pubChemCompound:17397414,url:http://en.wikipedia.org/wiki/Tyloxapol','CN(C1=CC=CC=C1C(=O)NCC2=CC=CO2)C(=O)COC3=CC=CC=C3'),('PA164743727','aceprometazine','10-(2-(Dimethylamino)propyl)phenothiazin-2-yl methyl ketone,Aceprometazina [inn-spanish],Aceprometazinum [inn-latin],Acepromethazine','Mepronizine','Drug/Small Molecule','TTD:DAP001075,chebi:53770,chemSpider:24249,drugBank:DB01615,pubChemCompound:26035,pubChemSubstance:10487300,pubChemSubstance:46506646,url:http://en.wikipedia.org/wiki/Aceprometazine',''),('PA164743728','reteplase','Tissue-type plasminogen activator precursor,t- PA,t-plasminogen activator,tPA','Retavase','Drug/Small Molecule','DailyMed:e9ae6656-977c-4105-8528-bee664aab27a,TTD:DAP001195,dpd:2233013,drugBank:DB00015,genBank:L00153,ndc:24477-041-02,uniProtKb:P00750,url:http://en.wikipedia.org/wiki/Reteplase',''),('PA164743961','fludrocortisone','','9 .Alpha. Ff,9 Alpha Ff,9 alpha-Fludrocortisone,9 ','Drug/Small Molecule','DailyMed:2e6ee871-d855-44c3-9319-8ea49035521b,TTD:DAP001105,chebi:50885,chemSpider:29111,dpd:2086026,drugBank:DB00687,keggCompound:C07004,ndc:42291-529-01,pubChemCompound:31378,pubChemSubstance:46508616,pubChemSubstance:9217,url:http://en.wikipedia.org/wiki/Fludrocortisone',''),('PA164743977','arformoterol','(R,R)-formoterol,arformoterol','Brovana','Drug/Small Molecule','DailyMed:7134ae7c-6c64-470d-ab4e-81e35413b839,TTD:DAP000943,bindingDb:50151720,chebi:408174,chemSpider:2340731,drugBank:DB01274,ndc:63402-911-30,pubChemCompound:3083544,pubChemSubstance:3884858,pubChemSubstance:46506392',''),('PA164743987','etomidate','Etomidic acid','Amidate,Hypnomidate','Drug/Small Molecule','DailyMed:b7ed5bf8-ba75-44dc-8f81-96b4ad5766be,TTD:DAP000669,bindingDb:50125938,chebi:4910,drugBank:DB00292,keggCompound:C07522,keggDrug:D00548,ndc:0409-6695-01,pubChemCompound:36339,pubChemSubstance:9725,url:http://en.wikipedia.org/wiki/Etomidate','CCOC(=O)c1cncn1[C@H](C)c2ccccc2'),('PA164744009','trimeprazine','(+-)-Alimemazine,(+-)-Trimeprazine,Alimemazine,Alimemazine S,S-dioxide,Bayer 1219,Methylpromazine,Oxomemazin,Oxomemazina [INN-Spanish],Oxomemazine,Oxo','Alimezine,Dosegran,Doxergan,Dysedon,Imakol,Levopro','','',''),('PA164744013','clocortolone','Clocortolone pivalate','Cloderm','Drug/Small Molecule','TTD:DAP001190,chebi:59582,drugBank:DB00838,keggDrug:D02287,pubChemCompound:5282493,pubChemSubstance:7849346,url:http://en.wikipedia.org/wiki/Clocortolone',''),('PA164744014','palifermin','FGF-7,Fibroblast growth factor- 7,HBGF-7,KGF,Keratinocyte growth factor precursor','Kepivance','Drug/Small Molecule','DailyMed:007b604f-9776-4f64-95db-c0aac776fa5d,TTD:DAP001026,dpd:2274221,drugBank:DB00039,genBank:M60828,ndc:55513-520-06,uniProtKb:P21781,url:http://en.wikipedia.org/wiki/Palifermin',''),('PA164744325','natamycin','','Natacyn,Pimaricin','Drug/Small Molecule','DailyMed:d262661c-860d-482e-aa8d-3cf1f252b32a,TTD:DAP001331,drugBank:DB00826,keggCompound:C08073,keggDrug:D00884,ndc:0065-0645-15,pubChemCompound:5281099,pubChemSubstance:10273,pubChemSubstance:46509171,url:http://en.wikipedia.org/wiki/Natamycin',''),('PA164744326','pentazocine','L-pentazocine,Pentazocaine,Pentazocin','Fortalgesic,Fortalin,Fortral,Liticon,Pentagin,Sose','','',''),('PA164744345','dihydrotachysterol','Dihydrotachysterol,Vitamin D4','Antitanil,Calcamine,DHT Intensol,Dichystrolum,Dihy','Drug/Small Molecule','TTD:DAP000365,chebi:4591,dpd:2017601,drugBank:DB01070,keggCompound:C06957,keggDrug:D00299,pubChemCompound:5281010,pubChemSubstance:149136,url:http://en.wikipedia.org/wiki/Dihydrotachysterol',''),('PA164744346','norgestimate','Dexnorgestrel Acetime,Norgestimato [INN-Spanish],Norgestimatum [INN-Latin]','Ortho Cyclen-21,Ortho Cyclen-28,Ortho Tri-Cyclen,O','','',''),('PA164744368','levorphanol','Dea No. 9220,Dea No. 9733,Levorfanol [INN-Spanish],Levorfanolo [Dcit],Levorphan,Levorphanal,Levorphanol Dl-Form,Levorphanol Tartrate,Levorphanolum [IN','Antalgin,Aromarone,Cetarin,Dromoran,Lemoran,Levo-D','Drug/Small Molecule','DailyMed:a6120c36-30b8-491e-8555-29a60d6f9f5b,TTD:DAP000268,bindingDb:50017233,drugBank:DB00854,keggCompound:C08014,ndc:0187-3072-10,pubChemCompound:5359272,pubChemSubstance:10214,url:http://en.wikipedia.org/wiki/Levorphanol','CN1CC[C@]23CCCC[C@H]2[C@H]1Cc4c3cc(cc4)O'),('PA164744372','amikacin','ANTIBIOTIC BB-K8,Amikacin Base,Amikacin Dihydrate,Amikacin Sulfate,Amikacina [INN-Spanish],Amikacine [INN-French],Amikacinum [INN-Latin],BB-K8,amikaci','Amicacin,Amiglyde-V,Amikavet,Amikin,Briclin','Drug/Small Molecule','DailyMed:6ec3129b-c53b-4bdb-913d-a2d0060fa140,TTD:DAP000400,chebi:2637,chemSpider:34635,dpd:2242971,drugBank:DB00479,keggCompound:C06820,keggDrug:D02543,ndc:0703-9032-03,pubChemCompound:37768,pubChemSubstance:46506386,pubChemSubstance:9038,url:http://en.wikipedia.org/wiki/Amikacin',''),('PA164744373','quazepam','Quazepamum [inn-latin]','Cetrane,Doral,Dormalin,Oniria,Prosedar,Quazium,Sel','Drug/Small Molecule','TTD:DAP000690,chemSpider:4825,drugBank:DB01589,keggCompound:C07336,keggDrug:D00457,pubChemCompound:4999,pubChemSubstance:12012678,pubChemSubstance:46505952,url:http://en.wikipedia.org/wiki/Quazepam','c1ccc(c(c1)C2=NCC(=S)N(c3c2cc(cc3)Cl)CC(F)(F)F)F'),('PA164744374','felypressin','2-(L-Phenylalanine)-8-L-lysinevasopressin','Felipresina [INN-Spanish],Felipressina [DCIT],Fely','Drug/Small Molecule','TTD:DAP000217,drugBank:DB00093,pubChemCompound:5956,pubChemSubstance:148784,url:http://en.wikipedia.org/wiki/Felypressin','C1C[C@@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=CC=C4)N)C(=O)N[C@H](CCCCN)C(=O)NCC(=O)N'),('PA164744375','clobetasol','','Clobesol,Clobetasol Propionate,Clobetasol propiona','Drug/Small Molecule','DailyMed:b269d3ad-fbae-4ef9-8b3e-e0477ab4615a,TTD:DAP001183,chebi:205919,dpd:2245524,drugBank:DB01013,keggDrug:D01272,ndc:0462-0269-50,pubChemCompound:32798,pubChemSubstance:7848335,url:http://en.wikipedia.org/wiki/Clobetasol',''),('PA164744376','adenosine monophosphate','5\'-AMP,5\'-Adenosine monophosphate,5\'-Adenylic acid,AMP,Adenosine 5\'-(dihydrogen phosphate),Adenosine 5\'-monophosphate,Adenosine 5\'-phosphate,Adenosine','Adenovite,Cardiomone,Lycedan,My-B-Den,Phosaden,Pho','Drug/Small Molecule','TTD:DAP001319,bindingDb:18137,chebi:16027,chemSpider:5858,drugBank:DB00131,iupharLigand:2455,keggCompound:C00020,keggDrug:D02769,pubChemCompound:6083,pubChemSubstance:3322,pubChemSubstance:46507628,url:http://en.wikipedia.org/wiki/Adenosine_monophosphate',''),('PA164744506','pheniramine','1-Phenyl-1-(2-pyridyl)-3-dimethylaminopropane,2-(3-Dimethylamino-1-phenylpropyl)pyridine,2-(alpha-(2-Dimethylaminoethyl)benzyl)pyridine,2-[.alpha.-(2-','AVIL,Inhiston,Metron,Pyriton,Trimeton,Tripoton','','',''),('PA164744510','lofexidine','2-(1-(2,6-Dichlorophenoxy)ethyl)-4,5-dihydro-1H-imidazole,2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazoline,Lofexidina [inn-spanish],Lofexidine hydroc','BritLofex','Drug/Small Molecule','TTD:DAP000064,chebi:51368,chemSpider:28460,drugBank:DB04948,pubChemCompound:30668,pubChemSubstance:14774610,pubChemSubstance:46508453,url:http://en.wikipedia.org/wiki/Lofexidine',''),('PA164744517','enfuvirtide','Envelope polyprotein GP160 precursor [Contains: Exterior membrane glycoprotein,GP120, Transmembrane glycoprotein,GP41],enfuvirtide','Fuzeon','Drug/Small Molecule','DailyMed:6935e846-d5a1-49e5-89a2-f8ebe4d5590d,TTD:DAP000157,bindingDb:50271301,dpd:2247725,drugBank:DB00109,genBank:U12055,ndc:0004-0380-39,pubChemCompound:16130199,pubChemSubstance:623635,uniProtKb:Q70626,url:http://en.wikipedia.org/wiki/Enfuvirtide','CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)C'),('PA164744518','fluoxymesterone','Androfluorene,Androfluorone,FXM,Fluossimesterone [DCIT],Fluoximesterona [INN-Spanish],Fluoximesterone,Fluoximesteronum,Fluoxymesteronum [INN-Latin],Fl','Anadroid-F,Android-f,Androsterolo,Fluosterone,Fluo','Drug/Small Molecule','DailyMed:09bafc2d-1893-4618-86dc-e9403407cd41,TTD:DAP000904,bindingDb:18189,chebi:5120,chemSpider:6205,dpd:30902,drugBank:DB01185,keggDrug:D00327,ndc:0009-0014-01,pubChemCompound:6446,pubChemSubstance:46508867,pubChemSubstance:7847393,url:http://en.wikipedia.org/wiki/Fluoxymesterone',''),('PA164744555','ceftibuten','','Cedax','Drug/Small Molecule','TTD:DAP000456,chebi:3510,chemSpider:4445418,drugBank:DB01415,keggCompound:C08117,keggDrug:D00922,ndc:45809-401-20,pubChemCompound:5282241,pubChemCompound:5282242,pubChemSubstance:10317,pubChemSubstance:46507324,url:http://en.wikipedia.org/wiki/Ceftibuten',''),('PA164744571','insulin recombinant','Insulin precursor','Novolin R','Drug/Small Molecule','TTD:DAP000802,dpd:795879,drugBank:DB00030,genBank:AY137503,keggCompound:C00723,keggDrug:D00085,pubChemSubstance:3989,uniProtKb:Q8HXV2',''),('PA164744894','alizapride','Alizaprida [inn-spanish],Alizapridum [inn-latin]','Limican,Liticum','Drug/Small Molecule','bindingDb:50023804,chemSpider:39202,drugBank:DB01425,pubChemCompound:43008,pubChemSubstance:183472,pubChemSubstance:46505555,url:http://en.wikipedia.org/wiki/Alizapride',''),('PA164744895','gliquidone','','Glurenorm','Drug/Small Molecule','TTD:DAP000924,chemSpider:82719,drugBank:DB01251,keggDrug:D02430,pubChemCompound:91610,pubChemSubstance:10224909,pubChemSubstance:46508425,url:http://en.wikipedia.org/wiki/Gliquidone',''),('PA164744896','ramelteon','TAK-375,ramelteon','Rozerem','Drug/Small Molecule','DailyMed:9de82310-70e8-47b9-b1fc-6c6848b99455,TTD:DAP000070,bindingDb:50118470,chemSpider:181000,drugBank:DB00980,iupharLigand:1356,ndc:64764-805-30,pubChemCompound:208902,pubChemSubstance:46505923,pubChemSubstance:783731,url:http://en.wikipedia.org/wiki/Ramelteon',''),('PA164744924','trimethadione','Trimetadione,Trimethadion,Trimethdione','Absentol,Absetil,Convenixa,Convexina,Edion,Epidion','Drug/Small Molecule','TTD:DAP001265,bindingDb:50019167,chemSpider:5374,drugBank:DB00347,keggDrug:D00392,pubChemCompound:5576,pubChemSubstance:46504478,pubChemSubstance:7847458,url:http://en.wikipedia.org/wiki/Trimethadione','CC1(C(=O)N(C(=O)O1)C)C'),('PA164744925','cisatracurium besylate','','Atracurium Besylate,Atracurium Besylate Preservati','Drug/Small Molecule','DailyMed:3db3b76c-3e5a-456e-46a8-456fde1e6195,TTD:DAP000196,chemSpider:56614,dpd:2229423,drugBank:DB00565,keggDrug:D00759,ndc:0074-4378-05,pubChemCompound:62886,pubChemSubstance:46506666,pubChemSubstance:7847824',''),('PA164744926','pralidoxime','Pralidoxime Chloride','ComboPen,Protopam','Drug/Small Molecule','DailyMed:2741d8fd-51c2-46be-880b-99f2b20a6137,bindingDb:50241085,chebi:8354,dpd:2043475,drugBank:DB00733,keggCompound:C07400,ndc:60977-141-01,pubChemCompound:5353894,pubChemSubstance:9604,url:http://en.wikipedia.org/wiki/Pralidoxime','C[n+]1ccccc1C=NO'),('PA164744927','doxacurium','doxacurium chloride','Nuromax','Drug/Small Molecule','TTD:DAP000350,chebi:4707,chemSpider:54249,dpd:1924656,drugBank:DB01135,drugBank:DB01334,keggCompound:C07549,keggDrug:D00760,ndc:0074-4437-05,pubChemCompound:60168,pubChemCompound:60169,pubChemSubstance:196533,pubChemSubstance:46506733,url:http://en.wikipedia.org/wiki/Doxacurium,url:http://en.wikipedia.org/wiki/Doxacurium_chloride','COC1=CC(CC2C3=C(CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCC4=C(C2CC2=CC(OC)=C(OC)C(OC)=C2)C(OC)=C(OC)C(OC)=C4)C=C(OC)C(OC)=C3OC)=CC(OC)=C1OC'),('PA164744928','dicyclomine','','Atumin,Bentomine,Bentyl,Bentyl Hydrochloride,Benty','Drug/Small Molecule','DailyMed:ac145b81-5f26-4914-b47f-6c4958e94146,TTD:DAP001118,bindingDb:50010101,chebi:4514,chemSpider:2934,dpd:392820,drugBank:DB00804,iupharLigand:355,keggCompound:C06951,ndc:0378-1610-01,pubChemCompound:3042,pubChemSubstance:46505371,pubChemSubstance:9166,url:http://en.wikipedia.org/wiki/Dicyclomine',''),('PA164744929','brinzolamide','','Azopt','Drug/Small Molecule','HET:BZU,TTD:DAP000602,bindingDb:10885,chebi:3176,chemSpider:62077,dpd:2238873,drugBank:DB01194,keggCompound:C07760,keggDrug:D00652,ndc:0065-0275-25,pdb:BZU,pubChemCompound:68844,pubChemSubstance:210988,pubChemSubstance:46507071,url:http://en.wikipedia.org/wiki/Brinzolamide',''),('PA164744951','silver sulfadiazine','SSD,Silver sulfadiazinate,Silver sulphadiazine,Sulfadiazine silver','Dermazin,Flamazine,SSD (1% Silver Sulfadiazine Cre','Drug/Small Molecule','DailyMed:27c5999a-0bbe-4d20-9a9e-3546c8189ae3,TTD:DAP001321,chebi:9142,chemSpider:390017,dpd:323098,drugBank:DB05245,keggDrug:D00433,ndc:68387-450-01,pubChemCompound:441244,pubChemSubstance:10298772,pubChemSubstance:46507881,url:http://en.wikipedia.org/wiki/Silver_sulfadiazine','c1cnc(nc1)NS(=O)(=O)c2ccc(cc2)N.[Ag+]'),('PA164744952','coagulation factor ix','Christmas factor,Coagulation factor IX precursor,PTC,Plasma thromboplastin component','Benefix','Drug/Small Molecule','TTD:DAP000964,dpd:2228998,drugBank:DB00100,genBank:K02402,keggCompound:C03101,ndc:0053-7668-02,pubChemSubstance:5997,uniProtKb:P00740,url:http://en.wikipedia.org/wiki/Factor_IX',''),('PA164745088','gallamine triethiodide','Benzcurine Iodide,Benzkurin,Gallamin,Gallamin Triethiodide,Gallamine,Gallamine Iodide,Gallamine Triethiiodide,Gallamine Triiodoethylate,Gallamone Trie','Flacedil,Flaxedil,Fourneau 2559,Gallaflex,Miowas G','Drug/Small Molecule','TTD:DAP001127,dpd:1927574,drugBank:DB00483,pubChemCompound:67425,pubChemSubstance:209540',''),('PA164745110','tetrahydrofolic acid','(6S)-tetrahydrofolate,5,6,7,8-tetrahydrofolate,5,6,7,8-tetrahydrofolic acid,FH4,H4PteGlu,N-(4-(((2-Amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)meth','','Drug/Small Molecule','HET:THL,TTD:DAP001308,chebi:20506,chemSpider:82572,drugBank:DB00116,keggCompound:C00101,pdb:THL,pubChemCompound:91443,pubChemSubstance:46504756,pubChemSubstance:8146989,url:http://en.wikipedia.org/wiki/Tetrahydrofolic_acid',''),('PA164745307','allylestrenol','','Gestanin,Gestanol,Gestanon,Gestormone,Orageston,Or','Drug/Small Molecule','TTD:DPR000085,chemSpider:205855,drugBank:DB01431,keggCompound:C12811,keggDrug:D01374,pubChemCompound:235905,pubChemSubstance:46506946,pubChemSubstance:583200',''),('PA164745308','guanadrel sulfate','Guanadrelum [INN-Latin]','Guanadrel,Hylorel','Drug/Small Molecule','TTD:DAP000059,chemSpider:35305,drugBank:DB00226,keggDrug:D00607,pubChemCompound:38521,pubChemSubstance:179728,pubChemSubstance:46506457','C1CCC2(CC1)OCC(O2)CNC(=N)N.[O-]S(=O)(=O)[O-]'),('PA164745309','phenacemide','Carbamide phenylacetate,PA,Phenacetylcarbamide,Phenacetylurea,Phenylacetylurea,Phenylacetyluree','Acetylureum,Carbanmide,Cetylureum,Comitiadone,Efer','Drug/Small Molecule','TTD:DAP000501,chemSpider:4589,drugBank:DB01121,keggCompound:C07428,keggDrug:D00504,pubChemCompound:4753,pubChemSubstance:46508400,pubChemSubstance:9632,url:http://en.wikipedia.org/wiki/Phenacemide','c1ccc(cc1)CC(=O)NC(=O)N'),('PA164745310','amlexanox','Amlexanox [USAN:INN:JAN],Amlexanoxo [Spanish],Amlexanoxum [Latin],amlexanox','Amlenanox,Amoxanox,Aphthasol,Elics,OraDisc,Solfa','Drug/Small Molecule','TTD:DAP000321,chebi:31205,chemSpider:2076,drugBank:DB01025,keggDrug:D01828,pubChemCompound:2161,pubChemSubstance:46504508,pubChemSubstance:7848890',''),('PA164745371','satumomab pendetide','indium (111in) satumomab pendetide,indium-111 satumomab pendetide','OncoScint','Drug/Small Molecule','TTD:DAP001299,drugBank:DB00057',''),('PA164745372','nalbuphine','','Nalbufina [DCIT],Nalbuphine HCL,Nalbuphinum [INN-L','Drug/Small Molecule','DailyMed:ef136b5b-9c87-456d-b739-f9cd50687885,TTD:DAP000380,chebi:7454,dpd:1913972,drugBank:DB00844,iupharLigand:1663,keggCompound:C07251,keggDrug:D08246,ndc:0555-1121-05,pubChemCompound:5360630,pubChemSubstance:9460,url:http://en.wikipedia.org/wiki/Nalbuphine',''),('PA164745394','ethinamate','Ethinamat,Ethinimate,Etinamate,USAF EL-42','Valamin,Valaminettae,Valaminetten,Valmid,Valmidate','Drug/Small Molecule','TTD:DAP000606,chebi:4884,chemSpider:3169,drugBank:DB01031,keggCompound:C07832,keggDrug:D00703,pubChemCompound:3284,pubChemSubstance:10034,pubChemSubstance:46507468,url:http://en.wikipedia.org/wiki/Ethinamate','C#CC1(CCCCC1)OC(=O)N'),('PA164745398','butorphanol','Butorfanol,Butorfanol [INN-Spanish],Butorphanol Tartrate,Butorphanolum [INN-Latin]','Beforal,Moradol,Stadol,Stadol NS','Drug/Small Molecule','DailyMed:9c069ce5-ea67-4f42-afe4-30b01b4ce24d,TTD:DAP000214,bindingDb:50240437,chebi:3242,chemSpider:4514667,dpd:844977,drugBank:DB00611,keggDrug:D00837,ndc:0378-9639-43,pubChemCompound:5361092,pubChemCompound:6916249,pubChemSubstance:46507553,url:http://en.wikipedia.org/wiki/Butorphanol',''),('PA164745426','gadobenate dimeglumine','Gadobenic acid','Gd-BOPTA,Gd-BOPTA/Dimeg,Multihance,Multihance Mult','Drug/Small Molecule','DailyMed:59077a3e-5f03-4342-ae24-856267545631,TTD:DAP001225,chemSpider:170831,dpd:2248302,drugBank:DB00743,ndc:0270-5164-12,pubChemCompound:6918204,pubChemSubstance:3733331,pubChemSubstance:46506805',''),('PA164745442','penicillin v','Fenossimetilpenicillina [Dcit],Fenoximetilpenicilina [INN-Spanish],Penicillin Phenoxymethyl,Penicillin V Potassium,Phenoximethylpenicillinum,Phenoxyme','Acipen V,Apopen,Beepen-Vk,Beromycin,Betapen-Vk,Cal','','',''),('PA164745443','dydrogesterone','10alpha-Isopregnenone,Didrogesterone [DCIT],Dydrogesterona [INN-Spanish],Dydrogesteronum [INN-Latin],Hydrogesterone,Hydrogestrone,Isopregnenone','Diphaston,Dufaston,Duphaston,Duvaron,Gestatron,Gyn','Drug/Small Molecule','TTD:DAP001205,chebi:31527,chemSpider:8699,drugBank:DB00378,keggDrug:D01217,pubChemCompound:9051,pubChemSubstance:46506195,pubChemSubstance:7848280,url:http://en.wikipedia.org/wiki/Dydrogesterone',''),('PA164745459','benzonatate','Benzonatato [INN-Spanish],Benzonatatum [INN-Latin],Benzononatine','Benzononantin,Exangit,Tesalon,Tessalin,Tessalon,Te','Drug/Small Molecule','DailyMed:29a88bdc-0aa7-4a4b-bbd5-47998ad1d87e,TTD:DAP000514,chebi:3032,chemSpider:7413,drugBank:DB00868,keggDrug:D00242,ndc:0904-5904-60,pubChemCompound:7699,pubChemSubstance:46506376,url:http://en.wikipedia.org/wiki/Benzonatate','CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC'),('PA164745460','crotamiton','Crotaglin,Crotalgin,Crotamitone','Crotamitex,Crotan,Eurasil,Eurax,Eurax Cream,Eurax ','Drug/Small Molecule','DailyMed:1f92ffec-e5d3-cc82-b8a8-fcc01be2aee9,chemSpider:2780,dpd:623377,drugBank:DB00265,keggDrug:D01381,ndc:0072-2103-60,pubChemCompound:2883,pubChemCompound:688020,pubChemSubstance:46508599,url:http://en.wikipedia.org/wiki/Crotamiton',''),('PA164745461','bacampicillin','bacampicillin hydrochloride','Penglobe,Spectrobid','Drug/Small Molecule','TTD:DAP001162,chebi:2968,chemSpider:390135,drugBank:DB01602,keggCompound:C08122,pubChemCompound:441397,pubChemSubstance:10298823,pubChemSubstance:46507859',''),('PA164745462','salsalate','Salsalatum [inn-latin],Sasapyrine,salicylsalicylic acid','Disalcid','Drug/Small Molecule','TTD:DAP000734,chemSpider:4977,drugBank:DB01399,keggDrug:D00428,pubChemCompound:5161,pubChemSubstance:46506882,pubChemSubstance:7847494','c1ccc(c(c1)C(=O)Oc2ccccc2C(=O)O)O'),('PA164745478','butenafine','Butenafina [INN-Spanish],Butenafine HCL,Butenafine [INN],Butenafine hydrochloride,Butenafinum [INN-Latin]','Lotrimin Ultra,Mentax,Mentax-tc','Drug/Small Molecule','DailyMed:167ecefd-4553-41b8-8160-81a48dbca076,TTD:DAP001236,chebi:3238,chemSpider:2390,dpd:2231063,drugBank:DB01091,keggCompound:C08067,ndc:0378-6151-46,pubChemCompound:2484,pubChemSubstance:10267,pubChemSubstance:46506191,url:http://en.wikipedia.org/wiki/Butenafine',''),('PA164745485','sulpiride','Levosulpirida [INN-Spanish],Levosulpiride,Levosulpiride [INN],Levosulpiridum [INN-Latin],Sulpirid,Sulpirida [INN-Spanish],Sulpiridum [INN-Latin],Sulpy','Abilit,Aiglonyl,Alimoral,Calmoflorine,Championyl,C','Drug/Small Molecule','TTD:DAP000310,bindingDb:11638,chemSpider:5162,drugBank:DB00391,keggDrug:D01226,pubChemCompound:5355,pubChemSubstance:46504855,url:http://en.wikipedia.org/wiki/Sulpiride','CCN1CCCC1CNC(=O)c2cc(ccc2OC)S(=O)(=O)N'),('PA164745489','capromab','Capromab pendetide,ProstaScint,in 111 capromab pendetide','ProstaScint','Drug/Small Molecule','DailyMed:7e227d16-4cbf-4c17-95ef-b7adbcdc0580,TTD:DAP001049,drugBank:DB00089,ndc:57902-817-01,url:http://en.wikipedia.org/wiki/Capromab',''),('PA164745502','alosetron','Alosetron HCl','Lotronex','Drug/Small Molecule','TTD:DAP000369,bindingDb:50131429,chebi:253342,chemSpider:2015,drugBank:DB00969,iupharLigand:2296,ndc:0173-0738-00,pubChemCompound:2099,pubChemSubstance:46506274,pubChemSubstance:655047,url:http://en.wikipedia.org/wiki/Alosetron','Cc1c([nH]cn1)CN2CCc3c(c4ccccc4n3C)C2=O'),('PA164745512','dichlorphenamide','4,5-dicholorobenzene-1,3-disulfonamide,Dichlofenamide,Dichlorophenamide,Dichlorphenamid,Diclofenamida [INN-Spanish],Diclofenamide,Diclofenamidum [INN-','Antidrasi,Daranide,Dasanide,Glaucol,Oratrol','Drug/Small Molecule','HET:I7A,TTD:DAP000601,bindingDb:10883,chebi:101085,chemSpider:2930,drugBank:DB01144,keggCompound:C07459,keggDrug:D00518,pdb:I7A,pubChemCompound:3038,pubChemSubstance:46505039,pubChemSubstance:9662,url:http://en.wikipedia.org/wiki/Dichlorphenamide',''),('PA164745513','demeclocycline','','6-Demethyl-7-chlorotetracycline,6-Demethylchlorote','Drug/Small Molecule','DailyMed:1a4ce717-7a29-4308-8180-91f923d45a03,TTD:DAP000402,chebi:4392,dpd:2169924,drugBank:DB00618,keggCompound:C06942,keggDrug:D00290,ndc:61748-115-01,pubChemCompound:5311063,pubChemSubstance:173448,url:http://en.wikipedia.org/wiki/Demeclocycline',''),('PA164745514','hydroxystilbamidine isethionate','HSB','','Drug/Small Molecule','TTD:DAP000850,chemSpider:13180289,drugBank:DB01040,pubChemCompound:16051924,pubChemSubstance:24438506,pubChemSubstance:46508302',''),('PA164745515','hydrocortamate','','Hydrocortamate Hydrochloride,Magnacort,Ulcort','Drug/Small Molecule','TTD:DAP001187,chebi:50851,drugBank:DB00769,pubChemCompound:408334,pubChemSubstance:10535192',''),('PA164745516','argatroban','argatroban','','Drug/Small Molecule','DailyMed:9c9616c0-a299-4fd5-c8ae-79e6db453595,TTD:DAP000758,bindingDb:50101744,chemSpider:134807,dpd:2243835,drugBank:DB00278,keggCompound:C04931,ndc:0007-4407-01,pubChemCompound:152951,pubChemSubstance:46507650,pubChemSubstance:730451,url:http://en.wikipedia.org/wiki/Argatroban',''),('PA164745532','iodipamide','3,3\'-[(1,6-dioxohexane-1,6-diyl)diimino]bis(2,4,6-triiodobenzoic acid),Adipiodona [INN-Spanish],Adipiodone,Adipiodonum [INN-Latin],IDB,Iodipamic acid','Bilignost,Bilignostum,Biligrafin,Cholografin,Cholo','Drug/Small Molecule','HET:IDB,TTD:DAP001226,chemSpider:3608,drugBank:DB04711,keggDrug:D01774,pdb:IDB,pubChemCompound:3739,pubChemSubstance:46507320,pubChemSubstance:7888314','c1c(c(c(c(c1I)NC(=O)CCCCC(=O)Nc2c(cc(c(c2I)C(=O)O)I)I)I)C(=O)O)I'),('PA164745533','mephentermine','Mefenterdrin,Mefentermin,Mephenterdrine,Mephenterdrinum,Mephetedrine,N-methylphentermine','Mephine,Vialin,Wyamine,Wyfentermina','Drug/Small Molecule','TTD:DAP000898,chemSpider:3549,drugBank:DB01365,keggCompound:C07889,pubChemCompound:3677,pubChemSubstance:10091,pubChemSubstance:46505918',''),('PA164745534','dienestrol','Dehydrostilbestrol,Dehydrostilboestrol,Dienesterol,Dienoestrol','Agaldog,Cycladiene,DV,Dienoestrol BP,Dienol,Dinest','Drug/Small Molecule','TTD:DAP001015,chebi:4518,dpd:441295,drugBank:DB00890,keggCompound:C08090,keggDrug:D00898,pubChemCompound:3049,pubChemSubstance:10290,url:http://en.wikipedia.org/wiki/Dienestrol',''),('PA164745550','papaverine','Chlorhydrate de Papaverine,Papavarine Chlorhydrate,Papaverin,Papaverine Chlorohydrate,Papaverine Hcl,Papaverine Hydrochloride,Papaverine Monohydrochlo','Alapav,Artegodan,Cardiospan,Cardoverina,Cepaverin,','Drug/Small Molecule','HET:EV1,TTD:DAP000959,bindingDb:14754,chemSpider:4518,dpd:9881,drugBank:DB01113,keggCompound:C06533,pdb:EV1,pubChemCompound:4680,pubChemSubstance:46508003,pubChemSubstance:8763,url:http://en.wikipedia.org/wiki/Papaverine','COc1ccc(cc1OC)Cc2c3cc(c(cc3ccn2)OC)OC'),('PA164745551','quinacrine','Quinacrine Dihydrochloride','Acrichine,Acrinamine,Acriquine,Akrichin,Antimalari','Drug/Small Molecule','HET:QUM,TTD:DNC001181,chebi:8711,chemSpider:232,drugBank:DB01103,keggCompound:C07339,pdb:QUM,pubChemCompound:237,pubChemSubstance:46507828,pubChemSubstance:9546,url:http://en.wikipedia.org/wiki/Quinacrine','CCN(CC)CCCC(C)Nc1c2ccc(cc2nc3c1cc(cc3)OC)Cl'),('PA164745609','fludiazepam','Fludiazepamum [inn-latin]','Erispan','Drug/Small Molecule','TTD:DAP000934,chebi:31618,chemSpider:3252,drugBank:DB01567,keggDrug:D01354,pubChemCompound:3369,pubChemSubstance:10469517,pubChemSubstance:46507563,url:http://en.wikipedia.org/wiki/Fludiazepam','CN1c2ccc(cc2C(=NCC1=O)c3ccccc3F)Cl'),('PA164745610','demecarium bromide','demecarium bromide','','Drug/Small Molecule','TTD:DAP000894,drugBank:DB00944,keggDrug:D00667,pubChemCompound:5965,pubChemSubstance:46507824,pubChemSubstance:7847733,url:http://en.wikipedia.org/wiki/Demecarium_bromide',''),('PA164745614','calcidiol','Calcifediol,Calcifediol Anhydrous,Calcifediolum [INN-Latin],Calcifidiol','Calderol,Delakmin','Drug/Small Molecule','TTD:DAP000290,chebi:17933,drugBank:DB00146,keggCompound:C01561,pubChemCompound:6433735,pubChemSubstance:171856,url:http://en.wikipedia.org/wiki/Calcidiol',''),('PA164745627','insulin lyspro recombinant','Humalog,Insulin Lispro','Humalog,Humalog Mix 75/25 Pen,Insulin Lispro','Drug/Small Molecule','DailyMed:c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f,TTD:DNC000800,dpd:2241283,drugBank:DB00046,keggDrug:D04477,ndc:0002-7510-01,url:http://en.wikipedia.org/wiki/Insulin_lispro',''),('PA164745640','clenbuterol','Clenbuterolum [inn-latin]','Planipart','Drug/Small Molecule','TTD:DAP000945,bindingDb:27958,chebi:174690,chemSpider:2681,drugBank:DB01407,pubChemCompound:2783,pubChemSubstance:10366793,pubChemSubstance:46508373,url:http://en.wikipedia.org/wiki/Clenbuterol',''),('PA164745713','hyaluronidase','Hyal-1,Hyaluronidase 1 precursor,Hyaluronidase PH-20,Sperm adhesion molecule 1,Sperm surface protein PH-20,hyaluronidase','Vitragan,Vitrase','Drug/Small Molecule','DailyMed:8396ea96-7cb5-4e26-87a4-90bca9c3c6dd,dpd:2041278,drugBank:DB00070,genBank:L13781,ndc:0548-9090-10,uniProtKb:P38567,url:http://en.wikipedia.org/wiki/Hyaluronidase',''),('PA164746007','ranolazine','(-)-Ranolazine,Ranolazine 2HCl,Ranolazine Dihydrochloride,ranolazine','Ranexa','Drug/Small Molecule','DailyMed:8d442b8c-97a8-40a9-8603-f9cd0542cedc,TTD:DAP000875,chemSpider:51354,drugBank:DB00243,ndc:61958-1001-1,pubChemCompound:56959,pubChemSubstance:194150,pubChemSubstance:46505145,url:http://en.wikipedia.org/wiki/Ranolazine','Cc1cccc(c1NC(=O)CN2CCN(CC2)CC(COc3ccccc3OC)O)C'),('PA164746009','fluorescein','2-(6-hydroxy-3-oxo-3h-xanthen-9-yl)-benzoic acid','Acid Yellow 73,Eosin,Fluorescein Sodium salt,Fluor','','',''),('PA164746010','econazole','','Econazole Nitrate,Ecostatin,Ecostatin Vaginal Ovul','Drug/Small Molecule','DailyMed:b0bb5206-3698-4a6b-9100-40bb86f1a0ca,TTD:DAP001269,chebi:4754,chemSpider:3086,dpd:2011948,drugBank:DB01127,iupharLigand:2446,keggCompound:C08068,keggDrug:D03936,ndc:0168-0312-15,pubChemCompound:3198,pubChemSubstance:10268,pubChemSubstance:46508881,url:http://en.wikipedia.org/wiki/Econazole',''),('PA164746011','desoximetasone','','Topicort,Topicort LP','Drug/Small Molecule','DailyMed:37eb1205-1743-4480-8631-b0bbcaeb8359,TTD:DAP001185,chebi:691037,chemSpider:4470604,dpd:2241887,drugBank:DB00547,ndc:51672-1271-1,pubChemCompound:5311067,pubChemSubstance:46506793,pubChemSubstance:855924,url:http://en.wikipedia.org/wiki/Desoximetasone',''),('PA164746012','ranibizumab','ranibizumab,rhuFab V2','Lucentis','Drug/Small Molecule','DailyMed:de4e66cc-ca05-4dc9-8262-e00e9b41c36d,TTD:DAP001260,drugBank:DB01270,keggDrug:D05697,ndc:50242-080-01,url:http://en.wikipedia.org/wiki/Ranibizumab',''),('PA164746030','oxybutynin','Oxibutinina [INN-Spanish],Oxibutyninum,Oxybutinin,Oxybutynin Base,Oxybutynin Chloride,Oxybutynin Hydrochloride,Oxybutynine [INN-French],Oxybutyninum [','Ditropan,Ditropan Xl,Oxytrol','Drug/Small Molecule','DailyMed:a162fd5b-b2ab-4d45-8861-71b60b92acb4,TTD:DAP001128,chebi:7856,chemSpider:4473,dpd:2260751,drugBank:DB01062,iupharLigand:359,keggCompound:C07360,keggDrug:D00465,ndc:52544-920-08,pubChemCompound:4634,pubChemSubstance:164556,pubChemSubstance:46508005,url:http://en.wikipedia.org/wiki/Oxybutynin','CCN(CC)CC#CCOC(=O)C(c1ccccc1)(C2CCCCC2)O'),('PA164746037','diphenidol','Difenidol,Difenidol HCl,Difenidol hydrochloride,Difenidolo [DCIT],Difenidolum [INN-Latin],Diphenidol HCl,Diphenidol hydrochloride','Ansmin,Avomol,Celmidol,Cephadol,Cerrosa,Maniol,Nom','Drug/Small Molecule','TTD:DAP001133,chebi:4638,chemSpider:2947,drugBank:DB01231,keggCompound:C06961,keggDrug:D03858,pubChemCompound:3055,pubChemSubstance:46506486,pubChemSubstance:9175',''),('PA164746057','ceforanide','Ceforanido [INN-Spanish],Ceforanidum [INN-Latin]','Precef','Drug/Small Molecule','TTD:DAP001175,chebi:3495,chemSpider:39656,drugBank:DB00923,keggCompound:C06884,keggDrug:D00259,pubChemCompound:43507,pubChemSubstance:46504532,pubChemSubstance:9101,url:http://en.wikipedia.org/wiki/Ceforanide','c1ccc(c(c1)CC(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSc4nnnn4CC(=O)O)C(=O)O)CN'),('PA164746058','albendazole','','Albenza,Eskazole,Valbazen,Zentel','Drug/Small Molecule','DailyMed:24c6007b-ac07-4086-c3ad-9ca8ec6c48a8,HET:ALW,TTD:DAP000951,bindingDb:50241293,chebi:16664,chemSpider:1998,dpd:1904779,drugBank:DB00518,keggCompound:C01779,keggDrug:D00134,ndc:0007-5500-40,pdb:ALW,pubChemCompound:2082,pubChemSubstance:46506472,pubChemSubstance:4909,url:http://en.wikipedia.org/wiki/Albendazole','CCCSc1ccc2c(c1)nc([nH]2)NC(=O)OC'),('PA164746059','dezocine','Dezocina [INN-Spanish],Dezocinum [INN-Latin]','Dalgan','Drug/Small Molecule','TTD:DAP001100,chebi:4474,drugBank:DB01209,keggCompound:C08010,keggDrug:D00838,pubChemCompound:40841,pubChemSubstance:10210',''),('PA164746074','amcinonide','','Cyclocort','Drug/Small Molecule','TTD:DAP001044,chebi:31199,chemSpider:392009,dpd:2247097,drugBank:DB00288,keggDrug:D01387,ndc:0168-0279-30,pubChemCompound:443958,pubChemSubstance:46506705,pubChemSubstance:7848450,url:http://en.wikipedia.org/wiki/Amcinonide','CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3CCC5=CC(=O)C=C[C@@]54C)F)O)C)OC6(O2)CCCC6'),('PA164746077','icosapent','EPA,Eicosapentaenoic acid,Icosapentaenoic acid,Timnodonic acid','','Drug/Small Molecule','HET:EPA,TTD:DAP000969,chebi:28364,chemSpider:393682,drugBank:DB00159,keggCompound:C06428,pdb:EPA,pubChemCompound:446284,pubChemSubstance:11533194,pubChemSubstance:46506267',''),('PA164746156','tioconazole','Tioconazol [INN-Spanish],Tioconazolum [INN-Latin]','Fungibacid,GyneCure,Gyno-trosyd,Monistat 1,Trosyd,','','',''),('PA164746157','mitotane','','Chloditan,Chlodithan,Chlodithane,Khlodithan,Lysodr','Drug/Small Molecule','DailyMed:e9fba7d4-a0ec-4bfa-9b5b-ec97a9710fd3,TTD:DAP000033,chemSpider:4066,dpd:463221,drugBank:DB00648,keggDrug:D00420,ndc:0015-3080-60,pubChemCompound:4211,pubChemSubstance:148675,pubChemSubstance:46508319,url:http://en.wikipedia.org/wiki/Mitotane',''),('PA164746224','propantheline','Propantheline Bromide,Propanthelinium,Propanthelinum','Pro-Banthine,Propanthel','Drug/Small Molecule','DailyMed:84a920c8-b637-4741-b9b2-fc607e245ce0,TTD:DAP001123,chemSpider:4765,dpd:2030837,drugBank:DB00782,iupharLigand:329,keggCompound:C07506,ndc:0054-4721-25,pubChemCompound:4934,pubChemSubstance:46507187,pubChemSubstance:9709,url:http://en.wikipedia.org/wiki/Propantheline',''),('PA164746226','capreomycin','Capastat,Capastat sulfate,Capreomycin,Capreomycin sulfate,Capreomycin sulphate','Caprocin,Ogostal','Drug/Small Molecule','TTD:DAP000892,chemSpider:2272094,dpd:2025396,drugBank:DB00314,keggCompound:C01790,keggDrug:D00135,ndc:0002-1485-01,pubChemCompound:3000502,pubChemSubstance:46508514,url:http://en.wikipedia.org/wiki/Capreomycin',''),('PA164746228','interferon alfa-n3','interferon alfa-n3','Alferon,Alferon LDO,Alferon N Injection','Drug/Small Molecule','TTD:DAP001281,drugBank:DB00018',''),('PA164746229','tridihexethyl','','Pathilon,Propethonum','Drug/Small Molecule','TTD:DAP000836,chebi:9701,chemSpider:19124,drugBank:DB00505,keggCompound:C07861,pubChemCompound:20299,pubChemSubstance:10063,pubChemSubstance:46506672',''),('PA164746233','calcium gluceptate','Calcium glucoheptonate,Trimethylene chlorobromide','Calcium Stanley','Drug/Small Molecule','chemSpider:56591,drugBank:DB00326,keggDrug:D00934,pubChemCompound:62859,pubChemSubstance:205041,pubChemSubstance:46507233',''),('PA164746234','dalfopristin','Dalfopristina [inn-spanish],Dalfopristine [inn-french],Dalfopristinum [inn-latin]','','','',''),('PA164746235','galsulfase','galsulfase','Naglazyme','Drug/Small Molecule','TTD:DAP001290,drugBank:DB01279,url:http://en.wikipedia.org/wiki/Galsulfase',''),('PA164746244','teicoplanin','Antibiotic 8327A,Antibiotic MDL 507,Teichomycin,Teicomycin A2,Teicoplanin','Tagocid,Targocid','Drug/Small Molecule','drugBank:DB06149,keggCompound:C15820,keggDrug:D02142,pubChemCompound:16131923,pubChemSubstance:602927,url:http://en.wikipedia.org/wiki/Teicoplanin','CCCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)O[C@@H]8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C)Cl)CO)O)O'),('PA164746246','acetyldigitoxin','3\'\'\'-o-acetyldigitoxin,acetyldiginatin,acetylgitoxin,alpha-acetyldigitoxin,alpha-monoacetyldigitoxin,desglucolanatoside a','Acigoxin,Acylanid,Crystodigin','Drug/Small Molecule','TTD:DAP000119,chebi:53773,drugBank:DB00511,keggDrug:D06881,pubChemCompound:68949,pubChemSubstance:211111,url:http://en.wikipedia.org/wiki/Acetyldigitoxin',''),('PA164746250','mepenzolate','1-Methyl-3-piperidyl benzilate methyl bromide,Mepenzolate bromide,Mepenzolic acid,N-Methyl-3-piperidyl benzilate methyl bromide,N-Methyl-3-piperidyldi','Cantil,Cantilaque,Cantilon,Cantril,Colibantil,Colo','Drug/Small Molecule','DailyMed:71b7afe6-4625-4467-adb7-510769da2b17,TTD:DAP001115,bindingDb:50253050,chemSpider:3917,drugBank:DB04843,keggCompound:C07818,ndc:0068-0037-01,pubChemCompound:4057,pubChemSubstance:10020,pubChemSubstance:46508905',''),('PA164746251','dexbrompheniramine','D-Brompheniramine,Parabromdylamine,Parabromodylamine','Ilvin','','',''),('PA164746255','bicalutamide','','Casodex','Drug/Small Molecule','DailyMed:0c3b8420-01ec-4a4a-97a2-222884522963,TTD:DAP000092,bindingDb:18678,chebi:100717,chemSpider:50614,dpd:2184478,drugBank:DB01128,keggCompound:C08160,keggDrug:D00961,ndc:0378-7017-93,pubChemCompound:2375,pubChemCompound:56069,pubChemSubstance:193420,pubChemSubstance:46505386,url:http://en.wikipedia.org/wiki/Bicalutamide',''),('PA164746281','nandrolone','19NTPP,NPP,NTPP,Nadrolone Phenylpropionate,Nandrolin,Nandrolon Phenylpropionate,Nandrolone Phenylpionate,Nandrolone Phenylpropionate,Norandrolone Phen','Activin,Deca-Durabolin,Durabol,Durabolin,FTS,Fenob','Drug/Small Molecule','TTD:DAP000903,chebi:7466,chebi:7468,chemSpider:199761,dpd:270687,drugBank:DB00984,keggCompound:C07254,keggCompound:C08155,keggDrug:D00956,pubChemCompound:229455,pubChemCompound:9904,pubChemSubstance:14718104,pubChemSubstance:46506276,url:http://en.wikipedia.org/wiki/Nandrolone',''),('PA164746297','fondaparinux sodium','Arixtra','Fondaparinux,fondaparinux sodium','Drug/Small Molecule','DailyMed:05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f,TTD:DNC000658,chebi:31632,dpd:2245531,drugBank:DB00569,keggDrug:D01844,ndc:0007-3230-02,pubChemCompound:636380,pubChemSubstance:7848906,url:http://en.wikipedia.org/wiki/Fondaparinux_sodium',''),('PA164746311','everolimus','everolimus','Certican','Drug/Small Molecule','DailyMed:e082a024-7850-400b-a5c2-2a140612562a,TTD:DAP001223,drugBank:DB01590,ndc:0078-0417-20,pubChemCompound:6442177,pubChemSubstance:12014881,url:http://en.wikipedia.org/wiki/Everolimus',''),('PA164746334','cilostazol','Cilostazole,Cilostazolum [INN-Latin]','Pletaal,Pletal','Drug/Small Molecule','DailyMed:9dfc5f4b-3936-4607-8495-439a27433e81,TTD:DAP000191,bindingDb:50070490,chebi:31401,chemSpider:2652,drugBank:DB01166,keggDrug:D01896,ndc:0378-2979-91,pubChemCompound:2754,pubChemSubstance:190773,pubChemSubstance:46506317,url:http://en.wikipedia.org/wiki/Cilostazol',''),('PA164746338','saprisartan','','','Drug/Small Molecule','TTD:DAP001257,chemSpider:54892,drugBank:DB01347,pubChemCompound:60921,pubChemSubstance:12014753,pubChemSubstance:46508176',''),('PA164746342','cefprozil','Cefprozil anhydrous,Cefprozilo [INN-Spanish],Cefprozilum [INN-Latin]','Arzimol,Brisoral,Cronocef,Procef,Serozil','Drug/Small Molecule','TTD:DAP000447,chebi:3506,dpd:2163667,drugBank:DB01150,keggCompound:C06888,ndc:0087-7720-60,pubChemCompound:5281006,pubChemSubstance:205164,url:http://en.wikipedia.org/wiki/Cefprozil','CC=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](c3ccc(cc3)O)N)SC1)C(=O)O'),('PA164746343','sulodexide','KRX-101,sulodexide','Sulonex','Drug/Small Molecule','TTD:DAP000866,drugBank:DB06271,url:http://en.wikipedia.org/wiki/Sulodexide',''),('PA164746377','diphenylpyraline','Diphenylpyralamine,Diphenylpyraline Hydrochloride,Diphenylpyrilene','Allergen,Belfene,Dafen,Dayfen,Diafen,Hispril,Histr','','',''),('PA164746383','ethchlorvynol','Aethyl-chlorvynol,Etchlorvinolo,Ethchlorovynol,Ethchlorvinol,Ethchlorvinyl,Ethclorvynol,Ethochlorvynol,Ethychlorvynol','Alvinol,Arvynol,Normonson,Normosan,Normoson,Nostel','Drug/Small Molecule','TTD:DAP000163,chebi:4882,dpd:27,drugBank:DB00189,keggCompound:C07833,keggDrug:D00704,pubChemCompound:3281,pubChemSubstance:10035,url:http://en.wikipedia.org/wiki/Ethchlorvynol','CCC(C=CCl)(C#C)O'),('PA164746384','nalidixic acid','','Cybis,Dixiben,Dixinal,Eucistin,Innoxalon,Jicsron,N','Drug/Small Molecule','DailyMed:d61be7a2-0f54-44c2-9ed0-2316f4cb6128,TTD:DAP000817,bindingDb:21691,chebi:100147,chemSpider:4268,drugBank:DB00779,keggCompound:C05079,keggDrug:D00183,ndc:0024-1322-03,pubChemCompound:4421,pubChemSubstance:46507401,pubChemSubstance:7525','CCn1cc(c(=O)c2c1nc(cc2)C)C(=O)O'),('PA164746385','cefpodoxime','CPDX-PR,Cefpodoxime proxetil,ru 51807','Banan,Doxef,Orelox,Otreon,Podomexef,Vantin','Drug/Small Molecule','DailyMed:7aa8637a-2b2f-4a24-b1c2-b2eba8b008cf,TTD:DAP000457,chemSpider:4891496,drugBank:DB01416,ndc:0009-3617-01,pubChemCompound:6335986,pubChemSubstance:14832042,pubChemSubstance:46504897,url:http://en.wikipedia.org/wiki/Cefpodoxime','COCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)C(=NOC)c3csc(n3)N)SC1)C(=O)O'),('PA164746386','interferon gamma-1b','IFN-gamma,Immune interferon,Interferon gamma precursor,interferon gamma-1b','Actimmune','Drug/Small Molecule','TTD:DAP001286,drugBank:DB00033,genBank:X13274,uniProtKb:P01579,url:http://en.wikipedia.org/wiki/Interferon_gamma-1b',''),('PA164746411','alseroxylon','','Rautensin,Rauwiloid','Drug/Small Molecule','TTD:DAP001243,drugBank:DB00386,pubChemSubstance:3730522',''),('PA164746412','tigecycline','GAR-936,GAR-936,Tigecycline,WAY-GAR-936','Tygacil','Drug/Small Molecule','TTD:DAP000880,chebi:149836,chemSpider:4445273,drugBank:DB00560,keggCompound:C12012,keggDrug:D01079,pubChemCompound:5282044,pubChemSubstance:14170,pubChemSubstance:46509041,url:http://en.wikipedia.org/wiki/Tigecycline',''),('PA164746413','ridogrel','Ridogrelum [INN-Latin]','','Drug/Small Molecule','TTD:DAP000469,bindingDb:50003795,chemSpider:4515025,drugBank:DB01207,pubChemCompound:5362391,pubChemSubstance:196719,pubChemSubstance:46506774',''),('PA164746463','gadoteridol','','ProHance,Prohance Multipack','Drug/Small Molecule','DailyMed:e8b76200-c0aa-491b-aad7-e22d2f68496f,chemSpider:54719,dpd:2229056,drugBank:DB00597,keggDrug:D01137,ndc:0270-1111-70,pubChemCompound:60714,pubChemSubstance:46505738,pubChemSubstance:7848200',''),('PA164746464','bifonazole','(+-)-1-(p,alpha-Diphenylbenzyl)imidazole,(+-)1-([1,1\'-Biphenyl]-4-ylphenylmethyl)-1H-imidazole,1-((4-Biphenylyl)phenylmethyl)-1H-imidazole,1-(alpha-(4','Amycor,Azolmen,Mycospor','Drug/Small Molecule','HET:TMI,TTD:DAP000877,bindingDb:50128548,chemSpider:2287,drugBank:DB04794,pdb:TMI,pubChemCompound:2378,pubChemSubstance:10461678,pubChemSubstance:46507284,url:http://en.wikipedia.org/wiki/Bifonazole','c1ccc(cc1)c2ccc(cc2)C(c3ccccc3)n4ccnc4'),('PA164746466','thiabendazole','2-(1,3-thiazol-4-yl)-1h-benzimidazole,TBDZ,TBZ,Thiabendazol,Thiabendole,Thiabenzazole,Thiabenzole,Tiabendazol,Tiabendazole','Apl-Luster,Arbotect,Bioguard,Bovizole,Chemviron TK','','',''),('PA164746467','anisindione','Anisin indandione','Miradon,Unidone','Drug/Small Molecule','TTD:DAP001274,chebi:133809,chemSpider:2112,drugBank:DB01125,pubChemCompound:2197,pubChemSubstance:151473,pubChemSubstance:46504660,url:http://en.wikipedia.org/wiki/Anisindione',''),('PA164746469','alfacalcidol','1-hydroxycholecalciferol,1alpha-hydroxycholecalciferol,1alpha-hydroxyvitamin D3','Alsiodol,One Alpha','Drug/Small Molecule','chemSpider:4445376,dpd:474517,drugBank:DB01436,keggDrug:D01518,pubChemCompound:5282181,pubChemSubstance:46505115,pubChemSubstance:7848581',''),('PA164746470','insulin-detemir','29b-[n6-(oxo-tetradecy)-l-lysine]-(1a-21a),(1b-29b)-insulin (human)','Levemir','Drug/Small Molecule','DailyMed:d38d65c1-25bf-401d-9c7e-a2c3222da8af,TTD:DAP001090,drugBank:DB01307,keggDrug:D04539,ndc:0169-3687-12,url:http://en.wikipedia.org/wiki/Insulin_detemir',''),('PA164746489','hexylcaine','','Cyclaine,Hexilcaina [INN-Spanish],Hexylcaine hydro','Drug/Small Molecule','TTD:DAP000506,bindingDb:50017670,chemSpider:10315,drugBank:DB00473,keggCompound:C14172,pubChemCompound:10770,pubChemSubstance:46506241,pubChemSubstance:7846984,url:http://en.wikipedia.org/wiki/Hexylcaine',''),('PA164746490','deferoxamine','DF B,DFO,DFOA,DFOM,Deferoxamide B,Deferoxamin,Deferoxamine B,Deferoxamine mesylate,Deferoxaminum,Deferrioxamine,Deferrioxamine B,Desferrioxamine,Desfe','Desferal,Desferan,Desferex,Desferin,Desferral,Desf','Drug/Small Molecule','DailyMed:f9ab6b1c-98d0-4373-0e9b-b10cb4a67543,chebi:4356,chemSpider:2867,dpd:2243450,drugBank:DB00746,keggCompound:C06940,keggDrug:D03670,ndc:0409-2336-10,pubChemCompound:2973,pubChemSubstance:46506395,pubChemSubstance:9155,url:http://en.wikipedia.org/wiki/Deferoxamine',''),('PA164746492','hydroxypropyl cellulose','Hydroxypropylmethylcellulose phthalate,Hypromellose phthtalate','Lacrisert','Drug/Small Molecule','DailyMed:b33529a0-50c7-474a-daba-80c607a53197,drugBank:DB00840,keggDrug:D01536,ndc:0006-3380-60,pubChemSubstance:7848599,url:http://en.wikipedia.org/wiki/Hydroxypropyl_cellulose',''),('PA164746493','masoprocol','Dihydronorguaiaretic acid,Masoprocolum [INN-Latin],NDGA,Nordihydroguaiaretic acid,Nordihydroguairaretic acid,meso-NDGA,meso-Nordihydroguaiaretic acid','Actinex','Drug/Small Molecule','TTD:DNC001037,bindingDb:22372,chemSpider:64490,drugBank:DB00179,keggCompound:C10719,pubChemCompound:71398,pubChemSubstance:12902,pubChemSubstance:46508042,url:http://en.wikipedia.org/wiki/Masoprocol',''),('PA164746525','metharbital','','Endiemal,Endiemalum,Gemonal,Gemonil,Gemonit,Metaba','Drug/Small Molecule','TTD:DAP000675,chemSpider:3957,drugBank:DB00463,keggDrug:D01382,pubChemCompound:4099,pubChemSubstance:46508167,url:http://en.wikipedia.org/wiki/Metharbital','CCC1(C(=O)NC(=O)N(C1=O)C)CC'),('PA164746526','halazepam','Halazepamum [INN-Latin]','Pacinone,Paxipam','Drug/Small Molecule','TTD:DAP000679,chemSpider:29343,drugBank:DB00801,keggDrug:D00338,pubChemCompound:31640,pubChemSubstance:46508415,pubChemSubstance:7847404,url:http://en.wikipedia.org/wiki/Halazepam','c1ccc(cc1)C2=NCC(=O)N(c3c2cc(cc3)Cl)CC(F)(F)F'),('PA164746527','agalsidase beta','Agalsidase alfa,Alpha-D- galactoside galactohydrolase,Alpha-D-galactosidase A,Alpha-galactosidase A precursor,Melibiase,agalsidase beta','Fabrazyme,Replagal','Drug/Small Molecule','DailyMed:988513ab-b06f-4dd0-93f7-d2d4531dcce4,dpd:2248966,drugBank:DB00103,genBank:X14448,ndc:58468-0040-1,uniProtKb:P06280,url:http://en.wikipedia.org/wiki/Agalsidase_beta',''),('PA164746528','erythrityl tetranitrate','1,2,3,4-Butanetetralyl tetranitrate,ETN,Eritritile tetranitrato [dcit],Eritrityl tetranitrate,Eritrityli tetranitras [inn-latin],Erythritol tetranitra','Cardilate,Cardiloid,Cardivell,Cardiwell,Tetranitri','Drug/Small Molecule','TTD:DAP001060,chebi:60072,drugBank:DB01613,pubChemCompound:23723,pubChemSubstance:10507903',''),('PA164746538','interferon alfa-n1','Interferon alpha-2,Interferon alpha-A,LeIF A','Wellferon','Drug/Small Molecule','TTD:DAP001280,dpd:1959077,drugBank:DB00011,genBank:J00207,uniProtKb:P01563',''),('PA164746539','diphenoxylate','Dea No. 9170,Difenossilato [Dcit],Difenoxilato [INN-Spanish],Diphenoxalate,Diphenoxylate Hydrochloride,Diphenoxylatum [INN-Latin]','Lomotil','','',''),('PA164746540','arcitumomab','CEA-Scan,anti-carcinoembryonic antigen monoclonal antibody fab\' fragment,arcitumomab,immu-4','CEA-Scan','Drug/Small Molecule','TTD:DAP001303,drugBank:DB00113,url:http://en.wikipedia.org/wiki/Arcitumomab',''),('PA164746559','hetacillin','','Hetacillin potassium,Versapen,Versapen-k','Drug/Small Molecule','TTD:DAP001167,chebi:5683,chemSpider:391616,drugBank:DB00739,keggCompound:C11729,keggDrug:D01074,pubChemCompound:443387,pubChemSubstance:13894,pubChemSubstance:46504545,url:http://en.wikipedia.org/wiki/Hetacillin','CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N3C(=O)[C@H](NC3(C)C)c4ccccc4)C(=O)O)C'),('PA164746560','thyrotropin alfa','FSH-B,FSH-beta,Follicle-stimulating hormone beta subunit,Follitropin beta chain precursor','Thyrogen','Drug/Small Molecule','DailyMed:b52dfa36-f90b-4e19-9b5e-26db9d04df2b,TTD:DAP001248,dpd:2246016,drugBank:DB00024,genBank:M16647,ndc:58468-1849-4,uniProtKb:P01225',''),('PA164746748','methyprylon','Dea No. 2575,Methprylon,Methyprolon,Methyprylon [INN],Methyprylone [INN-French],Methyprylonum [INN-Latin],Metiprilon,Metiprilona [INN-Spanish],Metipri','Dimerin,Noctan,Nodular,Noludar','Drug/Small Molecule','TTD:DAP000683,chemSpider:4018,drugBank:DB01107,keggDrug:D01150,pubChemCompound:4162,pubChemSubstance:46506891,url:http://en.wikipedia.org/wiki/Methyprylon',''),('PA164746749','niflumic acid','2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid,2-(3-(Trifluoromethyl)anilino)nicotinic acid,2-(3-Trifluoromethyl-phenylamino)-nicotinic acid,2-(alp','Actol,Flogovital,Forenol,Landruma,Niflam,Nifluril','Drug/Small Molecule','HET:NFL,TTD:DAP000972,chemSpider:4333,drugBank:DB04552,iupharLigand:2439,keggCompound:C13698,pdb:NFL,pubChemCompound:4488,pubChemSubstance:46504657,pubChemSubstance:7889362','c1cc(cc(c1)Nc2c(cccn2)C(=O)O)C(F)(F)F'),('PA164746756','molindone','(+-)-molindone,Molindona [inn-spanish],Molindonum [inn-latin]','Moban','Drug/Small Molecule','TTD:DAP000979,bindingDb:50130290,chemSpider:22342,drugBank:DB01618,iupharLigand:207,keggCompound:C07230,ndc:63481-072-70,pubChemCompound:23897,pubChemSubstance:46504744,pubChemSubstance:9439,url:http://en.wikipedia.org/wiki/Molindone',''),('PA164746757','tolterodine','Tolterodina [INN-Spanish],Tolterodine L-Tartrate,Tolterodine Tartrate,Tolterodine [INN],Tolterodinum [INN-Latin],Tolterondine Tartrate,tolterodine ext','Detrol,Detrol LA','Drug/Small Molecule','DailyMed:c98eb213-9c80-4698-9710-a9855059b8bb,TTD:DAP000376,chebi:9622,dpd:2244612,drugBank:DB01036,iupharLigand:360,keggCompound:C07750,keggDrug:D00646,ndc:0009-5190-01,pubChemCompound:60774,pubChemSubstance:197020,url:http://en.wikipedia.org/wiki/Tolterodine',''),('PA164746758','ethanolamine oleate','Monoethanolamine oleate,beta-Hydroxyethylammonium oleate,cis-9-Octadecenoic acid, ethanolamine salt','Ethamolin,Monolate,Moramin,Neosclerol,Oldamin,Vare','Drug/Small Molecule','DailyMed:a9c1d8c5-443e-400e-a42c-16a25fb47231,chemSpider:4445632,drugBank:DB06689,keggDrug:D02276,ndc:67871-479-06,pubChemCompound:5282489,pubChemCompound:6433328,pubChemSubstance:7849335,pubChemSubstance:99443246,url:http://en.wikipedia.org/wiki/Monoethanolamine_oleate','CCCCCCCC/C=CCCCCCCCC(=O)[O-].C(CO)N'),('PA164746759','sodium tetradecyl sulfate','Monotetradecylsulfate sodium salt,S.T.D.,STD,Sodium myristyl sulfate,Tetradecyl hydrogen sulphate,Tetradecyl sodium sulfate,Tetradecyl sulfate,Tetrade','Niaproof-4,Sotradecol,Tergitol-4,Texapon K 14','Drug/Small Molecule','DailyMed:f1756c28-dcd2-4b49-be62-07ca20682018,TTD:DAP001276,chemSpider:5058,dpd:363332,drugBank:DB00464,ndc:67457-162-02,pubChemCompound:14492,pubChemCompound:5248,pubChemSubstance:14874529,pubChemSubstance:46505919','CCCCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]'),('PA164746760','furazolidone','Nitrofurazolidone,Nitrofurazolidonum,USAF EA-1','Bifuron,Corizium,Coryzium,Diafuron,Enterotoxon,Fiu','Drug/Small Molecule','TTD:DAP000993,chebi:5195,chemSpider:3317,dpd:674761,drugBank:DB00614,keggCompound:C07999,keggDrug:D00830,pubChemCompound:3435,pubChemCompound:5323714,pubChemSubstance:10200,pubChemSubstance:46507291,url:http://en.wikipedia.org/wiki/Furazolidone',''),('PA164746763','dihydroxyaluminium','','','Drug/Small Molecule','TTD:DAP000798,chemSpider:17615602,drugBank:DB01375,pubChemCompound:16683036,pubChemCompound:18502861,pubChemSubstance:179984,pubChemSubstance:46505934,url:http://en.wikipedia.org/wiki/Aluminium_monostearate',''),('PA164746803','amrinone','Amrinona [inn-spanish],Amrinonum [inn-latin],Inamrinone,Inamrinone lactate','Amcoral,Cartonic,Cordarex,Cordemcura,Inocor,Wincor','Drug/Small Molecule','DailyMed:42cd4847-b706-4d51-97e3-b736839c2d24,TTD:DAP001392,bindingDb:34651,chemSpider:3570,drugBank:DB01427,keggCompound:C13594,keggDrug:D00231,ndc:55390-042-10,pubChemCompound:3698,pubChemSubstance:12013242,pubChemSubstance:46504647,url:http://en.wikipedia.org/wiki/Amrinone',''),('PA164746819','cefmetazole','Cefmetazole sodium,Cefmetazolo [INN-Spanish],Cefmetazolum [INN-Latin]','Zefazone','Drug/Small Molecule','TTD:DAP001179,chebi:3489,chemSpider:38311,drugBank:DB00274,keggCompound:C08103,keggDrug:D00910,pubChemCompound:42008,pubChemSubstance:10303,pubChemSubstance:46504461,url:http://en.wikipedia.org/wiki/Cefmetazole','Cn1c(nnn1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O'),('PA164746820','fosphenytoin','(3-Phosphoryloxymethyl)phenytoin,Fosfenitoina [inn-spanish],Fosphenytoin sodium,Fosphenytoine [inn-french],Fosphenytoinum [inn-latin]','Cerebyx,Prodilantin','Drug/Small Molecule','TTD:DAP000520,chemSpider:50839,dpd:2230988,drugBank:DB01320,keggCompound:C07840,ndc:0071-4007-05,pubChemCompound:56339,pubChemSubstance:10042,pubChemSubstance:46505168,url:http://en.wikipedia.org/wiki/Fosphenytoin','c1ccc(cc1)C2(C(=O)N(C(=O)N2)COP(=O)(O)O)c3ccccc3'),('PA164746821','tazarotene','tazarotene','Tazarotene [USAN:INN],Tazorac,Zorac','Drug/Small Molecule','DailyMed:cd8a3be3-8f83-42cf-8752-6fd16da65150,TTD:DAP000462,chebi:32184,chemSpider:5188,dpd:2243894,drugBank:DB00799,keggCompound:C12531,keggDrug:D01132,ndc:0023-9236-30,pubChemCompound:5381,pubChemSubstance:46508992,pubChemSubstance:582921,url:http://en.wikipedia.org/wiki/Tazarotene',''),('PA164746843','iloprost','iloprost','Ventavis','Drug/Small Molecule','DailyMed:d3bebc1c-f032-402a-bbc9-aff024276ed1,TTD:DAP000273,chemSpider:4947911,drugBank:DB01088,ndc:66215-302-30,pubChemCompound:6443959,pubChemSubstance:46507818,pubChemSubstance:772634,url:http://en.wikipedia.org/wiki/Iloprost',''),('PA164746889','methadyl acetate','Acetilmetadol [inn-spanish],Acetylmethadol,Acetylmethadolum [inn-latin],Betamethadol','','Drug/Small Molecule','TTD:DAP001137,bindingDb:50027391,chemSpider:10080,drugBank:DB01433,pubChemCompound:10517,pubChemSubstance:10354601,pubChemSubstance:46505532','CCC(OC(C)=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1'),('PA164746890','temsirolimus','CCI-779,temsirolimus','Torisel','Drug/Small Molecule','TTD:DAP001222,chemSpider:21468899,drugBank:DB06287,keggCompound:C15182,keggDrug:D06068,pubChemCompound:23724530,pubChemCompound:6918289,pubChemSubstance:99443243,url:http://en.wikipedia.org/wiki/Temsirolimus',''),('PA164746897','calcium acetate','Acetic acid, calcium salt,Brown acetate,Brown acetate of lime,Calcium acetate hydrate,Calcium acetate monohydrate,Calcium diacetate,Gray acetate,Gray ','Calac,Niacet calcium acetate tech,PhosLo,PhosLo Ge','','',''),('PA164746898','carbinoxamine','Carbinoxamine Maleate,Paracarbinoxamine,Paracarinoxamine','Allergefon,Clistin,Rotoxamine,Twiston','Drug/Small Molecule','DailyMed:0ec4cd71-5196-4fe7-a007-4689b3357c74,TTD:DAP001069,bindingDb:50240487,chebi:3398,chemSpider:2466,drugBank:DB00748,keggCompound:C06871,ndc:0525-6748-01,pubChemCompound:2564,pubChemSubstance:46506787,pubChemSubstance:9088,url:http://en.wikipedia.org/wiki/Carbinoxamine','CN(C)CCOC(c1ccc(cc1)Cl)c2ccccn2'),('PA164746899','phenazopyridine','PAP,PDP,Pyridacil','Azo-Standard,Baridium,Phenazodine,Phenylazo,Prodiu','Drug/Small Molecule','chemSpider:4592,dpd:271489,drugBank:DB01438,keggCompound:C07429,pubChemCompound:4756,pubChemSubstance:46507962,pubChemSubstance:9633,url:http://en.wikipedia.org/wiki/Phenazopyridine','c1ccc(cc1)N=Nc2ccc(nc2N)N'),('PA164746900','alitretinoin','9-cis-retinoic acid,ALRT-1057,BAL4079,Retinoic Acid,alitretinoin','Panretin,Panretin Gel,Panretyn,Panrexin,Renova,Ret','Drug/Small Molecule','DailyMed:9cf04dad-e312-4b8f-a297-1e002d43e151,TTD:DAP000275,bindingDb:31883,chebi:50648,drugBank:DB00523,ndc:64365-501-01,pubChemCompound:444795,pubChemSubstance:164122,url:http://en.wikipedia.org/wiki/Alitretinoin',''),('PA164746997','thiamylal','','Surital,Thioseconal','Drug/Small Molecule','TTD:DAP000684,chebi:30490,chebi:9536,chemSpider:2297298,dpd:620823,drugBank:DB01154,keggCompound:C07846,keggDrug:D06106,pubChemCompound:3032285,pubChemSubstance:10048,pubChemSubstance:46506261,url:http://en.wikipedia.org/wiki/Thiamylal',''),('PA164746998','nabilone','nabilone','Cesamet','Drug/Small Molecule','DailyMed:10553514-8001-4281-85b6-96d99ef6822a,TTD:DAP000067,chemSpider:4447641,dpd:2256193,drugBank:DB00486,keggDrug:D05099,ndc:0187-1221-03,pubChemCompound:5284592,pubChemSubstance:46505171,url:http://en.wikipedia.org/wiki/Nabilone',''),('PA164747026','trihexyphenidyl','Trihexifenidilo [INN-Spanish],Trihexylphenidyl,Trihexylphenidyle,Trihexylphenizyl,Trihexyphenidyl HCl,Trihexyphenidyle,Trihexyphenidyle [INN-French],T','Apo-Trihex,Artane,Artane Sequels,Benzhexol,Benzhex','Drug/Small Molecule','TTD:DAP001532,chemSpider:5371,dpd:726265,drugBank:DB00376,keggCompound:C07171,ndc:61748-054-36,pubChemCompound:5572,pubChemSubstance:46507717,pubChemSubstance:9380,url:http://en.wikipedia.org/wiki/Trihexyphenidyl',''),('PA164747027','levobunolol','Levobunolol HCl,Levobunololum [INN-Latin]','Akbeta,Betagan','Drug/Small Molecule','DailyMed:1a32c0e8-7d10-447e-a7c4-252c98b629bd,TTD:DAP000303,chebi:6438,chemSpider:36089,dpd:2241575,drugBank:DB01210,iupharLigand:570,keggCompound:C07914,ndc:0023-4526-10,pubChemCompound:39468,pubChemSubstance:10116,pubChemSubstance:46507518,url:http://en.wikipedia.org/wiki/Levobunolol','CC(C)(C)NC[C@@H](COc1cccc2c1CCCC2=O)O'),('PA164747037','methantheline','Banthine Bromide,MTB 51,Methantheline Bromide,Methanthelinium,Methanthelinium Bromide,Methanthelinum,Methanthine Bromide','Asabaine,Avagal,Banthin,Banthine,Dixamone Bromide,','Drug/Small Molecule','TTD:DAP001109,chemSpider:3955,drugBank:DB00940,keggCompound:C07849,pubChemCompound:4097,pubChemSubstance:10051,pubChemSubstance:46505807',''),('PA164747038','sulfametopyrazine','','Dalysep,Farmitalia 204/122,Kelfizin,Kelfizina,Kelf','Drug/Small Molecule','TTD:DAP001199,chemSpider:8695,drugBank:DB00664,keggCompound:C12616,keggDrug:D01216,pubChemCompound:9047,pubChemSubstance:46505111,pubChemSubstance:583006',''),('PA164747039','aprepitant','MK-0517,MK-869,aprepitant,fosaprepitant','Emend','Drug/Small Molecule','DailyMed:696f9e80-9cae-403b-de9e-078343ce4713,TTD:DNC000952,chebi:499361,drugBank:DB00673,ndc:0006-0461-02,pubChemCompound:151165,pubChemSubstance:728707,url:http://en.wikipedia.org/wiki/Aprepitant',''),('PA164747055','fencamfamine','2-Aethylamino-3-phenyl-nor-camphan,2-Ethylamino-3-phenyl-norcamphane hydrochloride,2-Ethylamino-3-phenylnorcamphane hydrochloride,Fencamfamin,Fencamfa','Euvitol,Glucoenergan,Reactivan','Drug/Small Molecule','TTD:DAP001007,chemSpider:13922,drugBank:DB01463,pubChemCompound:14584,pubChemSubstance:10452544,pubChemSubstance:46508161,url:http://en.wikipedia.org/wiki/Fencamfamine','CCNC1C2CCC(C2)C1c3ccccc3'),('PA164747059','insulin-lispro','','','Drug/Small Molecule','drugBank:DB01310,url:http://en.wikipedia.org/wiki/Insulin_lispro',''),('PA164747060','ciclopirox','CPO,Ciclopirox Olamin,Ciclopirox-Olamin,Ciclopiroxum [INN-Latin],HOE 296b,HOE-296b,ciclopirox,ciclopiroxolamine','Loprox,Loprox Shampoo,Penlac,Penlac Nail Lacquer,S','Drug/Small Molecule','DailyMed:3f82e6b5-c6b6-4d96-8295-948fec7e7fdb,TTD:DAP000466,bindingDb:50231223,chemSpider:2647,dpd:2247228,drugBank:DB01188,keggDrug:D01364,ndc:0066-8008-01,pubChemCompound:2749,pubChemSubstance:213640,pubChemSubstance:46506333,url:http://en.wikipedia.org/wiki/Ciclopirox',''),('PA164747061','botulinum toxin type b','BTX-B,Botulinum neurotoxin type B precursor','Myobloc,Neurobloc','Drug/Small Molecule','TTD:DAP001272,dpd:75108,drugBank:DB00042,genBank:M81186,keggDrug:D02735,uniProtKb:P10844,url:http://en.wikipedia.org/wiki/Botulinum_toxin',''),('PA164747080','abatacept','CTLA4-Ig,CTLA4-IgG4m,CTLA4Ig,CTLA4IgG4m,RG-1046,RG-2077,RG1046,RG2077,abatacept','Orencia','Drug/Small Molecule','DailyMed:0836c6ac-ee37-5640-2fed-a3185a0b16eb,TTD:DAP000867,dpd:2282097,drugBank:DB01281,keggDrug:D03203,ndc:0003-2187-10,url:http://en.wikipedia.org/wiki/Abatacept',''),('PA164747126','basiliximab','Ig gamma-1 chain C region,chimeric mouse-human antiCD25','Simulect','Drug/Small Molecule','DailyMed:1af01887-b69d-444b-91ed-ebfe12784440,TTD:DAP000388,dpd:2242815,drugBank:DB00074,genBank:J00228,ndc:0078-0393-61,uniProtKb:P01857,url:http://en.wikipedia.org/wiki/Basiliximab',''),('PA164747157','azatadine','Azatadina [INN-Spanish],Azatadine Maleate,Azatadinum [INN-Latin],Azatidine','Optimine','','',''),('PA164747170','fulvestrant','ICI 182,780,fulvestrant','Faslodex','Drug/Small Molecule','DailyMed:83d7a440-e904-4e36-afb5-cb02b1c919f7,TTD:DAP000319,bindingDb:50169743,chebi:31638,dpd:2248624,drugBank:DB00947,iupharLigand:1015,keggDrug:D01161,ndc:0310-0720-50,pubChemCompound:104741,url:http://en.wikipedia.org/wiki/Fulvestrant',''),('PA164747186','trioxsalen','trimethylpsoralen,trioxysalen,trisoralen','','Drug/Small Molecule','drugBank:DB04571,keggCompound:C09314,keggDrug:D01034,url:http://en.wikipedia.org/wiki/Trioxsalen','CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1'),('PA164747187','cefditoren','CDTR-PI,Cefditoren Pivaloyloxymethyl Ester,Cefditoren Pivoxil','Meiact,Spectracef','Drug/Small Molecule','DailyMed:f732ed2f-48b9-4331-87ab-81b5fbe728aa,TTD:DAP000444,chebi:59343,drugBank:DB01066,keggDrug:D01628,ndc:10122-802-20,pubChemCompound:9571074,pubChemSubstance:213535,url:http://en.wikipedia.org/wiki/Cefditoren','Cc1c(scn1)C=CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(=NOC)c4csc(n4)N)SC2)C(=O)O'),('PA164747188','phenmetrazine','2-Phenyl-3-Methylmorpholine,3-Methyl-2-phenylmorpholine,Defenmetrazin,Dexphenmetrazine,Fenmetrazin,Fenmetrazina [INN-Spanish],Oxazimedrine,Phenmetrali','Bromadryl,Cafilon,Marsin,Mefolin,Neo-zine,Phenmetr','Drug/Small Molecule','TTD:DAP000860,chemSpider:4598,drugBank:DB00830,keggCompound:C07432,pubChemCompound:4762,pubChemSubstance:46504524,pubChemSubstance:9636,url:http://en.wikipedia.org/wiki/Phenmetrazine','CC1C(OCCN1)c2ccccc2'),('PA164747189','metaxalone','Metassalone [Dcit],Metaxalon,Metaxalona [INN-Spanish],Metaxalonum [INN-Latin],Metaxalonum [Latin],Metazalone,Metazolone,Methaxalonum,Methoxolone','Skelaxin,Zorane','Drug/Small Molecule','DailyMed:0aff6dda-b9fd-4f01-85b2-eb3097b760b0,chemSpider:14709,drugBank:DB00660,keggCompound:C07934,keggDrug:D00773,ndc:0185-0448-01,pubChemCompound:15459,pubChemSubstance:158778,pubChemSubstance:46506253,url:http://en.wikipedia.org/wiki/Metaxalone',''),('PA164747190','lymecycline','7-Chlorotetracycline,CLTC,CTC,Chlorotetracycline,Chlorotetracycline hydrochloride,Chlortetracyclin,Chlortetracycline,Chlortetracycline hydrochloride,C','Acronize,Acronize PD,Aureocarmyl,Aureociclin,Aureo','Drug/Small Molecule','HET:CTC,TTD:DAP000881,chebi:59040,chemSpider:23501197,drugBank:DB00256,keggDrug:D06884,pdb:CTC,pubChemCompound:24757945,pubChemCompound:5280963,pubChemSubstance:46505518,url:http://en.wikipedia.org/wiki/Lymecycline',''),('PA164747191','natalizumab','Anti-VLA4,Anti-alpha4 integrin,natalizumab','Tysabri','Drug/Small Molecule','DailyMed:6fa00cb8-4229-4770-9d2a-d4a8542b3180,TTD:DAP001094,dpd:2286386,drugBank:DB00108,ndc:59075-730-15,url:http://en.wikipedia.org/wiki/Natalizumab',''),('PA164747225','l-citrulline','2-Amino-5-uredovaleric acid,Citrulline,N5-(Aminocarbonyl)ornithine,N5-Carbamoyl-L-ornithine,N5-carbamoylornithine,N5-carbamylornithine,Sitrulline,delt','','Drug/Small Molecule','HET:CIR,chebi:16349,chemSpider:9367,drugBank:DB00155,iupharLigand:722,keggCompound:C00327,pdb:CIR,pubChemCompound:9750,pubChemSubstance:46506583',''),('PA164747478','deslanoside','','Cedilanid-d,Deacetyllanatoside C','Drug/Small Molecule','TTD:DAP000464,chebi:31468,drugBank:DB01078,keggDrug:D01240,pubChemCompound:443932,pubChemSubstance:7848303,url:http://en.wikipedia.org/wiki/Deslanoside',''),('PA164747613','glucosamine','','','Drug/Small Molecule','TTD:DAP001097,chebi:5417,chemSpider:388352,drugBank:DB01296,pubChemCompound:439213,pubChemSubstance:46506420,url:http://en.wikipedia.org/wiki/Glucosamine',''),('PA164747650','alclometasone','Alclometasone dipropionate','Aclovate','Drug/Small Molecule','DailyMed:63e635e0-65d8-4b30-9f2a-ab16deba90bd,TTD:DAP000415,chebi:53776,drugBank:DB00240,keggDrug:D01820,ndc:68462-300-17,pubChemCompound:636374,pubChemSubstance:7848882,url:http://en.wikipedia.org/wiki/Alclometasone','C[C@@H]1C[C@H]2[C@@H]3[C@@H](CC4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)C)Cl'),('PA164747651','ergotamine','','Ergomar,Ergostat,Ergotamin,Ergoton-A,Medihaler Erg','','',''),('PA164747673','pipobroman','','Amedel,Vercyte','Drug/Small Molecule','TTD:DAP000988,chemSpider:4676,drugBank:DB00236,keggCompound:C07362,keggDrug:D00467,pubChemCompound:4842,pubChemSubstance:148729,pubChemSubstance:46506548,url:http://en.wikipedia.org/wiki/Pipobroman',''),('PA164747674','goserelin','Goserelin acetate','Zoladex','Drug/Small Molecule','DailyMed:4ff62a5a-77ba-4bf5-0497-95ccca842315,TTD:DAP000023,dpd:2225905,drugBank:DB00014,keggDrug:D00573,ndc:0310-0951-30,pubChemCompound:47725,pubChemSubstance:186963,url:http://en.wikipedia.org/wiki/Goserelin','CC(C[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1NC(=O)CC1)CC2=CN=CN2)CC3=CNC4=CC=CC=C34)CO)CC5=CC=C(C=C5)O)COC(C)(C)C)C(=O)N[C@@H](C(=O)N6[C@@H](CCC6)C(=O)NNC(=O)N)CCC/N=C(N)/N)C'),('PA164747738','moricizine','Moracizina [INN-Spanish],Moracizine,Moracizinum [INN-Latin]','Ethmozine','Drug/Small Molecule','DailyMed:c8fe88f7-b72d-406b-a883-d3419a5e065a,TTD:DAP000510,chebi:6997,chemSpider:31872,drugBank:DB00680,keggCompound:C07743,keggDrug:D05077,ndc:54092-046-01,pubChemCompound:34633,pubChemSubstance:46509072,pubChemSubstance:9945,url:http://en.wikipedia.org/wiki/Moricizine','CCOC(=O)Nc1ccc2c(c1)N(c3ccccc3S2)C(=O)CCN4CCOCC4'),('PA164747739','succinic acid','1,2-Ethanedicarboxylic acid,Acid of amber,Amber acid,Asuccin,Bernsteinsaure,Butanedioic acid,Butanedionic acid,Dicarboxylic acid,Dihydrofumaric acid,E','Katasuccin,Kyselina jantarova','','',''),('PA164747936','dexfenfluramine','(+)-fenfluramine,(s)-fenfluramine,D-Fenfluramine,Dexafenfluramine,Dexfenfluramina [Spanish],Dexfenfluramine Hydrochloride,Dexfenfluraminum [Latin],Dex','Adifax,Redux','Drug/Small Molecule','TTD:DAP001224,chebi:439329,drugBank:DB01191,keggDrug:D07805,pubChemCompound:3337,pubChemSubstance:161613,url:http://en.wikipedia.org/wiki/Dexfenfluramine',''),('PA164747979','arbutamine','','GenESA','Drug/Small Molecule','TTD:DAP000936,chebi:50580,chemSpider:54785,drugBank:DB01102,pubChemCompound:60789,pubChemSubstance:197034,pubChemSubstance:46509010',''),('PA164747980','decamethonium','Decamethonum','Lopac-D-1260,Syncurine','Drug/Small Molecule','HET:DME,TTD:DAP000378,chebi:4346,chemSpider:2862,drugBank:DB01245,keggCompound:C11733,pdb:DME,pubChemCompound:2968,pubChemSubstance:13898,pubChemSubstance:46507737,url:http://en.wikipedia.org/wiki/Decamethonium','C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C'),('PA164747990','progabide','Halogabide,Progabida [INN-Spanish],Progabide [Usan:Ban:Inn],Progabidum [INN-Latin]','Gabren,Gabrene','Drug/Small Molecule','TTD:DAP000258,chemSpider:4514729,drugBank:DB00837,pubChemCompound:5361323,pubChemSubstance:184378,pubChemSubstance:46506568,url:http://en.wikipedia.org/wiki/Progabide','c1cc(ccc1C(=NCCCC(=O)N)c2cc(ccc2O)F)Cl'),('PA164747991','oprelvekin','AGIF,Adipogenesis inhibitory factor,IL-11,Interleukin-11 precursor,oprelvekin','Neumega','Drug/Small Molecule','TTD:DAP001287,drugBank:DB00038,genBank:M57765,ndc:58394-004-01,uniProtKb:P20809,url:http://en.wikipedia.org/wiki/Oprelvekin',''),('PA164748010','mequitazine','Mequitazina [INN-Spanish],Mequitazina [Spanish],Mequitazinum [INN-Latin]','Butix,Instotal,Kitazemin,Metaplexan,Mircol,Primala','Drug/Small Molecule','TTD:DAP001078,chemSpider:3926,drugBank:DB01071,keggCompound:C12755,keggDrug:D01324,pubChemCompound:4066,pubChemSubstance:46505779,pubChemSubstance:583144,url:http://en.wikipedia.org/wiki/Mequitazine',''),('PA164748026','cyclandelate','3,3,5-Trimethylcyclohexyl mandelate,3,5,5-Trimethylcyclohexyl amygdalate,3,5,5-Trimethylcyclohexyl mandelate,Ciclandelato [inn-spanish],Cyclandelatum ','Arto-espasmol,Capilan,Ciclospasmol,Clandilon,Cycle','Drug/Small Molecule','chebi:3988,chemSpider:2790,drugBank:DB04838,pubChemCompound:2893,pubChemSubstance:10386674,pubChemSubstance:46505740','CC1CC(CC(C1)(C)C)OC(=O)C(c2ccccc2)O'),('PA164748027','dyphylline','DT,Dihydroxypropyl Theophylline,Dihydroxypropyl Theopylin,Diprofillin,Diprofilline,Diprophyllin,Diprophylline,Dipropylline','Afi-Phyllin,Aristophyllin,Asthmolysin,Astrophyllin','Drug/Small Molecule','DailyMed:6d7ed7c0-9646-11de-a404-0002a5d5c51b,TTD:DAP000596,chebi:4728,chemSpider:3070,dpd:26751,drugBank:DB00651,keggCompound:C07819,keggDrug:D00691,ndc:0037-0521-92,pubChemCompound:3182,pubChemSubstance:10021,pubChemSubstance:46504443',''),('PA164748034','cinolazepam','Cinolazepamum [inn-latin]','Gerodorm','Drug/Small Molecule','TTD:DAP001250,chebi:59514,chemSpider:2298251,drugBank:DB01594,pubChemCompound:3033621,pubChemSubstance:10047721,pubChemSubstance:46508803,url:http://en.wikipedia.org/wiki/Cinolazepam','c1ccc(c(c1)C2=NC(C(=O)N(c3c2cc(cc3)Cl)CCC#N)O)F'),('PA164748035','butethal','5-Butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione,5-Butyl-5-ethylbarbituric acid,5-Ethyl-5-N-butylbarbituric acid,5-Ethyl-5-butylbarbituric acid,Butaba','Budorm,Etoval,Hyperbutal,Longanoct,Meonal,Monodorm','Drug/Small Molecule','TTD:DAP000687,chemSpider:6229,drugBank:DB01353,keggDrug:D02618,pubChemCompound:6473,pubChemSubstance:10413788,pubChemSubstance:46508397,url:http://en.wikipedia.org/wiki/Butobarbital',''),('PA164748036','liotrix','','Bitiron,Combithyrex,Cynoplus,Dithyron,Euthroid,Eut','Drug/Small Molecule','chemSpider:64467,drugBank:DB01583,pubChemCompound:71371,pubChemSubstance:213602,pubChemSubstance:46506203',''),('PA164748037','dyclonine','','Diclonia,Diclonina,Diclonina [INN-Spanish],Dycloca','','',''),('PA164748038','rimantadine','rimantadine hydrochloride','Flumadine,Levofloxacin hydrochloride,Rimantadine H','Drug/Small Molecule','DailyMed:9c7bb7e7-a775-4f93-bd77-d08c48a86f7c,TTD:DAP001087,bindingDb:50216627,chemSpider:4893,drugBank:DB00478,keggCompound:C07236,keggDrug:D08483,ndc:0456-0521-01,pubChemCompound:5071,pubChemSubstance:46505973,pubChemSubstance:9445,url:http://en.wikipedia.org/wiki/Rimantadine',''),('PA164748039','fosfomycin','Fosfocina,Fosfomycin disodium salt,Fosfomycin sodium,Fosfonomycin,Phosphomycin,Phosphonomycin,phosphomycin disodium salt','Monurol,Veramina','Drug/Small Molecule','DailyMed:ad155d62-9b49-4a50-a2ae-d3aad8155936,HET:FCN,TTD:DAP000767,chemSpider:394204,dpd:2240335,drugBank:DB00828,keggCompound:C06454,keggDrug:D04253,ndc:0456-4300-08,pdb:FCN,pubChemCompound:446987,pubChemSubstance:46506665,pubChemSubstance:8687,url:http://en.wikipedia.org/wiki/Fosfomycin',''),('PA164748040','alefacept','ASP0485,Amevive,alefacept','Amevive','Drug/Small Molecule','TTD:DAP000540,dpd:2259052,drugBank:DB00092,url:http://en.wikipedia.org/wiki/Alefacept',''),('PA164748092','malathion','Carbofos,Carbophos,Compound 4049,Experimental insecticide 4049,Insecticide no. 4049,MLT,Malathione,Maldison,Mercaptosuccinic acid diethyl ester,Mercap','Calmathion,Carbethoxy malathion,Carbetovur,Carbeto','Drug/Small Molecule','DailyMed:0679f4fa-9e18-4da6-83a4-043100a42db4,TTD:DAP000895,bindingDb:50240924,chebi:6651,chemSpider:3864,drugBank:DB00772,keggCompound:C07497,keggDrug:D00534,ndc:68882-014-60,pubChemCompound:4004,pubChemSubstance:46505287,pubChemSubstance:9700,url:http://en.wikipedia.org/wiki/Malathion',''),('PA164748093','alglucerase','Acid beta-glucosidase,Beta-glucocerebrosidase,D-glucosyl-N-acylsphingosine glucohydrolase,Glucosylceramidase precursor','Ceredase','Drug/Small Molecule','drugBank:DB00088,genBank:M16328,keggDrug:D09675,ndc:58468-1060-1,uniProtKb:P04062,url:http://en.wikipedia.org/wiki/Alglucerase',''),('PA164748094','methyclothiazide','Methychlothiazide,Methyclothiazid,Methycyclothiazide,Methylchlorothiazide,Methylclothiazide,Methylcyclothiazide','Aquaresen,Aquatensen,Duretic,Enduron,Enduronum','Drug/Small Molecule','DailyMed:4910dad2-c533-4232-85bf-e6b0235379c2,TTD:DAP000746,chemSpider:3978,dpd:485,drugBank:DB00232,keggCompound:C07765,keggDrug:D00656,ndc:0378-0160-01,pubChemCompound:4121,pubChemSubstance:46509197,pubChemSubstance:9967',''),('PA164748098','bentoquatam','','Bentone 34,Ivy Block,IvyBlock','Drug/Small Molecule','chemSpider:451302,drugBank:DB00516,pubChemCompound:517273,pubChemSubstance:10501170,pubChemSubstance:46508055,url:http://en.wikipedia.org/wiki/Bentoquatam',''),('PA164748099','phentermine','(alpha,alpha)-Dimethylphenethylamine,Phentermine Hcl,Phentermine Hydrochloride','Adipex-P,Duromine,Fastin,Inoamin,Ionamin,Linyl,Lip','','',''),('PA164748124','mitiglinide','KAD-1229,Mitiglinide calcium hydrate,mitiglinide','Glufast','Drug/Small Molecule','TTD:DAP000917,chemSpider:2310083,drugBank:DB01252,keggDrug:D01854,pubChemCompound:3047758,pubChemSubstance:10053765,pubChemSubstance:46506527,url:http://en.wikipedia.org/wiki/Mitiglinide',''),('PA164748134','chlophedianol','1-(2-Chlorophenyl)-3-(dimethylamino)-1-phenyl-1-propanol,1-Phenyl-1-(o-chlorophenyl)-3-dimethylaminopropanol,2-Chloro-alpha-(2-(dimethylamino)ethyl)be','Calmotusin,Coldrin,Dencyl,Detigon,Eutus,Tussistop,','Drug/Small Molecule','TTD:DAP001080,chemSpider:2693,dpd:1966294,drugBank:DB04837,pubChemCompound:2795,pubChemSubstance:10347370,pubChemSubstance:46505324,url:http://en.wikipedia.org/wiki/Clofedanol',''),('PA164748135','aminophenazone','4-Dimethylaminoantipyrine,Aminopyrine,Dipyrine','','Drug/Small Molecule','chebi:160246,chemSpider:5787,drugBank:DB01424,keggCompound:C07539,keggDrug:D00556,pubChemCompound:6009,pubChemSubstance:46504975,pubChemSubstance:7847622,url:http://en.wikipedia.org/wiki/Aminophenazone',''),('PA164748136','cefpiramide','sm-1652','Cefpiramide Sodium,Cefpiramide [USAN:INN],Cefpiram','Drug/Small Molecule','TTD:DAP001157,chebi:59213,drugBank:DB00430,keggCompound:C13376,keggDrug:D01904,pubChemCompound:107654,pubChemSubstance:684895,url:http://en.wikipedia.org/wiki/Cefpiramide','Cc1cc(c(cn1)C(=O)N[C@H](c2ccc(cc2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSc5nnnn5C)C(=O)O)O'),('PA164748137','oxtriphylline','Choline theophylline','Choledyl,Theocolin','Drug/Small Molecule','TTD:DAP000868,chemSpider:571001,drugBank:DB01303,keggDrug:D02017,pubChemCompound:656652,pubChemSubstance:46507376,pubChemSubstance:7849079,url:http://en.wikipedia.org/wiki/Oxtriphylline',''),('PA164748138','cholecalciferol','(+)-vitamin d3,CC,Cholecalciferol, D3,Colecalciferol,Vitamin D3','Calciol,Delsterol,Delta-D,Deparal,Ebivit,Micro-Dee','','',''),('PA164748223','buclizine','Buclizina [INN-Spanish],Buclizine Dihydrochloride,Buclizine Hydrochloride,Buclizinum [INN-Latin],Histabutyzine Dihydrochloride,Vibazine Hydrochloride','Aphilan R,Aphilan-R Base,Bucladin,Bucladin-S,Bucli','Drug/Small Molecule','TTD:DAP001076,chebi:3205,chemSpider:6473,drugBank:DB00354,keggCompound:C07777,pubChemCompound:6729,pubChemSubstance:46507608,pubChemSubstance:9979,url:http://en.wikipedia.org/wiki/Buclizine','CC(C)(C)c1ccc(cc1)CN2CCN(CC2)C(c3ccccc3)c4ccc(cc4)Cl'),('PA164748224','vorinostat','MK0683,N-hydroxy-n\'-phenyloctanediamide,N-hyrdroxy-n\'-phenyloctanediamide,SAHA,SHH,Suberanilohydroxamic acid,suberoylanilide hydroxamic acid,vorinosta','Zolinza','Drug/Small Molecule','DailyMed:cd86ee78-2781-468b-930c-3c4677bcc092,HET:SHH,TTD:DAP001082,bindingDb:19149,chemSpider:5120,drugBank:DB02546,ndc:0006-0568-40,pdb:SHH,pubChemCompound:5311,pubChemSubstance:12015019,pubChemSubstance:46508989,url:http://en.wikipedia.org/wiki/Vorinostat',''),('PA164748302','cilazapril','inhibace','','Drug/Small Molecule','TTD:DAP000912,dpd:1911465,drugBank:DB01340,pubChemCompound:56329,pubChemSubstance:193657,url:http://en.wikipedia.org/wiki/Cilazapril',''),('PA164748318','xanthophyll','(3R,3\'R)-Beta,Beta-Carotene-3,3\'-Diol, Lutein,(3R,3\'R,6\'R)-Lutein,(3R,3\'R,6S)-4,5-Didehydro-5,6-Dihydro-Beta,Beta-Carotene-3,3\'-Diol,4,5-Didehydro-5,6','Bo-Xan','Drug/Small Molecule','HET:LUT,chebi:27325,chemSpider:4519703,drugBank:DB00137,pdb:LUT,pubChemCompound:5368396,pubChemSubstance:46508835,pubChemSubstance:548587,url:http://en.wikipedia.org/wiki/Xanthophyll',''),('PA164748328','sertaconazole','Sertaconazol [Spanish],Sertaconazolum [Latin]','Ertaczo','Drug/Small Molecule','DailyMed:07d47bbe-4a4f-4042-8534-d48aa6ce1cd0,TTD:DAP001270,chemSpider:59273,drugBank:DB01153,ndc:0062-1650-03,pubChemCompound:65863,pubChemSubstance:207904,pubChemSubstance:46507290,url:http://en.wikipedia.org/wiki/Sertaconazole',''),('PA164748329','marimastat','marimastat','Marimastat [Usan]','Drug/Small Molecule','HET:097,TTD:DCL000005,chebi:50662,chemSpider:106358,drugBank:DB00786,pdb:097,pubChemCompound:119031,pubChemSubstance:46505547,pubChemSubstance:695683,url:http://en.wikipedia.org/wiki/Marimastat',''),('PA164748351','minaprine','Minaprina [INN-Spanish],Minaprine Dihydrochloride,Minaprine Hydrochloride,Minaprinum [INN-Latin]','Brantur,Cantor','Drug/Small Molecule','TTD:DAP000475,chebi:51038,chemSpider:4054,drugBank:DB00805,pubChemCompound:4199,pubChemSubstance:213627,pubChemSubstance:46505380','Cc1cc(nnc1NCCN2CCOCC2)c3ccccc3'),('PA164748364','tositumomab','Ig gamma-1 chain C region','Bexxar','Drug/Small Molecule','DailyMed:0d706611-abab-42f1-ae8a-2097eb1be38d,TTD:DAP000384,dpd:2270471,drugBank:DB00081,genBank:J00228,ndc:0007-3260-31,uniProtKb:P01857,url:http://en.wikipedia.org/wiki/Tositumomab',''),('PA164748386','droxidopa','Droxydopa,L-DOPS,L-dihydroxyphenylserine,L-threo-3,4-dihydroxyphenylserine','Dops','Drug/Small Molecule','chemSpider:391994,drugBank:DB06262,keggDrug:D01277,pubChemCompound:443940,pubChemSubstance:24560805,pubChemSubstance:99443239,url:http://en.wikipedia.org/wiki/Droxidopa','c1cc(c(cc1C(C(C(=O)O)N)O)O)O'),('PA164748387','thymalfasin','Talpha1,Thymosin alpha 1,Valopicitabine,thymalfasin','Zadaxin','Drug/Small Molecule','drugBank:DB04900,pubChemCompound:16130571,pubChemSubstance:14842665','CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)C'),('PA164748388','diphemanil methylsulfate','','Prantal','Drug/Small Molecule','TTD:DAP001130,chebi:59782,chemSpider:5896,dpd:176885,drugBank:DB00729,pubChemCompound:6126,pubChemSubstance:149020,pubChemSubstance:46506069',''),('PA164748389','coagulation factor viia','Coagulation factor VII precursor,Eptacog alfa,Proconvertin,SPCA,Serum prothrombin conversion accelerator','NovoSeven','Drug/Small Molecule','DailyMed:ea65c32f-8518-4383-b621-17056c0eebc0,drugBank:DB00036,genBank:M13232,keggCompound:C03378,keggDrug:D00172,ndc:0169-7010-01,pubChemSubstance:6213,uniProtKb:P08709,url:http://en.wikipedia.org/wiki/Factor_VII',''),('PA164748507','trilostane','trilostane','Desopan,Modrastane,Modrenal','Drug/Small Molecule','TTD:DAP000148,chebi:32260,chemSpider:570949,drugBank:DB01108,keggDrug:D01180,pubChemCompound:656583,pubChemSubstance:46507062,pubChemSubstance:7848243,url:http://en.wikipedia.org/wiki/Trilostane',''),('PA164748616','valrubicin','Antibiotic Ad 32','Valstar,Valstar Preservative Free','Drug/Small Molecule','DailyMed:e96f30a0-6662-11de-8f80-0002a5d5c51b,TTD:DAP000650,chemSpider:38088,dpd:2242466,drugBank:DB00385,ndc:67979-001-01,pubChemCompound:41744,pubChemSubstance:182424,pubChemSubstance:46506642,url:http://en.wikipedia.org/wiki/Valrubicin',''),('PA164748617','naftifine','','Naftifine HCl,Naftin','Drug/Small Molecule','DailyMed:e516fb5a-5c9b-4a74-9beb-423f2b345dde,TTD:DAP000752,chemSpider:66071,dpd:2011255,drugBank:DB00735,keggCompound:C08071,ndc:0259-4770-40,pubChemCompound:47641,pubChemCompound:73342,pubChemSubstance:10271,pubChemSubstance:46504777,url:http://en.wikipedia.org/wiki/Naftifine',''),('PA164748630','stepronin','Stepronine [inn-french],Stepronino [inn-spanish],Steproninum [inn-latin]','Bronco-plus,Tiase,Tiofacic','Drug/Small Molecule','chemSpider:48889,drugBank:DB01423,pubChemCompound:54120,pubChemSubstance:14799391,pubChemSubstance:46507364,url:http://en.wikipedia.org/wiki/Stepronin','CC(C(=O)NCC(=O)O)SC(=O)c1cccs1'),('PA164748631','sargramostim','CSF,Colony-stimulating factor,GM-CSF,Granulocyte-macrophage colony-stimulating factor precursor,Molgramostin,sargramostim','Immunex,Leucomax,Leukine','Drug/Small Molecule','DailyMed:723782d7-a2ab-4cc6-a767-387975ccec80,TTD:DAP001053,drugBank:DB00020,genBank:M13207,ndc:50419-002-33,uniProtKb:P04141,url:http://en.wikipedia.org/wiki/Sargramostim',''),('PA164748726','entacapone','Entacapona [INN-Spanish],Entacapone [Usan:Inn],Entacaponum [INN-Latin],entacapone','Comtan,Comtess','Drug/Small Molecule','DailyMed:b1aceb59-9be8-43b8-83d6-81e05e4b51e4,TTD:DAP000608,chebi:4798,chemSpider:4444537,dpd:2243763,drugBank:DB00494,keggCompound:C07943,keggDrug:D00781,ndc:0078-0327-05,pubChemCompound:5281081,pubChemSubstance:197051,pubChemSubstance:46508734,url:http://en.wikipedia.org/wiki/Entacapone','CCN(CC)C(=O)/C(=C/c1cc(c(c(c1)O)O)N(=O)=O)/C#N'),('PA164748727','metipranolol','Metipranolol hydrochloride,Metipranololum [INN-Latin]','Disorat,OptiPranolol,Trimepranol','Drug/Small Molecule','DailyMed:ac780ffb-7b9c-4098-88d7-8148eff3b6d1,TTD:DAP000480,chemSpider:29193,drugBank:DB01214,keggCompound:C07915,keggDrug:D02374,ndc:24208-275-07,pubChemCompound:31477,pubChemSubstance:10117,pubChemSubstance:46505935,url:http://en.wikipedia.org/wiki/Metipranolol','Cc1cc(c(c(c1OC(=O)C)C)C)OCC(CNC(C)C)O'),('PA164748728','mycophenolic acid','Mycophenoic acid','Melbex,Myfortic','Drug/Small Molecule','DailyMed:eed26501-890d-4ff6-88e7-6dbea4726e53,HET:MOA,TTD:DAP000784,bindingDb:19264,chebi:168396,chemSpider:393865,dpd:2264560,drugBank:DB01024,ndc:0078-0386-66,pdb:MOA,pubChemCompound:446541,pubChemSubstance:46504559,pubChemSubstance:602720,url:http://en.wikipedia.org/wiki/Mycophenolic_acid',''),('PA164748741','mepivacaine','DL-Mepivacaine,Mepivacaina [INN-Spanish],Mepivacaine HCL,Mepivacainum [INN-Latin],Mepivicaine,S-Ropivacaine Mesylate,mepivacaine hydrochloride','Arestocaine HCL,Carbocain,Carbocaine,Isocaine HCL,','','',''),('PA164748742','proflavine','','Isoflav Base,Pro-Gen,Proflavin,Profoliol-B,Proform','','',''),('PA164748758','ceftizoxime','Ceftizoxima [inn-spanish],Ceftizoximum [inn-latin]','Cefizox,Cefizox in plastic container,Ceftix,Epocel','Drug/Small Molecule','DailyMed:0013824b-6aee-4da4-affd-35bc6bf19d91,TTD:DAP000453,chebi:553473,chemSpider:5018818,drugBank:DB01332,keggCompound:C06890,ndc:0469-7271-01,pubChemCompound:6533629,pubChemSubstance:11641637,pubChemSubstance:46505647,url:http://en.wikipedia.org/wiki/Ceftizoxime','CON=C(c1csc(n1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=CCS3)C(=O)O'),('PA164748759','clofazimine','Chlofazimine,Clofazimina [INN-Spanish],Clofaziminum [INN-Latin]','Lampren,Lamprene','Drug/Small Molecule','TTD:DAP000789,chebi:3749,drugBank:DB00845,keggCompound:C06915,keggDrug:D00278,pubChemCompound:2794,pubChemSubstance:159498,url:http://en.wikipedia.org/wiki/Clofazimine','CC(C)N=c1cc-2n(c3ccccc3nc2cc1Nc4ccc(cc4)Cl)c5ccc(cc5)Cl'),('PA164748760','gadopentetate dimeglumine','','Gadopentetic Acid Dimeglumine Salt,Magnevist','Drug/Small Molecule','DailyMed:abef9e9b-a29f-4abe-aeff-88ae42648057,chebi:31797,chemSpider:50087,dpd:1989987,drugBank:DB00789,keggDrug:D01707,ndc:50419-188-58,pubChemCompound:55466,pubChemSubstance:192903,pubChemSubstance:46504878,url:http://en.wikipedia.org/wiki/Gadopentetate_dimeglumine',''),('PA164748761','metaraminol','Hydroxynorephedrine,L-Metaraminol,M-Hydroxy Norephedrine,M-Hydroxyphenylpropanolamine,M-Hydroxypropadrine,Metaraminol Bitartrate,Metaraminolum [INN-La','Aramine,Icoral B,Metaradrine,Pressonex,Pressorol','Drug/Small Molecule','TTD:DAP000225,chebi:6794,chemSpider:5695,drugBank:DB00610,keggCompound:C07146,pubChemCompound:5906,pubChemSubstance:46505593,pubChemSubstance:9355,url:http://en.wikipedia.org/wiki/Metaraminol',''),('PA164748762','lactulose','','Acilac,Bifiteral,Cephulac,Cholac,Chronulac,Constil','Drug/Small Molecule','DailyMed:183c0621-d058-4600-9345-2b01d66cb65a,chebi:6359,chemSpider:10856,dpd:690686,drugBank:DB00581,keggCompound:C07064,keggDrug:D00352,ndc:0054-8486-16,pubChemCompound:11333,pubChemSubstance:46506757,pubChemSubstance:9276,url:http://en.wikipedia.org/wiki/Lactulose',''),('PA164748763','polythiazide','','','Drug/Small Molecule','DailyMed:abd6ecf0-dc8e-41de-89f2-1e36ed9d6535,TTD:DAP000751,chemSpider:4704,drugBank:DB01324,keggCompound:C07766,keggDrug:D00657,ndc:0069-3750-66,pubChemCompound:4870,pubChemSubstance:10475848,pubChemSubstance:46508633','CN1C(Nc2cc(c(cc2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F'),('PA164748765','dorzolamide','','Trusopt','','',''),('PA164748781','palivizumab','Synagis,anti-RSV,palivizumab','Synagis','Drug/Small Molecule','DailyMed:8e35c4c8-bf56-458f-a73c-8f5733829788,TTD:DAP000386,dpd:2245889,drugBank:DB00110,ndc:60574-4114-1,url:http://en.wikipedia.org/wiki/Palivizumab',''),('PA164748782','oxamniquine','','Mansil,Vansil','Drug/Small Molecule','TTD:DAP000992,chemSpider:4451,drugBank:DB01096,keggCompound:C07341,keggDrug:D00460,pubChemCompound:4612,pubChemSubstance:46508789,pubChemSubstance:9548,url:http://en.wikipedia.org/wiki/Oxamniquine','CC(C)NCC1CCc2cc(c(cc2N1)N(=O)=O)CO'),('PA164748783','lucanthone','1-((2-(Diethylamino)ethyl)amino)-4-methylthioxanthen-9-one,1-[[2-(Diethylamino)ethyl]amino]-4-methylthioxanthone,Lucanthon,Lucanthone hydrochloride,Lu','Miracil D,Miracol,Nilodin,Scapuren,Tixantone','Drug/Small Molecule','TTD:DAP001003,chebi:51052,chemSpider:9772,drugBank:DB04967,keggCompound:C11715,pubChemCompound:10180,pubChemSubstance:11405383,pubChemSubstance:46507260',''),('PA164748817','efalizumab','Raptiva,anti alphaL integrin,antiCD11 alpha,efalizumab,hu1124','Raptiva','Drug/Small Molecule','TTD:DAP001095,dpd:2272504,drugBank:DB00095,url:http://en.wikipedia.org/wiki/Efalizumab',''),('PA164748839','glycodiazine','Glidiazine,Glymidine','','Drug/Small Molecule','TTD:DAP000921,chemSpider:9190,drugBank:DB01382,pubChemCompound:9565,pubChemSubstance:152778,pubChemSubstance:46507076',''),('PA164748840','oxymetazoline','Oximetazolinum,Oxymethazoline,Oxymetozoline,oxymetazoline hydrochloride crystalline','Afrin,Afrin Cherry 12 Hour Nasal Spray,Afrin Extra','Drug/Small Molecule','DailyMed:43fe343c-8238-4267-bbcc-b48d7b281be0,TTD:DAP000235,bindingDb:50027075,chemSpider:4475,dpd:2245578,drugBank:DB00935,iupharLigand:124,keggCompound:C07363,ndc:42002-204-05,pubChemCompound:4636,pubChemSubstance:46505622,pubChemSubstance:9567,url:http://en.wikipedia.org/wiki/Oxymetazoline','Cc1cc(c(c(c1CC2=NCCN2)C)O)C(C)(C)C'),('PA164748865','vecuronium','','','Drug/Small Molecule','TTD:DAP000354,chebi:9939,chemSpider:36357,dpd:687405,drugBank:DB01339,keggCompound:C07553,pubChemCompound:39764,pubChemCompound:39765,pubChemSubstance:12013268,pubChemSubstance:46507656,url:http://en.wikipedia.org/wiki/Vecuronium',''),('PA164748866','apraclonidine','Apraclonidina [INN-Spanish],Apraclonidinum [INN-Latin],P-Aminoclonidine Hydrochloride,apraclonidine hydrochloride','Aplonidine,Iopidine,Iopidine Eye','Drug/Small Molecule','DailyMed:de798d0d-a93c-40fb-95ea-10a4e6b287b7,TTD:DAP000236,bindingDb:50021812,chebi:2788,chemSpider:2130,dpd:2076306,drugBank:DB00964,keggCompound:C07668,ndc:0065-0665-05,pubChemCompound:2216,pubChemSubstance:46505614,pubChemSubstance:9870,url:http://en.wikipedia.org/wiki/Apraclonidine',''),('PA164748867','bimatoprost','AGN 192024,bimatoprost','Lumigan','Drug/Small Molecule','DailyMed:34f83d9d-2c64-463e-8a90-9a460fedfead,HET:15M,TTD:DAP001217,chebi:51230,chemSpider:4470565,dpd:2245860,drugBank:DB00905,iupharLigand:1958,ndc:0023-3616-03,pdb:15M,pubChemCompound:5311027,pubChemSubstance:46505334,pubChemSubstance:7978793,url:http://en.wikipedia.org/wiki/Bimatoprost',''),('PA164748880','paramethadione','','Isoethadione,Paradione,Parametadiona [INN-Spanish]','Drug/Small Molecule','TTD:DAP001266,chemSpider:7979,drugBank:DB00617,keggCompound:C07411,keggDrug:D00495,pubChemCompound:8280,pubChemSubstance:46509173,pubChemSubstance:9615,url:http://en.wikipedia.org/wiki/Paramethadione',''),('PA164748881','benzyl benzoate','','Ascabin,Ascabiol,Benylate,Benzoic acid benzyl este','','',''),('PA164748882','thiethylperazine','Ethylthioperazine,Theithylperazine','Norzine,Torecan','Drug/Small Molecule','TTD:DAP000315,chebi:9544,chemSpider:5245,drugBank:DB00372,keggCompound:C07132,keggDrug:D02354,pubChemCompound:5440,pubChemSubstance:46506502,pubChemSubstance:618292,url:http://en.wikipedia.org/wiki/Thiethylperazine','CCSc1ccc2c(c1)N(c3ccccc3S2)CCCN4CCN(CC4)C'),('PA164748883','diethylcarbamazine','Carbamazine,Carbilazine,Diethyl carbamazine,Ditrazine base,Ethodryl','Banocide,Bitirazine,Caracide,Caricide,Cypip,Decaci','','',''),('PA164748908','procaterol','','Pro-Air','Drug/Small Molecule','TTD:DAP000944,chemSpider:599984,drugBank:DB01366,pubChemCompound:688561,pubChemSubstance:11113915,pubChemSubstance:46507907','CCC(C(c1ccc(c2c1ccc(=O)[nH]2)O)O)NC(C)C'),('PA164748933','isoflurophate','DFP,Diflupyl,Diflurophate,Diisopropoxyphosphoryl Fluoride','Diisopropyl Fluoridophosphate,Diisopropyl Fluoroph','Drug/Small Molecule','TTD:DAP000896,chebi:17941,chemSpider:5723,drugBank:DB00677,keggCompound:C00202,keggDrug:D00043,pubChemCompound:5936,pubChemSubstance:3502,pubChemSubstance:46504499,url:http://en.wikipedia.org/wiki/Isoflurophate',''),('PA164748964','sulfisoxazole','Sulfadimethylisoxazole,Sulfafurazol,Sulfafurazole,Sulfaisoxazole,Sulfasoxazole,Sulfisonazole,Sulfisoxasole,Sulfisoxazol,Sulfisoxazole Dialamine,Sulfis','Accuzole,Alphazole,Amidoxal,Astrazolo,Azo Gantrisi','','',''),('PA164748965','phenylpropanolamine','(+-)-Phenylpropanolamine,(+/-)-Norephedrin,PPA','Acutrim,Ami-Tex,Codimal,Conex,Contuss,Despec,Dexat','','',''),('PA164748975','lisdexamfetamine','NRP104,lisdexamfetamine dimesylate','Vyvanse','Drug/Small Molecule','DailyMed:704e4378-ca83-445c-8b45-3cfa51c1ecad,TTD:DAP000571,chemSpider:9772458,drugBank:DB01255,ndc:59417-102-10,pubChemCompound:11597697,pubChemCompound:11597698,pubChemSubstance:16700339,pubChemSubstance:46505358,url:http://en.wikipedia.org/wiki/Lisdexamfetamine',''),('PA164748976','trospium','Trospium','Sanctura,Spasmex,Spasmoplex,Trosec','Drug/Small Molecule','DailyMed:f49bf265-01b1-484d-841b-342c3fb7b7f9,TTD:DAP000342,chemSpider:5394,drugBank:DB00209,keggDrug:D01103,ndc:0023-3513-60,pubChemCompound:5596,pubChemSubstance:46506398,pubChemSubstance:4894299,url:http://en.wikipedia.org/wiki/Trospium',''),('PA164748977','chlormerodrin','','Chlormerodrine,Chlormeroprin,Chloromeridin,Chlorom','Drug/Small Molecule','TTD:DAP000754,chebi:59445,chemSpider:2615,drugBank:DB00534,pubChemCompound:25210,pubChemCompound:2716,pubChemSubstance:46504793','COC(CNC(=O)N)C[Hg]Cl'),('PA164748978','sitagliptin','MK-0431,Sitagliptan,Sitagliptin phosphate,sitagliptin','Januvia,Xelevia','','',''),('PA164749018','benzquinamide','','BZQ,Benzchinamide,Emete-con,Emeticon,Promecon,Quan','Drug/Small Molecule','TTD:DAP000713,chebi:27662,chemSpider:2252,drugBank:DB00767,keggDrug:D00243,pubChemCompound:2342,pubChemSubstance:46506155','CCN(CC)C(=O)C1CN2CCc3cc(c(cc3C2CC1OC(=O)C)OC)OC'),('PA164749019','lisuride','','Lisurida [INN-Spanish],Lisuride Maleate,Lisuride [','Drug/Small Molecule','TTD:DAP000255,chebi:51164,chemSpider:26847,drugBank:DB00589,iupharLigand:227,iupharLigand:43,keggDrug:D08132,pubChemCompound:28864,pubChemSubstance:171280,pubChemSubstance:46505557,url:http://en.wikipedia.org/wiki/Lisuride',''),('PA164749035','ropinirole','Ropinirol [INN-Spanish],Ropinirole HCl,Ropinirole hydrochloride,Ropinirolum [INN-Latin],ropinirole','ReQuip CR,ReQuip XL,Requip','Drug/Small Molecule','DailyMed:de0bb94f-4fd8-4f27-5ba6-6f392dd5160f,TTD:DAP001515,chebi:8888,chemSpider:4916,dpd:2232567,drugBank:DB00268,keggCompound:C07564,ndc:0007-4890-20,pubChemCompound:5095,pubChemSubstance:46507918,pubChemSubstance:7980537,url:http://en.wikipedia.org/wiki/Ropinirole','CCCN(CCC)CCc1cccc2c1CC(=O)N2'),('PA164749042','quinestrol','17-alpha-Ethinylestradiol 3-cyclopentyl ether,17alpha-Ethynylestradiol 3-cyclopentyl ether,Estradiol-17-beta 3-cyclopentyl ether,Quinestrolo [dcit],Qu','Eston,Estrovis,Estrovis 4000,Estrovister,Plestrovi','Drug/Small Molecule','TTD:DAP001016,chebi:8716,chemSpider:8694,drugBank:DB04575,keggCompound:C07619,keggDrug:D00576,pubChemCompound:9046,pubChemSubstance:46508939,pubChemSubstance:7847642,url:http://en.wikipedia.org/wiki/Quinestrol','C[C@]12CC[C@@H]3c4ccc(cc4CC[C@H]3[C@@H]1CC[C@]2(C#C)O)OC5CCCC5'),('PA164749044','eplerenone','Epoxymexrenone','INSPRA','Drug/Small Molecule','DailyMed:cd6cbf0b-34b8-43aa-8037-360480a19cf8,TTD:DAP000085,chebi:31547,drugBank:DB00700,keggCompound:C12512,keggDrug:D01115,ndc:0185-5368-30,pubChemCompound:150310,pubChemSubstance:727860,url:http://en.wikipedia.org/wiki/Eplerenone',''),('PA164749051','remoxipride','Remoxiprida [INN-Spanish],Remoxipride [Usan:Ban:Inn],Remoxipridum [INN-Latin],Romoxipride','','Drug/Small Molecule','TTD:DAP000312,bindingDb:50026045,chemSpider:49195,drugBank:DB00409,pubChemCompound:54477,pubChemSubstance:192058,pubChemSubstance:46508689,url:http://en.wikipedia.org/wiki/Remoxipride','CCN1CCC[C@H]1CNC(=O)c2c(ccc(c2OC)Br)OC'),('PA164749052','cosyntropin','Tetracosactide','Cortrosyn,Synacthen depot','Drug/Small Molecule','DailyMed:c9e0a573-9384-4291-bc90-1d250f5da65b,TTD:DAP000284,dpd:22381,drugBank:DB01284,keggCompound:C06926,keggDrug:D00284,ndc:0781-3052-95,pubChemCompound:16129617,pubChemSubstance:7847350,url:http://en.wikipedia.org/wiki/Cosyntropin','CC(C)[C@@H](C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC5=CNC6=C5C=CC=C6)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC8=CNC=N8)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)[C@@H](CO)N'),('PA164749056','danazol','','Anatrol,Chronogyn,Cyclomen,Danocrine','Drug/Small Molecule','DailyMed:57cebff0-1c66-4fd1-96ec-45ab7a4b801b,TTD:DAP001017,chebi:4315,chemSpider:26436,dpd:2018144,drugBank:DB01406,keggDrug:D00289,ndc:0024-0305-60,pubChemCompound:28417,pubChemSubstance:170876,pubChemSubstance:46506475,url:http://en.wikipedia.org/wiki/Danazol',''),('PA164749105','defibrotide','defibrotide','Dasovas,Noravid,Prociclide','Drug/Small Molecule','drugBank:DB04932,url:http://en.wikipedia.org/wiki/Defibrotide',''),('PA164749109','dapiprazole','','Rev-Eyes','Drug/Small Molecule','TTD:DAP000298,chebi:51066,chemSpider:2298190,drugBank:DB00298,pubChemCompound:3033538,pubChemSubstance:189873,pubChemSubstance:46508859,url:http://en.wikipedia.org/wiki/Dapiprazole','Cc1ccccc1N2CCN(CC2)CCc3nnc4n3CCCC4'),('PA164749110','sermorelin','Geref','Geref','Drug/Small Molecule','TTD:DAP001055,drugBank:DB00010,keggCompound:C08192,pubChemCompound:16129620,pubChemSubstance:10391,url:http://en.wikipedia.org/wiki/Sermorelin','CC[C@@H](C)[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N'),('PA164749133','josamycin','Antibiotic yl-704 A3,JM,Josamicina [inn-spanish],Josamycine [inn-french],Josamycinum [inn-latin],Leucomycin A3,Leucomycin V, 3-acetate 4(sup B)-(3-met','Josacine,Kitasamycin A3,Turimycin A5','Drug/Small Molecule','TTD:DAP000887,chemSpider:4445361,drugBank:DB01321,keggCompound:C12662,keggDrug:D01235,pubChemCompound:5282165,pubChemSubstance:46505431,pubChemSubstance:7848298,url:http://en.wikipedia.org/wiki/Josamycin',''),('PA164749134','idursulfase','','Elaprase','Drug/Small Molecule','DailyMed:60cba843-5aab-4dd7-96dc-66648d413be3,drugBank:DB01271,ndc:54092-700-01,url:http://en.wikipedia.org/wiki/Idursulfase',''),('PA164749135','azlocillin','Azlocilina [INN-Spanish],Azlocillin sodium salt,Azlocilline [INN-French],Azlocillinum [INN-Latin]','Azlin,Bayer Brand of Azlocillin,Securopen','Drug/Small Molecule','TTD:DAP001169,chebi:2956,drugBank:DB01061,keggCompound:C06839,keggDrug:D02339,pubChemCompound:37625,pubChemSubstance:9057,url:http://en.wikipedia.org/wiki/Azlocillin',''),('PA164749136','desflurane','Desflurano [INN-Spanish],Desfluranum [INN-Latin]','Suprane','Drug/Small Molecule','DailyMed:3fe3d468-d283-4dd0-a1a7-29291a9b2d0b,TTD:DAP000693,chebi:4445,chemSpider:38403,dpd:2227428,drugBank:DB01189,keggCompound:C07519,keggDrug:D00546,ndc:10019-641-24,pubChemCompound:42113,pubChemSubstance:46505270,pubChemSubstance:9722,url:http://en.wikipedia.org/wiki/Desflurane','C(C(F)(F)F)(OC(F)F)F'),('PA164749137','cefaclor','CCL,Cefaclor anhydrous,Cefaclorum [INN-Latin],Cephaclor','Alenfral,Alfacet,Alfatil,Ceclor,Ceclor CD,Distaclo','Drug/Small Molecule','DailyMed:6e88b4d2-223e-44ac-8b9c-3eecf4d573a5,TTD:DAP000442,chebi:3478,dpd:2237730,drugBank:DB00833,keggCompound:C06877,keggDrug:D00256,ndc:63304-658-30,pubChemCompound:40958,pubChemSubstance:181752,url:http://en.wikipedia.org/wiki/Cefaclor','c1ccc(cc1)[C@H](C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)Cl)C(=O)O)N'),('PA164749138','levosimendan','Levosimedan','Simdax,Simendan','Drug/Small Molecule','TTD:DAP000797,chebi:50567,chemSpider:2298414,drugBank:DB00922,pubChemCompound:3033825,pubChemSubstance:197103,pubChemSubstance:46507149,url:http://en.wikipedia.org/wiki/Levosimendan','C[C@@H]1CC(=O)NN=C1c2ccc(cc2)NN=C(C#N)C#N'),('PA164749157','ethynodiol diacetate','Ethinodiol Diacetate,Ethynodiol,Etynodiol','Cervicundin,Continuin,Femulen,Luteonorm,Luto-Metro','','',''),('PA164749164','trisalicylate-choline','','','Drug/Small Molecule','drugBank:DB01401','[Mg++].C[N+](C)(C)CCO.OC(=O)C1=CC=CC=C1O.OC1=CC=CC=C1C([O-])=O'),('PA164749165','lomefloxacin','LFLX,Lomefloxacine [French],Lomefloxacino [Spanish],Lomefloxacinum [Latin],lomefloxacin hydrochloride','Bareon,Maxaquin','Drug/Small Molecule','DailyMed:173018f5-fd76-4480-90f8-4b7efe328444,TTD:DAP000653,bindingDb:50240373,chebi:116278,chemSpider:3811,drugBank:DB00978,keggCompound:C07078,keggDrug:D02318,ndc:0025-5501-01,pubChemCompound:3948,pubChemSubstance:46508499,pubChemSubstance:9289,url:http://en.wikipedia.org/wiki/Lomefloxacin',''),('PA164749166','pyridoxal','PL,Pyridoxaldehyde,Vitamin B6 hydrochloride','','Drug/Small Molecule','HET:PXL,chebi:17310,chemSpider:1021,drugBank:DB00147,keggCompound:C00250,pdb:PXL,pubChemCompound:1050,pubChemSubstance:46506282,pubChemSubstance:602424,url:http://en.wikipedia.org/wiki/Pyridoxal','Cc1c(c(c(cn1)CO)C=O)O'),('PA164749171','milrinone','Milrinone Lactate','Corotrop,Corotrope,Milrila,Primacor','Drug/Small Molecule','DailyMed:8ccf2689-4372-4aa0-b964-c447704c0aed,TTD:DAP000150,bindingDb:15296,chebi:50693,chemSpider:4052,dpd:2244811,drugBank:DB00235,keggCompound:C07224,keggDrug:D00417,ndc:55390-078-01,pubChemCompound:4197,pubChemSubstance:46507838,pubChemSubstance:9433,url:http://en.wikipedia.org/wiki/Milrinone',''),('PA164749184','trovafloxacin','TVFX,Trovafloxacin mesylate','Trovan','','',''),('PA164749185','icatibant','JE049,icatibant','Firazyr','Drug/Small Molecule','TTD:DCL000131,bindingDb:50142947,chemSpider:64461,drugBank:DB06196,iupharLigand:667,pubChemCompound:71364,pubChemSubstance:99443237,url:http://en.wikipedia.org/wiki/Icatibant',''),('PA164749211','docosanol','Behenyl alcohol,docosanol','Abreva','Drug/Small Molecule','DailyMed:c39b38a7-dcdd-4c32-8f35-b565c4d3cec6,TTD:DAP001249,chebi:31000,chemSpider:12100,dpd:2245677,drugBank:DB00632,ndc:0135-0200-01,pubChemCompound:12620,pubChemSubstance:207364,pubChemSubstance:46508049,url:http://en.wikipedia.org/wiki/Docosanol','CCCCCCCCCCCCCCCCCCCCCCO'),('PA164749212','lincomycin','LCM,Lincomycin hydrochloride,Lincomycine,Lincomyocin','Lincocin,Lincocine,Lincolcina,Lincolnensin,Lincomi','Drug/Small Molecule','DailyMed:c01906fa-2c73-4c13-9765-2fd06628d263,TTD:DAP000839,chebi:6472,chemSpider:570892,dpd:30732,drugBank:DB01627,keggCompound:C06812,keggDrug:D00223,ndc:0009-0555-01,pubChemCompound:656509,pubChemSubstance:46506668,pubChemSubstance:7847290,url:http://en.wikipedia.org/wiki/Lincomycin','CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O'),('PA164749213','acetohydroxamic acid','AHA,Acethydroxamsaure,Acetic acid, oxime,Acetohydroxamate,Acetohydroximic acid,Acetyl hydroxyamino,Acetylhydroxamic acid,Cetohyroxamic acid,Methylhydr','Lithostat','Drug/Small Molecule','HET:HAE,TTD:DAP001277,chebi:27777,chemSpider:1913,drugBank:DB00551,keggCompound:C06808,keggDrug:D00220,pdb:HAE,pubChemCompound:1990,pubChemSubstance:46508546,pubChemSubstance:9027,url:http://en.wikipedia.org/wiki/Acetohydroxamic_acid','CC(=O)NO'),('PA164749238','exenatide','AC2993,Synthetic exendin-4,exenatide','Byetta','Drug/Small Molecule','DailyMed:751747da-7c1f-41ad-b1a6-a6d920f70599,TTD:DAP001038,drugBank:DB01276,keggDrug:D04121,ndc:66780-210-07,url:http://en.wikipedia.org/wiki/Exenatide',''),('PA164749284','levallorphan','','Levallofano [Dcit],Levallorphane [INN-French],Leva','Drug/Small Molecule','TTD:DAP000348,chemSpider:4514267,drugBank:DB00504,keggCompound:C07069,pubChemCompound:5359371,pubChemSubstance:152219,pubChemSubstance:46505682','C=CCN1CC[C@]23CCCC[C@H]2[C@H]1Cc4c3cc(cc4)O'),('PA164749297','clorazepate','','Chlorazepate,Chlorazepic acid,Clorazepate dipotass','Drug/Small Molecule','DailyMed:9acbb3f4-4bf6-40ae-89e3-303ec167912c,TTD:DAP000240,chebi:3761,chemSpider:2707,dpd:628190,drugBank:DB00628,keggDrug:D00694,ndc:0378-0030-01,pubChemCompound:2809,pubChemSubstance:46506595,pubChemSubstance:9138,url:http://en.wikipedia.org/wiki/Clorazepate',''),('PA164749298','cefotiam','CTM,Cefotiam hydrochloride,Cefotiamum [INN-Latin]','Ceradon','Drug/Small Molecule','TTD:DAP001177,chebi:355510,chemSpider:39831,drugBank:DB00229,keggCompound:C13289,keggDrug:D01819,pubChemCompound:43708,pubChemSubstance:46506679,url:http://en.wikipedia.org/wiki/Cefotiam','CN(C)CCn1c(nnn1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)Cc4csc(n4)N)SC2)C(=O)O'),('PA164749300','dutasteride','dutasteride','Avodart','Drug/Small Molecule','DailyMed:dc330e70-a1d3-400b-3aaf-46067e3fd090,TTD:DAP000044,chebi:521033,dpd:2247813,drugBank:DB01126,keggDrug:D03820,ndc:0173-0712-15,pubChemCompound:152945,pubChemSubstance:730446,url:http://en.wikipedia.org/wiki/Dutasteride',''),('PA164749340','cephapirin','Cefapirin,Cefapirina [INN-Spanish],Cefapirine [INN-French],Cefapirinum [INN-Latin],Cefaprin,Cefaprin sodium,Cephapirin Sodium,Cephapirine','Ambrocef,Cefa,Cefadyl,Cefatrex,Cefatrexyl','Drug/Small Molecule','TTD:DAP001160,chebi:554446,chemSpider:28486,dpd:2173255,drugBank:DB01139,keggCompound:C06896,pubChemCompound:30699,pubChemSubstance:46505227,pubChemSubstance:9113',''),('PA164749341','retapamulin','SB 275833','Altabax','Drug/Small Molecule','TTD:DAP000886,drugBank:DB01256,ndc:0007-5180-05,pubChemCompound:6918462,pubChemSubstance:16578667,url:http://en.wikipedia.org/wiki/Retapamulin',''),('PA164749342','cinnarizine','','Abitrate,Aplactan,Aplexal,Apotomin,Artate,Carecin,','Drug/Small Molecule','TTD:DAP000325,chebi:31403,chemSpider:2659,drugBank:DB00568,keggDrug:D01295,pubChemCompound:1547484,pubChemCompound:2761,pubChemSubstance:46506769,pubChemSubstance:7848358,url:http://en.wikipedia.org/wiki/Cinnarizine','c1ccc(cc1)/C=C/CN2CCN(CC2)C(c3ccccc3)c4ccccc4'),('PA164749350','enprofylline','3-Propylxanthine,3-n-Propylxanthine,Enprofilina [INN-Spanish],Enprofyllinum [INN-Latin]','Nilyph,Oxeze','Drug/Small Molecule','TTD:DAP001375,bindingDb:50001493,chebi:126237,chemSpider:1613,drugBank:DB00824,pubChemCompound:1676,pubChemSubstance:179921,pubChemSubstance:46505790',''),('PA164749366','cyproheptadine','','Cypoheptadine,Cyproheptadiene,Cyproheptadine Hcl,D','Drug/Small Molecule','DailyMed:963ded24-0367-44ca-a68d-66c385e76e69,TTD:DAP000103,bindingDb:50017721,chebi:4046,chemSpider:2810,dpd:2245668,drugBank:DB00434,iupharLigand:277,ndc:49884-043-01,pubChemCompound:2913,pubChemSubstance:46508613,pubChemSubstance:597387,url:http://en.wikipedia.org/wiki/Cyproheptadine',''),('PA164749376','interferon alfacon-1','CIFN,IFN Alfacon-1,Interferon Consensus, Methionyl,Recombinant Consensus Interferon,Recombinant methionyl human consensus interferon,consensus interfe','Advaferon,Infergen','Drug/Small Molecule','DailyMed:a7248eca-45d6-472d-8c2a-d8887c2594d5,TTD:DAP001284,dpd:2239832,drugBank:DB00069,genBank:J00207,ndc:0187-2007-06',''),('PA164749380','serum albumin','Serum albumin precursor','Optison,Perflutren Protein-Type A Microspheres','Drug/Small Molecule','DailyMed:46bcf276-d423-408a-a410-f11383406a94,dpd:35408,drugBank:DB00096,genBank:M12523,ndc:0407-2707-03,uniProtKb:P02768,url:http://en.wikipedia.org/wiki/Serum_albumin',''),('PA164749381','midodrine','Midodrin,Midodrina [INN-Spanish],Midodrine HCL,Midodrinum [INN-Latin],midodrine hydrochloride','ProAmatine','Drug/Small Molecule','DailyMed:4c3517f3-1c68-4ade-b5f1-c488a3a335c1,TTD:DAP000229,chebi:6933,chemSpider:4050,dpd:1934406,drugBank:DB00211,keggCompound:C07890,ndc:0245-0211-11,pubChemCompound:4195,pubChemSubstance:10092,pubChemSubstance:46507373,url:http://en.wikipedia.org/wiki/Midodrine','COc1ccc(c(c1)C(CNC(=O)CN)O)OC'),('PA164749385','ketazolam','','','Drug/Small Molecule','chemSpider:31110,drugBank:DB01587,pubChemCompound:33746,pubChemSubstance:10465271,pubChemSubstance:46507008,url:http://en.wikipedia.org/wiki/Ketazolam',''),('PA164749386','polystyrene sulfonate','Polystyrene sulfonic acid,SPS,Sodium polystyrene sulfonate,Sodium polystyrene sulfonic acid','Kayexalate,Kionex','Drug/Small Molecule','DailyMed:d506116f-16a3-4f58-a432-7606c2179c9e,chemSpider:148572,drugBank:DB01344,ndc:0574-2004-16,pubChemCompound:169893,pubChemSubstance:46507832,pubChemSubstance:747421,url:http://en.wikipedia.org/wiki/Polystyrene_sulfonate',''),('PA164749387','cycrimine','Cycrimine hydrochloride','Pagitane','Drug/Small Molecule','TTD:DAP001120,chebi:59692,chemSpider:2808,drugBank:DB00942,pubChemCompound:2911,pubChemSubstance:10535560,pubChemSubstance:46506736',''),('PA164749388','flumethasone pivalate','','Locorten','','',''),('PA164749389','tropicamide','Tropicamid','I-Picamide,Minims Tropicamide,Mydriacyl,Mydriafair','','',''),('PA164749390','peginterferon alfa-2a','','Pegasys','Drug/Small Molecule','TTD:DAP001278,dpd:2248077,drugBank:DB00008,genBank:J00207,uniProtKb:P01563,url:http://en.wikipedia.org/wiki/Peginterferon_alfa-2a',''),('PA164749394','prednicarbate','','Dermatop,Dermatop E Emollient','Drug/Small Molecule','TTD:DAP001189,chemSpider:47402,dpd:2230642,drugBank:DB01130,ndc:0066-0507-15,pubChemCompound:52421,pubChemSubstance:190435,pubChemSubstance:46506799,url:http://en.wikipedia.org/wiki/Prednicarbate',''),('PA164749395','oxandrolone','Ossandrolone [DCIT],Oxandrolona [INN-Spanish],Oxandrolonum [INN-Latin],oxandrolone','Anavar,Lonavar,Oxandrin,Protivar,Provitar,Vasorome','Drug/Small Molecule','DailyMed:b4ba1f43-5628-4e79-a4aa-f5c466cb517a,TTD:DAP000905,chebi:7820,chemSpider:5667,drugBank:DB00621,keggCompound:C07346,keggDrug:D00462,ndc:0245-0271-11,pubChemCompound:5878,pubChemSubstance:46509027,pubChemSubstance:9553,url:http://en.wikipedia.org/wiki/Oxandrolone',''),('PA164749405','homatropine methylbromide','','Arkitropin,Camatropine,DL-Homatropine methyl bromi','','',''),('PA164749406','menotropins','LH-B,LSH- beta,LSH-B,Luteinizing hormone beta subunit,Lutropin beta chain precursor','Repronex','Drug/Small Molecule','TTD:DAP001027,dpd:2247790,drugBank:DB00032,genBank:X00264,uniProtKb:P01229,url:http://en.wikipedia.org/wiki/Menotropins',''),('PA164749407','lomustine','CCNU,Chloroethylcyclohexylnitrosourea,Lomustina [INN-Spanish],Lomustinum [INN-Latin]','Belustine,CINU,Cecenu,CeeNU','Drug/Small Molecule','DailyMed:17893de9-7d54-448c-9fca-d10642046d14,TTD:DAP000991,chemSpider:3813,dpd:360414,drugBank:DB01206,keggDrug:D00363,ndc:0015-3030-20,pubChemCompound:3950,pubChemSubstance:168381,pubChemSubstance:46506562,url:http://en.wikipedia.org/wiki/Lomustine',''),('PA164749408','diflorasone','Diflorasone Diacetate','Florone,Florone E,Maxiflor,Psorcon','Drug/Small Molecule','DailyMed:b20c9420-8fb4-4a49-93f0-c0e4074d6d71,TTD:DAP001184,chebi:59750,dpd:481807,drugBank:DB00223,keggDrug:D01327,ndc:51672-1296-1,pubChemCompound:71414,pubChemSubstance:7848390,url:http://en.wikipedia.org/wiki/Diflorasone',''),('PA164749409','drospirenone','6beta,7beta,15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17 carbolactone,DRSP,Drospirenona [inn-spanish],Drospirenonum [inn-latin]','','','',''),('PA164749431','gemtuzumab ozogamicin','Mylotarg,anti-CD33,gemtuzumab ozogamicin','Mylotarg','Drug/Small Molecule','DailyMed:32fd2bb2-1cfa-4250-feb8-d7956c794e05,TTD:DAP000390,drugBank:DB00056,ndc:0008-4510-01,url:http://en.wikipedia.org/wiki/Gemtuzumab_ozogamicin',''),('PA164749474','penbutolol','Penbutolol sulfate','Betapressin,Levatol,Levatolol,Lobeta,Paginol','Drug/Small Molecule','DailyMed:38a78eca-f770-49a3-8a3a-3f536f3039ec,TTD:DAP000938,chemSpider:34369,drugBank:DB01359,ndc:0091-4500-15,pubChemCompound:37464,pubChemSubstance:15902888,pubChemSubstance:46504929,url:http://en.wikipedia.org/wiki/Penbutolol',''),('PA164749505','glutethimide','Glutathimid,Glutethimid,Glutetimid,Glutetimide,Gluthetimide','Alfimid,Doriden,Elrodorm,Gimid,Glimid,Noxiron,Noxy','Drug/Small Molecule','TTD:DAP001305,chemSpider:3367,drugBank:DB01437,keggCompound:C07489,keggDrug:D00532,pubChemCompound:3487,pubChemSubstance:46506283,pubChemSubstance:7847598,url:http://en.wikipedia.org/wiki/Glutethimide','CCC1(CCC(=O)NC1=O)c2ccccc2'),('PA164749506','methocarbamol','','AHR 85,Avetil,Delaxin,Etroflex,Forbaxin,Glycerylgu','','',''),('PA164749507','metocurine','(+)-O,O\'-Dimethylchondrocurarine Di-iodide,Dimethyl Tubocurarine Iodide,Dimethyltubocurarine Iodide,Dimetiltubocurarinio, ioduro de,Metocurini Iodidum','Metubine,Metubine iodide,Mutubine Iodide','Drug/Small Molecule','TTD:DAP000352,TTD:DAP000824,bindingDb:50094708,chemSpider:19961,chemSpider:22666,dpd:466948,drugBank:DB00416,drugBank:DB01336,keggCompound:C07919,keggDrug:D00761,pubChemCompound:21233,pubChemCompound:24244,pubChemSubstance:10121,pubChemSubstance:166758,pubChemSubstance:46507773,pubChemSubstance:46508044,url:http://en.wikipedia.org/wiki/Dimethyltubocurarinium',''),('PA164749508','kunecatechins','','Veregen','Drug/Small Molecule','DailyMed:2c1cd745-79ab-487d-b759-995794cedb92,drugBank:DB01266,ndc:10337-450-15',''),('PA164749509','colistimethate','Colistimethale Sodium,Colistimethate sodium,Colistin methanesulfonate sodium salt,Colistin sodium methanesulfonate,Colistin sodium methanesulfonate fr','Coly-Mycin,Coly-Mycin M','Drug/Small Molecule','DailyMed:91c7f6d0-d056-42de-9f0b-97e30c1279f9,TTD:DAP001329,dpd:2244849,drugBank:DB01111,keggCompound:C13553,keggDrug:D02049,ndc:0574-0858-01,pubChemCompound:216258,pubChemSubstance:46508586,pubChemSubstance:789446',''),('PA164749510','cryptenamine','','Unitensen','Drug/Small Molecule','TTD:DAP000479,drugBank:DB00785,pubChemSubstance:3728148',''),('PA164749511','becaplermin','PDGF B-chain,PDGF-2,Platelet-derived growth factor B chain precursor,Platelet-derived growth factor beta polypeptide,becaplermin,c-sis','Regranex','Drug/Small Molecule','TTD:DAP000028,dpd:2239405,drugBank:DB00102,genBank:K01401,uniProtKb:P01127,url:http://en.wikipedia.org/wiki/Becaplermin',''),('PA164749630','pegvisomant','GH,GH-N,Growth hormone,Growth hormone 1,Pituitary growth hormone,Somatotropin precursor','Somavert','Drug/Small Molecule','DailyMed:222a28ca-70c3-474c-850e-fae39eaaf40f,TTD:DAP000286,dpd:2272199,drugBank:DB00082,genBank:AF374232,ndc:0009-5176-01,uniProtKb:P58756',''),('PA164749631','decitabine','5-aza-2\'-deoxycytidine,Azadc,DAC,Dezocitidine,decitabine','Dacogen','Drug/Small Molecule','DailyMed:acaf6e50-7cd3-4431-98ef-d1c07e3ed8c2,TTD:DAP000641,chebi:50131,chemSpider:397844,drugBank:DB01262,keggDrug:D03665,ndc:62856-600-01,pubChemCompound:451668,pubChemSubstance:17397761,pubChemSubstance:46505657,url:http://en.wikipedia.org/wiki/Decitabine',''),('PA164749647','quinupristin','','','','',''),('PA164749648','fusidic acid','Diethanolamine fusidate,Fucidate,Fucidate Sodium,Fucidic acid,Fusidate,Fusidate Sodium','Fucidin,Fucidin Cream 2%,Fucidin acid,Fucidine,Fuc','','',''),('PA164749649','dicloxacillin','Diclossacillina [DCIT],Dicloxacilin,Dicloxacilina [INN-Spanish],Dicloxacillin Sodium,Dicloxacilline [INN-French],Dicloxacillinum [INN-Latin],Dicloxacy','Dycill,Dynapen,Maclicine,Pathocil','Drug/Small Molecule','DailyMed:65c3e99b-ec77-416c-ad70-596d6f0a9c31,TTD:DAP000435,chebi:4511,chemSpider:17358,drugBank:DB00485,keggCompound:C06950,keggDrug:D02348,ndc:0781-2248-01,pubChemCompound:18381,pubChemSubstance:46508182,pubChemSubstance:9165,url:http://en.wikipedia.org/wiki/Dicloxacillin',''),('PA164749650','pyridoxal phosphate','Codecarboxylase,PLP,Pyridoxal 5\'-phosphate,Pyridoxal 5-phosphate,Pyridoxal P,Pyridoxal-5P,Pyridoxal-P,Pyromijin,Vitamin B6','Biosechs,Hairoxal,Hiadelon,Himitan,Pidopidon,Vitaz','Drug/Small Molecule','chebi:18405,chemSpider:1022,drugBank:DB00114,keggCompound:C00018,keggDrug:D00006,pdb:PLP,pubChemCompound:1051,pubChemSubstance:3320,pubChemSubstance:46506428,url:http://en.wikipedia.org/wiki/Pyridoxal-phosphate',''),('PA164750167','pivmecillinam','Amdinocillin pivoxil,Pivmecilinamo [inn-spanish],Pivmecillinamum [inn-latin]','Coactabs,Selexid','Drug/Small Molecule','TTD:DAP001174,chebi:51210,dpd:657212,drugBank:DB01605,keggDrug:D02889,pubChemCompound:36272,pubChemSubstance:177795',''),('PA164750168','antihemophilic factor','AHF,Coagulation factor VIII precursor,Procoagulant component,antihemophilic factor','Advate,Alphanate,Bioclate,Helixate,Helixate FS,Hem','Drug/Small Molecule','DailyMed:6d2e4c97-0fb1-4ba4-9c58-3de071029e9b,dpd:2242491,drugBank:DB00025,genBank:M14113,ndc:0026-3782-20,uniProtKb:P00451,url:http://en.wikipedia.org/wiki/Antihemophilic_Factor',''),('PA164750430','l-isoleucine','(2S,3S)-2-Amino-3-methylpentanoic acid,(2S,3S)-a-Amino-b-methyl-n-valeric acid,(2S,3S)-a-Amino-b-methylvaleric acid,(S)-Isoleucine,(S,S)-Isoleucine,2-','','Drug/Small Molecule','HET:ILE,chebi:17191,chemSpider:6067,drugBank:DB00167,keggCompound:C00407,keggDrug:D00065,pdb:ILE,pubChemCompound:6306,pubChemSubstance:3697,pubChemSubstance:46506864',''),('PA164750491','phenindamine','Fenindamina [inn-spanish],Phenindaminum [inn-latin],Phenindiamine','Amilon (),Nolahist,Thephorin','Drug/Small Molecule','TTD:DAP001073,bindingDb:50089147,chemSpider:10817,drugBank:DB01619,keggCompound:C07790,pubChemCompound:11291,pubChemSubstance:46508187,pubChemSubstance:9992','CN1CCC2=C(C1)C(c3c2cccc3)c4ccccc4'),('PA164750492','almitrine','Almitrine bismesylate,Almitrine dimesylate,Almitrine mesylate','Doxil,Duxil,Vectarion','Drug/Small Molecule','TTD:DAP000468,chebi:53778,chemSpider:31235,drugBank:DB01430,keggDrug:D02822,pubChemCompound:33887,pubChemSubstance:16862494,pubChemSubstance:46505517,url:http://en.wikipedia.org/wiki/Almitrine',''),('PA164750505','roxithromycin','','ROX,Rulid,Rulide,Surlid','Drug/Small Molecule','HET:ROX,TTD:DAP000885,chebi:48844,drugBank:DB00778,keggCompound:C13173,keggDrug:D01710,pdb:ROX,pubChemCompound:444037,pubChemSubstance:585237,url:http://en.wikipedia.org/wiki/Roxithromycin',''),('PA164750512','methacycline','Metacycline,Methacyclin','Rondomycin','Drug/Small Molecule','TTD:DAP000883,bindingDb:50046500,drugBank:DB00931,keggCompound:C07654,keggDrug:D04972,pubChemCompound:5281054,pubChemSubstance:9856,url:http://en.wikipedia.org/wiki/Methacycline',''),('PA164750513','flurandrenolide','Floudroxycortide,Fludrossicortide [DCIT],Fludroxicortida [INN-Spanish],Fludroxicortidum,Fludroxycortide,Fludroxycortidum [INN-Latin],Fluorandrenolone,','Alondra-F,Cordran,Drenison,Drocort,Haelan,Haldrone','Drug/Small Molecule','TTD:DAP000418,chemSpider:14475,dpd:128724,drugBank:DB00846,keggDrug:D00328,ndc:55515-052-15,pubChemCompound:15209,pubChemSubstance:46505159,pubChemSubstance:7847394,url:http://en.wikipedia.org/wiki/Fludroxycortide',''),('PA164750514','tranexamic acid','Tranexamsaeure,Tranhexamic acid,Trans AMCHA,tranexmic acid,trans-4-aminomethylcyclohexane-1-carboxylic acid,trans-Amcha,trans-Tranexamic acid','Amcha,Amikapron,Amstat,Anvitoff,Carxamin,Cyclocapr','Drug/Small Molecule','DailyMed:6e89a7d9-4da4-42aa-b7f8-c602c24eefe5,HET:AMH,TTD:DAP000199,chebi:48669,dpd:2064413,drugBank:DB00302,keggDrug:D01136,ndc:0013-1114-10,pdb:AMH,pubChemCompound:5526,url:http://en.wikipedia.org/wiki/Tranexamic_acid','C1[C@@H](CC[C@H](C1)C(=O)O)CN'),('PA164750539','lutropin alfa','LH-B,LSH- beta,LSH-B,Luteinizing hormone beta subunit,Lutropin beta chain precursor','Luveris','Drug/Small Molecule','DailyMed:ae1977ed-32ea-4cbf-b51d-ce4a438215b8,TTD:DAP001103,dpd:2269066,drugBank:DB00044,genBank:X00264,ndc:44087-1375-1,uniProtKb:P01229,url:http://en.wikipedia.org/wiki/Lutropin_alfa',''),('PA164750540','mezlocillin','','Mezlin','Drug/Small Molecule','TTD:DAP001180,chebi:6919,chemSpider:570894,drugBank:DB00948,keggCompound:C07221,keggDrug:D05021,pubChemCompound:656511,pubChemSubstance:46506692,pubChemSubstance:9430,url:http://en.wikipedia.org/wiki/Mezlocillin',''),('PA164750541','alprenolol','Alfeprol [Russian],Alpheprol,Alprenololum [INN-Latin]','Apllobal,Aptine,Aptol Duriles,Gubernal,Regletin,Yo','Drug/Small Molecule','TTD:DAP000941,bindingDb:25764,chebi:51211,chemSpider:2035,drugBank:DB00866,iupharLigand:563,pubChemCompound:2119,pubChemSubstance:168916,pubChemSubstance:46506033','CC(C)NCC(COc1ccccc1CC=C)O'),('PA164750569','cefmenoxime','Cefmenoxima [INN-Spanish],Cefmenoxime hydrochloride,Cefmenoximum [INN-Latin]','Bestcall,Cefmax,Tacef','Drug/Small Molecule','TTD:DAP001178,chebi:55490,drugBank:DB00267,keggCompound:C13206,keggDrug:D01739,pubChemCompound:5361486,url:http://en.wikipedia.org/wiki/Cefmenoxime','Cn1c(nnn1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(=NOC)c4csc(n4)N)SC2)C(=O)O'),('PA164750570','amyl nitrite','3-Methylbutanol nitrite,3-Methylbutyl nitrite,Amilnitrit,Amilnitrite,Amyl nitrit,Amyl nitrite I,Amyl nitrosum,IPN,Isoamyl nitrite,Isopentyl nitrite,Ni','Aspiral,Vaporole','Drug/Small Molecule','chebi:55344,dpd:677930,drugBank:DB01612,keggCompound:C07457,keggDrug:D00517,pubChemCompound:8053,pubChemSubstance:7847583,url:http://en.wikipedia.org/wiki/Amyl_nitrite','CCCCCON=O'),('PA164750571','carphenazine','Carfenazine,Carphenazin','Procethazine,Proketazin,Proketazine','Drug/Small Molecule','TTD:DAP000846,chebi:51235,drugBank:DB01038,pubChemCompound:18104,pubChemSubstance:10516134',''),('PA164750572','bentiromide','BTPABA,Bentiromide [USAN:BAN:INN:JAN],Bentiromido [INN-Spanish],Bentiromidum [INN-Latin],PFD,PFT','Chymex','Drug/Small Molecule','chebi:31263,drugBank:DB00522,keggDrug:D01346,pubChemCompound:2329,pubChemSubstance:7848409,url:http://en.wikipedia.org/wiki/Bentiromide',''),('PA164750594','denileukin diftitox','DT,Diphtheria toxin precursor,NAD(+--diphthamide ADP- ribosyltransferase),denileukin diftitox','Ontak','Drug/Small Molecule','DailyMed:42dfffb1-d0f3-42d5-944c-64f092fc436e,TTD:DAP001098,drugBank:DB00004,genBank:V01536,ndc:62856-603-01,uniProtKb:P00587,url:http://en.wikipedia.org/wiki/Denileukin_diftitox',''),('PA164751373','testosterone propionate','','Agovirin,Testex','Drug/Small Molecule','bindingDb:50215709,chemSpider:5774,drugBank:DB01420,keggCompound:C08158,keggDrug:D00959,pubChemCompound:5995,pubChemSubstance:46508693,pubChemSubstance:7848022','CCC(=O)[O-].C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C'),('PA164751802','emedastine','Emedastina [INN-Spanish],Emedastine difumarate,Emedastinum [INN-Latin]','Emadine','Drug/Small Molecule','DailyMed:98a010d5-4905-4abf-a9d2-c85a07daa23b,TTD:DAP001067,bindingDb:50019624,chebi:4779,chemSpider:3106,dpd:2237355,drugBank:DB01084,keggCompound:C07785,ndc:0065-0325-05,pubChemCompound:3219,pubChemSubstance:46505109,pubChemSubstance:9987,url:http://en.wikipedia.org/wiki/Emedastine','CCOCCn1c2ccccc2nc1N3CCCN(CC3)C'),('PA164752234','nizatidine','','Acinon,Antizid,Axid,Axid Ar,Calmaxid,Cronizat,Dist','Drug/Small Molecule','DailyMed:db844934-9c1d-4576-a1b5-ef9b9c66a940,TTD:DAP000339,chemSpider:2298266,dpd:2246046,drugBank:DB00585,keggCompound:C07270,keggDrug:D00440,ndc:0378-5150-91,pubChemCompound:3033637,pubChemSubstance:191384,pubChemSubstance:46507554,url:http://en.wikipedia.org/wiki/Nizatidine',''),('PA164752250','bexarotene','bexarotene','Targret,Targretin,Targretin-gel,Targretyn,Targrexi','Drug/Small Molecule','DailyMed:63656f64-e240-4855-8df9-ca1655863735,TTD:DAP000276,chebi:50859,chemSpider:74139,drugBank:DB00307,ndc:64365-502-01,pubChemCompound:82146,pubChemSubstance:46509119,pubChemSubstance:659076,url:http://en.wikipedia.org/wiki/Bexarotene','Cc1cc2c(cc1C(=C)c3ccc(cc3)C(=O)O)C(CCC2(C)C)(C)C'),('PA164752251','rimexolone','','Vexol','Drug/Small Molecule','DailyMed:b1699f4e-40d5-49d0-ab80-1c8cc68e80a4,TTD:DAP000420,chemSpider:36120,dpd:2163691,drugBank:DB00896,keggDrug:D05729,ndc:0065-0627-07,pubChemCompound:39507,pubChemSubstance:180512,pubChemSubstance:46504820,url:http://en.wikipedia.org/wiki/Rimexolone',''),('PA164752252','oxyphenonium','DCF,Hydroxymethylgramicidin,Methocidin [Dcf:Inn],Methocidine [INN-French],Methocidinum [INN-Latin],Metocidina [INN-Spanish],Oxiphenonum,Oxyphenonium B','Antrenyl,Argicillin,Methacin,Methocidin','Drug/Small Molecule','TTD:DAP001124,chemSpider:5547,drugBank:DB00219,pubChemCompound:5749,pubChemSubstance:169280,pubChemSubstance:46508840','CC[N+](C)(CC)CCOC(=O)C(c1ccccc1)(C2CCCCC2)O'),('PA164752253','omalizumab','Ig gamma-1 chain C region','Xolair','Drug/Small Molecule','DailyMed:7f6a2191-adfb-48b9-9bfa-0d9920479f0d,TTD:DAP000387,dpd:2260565,drugBank:DB00043,genBank:J00228,ndc:50242-040-62,uniProtKb:P01857,url:http://en.wikipedia.org/wiki/Omalizumab',''),('PA164752287','n-acetyl-d-glucosamine','2-Acetamido-2-deoxy-D-glucose,GlcNAc,Glucosamine Complex,N-Acetylchitosamine,NAG','Aflexa,GS-500,Maxi GS,Natures Blend Glucosamine','Drug/Small Molecule','HET:NAG,TTD:DAP000872,bindingDb:50223349,chebi:17411,drugBank:DB00141,keggCompound:C00140,pdb:NAG,pubChemCompound:439174,pubChemSubstance:3440',''),('PA164752425','nelarabine','GW-506U78,Nelzarabine,nelarabine','Arranon,Atriance','Drug/Small Molecule','DailyMed:893c95d7-d9b6-4064-db97-91dd21ce7e40,TTD:DAP000985,chemSpider:2280207,drugBank:DB01280,keggDrug:D05134,ndc:0007-4401-06,pubChemCompound:3011155,pubChemSubstance:14922755,pubChemSubstance:46506325,url:http://en.wikipedia.org/wiki/Nelarabine',''),('PA164752426','trichlormethiazide','','Achletin,Anatran,Anistadin,Aponorin,Carvacron,Chlo','Drug/Small Molecule','TTD:DAP000035,bindingDb:26998,chemSpider:5359,drugBank:DB01021,keggCompound:C07767,keggDrug:D00658,pubChemCompound:5560,pubChemSubstance:46508880,pubChemSubstance:9969',''),('PA164752433','voglibose','voglibose','Basen,Glustat,Vocarb,Volix','Drug/Small Molecule','TTD:DAP001104,bindingDb:50263044,chemSpider:392046,drugBank:DB04878,keggDrug:D01665,pubChemCompound:444020,pubChemSubstance:10299466,pubChemSubstance:46504462,url:http://en.wikipedia.org/wiki/Voglibose',''),('PA164752437','clotiazepam','Clotiazepamum [inn-latin]','Clozan,Distensan,Rize,Rizen,Tienor,Trecalmo,Veratr','Drug/Small Molecule','TTD:DAP000932,chemSpider:2709,drugBank:DB01559,pubChemCompound:2811,pubChemSubstance:10472457,pubChemSubstance:46508776,url:http://en.wikipedia.org/wiki/Clotiazepam','CCc1cc2c(s1)N(C(=O)CN=C2c3ccccc3Cl)C'),('PA164752438','tolnaftate','','2-Naphthyl N-methyl-N-(3-tolyl)thionocarbamate,Aft','','',''),('PA164752439','ergoloid mesylate','','Alkergot,Circanol,Co-Dergocrine Mesylate,Deapril-S','Drug/Small Molecule','TTD:DAP000901,chebi:34706,dpd:176176,drugBank:DB01049,keggCompound:C14055,keggDrug:D02268,ndc:0078-0101-05,pubChemCompound:592735,pubChemSubstance:10422210,url:http://en.wikipedia.org/wiki/Ergoloid',''),('PA164752443','rifaximin','Rifamixin,Rifamycin L 105,Rifamycin L 105SV,Rifaxidin,Rifaximin [USAN:INN],Rifaximina [Spanish],Rifaximine [French],Rifaximinum [Latin],rifaximin','Fatroximin,Normix,Rifacol,Ritacol,Xifaxan','Drug/Small Molecule','DailyMed:c5e8e2fd-7087-4b78-9181-cc259c0be2f1,TTD:DAP001006,chemSpider:4940837,drugBank:DB01220,keggDrug:D02554,ndc:65649-301-03,pubChemCompound:6436173,pubChemSubstance:214371,pubChemSubstance:46508705,url:http://en.wikipedia.org/wiki/Rifaximin',''),('PA164752444','dextrothyroxine','d-thyroxine','Choloxin,Dynothel,Eulipos,Lisolipin','Drug/Small Molecule','chebi:30659,dpd:2170299,drugBank:DB00509,pubChemCompound:853,pubChemSubstance:93081,url:http://en.wikipedia.org/wiki/Dextrothyroxine',''),('PA164752445','mimosine','L-Mimosine,Leucaenine,Leucaenol,Leucenine,Leucenol,Mimosin','','Drug/Small Molecule','TTD:DNC000947,chemSpider:389405,drugBank:DB01055,pubChemCompound:440473,pubChemSubstance:46505895,pubChemSubstance:7336,url:http://en.wikipedia.org/wiki/Mimosine','c1cn(cc(c1=O)O)CC(C(=O)O)N'),('PA164752557','hydroflumethiazide','Dihydroflumethazide,Hidroflumetiazid,Hydroflumethazide,Hydroflumethizide,Trifluoromethylhydrazide,Trifluoromethylhydrothiazide','Diuredemina,Diurometon,Enjit,Flutizide,Glomerulin,','Drug/Small Molecule','TTD:DAP000747,bindingDb:25897,chemSpider:3521,drugBank:DB00774,keggCompound:C07763,keggDrug:D00654,pubChemCompound:3647,pubChemSubstance:46505220,pubChemSubstance:9965','c1c(c(cc2c1NCNS2(=O)=O)S(=O)(=O)N)C(F)(F)F'),('PA164752558','melatonin','mel,mlt,n-acetyl-5-methoxytryptamine,pineal hormone','Circadin,MT6,Mela-T,Melatol,Melatonex,Melatonin,Me','Drug/Small Molecule','HET:ML1,TTD:DAP000429,bindingDb:9019,chebi:16796,chemSpider:872,dpd:793167,drugBank:DB01065,iupharLigand:1357,iupharLigand:224,keggCompound:C01598,pdb:ML1,pubChemCompound:896,pubChemSubstance:149246,pubChemSubstance:46509101,url:http://en.wikipedia.org/wiki/Melatonin',''),('PA164752658','porfimer','DHE,DHP ether,Dihematoporphyrin ether,Porfimer sodium','Photofrin','Drug/Small Molecule','DailyMed:f5fdda24-da7d-4e61-936e-9d1a55056b82,chebi:60652,dpd:2019876,drugBank:DB00707,ndc:58914-155-75,pubChemCompound:57166,pubChemSubstance:194300,url:http://en.wikipedia.org/wiki/Porfimer',''),('PA164752812','milnacipran','(-)-milnacipran,F 2207,Midalcipran,Milnacipranum [latin],milnacipran','Ixel,Toledomin','Drug/Small Molecule','DailyMed:16a4a314-f97e-4e91-95e9-576a3773d284,TTD:DAP001155,bindingDb:50239538,chemSpider:59245,drugBank:DB04896,ndc:0456-1512-60,pubChemCompound:65833,pubChemSubstance:15122095,pubChemSubstance:46506141,url:http://en.wikipedia.org/wiki/Milnacipran',''),('PA164752819','dihydroergotoxine','','','Drug/Small Molecule','TTD:DAP000852,chemSpider:4925595,drugBank:DB01287,pubChemCompound:6420006,pubChemSubstance:10321698,pubChemSubstance:46505136',''),('PA164752820','practolol','Tocris-0831','','Drug/Small Molecule','TTD:DAP000940,chebi:258351,drugBank:DB01297,iupharLigand:555,keggCompound:C11696,keggDrug:D05587,pubChemCompound:443371,pubChemSubstance:10299290,url:http://en.wikipedia.org/wiki/Practolol','CC(C)NCC(COc1ccc(cc1)NC(=O)C)O'),('PA164752827','serum albumin iodonated','Serum albumin precursor','Megatope','Drug/Small Molecule','drugBank:DB00064,genBank:M12523,uniProtKb:P02768',''),('PA164754741','levobupivacaine','levobupivacaine hydrochloride','Chirocaine','Drug/Small Molecule','TTD:DAP001233,chebi:6149,chemSpider:83289,drugBank:DB01002,iupharLigand:2397,keggCompound:C07887,pubChemCompound:92253,pubChemSubstance:10089,pubChemSubstance:46505295,url:http://en.wikipedia.org/wiki/Levobupivacaine',''),('PA164754742','oxiconazole','Oxiconazol [INN-Spanish],Oxiconazole Nitrate,Oxiconazolum [INN-Latin]','Oxistat','Drug/Small Molecule','DailyMed:lb28113c1-3d01-4084-a69e-df8f481488d6,TTD:DAP001204,chemSpider:4514745,dpd:2230452,drugBank:DB00239,keggCompound:C08075,keggDrug:D00885,ndc:0173-0423-00,pubChemCompound:5361463,pubChemSubstance:46504752,pubChemSubstance:668922,url:http://en.wikipedia.org/wiki/Oxiconazole','c1cc(c(cc1Cl)Cl)CON=C(Cn2ccnc2)c3ccc(cc3Cl)Cl'),('PA164754743','ethoxzolamide','6-ethoxy-1,3-benzothiazole-2-sulfonamide,Ethoxazolamide,Ethoxyzolamide,Etoxzolamide','Cardrase,Diuretic C,Ethamide,Glaucotensil,Redupres','Drug/Small Molecule','HET:EZL,TTD:DAP000598,bindingDb:10882,chebi:101096,chemSpider:3179,drugBank:DB00311,keggDrug:D02441,pdb:EZL,pubChemCompound:3295,pubChemSubstance:46509023,pubChemSubstance:7849499,url:http://en.wikipedia.org/wiki/Ethoxzolamide','CCOc1ccc2c(c1)sc(n2)S(=O)(=O)N'),('PA164754753','alglucosidase alfa','','Myozyme','Drug/Small Molecule','DailyMed:f19adae6-9125-4765-8aec-302c9efe9b31,TTD:DAP001289,dpd:2284863,drugBank:DB01272,keggDrug:D03207,ndc:58468-0150-1,url:http://en.wikipedia.org/wiki/Alglucosidase_alfa',''),('PA164754754','cevimeline','Cevimeline hydrochloride,Cevimeline hydrochloride hemihydrate,Cevimeline hydrochloride hydrate','Evoxac,Saligren','Drug/Small Molecule','DailyMed:0679dd4c-fece-4c6d-b273-2c62237e8973,TTD:DAP000075,chebi:3568,drugBank:DB00185,keggDrug:D00661,ndc:63395-201-13,pubChemCompound:83898,pubChemSubstance:660798,url:http://en.wikipedia.org/wiki/Cevimeline',''),('PA164754755','bepridil','Bepadin','Vascor','Drug/Small Molecule','HET:BEP,TTD:DAP000525,chebi:3061,chemSpider:2261,drugBank:DB01244,iupharLigand:2337,keggCompound:C06847,pdb:BEP,pubChemCompound:2351,pubChemSubstance:186733,pubChemSubstance:46506353,url:http://en.wikipedia.org/wiki/Bepridil','CC(C)COCC(CN(Cc1ccccc1)c2ccccc2)N3CCCC3'),('PA164754789','conjugated estrogens','Estrogens,Estrone Estrone Hydrogen Sulfate,Estrone Hydrogen Sulfate,Estrone Sodium Sulfate,Estrone Sulfate,Estrone Sulfate Sodium,Estrone Sulphate,Est','Conestoral,Evex,Hyhorin,Morestin,Par Estro,Premari','','',''),('PA164754805','nafarelin','Nafarelin acetate','Synarel','Drug/Small Molecule','DailyMed:d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6,TTD:DAP001051,chemSpider:10605761,dpd:2188783,drugBank:DB00666,keggCompound:C07613,ndc:0025-0166-08,pubChemCompound:16129618,pubChemCompound:25077649,pubChemSubstance:46506496,pubChemSubstance:9815,url:http://en.wikipedia.org/wiki/Nafarelin',''),('PA164754806','loracarbef','Loracarbefum [INN-Latin]','Lorabid,Loribid','Drug/Small Molecule','TTD:DAP000434,chebi:47544,drugBank:DB00447,keggCompound:C08109,keggDrug:D00916,ndc:61570-170-01,pubChemCompound:3956,pubChemSubstance:191326,url:http://en.wikipedia.org/wiki/Loracarbef',''),('PA164754807','amdinocillin','Amdinocillin mecillinam,mecillinam,penicillin hx','Coactin','Drug/Small Molecule','TTD:DAP001176,chebi:51208,drugBank:DB01163,keggDrug:D02888,pubChemCompound:36273,pubChemSubstance:10823391',''),('PA164754808','sulfacytine','1-ethyl N4-sulfanilylcytosin,1-ethyl-N-sulfanilylcytosine,N-sulfanilyl-l-ethylcytosine,Sulfacitina [inn-spanish],Sulfacitinum [inn-latin]','Renoquid','Drug/Small Molecule','TTD:DAP001201,chemSpider:5131,drugBank:DB01298,pubChemCompound:5322,pubChemSubstance:10349273,pubChemSubstance:46505483',''),('PA164754809','aprobarbital','','','Drug/Small Molecule','TTD:DAP001034,chebi:2791,chemSpider:29066,drugBank:DB01352,keggCompound:C07826,keggDrug:D00698,pubChemCompound:31332,pubChemCompound:6464,pubChemSubstance:10028,pubChemSubstance:46504558,url:http://en.wikipedia.org/wiki/Aprobarbital','CC(C)C1(C(=O)NC(=O)NC1=O)CC=C'),('PA164754810','benzylpenicilloyl polylysine','','Pre-pen','Drug/Small Molecule','TTD:DAP001314,chebi:59297,drugBank:DB00895,pubChemCompound:119212,pubChemSubstance:695873',''),('PA164754814','pregabalin','pregabalin','Lyrica','Drug/Small Molecule','DailyMed:60185c88-ecfd-46f9-adb9-b97c6b00a553,TTD:DAP001264,bindingDb:50164279,chemSpider:4589156,dpd:2268418,drugBank:DB00230,keggDrug:D02716,ndc:0071-1012-68,pubChemCompound:5486971,pubChemSubstance:46504934,pubChemSubstance:702621,url:http://en.wikipedia.org/wiki/Pregabalin','CC(C)C[C@@H](CC(=O)O)CN'),('PA164754818','betamethasone','','Alphatrex,Bebate,Becort,Bedifos,Beta-Methasone,Bet','','',''),('PA164754825','botulinum toxin type a','BTX-A,BoNT/A,Bontoxilysin A,Botulinum neurotoxin type A precursor,botulinum toxin type A','BOTOX,BOTOX Cosmetic,Botox,Dysport','Drug/Small Molecule','DailyMed:195ebbc0-eaac-4015-97fd-3653b815a758,TTD:DAP001298,dpd:2243721,drugBank:DB00083,genBank:X52066,keggCompound:C07946,keggDrug:D00783,ndc:99207-500-30,pubChemSubstance:7847848,uniProtKb:P10845,url:http://en.wikipedia.org/wiki/Botox',''),('PA164754850','azelaic acid','Anchoic acid,Azalaic Acid,Azelainic acid,Heptanedicarboxylic acid,Lepargylic acid,Nonanedioic acid,n-Nonanedioic acid','Azelex,Emerox 1110,Emerox 1144,Emery\'s L-110,Finac','Drug/Small Molecule','DailyMed:63773349-0295-4d56-a72e-0d7cade88ddb,HET:AZ1,TTD:DAP000889,chebi:48131,chemSpider:2179,drugBank:DB00548,keggCompound:C08261,keggDrug:D03034,ndc:10922-825-02,pdb:AZ1,pubChemCompound:2266,pubChemSubstance:10460,pubChemSubstance:46506284','C(CCCC(=O)O)CCCC(=O)O'),('PA164754863','clofarabine','clofarabine','Clolar,Evoltra','Drug/Small Molecule','DailyMed:c35903cd-e9eb-4841-93d1-fc14249d1e9f,HET:CFB,TTD:DAP000849,chebi:681569,chemSpider:106472,drugBank:DB00631,ndc:58468-0100-1,pdb:CFB,pubChemCompound:119182,pubChemSubstance:46504968,pubChemSubstance:695844,url:http://en.wikipedia.org/wiki/Clofarabine',''),('PA164754864','alvimopan','ADL 8-2698,alvimopan','Entereg','Drug/Small Molecule','DailyMed:826f647e-1c29-4f27-2db7-89d4d0f5f105,TTD:DAP001140,chemSpider:4589864,drugBank:DB06274,ndc:11227-010-30,pubChemCompound:5488548,pubChemSubstance:99443242,url:http://en.wikipedia.org/wiki/Alvimopan',''),('PA164754874','nitazoxanide','2-(Acetolyloxy)-N-(5-nitro-2-thiazolyl)benzamide,2-Acetyloxy-N-[(5-nitro-2-thiazolyl)]benzamide,NTZ,Nitazoxanid,Nitazoxanida [INN-Spanish],Nitazoxanid','Alinia,Fental,Phavic-1','Drug/Small Molecule','DailyMed:56b1575a-dff4-4c5a-a159-2f858e7a0cb8,TTD:DAP001293,bindingDb:50182652,chemSpider:38037,drugBank:DB00507,keggDrug:D02486,ndc:67546-111-12,pubChemCompound:41684,pubChemSubstance:182380,pubChemSubstance:46507813,url:http://en.wikipedia.org/wiki/Nitazoxanide','CC(=O)Oc1ccccc1C(=O)Nc2ncc(s2)N(=O)=O'),('PA164754875','thioproperazine','Thioperazine,Thioproperazin,Thioproperazinum [inn-latin],Thiproperazine,Tioproferazina [inn-spanish]','Cephalmin,Majeptyl,Mazeptil,Mazeptyl,Megeptil,Sulf','Drug/Small Molecule','chebi:59120,chemSpider:9058,dpd:1927639,drugBank:DB01622,keggDrug:D08585,pubChemCompound:9429,pubChemSubstance:10353484,pubChemSubstance:46507111','CN1CCN(CC1)CCCN2c3ccccc3Sc4c2cc(cc4)S(=O)(=O)N(C)C'),('PA164754876','cefepime','Cefepima [spanish],Cefepimum [latin]','Axepim,Cepimax,Cepimex,Maxcef,Maxipime','Drug/Small Molecule','DailyMed:be5f8ca6-7232-423a-a2d5-cccb7abe7921,TTD:DAP000455,chebi:478164,chemSpider:4586395,dpd:2163632,drugBank:DB01413,keggCompound:C08111,keggDrug:D02376,ndc:0338-1301-41,pubChemCompound:5479537,pubChemSubstance:46507919,pubChemSubstance:7849435,url:http://en.wikipedia.org/wiki/Cefepime','C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(=NOC)c4csc(n4)N)SC2)C(=O)[O-]'),('PA164754877','nitrofurazone','NF,NFZ,Nitrofurazan','Actin-N,Aldomycin,Alfucin,Amifur,Babrocid,Becafura','Drug/Small Molecule','HET:NFZ,chemSpider:4566720,dpd:575011,drugBank:DB00336,keggCompound:C08042,keggDrug:D00862,pdb:NFZ,pubChemCompound:5447130,pubChemSubstance:46506509,pubChemSubstance:7847927,url:http://en.wikipedia.org/wiki/Nitrofurazone','c1cc(oc1C=NNC(=O)N)N(=O)=O'),('PA164754878','ardeparin','','Normiflo','Drug/Small Molecule','TTD:DAP000428,chebi:28304,chemSpider:751,drugBank:DB00407,keggCompound:C00374,pubChemCompound:772,pubChemSubstance:46505194,url:http://en.wikipedia.org/wiki/Ardeparin','CC(=O)NC1C(O)OC(COS(O)(=O)=O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(O)(=O)=O)C(O)=O)C(OS(O)(=O)=O)C3NS(O)(=O)=O)C(O)C2OS(O)(=O)=O)C(O)=O)C1O'),('PA164754879','chloroxine','CHQ,Chloroxyquinoline,Chlorquinol,Dichlorohydroxyquinoline,Dichloroquinolinol,Dichloroxin,Dikhloroskin','Capitrol,Chlofucid,Clofuzid,Endiaron,Quesyl,Quinol','Drug/Small Molecule','DailyMed:aae9e7f2-c7b8-5431-8265-7af04c18fc20,chemSpider:2621,drugBank:DB01243,ndc:0072-6850-04,pubChemCompound:2722,pubChemSubstance:156401,pubChemSubstance:46508620','c1cc2c(cc(c(c2nc1)O)Cl)Cl'),('PA164754880','anisotropine methylbromide','','Anisotropine methobromide,Endovalpin,Lytispasm,Met','Drug/Small Molecule','TTD:DAP000837,chebi:2739,drugBank:DB00517,keggCompound:C06830,keggDrug:D00232,pubChemCompound:6647,pubChemSubstance:9048',''),('PA164754881','indecainide','9-(3-(Isopropylamino)propyl))fluorene-9-carboxamide,9-(3-(Isopropylamino)propyl)-9-fluorenylcarboxamid,Indecainida [Spanish],Indecainidum [Latin],Rica','Decabid','Drug/Small Molecule','TTD:DAP000503,chemSpider:47194,drugBank:DB00192,pubChemCompound:52195,pubChemSubstance:46506714,pubChemSubstance:667965','CC(C)NCCCC1(c2ccccc2-c3c1cccc3)C(=O)N'),('PA164754882','glycopyrrolate','Glycopyrronium bromide,glycopyrrolate','Asecryl,Gastrodyn,Nodapton,Robanul,Robinal,Robinul','Drug/Small Molecule','DailyMed:9690ebaf-be1b-4968-a578-28bd5372f022,TTD:DAP001116,chemSpider:3374,dpd:2039508,drugBank:DB00986,keggDrug:D00540,ndc:0143-1250-01,pubChemCompound:3494,pubChemSubstance:46509133,pubChemSubstance:794728,url:http://en.wikipedia.org/wiki/Glycopyrrolate',''),('PA164754883','carboprost tromethamine','','Carboprost,Hemabate,Tham','Drug/Small Molecule','DailyMed:3d282998-ff0c-480a-bd80-155606ef0a65,TTD:DAP001215,chebi:3404,dpd:2230417,drugBank:DB00429,keggDrug:D00682,ndc:0009-0856-05,pubChemCompound:5284525',''),('PA164754884','immune globulin','Ig alpha-2 chain C region,immune globulin,immunoglobulin g','Civacir,Flebogamma,Gamunex','Drug/Small Molecule','DailyMed:810c8752-a7cb-0bce-777d-8539429773c2,dpd:2230920,drugBank:DB00028,genBank:J00221,ndc:67467-843-01,uniProtKb:P01877',''),('PA164754891','frovatriptan','Frovatriptan succinate,frovatriptan','Frova,Frovelan,Miguard','Drug/Small Molecule','DailyMed:c0703630-9ce8-4259-841e-71fd2019fa66,TTD:DAP000063,bindingDb:50073689,chemSpider:70378,drugBank:DB00998,ndc:63481-025-09,pubChemCompound:77992,pubChemSubstance:46506288,pubChemSubstance:655050,url:http://en.wikipedia.org/wiki/Frovatriptan',''),('PA164754910','thyroglobulin','','','Drug/Small Molecule','drugBank:DB01584,url:http://en.wikipedia.org/wiki/Thyroglobulin',''),('PA164754911','candicidin','','Candicidin A,Candicidin D,FR-008-III,Vanobid','Drug/Small Molecule','TTD:DAP001325,chemSpider:10128184,drugBank:DB01152,keggCompound:C06690,pubChemCompound:11953885,pubChemCompound:441142,pubChemSubstance:46504812,pubChemSubstance:8915',''),('PA164754912','fluocinolone acetonide','Fluocinolonacetonidum,Fluocinolone acetonide [DCIT],Fluocinoloni acetonidum [INN-Latin],flucinolone','Coriphate,Derma-smoothe/fs,Dermalar,FS Shampoo,Flu','','',''),('PA164754913','netilmicin','1-N-Ethylsisomicin,netilmycin','Netromycin','Drug/Small Molecule','TTD:DAP000404,chebi:7528,dpd:503371,drugBank:DB00955,keggCompound:C07657,pubChemCompound:441306,pubChemSubstance:9859,url:http://en.wikipedia.org/wiki/Netilmicin',''),('PA164754914','lindane','gamma-benzene hexachloride,gamma-bhc,gamma-hch,gamma-hexachlorocyclohexane,gamma-hexachlorzyklohexan,gamma-lindane,lindan','Aalindan,Aficide,Agrocide,Agrocide III,Agrocide WP','','',''),('PA164754915','abarelix','abarelix','Plenaxis','Drug/Small Molecule','TTD:DAP000094,bindingDb:50102442,drugBank:DB00106,iupharLigand:1188,keggDrug:D02738,pubChemCompound:16131215,pubChemSubstance:12015126,url:http://en.wikipedia.org/wiki/Abarelix','C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=C(C=CC=C6)C=C5)NC(=O)C'),('PA164754919','streptokinase','Streptokinase C precursor','Streptase','Drug/Small Molecule','TTD:DAP001198,dpd:2018993,drugBank:DB00086,genBank:K02986,uniProtKb:P00779,url:http://en.wikipedia.org/wiki/Streptokinase',''),('PA164754992','rocuronium','','Esmeron,Rocuronium bromide,Zemuron','Drug/Small Molecule','DailyMed:cb28d869-6510-4402-9462-f6bb25fa0fa8,TTD:DAP000349,chebi:8884,chemSpider:390053,dpd:2108208,drugBank:DB00728,keggDrug:D00765,ndc:0781-3220-75,pubChemCompound:441290,pubChemSubstance:46506855,pubChemSubstance:7980535,url:http://en.wikipedia.org/wiki/Rocuronium',''),('PA164754993','nitroxoline','5-NOK,5-Nitroks,5-Nitrox,5-Nitroxine,Nitroxolina [inn-spanish],Nitroxolinum [inn-latin]','Galinok,Isinok,Nicene forte,Noxibiol,Noxin','Drug/Small Molecule','chemSpider:18756,drugBank:DB01422,pubChemCompound:19910,pubChemSubstance:162775,pubChemSubstance:46505497,url:http://en.wikipedia.org/wiki/Nitroxoline','c1cc2c(ccc(c2nc1)O)N(=O)=O'),('PA164754994','s-adenosylmethionine','Acylcarnitine,AdoMet,S-Adenosyl-L-methionine,SAM,SAM-e,same','SAMe Rx-Mood,Sam-Sulfate','Drug/Small Molecule','HET:SAM,chebi:15414,chemSpider:31983,drugBank:DB00118,keggCompound:C00019,pdb:SAM,pubChemCompound:34756,pubChemSubstance:3321,pubChemSubstance:46505280,url:http://en.wikipedia.org/wiki/S-Adenosylmethionine',''),('PA164755085','nadh','Coenzyme I, reduced,Cozymase I, reduced,DPN,DPN+,DPNH,Diphosphopyridine nucleotide,NAD+,NAD-reduced,NADH+H+,NADH2,Nicotinamide adenine dinucleotide,Ni','Nadide','Drug/Small Molecule','HET:NAI,TTD:DAP001291,chebi:16908,chemSpider:388299,drugBank:DB00157,keggCompound:C00004,pdb:NAI,pubChemCompound:439153,pubChemSubstance:3306,pubChemSubstance:46504879,url:http://en.wikipedia.org/wiki/Nicotinamide_adenine_dinucleotide',''),('PA164760843','deferasirox','Deferasiroxum [inn-latin],ICL 670,deferasirox','Exjade','Drug/Small Molecule','DailyMed:3495a70c-870c-4968-940e-8baea152cf85,chemSpider:4591431,dpd:1926756,drugBank:DB01609,keggDrug:D03669,ndc:0078-0468-15,pubChemCompound:5493381,pubChemSubstance:46506791,pubChemSubstance:5493381,url:http://en.wikipedia.org/wiki/Deferasirox',''),('PA164760844','secretin','Secremax, SecreFlo,secretin','SecreFlo,Secremax, SecreFlo','Drug/Small Molecule','TTD:DAP001296,dpd:874000,drugBank:DB00021,url:http://en.wikipedia.org/wiki/Secretin',''),('PA164760854','bromodiphenhydramine','Ambodryl Hydrochloride,Amodryl,Bromanautine,Bromazin,Bromazine,Bromazine hydrochloride,Bromdiphenhydramine,Bromdiphenhydramine hydrochloride,Bromdiphe','Bromo-Benadryl,Bromo-Benzdryl,Deserol,Histabromami','','',''),('PA164760855','dromostanolone','2M-DHTP,2MDTP,Blackburn Compound,Dromostanolone propionate,Dromostanolone proprionate,Drostanolone,Drostanolone propionate,MDHT,Medrotestron propionat','Drolban,Emdisterone,Masterid,Masteril,Masteron,Mas','Drug/Small Molecule','TTD:DAP000840,chebi:34838,drugBank:DB00858,keggCompound:C14605,pubChemCompound:224004,pubChemSubstance:7848597',''),('PA164760859','insulin-glulisine','','Apidra','Drug/Small Molecule','DailyMed:e7af6a7a-8046-4fb4-9979-4ec4230b23aa,TTD:DAP001093,drugBank:DB01309,keggDrug:D04540,ndc:0088-2500-33,url:http://en.wikipedia.org/wiki/Insulin_glulisine',''),('PA164760860','pegaspargase','L-asparagine amidohydrolase,Putative L-asparaginase precursor','Oncaspar','Drug/Small Molecule','DailyMed:d046ec54-9ac8-4c9f-87a7-69e9900d8016,dpd:2236849,drugBank:DB00059,genBank:U00096,ndc:57665-002-02,uniProtKb:P37595,url:http://en.wikipedia.org/wiki/Pegaspargase',''),('PA164760861','telbivudine','2\'-Deoxy-L-thymidine,Beta-l-thymidine,Epavudine,L-DT,L-deoxythymidine,L-thymidine,LDT,Telbivudin,telbivudine','Sebivo,Tyzeka','Drug/Small Molecule','DailyMed:0664309d-1342-4a63-ba5f-4b899cdf3bec,TTD:DAP000698,bindingDb:50156567,chemSpider:140081,dpd:2288389,drugBank:DB01265,ndc:0078-0539-85,pubChemCompound:159269,pubChemSubstance:15220961,pubChemSubstance:46508706',''),('PA164760862','colistin','','Colistin sulfate,Colistin sulfate, nonsterile,Coli','Drug/Small Molecule','TTD:DAP001324,chemSpider:4470591,drugBank:DB00803,keggCompound:C13768,keggDrug:D02138,pubChemCompound:5311054,pubChemSubstance:46505467,pubChemSubstance:7978985,url:http://en.wikipedia.org/wiki/Colistin',''),('PA164760863','quinethazone','Chinetazone [dcit],Chinethazonum,Quinetazona [inn-spanish],Quinethazon,Quinethazonum [inn-latin]','Aquamox,Hydromox,Idrokin','','',''),('PA164760864','aluminium','','','Drug/Small Molecule','TTD:DAP000467,chebi:28984,chemSpider:4514248,dpd:13838,drugBank:DB01370,keggCompound:C06264,pubChemCompound:5359268,pubChemSubstance:10534431,pubChemSubstance:46504765,url:http://en.wikipedia.org/wiki/Aluminium','[Al]'),('PA164764429','tripelennamine','','Benzoxale,Cizaron,Dehistin,PBZ,Pbz-Sr,Piribenzil,P','Drug/Small Molecule','TTD:DAP000328,chemSpider:5385,dpd:2239338,drugBank:DB00792,keggCompound:C07180,pubChemCompound:5587,pubChemSubstance:46506125,pubChemSubstance:9389,url:http://en.wikipedia.org/wiki/Tripelennamine','CN(C)CCN(Cc1ccccc1)c2ccccn2'),('PA164764445','meropenem','Antibiotic SM 7338,Meropenem anhydrous,Meropenemum [INN-Latin],meropenem','Meronem,Merrem,Merrem I.V.','Drug/Small Molecule','DailyMed:c15e88d3-d903-4e7a-f683-e29f51afa848,HET:MER,TTD:DAP000441,chebi:43968,dpd:2218496,drugBank:DB00760,keggDrug:D02222,ndc:0310-0325-20,pdb:MER,pubChemCompound:64778,pubChemSubstance:206724,url:http://en.wikipedia.org/wiki/Meropenem',''),('PA164764446','daclizumab','Anti-IL-2,Humanized antiCD25,Ig gamma-1 chain C region','Zenapax','Drug/Small Molecule','TTD:DAP000389,dpd:2241473,drugBank:DB00111,genBank:J00228,uniProtKb:P01857,url:http://en.wikipedia.org/wiki/Daclizumab',''),('PA164764489','epinastine','Epinastina [Spanish],Epinastinum [Latin],epinastine','Elestat','Drug/Small Molecule','DailyMed:a9628ec7-bbeb-4cfa-932f-645a8aca8987,TTD:DAP001074,chebi:51032,chemSpider:3128,drugBank:DB00751,keggDrug:D01713,ndc:0023-9201-05,pubChemCompound:3241,pubChemSubstance:213455,pubChemSubstance:46509056,url:http://en.wikipedia.org/wiki/Epinastine','c1ccc2c(c1)Cc3ccccc3N4C2CN=C4N'),('PA164764496','aprindine','Aprindin,Aprindina [inn-spanish],Aprindinum [inn-latin],Aprinidine','Aspenon,Fibocil','Drug/Small Molecule','TTD:DAP000954,chemSpider:2132,drugBank:DB01429,keggDrug:D01326,pubChemCompound:2218,pubChemSubstance:46505478,url:http://en.wikipedia.org/wiki/Aprindine',''),('PA164764503','tiaprofenic acid','2-(5-Benzyl-2-thienyl)propionsaeure,5-Benzoyl-alpha-methyl-2-thiopheneacetic acid,Acide tiaprofenique [inn-french],Acido tiaprofenico [inn-spanish],Ac','Apo-Tiaprofenic Tablets,Dom-tiaprofenic,Novo-Tiapr','Drug/Small Molecule','TTD:DAP000973,chebi:32221,chemSpider:5269,dpd:2136112,drugBank:DB01600,pubChemCompound:5468,pubChemSubstance:10321760,pubChemSubstance:46504590,url:http://en.wikipedia.org/wiki/Tiaprofenic_acid',''),('PA164764504','tazobactam','','','','',''),('PA164764505','alverine','Alverina [inn-spanish],Alverine citrate,Alverinum [inn-latin],Bis(gamma-phenylpropyl)ethylamine,Di(phenylpropyl)ethylamine,N,N-Bis(3-phenylpropyl)ethy','Antispasmin,Dipropylin,Dipropyline,Gamatran citrat','Drug/Small Molecule','chebi:518413,chemSpider:3550,drugBank:DB01616,pubChemCompound:3678,pubChemSubstance:10355027,pubChemSubstance:46506981',''),('PA164764506','cetrorelix','Cetrorelix Acetate,Cetrorelixum [INN-Latin],PT-141,SB 75,SB-75,bremelanotide','Cetrotide','Drug/Small Molecule','DailyMed:aca7768e-28a7-4027-b1d8-e66247665f79,TTD:DAP000096,dpd:2247767,drugBank:DB00050,keggDrug:D01685,ndc:44087-1225-1,pubChemCompound:16129715,pubChemSubstance:7848748,url:http://en.wikipedia.org/wiki/Cetrorelix','C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CC=CN=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C.CC(=O)O'),('PA164764516','trimethobenzamide','Trimethobenzamide HCL,Trimethobenzamide hydrochloride,Trimethobenzamidum [INN-Latin],Trimetobenzamida [INN-Spanish]','Ametik hydrochloride,Benzacot,Nauseton,Stemetic,Te','Drug/Small Molecule','DailyMed:43a47783-c605-49eb-a4fa-8524e75e69de,chemSpider:5375,drugBank:DB00662,keggCompound:C07178,ndc:21695-448-10,pubChemCompound:5577,pubChemSubstance:46507787,pubChemSubstance:9387,url:http://en.wikipedia.org/wiki/Trimethobenzamide',''),('PA164764517','candoxatril','','Candoxatrilat','Drug/Small Molecule','TTD:DAP001145,bindingDb:50084625,chebi:3353,drugBank:DB00616,keggDrug:D01070,pubChemCompound:5362417',''),('PA164764551','cerulenin','','Helicocerin','Drug/Small Molecule','HET:CER,TTD:DAP000659,chebi:171741,chemSpider:26530,drugBank:DB01034,keggCompound:C12058,pdb:CER,pubChemCompound:28517,pubChemCompound:5282054,pubChemSubstance:14213,pubChemSubstance:46508217,url:http://en.wikipedia.org/wiki/Cerulenin',''),('PA164764567','pipecuronium','Pipecurium,Pipecuronium bromide','Arduan,Raplon','Drug/Small Molecule','TTD:DAP000353,chemSpider:45517,drugBank:DB01338,keggCompound:C07554,pubChemCompound:50192,pubChemSubstance:14764962,pubChemSubstance:46508493,url:http://en.wikipedia.org/wiki/Pipecuronium',''),('PA164764568','mupirocin','MRC,Mupirocine,Pseudomonic acid,mupirocin','Bactoderm,Bactroban,Bactroban Nasal,Centany,Turixi','Drug/Small Molecule','DailyMed:ae3defca-06d5-49ac-8a27-be5c4e9304d1,HET:MRC,TTD:DAP000711,chemSpider:393914,dpd:2239757,drugBank:DB00410,keggCompound:C11758,keggDrug:D01076,ndc:0062-1610-01,pdb:MRC,pubChemCompound:446596,pubChemSubstance:46505594,pubChemSubstance:7848139,url:http://en.wikipedia.org/wiki/Mupirocin',''),('PA164764569','loteprednol etabonate','Loteprednol etabonate','Alrex,Loteflam,Lotemax,Zylet','','',''),('PA164764582','monobenzone','Benzoquin,Benzyl hydroquinone,Benzyl p-hydroxyphenyl ether,Hydrochinon monobenzylether [Czech],Hydroquinone benzyl ether,Hydroquinone monobenzyl ether','AgeRite Alba,Agerite,Alba,Alba-Dome,Benoquin,Carmi','Drug/Small Molecule','DailyMed:addb5a47-6693-4f77-8622-c2631c17a119,TTD:DAP000830,chebi:34380,chemSpider:7356,dpd:1966391,drugBank:DB00600,keggCompound:C14244,keggDrug:D05072,ndc:0187-0380-34,pubChemCompound:7638,pubChemSubstance:46507466,pubChemSubstance:7847054,url:http://en.wikipedia.org/wiki/Monobenzone','c1ccc(cc1)COc2ccc(cc2)O'),('PA164764583','praziquantel','','Biltricide','','',''),('PA164764584','rasagiline','RAS','Azilect','Drug/Small Molecule','DailyMed:a40d0e73-3f9f-4b01-979d-402c9cdaeb60,HET:RAS,TTD:DAP001107,bindingDb:10989,chemSpider:2314553,dpd:2284642,drugBank:DB01367,keggDrug:D02562,ndc:68546-142-56,pdb:RAS,pubChemCompound:3052776,pubChemSubstance:10056118,pubChemSubstance:46506045,url:http://en.wikipedia.org/wiki/Rasagiline',''),('PA164764600','cycloserine','Cicloserina,D-CS,D-Cycloserine,D-Cycloserine synth. BP 88,D-Cycloserine, synthetic,D-Oxamicina,D-Oxamycin,DL-Cycloserine,L-Cycloserine,alpha-Cycloseri','Closerin,Closina,Cyclomycin,Cyclorin,Cycloserin,Fa','Drug/Small Molecule','DailyMed:13cd5f93-33f2-4ff7-bf96-e8357256041b,TTD:DAP001468,bindingDb:50016698,chebi:40009,dpd:2032414,drugBank:DB00260,keggCompound:C06682,ndc:0002-0604-40,pubChemCompound:401,pubChemSubstance:8907,url:http://en.wikipedia.org/wiki/Cycloserine','C1C(C(=O)NO1)N'),('PA164764601','ambenonium','Ambenonum','Mytelase','Drug/Small Molecule','DailyMed:d323d428-97c7-495d-8f65-58b5f0e8afda,TTD:DAP000893,chebi:2627,chemSpider:2046,drugBank:DB01122,keggCompound:C07773,ndc:0024-1287-04,pubChemCompound:2131,pubChemSubstance:46508143,pubChemSubstance:9975,url:http://en.wikipedia.org/wiki/Ambenonium',''),('PA164764617','oxybuprocaine','Benoxinate,Benoxinate HCL,Benoxinate hydrochloride,Dorsacaine hydrochloride,Oxbarukain,Oxibuprocainum,Oxibuprokain,Oxybucaine,Oxybuprocaine HCL,Oxybup','Benoxil,Cebesine,Conjucain,Conjuncain,Dorsacain,Do','','',''),('PA164764618','iron dextran','Dexferrum,Dextran iron','Imferon,Infed,Proferdex','','',''),('PA164768689','hydroxocobalamin','Hydroxocobalamin Vitamin B12,Hydroxocobalamin acetate,Hydroxocobalamin monohydrochloride,Hydroxocobalaminacetat,Hydroxomin,Vitamin B12a','Acti-B12,Alpharedisol,Cyanokit,Hydro Cobex,Hydroxy','','',''),('PA164768735','ethotoin','Ethotoine [INN-French],Ethotoinum [INN-Latin],Etotoina [INN-Spanish]','Accenon,Peganone,Pegoanone','Drug/Small Molecule','DailyMed:a9ad9c6e-bce5-4d0d-a2dd-b8fd1ef0b565,TTD:DAP000512,chebi:4888,chemSpider:3176,drugBank:DB00754,keggCompound:C07839,keggDrug:D00708,ndc:67386-601-01,pubChemCompound:3292,pubChemSubstance:10041,pubChemSubstance:46504521,url:http://en.wikipedia.org/wiki/Ethotoin','CCN1C(=O)C(NC1=O)c2ccccc2'),('PA164768736','carteolol','Carteolol HCl,Carteolol Hydrochloride,Carteololum [INN-Latin]','Cartrol,Endak Hydrochloride,Ocupress','Drug/Small Molecule','DailyMed:5f82e53e-d6db-432f-af68-9de88d1b1720,TTD:DAP000065,chebi:3437,chemSpider:2485,drugBank:DB00521,keggCompound:C06874,ndc:58768-001-01,pubChemCompound:2583,pubChemSubstance:46507513,pubChemSubstance:9091,url:http://en.wikipedia.org/wiki/Carteolol',''),('PA164768737','haloprogin','','Aloprogen,Haloprogin [USAN:INN:JAN],Haloprogina [I','Drug/Small Molecule','TTD:DAP001332,bindingDb:50194601,chemSpider:3440,drugBank:DB00793,keggDrug:D00339,pubChemCompound:3561,pubChemSubstance:46504892,pubChemSubstance:7847405,url:http://en.wikipedia.org/wiki/Haloprogin','c1c(c(cc(c1Cl)Cl)Cl)OCC#CI'),('PA164768738','ethionamide','ET,ETH,ETP,Ethinamide,Ethionamid prothionamid,Ethionamidum [INN-Latin],Ethioniamide,Ethylisothiamide,Ethyonomide,Etionamid,Etionamida [INN-Spanish],Et','Aethionamidum,Aetina,Aetiva,Amidazin,Amidazine,Ati','Drug/Small Molecule','DailyMed:04a413fe-95f4-47a7-42ac-283a9e78297d,TTD:DAP001141,chebi:4885,chemSpider:2041901,drugBank:DB00609,keggCompound:C07665,keggDrug:D00591,ndc:0008-4117-01,pubChemCompound:2761171,pubChemSubstance:46506077,pubChemSubstance:9867,url:http://en.wikipedia.org/wiki/Ethionamide','CCc1cc(ccn1)C(=S)N'),('PA164768739','cefdinir','CFDN,Cefdirnir','Cefzon,Omnicef','Drug/Small Molecule','DailyMed:06fbdb63-d32f-4212-9962-f1de15597dda,TTD:DAP000436,chebi:3485,chemSpider:5291705,drugBank:DB00535,keggCompound:C08110,keggDrug:D00917,ndc:65862-218-60,pubChemCompound:6915944,pubChemSubstance:46505573,pubChemSubstance:7847980,url:http://en.wikipedia.org/wiki/Cefdinir','C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)C(=NO)c3csc(n3)N)SC1)C(=O)O'),('PA164768794','enoximone','enoximone','Perfan','Drug/Small Molecule','TTD:DAP000611,bindingDb:50241379,chemSpider:48492,drugBank:DB04880,keggDrug:D04004,pubChemCompound:53708,pubChemSubstance:11111134,pubChemSubstance:46505575,url:http://en.wikipedia.org/wiki/Enoximone','Cc1c([nH]c(=O)[nH]1)C(=O)c2ccc(cc2)SC'),('PA164768801','treprostinil','treprostinil','Remodulin,Viveta','Drug/Small Molecule','DailyMed:cbc31ab1-a80f-4b50-a3b1-39910b0fb609,TTD:DAP001214,chebi:50861,dpd:2246552,drugBank:DB00374,ndc:66302-206-01,pubChemCompound:54786,pubChemSubstance:192299,url:http://en.wikipedia.org/wiki/Treprostinil',''),('PA164768817','anileridine','Anileridina [INN-Spanish],Anileridinum [INN-Latin],Phthalylsulfathiazole,Sulfathalidine','Adopol,Alidine,Apidol,Apodol,Leritin,Leritine,Nipe','Drug/Small Molecule','TTD:DAP001135,chebi:61203,chemSpider:8600,dpd:10014,drugBank:DB00913,pubChemCompound:8944,pubChemSubstance:152095,pubChemSubstance:46505199,url:http://en.wikipedia.org/wiki/Anileridine','CCOC(=O)C1(CCN(CC1)CCc2ccc(cc2)N)c3ccccc3'),('PA164768818','rescinnamine','Methyl Trimethoxycinnamoylreserpate,Recinnamine,Rescinnamin,Reserpinene,Reserpinin,Reserpinine,Trimethoxycinnamoyl Methyl Reserpate','Anapral,Anaprel,Apolon,Apoterin,Apoterin S,Cartric','Drug/Small Molecule','TTD:DAP000910,chebi:28572,chemSpider:30295,drugBank:DB01180,keggCompound:C06540,keggDrug:D00198,pubChemCompound:32681,pubChemCompound:5280954,pubChemSubstance:46507786,pubChemSubstance:8770,url:http://en.wikipedia.org/wiki/Rescinnamine',''),('PA164768819','novobiocin','Antibiotic Pa-93,Crystallinic Acid,NOV,Novobiocina [INN-Spanish],Novobiocine [INN-French],Novobiocinum [INN-Latin]','Albamix,Albamycin,Cardelmycin,Cathocin,Cathomycin,','','',''),('PA164768820','daptomycin','LY 146032,daptomycin','Cubicin','Drug/Small Molecule','DailyMed:a7975871-46a6-4e9b-a8b5-38bfcb465f0e,TTD:DAP001328,drugBank:DB00080,keggCompound:C12013,keggDrug:D01080,ndc:67919-011-01,pubChemCompound:16129629,pubChemSubstance:14171,url:http://en.wikipedia.org/wiki/Daptomycin','CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]3[C@H](OC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)[C@@H](C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C'),('PA164768821','cefixime','Cefixim,Cefixima [Spanish],Cefixime Anhydrous,Cefiximum [Latin]','CFIX,Cefixoral,Cefspan,Cephoral,Oroken,Suprax,Unix','Drug/Small Molecule','TTD:DAP000439,chebi:472657,dpd:2195992,drugBank:DB00671,keggCompound:C06881,keggDrug:D00258,pubChemCompound:54362,pubChemSubstance:9098,url:http://en.wikipedia.org/wiki/Cefixime','C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)C(=NOCC(=O)O)c3csc(n3)N)SC1)C(=O)O'),('PA164768822','chlorotrianisene','CTA,Chloortrianisestrol,Chlorestrolo,Chlorotrianisenum [INN-Latin],Chlorotrianisine,Chlorotrianizen,Chlortrianisen,Chlortrianisene,Chlortrianisenum,Ch','Anisene,Chlorotrisin,Clorestrolo,Clorotrisin,Hormo','Drug/Small Molecule','TTD:DAP001012,chebi:3641,chemSpider:10815,drugBank:DB00269,keggDrug:D00269,pubChemCompound:11289,pubChemSubstance:46508811,url:http://en.wikipedia.org/wiki/Chlorotrianisene',''),('PA164768832','halobetasol propionate','','Halobetasol,Ulobetasol Propionate,Ultravate','Drug/Small Molecule','DailyMed:7f22c10f-2691-a0a5-901e-a7c0fe41611f,TTD:DAP001186,chemSpider:43819,dpd:1962701,drugBank:DB00596,ndc:0713-0639-15,pubChemCompound:48175,pubChemSubstance:187307,pubChemSubstance:46506187',''),('PA164768833','ethiodized oil','EOE 13','Ethiodol','Drug/Small Molecule','DailyMed:23688476-d9ee-4df6-a2cc-73594ab22066,dpd:386685,drugBank:DB00965,keggDrug:D04082,ndc:0281-7062-37,pubChemSubstance:167250,url:http://en.wikipedia.org/wiki/Ethiodized_oil',''),('PA164768834','terconazole','Triaconazole','Fungistat,Gyno-Terazol,Terazol,Terazol 3,Terazol 7','Drug/Small Molecule','DailyMed:f59448bd-f730-46d2-a785-c2d6205579ff,TTD:DAP000629,chemSpider:390122,dpd:2247651,drugBank:DB00251,keggCompound:C08080,keggDrug:D00888,ndc:0168-0347-20,pubChemCompound:441383,pubChemSubstance:46505257,pubChemSubstance:7847952,url:http://en.wikipedia.org/wiki/Terconazole',''),('PA164768835','maraviroc','maraviroc','Celsentri,Selzentry','Drug/Small Molecule','DailyMed:a94a9a2b-337b-4c13-8622-fc392194dc21,TTD:DNC001487,chemSpider:2273675,drugBank:DB04835,iupharLigand:803,iupharLigand:806,ndc:0069-0807-60,pubChemCompound:3002977,pubChemSubstance:12015618,pubChemSubstance:46508040,url:http://en.wikipedia.org/wiki/Maraviroc',''),('PA164768860','phosphatidylserine','1,2-Diacyl-sn-glycerol 3-phospho-L-serine,3-O-sn-Phosphatidyl-L-serine,O3-Phosphatidyl-L-serine,PS,Phosphatidyl-L-serine','LifeExtension PS Caps','Drug/Small Molecule','HET:PSF,chebi:18303,chemSpider:13628254,drugBank:DB00144,pdb:PSF,pubChemCompound:6323481,pubChemSubstance:46505650,url:http://en.wikipedia.org/wiki/Phosphatidylserine',''),('PA164769030','digoxin immune fab','Ig gamma-2A chain C region, A allele','DigiFab','Drug/Small Molecule','DailyMed:6832767f-db6b-4eea-b88b-bdfc905749e1,dpd:2146967,drugBank:DB00076,ndc:0281-0365-10',''),('PA164769031','lumiracoxib','COX 189,lumiracoxib','Prexige','Drug/Small Molecule','TTD:DAP000970,bindingDb:50207446,chemSpider:133236,dpd:2288036,drugBank:DB01283,keggDrug:D03714,pubChemCompound:151166,pubChemSubstance:17397805,pubChemSubstance:46506378,url:http://en.wikipedia.org/wiki/Lumiracoxib',''),('PA164769056','tiotropium','Tiotropium bromide','Spiriva','Drug/Small Molecule','DailyMed:820839ef-e53d-47e8-a3b9-d911ff92e6a9,TTD:DAP000344,dpd:2246793,drugBank:DB01409,ndc:0597-0075-75,pubChemCompound:3086654,pubChemCompound:5487426,pubChemSubstance:12014767,pubChemSubstance:46504448,url:http://en.wikipedia.org/wiki/Tiotropium',''),('PA164769057','tasosartan','','','Drug/Small Molecule','TTD:DAP001258,bindingDb:50040439,chemSpider:54890,drugBank:DB01349,pubChemCompound:60919,pubChemSubstance:12014735,pubChemSubstance:46504809,url:http://en.wikipedia.org/wiki/Tasosartan','Cc1c2c(nc(n1)C)N(C(=O)CC2)Cc3ccc(cc3)c4ccccc4c5n[nH]nn5'),('PA164769058','lercanidipine','lercanidipine','Lercanidipine [INN]','Drug/Small Molecule','TTD:DAP001261,chemSpider:59276,drugBank:DB00528,pubChemCompound:65866,pubChemSubstance:207908,pubChemSubstance:46508865,url:http://en.wikipedia.org/wiki/Lercanidipine','CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c3ccccc3)c4cccc(c4)N(=O)=O)C(=O)OC'),('PA164769059','moexipril','Moexipril HCl,Moexipril hydrochloride,Moexiprilum [INN-Latin]','Univasc','Drug/Small Molecule','DailyMed:0374eac3-41eb-4f92-b192-b8c8058e5838,TTD:DAP000586,bindingDb:50084673,chemSpider:82418,drugBank:DB00691,keggCompound:C07704,ndc:0574-0110-01,pubChemCompound:91270,pubChemSubstance:46508441,pubChemSubstance:9906',''),('PA164769075','anistreplase','Tissue-type plasminogen activator precursor,t- PA,t-plasminogen activator,tPA','Eminase','Drug/Small Molecule','TTD:DAP001197,dpd:2229390,drugBank:DB00029,genBank:L00153,uniProtKb:P00750,url:http://en.wikipedia.org/wiki/Anistreplase',''),('PA164769104','estriol','(16alpha,17beta)-Oestra-1,3,5(10)-triene-3,16,17-triol,(16alpha,17beta)-estra-1,3,5(10)-triene-3,16,17-triol,1,3,5(10)-Estratriene-3,16,17-Triol,1,3,5','Deuslon-A,Estriel','Drug/Small Molecule','HET:ESL,TTD:DAP001019,chebi:27974,chemSpider:5553,drugBank:DB04573,keggCompound:C05141,keggDrug:D00185,pdb:ESL,pubChemCompound:5756,pubChemSubstance:14897919,pubChemSubstance:46505881,url:http://en.wikipedia.org/wiki/Estriol','C[C@]12CC[C@@H]3c4ccc(cc4CC[C@H]3[C@@H]1C[C@H]([C@@H]2O)O)O'),('PA164771230','phensuximide','','1-Methyl-3-Phenylsuccinimide,Epimid,Fenosuccimide,','','',''),('PA164771231','etonogestrel','etonogestrel','Implanon','','',''),('PA164771235','clomocycline','Chlormethylenecycline,Clomociclina [INN-Spanish],Clomocyclinum [INN-Latin]','','Drug/Small Molecule','TTD:DAP000882,chebi:59589,chemSpider:4576619,drugBank:DB00453,keggDrug:D06885,pubChemCompound:5464321,pubChemSubstance:214075,pubChemSubstance:46505301,url:http://en.wikipedia.org/wiki/Clomocycline','C[C@]1(c2c(ccc(c2C(=O)C3=C([C@]4([C@@H](CC31)[C@@H](C(=C(C4=O)C(=O)NCO)O)N(C)C)O)O)O)Cl)O'),('PA164771236','pegaptanib','pegaptanib','Macugen','Drug/Small Molecule','TTD:DAP001259,dpd:2267225,drugBank:DB04895,url:http://en.wikipedia.org/wiki/Pegaptanib',''),('PA164771240','selenium sulfide','SeS,Selenium Disulfide,Selenium sulfide red powder,Selenium sulphide,Sulfur selenide','Exsel,Exsel Lotion Shampoo,Glo-Sel,Head & Shoulder','','',''),('PA164774762','fleroxacin','fleroxacin (jan/usan/inn),fleroxacin [usan:ban:inn:jan],fleroxacine,fleroxacine [french],fleroxacino [spanish],fleroxacinum [latin],fleroxicin,flrx,me','','Drug/Small Molecule','TTD:DAP000928,drugBank:DB04576,keggCompound:C13179,keggDrug:D01716','CN1CCN(CC1)c2c(cc3c(c2F)n(cc(c3=O)C(=O)O)CCF)F'),('PA164774763','latanoprost','latanoprost','Xalatan,Xalatan Fixed Flow Device','','',''),('PA164774779','remikiren','Ro 42-5892','','Drug/Small Molecule','TTD:DAP001220,chemSpider:4575384,drugBank:DB00212,keggCompound:C07465,pubChemCompound:5462340,pubChemSubstance:46507286,pubChemSubstance:9668,url:http://en.wikipedia.org/wiki/Remikiren',''),('PA164774795','alfuzosin','Alfusosine,alfuzosin','Uroxatral,Xatral','Drug/Small Molecule','TTD:DCL000664,chebi:51141,chemSpider:2008,dpd:2245565,drugBank:DB00346,keggDrug:D01692,ndc:0024-4200-30,pubChemCompound:2092,pubChemSubstance:46508512,pubChemSubstance:682525,url:http://en.wikipedia.org/wiki/Alfuzosin',''),('PA164774805','bismuth subsalicylate','Bismuth oxide salicylate,Bismuth oxysalicylate,Bismuth(III) subsalicylate,Bismuthi subsalicylas,Bismutum subsalicylicum,bismuth','Bismatrol,Bismed,Bismuth caplets,Bismuth chewables','','',''),('PA164774806','pentosan polysulfate','','Elmiron','Drug/Small Molecule','TTD:DAP001025,chemSpider:34595,dpd:2082101,drugBank:DB00686,pubChemCompound:37720,pubChemSubstance:179048,pubChemSubstance:46509187',''),('PA164774876','mecasermin','Mecasermin rinfabate,mecasermin','Increlex,Iplex','Drug/Small Molecule','DailyMed:a8b27a1b-a611-4f91-ad22-76d4b390c3ae,TTD:DAP000287,drugBank:DB01277,keggDrug:D04870,ndc:15054-1040-5',''),('PA164774901','darifenacin','darifenacin','Emselex,Enablex','Drug/Small Molecule','DailyMed:cdf1487b-9f1d-42c6-9184-0015fff0b48f,TTD:DAP001131,bindingDb:50109647,chebi:391960,chemSpider:392054,drugBank:DB00496,iupharLigand:319,iupharLigand:321,keggDrug:D01699,ndc:0078-0419-15,pubChemCompound:444031,pubChemSubstance:46508104,pubChemSubstance:7979027,url:http://en.wikipedia.org/wiki/Darifenacin',''),('PA164774902','tolazamide','','Norglycin,Tolanase,Tolinase','Drug/Small Molecule','DailyMed:5cde1f9b-74f6-6c03-6329-20969b6f1cbb,TTD:DAP000919,chemSpider:5302,drugBank:DB00839,keggDrug:D00379,ndc:0378-0217-01,pubChemCompound:5503,pubChemSubstance:46505642,pubChemSubstance:7847445,url:http://en.wikipedia.org/wiki/Tolazamide','Cc1ccc(cc1)S(=O)(=O)NC(=O)NN2CCCCCC2'),('PA164774903','guanabenz','','GBZ,Guanabenz,Guanabenz Acetate,Guanabenz [USAN:IN','Drug/Small Molecule','TTD:DAP000232,chemSpider:3397,drugBank:DB00629,keggCompound:C07034,keggDrug:D04375,pubChemCompound:3517,pubChemCompound:5702063,pubChemSubstance:46505200,pubChemSubstance:9246,url:http://en.wikipedia.org/wiki/Guanabenz','c1cc(c(c(c1)Cl)C=NNC(=N)N)Cl'),('PA164774919','ceruletide','','Tymtran','Drug/Small Molecule','TTD:DAP000961,chebi:59219,drugBank:DB00403,pubChemCompound:168399,pubChemSubstance:745880',''),('PA164774947','aminocaproic acid','6-aminohexanoic acid,ACS,Aminocaproate,Aminocaproic,aminocaproic acid,e-aminocaproic acid,epsilon-ahx,epsilon-amino caproic acid','Acepramin,Acepramine,Afibrin,Amicar,Amikar,Aminoka','Drug/Small Molecule','HET:ACA,TTD:DAP000200,chebi:16586,chemSpider:548,drugBank:DB00513,keggCompound:C02378,keggDrug:D00160,ndc:61748-044-08,pdb:ACA,pubChemCompound:564,pubChemSubstance:46506934,pubChemSubstance:5420,url:http://en.wikipedia.org/wiki/Aminocaproic_acid','CCCCC(C(=O)O)N'),('PA164776605','menthol','(-)-menthol,(r)-(-)-menthol,L-(-)-menthol,L-menthol,Levomenthol','','','',''),('PA164776636','flunarizine','(E)-1-[Bis-(p-fluorophenyl)methyl]-4-cinnamylpiperazine,1-(Bis(4-fluorophenyl)methyl)-4-cinnamylpiperazine,Flunarizina [inn-spanish],Flunarizine Hydro','Apo-flunarizine capsules,Flufenal,Fluvert,Issium,N','Drug/Small Molecule','TTD:DAP000142,bindingDb:50017702,chemSpider:819216,dpd:846341,drugBank:DB04841,keggDrug:D01303,pubChemCompound:941361,pubChemSubstance:181267,pubChemSubstance:46507129,url:http://en.wikipedia.org/wiki/Flunarizine','c1ccc(cc1)/C=C/CN2CCN(CC2)C(c3ccc(cc3)F)c4ccc(cc4)F'),('PA164776637','eculizumab','5G1.1,eculizumab','Soliris','Drug/Small Molecule','DailyMed:ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722,TTD:DAP000967,drugBank:DB01257,ndc:25682-001-01,url:http://en.wikipedia.org/wiki/Eculizumab',''),('PA164776668','prazepam','Prazepamum [inn-latin]','Centrax,Demetrin,Lysanxia,Prazeene,Prazene,Sedapra','Drug/Small Molecule','TTD:DAP000689,chemSpider:4721,drugBank:DB01588,keggCompound:C07366,keggDrug:D00470,pubChemCompound:4890,pubChemSubstance:10468346,pubChemSubstance:46505417,url:http://en.wikipedia.org/wiki/Prazepam','c1ccc(cc1)C2=NCC(=O)N(c3c2cc(cc3)Cl)CC4CC4'),('PA164776669','mebendazole','','Bantenol,Besantin,Equivurm Plus,Lomper,MBDZ,MEBEND','','',''),('PA164776670','laronidase','Alpha-L-iduronidase precursor','Aldurazyme','Drug/Small Molecule','dpd:2254506,drugBank:DB00090,genBank:M74715,uniProtKb:P35475,url:http://en.wikipedia.org/wiki/Laronidase',''),('PA164776671','cinacalcet','','Sensipar','Drug/Small Molecule','DailyMed:45028573-13c4-4c8b-ae62-6c75bba97c81,TTD:DAP000256,chebi:48390,chemSpider:137743,dpd:2257157,drugBank:DB01012,ndc:55513-073-30,pubChemCompound:156419,pubChemSubstance:46506315,pubChemSubstance:783756,url:http://en.wikipedia.org/wiki/Cinacalcet',''),('PA164776726','miglitol','','Glyset','Drug/Small Molecule','DailyMed:75711d16-2d27-476e-a312-d5af448a0e25,TTD:DAP000712,chemSpider:390074,drugBank:DB00491,keggCompound:C07708,keggDrug:D00625,ndc:0009-5012-01,pubChemCompound:441314,pubChemSubstance:46504492,pubChemSubstance:9910,url:http://en.wikipedia.org/wiki/Miglitol',''),('PA164776730','alteplase','Tissue-type plasminogen activator precursor,t-PA,t-plasminogen activator,tPA','Activase','Drug/Small Molecule','TTD:DAP000203,dpd:2245859,drugBank:DB00009,genBank:L00153,keggDrug:D02837,uniProtKb:P00750,url:http://en.wikipedia.org/wiki/Alteplase',''),('PA164776752','cefacetrile','7-Cyanacetylamino-cephalosporansaeure,Cefacetrilo [inn-spanish],Cefacetrilum [inn-latin],Cephacetrile','Celospor,Celtol,Cristacef','Drug/Small Molecule','TTD:DAP001172,chemSpider:82675,drugBank:DB01414,keggDrug:D07629,pubChemCompound:91562,pubChemSubstance:10224877,pubChemSubstance:46504767,url:http://en.wikipedia.org/wiki/Cefacetrile',''),('PA164776753','udenafil','','Zydena','Drug/Small Molecule','TTD:DAP000960,chemSpider:5293720,drugBank:DB06267,pubChemCompound:6918523,pubChemSubstance:99443240,url:http://en.wikipedia.org/wiki/Udenafil',''),('PA164776757','tenecteplase','Tissue-type plasminogen activator precursor,t- PA,t-plasminogen activator,tPA','TNKase','Drug/Small Molecule','DailyMed:69e391bf-1250-4083-aa60-6aa41c33657f,TTD:DAP000204,dpd:2244826,drugBank:DB00031,genBank:L00153,keggDrug:D06070,ndc:50242-038-61,uniProtKb:P00750,url:http://en.wikipedia.org/wiki/Tenecteplase',''),('PA164776839','ajmaline','Ajmalin','','Drug/Small Molecule','chebi:28462,drugBank:DB01426,keggCompound:C06542,keggDrug:D00199,pubChemCompound:441080,pubChemSubstance:7847267,url:http://en.wikipedia.org/wiki/Ajmaline',''),('PA164776840','atracurium','','','Drug/Small Molecule','TTD:DAP000105,bindingDb:50149881,chebi:2914,chemSpider:43067,dpd:2236319,drugBank:DB00732,keggCompound:C07548,pubChemCompound:47319,pubChemSubstance:46504689,pubChemSubstance:9751,url:http://en.wikipedia.org/wiki/Atracurium',''),('PA164776841','benzthiazide','','Aquatag,Benzothiazide,Benzthazide,Dihydrex,Diucen,','Drug/Small Molecule','TTD:DAP000603,chebi:3047,chemSpider:2253,drugBank:DB00562,keggCompound:C07759,keggDrug:D00651,pubChemCompound:2343,pubChemSubstance:46506752,pubChemSubstance:9961',''),('PA164776842','sulfamerazine','','','Drug/Small Molecule','TTD:DAP001240,chebi:102130,chemSpider:5134,drugBank:DB01581,pubChemCompound:5325,pubChemSubstance:10321119,pubChemSubstance:46505036,url:http://en.wikipedia.org/wiki/Sulfamerazine','Cc1ccnc(n1)NS(=O)(=O)c2ccc(cc2)N'),('PA164776843','rosoxacin','Acrosoxacin,ROS,Rosoxacine [INN-French],Rosoxacino [INN-Spanish]','Eracine,Eradacil,Eradacin,Roxadyl,Winuron','Drug/Small Molecule','TTD:DAP000929,chemSpider:253208,drugBank:DB00817,keggDrug:D02305,pubChemCompound:287180,pubChemSubstance:429531,pubChemSubstance:46508469',''),('PA164776844','hyoscyamine','(s)-(?)-hyoscyamine,(s)-atropine,(?)-atropine,(?)-hyoscyamine,Hyocyamine,L-Atropine,L-Hyopscyamine,L-Hyoscamine,L-Hyoscyamine,L-Tropine Tropate','Anaspaz,Buwecon,Cystospaz,Daturine,Donnamar,Dubois','Drug/Small Molecule','TTD:DNC000758,chebi:17486,dpd:125857,drugBank:DB00424,iupharLigand:320,pubChemCompound:64692,pubChemSubstance:206628,url:http://en.wikipedia.org/wiki/Hyoscyamine','CN1C2CCC1CC(C2)OC(=O)[C@H](CO)c3ccccc3'),('PA164776845','forasartan','','','Drug/Small Molecule','TTD:DAP001256,bindingDb:50049209,chemSpider:117146,drugBank:DB01342,pubChemCompound:132706,pubChemSubstance:14904609,pubChemSubstance:46505698',''),('PA164776849','proparacaine','Proparacaine Hcl,Prossimetacaina [Dcit],Proximetacaina [INN-Spanish],Proximetacainum,Proxymetacaine,Proxymetacaine Hcl,Proxymetacainum [INN-Latin]','Ak-Taine,Alcaine,Diocaine,Kainair,Ocu-Caine,Ophtha','Drug/Small Molecule','DailyMed:37cde651-2549-43f3-97b9-cdc442a0aa7a,TTD:DAP000513,bindingDb:50017718,chemSpider:4766,dpd:872857,drugBank:DB00807,keggCompound:C07383,ndc:17478-263-12,pubChemCompound:4935,pubChemSubstance:46507960,pubChemSubstance:9587,url:http://en.wikipedia.org/wiki/Proparacaine',''),('PA164776853','etoricoxib','MK-663,etoricoxib','Algix,Arcoxia,Nucoxia,Tauxib','Drug/Small Molecule','HET:5CH,TTD:DAP000738,bindingDb:50072064,chebi:6339,chemSpider:110209,drugBank:DB01628,keggCompound:C11718,keggDrug:D03710,pdb:5CH,pubChemCompound:123619,pubChemSubstance:13883,pubChemSubstance:46504505,url:http://en.wikipedia.org/wiki/Etoricoxib',''),('PA164776863','chlorhexidine','Chlorhexidin [Czech],Chlorhexidine Base,Chlorhexidine Gluconate,Chlorhexidinum [INN-Latin],Cloresidina [DCIT],Clorhexidina [INN-Spanish],Decanoylaceta','Bioscrub,Brian Care,Cida-Stat,Dyna-Hex,Exidine,Fim','','',''),('PA164776864','orlistat','(-)-Tetrahydrolipstatin,Orlipastat,Orlipastatum [INN-Latin],Tetrahydrolipstatin,orlistat','Alli,Xenical','Drug/Small Molecule','DailyMed:5bbdc95b-82a1-4ba5-8185-6504ff68cc06,TTD:DAP000053,bindingDb:24567,chemSpider:2298564,dpd:2240325,drugBank:DB01083,ndc:0004-0256-52,pubChemCompound:3034010,pubChemSubstance:213522,pubChemSubstance:46508309,url:http://en.wikipedia.org/wiki/Orlistat',''),('PA164776910','oxyphencyclimine','Oxifencicliminum [INN-Spanish],Oxiphencycliminum,Oxyphencyclimine Hydrochloride,Oxyphencycliminum [INN-Latin]','Antulcus,Caridan,Cycmin,Daricol,Daricon,Dominil,En','Drug/Small Molecule','TTD:DAP000835,chemSpider:4481,drugBank:DB00383,keggCompound:C07851,pubChemCompound:4642,pubChemSubstance:10053,pubChemSubstance:46507487','CN1CCCN=C1COC(=O)C(c2ccccc2)(C3CCCCC3)O'),('PA164776911','sulfoxone','Adesulfone Sodium,Aldesulfone Sodium,Sodium Aldesulphone,Sodium Sulfoxone,Sulfoxone Sodium','Aldapsone,DDF,Diamidin,Diason,Diasone,Diasone Sodi','Drug/Small Molecule','TTD:DAP001192,chemSpider:5158,drugBank:DB01145,pubChemCompound:5351,pubChemSubstance:152108,pubChemSubstance:46507392',''),('PA164776912','pivampicillin','Ampicillin pivaloyloxymethyl ester,Pivaloylampicillin,Pivaloyloxymethyl ampicillinate,Pivampicilina [inn-spanish],Pivampicilline [inn-french],Pivampic','Pondocillin','Drug/Small Molecule','TTD:DAP001171,chebi:8255,chemSpider:30899,dpd:582247,drugBank:DB01604,keggCompound:C11750,pubChemCompound:33478,pubChemSubstance:11467037,pubChemSubstance:46505340,url:http://en.wikipedia.org/wiki/Pivampicillin',''),('PA164776913','spirapril','','Renormax','Drug/Small Molecule','TTD:DAP000911,bindingDb:50017124,chemSpider:4470933,drugBank:DB01348,pubChemCompound:5311447,pubChemSubstance:12013873,pubChemSubstance:46506126,url:http://en.wikipedia.org/wiki/Spirapril',''),('PA164776929','lipoic acid','1,2-Dithiolane-3R-pentanoic acid,Lipoate,Thioctic acid,alpha-Lipoic acid','Biletan,Heparlipon,Thioctsan','Drug/Small Molecule','HET:LPA,chebi:16494,chebi:30314,drugBank:DB00166,keggCompound:C00725,keggDrug:D00086,pdb:LPA,pubChemCompound:6112,pubChemSubstance:3990,url:http://en.wikipedia.org/wiki/Lipoic_Acid',''),('PA164776964','desloratadine','Descarboethoxyloratadine,Descarboethoxyoratidine,Desloratidine,desloratadine','Aerius,Claramax,Clarinex,Clarinex Reditabs,NeoClar','','',''),('PA164776968','l-asparagine','(-)-Asparagine,(S)-2,4-Diamino-4-oxobutanoic acid,(S)-Asparagine,2-Aminosuccinamic acid,Asn,Asparagine,Asparagine acid,Asparamide,Aspartamic acid,Aspa','Agedoite,Altheine,Crystal VI','Drug/Small Molecule','HET:ASN,chebi:17196,chemSpider:6031,drugBank:DB00174,keggCompound:C00152,pdb:ASN,pubChemCompound:6267,pubChemSubstance:3452,pubChemSubstance:46507804',''),('PA164776996','desonide','','Desilux,Desocort,Desowen,Tridesilon','Drug/Small Molecule','DailyMed:a7e5f030-b849-4805-94e6-f45631eaa37f,TTD:DAP001188,chebi:204734,chemSpider:4470603,dpd:2048639,drugBank:DB01260,keggDrug:D03696,ndc:0299-5770-60,pubChemCompound:5311066,pubChemSubstance:17397789,pubChemSubstance:46506186,url:http://en.wikipedia.org/wiki/Desonide',''),('PA164776997','clemastine','Clemastina [INN-Spanish],Clemastine Fumarate,Clemastinum [INN-Latin]','Meclastin,Mecloprodin,Tavist,Tavist-1','','',''),('PA164777007','picrotoxin','','Cocculin,Cocculine,Cocculus,Coques du levant,Fish ','Drug/Small Molecule','TTD:DAP000676,chemSpider:29044,drugBank:DB00466,pubChemCompound:31304,pubChemSubstance:173365,pubChemSubstance:46506796,url:http://en.wikipedia.org/wiki/Picrotoxin',''),('PA164777011','acetohexamide','Acetohexamid','Cyclamide,Dimelin,Dimelor,Dymelor,Gamadiabet,Hypog','Drug/Small Molecule','TTD:DAP000922,chebi:28052,chemSpider:1912,dpd:15598,drugBank:DB00414,keggCompound:C06806,keggDrug:D00219,pubChemCompound:1989,pubChemSubstance:46505821,pubChemSubstance:9025,url:http://en.wikipedia.org/wiki/Acetohexamide',''),('PA164777012','lubiprostone','RU-0211,lubiprostone','Amitiza','Drug/Small Molecule','DailyMed:d474ac6a-444d-4aa6-9986-24be6fcf811d,TTD:DAP000208,chemSpider:571057,drugBank:DB01046,keggCompound:C13707,keggDrug:D04790,ndc:64764-080-60,pubChemCompound:656719,pubChemSubstance:46505874,pubChemSubstance:586296,url:http://en.wikipedia.org/wiki/Lubiprostone',''),('PA164777031','ephedra','Chinese jointfir,Indian jointfir,Ma huang','Ephedra vulgaris,Sinueaze','','',''),('PA164777032','ertapenem','ertapenem','Invanz','Drug/Small Molecule','DailyMed:33f3b99b-fa82-42e0-26bf-f49891ae3d22,TTD:DAP000431,chebi:15449,chebi:404903,chemSpider:132758,dpd:2247437,drugBank:DB00303,keggDrug:D04049,keggDrug:D07908,ndc:0006-3845-71,pubChemCompound:150610,pubChemSubstance:46506508,pubChemSubstance:728127,url:http://en.wikipedia.org/wiki/Ertapenem',''),('PA164777033','pentolinium','Pentolinium tartrate,Pentolonium,Pentolonum','Ansolysen','Drug/Small Molecule','TTD:DAP001144,bindingDb:50084945,chemSpider:5641,drugBank:DB01090,pubChemCompound:5850,pubChemSubstance:46507977,pubChemSubstance:741991',''),('PA164777034','meticillin','(2,6-Dimethoxyphenyl)penicillin,6-(2,6-Dimethoxybenzamido)penicillanic acid,Methicillinum,Methycillin,Meticilina [inn-spanish],Meticillin,Meticilline ','Dimocillin,Metacillin','Drug/Small Molecule','TTD:DAP001170,chebi:6827,chemSpider:5862,drugBank:DB01603,keggCompound:C07177,pubChemCompound:6087,pubChemSubstance:11335275,pubChemSubstance:46508973,url:http://en.wikipedia.org/wiki/Methicillin',''),('PA164777035','paramethasone','','Haldrone','Drug/Small Molecule','TTD:DAP000422,chemSpider:5664,drugBank:DB01384,keggCompound:C07413,pubChemCompound:5875,pubChemSubstance:46504651,pubChemSubstance:9617,url:http://en.wikipedia.org/wiki/Paramethasone',''),('PA164777036','hydroxychloroquine','2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol,Gen-Hydroxychloroquine 200mg Tablets,HCQ,Hidroxicloroquina [inn-spanish],Hydroxychloroguin','Axemal,Dolquine,Ercoquin,Plaquenil,Polirreumin,Que','Drug/Small Molecule','DailyMed:1f438335-0104-4af4-ad42-03610ae96ee7,TTD:DAP000878,chemSpider:3526,dpd:2017709,drugBank:DB01611,keggCompound:C07043,keggDrug:D08050,ndc:0955-0790-01,pubChemCompound:3652,pubChemSubstance:46508459,pubChemSubstance:9255,url:http://en.wikipedia.org/wiki/Hydroxychloroquine',''),('PA164777037','nitisinone','nitisinone','Orfadin','Drug/Small Molecule','DailyMed:1eecf439-77ff-40c8-aef8-71e024ea8b7c,TTD:DAP000774,chebi:50378,chemSpider:103195,drugBank:DB00348,ndc:66621-1002-6,pubChemCompound:115355,pubChemSubstance:46507380,pubChemSubstance:692349,url:http://en.wikipedia.org/wiki/Nitisinone','c1cc(c(cc1C(F)(F)F)N(=O)=O)C(=O)C2C(=O)CCCC2=O'),('PA164778098','diethylpropion','Amfepramone HCL,Amfepramone Hydrochloride,Amfepramonum [INN-Latin],Amphepramonum hydrochloride,Anfepramona [INN-Spanish],DEA No. 1610,Diethylcathinone','Adiposon,Amfepramon,Amfepramone,Amphepramon,Amphep','Drug/Small Molecule','DailyMed:701ba14c-e668-4308-8430-765a7aad47fa,TTD:DAP001452,chebi:4530,chemSpider:6762,dpd:2047675,drugBank:DB00937,keggCompound:C06954,ndc:64720-208-10,pubChemCompound:7029,pubChemSubstance:46506622,pubChemSubstance:9169,url:http://en.wikipedia.org/wiki/Diethylpropion',''),('PA164778685','propiomazine','','Largon,Phenoctyl,Propiomazina [INN-Spanish],Propio','Drug/Small Molecule','TTD:DAP000327,chebi:8491,chemSpider:4771,drugBank:DB00777,keggCompound:C07405,keggDrug:D02361,pubChemCompound:4940,pubChemSubstance:46506205,pubChemSubstance:7849420,url:http://en.wikipedia.org/wiki/Propiomazine',''),('PA164778686','pyruvic acid','2-Oxopropanoate,2-Oxopropanoic acid,2-Oxopropionic acid,Acetylformic acid,BTS,Pyroracemic acid,Pyruvate,a-Ketopropionic acid','','Drug/Small Molecule','HET:PYR,TTD:DAP000543,bindingDb:19473,chebi:32816,chemSpider:1031,drugBank:DB00119,keggCompound:C00022,pdb:PYR,pubChemCompound:1060,pubChemSubstance:3324,pubChemSubstance:46505692,url:http://en.wikipedia.org/wiki/Pyruvic_acid','CC(=O)C(=O)O'),('PA164778866','liothyronine','L-Liothyronine,Liothyronin,Liothyronine Sodium,T3 liothyronine,Triiodothyronine','Cytomel,Tertroxin,Tresitope,Triostat','','',''),('PA164778930','creatine','(alpha-Methylguanido)acetic acid,Creatine (8CI),Creatine, hydrate,Methylguanidoacetic acid,N-Amidinosarcosine,N-Methyl-N-guanylglycine','Cosmocair C 100,Creatin,Kreatin,Krebiozon,Phosphag','Drug/Small Molecule','HET:CRN,chebi:16919,chemSpider:566,drugBank:DB00148,keggCompound:C00300,pdb:CRN,pubChemCompound:586,pubChemSubstance:148804,pubChemSubstance:46504868,url:http://en.wikipedia.org/wiki/Creatine','CN(CC(=O)O)C(=N)N'),('PA164779048','interferon alfa-2a, recombinant','Interferon alfa-2a,Oral interferon alfa,rIFN-alpha-2a','Roferon A,Veldona','Drug/Small Molecule','DailyMed:4c918b02-f158-4f7c-8ecc-fd49574ec228,TTD:DAP000801,dpd:2217066,drugBank:DB00034,genBank:J00207,ndc:0004-2015-09,uniProtKb:P01563',''),('PA164779049','rolitetracycline','','','Drug/Small Molecule','TTD:DAP000884,chemSpider:4445374,drugBank:DB01301,keggDrug:D02282,pubChemCompound:5282179,pubChemSubstance:14811900,pubChemSubstance:46507805,url:http://en.wikipedia.org/wiki/Rolitetracycline',''),('PA164779050','sulfapyridine','2-Sulfanilamidopyridin,2-Sulfanilamidopyridine,2-Sulfanilylaminopyridine,2-Sulfapyridine,4-(2-Pyridinylsulfonyl)aniline,4-[(2-Pyridylamino)sulfonyl]an','Adiplon,Coccoclase,Dagenan,Eubasin,Eubasinum,Hapto','','',''),('PA164779051','talbutal','5-Allyl-5-sec-butylbarbituric acid,sec-Butyl allyl barbituric acid','Latusate,Lotusate,Profundol','Drug/Small Molecule','TTD:DAP000670,chemSpider:527603,drugBank:DB00306,pubChemCompound:606974,pubChemSubstance:10444920,pubChemSubstance:46507821,url:http://en.wikipedia.org/wiki/Talbutal','CCC(C)C1(C(=O)NC(=O)NC1=O)CC=C'),('PA164779052','glucagon recombinant','','GlucaGen,Glucagon','Drug/Small Molecule','DailyMed:f143db10-e889-41c3-84ed-603a0ab02f61,TTD:DAP001037,dpd:2243297,drugBank:DB00040,genBank:AF529185,keggCompound:C01501,keggDrug:D00116,ndc:0002-8031-01,pubChemSubstance:4670,uniProtKb:Q8MJ25,url:http://en.wikipedia.org/wiki/Glucagon_recombinant',''),('PA164781017','attapulgite','','','Drug/Small Molecule','dpd:2229950,drugBank:DB01574,url:http://en.wikipedia.org/wiki/Attapulgite',''),('PA164781018','pemirolast','Pemirolast Potassium,Pemirolastum [INN-Latin],Pemiroplast Potassium','Alamast','Drug/Small Molecule','DailyMed:18836374-7e66-45bd-8380-3f9714de0b40,TTD:DAP001064,chemSpider:51990,drugBank:DB00885,keggDrug:D01088,ndc:68669-711-10,pubChemCompound:57697,pubChemSubstance:46509034,pubChemSubstance:654148',''),('PA164781019','idoxuridine','5-iododeoxyuridine,5IDU,5IUDR,Allergan 201,Allergan 211,ID2,IDU,IDUR,IUDR,Idossuridina [DCIT],Idoxuridin,Idoxuridina [INN-Spanish],Idoxuridinum [INN-L','Antizona,Dendrid,Emanil,Heratil,Herpe-Gel,Herpes-G','Drug/Small Molecule','DailyMed:3537dd95-954c-459f-97a9-54a861bed265,HET:ID2,TTD:DAP000997,chebi:147675,chemSpider:5694,dpd:2237187,drugBank:DB00249,keggDrug:D00342,ndc:0065-0029-15,pdb:ID2,pubChemCompound:5905,pubChemSubstance:46507573,pubChemSubstance:7847408,url:http://en.wikipedia.org/wiki/Idoxuridine',''),('PA164781020','terlipressin','N-(N-(N-Glycylglycyl)glycyl)-8-L-lysinevasopressin,Terlipressina [INN-Spanish],Terlipressine [INN-French],Terlipressinum [INN-Latin],terlipressin','Glypressin,Lucassin','Drug/Small Molecule','TTD:DAP000058,chemSpider:65067,drugBank:DB02638,pubChemCompound:72081,pubChemSubstance:46504626,url:http://en.wikipedia.org/wiki/Terlipressin',''),('PA164781022','metolazone','Metolazona [INN-Spanish],Metolazonum [INN-Latin]','Diulo,Metalazone,Metalozone,Metenix,Microx,Mykrox,','Drug/Small Molecule','DailyMed:6639d111-eb21-4997-b964-f5c61bc088f2,TTD:DAP000749,bindingDb:25899,chemSpider:4026,dpd:888400,drugBank:DB00524,keggDrug:D00431,ndc:0378-6172-01,pubChemCompound:4170,pubChemSubstance:46509058,pubChemSubstance:7847497,url:http://en.wikipedia.org/wiki/Metolazone','Cc1ccccc1N2C(Nc3cc(c(cc3C2=O)S(=O)(=O)N)Cl)C'),('PA164781026','micafungin','FK-463,micafungin','Mycamine','Drug/Small Molecule','DailyMed:a064c4a7-25ec-4a2c-afc2-703491a4a38b,TTD:DAP000548,chebi:600520,chemSpider:2339421,drugBank:DB01141,keggCompound:C15819,keggDrug:D02465,ndc:0469-3250-10,pubChemCompound:3081921,pubChemCompound:477468,pubChemSubstance:3884856,pubChemSubstance:46508208,url:http://en.wikipedia.org/wiki/Micafungin',''),('PA164781027','cephaloglycin','','CEG,Cefaloglicina [INN-Spanish],Cefaloglycin,Cefal','Drug/Small Molecule','TTD:DAP001158,chemSpider:18069,drugBank:DB00689,keggCompound:C13440,keggDrug:D01949,pubChemCompound:19150,pubChemSubstance:46506850,pubChemSubstance:586181,url:http://en.wikipedia.org/wiki/Cephaloglycin',''),('PA164781028','guanidine','Aminomethanamidine,Carbamamidine,Carbamidine,Guanidin,Guanidine Hydrochloride,Guanidinium Chloride,Guanidinium Sulfate,Imidourea,Iminourea','Guanidine hydrochloride','Drug/Small Molecule','DailyMed:903fbd33-e5d9-41fb-9414-7bd6f42a8593,HET:GAI,chebi:24435,chemSpider:3400,drugBank:DB00536,ndc:0085-0492-01,pdb:GAI,pubChemCompound:3520,pubChemSubstance:218736,pubChemSubstance:46507543,url:http://en.wikipedia.org/wiki/Guanidine','C(=N)(N)N'),('PA164781029','aminophylline','Aminophyllin,Aminophylline Anhydrous,Aminophylline Dihydrate,Aminophylline Dye Free','Aminocardol,Aminodur,Ammophyllin,Cardiofilina,Card','','',''),('PA164781042','flucloxacillin','Floxacillin,Flucloxacilina [INN-Spanish],Flucloxacillin Sodium,Flucloxacillin-Sodium,Flucloxacilline [INN-French],Flucloxacillinum [INN-Latin]','Floxapen,Fluclox,Sesamol','Drug/Small Molecule','TTD:DAP001163,chebi:5098,chemSpider:20037,dpd:525561,drugBank:DB00301,keggCompound:C11748,keggDrug:D04196,pubChemCompound:21319,pubChemSubstance:13913,pubChemSubstance:46508276,url:http://en.wikipedia.org/wiki/Flucloxacillin',''),('PA164781043','propericiazine','Pericyazine','Neuleptil,Yaz','Drug/Small Molecule','TTD:DAP000413,chebi:31981,chemSpider:4585,dpd:1926756,drugBank:DB01608,pubChemCompound:4747,pubChemSubstance:10391833,pubChemSubstance:46505085',''),('PA164781044','clidinium','','Quarzan','','',''),('PA164781045','nesiritide','BNP,Brain natriuretic peptide 32,Natriuretic peptides B,nesiritide','Natrecor','Drug/Small Molecule','DailyMed:44c45bfe-461f-4398-8f20-ea771b2403ee,TTD:DAP001320,drugBank:DB04899,ndc:65847-205-25,uniProtKb:P16860,url:http://en.wikipedia.org/wiki/Nesiritide',''),('PA164781053','insulin, porcine','Insulin precursor','Iletin II','Drug/Small Molecule','TTD:DAP001089,dpd:513644,drugBank:DB00071,genBank:AY137503,uniProtKb:Q8HXV2',''),('PA164781150','ginseng','','','Drug/Small Molecule','dpd:682667,drugBank:DB01404,url:http://en.wikipedia.org/wiki/Ginseng',''),('PA164781163','apomorphine','Apomorfin,Apomorphine Hydrochloride Hemihydrate,Apomorphinium Chloride Hemihydrate,Apormorphine,L-Apomorphine,VR-040,VR-400,VR004,apomorphine,apomorph','APOKYN,Ixense,Uprima','','',''),('PA164781197','sevelamer','','Renagel','Drug/Small Molecule','DailyMed:5e30120b-f2bf-43a0-86b2-44ae996dc681,chemSpider:2341997,dpd:2244310,drugBank:DB00658,keggDrug:D01983,ndc:58468-0021-3,pubChemCompound:3085017,pubChemSubstance:3887352,pubChemSubstance:46505951,url:http://en.wikipedia.org/wiki/Sevelamer',''),('PA164781198','gallium nitrate','gallium nitrate','Ganite','Drug/Small Molecule','DailyMed:8bc2ddf8-d695-46b3-bf76-9f85ce6027e3,TTD:DAP001096,chemSpider:55543,drugBank:DB05260,ndc:66657-301-05,pubChemCompound:61635,pubChemSubstance:15490402,pubChemSubstance:46508923',''),('PA164781199','spermine','1, 4-Bis(aminopropyl)butanediamine,4,9-Diaza-1,12-dodecanediamine,4,9-Diazadodecane-1,12-diamine,Spermin,Spermine dihydrate','Gerontine,Musculamine,Neuridine','Drug/Small Molecule','HET:SPM,chebi:15746,chemSpider:1072,drugBank:DB00127,iupharLigand:710,keggCompound:C00750,pdb:SPM,pubChemCompound:1103,pubChemSubstance:4012,pubChemSubstance:46507215,url:http://en.wikipedia.org/wiki/Spermine','C(CCNCCCN)CNCCCN'),('PA164781307','sulfamethizole','','Ayerlucil,Famet,Lucosil,Methazol,Microsul,Proklar,','Drug/Small Molecule','TTD:DAP001202,chebi:9331,chemSpider:5137,drugBank:DB00576,keggCompound:C08050,keggDrug:D00870,pubChemCompound:5328,pubChemSubstance:10250,pubChemSubstance:46508656,url:http://en.wikipedia.org/wiki/Sulfamethizole',''),('PA164781320','flunitrazepam','Flunitrazepamum [inn-latin]','Narcozep,Primun,Rohypnol,Roipnol','Drug/Small Molecule','TTD:DAP000931,bindingDb:25878,chemSpider:3263,drugBank:DB01544,keggDrug:D01230,pubChemCompound:3380,pubChemSubstance:10476153,pubChemSubstance:46504553,url:http://en.wikipedia.org/wiki/Flunitrazepam','CN1c2ccc(cc2C(=NCC1=O)c3ccccc3F)N(=O)=O'),('PA164781342','spectinomycin','Actinospectacina [Italian],Antibiotic 2233wp,Espectinomicina [INN-Spanish],SCM,Spectinomicina [Italian],Spectinomycin Di HCl,Spectinomycin HCl/ Sulpha','Actinospectacin,Spectam,Togamycin,Trobicin','','',''),('PA164781343','varenicline','CP-526,555,Varenicline tartrate,varenicline','Champix,Chantix','Drug/Small Molecule','DailyMed:f0ff4f27-5185-4881-a749-c6b7a0ca5696,TTD:DAP001535,chemSpider:4470510,drugBank:DB01273,ndc:0069-0471-97,pubChemCompound:5310966,pubChemSubstance:16411442,pubChemSubstance:46505502,url:http://en.wikipedia.org/wiki/Varenicline',''),('PA164781353','butoconazole','Butoconazol [INN-Spanish],Butoconazole nitrate,Butoconazolum [INN-Latin]','Femstat,Femstat 3,Gynazole-1','Drug/Small Molecule','DailyMed:af4a7c80-ff0e-4746-9d45-f60149cd1395,TTD:DAP001267,chemSpider:43192,dpd:2248417,drugBank:DB00639,keggCompound:C08066,keggDrug:D00880,ndc:64011-001-08,pubChemCompound:47472,pubChemSubstance:46508016,pubChemSubstance:606881,url:http://en.wikipedia.org/wiki/Butoconazole',''),('PA164781354','perflutren','','Definity,Freon 218,Genetron 218,Octafluoropropane,','','',''),('PA164781355','fluorometholone','FML,Fluormetholon,Fluormetholone,Fluoromethalone','Cortilet,Delmeson,Efflumidex,FML Forte,FML Liquifi','','',''),('PA164781356','bepotastine','Bepotastine besilate,Betotastine besilate,TAU-284DS,bepotastine','Talion','Drug/Small Molecule','DailyMed:adba6255-f2be-4958-9e95-93000aff74f6,TTD:DCL000719,chemSpider:2260,drugBank:DB04890,keggDrug:D01654,ndc:67425-007-75,pubChemCompound:2350,pubChemSubstance:46504940,pubChemSubstance:5424487',''),('PA164781360','acetophenazine','','Tindal','Drug/Small Molecule','TTD:DAP000844,chebi:2401,drugBank:DB01063,keggCompound:C06807,pubChemCompound:441185,pubChemSubstance:9026,url:http://en.wikipedia.org/wiki/Acetophenazine','CC(=O)c1ccc2c(c1)N(c3ccccc3S2)CCCN4CCN(CC4)CCO'),('PA164781361','carprofen','2-(6-Chloro-9H-carbazol-2-yl)propanoic acid,6-Chloro-alpha-methyl-9H-carbazole-2-acetic acid,6-Chloro-alpha-methylcarbazole-2-acetic acid,Carprofene [','Ridamyl,Rimadyl','Drug/Small Molecule','TTD:DAP000975,bindingDb:50097346,chebi:364453,chemSpider:2483,dpd:2246557,drugBank:DB00821,pubChemCompound:2581,pubChemSubstance:181659,pubChemSubstance:46505357,url:http://en.wikipedia.org/wiki/Carprofen',''),('PA164781371','travoprost','','Travatan,Travatan Z','Drug/Small Molecule','TTD:DAP000274,chebi:746859,chemSpider:4445407,dpd:2244896,drugBank:DB00287,keggDrug:D01964,ndc:0065-0266-25,pubChemCompound:5282226,pubChemSubstance:46507637,pubChemSubstance:7849026,url:http://en.wikipedia.org/wiki/Travoprost',''),('PA164781375','ibritumomab','Ig gamma-2A chain C region, membrane-bound form,radiolabeled murine anti-CD20','Zevalin','Drug/Small Molecule','TTD:DAP000383,drugBank:DB00078,genBank:J00470,uniProtKb:P01865,url:http://en.wikipedia.org/wiki/Ibritumomab',''),('PA164781385','dinoprost tromethamine','Dinoprost, trometamol salt,PGF2-alpha THAM,PGF2alpha THAM,Prostaglandin F2-alpha THAM,Prostaglandin F2a tromethamine,Prostaglandin F2alpha tham,Prosti','Dinolytic,Ensaprost,Lutalyse,Panacelan F trometham','Drug/Small Molecule','TTD:DAP000826,chemSpider:4445570,dpd:813605,drugBank:DB01160,keggDrug:D01352,pubChemCompound:5282415,pubChemSubstance:213676,pubChemSubstance:46509164',''),('PA164781386','flavoxate','Flavoxate HCI,Flavoxate HCL','Urispas','Drug/Small Molecule','DailyMed:a9c44c4b-5b3c-45bf-9bc9-ce858e3d06c5,TTD:DAP001114,chebi:5088,chemSpider:3237,dpd:2245480,drugBank:DB01148,keggCompound:C07809,ndc:0574-0115-01,pubChemCompound:3354,pubChemSubstance:10011,pubChemSubstance:46505138,url:http://en.wikipedia.org/wiki/Flavoxate',''),('PA164781387','pegfilgrastim','G-CSF,Granulocyte colony-stimulating factor precursor,Lenograstim,Pluripoietin','Neulasta','Drug/Small Molecule','DailyMed:fdfe5d72-6b80-435a-afa4-c5d74dd852ce,TTD:DAP000395,dpd:2249790,drugBank:DB00019,genBank:X03438,ndc:55513-190-01,uniProtKb:P09919,url:http://en.wikipedia.org/wiki/Pegfilgrastim',''),('PA164781394','pramlintide','Pramlintide acetate,pramlintide','Symlin','Drug/Small Molecule','DailyMed:d2262f20-bedb-43d9-b274-6ce275b0a69e,TTD:DCL000936,drugBank:DB01278,keggDrug:D05595,ndc:66780-115-02,url:http://en.wikipedia.org/wiki/Pramlintide',''),('PA164781398','isopropamide','2,2-Diphenyl-4-diisopropylaminobutyramide methiodide,4-(Diisopropylamino)-2,2-diphenylbutyramide methiodide,Chloroisopropamide,Isopropamide iodide,Iso','Darbid,Dipramid,Dipramide,Isamid,Marygin-M,Piaccam','Drug/Small Molecule','chemSpider:3643,drugBank:DB01625,keggCompound:C07055,pubChemCompound:3775,pubChemSubstance:46507726,pubChemSubstance:9267,url:http://en.wikipedia.org/wiki/Isopropamide_iodide',''),('PA164781399','ciclesonide','ciclesonide','Alvesco','Drug/Small Molecule','DailyMed:a1a31258-d164-4369-91f0-52900bbd1509,TTD:DAP000423,chemSpider:392056,dpd:2285606,drugBank:DB01410,keggDrug:D01703,ndc:63402-711-01,pubChemCompound:444033,pubChemSubstance:10299472,pubChemSubstance:46508553,url:http://en.wikipedia.org/wiki/Ciclesonide',''),('PA164781400','chlorprothixene','Alpha-Chlorprothixene,CPT,CPX,Chloroprothixene,Chlorprothixen,Chlorprothixine,Chlorprotixen,Chlorprotixene,Chlorprotixine,Chlothixen,Cis-Chlorprothixe','Iaractan,Paxyl,Rentovet,Tactaran,Taractan,Tarasan,','Drug/Small Molecule','TTD:DAP000833,chebi:3651,drugBank:DB01239,keggCompound:C07953,keggDrug:D00790,pubChemCompound:2729,pubChemSubstance:10154,url:http://en.wikipedia.org/wiki/Chlorprothixene','CN(C)CCC=C1c2ccccc2Sc3c1cc(cc3)Cl'),('PA164783479','divalproex sodium','Divalproex sodium,Valproate semisodium','Depakote,Depakote CP,Depakote ER,Depakote Sprinkle','Drug/Small Molecule','drugBank:DB00510,keggDrug:D00304,pubChemCompound:53519,pubChemSubstance:7847370,url:http://en.wikipedia.org/wiki/Divalproex_sodium','[Na+].CCCC(CCC)C(O)=O.CCCC(CCC)C([O-])=O'),('PA164783790','pimecrolimus','ASM 981,SDZ ASM 981,pimecrolimus','Elidel','Drug/Small Molecule','DailyMed:d8b4ec77-5f93-4a4f-9a4c-ee0767ac6ac5,TTD:DAP000594,dpd:2247238,drugBank:DB00337,ndc:0078-0375-46,pubChemCompound:17753757,pubChemCompound:6447131,pubChemSubstance:3859844,pubChemSubstance:46505748,url:http://en.wikipedia.org/wiki/Pimecrolimus',''),('PA164783809','rifapentine','Cyclopentyl rifampin','Priftin','Drug/Small Molecule','DailyMed:f768e337-a948-420a-9fbe-9be359c7a170,HET:RPT,TTD:DAP000426,chebi:8861,chemSpider:4883449,drugBank:DB01201,keggCompound:C08059,keggDrug:D00879,ndc:0088-2100-03,pdb:RPT,pubChemCompound:6323497,pubChemSubstance:46507322,url:http://en.wikipedia.org/wiki/Rifapentine',''),('PA164783810','solifenacin','solifenacin succinate','Vesicare,Vesikur','Drug/Small Molecule','DailyMed:9acee910-cdb2-4052-b8b3-c26aff1c8716,TTD:DAP001129,chemSpider:187603,dpd:2277263,drugBank:DB01591,ndc:51248-150-01,pubChemCompound:216457,pubChemSubstance:12015109,pubChemSubstance:46506006,url:http://en.wikipedia.org/wiki/Solifenacin',''),('PA164783811','metixene','Methixen [German],Methixene,Methixene hydrochloride,Metisene [DCIT],Metixene hydrochloride,Metixeno [INN-Spanish],Metixenum [INN-Latin]','Atosil,Contalyl,Methixart,Tremaril,Tremaril hydroc','Drug/Small Molecule','TTD:DAP000346,chebi:51024,chemSpider:4023,drugBank:DB00340,keggDrug:D01871,pubChemCompound:4167,pubChemSubstance:46508970,pubChemSubstance:551137,url:http://en.wikipedia.org/wiki/Metixene',''),('PA164783812','heptabarbital','heptabarb,heptabarbitone,heptabarbum,heptadorm,heptamal,heptamalum,heptbarbital,medapan,medomine','','Drug/Small Molecule','TTD:DAP001032,chebi:16130,chebi:588074,chemSpider:10081,drugBank:DB01354,keggCompound:C04623,keggCompound:C17725,pubChemCompound:10518,pubChemSubstance:10454744,pubChemSubstance:46508321,url:http://en.wikipedia.org/wiki/Heptabarbital','CCC1(C(=O)NC(=O)NC1=O)C2=CCCCCC2'),('PA164783813','adinazolam','Adinazolamum [INN-Latin]','Deracyn','Drug/Small Molecule','TTD:DAP001251,chebi:251412,chemSpider:34519,drugBank:DB00546,keggDrug:D02770,pubChemCompound:37632,pubChemSubstance:178987,pubChemSubstance:46509054,url:http://en.wikipedia.org/wiki/Adinazolam','CN(C)Cc1nnc2n1-c3ccc(cc3C(=NC2)c4ccccc4)Cl'),('PA164783814','l-ornithine','(s)-2,5-diaminopentanoate,(s)-2,5-diaminopentanoic acid,(s)-2,5-diaminovaleric acid,(s)-ornithine,2,5-Diaminopentanoate,2,5-Diaminopentanoic acid,2,5-','OKG','Drug/Small Molecule','HET:ORN,chebi:15729,chebi:18257,chemSpider:6026,drugBank:DB00129,iupharLigand:725,keggCompound:C01602,pdb:ORN,pubChemCompound:6262,pubChemSubstance:46505239,pubChemSubstance:8143361',''),('PA164783947','choriogonadotropin alfa','CG-beta,Choriogonadotropin beta chain precursor,Chorionic gonadotrophin beta subunit','Novarel,Ovidrel,Pregnyl,Profasi','Drug/Small Molecule','DailyMed:a683e58a-63ea-44b8-a326-1a99a537bcf2,TTD:DAP001030,dpd:2262088,drugBank:DB00097,genBank:J00117,ndc:44087-1150-1,uniProtKb:P01233,url:http://en.wikipedia.org/wiki/Choriogonadotropin_alfa',''),('PA164783957','quinidine barbiturate','','','Drug/Small Molecule','TTD:DAP000915,drugBank:DB01346','CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=C1)N=CC=C2C(O)C1CC2CCN1CC2C=C'),('PA164783958','alemtuzumab','alemtuzumab','Campath,MabCampath','Drug/Small Molecule','TTD:DAP000385,dpd:2273993,drugBank:DB00087,ndc:50419-357-03,pubChemSubstance:533268,url:http://en.wikipedia.org/wiki/Alemtuzumab',''),('PA164783990','interferon alfa-2b, recombinant','Interferon alfa-2b,rIFN-alpha-2b','Intron A','Drug/Small Molecule','DailyMed:fd653d74-48ab-49e4-a42d-ec1cbc59badb,TTD:DAP001285,dpd:2240695,drugBank:DB00105,ndc:0085-0571-02,uniProtKb:P01563',''),('PA164783998','iodixanol','Indixanol,Iodixanolum','Visipaque,Visipaque 270,Visipaque 320','Drug/Small Molecule','DailyMed:e9d87b8c-7695-4c0f-8e81-000dedb5f66d,chemSpider:3593,dpd:2145766,drugBank:DB01249,keggDrug:D01474,ndc:0407-2222-01,pubChemCompound:3724,pubChemSubstance:11466876,pubChemSubstance:46504687,url:http://en.wikipedia.org/wiki/Iodixanol',''),('PA164783999','acepromazine','10-(3-dimethylaminopropyl)phenothiazin-3-yl methyl ketone,10-(3-dimethylaminopropyl)phenothiazine-3-ethylone,ACP,Ace,Acetylpromazine','Acezine 2,Atravet','Drug/Small Molecule','HET:PMZ,chebi:44932,chemSpider:5852,drugBank:DB01614,keggDrug:D02604,pdb:PMZ,pubChemCompound:6077,pubChemSubstance:26697123,pubChemSubstance:46508205,url:http://en.wikipedia.org/wiki/Acepromazine','CC(=O)c1ccc2c(c1)N(c3ccccc3S2)CCCN(C)C'),('PA164784000','antrafenine','','','Drug/Small Molecule','chemSpider:61973,drugBank:DB01419,pubChemCompound:68723,pubChemSubstance:15012903,pubChemSubstance:46507354,url:http://en.wikipedia.org/wiki/Antrafenine',''),('PA164784001','procyclidine','Prociclidina [INN-Spanish],Procyclidinum [INN-Latin]','Arpicolin,Elorine,Kemadrin,Kemadrine,Lergine,Metan','Drug/Small Molecule','TTD:DAP001110,chebi:8448,chemSpider:4750,dpd:587354,drugBank:DB00387,keggCompound:C07378,ndc:61570-059-01,pubChemCompound:4919,pubChemSubstance:46505553,pubChemSubstance:9582,url:http://en.wikipedia.org/wiki/Procyclidine','c1ccc(cc1)C(CCN2CCCC2)(C3CCCCC3)O'),('PA164784002','sertindole','Sertindol [inn-spanish],Sertindolum [inn-latin]','Serdolect,Serlect','Drug/Small Molecule','TTD:DAP000832,chebi:9122,chemSpider:54229,drugBank:DB06144,iupharLigand:98,keggCompound:C07567,keggDrug:D00561,pubChemCompound:60149,pubChemSubstance:46504717,pubChemSubstance:7847627,url:http://en.wikipedia.org/wiki/Sertindole','c1cc(ccc1n2cc(c3c2ccc(c3)Cl)C4CCN(CC4)CCN5CCNC5=O)F'),('PA164784021','ethambutol','Aethambutolum,D-Ethambutol,EMB,Etambutol [INN-Spanish],Etambutolo [DCIT],Ethambutol HCL,Ethambutol Hydrochloride,Ethambutol dihydrochloride,Ethambutol','Dadibutol,Diambutol,Etibi,Myambutol,Tibutol','Drug/Small Molecule','DailyMed:b9487a8c-5b28-4592-a994-3e378635983f,TTD:DAP000055,bindingDb:50204422,chebi:4877,dpd:247960,drugBank:DB00330,keggCompound:C06984,ndc:0555-0923-02,pubChemCompound:3279,pubChemSubstance:9198,url:http://en.wikipedia.org/wiki/Ethambutol','CCC(CO)NCCNC(CC)CO'),('PA164784022','chlorphenesin','Chlorophenesin,Chlorphenesine [INN-French],Chlorphenesinum [INN-Latin],Clorfenesina [INN-Spanish],alpha-Glyceryl ether,p-Chlorophenyl,p-Chlorophenyl g','Adermykon,Demykon,Gechophen,Gecophen,Maolate,Mycil','','',''),('PA164784023','paromomycin','Aminosidin,Aminosidine,Paramomycin sulfate,paromomycin','Humatin','Drug/Small Molecule','TTD:DAP000407,chemSpider:145115,dpd:2078759,drugBank:DB01421,ndc:61570-529-10,pubChemCompound:165580,pubChemSubstance:10255961,pubChemSubstance:46505391,url:http://en.wikipedia.org/wiki/Paromomycin_sulfate',''),('PA164784024','peginterferon alfa-2b','','PEG-Intron,Unitron PEG','Drug/Small Molecule','DailyMed:0a8f3137-0e3a-4a60-a872-cb7d761b30e1,TTD:DAP001279,dpd:2242966,drugBank:DB00022,ndc:0085-1323-01,uniProtKb:P01563,url:http://en.wikipedia.org/wiki/Peginterferon_alfa-2b',''),('PA164784025','entecavir','entecavir','Baraclude','Drug/Small Molecule','DailyMed:046e61c9-9298-4b2e-b76e-b26b81fecd20,TTD:DAP000697,chemSpider:135679,dpd:2282224,drugBank:DB00442,keggDrug:D04008,ndc:0003-1611-12,pubChemCompound:153941,pubChemSubstance:46504864,pubChemSubstance:641041,url:http://en.wikipedia.org/wiki/Entecavir',''),('PA164784026','doxapram','','Dopram,Doxapram HCL,Doxapram hydrochloride,Stimule','Drug/Small Molecule','DailyMed:7bdc52a1-4c3f-4b84-a7e8-4df0c5af0cce,TTD:DAP001295,chebi:681848,chemSpider:3044,dpd:1914154,drugBank:DB00561,keggDrug:D01872,ndc:55390-035-01,pubChemCompound:3156,pubChemSubstance:152600,pubChemSubstance:46506829,url:http://en.wikipedia.org/wiki/Doxapram','CCN1CC(C(C1=O)(c2ccccc2)c3ccccc3)CCN4CCOCC4'),('PA164784027','gadodiamide','Gadodiamide hydrate','Omniscan','Drug/Small Molecule','DailyMed:1e9a37e2-f28a-4373-bf0f-3e9b60f42d8a,chemSpider:54756,dpd:2172771,drugBank:DB00225,keggCompound:C13106,keggDrug:D01645,ndc:0407-0690-05,pubChemCompound:60754,pubChemSubstance:46504789,pubChemSubstance:7848708,url:http://en.wikipedia.org/wiki/Gadodiamide',''),('PA164784028','methyl aminolevulinate','5-Aminolevulinic acid methyl ester,Aminolevulinic acid methyl ester','Metvix','Drug/Small Molecule','DailyMed:a71a83c2-2289-4e9a-b15f-1bea81d49aa0,TTD:DAP001024,chebi:724125,chemSpider:138950,drugBank:DB00992,ndc:0299-6300-02,pubChemCompound:157922,pubChemSubstance:46507004,pubChemSubstance:791577,url:http://en.wikipedia.org/wiki/Methyl_aminolevulinate','COC(=O)CCC(=O)CN'),('PA164784029','insulin-aspart','aspart,aspart insulin,b28-aspart-insulin,ina-x14,insulin x14,insulin, asp(b28)','NovoLog,NovoRapid,NovoRapid Penfill,Novolog FlexPe','Drug/Small Molecule','DailyMed:3a1e73a2-3009-40d0-876c-b4cb2be56fc5,TTD:DAP001092,drugBank:DB01306,keggDrug:D04475,ndc:0169-7501-11,url:http://en.wikipedia.org/wiki/Insulin_aspart',''),('PA164784030','methohexital','Methodrexitone,Methohexitone','Brevital,Brevital sodium,Brietal','Drug/Small Molecule','DailyMed:eccd8340-ead3-4363-8902-0c19d33aa2ac,TTD:DAP000677,chebi:102216,chemSpider:8683,dpd:128678,drugBank:DB00474,keggCompound:C07844,keggDrug:D04985,ndc:42023-105-01,pubChemCompound:9034,pubChemSubstance:10046,pubChemSubstance:46507954,url:http://en.wikipedia.org/wiki/Methohexital',''),('PA164784031','phenindione','','Athrombon,Bindan,Cronodione,Danedion,Danilon,Danil','Drug/Small Molecule','TTD:DAP000769,chebi:8066,chemSpider:4596,drugBank:DB00498,keggCompound:C07584,pubChemCompound:4760,pubChemSubstance:46505018,pubChemSubstance:9786,url:http://en.wikipedia.org/wiki/Phenindione','c1ccc(cc1)C2C(=O)c3ccccc3C2=O'),('PA164784032','methylscopolamine','Epoxymethamine Bromide,Epoxytropine Tropate Methylbromide,Hyoscine Methobromide,Hyoscine Methylbromide,Lescopine Bromide,Methoscopylamine Bromide,Meth','Ampyrox,Blocan,Daipin,Diopal,Holopon,Mescopil,Neo-','','',''),('PA164784033','cefotetan','Cefotetanum [inn-latin]','Cefotan,Yamatetan','Drug/Small Molecule','DailyMed:56912a83-4cba-4461-d983-3a0656515458,DailyMed:a71fbab2-1d12-4392-f78b-e8b94212b413,TTD:DAP000451,chebi:3499,drugBank:DB01330,keggCompound:C06886,keggDrug:D00260,ndc:0310-0376-31,pubChemCompound:50614,pubChemSubstance:11011827,url:http://en.wikipedia.org/wiki/Cefotetan','Cn1c(nnn1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)O)S4)OC)SC2)C(=O)O'),('PA164784034','fenoldopam','Fenodopam mesylate,Fenoldopam mesylate,Fenoldopamum [Latin]','Corlopam','Drug/Small Molecule','DailyMed:7b5f7dd0-0bfc-4da4-9619-4fd0afeb98a7,DailyMed:e7d44c5a-0b20-45be-8b56-099ea883662d,TTD:DAP000254,chebi:5002,chemSpider:3224,drugBank:DB00800,keggDrug:D00613,ndc:55390-071-01,pubChemCompound:3341,pubChemSubstance:188303,pubChemSubstance:46504963,url:http://en.wikipedia.org/wiki/Fenoldopam','c1cc(ccc1C2CNCCc3c2cc(c(c3Cl)O)O)O'),('PA164784035','secobarbital','(+/-)-Secobarbital,Secobarbital Sodium,Secobarbitale [DCIT],Secobarbitalum [INN-Latin],Sodium Secobarbital,Sodium quinalbarbitone','Barbosec,Bipanal,Bipinal sodium,Evronal,Evronal So','Drug/Small Molecule','DailyMed:6698bc44-b971-49cc-a5de-11e569493c59,TTD:DAP000674,chebi:9073,dpd:21032,drugBank:DB00418,keggDrug:D00430,ndc:63304-679-01,pubChemCompound:31143,pubChemSubstance:173168,url:http://en.wikipedia.org/wiki/Secobarbital',''),('PA164784036','betazole','Ametazole,Betazol [INN-Spanish],Betazolo [DCIT],Betazolum [INN-Latin]','Histalog','Drug/Small Molecule','TTD:DAP001081,chebi:59170,chemSpider:7455,drugBank:DB00272,pubChemCompound:7741,pubChemSubstance:10503079,pubChemSubstance:46506808,url:http://en.wikipedia.org/wiki/Betazole','c1cn[nH]c1CCN'),('PA164888966','Raltegravir','','','Drug/Small Molecule','',''),('PA164920420','Olaparib','','','Drug/Small Molecule','',''),('PA164924486','st. john\'s wort','','','Drug/Small Molecule','dpd:2119897,drugBank:DB01323,url:http://en.wikipedia.org/wiki/St_John%27s_wort',''),('PA164924487','aldosterone','(+)-aldosterone,11beta,21-Dihydroxy-3,20-diketo-4-pregnen-18-al,11beta,21-Dihydroxy-3,20-diketopregn-4-ene-18-al,11beta,21-Dihydroxypregn-4-ene-3,18,2','','Drug/Small Molecule','chebi:27584,chemSpider:5633,drugBank:DB04630,keggCompound:C01780,pdb:AS4,pubChemCompound:5839,pubChemSubstance:46505770,pubChemSubstance:7885975,url:http://en.wikipedia.org/wiki/Aldosterone','C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@H]4C(=O)CO)C=O)O'),('PA164924491','cilengitide','','','Drug/Small Molecule','',''),('PA164924492','brivanib','','','Drug/Small Molecule','',''),('PA164924493','axitinib','','','Drug/Small Molecule','',''),('PA164924560','Biricodar','','Incel,VX-170','Drug/Small Molecule','pubChemCompound:3037617',''),('PA164924561','Celiprolol','','','Drug/Small Molecule','',''),('PA164924562','Elacridar','','','Drug/Small Molecule','',''),('PA164924563','OC144-093','','','Drug/Small Molecule','',''),('PA164924564','R101933','','','Drug/Small Molecule','',''),('PA164924565','Valspodar','','','Drug/Small Molecule','',''),('PA164924566','XR9051','','','Drug/Small Molecule','',''),('PA164924567','Zosuquidar','','','Drug/Small Molecule','',''),('PA164953212','norelgestromin','','Orthra Evra','Drug/Small Molecule','',''),('PA165107052','Rupatadine','','Alergoliber,Rupafin,Rupatall,Tamalis,Wystamm','Drug/Small Molecule','pubChemCompound:133017',''),('PA165107055','certolizumab pegol','CDP870','cimzia','Drug/Small Molecule','pubChemSubstance:10549841,url:http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11450',''),('PA165107062','CP-800,569','','','Drug/Small Molecule','',''),('PA165107357','chlorcycloguanil','','','Drug/Small Molecule','',''),('PA165107975','fructose 1,6 bisphosphate','','','Drug/Small Molecule','',''),('PA165107990','myclobutanil','','','Drug/Small Molecule','',''),('PA165107991','propiconazole','','','Drug/Small Molecule','',''),('PA165107992','triadimefon','','','Drug/Small Molecule','',''),('PA165109541','aminopterin','4-Aminofolic acid,4-Aminopteroyl-L-glutamic acid,Aminopterin sodium,Aminopteroylglutamic acid','','Drug/Small Molecule','pubChemCompound:2154',''),('PA165109542','talotrexin','','','Drug/Small Molecule','',''),('PA165109623','staurosporine','STS,antibiotic AM-2282','','Drug/Small Molecule','bindingDb:2579,chebi:15738,chemSpider:5089,drugBank:DB02010,keggCompound:C02079,pdb:STO,pubChemCompound:44120114,pubChemCompound:5280487,pubChemSubstance:46504923',''),('PA165109660','genistein','4\',5,7-Trihydroxyisoflavone','Differenol A,Genisteol,Genisterin,Prunetol,Sophori','Drug/Small Molecule','pubChemCompound:5280961',''),('PA165109661','MK-571','','','Drug/Small Molecule','',''),('PA165110351','Dabigatran','','','Drug/Small Molecule','',''),('PA165110439','Ixabepilone','','','Drug/Small Molecule','',''),('PA165110729','rhodamine 123','','','Drug/Small Molecule','',''),('PA165110775','SN-38','','','Drug/Small Molecule','',''),('PA165110778','Tipifarnib','','','Drug/Small Molecule','',''),('PA165111677','Cremophor EL','','','Drug/Small Molecule','',''),('PA165111696','artemisinin','','','Drug/Small Molecule','pubChemCompound:68827',''),('PA165111697','artesunate','','','Drug/Small Molecule','pubChemCompound:5464098',''),('PA165111698','artemether','dihydroartemisinin methyl ether','','Drug/Small Molecule','pubChemCompound:9796294',''),('PA165111722','lumefantrine','benflumetol','','Drug/Small Molecule','DailyMed:7866ec19-dfac-47d4-a53f-511a12643cbf,pubChemCompound:6437380',''),('PA165260403','arteether','','','Drug/Small Molecule','pubChemCompound:72416',''),('PA165282096','Tariquidar','','','Drug/Small Molecule','',''),('PA165282097','Bromperidol','','','Drug/Small Molecule','',''),('PA165290925','Vicodin','','','Drug/Small Molecule','',''),('PA165290926','fluticasone/salmeterol','','Advair Diskus','Drug/Small Molecule','',''),('PA165290927','acetaminophen/propoxyphene napsylate','','Darvocet','Drug/Small Molecule','',''),('PA165290928','drospirenone/ethinyl estradiol','','Yaz','Drug/Small Molecule','',''),('PA165290929','norelgestromin/ethinyl estradiol','','Ortho Evra','Drug/Small Molecule','',''),('PA165290930','medroxyprogesterone/conjugated estrogens','','Prempro','Drug/Small Molecule','',''),('PA165290931','Nutlin-3','','','Drug/Small Molecule','',''),('PA165290932','MI-63','','','Drug/Small Molecule','pubChemCompound:11512578',''),('PA165290933','Pertuzumab','Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer,LS','','Drug/Small Molecule','pubChemSubstance:47207115',''),('PA165291442','ertumaxomab','','','Drug/Small Molecule','',''),('PA165291460','DPCPX','','','Drug/Small Molecule','',''),('PA165291471','perifosine','','','Drug/Small Molecule','',''),('PA165291472','neratinib','','','Drug/Small Molecule','',''),('PA165291473','maytansine','','','Drug/Small Molecule','',''),('PA165291474','BSI-201','','','Drug/Small Molecule','',''),('PA165291475','ridaforolimus','','','Drug/Small Molecule','',''),('PA165291490','tanespimycin','','','Drug/Small Molecule','',''),('PA165291491','alvespimycin','','','Drug/Small Molecule','',''),('PA165291492','pazopanib','','','Drug/Small Molecule','',''),('PA165291493','ofatumumab','','','Drug/Small Molecule','',''),('PA165291498','elvitegravir','','','Drug/Small Molecule','',''),('PA165291499','GS-9350','','','Drug/Small Molecule','',''),('PA165291546','perospirone','','','Drug/Small Molecule','pubChemCompound:115367',''),('PA165291838','Resveratrol','','','Drug/Small Molecule','',''),('PA165291843','resveratrol','(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol,(E)-5-(p-Hydroxystyryl)resorcinol,(E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol,(E)-5-[2-(4-hy','','Drug/Small Molecule','bindingDb:23926,chebi:27881,chemSpider:4880,drugBank:DB02709,keggCompound:C03582,pdb:STL,pubChemCompound:445154,pubChemSubstance:46504705,pubChemSubstance:6374,url:http://en.wikipedia.org/wiki/Resveratrol',''),('PA165291889','silodosin','','','Drug/Small Molecule','',''),('PA165291922','doxorubicinol','','','Drug/Small Molecule','',''),('PA165291923','doxorubicin seminquinone radical','','','Drug/Small Molecule','',''),('PA165291924','7-deoxydoxorubicinone','','','Drug/Small Molecule','',''),('PA165291925','doxorubicinol aglycone','','','Drug/Small Molecule','',''),('PA165291926','doxorubicin hydroxyaglycone','','','Drug/Small Molecule','',''),('PA165292659','tocilizumab','','','Drug/Small Molecule','',''),('PA165360203','Benserazide','','','Drug/Small Molecule','pubChemCompound:2327,pubChemSubstance:17397237',''),('PA165360204','Nepicastat','','','Drug/Small Molecule','pubChemCompound:6367078,pubChemSubstance:3853882',''),('PA165374637','Oltipraz','','','Drug/Small Molecule','',''),('PA165374638','Noscapine','','','Drug/Small Molecule','',''),('PA165374673','ticagrelor','','','Drug/Small Molecule','pubChemCompound:9871419',''),('PA165815771','Farglitazar','','','Drug/Small Molecule','',''),('PA165816878','methylcholanthrene','','','Drug/Small Molecule','',''),('PA165816891','LY2140023','LY2140023','','Drug/Small Molecule','pubChemCompound:25195354',''),('PA165817196','carbamazepine epoxide','Carbamazepine 10,11-epoxide','','Drug/Small Molecule','pubChemCompound:2555',''),('PA165817197','3-hydroxycarbamazepine','','','Drug/Small Molecule','pubChemCompound:135290',''),('PA165817198','10,11-dihydro-10,11-dihydroxy-5h-dibenzazepine-5-carboxamide','CBZ diol,carbamazepine diol,cbz-diol','','Drug/Small Molecule','pubChemCompound:83852',''),('PA165817199','carbamazepine glucuronide','','','Drug/Small Molecule','pubChemCompound:83870',''),('PA165817200','2-hydroxycarbamazepine','','','Drug/Small Molecule','pubChemCompound:129274',''),('PA165817516','1,25-dihydroxyvitamin d3','','','Drug/Small Molecule','',''),('PA165817936','desmethylastemizole','','','Drug/Small Molecule','pubChemCompound:155805',''),('PA165817938','prenylamine','','','Drug/Small Molecule','',''),('PA165817939','pyrilamine','','','Drug/Small Molecule','pubChemCompound:4992',''),('PA165817950','terodiline','','','Drug/Small Molecule','pubChemCompound:23480',''),('PA165818137','lidoflazine','','','Drug/Small Molecule','pubChemCompound:3926',''),('PA165820585','1,7-dimethylxanthine','17X,paraxanthine','','Drug/Small Molecule','pubChemCompound:4687',''),('PA165823907','hydroxyphenytoin','5-(4?-hydroxyphenyl)-5-phenylhydantoin,p-HPPH','','Drug/Small Molecule','pubChemCompound:17732',''),('PA165823908','5-phenyl-5-(4-hydroxyphenyl)hydantoin glucuronide','hydroxyphenytoin glucuronide,p-HPPH glucuronide','','Drug/Small Molecule','pubChemCompound:135250',''),('PA165857067','chlorproguanil','','','Drug/Small Molecule','pubChemCompound:9571037',''),('PA165858618','3-aminopyridine-2-carboxaldehyde thiosemicarbazone','','','Drug/Small Molecule','pubChemCompound:9571836',''),('PA165860521','ambrisentan','','','Drug/Small Molecule','',''),('PA165860788','evodiamine','','','Drug/Small Molecule','',''),('PA165860812','berberine','','','Drug/Small Molecule','chebi:16118,drugBank:DB04115,keggCompound:C00757,keggDrug:D00092,pdb:BER,pubChemCompound:2353,pubChemSubstance:46506051','COC1=CC=C2C=C3C4=CC5=C(OCO5)C=C4CC[N+]3=CC2=C1OC'),('PA165884699','darapladib','','','Drug/Small Molecule','pubChemCompound:9939609',''),('PA165906891','cabozantinib','XL-184','','Drug/Small Molecule','',''),('PA165945763','cangrelor','','','Drug/Small Molecule','pubChemCompound:9854012',''),('PA165945764','bucindolol','','','Drug/Small Molecule','pubChemCompound:51045',''),('PA165945765','3-((6-amino-(4-chlorobenzenesulfonyl)-2-methyl-5,6,7,8-tetrahydronapht)-1-yl)propionic acid','terutroban','','Drug/Small Molecule','pubChemCompound:23674098',''),('PA165946121','fasudil','','','Drug/Small Molecule','',''),('PA165946122','crizotinib','crizotinib','Xalkori','Drug/Small Molecule','pubChemCompound:11626560',''),('PA165946719','10-hydroxynortriptyline','','','Drug/Small Molecule','',''),('PA165946746','desmethylnortriptyline','','','Drug/Small Molecule','pubChemCompound:160755',''),('PA165946747','10-hydroxyamitriptyline','','','Drug/Small Molecule','pubChemCompound:6420900',''),('PA165946873','vemurafenib','PLX4032','Zelboraf','Drug/Small Molecule','pubChemCompound:42611257',''),('PA165947475','eslicarbazepine','','','Drug/Small Molecule','',''),('PA165947499','ilaprazole','','','Drug/Small Molecule','pubChemCompound:214351',''),('PA165947835','dichloroacetic acid','DCA,dichloroacetate','','Drug/Small Molecule','chebi:36386,drugBank:DB08809,keggCompound:C11149,url:http://en.wikipedia.org/wiki/Dichloroacetic_acid','OC(=O)C(Cl)Cl'),('PA165948031','cilomilast','','','Drug/Small Molecule','pubChemCompound:151170',''),('PA165948052','roflumilast','','','Drug/Small Molecule','pubChemCompound:449193',''),('PA165948902','boceprevir','n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3','','Drug/Small Molecule','pubChemCompound:10324367',''),('PA165948903','brentuximab vedotin','124490327,SGN-35,brentuximab vedotin','','Drug/Small Molecule','pubChemSubstance:124490327,pubChemSubstance:131277422',''),('PA165949675','pactimibe','','','Drug/Small Molecule','pubChemCompound:3081927',''),('PA165949694','iptakalim','','','Drug/Small Molecule','',''),('PA165949771','Glucarpidase','','','Drug/Small Molecule','',''),('PA165950341','ivacaftor','ivacaftor,vx-770','Kalydeco','Drug/Small Molecule','pubChemCompound:16220172',''),('PA165950342','phenylacetic acid','sodium phenylacetate','','Drug/Small Molecule','pubChemCompound:23690424',''),('PA165958321','3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one','( )-cis-3,5-Dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride,130841-70-2,158511-47-8,3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one,4-Thiazolidinone','','Drug/Small Molecule','pubChemCompound:178014',''),('PA165958341','insulin glargine','insulin glargine (rdna origin)','Lantus,Lantus SoloStar','Drug/Small Molecule','dpd:2245689,drugBank:DB00047,keggDrug:D03250,ndc:0088-2220-60',''),('PA165958342','estropipate','estropipate (usp),ogen,ogen (tn),ogen 2.5','ORTHO-EST,Ogen','Drug/Small Molecule','dpd:2089769,drugBank:DB04574,keggDrug:D00948,pubChemCompound:5284555,pubChemSubstance:46508976',''),('PA165958343','ixabepilone','aza-epothilone b,azaepothilone b,bms-247550','Ixempra','Drug/Small Molecule','chemSpider:4949236,drugBank:DB04845,keggDrug:D04645,pubChemCompound:23305354,pubChemSubstance:99443224',''),('PA165958345','nilotinib','amn-107,amn107','Tasigna','Drug/Small Molecule','chebi:52172,chemSpider:559260,drugBank:DB04868,pubChemCompound:644241,pubChemSubstance:99443226','Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F'),('PA165958346','vildagliptin','equa,galvus,jalra,laf 237,laf237,nvp-laf-237,nvp-laf237,xiliarx','Galvus','Drug/Small Molecule','bindingDb:11695,chemSpider:5293734,drugBank:DB04876,pubChemCompound:6918537,pubChemSubstance:99443227',''),('PA165958347','voacamine','mmh,voacanginine,vocamine','MMH','Drug/Small Molecule','chemSpider:10128230,drugBank:DB04877,keggCompound:C09252,pubChemCompound:11953931,pubChemSubstance:99443228',''),('PA165958348','indacaterol','5-(2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1h-quinolin-2-one','Arcapta,Onbrez','Drug/Small Molecule','drugBank:DB05039,keggDrug:D09318',''),('PA165958349','trabectedin','ecteinascidin,ecteinascidin 743,et-743,et743,nsc 684766','Yondelis','Drug/Small Molecule','chemSpider:97236,drugBank:DB05109,pubChemCompound:108150,pubChemSubstance:99443229',''),('PA165958350','ecabet','','Gastrom','Drug/Small Molecule','chemSpider:570992,drugBank:DB05265,keggDrug:D07885,pubChemCompound:65781,pubChemSubstance:99443230',''),('PA165958351','ibudilast','2-isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine,3-isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine,3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine,av-411','','Drug/Small Molecule','bindingDb:50240404,chemSpider:3543,drugBank:DB05266,pubChemCompound:3671,pubChemSubstance:99443231',''),('PA165958352','rotigotine transdermal patch','','Neupro','Drug/Small Molecule','bindingDb:50054062,chemSpider:51867,drugBank:DB05271,pubChemCompound:57537,pubChemSubstance:99443232',''),('PA165958353','interferon alpha-2b','','PEG-Intron','Drug/Small Molecule','',''),('PA165958354','telaprevir','aids-213006,aids213006,ly-570310,mp-424,vx-950','Incivek','Drug/Small Molecule','bindingDb:50212208,chemSpider:2279948,drugBank:DB05521,keggDrug:D09012,pubChemCompound:3010818',''),('PA165958355','preotact','hpth,hpth(1-84),parathormone (human recombinant),parathyroid hormone,parathyroid hormone (r.e.coli),pth(1-84),rhpth,rhpth(1-84),rpth,rpth(1-84)','Preos','Drug/Small Molecule','',''),('PA165958356','sulfathiazole','sodium sulfathiazole,sulphathiazole','Neo-Strepsan','Drug/Small Molecule','chebi:9337,drugBank:DB06147,keggCompound:C11169,keggDrug:D01047',''),('PA165958357','sulfadimethoxine','sulphadimethoxine','Agribon,Albon,Di-Methox','Drug/Small Molecule','chebi:32161,chemSpider:5132,drugBank:DB06150,pubChemCompound:5323,pubChemSubstance:99443234',''),('PA165958358','canakinumab','acz-885,acz885','Ilaris','Drug/Small Molecule','',''),('PA165958360','rivaroxaban','bay 59-7939','Xarelto','Drug/Small Molecule','',''),('PA165958361','sitaxentan','sitaxsentan,tbc-11251','Thelin','Drug/Small Molecule','bindingDb:50058126,chebi:123417,chemSpider:187436,drugBank:DB06268,keggDrug:D07171,pubChemCompound:216235,pubChemSubstance:99443241',''),('PA165958362','saxagliptin','bms-477118,onglyza','Onglyza','Drug/Small Molecule','DailyMed:ba48ac4b-9503-4006-f6e2-3b8a83059c03,chebi:618213,chemSpider:9419005,drugBank:DB06335,ndc:0003-4215-11,pubChemCompound:11243969,pubChemSubstance:99443245',''),('PA165958363','agomelatine','s-20098,s20098','Melitor,Valdoxan','Drug/Small Molecule','bindingDb:50035179,chemSpider:74141,drugBank:DB06594,keggDrug:D02578,pubChemCompound:82148',''),('PA165958364','liraglutide','nn 2211,nn2211','Victoza','Drug/Small Molecule','drugBank:DB06655,keggDrug:D06404',''),('PA165958365','vilazodone','sb 659746a','','Drug/Small Molecule','',''),('PA165958366','mepyramine','pyrilamine','','Drug/Small Molecule','chebi:6762,drugBank:DB06691,keggDrug:D08183',''),('PA165958368','xylometazoline','xylomethazoline','Otriven,Otrivin,Otrivine,Otrix','Drug/Small Molecule','bindingDb:50027068,chemSpider:5507,drugBank:DB06694,keggCompound:C07913,pubChemCompound:5709,pubChemSubstance:99443248',''),('PA165958369','dabigatran etexilate','dabigatran etexilate mesilate (salt form),ethyl 3-[[[4-[[[(hexyloxyl)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1h-benzimidazol-5-yl]car','Pradax,Pradaxa,Rendix','Drug/Small Molecule','chemSpider:4948999,drugBank:DB06695,keggDrug:D07144,pubChemCompound:6445226,pubChemSubstance:99443249',''),('PA165958370','arbekacin','arbekacina,arbekacine,arbekacinum,habekacin,haberacin','','Drug/Small Molecule','chebi:37922,drugBank:DB06696,keggDrug:D07462',''),('PA165958372','betahistine','','Serc','Drug/Small Molecule','chebi:35677,chemSpider:2276,drugBank:DB06698,keggDrug:D07522,pubChemCompound:2366,pubChemSubstance:99443252',''),('PA165958373','degarelix','','Firmagon','Drug/Small Molecule','drugBank:DB06699,keggDrug:D08901,pubChemCompound:44151801,pubChemSubstance:99443253',''),('PA165958374','desvenlafaxine','','Pristiq','Drug/Small Molecule','DailyMed:0f43610c-f290-46ea-d186-4f998ed99fce,bindingDb:50010875,chemSpider:111300,dpd:2321092,drugBank:DB06700,keggDrug:D02570,ndc:0008-1211-14,pubChemCompound:125017,pubChemSubstance:99443254',''),('PA165958376','fesoterodine','','Toviaz','Drug/Small Molecule','chemSpider:5293755,drugBank:DB06702,keggDrug:D07226,pubChemCompound:6918558,pubChemSubstance:99443256',''),('PA165958377','gadobutrol','','Gadovist','Drug/Small Molecule','drugBank:DB06703,pubChemCompound:15814656,pubChemSubstance:99443257',''),('PA165958378','gadofosveset trisodium','gadofosveset','Ablavar,Vasovist','Drug/Small Molecule','drugBank:DB06705,keggDrug:D04286',''),('PA165958379','isometheptene','','','Drug/Small Molecule','drugBank:DB06706,pubChemCompound:22297,pubChemSubstance:99443258',''),('PA165958380','levonordefrin','','Nordefrin','Drug/Small Molecule','bindingDb:50029048,drugBank:DB06707,pubChemCompound:164739,pubChemSubstance:99443259',''),('PA165958382','methacholine','','Provocholine','Drug/Small Molecule','chebi:6804,drugBank:DB06709,keggCompound:C07471,pubChemCompound:1993,pubChemSubstance:99443261',''),('PA165958383','methyltestosterone','17-methyltestosterone,17alpha-methyl-delta4-androsten-17beta-ol-3-one,17alpha-methyltestosterone','Android,Methitest,Testred,Virilon','Drug/Small Molecule','chebi:27436,drugBank:DB06710,keggCompound:C07198,keggDrug:D00408',''),('PA165958384','naphazoline','','Albalon','Drug/Small Molecule','bindingDb:50027061,drugBank:DB06711,keggDrug:D08253,pubChemCompound:4436,pubChemSubstance:99443263',''),('PA165958385','nilvadipine','','Nivadil','Drug/Small Molecule','bindingDb:50017328,drugBank:DB06712,keggDrug:D01908,pubChemCompound:4494,pubChemSubstance:99443264',''),('PA165958387','propylhexedrine','','Benzedrex,Dristan,Obesin','Drug/Small Molecule','drugBank:DB06714,keggDrug:D05637,pubChemCompound:7558,pubChemSubstance:99443266',''),('PA165958389','fospropofol','','Lusedra','Drug/Small Molecule','drugBank:DB06716,keggDrug:D04257,pubChemCompound:3038497,pubChemSubstance:99443268',''),('PA165958390','fosaprepitant','','Emend? IV','Drug/Small Molecule','drugBank:DB06717,keggDrug:D06597,pubChemCompound:219090,pubChemSubstance:99443269',''),('PA165958391','stanozolol','','Stromba,Winstrol,Winstrol Depot (intramuscular inj','Drug/Small Molecule','drugBank:DB06718,keggCompound:C07311,pubChemCompound:5277,pubChemSubstance:99443270',''),('PA165958393','aluminum hydroxide','','AlternaGel,Alu-Cap,Amphojel','Drug/Small Molecule','',''),('PA165958395','lornoxicam','acabel,chlortenoxicam,cltx,ctx,lorcam,lorcam (tn),lornoxicamum,lornoxicamum [inn-latin],safem,taigalor,telos,xefo,xefocam','Lorcam,Xafon','Drug/Small Molecule','chemSpider:4445392,drugBank:DB06725,keggDrug:D01866,pubChemCompound:5282204,pubChemSubstance:99443271',''),('PA165958397','gestodene','gestoden,gestodeno [inn-spanish],gestodenum [inn-latin]','','Drug/Small Molecule','chemSpider:2298532,drugBank:DB06730,pubChemCompound:3033968,pubChemSubstance:99443276',''),('PA165958398','drotaverine','drotaverin','Drotin,No-Spa','Drug/Small Molecule','chemSpider:1361582,drugBank:DB06751,pubChemCompound:1712095,pubChemSubstance:99443287',''),('PA165958399','alcaftadine','','Lastacaft','Drug/Small Molecule','chemSpider:14201635,drugBank:DB06766,keggDrug:D06552,ndc:68669-412-03,pubChemCompound:19371515,pubChemSubstance:99443288',''),('PA165958400','ammonium lactate','ammonium (+-)-lactate,lactic acid ammonium salt','Lac-Hydrin,Laclotion','Drug/Small Molecule','DailyMed:dc3a6462-0f2c-4306-b5ef-c7b47395e959,dpd:1909150,drugBank:DB06768,keggDrug:D02920,ndc:45802-419-54',''),('PA165958401','cabazitaxel','taxoid xrp6258','Jevtana','Drug/Small Molecule','DailyMed:de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,chemSpider:8029779,drugBank:DB06772,ndc:0024-5824-11,pubChemCompound:9854073,pubChemSubstance:99443289',''),('PA165958402','carglumic acid','(s)-2-ureidopentanedioic acid,n-carbamyl-l-glutamate','Carbaglu','Drug/Small Molecule','chemSpider:108351,drugBank:DB06775,pubChemCompound:121396,pubChemSubstance:99443290',''),('PA165958403','chenodeoxycholic acid','chenocholic acid,chenodesoxycholic acid,chenodiol','Chenix,Chenodal,Chenodiol','Drug/Small Molecule','DailyMed:bbb86251-9423-40e6-9117-9511ab5fbf63,chebi:16755,chemSpider:9728,drugBank:DB06777,keggCompound:C02528,keggDrug:D00163,ndc:0722-7121-01,pubChemCompound:10133,pubChemSubstance:99443291',''),('PA165958404','dalteparin','daltepariininatrium,dalteparin sodn? s?l,dalteparin sodyum,dalteparin-n?trium,dalteparina s?dica,dalteparinnatrium,dalteparino natrio druska,daltepari','Boxol,Eurodal,Fragmin,Ligoframin,Low Liquemine','Drug/Small Molecule','',''),('PA165958405','difluprednate','dfba,difluoroprednisolone butyrate acetate','Durezol','Drug/Small Molecule','chemSpider:391990,drugBank:DB06781,pubChemCompound:443936,pubChemSubstance:99443292',''),('PA165958406','dimercaprol','2,3-dimercapro,2,3-dimercaptopropanol,bal,british anti-lewisite','Bal In Oil Injection,Dimercaprol','Drug/Small Molecule','DailyMed:2ed1fc15-ca74-400e-bfdb-64483b2c590b,chebi:554382,chemSpider:2971,drugBank:DB06782,keggCompound:C02924,keggDrug:D00167,ndc:11098-526-03,pubChemCompound:3080,pubChemSubstance:99443293',''),('PA165958407','nepafenac','amfenac amide','Nevanac','Drug/Small Molecule','chemSpider:133160,drugBank:DB06802,keggDrug:D05143,ndc:0065-0002-01,pubChemCompound:151075,pubChemSubstance:99443294',''),('PA165958408','niclosamide','','Niclocide','Drug/Small Molecule','chemSpider:4322,drugBank:DB06803,keggDrug:D00436,pubChemCompound:4477,pubChemSubstance:99443295',''),('PA165958410','plerixafor','amd3100','Mozobil','Drug/Small Molecule','DailyMed:a56b1b78-0ae2-41b4-9c76-98ad9d439199,chebi:120346,chemSpider:58531,drugBank:DB06809,keggDrug:D08971,ndc:58468-0140-1,pubChemCompound:65015,pubChemSubstance:99443297',''),('PA165958411','plicamycin','mithramycin','Mithracin','Drug/Small Molecule','chebi:31856,drugBank:DB06810,keggCompound:C12389,keggDrug:D00468',''),('PA165958413','diloxanide','diloxanide furoate','','Drug/Small Molecule','chemSpider:18400,drugBank:DB08792',''),('PA165958414','azidocillin','','','Drug/Small Molecule','chebi:51758,drugBank:DB08795',''),('PA165958415','pipazethate','pipazetate','Theratuss','Drug/Small Molecule','chemSpider:21046,drugBank:DB08796,keggDrug:D05484',''),('PA165958416','salicylamide','o-hydroxybenzamide','','Drug/Small Molecule','',''),('PA165958417','sulfamoxole','sulfamoxol,sulfamoxolum,sulfono,sulphamoxole','Justamil,Sulfavigor,Sulfmidil,Tardamid,Vetranal','Drug/Small Molecule','chebi:55548,chemSpider:12361,drugBank:DB08798,keggDrug:D02516',''),('PA165958418','antazoline','phenazolin,phenazoline','Antastan,Antasten,Antihistal,Antistin,Histostab','Drug/Small Molecule','chebi:358709,chemSpider:2115,drugBank:DB08799,keggDrug:D07458',''),('PA165958419','chloropyramine','anaphylline,chlorpyramine,chlorpyraminum,halopyramine','Avapena,Suprastin,Synopen,Synpen','Drug/Small Molecule','HET:C4C,chemSpider:23628,drugBank:DB08800,keggDrug:D07195,pdb:C4C',''),('PA165958420','dimethindene','(?)-dimet?hindene,dimethylp?yrindene','Fengel,Fenistil,Foristal,Pecofenil,Triten','Drug/Small Molecule','chebi:126443,chemSpider:20541,drugBank:DB08801,keggDrug:D07853',''),('PA165958421','isothipendyl','isothipendylum','Actapront,Andanton,Nilergex,Odantol,Udantol','Drug/Small Molecule','chemSpider:3649,drugBank:DB08802,keggDrug:D08091',''),('PA165958422','tymazoline','pernazene','Thymazen','Drug/Small Molecule','chemSpider:31478,drugBank:DB08803,keggDrug:D07373',''),('PA165958423','nandrolone decanoate','norandrostenolone decanoate,nortestosterone decanoate','Deca Durabolin,Deca-Durabol,Deca-durabolin,Retabol','Drug/Small Molecule','TTD:DAP000903,chemSpider:9296,dpd:270687,drugBank:DB08804,keggCompound:C08154,keggDrug:D00955',''),('PA165958424','roxatidine acetate','aceroxatidine,pifatidine,roxatidina,roxatidine,roxatidinum','Roxit','Drug/Small Molecule','chemSpider:4926,drugBank:DB08806,keggDrug:D08495',''),('PA165958425','bopindolol','','Sandonorm','Drug/Small Molecule','chebi:355377,chemSpider:40146,drugBank:DB08807,keggDrug:D07537',''),('PA165958426','bupranolol','bupranol,bupranololum','Adomed,Betadrenol,Ophtorenin','Drug/Small Molecule','chebi:200929,chemSpider:2381,drugBank:DB08808,keggDrug:D07590',''),('PA165958427','cinitapride','','Blaston,Cidine,Cinmove,Cintapro,Paxapride,Pemix','Drug/Small Molecule','drugBank:DB08810,keggDrug:D07700',''),('PA165958428','tofisopam','tofizopam','Emandaxin,Grandaxin,Seriel','Drug/Small Molecule','chebi:518452,drugBank:DB08811,keggDrug:D01254',''),('PA165958430','triflusal','','','Drug/Small Molecule','',''),('PA165958431','hyaluronan','hyaluronate,hyaluronic acid,hyaluronic acid sodium salt,sodium hyaluronate','AMO Vitrax,AMVISIC Plus,Cystistar,Euflexxa,Goniler','Drug/Small Molecule','drugBank:DB08818,keggDrug:D03354',''),('PA165958432','tafluprost','afp-168,saflutan','Zioptan','Drug/Small Molecule','drugBank:DB08819,keggDrug:D06274',''),('PA165958441','trastuzumab emtansine','T-DM1,Trastuzumab-DM1,Trastuzumab-MCC-DM1,Trastuzumab-MCC-DM1 antibody-drug conjugate','','Drug/Small Molecule','pubChemSubstance:135353969',''),('PA165958501','Saracatinib','','','Drug/Small Molecule','',''),('PA165958521','febuxostat','','','Drug/Small Molecule','',''),('PA165958661','triciribine','','','Drug/Small Molecule','',''),('PA165960688','anacetrapib','','','Drug/Small Molecule','',''),('PA165963961','pegloticase','885051-90-1,D09316','Krystexxa','Drug/Small Molecule','',''),('PA165964366','MK-7246','','','Drug/Small Molecule','pubChemCompound:15950362',''),('PA165971474','Belinostat','','','Drug/Small Molecule','',''),('PA165980594','ap24534','AP24534','','Drug/Small Molecule','pubChemCompound:24826799',''),('PA165980595','telatinib','','','Drug/Small Molecule','pubChemCompound:9808844',''),('PA165980596','3-((6-amino-(4-chlorobenzenesulfonyl)-2-methyl-5,6,7,8-tetrahydronapht)-1-yl)propionic acid','3-((6-amino-(4-chlorobenzenesulfonyl)-2-methyl-5,6,7,8-tetrahydronapht)-1-yl)propionic acid','','Drug/Small Molecule','pubChemCompound:23674098',''),('PA165980614','fluindione','','','Drug/Small Molecule','',''),('PA165981139','afatinib dimaleate','afatinib maleate (jan),d09733','','Drug/Small Molecule','pubChemSubstance:124490473',''),('PA165981154','afatinib','BIBW 2992','Tomtovok,Tovok','Drug/Small Molecule','pubChemCompound:10184653',''),('PA165981594','eltrombopag','Eltrombopag olamine','Promacta','Drug/Small Molecule','pubChemCompound:9915926',''),('PA448004','abacavir','ABC,abacavir','Epzicom,Ziagen','','',''),('PA448006','abciximab','7E3 antibody,ReoPro,abciximab,antiGPIIBIIIa,c7E3','ReoPro','Drug/Small Molecule','DailyMed:033d4c3b-4630-4256-b8f7-9ed5f15de9a3,TTD:DAP000473,dpd:2216973,drugBank:DB00054,ndc:0002-7140-01,url:http://en.wikipedia.org/wiki/Abciximab',''),('PA448010','acarbose','','Glucobay,Prandase,Precose','Drug/Small Molecule','DailyMed:6c2db888-775c-4baf-a1b4-1cfa63b83357,TTD:DCL000309,chebi:2376,chemSpider:389971,dpd:2190893,drugBank:DB00284,keggCompound:C06802,keggDrug:D00216,ndc:16252-523-01,pubChemCompound:441184,pubChemSubstance:46508248,pubChemSubstance:7847283,url:http://en.wikipedia.org/wiki/Acarbose',''),('PA448011','acebutolol','Acebutolol HCL,Acebutololo,Acetobutolol,acebutolol hydrochloride,dl-Acebutolol','Monitan,Neptal,Prent,Sectral','Drug/Small Molecule','DailyMed:6bfb00a0-c057-4dfb-9ae3-e5b7d782cd24,TTD:DAP000484,bindingDb:25755,chebi:2379,chemSpider:1901,dpd:2257599,drugBank:DB01193,keggCompound:C06803,keggDrug:D02338,ndc:0378-1200-01,pubChemCompound:1978,pubChemSubstance:46509113,pubChemSubstance:9022,url:http://en.wikipedia.org/wiki/Acebutolol','CCCC(=O)Nc1ccc(c(c1)C(=O)C)OCC(CNC(C)C)O'),('PA448014','acetamide mea','','','Drug/Small Molecule','',''),('PA448015','acetaminophen','APAP,Acetaminofen,Paracetamol,Paracetamolo,Paracetanol','Abenol,Abensanil,Acamol,Accu-Tap,Acephen,Aceta Eli','','',''),('PA448016','acetanilide','','','Drug/Small Molecule','','CC(=O)Nc1ccccc1'),('PA448018','acetazolamide','Acetamidothiadiazolesulfonamide,Acetazolamid,Acetazolamide Sodium,Acetazolamine,Acetazoleamide,Acetozalamide,Carbonic Anhydrase Inhibitor 6063','Acetamox,Acetazolam,Ak-Zol,Apo-Acetazolamide,Atene','Drug/Small Molecule','DailyMed:df0f2293-3a46-4eda-ad28-6e713bb6c3a3,HET:AZM,TTD:DAP000600,bindingDb:10880,chebi:27690,chemSpider:1909,dpd:545015,drugBank:DB00819,keggCompound:C06805,keggDrug:D00218,ndc:0555-0513-02,pdb:AZM,pubChemCompound:1986,pubChemSubstance:46504493,pubChemSubstance:9024,url:http://en.wikipedia.org/wiki/Acetazolamide','CC(=O)Nc1nnc(s1)S(=O)(=O)N'),('PA448021','acetic acid','acetate,ethanoat,ethanoate,ethanoic acid,glacial acetic acid','Acetasol,Borofair,Volsol','Drug/Small Molecule','DailyMed:dd45cee3-9938-4dad-a5e1-1dd4baea85a9,HET:ACY,chebi:30089,drugBank:DB03166,iupharLigand:1058,keggCompound:C00033,keggDrug:D00010,ndc:0264-2304-00,pdb:ACY,pubChemCompound:176,pubChemSubstance:3335','CC(=O)O'),('PA448025','acetone','','','Drug/Small Molecule','','CC(=O)C'),('PA448031','acetylcholine','acetylcholine chloride','','Drug/Small Molecule','chebi:15355,drugBank:DB03128,iupharLigand:294,keggCompound:C01996,pdb:ACH,pubChemCompound:187,pubChemSubstance:46504484,pubChemSubstance:5093','CC(=O)OCC[N+](C)(C)C'),('PA448033','acetylcysteine','N-acetylcysteine,NAC','ACC,Acetadote,Fluimucil,Lysox,Mucolysin,Mucomyst,P','Drug/Small Molecule','DailyMed:f56b4087-db48-4fd7-84ec-9c927962b805,HET:SC2,TTD:DNC000981,chebi:28939,chemSpider:11540,dpd:2091526,drugBank:DB06151,keggCompound:C06809,keggDrug:D00221,ndc:0517-7604-25,pdb:SC2,pubChemCompound:12035,pubChemSubstance:11371394,pubChemSubstance:99443235,url:http://en.wikipedia.org/wiki/Acetylcysteine','CC(=O)NC(CS)C(=O)O'),('PA448039','acitretin','','Acetretin,Neotigason,Soriatane','Drug/Small Molecule','DailyMed:cec7851f-c7af-4e9e-a5e4-a585c70510d2,TTD:DAP000743,chebi:50173,dpd:2070847,drugBank:DB00459,keggDrug:D02754,ndc:0145-0090-25,pubChemCompound:6437841,pubChemSubstance:691722,url:http://en.wikipedia.org/wiki/Acitretin',''),('PA448045','aciclovir','9-Hyroxyethoxymethylguanine,AC2,Aciclovier,Aciclovir Sodium,Acycloguanosine,Acyclovir,Acyclovir Sodium,Wellcome-248u','Alti-Acyclovir,Avirax,Vipral,Virorax,Zovir,Zovirax','Drug/Small Molecule','DailyMed:ab044c63-96b6-4b02-86cb-e1b93c59eb63,HET:AC2,TTD:DNC000157,chebi:2453,chemSpider:1945,dpd:2242784,drugBank:DB00787,keggCompound:C06810,keggDrug:D00222,ndc:0228-2605-11,pdb:AC2,pubChemCompound:2022,pubChemSubstance:46506002,pubChemSubstance:7847289,url:http://en.wikipedia.org/wiki/Aciclovir','c1nc2c(=O)[nH]c(nc2n1COCCO)N'),('PA448047','adapalene','Adapaleno [INN-Spanish],Adapalenum [INN-Latin]','Adaferin,Differin','Drug/Small Molecule','DailyMed:ad56e40f-d63d-428f-a58c-8ae733b63c7f,TTD:DAP000115,chebi:31174,chemSpider:54244,dpd:2231592,drugBank:DB00210,keggDrug:D01112,ndc:0299-5910-45,pubChemCompound:60164,pubChemSubstance:46505019,url:http://en.wikipedia.org/wiki/Adapalene',''),('PA448048','adenine','1H-Purin-6-amine,6-Aminopurine,Adenin,Adeninimine,Vitamin B4','Leuco-4,Pedatisectine B','Drug/Small Molecule','HET:ADE,TTD:DAP000982,bindingDb:33218,chebi:16708,chemSpider:185,drugBank:DB00173,keggCompound:C00147,keggDrug:D00034,pdb:ADE,pubChemCompound:190,pubChemSubstance:3447,pubChemSubstance:46507319,url:http://en.wikipedia.org/wiki/Adenine','c1[nH]c2c(n1)c(ncn2)N'),('PA448049','adenosine','2\'-Deoxyadenosine,Adenine Deoxy Nucleoside,Adenine Deoxyribonucleoside,Adenine Deoxyribose,Adenine Nucleoside,Adenine Riboside,Adenyldeoxyriboside,Deo','Adenocard,Adenocor,Adenoscan,Adenosin,Adensoine,Bo','Drug/Small Molecule','DailyMed:19977c31-02d3-40fa-bcad-9c3c88768e11,HET:101,TTD:DAP000223,chebi:16335,chemSpider:54923,dpd:2243435,drugBank:DB00640,keggCompound:C00212,keggDrug:D00045,ndc:0703-8771-03,pdb:101,pubChemCompound:60961,pubChemSubstance:3512,pubChemSubstance:46508728,url:http://en.wikipedia.org/wiki/Adenosine',''),('PA448055','l-alanine','(2S)-2-Aminopropanoic acid,(S)-(+)-Alanine,(S)-2-Aminopropanoic acid,(S)-Alanine,2-Aminopropanoic acid,2-Aminopropionic acid,ALA,Alanine,L-(+)-Alanine','','','',''),('PA448068','salbutamol','Albuterol,Albuterol Sulfate,Albuterol Sulphate,Levalbuterol,Salbutamol Sulfate,Salbutamol Sulphate','Accuneb,Aerolin,Airomir,Asmaven,Asmol,Asthalin,Ast','','',''),('PA448073','ethanol','Absolute Alcohol,Absolute Ethanol,Alcohol,Alcohol Anhydrous,Alcohol, Dehydrated,Alcohol, Diluted,Alcool Ethylique,Alcool Etilico,Alkohol,Alkoholu Etyl','Aethanol,Aethylalkohol,Alcare Hand Degermer,Algrai','Drug/Small Molecule','HET:168,TTD:DAP000681,chebi:16236,chemSpider:682,dpd:724947,drugBank:DB00898,iupharLigand:2299,keggCompound:C00469,keggDrug:D00068,pdb:168,pubChemCompound:702,pubChemSubstance:3752,pubChemSubstance:46506969,url:http://en.wikipedia.org/wiki/Ethanol','CCO'),('PA448081','aldesleukin','IL-2,Interleukin-2 precursor,T-cell growth factor,TCGF,aldesleukin','Proleukin','Drug/Small Molecule','DailyMed:a588140c-f9ed-4a9b-a9a6-bf3daafd8a5a,TTD:DAP001099,dpd:2130181,drugBank:DB00041,genBank:M11144,ndc:0078-0495-61,uniProtKb:P60569,url:http://en.wikipedia.org/wiki/Aldesleukin',''),('PA448082','alendronate','Acide Alendronique [INN-French],Acido Alendronico [INN-Spanish],Acidum Alendronicum [INN-Latin],Alendronate Sodium,Alendronic acid','Adronat,Alendros,Arendal,Fosamax,Fosamax Plus D,On','Drug/Small Molecule','HET:AHD,TTD:DAP000182,bindingDb:25313,chebi:2567,chemSpider:2004,dpd:2261715,drugBank:DB00630,keggCompound:C07752,ndc:0006-0925-31,pdb:AHD,pubChemCompound:2088,pubChemSubstance:46507199,pubChemSubstance:9954,url:http://en.wikipedia.org/wiki/Alendronate',''),('PA448084','alfentanil','Alfentanilum [INN-Latin],Alfentanyl','Alfenta','Drug/Small Molecule','DailyMed:098af6c6-7400-4b2b-bae6-03d5913ad712,TTD:DAP001134,bindingDb:50008979,chebi:2569,chemSpider:46451,dpd:2248181,drugBank:DB00802,keggCompound:C08005,ndc:17478-067-02,pubChemCompound:51263,pubChemSubstance:189496,pubChemSubstance:46505618,url:http://en.wikipedia.org/wiki/Alfentanil','CCC(=O)N(c1ccccc1)C2(CCN(CC2)CCn3c(=O)n(nn3)CC)COC'),('PA448320','allopurinol','Allopurinol Sodium,Allopurinolum [INN-Latin],Alopurinol [INN-Spanish]','7HP,Adenock,Ailural,Allo-Puren,Allohexal,Allopur,A','Drug/Small Molecule','DailyMed:19a138b8-d225-03e6-f762-abe71560204b,HET:7HP,TTD:DAP000773,bindingDb:50241255,chebi:40279,chemSpider:2010,dpd:555681,drugBank:DB00437,keggDrug:D00224,ndc:55111-729-01,pdb:7HP,pubChemCompound:2094,pubChemSubstance:152626,pubChemSubstance:46508516,url:http://en.wikipedia.org/wiki/Allopurinol','c1c2c([nH]n1)ncnc2O'),('PA448322','aloe','','','Drug/Small Molecule','',''),('PA448333','alprazolam','TUS-1,alprazolam','Alplax,Alpronax,Alviz,Bestrol,Cassadan,Constan,D 6','Drug/Small Molecule','DailyMed:ea350660-9be8-40b2-98f9-af759a8f7864,TTD:DAP000239,chebi:2611,chemSpider:2034,dpd:2248706,drugBank:DB00404,keggCompound:C06817,keggDrug:D00225,ndc:64980-140-06,pubChemCompound:2118,pubChemSubstance:176116,pubChemSubstance:46507078,url:http://en.wikipedia.org/wiki/Alprazolam','Cc1nnc2n1-c3ccc(cc3C(=NC2)c4ccccc4)Cl'),('PA448334','alprostadil','alprostadil','Alista,Alprostadil Prostoglandin E1,Alprox-TD,Befa','','',''),('PA448348','aluminum chloride','','','Drug/Small Molecule','','[Al+3].[Cl-]'),('PA448360','amantadine','1-aminoadamantane,Adamantamine,Adamantanamine,Adamantylamine,Amantadine Base,Amantadine HCL,Amantidine,Aminoadamantane,amantadine hydrochloride','Endantadine,Gen-Amantadine,Mantadine,Pk-Merz,Symad','Drug/Small Molecule','DailyMed:5232b933-1df9-43b4-8ac2-61bfa4855e68,TTD:DAP000781,chebi:2618,dpd:2262649,drugBank:DB00915,keggCompound:C06818,ndc:0832-1015-00,pubChemCompound:2130,pubChemSubstance:9036,url:http://en.wikipedia.org/wiki/Amantadine','C1C2CC3CC1CC(C2)(C3)N'),('PA448365','amifostine','Amifostine Ethiofos,Aminopropylaminoethyl Thiophosphate,Apaetp,Ethiofos,Gammaphos,SAPEP,WR-1065,amifostine','Ethyol','Drug/Small Molecule','DailyMed:18f335df-d664-4850-9efc-8b26adea9d69,chebi:2636,chemSpider:2056,dpd:2218054,drugBank:DB01143,keggCompound:C06819,ndc:58178-017-01,pubChemCompound:2141,pubChemSubstance:172354,pubChemSubstance:46505305,url:http://en.wikipedia.org/wiki/Amifostine',''),('PA448368','amiloride','AMR,Amilorida [INN-Spanish],Amiloride HCL,Amiloride hydrochloride,Amiloride hydrochloride hydrate,Amiloridum [INN-Latin],Amyloride','Amipramidin,Amipramizid,Amipramizide,Amiprazidine,','','',''),('PA448372','amino acids','','','Drug Class','',''),('PA448375','aminoglutethimide','Dl-Aminoglutethimide,P-Aminoglutethimide','Cytadren,Elipten,Orimeten','Drug/Small Molecule','TTD:DAP000842,bindingDb:9460,chebi:2654,chemSpider:2060,dpd:587729,drugBank:DB00357,keggCompound:C07617,keggDrug:D00574,ndc:0083-0024-30,pubChemCompound:2145,pubChemSubstance:46506066,pubChemSubstance:9819,url:http://en.wikipedia.org/wiki/Aminoglutethimide','CCC1(CCC(=O)NC1=O)c2ccc(cc2)N'),('PA448382','aminosalicylic acid','4-ASA,4-aminosalicylic acid,APAS,Amino-PAS,Aminosalicylate Sodium,P-Aminosalicylic Acid,PAS,PASK,Para-Amino Salicylic Acid,Para-aminosalicylic acid','Aminopar,Aminox,Apacil,Deapasil,Entepas,Ferrosan,G','Drug/Small Molecule','HET:BHA,chebi:27565,chemSpider:4488,drugBank:DB00233,keggCompound:C02518,keggDrug:D00162,pdb:BHA,pubChemCompound:4649,pubChemSubstance:46505572,pubChemSubstance:5528,url:http://en.wikipedia.org/wiki/Aminosalicylic_acid',''),('PA448383','amiodarone','Amiodarona [INN-Spanish],Amiodarone Base,Amiodarone HCL,Amiodarone Hydrochloride,Amiodaronum [INN-Latin]','Aminodarone,Amio-Aqueous IV,Amiodarons,Aratac,Aryc','Drug/Small Molecule','TTD:DAP000496,bindingDb:18957,chebi:2663,chemSpider:2072,dpd:2243836,drugBank:DB01118,iupharLigand:2566,keggCompound:C06823,keggDrug:D02910,ndc:0703-1332-03,pubChemCompound:2157,pubChemSubstance:159329,pubChemSubstance:46507387,url:http://en.wikipedia.org/wiki/Amiodarone','CCCCc1c(c2ccccc2o1)C(=O)c3cc(c(c(c3)I)OCCN(CC)CC)I'),('PA448385','amitriptyline','Amitriprolidine,Amitriptylin,Amitriptyline HCL,Amitriptyline Hydrochloride,Amitryptiline,Amitryptyline,Amytriptiline','Adepress,Adepril,Amitid,Amitril,Damilan,Damilen,El','','',''),('PA448388','amlodipine','Amlodipine Benzenesulfonate,Amlodipine Besilate,Amlodipine Besylate,Amlodipine Free Base,Amlodipino [Spanish],Amlodipinum [Latin]','Amlocard,Amlodis,Amvaz,Coroval,Lipinox,Lotrel,Norv','','',''),('PA448392','ammonium chloride','','','Drug/Small Molecule','','[NH4+].[Cl-]'),('PA448401','amobarbital','','Isomytal','Drug/Small Molecule','TTD:DAP000686,chebi:2673,chemSpider:2079,drugBank:DB01351,keggCompound:C07536,keggDrug:D00555,pubChemCompound:2164,pubChemSubstance:46508165,pubChemSubstance:7847621,url:http://en.wikipedia.org/wiki/Amobarbital','CCC1(C(=O)NC(=O)NC1=O)CCC(C)C'),('PA448404','amodiaquine','Amodiaquin,Amodiaquine USP24,Amodiaquine, ring-closed,amodiaquine hydrochloride','Basoquin,CAM-AQ1,CAM-AQI,Camochin,Camoquin,Camoqui','','',''),('PA448405','amoxapine','Amoxepine','Ascendin,Asendis,Defanyl,Demolox,Moxadil','Drug/Small Molecule','DailyMed:a16297df-3158-48db-85e5-5cd506885556,TTD:DAP001149,bindingDb:22870,chebi:2675,chemSpider:2085,dpd:527106,drugBank:DB00543,iupharLigand:201,keggDrug:D00228,ndc:0591-5713-01,pubChemCompound:2170,pubChemSubstance:46509117,pubChemSubstance:7847295,url:http://en.wikipedia.org/wiki/Amoxapine','c1ccc2c(c1)N=C(c3cc(ccc3O2)Cl)N4CCNCC4'),('PA448406','amoxicillin','AMC,Amoxicilina [INN-Spanish],Amoxicillin Trihydrate,Amoxicillin anhydrous,Amoxicilline [INN-French],Amoxicillinum [INN-Latin],Amoxycillin,Amoxycillin','AMPC,Actimoxi,Amoclen,Amolin,Amopen,Amopenixin,Amo','','',''),('PA448408','amphetamine','(+/-)-Benzedrine,(+/-)-Desoxynorephedrine,(+/-)-beta-Phenylisopropylamine,1-Methyl-2-phenylethylamine,1-Phenyl-2-aminopropane,3-Methoxy-a-methylbenzen','Actedron,Adipan,Allodene,Anorexide,Anorexine,Benze','','',''),('PA448415','amphotericin b','AMPH-B,Amphortericin B,Amphotericine B,Liposomal Amphotericin B,amphotericin B','ABLC,Abelcet,AmB,AmBisome,Ampho-Moronal,Amphocin,A','Drug/Small Molecule','DailyMed:f7be6506-4d20-401e-a0ff-02ad7c33158a,TTD:DAP001322,chemSpider:14245,dpd:29149,drugBank:DB00681,keggCompound:C06573,keggDrug:D00203,ndc:0469-3051-30,pubChemCompound:14956,pubChemCompound:5280965,pubChemSubstance:46505473,pubChemSubstance:8802,url:http://en.wikipedia.org/wiki/Amphotericin_B','C[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O'),('PA448419','ampicillin','Aminobenzylpenicillin,Ampicilina [INN-Spanish],Ampicillin Acid,Ampicillin Anhydrate,Ampicillin Anhydrous,Ampicillin Base,Ampicillin Sodium,Ampicillin ','AB-PC,Ab-Pc Sol,Acillin,Adobacillin,Alpen,Amblosin','','',''),('PA448422','amprenavir','AMP,AMV,APV,VX-478','Agenerase,Prozei,Vertex','Drug/Small Molecule','TTD:DAP000170,bindingDb:577,chebi:2684,chemSpider:58532,dpd:2243542,drugBank:DB00701,keggCompound:C08086,keggDrug:D00894,pubChemCompound:65016,pubChemSubstance:46507537,pubChemSubstance:7847958,url:http://en.wikipedia.org/wiki/Amprenavir',''),('PA448428','pancrelipase','1,4-alpha-D- glucan glucanohydrolase,PA,Pancreatic alpha-amylase precursor,pancrelipase','Cotazym,Creon,Ku-Zyme,Pancrease,Ultrase,Zymase','Drug/Small Molecule','DailyMed:85e78b3c-66ac-4012-899b-1a55afe5110e,dpd:783382,drugBank:DB00085,genBank:M18785,ndc:54868-6067-0,uniProtKb:P04746,url:http://en.wikipedia.org/wiki/Pancrelipase',''),('PA448432','anastrozole','Anastrozol,anastrozole','Anastrole,Arimidex','Drug/Small Molecule','DailyMed:11628cdc-4e3c-4063-ee9f-c51e2386a820,TTD:DAP000627,bindingDb:10015,chebi:2704,chemSpider:2102,dpd:2224135,drugBank:DB01217,keggCompound:C08159,keggDrug:D00960,ndc:0310-0201-30,pubChemCompound:2187,pubChemSubstance:196979,pubChemSubstance:46504987,url:http://en.wikipedia.org/wiki/Anastrozole','CC(C)(C#N)c1cc(cc(c1)C(C)(C)C#N)Cn2cncn2'),('PA448452','antimony potassium tartrate','','','Drug/Small Molecule','',''),('PA448453','antipyrine','Acetasol,Analgesine,Anodynin,Anodynine,Antipirin,Antipyrin,Antipyrinum,Azophen,Azophenum,Fenazon [czech],Fenazona [inn-spanish],Fenazone,Phenazon,Phen','Apirelina,Auralgan,Sedatin,Sedatine','','',''),('PA448472','aprotinin','bayer a 128,bovine pancreatic trypsin inhibitor,bpti,iniprol,trazinin','Trasylol','Drug/Small Molecule','DailyMed:8a5982c6-825f-4d05-90f5-1519a7291d15',''),('PA448478','l-arginine','(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid,(s)-2-amino-5-guanidinovaleric acid,2-Amino-5-guanidinovaleric acid,Arginine,L-(+)-Arginine,L-Ar','Argamine,Argivene,Detoxargin,Levargin,Minophagen A','Drug/Small Molecule','DailyMed:6accf33f-9841-4327-8923-93c42020ef12,HET:ARG,bindingDb:21959,chebi:16467,chebi:29016,chemSpider:6082,drugBank:DB00125,iupharLigand:721,keggCompound:C00062,keggDrug:D02982,ndc:0009-0436-24,pdb:ARG,pubChemCompound:6322,pubChemSubstance:17397138,pubChemSubstance:46507180,url:http://en.wikipedia.org/wiki/L-Arginine',''),('PA448486','arsenic trioxide','Acide Arsenieux [French],Anhydride Arsenieux [French],Arseni Trioxydum,Arsenic Blanc [French],Arsenic Oxide,Arsenic Oxidearsenous Trioxide,Arsenic Ses','Arsenite,Arsenolite,Arsodent,Claudelite,Claudetite','Drug/Small Molecule','DailyMed:dec51fab-3784-deb7-752f-2d4d5692a20f,TTD:DNC000255,chemSpider:452539,dpd:718777,drugBank:DB01169,keggDrug:D02106,ndc:63459-600-10,pubChemCompound:518740,pubChemSubstance:10506726,pubChemSubstance:46506448,url:http://en.wikipedia.org/wiki/Arsenic_trioxide','O=[As](=O)=O'),('PA448492','asparaginase','L-asparagine amidohydrolase,Putative L-asparaginase precursor','Elspar','Drug/Small Molecule','dpd:1926438,drugBank:DB00023,genBank:U00096,uniProtKb:P37595,url:http://en.wikipedia.org/wiki/Asparaginase',''),('PA448493','aspartame','1-Methyl N-L-alpha-aspartyl-L-phenylalanate,1-Methyl N-L-alpha-aspartyl-L-phenylalanine,3-Amino-N-(alpha-carboxyphenethyl)succinamic acid N-methyl est','Aminosweet,Canderel,Equal,Nutrasweet,Tri-sweet','Drug/Small Molecule','HET:PME,chebi:2877,drugBank:DB00168,keggCompound:C11045,keggDrug:D02381,pdb:PME,pubChemCompound:2242,pubChemSubstance:173626,url:http://en.wikipedia.org/wiki/Aspartame',''),('PA448494','l-aspartic acid','(+)-Aspartic acid,(2S)-Aspartic acid,(L)-Aspartic acid,(S)-Aminobutanedioic acid,(S)-Aspartic acid,Acide aspartique [INN-French],Acido aspartico [INN-','Aspatofort','Drug/Small Molecule','HET:ASP,chebi:17053,chemSpider:5745,drugBank:DB00128,keggCompound:C00049,keggDrug:D00013,pdb:ASP,pubChemCompound:5960,pubChemSubstance:148792,pubChemSubstance:46507997,url:http://en.wikipedia.org/wiki/L-Aspartic_Acid',''),('PA448497','aspirin','2-Acetoxybenzenecarboxylic acid,2-Acetoxybenzoic acid,2-Carboxyphenyl acetate,A.S.A.,ASA,Acetilsalicilico,Acetilum acidulatum,Acetosalic acid,Acetoxyb','8-hour Bayer,A.S.A. Empirin,Acenterine,Acesal,Acet','','',''),('PA448498','astemizole','','Alermizol,Astemisan,Astemisol,Astemison,Hismanal,H','Drug/Small Molecule','TTD:DAP000326,bindingDb:24226,chebi:2896,chemSpider:2160,dpd:2182912,drugBank:DB00637,iupharLigand:2603,keggCompound:C06832,keggDrug:D00234,pubChemCompound:2247,pubChemSubstance:188751,pubChemSubstance:46508569,url:http://en.wikipedia.org/wiki/Astemizole','COc1ccc(cc1)CCN2CCC(CC2)Nc3nc4ccccc4n3Cc5ccc(cc5)F'),('PA448499','atenolol','','Aircrit,Alinor,Altol,Anselol,Antipressan,Apo-Ateno','','',''),('PA448500','atorvastatin','Atorvastatin calcium','Atogal,Atorpic,Cardyl,Faboxim,Hipolixan,Lipitor,Li','Drug/Small Molecule','DailyMed:c6e131fe-e7df-4876-83f7-9156fc4e8228,HET:117,TTD:DAP000553,bindingDb:22164,chebi:2910,chemSpider:54810,dpd:2243097,drugBank:DB01076,keggCompound:C06834,ndc:0071-0155-23,pdb:117,pubChemCompound:60823,pubChemSubstance:205162,pubChemSubstance:46506188,url:http://en.wikipedia.org/wiki/Atorvastatin','CC(C)c1c(c(c(n1CC[C@H](C[C@H](CC(=O)O)O)O)c2ccc(cc2)F)c3ccccc3)C(=O)Nc4ccccc4'),('PA448502','atovaquone','','Malarone,Malarone Pediatric','','',''),('PA448505','atropine','Atropin [German],Atropina [Italian],Atropine Sulfate,DL-Hyoscyamine,DL-Tropyl tropate','Atnaa,Atropair,Atropen,Atropin,Atropin-flexiolen,A','','',''),('PA448510','auranofin','Auroafen','Ridaura','Drug/Small Molecule','DailyMed:05c34ddf-a0f7-4267-83f5-d02be3defc37,TTD:DAP000757,chebi:2922,dpd:1916823,drugBank:DB00995,keggDrug:D00237,ndc:65483-093-06,pubChemCompound:6333901,pubChemSubstance:574276,url:http://en.wikipedia.org/wiki/Auranofin',''),('PA448515','azathioprine','Azathioprin,Azathioprine Sodium,Azatioprin,Azothioprine','Azamun,Azanin,Azasan,Ccucol,Imuran,Imurek,Imurel,M','Drug/Small Molecule','DailyMed:0a83e716-b688-433f-ac27-ae95132810cf,TTD:DAP000782,chebi:2948,chemSpider:2178,dpd:2242907,drugBank:DB00993,keggDrug:D00238,ndc:0378-1005-01,pubChemCompound:2265,pubChemSubstance:46508252,pubChemSubstance:9055,url:http://en.wikipedia.org/wiki/Azathioprine',''),('PA448517','azelastine','Azelastina [INN-Spanish],Azelastinum [INN-Latin],azelastine hydrochloride','Astelin,Optivar','Drug/Small Molecule','DailyMed:f4b9597c-5b50-4889-be41-20bd1f13aaa5,TTD:DNC000270,chebi:2950,chemSpider:2180,drugBank:DB00972,keggCompound:C07768,ndc:0037-7025-60,pubChemCompound:2267,pubChemSubstance:46507582,pubChemSubstance:9970,url:http://en.wikipedia.org/wiki/Azelastine',''),('PA448519','azithromycin','Aritromicina [Spanish],Azithramycine,Azithromycin Dihydrate,Azithromycine [French],Azithromycinum [Latin]','Azenil,Azibiot,Azifine,Azitromax,Aziwok,Aztrin,Hem','Drug/Small Molecule','DailyMed:db52b91e-79f7-4cc1-9564-f2eee8e31c45,HET:ZIT,TTD:DNC001539,bindingDb:50197040,chebi:2955,dpd:2255340,drugBank:DB00207,keggCompound:C06838,ndc:0069-3060-30,pdb:ZIT,pubChemCompound:55185,pubChemSubstance:9056,url:http://en.wikipedia.org/wiki/Azithromycin',''),('PA448523','aztreonam','AZT','Azactam,Corus 1020,Dynabiotic,Monobactam,Primbacta','Drug/Small Molecule','DailyMed:bcd26183-313e-e4e1-092b-49b35b12863f,HET:AZR,TTD:DAP000117,chebi:161680,drugBank:DB00355,keggCompound:C06840,keggDrug:D00240,ndc:51479-041-15,pdb:AZR,pubChemCompound:5362041,pubChemSubstance:9058,url:http://en.wikipedia.org/wiki/Aztreonam','C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)C(=NOC(C)(C)C(=O)O)c2csc(n2)N'),('PA448531','bacitracin','','Baci-rx,Baciguent,Baciim,Bacitracin Bacillus liche','','',''),('PA448533','baclofen','','Apo-Baclofen,Baclon,Kemstro,Lioresal,Lioresal Intr','Drug/Small Molecule','DailyMed:f133fe04-1550-4fa4-9dc4-652c27936bf2,TTD:DAP000257,bindingDb:24182,chebi:2972,chemSpider:2197,dpd:2242151,drugBank:DB00181,iupharLigand:1064,iupharLigand:1084,keggDrug:D00241,ndc:0091-3351-01,pubChemCompound:2284,pubChemSubstance:46508181,url:http://en.wikipedia.org/wiki/Baclofen',''),('PA448536','balsalazide','Balsalazida [Spanish],Balsalazide disodium,Balsalazido [Spanish],Balsalazidum [Latin],balsalazide','Carbadox,Colazal','Drug/Small Molecule','DailyMed:22f41e83-b9fb-4c9e-8cc3-f457034191a8,TTD:DAP000733,chebi:267413,drugBank:DB01014,ndc:65649-101-02,pubChemCompound:6335412,pubChemSubstance:192139,url:http://en.wikipedia.org/wiki/Balsalazide',''),('PA448538','barbital','','','Drug/Small Molecule','chebi:31252,chemSpider:2206,drugBank:DB01483,keggCompound:C02517,pubChemCompound:2294,pubChemSubstance:46508979,pubChemSubstance:5527,url:http://en.wikipedia.org/wiki/Barbital','CCC1(C(=O)NC(=O)NC1=O)CC'),('PA448540','barium sulfate','','ACB,Anatrast,Baricon,Baro-cat,Barobag,Barosperse,E','Drug/Small Molecule','','[O-]S(=O)(=O)[O-].[Ba+2]'),('PA448547','beclomethasone','Beclometasona [INN-Spanish],Beclometasone,Beclometasonum [INN-Latin],beclomethasone dipropionate','Aerobec,Aldecin,Anceron,Andion,Beclacin,Becloforte','Drug/Small Molecule','DailyMed:ccc8c882-e4d1-4ce6-9817-e212f4c9527f,TTD:DAP000416,chebi:3002,dpd:2238796,drugBank:DB00394,keggCompound:C06842,keggCompound:C07813,keggDrug:D00689,ndc:59310-175-40,pubChemCompound:20469,pubChemSubstance:9060,url:http://en.wikipedia.org/wiki/Beclomethasone','C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C'),('PA448561','benazepril','benazepril','Benazepril HCl,Benazepril Hydrochloride,Benazepril','','',''),('PA448563','bendroflumethiazide','BHFT,Bendrofluazide,Bendroflumethazide,Bendroflumethiazidum [INN-Latin],Bendroflumetiazida [INN-Spanish],Bendrofumethiazide,Benzhydroflumethiazide,Ben','Aprinox,Bentride,Benuron,Benzy-Rodiuran,Benzylrodi','','',''),('PA448571','benzaldehyde','','','Drug/Small Molecule','','c1ccc(cc1)C=O'),('PA448576','benzocaine','Ethyl Aminobenzoate,Ethyl P-Aminobenzoate,Ethyl P-Aminophenylcarboxylate,Ethylester Kyseliny P-Aminobenzoove,P-Aminobenzoic Acid, Ethyl Ester,P-Carbet','Aethoform,Amben Ethyl Ester,Americaine,Anaesthan-S','','',''),('PA448578','benzoic acid','','','Drug/Small Molecule','chebi:30746,drugBank:DB03793,keggCompound:C00180,keggDrug:D00038,pdb:BEZ,pubChemCompound:243,pubChemSubstance:3480,pubChemSubstance:46504911','c1ccc(cc1)C(=O)O'),('PA448586','benzphetamine','Benzfetamine,Benzylamphetamine,benzphetamine hydrochloride','Didrex','Drug/Small Molecule','DailyMed:fe6d8813-25d9-4e56-84c7-ca6c3111a19a,TTD:DAP001147,chebi:3044,drugBank:DB00865,keggCompound:C07538,ndc:0009-0024-01,pubChemCompound:2341,pubChemSubstance:152260,url:http://en.wikipedia.org/wiki/Benzphetamine',''),('PA448591','benztropine','Benzatropina [INN-Spanish],Benzatropine,Benzatropine mesilate,Benzatropinum [INN-Latin],Benztropine Mesylate,Benztropinum,Tropine Benzohydryl Ether,be','Akitan,Apo-Benztropine,Cobrentin,Cogentin,Cogentin','Drug/Small Molecule','TTD:DAP001460,chebi:3048,dpd:706531,drugBank:DB00245,keggCompound:C06846,ndc:0182-1299-89,pubChemCompound:6832,pubChemSubstance:9064,url:http://en.wikipedia.org/wiki/Benztropine',''),('PA448594','benzyl alcohol','','','Drug/Small Molecule','','c1ccc(cc1)CO'),('PA448601','beta carotene','beta-carotene','','Drug/Small Molecule','',''),('PA448603','betaine','','','Drug/Small Molecule','',''),('PA448611','betaxolol','Betaxolol HCL,Betaxololum [INN-Latin],Betazolol','Betaxon,Betoptic,Betoptic S,Kerlone','Drug/Small Molecule','DailyMed:31b9b263-11fd-4495-83dd-ababf0d70e9e,TTD:DAP000305,bindingDb:50026854,chebi:3082,chemSpider:2279,dpd:2235971,drugBank:DB00195,iupharLigand:549,keggCompound:C06849,ndc:0065-0245-20,pubChemCompound:2369,pubChemSubstance:46506041,pubChemSubstance:9067,url:http://en.wikipedia.org/wiki/Betaxolol',''),('PA448613','bethanechol','Amidopropyldimethylbetaine,BTC,Besacholine,Beta-Methyl Carbachol Chloride,Bethaine Choline Chloride,Bethanechol Chloride,Carbamylmethylcholine Chlorid','Duvoid,Mechotane,Mechothane,Mecothane,Mictone,Mict','Drug/Small Molecule','DailyMed:cb6a43e9-5663-47e1-8f77-ed4cb806436d,TTD:DAP000263,chebi:3084,chemSpider:2280,dpd:2237048,drugBank:DB01019,iupharLigand:297,keggCompound:C06850,ndc:0527-1332-01,pubChemCompound:2370,pubChemSubstance:46507707,pubChemSubstance:9068,url:http://en.wikipedia.org/wiki/Bethanechol',''),('PA448617','bile acid preparations','','','Drug Class','',''),('PA448625','biotin','(+)-Biotin,(+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valeric acid,Coenzyme R,D(+)-Biotin,D-Biotin,Vitamin B7,Vitamin H,cis-(+)-Tetrahydro-2-ox','Biodermatin,Bioepiderm,Bios II,Biotin Forte,Factor','Drug/Small Molecule','HET:BTN,bindingDb:12,chebi:15956,chemSpider:149962,dpd:189189,drugBank:DB00121,keggCompound:C00120,keggDrug:D00029,pdb:BTN,pubChemCompound:171548,pubChemSubstance:3420,pubChemSubstance:46508694,url:http://en.wikipedia.org/wiki/Biotin','C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)NC(=O)N2'),('PA448626','biperiden','Beperiden,Biperiden Hydrochloride,Biperiden [Usan:Ban:Inn:Jan],Biperidene Hydrochloride,Biperidene [INN-French],Biperideno [INN-Spanish],Biperidenum [','Akineton,Akinophyl','Drug/Small Molecule','DailyMed:b4dc473f-fbd3-4ad9-83af-5ed2a33e6eae,TTD:DAP001125,bindingDb:50240680,chebi:3112,chemSpider:2289,dpd:124982,drugBank:DB00810,keggCompound:C07941,keggDrug:D00779,ndc:49884-693-01,pubChemCompound:2381,pubChemSubstance:153864,pubChemSubstance:46508325,url:http://en.wikipedia.org/wiki/Biperiden',''),('PA448641','bisoprolol','Bisoprolol Fumarate,Bisoprolol Hemifumarate,Bisoprolol fumerate','Cardicor,Concor,Condyline,Condylox,Detensiel,Emcon','','',''),('PA448645','bleomycin','BLM,Bleocin,Bleomicin,Bleomicina [INN-Spanish],Bleomycin A2,Bleomycin B2,Bleomycin sulfate,Bleomycine [INN-French],Bleomycinum [INN-Latin]','Blenoxane,Bleo','Drug/Small Molecule','DailyMed:2ef2901b-e3ee-47ba-81d9-48c6668fd19b,HET:BLM,TTD:DAP000531,bindingDb:50122169,chebi:22907,chebi:3139,chemSpider:4514492,dpd:2131692,drugBank:DB00290,keggCompound:C06854,ndc:0703-3154-01,pdb:BLM,pubChemCompound:5360373,pubChemSubstance:46509116,pubChemSubstance:9072,url:http://en.wikipedia.org/wiki/Bleomycin',''),('PA448662','bretylium','Bretylate,Bretylium p-toluenesulfonate,Bretylium tolsylate,Bretylium tosylate,Bretylum','Bretylan,Bretylol,Darenthin,Darentin,Ornid','Drug/Small Molecule','TTD:DAP000939,chebi:3172,chemSpider:2337,dpd:2185377,drugBank:DB01158,keggDrug:D00645,pubChemCompound:2431,pubChemSubstance:46505320,pubChemSubstance:794516,url:http://en.wikipedia.org/wiki/Bretylium',''),('PA448665','brimonidine','Brimonidine tartrate,Bromoxidine','Alphagan,Alphagan P','Drug/Small Molecule','DailyMed:d8a94e6e-2f61-4589-bb73-65c9c7884797,TTD:DAP000280,chebi:3175,chemSpider:2341,dpd:2243026,drugBank:DB00484,iupharLigand:520,keggCompound:C07886,keggDrug:D02076,ndc:60758-866-05,pubChemCompound:2435,pubChemSubstance:213378,pubChemSubstance:46507305,url:http://en.wikipedia.org/wiki/Brimonidine','c1cc(c(c2c1nccn2)Br)NC3=NCCN3'),('PA448670','bromfenac','Bromfenac sodium','Duract,Xibrom','Drug/Small Molecule','DailyMed:8ff9987b-8133-4f46-aadf-35c44005b8e2,TTD:DAP000732,chebi:240107,chemSpider:54730,drugBank:DB00963,ndc:67425-004-50,pubChemCompound:60726,pubChemSubstance:46508121,pubChemSubstance:685533',''),('PA448671','bromocriptine','Bromergocryptine,Bromocriptin,Bromocriptina [INN-Spanish],Bromocriptine Mesylate,Bromocriptine Methanesulfonate,Bromocriptinum [INN-Latin],Bromocrypti','Alti-Bromocriptine,Apo-Bromocriptine,Bagren,Ergose','Drug/Small Molecule','DailyMed:b767d7cc-67c7-49d6-a456-227dcade7daf,TTD:DAP001462,chebi:3181,chemSpider:28858,dpd:2236949,drugBank:DB01200,iupharLigand:35,keggCompound:C06856,keggDrug:D03165,ndc:0078-0017-15,pubChemCompound:31101,pubChemSubstance:174998,pubChemSubstance:46505504,url:http://en.wikipedia.org/wiki/Bromocriptine','CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5Cc6c7c(cccc7[nH]c6Br)C5=C4)C)O'),('PA448675','brompheniramine','Brompheniramine Maleate','Bromfed,Bromfenex,Dimetane,Veltane','','',''),('PA448681','budesonide','budesonide','Bidien,Budeson,Budicort,Cortivent,Desowen,Entocort','','',''),('PA448682','bumetanide','Bumetanida [INN-Spanish],Bumetanidum [INN-Latin]','Bumex,Burine,Burinex,Fontego,Fordiuran,Lixil,Lunet','Drug/Small Molecule','DailyMed:a4987159-7590-47a6-be10-b50557c30fab,TTD:DAP000361,bindingDb:25903,chebi:3213,chemSpider:2377,dpd:728284,drugBank:DB00887,keggDrug:D00247,ndc:0004-0125-01,pubChemCompound:2471,pubChemSubstance:175984,pubChemSubstance:46508147,url:http://en.wikipedia.org/wiki/Bumetanide','CCCCNc1cc(cc(c1Oc2ccccc2)S(=O)(=O)N)C(=O)O'),('PA448685','buprenorphine','Buprenophine,Buprenorfina [INN-Spanish],Buprenorphine Hcl,Buprenorphinum [INN-Latin],buprenorphine','Buprel,Buprenex,Probuphine,Subutex,Temgesic','Drug/Small Molecule','DailyMed:b086772e-d15a-4d13-b1a2-38bfbde1f18c,TTD:DAP001353,chebi:3216,drugBank:DB00921,iupharLigand:1670,keggCompound:C08007,ndc:12496-0757-1,pubChemCompound:40400,pubChemSubstance:181274,pubChemSubstance:46505782,url:http://en.wikipedia.org/wiki/Buprenorphine',''),('PA448687','bupropion','Amfebutamone,Bupropion Hcl','Wellbatrin,Wellbutrin,Wellbutrin SR,Wellbutrin XL,','Drug/Small Molecule','DailyMed:76e29f61-4f1e-4426-9865-b88dea3d0bb4,TTD:DAP000052,chebi:3219,chemSpider:431,dpd:2260239,drugBank:DB01156,keggCompound:C06860,keggDrug:D07591,ndc:0179-0022-44,pubChemCompound:444,pubChemSubstance:178415,pubChemSubstance:46506896,url:http://en.wikipedia.org/wiki/Bupropion','CC(C(=O)c1cccc(c1)Cl)NC(C)(C)C'),('PA448689','buspirone','Buspirona [INN-Spanish],Buspirone,Buspirone HCL,Buspironum [INN-Latin]','Ansial,Ansiced,Anxiron,Axoren,Bespar,Buspar,Buspim','Drug/Small Molecule','DailyMed:7c9eafb9-9ce1-4b28-900c-8fcb4b23424e,TTD:DAP000031,chebi:3223,chemSpider:2383,dpd:2242149,drugBank:DB00490,iupharLigand:36,keggCompound:C06861,ndc:0378-1140-01,pubChemCompound:2477,pubChemSubstance:46508113,pubChemSubstance:9079,url:http://en.wikipedia.org/wiki/Buspirone','c1cnc(nc1)N2CCN(CC2)CCCCN3C(=O)CC4(CCCC4)CC3=O'),('PA448691','busulfan','Busulphan,Busulphane,Butanedioldimethanesulfonate,Buzulfan,Sulfabutin,Sulphabutin,Tetramethylene Dimethane Sulfonate,Tetramethylenester Kyseliny Metha','Busulfex,Citosulfan,Leucosulfan,Mablin,Mielevcin,M','Drug/Small Molecule','DailyMed:03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,chebi:28901,chemSpider:2384,dpd:2240602,drugBank:DB01008,keggDrug:D00248,ndc:67286-0054-2,pubChemCompound:2478,pubChemSubstance:148760,pubChemSubstance:46506234,url:http://en.wikipedia.org/wiki/Busulfan','CS(=O)(=O)OCCCCOS(=O)(=O)C'),('PA448695','butalbital','Allylbarbital,Butalbital M (OH)','','','',''),('PA448704','butylated hydroxytoluene','','','Drug/Small Molecule','',''),('PA448708','cabergoline','Cabergolina [Spanish],Cabergolinum [Latin]','Cabaser,Dostinex','Drug/Small Molecule','DailyMed:ce51c53d-1cfa-4e5c-84d7-81024e10b4e8,TTD:DAP000251,chebi:3286,chemSpider:49452,dpd:2242471,drugBank:DB00248,iupharLigand:37,keggCompound:C08187,keggDrug:D00987,ndc:49884-673-14,pubChemCompound:54746,pubChemSubstance:10387,pubChemSubstance:46508571,url:http://en.wikipedia.org/wiki/Cabergoline','CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@@H]2c3cccc4c3c(c[nH]4)C[C@H]2N(C1)CC=C'),('PA448710','caffeine','1,3,7-trimethylxanthine,137X,CFF,Cafeina,Caffein,Caffeine Pure,Caffeine, Anhydrous,Caffeine, Monohydrate,Caffeine, Synthetic,Compound 65,Methyltheobro','Alert-Pep,Anoquan,Cafamil,Cafcit,Cafecon,Cafergot,','','',''),('PA448714','calcipotriol','Calcipotriene','Davonex,Dovonex','Drug/Small Molecule','DailyMed:fff63bc7-6b92-4080-9a11-017124d95162,HET:MC9,TTD:DAP000292,chebi:50749,dpd:1976133,drugBank:DB02300,keggDrug:D01125,ndc:0168-0400-60,pdb:MC9,pubChemCompound:5282134,pubChemSubstance:7848188,url:http://en.wikipedia.org/wiki/Calcipotriol',''),('PA448715','salmon calcitonin','Calcitonin 1 precursor,Calcitonin, salmon,Calcitonin-salmon,Salmotonin,salmon calcitonin','Calcimar,Miacalcin','Drug/Small Molecule','DailyMed:c82eb602-12e1-692b-d660-f8d5b5736b54,TTD:DAP001302,drugBank:DB00017,genBank:Y00765,iupharLigand:690,keggCompound:C06865,keggDrug:D00249,ndc:60505-0823-6,pubChemCompound:16129616,pubChemSubstance:7847315,uniProtKb:P01263,url:http://en.wikipedia.org/wiki/Calcitonin','C[C@H]([C@@H]1C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CO)CC(C)C)CC(=O)N)CO)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)N)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@H](CC3=CC=C(C=C3)O)C(=O)N4CCC[C@@H]4C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@H]([C@@H](C)O)C(=O)NCC(=O)N[C@H](CO)C(=O)NCC(=O)N[C@H]([C@H](C)O)C(=O)N5CCC[C@@H]5C(=O)N)O'),('PA448717','calcitriol','1,25-(OH)2D3,1,25-(oh)<sub>2</sub>d3,1,25-dihydroxycholecalciferol','Calcijex,Calcitriol Oral Solution,Decostriol,Rocal','Drug/Small Molecule','DailyMed:dc293a1c-995d-40fa-ac99-68df12eb6d9e,TTD:DAP000289,chebi:17823,dpd:2245686,drugBank:DB00136,keggCompound:C01673,keggDrug:D00129,ndc:0004-0143-23,pubChemCompound:134070,pubChemSubstance:4817,url:http://en.wikipedia.org/wiki/Calcitriol',''),('PA448718','calcium','','','Drug/Small Molecule','chebi:22984,drugBank:DB01373,url:http://en.wikipedia.org/wiki/Calcium',''),('PA448726','calcium carbonate','','','Drug/Small Molecule','','C(=O)([O-])[O-].[Ca+2]'),('PA448729','calcium chloride','Anhydrous calcium chloride,CaCl2,Calcium Chloride Dihydrate BP,Calcium chloride anhydrous,Calcium chloride dihydrate,Calcium chloride fused,Calcium ch','Bovikalc,Calcosan,Calmate R,Calol,Caloride,Calplus','','',''),('PA448735','calcium gluconate','','','Drug/Small Molecule','',''),('PA448744','calcium pantothenate','','','Drug/Small Molecule','',''),('PA448765','candesartan','Candesartan cilexetil','Amias,Atacand,Blopress,Ratacand','','',''),('PA448771','capecitabine','R340,capecitabine','Xeloda','Drug/Small Molecule','DailyMed:a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8,TTD:DAP000761,chebi:31348,chemSpider:54916,dpd:2238454,drugBank:DB01101,keggCompound:C12650,keggDrug:D01223,ndc:0004-1100-20,pubChemCompound:60953,pubChemSubstance:197173,pubChemSubstance:46508686,url:http://en.wikipedia.org/wiki/Capecitabine',''),('PA448776','capsaicin','','','Drug/Small Molecule','','CC(C)C=CCCCCC(=O)NCc1ccc(c(c1)OC)O'),('PA448780','captopril','Captoprilum [INN-Latin],Captopryl,L-Captopril','Acediur,Aceplus,Acepress,Acepril,Alopresin,Apopril','Drug/Small Molecule','DailyMed:5599d8f8-efc8-4acc-a507-280b89fd1dda,TTD:DAP000589,bindingDb:21642,chebi:3380,chemSpider:40130,dpd:2242791,drugBank:DB01197,keggDrug:D00251,ndc:0378-3007-01,pubChemCompound:44093,pubChemSubstance:46506879,pubChemSubstance:7847317,url:http://en.wikipedia.org/wiki/Captopril','C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O'),('PA448784','carbachol','','CB,Carbachol USP27,Carbachol chloride,Carbachol hy','Drug/Small Molecule','DailyMed:048af9c6-4866-4500-9914-cd7071a19b63,HET:CCE,TTD:DAP000347,chebi:3385,dpd:655,drugBank:DB00411,iupharLigand:298,keggDrug:D00524,ndc:58768-735-12,pdb:CCE,pubChemCompound:2551,pubChemSubstance:7978854,url:http://en.wikipedia.org/wiki/Carbachol','C[N+](C)(C)CCOC(=O)N.[Cl-]'),('PA448785','carbamazepine','Carbamezepine,carbamazepine','Apo-Carbamazepine,Atretol,Biston,Calepsin,Carbamaz','Drug/Small Molecule','DailyMed:a3360ae2-3ead-40bc-a967-2abecc9f9b7c,TTD:DAP000129,chebi:3387,chemSpider:2457,dpd:2241882,drugBank:DB00564,keggCompound:C06868,keggDrug:D00252,ndc:0228-2143-10,pubChemCompound:2554,pubChemSubstance:46507583,pubChemSubstance:7847318,url:http://en.wikipedia.org/wiki/Carbamazepine','c1ccc2c(c1)C=Cc3ccccc3N2C(=O)N'),('PA448788','carbenicillin','Carbenicilina [INN-Spanish],Carbenicillina [DCIT],Carbenicilline [INN-French],Carbenicillinum [INN-Latin],Carboxybenzylpenicillin,Carboxybenzylpenicil','Geopen,Pyopen','Drug/Small Molecule','TTD:DAP000438,chebi:3393,chemSpider:19599,drugBank:DB00578,keggCompound:C06869,pubChemCompound:20824,pubChemSubstance:46505653,pubChemSubstance:9086,url:http://en.wikipedia.org/wiki/Carbenicillin','CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(c3ccccc3)C(=O)O)C(=O)O)C'),('PA448794','carbidopa','Alpha-Methyldopahydrazine,Carbidopa Anhydrous,Carbidopa Monohydrate,Carbidopum [INN-Latin],N-Aminomethyldopa,c-dopa,mk-486','Atamet,HMD,Lodosin,Lodosyn','','',''),('PA448797','carbohydrates','','','Drug Class','',''),('PA448801','carbon dioxide','','','Drug/Small Molecule','','C(=O)=O'),('PA448803','carboplatin','CBDCA,cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)','Paraplatin,Paraplatin-AQ','Drug/Small Molecule','DailyMed:bdb0b6dd-91d3-4896-be6e-313ea907d8bb,TTD:DAP000535,chebi:31355,chemSpider:436073,dpd:2126680,drugBank:DB00958,keggDrug:D01363,ndc:0703-3249-11,pubChemCompound:38904,pubChemCompound:498142,pubChemSubstance:46507170,pubChemSubstance:794720,url:http://en.wikipedia.org/wiki/Carboplatin',''),('PA448809','carisoprodol','Carisoprodate,Carisoprodatum,Isomeprobamate,Isoprotane,Isoprothane','Apesan,Artifar,Arusal,Atonalyt,Caridolin,Carisoma,','Drug/Small Molecule','DailyMed:7d7d44b4-d405-4c48-9e79-cc128dd7aaeb,chebi:3419,chemSpider:2478,dpd:116629,drugBank:DB00395,keggCompound:C07927,keggDrug:D00768,ndc:12634-437-91,pubChemCompound:2576,pubChemSubstance:10129,pubChemSubstance:46506377,url:http://en.wikipedia.org/wiki/Carisoprodol','CCCC(C)(COC(=O)N)COC(=O)NC(C)C'),('PA448810','carmustine','BCNU,Bischlorethylnitrosourea,Bischlorethylnitrosurea,Carmustin','Becenun,Bi CNU,BiCNU,Carmubris,Gliadel,Gliadel Waf','Drug/Small Molecule','DailyMed:be6776fe-7f24-417d-ef08-8830c4eca959,TTD:DAP000041,chebi:3423,chemSpider:2480,dpd:2238985,drugBank:DB00262,keggDrug:D00254,ndc:0015-3012-60,pubChemCompound:2578,pubChemSubstance:152253,pubChemSubstance:46506980,url:http://en.wikipedia.org/wiki/Carmustine',''),('PA448814','carrageenan','','','Drug/Small Molecule','',''),('PA448817','carvedilol','Carvedilolum [Latin],carvedilol','Coreg,Coreg CR','Drug/Small Molecule','DailyMed:a6eb861c-085e-442a-8e71-722587493d5d,TTD:DAP000135,bindingDb:25759,chebi:3441,chemSpider:2487,dpd:2252317,drugBank:DB01136,iupharLigand:551,keggCompound:C06875,keggDrug:D00255,ndc:0228-2175-11,pubChemCompound:2585,pubChemSubstance:189887,pubChemSubstance:46505146,url:http://en.wikipedia.org/wiki/Carvedilol',''),('PA448827','castor oil','','','Drug/Small Molecule','',''),('PA448835','cefadroxil','CDX,Cefadroxil Monohydrate,Cefradroxil','Baxan,Bidocef,Cefa-Drops,Cefamox,Cephos,Duracef,Ke','Drug/Small Molecule','DailyMed:0ee42c97-d20c-4ee5-8f25-3a7539bda43b,TTD:DAP000446,chebi:3479,dpd:2240774,drugBank:DB01140,keggCompound:C06878,keggDrug:D00257,ndc:0781-2938-50,pubChemCompound:2610,pubChemSubstance:180636,url:http://en.wikipedia.org/wiki/Cefadroxil','c1cc(ccc1[C@H](C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)Cl)C(=O)O)N)O'),('PA448837','cefamandole','Cefadole,Cefamandole nafate','Mandol','Drug/Small Molecule','TTD:DAP000448,chebi:3480,chemSpider:401748,drugBank:DB01326,keggCompound:C06879,keggDrug:D02344,pubChemCompound:456255,pubChemSubstance:10302112,pubChemSubstance:46508882,url:http://en.wikipedia.org/wiki/Cefamandole','Cn1c(nnn1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)[C@@H](c4ccccc4)O)SC2)C(=O)O'),('PA448839','cefazolin','CEZ,Cefazolin sodium,Cefazoline,Cephazolin','Ancef','Drug/Small Molecule','DailyMed:4e9a1841-b44d-413e-6b98-c33c25095ba1,TTD:DAP000449,chebi:474053,dpd:2108119,drugBank:DB01327,keggCompound:C06880,keggDrug:D02299,ndc:0074-4732-03,pubChemCompound:656510,pubChemSubstance:9097,url:http://en.wikipedia.org/wiki/Cefazolin','Cc1nnc(s1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)Cn4cnnn4)SC2)C(=O)O'),('PA448849','cefoperazone','Cefoperazono [inn-spanish],Cefoperazonum [inn-latin]','Cefobid','Drug/Small Molecule','DailyMed:c6c2ef3b-2c53-4737-9f7d-2d7e040c6e87,TTD:DAP000450,chebi:3493,chemSpider:40204,drugBank:DB01329,keggCompound:C06883,ndc:0049-1201-83,pubChemCompound:44185,pubChemSubstance:184435,pubChemSubstance:46504543,url:http://en.wikipedia.org/wiki/Cefoperazone','CCN1CCN(C(=O)C1=O)C(=O)N[C@H](c2ccc(cc2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSc5nnnn5C)C(=O)O'),('PA448852','cefotaxime','Cefotaxime sodium,Cephotaxime','Claforan','Drug/Small Molecule','DailyMed:f3c5895f-f54b-43d4-9b38-7bfbdf8335b7,HET:CEF,TTD:DAP000146,chebi:204928,dpd:2225085,drugBank:DB00493,keggCompound:C06885,ndc:64679-947-01,pdb:CEF,pubChemCompound:456256,pubChemSubstance:9102,url:http://en.wikipedia.org/wiki/Cefotaxime','CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)C(=NOC)c3csc(n3)N)SC1)C(=O)O'),('PA448856','cefoxitin','','Mefoxin,Mefoxitin','Drug/Small Molecule','DailyMed:d2c449b9-5624-4166-95b1-d7813b3d0445,TTD:DAP000452,chebi:209807,chemSpider:389981,dpd:2128187,drugBank:DB01331,keggCompound:C06887,keggDrug:D02345,ndc:0143-9878-25,pubChemCompound:441199,pubChemSubstance:10298759,pubChemSubstance:46505845,url:http://en.wikipedia.org/wiki/Cefoxitin','CO[C@@]1([C@@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)Cc3cccs3'),('PA448861','ceftazidime','','Ceftazidima [INN-Spanish],Ceftazidime Sodium In Pl','Drug/Small Molecule','DailyMed:112c5457-8d71-49f5-b531-9761d7d38c93,HET:CAZ,TTD:DAP000433,chebi:3508,chemSpider:4587145,dpd:886963,drugBank:DB00438,keggCompound:C06889,ndc:25021-127-20,pdb:CAZ,pubChemCompound:5481173,pubChemSubstance:46506143,pubChemSubstance:9106,url:http://en.wikipedia.org/wiki/Ceftazidime','CC(C)(C(=O)O)ON=C(c1csc(n1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[n+]4ccccc4)C(=O)[O-]'),('PA448866','ceftriaxone','Cefatriaxone,Ceftriaxona [INN-Spanish],Ceftriaxonum [INN-Latin],Ceftriazone','Biotrakson,Rocephine','Drug/Small Molecule','DailyMed:60bc6eab-fc04-476f-a894-d3cd56fe8f6f,TTD:DAP000145,chebi:29007,chemSpider:4514885,dpd:657409,drugBank:DB01212,keggCompound:C06683,ndc:0703-0315-03,pubChemCompound:5361919,pubChemCompound:5479530,pubChemSubstance:189949,pubChemSubstance:46506458,url:http://en.wikipedia.org/wiki/Ceftriaxone','Cn1c(nc(=O)c(=O)[nH]1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(=NOC)c4csc(n4)N)SC2)C(=O)O'),('PA448868','cefuroxime','Cefuroxim,Cefuroxime [USAN:BAN:INN],Cefuroximo [INN-Spanish],Cefuroximum [INN-Latin]','Ancef,Biofuroksym,Cedax,Cefizox,Cefobid,Cefotan,Ce','Drug/Small Molecule','DailyMed:888998cc-c7f7-4f2a-8479-df60f77bc2a1,HET:CES,TTD:DAP000445,chebi:3515,dpd:2242657,drugBank:DB01112,keggCompound:C06894,keggDrug:D00262,ndc:0469-7220-01,pdb:CES,pubChemCompound:5361202,pubChemSubstance:182117,url:http://en.wikipedia.org/wiki/Cefuroxime','CON=C(c1ccco1)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O'),('PA448871','celecoxib','Celocoxib,celecoxib','Celebra,Celebrex','Drug/Small Molecule','DailyMed:8d52185d-421f-4e34-8db7-f7676db2a226,HET:CEL,TTD:DAP000737,bindingDb:11639,chebi:3520,chemSpider:2562,dpd:2239941,drugBank:DB00482,keggCompound:C07589,keggDrug:D00567,ndc:0025-1515-01,pdb:CEL,pubChemCompound:2662,pubChemSubstance:205043,pubChemSubstance:46505596,url:http://en.wikipedia.org/wiki/Celecoxib','Cc1ccc(cc1)c2cc(nn2c3ccc(cc3)S(=O)(=O)N)C(F)(F)F'),('PA448873','cellulose','','','Drug/Small Molecule','',''),('PA448883','cephalexin','CEX,Cefalessina [DCIT],Cefalexin,Cefalexin Sodium,Cefalexina [INN-Spanish],Cefalexine [INN-French],Cefalexinum [INN-Latin],Cephalexin 1-hydrate,Cephal','Alcephin,Alexin,Alsporin,Biocef,Carnosporin,Cefa-i','Drug/Small Molecule','DailyMed:25b87a16-3e28-45b5-9ae8-98053f1f387a,TTD:DAP000437,bindingDb:50139896,chebi:3534,chemSpider:25541,dpd:828858,drugBank:DB00567,keggCompound:C06895,keggDrug:D00263,ndc:16714-641-01,pubChemCompound:27447,pubChemSubstance:46506749,pubChemSubstance:625390,url:http://en.wikipedia.org/wiki/Cephalexin','CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](c3ccccc3)N)SC1)C(=O)O'),('PA448886','cefalotin','CLS,Cefalothin,Cefalotina [INN-Spanish],Cefalotine [INN-French],Cefalotinum [INN-Latin],Cephalothin,Cephalothin Sodium,Cephalothinum,Cephalotin','Averon-1,Cemastin,Coaxin,Keflin,Seffin','Drug/Small Molecule','HET:CEO,TTD:DAP000155,chebi:124991,chemSpider:5802,dpd:2060051,drugBank:DB00456,keggCompound:C07761,pdb:CEO,pubChemCompound:6024,pubChemSubstance:46509079,pubChemSubstance:9963,url:http://en.wikipedia.org/wiki/Cefalotin',''),('PA448890','cefradine','Cephradine','','Drug/Small Molecule','TTD:DAP000454,chebi:3547,chemSpider:34933,drugBank:DB01333,keggCompound:C06897,keggDrug:D00264,ndc:0003-0113-24,pubChemCompound:38103,pubChemSubstance:11335914,pubChemSubstance:46505082,url:http://en.wikipedia.org/wiki/Cefradine',''),('PA448897','cerivastatin','Cerivastatin sodium,Cerivastatin, sodium salt','Baycol,Lipobay,Rivastatin','Drug/Small Molecule','bindingDb:18376,chebi:3558,chemSpider:393588,dpd:2237325,drugBank:DB00439,keggCompound:C07966,pdb:116,pubChemCompound:446156,pubChemSubstance:206660,pubChemSubstance:46505877,url:http://en.wikipedia.org/wiki/Cerivastatin','CC(C)c1c(c(c(c(n1)C(C)C)/C=C/[C@H](C[C@H](CC(=O)O)O)O)c2ccc(cc2)F)COC'),('PA448905','cetirizine','Cetirizina [Spanish],Cetirizinum [Latin],Cetrizine Hcl','Alerlisin,Cetryn,Formistin,Hitrizin Film Tablet,Re','Drug/Small Molecule','DailyMed:d2166bf5-41a2-4592-8428-818f0dad402d,TTD:DAP000323,bindingDb:22890,chebi:3561,chemSpider:2577,dpd:2240910,drugBank:DB00341,iupharLigand:1214,iupharLigand:1215,iupharLigand:1222,keggCompound:C07778,ndc:16714-271-02,pubChemCompound:2678,pubChemSubstance:192657,pubChemSubstance:46508368,url:http://en.wikipedia.org/wiki/Cetirizine','c1ccc(cc1)C(c2ccc(cc2)Cl)N3CCN(CC3)CCOCC(=O)O'),('PA448918','charcoal preparations','','','Drug Class','',''),('PA448925','chloral hydrate','','Aquachloral Supprettes,Somnote','Drug/Small Molecule','chebi:28142,chemSpider:2606,dpd:792659,drugBank:DB01563,keggCompound:C06899,keggDrug:D01302,pubChemCompound:2707,pubChemSubstance:46507155,pubChemSubstance:9116,url:http://en.wikipedia.org/wiki/Chloral_hydrate',''),('PA448926','chlorambucil','Chlocambucil,Chloraminophen,Chloraminophene,Chlorbutin,Chlorbutine,Chloroambucil,Chlorobutin,Chlorobutine,Phenylbutyric Acid Nitrogen Mustard','Ambochlorin,Amboclorin,Ecloril,Elcoril,Leukeran,Le','Drug/Small Molecule','DailyMed:6b2023e7-50dc-49c3-949d-1bc10ba256f0,TTD:DNC001110,chebi:28830,chemSpider:2607,dpd:4626,drugBank:DB00291,keggDrug:D00266,ndc:0173-0635-35,pubChemCompound:2708,pubChemSubstance:152571,pubChemSubstance:46506842,url:http://en.wikipedia.org/wiki/Chlorambucil','c1cc(ccc1CCCC(=O)O)N(CCCl)CCCl'),('PA448927','chloramphenicol','CAF,CAM,CAP,CPh,Chloramfenikol,Chloramphenicole,Chloroamphenicol,Cloroamfenicolo,D-Chloramphenicol','Ak-Chlor Ophthalmic Ointment,Ak-Chlor Ophthalmic S','','',''),('PA448932','chlordiazepoxide','','A-Poxide,Abboxide,Apo-Chlordiazepoxide,Balance,CD ','','',''),('PA448939','chlormezanone','Chlormethazanone,Chlormethazone,Chlormezanon,Chlormezanone [BAN:INN:JAN],Chlormezanonum [INN-Latin],Clormetazanone,Clormetazon,Clormezanona [INN-Spani','Alinam,Banabil-sintyal,Banabin,Banabin-Sintyal,Ban','','',''),('PA448942','chlorophyll','','','Drug/Small Molecule','',''),('PA448946','chloroprocaine','Chloroprocain,Chloroprocaine hydrochloride,Chlorprocaine','Halestyn,Nesacaine-CE,Nesacaine-MPF','Drug/Small Molecule','DailyMed:ec4ab877-878f-4b0e-3eb6-106a606479ad,TTD:DAP000131,chebi:3636,chemSpider:8293,dpd:613304,drugBank:DB01161,keggDrug:D00732,ndc:0409-4169-01,pubChemCompound:8612,pubChemSubstance:10079,pubChemSubstance:46508245,url:http://en.wikipedia.org/wiki/Chloroprocaine',''),('PA448948','chloroquine','Chloraquine,Chlorochine,Chloroquina,Chloroquine Phosphate,Chloroquinium,Chlorquin,Clorochina,Hydroxychloroquine Sulfate','3377 RP opalate,Amokin,Aralen,Aralen HCl,Arechin,A','Drug/Small Molecule','DailyMed:b48476e0-9f63-483e-89fe-1af123665951,HET:CLQ,TTD:DAP001357,bindingDb:22985,chebi:3638,chemSpider:2618,dpd:21261,drugBank:DB00608,keggCompound:C07625,keggDrug:D02366,ndc:0024-0084-01,pdb:CLQ,pubChemCompound:2719,pubChemSubstance:46506925,pubChemSubstance:9827,url:http://en.wikipedia.org/wiki/Chloroquine','CCN(CC)CCCC(C)Nc1ccnc2c1ccc(c2)Cl'),('PA448953','chlorothiazide','Chlorothiazid,Chlorthiazide,Chlortiazid','Aldoclor,Alurene,Azide,Chloriazid,Chlorosal,Chloru','','',''),('PA448960','chlorpheniramine','Chloropheniramine,Chlorophenylpyridamin,Chlorophenylpyridamine,Chloroprophenpyridamine,Chlorphenamine,Chlorpheniramine Maleate,Chlorprophenpyridamine,','Aller-Chlor,Allergican,Allergisan,Antagonate,Chlo-','','',''),('PA448964','chlorpromazine','','Chloropromazine,Chlorpromanyl,Chlorpromanyl-20,Chl','Drug/Small Molecule','DailyMed:f15e9f35-1e3e-4217-b8e2-1d6096dbee1b,TTD:DAP000374,chebi:3647,chemSpider:2625,dpd:21342,drugBank:DB00477,iupharLigand:83,keggCompound:C06906,keggDrug:D00270,ndc:0781-1715-01,pubChemCompound:2726,pubChemSubstance:148556,pubChemSubstance:46508395,url:http://en.wikipedia.org/wiki/Chlorpromazine','CN(C)CCCN1c2ccccc2Sc3c1cc(cc3)Cl'),('PA448966','chlorpropamide','chlorporpamide','Adiaben,Apo-Chlorpropamide,Asucrol,Catanil,Chlorod','Drug/Small Molecule','DailyMed:baa54287-8065-da1a-f19e-ce8daf61bd01,TTD:DAP000923,chebi:3650,chemSpider:2626,dpd:156728,drugBank:DB00672,keggDrug:D00271,ndc:0378-0197-01,pubChemCompound:2727,pubChemSubstance:150222,pubChemSubstance:46506402,url:http://en.wikipedia.org/wiki/Chlorpropamide','CCCNC(=O)NS(=O)(=O)c1ccc(cc1)Cl'),('PA448970','chlorthalidone','Chlorothalidone,Chlorphthalidolone,Chlorphthalidone,Chlortalidone,Chlorthalidon,Clodronic Acid','Higroton,Hydro-Long,Hygroton,Igroton,Isoren,Natriu','','',''),('PA448971','chlorzoxazone','Chloroxazone,Chlorzoxane,Chlorzoxazon','Biomioran,EZE-DS,Escoflex,Flexazone,Mioran,Miotran','','',''),('PA448974','cholestyramine','Colestyramine','Cholybar,Locholest,Locholest light,Novo-Cholamine,','Drug/Small Molecule','DailyMed:9269d9ba-d791-4865-8a39-abd1733d79bd,dpd:890960,drugBank:DB01432,ndc:0185-0940-97,url:http://en.wikipedia.org/wiki/Cholestyramine',''),('PA448976','choline','(2-Hydroxyethyl)trimethylammonium,2-Hydroxy-N,N,N-trimethylethanaminium,Bilineurine,Choline cation,Choline ion,Cholinum,n,n,n-trimethylethanol-ammoniu','','Drug/Small Molecule','HET:CHT,chebi:15354,chemSpider:299,drugBank:DB00122,keggCompound:C00114,pdb:CHT,pubChemCompound:305,pubChemSubstance:149004,pubChemSubstance:46508132,url:http://en.wikipedia.org/wiki/Choline','C[N+](C)(C)CCO'),('PA448989','chromium','','','Drug/Small Molecule','','[Cr]'),('PA448994','chymotrypsin','','','Drug/Small Molecule','',''),('PA448997','cidofovir','CDV,Cidofovir Anhydrous','HPMPC,Vistide','Drug/Small Molecule','DailyMed:90639fc6-0295-4115-98f0-054b783850ce,TTD:DAP001083,bindingDb:31915,chebi:3696,chemSpider:54636,drugBank:DB00369,keggCompound:C06909,ndc:61958-0101-1,pubChemCompound:60613,pubChemSubstance:196891,pubChemSubstance:46506054,url:http://en.wikipedia.org/wiki/Cidofovir',''),('PA448998','cilastatin','','','','',''),('PA449001','cimetidine','Cimetidine A/AB,Cimetidine Hcl','Acibilin,Acinil,Cimal,Cimetag,Cimetum,Dyspamet,Eda','Drug/Small Molecule','TTD:DAP000338,bindingDb:22889,chebi:30731,chebi:3699,chemSpider:2654,dpd:749494,drugBank:DB00501,iupharLigand:1231,keggDrug:D00295,ndc:0093-8181-01,pubChemCompound:2756,pubChemSubstance:180968,pubChemSubstance:46505360,url:http://en.wikipedia.org/wiki/Cimetidine','Cc1c(nc[nH]1)CSCCNC(=NC#N)NC'),('PA449007','cinoxacin','','Cinobac','Drug/Small Molecule','TTD:DAP000999,chebi:3716,chemSpider:2660,drugBank:DB00827,keggCompound:C08052,keggDrug:D00872,pubChemCompound:2762,pubChemSubstance:10252,pubChemSubstance:46507547,url:http://en.wikipedia.org/wiki/Cinoxacin',''),('PA449009','ciprofloxacin','Ciprofloxacin HCl,Ciprofloxacin dihydrochloride,Ciprofloxacin hydrochloride,Ciprofloxacin monohydrochloride,Ciprofloxacina,ciprofloxacin','Bacquinor,Baycip,Bernoflox,Ciflox,Cifloxin,Ciloxan','','',''),('PA449011','cisapride','cisapride','Acenalin,Alimix,Cipril,Enteropride,Kinestase,Prepu','Drug/Small Molecule','TTD:DAP000222,bindingDb:50005836,chebi:3720,dpd:2054817,drugBank:DB00604,iupharLigand:240,keggCompound:C06910,keggDrug:D00274,pubChemCompound:2769,pubChemSubstance:192212,url:http://en.wikipedia.org/wiki/Cisapride','COc1cc(c(cc1C(=O)N[C@H]2CCN(C[C@@H]2OC)CCCOc3ccc(cc3)F)Cl)N'),('PA449014','cisplatin','CACP,CPDC,CPDD,Cis-DDP,Cis-Diaminedichloroplatinum,Cis-Diamminedichloroplatinum,DDP,DDPT,Diamminedichloroplatinum,Platinum Ammine Chloride,Platinum Am','Abiplatin,Biocisplatinum,Briplatin,Carboquone,Cis ','Drug/Small Molecule','TTD:DAP000215,chebi:27899,chemSpider:389985,dpd:2126613,drugBank:DB00515,keggCompound:C06911,keggDrug:D00275,ndc:0015-3072-20,pubChemCompound:441203,pubChemSubstance:46504561,pubChemSubstance:7847341,url:http://en.wikipedia.org/wiki/Cisplatin','[NH3][Pt]([NH3])(Cl)Cl'),('PA449015','citalopram','Citalopram Hydrobromide,Citalopramum [INN-Latin]','Akarin,Celapram,Celexa,Celius,Ciazil,Cilift,Cipram','Drug/Small Molecule','DailyMed:825c0c49-5fbf-6d8b-cb8c-94ebf0eda043,TTD:DAP000118,bindingDb:25870,chebi:3723,chemSpider:2669,dpd:2248051,drugBank:DB00215,keggCompound:C07572,keggDrug:D07704,ndc:0378-6231-01,pubChemCompound:2771,pubChemSubstance:183529,pubChemSubstance:46508746,url:http://en.wikipedia.org/wiki/Citalopram','CN(C)CCCC1(c2ccc(cc2CO1)C#N)c3ccc(cc3)F'),('PA449021','citric acid','','','Drug/Small Molecule','bindingDb:14672,chebi:30769,drugBank:DB04272,iupharLigand:2478,keggCompound:C00158,keggDrug:D00037,pdb:CIT,pubChemCompound:311,pubChemSubstance:3458','C(C(=O)O)C(CC(=O)O)(C(=O)O)O'),('PA449027','cladribine','2-CdA,2-Chloro-2\'-deoxy-beta-adenosine,2-Chloro-2\'-deoxyadenosine,2-Chlorodeoxyadenosine,Chlorodeoxyadenosine,cladribine','Leustatin,Mylinax','Drug/Small Molecule','DailyMed:a8675658-29a2-4af8-9a51-3fa3f7ddc5d5,TTD:DAP000565,chebi:567361,chemSpider:19105,dpd:2022117,drugBank:DB00242,keggDrug:D01370,ndc:59676-201-01,pubChemCompound:20279,pubChemSubstance:46504588,pubChemSubstance:7848433,url:http://en.wikipedia.org/wiki/Cladribine',''),('PA449028','clarithromycin','CLA,Clarithromycine,Clathromycin','Biaxin,Biaxin XL,Clarithriomycin,Klacid,Klaricid,M','Drug/Small Molecule','DailyMed:fa1a9323-3b54-4b6b-850d-ae5b7d5ccbc6,TTD:DAP000410,chebi:3732,dpd:2244756,drugBank:DB01211,keggCompound:C06912,keggDrug:D00276,ndc:0378-8250-91,pubChemCompound:84029,pubChemSubstance:602963,url:http://en.wikipedia.org/wiki/Clarithromycin',''),('PA449035','clindamycin','Clindamicina [INN-Spanish],Clindamycin Hcl,Clindamycin Hydrochloride,Clindamycin Phosphate,Clindamycine [French],Clindamycine [INN-French],Clindamycin','Chlolincocin,Cleocin,Cleocin Hcl,Cleocin Pediatric','Drug/Small Molecule','DailyMed:df9a2a41-b132-4f43-8940-b2d773b1369a,HET:CLY,TTD:DAP000409,chebi:3745,chemSpider:27005,dpd:2258331,drugBank:DB01190,keggCompound:C06914,keggDrug:D00277,ndc:0009-0331-02,pdb:CLY,pubChemCompound:29029,pubChemSubstance:171415,pubChemSubstance:46506073,url:http://en.wikipedia.org/wiki/Clindamycin',''),('PA449045','clofibrate','CPIB,Chlorfenisate,Chlorphenisate,Clofibate,Clofibrato,Clofibratum,EPIB,Ethyl chlorophenoxyisobutyrate,Ethyl clofibrate,Ethyl p-chlorophenoxyisobutyra','Amotril,Amotril S,Angiokapsul,Anparton,Antilipid,A','Drug/Small Molecule','TTD:DAP000262,chebi:3750,chemSpider:2694,dpd:2038,drugBank:DB00636,keggCompound:C06916,keggDrug:D00279,pubChemCompound:2796,pubChemSubstance:46504748,pubChemSubstance:9133,url:http://en.wikipedia.org/wiki/Clofibrate','CCOC(=O)C(C)(C)Oc1ccc(cc1)Cl'),('PA449046','clomifene','Chlomaphene,Chloramifene,Chloramiphene,Cisclomiphene,Clomifene citrate,Clomifeno,Clomiphene Citrate,Clomiphene citrate,Clomiphene dihydrogen citrate,R','Androxal,Clomid,Clomifert,Clomiphene,Clomiphene B,','Drug/Small Molecule','DailyMed:df518802-0efd-4da4-816d-65a7e92cecd2,TTD:DAP001013,bindingDb:50170640,chebi:3752,dpd:640158,drugBank:DB00882,keggCompound:C06917,keggDrug:D00962,ndc:0068-0226-30,pubChemCompound:1548955,pubChemSubstance:156834,url:http://en.wikipedia.org/wiki/Clomifene',''),('PA449048','clomipramine','3-Chloroimipramine,Chlorimipramine,Clomipramina [INN-Spanish],Clomipramine HCL,Clomipraminum [INN-Latin],Monochlorimipramine','Anafranil,Hydiphen','Drug/Small Molecule','DailyMed:3823106e-6be3-4154-a607-caa3a69dc75c,HET:CXX,TTD:DAP000742,bindingDb:50021927,chebi:47780,chemSpider:2699,dpd:2244818,drugBank:DB01242,iupharLigand:2398,keggCompound:C06918,ndc:0781-2027-31,pdb:CXX,pubChemCompound:2801,pubChemSubstance:152550,pubChemSubstance:46505157,url:http://en.wikipedia.org/wiki/Clomipramine','CN(C)CCCN1c2ccccc2CCc3c1cc(cc3)Cl'),('PA449050','clonazepam','Chlonazepam,Clonazepamum','Antelepsin,Antilepsin,Cloazepam,Clonopin,Iktorivil','Drug/Small Molecule','DailyMed:542f22e8-dad2-47a8-93b6-30936715d73b,TTD:DAP000259,bindingDb:50019213,chebi:3756,chemSpider:2700,dpd:2242078,drugBank:DB01068,keggDrug:D00280,ndc:0004-0068-01,pubChemCompound:2802,pubChemSubstance:158706,pubChemSubstance:46507677,url:http://en.wikipedia.org/wiki/Clonazepam','c1ccc(c(c1)C2=NCC(=O)Nc3c2cc(cc3)N(=O)=O)Cl'),('PA449051','clonidine','Chlornidinum,Clonidin,Clonidine HCl,Clonidinhydrochlorid,Clonidinum [INN-Latin],ST 155BS','Adesipress,Catapres,Catapres-TTS,Catapresan,Catapr','','',''),('PA449053','clopidogrel','','Clopidogrel [Ban:Inn],Clopidogrel sulfate,Plavix','Drug/Small Molecule','DailyMed:01b14603-8f29-4fa3-8d7e-9d523f802e0b,TTD:DAP000178,chebi:37941,chemSpider:54632,dpd:2238682,drugBank:DB00758,keggDrug:D00769,ndc:63653-1171-6,pubChemCompound:60606,pubChemSubstance:196885,pubChemSubstance:46507295,url:http://en.wikipedia.org/wiki/Clopidogrel','COC(=O)[C@H](c1ccccc1Cl)N2CCc3c(ccs3)C2'),('PA449057','clotrimazole','Chlotrimazole,Clotrimazol','Canesten,Canesten 1-Day Cream Combi-Pak,Canesten 1','','',''),('PA449059','cloxacillin','Cloxacillin Sodium','Novo-Cloxin,Nu-Cloxi','Drug/Small Molecule','HET:CXN,TTD:DAP001161,chebi:3765,chemSpider:5873,dpd:337757,drugBank:DB01147,keggCompound:C06923,pdb:CXN,pubChemCompound:6098,pubChemSubstance:46507109,pubChemSubstance:9140,url:http://en.wikipedia.org/wiki/Cloxacillin','Cc1c(c(no1)c2ccccc2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O'),('PA449061','clozapine','Clozapin','Asaleptin,Clozaril,Fazaclo ODT,Iprox,Leponex,Lepot','Drug/Small Molecule','DailyMed:53bdb79c-c4cf-4818-b1f0-225e67a14536,TTD:DAP000029,bindingDb:22869,chebi:3766,chemSpider:2716,dpd:2240669,drugBank:DB00363,iupharLigand:38,keggCompound:C06924,keggDrug:D00283,ndc:57664-345-88,pubChemCompound:2818,pubChemSubstance:46506474,pubChemSubstance:7847349,url:http://en.wikipedia.org/wiki/Clozapine','CN1CCN(CC1)C2=Nc3cc(ccc3Nc4c2cccc4)Cl'),('PA449069','vitamin b12 and folic acid','','','Drug Class','',''),('PA449072','cocaine','Badrock,Bazooka,Benzoylethylecgonine,Benzoylmethylecgonine,Bernice,Bernies,Beta-Cocain,Blast,Blizzard,Blow,Bouncing Powder,Bump,Burese,COC,Cabello,Can','Cocaine','Drug/Small Molecule','TTD:DAP000834,bindingDb:50006232,chebi:27958,dpd:2006308,drugBank:DB00907,iupharLigand:2286,keggCompound:C01416,keggDrug:D00110,pubChemCompound:5760,pubChemSubstance:148543,url:http://en.wikipedia.org/wiki/Cocaine','CN1C2CCC1[C@H]([C@H](C2)OC(=O)c3ccccc3)C(=O)OC'),('PA449088','codeine','Codeine anhydrous,L-Codeine,Methylmorphine,Morphine monomethyl ether,Norcodeine, N-Methyl,Norcodine, N-Methyl','Codicept,Coducept','Drug/Small Molecule','TTD:DAP000213,chebi:16714,chemSpider:4447447,dpd:593451,drugBank:DB00318,iupharLigand:1673,keggCompound:C06174,pubChemCompound:5284371,pubChemSubstance:149398,pubChemSubstance:46507764,url:http://en.wikipedia.org/wiki/Codeine','CN1CC[C@]23c4c5ccc(c4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)OC'),('PA449092','colchicine','Colchicin,Colchicina,Colchicinum','Col-probenecid,Colbenemid,Colcrys,Condylon,Proben-','','',''),('PA449095','colesevelam','Colesevelam hydrochloride','CholestaGel,Welchol','Drug/Small Molecule','DailyMed:4a06d3b2-7229-4398-baba-5d0a72f63821,chemSpider:140701,drugBank:DB00930,ndc:65597-701-18,pubChemCompound:160051,pubChemSubstance:737515,url:http://en.wikipedia.org/wiki/Colesevelam','CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C.C=CCN.C1[C@H](O1)CCl.Cl.[Cl-]'),('PA449096','colestipol','Colestipolum [INN-Latin]','Cholestabyl,Colestid','Drug/Small Molecule','chemSpider:56550,dpd:642975,drugBank:DB00375,keggCompound:C06925,ndc:59762-0260-1,pubChemCompound:62816,pubChemSubstance:429654,pubChemSubstance:46505777,url:http://en.wikipedia.org/wiki/Colestipol',''),('PA449107','collagenase','AA4500,collagenase','Cordase,Santyl,Xiaflextm','Drug/Small Molecule','TTD:DAP000965,dpd:2063670,drugBank:DB00048,keggCompound:C00816,pubChemSubstance:4074,url:http://en.wikipedia.org/wiki/Collagenase',''),('PA449114','copper','','Copper T Model Tcu 380a,Cu-7,Tatum-T','Drug/Small Molecule','','[Cu]'),('PA449119','copper sulfate','copper sulfate','','Drug/Small Molecule','','[O-]S(=O)(=O)[O-].[Cu+2]'),('PA449122','corn oil','','','Drug/Small Molecule','',''),('PA449129','corticotropin','ACTH,Adrenocorticotopin,Adrenocorticotropic hormone,Corticotrophin,Cortrophin','Acethropan,Acortan,Acthar,Exacthin,H.P. Acthar Gel','Drug/Small Molecule','drugBank:DB01285,keggCompound:C02017,keggDrug:D00146,pubChemSubstance:7847214,url:http://en.wikipedia.org/wiki/Adrenocorticotropic_hormone',''),('PA449130','cortisone acetate','','','Drug/Small Molecule','DailyMed:73673e2d-8d33-4719-92ce-ab619de343b0,chemSpider:5543,dpd:280437,drugBank:DB01380,keggCompound:C08173,keggDrug:D00973,ndc:0009-0015-01,pubChemCompound:5745,pubChemSubstance:10373,pubChemSubstance:46508852,url:http://en.wikipedia.org/wiki/Cortisone_acetate','CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O'),('PA449138','cromoglicate','Acide Cromoglicique [INN-French],Acido Cromoglicico [INN-Spanish],Acidum Cromoglicicum [INN-Latin],Cromoglicic Acid,Cromoglycate,Cromoglycic Acid,Crom','Aarane,Alercom,Alerion,Allergocrom,Apo-Cromolyn,Ch','Drug/Small Molecule','DailyMed:a6db4e26-c124-4869-ad33-7082026ea774,TTD:DAP000819,chebi:3922,chebi:59773,dpd:2231671,drugBank:DB01003,keggCompound:C06928,keggDrug:D07753,ndc:24208-300-10,pubChemCompound:27686,pubChemSubstance:170250,url:http://en.wikipedia.org/wiki/Cromoglicate',''),('PA449160','cyclobenzaprine','Cyclobenzaprine HCL','Cyclobenz,Flexeril,Flexiban,Proeptatriene,Prohepta','Drug/Small Molecule','DailyMed:c21a7f59-09c3-485a-b6d9-3b784b7e9042,TTD:DAP000891,chebi:3996,chemSpider:2792,dpd:2249359,drugBank:DB00924,keggCompound:C06931,ndc:0179-0057-30,pubChemCompound:2895,pubChemSubstance:46508313,pubChemSubstance:9148,url:http://en.wikipedia.org/wiki/Cyclobenzaprine','CN(C)CCC=C1c2ccccc2C=Cc3c1cccc3'),('PA449165','cyclophosphamide','cyclophosphamide','ASTA,Asta B 518,CP,CPA,CTX,CY,Clafen,Claphene,Cycl','','',''),('PA449167','cyclosporine','Ciclosporin,Cyclosporin,Cyclosporin A,cyclosporine','Gengraf,Neoral,Restasis,Sandimmune,Sangcya','Drug/Small Molecule','DailyMed:5e5926a7-1de0-4b54-a5c0-286b6200ff82,TTD:DNC001177,chebi:4031,dpd:593257,drugBank:DB00091,keggCompound:C05086,keggDrug:D00184,ndc:0078-0240-15,pubChemCompound:6435893,pubChemSubstance:199551,url:http://en.wikipedia.org/wiki/Cyclosporine','CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C'),('PA449168','cyclothiazide','Ciclotiazida [INN-Spanish],Ciclotiazide [DCIT],Cyclothiazidum [INN-Latin]','Anhydron,Aquirel,Doburil,Fluidil,Renazide,Valmiran','Drug/Small Molecule','HET:CYZ,TTD:DAP000604,bindingDb:50192229,chebi:31448,chemSpider:2807,drugBank:DB00606,keggCompound:C12685,keggDrug:D01256,pdb:CYZ,pubChemCompound:2910,pubChemSubstance:46508269,pubChemSubstance:583075',''),('PA449171','cysteamine','(2-Mercaptoethyl)amine,2-Amino-1-ethanethiol,2-Aminoethanethiol,2-Aminoethyl mercaptan,2-Mercaptoethanamine,Aminoethyl mercaptan,Cisteamina,Cysteamide','Becaptan,Cystavision,Lambraten,Lambratene,Mecramin','Drug/Small Molecule','DailyMed:f495b76d-96c6-48e5-8fa3-30a4336628eb,TTD:DAP001297,bindingDb:7968,chebi:17141,chemSpider:5834,drugBank:DB00847,keggCompound:C01678,keggDrug:D03634,ndc:0378-9040-05,pubChemCompound:6058,pubChemSubstance:46507730,pubChemSubstance:4821,url:http://en.wikipedia.org/wiki/Cysteamine',''),('PA449173','l-cysteine','(R)-2-Amino-3-mercaptopropanoic acid,(R)-Cysteine,2-Amino-3-mercaptopropionic acid,3-mercapto-L-Alanine,Cys,Cystein,Half-cystine,L-(+)-Cysteine,L-2-Am','','','',''),('PA449176','l-cystine','(-)-Cystine,Cysteine disulfide,Cystine acid,L-Dicysteine,L-alpha-Diamino-beta-dithiolactic acid','','Drug/Small Molecule','chebi:16283,chemSpider:60997,drugBank:DB00138,keggCompound:C00491,keggDrug:D03636,pubChemCompound:67678,pubChemSubstance:3774,pubChemSubstance:46506670',''),('PA449177','cytarabine','Ara-C,AraC,Arabinocytidine,Arabinofuranosylcytosine,Arabinosylcytosine,Aracytidine,Aracytin,Aracytine,Beta-cytosine arabinoside,Citarabina [INN-Spanis','AR3,Alexan,Arabitin,Arafcyt,Cytarbel,Cytosar,Cytos','Drug/Small Molecule','DailyMed:9d05d299-b9b0-4bf6-95cf-904dcc4e1f84,HET:AR3,TTD:DNC001551,chebi:28680,chemSpider:6017,dpd:2167883,drugBank:DB00987,keggCompound:C02961,keggDrug:D00168,ndc:57665-331-01,pdb:AR3,pubChemCompound:6253,pubChemSubstance:46505879,pubChemSubstance:7847236,url:http://en.wikipedia.org/wiki/Cytarabine','c1cn(c(=O)nc1N)C[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O'),('PA449197','dacarbazine','Biocarbazine R,DIC,DTIC,DTIE,Dacarbazino [INN-Spanish],Dacarbazinum [INN-Latin],Dtic-Dome,ICDMT,ICDT,Imidazole Carboxamide','Deticene','Drug/Small Molecule','DailyMed:26e91082-7698-4680-beab-07c47802f0f9,TTD:DAP000533,chebi:4305,dpd:2241445,drugBank:DB00851,keggDrug:D00288,ndc:0703-5075-01,pubChemCompound:5351166,pubChemSubstance:163170,url:http://en.wikipedia.org/wiki/Dacarbazine','CN(C)N=Nc1c(nc[nH]1)C(=O)N'),('PA449208','dantrolene','Dantrolene Sodium,Dantroleno [INN-Spanish],Dantrolenum [INN-Latin]','Dantrium,Dantrium Intravenous','Drug/Small Molecule','TTD:DNC001623,chebi:4317,dpd:1997602,drugBank:DB01219,keggCompound:C06939,keggDrug:D02347,ndc:27505-001-66,pubChemCompound:2952,pubChemSubstance:9154,url:http://en.wikipedia.org/wiki/Dantrolene',''),('PA449211','dapsone','Acedapsone,DADPS,DDS,DSS,Dapson,Dapsonum,Dds, Diaphenylsulfone,Dds, Pharmaceutical,Diamino-diphenyl sulphone,Diaminodifenilsulfona,Diaminodiphenyl Sul','Araldite Ht,Avlosulfon,Avlosulfone,Avlosulphone,Cr','Drug/Small Molecule','DailyMed:aa249ecd-afd3-4800-b196-d4f7b8c8fc6e,TTD:DAP000637,bindingDb:50029764,chebi:4325,chemSpider:2849,dpd:2041510,drugBank:DB00250,keggCompound:C07666,keggDrug:D00592,ndc:0469-5005-03,pubChemCompound:2955,pubChemSubstance:46505300,pubChemSubstance:7847658,url:http://en.wikipedia.org/wiki/Dapsone','c1cc(ccc1N)S(=O)(=O)c2ccc(cc2)N'),('PA449212','daunorubicin','','Acetyladriamycin,Anthracyline,Antibiotics From Str','Drug/Small Molecule','DailyMed:29fe455e-f177-4b0e-99fb-60a53016db72,HET:BNR,TTD:DNC000517,chebi:4330,chemSpider:28163,dpd:2231420,drugBank:DB00694,keggCompound:C01907,ndc:0703-5233-13,pdb:BNR,pubChemCompound:30323,pubChemSubstance:172470,pubChemSubstance:46508433,url:http://en.wikipedia.org/wiki/Daunorubicin',''),('PA449223','delavirdine','DLV,SPP','Bhap Der,Rescriptor','Drug/Small Molecule','DailyMed:2d16f118-c185-4956-8a55-f0dbd5182b50,HET:SPP,TTD:DAP000183,bindingDb:1944,chebi:119573,chemSpider:5423,dpd:2238348,drugBank:DB00705,keggCompound:C06941,ndc:63010-020-36,pdb:SPP,pubChemCompound:5625,pubChemSubstance:206947,pubChemSubstance:46508878,url:http://en.wikipedia.org/wiki/Delavirdine',''),('PA449233','desipramine','DMI,Demethylimipramine,Desimipramine,Desimpramine,Desipramin,Desipramine Hcl,Desmethylimipramine,Dezipramine,Dimethylimipramine,Methylaminopropylimino','Norpramin,Pentofran,Pertofran,Pertrofane,Sertofran','Drug/Small Molecule','DailyMed:7ec5f73f-32b6-48c3-b16e-891d06edf6eb,HET:DSM,TTD:DAP001151,bindingDb:35229,chebi:47781,chemSpider:2888,dpd:2216272,drugBank:DB01151,iupharLigand:2399,keggCompound:C06943,ndc:0781-1971-01,pdb:DSM,pubChemCompound:2995,pubChemSubstance:148551,pubChemSubstance:46504624,url:http://en.wikipedia.org/wiki/Desipramine','CNCCCN1c2ccccc2CCc3c1cccc3'),('PA449237','desmopressin','1-Deamino-8-D-arginine vasopressin,1-Desamino-8-D-arginine vasopressin,1-Desamino-8-d-arginine-vasopressin,DDAVP,Desmopresina [INN-Spanish],Desmopress','Adiuretin,Concentraid,Stimate','Drug/Small Molecule','DailyMed:3f0f29b0-1ffb-4b14-9eb0-e620151c565c,TTD:DNC000526,dpd:2257718,drugBank:DB00035,ndc:55566-5020-1,pubChemCompound:27991,pubChemSubstance:170515,url:http://en.wikipedia.org/wiki/Desmopressin','C1CN([C@H](C1)C(=O)N[C@@H](C(=O)NCC(=O)N)CCC/N=C(N)/N)C(=O)[C@H]2NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)CCSSC2)CC3=CC=C(C=C3)O)CC4=CC=CC=C4)CCC(=O)N)CC(=O)N'),('PA449238','desogestrel','Desogestrelum [INN-Latin]','Cerazette,Cyclessa,Desogen,Kariva,Mircette','','',''),('PA449245','desoxycorticosterone pivalate','DOCP,DTMA,Deoxycorticosterone Pivalate,Deoxycorticosterone Trimethylacetate,Deoxycortolone Pivalate,Deoxycortone Pivalate,Deoxycortone Trimethylacetat','Cortexone M,Neodin-Depositum,Percorten,Percorten M','Drug/Small Molecule','chemSpider:12574,dpd:2139227,drugBank:DB01134,pubChemCompound:13126,pubChemSubstance:156479,pubChemSubstance:46506381',''),('PA449247','dexamethasone','DEX,DXM,Desametasone,Desametasone [Dcit],Desamethasone,Dexametasona [INN-Spanish],Dexamethasone Acetate,Dexamethasone Alcohol,Dexamethasone Base,Dexam','Adexone,Aeroseb-D,Aeroseb-Dex,Anaflogistico,Aphtas','','',''),('PA449256','dexmedetomidine','Medetomidina [Spanish],Medetomidine,Medetomidinum [Latin]','PRECEDEX','Drug/Small Molecule','DailyMed:548a88c0-afda-427e-75ac-5af0cfa2224c,TTD:DAP000233,chebi:4466,drugBank:DB00633,iupharLigand:521,keggCompound:C07450,keggDrug:D00514,ndc:0409-1638-02,pubChemCompound:68602,pubChemSubstance:9653,url:http://en.wikipedia.org/wiki/Dexmedetomidine',''),('PA449259','dexrazoxane','Desrazoxane,Dexrazoxano [INN-Spanish],Dexrazoxanum [INN-Latin],Dextrorazoxane,Razoxana [INN-Spanish],Razoxanum [INN-Latin],icrf-187','Cardioxane,Dyzoxane,Eucardion,Razoxane,Razoxin,Tep','Drug/Small Molecule','DailyMed:071340ec-9d21-484e-93d4-f49c98df8c5e,HET:CDX,TTD:DAP000649,chebi:50223,chemSpider:64479,dpd:2153440,drugBank:DB00380,ndc:38423-110-01,pdb:CDX,pubChemCompound:71384,pubChemSubstance:213617,pubChemSubstance:46505982,url:http://en.wikipedia.org/wiki/Dexrazoxane',''),('PA449261','dextran','','','Drug/Small Molecule','',''),('PA449269','dextroamphetamine','(+)-(s)-amphetamine,(+)-alpha-methylphenethylamine,(+)-alpha-methylphenylethylamine,(+)-amphetamine,(+)-phenaminum,(2S)-(+)-Amphetamine,(2S)-1-phenylp','Amsustain,Dephadren,Desoxyn,Dexacaps,Dexadrine,Dex','','',''),('PA449273','dextromethorphan','D-Methorphan,D-Methorphan Hydrobromide,Delta-Methorphan,Demorphan,Demorphan Hydrobromide,Demorphine,Destrometerfano [Dcit],Dextromethorfan [Czech],Dex','Antussan,Balminil DM,Balminil DM Children,Benylin ','','',''),('PA449281','diatrizoate','Amidotrizoate,Amidotrizoic Acid,Diatriazoate,Diatrizoate sodium,Diatrizoate sodium salt,Diatrizoic acid,Diatrizoic acid sodium salt,Meglumine diatrizo','Angiovist 282,Cardiografin,Conray 35,Diat,Gastrogr','','',''),('PA449283','diazepam','DAP,Methyldiazepinone','Alboral,Aliseum,Alupram,Amiprol,An-Ding,Ansiolin,A','Drug/Small Molecule','DailyMed:554baee5-b171-4452-a50a-41a0946f956c,HET:DZP,TTD:DNC000549,chebi:4494,chebi:49575,chemSpider:2908,dpd:2247176,drugBank:DB00829,keggCompound:C06948,keggDrug:D00293,ndc:0140-0005-01,pdb:DZP,pubChemCompound:3016,pubChemSubstance:153142,pubChemSubstance:46505210,url:http://en.wikipedia.org/wiki/Diazepam','CN1c2ccc(cc2C(=NCC1=O)c3ccccc3)Cl'),('PA449285','diazoxide','','Dizoxide,Eudemine,Hyperstat,Hypertonalum,Mutabase,','Drug/Small Molecule','TTD:DAP000956,chebi:4495,chemSpider:2911,dpd:503347,drugBank:DB01119,iupharLigand:2409,keggCompound:C06949,keggDrug:D00294,ndc:0575-6000-01,pubChemCompound:3019,pubChemSubstance:46508027,pubChemSubstance:9164,url:http://en.wikipedia.org/wiki/Diazoxide','CC1=Nc2ccc(cc2S(=O)(=O)N1)Cl'),('PA449286','dibucaine','','Cinchocaine,Cinchocaine HCL,Dermacaine,Dibucain,Di','','',''),('PA449293','diclofenac','Diclofenac Acid,Diclofenac Potassium,Diclofenac Sodium,ISV-205','Allvoran,Apo-Diclo,Assaren,Benfofen,Cataflam,Delph','Drug/Small Molecule','DailyMed:a0a86ecf-e6fe-4c85-ac60-f62fd63e2590,HET:DIF,TTD:DAP000620,bindingDb:13066,chebi:4507,chemSpider:2925,dpd:2241225,drugBank:DB00586,keggCompound:C01690,ndc:0781-5017-01,pdb:DIF,pubChemCompound:3033,pubChemSubstance:46504644,pubChemSubstance:4831,url:http://en.wikipedia.org/wiki/Diclofenac','c1ccc(c(c1)CC(=O)O)Nc2c(cccc2Cl)Cl'),('PA449298','dicumarol','BHC,Bis-Hydroxycoumarin,Bishydroxycoumarin,Dicoumarin,Dicoumarol','Acadyl,Acavyl,Antitrombosin,Baracoumin,Cuma,Cumid,','Drug/Small Molecule','TTD:DAP000768,bindingDb:35525,chebi:4513,drugBank:DB00266,keggCompound:C00796,keggDrug:D03798,pubChemCompound:653,pubChemSubstance:4054,url:http://en.wikipedia.org/wiki/Dicumarol',''),('PA449301','didanosine','DDI,Dideoxyinosine','Videx,Videx EC','Drug/Small Molecule','DailyMed:d4401ca0-98ae-af38-84c7-2f615d0706b9,HET:2DI,TTD:DNC000528,chebi:490877,chemSpider:45864,dpd:2244596,drugBank:DB00900,keggCompound:C06953,keggDrug:D00296,ndc:0087-6632-41,pdb:2DI,pubChemCompound:50599,pubChemSubstance:189028,pubChemSubstance:46506255,url:http://en.wikipedia.org/wiki/Didanosine',''),('PA449307','diethylstilbestrol','DEB,DES,Diethylstilbesterol,Diethylstilbestrol BP,Diethylstilboesterol,Dietilestilbestrol,Percutatrine oestrogenique iscovesco,Rcra waste number U089,','Acnestrol,Agostilben,Antigestil,Bio-des,Bufon,Clim','Drug/Small Molecule','HET:DES,TTD:DAP001011,chebi:4531,chemSpider:2946,dpd:2100304,drugBank:DB00255,keggCompound:C07620,keggDrug:D00577,pdb:DES,pubChemCompound:3054,pubChemCompound:448537,pubChemSubstance:46507453,pubChemSubstance:9822,url:http://en.wikipedia.org/wiki/Diethylstilbestrol','CC/C(=C(/CC)c1ccc(cc1)O)/c2ccc(cc2)O'),('PA449313','diflunisal','','Adomal,Difludol,Dolisal,Dolobid,Dolobil,Dolobis,Fl','Drug/Small Molecule','HET:FHI,TTD:DAP000152,chebi:39669,chebi:4538,chemSpider:2951,dpd:2058413,drugBank:DB00861,keggCompound:C01691,keggDrug:D00130,ndc:54868-3049-3,pdb:FHI,pubChemCompound:3059,pubChemSubstance:46507807,pubChemSubstance:4832,url:http://en.wikipedia.org/wiki/Diflunisal','c1cc(c(cc1c2ccc(cc2F)F)C(=O)O)O'),('PA449316','digitoxin','Digitalin,Digitoksin,Digitoxinum,Digitoxoside','Crystodigin,Tardigal,Unidigin','Drug/Small Molecule','TTD:DAP000120,chebi:28544,chemSpider:389987,dpd:2236621,drugBank:DB01396,keggCompound:C06955,keggDrug:D00297,pubChemCompound:441207,pubChemSubstance:46506035,pubChemSubstance:7847363,url:http://en.wikipedia.org/wiki/Digitoxin',''),('PA449319','digoxin','Digitalis Glycoside','Cardoxin,Cogoxin,Cordioxil,Davoxin,Digacin,Digitek','Drug/Small Molecule','TTD:DAP000744,bindingDb:50115625,chebi:4551,dpd:2242323,drugBank:DB00390,keggCompound:C06956,keggDrug:D00298,ndc:62584-989-01,pubChemCompound:30322,pubChemSubstance:172469,url:http://en.wikipedia.org/wiki/Digoxin',''),('PA449334','diltiazem','d-cis-Diltiazem','Acalix,Adizem,Altiazem,Anginyl,Angizem,Anoheal,Apo','Drug/Small Molecule','DailyMed:61bf535a-3ed5-4c50-b285-6dcee0624c2d,TTD:DAP001262,bindingDb:50004704,chebi:101278,chemSpider:35850,dpd:2244728,drugBank:DB00343,iupharLigand:2298,iupharLigand:2349,iupharLigand:2512,iupharLigand:2526,keggCompound:C06958,ndc:54868-4970-0,pubChemCompound:39186,pubChemSubstance:180243,pubChemSubstance:46505667,url:http://en.wikipedia.org/wiki/Diltiazem','CC(=O)O[C@@H]1[C@@H](Sc2ccccc2N(C1=O)CCN(C)C)c3ccc(cc3)OC'),('PA449338','dimenhydrinate','Diphenhydramine Theoclate,Diphenhydrinate','Amosyt,Anautine,Andramine,Antemin,Aviomarin,Chlora','Drug/Small Molecule','DailyMed:fd0b42d6-6733-4525-6283-715ee5a466a9,TTD:DAP000333,chebi:4604,chemSpider:390044,dpd:2241532,drugBank:DB00985,keggDrug:D00520,ndc:0409-0468-05,pubChemCompound:441281,pubChemSubstance:46504881,pubChemSubstance:7847586,url:http://en.wikipedia.org/wiki/Dimenhydrinate',''),('PA449342','dimethyl sulfoxide','Diemthyl sulfoxide,Dimethyl sulfoxide BP,Dimethyl sulfur oxide,Dimethyl sulphoxide,Dimethyl sulpoxide,Dimexidum,Methyl sulfoxide,Methylsulfinylmethane','Decap,Deltan,Demasorb,Demavet,Demeso,Demsodrox,Der','','',''),('PA449345','dinoprostone','Dinoprostone Prostaglandin E2,PGE2,Prostaglandin E2','Cervidil,Prepidil,Propess,Prostarmon E,Prostin E,P','Drug/Small Molecule','DailyMed:ab03de5b-782c-4f81-a8dc-7ef9969dd0cf,TTD:DAP000360,bindingDb:35847,chebi:15551,chemSpider:4444059,dpd:2231047,drugBank:DB00917,iupharLigand:1883,iupharLigand:1916,keggCompound:C00584,keggDrug:D00079,ndc:0009-3359-02,pubChemCompound:5280360,pubChemSubstance:46505549,pubChemSubstance:7847147,url:http://en.wikipedia.org/wiki/Dinoprostone',''),('PA449349','diphenhydramine','2-diphenylmethoxy-n,n-demthylethanamine,Diphenhydramine Base,Diphenhydramine Hcl,Diphenhydramine Salicylate,Diphenylhydramine,beta-dimethylaminoethyl ','Aleryl,Alledryl,Aller-Med,Allerdryl,Allergan B,All','','',''),('PA449364','dipivefrin','','AKPro,DPE,Dipivefrin HCL,Dipivefrin [USAN],Dipivef','','',''),('PA449367','dipyridamole','Dipiridamol,Dipyridamine,Dipyridamol,Dipyudamine,Dypyridamol,Usaf Ge-12','Aggrenox,Agilease,Anginal,Apo-Dipyridamole Fc,Apo-','Drug/Small Molecule','DailyMed:af761b27-1df6-4d2f-a621-8b9950538e1c,TTD:DNC001625,bindingDb:23620,chebi:4653,chemSpider:2997,dpd:2244475,drugBank:DB00975,keggDrug:D00302,ndc:55390-555-10,pubChemCompound:3108,pubChemSubstance:148864,pubChemSubstance:46506292,url:http://en.wikipedia.org/wiki/Dipyridamole','C1CCN(CC1)c2c3c(c(nc(n3)N(CCO)CCO)N4CCCCC4)nc(n2)N(CCO)CCO'),('PA449368','dirithromycin','','Dynabac','Drug/Small Molecule','TTD:DAP000888,drugBank:DB00954,keggDrug:D03865,pubChemCompound:5464388,pubChemSubstance:214716,url:http://en.wikipedia.org/wiki/Dirithromycin',''),('PA449373','disopyramide','Disopiramida [INN-Spanish],Disopyramide Free Base,Disopyramide Phosphate,Disopyramidum [INN-Latin]','Dicorantil,Isorythm,Lispine,Norpace,Norpace CR,Rit','Drug/Small Molecule','DailyMed:3b95acd8-1cce-4b76-9cb2-6e9ea40e54b1,TTD:DAP000504,chebi:4657,chemSpider:3002,dpd:2224828,drugBank:DB00280,keggCompound:C06965,keggDrug:D00303,ndc:58177-002-04,pubChemCompound:3114,pubChemSubstance:162448,pubChemSubstance:46508226,url:http://en.wikipedia.org/wiki/Disopyramide',''),('PA449376','disulfiram','Disulfuram,Disulphuram,Dupon 4472,Dupont Fungicide 4472,TATD,TETD,TTD,Tetraethylthioperoxydicarbonic Diamide,Tetraethylthiram Disulfide,Tetraethylthir','Abstensil,Abstinil,Abstinyl,Accel Tet,Accel Tet-R,','Drug/Small Molecule','DailyMed:5fa6a93d-e41a-4942-b725-5f868ed96d53,TTD:DAP000012,chebi:4659,chemSpider:3005,dpd:2534,drugBank:DB00822,keggCompound:C01692,keggDrug:D00131,ndc:49884-153-01,pubChemCompound:3117,pubChemSubstance:46506008,pubChemSubstance:4833,url:http://en.wikipedia.org/wiki/Disulfiram','CCN(CC)C(=S)SSC(=S)N(CC)CC'),('PA449381','dobutamine','','Dobutamina [INN-Spanish],Dobutamine Hcl,Dobutamine','Drug/Small Molecule','DailyMed:402f24d2-5e67-4dd6-99c6-84bb7c1c29e7,TTD:DAP000245,bindingDb:50028971,chebi:4670,chemSpider:33786,dpd:2242010,drugBank:DB00841,iupharLigand:535,keggCompound:C06967,keggDrug:D03879,ndc:55390-560-90,pubChemCompound:36811,pubChemSubstance:46505241,pubChemSubstance:9181,url:http://en.wikipedia.org/wiki/Dobutamine','CC(CCc1ccc(cc1)O)NCCc2ccc(c(c2)O)O'),('PA449383','docetaxel','Docetaxel anhydrous,Docetaxel, Trihydrate,TXL,docetaxel','Taxotere','Drug/Small Molecule','DailyMed:82731db6-92fc-483b-9d73-9b2aed79b104,TTD:DAP000590,chebi:4672,chemSpider:130581,dpd:2177080,drugBank:DB01248,keggCompound:C11231,ndc:0075-8001-80,pubChemCompound:148124,pubChemSubstance:13410,pubChemSubstance:46506766,url:http://en.wikipedia.org/wiki/Docetaxel','CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](c5ccccc5)NC(=O)OC(C)(C)C)O)O)OC(=O)c6ccccc6)(CO4)OC(=O)C)O)C)O'),('PA449384','alpha-linolenic acid','(9Z,12Z,15Z)-Octadecatrienoic acid,9,12,15-Octadecatrienoic acid,ALA,alpha-Linolenate,linolenate','','Drug/Small Molecule','HET:LNL,chebi:27432,chemSpider:4444437,drugBank:DB00132,iupharLigand:1049,keggCompound:C06427,pdb:LNL,pubChemCompound:5280934,pubChemSubstance:10326285,pubChemSubstance:46507620,url:http://en.wikipedia.org/wiki/Alpha-linolenic_acid',''),('PA449389','dofetilide','Dofetilida [INN-Spanish],Dofetilidum [INN-Latin]','Dofetilida,Tikosyn','Drug/Small Molecule','DailyMed:02438044-d6a3-49e9-a1ac-3aad21ef2c8c,TTD:DAP000495,chebi:4681,chemSpider:64435,drugBank:DB00204,iupharLigand:2604,keggCompound:C07751,keggDrug:D00647,ndc:0069-5800-43,pubChemCompound:71329,pubChemSubstance:213557,pubChemSubstance:46509127,url:http://en.wikipedia.org/wiki/Dofetilide','CN(CCc1ccc(cc1)NS(=O)(=O)C)CCOc2ccc(cc2)NS(=O)(=O)C'),('PA449390','dolasetron','','Anzemet,Dolasetronum [INN-Latin],Dolasteron','Drug/Small Molecule','DailyMed:6600dfea-fcf2-4f89-ab45-66282dee969f,TTD:DAP000368,chemSpider:54666,dpd:2231380,drugBank:DB00757,keggCompound:C07866,ndc:0088-1208-06,pubChemCompound:60654,pubChemSubstance:210767,pubChemSubstance:46505209,url:http://en.wikipedia.org/wiki/Dolasetron','c1ccc2c(c1)c(c[nH]2)C(=O)OC3CC4CC5CC(C3)N4CC5=O'),('PA449394','donepezil','','Aricept,Aricept ODT,Eranz','Drug/Small Molecule','DailyMed:2b1b7b5f-2f20-418c-b1ac-794c2ef1ce5e,TTD:DAP000560,bindingDb:8960,chebi:53289,chemSpider:3040,dpd:2232044,drugBank:DB00843,keggDrug:D00670,ndc:62856-851-30,pubChemCompound:3152,pubChemSubstance:207105,pubChemSubstance:46504803,url:http://en.wikipedia.org/wiki/Donepezil','COc1cc2c(cc1OC)C(=O)C(C2)CC3CCN(CC3)Cc4ccccc4'),('PA449396','dopamine','DA,Deoxyepinephrine,Dopamin,Dopamine HCl,Dophamine,Hydroxytyramin,Hydroxytyramine,Oxytyramine','Intropin,Revimine','Drug/Small Molecule','DailyMed:e061fb3e-afd7-4188-b5fb-617ac1d3e38d,HET:LDP,TTD:DAP000212,chebi:18243,chemSpider:661,dpd:1914014,drugBank:DB00988,keggCompound:C03758,ndc:0517-1805-25,pdb:LDP,pubChemCompound:681,pubChemSubstance:2667,pubChemSubstance:46506043,url:http://en.wikipedia.org/wiki/Dopamine','c1cc(c(cc1CCN)O)O'),('PA449407','doxazosin','doxazosin mesilate','Alfadil,Cardenalin,Cardular,Cardura,Cardura XL,Car','Drug/Small Molecule','DailyMed:3ed04255-7d9c-464c-bfa6-c355755862d8,TTD:DAP000381,chebi:4708,chemSpider:3045,dpd:2243217,drugBank:DB00590,keggCompound:C06970,ndc:0378-4021-01,pubChemCompound:3157,pubChemSubstance:46506825,pubChemSubstance:9184,url:http://en.wikipedia.org/wiki/Doxazosin','COc1cc2c(cc1OC)nc(nc2N)N3CCN(CC3)C(=O)C4COc5ccccc5O4'),('PA449409','doxepin','Doxepin Hcl,Doxepin, Hydrochloride,Doxepina [INN-Spanish],Doxepine,Doxepinum [INN-Latin]','Adapin,Aponal,Curatin,Quitaxon,Sinequan,Triadapin,','Drug/Small Molecule','DailyMed:1533343b-f1ed-4c3a-bb36-23a748452b05,TTD:DAP000177,chebi:4710,dpd:1913425,drugBank:DB01142,iupharLigand:1225,keggCompound:C06971,ndc:0378-1049-01,pubChemCompound:667477,pubChemSubstance:158785,url:http://en.wikipedia.org/wiki/Doxepin','CN(C)CCC=C1c2ccccc2COc3c1cccc3'),('PA449412','doxorubicin','Doxorubicin HCl,Doxorubicin Hydrochloride,Doxorubicina [INN-Spanish],Doxorubicine [INN-French],Doxorubicinum [INN-Latin],doxorubicin','ADM,Adriablastin,Adriamycin,Adriamycin PFS,Adriamy','Drug/Small Molecule','DailyMed:102358dc-2109-4829-b333-b99417334e39,TTD:DNC000163,bindingDb:22984,chebi:28748,chemSpider:29400,dpd:2194465,drugBank:DB00997,keggCompound:C01661,keggDrug:D03899,ndc:0703-5043-03,pubChemCompound:31703,pubChemSubstance:173764,pubChemSubstance:46507641,url:http://en.wikipedia.org/wiki/Doxorubicin','C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5cccc(c5C4=O)OC)O)(C(=O)CO)O)N)O'),('PA449415','doxycycline','Doxcycline anhydrous,Doxycycline Hyclate,Doxycycline Monohydrate,Doxytetracycline','Alti-Doxycycline,Apo-Doxy,Atridox,Doryx,Doxy 100,D','Drug/Small Molecule','DailyMed:86e1102c-47bc-4f27-a4d0-7261b3deba63,TTD:DAP001371,bindingDb:50041429,chebi:50845,chemSpider:4444486,dpd:742562,drugBank:DB00254,keggCompound:C06973,ndc:49884-091-01,pubChemCompound:5281011,pubChemSubstance:154560,pubChemSubstance:46506491,url:http://en.wikipedia.org/wiki/Doxycycline','C[C@H]1c2cccc(c2C(=O)C3=C([C@]4([C@@H]([C@H]([C@H]13)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O.O'),('PA449419','doxylamine','Dossilamina [DCIT],Doxilminio [INN-Spanish],Doxylaminum [INN-Latin]','','','',''),('PA449421','marinol','','&Delta;9-THC,&Delta;9-tetrahydrocannabinol,Abbott ','Drug/Small Molecule','DailyMed:5bbac0b1-ddc2-400b-8e0d-1e1d484720ca,TTD:DAP000207,bindingDb:50007391,chemSpider:15266,dpd:611204,drugBank:DB00470,iupharLigand:2424,keggCompound:C06972,keggDrug:D00306,ndc:0051-0021-21,pubChemCompound:16078,pubChemSubstance:46508472,url:http://en.wikipedia.org/wiki/Marinol',''),('PA449422','droperidol','','DHBP,Dehidrobenzperidol,Dehydrobenzperidol,Deidrob','','',''),('PA449437','edrophonium','EDR,Edrophone Chloride,Edrophonium Chloride,Edrophonium Ion,Edrophonum','Antirex,Enlon,Enlon Plus,Reversol,Tensilon,Tensilo','Drug/Small Molecule','DailyMed:312042cf-df60-4dc5-90dd-4e77ebd4a781,HET:EDR,TTD:DAP000562,chebi:251408,chemSpider:3090,dpd:2188848,drugBank:DB01010,keggCompound:C06976,ndc:10019-873-15,pdb:EDR,pubChemCompound:3202,pubChemSubstance:46507530,pubChemSubstance:9190,url:http://en.wikipedia.org/wiki/Edrophonium',''),('PA449439','edetic acid','CaEDTA,Calcium Disodium Edetate,Calcium Disodium Versenate,Calcium disodium versenate,EDT,EDTA,Edetate Calcium,Edetate calcium disodium','Cheladrate,Endrate,Havidote,Titriplex,Versenate','Drug/Small Molecule','DailyMed:f960dbfa-b00c-4f3e-ad32-ed6a5deea831,HET:EDT,TTD:DNC000594,chemSpider:5826,drugBank:DB00974,keggDrug:D00571,ndc:0089-0510-06,pdb:EDT,pubChemCompound:6049,pubChemSubstance:46508301,url:http://en.wikipedia.org/wiki/EDTA',''),('PA449441','efavirenz','EFV,efavirenz','Stocrin,Sustiva','Drug/Small Molecule','DailyMed:32d6371e-ba56-4294-b732-6d43627c5c47,HET:EFZ,TTD:DAP000709,bindingDb:2483,chebi:119486,chemSpider:57715,dpd:2246045,drugBank:DB00625,keggCompound:C08088,keggDrug:D00896,ndc:0056-0474-92,pdb:EFZ,pubChemCompound:64139,pubChemSubstance:206181,pubChemSubstance:46506827,url:http://en.wikipedia.org/wiki/Efavirenz',''),('PA449456','enalapril','Enalapril Maleate,Enalaprila [INN-Spanish],Enalaprilat,Enalaprilum [INN-Latin]','Bonuten,Enalapril Bp,Enalapril Richet,Gadopril,Kin','','',''),('PA449459','encainide','Encainida [Spanish],Encainide [French],Encainidum [Latin]','Enkaid','Drug/Small Molecule','TTD:DAP000519,chebi:4788,drugBank:DB01228,keggCompound:C06978,ndc:0087-0732-41,pubChemCompound:48033,pubChemSubstance:9192,url:http://en.wikipedia.org/wiki/Encainide','CN1CCCCC1CCc2ccccc2NC(=O)c3ccc(cc3)OC'),('PA449461','enflurane','Anesthetic 347,Anesthetic Compound No. 347,Compound 347,Enflurano [INN-Spanish],Enfluranum [INN-Latin],Methylflurether,Ohio 347','Alyrane,Efrane,Ethrane','Drug/Small Molecule','TTD:DAP000799,chebi:4792,chemSpider:3113,dpd:778370,drugBank:DB00228,keggCompound:C07516,keggDrug:D00543,pubChemCompound:3226,pubChemSubstance:169039,pubChemSubstance:46505314,url:http://en.wikipedia.org/wiki/Enflurane','C(C(OC(F)F)(F)F)(F)Cl'),('PA449462','enoxacin','','Penetrex','Drug/Small Molecule','TTD:DAP001000,chebi:157175,chemSpider:3116,drugBank:DB00467,keggCompound:C06979,keggDrug:D00310,pubChemCompound:3229,pubChemSubstance:46507505,pubChemSubstance:9193,url:http://en.wikipedia.org/wiki/Enoxacin','CCn1cc(c(=O)c2c1nc(c(c2)F)N3CCNCC3)C(=O)O'),('PA449463','enoxaparin','LMWH,Low Molecular Weight Heparin,enoxaparin','Clexane,Lovenox,Lovenox HP','Drug/Small Molecule','DailyMed:5017a927-2a24-4f27-89f9-27c805bf7d59,TTD:DAP000616,chebi:28304,chemSpider:751,dpd:2242692,drugBank:DB01225,keggCompound:C00374,ndc:0075-2915-01,pubChemCompound:772,pubChemSubstance:2789,pubChemSubstance:46507450,url:http://en.wikipedia.org/wiki/Enoxaparin','CC(=O)NC1C(O)OC(COS(O)(=O)=O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(O)(=O)=O)C(O)=O)C(OS(O)(=O)=O)C3NS(O)(=O)=O)C(O)C2OS(O)(=O)=O)C(O)=O)C1O'),('PA449466','ephedrine','','','Drug/Small Molecule','TTD:DAP000228,chebi:15407,chemSpider:8935,dpd:38121,drugBank:DB01364,iupharLigand:556,keggCompound:C01575,keggDrug:D00124,pubChemCompound:9294,pubChemSubstance:10517637,pubChemSubstance:46507538,url:http://en.wikipedia.org/wiki/Ephedrine','C[C@H]([C@@H](c1ccccc1)O)NC'),('PA449470','epinephrine','ADR Adrenaline,Adrenalin,Adrenalin Chloride,Adrenalina,Adrenaline,Adrenalinum,D-Adrenaline,D-Epifrin,D-Epinephrine,Epinefrin [Czech],Epinefrina [INN-S','ADROP,Adnephrine,Adrenal,Adrenalin-Medihaler,Adren','','',''),('PA449476','epirubicin','','4\'-Epiadriamycin,4\'-Epidoxorubicin,Ellence,Epi-Dx,','Drug/Small Molecule','DailyMed:fcca49a1-8009-4375-47b3-543a4f437e02,TTD:DAP000193,chebi:47898,chemSpider:38201,dpd:2069512,drugBank:DB00445,keggCompound:C11230,ndc:61703-347-35,pubChemCompound:41867,pubChemSubstance:182518,pubChemSubstance:46507282,url:http://en.wikipedia.org/wiki/Epirubicin','C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5cccc(c5C4=O)OC)O)(C(=O)CO)O)N)O'),('PA449479','epoprostenol','PGI2,Prostacyclin,Prostaglandin I2','Flolan','Drug/Small Molecule','DailyMed:8e4b636e-ee9c-4111-779d-28c8369d283b,TTD:DAP001213,chebi:15552,chemSpider:4444093,dpd:2230845,drugBank:DB01240,iupharLigand:1915,keggCompound:C01312,keggDrug:D00106,ndc:0173-0517-00,pubChemCompound:5280427,pubChemCompound:5282411,pubChemSubstance:46507362,pubChemSubstance:7847174,url:http://en.wikipedia.org/wiki/Epoprostenol','CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/O2)O)O'),('PA449481','eprosartan','','Teveten','','',''),('PA449483','eptifibatide','Integrelin,Intrifiban,eptifibatide','Integrilin','Drug/Small Molecule','DailyMed:5ad82e30-50d8-450c-8a2a-b4b507ed1ce2,TTD:DAP000285,dpd:2240352,drugBank:DB00063,ndc:0085-1177-01,pubChemCompound:123610,pubChemSubstance:700331,url:http://en.wikipedia.org/wiki/Eptifibatide','C1CN2C(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@H](NC(=O)CCSSC[C@H](NC(=O)[C@H]2C1)C(=O)N)CCCC/N=C(N)/N)CC(=O)O)CC3=CNC4=CC=CC=C34'),('PA449484','ergocalciferol','Synthetic Vitamin D,Vitamin D2','Buco-D,Calciferol,Calciferon 2,Condacaps,Condocaps','','',''),('PA449487','ergonovine','Ergobasine,Ergometrine,Ergotrate maleate','Ergotrate','Drug/Small Molecule','TTD:DAP000227,chebi:4822,chemSpider:391970,dpd:497312,drugBank:DB01253,iupharLigand:148,keggCompound:C07543,pubChemCompound:443884,pubChemSubstance:148957,pubChemSubstance:46506922,url:http://en.wikipedia.org/wiki/Ergonovine',''),('PA449493','erythromycin','EM,Erythrocin,Erythrocin Stearate,Erythromycin Stearate,Erythromycin estolate,Erythromycin ethylsuccinate,Erythromycin glucoheptonate,Erythromycin lac','Abboticin,Abomacetin,Ak-mycin,Akne-Mycin,Aknin,Ben','','',''),('PA449500','esmolol','','Brevibloc,Esmolol HCL,Esmolol Hydrochloride','Drug/Small Molecule','DailyMed:a70baf53-e38a-4b23-8905-ee284170236d,TTD:DAP000304,chebi:4856,chemSpider:53916,dpd:2188864,drugBank:DB00187,keggCompound:C06980,ndc:0641-2965-45,pubChemCompound:59768,pubChemSubstance:46506146,pubChemSubstance:9194,url:http://en.wikipedia.org/wiki/Esmolol',''),('PA449502','estazolam','','Cannoc,D 40TA,Esilgan,Eurodin,Julodin,Nemurel,Nuct','Drug/Small Molecule','DailyMed:f91d9ce0-299e-4d48-a4e7-cb5b87bbae99,TTD:DAP000930,bindingDb:50240450,chebi:4858,chemSpider:3146,dpd:2016060,drugBank:DB01215,keggDrug:D00311,ndc:49884-349-01,pubChemCompound:3261,pubChemSubstance:46507430,url:http://en.wikipedia.org/wiki/Estazolam','c1ccc(cc1)C2=NCc3nncn3-c4c2cc(cc4)Cl'),('PA449503','estradiol','17-beta,Beta-Estradiol,Cis-Estradiol,Cis-Oestradiol,D-Estradiol,D-Oestradiol,Dihydrofollicular Hormone,Dihydrofolliculin,Dihydroxyesterin,Dihydroxyest','Aerodiol,Agofollin,Alora,Altrad,Amnestrogen,Aquadi','','',''),('PA449507','estramustine','Estramustin Sodium Phosphate,Estramustina [INN-Spanish],Estramustine Sodium Phosphate,Estramustinum [INN-Latin]','Emcyt,Estracyt','Drug/Small Molecule','DailyMed:a9b01bc6-95ac-46f9-befa-d845a74d53c1,TTD:DAP001307,bindingDb:50025102,chebi:4868,dpd:2063794,drugBank:DB01196,keggCompound:C11228,keggDrug:D04066,ndc:0013-0132-02,pubChemCompound:18140,pubChemSubstance:161211,url:http://en.wikipedia.org/wiki/Estramustine',''),('PA449509','estrogens','','','Drug Class','',''),('PA449512','estrone','','Aquacrine,Crinovaryl,Cristallovar,Crystogen,Destro','','',''),('PA449515','etanercept','CD120b,TNF-R2,Tumor necrosis factor receptor 2,Tumor necrosis factor receptor superfamily member 1B precursor,Tumor necrosis factor receptor type II,e','Enbrel,Enbrel Sureclick','Drug/Small Molecule','DailyMed:a002b40c-097d-47a5-957f-7a7b1807af7f,TTD:DNC000605,dpd:2242903,drugBank:DB00005,genBank:M32315,keggCompound:C07897,keggDrug:D00742,ndc:58406-455-04,pubChemSubstance:10099,uniProtKb:P20333,url:http://en.wikipedia.org/wiki/Etanercept',''),('PA449518','ethacrynic acid','Etacrinic acid,Etacrynic acid,Etakrinic acid,Ethacrynate,Methylenebutyrylphenoxyacetic acid,ethacryinic acid','Crinuryl,Edecril,Edecrin,Edecrina,Endecril,Hidrome','Drug/Small Molecule','DailyMed:1720bc0e-4fae-40de-bcb4-8361c2e3c5f6,HET:EAA,TTD:DAP000748,chebi:4876,chemSpider:3163,dpd:2258528,drugBank:DB00903,keggDrug:D00313,ndc:0006-0065-68,pdb:EAA,pubChemCompound:3278,pubChemSubstance:46507562,url:http://en.wikipedia.org/wiki/Ethacrynic_acid',''),('PA449525','ether','','','Drug/Small Molecule','','CCOCC'),('PA449527','ethinyl estradiol','17 alpha-Ethinylestradiol,17 alpha-Ethynylestradiol,17 alpha-Ethynyloestradiol,Aethinyloestradiolum,Aethinyoestradiol [German],EE,EO,Ethinyl-Oestranol','Amenoron,Amenorone,Anovlar,Cyclosa,Dicromil,Diogna','','',''),('PA449531','ethopropazine','Aethopropropazin,Athapropazine,Athopropazin,Ethapropazine,Ethopromazine,Ethopropazine Hydrochloride,Etopropezina,Fempropazine,Fenpropazina,Isopthazine','Dibutil,Lysivane,Parcidol,Pardidol,Pardisol,Parfez','Drug/Small Molecule','TTD:DAP001119,bindingDb:8958,chebi:313639,chemSpider:3174,dpd:1927744,drugBank:DB00392,keggDrug:D01118,pubChemCompound:3290,pubChemSubstance:153942,pubChemSubstance:46507375,url:http://en.wikipedia.org/wiki/Ethopropazine','CCN(CC)C(C)CN1c2ccccc2Sc3c1cccc3'),('PA449533','ethosuximide','Aethosuximide,Ethosuccimide,Ethosuccinimide,Ethosuxide,Etosuximida','Asamid,Atysmal,Capitus,Emeside,Epileo Petit Mal,Et','Drug/Small Molecule','DailyMed:0e008f33-70a1-4bc6-b3a0-d45214418ab6,TTD:DAP000526,bindingDb:50240424,chebi:4887,chemSpider:3175,dpd:23485,drugBank:DB00593,keggCompound:C07505,keggDrug:D00539,ndc:0071-0237-24,pubChemCompound:3291,pubChemSubstance:46507617,pubChemSubstance:7847605,url:http://en.wikipedia.org/wiki/Ethosuximide','CCC1(CC(=O)NC1=O)C'),('PA449548','etidronic acid','Acetodiphosphonic acid,Acide etidronique [INN-French],Acido etidronico [INN-Spanish],Acidum etidronicum [INN-Latin],EHDP,Etidronate,Etidronate Disodiu','Cintichem Technetium 99m Hedspa,Dequest 2010,Deque','','',''),('PA449550','etodolac','etodolac','Etodolac [Usan:Ban:Inn],Etodolacetodolic acid,Etod','Drug/Small Molecule','DailyMed:a8984705-a43a-4977-808a-44df42930de1,TTD:DAP000778,bindingDb:50016799,chebi:4909,chemSpider:3192,dpd:2242915,drugBank:DB00749,keggDrug:D00315,ndc:0228-2599-11,pubChemCompound:3308,pubChemSubstance:179980,pubChemSubstance:46505184,url:http://en.wikipedia.org/wiki/Etodolac','CCc1cccc2c1[nH]c3c2CCOC3(CC)CC(=O)O'),('PA449552','etoposide','(-)-Etoposide,Etoposidum [INN-Latin],trans-Etoposide','Eposin,Etopophos,Lastet,Toposar,Vepesid,Vepesid J,','Drug/Small Molecule','TTD:DAP000786,chebi:4911,chemSpider:33510,dpd:2241182,drugBank:DB00773,keggCompound:C01576,keggDrug:D00125,ndc:0015-3091-45,pubChemCompound:36462,pubChemSubstance:177966,pubChemSubstance:46505434,url:http://en.wikipedia.org/wiki/Etoposide','C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)OC3c4cc5c(cc4[C@H]([C@@H]6C3COC6=O)c7cc(c(c(c7)OC)O)OC)OCO5)O)O'),('PA449554','etretinate','','Tegison,Tigason','Drug/Small Molecule','chebi:4913,chemSpider:3196,drugBank:DB00926,keggDrug:D00316,pubChemCompound:3312,pubChemCompound:5282375,pubChemSubstance:46504486,pubChemSubstance:7847382,url:http://en.wikipedia.org/wiki/Etretinate',''),('PA449563','exemestane','Exemestano [INN-Spanish],Exemestanum [INN-Latin],exemestane','Aromasin,Exemestance','Drug/Small Molecule','DailyMed:cf066b7a-032a-416c-8d40-15ba581423e3,TTD:DAP000625,chebi:4953,chemSpider:54278,dpd:2242705,drugBank:DB00990,keggCompound:C08162,keggDrug:D00963,ndc:0009-7663-04,pubChemCompound:60198,pubChemSubstance:196561,pubChemSubstance:46508243,url:http://en.wikipedia.org/wiki/Exemestane',''),('PA449585','famciclovir','FCV,Famciclovirum [INN-Latin]','Famvir','Drug/Small Molecule','DailyMed:3c6194c0-ba69-4b16-b882-caf736a02348,TTD:DAP000489,bindingDb:50066502,chebi:4974,chemSpider:3207,dpd:2229110,drugBank:DB00426,keggDrug:D00317,ndc:0078-0366-15,pubChemCompound:3324,pubChemSubstance:196284,pubChemSubstance:46507561,url:http://en.wikipedia.org/wiki/Famciclovir','CC(=O)OCC(CCn1cnc2c1nc(nc2)N)COC(=O)C'),('PA449586','famotidine','Famotidina [Spanish],Famotidinum [Latin]','Amfamox,Antodine,Apo-Famotidine,Apogastine,Bestidi','Drug/Small Molecule','DailyMed:4acdfa96-bd62-4289-8454-276d3886a1a7,TTD:DAP000341,chebi:4975,chemSpider:3208,dpd:2242327,drugBank:DB00927,keggDrug:D00318,ndc:0006-3537-50,pubChemCompound:3325,pubChemCompound:5702160,pubChemSubstance:191368,pubChemSubstance:46507397,url:http://en.wikipedia.org/wiki/Famotidine','c1c(nc(s1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N'),('PA449590','felbamate','','Felbamyl,Felbatol,Taloxa','Drug/Small Molecule','DailyMed:2f522701-397a-11de-8a39-0800200c9a66,TTD:DAP000093,bindingDb:50240678,chebi:4995,chemSpider:3214,drugBank:DB00949,keggCompound:C07501,keggDrug:D00536,ndc:0037-0430-01,pubChemCompound:3331,pubChemSubstance:46506375,pubChemSubstance:7847602,url:http://en.wikipedia.org/wiki/Felbamate','c1ccc(cc1)C(COC(=O)N)COC(=O)N'),('PA449591','felodipine','Dl-Felodipine,Felodipina [INN-Spanish],Felodipine [Usan:Ban:Inn],Felodipinum [INN-Latin],felodipine','AGON SR,Agon,Feloday,Felodur ER,Felogard,Flodil,Hy','Drug/Small Molecule','DailyMed:f94ae052-5d59-4750-aab7-1fdb989503aa,TTD:DAP000487,bindingDb:50017710,chebi:585948,chemSpider:3216,dpd:2222000,drugBank:DB01023,keggDrug:D00319,ndc:0378-5011-01,pubChemCompound:3333,pubChemSubstance:189780,pubChemSubstance:46506968,url:http://en.wikipedia.org/wiki/Felodipine','CCOC(=O)C1=C(NC(=C(C1c2cccc(c2Cl)Cl)C(=O)OC)C)C'),('PA449592','fenfluramine','DEA No. 1670,Fenfluramina [DCIT],Fenfluramine Hydrochloride,Fenfluraminum [INN-Latin]','Acino,Adipomin,Obedrex,Pesos,Ponderax Pa,Ponderex,','','',''),('PA449594','fenofibrate','FNF,Fenofibrato [INN-Spanish],Fenofibratum [INN-Latin],Finofibrate,fenofibric acid','Ankebin,Antara,Elasterate,Elasterin,Fenobrate,Feno','Drug/Small Molecule','DailyMed:c53c20ed-a944-4b35-b5db-91d9f67240e8,TTD:DAP000270,chebi:5001,chemSpider:3222,dpd:2250039,drugBank:DB01039,keggCompound:C07586,keggDrug:D00565,ndc:0378-7100-77,pubChemCompound:3339,pubChemSubstance:180502,pubChemSubstance:46507371,url:http://en.wikipedia.org/wiki/Fenofibrate','CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(cc2)Cl'),('PA449597','fenoprofen','Feneprofen calcium salt dihydrate,Fenoprofen calcium,Fenoprofen calcium hydrate','Nalfon','Drug/Small Molecule','TTD:DAP000619,chebi:5004,chemSpider:3225,dpd:345504,drugBank:DB00573,keggDrug:D00968,pubChemCompound:3342,pubChemSubstance:46504597,url:http://en.wikipedia.org/wiki/Fenoprofen','CC(c1cccc(c1)Oc2ccccc2)C(=O)O'),('PA449599','fentanyl','Fentanila [INN-Spanish],Fentanyl citrate,Fentanylum [INN-Latin],fentanyl','Actiq,Duragesic,Duragesic-100,Durogesic,Fentanest,','','',''),('PA449617','ferrous sulfate','','','Drug/Small Molecule','','[O-]S(=O)(=O)[O-].[Fe+2]'),('PA449621','fexofenadine','Carboxyterfenadine,Fexofenadine hydrochloride,Fexofendine,Terfenadine acid metabolite,Terfenadine carboxylate,Terfenadine-COOH','Allegra,Allegra-D 12 Hour,Allegra-D 24 Hour','','',''),('PA449626','filgrastim','G-CSF,Granulocyte colony-stimulating factor precursor,Lenograstim,Pluripoietin','Neupogen','Drug/Small Molecule','DailyMed:97cc73cc-b5b7-458a-a933-77b00523e193,TTD:DAP000113,dpd:1968017,drugBank:DB00099,genBank:X03438,ndc:55513-530-10,uniProtKb:P09919,url:http://en.wikipedia.org/wiki/Filgrastim',''),('PA449627','finasteride','Finasterida [INN-Spanish],Finasteridum [INN-Latin]','Chibro-Proscar,Finastid,Finpecia,Propecia,Proscar,','Drug/Small Molecule','DailyMed:be37d74f-2c78-41bc-8a17-cd53d1a92d2e,HET:FIT,TTD:DAP000045,chebi:5062,chemSpider:51714,dpd:2238213,drugBank:DB01216,keggDrug:D00321,ndc:0378-3151-93,pdb:FIT,pubChemCompound:57363,pubChemSubstance:194453,pubChemSubstance:46507645,url:http://en.wikipedia.org/wiki/Finasteride',''),('PA449646','flecainide','Flecainida [INN-Spanish],Flecainide acetate,Flecainidum [INN-Latin]','Flecaine,Tambocor','Drug/Small Molecule','DailyMed:b764c8b8-7e23-4016-830f-68312d84f3d3,TTD:DAP000518,bindingDb:50131434,chemSpider:3239,dpd:1966197,drugBank:DB01195,iupharLigand:2560,keggCompound:C07001,ndc:0089-0305-10,pubChemCompound:3356,pubChemSubstance:181803,pubChemSubstance:46508078,url:http://en.wikipedia.org/wiki/Flecainide','c1cc(c(cc1OCC(F)(F)F)C(=O)NCC2CCCCN2)OCC(F)(F)F'),('PA449652','floxuridine','5 Fluorodeoxyuridine,5FDU,Deoxyfluorouridine,FDUR,FDURD,Floxiridina [INN-Spanish],Floxuridin,Floxuridinum [INN-Latin],Fluorodeoxyuridine,Fluoruridine ','FUDR','Drug/Small Molecule','DailyMed:3f89fb83-49ea-467f-6e9a-68fd1ee12ed7,TTD:DAP001245,bindingDb:50042595,chebi:60761,chemSpider:5586,drugBank:DB00322,keggCompound:C11736,keggDrug:D04197,ndc:61703-331-09,pubChemCompound:5790,pubChemSubstance:148580,pubChemSubstance:46508645,url:http://en.wikipedia.org/wiki/Floxuridine',''),('PA449653','fluconazole','','Biocanol,Biozolene,Diflucan,Elazor,Flucazol,Flucos','Drug/Small Molecule','DailyMed:bf92a7d7-395b-4e2c-a3c4-66ebdbfd1052,HET:TPF,TTD:DAP000628,bindingDb:25817,chebi:46081,chemSpider:3248,dpd:2245697,drugBank:DB00196,keggDrug:D00322,ndc:0054-0002-85,pdb:TPF,pubChemCompound:3365,pubChemSubstance:192927,pubChemSubstance:46505735,url:http://en.wikipedia.org/wiki/Fluconazole','c1cc(c(cc1F)F)C(Cn2cncn2)(Cn3cncn3)O'),('PA449654','flucytosine','5-FC,5-Fluorocystosine,5-Fluorocytosin,5-Fluorocytosine,5-Flurocytosine,Flucytosin,Fluocytosine,Fluorcytosine','Ancobon,Ancotil','Drug/Small Molecule','DailyMed:aea0df00-a88c-4a16-abcf-750f3ff2004e,TTD:DAP001542,bindingDb:50241247,chebi:5100,chemSpider:3249,drugBank:DB01099,keggDrug:D00323,ndc:0187-3554-10,pubChemCompound:3366,pubChemSubstance:405592,pubChemSubstance:46504735,url:http://en.wikipedia.org/wiki/Flucytosine','c1c(c(nc(=O)[nH]1)N)F'),('PA449655','fludarabine','FAMP,Fludarabine 5\'-monophosphate,Fludarabine monophosphate,Fludarabine phosphate','Fludara,Fludura','Drug/Small Molecule','DailyMed:30bac07f-86bd-4a03-8ea1-7ab2d42d3ea3,TTD:DAP000567,chemSpider:28532,dpd:2246226,drugBank:DB01073,keggDrug:D01907,ndc:0024-5820-15,pubChemCompound:30751,pubChemSubstance:46507525,pubChemSubstance:7848969,url:http://en.wikipedia.org/wiki/Fludarabine','c1nc2c(nc(nc2n1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N'),('PA449659','flumazenil','Flumazenilo [Spanish],Flumazenilum [Latin]','Anexate,Flumazepil,Lanexat,Mazicon,Romazicon','Drug/Small Molecule','DailyMed:2abb038b-ad3a-407e-bfda-c82e3bd09742,TTD:DAP000685,bindingDb:26263,chebi:5103,chemSpider:3256,dpd:2249561,drugBank:DB01205,keggCompound:C07825,keggDrug:D00697,ndc:0004-6911-06,pubChemCompound:3373,pubChemSubstance:10027,pubChemSubstance:46507438,url:http://en.wikipedia.org/wiki/Flumazenil','CCOC(=O)c1c2n(cn1)-c3ccc(cc3C(=O)N(C2)C)F'),('PA449661','flunisolide','Flunisolide [anhydrous],flunisolide','Aerobid,Bronalide,Lunis,Nasalide,Nasarel,Rhinalar,','Drug/Small Molecule','DailyMed:77104557-087c-4bc5-9bea-521843b83e07,TTD:DAP001046,chebi:5106,chemSpider:74144,dpd:2239288,drugBank:DB00180,keggDrug:D00324,ndc:0456-0672-99,pubChemCompound:82153,pubChemSubstance:46507894,pubChemSubstance:659083,url:http://en.wikipedia.org/wiki/Flunisolide','C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@]35C)F)O'),('PA449664','fluocinonide','Fluocinolide,Fluocinolide acetate,Fluocinolone acetonide acetate,Fluocinonide Emulsified Base,Fluocinonide [USAN:BAN:INN:JAN],Fluocinonido [INN-Spanis','Bestasone,Biscosal,Cortalar,Fluonex,Fluzon,Lidex,L','','',''),('PA449667','fluoride','','','Drug Class','',''),('PA449673','fluoxetine','Fluoxetina [INN-Spanish],Fluoxetina [Spanish],Fluoxetine Hcl,Fluoxetine Hydrochloride,Fluoxetinum [INN-Latin]','Adofen,Animex-On,Deprex,Eufor,Fluctin,Fluoxeren,Fl','Drug/Small Molecule','DailyMed:bfd18a45-06cc-4281-b181-40eb5d192a9b,TTD:DAP000186,bindingDb:30130,chebi:5118,chemSpider:3269,dpd:2242124,drugBank:DB00472,iupharLigand:203,keggDrug:D00823,ndc:63304-632-30,pubChemCompound:3386,pubChemSubstance:181999,pubChemSubstance:46507902,url:http://en.wikipedia.org/wiki/Fluoxetine','CNCCC(c1ccccc1)Oc2ccc(cc2)C(F)(F)F'),('PA449676','fluphenazine','Fluorfenazine,Fluorophenazine,Fluorphenazine,Fluphenazine Decanoate,Fluphenazine Hcl,Triflumethazine','Apo-Fluphenazine,Elinol,Modecate,Moditen Enanthate','Drug/Small Molecule','TTD:DCL000806,bindingDb:50017655,chebi:5123,chemSpider:3255,dpd:2244166,drugBank:DB00623,iupharLigand:204,ndc:0003-0801-10,pubChemCompound:3372,pubChemSubstance:149164,pubChemSubstance:46506645,url:http://en.wikipedia.org/wiki/Fluphenazine','c1ccc2c(c1)N(c3cc(ccc3S2)C(F)(F)F)CCCN4CCN(CC4)CCO'),('PA449681','flurazepam','Flurazepam HCL','Dalmadorm,Dalmane,Felison,Felmane,Flunox,Insumin,N','Drug/Small Molecule','DailyMed:2f2db2f5-49d3-4d47-a08a-628df49d2120,TTD:DAP000242,chemSpider:3276,dpd:2248127,drugBank:DB00690,keggDrug:D00329,ndc:0378-4415-01,pubChemCompound:3393,pubChemSubstance:46508451,pubChemSubstance:7847395,url:http://en.wikipedia.org/wiki/Flurazepam','CCN(CC)CCN1c2ccc(cc2C(=NCC1=O)c3ccccc3F)Cl'),('PA449683','flurbiprofen','FLP,Flurbiprofen Sodium,Flurbiprofene [INN-French],Flurbiprofeno [INN-Spanish],Flurbiprofenum [INN-Latin]','Adfeed,Ansaid,Antadys,Apo-Flurbiprofen,Cebutid,Flu','Drug/Small Molecule','DailyMed:86b915c9-9c00-46c2-8dd9-3e15a6b42323,HET:FL2,TTD:DAP000621,chebi:5130,chemSpider:3277,dpd:2020661,drugBank:DB00712,keggDrug:D00330,ndc:0378-0076-01,pdb:FL2,pubChemCompound:3394,pubChemSubstance:163961,pubChemSubstance:46505550,url:http://en.wikipedia.org/wiki/Flurbiprofen','CC(c1ccc(c(c1)F)c2ccccc2)C(=O)O'),('PA449685','flutamide','FTA,Flutamide USP25','Cebatrol,Eulexin,Niftholide,Niftolide','Drug/Small Molecule','DailyMed:9b59dc6e-4ae6-4d5a-a313-7732a0ce4380,HET:HFT,TTD:DAP000301,chebi:5132,chemSpider:3280,dpd:2239388,drugBank:DB00499,keggCompound:C07653,keggDrug:D00586,ndc:0555-0870-01,pdb:HFT,pubChemCompound:3397,pubChemSubstance:46508874,pubChemSubstance:9855,url:http://en.wikipedia.org/wiki/Flutamide','CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)N(=O)=O'),('PA449686','fluticasone propionate','fluticasone propionate','Advair Diskus,Advair Diskus 100/50,Advair Diskus 2','Drug/Small Molecule','DailyMed:8664a829-6b81-4249-8252-3d20f93097dc,TTD:DAP001039,chebi:31441,chemSpider:392059,dpd:2244293,drugBank:DB00588,keggDrug:D01708,ndc:0462-0333-15,pubChemCompound:444036,pubChemSubstance:46506140',''),('PA449688','fluvastatin','Fluindostatin,Fluvastatina [INN-Spanish],Fluvastatine [INN-French],Fluvastatinum [INN-Latin],fluvastatin sodium','Canef,Cranoc,Lescol,Lescol XL','Drug/Small Molecule','DailyMed:8a1823e7-26fb-4858-bac7-9e152e5ea16a,TTD:DAP000554,chebi:5136,chemSpider:1265982,dpd:2250527,drugBank:DB01095,keggCompound:C07014,ndc:0078-0176-05,pubChemCompound:1548972,pubChemSubstance:206649,pubChemSubstance:46505668,url:http://en.wikipedia.org/wiki/Fluvastatin','CC(C)n1c2ccccc2c(c1/C=C/[C@@H](C[C@@H](CC(=O)O)O)O)c3ccc(cc3)F'),('PA449690','fluvoxamine','Fluvoxamina [INN-Spanish],Fluvoxamine maleate,Fluvoxaminum [INN-Latin],fluvoxamine,fluvoxamine-CR','Dumirox,Dumyrox,Faverin,Fevarin,Floxyfral,Luvox,Ma','Drug/Small Molecule','DailyMed:4fa83401-321d-4fb9-bd7f-8cfa966782e3,TTD:DNC000897,chebi:5138,chemSpider:3287,dpd:2262630,drugBank:DB00176,keggCompound:C07571,ndc:57664-357-88,pubChemCompound:3404,pubChemCompound:5324346,pubChemSubstance:46507588,pubChemSubstance:9774,url:http://en.wikipedia.org/wiki/Fluvoxamine',''),('PA449692','folic acid','Folate,PGA,Pteroyl-L-glutamic acid,Pteroyl-L-monoglutamic acid,Pteroylglutamic acid,Pteroylmonoglutamic acid,Vitamin B9,Vitamin Bc,Vitamin Be,Vitamin ','Acifolic,Apo-Folic,Cytofol,Dosfolat B activ,Folaci','Drug/Small Molecule','HET:FOL,TTD:DAP001309,chebi:27470,chemSpider:5815,drugBank:DB00158,keggCompound:C00504,keggDrug:D00070,ndc:42291-533-10,pdb:FOL,pubChemCompound:6037,pubChemSubstance:3787,pubChemSubstance:46508092,url:http://en.wikipedia.org/wiki/Folic_Acid','c1cc(ccc1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCc2cnc3c(n2)c(nc(n3)N)O'),('PA449693','follitropin beta','FSH-B,FSH-beta,Follicle-stimulating hormone beta subunit,Follitropin alfa/beta,Follitropin beta chain precursor','Follistim,Gonal F,Gonal-F','Drug/Small Molecule','DailyMed:4e07acff-27c2-4f5a-9d12-c9598496e9a0,TTD:DAP001028,dpd:2243949,drugBank:DB00066,genBank:M16647,ndc:0052-0306-31,uniProtKb:P01225,url:http://en.wikipedia.org/wiki/Follicle-stimulating_hormone',''),('PA449697','fomepizole','4-methylpyrazole,Fomepizol [INN-Spanish],Fomepizole [USAN:INN],Fomepizolum [INN-Latin]','Antizol','Drug/Small Molecule','DailyMed:c045b5a8-b220-4f0a-a831-155b29c19454,TTD:DAP000568,chebi:5141,chemSpider:3289,dpd:2242980,drugBank:DB01213,keggCompound:C07837,keggDrug:D00707,ndc:46129-200-02,pubChemCompound:3406,pubChemSubstance:10039,pubChemSubstance:46508566,url:http://en.wikipedia.org/wiki/Fomepizole','CC1=CNN=C1'),('PA449703','formaldehyde','Methanal,Methyl aldehyde,Methylene oxide,Oxomethane,Oxomethylene,Oxymethylene,Paraform,Paraformaldehyde','Formalin,Formol','','',''),('PA449705','formic acid','Aminic acid,Formate,Formylic acid,Hydrogen carboxylic acid,Methanoic acid','','Drug/Small Molecule','chebi:30751,chemSpider:278,drugBank:DB01942,keggCompound:C00058,pdb:FMT,pubChemCompound:284,pubChemSubstance:3358,pubChemSubstance:46508355,url:http://en.wikipedia.org/wiki/Formic_Acid','C(=O)O'),('PA449706','foscarnet','Carboxyphosphonic acid,Dihydroxyphosphinecarboxylic acid oxide,Forscarnet sodium,Foscarnet sodium,PFA,Phgosphonocarboxylic acid,Phosphonoformate,Phosp','Foscarmet,Foscavir,Triapten','Drug/Small Molecule','DailyMed:e177c228-33e1-4074-3e98-7d484c370e58,TTD:DAP001383,chebi:127780,chemSpider:3297,drugBank:DB00529,keggDrug:D00579,ndc:0186-1906-01,pubChemCompound:3415,pubChemSubstance:46507873,pubChemSubstance:595937,url:http://en.wikipedia.org/wiki/Foscarnet',''),('PA449710','fosinopril','Fosinopril Sodium','Acecor,Monopril,Secorvas,Staril','Drug/Small Molecule','DailyMed:cfd96e4b-fcf1-4959-aaf4-7aabe0d80ab5,TTD:DAP000582,chebi:5163,chemSpider:50469,dpd:2262428,drugBank:DB00492,keggCompound:C07016,keggDrug:D00622,ndc:62037-935-90,pubChemCompound:55891,pubChemSubstance:194429,pubChemSubstance:46506495,url:http://en.wikipedia.org/wiki/Fosinopril',''),('PA449716','fructose','','','Drug/Small Molecule','chebi:28757,drugBank:DB04173,pdb:FRU,pubChemCompound:439553,pubChemCompound:439709,pubChemSubstance:46504785,pubChemSubstance:7887582',''),('PA449719','furosemide','Dihydroflumethiazide,Frusemid,Frusemide,Furosemid,Furosemida [INN-Spanish],Furosemidu [Polish],Furosemidum [INN-Latin],Fursemid,Fursemida,Fursemide,Me','Aisemide,Aldalix,Aldic,Aluzine,Anfuramaide,Apo-Fru','Drug/Small Molecule','DailyMed:18823ba7-c4c1-4944-9af5-41d7015f9b53,HET:FUN,TTD:DAP000043,bindingDb:25902,chebi:47426,chemSpider:3322,dpd:2247372,drugBank:DB00695,keggDrug:D00331,ndc:0548-1431-00,pdb:FUN,pubChemCompound:3440,pubChemSubstance:148711,pubChemSubstance:46506779,url:http://en.wikipedia.org/wiki/Furosemide','c1cc(oc1)CNc2cc(c(cc2C(=O)O)S(=O)(=O)N)Cl'),('PA449720','gabapentin','Gabapentin GR,Gabapentine [INN-French],Gabapentino [INN-Spanish],Gabapentino [Spanish],Gabapentinum [INN-Latin],Gabapetin,gabapentin','Aclonium,Neurontin,Novo-Gabapentin','Drug/Small Molecule','DailyMed:a4c5d9e0-1de0-4de6-a382-5e5f56bf16e3,HET:GBN,TTD:DNC000670,chemSpider:3328,dpd:2260905,drugBank:DB00996,keggDrug:D00332,ndc:0228-2665-11,pdb:GBN,pubChemCompound:3446,pubChemSubstance:183654,pubChemSubstance:46506529,url:http://en.wikipedia.org/wiki/Gabapentin','C1CCC(CC1)(CC(=O)O)CN'),('PA449725','galactose','','','Drug/Small Molecule','',''),('PA449726','galantamine','(-)-Galanthamine,Galanthamine,Galanthamine hydrobromide','Galantamin,Jilkon,Lycoremin,Lycoremine,Reminyl','Drug/Small Molecule','HET:GNT,TTD:DAP000559,bindingDb:10404,chebi:5264,chemSpider:23175565,dpd:2266717,drugBank:DB00674,keggCompound:C08526,keggDrug:D04292,ndc:0378-8104-91,pdb:GNT,pubChemCompound:908828,pubChemCompound:9651,pubChemSubstance:10719,pubChemSubstance:46505659,url:http://en.wikipedia.org/wiki/Galantamine',''),('PA449733','ganciclovir','GA2,Ganciclovir Sodium,ganciclovir','Cytovene,Cytovene IV,Cytovene-IV,Vitrasert','Drug/Small Molecule','DailyMed:38e8f819-985c-4d20-aafd-3ba953af26ca,HET:GA2,TTD:DAP000645,chebi:465284,chemSpider:3336,dpd:2240362,drugBank:DB01004,keggDrug:D00333,ndc:0004-6940-03,pdb:GA2,pubChemCompound:3454,pubChemSubstance:192372,pubChemSubstance:46507294,url:http://en.wikipedia.org/wiki/Ganciclovir','c1nc2c(=O)[nH]c(nc2n1COC(CO)CO)N'),('PA449737','garlic oil','','','Drug/Small Molecule','',''),('PA449738','gatifloxacin','gatifloxacin','Tequin,Zymar','Drug/Small Molecule','DailyMed:a5b0725e-9b7e-426b-ab1c-fcca3b1972fd,TTD:DAP001387,chebi:5280,chemSpider:5186,dpd:2243181,drugBank:DB01044,keggCompound:C07661,ndc:0023-9218-05,pubChemCompound:5379,pubChemSubstance:46506159,pubChemSubstance:9863,url:http://en.wikipedia.org/wiki/Gatifloxacin',''),('PA449741','gelatin agents','','','Drug/Small Molecule','',''),('PA449748','gemcitabine','','DDFC,DFDC,GEO,Gemcin,Gemcitabina [INN-Spanish],Gem','Drug/Small Molecule','DailyMed:9dc35c59-f4f3-43b4-8251-0cf5c06cdc80,HET:GEO,TTD:DAP001246,chebi:175901,chemSpider:54753,dpd:2230309,drugBank:DB00441,keggCompound:C07650,keggDrug:D02368,ndc:0002-7501-01,pdb:GEO,pubChemCompound:60750,pubChemSubstance:46506425,pubChemSubstance:9852,url:http://en.wikipedia.org/wiki/Gemcitabine','c1cn(c(=O)nc1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F'),('PA449750','gemfibrozil','','Apo-Gemfibrozil,Bolutol,Cholespid,Decrelip,Fibrato','Drug/Small Molecule','DailyMed:0ce067fa-abeb-41a3-9bbe-7956f9a96278,TTD:DAP000210,chebi:5296,chemSpider:3345,dpd:2241608,drugBank:DB01241,keggDrug:D00334,ndc:0115-9911-13,pubChemCompound:3463,pubChemSubstance:175056,pubChemSubstance:46508264,url:http://en.wikipedia.org/wiki/Gemfibrozil',''),('PA449753','gentamicin','','Alcomicin,Apogen,Bristagen,G-Mycin,G-Myticin,Garam','','',''),('PA449755','gentian violet','Crystal Violet','Adergon,Aizen Crystal Violet,Aizen Crystal Violet ','','',''),('PA449758','ginkgo biloba','adiantifolia,bai guo ye,baiguo,fossil tree,ginkgo folium,herba ginkgo biloba,japanese silver apricot,kew tree,maidenhair tree,pei go su ye,salisburia ','','Drug/Small Molecule','dpd:889660,drugBank:DB01381,url:http://en.wikipedia.org/wiki/Ginkgo_biloba',''),('PA449760','glatiramer acetate','COP-1,Copolymer-1,Copoylmer 1,glatiramer acetate','Copaxone','Drug/Small Molecule','DailyMed:45dc1f57-a98a-495c-a5df-855852a0112f,TTD:DAP001315,dpd:2233014,drugBank:DB05259,ndc:0088-1153-30,pubChemCompound:3081884,pubChemSubstance:14863134,url:http://en.wikipedia.org/wiki/Glatiramer_acetate','C[C@@H](C(=O)O)N.CC(=O)O.c1cc(ccc1C[C@@H](C(=O)O)N)O.C(CCN)C[C@@H](C(=O)O)N.C(CC(=O)O)[C@@H](C(=O)O)N'),('PA449761','glimepiride','Glimepirid,Glimepirida,Glimepiridum,Glimepride','Amarel,Amaryl,Endial,Novo-glimepiride,PMS-glimepir','','',''),('PA449762','glipizide','Glipizida [INN-Spanish],Glipizidum [INN-Latin],Glydiazinamide','Aldiab,Digrin,Dipazide,Glibenese,Glibetin,Glican,G','Drug/Small Molecule','DailyMed:3e21bcc7-6f0d-4d63-befd-aa3ac8c63e37,TTD:DAP000920,bindingDb:50012956,chemSpider:3359,drugBank:DB01067,keggDrug:D00335,ndc:0378-1105-01,pubChemCompound:3478,pubChemSubstance:46505865,pubChemSubstance:7847401,url:http://en.wikipedia.org/wiki/Glipizide','Cc1cnc(cn1)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3'),('PA449770','gluconic acid','','','Drug/Small Molecule','chebi:24266,drugBank:DB04304,pdb:GCO,pubChemCompound:10690,pubChemCompound:6857417,pubChemSubstance:46509025,pubChemSubstance:7887784',''),('PA449773','glucose','','','Drug/Small Molecule','',''),('PA449776','l-glutamic acid','(2S)-2-Aminopentanedioic acid,(S)-(+)-Glutamic acid,(S)-2-Aminopentanedioic acid,(S)-Glutamic acid,1-Aminopropane-1,3-dicarboxylic acid,2-Aminoglutari','Aciglut,Glusate,Glutacid,Glutamicol,Glutamidex,Glu','Drug/Small Molecule','HET:GLU,TTD:DAP000015,bindingDb:17657,chebi:16015,chemSpider:30572,drugBank:DB00142,iupharLigand:1369,keggCompound:C00025,keggDrug:D00007,pdb:GLU,pubChemCompound:33032,pubChemSubstance:3327,pubChemSubstance:46505816,url:http://en.wikipedia.org/wiki/L-Glutamic_Acid',''),('PA449777','glutaraldehyde','','','Drug/Small Molecule','','C(CC=O)CC=O'),('PA449780','glutathione','5-L-Glutamyl-L-cysteinylglycine,GSH,Gluthathione,N-(N-gamma-L-Glutamyl-L-cysteinyl)glycine,gamma-L-Glutamyl-L-cysteinyl-glycine','Copren,Isethion,Ledac,Neuthion,Tathion','','',''),('PA449782','glibenclamide','Apo-Glibenclamide,Glibenclamida [INN-Spanish],Glibenclamidum [INN-Latin],Glyburide,glibenclamide','Abbenclamide,Adiab,Azuglucon,Bastiverit,Benclamin,','','',''),('PA449783','glycerin','','Glyrol,Osmoglyn,Procalamine','Drug/Small Molecule','','C(C(CO)O)O'),('PA449789','glycine','2-Aminoacetic acid,Aminoacetic acid,Aminoethanoic acid,Gly','Aciport,Glicoamin,Glycocoll,Glycolixir,Glycosthene','Drug/Small Molecule','DailyMed:d4665408-04d8-4ad7-8589-708d4defb869,HET:GLY,TTD:DAP000288,chebi:15428,chemSpider:730,drugBank:DB00145,iupharLigand:727,keggCompound:C00037,keggDrug:D00011,ndc:0338-0289-47,pdb:GLY,pubChemCompound:750,pubChemSubstance:3339,pubChemSubstance:46508219,url:http://en.wikipedia.org/wiki/Glycine','C(C(=O)O)N'),('PA449798','gold preparations','','','Drug Class','',''),('PA449801','gonadorelin','','Dirigestran,Dirigestran Spofa,Factrel,Fertagyl,Gon','Drug/Small Molecule','TTD:DAP001052,chemSpider:33562,dpd:573760,drugBank:DB00644,keggCompound:C07607,pubChemCompound:36523,pubChemSubstance:46506144,pubChemSubstance:9809,url:http://en.wikipedia.org/wiki/Gonadorelin',''),('PA449804','gonadotropin,chorionic','human chorionic gonadotropin','A.P.L.,Chorex,Chorionic Gonadotropin,Follutein,Nov','Drug/Small Molecule','',''),('PA449808','gramicidin d','Neosporin','Neosporin','Drug/Small Molecule','TTD:DAP001327,dpd:422908,drugBank:DB00027,pubChemCompound:16130140,pubChemSubstance:597752,url:http://en.wikipedia.org/wiki/Gramicidin_D','C[C@@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC7=CNC8=CC=CC=C87)C(=O)NCCO)NC(=O)CNC(=O)[C@H](C(C)C)NC=O'),('PA449809','granisetron','APF530,Granisetron HCl,Granisetron base,Granisetron hydrochloride,Granisetronum [INN-Latin]','Kytril','Drug/Small Molecule','DailyMed:8206d0ce-030e-4eb0-a1b2-16aeda592112,TTD:DAP000295,bindingDb:50000483,chemSpider:3390,dpd:2088371,drugBank:DB00889,iupharLigand:2292,iupharLigand:2300,keggCompound:C07023,keggDrug:D04370,ndc:0378-1003-94,pubChemCompound:3510,pubChemSubstance:46505137,pubChemSubstance:9235,url:http://en.wikipedia.org/wiki/Granisetron',''),('PA449812','grepafloxacin','','Raxar','Drug/Small Molecule','TTD:DAP001005,bindingDb:50117924,chemSpider:65391,dpd:2237735,drugBank:DB00365,keggCompound:C11368,pubChemCompound:72474,pubChemSubstance:13542,pubChemSubstance:46507253,url:http://en.wikipedia.org/wiki/Grepafloxacin',''),('PA449814','griseofulvin','Griseofulvina [INN-Spanish],Griseofulvine [INN-French],Griseofulvinum [INN-Latin]','Amudane,Biogrisin-fp,Curling factor,Delmofulvina,F','Drug/Small Molecule','DailyMed:e5268c61-85f5-4de2-81ff-02cbaa866b11,TTD:DAP000539,bindingDb:31775,chebi:27779,chemSpider:389934,dpd:332259,drugBank:DB00400,keggCompound:C06686,keggDrug:D00209,ndc:10147-0810-4,pubChemCompound:441140,pubChemSubstance:46508437,pubChemSubstance:8911,url:http://en.wikipedia.org/wiki/Griseofulvin','C[C@@H]1CC(=O)C=C([C@]12C(=O)c3c(cc(c(c3O2)Cl)OC)OC)OC'),('PA449818','guaifenesin','Glycerin guaiacolate,Glycerin monoguaiacol ether,Glycero-guaiacol ether,Glycerol guaiacolate,Glyceryl guaiacol,Glyceryl guaiacol ether,Glyceryl guaiac','Actifed-C,Aeronesin,Amonidren,Amonidrin,Anti-Tuss,','','',''),('PA449823','guanethidine','Guanethidine Monosulfate,Guanethidine Sulphae','Abapresin,Apo-Guanethidine,Eutensol,Ismelin,Oktadi','Drug/Small Molecule','TTD:DAP000124,chebi:5557,chemSpider:3398,drugBank:DB01170,keggDrug:D02237,ndc:0083-0049-30,pubChemCompound:3518,pubChemSubstance:46507567,url:http://en.wikipedia.org/wiki/Guanethidine','C1CCCN(CCC1)CCNC(=N)N'),('PA449825','guanfacine','Guanfacina [INN-Spanish],Guanfacine HCl,Guanfacine Hydrochloride,Guanfacinum [INN-Latin],SPD 503,guanfacine','Estulic,Intuniv,Tenex','Drug/Small Molecule','DailyMed:9fc0bdc2-5ba2-48dd-aa87-7b0050a2d6ce,TTD:DAP000900,chemSpider:3399,drugBank:DB01018,iupharLigand:522,keggCompound:C07037,ndc:55567-051-18,pubChemCompound:3519,pubChemSubstance:176213,pubChemSubstance:46506169,url:http://en.wikipedia.org/wiki/Guanfacine','c1cc(c(c(c1)Cl)CC(=O)NC(=N)N)Cl'),('PA449839','halofantrine','Halofantrina [INN-Spanish],Halofantrine [Usan],Halofantrinum [INN-Latin]','Halfan','Drug/Small Molecule','TTD:DAP000953,bindingDb:50096846,chemSpider:34303,dpd:2162857,drugBank:DB01218,keggCompound:C07634,pubChemCompound:37393,pubChemSubstance:46506753,pubChemSubstance:603092,url:http://en.wikipedia.org/wiki/Halofantrine','CCCCN(CCCC)CCC(c1cc2c(cc(cc2Cl)Cl)c3c1ccc(c3)C(F)(F)F)O'),('PA449841','haloperidol','','ALDO,Aloperidin,Aloperidol,Aloperidolo,Aloperidon,','Drug/Small Molecule','DailyMed:b488c106-f1ee-4b7b-8516-01162fb929f7,TTD:DAP000313,bindingDb:21398,chebi:5613,chemSpider:3438,dpd:761745,drugBank:DB00502,iupharLigand:86,keggCompound:C01814,keggDrug:D00136,ndc:0121-0581-04,pubChemCompound:3559,pubChemSubstance:148665,pubChemSubstance:46508794,url:http://en.wikipedia.org/wiki/Haloperidol','c1cc(ccc1C(=O)CCCN2CCC(CC2)(c3ccc(cc3)Cl)O)F'),('PA449845','halothane','2-bromo-2-chloro-1,1,1-trifluoroethane,Alotano [Dcit],Bromchlortrifluoraethanum,Bromochlorotrifluoroethane,Cf3chclbr,Fluorotane,Fluorothane,Freon 123b','Anestan,Chalothane,Fluktan,Fluothane,Halan,Halotan','Drug/Small Molecule','DailyMed:c690b127-9c05-462d-d083-361002d49e1d,HET:HLT,TTD:DAP000692,chebi:5615,chemSpider:3441,dpd:589187,drugBank:DB01159,iupharLigand:2401,keggCompound:C07515,keggDrug:D00542,ndc:0409-4894-02,pdb:HLT,pubChemCompound:3562,pubChemSubstance:46506589,pubChemSubstance:7847608,url:http://en.wikipedia.org/wiki/Halothane','C(C(F)(F)F)(Cl)Br'),('PA449848','helium','','','Drug/Small Molecule','','[He]'),('PA449849','hemin','','','Drug/Small Molecule','',''),('PA449855','heparin','Alpha-Heparin,Heparin sodium,Heparin sodium preservative Free,Heparin sodium salt,Heparin sulfate,Heparinate,Heparinic acid,Low molecular weight hepar','Ariven,Arteven,Bemiparin,Calcilean,Calciparine,Cer','Drug/Small Molecule','DailyMed:efcdb321-832b-4554-8049-dbbb33b48334,TTD:DAP000189,chebi:28304,chemSpider:751,dpd:453781,drugBank:DB01109,keggCompound:C00374,ndc:0009-0268-01,pubChemCompound:772,pubChemSubstance:2789,pubChemSubstance:46507594,url:http://en.wikipedia.org/wiki/Heparin','CC(=O)NC1C(O)OC(COS(O)(=O)=O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(O)(=O)=O)C(O)=O)C(OS(O)(=O)=O)C3NS(O)(=O)=O)C(O)C2OS(O)(=O)=O)C(O)=O)C1O'),('PA449867','hesperidin','','','Drug/Small Molecule','chebi:28775,drugBank:DB04703,pdb:H1N,pubChemSubstance:7888042',''),('PA449871','hexachlorophene','','AT-7,Acigena,Almederm,Bilevon,Bivelon,Compound G-1','','',''),('PA449875','hexobarbital','5-(1-cyclohexen-1-yl)-1,5-dimethylbarbituric acid,Hexobarbitone,Methexenyl,Methylhexabital','Barbidorm,Citopan,Cyclopal,Cyclopan,Evipal,Evipan,','Drug/Small Molecule','TTD:DAP000688,chebi:5706,drugBank:DB01355,keggCompound:C11723,keggDrug:D01071,pubChemCompound:3608,pubChemSubstance:7848134,url:http://en.wikipedia.org/wiki/Hexobarbital',''),('PA449877','hexocyclium','','','Drug/Small Molecule','',''),('PA449880','histamine phosphate','','Histamine,Histamine biphosphate,Histamine dihydrog','Drug/Small Molecule','DailyMed:1159c24c-d9ce-49a2-b0bd-dc27c710f146,TTD:DNC000732,chemSpider:58959,dpd:2094673,drugBank:DB00667,ndc:0268-0248-05,pubChemCompound:65513,pubChemSubstance:207516,pubChemSubstance:46509118','c1c(nc[nH]1)CCN.[O-]P(=O)([O-])[O-]'),('PA449882','l-histidine','(S)-4-(2-Amino-2-carboxyethyl)imidazole,(S)-Histidine,(S)-a-Amino-1H-imidazole-4-propanoic acid,(S)-alpha-Amino-1H-imidazole-4-propionic acid,Glyoxali','','Drug/Small Molecule','HET:HIS,bindingDb:7953,chebi:15971,chemSpider:6038,drugBank:DB00117,keggCompound:C00135,keggDrug:D00032,pdb:HIS,pubChemCompound:6274,pubChemSubstance:3435,pubChemSubstance:46507001,url:http://en.wikipedia.org/wiki/L-Histidine',''),('PA449894','hydralazine','Hydralazine hydrochloride','Apresoline','','',''),('PA449899','hydrochlorothiazide','Dihydrochlorothiazid,Dihydrochlorothiazide,Dihydrochlorothiazidum,Dihydrochlorurit,Dihydrochlorurite,Dihydroxychlorothiazidum,HCTZ,HCZ,Hydrochlorothia','Acuretic,Aldoril,Apresazide,Aquarills,Aquarius,Bre','Drug/Small Molecule','DailyMed:091691f1-260b-4ae3-9484-a945a905fffd,TTD:DAP000750,bindingDb:13076,dpd:2247386,drugBank:DB00999,keggDrug:D00340,ndc:0378-3603-01,pubChemCompound:3639,pubChemSubstance:7847406,url:http://en.wikipedia.org/wiki/Hydrochlorothiazide','c1c2c(cc(c1Cl)S(=O)(=O)N)S(=O)(=O)NCN2'),('PA449900','hydrocodone','Dihydrocodeinone,Hidrocodona [INN-Spanish],Hydrocodon,Hydrocodonum [INN-Latin],Hydrocone,Hydroconum,Idrocodone [Dcit]','Bekadid,Codinovo,Dico,Dicodid,Multacodin','','',''),('PA449905','hydrocortisone','11beta-Hydroxycortisone,17alpha-Hydroxycorticosterone,Anti-inflammatory hormone,Dihydrocostisone,Hidrocortisona [INN-Spanish],Hydrocorticosterone,Hydr','Acticort,Aeroseb HC,Aeroseb-HC,Ala-Scalp,Ala-cort,','','',''),('PA449917','hydrogen peroxide','','','Drug/Small Molecule','','OO'),('PA449918','hydromorphone','Dihydromorfinon [Czech],Dihydromorphinone,Hidromorfona [INN-Spanish],Hydromorfona [Spanish],Hydromorphon,Hydromorphone HCL,Hydromorphonum [INN-Latin]','DiMo,Dilaudid,Dilaudid Oros,Dilaudid-hp,Dimorphone','Drug/Small Molecule','DailyMed:a6c981fb-28f9-4eff-962b-226736f7d0c8,TTD:DAP000472,chebi:5790,chemSpider:4447624,dpd:2249936,drugBank:DB00327,keggCompound:C07042,ndc:0527-1353-01,pubChemCompound:5284570,pubChemSubstance:46508700,pubChemSubstance:9254,url:http://en.wikipedia.org/wiki/Hydromorphone',''),('PA449924','hydroquinone','','','Drug/Small Molecule','','c1cc(ccc1O)O'),('PA449932','hydroxyprogesterone','','','Drug/Small Molecule','',''),('PA449942','hydroxyurea','Carbamohydroxamic Acid,Carbamohydroximic Acid,Carbamohydroxyamic Acid,Carbamoyl Oxime,Carbamyl Hydroxamate,HU,Hydroxicarbamidum,Hydroxycarbamide,Hydro','Biosupressin,Droxia,Hidrix,Hydrea,Hydreia,Hydura,H','Drug/Small Molecule','DailyMed:b9514ae5-79ae-4cc2-9d7f-c8f7806d1694,TTD:DAP000739,chebi:5816,chemSpider:3530,dpd:2247937,drugBank:DB01005,keggCompound:C07044,keggDrug:D00341,ndc:0555-0882-02,pubChemCompound:3657,pubChemSubstance:46506927,pubChemSubstance:90752,url:http://en.wikipedia.org/wiki/Hydroxyurea','C(=O)(N)NO'),('PA449943','hydroxyzine','Hidroxizina [INN-Spanish],Hydroksyzyny [Polish],Hydroxine,Hydroxizine,Hydroxizinum,Hydroxycine,Hydroxyzin,Hydroxyzine Base,Hydroxyzine Hcl,Hydroxyzine','Alamon,Atara,Atarax,Ataraxoid,Atarazoid,Atarox,Ata','Drug/Small Molecule','DailyMed:aed7d120-5f3d-4276-b341-737244d4f8a5,TTD:DAP000324,bindingDb:22875,chebi:5818,chemSpider:3531,dpd:739618,drugBank:DB00557,keggCompound:C07045,ndc:0049-5460-74,pubChemCompound:3658,pubChemSubstance:46508556,pubChemSubstance:9257,url:http://en.wikipedia.org/wiki/Hydroxyzine','c1ccc(cc1)C(c2ccc(cc2)Cl)N3CCN(CC3)CCOCCO'),('PA449957','ibuprofen','Ibuprophen,P-Isobutylhydratropic Acid,Para-Isobutylhydratropic Acid','Actiprofen,Adran,Advil,Advil Liqui-Gels,Amersol,Am','','',''),('PA449958','ibutilide','Ibutilida [INN-Spanish],Ibutilide,Ibutilide Fumarate,Ibutilidum [INN-Latin]','Corvert','Drug/Small Molecule','DailyMed:28a9e689-e272-4ff4-91b8-95299d66b7f5,TTD:DAP000279,bindingDb:50131432,chemSpider:54755,dpd:2242470,drugBank:DB00308,keggCompound:C07753,keggDrug:D00648,ndc:0574-0840-01,pubChemCompound:60753,pubChemSubstance:46507904,pubChemSubstance:731244,url:http://en.wikipedia.org/wiki/Ibutilide','CCCCCCCN(CC)CCCC(c1ccc(cc1)NS(=O)(=O)C)O'),('PA449961','idarubicin','Idarubicin Hcl,Idarubicin Hydrochloride,Idarubicina [INN-Spanish],Idarubicine [INN-French],Idarubicinum [INN-Latin]','Idamycin,Idamycin PFS,Idarubicin Aglycone,Idarubic','Drug/Small Molecule','TTD:DAP000050,chebi:42068,chemSpider:39117,dpd:2065630,drugBank:DB01177,ndc:0013-2526-86,pubChemCompound:42890,pubChemSubstance:183368,pubChemSubstance:46506973,url:http://en.wikipedia.org/wiki/Idarubicin',''),('PA449964','ifosfamide','Asta Z 4942,I-Phosphamide,Ifosfamid,Ifosfamide Sterile,Ifsofamide,Iphosphamid,Iphosphamide,Isofosfamide,Isophosphamide,ifosphamide','Cyfos,Holoxan 1000,IFEX,Ifex/Mesnex Kit,Ifosfamide','Drug/Small Molecule','DailyMed:14f535d7-4593-4cee-94fb-54ee239d95d2,TTD:DAP000537,chebi:5864,chemSpider:3562,dpd:2246565,drugBank:DB01181,keggDrug:D00343,ndc:0703-3427-11,pubChemCompound:3690,pubChemSubstance:162510,pubChemSubstance:46508335,url:http://en.wikipedia.org/wiki/Ifosfamide','C1CN(P(=O)(OC1)NCCCl)CCCl'),('PA449968','imipenem','IMP,Imipemide,Imipenem, n-formimidoyl thienamycin,N-formimidoylthienamycin','Tienamycin','Drug/Small Molecule','TTD:DAP000459,chebi:471744,chemSpider:94631,dpd:717274,drugBank:DB01598,pubChemCompound:104838,pubChemSubstance:10321787,pubChemSubstance:46505744,url:http://en.wikipedia.org/wiki/Imipenem','C[C@H]([C@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCNC=N)O.O'),('PA449969','imipramine','','Antideprin,Berkomine,Censtim,Censtin,DPID,Declomip','Drug/Small Molecule','DailyMed:a6fe8e00-a1ee-4dbb-bac7-46ac2af9aee9,HET:IXX,TTD:DAP001154,chebi:5881,chemSpider:3568,dpd:726397,drugBank:DB00458,iupharLigand:357,keggCompound:C07049,ndc:53489-330-07,pdb:IXX,pubChemCompound:3696,pubChemSubstance:46507351,pubChemSubstance:9261,url:http://en.wikipedia.org/wiki/Imipramine','CN(C)CCCN1c2ccccc2CCc3c1cccc3'),('PA449972','imiquimod','Imiquimod acetate,imiquimod','Aldara','Drug/Small Molecule','DailyMed:a1dfc325-cc63-4347-9497-f6baf874963c,TTD:DAP000278,chebi:36704,chemSpider:51809,dpd:2239505,drugBank:DB00724,keggDrug:D02500,ndc:0168-0432-24,pubChemCompound:57469,pubChemSubstance:194523,pubChemSubstance:46505394,url:http://en.wikipedia.org/wiki/Imiquimod','CC(C)Cn1cnc2c1c3ccccc3nc2N'),('PA449975','indapamide','Indapamida [INN-Spanish],Indapamidum [INN-Latin]','Apo-Indapamide,Arifon,Bajaten,Cormil,Damide,Fludex','Drug/Small Molecule','DailyMed:c57cd71d-f124-4cac-9c90-fa24ebff9dea,TTD:DAP000498,bindingDb:25901,chemSpider:3574,dpd:2240350,drugBank:DB00808,keggDrug:D00345,ndc:0339-6494-11,pubChemCompound:3702,pubChemSubstance:46508626,pubChemSubstance:7847411,url:http://en.wikipedia.org/wiki/Indapamide','CC1Cc2ccccc2N1NC(=O)c3ccc(c(c3)S(=O)(=O)N)Cl'),('PA449977','indinavir','Compound J,Indinavir sulfate','Crixivan','Drug/Small Molecule','DailyMed:e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f,TTD:DAP000168,bindingDb:517,chebi:5898,chemSpider:4515036,dpd:2229161,drugBank:DB00224,keggCompound:C07051,ndc:0006-0570-62,pubChemCompound:5362440,pubChemSubstance:197165,pubChemSubstance:46506442,url:http://en.wikipedia.org/wiki/Indinavir','CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](Cc2ccccc2)C(=O)N[C@H]3c4ccccc4C[C@H]3O)O)Cc5cccnc5'),('PA449981','indocyanine green','','Cardio-Green','Drug/Small Molecule','',''),('PA449982','indomethacin','IMN,Indometacine,Indometacyna,Indomethacine,Indomethacinum,Indomethancin,Indomethazine,Indomethine,Indometicina,indomethacin','Amuno,Apo-Indomethacin,Argun,Arthrexin,Artracin,Ar','Drug/Small Molecule','DailyMed:06de3c9d-63bf-47c1-f78c-4fbdd482928a,TTD:DAP000617,bindingDb:17638,chebi:5918,chemSpider:3584,dpd:2143372,drugBank:DB00328,iupharLigand:1909,keggCompound:C01926,keggDrug:D00141,ndc:42211-101-11,pubChemCompound:3715,pubChemSubstance:148696,pubChemSubstance:46508291,url:http://en.wikipedia.org/wiki/Indomethacin','Cc1c(c2cc(ccc2n1C(=O)c3ccc(cc3)Cl)OC)CC(=O)O'),('PA449992','insulin-glargine','Insulin glargine,insulin glargine recombinant','Lantus','Drug/Small Molecule','drugBank:DB00047,url:http://en.wikipedia.org/wiki/Insulin_glargine',''),('PA450037','interferon beta-1a','Fibroblast interferon,IFN-beta,Interferon beta precursor','Avonex,Belerofon','Drug/Small Molecule','DailyMed:c6fcb5d2-8fcd-44fa-a838-b84ee5f44f0f,TTD:DAP001282,dpd:2237319,drugBank:DB00060,genBank:V00534,ndc:44087-8822-1,uniProtKb:P01574,url:http://en.wikipedia.org/wiki/Interferon_beta-1a',''),('PA450039','interferon beta-1b','Fibroblast interferon,IFN-beta,Interferon beta precursor','Betaseron','Drug/Small Molecule','DailyMed:261fde67-efb2-4bd7-947e-4f68a56e76ff,TTD:DAP001283,dpd:2169649,drugBank:DB00068,genBank:V00534,keggCompound:C07901,keggDrug:D00746,ndc:50419-523-35,pubChemSubstance:10103,uniProtKb:P01574,url:http://en.wikipedia.org/wiki/Interferon_beta-1b',''),('PA450043','inulin','','Inulin USP 27,Inulin from Jerusalem artichokes','Drug/Small Molecule','TTD:DAP001304,chebi:15443,chemSpider:23149,drugBank:DB00638,keggCompound:C03323,keggDrug:D00171,pubChemCompound:24763,pubChemSubstance:46508287,pubChemSubstance:6172,url:http://en.wikipedia.org/wiki/Inulin',''),('PA450049','iodine','','','Drug/Small Molecule','','[I]'),('PA450061','iohexol','','Exypaque,Histodenz,Nycodenz,Omnipaque','Drug/Small Molecule','chemSpider:3599,dpd:2172720,drugBank:DB01362,ndc:0407-1401-50,pubChemCompound:3730,pubChemSubstance:10321749,pubChemSubstance:46506178,url:http://en.wikipedia.org/wiki/Iohexol',''),('PA450082','ipratropium','Ipatropium Bromide,Ipratropium Bromide,N-Isopropylatropine,ipratropium','Aerodose,Aerovent,Apo-Ipravent,Apovent,Atronase,At','','',''),('PA450084','irbesartan','irbesartan','Avalide,Avapro,Irbesarran,Irbesartan [Usan:Inn],Lr','','',''),('PA450085','irinotecan','Irinotecan Hcl,Irinotecan Hydrochloride,Irinotecan Hydrochloride Trihydrate,Irinotecanum [INN-Latin],irinotecan','CP0,Camptosar,IRINOTECAN, CPT-11','Drug/Small Molecule','DailyMed:e98886aa-933c-430f-bb56-f1eb3862aae4,TTD:DAP001339,chemSpider:54825,dpd:2231622,drugBank:DB00762,keggDrug:D08086,ndc:0703-4432-11,pubChemCompound:60838,pubChemSubstance:217212,pubChemSubstance:46505871,url:http://en.wikipedia.org/wiki/Irinotecan',''),('PA450087','iron','','Ed-In-Sol,Fe-40,Feosol,Feostat,Fer-In-Sol,Feratab,','Drug/Small Molecule','TTD:DAP001313,chebi:18248,chemSpider:22368,drugBank:DB01592,keggCompound:C00023,pubChemCompound:23925,pubChemSubstance:3325,pubChemSubstance:46509190,url:http://en.wikipedia.org/wiki/Iron','[Fe]'),('PA450101','isocarboxazid','Isocarbonazid,Isocarbossazide [Dcit],Isocarboxazida [INN-Spanish],Isocarboxazide,Isocarboxazide [INN-French],Isocarboxazidum [INN-Latin],Isocarboxyzid','BMIH,Benazide,Enerzer,Maraplan,Marplan,Marplon','Drug/Small Molecule','DailyMed:ac387aa0-3f04-4865-a913-db6ed6f4fdc5,TTD:DAP000577,chemSpider:3628,drugBank:DB01247,keggDrug:D02580,ndc:30698-032-01,pubChemCompound:3759,pubChemSubstance:148916,pubChemSubstance:46505330,url:http://en.wikipedia.org/wiki/Isocarboxazid','Cc1cc(no1)C(=O)NNCc2ccccc2'),('PA450103','isoetharine','Isoetarina [INN-Spanish],Isoetarinum [INN-Latin],Isoetharine Hcl,Isoetharine mesylate','Beta-2,Bronkometer,Bronkosol,Dey-Lute Isoetharine,','Drug/Small Molecule','TTD:DAP000935,chemSpider:3630,drugBank:DB00221,keggCompound:C07053,keggDrug:D04625,pubChemCompound:3762,pubChemSubstance:46505384,pubChemSubstance:9265,url:http://en.wikipedia.org/wiki/Isoetharine',''),('PA450106','isoflurane','','Aerrane,Ethane,Forane,Forene,Isoflurane [Usan:Ban:','Drug/Small Molecule','DailyMed:3e28cf99-2b70-4fd7-7988-a808dfac54c4,HET:ICF,TTD:DAP001033,chebi:6015,chemSpider:3631,dpd:2241315,drugBank:DB00753,keggCompound:C07518,keggDrug:D00545,ndc:0409-3292-01,pdb:ICF,pubChemCompound:3763,pubChemSubstance:175428,pubChemSubstance:46505880,url:http://en.wikipedia.org/wiki/Isoflurane','C(C(F)(F)F)(OC(F)F)Cl'),('PA450112','isoniazid','HIA,Hydrazid,Hydrazide,INH,Isohydrazide,Isonicotinhydrazid,Isonicotinic acid hydrazide,Isonicotinic hydrazide,Isonicotinohydrazide,Isonicotinoyl hydra','Andrazide,Antimicina,Antituberkulosum,Armacide,Arm','','',''),('PA450117','isopropyl alcohol','','','Drug/Small Molecule','chebi:17824,drugBank:DB02325,keggCompound:C01845,keggDrug:D00137,pubChemCompound:3776,pubChemSubstance:10317679','CC(C)O'),('PA450121','isoproterenol','Epinephrine Isopropyl Homolog,IPA,Isoprenalin,Isoprenaline,Isopropydrin,Isopropyladrenaline,Isopropylarterenol,Isopropylnoradrenaline,Isopropylnorepin','Aerolone,Aleudrin,Aleudrine,Aludrin,Aludrine,Asipr','Drug/Small Molecule','DailyMed:394d3238-f763-4f67-bb9d-08751ec6ed31,TTD:DNC000819,bindingDb:25392,chebi:6046,chemSpider:3647,dpd:897639,drugBank:DB01064,iupharLigand:536,keggCompound:C07056,ndc:0089-0785-21,pubChemCompound:3779,pubChemSubstance:46507323,pubChemSubstance:9268,url:http://en.wikipedia.org/wiki/Isoproterenol','CC(C)NCC(c1ccc(c(c1)O)O)O'),('PA450125','isosorbide dinitrate','Dianhydrosorbitol 2,5-dinitrate,Sorbide nitrate,Sorbide, dinitrate,Sorbidnitrate','Cardio 10,Cardis,Carvanil,Carvasin,Cedocard,Claodi','','',''),('PA450126','isosorbide mononitrate','IHD,ISMN,Isosorbidi Mononitras [Latin],Mononitrate d\'Isosorbide [French],Mononitrato de Isosorbida [Spanish],Monosorbitrate','Conpin,Conpin Retardkaps,Corangin,Corangin Sr,Duri','Drug/Small Molecule','TTD:DAP001058,chebi:6062,chemSpider:25736,dpd:2126559,drugBank:DB01020,keggCompound:C07714,keggDrug:D00630,ndc:0085-3306-03,pubChemCompound:27661,pubChemSubstance:46506594,pubChemSubstance:9916,url:http://en.wikipedia.org/wiki/Isosorbide_mononitrate',''),('PA450128','isotretinoin','','Accutane Roche','Drug/Small Molecule','TTD:DAP000009,chebi:6067,dpd:582344,drugBank:DB00982,keggDrug:D00348,ndc:0004-0155-49,pubChemCompound:5538,pubChemSubstance:7847414,url:http://en.wikipedia.org/wiki/Isotretinoin',''),('PA450131','isradipine','(+-)-Isradipine,(+/-)-Isradipine,Isradipin,Isradipino [Spanish],Isradipinum [Latin],Isrodipine','Clivoten,DynaCirc,DynaCire,DynaCire CR,Dynacirc CR','Drug/Small Molecule','DailyMed:c5745462-fab9-4916-acee-1bc6f9e63560,TTD:DAP000134,chemSpider:3652,drugBank:DB00270,iupharLigand:2513,iupharLigand:2733,keggDrug:D00349,ndc:0173-0784-01,pubChemCompound:3784,pubChemSubstance:191160,pubChemSubstance:46505034,url:http://en.wikipedia.org/wiki/Isradipine',''),('PA450132','itraconazole','ITC,ITCZ,ITR,ITZ,Itraconazol [Spanish],Itraconazolum [Latin],itraconazole','Hyphanox,Itrizole,Oriconazole,Sporal,Sporanos,Spor','Drug/Small Molecule','DailyMed:ae50721d-ee15-4ee7-9fe7-afd98c56461b,TTD:DAP000631,chebi:6076,chemSpider:49927,dpd:2231347,drugBank:DB01167,keggDrug:D00350,ndc:50458-295-15,pubChemCompound:55283,pubChemSubstance:192757,pubChemSubstance:46505954,url:http://en.wikipedia.org/wiki/Itraconazole',''),('PA450133','ivermectin','22,23-Dihydroxy-avermectin B,22,23-Dihyroavermectin B1,5-O-demethyl-22,23-dihydro-avermectin A1a','Ivermectin B1,Ivermectin-luminol,Mectizan,Sklice,S','','',''),('PA450137','kanamycin','Aminodeoxykanamycin,KAN,Kanamycin Base,Kanamycin Sulfate,Nebramycin Factor 5','Bekanamycin,Kanamycin A,Kanamycin B,Kenamycin A,Kl','Drug/Small Molecule','TTD:DNC000201,chebi:17630,chebi:24945,chemSpider:5810,drugBank:DB01172,keggCompound:C00304,ndc:0015-3503-20,pubChemCompound:6032,pubChemSubstance:46508178,url:http://en.wikipedia.org/wiki/Kanamycin',''),('PA450144','ketamine','(-)-Ketamine,(S)-(-)-Ketamine,(S)-Ketamine,CI 581 base,Ketamine Base,Ketamine HCL,l-Ketamine','CLSTA 20,Esketamine,Ketaject,Ketalar,Ketalar base,','Drug/Small Molecule','TTD:DAP001148,bindingDb:50044140,chebi:6121,chemSpider:3689,dpd:2246796,drugBank:DB01221,keggCompound:C07525,ndc:61570-581-10,pubChemCompound:3821,pubChemSubstance:46508295,pubChemSubstance:9728,url:http://en.wikipedia.org/wiki/Ketamine','CNC1(CCCCC1=O)c2ccccc2Cl'),('PA450146','ketoconazole','2%,Ketocanazole,Ketoconazol,Ketoconazol [INN-Spanish],Ketoconazole [Usan:Ban:Inn:Jan],Ketoconazolum [INN-Latin],ketoconazole','Extina,Fungarest,Fungoral,Ketoderm,Ketoisdin,Ketoz','Drug/Small Molecule','HET:KTN,TTD:DAP000630,bindingDb:31768,chebi:48339,dpd:2237235,drugBank:DB01026,iupharLigand:2568,keggDrug:D00351,ndc:0145-0003-05,pdb:KTN,pubChemCompound:47576,pubChemSubstance:186839,url:http://en.wikipedia.org/wiki/Ketoconazole','CC(=O)N1CCN(CC1)c2ccc(cc2)OC[C@@H]3CO[C@@](O3)(Cn4ccnc4)c5ccc(cc5Cl)Cl'),('PA450149','ketoprofen','m-Benzoylhydratropic acid','Actron,Alrheumat,Alrheumun,Capisten,Dexal,Epatec,F','Drug/Small Molecule','DailyMed:198a4140-f4c0-4478-9157-ee1d68d0bb96,TTD:DAP000623,chebi:6128,chemSpider:3693,dpd:2245967,drugBank:DB01009,keggCompound:C01716,keggDrug:D00132,ndc:0378-4070-01,pubChemCompound:3825,pubChemSubstance:46505715,pubChemSubstance:4853,url:http://en.wikipedia.org/wiki/Ketoprofen','CC(c1cccc(c1)C(=O)c2ccccc2)C(=O)O'),('PA450150','ketorolac','Ketoralac,Ketorolac Tromethamine,Ketorolaco [Spanish],Ketorolacum [Latin]','Acular,Acular LS,Acular Preservative Free,Toradol','Drug/Small Molecule','DailyMed:9a6df709-e016-44e1-8e1d-dea46689c3c8,TTD:DAP000618,bindingDb:50009855,chemSpider:3694,dpd:2239944,drugBank:DB00465,keggCompound:C07062,ndc:68387-440-20,pubChemCompound:3826,pubChemSubstance:46507019,pubChemSubstance:9274,url:http://en.wikipedia.org/wiki/Ketorolac','c1ccc(cc1)C(=O)c2ccc3n2CCC3C(=O)O'),('PA450152','ketotifen','Ketotifen Fumarate,Ketotifene [INN-French],Ketotifene fumarate,Ketotifeno [INN-Spanish],Ketotifenum [INN-Latin]','Ketotifen,Zaditor','Drug/Small Molecule','DailyMed:7ca8b8df-6910-4a78-82a6-c5217ac5a9ae,TTD:DAP000329,bindingDb:50002087,chemSpider:3695,dpd:2242324,drugBank:DB00920,keggDrug:D01332,ndc:50580-732-05,pubChemCompound:3827,pubChemSubstance:46508921,url:http://en.wikipedia.org/wiki/Ketotifen',''),('PA450154','l-carnitine','(-)-Carnitine,(-)-L-Carnitin,(S)-Carnitine,3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium,Carnitine,Vitamin BT','Carnitor,Karnitin,Nicetile','Drug/Small Molecule','TTD:DAP000958,chebi:16347,chemSpider:10455,dpd:2144344,drugBank:DB00583,keggCompound:C00318,keggDrug:D02176,ndc:0517-1055-25,pubChemCompound:10917,pubChemSubstance:46505864,pubChemSubstance:7849237,url:http://en.wikipedia.org/wiki/L-Carnitine',''),('PA450161','lactose','','','Drug/Small Molecule','chebi:36219,drugBank:DB04465,keggCompound:C00243,keggDrug:D00046,pdb:LAT,pubChemCompound:84571,pubChemSubstance:3542',''),('PA450163','lamivudine','Lamivudine [Usan:Ban:Inn],lamivudine','3TC,Epivir,Epivir-HBV,Epzicom,Hepitec,Heptovir,Zef','','',''),('PA450164','lamotrigine','GW 273293,Lamotrigina [Spanish],Lamotriginum [Latin],lamotrigine','Lamictal,Lamictal CD,Lamictal XR,Lamictin','Drug/Small Molecule','DailyMed:d7e3572d-56fe-4727-2bb4-013ccca22678,TTD:DAP000039,bindingDb:50031299,chebi:6367,chemSpider:3741,dpd:2248232,drugBank:DB00555,iupharLigand:2622,keggDrug:D00354,ndc:0173-0633-02,pubChemCompound:3878,pubChemSubstance:46505408,pubChemSubstance:7847420,url:http://en.wikipedia.org/wiki/Lamotrigine','c1cc(c(c(c1)Cl)Cl)c2c(nc(nn2)N)N'),('PA450180','lansoprazole','AG 1749,lansoprazole','Agopton,Amarin,Aprazol,Bamalite,Biuret,Biuret Gr,B','Drug/Small Molecule','DailyMed:68c5c707-4539-4ed9-ab12-4ac138c62ff3,TTD:DAP000725,chebi:6375,chemSpider:3746,dpd:2165503,drugBank:DB00448,keggDrug:D00355,ndc:0339-6489-11,pubChemCompound:3883,pubChemSubstance:196229,pubChemSubstance:46508975,url:http://en.wikipedia.org/wiki/Lansoprazole','Cc1c(ccnc1CS(=O)c2[nH]c3ccccc3n2)OCC(F)(F)F'),('PA450191','lecithin','','','Drug/Small Molecule','',''),('PA450192','leflunomide','Leflunomidum [INN-Latin],Lefunomide [INN-Spanish],leflunomide','Arava','Drug/Small Molecule','DailyMed:151ffcf4-e503-4954-af7c-93d0a4f9f80e,TTD:DAP000636,chebi:6402,chemSpider:3762,dpd:2261278,drugBank:DB01097,keggCompound:C07905,keggDrug:D00749,ndc:0555-0351-01,pubChemCompound:3899,pubChemSubstance:191162,pubChemSubstance:46506013,url:http://en.wikipedia.org/wiki/Leflunomide','Cc1c(cno1)C(=O)Nc2ccc(cc2)C(F)(F)F'),('PA450195','lepirudin','Hirudin variant-1','Refludan','Drug/Small Molecule','DailyMed:6d4819a3-b934-40a8-a967-947cc456c53c,TTD:DAP000541,dpd:2240996,drugBank:DB00001,ndc:50419-150-57,pubChemCompound:16132441,pubChemSubstance:14818038,uniProtKb:P01050,url:http://en.wikipedia.org/wiki/Lepirudin','CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(C)C)CC(=O)N)CCC(=O)N)CO)CCC(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)C(=O)N1)CCCCN)CC(=O)N)CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCCN)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC7=CN=CN7)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N9CCC[C@H]9C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCCN)CCC(=O)O)CC(=O)O)CO)CC(C)C'),('PA450196','letrozole','Letrozol,letrozole','Femara','Drug/Small Molecule','TTD:DAP000626,bindingDb:13061,chebi:6413,chemSpider:3765,dpd:2231384,drugBank:DB01006,keggCompound:C08163,keggDrug:D00964,pubChemCompound:3902,pubChemSubstance:10363,pubChemSubstance:46504610,url:http://en.wikipedia.org/wiki/Letrozole','c1cc(ccc1C#N)C(c2ccc(cc2)C#N)n3cncn3'),('PA450197','l-leucine','(2S)-2-Amino-4-methylpentanoic acid,(S)-(+)-Leucine,(S)-2-Amino-4-methylpentanoic acid,(S)-2-Amino-4-methylvaleric acid,(S)-Leucine,1-Leucine,2-Amino-','','','',''),('PA450198','leucovorin','Calcium folinate,Folinic acid,Folinic acid calcium salt,Folinic acid calcium salt USP27,L-leucovorin,Leucovorin calcium,Leucovorin folinic acid,Leukov','Calcium citrovorum factor,Citrovorum factor,Folini','Drug/Small Molecule','TTD:DAP001244,chemSpider:49292,dpd:2182998,drugBank:DB00650,keggDrug:D01211,ndc:0555-0484-18,pubChemCompound:54575,pubChemSubstance:148853,pubChemSubstance:46505436,url:http://en.wikipedia.org/wiki/Leucovorin',''),('PA450203','leuprolide','Eligard,inhalable,leuprolide,leuprorelin','Eligard,Enantone,LeuProMaxx,Leuplin,Leupromer,Lupr','Drug/Small Molecule','DailyMed:fe3228a7-a5e4-40e4-9fe6-b35db60a71ce,TTD:DAP000020,chebi:6427,drugBank:DB00007,iupharLigand:1175,keggCompound:C07612,keggDrug:D08113,ndc:0024-0793-75,pubChemCompound:3911,pubChemSubstance:9814,url:http://en.wikipedia.org/wiki/Leuprolide','CCNC(=O)[C@H]1N(CCC1)C(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2NC(=O)CC2)CC3=CN=CN3)CC4=CNC5=CC=CC=C45)CO)CC6=CC=C(C=C6)O)CC(C)C)CC(C)C)CCC/N=C(N)/N'),('PA450205','levamisole','L-Tetramisole,Levamisol [INN-Spanish],Levamisole hydrochloride,Levamisolum [INN-Latin],Phenyl imidothiazole,dl-Tetramisol,dl-Tetramisole','Ergamisol,Ketrax,LEVOMYSOL,Lepuron,Levamisol,Nilve','Drug/Small Molecule','TTD:DAP000570,bindingDb:50241179,chebi:30524,chemSpider:25037,dpd:645699,drugBank:DB00848,keggCompound:C07070,keggDrug:D08114,pubChemCompound:26879,pubChemSubstance:46509052,pubChemSubstance:9282,url:http://en.wikipedia.org/wiki/Levamisole','c1ccc(cc1)[C@H]2CN3CCSC3=N2'),('PA450206','levetiracetam','Levetiracetam [INN],Levetiracetamum [INN-Latin],Levitiracetam,levetiracetam','Keppra','Drug/Small Molecule','DailyMed:94a972db-11b3-419e-9410-8d923c9f1489,TTD:DAP000502,chemSpider:390096,dpd:2247028,drugBank:DB01202,keggCompound:C07841,keggDrug:D00709,ndc:0121-4802-05,pubChemCompound:441341,pubChemSubstance:10043,pubChemSubstance:46508406,url:http://en.wikipedia.org/wiki/Levetiracetam','CC[C@@H](C(=O)N)N1CCCC1=O'),('PA450213','levodopa','3,4-dihydroxyphenylalanine,DOPA,L-DOPA,L-Dihydroxyphenylalanine','Bendopa,Brocadopa,Cidandopa,Deadopa,Dopaflex,Dopai','','',''),('PA450214','levofloxacin','L-Ofloxacin,levofloxacin','Cravit,Cravit Ophthalmic,Elequine,Floxel,Iquix,Ler','Drug/Small Molecule','DailyMed:09b3a912-97f9-45ae-a162-9f45c860dc22,TTD:DAP000160,bindingDb:50167506,chemSpider:131410,dpd:2248263,drugBank:DB01137,keggCompound:C07660,ndc:68669-135-05,pubChemCompound:149096,pubChemSubstance:195031,pubChemSubstance:46505134,url:http://en.wikipedia.org/wiki/Levofloxacin',''),('PA450215','levomethadyl acetate','1-alpha-acetylmethadol,LAAM,Levacetilmetadol [INN-Spanish],Levacetylmethadol,Levacetylmethadolum [INN-Latin],Levo-Alphacetylmethadol,Levo-Methadyl Ace','Orlaam','Drug/Small Molecule','TTD:DAP001139,chebi:6441,chemSpider:14401,drugBank:DB01227,keggCompound:C08012,keggDrug:D04716,pubChemCompound:15130,pubChemSubstance:158449,pubChemSubstance:46507749,url:http://en.wikipedia.org/wiki/Levomethadyl_Acetate',''),('PA450218','levonorgestrel','Levonorgestrelum [INN-Latin],SOH-075','72-HOURS,Follistrel,Jadelle,Levlen,Levlen Ed,Levon','','',''),('PA450221','levothyroxine','(-)-Thyroxine,3,3\',5,5\'-Tetraiodo-L-thyronine,L-Thryoxin,L-Thyroxine,Laevothyroxinum,Levo-t,Levothyroxin,Levothyroxine Sodium,O-(4-Hydroxy-3,5-diidoph','Eltroxin,Euthyrox,Laevoxin,Letter,Levaxin,Levolet,','','',''),('PA450226','lidocaine','Dilocaine,L-Caine','After Burn Double Strength Gel,After Burn Double S','','',''),('PA450233','linezolid','linezolid','Linezlid,Zyvox,Zyvoxid','Drug/Small Molecule','DailyMed:6e70e63b-bfd5-478d-a8ee-8ba22c9efabd,HET:ZLD,TTD:DAP000398,bindingDb:50116067,chemSpider:390139,dpd:2243684,drugBank:DB00601,keggCompound:C08146,keggDrug:D00947,ndc:0009-5137-01,pdb:ZLD,pubChemCompound:441401,pubChemSubstance:10346,pubChemSubstance:46504452,url:http://en.wikipedia.org/wiki/Linezolid',''),('PA450239','lipase','','Cotazym','Drug/Small Molecule','',''),('PA450242','lisinopril','lisinopril','Acercomp,Inhibril,Linopril,Lisinopril Dihydrate,Li','','',''),('PA450243','lithium','','Eskalith,LithoTab','Drug/Small Molecule','TTD:DNC000879,chebi:30142,chebi:49713,chemSpider:26502,dpd:236683,drugBank:DB01356,keggCompound:C15473,pubChemCompound:28486,pubChemSubstance:11538471,pubChemSubstance:46505392,url:http://en.wikipedia.org/wiki/Lithium',''),('PA450249','liver extract','','','Drug/Small Molecule','',''),('PA450262','loperamide','','Apo-Loperamide,Diarr-Eze,Imodium,Imodium A-D,Imodi','Drug/Small Molecule','DailyMed:72a7ae47-cdf3-4949-b9f8-f29b153f787f,TTD:DAP000425,bindingDb:50017698,chebi:6532,chemSpider:3818,dpd:2240415,drugBank:DB00836,keggCompound:C07080,ndc:0378-2100-01,pubChemCompound:3955,pubChemSubstance:46504591,pubChemSubstance:9291,url:http://en.wikipedia.org/wiki/Loperamide',''),('PA450264','lopinavir','ABT-378,LPV','Aluviran,Koletra','','',''),('PA450266','loratadine','Loratadina [Spanish],Loratadinum [Latin]','Aerotina,Alarin,Alavert,Alerpriv,Allertidin,Bedix ','','',''),('PA450267','lorazepam','(+/-)-Lorazepam,L-Lorazepam Acetate,O-Chlorooxazepam,O-Chloroxazepam','Almazine,Alzapam,Anxiedin,Aplacassee,Ativan,Bonatr','Drug/Small Molecule','DailyMed:5ff82103-cc57-4af9-9362-82a7c686271d,TTD:DAP000237,chemSpider:3821,dpd:2243278,drugBank:DB00186,keggDrug:D00365,ndc:0054-3532-44,pubChemCompound:3958,pubChemSubstance:156663,pubChemSubstance:46508468,url:http://en.wikipedia.org/wiki/Lorazepam','c1ccc(c(c1)C2=NC(C(=O)Nc3c2cc(cc3)Cl)O)Cl'),('PA450268','losartan','losartan potassium','Cozaar,DUP 89,Hyzaar,Lacidipine,Lortaan','Drug/Small Molecule','DailyMed:5ac32c20-169d-475a-fc8a-934f758d6ab0,TTD:DAP000523,chebi:6541,chemSpider:3824,dpd:2182882,drugBank:DB00678,iupharLigand:590,keggCompound:C07072,ndc:0006-0951-54,pubChemCompound:3961,pubChemSubstance:205151,pubChemSubstance:46506538,url:http://en.wikipedia.org/wiki/Losartan','CCCCc1nc(c(n1Cc2ccc(cc2)c3ccccc3c4[nH]nnn4)CO)Cl'),('PA450272','lovastatin','6 alpha-Methylcompactin,Lovastatina [Spanish],Lovastatine [French],Lovastatinum [Latin],lovastatin','Altocor,Altoprev,Artein,Belvas,Cholestra,Closterol','Drug/Small Molecule','DailyMed:73f92f9b-3715-4699-ba60-1ffecd677e23,HET:803,TTD:DAP000551,chebi:40303,chemSpider:48085,dpd:2243127,drugBank:DB00227,keggCompound:C07074,keggDrug:D00359,ndc:0378-6510-91,pdb:803,pubChemCompound:53232,pubChemSubstance:191104,pubChemSubstance:46508223,url:http://en.wikipedia.org/wiki/Lovastatin','CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C'),('PA450273','loxapine','','Cloxazepine,Dibenzacepin,Dibenzoazepine,Hydrofluor','Drug/Small Molecule','DailyMed:1a03c19b-d44f-ae98-f404-022eb8392677,TTD:DAP000311,bindingDb:22871,chebi:50841,chemSpider:3827,dpd:2255448,drugBank:DB00408,iupharLigand:205,keggCompound:C07104,keggDrug:D02340,ndc:0378-7005-01,pubChemCompound:3964,pubChemSubstance:46505047,pubChemSubstance:9315,url:http://en.wikipedia.org/wiki/Loxapine','CN1CCN(CC1)C2=Nc3ccccc3Oc4c2cc(cc4)Cl'),('PA450280','l-lysine','(s)-2,6-diaminohexanoic acid,(s)-alpha,epsilon-diaminocaproic acid,(s)-lysine,2,6-diaminohexanoic acid,L-lys,LYS,lysine,lysine acid','Enisyl','Drug/Small Molecule','HET:LYS,chebi:18019,chemSpider:5747,drugBank:DB00123,iupharLigand:724,keggCompound:C00047,keggDrug:D02304,pdb:LYS,pubChemCompound:5962,pubChemSubstance:3349,pubChemSubstance:46504770,url:http://en.wikipedia.org/wiki/L-Lysine',''),('PA450287','magnesium','','','Drug/Small Molecule','bindingDb:15,chebi:25107,chemSpider:865,dpd:13838,drugBank:DB01378,keggCompound:C00305,pubChemCompound:888,pubChemSubstance:22394505,pubChemSubstance:46508750,url:http://en.wikipedia.org/wiki/Magnesium','[Mg]'),('PA450290','magnesium acetate','','Aminosyn 3.5% M,Aminosyn 3.5% M In Plastic Contain','Drug/Small Molecule','','CC(=O)[O-].[Mg+2]'),('PA450294','magnesium chloride','','','Drug/Small Molecule','','[Mg+2].[Cl-]'),('PA450296','magnesium gluconate','','','Drug/Small Molecule','',''),('PA450298','magnesium oxide','','','Drug/Small Molecule','chebi:31794,chemSpider:14108,dpd:39365,drugBank:DB01377,keggCompound:C12567,keggDrug:D01167,pubChemCompound:14792,pubChemSubstance:10506457,pubChemSubstance:46504815,url:http://en.wikipedia.org/wiki/Magnesia','[O-2].[Mg+2]'),('PA450300','salicylate-magnesium','','','Drug/Small Molecule','drugBank:DB01397,url:http://en.wikipedia.org/wiki/Magnesium_salicylate','c1ccc(c(c1)C(=O)[O-])O.[Mg+2]'),('PA450302','magnesium sulfate','Bitter salt,Magnesium Sulphate Heptahydrate,Magnesium Sulphate Hydrate,Magnesium sulfate anhydrous,Magnesium sulfate dried,Magnesium sulfate heptahydr','Elliotts B Solution,Epsom salts,Hair salt,Kieserit','','',''),('PA450320','mannitol','Cordycepic acid,D-Mannitol,mannitol','Bronchitol,Diosmol,Hexanhexol,Hexitol,Isotol,Manic','','',''),('PA450322','maprotiline','Maprotilina [INN-Spanish],Maprotiline Hcl,Maprotilinum [INN-Latin],Maprotylina [Polish]','Deprilept,Ludiomil,Psymion','Drug/Small Molecule','DailyMed:c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87,TTD:DAP001150,bindingDb:35228,chemSpider:3871,drugBank:DB00934,iupharLigand:2402,keggCompound:C07107,keggDrug:D02566,ndc:0378-0060-01,pubChemCompound:4011,pubChemSubstance:46508358,pubChemSubstance:9318,url:http://en.wikipedia.org/wiki/Maprotiline','CNCCCC12CCC(c3c1cccc3)c4c2cccc4'),('PA450326','mazindol','','DEA No. 1605,Dimagrir,Magrilon,Mazanor,Mazildene,M','Drug/Small Molecule','TTD:DAP000722,bindingDb:50005536,chemSpider:3880,dpd:432407,drugBank:DB00579,keggDrug:D00367,pubChemCompound:4020,pubChemSubstance:46509094,pubChemSubstance:7847433,url:http://en.wikipedia.org/wiki/Mazindol',''),('PA450334','mecamylamine','2-Methylamino-2,3,3-trimethylnorbornane,2-Methylaminoisocamphane,3-Methylaminoisocamphane,3-Methylaminoisocamphane hydrochloride,Mecamilamina,Mecamyla','Inversine,Inversine hydrochloride,Mecamine,Mecamin','Drug/Small Molecule','DailyMed:e1fc95fe-7816-47b6-b73d-b2f644f79872,TTD:DAP000027,bindingDb:50061565,chemSpider:3892,drugBank:DB00657,keggCompound:C07511,ndc:17205-0626-1,pubChemCompound:4032,pubChemSubstance:46508607,pubChemSubstance:9714,url:http://en.wikipedia.org/wiki/Mecamylamine',''),('PA450336','mechlorethamine','Chlorethazine,Chlormethine,HN2,MBA,Mechloroethamine,Mecloretamina,Mustine,Nitrogen mustard','Caryolysin,Caryolysine,Cloramin,Dichloren,Embichin','Drug/Small Molecule','TTD:DAP000790,chebi:28925,chemSpider:3893,dpd:16063,drugBank:DB00888,keggCompound:C07115,pubChemCompound:4033,pubChemSubstance:46505784,pubChemSubstance:9326,url:http://en.wikipedia.org/wiki/Mechlorethamine','CN(CCCl)CCCl'),('PA450338','meclizine','','Ancolan,Ancolon,Antivert,Antivert/25,Antivert/50,B','','',''),('PA450341','meclofenamic acid','Acide meclofenamique [INN-French],Acido meclofenamico [INN-Spanish],Acidum meclofenamicum [INN-Latin],Meclofenamate,Meclomen (free acid),Meclophenamic','Arquel','Drug/Small Molecule','DailyMed:96f19af4-de8f-4fd7-90d8-55fe6ebdd81d,TTD:DNC000919,bindingDb:22971,chemSpider:3897,drugBank:DB00939,keggCompound:C02996,keggDrug:D02341,ndc:0378-2150-01,pubChemCompound:4037,pubChemSubstance:46507887,pubChemSubstance:7849400,url:http://en.wikipedia.org/wiki/Meclofenamic_acid',''),('PA450344','medroxyprogesterone','CBP-1011,Hydroxymethylprogesterone,MAP,Medroprogesterone Acetate,Medrossiprogesterone [Dcit],Medroxiprogesterona [INN-Spanish],Medroxiprogesteronum,Me','Aragest,Aragest 5,Asconale,Clinofem,Clinovir,Colir','','',''),('PA450346','medrysone','Hydroxymesterone','HMS,HMS Liquifilm,Medrifar,Medritonic,Medrocort,Vi','Drug/Small Molecule','DailyMed:1612d931-d86e-4dba-bbd7-0aac3eaee131,TTD:DAP001048,chemSpider:216968,dpd:36676,drugBank:DB00253,keggCompound:C14643,keggDrug:D02289,ndc:11980-074-05,pubChemCompound:247839,pubChemSubstance:46506584,pubChemSubstance:7849348,url:http://en.wikipedia.org/wiki/Medrysone',''),('PA450347','mefenamic acid','Acide Mefenamique,Mefanamic Acid,Mefenacid,Mefenaminsaeure,Mephenamic Acid,Mephenaminic Acid,Methenamic Acid','Bafameritin-M,Bafhameritin-M,Bonabol,Coslan,HL 1,I','Drug/Small Molecule','DailyMed:62bd8d9d-0806-4e8d-a6e1-e7dddc2b5404,TTD:DAP000779,bindingDb:50134036,chemSpider:3904,dpd:2237826,drugBank:DB00784,iupharLigand:2593,keggCompound:C02168,keggDrug:D00151,ndc:0677-1934-01,pubChemCompound:4044,pubChemSubstance:148984,pubChemSubstance:46505405,url:http://en.wikipedia.org/wiki/Mefenamic_acid','Cc1cccc(c1C)Nc2ccccc2C(=O)O'),('PA450348','mefloquine','Mefloquine HCL,Mefloquine aziridine,Mefloquinone','Lariam','Drug/Small Molecule','DailyMed:1c47fd79-c0ca-42d6-9910-774272b25bc1,TTD:DAP001310,bindingDb:50022889,chemSpider:3906,dpd:2244366,drugBank:DB00358,keggCompound:C07633,keggDrug:D04895,ndc:54868-5434-0,pubChemCompound:4046,pubChemSubstance:46505610,pubChemSubstance:9835,url:http://en.wikipedia.org/wiki/Mefloquine','c1cc2c(cc(nc2c(c1)C(F)(F)F)C(F)(F)F)C(C3CCCCN3)O'),('PA450351','megestrol','MGA,Megestrol Acetate,Megestrolo [DCIT],Megestrolum [INN-Latin],Megestryl acetate','Magestin,Maygace,Megace,Megeron,Megestat,Megestil,','Drug/Small Molecule','DailyMed:2bd8c04f-491c-4269-9281-642efa05a7c8,TTD:DAP000861,chebi:6722,dpd:2223112,drugBank:DB00351,keggCompound:C07120,ndc:0054-3542-58,pubChemCompound:19090,pubChemSubstance:9331,url:http://en.wikipedia.org/wiki/Megestrol',''),('PA450353','meloxicam','Meloxicamum [latin]','Apo-meloxicam,Co Meloxicam,Dom-meloxicam,Gen-melox','Drug/Small Molecule','DailyMed:cf741f27-d8d0-4c47-a583-f7ed2e90c3de,TTD:DAP000971,bindingDb:50056998,chemSpider:4444553,dpd:2248031,drugBank:DB00814,keggCompound:C08169,keggDrug:D00969,ndc:0378-1066-01,pubChemCompound:5281106,pubChemSubstance:10369,pubChemSubstance:46506624,url:http://en.wikipedia.org/wiki/Meloxicam','Cc1cnc(s1)NC(=O)C2=C(c3ccccc3S(=O)(=O)N2C)O'),('PA450354','melphalan','','Alkeran,L-PAM,L-Phenylalanine mustard,L-Sarcolysin','Drug/Small Molecule','TTD:DAP000791,bindingDb:50038356,chebi:28876,dpd:4715,drugBank:DB01042,keggDrug:D00369,ndc:0173-0045-35,pubChemCompound:4053,pubChemSubstance:7847435,url:http://en.wikipedia.org/wiki/Melphalan','c1cc(ccc1C[C@@H](C(=O)O)N)N(CCCl)CCCl'),('PA450358','menadione','2-Methyl-1,4-Naphthalenedione,2-Methyl-1,4-naphthoquinone,Kayquinone,Menaphthone,Thyloquinone,Vitamin K 3,Vitamin K3','Kappaxin,Kayklot,Klottone,Kolklot,Panosine,Synkavi','Drug/Small Molecule','HET:VK3,TTD:DNC001501,bindingDb:24778,chebi:28869,chemSpider:3915,drugBank:DB00170,keggCompound:C05377,keggDrug:D02335,pdb:VK3,pubChemCompound:4055,pubChemSubstance:46505447,pubChemSubstance:7751,url:http://en.wikipedia.org/wiki/Menadione','CC1=CC(=O)c2ccccc2C1=O'),('PA450369','meperidine','','Centralgin,Demarol,Demerol,Dispadol,Dolantin,Dolco','Drug/Small Molecule','DailyMed:15bc51a8-1e24-4d33-9a2f-05a41c29acf0,DailyMed:9c4f12e5-5e69-44d4-81a5-bd72c375eef5,TTD:DAP000230,bindingDb:50026752,chemSpider:3918,dpd:640409,drugBank:DB00454,keggCompound:C07128,ndc:0054-8595-11,pubChemCompound:4058,pubChemSubstance:148822,pubChemSubstance:46506899,url:http://en.wikipedia.org/wiki/Meperidine',''),('PA450373','mephenytoin','Mephentoin,Methyl Hydantoin,Methylphenetoin','Epiazin,Gerot-Epilan,Insulton,Mesdontoin,Mesontoin','Drug/Small Molecule','DailyMed:9370d8e6-7db4-452d-9792-9093e7b4f4bd,TTD:DAP000508,chemSpider:3920,drugBank:DB00532,keggDrug:D00375,ndc:0078-0052-05,pubChemCompound:4060,pubChemSubstance:148526,pubChemSubstance:46508677,url:http://en.wikipedia.org/wiki/Mephenytoin','CCC1(C(=O)N(C(=O)N1)C)c2ccccc2'),('PA450374','methylphenobarbital','Mephobarbital,Mephobarbitone,Methyl Phenobarbitone,Methylphenobarbitalum [INN-Latin],Methylphenobarbitonum,Methylphenolbarbital,Methylphenylbarbituric','Enfenemal,Enphenemal,Enphenemalum,Isonal,Mebaral,M','Drug/Small Molecule','TTD:DAP000680,chebi:6758,chemSpider:7972,drugBank:DB00849,keggCompound:C07829,keggDrug:D00700,pubChemCompound:8271,pubChemSubstance:46505197,pubChemSubstance:7847765,url:http://en.wikipedia.org/wiki/Mephobarbital',''),('PA450377','meprobamate','DEA No. 2820,Meprobamat [German],Meprobamato [INN-Spanish],Meprobamato [Italian],Meprobamatum [INN-Latin],Meprobamic acid,Procarbamide','3P bamate,Amepromat,Amosene,Anastress,Anathylmon,A','','',''),('PA450379','mercaptopurine','6 MP,6-Mercaptopurine,MP,Mercaptopurine Monohydrate,Mercapurin','Ismipur,Leukerin,Leupurin,Mercaleukim,Mercaleukin,','Drug/Small Molecule','DailyMed:15904472-4c32-4224-95d3-eb131a7ff9c8,TTD:DAP000147,bindingDb:50200098,chebi:2208,chemSpider:580869,dpd:4723,drugBank:DB01033,keggCompound:C02380,keggDrug:D04931,ndc:0378-3547-52,pubChemCompound:667490,pubChemSubstance:46506988,pubChemSubstance:5422,url:http://en.wikipedia.org/wiki/Mercaptopurine','S=C1N=CNC2=C1NC=N2'),('PA450384','mesalazine','5-ASA,5-aminosalicylate,5-aminosalicylic acid,Mesalamine','Asacol,Asacolitin,Canasa,Claversal,Fisalamine,Lixa','Drug/Small Molecule','DailyMed:83864c82-9114-4523-bab8-2b47beb88d4e,TTD:DAP000729,chebi:6775,chemSpider:3933,drugBank:DB00244,keggDrug:D00377,ndc:53808-0205-1,pubChemCompound:4075,pubChemSubstance:46509142,pubChemSubstance:7847443,url:http://en.wikipedia.org/wiki/Mesalazine',''),('PA450385','mesna','','','Drug/Small Molecule','',''),('PA450386','mesoridazine','TPS-23,TPS23,Thioridazien Thiomethyl Sulfoxide,Thioridazine Monosulfoxide Analog,Thioridazine Thiomethyl Sulfoxide','Calodal,Lidanar,Lidanil,Serentil,Serentil Concentr','Drug/Small Molecule','DailyMed:d8667bac-e664-4599-9156-0a9dada85700,TTD:DAP000252,bindingDb:50131440,chebi:6780,chemSpider:3936,dpd:27464,drugBank:DB00933,keggCompound:C07143,keggDrug:D02671,ndc:0597-0020-01,pubChemCompound:4078,pubChemSubstance:46506724,pubChemSubstance:9352,url:http://en.wikipedia.org/wiki/Mesoridazine','CN1CCCCC1CCN2c3ccccc3Sc4c2cc(cc4)S(=O)C'),('PA450388','mestranol','','','Drug/Small Molecule','TTD:DAP001014,chebi:6784,chemSpider:6054,drugBank:DB01357,keggCompound:C07618,keggDrug:D00575,pubChemCompound:6291,pubChemSubstance:10321875,pubChemSubstance:46507679,url:http://en.wikipedia.org/wiki/Mestranol',''),('PA450390','orciprenaline','Metaproterenol,Metaproterenol Sulfate,Orciprenalina [INN-Spanish],Orciprenaline Sulfate,Orciprenalinum [INN-Latin]','Alotec,Alupent,Metaprel,Metaproterenol Polistirex,','Drug/Small Molecule','DailyMed:f35e3310-0246-446a-aabe-c17f9000ce26,TTD:DNC000927,chemSpider:3944,drugBank:DB00816,keggCompound:C07144,keggDrug:D00685,ndc:0597-0070-08,pubChemCompound:4086,pubChemSubstance:46504464,pubChemSubstance:9353,url:http://en.wikipedia.org/wiki/Orciprenaline',''),('PA450395','metformin','Metformin HCL,metformin hydrochloride','Apo-Metformin,Fortamet,Gen-Metformin,Glucophage,Gl','Drug/Small Molecule','DailyMed:e455ec79-08cd-4d75-9cb2-625d3912ee88,TTD:DAP000205,chebi:6801,chemSpider:3949,dpd:2265583,drugBank:DB00331,keggCompound:C07151,keggDrug:D04966,ndc:0781-5050-61,pubChemCompound:4091,pubChemSubstance:46507752,pubChemSubstance:9360,url:http://en.wikipedia.org/wiki/Metformin','CC(=N)NC(=N)N(C)C'),('PA450398','methacholine chloride','','Provocholine','Drug/Small Molecule','',''),('PA450401','methadone','(+/-)-Methadone,(+/-)-Methadone hydrochloride,DL-Methadone hydrochloride,Methadon,Methadone HCL,Methadone hydrochloride,Phenadone hydrochloride,dl-Met','Adanon,Adanon hydrochloride,Adolan,Algidon,Algolys','','',''),('PA450403','methamphetamine','(+ )-methylamphetamine,(+)-(s)-deoxyephedrine,(+)-(s)-n-alpha-dimethylphenethylamine,(+)-2-(N-Methylamino)-1-phenylpropane,(+)-methamphetamine,(+)-met','Desoxyn,Desyphed,Desyphed hydrochloride,Metamfetam','Drug/Small Molecule','DailyMed:15e150c7-1347-40fb-9f58-c390521bc6f9,TTD:DAP001496,chebi:6809,chemSpider:10379,drugBank:DB01577,keggCompound:C07164,ndc:0378-8115-01,pubChemCompound:10836,pubChemSubstance:10318874,pubChemSubstance:46508541,url:http://en.wikipedia.org/wiki/Methamphetamine','C[C@@H](Cc1ccccc1)NC'),('PA450413','methazolamide','','MZM,Methenamide,Naptazane,Neptazane,Neptazaneat','Drug/Small Molecule','DailyMed:4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6,TTD:DAP000599,bindingDb:10881,chemSpider:3958,dpd:2245882,drugBank:DB00703,keggCompound:C07764,keggDrug:D00655,ndc:0781-1072-01,pubChemCompound:4100,pubChemSubstance:46506393,pubChemSubstance:9966,url:http://en.wikipedia.org/wiki/Methazolamide',''),('PA450422','methimazole','Mercaptazole,Mercasolyl,Mercazole,Mercazolyl,Merkazolil,Metazolo,Methamazole,Methiamazole,Methimazol,Metothyrin,Metothyrine,Thiamazol,Thiamazole,Thima','Basolan,Danantizol,Favistan,Frentirox,Merkastan,Me','Drug/Small Molecule','DailyMed:dc92f45f-8d27-4dcb-b72d-6b8b04c6f0ce,HET:MMZ,TTD:DNC001429,chebi:50673,chemSpider:1131173,dpd:2258935,drugBank:DB00763,keggDrug:D00401,ndc:0677-1945-01,pdb:MMZ,pubChemCompound:1349907,pubChemSubstance:46506536,pubChemSubstance:7847467,url:http://en.wikipedia.org/wiki/Methimazole','Cn1ccnc1S'),('PA450423','l-methionine','(S)-2-Amino-4-(methylthio)butanoic acid,(s)-2-amino-4-(methylthio)butyric acid,(s)-methionine,2-Amino-4-(methylthio)butyric acid,L-(-)-Methionine,L-a-','Acimethin,Cymethion','Drug/Small Molecule','HET:MET,chebi:16643,chebi:16811,chemSpider:5907,drugBank:DB00134,keggCompound:C01733,keggDrug:D04983,pdb:MET,pubChemCompound:6137,pubChemSubstance:46505750,pubChemSubstance:8144963',''),('PA450428','methotrexate','Amethopterin,Amethopterine,HDMTX,L-Amethopterin,MTX,Methopterin,Methotextrate,Methotrexat,Methotrexate Sodium,Methylaminopterin,Methylaminopterinum,N-','Abitrexate,Antifolan,Arbitrexate,Emtexate,Folex,Le','Drug/Small Molecule','DailyMed:9c4a4784-b063-4c8f-b915-aeb18cb149be,HET:MTX,TTD:DNC000933,bindingDb:18050,chebi:6837,chemSpider:112728,dpd:2244798,drugBank:DB00563,keggCompound:C01937,keggDrug:D00142,ndc:67253-320-10,pdb:MTX,pubChemCompound:126941,pubChemSubstance:46507678,pubChemSubstance:7847210,url:http://en.wikipedia.org/wiki/Methotrexate','CN(Cc1cnc2c(n1)c(nc(n2)N)N)c3ccc(cc3)C(=O)NC(CCC(=O)O)C(=O)O'),('PA450431','methoxamine','','Methoxamedrine,Methoxamin,Methoxaminum [INN-Latin]','Drug/Small Molecule','TTD:DAP000796,bindingDb:50026777,chemSpider:5857,dpd:4480,drugBank:DB00723,iupharLigand:483,keggCompound:C07513,pubChemCompound:6082,pubChemSubstance:46506264,pubChemSubstance:9716,url:http://en.wikipedia.org/wiki/Methoxamine',''),('PA450433','methoxsalen','','Ammodin,Ammoidin,Meladinin,Meladinine,Meladoxen,Me','Drug/Small Molecule','DailyMed:a4c61db9-b72d-4b67-b69b-a97257b614ad,HET:8MO,TTD:DAP000996,chebi:18358,chemSpider:3971,dpd:698059,drugBank:DB00553,keggCompound:C01864,keggDrug:D00139,ndc:0187-0651-42,pdb:8MO,pubChemCompound:4114,pubChemSubstance:152480,pubChemSubstance:46506275,url:http://en.wikipedia.org/wiki/Methoxsalen',''),('PA450434','methoxyflurane','MOF,Methoflurane,Methoxiflurane,Methoxifluranum,Methoxyfluoran,Methoxyfluorane,Methoxyfluran,Methoxyfluranum [INN-Latin],Metossiflurano [Dcit],Metoxfl','Analgizer,Anecotan,Ingalan,Inhalan,Methofane,Metho','Drug/Small Molecule','TTD:DAP000682,chemSpider:3973,dpd:2019027,drugBank:DB01028,keggCompound:C07517,keggDrug:D00544,pubChemCompound:4116,pubChemSubstance:149389,pubChemSubstance:46508879,url:http://en.wikipedia.org/wiki/Methoxyflurane','COC(C(Cl)Cl)(F)F'),('PA450453','l-methyldopa','AMD,Alpha medopa,Alphamethyldopa,L-Methyl Dopa,Methyldopa anhydrous,Methyldopate,Methyldopate HCL,Mk. b51','Aldoclor-150,Aldoclor-250,Aldomet,Aldometil,Aldomi','','',''),('PA450457','methylene blue','aniline violet,methylthionine chloride,tetrametylthionine chloride','Urolene Blue','Drug/Small Molecule','',''),('PA450461','methylergonovine','Methylergobasin,Methylergobasine,Methylergobrevin,Methylergometrin,Methylergometrine,Methylergonovin,methylergonovine maleate','Basofortina,Metenarin,Methergen,Methergin,Methergi','Drug/Small Molecule','DailyMed:b91d1729-2e8e-4398-9a0d-02763bcfe284,TTD:DAP000978,chemSpider:7933,drugBank:DB00353,iupharLigand:150,keggDrug:D00680,ndc:12634-179-96,pubChemCompound:8226,pubChemSubstance:151359,pubChemSubstance:46507746,url:http://en.wikipedia.org/wiki/Methylergonovine',''),('PA450464','methylphenidate','Methyl phenidyl acetate,Methylphenidate HCl,Methylphenidate hydrochloride,Methylphenidatum [INN-Latin],Methylphenidylacetate hydrochloride,Metilfenida','4311/B Ciba,Calocain,Centedein,Centedrin,Centedrin','Drug/Small Molecule','DailyMed:12a36e92-cb00-48d5-8981-89d8cce8c4c6,TTD:DAP000024,chebi:6887,chemSpider:4015,dpd:2249332,drugBank:DB00422,keggCompound:C07196,keggDrug:D04999,ndc:54092-552-30,pubChemCompound:4158,pubChemSubstance:46505929,url:http://en.wikipedia.org/wiki/Methylphenidate','COC(=O)C(c1ccccc1)C2CCCCN2'),('PA450466','methylprednisolone','6alpha-Methylprednisolone,Methyleneprednisolone,Methylprednisolon,Methylprednisolonum [INN-Latin],Metilprednisolona [INN-Spanish],Metilprednisolone [D','Artisone-Wyeth,Besonia,Dopomedrol,Esametone,Firmac','','',''),('PA450475','metoclopramide','Metaclopramide,Metaclopromide,Methochlopramide,Methoclopramide,Metochlopramide,Metoclopramida [INN-Spanish],Metoclopramide Hcl,Metoclopramide Hydrochl','Apo-Metoclop,Cerucal,Clopra,Clopra-Yellow,Cloproma','Drug/Small Molecule','DailyMed:10a7bd47-d6fe-4e10-8d2a-30c81cee4c2d,TTD:DAP000530,bindingDb:50000491,chebi:107736,chemSpider:4024,dpd:2243563,drugBank:DB01233,iupharLigand:241,keggCompound:C07868,keggDrug:D00726,ndc:0591-2228-05,pubChemCompound:4168,pubChemSubstance:152911,pubChemSubstance:46505631,url:http://en.wikipedia.org/wiki/Metoclopramide','CCN(CC)CCNC(=O)c1cc(c(cc1CO)N)Cl'),('PA450480','metoprolol','Metoprolol Tartrate,Metoprolol succinate','Beloc,Betaloc,Lopresor,Lopresoretic,Lopressor,Lopr','Drug/Small Molecule','DailyMed:a8374722-d2b5-4eb3-bbcd-6ddc52e763ba,TTD:DAP000481,bindingDb:25756,chebi:6904,chemSpider:4027,dpd:2253518,drugBank:DB00264,iupharLigand:553,keggCompound:C07202,keggDrug:D02358,ndc:58177-293-04,pubChemCompound:4171,pubChemSubstance:205122,pubChemSubstance:46506211,url:http://en.wikipedia.org/wiki/Metoprolol','CC(C)NCC(COc1ccc(cc1)CCOC)O'),('PA450484','metronidazole','Methronidazole,Metronidazol,Metronidazole Benzoate,Metronidazole Hcl,Metronidazole in Plastic Container,Metronidazolo','Acromona,Anagiardil,Apo-Metronidazole,Arilin,Atriv','','',''),('PA450486','metyrapone','Mepyrapone,Methapyrapone,Methbipyranone,Methopirapone,Methopyrapone,Methopyrinine,Methopyrone,Metroprione,Metyrapon','Metapirone,Metapyron,Metapyrone,Metopiron,Metopiro','Drug/Small Molecule','DailyMed:d6d1afeb-55d6-494c-9226-e6ad4232a7cf,HET:MYT,TTD:DAP000424,chebi:6911,chemSpider:4030,drugBank:DB01011,keggCompound:C07205,keggDrug:D00410,ndc:0078-0455-17,pdb:MYT,pubChemCompound:4174,pubChemSubstance:46504862,pubChemSubstance:9414,url:http://en.wikipedia.org/wiki/Metyrapone','CC(C)(c1cccnc1)C(=O)c2cccnc2'),('PA450487','metyrosine','Methyltyrosine,Metirosine','Demser','Drug/Small Molecule','DailyMed:6118e185-5226-4676-1dbc-42554fd53d50,TTD:DAP000471,chemSpider:390103,drugBank:DB00765,keggCompound:C07921,keggDrug:D00762,ndc:0006-0690-68,pubChemCompound:441350,pubChemSubstance:10123,pubChemSubstance:46506079',''),('PA450488','mexiletine','Mexiletina [INN-Spanish],Mexiletine HCL,Mexiletinum [INN-Latin],Mexilitine','Mexitil','Drug/Small Molecule','DailyMed:e35aa027-aef2-485d-927c-ab350f51f977,TTD:DAP000505,bindingDb:50117271,chebi:6916,chemSpider:4034,dpd:2230359,drugBank:DB00379,iupharLigand:2629,keggCompound:C07220,ndc:0597-0068-01,pubChemCompound:4178,pubChemSubstance:46505491,pubChemSubstance:9429,url:http://en.wikipedia.org/wiki/Mexiletine','Cc1cccc(c1OCC(C)N)C'),('PA450492','mibefradil','','Posicor','Drug/Small Molecule','bindingDb:50117922,chemSpider:54673,drugBank:DB01388,iupharLigand:2522,keggCompound:C07222,pubChemCompound:60663,pubChemSubstance:46504498,pubChemSubstance:9431,url:http://en.wikipedia.org/wiki/Mibefradil','CC(C)[C@H]1c2ccc(cc2CC[C@@]1(CCN(C)CCCc3[nH]c4ccccc4n3)OC(=O)COC)F'),('PA450494','miconazole','MCZ,miconazole','Daktarin,Femizol-M,M-zole 3 Combination Pack,M-zol','Drug/Small Molecule','DailyMed:a1cd682a-fa73-491d-b276-8c96d801b083,TTD:DAP000154,bindingDb:31772,chebi:6923,chemSpider:4044,dpd:2245546,drugBank:DB01110,iupharLigand:2449,keggCompound:C08070,keggDrug:D00882,ndc:0062-5437-01,pubChemCompound:4189,pubChemSubstance:46506017,pubChemSubstance:602748,url:http://en.wikipedia.org/wiki/Miconazole','c1cc(c(cc1Cl)Cl)COC(Cn2ccnc2)c3ccc(cc3Cl)Cl'),('PA450496','midazolam','Dea No. 2884,Midazolam Base,Midazolam Hcl,Midazolamum [INN-Latin]','Dormicum,Versed','Drug/Small Molecule','DailyMed:0be63f63-6a93-4782-8f9c-d13ca5ae44bd,TTD:DAP000241,bindingDb:21363,chemSpider:4047,dpd:2240286,drugBank:DB00683,keggCompound:C07524,keggDrug:D00550,ndc:0574-0150-04,pubChemCompound:4192,pubChemSubstance:183492,pubChemSubstance:46507611,url:http://en.wikipedia.org/wiki/Midazolam','Cc1ncc2n1-c3ccc(cc3C(=NC2)c4ccccc4F)Cl'),('PA450500','mifepristone','Mifepriston,Mifepristona [Spanish],Mifepristonum [Latin],RU486,mifepristone','Corlux,Korlym,Mifegyne,Mifeprex','Drug/Small Molecule','HET:486,TTD:DAP000090,bindingDb:18627,chebi:50692,chemSpider:49889,drugBank:DB00834,keggCompound:C07652,keggDrug:D00585,pdb:486,pubChemCompound:55245,pubChemSubstance:46505795,pubChemSubstance:7847651,url:http://en.wikipedia.org/wiki/Mifepristone',''),('PA450519','minocycline','minocycline','Alti-Minocycline,Apo-Minocycline,Arestin,Dynacin,G','Drug/Small Molecule','DailyMed:072017ee-a92c-4bdf-b1be-76f1d1262fcb,TTD:DAP000405,bindingDb:50046515,chebi:50694,dpd:2242080,drugBank:DB01017,keggCompound:C07225,keggDrug:D05045,ndc:0781-5385-31,pubChemCompound:5281021,pubChemSubstance:167749,url:http://en.wikipedia.org/wiki/Minocycline','CN(C)c1ccc(c2c1C[C@H]3C[C@H]4[C@@H](C(=C(C(=O)[C@]4(C(=C3C2=O)O)O)C(=O)N)O)N(C)C)O'),('PA450521','minoxidil','Minossidile [Italian],Minoxidilum [INN-Latin]','Alopexil,Alostil,Apo-Gain,Gen-Minoxidil,Loniten,Lo','Drug/Small Molecule','DailyMed:0354a7f5-5917-44dc-9963-411104008cb5,HET:MXD,TTD:DAP000143,chebi:6942,dpd:2065800,drugBank:DB00350,keggDrug:D00418,ndc:53489-386-01,pdb:MXD,pubChemCompound:4201,pubChemSubstance:46508344,pubChemSubstance:7847484,url:http://en.wikipedia.org/wiki/Minoxidil',''),('PA450522','mirtazapine','Mepirzepine,Mirtazapina [INN-Spanish],Mirtazapine [Usan:Ban:Inn],Mirtazapinum [INN-Latin],Mirtazepine,mirtazapine','Avanza,Axit,Mirtabene,Mirtaz,Mirtazon,Norset,Promy','Drug/Small Molecule','DailyMed:b8df747e-dfce-4411-b892-086532ffabfb,TTD:DAP000010,chebi:6950,chemSpider:4060,dpd:2256126,drugBank:DB00370,keggCompound:C07570,keggDrug:D00563,ndc:0185-0020-30,pubChemCompound:4205,pubChemSubstance:183976,pubChemSubstance:46506965,url:http://en.wikipedia.org/wiki/Mirtazapine','CN1CCN2c3c(cccn3)Cc4ccccc4C2C1'),('PA450523','misoprostol','Misoprostolum [INN-Latin]','Arthrotec,Cytotec','Drug/Small Molecule','DailyMed:150b4d91-7a2a-4c01-877d-bbafd3a7a74e,TTD:DAP000358,chemSpider:4445541,dpd:2248846,drugBank:DB00929,iupharLigand:1936,keggDrug:D00419,ndc:0172-4430-49,pubChemCompound:5282381,pubChemSubstance:183429,pubChemSubstance:46505041,url:http://en.wikipedia.org/wiki/Misoprostol',''),('PA450524','mitomycin','7-Amino-9&alpha;-methoxymitosane,MMC,Mitamycin','Ametycin,Ametycine,Mit-C,Mito-C,Mitocin-C,Mitomyci','Drug/Small Molecule','DailyMed:729a1d0a-4a03-41c7-abdd-62062a63643b,TTD:DAP001402,chebi:27504,chemSpider:5544,dpd:2230729,drugBank:DB00305,keggCompound:C06681,keggDrug:D00208,ndc:55390-451-01,pubChemCompound:5746,pubChemSubstance:148522,pubChemSubstance:46508353,url:http://en.wikipedia.org/wiki/Mitomycin',''),('PA450526','mitoxantrone','DHAD,DHAQ,DHAQ HCl,Dihydroxyanthraquinone,Mitoxanthrone,Mitoxantron,Mitoxantrona [INN-Spanish],Mitoxantrone 2HCl,Mitoxantrone HCl,Mitoxantrone dihydro','Mitox,Novantron,Novantrone','Drug/Small Molecule','DailyMed:4d0f0f1a-31af-40fa-9c64-e90891fa6ce4,TTD:DAP000057,chebi:50729,chemSpider:4067,dpd:2244614,drugBank:DB01204,keggCompound:C11195,ndc:0703-4685-01,pubChemCompound:4212,pubChemSubstance:13376,pubChemSubstance:46504608,url:http://en.wikipedia.org/wiki/Mitoxantrone',''),('PA450528','mivacurium','','Mivacron','Drug/Small Molecule','TTD:DAP000716,chemSpider:4444509,dpd:2087308,drugBank:DB01226,keggCompound:C07550,ndc:0409-4375-20,pubChemCompound:5281042,pubChemSubstance:46505071,pubChemSubstance:9753,url:http://en.wikipedia.org/wiki/Mivacurium',''),('PA450529','mivacurium chloride','','','Drug/Small Molecule','',''),('PA450530','modafinil','modafinil','Dea No. 1680,Modafinil [Usan:Inn],Modafinilo [Span','Drug/Small Molecule','DailyMed:def2a743-ec37-452e-8e6b-b15f72ad2215,bindingDb:50156055,chemSpider:4088,dpd:2239665,drugBank:DB00745,keggDrug:D01832,ndc:0339-4168-11,pubChemCompound:4236,pubChemSubstance:188735,pubChemSubstance:46504648,url:http://en.wikipedia.org/wiki/Modafinil',''),('PA450536','molybdenum','','','Drug/Small Molecule','','[Mo]'),('PA450541','mometasone','','Asmanex,Asmanex Twisthaler,Elocom,Elocon,Mometason','','',''),('PA450546','montelukast','','Montair,Singulair,Singular','Drug/Small Molecule','DailyMed:8c166755-7711-4df9-d689-8836a1a70885,TTD:DAP000309,chebi:6992,chemSpider:4444507,dpd:2243602,drugBank:DB00471,keggCompound:C07482,ndc:0006-0275-82,pubChemCompound:5281040,pubChemSubstance:46505585,pubChemSubstance:9685,url:http://en.wikipedia.org/wiki/Montelukast','CC(C)(c1ccccc1CC[C@H](c2cccc(c2)/C=C/c3ccc4ccc(cc4n3)Cl)SCC5(CC5)CC(=O)O)O'),('PA450550','morphine','(-)-Heroin hydrochloride,(-)-Morphine,D-(-)-Morphine,Diacetylmorphine hydrochloride,Diamorphine hydrochloride,Heroin hydrochloride,Heroine hydrochlori','Apokyn,Astramorph PF,Avinza,Depodur,Dulcontin,Dura','','',''),('PA450555','moxifloxacin','BAY 12-8039,Moxifloxacin HCl,Moxifloxacin hydrochloride,moxifloxacin','Avelox,Avelox I.V.,Vigamox','Drug/Small Molecule','DailyMed:56b4f979-bf20-4908-9d7c-5536221d77f8,TTD:DAP000158,bindingDb:50146367,chemSpider:134802,dpd:2246414,drugBank:DB00218,keggCompound:C07663,ndc:0085-1733-01,pubChemCompound:152946,pubChemSubstance:46508509,pubChemSubstance:730447,url:http://en.wikipedia.org/wiki/Moxifloxacin',''),('PA450566','mycophenolate mofetil','Mycophenylate mofetil','CellCept,Munoloc','Drug/Small Molecule','DailyMed:99b2eb58-8d14-48fc-bbe1-aacb711a783e,TTD:DNC000397,chemSpider:4444535,dpd:2240347,drugBank:DB00688,keggCompound:C07908,keggDrug:D00752,ndc:0781-2067-01,pubChemCompound:5281078,pubChemSubstance:46505626,pubChemSubstance:7847817,url:http://en.wikipedia.org/wiki/Mycophenolate_mofetil',''),('PA450570','n,n-dimethylacetamide','','','Drug/Small Molecule','','CC(=O)N(C)C'),('PA450572','nabumetone','Nabumetona,Nabumetonum [INN-Latin]','Arthaxan,Balmox,Consolan,Dolsinal,Flambate,Listran','Drug/Small Molecule','DailyMed:fcbc1d42-a883-435a-a8a8-e12c308a87d8,TTD:DAP000735,bindingDb:50240662,chemSpider:4256,dpd:2238639,drugBank:DB00461,keggDrug:D00425,ndc:49884-649-01,pubChemCompound:4409,pubChemSubstance:46507729,pubChemSubstance:7847491,url:http://en.wikipedia.org/wiki/Nabumetone','CC(=O)CCc1ccc2cc(ccc2c1)OC'),('PA450573','nadolol','','Anabet,Corgard,Solgol','','',''),('PA450576','nafcillin','Nafcilina [INN-Spanish],Nafcillin Sodium,Nafcillin sodium salt,Nafcilline [INN-French],Nafcillinum [INN-Latin]','Nafcilin-1,Nafcillin sodium for injection,Nallpen,','Drug/Small Molecule','DailyMed:5df2c199-76f1-4a4d-b7a8-95d09b59e391,HET:NFN,TTD:DAP001166,chebi:7447,chemSpider:8634,dpd:2043785,drugBank:DB00607,keggCompound:C07250,ndc:0781-3128-92,pdb:NFN,pubChemCompound:8982,pubChemSubstance:46508100,pubChemSubstance:9459,url:http://en.wikipedia.org/wiki/Nafcillin',''),('PA450586','naloxone','EN 1530 Base,L-Naloxone,N-Allylnoroxymorphone,Nalossone [Dcit],Naloxona [INN-Spanish],Naloxone HCl,Naloxonum [INN-Latin]','Nalone,Narcan,Narcanti,Narcon','Drug/Small Molecule','DailyMed:8535cc84-ad4a-4d67-8480-fb5a2e3406f8,TTD:DAP000097,chebi:7459,chemSpider:4447644,dpd:2148706,drugBank:DB01183,iupharLigand:1638,iupharLigand:1676,keggCompound:C07252,ndc:0409-1212-01,pubChemCompound:5284596,pubChemSubstance:46508816,pubChemSubstance:9461,url:http://en.wikipedia.org/wiki/Naloxone','C=CCN1CC[C@]23c4c5ccc(c4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)O'),('PA450588','naltrexone','PTI-555,naltrexone','Celupan,MorViva,N-Cyclopropylmethylnoroxymorphone,','Drug/Small Molecule','DailyMed:4a63f1e0-b2a3-4355-af61-852ea3521707,TTD:DAP000379,chebi:7465,chemSpider:4514524,dpd:2213826,drugBank:DB00704,iupharLigand:1639,keggCompound:C07253,keggDrug:D05113,ndc:0555-0902-01,pubChemCompound:5360515,pubChemSubstance:46505333,pubChemSubstance:9462,url:http://en.wikipedia.org/wiki/Naltrexone','c1cc(c2c3c1C[C@@H]4[C@]5([C@]3(CCN4CC6CC6)[C@@H](O2)C(=O)CC5)O)O'),('PA450595','naproxen','','Aleve,Anaprox,Bonyl,DL Naproxen,DL-Naproxen,Diocod','Drug/Small Molecule','DailyMed:68848217-03c9-4377-9be6-6f567e629129,TTD:DAP000968,bindingDb:50009860,chebi:7476,dpd:618721,drugBank:DB00788,keggCompound:C01517,keggDrug:D00118,ndc:0004-6313-01,pubChemCompound:1302,pubChemSubstance:4682,url:http://en.wikipedia.org/wiki/Naproxen','C[C@@H](c1ccc2cc(ccc2c1)OC)C(=O)O'),('PA450597','naratriptan','naratriptan','Amerge,Naramig','Drug/Small Molecule','DailyMed:13f4a8ec-75a3-4c51-b3bc-6244f3c79e95,TTD:DAP000890,chebi:7478,chemSpider:4287,dpd:2237821,drugBank:DB00952,iupharLigand:45,keggCompound:C07792,ndc:0173-0561-00,pubChemCompound:4440,pubChemSubstance:46507243,pubChemSubstance:9994,url:http://en.wikipedia.org/wiki/Naratriptan','CNS(=O)(=O)CCc1ccc2c(c1)c(c[nH]2)C3CCN(CC3)C'),('PA450600','nateglinide','Nateglinide [INN],SDZ-DJN 608,nateglinide','Fastic,Starlix,Starsis','Drug/Small Molecule','DailyMed:5cbda9bc-3c0d-4d75-a37a-994844680c8c,TTD:DAP000918,chebi:146727,dpd:2245439,drugBank:DB00731,keggCompound:C12508,keggDrug:D01111,ndc:0078-0351-05,pubChemCompound:60026,pubChemSubstance:196417,url:http://en.wikipedia.org/wiki/Nateglinide',''),('PA450601','nedocromil','','Alocril,Nedocromil [USAN:BAN:INN],Nedocromilo [Spa','Drug/Small Molecule','DailyMed:2fe8d7ad-2158-4169-94b0-719ad20242b7,chebi:7492,chemSpider:45608,dpd:2241407,drugBank:DB00716,keggCompound:C07255,keggDrug:D05129,ndc:0023-8842-05,pubChemCompound:50294,pubChemSubstance:46507587,pubChemSubstance:9464,url:http://en.wikipedia.org/wiki/Nedocromil','CCCc1c2c(cc3c1oc(cc3=O)C(=O)O)c(=O)cc(n2CC)C(=O)O'),('PA450603','nefazodone','Nefazodona [Spanish],Nefazodone Hcl,Nefazodone Hydrochloride,Nefazodonum [Latin]','Dutonin,Serzone','Drug/Small Molecule','TTD:DAP000042,chebi:7494,chemSpider:4294,dpd:2242822,drugBank:DB01149,keggCompound:C07256,ndc:0087-0031-47,pubChemCompound:4449,pubChemSubstance:205126,pubChemSubstance:46508323,url:http://en.wikipedia.org/wiki/Nefazodone','CCc1nn(c(=O)n1CCOc2ccccc2)CCCN3CCN(CC3)c4cccc(c4)Cl'),('PA450606','nelfinavir','1UN,NFV,NLF,Nelfinavir mesylate,ag1343','Viracept','Drug/Small Molecule','DailyMed:e72c2bc6-9462-4a2e-8e1d-b97592376cbd,TTD:DAP000705,bindingDb:518,chemSpider:57718,dpd:2248761,drugBank:DB00220,keggCompound:C07257,ndc:63010-010-30,pubChemCompound:64143,pubChemSubstance:206971,pubChemSubstance:46507719,url:http://en.wikipedia.org/wiki/Nelfinavir','Cc1c(cccc1O)C(=O)N[C@@H](CSc2ccccc2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O'),('PA450608','neomycin','Caswell No. 595,Neomycin B Sulfate,Neomycin Sulfate,Neomycin Sulphate,Neomycin trisulfate salt hydrate,USAF CB-19','Biosol,Bykomycin,Endomixin,Fradiomycin,Fradiomycin','','',''),('PA450611','neostigmine','','Neostigmine omega,Prostigmin','Drug/Small Molecule','TTD:DAP000563,chebi:7514,chemSpider:4301,dpd:868906,drugBank:DB01400,keggCompound:C07258,pubChemCompound:4456,pubChemSubstance:46509161,pubChemSubstance:9467,url:http://en.wikipedia.org/wiki/Neostigmine','CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C'),('PA450616','nevirapine','NEV,NVP','Viramune','Drug/Small Molecule','DailyMed:5ec05500-6333-4bd0-ac83-464fad0d5162,HET:NVP,TTD:DAP000184,bindingDb:1434,chemSpider:4308,dpd:2238748,drugBank:DB00238,keggCompound:C07263,keggDrug:D00435,ndc:0597-0046-60,pdb:NVP,pubChemCompound:4463,pubChemSubstance:197039,pubChemSubstance:46506789,url:http://en.wikipedia.org/wiki/Nevirapine','Cc1ccnc2c1NC(=O)c3cccnc3N2C4CC4'),('PA450617','niacin','3-Pyridinecarboxylic acid,Acide Nicotinique,Acidum Nicotinicum,M-Pyridinecarboxylic Acid,NAH,Nicotine Acid,Nicotinic Acid,Pyridinecarboxylic Acid,Pyri','Akotin,Anti-Pellagra Vitamin,Apelagrin,Bionic,Dask','','',''),('PA450620','nicardipine','Nicardipine HCl,Nicardipino [INN-Spanish],Nicardipinum [INN-Latin]','Cardene,Cardene IV,Cardene SR','Drug/Small Molecule','TTD:DAP000486,bindingDb:50017085,chemSpider:4319,dpd:2162733,drugBank:DB00622,iupharLigand:2559,keggCompound:C07264,ndc:0703-8315-03,pubChemCompound:4474,pubChemSubstance:182381,pubChemSubstance:46504482,url:http://en.wikipedia.org/wiki/Nicardipine',''),('PA450626','nicotine','L-Nicotine,Nicotine Alkaloid','Black Leaf,Black Leaf 40,Campbell\'s Nico-Soap,Comm','Drug/Small Molecule','DailyMed:62245d7d-b50d-48d9-9f03-071c61620ccf,HET:NCT,TTD:DAP000175,chebi:17688,chebi:18723,chemSpider:917,dpd:2241228,drugBank:DB00184,iupharLigand:2585,keggCompound:C00745,keggDrug:D03365,ndc:0009-5400-01,pdb:NCT,pubChemCompound:942,pubChemSubstance:148704,pubChemSubstance:46506924,url:http://en.wikipedia.org/wiki/Nicotine','CN1CCC[C@H]1c2cccnc2'),('PA450631','nifedipine','','Adalat,Adalat 10,Adalat 20,Adalat 5,Adalat CC,Adal','Drug/Small Molecule','DailyMed:62069120-e894-42fd-8927-f1d74e449ca6,TTD:DAP000529,bindingDb:50000778,chebi:7565,chemSpider:4330,dpd:2235898,drugBank:DB01115,iupharLigand:2514,keggCompound:C07266,keggDrug:D00437,ndc:0378-3475-01,pubChemCompound:4485,pubChemSubstance:172894,pubChemSubstance:46505103,url:http://en.wikipedia.org/wiki/Nifedipine','CC1=C(C(C(=C(N1)C)C(=O)OC)c2ccccc2N(=O)=O)C(=O)OC'),('PA450632','nilutamide','','Anandron,Nilandron,Nilandrone,Nilutamida [Spanish]','Drug/Small Molecule','DailyMed:6d2e5c32-3221-4605-955f-37c6bb61aef7,TTD:DAP000302,chebi:7573,chemSpider:4337,dpd:2221861,drugBank:DB00665,keggCompound:C08164,keggDrug:D00965,ndc:0088-1111-14,pubChemCompound:4493,pubChemSubstance:46505381,pubChemSubstance:7848028,url:http://en.wikipedia.org/wiki/Nilutamide','CC1(C(=O)N(C(=O)N1)c2ccc(c(c2)C(F)(F)F)N(=O)=O)C'),('PA450633','nimodipine','Nimodipino [INN-Spanish],Nimodipinum [INN-Latin]','Nimotop,Periplum','Drug/Small Molecule','DailyMed:d6a161d9-7e7a-4711-ba0e-c9040c42268d,TTD:DAP000306,bindingDb:50011690,chemSpider:4341,dpd:2155923,drugBank:DB00393,iupharLigand:2523,keggCompound:C07267,keggDrug:D00438,ndc:57664-135-64,pubChemCompound:4497,pubChemSubstance:187034,pubChemSubstance:46508497,url:http://en.wikipedia.org/wiki/Nimodipine','CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)c2cccc(c2)N(=O)=O)C(=O)OCCOC'),('PA450634','nisoldipine','Nisoldipin,Nisoldipino [INN-Spanish],Nisoldipinum [INN-Latin]','Baymycard,Nisocor,Sular,Syscor,Zadipina','Drug/Small Molecule','DailyMed:2abc5435-b2ca-4e08-89bc-ab7526781819,TTD:DAP000595,bindingDb:50011689,chemSpider:4343,drugBank:DB00401,iupharLigand:2524,keggCompound:C07699,keggDrug:D00618,ndc:0677-1978-01,pubChemCompound:4499,pubChemSubstance:184770,pubChemSubstance:46504546,url:http://en.wikipedia.org/wiki/Nisoldipine','CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)c2ccccc2N(=O)=O)C(=O)OC'),('PA450635','nitric oxide','','Amidogen, oxo-,INOmax,Mononitrogen monoxide,NMO,NO','Drug/Small Molecule','DailyMed:762b51be-1893-4cd1-9511-e645fc420d3a,TTD:DAP001056,chebi:16480,chemSpider:127983,drugBank:DB00435,keggCompound:C00533,keggDrug:D00074,ndc:64693-002-01,pubChemCompound:145068,pubChemSubstance:3815,pubChemSubstance:46506897,url:http://en.wikipedia.org/wiki/Nitric_Oxide','[N]=O'),('PA450636','nitrile','','','Drug/Small Molecule','',''),('PA450640','nitrofurantoin','','Alfuran,Apo-Nitrofurantoin,Benkfuran,Berkfurin,Ced','Drug/Small Molecule','DailyMed:944c0e5f-88ff-4a46-95ef-2ea7d55063ce,TTD:DAP000998,chemSpider:4510228,dpd:319511,drugBank:DB00698,keggDrug:D00439,ndc:0378-1650-01,pubChemCompound:5353830,pubChemSubstance:149113,pubChemSubstance:46504447,url:http://en.wikipedia.org/wiki/Nitrofurantoin','c1cc(oc1C=NN2CC(=O)NC2=O)N(=O)=O'),('PA450643','nitrogen','','','Drug/Small Molecule','','[N]'),('PA450644','nitroglycerin','Glyceryl trinitrate,NG,NTG,Nitroglycerine,TNG,Trinitroglycerin,nitroglycerin ointment','Cellegesic,Minitran,Natispray,Nitro-Dur,Nitrocap,N','','',''),('PA450645','nitrous oxide','','','Drug/Small Molecule','','[N-]=[N+]=O'),('PA450648','nonoxynol-9','n-9','Advantage 24,Conceptrol,Conceptrol Contraceptive I','Drug/Small Molecule','',''),('PA450649','norepinephrine','Arterenol,L-Norepinephrine,L-noradrenaline,Noradrenaline,Norepinephrine','Levophed','Drug/Small Molecule','DailyMed:c4de72a8-2a75-4984-ce90-e4870226dc12,HET:LNR,TTD:DNC001034,chebi:18357,chemSpider:388394,drugBank:DB00368,iupharLigand:484,iupharLigand:505,keggCompound:C00547,keggDrug:D00076,ndc:0409-3375-04,pdb:LNR,pubChemCompound:439260,pubChemSubstance:10298272,pubChemSubstance:46506201,url:http://en.wikipedia.org/wiki/Norepinephrine','c1cc(c(cc1[C@H](CN)O)O)O'),('PA450651','norethindrone','','Anhydrohydroxynorprogesterone,Anovulatorio,Anovule','','',''),('PA450654','norfloxacin','','Chibroxin,Noroxin','Drug/Small Molecule','TTD:DAP000654,bindingDb:50045000,chebi:100246,chemSpider:4380,dpd:2246596,drugBank:DB01059,keggCompound:C06687,keggDrug:D00210,ndc:0006-0705-68,pubChemCompound:4539,pubChemSubstance:46508634,pubChemSubstance:8912,url:http://en.wikipedia.org/wiki/Norfloxacin','CCn1cc(c(=O)c2c1cc(c(c2)F)N3CCNCC3)C(=O)O'),('PA450656','norgestrel','','Alesse,Alpha-Norgestrel,Component of Lo/Ovral,Comp','','',''),('PA450657','nortriptyline','','AVENTYL HCL,Acetexa,Allegron,Altilev,Amitryptyline','Drug/Small Molecule','DailyMed:7b4a3438-57b4-4d88-9843-cc9da529f6f2,TTD:DAP001152,chebi:7640,chemSpider:4384,dpd:2240789,drugBank:DB00540,iupharLigand:2404,keggCompound:C07274,ndc:54868-2835-2,pubChemCompound:4543,pubChemSubstance:149239,pubChemSubstance:46507783,url:http://en.wikipedia.org/wiki/Nortriptyline','CNCCC=C1c2ccccc2CCc3c1cccc3'),('PA450666','nystatin','','Barstatin 100,Candex,Korostatin,Myco-Triacet Ii,My','','',''),('PA450678','octreotide','Octreotida [Spanish],Octreotide acetate,Octreotidum [Latin],Octrotide','Atrigel,Longastatin,Sandostatin,Sandostatin LAR','Drug/Small Molecule','DailyMed:4e2c9856-1836-49f0-9472-4dbeeb408f39,TTD:DAP000397,bindingDb:50175592,dpd:2248639,drugBank:DB00104,iupharLigand:2055,keggCompound:C07306,keggDrug:D00442,ndc:0078-0180-01,pubChemCompound:383414,pubChemSubstance:7847508,url:http://en.wikipedia.org/wiki/Octreotide','C[C@H]([C@@H]1C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=CC=C5)N)C(=O)N[C@@H](CO)[C@H](C)O)O'),('PA450684','ofloxacin','','Akilen,Baccidal,Bactocin,Danoflox,Effexin,Exocin,E','Drug/Small Molecule','HET:XED,TTD:DAP000655,chebi:7731,chemSpider:4422,dpd:2243474,drugBank:DB01165,keggCompound:C07321,keggDrug:D00453,ndc:0062-1542-01,pdb:XED,pubChemCompound:4583,pubChemSubstance:192373,pubChemSubstance:46507574,url:http://en.wikipedia.org/wiki/Ofloxacin','CC1COc2c3n1cc(c(=O)c3cc(c2N4CCN(CC4)C)F)C(=O)O'),('PA450688','olanzapine','olanzapine','Olansek,Symbyax,Zydis,Zyprexa,Zyprexa Intramuscula','Drug/Small Molecule','DailyMed:d5051fbc-846b-4946-82df-341fb1216341,TTD:DAP000022,bindingDb:35254,chebi:7735,dpd:2247099,drugBank:DB00334,iupharLigand:47,keggCompound:C07322,keggDrug:D00454,ndc:0002-4112-30,pubChemCompound:4585,pubChemSubstance:197059,url:http://en.wikipedia.org/wiki/Olanzapine','Cc1cc2c(s1)Nc3ccccc3N=C2N4CCN(CC4)C'),('PA450698','olopatadine','','Olopatadine Hydrochloride,Patanol','Drug/Small Molecule','DailyMed:eae41728-12e3-4bde-a6bb-b384a5cbae41,DailyMed:leae41728-12e3-4bde-a6bb-b384a5cbae41,TTD:DAP001062,chemSpider:4444528,dpd:2233143,drugBank:DB00768,keggCompound:C07789,ndc:0065-0271-05,pubChemCompound:5281071,pubChemSubstance:46506025,pubChemSubstance:698647,url:http://en.wikipedia.org/wiki/Olopatadine','CN(C)CC/C=C1/c2ccccc2COc3c1cc(cc3)CC(=O)O'),('PA450700','olsalazine','Olsalazine sodium','Dipentum','Drug/Small Molecule','DailyMed:75a96561-6f52-4c11-a105-391fbbfe4827,chemSpider:4777171,dpd:2063808,drugBank:DB01250,keggCompound:C07323,keggDrug:D00727,ndc:53014-726-71,pubChemCompound:6003770,pubChemSubstance:207208,pubChemSubstance:46506356,url:http://en.wikipedia.org/wiki/Olsalazine','c1cc(c(cc1N=Nc2ccc(c(c2)C(=O)O)O)C(=O)O)O'),('PA450702','omega-3 polyunsaturated fatty acids','','','Drug Class','',''),('PA450704','omeprazole','OMEP,OMP,OMZ,Omeprazol [INN-Spanish],Omeprazole magnesium,Omeprazolum [INN-Latin],omeprazole','Antra,Audazol,Aulcer,Belmazol,Ceprandal,Danlox,Dem','Drug/Small Molecule','DailyMed:0dc9682c-a4ae-4786-8dd9-31e33ce9861b,TTD:DAP000180,bindingDb:50241343,chebi:7772,chemSpider:4433,dpd:2260867,drugBank:DB00338,keggCompound:C07324,keggDrug:D00455,ndc:63739-358-10,pubChemCompound:4594,pubChemSubstance:189970,pubChemSubstance:46509065,url:http://en.wikipedia.org/wiki/Omeprazole','Cc1cnc(c(c1OC)C)CS(=O)c2[nH]c3ccc(cc3n2)OC'),('PA450705','ondansetron','','Apo-ondansetron,Novo-ondansetron,PHL-ondansetron,P','Drug/Small Molecule','DailyMed:8e66d883-2977-46c3-be24-41eba7a903b3,TTD:DAP000221,bindingDb:50000493,chemSpider:4434,dpd:2239372,drugBank:DB00904,iupharLigand:2290,keggCompound:C07325,keggDrug:D00456,ndc:0338-1762-41,pubChemCompound:4595,pubChemSubstance:194568,pubChemSubstance:46504819,url:http://en.wikipedia.org/wiki/Ondansetron','Cc1nccn1CC2CCc3c(c4ccccc4n3C)C2=O'),('PA450715','orphenadrine','Mephenamine,O-Methyldiphenhydramine,Orphenadine,Orphenadrin,Orphenadrine Citrate,Orphenate,Orphenedrine','Antiflex,Banflex,Biorphen,Brocadisipal,Brocasipal,','Drug/Small Molecule','DailyMed:8768cd6b-e79d-4b6d-8981-2f01ce28047b,TTD:DAP000858,chebi:7789,chemSpider:4440,dpd:2243559,drugBank:DB01173,keggCompound:C07935,ndc:0089-0221-10,pubChemCompound:4601,pubChemSubstance:10137,pubChemSubstance:46506085,url:http://en.wikipedia.org/wiki/Orphenadrine','Cc1ccccc1C(c2ccccc2)OCCN(C)C'),('PA450721','oseltamivir','Oseltamivir phosphate','Tamiflu','Drug/Small Molecule','DailyMed:ee3c9555-60f2-4f82-a760-11983c86e97b,TTD:DAP000714,bindingDb:5025,chebi:7798,chemSpider:58540,dpd:2245549,drugBank:DB00198,keggCompound:C08093,keggDrug:D00900,ndc:0004-0802-85,pubChemCompound:65028,pubChemSubstance:46507602,pubChemSubstance:626306,url:http://en.wikipedia.org/wiki/Oseltamivir','CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)OCC'),('PA450725','oxacillin','Oxacillin Sodium','Bactocill','Drug/Small Molecule','DailyMed:81f25efc-fb1d-40d6-bd55-c72753c32459,HET:105,TTD:DAP000440,chebi:7809,chemSpider:5961,drugBank:DB00713,keggCompound:C07334,ndc:0781-3099-95,pdb:105,pubChemCompound:6196,pubChemSubstance:46505710,pubChemSubstance:9541,url:http://en.wikipedia.org/wiki/Oxacillin','Cc1c(c(no1)c2ccccc2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O'),('PA450730','oxaprozin','Oxaprozina [INN-Spanish],Oxaprozine [INN-French],Oxaprozinum [INN-Latin]','Alvo,Daypro,Daypro Alta,Deflam,Voir','Drug/Small Molecule','DailyMed:ea1de47e-3101-4414-817c-0a098af8988c,TTD:DAP000622,bindingDb:50002861,chemSpider:4453,dpd:2243661,drugBank:DB00991,keggCompound:C07356,keggDrug:D00463,ndc:0025-1381-31,pubChemCompound:4614,pubChemSubstance:172661,pubChemSubstance:46506429,url:http://en.wikipedia.org/wiki/Oxaprozin','c1ccc(cc1)c2c(oc(n2)CCC(=O)O)c3ccccc3'),('PA450731','oxazepam','Oxazipam,Oxozepam,d-Oxazepam hemisuccinate','Adumbran,Ansioxacepam,Anxiolit,Aplakil,Astress,Azu','Drug/Small Molecule','DailyMed:a0d5a4c1-ec79-42e6-8e8f-ae4d144edb43,TTD:DAP000243,chebi:7823,chemSpider:4455,dpd:726370,drugBank:DB00842,keggCompound:C07359,keggDrug:D00464,ndc:0228-2067-10,pubChemCompound:4616,pubChemSubstance:46506031,pubChemSubstance:9563,url:http://en.wikipedia.org/wiki/Oxazepam','c1ccc(cc1)C2=NC(C(=O)Nc3c2cc(cc3)Cl)O'),('PA450732','oxcarbazepine','Oxcarbamazepine','Trileptal','Drug/Small Molecule','DailyMed:4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b,TTD:DAP000528,bindingDb:34179,chemSpider:31608,dpd:2244673,drugBank:DB00776,keggCompound:C07492,keggDrug:D00533,ndc:0078-0456-05,pubChemCompound:34312,pubChemSubstance:46507580,pubChemSubstance:9695,url:http://en.wikipedia.org/wiki/Oxcarbazepine','c1ccc2c(c1)CC(=O)c3ccccc3N2C(=O)N'),('PA450741','oxycodone','Dihydrohydroxycodeinone,Dihydrohydroxycondeinone,Dihydrone,Oxicodona [INN-Spanish],Oxycodone Hcl,Oxycodone Hydrochloride,Oxycodonum [INN-Latin],PTI-82','Combunox,Dihydroxycodeinone,Dinarkon,Diphydrone,En','','',''),('PA450744','oxygen','','','Drug/Small Molecule','','[O]'),('PA450748','oxymorphone','14-Hydroxydihydromorphinone,Dihydrohydroxymorphinone,Dihydroxymorphinone,EN3202,Oximorphonum,Oxymorphine,oxymorphone','Numorphan,OPANA ER,Opana','Drug/Small Molecule','DailyMed:10d4a5d9-9cb8-4dcf-9836-34c377990128,TTD:DAP001138,bindingDb:50001707,chemSpider:4447650,dpd:1916505,drugBank:DB01192,keggCompound:C08019,ndc:63481-612-70,pubChemCompound:5284604,pubChemSubstance:10219,pubChemSubstance:46505296,url:http://en.wikipedia.org/wiki/Oxymorphone','CN1CC[C@]23c4c5ccc(c4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)O'),('PA450750','oxyphenbutazone','1-(p-Hydroxyphenyl)-2-phenyl-4-butyl-3,5-pyrazolidinedione,1-Phenyl-2-(p-hydroxyphenyl)-3,5-dioxo-4-butylpyrazolidine,1-p-Hydroxyphenyl-2-phenyl-3,5-d','Aradinum,Artroflog,Butaflogin,Butanora,Butanova,Bu','Drug/Small Molecule','chemSpider:4480,drugBank:DB03585,pdb:OPB,pubChemCompound:4641,pubChemSubstance:10446442,pubChemSubstance:46507285,url:http://en.wikipedia.org/wiki/Oxyphenbutazone','CCCCC1C(=O)N(N(C1=O)c2ccc(cc2)O)c3ccccc3'),('PA450757','oxytetracycline','','Oxytetracycline HCl,Oxytetracycline anhydrous,Terr','Drug/Small Molecule','DailyMed:6b4de8c9-8a32-4a07-9183-419d6177ea08,TTD:DAP000401,chebi:27701,chemSpider:4444458,dpd:719315,drugBank:DB00595,keggCompound:C06624,ndc:0069-0730-66,pubChemCompound:5280972,pubChemSubstance:46507025,pubChemSubstance:8850,url:http://en.wikipedia.org/wiki/Oxytetracycline','C[C@]1(c2cccc(c2C(=O)C3=C([C@]4([C@@H]([C@H]([C@@H]31)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O)O'),('PA450760','oxytocin','Pitocin,Syntocinon','Oxytocin,Pitocin,Syntocinon','Drug/Small Molecule','DailyMed:8fbd0773-6645-4235-9ef2-56edf9c7fb83,TTD:DAP001156,drugBank:DB00107,keggCompound:C00746,keggDrug:D00089,ndc:0591-3553-69,pubChemCompound:439302,pubChemSubstance:4008,url:http://en.wikipedia.org/wiki/Oxytocin','CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N'),('PA450761','paclitaxel','7-Epipaclitaxel,7-Epitaxol,7-epi-Paclitaxel,7-epi-Taxol,abi-007','Abraxane,Epitaxol,LipoPac,Onxol,Paxceed,Paxene,Tax','Drug/Small Molecule','DailyMed:88d7cdd2-e650-4a16-adec-873927e03e93,TTD:DNC001411,chebi:7887,chemSpider:33395,dpd:2244372,drugBank:DB01229,keggCompound:C07394,keggDrug:D00491,ndc:0703-4764-01,pubChemCompound:36314,pubChemSubstance:177831,pubChemSubstance:46506910,url:http://en.wikipedia.org/wiki/Paclitaxel','CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](c5ccccc5)NC(=O)c6ccccc6)O)O)OC(=O)c7ccccc7)(CO4)OC(=O)C)O)C)OC(=O)C'),('PA450767','pamidronate','APD,Acide pamidronique [INN-French],Acido pamidronico [INN-Spanish],Acidum pamidronicum [INN-Latin],Pamidronate Disodium,Pamidronic acid','Amidronate,Aminomux,Aredia','Drug/Small Molecule','DailyMed:d3f15563-21af-4e0d-a9f1-1ebc596c848f,HET:210,TTD:DAP001416,bindingDb:12581,chemSpider:4512,dpd:2246597,drugBank:DB00282,keggCompound:C07395,ndc:0703-4075-51,pdb:210,pubChemCompound:4674,pubChemSubstance:46504823,pubChemSubstance:9599,url:http://en.wikipedia.org/wiki/Pamidronate',''),('PA450771','pancuronium','Bromure de pancuronium [inn-french],Bromuro de pancuronio [inn-spanish],Pancuronium bromide,Pancuronium dibromide','Mioblock,Pavulon','Drug/Small Molecule','DailyMed:a95893be-9df7-4f3e-ad72-3298dab8b187,TTD:DAP000123,chebi:7907,chemSpider:25453,dpd:2078570,drugBank:DB01337,keggCompound:C07551,ndc:0703-2812-04,pubChemCompound:27350,pubChemCompound:441289,pubChemSubstance:169954,pubChemSubstance:46506118,url:http://en.wikipedia.org/wiki/Pancuronium',''),('PA450774','pantoprazole','Pantoprazol [INN-Spanish],Pantoprazole Na,Pantoprazole Sodium,Pantoprazolum [INN-Latin],Pantoprozole','Astropan,Pantoloc,Pantopan,Pantor,Pantozol,Protium','Drug/Small Molecule','DailyMed:51e4144a-489e-436c-609a-39305f8f56ba,TTD:DAP000724,bindingDb:50241342,chebi:7915,chemSpider:4517,dpd:2241804,drugBank:DB00213,keggCompound:C11806,keggDrug:D05353,ndc:0008-0923-51,pubChemCompound:4679,pubChemSubstance:213529,pubChemSubstance:46504622,url:http://en.wikipedia.org/wiki/Pantoprazole','COc1ccnc(c1OC)CS(=O)c2[nH]c3cc(ccc3n2)OC(F)F'),('PA450778','papain','','','Drug/Small Molecule','',''),('PA450787','soft paraffin dressings','','','Drug Class','',''),('PA450790','paraformaldehyde','','','Drug/Small Molecule','',''),('PA450797','pargyline','Benzyl-methyl-2-propinylamin,Methylbenzylpropynylamine,Methylbenzylpropynylamine hydrochloride,N-Benzyl-N-methyl-2-propyn-1-amine,N-Benzyl-N-methyl-2-','Eudatin,Eutonyl,Eutonyl-ten,Lopac-P-8013,Supirdyl','Drug/Small Molecule','TTD:DAP000580,bindingDb:50172756,chemSpider:4526,drugBank:DB01626,keggCompound:C07414,pubChemCompound:4688,pubChemSubstance:46507368,pubChemSubstance:9618,url:http://en.wikipedia.org/wiki/Pargyline','CN(CC#C)Cc1ccccc1'),('PA450798','paricalcitol','paricalcitol','Zemplar','Drug/Small Molecule','DailyMed:7259652f-81bc-4ad1-bba5-d01f9fac1b80,TTD:DAP000211,chebi:7931,chemSpider:4444552,dpd:2266202,drugBank:DB00910,keggCompound:C08127,keggDrug:D00930,ndc:0074-4637-01,pubChemCompound:5281104,pubChemSubstance:10327,pubChemSubstance:46505780',''),('PA450801','paroxetine','Paroxetina [INN-Spanish],Paroxetine Hcl,Paroxetinum [INN-Latin],paroxetine','Aropax,Paxil,Paxil CR,Pexeva,Seroxat,Seroxat CR','Drug/Small Molecule','DailyMed:65ee7ef8-cc68-41d1-cc8b-c01a056409a9,TTD:DAP001428,bindingDb:22416,chebi:7936,chemSpider:39888,dpd:2262746,drugBank:DB00715,keggCompound:C07415,keggDrug:D02362,ndc:0029-3210-13,pubChemCompound:43815,pubChemSubstance:46504821,pubChemSubstance:9619,url:http://en.wikipedia.org/wiki/Paroxetine','c1cc(ccc1[C@@H]2CCNC[C@H]2COc3ccc4c(c3)OCO4)F'),('PA450831','pegademase bovine','Adenosine aminohydrolase,Adenosine deaminase','Adagen','Drug/Small Molecule','DailyMed:9880b900-ea23-11dc-ad56-0002a5d5c51b,drugBank:DB00061,genBank:AF280603,ndc:57665-001-01,uniProtKb:P56658',''),('PA450836','pemoline','Pheniminooxazolidinone,Phenoxazole,Phenylisohydantoin,Phenylpseudohydantoin','Azoksodon,Azoxodon,Azoxodone,Betanamin,Centramin,C','','',''),('PA450839','penciclovir','PE2,Penciclovirum [INN-Latin]','Denavir','Drug/Small Molecule','DailyMed:a6b7ea1c-39d9-4949-a6bd-c808dbf6dda2,HET:PE2,TTD:DAP000488,chebi:7956,chemSpider:4563,drugBank:DB00299,keggCompound:C07417,keggDrug:D05407,ndc:0067-6024-15,pdb:PE2,pubChemCompound:4725,pubChemSubstance:213685,pubChemSubstance:46506498,url:http://en.wikipedia.org/wiki/Penciclovir','c1nc2c(=O)[nH]c(nc2n1CCC(CO)CO)N'),('PA450840','penicillamine','D-Mercaptovaline,D-Penamine,D-Penicilamine,D-Penicillamine,D-Penicyllamine,Dimethylcysteine,L-Penicillamine,PCA,Penicilamina [INN-Spanish],Penicillami','Artamine,Cuprenil,Cuprimine,Cupripen,Depamine,Depe','Drug/Small Molecule','DailyMed:38f8ae60-b354-11de-8a39-0800200c9a66,TTD:DNC000575,chebi:50868,dpd:16055,drugBank:DB00859,keggCompound:C07418,keggDrug:D00496,ndc:0037-4401-01,pubChemCompound:5852,pubChemSubstance:9622,url:http://en.wikipedia.org/wiki/Penicillamine',''),('PA450842','penicillin g','','Abbocillin,Ayercillin,Benzopenicillin,Benzylpenici','Drug/Small Molecule','DailyMed:9e58122f-5c75-4905-a774-d3a4dae4ff8c,HET:PG1,TTD:DNC001109,chebi:18208,chemSpider:5693,dpd:712981,drugBank:DB01053,keggCompound:C05551,keggDrug:D02336,ndc:0338-1021-41,pdb:PG1,pubChemCompound:5904,pubChemSubstance:46506778,pubChemSubstance:7885','CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)Cc3ccccc3)C(=O)O)C'),('PA450849','pentagastrin','','Peptavlon','Drug/Small Molecule','TTD:DNC001170,chemSpider:392037,dpd:2043319,drugBank:DB00183,iupharLigand:870,keggDrug:D01631,pubChemCompound:444007,pubChemSubstance:46507747,pubChemSubstance:7848694,url:http://en.wikipedia.org/wiki/Pentagastrin',''),('PA450850','pentamidine','1,3-bis(4-amidinophenoxy)pentane,4, 4\'-Diamidinodiphenoxypentane,PNT,Pentamide,Pentamidine Isethionate','NebuPent,Pentacarinat,Pentam,Pentam 300,Pneumopent','Drug/Small Molecule','HET:PNT,TTD:DAP000764,chebi:45081,chemSpider:4573,dpd:2183080,drugBank:DB00738,keggCompound:C07420,pdb:PNT,pubChemCompound:4735,pubChemSubstance:150570,pubChemSubstance:46508562,url:http://en.wikipedia.org/wiki/Pentamidine','c1cc(ccc1C(=N)N)OCCCCCOc2ccc(cc2)C(=N)N'),('PA450851','pentamidine isethionate','','','Drug/Small Molecule','',''),('PA450859','pentobarbital','Pentabarbital,Pentabarbitone,Pentobarbital Sodium,Pentobarbitone,Pentobarbiturate,Pentobarbituric acid,Sodium Pentobarbital','Dorsital,Ethaminal,Mebubarbital,Mebumal,Nebralin,N','','',''),('PA450863','pentostatin','2\'-DCF,2\'-Deoxycoformycin,2\'-Dexoycoformycin,Deoxycoformycin,pentostatin','Co-V,Co-Vidarabine,Covidarabine,Nipent,PD-ADI,Vida','Drug/Small Molecule','DailyMed:674e0e6d-46ed-4868-9196-04019d667716,TTD:DAP000566,bindingDb:50003603,chemSpider:37371,dpd:2011247,drugBank:DB00552,keggCompound:C02267,keggDrug:D00155,ndc:0409-0801-01,pubChemCompound:40926,pubChemCompound:439693,pubChemSubstance:181721,pubChemSubstance:46507116,url:http://en.wikipedia.org/wiki/Pentostatin',''),('PA450864','pentoxifylline','EHT0201,pentoxifylline','Azupentat,Dimethyloxohexylxanthine,Durapental,Oxpe','Drug/Small Molecule','DailyMed:0ea37402-987c-4964-a810-e8989e0e5358,TTD:DAP000048,bindingDb:10850,chemSpider:4578,dpd:1968432,drugBank:DB00806,keggCompound:C07424,keggDrug:D00501,ndc:0378-0357-01,pubChemCompound:4740,pubChemSubstance:165572,pubChemSubstance:46505940,url:http://en.wikipedia.org/wiki/Pentoxifylline','CC(=O)CCCCn1c(=O)c2c(ncn2C)n(c1=O)C'),('PA450868','pepsin','','','Drug/Small Molecule','',''),('PA450873','pergolide','Pergolida [INN-Spanish],Pergolide Mesylate,Pergolide Methanesulfonate,Pergolidum [INN-Latin]','Permax','Drug/Small Molecule','DailyMed:a26390e8-eb86-4623-8cdd-45b24b14df74,TTD:DAP000069,bindingDb:50017543,chemSpider:43503,dpd:2123320,drugBank:DB01186,iupharLigand:48,keggCompound:C07425,ndc:0187-0839-01,pubChemCompound:47811,pubChemSubstance:46507604,pubChemSubstance:9629,url:http://en.wikipedia.org/wiki/Pergolide',''),('PA450877','perindopril','Perindopril Erbumine','Aceon,Coversyl','','',''),('PA450882','perphenazine','Chlorperphenazine,Etaperazin,Etaperazine,Ethaperazine,PZC,Perfenazina,Perfenazine,Perphenazin','Apo-Perphenazine,Decentan,Emesinal,Etrafon-A,Etraf','','',''),('PA450897','phenacetin','Acetophenetidin,Acetophenetidine,Acetophenetin,Acetphenetidin','Achrocidin,Codempiral,Commotional,Contradol,Contra','Drug/Small Molecule','chebi:8050,chemSpider:4590,drugBank:DB03783,keggCompound:C07591,keggDrug:D00569,pubChemCompound:4754,pubChemSubstance:46507394,pubChemSubstance:9793,url:http://en.wikipedia.org/wiki/Phenacetin','CCOc1ccc(cc1)NC(=O)C'),('PA450902','phendimetrazine','(+)-3,4-Dimethyl-2-phenylmorpholine,(+)-phendimetrazine,(2S,3S)-3,4-Dimethyl-2-phenylmorpholine,3,4-Dimethyl-2-phenylmorpholine,3-Phenyl-2-methylmorph','Adphen,Antapentan,Bacarate,Bontril,Dyrexan,Hyrex,M','Drug/Small Molecule','DailyMed:6f92c851-62d1-4bf5-b021-24e9d75712c9,TTD:DAP000574,chemSpider:11950,drugBank:DB01579,keggCompound:C07904,ndc:0187-0498-02,pubChemCompound:12460,pubChemSubstance:10106,pubChemSubstance:46506122,url:http://en.wikipedia.org/wiki/Phendimetrazine','CC1C(OCCN1C)c2ccccc2'),('PA450903','phenelzine','','Beta-phenylethylhydrazine,Fenelzina [INN-Spanish],','Drug/Small Molecule','DailyMed:513a41d0-37d4-4355-8a6d-a2c643bce6fa,TTD:DAP000578,bindingDb:50105417,chemSpider:3547,dpd:476552,drugBank:DB00780,keggCompound:C07430,ndc:0071-0350-60,pubChemCompound:3675,pubChemSubstance:46507348,pubChemSubstance:9634,url:http://en.wikipedia.org/wiki/Phenelzine','c1ccc(cc1)CCNN'),('PA450911','phenobarbital','Fenobarbital,Phenobarbitol,Phenobarbituric Acid,Phenylethylbarbiturate,Phenylethylbarbituric Acid,Phenylethylmalonylurea,phenobarbitone','Adonal,Aephenal,Agrypnal,Amylofene,Aphenylbarbit,A','Drug/Small Molecule','TTD:DAP000061,chebi:8069,chemSpider:4599,dpd:178799,drugBank:DB01174,keggCompound:C07434,keggDrug:D00506,pubChemCompound:4763,pubChemSubstance:46505776,pubChemSubstance:7847572,url:http://en.wikipedia.org/wiki/Phenobarbital','CCC1(C(=O)NC(=O)NC1=O)c2ccccc2'),('PA450913','phenol','','','Drug/Small Molecule','bindingDb:26187,chebi:15882,drugBank:DB03255,keggCompound:C00146,keggDrug:D00033,pdb:IPH,pubChemCompound:996,pubChemSubstance:3446,pubChemSubstance:46508193','c1ccc(cc1)O'),('PA450918','phenolsulfonphthalein','','','Drug/Small Molecule','',''),('PA450919','phenoxybenzamine','Fenossibenzamina [Dcit],Fenoxibenzamina [INN-Spanish],POB HCl,Phenoxybenzamine Hcl,Phenoxybenzamine Hydrochloride,Phenoxybenzaminum [INN-Latin]','Bensylyt,Bensylyt Nen,Bensylyte,Benzylyt,Dibenylin','Drug/Small Molecule','DailyMed:4fcdf9ca-78a8-4e4b-958e-2f795bbbf9ca,TTD:DAP000478,bindingDb:50017679,chemSpider:4604,drugBank:DB00925,keggCompound:C07435,ndc:65197-001-01,pubChemCompound:4768,pubChemSubstance:46507191,pubChemSubstance:9639,url:http://en.wikipedia.org/wiki/Phenoxybenzamine','c1ccc(cc1)Oc2ccccc2C(=O)N'),('PA450921','phenprocoumon','Fenprocumone [DCIT],Phenprocoumarol,Phenprocoumarole,Phenprocoumone,Phenprocumone','Falithiom,Falithrom,Fencumar,Liquamar,Marcoumar,Ma','Drug/Small Molecule','TTD:DAP000771,bindingDb:768,chebi:50438,drugBank:DB00946,pubChemCompound:9908,pubChemSubstance:153131,url:http://en.wikipedia.org/wiki/Phenprocoumon','CCC(c1ccccc1)c2c(c3ccccc3oc2=O)O'),('PA450926','phentolamine','','Phenotolamine,Phentalamine,Phentolamine Mesilate,P','Drug/Small Molecule','DailyMed:6db10859-2a3f-4782-ac33-94300463658f,TTD:DAP000299,bindingDb:50008789,chemSpider:5571,dpd:2243737,drugBank:DB00692,iupharLigand:502,ndc:0083-6830-02,pubChemCompound:5775,pubChemSubstance:148562,pubChemSubstance:46506535,url:http://en.wikipedia.org/wiki/Phentolamine','Cc1ccc(cc1)N(CC2=NCCN2)c3cccc(c3)O'),('PA450931','l-phenylalanine','(S)-alpha-Amino-beta-phenylpropionic acid,3-phenyl-l-alanine,beta-phenyl-l-alanine,phe','','Drug/Small Molecule','HET:PHE,TTD:DAP000807,chebi:17295,chemSpider:5910,drugBank:DB00120,keggCompound:C00079,keggDrug:D00021,pdb:PHE,pubChemCompound:6140,pubChemSubstance:3379,pubChemSubstance:46505708,url:http://en.wikipedia.org/wiki/L-Phenylalanine',''),('PA450932','phenylbutazone','','\"\'Esteve\',Alindor,Alka Butazolidin,Alkabutazona,Al','','',''),('PA450935','phenylephrine','Fenilefrina [INN-Spanish],L-Phenylephedrine,L-Phenylephrine,M-Methylaminoethanolphenol,M-Oxedrine,Metaoxedrin,Metaoxedrine,Metaoxedrinum,Metasynephrin','AK-Dilate,AK-Nefrin,Adrianol,Alcon Efrin,Alconefri','','',''),('PA450947','phenytoin','5,5-Dwufenylohydantoina,5,5-diphenylhydantoin,DPH,Difenilhidantoina [Spanish],Dihydantoin,Diphenylan Sodium,Diphenylhydantoin,Diphenylhydantoine [Fren','Aleviatin,Antisacer,Auranile,Causoin,Citrullamon,C','','',''),('PA450952','phospholipids','','','Drug/Small Molecule','',''),('PA450953','phosphoric acid','','Aminosyn 3.5% M,Aminosyn 3.5% M In Plastic Contain','Drug/Small Molecule','','OP(=O)(O)O'),('PA450954','phosphorus','','','Drug/Small Molecule','','[P]'),('PA450957','physostigmine','Erserine,Eserine,Eserine Salicylate,Eserine Sulfate,Eserolein, Methylcarbamate,Isopto Eserine','Antilirium,Esromiotin,Ezerin,Fysostigmin,Physostol','Drug/Small Molecule','TTD:DAP000561,chebi:27953,chemSpider:5763,dpd:344931,drugBank:DB00981,keggCompound:C06535,keggDrug:D00196,pubChemCompound:5983,pubChemSubstance:46506998,pubChemSubstance:7847264,url:http://en.wikipedia.org/wiki/Physostigmine',''),('PA450961','phytonadione','2\', 3\'-trans-Vitamin K1,2-Methyl-3-phythyl-1,4-naphthochinon,3-Phytylmenadione,Antihemorrhagic vitamin,Phyllochinon,Phylloquinone,Phythyl-menadion,Phy','Aqua-Mephytin,AquaMEPHYTON,Combinal K1,K-Ject,Kati','Drug/Small Molecule','DailyMed:78cb045a-6774-4b94-9b14-398009a2b923,TTD:DNC001500,chebi:18067,dpd:243876,drugBank:DB01022,keggCompound:C02059,keggDrug:D00148,ndc:0548-1240-00,pubChemCompound:4812,pubChemSubstance:5148,url:http://en.wikipedia.org/wiki/Phytonadione',''),('PA450962','pilocarpine','Adsorbocarpine,Beta-pilocarpine hydrochloride,Pilocarpin,Pilocarpine HCl,Pilocarpine chloride,Pilocarpine hydrochloride,Pilocarpine monohydrochloride,','Akarpine,Almocarpine,Ami-Pilo,Amistura P,Epicar,Is','','',''),('PA450965','pimozide','Pimozida [INN-Spanish],Pimozidum [INN-Latin]','Halomonth,Neoperidole,Opiran,Orap','Drug/Small Molecule','TTD:DAP000316,chebi:8212,chemSpider:15520,dpd:573817,drugBank:DB01100,iupharLigand:90,keggCompound:C07566,keggDrug:D00560,pubChemCompound:16362,pubChemSubstance:46507096,pubChemSubstance:9769,url:http://en.wikipedia.org/wiki/Pimozide','c1ccc2c(c1)[nH]c(=O)n2C3CCN(CC3)CCCC(c4ccc(cc4)F)c5ccc(cc5)F'),('PA450966','pindolol','Betapindol,Prinodolol','Blockin L,Blocklin L,Calvisken,Cardilate,Decreten,','','',''),('PA450970','pioglitazone','Pioglitazona [INN-Spanish],Pioglitazone Hydrochloride,Pioglitazone [Ban:Inn],Pioglitazonum [INN-Latin],pioglitazone HCl','Actos,Actost,Glustin','','',''),('PA450975','piperacillin','Piperacillin Anhydrous','Pipracil','','',''),('PA450977','piperazine','Diethylenediamine,Diethyleneimine,Diketopiperazine,Glycine anhydride,Hexahydropyrazine,Piperazin,Piperazin [Germany],Piperazine Citrate,Piperazine hex','Anatensol,Antepan,Antepar,Antiren,Asca-Trol No. 3,','','',''),('PA450980','piperonyl butoxide','','Rid Mousse','Drug/Small Molecule','',''),('PA450983','pirbuterol','Pirbuterol hydrochloride,Pirbuterolum [inn-latin]','Maxair','Drug/Small Molecule','DailyMed:c7ef31c4-e3d9-4a9b-98bd-46b609f7f3aa,TTD:DAP000249,chemSpider:4679,drugBank:DB01291,keggCompound:C07807,ndc:0089-0815-21,pubChemCompound:4845,pubChemSubstance:10009,pubChemSubstance:46506379',''),('PA450985','piroxicam','AK1015,piroxicam','Akten,Apo-Piroxicam,Artroxicam,Baxo,Bruxicam,Calim','Drug/Small Molecule','DailyMed:aa447bac-dfbd-44ae-b1d1-3e1be6d7ef9e,TTD:DAP000181,chebi:8249,dpd:658839,drugBank:DB00554,keggCompound:C01608,keggDrug:D00127,ndc:0378-1010-01,pubChemCompound:5280452,pubChemSubstance:4761,url:http://en.wikipedia.org/wiki/Piroxicam','CN1C(=C(c2ccccc2S1(=O)=O)O)C(=O)Nc3ccccn3'),('PA450993','podofilox','Podophyllinic acid lactone','Podophyllotoxin,Podophyllotoxin 7','Drug/Small Molecule','DailyMed:6af07697-5203-43e0-ba35-83683af851c3,HET:POD,TTD:DNC001139,chebi:50305,chemSpider:10162,drugBank:DB01179,keggCompound:C10871,ndc:0574-0611-05,pdb:POD,pubChemCompound:10607,pubChemSubstance:153901,pubChemSubstance:46505716,url:http://en.wikipedia.org/wiki/Podofilox',''),('PA450999','poliomyelitis vaccines','','','Drug Class','',''),('PA451013','polyethylene glycol','','','Drug/Small Molecule','',''),('PA451018','polyethylene glycol 400','','','Drug/Small Molecule','',''),('PA451020','polyethylene glycol 6000','','','Drug/Small Molecule','',''),('PA451023','polyethylene glycol 8000','','','Drug/Small Molecule','',''),('PA451027','polymyxin b sulfate','Polymixin B sulfate,Polymyxin B sulfate salt,Polymyxin B sulphate','Aerosporin,Poly-RX','','',''),('PA451038','polysorbate 80','','','Drug/Small Molecule','',''),('PA451047','potassium','','','Drug/Small Molecule','chebi:26216,drugBank:DB01345,url:http://en.wikipedia.org/wiki/Potassium',''),('PA451049','potassium acetate','','Aminosyn 3.5% M,Aminosyn 3.5% M In Plastic Contain','Drug/Small Molecule','','CC(=O)[O-].[K+]'),('PA451055','potassium chloride','Chlorid draselny [Czech],Chloride of potash,ClK,Dipotassium dichloride,Hydrochloric acid potassium salt (1:1),Monopotassium chloride,Potassium monochl','Acronitol,Addi-K,Apo-K,Celeka,Cena-K,Chloropotassu','','',''),('PA451057','potassium gluconate','','','Drug/Small Molecule','',''),('PA451060','potassium iodide','','ThyroShield','Drug/Small Molecule','','[K+].[I-]'),('PA451071','potassium phosphate, incl. comb. with other potassium salts','','','Drug/Small Molecule','',''),('PA451089','pravastatin','Pravastatin Sodium,Pravastatina [Spanish],Pravastatine [French],Pravastatinum [Latin]','Compactin,Elisor,Lipostat,Mevalotin,Mevastatin,Mev','Drug/Small Molecule','DailyMed:897ad8b7-921d-eb02-a61c-3419e662a2da,TTD:DAP000550,bindingDb:20688,chemSpider:49398,dpd:2247008,drugBank:DB00175,keggCompound:C01844,ndc:0003-5154-05,pubChemCompound:54687,pubChemSubstance:192211,pubChemSubstance:46504851,url:http://en.wikipedia.org/wiki/Pravastatin','CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](CC(CC(=O)O)O)O)O'),('PA451093','prazosin','Prazocin,Prazosin HCl,Prazosin Hydrochloride,Prazosina [INN-Spanish],Prazosine [INN-French],Prazosinum [INN-Latin]','Furazosin,Lentopres,Minipress,Minipress Xl,Vasofle','Drug/Small Molecule','DailyMed:36c4da56-502e-4da1-acf7-8e81ee453dcc,TTD:DAP000300,bindingDb:29568,chebi:8364,chemSpider:4724,dpd:1910302,drugBank:DB00457,iupharLigand:503,keggCompound:C07368,ndc:0069-4310-71,pubChemCompound:4893,pubChemSubstance:46508594,pubChemSubstance:9572,url:http://en.wikipedia.org/wiki/Prazosin','COc1cc2c(cc1OC)nc(nc2N)N3CCN(CC3)C(=O)c4ccco4'),('PA451096','prednisolone','Deltahydrocortisone,Methylprednisolone Acetate,PRDL,Predisolone Sodium Phosphate,Prednisolona [INN-Spanish],Prednisolone Acetate,Prednisolone Sodium P','Ak-Pred,Ak-Tate,Alphadrol,Articulose-50,Co-Hydeltr','','',''),('PA451100','prednisone','Dehydrocortisone,PRD,Prednisona [INN-Spanish],Prednisonum [INN-Latin]','Adasone,Ancortone,Apo-prednisone,Betapar,Bicortone','','',''),('PA451101','prilocaine','','Astra 1512,Astra 1515,Citanest,Citanest Plain,Prop','Drug/Small Molecule','TTD:DAP000511,bindingDb:50017654,chebi:8404,chemSpider:4737,dpd:519235,drugBank:DB00750,keggCompound:C07531,keggDrug:D00553,ndc:66312-520-14,pubChemCompound:4906,pubChemSubstance:46505066,pubChemSubstance:9734,url:http://en.wikipedia.org/wiki/Prilocaine','CCCNC(C)C(=O)Nc1ccccc1C'),('PA451103','primaquine','','Neo-Quipenyl,Primachin','Drug/Small Molecule','TTD:DAP000216,bindingDb:50203193,chebi:8405,chemSpider:4739,dpd:2017776,drugBank:DB01087,keggCompound:C07627,pubChemCompound:4908,pubChemSubstance:46508222,pubChemSubstance:9829,url:http://en.wikipedia.org/wiki/Primaquine','CC(CCCN)Nc1cc(cc2c1nccc2)OC'),('PA451105','primidone','','\"Apo-Primidone,Cyral,Desoxyphenobarbitone,Hexadion','Drug/Small Molecule','DailyMed:a1a817f7-c190-4825-94eb-442f477187e3,TTD:DAP000678,chemSpider:4740,dpd:396761,drugBank:DB00794,keggCompound:C07371,keggDrug:D00474,ndc:0527-1301-01,pubChemCompound:4909,pubChemSubstance:173378,pubChemSubstance:46507775,url:http://en.wikipedia.org/wiki/Primidone','CCC1(C(=O)NCNC1=O)c2ccccc2'),('PA451106','probenecid','probenicid','Apurina,Benecid,Benemid,Benuryl,Col-Probenecid,Col','Drug/Small Molecule','DailyMed:11e8d542-e79f-4665-8b35-8aa194c55f33,TTD:DAP001292,chemSpider:4742,dpd:294926,drugBank:DB01032,keggCompound:C07372,keggDrug:D00475,ndc:0378-0156-01,pubChemCompound:4911,pubChemSubstance:46506554,pubChemSubstance:9576,url:http://en.wikipedia.org/wiki/Probenecid','CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(=O)O'),('PA451107','probucol','4,4\'- (Isopropylidenedithio)bis(2, 6-di-tert-butylphenol),4,4\'-(Isopropylidenedithio)bis(2, 6-di-tert-butylphenol),4,4\'-(Isopropylidenedithio)bis(2,6-','Biphenabid,Bisbid,Bisphenabid,Lesterol,Lorelco,Lur','Drug/Small Molecule','TTD:DAP000916,bindingDb:50007260,chemSpider:4743,dpd:2091909,drugBank:DB01599,keggCompound:C07373,keggDrug:D00476,pubChemCompound:4912,pubChemSubstance:10321432,pubChemSubstance:46508876,url:http://en.wikipedia.org/wiki/Probucol',''),('PA451108','procainamide','','Biocoryl,Novocainamid,Novocainamide,Novocaine Amid','Drug/Small Molecule','TTD:DAP000516,chebi:8428,chemSpider:4744,dpd:713341,drugBank:DB01035,keggCompound:C07401,ndc:0003-0758-50,pubChemCompound:4913,pubChemSubstance:46507313,pubChemSubstance:9605,url:http://en.wikipedia.org/wiki/Procainamide','CCN(CC)CCNC(=O)c1ccc(cc1)N'),('PA451110','procaine','procaine HCl','Allocaine,Anticort,Chloroprocaine Hcl,Diethylamino','Drug/Small Molecule','TTD:DAP000296,chebi:8430,chemSpider:4745,dpd:2241979,drugBank:DB00721,keggCompound:C07375,ndc:61570-085-10,pubChemCompound:4914,pubChemSubstance:46507724,pubChemSubstance:9579,url:http://en.wikipedia.org/wiki/Procaine','CCN(CC)CCOC(=O)c1ccc(cc1)N'),('PA451112','procarbazine','IBZ,Ibenzmethyzin,Ibenzmethyzine,Ibenzmethyzine hydrochloride,MBH,MIH,MIH Hydrochloride,PCB,PCB hydrochloride,PCX,Procarbazin,Procarbazin [German],Pro','Matulane,Nathulane,Natulan,Natulan hydrochloride,N','Drug/Small Molecule','TTD:DAP000986,chemSpider:4746,dpd:12750,drugBank:DB01168,keggCompound:C07402,keggDrug:D00478,pubChemCompound:4915,pubChemSubstance:46507706,pubChemSubstance:9606,url:http://en.wikipedia.org/wiki/Procarbazine','CC(C)NC(=O)c1ccc(cc1)CNNC'),('PA451114','prochlorperazine','Chlormeprazine,Chlorperazine,Prochloroperazine,Prochlorpemazine,Prochlorperazin,Prochlorperazine edisylate,Prochlorperazine maleate,Prochlorpromazine,','Bayer A 173,Buccastem,Capazine,Combid,Compazine,Co','Drug/Small Molecule','DailyMed:ea381bc5-0957-4c91-826a-0ff680cebacc,TTD:DAP000373,chebi:8435,chemSpider:4748,dpd:753637,drugBank:DB00433,keggCompound:C07403,keggDrug:D00493,ndc:0574-7226-12,pubChemCompound:4917,pubChemSubstance:46509018,pubChemSubstance:7847559,url:http://en.wikipedia.org/wiki/Prochlorperazine','CN1CCN(CC1)CCCN2c3ccccc3Sc4c2cc(cc4)Cl'),('PA451123','progesterone','Corpus Luteum Hormone,Progesterona [INN-Spanish],Progesteronum,Progesteronum [INN-Latin]','Agolutin,Amen,Bio-Luton,Colprosterone,Corlutin,Cor','','',''),('PA451124','proguanil','','Chloroguanide,Paludrine','Drug/Small Molecule','TTD:DAP000634,chebi:8455,chemSpider:4754,dpd:2043068,drugBank:DB01131,keggCompound:C07631,pubChemCompound:4923,pubChemCompound:6178111,pubChemSubstance:46506228,pubChemSubstance:9833,url:http://en.wikipedia.org/wiki/Proguanil','CC(C)/N=C(N)/N=C(N)/Nc1ccc(cc1)Cl'),('PA451125','l-proline','(-)-2-Pyrrolidinecarboxylic acid,(-)-Proline,(S)-2-Carboxypyrrolidine,(S)-2-Pyrrolidinecarboxylic acid,(S)-Proline,2-Pyrrolidinecarboxylic acid','','Drug/Small Molecule','HET:PRO,TTD:DAP000198,chebi:17203,chemSpider:128566,drugBank:DB00172,keggCompound:C00148,keggDrug:D00035,pdb:PRO,pubChemCompound:145742,pubChemSubstance:3448,pubChemSubstance:46506858,url:http://en.wikipedia.org/wiki/L-Proline',''),('PA451126','promazine','CPZ,Chlorpromazine Hcl,Phenothiazine,Promazin,Promazina,Promazine Hcl','AB,Aminazin,Aminazine,Ampazine,Ampliactil,Amplicti','Drug/Small Molecule','TTD:DAP000430,chebi:8459,chemSpider:4757,dpd:497509,drugBank:DB00420,keggCompound:C07379,keggDrug:D08430,pubChemCompound:4926,pubChemSubstance:46504504,pubChemSubstance:9583,url:http://en.wikipedia.org/wiki/Promazine','CN(C)CCCN1c2ccccc2Sc3c1cccc3'),('PA451128','promethazine','Isopromethazine,Lilly 1516,Proazaimine,Proazamine,Promazinamide,Promethazin,Promethazine Hcl,Promethiazine,Promezathine,Prothazin,Prothazine,prometazi','Allergan,Aprobit,Avomine,Dimapp,Diphergan,Diprazin','','',''),('PA451131','propafenone','Propafenona [INN-Spanish],Propafenone HCl,Propafenone hydrochloride,Propafenone-HCl,Propafenonum [INN-Latin]','Rythmol,Rythmol SR','Drug/Small Molecule','DailyMed:0e9d1433-a55e-4907-bb38-abac47c7d3c7,TTD:DAP000497,bindingDb:50067133,chemSpider:4763,dpd:2243728,drugBank:DB01182,iupharLigand:2561,keggCompound:C07381,ndc:0173-0786-01,pubChemCompound:4932,pubChemSubstance:181774,pubChemSubstance:46504529,url:http://en.wikipedia.org/wiki/Propafenone',''),('PA451140','propionic acid derivatives','','','Drug Class','',''),('PA451141','propofol','2,6-Diisopropylphenol,Diisopropylphenol,propofol','Diprivan,Disoprivan,Disoprofol,Rapinovet','Drug/Small Molecule','DailyMed:28d7ba00-f824-4e55-139a-03f509c099db,HET:PFL,TTD:DAP000662,chebi:8495,chemSpider:4774,dpd:2242973,drugBank:DB00818,keggCompound:C07523,keggDrug:D00549,ndc:0409-4699-30,pdb:PFL,pubChemCompound:4943,pubChemSubstance:46504991,pubChemSubstance:9726,url:http://en.wikipedia.org/wiki/Propofol','CC(C)c1cccc(c1O)C(C)C'),('PA451142','propoxyphene','D-Propoxyphene,Dextropropoxyphene,Dextropropoxyphene-M,Dextroproxifeno,Propoxyphene HCl','Algafan,Antalvic,Darvon,Darvon-N,Deprancol,Depromi','Drug/Small Molecule','DailyMed:c70198be-f3ad-49a1-b2e5-c11f1237971d,TTD:DAP000017,chebi:8497,drugBank:DB00647,keggCompound:C07406,ndc:0378-7065-01,pubChemCompound:15330,pubChemSubstance:9610,url:http://en.wikipedia.org/wiki/Propoxyphene','CCC(=O)OC(Cc1ccccc1)(c2ccccc2)C(C)CN(C)C'),('PA451145','propranolol','Dl-Propranolol Hydrochloride,Propanalol,Propanolol,Propranalol,Propranolol Hcl,Propranolol Hydrochloride,R,S-Propranolol Hydrochloride,propranolol','Angilol,Apsolol,Avlocardyl,Bedranol,Beprane,Berkol','Drug/Small Molecule','TTD:DAP000089,bindingDb:25761,chebi:8499,chemSpider:4777,dpd:663719,drugBank:DB00571,iupharLigand:564,iupharLigand:63,keggCompound:C07407,ndc:65726-251-10,pubChemCompound:4946,pubChemSubstance:153977,pubChemSubstance:46505387,url:http://en.wikipedia.org/wiki/Propranolol','CC(C)NCC(COc1cccc2c1cccc2)O'),('PA451156','propylthiouracil','PTU,Procasil,Propacil,Propilthiouracil,Propycil,Propyl-Thiorist,Propyl-Thiorit,Propyl-Thyracil,Propylthiorit,Propythiouracil,Prothiucil,Prothiurone,Pr','Thyreostat II','Drug/Small Molecule','DailyMed:b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0,TTD:DAP001247,chebi:8502,chemSpider:571424,dpd:10200,drugBank:DB00550,keggCompound:C07569,keggDrug:D00562,ndc:67253-651-10,pubChemCompound:657298,pubChemSubstance:46505181,pubChemSubstance:9772,url:http://en.wikipedia.org/wiki/Propylthiouracil','CCCc1cc(=O)[nH]c(=S)[nH]1'),('PA451159','protease inhibitors','protease inhibitors','','Drug Class','',''),('PA451168','protriptyline','Protryptyline','Amimetilina,Anafranil,Apo-Amitriptyline,Apo-Imipra','Drug/Small Molecule','DailyMed:a6be6521-7179-442f-8c45-69711a2c3290,TTD:DAP000863,chebi:8597,chemSpider:4805,dpd:322741,drugBank:DB00344,keggCompound:C07408,ndc:0555-0595-02,pubChemCompound:4976,pubChemSubstance:46505128,pubChemSubstance:9612,url:http://en.wikipedia.org/wiki/Protriptyline','CNCCCC1c2ccccc2C=Cc3c1cccc3'),('PA451170','pseudoephedrine','','Afrin,Afrinol,Balminil Decongestant Syrup,Benylin ','','',''),('PA451182','pyrazinamide','PZA,Pirazimida,Pirazinamid,Pyrazinamdie,Pyrazine carboxylamide,Pyrazineamide,Pyrazinecarboxamide,Pyrazinecarboxylic acid amide,Pyrazinoic acid amide','Aldinamid,Aldinamide,Braccopiral,Corsazinmid,Dipim','','',''),('PA451185','pyridostigmine','Pyridine N-Oxide,Pyridostigmine Bromide,Pyridostigmine Bromine,Pyridostigminum','Mestinon,Mestinon-SR,Regonol','Drug/Small Molecule','DailyMed:0f56facf-1f0a-4ba5-876d-757b114dfa45,TTD:DNC001171,bindingDb:50018231,chemSpider:4817,dpd:869953,drugBank:DB00545,keggCompound:C07410,keggDrug:D00487,ndc:0115-3511-01,pubChemCompound:4991,pubChemSubstance:46506129,pubChemSubstance:9614,url:http://en.wikipedia.org/wiki/Pyridostigmine','C[n+]1cccc(c1)OC(=O)N(C)C'),('PA451193','pyrimethamine','CD,Chloridin,Chloridine,Chloridyn,Diaminopyritamin,Ethylpyrimidine,Pirimetamin,Pirimetamina,Primethamine,Pyremethamine,Pyrimethamin,Pyrimethamine Hcl','Darachlor,Daraclor,Darapram,Daraprim,Daraprime,Dis','','',''),('PA451201','quetiapine','','Quetiapin hemifumarate,Quetiapine fumarate,Quetiap','Drug/Small Molecule','DailyMed:0584dda8-bc3c-48fe-1a90-79608f78e8a0,TTD:DAP000001,chebi:8707,chemSpider:4827,dpd:2240862,drugBank:DB01224,iupharLigand:50,keggCompound:C07397,ndc:0310-0275-10,pubChemCompound:5002,pubChemSubstance:46504800,pubChemSubstance:9601,url:http://en.wikipedia.org/wiki/Quetiapine','c1ccc2c(c1)C(=Nc3ccccc3S2)N4CCN(CC4)CCOCCO'),('PA451205','quinapril','Quinapril Hcl,Quinapril Hydrochloride,Quinaprilum [Latin]','Accupril,Accuprin,Accupro,Acequin,Acuitel,Korec,Qu','Drug/Small Molecule','DailyMed:43ed2312-ab65-4a1e-bfa2-76602a6b7c53,TTD:DAP000588,chebi:8713,chemSpider:49565,dpd:1947672,drugBank:DB00881,keggCompound:C07398,keggDrug:D03752,ndc:0378-1117-77,pubChemCompound:54892,pubChemSubstance:46506309,pubChemSubstance:9602,url:http://en.wikipedia.org/wiki/Quinapril','CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2Cc3ccccc3C[C@H]2C(=O)O'),('PA451209','quinidine','Quinidine Gluconate,Quinidine Sulfate','Apo-Quinidine,Biquin Durules,Cardioquin,Chinidin,C','Drug/Small Molecule','TTD:DAP000515,chebi:28593,chemSpider:389880,dpd:497525,drugBank:DB00908,iupharLigand:2342,keggCompound:C06527,ndc:53489-459-02,pubChemCompound:441074,pubChemSubstance:46505356,pubChemSubstance:8758,url:http://en.wikipedia.org/wiki/Quinidine','COc1ccc2c(c1)c(ccn2)[C@@H]([C@@H]3CC4CCN3C[C@H]4C=C)O'),('PA451213','quinine','6\'-Methoxycinchonidine,6\'-Methoxycinchonine,Quinine sulfate,Quinine, Anhydrous,Quinineanhydrous,Quinoline Alkaloid','Aflukin,Chinin,Chinine,Coco-Quinine,Quinine Dab','','',''),('PA451216','rabeprazole','Irsogladine Maleate,Rebeprazole sodium,rabeprazole sodium','AcipHex,Pariet','Drug/Small Molecule','DailyMed:5d103551-978f-472a-9c62-51e6e4dea068,TTD:DAP000727,chebi:8768,chebi:8769,chemSpider:4853,dpd:2243797,drugBank:DB01129,keggCompound:C07864,ndc:62856-243-30,pubChemCompound:5029,pubChemSubstance:10066,pubChemSubstance:46506366,url:http://en.wikipedia.org/wiki/Rabeprazole',''),('PA451219','rabies vaccines','','','Drug Class','',''),('PA451221','raloxifene','LY-139481,RAL,Raloxifene Hcl,Raloxifene Hydrochloride,Raloxifeno [Spanish],Raloxifenum [Latin],raloxifene','Evista,Keoxifene','Drug/Small Molecule','DailyMed:fcaaa6dc-74e8-4fb8-800c-5574bf0f8de9,HET:RAL,TTD:DAP000792,bindingDb:19441,chebi:8772,chemSpider:4859,dpd:2239028,drugBank:DB00481,keggCompound:C07228,ndc:0002-4165-02,pdb:RAL,pubChemCompound:5035,pubChemSubstance:148636,pubChemSubstance:46506514,url:http://en.wikipedia.org/wiki/Raloxifene','c1cc(ccc1c2c(c3ccc(cc3s2)O)C(=O)c4ccc(cc4)OCCN5CCCCC5)O'),('PA451223','ramipril','Ramiprilum [Latin]','Acovil,Altace,Carasel,Cardace,Delix,Hypren,Hytren,','Drug/Small Molecule','DailyMed:9d008401-4746-4dc5-94ab-4462f959fb73,TTD:DAP000581,chebi:8774,chemSpider:4514937,dpd:2221829,drugBank:DB00178,keggDrug:D00421,ndc:54868-5896-0,pubChemCompound:5362129,pubChemSubstance:193088,pubChemSubstance:46506390,url:http://en.wikipedia.org/wiki/Ramipril','CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O'),('PA451224','ranitidine','Ranitidine Base,Ranitidine HCL,Ranitidine hydrochloride,Rantidine HCL','Alquen,Alter-H2,Alvidina,Apo-Ranitidin,Artomil,Azu','Drug/Small Molecule','DailyMed:91fb6442-1059-4aeb-b562-62ded3932433,TTD:DAP000340,bindingDb:22893,chebi:8776,chemSpider:2272523,dpd:740748,drugBank:DB00863,iupharLigand:1234,keggDrug:D00422,ndc:0172-4357-49,pubChemCompound:3001055,pubChemSubstance:187111,pubChemSubstance:46505543,url:http://en.wikipedia.org/wiki/Ranitidine','CNC(=CN(=O)=O)NCCSCc1ccc(o1)CN(C)C'),('PA451232','remifentanil','Remifentanyl','Ultiva','Drug/Small Molecule','DailyMed:dbc63b6e-f8c5-4fd0-8ec3-4f5e19125313,TTD:DAP000264,bindingDb:50012491,chemSpider:54803,dpd:2230410,drugBank:DB00899,keggCompound:C08021,ndc:67457-198-03,pubChemCompound:60815,pubChemSubstance:10221,pubChemSubstance:46504538,url:http://en.wikipedia.org/wiki/Remifentanil','CCC(=O)N(c1ccccc1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC'),('PA451234','repaglinide','AG-EE 388 ZW,AG-EE 623 ZW,Repaglinida [INN-Spanish],Repaglinidum [INN-Latin],repaglinide','GlucoNorm,Prandin','Drug/Small Molecule','TTD:DAP000133,bindingDb:50153520,chemSpider:59377,dpd:2239925,drugBank:DB00912,keggCompound:C07670,keggDrug:D00594,pubChemCompound:65981,pubChemSubstance:208038,pubChemSubstance:46508150,url:http://en.wikipedia.org/wiki/Repaglinide','CCOc1cc(ccc1C(=O)O)CC(=O)N[C@@H](CC(C)C)c2ccccc2N3CCCCC3'),('PA451236','reserpine','','Cam-Ap-Es,Demi-Regroton,Diupres-250,Diupres-500,Di','','',''),('PA451241','ribavirin','RBV,Ribavirin Triphosphate,Ribavirina [INN-Spanish],Ribavirine [INN-French],Ribavirinum [INN-Latin]','Copegus,RIBAV,RTC,RTCA,RTP,Rebetol,Rebetron,Rebret','','',''),('PA451242','riboflavin','Lactoflavin,Lactoflavine,Riboflavina [INN-Spanish],Riboflavine [INN-French],Riboflavinum [INN-Latin],Russupteridine Yellow III,Vitamin B2,Vitamin Bi,V','Aqua-Flave,Beflavin,Beflavine,Bisulase,Dermadram,F','Drug/Small Molecule','chebi:17015,chemSpider:6501,dpd:2239929,drugBank:DB00140,keggCompound:C00255,keggDrug:D00050,pubChemCompound:493570,pubChemCompound:6759,pubChemSubstance:3554,pubChemSubstance:46507342,url:http://en.wikipedia.org/wiki/Riboflavin',''),('PA451249','rifabutin','Ansatipin,Ansatipine,Antibiotic LM 427,RBT,Rifabutina [Spanish],Rifabutine [French],Rifabutinum [Latin]','Alfacid,Ansamycin,Mycobutin','Drug/Small Molecule','DailyMed:3e1a6613-bdd3-4261-93b3-d7f5cc09064b,HET:RBT,TTD:DAP000656,chebi:8857,chemSpider:4883445,dpd:2063786,drugBank:DB00615,keggCompound:C07235,keggDrug:D00424,ndc:0013-5301-17,pdb:RBT,pubChemCompound:6323490,pubChemSubstance:189788,pubChemSubstance:46506468,url:http://en.wikipedia.org/wiki/Rifabutin',''),('PA451250','rifampin','RFP,rifampin','Archidyn,L-5103 Lepetit,R/AMP,RAMP,Rfamipicin,Rifa','','',''),('PA451251','riluzole','riluzole','Rilutek,Riluzole HCl','Drug/Small Molecule','DailyMed:e49d207d-8e32-4183-94ba-cd264f124090,TTD:DAP000527,bindingDb:30705,chemSpider:4892,dpd:2242763,drugBank:DB00740,iupharLigand:2326,keggCompound:C07937,keggDrug:D00775,ndc:0075-7700-60,pubChemCompound:5070,pubChemSubstance:46508094,pubChemSubstance:7847840,url:http://en.wikipedia.org/wiki/Riluzole','c1cc2c(cc1OC(F)(F)F)sc(n2)N'),('PA451255','risedronate','NE-58095,Risedronate sodium,Risedronic acid,risedronate','Actonel,Actonel 150,Benet','Drug/Small Molecule','DailyMed:563c6d6d-56df-43a7-a7aa-709c5ea3cdbe,HET:RIS,TTD:DAP000658,bindingDb:12576,chemSpider:5055,dpd:2242518,drugBank:DB00884,keggCompound:C08233,ndc:0149-0471-01,pdb:RIS,pubChemCompound:5245,pubChemSubstance:46507526,pubChemSubstance:634947,url:http://en.wikipedia.org/wiki/Risedronate',''),('PA451257','risperidone','Risperidona [Spanish],Risperidonum [Latin],risperdone,risperidone','Risperdal,Risperdal Consta,Risperdal M-Tab,Risperi','Drug/Small Molecule','DailyMed:1c572c5b-24f6-46c6-bdd2-6774ebefbb42,TTD:DAP000003,chebi:8871,chemSpider:4895,dpd:2247705,drugBank:DB00734,iupharLigand:96,keggDrug:D00426,ndc:0904-5973-61,pubChemCompound:5073,pubChemSubstance:46505850,pubChemSubstance:7847492,url:http://en.wikipedia.org/wiki/Risperidone','Cc1c(c(=O)n2c(n1)CCCC2)CCN3CCC(CC3)c4c5ccc(cc5on4)F'),('PA451258','ritodrine','Ritodrina [INN-Spanish],Ritodrine Hcl,Ritodrine Hydrochloride,Ritodrinium [INN-Latin]','Yutopar,Yutopar S.R','Drug/Small Molecule','TTD:DAP000937,chemSpider:30971,dpd:550140,drugBank:DB00867,keggCompound:C07239,keggDrug:D02359,pubChemCompound:33572,pubChemSubstance:46505273,pubChemSubstance:9448,url:http://en.wikipedia.org/wiki/Ritodrine',''),('PA451260','ritonavir','Abbott 84538,ritonavir','Norvir,Norvir Sec','','',''),('PA451261','rituximab','AntiCD20,Ig gamma-1 chain C region','MabThera,Rituxan','Drug/Small Molecule','DailyMed:b172773b-3905-4a1c-ad95-bab4b6126563,TTD:DAP000382,dpd:2241927,drugBank:DB00073,genBank:J00228,ndc:50242-053-06,uniProtKb:P01857,url:http://en.wikipedia.org/wiki/Rituximab',''),('PA451262','rivastigmine','Ena 713 Free Base,Rivastigmine Hydrogen Tartrate,rivastigmine','Exelon,Exelon Patch','Drug/Small Molecule','DailyMed:07c12e14-bbd5-4ec8-84e4-fbe7b5ba10e0,TTD:DAP000149,bindingDb:10620,chemSpider:70377,dpd:2242118,drugBank:DB00989,keggCompound:C11766,keggDrug:D03822,ndc:0078-0501-15,pubChemCompound:77991,pubChemSubstance:46507452,pubChemSubstance:655049,url:http://en.wikipedia.org/wiki/Rivastigmine','CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C'),('PA451264','rizatriptan','MK 462 Free Base,Risatriptan,Rizatriptan benzoat,Rizatriptan benzoate','Maxalt,Maxalt MLT,Maxalt-MLT','Drug/Small Molecule','DailyMed:d93286f5-99f7-4dc5-aa9d-ad73ab8490db,TTD:DAP000220,chebi:48273,chemSpider:4900,dpd:2240520,drugBank:DB00953,iupharLigand:51,keggDrug:D00675,ndc:0006-0266-12,pubChemCompound:5078,pubChemSubstance:46506557,url:http://en.wikipedia.org/wiki/Rizatriptan',''),('PA451268','rofecoxib','MK 966,MK 996,rofecoxib','Vioxx','Drug/Small Molecule','bindingDb:22369,chebi:8887,chemSpider:4911,dpd:2241109,drugBank:DB00533,keggCompound:C07590,keggDrug:D00568,pubChemCompound:5090,pubChemSubstance:207247,pubChemSubstance:46504787,url:http://en.wikipedia.org/wiki/Rofecoxib','CS(=O)(=O)c1ccc(cc1)C2=C(C(=O)OC2)c3ccccc3'),('PA451271','ropivacaine','Ropivacaina [INN-Spanish],Ropivacaina [Spanish],Ropivacaine [INN],Ropivacainum [INN-Latin],S-Ropivacaine','Naropin','Drug/Small Molecule','TTD:DAP001230,dpd:2229418,drugBank:DB00296,keggCompound:C07532,ndc:63323-288-27,pubChemCompound:71273,pubChemSubstance:213495,url:http://en.wikipedia.org/wiki/Ropivacaine',''),('PA451283','rosiglitazone','Rosigliazone maleate,Rosiglitazone maleate,rosiglitazone','Avandia,Rosiglizole','','',''),('PA451299','salicyclic acid','2-Carboxyphenol,2-Hydroxybenzenecarboxylic acid,2-Hydroxybenzoic acid,Acido salicilico,O-carboxyphenol,O-hydroxybenzoic acid,Orthohydroxybenzoic acid,','Advanced pain relief callus removers,Advanced pain','Drug/Small Molecule','HET:SAL,TTD:DAP000731,bindingDb:26193,chebi:16914,chemSpider:331,dpd:2241935,drugBank:DB00936,keggCompound:C00805,keggDrug:D00097,pdb:SAL,pubChemCompound:338,pubChemSubstance:4063,pubChemSubstance:46504942,url:http://en.wikipedia.org/wiki/Salicyclic_acid',''),('PA451300','salmeterol','Salmeterolum [Latin]','Aeromax,Arial,Astmerole,Fujimycin,Salmetedur,Serev','','',''),('PA451305','saquinavir','SQV,Saquinavir Mesylate,saquinavir','Fortovase,Invirase,ROC','Drug/Small Molecule','DailyMed:eca8bcbb-33e4-4ef9-9ba5-2d8c91e2daea,TTD:DAP000171,bindingDb:50114967,chemSpider:54783,dpd:2239083,drugBank:DB01232,keggDrug:D00429,ndc:0004-0246-48,pubChemCompound:60787,pubChemSubstance:197032,pubChemSubstance:46508726,url:http://en.wikipedia.org/wiki/Saquinavir',''),('PA451308','scopolamine','','Atrochin,Atroquin,Atroscine Hydrobromide,Beldavrin','Drug/Small Molecule','DailyMed:4d705c57-fa98-46e0-97f3-38e1b0ada76b,TTD:DNC000757,bindingDb:50015720,chebi:16794,dpd:2229868,drugBank:DB00747,iupharLigand:330,ndc:0067-4345-04,pubChemCompound:5184,pubChemSubstance:548858,url:http://en.wikipedia.org/wiki/Scopolamine','CN1C2CC(CC1C3C2O3)OC(=O)[C@H](CO)c4ccccc4'),('PA451316','selegiline','L-Deprenalin,Selegeline Hcl,Selegilina [INN-Spanish],Selegilinum [INN-Latin],selegiline','Apo-Selegiline,Carbex,Eldepryl,Emsam,Gen-Selegilin','Drug/Small Molecule','DailyMed:438207da-aff2-4e6e-8ef3-13b35295bea4,TTD:DAP000579,bindingDb:15579,chebi:50217,dpd:2238340,drugBank:DB01037,keggCompound:C07245,keggDrug:D03731,ndc:0378-9290-91,pubChemCompound:26757,pubChemSubstance:9454,url:http://en.wikipedia.org/wiki/Selegiline','C[C@H](CC1=CC=CC=C1)N(C)CC#C'),('PA451319','selenium','','','Drug Class','',''),('PA451330','l-serine','(-)-Serine,(S)-2-Amino-3-hydroxypropanoic acid,(S)-Serine,(S)-a-Amino-b-hydroxypropionic acid,2-Amino-3-hydroxypropionic acid,3-Hydroxyalanine,L-(-)-S','','Drug/Small Molecule','HET:SER,chebi:17115,chemSpider:5736,drugBank:DB00133,iupharLigand:726,keggCompound:C00065,keggDrug:D00016,pdb:SER,pubChemCompound:5951,pubChemSubstance:46506450,pubChemSubstance:8143701,url:http://en.wikipedia.org/wiki/Serine',''),('PA451333','sertraline','Sertralina [Spanish],Sertraline Hydrochloride,Sertralinum [Latin],Sultamicillin Tosylate','Apo-Sertraline,Lustral,Zoloft','Drug/Small Molecule','DailyMed:fe9e8b7d-61ea-409d-84aa-3ebd79a046b5,TTD:DAP000051,chebi:9123,chemSpider:61881,dpd:2245749,drugBank:DB01104,keggCompound:C07246,keggDrug:D02360,ndc:0049-4960-30,pubChemCompound:68617,pubChemSubstance:210738,pubChemSubstance:46505341,url:http://en.wikipedia.org/wiki/Sertraline','CN[C@H]1CC[C@H](c2c1cccc2)c3ccc(c(c3)Cl)Cl'),('PA451341','sevoflurane','Sevofluran,Sevoflurano [INN-Spanish],Sevofluranum [INN-Latin]','Sevorane,Ultane','Drug/Small Molecule','DailyMed:4c6e76bc-c964-4955-e0a3-511d3386a9cc,TTD:DAP000694,chebi:9130,chemSpider:5017,dpd:2172763,drugBank:DB01236,keggCompound:C07520,keggDrug:D00547,ndc:0074-4456-04,pubChemCompound:5206,pubChemSubstance:46508591,pubChemSubstance:9723,url:http://en.wikipedia.org/wiki/Sevoflurane','C(OC(C(F)(F)F)C(F)(F)F)F'),('PA451344','sibutramine','Sibutramina [Spanish],Sibutraminum [Latin],methylnaltrexone','Butramin,Medaria,Meridia,Reductil','Drug/Small Molecule','DailyMed:c0333e62-bb00-4722-27b6-dca6ab4d1eb1,TTD:DCL000881,chemSpider:5021,dpd:2243164,drugBank:DB01105,iupharLigand:2586,keggCompound:C07247,keggDrug:D08513,ndc:0074-2456-12,pubChemCompound:5210,pubChemSubstance:206707,pubChemSubstance:46507740,url:http://en.wikipedia.org/wiki/Sibutramine',''),('PA451346','sildenafil','Sildenafil Citrate','Revatio,Sildenafil Viagra,Viagra','Drug/Small Molecule','DailyMed:f158fe10-d5dc-4432-b2c9-fc665401291b,TTD:DAP000614,bindingDb:14390,chebi:9139,chemSpider:5023,dpd:2239766,drugBank:DB00203,keggCompound:C07259,keggDrug:D02229,ndc:0069-4190-68,pubChemCompound:5212,pubChemSubstance:205034,pubChemSubstance:46508371,url:http://en.wikipedia.org/wiki/Sildenafil','CCCc1c2c(c(=O)[nH]c(n2)c3cc(ccc3OCC)S(=O)(=O)N4CCN(CC4)C)n(n1)C'),('PA451355','silicone products','','','Drug Class','',''),('PA451357','silver nitrate','','','Drug/Small Molecule','','N(=O)(=O)[O-].[Ag+]'),('PA451363','simvastatin','Simvastatin [Usan:Ban:Inn],Simvastatina [Spanish],Simvastatine [French],Simvastatinum [Latin]','Cholestat,Coledis,Colemin,Corolin,Denan,Labistatin','','',''),('PA451365','sirolimus','(-)-rapamycin,Antibiotic AY 22989,rapamycin,sirolimus','Rapamune,Rapamycin','Drug/Small Molecule','HET:ARD,TTD:DNC001197,bindingDb:50240955,chebi:9168,dpd:2243237,drugBank:DB00877,keggCompound:C07909,keggDrug:D00753,pdb:ARD,pubChemCompound:6436030,pubChemSubstance:207443,url:http://en.wikipedia.org/wiki/Sirolimus',''),('PA451368','sodium','','','Drug Class','',''),('PA451369','sodium acetate','','','Drug/Small Molecule','','CC(=O)[O-].[Na+]'),('PA451374','sodium benzoate','','Ucephan','Drug/Small Molecule','','c1ccc(cc1)C(=O)[O-].[Na+]'),('PA451375','sodium bicarbonate','Bicarbonate of soda,Carbonic acid monosodium salt,Sodium acid carbonate,Sodium hydrocarbonate,Sodium hydrogen carbonate,Sodium hydrogencarbonate','800 Sodium Bicarbonate Powder,Acidosan,BSS plus,Ba','','',''),('PA451377','sodium bisulfite','','','Drug/Small Molecule','','OS(=O)[O-].[Na+]'),('PA451379','sodium carbonate','','Irrigating Solution G In Plastic Container,Urologi','Drug/Small Molecule','','C(=O)([O-])[O-].[Na+]'),('PA451382','sodium chloride','','','Drug/Small Molecule','','[Na+].[Cl-]'),('PA451384','sodium citrate','','','Drug/Small Molecule','','C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Na+]'),('PA451388','sodium fluoride','','','Drug/Small Molecule','','[F-].[Na+]'),('PA451398','sodium lauryl sulfate','Dodecyl alcohol, hydrogen sulfate, sodium salt,Dodecyl sodium sulfate,Dodecyl sulfate sodium,Dodecyl sulfate sodium salt,Dodecyl sulfate, sodium salt,','Adeka Hope LS 35,Adeka Hope LS 90,Akyposal NLS,Aky','','',''),('PA451406','nitroprusside','Disodium nitroprusside dihydrate,Sodium Nitroprusside,Sodium nitroferricyanide dihydrate,Sodium nitroprusside dihydrate,Sodium nitroprusside extra pur','Nipride,Nitropress','','',''),('PA451414','sodium phosphate','','','Drug/Small Molecule','','[O-]P(=O)([O-])[O-].[Na+]'),('PA451428','salicylate-sodium','','','Drug/Small Molecule','drugBank:DB01398,keggDrug:D00566,url:http://en.wikipedia.org/wiki/Sodium_salicylate','[Na+].OC1=CC=CC=C1C([O-])=O'),('PA451429','sodium selenite','','','Drug/Small Molecule','','[O-][Se](=O)[O-].[Na+]'),('PA451434','sodium succinate','','Sodium Succinate','Drug/Small Molecule','','C(CC(=O)[O-])C(=O)[O-].[Na+]'),('PA451435','sodium sulfate','','','Drug/Small Molecule','','[O-]S(=O)(=O)[O-].[Na+]'),('PA451446','somatropin recombinant','GH,GH-N,Growth hormone,Growth hormone 1,Pituitary growth hormone,Somatotropin precursor,Somatropin','BioTropin,Genotropin,Humatrope,Norditropin,Nutropi','Drug/Small Molecule','DailyMed:1058e17c-9261-459c-a3e6-fae38d196c14,TTD:DAP001054,dpd:2243079,drugBank:DB00052,genBank:AF374232,ndc:0169-7704-21,uniProtKb:P58756,url:http://en.wikipedia.org/wiki/Somatropin_recombinant',''),('PA451455','d-sorbitol','','','Drug/Small Molecule','DailyMed:5f7be402-f25a-428e-b81f-6a4a00de894c,chebi:17924,chemSpider:440,drugBank:DB01638,keggCompound:C00794,keggDrug:D00096,ndc:0264-2301-50,pdb:SOR,pubChemCompound:5780,pubChemSubstance:46507030,pubChemSubstance:7847164,url:http://en.wikipedia.org/wiki/Sorbitol',''),('PA451457','sotalol','Sotalol HCL','Betapace,Betapace AF,Sorine','Drug/Small Molecule','DailyMed:6ee6e904-a8e2-41d4-8261-67103ecfa605,TTD:DAP000372,bindingDb:25762,chemSpider:5063,dpd:2257858,drugBank:DB00489,keggCompound:C07309,ndc:0245-0012-11,pubChemCompound:5253,pubChemSubstance:46505012,pubChemSubstance:9517,url:http://en.wikipedia.org/wiki/Sotalol','CC(C)NCC(c1ccc(cc1)NS(=O)(=O)C)O'),('PA451465','protein supplements','','','Drug Class','',''),('PA451472','sparfloxacin','','Zagam','Drug/Small Molecule','TTD:DAP000161,chebi:9212,chemSpider:54517,drugBank:DB01208,keggCompound:C07662,keggDrug:D00590,pubChemCompound:60464,pubChemSubstance:46506453,pubChemSubstance:9864,url:http://en.wikipedia.org/wiki/Sparfloxacin','C[C@@H]1CN(C[C@@H](N1)C)c2c(c(c3c(c2F)n(cc(c3=O)C(=O)O)C4CC4)N)F'),('PA451483','spironolactone','','Abbolactone,Acelat,Aldace,Aldactazide,Aldactide,Al','','',''),('PA451492','starch','','','Drug/Small Molecule','',''),('PA451494','stavudine','2\',3\'-Didehydro-3\'-deoxythimidine,3\'-Deoxy-2\'-thymidinene,Estavudina [INN-Spanish],STV,Sanilvudine,Stavudine [Usan:Ban:Inn],Stavudinum [INN-Latin],sta','Zerit,Zerit XR,Zerut XR','Drug/Small Molecule','DailyMed:6d397a2a-06fc-467e-b014-c19e6384c8d9,TTD:DAP000172,bindingDb:50013111,chemSpider:17270,dpd:2216094,drugBank:DB00649,keggCompound:C07312,keggDrug:D00445,ndc:0179-0028-70,pubChemCompound:18283,pubChemSubstance:46506943,pubChemSubstance:9520,url:http://en.wikipedia.org/wiki/Stavudine',''),('PA451512','streptomycin','Streptomycin Sesquisulfate Hydrate,Streptomycin Sulfate,Streptomycin Sulphate,Streptomycin a Sulfate,Streptomycin, Sulfate Salt','Kantrex','','',''),('PA451514','streptozocin','','STREPTOZOTOCIN,STRZ,STZ,Streptozocin [Usan:Inn],St','Drug/Small Molecule','DailyMed:15d161ed-9e7b-4c92-ba45-0556d2423e67,TTD:DAP000984,chebi:9288,chemSpider:27273,dpd:622141,drugBank:DB00428,keggDrug:D05932,ndc:0703-4636-01,pubChemCompound:29327,pubChemSubstance:171661,pubChemSubstance:46508872,url:http://en.wikipedia.org/wiki/Streptozocin',''),('PA451521','succimer','DMSA,Dimercaptosuccinic acid','Chemet,MPI DMSA Kidney Reagent','Drug/Small Molecule','DailyMed:adb26da0-5494-4eab-975b-a1954a995ae8,bindingDb:50232640,chemSpider:8988,drugBank:DB00566,keggCompound:C07598,keggDrug:D00572,ndc:17156-525-01,pubChemCompound:9354,pubChemSubstance:46504680,pubChemSubstance:9800,url:http://en.wikipedia.org/wiki/Succimer',''),('PA451522','succinylcholine','Scoline,Succinylcholine Chloride,Suxamethonium chloride,succinyldicholine','Anectine,Quelicin,Quelicin Preservative Free,Sucos','Drug/Small Molecule','DailyMed:579ff759-3099-45f5-befe-c4b79106c87e,TTD:DAP001132,chebi:45652,chemSpider:5123,dpd:2062232,drugBank:DB00202,keggCompound:C07546,ndc:0781-3009-95,pubChemCompound:5314,pubChemSubstance:46506023,pubChemSubstance:9749,url:http://en.wikipedia.org/wiki/Succinylcholine','C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C'),('PA451524','sucralfate','sucralfate','Antepsin,Apo-sucralfate,Carafate,Sucramal,Sulcrate','Drug/Small Molecule','DailyMed:ec2db707-3cad-473d-8a04-05f23574b612,dpd:2239912,drugBank:DB00364,keggCompound:C07314,ndc:29033-003-01,pubChemCompound:6398525,pubChemSubstance:7980693,url:http://en.wikipedia.org/wiki/Sucralfate',''),('PA451525','sucrose','','','Drug/Small Molecule','chebi:17992,dpd:50121,drugBank:DB02772,keggCompound:C00089,keggDrug:D00025,pdb:SUC,pubChemCompound:46936484,pubChemCompound:5988,pubChemSubstance:3389,pubChemSubstance:46506134,url:http://en.wikipedia.org/wiki/Sucrose',''),('PA451527','sufentanil','Sufentanil Citrate,Sufentanilum [INN-Latin],Sufentanyl,Sulfentanil Citrate,sufentanil','Chronogesic,Sufenta','Drug/Small Molecule','DailyMed:39dc3695-dbf2-4783-b1bf-97237593f1c0,TTD:DAP000357,bindingDb:50012490,chebi:9316,chemSpider:38043,dpd:2244147,drugBank:DB00708,keggCompound:C08022,keggDrug:D05938,ndc:11098-050-01,pubChemCompound:41693,pubChemSubstance:10222,pubChemSubstance:46504737,url:http://en.wikipedia.org/wiki/Sufentanil','CCC(=O)N(c1ccccc1)C2(CCN(CC2)CCc3cccs3)COC'),('PA451529','sugar','','','Drug/Small Molecule','',''),('PA451536','sulfacetamide','','Acetocid,Acetosulfamin,Acetosulfamine,Ak-Sulf,Alba','','',''),('PA451539','sulfadiazine','SDA,Sulfadiazene,Sulfadiazin,Sulfanilamidopyrimidine,Sulfapirimidin,Sulfapyrimidin,Sulfapyrimidine,Sulphadiazine','Adiazin,Adiazine,Coco-Diazine,Cocodiazine,Codiazin','Drug/Small Molecule','DailyMed:10549cba-9c15-4d2e-a68c-5afbc178591d,TTD:DAP001238,chebi:9328,chemSpider:5026,drugBank:DB00359,keggCompound:C07658,keggDrug:D00587,ndc:0185-0757-10,pubChemCompound:5215,pubChemSubstance:46506164,pubChemSubstance:9860,url:http://en.wikipedia.org/wiki/Sulfadiazine','c1cnc(nc1)NS(=O)(=O)c2ccc(cc2)N'),('PA451540','sulfadoxine','','','Drug/Small Molecule','TTD:DAP000638,chebi:9329,chemSpider:16218,drugBank:DB01299,keggCompound:C07630,keggDrug:D00580,pubChemCompound:17134,pubChemSubstance:10462311,pubChemSubstance:46507915',''),('PA451542','sulfamethazine','','','Drug/Small Molecule','TTD:DAP001241,chebi:102265,chemSpider:5136,drugBank:DB01582,pubChemCompound:5327,pubChemSubstance:10452360,pubChemSubstance:46507146','Cc1cc(nc(n1)NS(=O)(=O)c2ccc(cc2)N)C'),('PA451544','sulfamethoxazole','','Apo-Sulfamethoxazole,Azo Gantanol,Azo-Gantanol,Bac','','',''),('PA451545','sulfanilamide','P-Aminobenzenesulfamide,P-Aminobenzenesulfonamide,P-Aminobenzenesulfonylamide,P-Aminobenzensulfonamide,P-Aminophenylsulfonamide,P-Anilinesulfonamide,P','AVC,Albexan,Albosal,Ambeside,Antistrept,Astreptine','','',''),('PA451547','sulfasalazine','Sulfasalazin,Sulphasalazine','Accucol,Alti-Sulfasalazine,Asulfidine,Azlufidine E','Drug/Small Molecule','DailyMed:b9ef541a-93c8-4428-ba45-398aa0b327d1,HET:SAS,TTD:DAP000153,chebi:9334,chemSpider:4510284,dpd:685933,drugBank:DB00795,keggCompound:C07316,keggDrug:D00448,ndc:0013-0102-01,pdb:SAS,pubChemCompound:5353980,pubChemCompound:5359476,pubChemSubstance:46505451,pubChemSubstance:9524,url:http://en.wikipedia.org/wiki/Sulfasalazine','c1ccnc(c1)NS(=O)(=O)c2ccc(cc2)N=Nc3ccc(c(c3)C(=O)O)O'),('PA451550','sulfinpyrazone','Diphenylpyrazone,Sulfinpyrazine,Sulfinpyrazon,Sulfoxyphenylpyrazolidine,Sulphinpyrazone,Usaf Ge-13','Anturan,Anturane,Anturanil,Anturano,Anturen,Anturi','Drug/Small Molecule','TTD:DAP000794,chebi:9342,chemSpider:5149,dpd:441759,drugBank:DB01138,keggCompound:C07317,keggDrug:D00449,ndc:0083-0041-30,pubChemCompound:5342,pubChemSubstance:46504918,pubChemSubstance:9525,url:http://en.wikipedia.org/wiki/Sulfinpyrazone','c1ccc(cc1)N2C(=O)C(C(=O)N2c3ccccc3)CCS(=O)c4ccccc4'),('PA451558','sulfur','','','Drug/Small Molecule','','[S]'),('PA451565','sulindac','','Clinoril','Drug/Small Molecule','TTD:DAP000569,chebi:9352,dpd:808636,drugBank:DB00605,keggCompound:C01531,keggDrug:D00120,ndc:0006-0941-68,pubChemCompound:5352,pubChemSubstance:4693,url:http://en.wikipedia.org/wiki/Sulindac','CC1=C(c2cc(ccc2C1=Cc3ccc(cc3)S(=O)C)F)CC(=O)O'),('PA451566','sumatriptan','NP101,Sumatriptan Succinate,Sumatriptanum [INN-Latin],estradiol,sumatriptan,triptan','Imigran,Imitrex,Imitrex Oral,Sumatran,Sumax','Drug/Small Molecule','DailyMed:cc11b09d-e6cc-4cf8-1495-5ac64d5aae5f,TTD:DNC001649,chebi:10650,chemSpider:5165,dpd:2239738,drugBank:DB00669,iupharLigand:119,iupharLigand:54,keggCompound:C07319,keggDrug:D00451,ndc:0173-0524-00,pubChemCompound:5358,pubChemSubstance:46506520,pubChemSubstance:7847517,url:http://en.wikipedia.org/wiki/Sumatriptan','CNS(=O)(=O)Cc1ccc2c(c1)c(c[nH]2)CCN(C)C'),('PA451569','suprofen','Suprofene [INN-French],Suprofenum [INN-Latin]','Maldocil,Masterfen,Profenal,Srendam,Sulproltin,Sup','Drug/Small Molecule','DailyMed:8de2c303-5d99-46b6-ad6d-a4caadea3604,TTD:DAP000730,bindingDb:50090676,chebi:9362,chemSpider:5166,drugBank:DB00870,keggCompound:C07320,keggDrug:D00452,ndc:0065-0348-25,pubChemCompound:5359,pubChemSubstance:179853,pubChemSubstance:46508210,url:http://en.wikipedia.org/wiki/Suprofen','CC(c1ccc(cc1)C(=O)c2cccs2)C(=O)O'),('PA451576','tacrine','THA,Tetrahydroaminacrine,Tetrahydroaminoacridine,Tetrahydroaminocrin,Tetrahydroaminocrine','Cognex,Romotal','Drug/Small Molecule','DailyMed:f31d1e8d-d0f3-4bfd-88b0-b2917365b0ca,HET:760,TTD:DAP000558,bindingDb:8961,chebi:9389,chemSpider:1859,drugBank:DB00382,keggCompound:C01453,ndc:59630-190-12,pdb:760,pubChemCompound:1935,pubChemSubstance:4630,pubChemSubstance:46505487,url:http://en.wikipedia.org/wiki/Tacrine','c1ccc2c(c1)c(c3c(n2)CCCC3)N'),('PA451578','tacrolimus','FK-506,FK5,FK506,K506,Tacarolimus,tacrolimus,tacrolimus hydrate','Fujimycin,LCP-Tacro,Prograf,Protopic','Drug/Small Molecule','DailyMed:7f667de1-9dfa-4bd6-8ba0-15ee2d78873b,HET:FK5,TTD:DAP000162,chebi:61049,dpd:2243144,drugBank:DB00864,keggCompound:C01375,ndc:0469-0607-73,pdb:FK5,pubChemCompound:439492,pubChemCompound:445647,pubChemSubstance:4572,pubChemSubstance:46506004,url:http://en.wikipedia.org/wiki/Tacrolimus',''),('PA451581','tamoxifen','Tamoxifen Citrate,Tamoxifene [INN-French],Tamoxifeno [INN-Spanish],Tamoxifenum [INN-Latin],Trans-Tamoxifen','Apo-Tamox,Citofen,Crisafeno,Diemon,Gen-Tamoxifen,I','Drug/Small Molecule','DailyMed:7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,HET:OHT,TTD:DAP000108,bindingDb:20607,chebi:9396,chemSpider:2015313,dpd:2237460,drugBank:DB00675,iupharLigand:1016,keggCompound:C07108,keggDrug:D00966,ndc:0378-0144-91,pdb:OHT,pubChemCompound:2733526,pubChemSubstance:46505515,pubChemSubstance:9319,url:http://en.wikipedia.org/wiki/Tamoxifen','CC/C(=C(c1ccccc1)/c2ccc(cc2)OCCN(C)C)/c3ccccc3'),('PA451583','tamsulosin','YM-617,tamsulosin','Flomax,Harnal,Omnic,Pradif,Tamsolusin,Tamsulosina ','Drug/Small Molecule','DailyMed:c00d5f7b-dad7-4479-aae2-fea7c0db40ed,TTD:DAP000086,chebi:9398,chemSpider:114457,dpd:2238123,drugBank:DB00706,iupharLigand:488,iupharLigand:504,keggCompound:C07124,ndc:0597-0058-01,pubChemCompound:129211,pubChemSubstance:46507763,pubChemSubstance:668003,url:http://en.wikipedia.org/wiki/Tamsulosin',''),('PA451585','tannic acid','','Depinar','Drug/Small Molecule','',''),('PA451590','taurine','','','Drug/Small Molecule','','C(CS(=O)(=O)O)N'),('PA451605','telmisartan','BIBR 277,BIBR 277SE,telmisartan','Micardis,Micardis HCT,Pritor','','',''),('PA451608','temazepam','Hydroxydiazepam,Methyloxazepam,N-Methyloxazepam,Oxydiazepam','Apo-Temazepam,Cerepax,Crisonar,Euhypnos,Euipnos,Ge','Drug/Small Molecule','DailyMed:3e4a35f8-77e5-4c9a-aad2-b0aeb98edd66,TTD:DAP000238,chemSpider:5198,dpd:2244815,drugBank:DB00231,keggDrug:D00370,ndc:53489-648-07,pubChemCompound:5391,pubChemSubstance:156664,pubChemSubstance:46506604,url:http://en.wikipedia.org/wiki/Temazepam',''),('PA451609','temozolomide','Methazolastone,Temozolamide,Temozolodida [Spanish],Temozolomidum [Latin],temozolomide','Temodal,Temodar','Drug/Small Molecule','DailyMed:046a9011-3911-4d3f-a15f-fbb56d5aad56,TTD:DAP000987,bindingDb:50034562,chemSpider:5201,dpd:2241094,drugBank:DB00853,ndc:0085-3004-02,pubChemCompound:5394,pubChemSubstance:46507934,pubChemSubstance:655054,url:http://en.wikipedia.org/wiki/Temozolomide',''),('PA451611','teniposide','Teniposido [INN-Spanish],Teniposidum [INN-Latin]','Vee M-26,Veham-Sandoz,Vehem,Vumon','Drug/Small Molecule','DailyMed:3231dc15-5ce2-cf61-7d1f-bd86704269ae,TTD:DAP000651,chemSpider:31930,dpd:588989,drugBank:DB00444,keggCompound:C11153,keggDrug:D02698,ndc:0015-3075-19,pubChemCompound:34698,pubChemSubstance:176397,pubChemSubstance:46507536,url:http://en.wikipedia.org/wiki/Teniposide',''),('PA451612','terazosin','Abbott 45975,Terazosin HCl,Terazosin hydrochloride,Terazosina [INN-Spanish],Terazosine,Terazosine [INN-French],Terazosinum [INN-Latin],Trazosin HCl','Blavin,Flumarc,Fosfomic,Heitrin,Hytracin,Hytrin,Hy','Drug/Small Molecule','DailyMed:24ce46de-cf8f-401f-8bb6-490b296513c5,TTD:DAP000371,chebi:9445,chemSpider:5208,dpd:2243749,drugBank:DB01162,keggCompound:C07127,ndc:0904-6126-61,pubChemCompound:5401,pubChemSubstance:46509129,pubChemSubstance:9337,url:http://en.wikipedia.org/wiki/Terazosin','COc1cc2c(cc1OC)nc(nc2N)N3CCN(CC3)C(=O)C4CCCO4'),('PA451614','terbinafine','Terbinafine HCl,Terbinafine hydrochloride,Ternbinafine HCl,terbinafine','Bramazil,Lamasil,Lamisil,Lamisil AT,Lamisil Oral,T','Drug/Small Molecule','DailyMed:8b6dab4d-5b80-4690-8d96-3438d69c7d1d,TTD:DAP000753,chemSpider:5209,dpd:2240346,drugBank:DB00857,keggCompound:C08079,keggDrug:D02375,ndc:0378-5710-93,pubChemCompound:1549008,pubChemCompound:5402,pubChemSubstance:46508519,pubChemSubstance:7849434,url:http://en.wikipedia.org/wiki/Terbinafine','CC(C)(C)C#C/C=C/CN(C)Cc1cccc2c1cccc2'),('PA451616','terbutaline','Terbutalin,Terbutalina [Dcit],Terbutaline Sulfate,Terbutalino [INN-Spanish],Terbutalinum [INN-Latin]','Brethaire,Brethine,Brican,Bricanyl,Bricar,Bricaril','Drug/Small Molecule','DailyMed:613df3cb-4d55-4d12-ab08-a932481aaa0b,TTD:DAP000246,bindingDb:25770,chemSpider:5210,dpd:786616,drugBank:DB00871,iupharLigand:560,keggCompound:C07129,ndc:0143-9746-10,pubChemCompound:5403,pubChemSubstance:46506887,pubChemSubstance:9339,url:http://en.wikipedia.org/wiki/Terbutaline','CC(C)(C)NCC(c1cc(cc(c1)O)O)O'),('PA451619','terfenadine','Ternadin','Aldaban,Allerplus,Cyater,Seldane,Teldane,Teldanex,','Drug/Small Molecule','TTD:DAP000102,bindingDb:50017376,chemSpider:5212,dpd:1913395,drugBank:DB00342,iupharLigand:2608,keggCompound:C07463,keggDrug:D00521,pubChemCompound:5405,pubChemSubstance:180732,pubChemSubstance:46507007,url:http://en.wikipedia.org/wiki/Terfenadine','CC(C)(C)c1ccc(cc1)C(CCCN2CCC(CC2)C(c3ccccc3)(c4ccccc4)O)O'),('PA451620','teriparatide','PTH1-34 nasal spray,ViaDerm hPTH 1-34,ViaDerm-hPTH (1-34),hPTH 1-34,synthetic human parathyroid hormone 1-34','Apthela,Forsteo,Forteo,Fortessa,Opthia,Optia,Optia','Drug/Small Molecule','DailyMed:aae667c5-381f-4f92-93df-2ed6158d07b0,TTD:DAP000396,drugBank:DB06285,keggDrug:D06078,ndc:0002-8400-01,pubChemCompound:16133850,url:http://en.wikipedia.org/wiki/Teriparatide','[H]/N=C(N)/NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN/C(=N/[H])/N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC3=CNC=N3)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N'),('PA451627','testosterone','Dea No. 4000,TES,Testosteron,Testosterona [INN-Spanish],Testosterone Cypionate,Testosterone Enanthate,Testosterone Hydrate,Testosteronum [INN-Latin],T','Andriol,Andro,Andro 100,Andro L.A. 200,Androderm,A','','',''),('PA451632','tetanus antitoxin','','','Drug/Small Molecule','',''),('PA451634','tetanus vaccines','','','Drug Class','',''),('PA451636','tetanus toxoid','','','Drug/Small Molecule','',''),('PA451638','tetracaine','','','Drug/Small Molecule','','CCCCNc1ccc(cc1)C(=O)OCCN(C)C'),('PA451640','tetracycline','Anhydrotetracycline,TC,Tetracycline HCl','Abramycin,Abricycline,Achromycin,Achromycin V,Acti','','',''),('PA451644','thalidomide','N-Phthalimidoglutamic acid imide,N-Phthaloylglutamimide,N-Phthalylglutamic acid imide,Thalidomine USP26,alpha-phthalimidoglutarimide,thalidomide','Algosediv,Asidon 3,Asmadion,Asmaval,Bonbrain,Bonbr','Drug/Small Molecule','DailyMed:2eda833b-1357-4ed4-a093-194524fcb061,TTD:DAP000865,bindingDb:50070114,chemSpider:5233,drugBank:DB01041,keggCompound:C07910,keggDrug:D00754,ndc:59572-205-14,pubChemCompound:5426,pubChemSubstance:10112,pubChemSubstance:46505665,url:http://en.wikipedia.org/wiki/Thalidomide','c1ccc2c(c1)C(=O)N(C2=O)C3CCC(=O)NC3=O'),('PA451646','theobromine','','','Drug/Small Molecule','chebi:28946,chemSpider:5236,dpd:2236220,drugBank:DB01412,keggCompound:C07480,pubChemCompound:5429,pubChemSubstance:10321963,pubChemSubstance:46508574,url:http://en.wikipedia.org/wiki/Theobromine','Cn1cnc2c1c(=O)[nH]c(=O)n2C'),('PA451647','theophylline','Dimethylxanthine,Pseudotheophylline,Theophyline,Theophyllin,Theophylline Anhydrous,Theophylline aminoacetate','Accurbron,Acet-Theocin,Aerobin,Aerolate,Aerolate I','','',''),('PA451652','thiamine','Thiadoxine,Thiamin,Thiamine Hcl,Vitamin B1,thiamine(1+)','Aneurin,Antiberiberi Factor,Betalin S,Betaxin,Bewo','','',''),('PA451663','thioguanine','2-Amino 6MP,2-Amino-6-mercaptopurine,2-Amino-6-merkaptopurin,2-Amino-6-purinethiol,2-Aminopurin-6-thiol,2-Aminopurine-6(1H)-thione,2-Aminopurine-6-thi','Lanvis,Tabloid,Wellcome U3B','Drug/Small Molecule','DailyMed:dfda4177-3c9d-44ab-3ca6-e4db8e9fc603,TTD:DAP000194,bindingDb:50200099,chemSpider:2005804,dpd:282081,drugBank:DB00352,keggCompound:C07648,ndc:0173-0880-25,pubChemCompound:2723601,pubChemSubstance:152248,pubChemSubstance:46508170,url:http://en.wikipedia.org/wiki/Thioguanine','c1[nH]c2c(=S)[nH]c(nc2n1)N'),('PA451664','thiopental','Penthiobarbital,Pentothal,Pentothiobarbital,Thiomebumal,Thionembutal,Thiopentobarbital,Thiopentobarbitone,Thiopentobarbituric acid,Thiopentone,Tiopent','Farmotal,Intraval,Nesdonal,Thiothal,Trapanal','','',''),('PA451666','thioridazine','Thioridazin,Thioridazine Chloride,Thioridazine Hcl,Thioridazine Hydrochloride,Thoridazine Hydrochloride','Aldazine,Mallorol,Malloryl,Meleril,Mellaril,Mellar','Drug/Small Molecule','DailyMed:56b3f4c2-52af-4947-b225-6808ae9f26f5,TTD:DAP000476,chebi:9566,chemSpider:5253,dpd:360244,drugBank:DB00679,iupharLigand:100,keggDrug:D00373,ndc:0378-0612-01,pubChemCompound:5452,pubChemSubstance:148555,pubChemSubstance:46509070,url:http://en.wikipedia.org/wiki/Thioridazine','CN1CCCCC1CCN2c3ccccc3Sc4c2cc(cc4)SC'),('PA451668','thiotepa','','','Drug/Small Molecule','DailyMed:b4e6b9e3-1c09-410e-a4bf-1e844887a201,drugBank:DB04572,keggCompound:C07641,keggDrug:D00583,ndc:55390-030-10,url:http://en.wikipedia.org/wiki/Thiotepa','S=P(N1CC1)(N1CC1)N1CC1'),('PA451669','thiothixene','(e)-thiothixene,Cis-thiothixene,Thiothixine,Tiotixene,Tiotixeno [inn-spanish],Tiotixenum [inn-latin]','Navan,Navane,Navaron,Orbinamon','Drug/Small Molecule','DailyMed:3fe9b451-da9d-4790-947e-15a535b369a5,TTD:DAP000318,chemSpider:819430,dpd:24430,drugBank:DB01623,iupharLigand:212,ndc:0049-5710-66,pubChemCompound:941651,pubChemSubstance:10391422,pubChemSubstance:46505564,url:http://en.wikipedia.org/wiki/Thiothixene',''),('PA451673','l-threonine','(S)-Threonine,2-Amino-3-hydroxybutyric acid,L-(-)-Threonine,Threonin,Threonine,[R-(R*,S*)]-2-Amino-3-hydroxybutanoic acid','','Drug/Small Molecule','HET:THR,chebi:16857,chemSpider:6051,drugBank:DB00156,keggCompound:C00188,keggDrug:D00041,pdb:THR,pubChemCompound:6288,pubChemSubstance:3488,pubChemSubstance:46506798,url:http://en.wikipedia.org/wiki/L-Threonine',''),('PA451674','thrombin','','','Drug/Small Molecule','',''),('PA451680','thyroid preparations','','','Drug Class','',''),('PA451682','tiagabine','Tiagabina [INN-Spanish],Tiagabinum [INN-Latin]','Gabitril','Drug/Small Molecule','DailyMed:cf97a72e-951e-a7db-a574-adac12a6b189,TTD:DAP000164,bindingDb:50039251,chemSpider:54661,drugBank:DB00906,keggCompound:C07503,ndc:63459-402-30,pubChemCompound:60648,pubChemSubstance:196924,pubChemSubstance:46505560,url:http://en.wikipedia.org/wiki/Tiagabine',''),('PA451684','ticarcillin','Ticarcilina [inn-spanish],Ticarcillin supplement,Ticarcilline [inn-french],Ticarcillinum [inn-latin]','','','',''),('PA451686','ticlopidine','Ticlopidine HCL,Ticlopidine Hydrochloride','Ticlid','Drug/Small Molecule','DailyMed:828c40f4-5969-4254-9008-36af15cc601b,TTD:DAP000723,chebi:9588,chemSpider:5273,dpd:2239744,drugBank:DB00208,keggCompound:C07140,ndc:0004-0018-23,pubChemCompound:5472,pubChemSubstance:46504438,pubChemSubstance:9349,url:http://en.wikipedia.org/wiki/Ticlopidine','c1ccc(c(c1)CN2CCc3c(ccs3)C2)Cl'),('PA451688','tiludronate','Acide tiludronique [INN-French],Acido tiludronico [INN-Spanish],Acidum tiludronicum [INN-Latin],Tiludronate disodium,Tiludronic Acid Disodium Salt,Til','Skelid','Drug/Small Molecule','DailyMed:25369752-9d6c-4802-823c-c4205339a525,chebi:15847,chemSpider:54905,drugBank:DB01133,keggCompound:C08141,ndc:0024-1800-16,pubChemCompound:60937,pubChemSubstance:10341,pubChemSubstance:46505302,url:http://en.wikipedia.org/wiki/Tiludronate',''),('PA451690','timolol','Timolol maleate,Timololum [INN-Latin]','Apo-Timol,Apo-Timop,Aquanil,Betim,Betimol,Blocadre','','',''),('PA451694','tinzaparin','','Innohep','Drug/Small Molecule','',''),('PA451698','tirofiban','','AGG,Aggrastat,Tirofiban [BAN:INN]','Drug/Small Molecule','HET:AGG,TTD:DAP000696,chebi:9605,chemSpider:54912,dpd:2240706,drugBank:DB00775,keggCompound:C07965,ndc:25208-001-01,pdb:AGG,pubChemCompound:60947,pubChemSubstance:46504678,pubChemSubstance:654151,url:http://en.wikipedia.org/wiki/Tirofiban',''),('PA451701','tizanidine','Tizanidina [INN-Spanish],Tizanidine Hcl,Tizanidinum [INN-Latin]','Sirdalud,Ternelin,Zanaflex','Drug/Small Molecule','DailyMed:b4227d39-6f9e-5ded-4169-087ce91a75b5,TTD:DAP000234,bindingDb:50240671,chemSpider:5287,dpd:2259893,drugBank:DB00697,keggCompound:C07452,ndc:0378-0722-01,pubChemCompound:5487,pubChemSubstance:180932,pubChemSubstance:46505373,url:http://en.wikipedia.org/wiki/Tizanidine','c1cc(c(c2c1nsn2)NC3=NCCN3)Cl'),('PA451704','tobramycin','3\'-Deoxykanamycin B,SPRC-AB01,Tobramycin Sulfate,tobramycin solution for inhalation','Aktob,Distobram,Gernebcin,NF 6,Nebcin,Nebramycin,N','Drug/Small Molecule','DailyMed:4b8716c4-0ffd-49aa-9006-a3bf5b6d19a6,HET:TOY,TTD:DAP000110,bindingDb:50090265,chebi:28864,chemSpider:33377,dpd:2241209,drugBank:DB00684,keggCompound:C00397,keggDrug:D00063,ndc:0065-0643-05,pdb:TOY,pubChemCompound:36294,pubChemCompound:5496,pubChemSubstance:447098,pubChemSubstance:46507662,url:http://en.wikipedia.org/wiki/Tobramycin',''),('PA451706','tocainide','Tocainida [INN-Spanish],Tocainidum [INN-Latin]','Tonocard','Drug/Small Molecule','TTD:DAP000517,bindingDb:50092595,chebi:9611,chemSpider:35632,dpd:598941,drugBank:DB01056,keggCompound:C07142,keggDrug:D06172,pubChemCompound:38945,pubChemSubstance:46505385,pubChemSubstance:9351,url:http://en.wikipedia.org/wiki/Tocainide','Cc1cccc(c1NC(=O)C(C)N)C'),('PA451716','tolazoline','','Artonil,Benzazoline,Benzidazol,Benzolin,Benzylimid','Drug/Small Molecule','TTD:DAP000477,chebi:28502,chemSpider:5303,dpd:2195887,drugBank:DB00797,keggCompound:C07147,ndc:0083-6733-04,pubChemCompound:5504,pubChemSubstance:46505641,pubChemSubstance:9356,url:http://en.wikipedia.org/wiki/Tolazoline','c1ccc(cc1)CC2=NCCN2'),('PA451718','tolbutamide','','Aglicid,Apo-Tolbutamide,Arkozal,Artosin,Artozin,Bu','Drug/Small Molecule','DailyMed:3995eed8-39ec-ce5e-8cc2-062f93445c8d,TTD:DAP000136,chebi:27999,chemSpider:5304,dpd:156663,drugBank:DB01124,iupharLigand:2415,keggCompound:C07148,keggDrug:D00380,ndc:0378-0215-01,pubChemCompound:5505,pubChemSubstance:149066,pubChemSubstance:46508421,url:http://en.wikipedia.org/wiki/Tolbutamide','CCCCNC(=O)NS(=O)(=O)c1ccc(cc1)C'),('PA451720','tolcapone','','Tasmar','Drug/Small Molecule','DailyMed:a0e47a9d-78e7-4523-983a-aa259f221736,TTD:DAP000607,bindingDb:50108877,chemSpider:3848682,dpd:2235914,drugBank:DB00323,keggCompound:C07949,keggDrug:D00786,ndc:0187-0938-01,pubChemCompound:4659569,pubChemSubstance:10150,pubChemSubstance:46504932,url:http://en.wikipedia.org/wiki/Tolcapone','Cc1ccc(cc1)C(=O)c2cc(c(c(c2)O)O)N(=O)=O'),('PA451721','tolmetin','Tolmetin Sodium,Tolmetina [DCIT],Tolmetine [INN-French],Tolmetino [INN-Spanish],Tolmetinum [INN-Latin]','Tolectin,Tolectin DS','Drug/Small Molecule','DailyMed:74e4d717-80c2-4d7d-a713-7c2b9e2b6b64,TTD:DAP000777,chemSpider:5308,dpd:632740,drugBank:DB00500,keggCompound:C02328,ndc:0093-8815-01,pubChemCompound:5509,pubChemSubstance:46507060,pubChemSubstance:7849414,url:http://en.wikipedia.org/wiki/Tolmetin','Cc1ccc(cc1)C(=O)c2ccc(n2C)CC(=O)O'),('PA451728','topiramate','Tipiramate [French],Tipiramato [Spanish],Topiramato [INN-Spanish],Topiramatum [INN-Latin],Topiramic acid,topiramate tablet','Topamax,Topamax Sprinkle','Drug/Small Molecule','DailyMed:61f36cba-e314-4ec9-8c84-5259153049b5,TTD:DAP000137,bindingDb:10887,chemSpider:4447672,dpd:2239908,drugBank:DB00273,keggCompound:C07502,keggDrug:D00537,ndc:0904-6016-04,pubChemCompound:5284627,pubChemSubstance:194321,pubChemSubstance:46508334,url:http://en.wikipedia.org/wiki/Topiramate',''),('PA451729','topotecan','TPT,TTC,Topotecan Hcl,Topotecan Hydrochloride,Topotecan Lactone,Topotecane [INN-French],Topotecanum [INN-Latin],topotecan','Hycamptamine,Hycamptin,Hycamtin','Drug/Small Molecule','DailyMed:3c15da96-d309-4b93-f5aa-cfb52c25c174,HET:TTC,TTD:DAP000648,chemSpider:54705,dpd:2231116,drugBank:DB01030,keggCompound:C11158,ndc:0007-4201-01,pdb:TTC,pubChemCompound:60700,pubChemSubstance:46505204,pubChemSubstance:606579,url:http://en.wikipedia.org/wiki/Topotecan','CC[C@@]1(c2cc-3n(c(=O)c2COC1=O)Cc4c3nc5ccc(c(c5c4)CN(C)C)O)O'),('PA451731','toremifene','toremifene','Acapodene,Fareston,Farestone,Toremifene Base,Torem','Drug/Small Molecule','DailyMed:a6ff9761-7442-4bff-9e50-858c03e27fd0,TTD:DAP000793,chebi:9635,chemSpider:2275722,drugBank:DB00539,keggCompound:C08166,ndc:11399-005-30,pubChemCompound:3005573,pubChemSubstance:193362,pubChemSubstance:46506087,url:http://en.wikipedia.org/wiki/Toremifene',''),('PA451733','torasemide','Torasemida [INN-Spanish],Torasemidum [INN-Latin],Torsemide','Demadex,Luprac','Drug/Small Molecule','TTD:DAP000745,chemSpider:38123,dpd:2129094,drugBank:DB00214,keggDrug:D00382,ndc:0093-7127-01,pubChemCompound:41781,pubChemSubstance:182449,pubChemSubstance:46504760,url:http://en.wikipedia.org/wiki/Torasemide',''),('PA451735','tramadol','Tramadol HCl,Tramadol hydrochloride,Tramadolum [INN-Latin],Tramodol Hcl,tramadol','Crispin,Ralivia ER,Ralivia Flashtab,Tramadol HCl B','Drug/Small Molecule','DailyMed:c0938808-fe14-4b8d-98c4-d04dcc5c9642,TTD:DAP000140,bindingDb:50176262,chemSpider:31105,drugBank:DB00193,keggCompound:C07153,ndc:0045-0659-60,pubChemCompound:33741,pubChemSubstance:175579,pubChemSubstance:46506256,url:http://en.wikipedia.org/wiki/Tramadol','CN(C)C[C@H]1CCCC[C@@]1(c2cccc(c2)OC)O'),('PA451737','trandolapril','','Mavik,Tarka,Trandolaprilum [Latin]','','',''),('PA451741','tranylcypromine','','Dl-Tranylcypromine,Parnate,Transamine','Drug/Small Molecule','HET:1LP,TTD:DAP000081,chemSpider:390008,dpd:1919598,drugBank:DB00752,keggCompound:C07155,pdb:1LP,pubChemCompound:441233,pubChemSubstance:46505832,pubChemSubstance:9364,url:http://en.wikipedia.org/wiki/Tranylcypromine',''),('PA451743','trastuzumab','Anti HER2,Ig gamma-1 chain C region','Herceptin','Drug/Small Molecule','DailyMed:492dbdb2-077e-4064-bff3-372d6af0a7a2,TTD:DAP000391,dpd:2240692,drugBank:DB00072,genBank:J00228,ndc:50242-134-68,pubChemSubstance:736684,uniProtKb:P01857,url:http://en.wikipedia.org/wiki/Trastuzumab',''),('PA451744','trazodone','Trazodona [INN-Spanish],Trazodone Hcl,Trazodone Hydrochloride,Trazodonum [INN-Latin],trazodone','Beneficat,Bimaran,Desirel,Desyrel,Desyrel Dividose','Drug/Small Molecule','TTD:DAP000104,chebi:9654,chemSpider:5332,dpd:2249804,drugBank:DB00656,iupharLigand:213,keggCompound:C07156,ndc:0087-0778-43,pubChemCompound:5533,pubChemSubstance:172043,pubChemSubstance:46506648,url:http://en.wikipedia.org/wiki/Trazodone','c1ccn2c(c1)nn(c2=O)CCCN3CCN(CC3)c4cccc(c4)Cl'),('PA451746','tretinoin','ATRA,All Trans Retinoic Acid,All Trans-Retinoic Acid,Retionic Acid,beta-Retinoic Acid,tretinoin','Aberel,Accutane,Airol,Aknefug,Aknoten,Amnesteem,At','Drug/Small Molecule','DailyMed:e334034e-36d5-4e2d-b2ec-d1410b3374c3,TTD:DNC000117,chebi:15367,chemSpider:5337,dpd:2243914,drugBank:DB00755,keggCompound:C00777,keggDrug:D00094,ndc:0062-0187-02,pubChemCompound:444795,pubChemCompound:5538,pubChemSubstance:46504843,pubChemSubstance:7847162,url:http://en.wikipedia.org/wiki/Tretinoin',''),('PA451749','triamcinolone','Fluoxiprednisolone,Fluoxyprednisolone,Tiamcinolonum [INN-Latin],Triamcinalone,Triamcinolona [INN-Spanish],Triamcinolone acetonide,Triamcinolone diacet','Adcortyl,Aristocort,Aristocort A,Aristocort Tablet','','',''),('PA451752','triamterene','Triamteren','Ademin,Ademine,Diren,Ditak,Diucelpin,Diurene,Dyazi','','',''),('PA451753','triazolam','DEA No. 2887,Triazolamum [INN-Latin]','Alti-Triazolam,Apo-Triazo,Clorazolam,Gen-Triazolam','Drug/Small Molecule','DailyMed:db564864-17fc-4ba5-a438-a467ef57a0ca,TTD:DAP000244,chebi:9674,chemSpider:5355,dpd:2230024,drugBank:DB00897,keggDrug:D00387,ndc:0054-4858-51,pubChemCompound:5556,pubChemSubstance:46509147,pubChemSubstance:7847453,url:http://en.wikipedia.org/wiki/Triazolam','Cc1nnc2n1-c3ccc(cc3C(=NC2)c4ccccc4Cl)Cl'),('PA451755','trichloroacetic acid','','','Drug/Small Molecule','','C(=O)(C(Cl)(Cl)Cl)O'),('PA451771','trifluoperazine','','Apo-Trifluoperazine,Eskazine,Eskazinyl,Fluoperazin','','',''),('PA451773','triflupromazine','','Adazine,Fluopromazine,Psyquil,Siquil,Trifluopromaz','Drug/Small Molecule','TTD:DAP000294,chebi:9711,chemSpider:5367,drugBank:DB00508,keggDrug:D00390,pubChemCompound:5568,pubChemSubstance:46507344,pubChemSubstance:7847456,url:http://en.wikipedia.org/wiki/Triflupromazine','CN(C)CCCN1c2ccccc2Sc3c1cc(cc3)C(F)(F)F'),('PA451775','trifluridine','','F3DThd,F3T,F3TDR,Fluridine,TFDU,TFT,Trifluoromethy','Drug/Small Molecule','DailyMed:f3a14d86-0ff2-4535-318c-ac8bc8ede42c,TTD:DAP000760,bindingDb:50132298,chemSpider:6020,dpd:2248529,drugBank:DB00432,keggDrug:D00391,ndc:61570-037-75,pubChemCompound:6256,pubChemSubstance:46506192,pubChemSubstance:7847457,url:http://en.wikipedia.org/wiki/Trifluridine',''),('PA451776','triglycerides','','','Drug/Small Molecule','',''),('PA451784','trimethaphan','Thimethaphan,Trimetaphan,Trimetaphanum','Arfonad','Drug/Small Molecule','TTD:DAP001143,chebi:9728,chemSpider:22044,drugBank:DB01116,keggCompound:C07174,pubChemCompound:23576,pubChemSubstance:166148,pubChemSubstance:46508994,url:http://en.wikipedia.org/wiki/Trimethaphan',''),('PA451788','trimethoprim','','Abacin,Abaprim,Alprim,Apo-Sulfatrim,Bactin,Bactram','Drug/Small Molecule','TTD:DAP000927,bindingDb:18069,chebi:9731,chemSpider:5376,dpd:2243116,drugBank:DB00440,keggCompound:C01965,keggDrug:D00145,ndc:61570-057-01,pubChemCompound:5578,pubChemSubstance:156267,pubChemSubstance:46507125,url:http://en.wikipedia.org/wiki/Trimethoprim','COc1cc(cc(c1OC)OC)Cc2cnc(nc2N)N'),('PA451790','trimetrexate','TMQ,TMX,Trimetrexato [INN-Spanish],Trimetrexatum [INN-Latin]','Neutrexin','Drug/Small Molecule','DailyMed:ad0f8925-f817-4460-aa6b-172a043a440b,HET:TMQ,TTD:DAP000635,bindingDb:18268,chemSpider:5381,dpd:2065770,drugBank:DB01157,keggCompound:C11154,keggDrug:D06238,ndc:58178-020-10,pdb:TMQ,pubChemCompound:5583,pubChemSubstance:181153,pubChemSubstance:46505247,url:http://en.wikipedia.org/wiki/Trimetrexate','Cc1c(ccc2c1c(nc(n2)N)N)CNc3cc(c(c(c3)OC)OC)OC'),('PA451791','trimipramine','Trimeprimina [Italian],Trimeprimine,Trimipramina [INN-Spanish],Trimipraminum [INN-Latin],beta-Methylimipramine','Sapilent,Surmontil,Surmontyl,Temaril','Drug/Small Molecule','TTD:DAP001153,chebi:9738,chemSpider:5382,dpd:761737,drugBank:DB00726,keggDrug:D00394,pubChemCompound:5584,pubChemSubstance:156272,pubChemSubstance:46507121,url:http://en.wikipedia.org/wiki/Trimipramine','CC(CN1c2ccccc2CCc3c1cccc3)CN(C)C'),('PA451797','triprolidine','','Actidil,Myidyl,Triprolidine HCL,Triprolidine Hydro','','',''),('PA451799','troglitazone','','Noscal,Prelay,Resulin,Rezulin,Romglizone,Romozin','Drug/Small Molecule','chebi:9753,chemSpider:5389,drugBank:DB00197,keggDrug:D00395,pubChemCompound:5591,pubChemSubstance:194350,pubChemSubstance:46504655,url:http://en.wikipedia.org/wiki/Troglitazone','Cc1c(c2c(c(c1O)C)CCC(O2)(C)COc3ccc(cc3)CC4C(=O)NC(=O)S4)C'),('PA451802','trometamol','','','Drug/Small Molecule','',''),('PA451806','trypsin','','','Drug/Small Molecule','',''),('PA451811','tubocurarine','D-Tubocurarine,D-Tubocurarine Chloride,Isoquinoline Alkaloid,Tubocurarin,Tubocurarine Chloride,Tubocurarinum','Curare,Delacurarine,Jexin,Tubarine','Drug/Small Molecule','TTD:DAP000351,chebi:9774,chemSpider:5778,dpd:640786,drugBank:DB01199,pubChemCompound:6000,pubChemSubstance:148848,pubChemSubstance:46505279,url:http://en.wikipedia.org/wiki/Tubocurarine','CN1CCc2cc(c3cc2[C@@H]1Cc4ccc(cc4)Oc5c6c(cc(c5O)OC)CC[N+]([C@@H]6Cc7ccc(c(c7)O3)O)(C)C)OC'),('PA451822','l-tyrosine','2-Amino-3-(p-hydroxyphenyl)propionic acid,3-(p-Hydroxyphenyl)alanine,Free-Form L-Tyrosine','Rxosine,Tyrosine,Tyrosine Power','Drug/Small Molecule','HET:TYR,TTD:DAP000808,chebi:17895,chebi:18186,chemSpider:5833,drugBank:DB00135,keggCompound:C01536,pdb:TYR,pubChemCompound:6057,pubChemSubstance:46507885,pubChemSubstance:8144790,url:http://en.wikipedia.org/wiki/L-Tyrosine',''),('PA451830','uracil mustard','','Aminouracil Mustard,Chlorethaminacil,Demethyldopan','Drug/Small Molecule','TTD:DAP000990,chemSpider:5959,drugBank:DB00791,keggCompound:C11686,keggDrug:D06265,pubChemCompound:6194,pubChemSubstance:13851,pubChemSubstance:46506168,url:http://en.wikipedia.org/wiki/Uracil_mustard','c1c(c(=O)[nH]c(=O)[nH]1)N(CCCl)CCCl'),('PA451831','urea','','','Drug/Small Molecule','bindingDb:24961,chebi:16199,drugBank:DB03904,keggCompound:C00086,keggDrug:D00023,pdb:URE,pubChemCompound:1176,pubChemSubstance:3386,pubChemSubstance:46508687','C(=O)(N)N'),('PA451835','urofollitropin','FSH-B,FSH-beta,Follicle-stimulating hormone beta subunit,Follitropin beta chain precursor','Fertinex','Drug/Small Molecule','DailyMed:46f7740f-c879-4a77-9a16-2821fd772641,DailyMed:9bb87daf-d156-504e-adaf-4c21383f8d16,TTD:DAP001029,dpd:2268140,drugBank:DB00094,genBank:M16647,iupharLigand:1157,ndc:55566-8505-2,pubChemCompound:62819,pubChemSubstance:204910,uniProtKb:P01225,url:http://en.wikipedia.org/wiki/Urofollitropin','CC[C@H](C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@@H]3C(=O)N[C@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O'),('PA451836','urokinase','U-plasminogen activator,Urokinase-type plasminogen activator precursor,uPA,urokinase','Abbokinase,Kinlytic','Drug/Small Molecule','DailyMed:bfe5cfb9-591d-4df8-12a3-6555cde3185d,TTD:DAP001194,dpd:749702,drugBank:DB00013,genBank:X02419,ndc:24430-1003-1,uniProtKb:P00749,url:http://en.wikipedia.org/wiki/Urokinase',''),('PA451837','ursodeoxycholic acid','(3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid,3,7-Dihydroxycholan-24-oic acid,3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid,3-alpha,7-beta-Dih','Actigall,Antigall,Arsacol,Cholit-ursan,Delursan,De','Drug/Small Molecule','DailyMed:2e799e93-b5a0-40f7-95c5-b40d8a948a0d,HET:IU5,TTD:DNC000420,chebi:9907,chemSpider:29131,dpd:2238984,drugBank:DB01586,iupharLigand:608,keggCompound:C07880,keggDrug:D00734,ndc:0527-1326-01,pdb:IU5,pubChemCompound:31401,pubChemSubstance:46508795,pubChemSubstance:7847799,url:http://en.wikipedia.org/wiki/Ursodiol',''),('PA451839','valaciclovir','Valaciclovir Hcl,Valaciclovir Hydrochloride,Valacyclover Hydrochloric,Valacyclover Hydrochloride,Valacyclovir,Valacyclovir Hydrochloride,valaciclovir','Valtrex,Zelitrex','Drug/Small Molecule','DailyMed:f8e0d8f8-cb73-4206-a484-88f5c4fbd719,TTD:DAP000643,bindingDb:50162073,chemSpider:54770,dpd:2246559,drugBank:DB00577,keggCompound:C07184,keggDrug:D00398,ndc:0173-0933-08,pubChemCompound:60773,pubChemSubstance:215420,pubChemSubstance:46508197,url:http://en.wikipedia.org/wiki/Valaciclovir','CC(C)[C@@H](C(=O)OCCOCn1cnc2c1nc([nH]c2=O)N)N'),('PA451843','l-valine','(2S)-2-Amino-3-methylbutanoic acid,(S)-2-Amino-3-methylbutanoic acid,(S)-2-Amino-3-methylbutyric acid,(S)-Valine,(S)-a-Amino-b-methylbutyric acid,2-Am','','Drug/Small Molecule','HET:VAL,chebi:16414,chebi:20506,chemSpider:6050,drugBank:DB00161,keggCompound:C00183,keggDrug:D00039,pdb:VAL,pubChemCompound:6287,pubChemSubstance:3483,pubChemSubstance:46504886',''),('PA451846','valproic acid','2-propylvaleric acid,DPA,Di-n-propylacetic acid,Di-n-propylessigsaure,Dipropylacetic acid,Kyselina 2-propylvalerova,Myproic Acid,Propylvaleric acid,So','Alti-Valproic,Avugane,Baceca,Convulex,Delepsine,De','Drug/Small Molecule','DailyMed:7d5cb52e-37dd-4dfa-a6f4-09f9548846c6,TTD:DNC001659,chebi:9926,chemSpider:3009,dpd:2260654,drugBank:DB00313,keggCompound:C07185,keggDrug:D00399,ndc:0121-0675-16,pubChemCompound:3121,pubChemSubstance:46505925,url:http://en.wikipedia.org/wiki/Valproic_Acid','CCCC(CCC)C(=O)O'),('PA451848','valsartan','valsartan','Diovan,Diovan HCT,Valsarran','Drug/Small Molecule','DailyMed:5ddba454-f3e6-43c2-a7a6-58365d297213,TTD:DAP000363,bindingDb:50049186,chebi:9927,chemSpider:54833,dpd:2244781,drugBank:DB00177,iupharLigand:593,keggDrug:D00400,ndc:0078-0360-34,pubChemCompound:60846,pubChemSubstance:197083,pubChemSubstance:46509000,url:http://en.wikipedia.org/wiki/Valsartan','CCCCC(=O)N(Cc1ccc(cc1)c2ccccc2c3[nH]nnn3)[C@@H](C(C)C)C(=O)O'),('PA451850','vancomycin','Vancomycin HCL','Vancocin,Vancocin HCL,Vancoled,Vancor','Drug/Small Molecule','DailyMed:99e523d8-9bde-43cb-8434-497015e5dcbd,HET:DVV,TTD:DAP001330,chebi:28001,chemSpider:389935,dpd:2241807,drugBank:DB00512,keggCompound:C06689,keggDrug:D00212,ndc:0338-3551-48,pdb:DVV,pubChemCompound:14969,pubChemCompound:441141,pubChemSubstance:46505261,pubChemSubstance:8914,url:http://en.wikipedia.org/wiki/Vancomycin','CC1C(C(CC(O1)OC2C(C(C(OC2Oc3c4cc5cc3Oc6ccc(cc6Cl)C(C(C(=O)NC(C(=O)NC5C(=O)NC7c8ccc(c(c8)-c9c(cc(cc9O)O)C(NC(=O)C(C(c1ccc(c(c1)Cl)O4)O)NC7=O)C(=O)O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)CO)O)O)(C)N)O'),('PA451852','vanillin','','','Drug/Small Molecule','','COc1cc(ccc1O)C=O'),('PA451858','vasopressin','3-Isoleucyl vasopressin,Arginine oxytocin,Arginine vasotocin,Argiprestocin,Pitressin tannate,Vasopressin, isoleucyl,Vasopressin, non-mammalian,Vasotoc','Pitressin,Pressyn','Drug/Small Molecule','TTD:DAP000018,dpd:693820,drugBank:DB00067,keggCompound:C00840,keggDrug:D00101,pubChemCompound:24774,pubChemSubstance:167533,url:http://en.wikipedia.org/wiki/Vasopressin','CC[C@@H]([C@H]1NC(=O)[C@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC1=O)CCC(=O)N)CC(=O)N)C(=O)N2[C@H](CCC2)C(=O)N[C@@H](C(=O)NCC(=O)N)CCC/N=C(N)/N)N)CC3=CC=C(C=C3)O)C'),('PA451862','vegetable oil','','','Drug/Small Molecule','',''),('PA451866','venlafaxine','Venlafaxina [INN-Spanish],Venlafaxine [INN:Ban],Venlafaxinum [INN-Latin]','Effexor,Effexor XR,Elafax','Drug/Small Molecule','DailyMed:2c3f8268-ef43-d58c-7da6-dd44f8feb3be,TTD:DAP000054,chebi:9943,chemSpider:5454,dpd:2237279,drugBank:DB00285,keggCompound:C07187,ndc:0378-4881-01,pubChemCompound:5656,pubChemSubstance:193901,pubChemSubstance:46504593,url:http://en.wikipedia.org/wiki/Venlafaxine','CN(C)CC(c1ccc(cc1)OC)C2(CCCCC2)O'),('PA451868','verapamil','Verapamil HCl,Verapamil [Usan:Ban:Inn],Verapamilo [INN-Spanish],Verapamilum [INN-Latin]','Apo-Verap,Arpamyl,Berkatens,Calan,Calan SR,Cardiag','','',''),('PA451871','verteporfin','verteporfin','Visudyne','Drug/Small Molecule','DailyMed:ac57f330-244d-48f8-a224-459c2bd2a970,chemSpider:4515032,dpd:2242367,drugBank:DB00460,keggDrug:D01162,ndc:0078-0437-61,pubChemCompound:5362420,pubChemSubstance:46506236,pubChemSubstance:7848225,url:http://en.wikipedia.org/wiki/Verteporfin',''),('PA451876','vidarabine','9-beta-D-arabinofuranosyl-adenine,Adenine Arabinoside,Ara Atp,Ara-A,Ara-Atp,Ara-a Triphosphate,Araadenosine,Arabinofuranosyladenine Triphosphate,Arabi','Arasena-A,Spongoadenosine,Vidarabin,Vira-A','Drug/Small Molecule','HET:RAB,TTD:DAP000642,chebi:45327,chemSpider:29966,drugBank:DB00194,keggCompound:C07195,keggDrug:D00406,ndc:61570-367-71,pdb:RAB,pubChemCompound:32326,pubChemSubstance:174304,pubChemSubstance:46506630,url:http://en.wikipedia.org/wiki/Vidarabine',''),('PA451877','vinblastine','','Nincaluicolflastine,Rozevin,Velban,Velbe,Vinblasti','Drug/Small Molecule','DailyMed:b8052de1-dc63-4bac-a2de-b932f6a31bd7,HET:KAR,TTD:DAP000785,bindingDb:50012278,chebi:27375,chemSpider:12773,dpd:2183056,drugBank:DB00570,keggCompound:C07201,ndc:55390-091-10,pdb:KAR,pubChemCompound:13342,pubChemCompound:241903,pubChemSubstance:156698,pubChemSubstance:46504550,url:http://en.wikipedia.org/wiki/Vinblastine',''),('PA451879','vincristine','22-Oxovincaleukoblastine,Indole alkaloid,LCR,Leurocristine,VCR,VIN,Vincristina [DCIT],Vincristine Sulfate,Vincristinum [INN-Latin],Vincrstine,Vincryst','Marqibo,Onco TCS,Oncovin,Vincasar,Vincasar PFS,Vin','Drug/Small Molecule','DailyMed:49596de6-ab18-49d1-9e5b-30968fc21c36,TTD:DAP000114,chebi:28445,chemSpider:5758,dpd:2143305,drugBank:DB00541,keggCompound:C07204,ndc:61703-309-06,pubChemCompound:5978,pubChemSubstance:148816,pubChemSubstance:46507033,url:http://en.wikipedia.org/wiki/Vincristine',''),('PA451881','vinorelbine','Vinorelbin,Vinorelbina [Spanish],Vinorelbine Bitartrate,Vinorelbine Ditartarate,Vinorelbine Ditartrate,Vinorelbine Tartrate,Vinorelbinum [Latin],vinor','Navelbine,Navelbine Base','Drug/Small Molecule','DailyMed:10a70995-e04d-4044-b1dc-c9aa27460397,TTD:DAP000765,chebi:480999,dpd:2257777,drugBank:DB00361,keggDrug:D08680,ndc:25021-204-01,pubChemCompound:60780,pubChemSubstance:668899,url:http://en.wikipedia.org/wiki/Vinorelbine',''),('PA451884','vitamin a','All-trans-Retinyl alcohol,All-trans-Vitamin A alcohol,Retin-11,12-t2-ol (9CI),Retinol,Vitamin A,Vitamin A Palmitate,Vitamin A Solubilized,Vitamin A al','A-Mulsal,A-Sol,A-Vi-Pel,A-Vitan,Acon,Afaxin,Agiola','','',''),('PA451892','cyanocobalamin','Cyanocob(III)alamin,Vitamin B12,Vitamin B12 complex,vitamine b12','Anacobin,Bedoz,Berocca PN,Berubigen,Betalin 12,Cer','','',''),('PA451897','pyridoxine','Adermin hydrochloride,Adermine hydrochloride,Aderomine hydrochloride,Hexabione hydrochloride,PN,Pyridoxin hydrochloride,Pyridoxine Chloride,Pyridoxine','Aderoxine,Alestrol,Becilan,Beesix,Benadon,Bonasani','Drug/Small Molecule','TTD:DAP000869,chebi:16709,chemSpider:1025,dpd:2246275,drugBank:DB00165,keggCompound:C00314,pubChemCompound:1054,pubChemSubstance:3123,pubChemSubstance:46508560,url:http://en.wikipedia.org/wiki/Pyridoxine','Cc1c(c(c(cn1)CO)CO)O'),('PA451898','vitamin c','AA,Ascorbate,Ascorbic Acid,L-Ascorbate,L-Ascorbic Acid,L-Lyxoascorbic Acid,L-Xyloascorbic Acid','Adenex,Allercorb,Antiscorbic Vitamin,Antiscorbutic','Drug/Small Molecule','TTD:DNC000259,bindingDb:50090256,chebi:17208,dpd:583960,drugBank:DB00126,keggCompound:C00072,keggDrug:D00018,pubChemCompound:5785,pubChemSubstance:597821,url:http://en.wikipedia.org/wiki/Vitamin_C','C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O'),('PA451899','vitamin d and analogues','','','Drug Class','',''),('PA451900','vitamin e','Tocopherol,alpha-Tocopherol','Amino-Opti-E,Aquasol E,Daltose,E-200 I.U. Softgels','Drug/Small Molecule','HET:VIT,chebi:18145,chemSpider:14265,drugBank:DB00163,keggCompound:C02477,pdb:VIT,pubChemCompound:14985,pubChemSubstance:46506524,pubChemSubstance:5492,url:http://en.wikipedia.org/wiki/Vitamin_E','Cc1c(c2c(c(c1O)C)CC[C@@](O2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C'),('PA451906','warfarin','Warfarin sodium','Athrombin,Athrombin-K,Athrombine-K,Brumolin,Co-Rax','Drug/Small Molecule','DailyMed:d91934a0-902e-c26c-23ca-d5accc4151b6,TTD:DAP000770,bindingDb:50088240,chebi:10033,dpd:2244463,drugBank:DB00682,keggCompound:C01541,ndc:0056-0169-70,pubChemCompound:6691,pubChemSubstance:4702,url:http://en.wikipedia.org/wiki/Warfarin','CC(=O)CC(c1ccccc1)c2c(c3ccccc3oc2=O)O'),('PA451935','xenon','','','Drug/Small Molecule','','[Xe]'),('PA451938','d-xylitol','','','Drug/Small Molecule','chebi:16772,chemSpider:804,dpd:2231395,drugBank:DB01904,keggCompound:C02895,pdb:XYL,pubChemCompound:6912,pubChemSubstance:46506507',''),('PA451946','yohimbine','Yohimbin','Actibine,Aphrodyne,Baron-X,Dayto himbin,Thybine,Yo','Drug/Small Molecule','TTD:DAP000087,chebi:10093,chemSpider:8622,dpd:795283,drugBank:DB01392,iupharLigand:102,iupharLigand:136,iupharLigand:223,keggCompound:C09256,pubChemCompound:8969,pubChemSubstance:11447,pubChemSubstance:46504602,url:http://en.wikipedia.org/wiki/Yohimbine','COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3c4c(c5ccccc5[nH]4)CCN3C2)O'),('PA451949','zafirlukast','zafirlukast','Accolate','Drug/Small Molecule','DailyMed:5550433b-8c9c-4378-058f-6bb724c4f18c,TTD:DAP000091,chebi:10100,chemSpider:5515,dpd:2236606,drugBank:DB00549,keggCompound:C07206,keggDrug:D00411,ndc:0310-0401-60,pubChemCompound:5717,pubChemSubstance:196556,pubChemSubstance:46506874,url:http://en.wikipedia.org/wiki/Zafirlukast','Cc1ccccc1S(=O)(=O)NC(=O)c2ccc(c(c2)OC)Cc3cn(c4c3cc(cc4)NC(=O)OC5CCCC5)C'),('PA451950','zalcitabine','DDC,DDCYD,Dideoxycytidine','HIVID','Drug/Small Molecule','DailyMed:a6ca918f-d031-4601-31a4-1848b580f2f0,TTD:DNC000527,chebi:10101,chemSpider:22498,dpd:1990896,drugBank:DB00943,keggCompound:C07207,keggDrug:D00412,ndc:0004-0220-01,pubChemCompound:24066,pubChemSubstance:166590,pubChemSubstance:46507879,url:http://en.wikipedia.org/wiki/Zalcitabine','c1cn(c(=O)nc1N)C[C@H]2CC[C@H](O2)CO'),('PA451952','zaleplon','DEA No. 2781,zaleplon','Sonata,Zalaplon','Drug/Small Molecule','DailyMed:9f581c98-0631-414e-9676-0865a66dbc44,TTD:DAP000266,chebi:10102,chemSpider:5517,dpd:2242219,drugBank:DB00962,keggCompound:C07484,keggDrug:D00530,ndc:0832-0400-00,pubChemCompound:5719,pubChemSubstance:46508267,pubChemSubstance:9687,url:http://en.wikipedia.org/wiki/Zaleplon','CCN(c1cccc(c1)c2ccnc3n2ncc3C#N)C(=O)C'),('PA451954','zidovudine','AZT','Apo-Zidovudine,Azidothymidine,Aztec,Compound S,Nov','','',''),('PA451955','zileuton','Zileutonum [INN-Latin],zileuton','Leutrol,Zyflo,Zyflo CR','Drug/Small Molecule','TTD:DAP000591,chebi:10112,chemSpider:54531,drugBank:DB00744,keggDrug:D00414,ndc:68734-700-10,pubChemCompound:60490,pubChemSubstance:196786,pubChemSubstance:46506394,url:http://en.wikipedia.org/wiki/Zileuton','CC(c1cc2ccccc2s1)N(C(=O)N)O'),('PA451956','zinc','','','Drug/Small Molecule','chebi:30185,chemSpider:22430,dpd:42595,drugBank:DB01593,keggCompound:C00038,pubChemCompound:23994,pubChemSubstance:3340,pubChemSubstance:46506903,url:http://en.wikipedia.org/wiki/Zinc','[Zn]'),('PA451961','zinc acetate','','','Drug/Small Molecule','','CC(=O)[O-].[Zn+2]'),('PA451965','zinc oxide','','','Drug/Small Molecule','','[O-2].[Zn+2]'),('PA451971','zinc sulfate','','','Drug/Small Molecule','','[O-]S(=O)(=O)[O-].[Zn+2]'),('PA451974','ziprasidone','Ziprasidone hydrochloride,Ziprasidone mesylate trihydrate','Geodon,Geodon Oral,Zeldox','Drug/Small Molecule','DailyMed:8326928a-2cb6-4f7f-9712-03a425a14c37,TTD:DAP000079,chebi:10119,chemSpider:54841,drugBank:DB00246,iupharLigand:59,keggCompound:C07568,ndc:0049-3960-60,pubChemCompound:60854,pubChemSubstance:210748,pubChemSubstance:46507627,url:http://en.wikipedia.org/wiki/Ziprasidone','c1ccc2c(c1)c(ns2)N3CCN(CC3)CCc4cc5c(cc4Cl)NC(=O)C5'),('PA451975','zolmitriptan','ZMT,zolmitriptan','AscoTop,Zomig,Zomig Rapimelt,Zomigon','Drug/Small Molecule','DailyMed:bac91e37-91ce-4bbf-77bc-ef5f242589f8,TTD:DAP000077,chebi:10124,dpd:2243045,drugBank:DB00315,iupharLigand:60,keggCompound:C07218,keggDrug:D00415,ndc:0310-0208-60,pubChemCompound:441240,pubChemSubstance:7847481,url:http://en.wikipedia.org/wiki/Zolmitriptan','CN(C)CCc1c[nH]c2c1cc(cc2)C[C@H]3COC(=O)N3'),('PA451976','zolpidem','Zolpidem tartrate,Zolpidemum [Latin]','Ambien,Ambien CR,Ivadal,Lorex,Niotal,Stilnoct,Stil','Drug/Small Molecule','DailyMed:f852e2c0-74fe-4389-ba96-d0c03f624c86,TTD:DAP000112,bindingDb:26266,chebi:10125,chemSpider:5530,drugBank:DB00425,keggCompound:C07219,ndc:54868-0845-0,pubChemCompound:5732,pubChemSubstance:199579,pubChemSubstance:46507949,url:http://en.wikipedia.org/wiki/Zolpidem','Cc1ccc(cc1)c2c(n3cc(ccc3n2)C)CC(=O)N(C)C'),('PA451978','zonisamide','Zonisamida [Spanish],Zonisamidum [Latin],zonisamide','Exceglan,Excegram,Excegran,Zonegran','Drug/Small Molecule','DailyMed:6d2f9c84-a597-4055-8815-8fbcdf4c4876,TTD:DAP000500,bindingDb:10888,chebi:10127,chemSpider:5532,drugBank:DB00909,keggCompound:C07504,keggDrug:D00538,ndc:0378-6725-01,pubChemCompound:5734,pubChemSubstance:188654,pubChemSubstance:46505278,url:http://en.wikipedia.org/wiki/Zonisamide','c1ccc2c(c1)c(no2)CS(=O)(=O)N'),('PA451988','dodecane-trimethylamine','','','Drug/Small Molecule','chebi:41378,chemSpider:7861,drugBank:DB02779,pdb:CAT,pubChemCompound:8153,pubChemSubstance:46506419,pubChemSubstance:7886471','CCCCCCCCCCCC[N+](C)(C)C'),('PA451991','1-methyloxy-4-sulfone-benzene','','','Drug/Small Molecule','drugBank:DB03033,pdb:MSB,pubChemCompound:3952261,pubChemSubstance:7889047','COC1=CC=C(C=C1)[S](=O)=O'),('PA451993','3-beta-hydroxy-5-androsten-17-one','3-beta-hydroxy-5-androsten-17-one,5-dehydroepiandrosterone,5-dhea,dha,dhea,prasterone','Fidelin,OVIGYN-D','Drug/Small Molecule','chebi:28689,chemSpider:5670,drugBank:DB01708,iupharLigand:2370,keggCompound:C01227,pdb:AND,pubChemCompound:5881,pubChemSubstance:4449,pubChemSubstance:46508824',''),('PA451996','azacitidine','5 AZC,Azacitidina [INN-Spanish],Azacitidinum [INN-Latin],Azacytidine,azacitidine','Ladakamycin,Mylosar,Vidaza','Drug/Small Molecule','DailyMed:e437efe0-9c6a-4f87-b3b4-de90443b095f,TTD:DAP000640,chebi:2038,chemSpider:9072,drugBank:DB00928,keggCompound:C11262,keggDrug:D03021,ndc:67211-102-01,pubChemCompound:9444,pubChemSubstance:13439,pubChemSubstance:46509032,url:http://en.wikipedia.org/wiki/Azacitidine',''),('PA451998','arylhydrazines','','','Drug Class','',''),('PA451999','interferons','','','Drug Class','',''),('PA452154','beta-lactam antibacterials, penicillins','','','Drug Class','',''),('PA452159','other beta-lactam antibacterials','','','Drug Class','',''),('PA452167','aminoglycoside antibacterials','','','Drug Class','',''),('PA452174','antivirals','','','Drug Class','',''),('PA452200','antithrombotic agents','Antithrombotic Agents','','Drug Class','',''),('PA452229','antidepressants','','','Drug Class','',''),('PA452233','antipsychotics','','','Drug Class','',''),('PA452244','digitalis glycosides','','','Drug Class','',''),('PA452249','antiarrhythmics, class i and iii','','','Drug Class','',''),('PA452298','antacids','','','Drug Class','',''),('PA452347','glucocorticoids','','','Drug Class','',''),('PA452359','progestogens and estrogens in combination','','','Drug Class','',''),('PA452363','prostaglandins','','','Drug Class','',''),('PA452389','muscle relaxants, peripherally acting agents','','','Drug Class','',''),('PA452604','xenobiotics','','','Drug Class','',''),('PA452605','cationic xenobiotics','','','Drug Class','',''),('PA452606','zoxazolamine','','','Drug/Small Molecule','','c1cc2c(cc1Cl)nc(o2)N'),('PA452609','aflatoxin b1','','','Drug/Small Molecule','',''),('PA452610','sparteine','','','Drug/Small Molecule','',''),('PA452611','epipodophyllotoxin','','','Drug/Small Molecule','',''),('PA452612','vinyl chloride','','','Drug/Small Molecule','','C=CCl'),('PA452613','fluoroquinolones','','','Drug Class','',''),('PA452614','furafylline','','','Drug/Small Molecule','',''),('PA452615','moclobemide','4-Chlor-N-(2-morpholinoethyl)benzamid,4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide,4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide,Moclaime,Moclamide,Mo','Aurorix,Manerix','Drug/Small Molecule','TTD:DAP000576,bindingDb:15613,chemSpider:4087,dpd:2243348,drugBank:DB01171,keggDrug:D02561,pubChemCompound:4235,pubChemSubstance:189524,pubChemSubstance:46504667,url:http://en.wikipedia.org/wiki/Moclobemide','c1cc(ccc1C(=O)NCCN2CCOCC2)Cl'),('PA452616','debrisoquine','Debrisochinum,Debrisoquin hemisulfate,Debrisoquin sulfate,Debrisoquina [inn-spanish],Debrisoquine sulfate,Debrisoquinum [inn-latin],Isocaramidine,Isoc','Declinax,Equitonil,Tendor','Drug/Small Molecule','TTD:DAP000125,chebi:34665,chemSpider:2860,drugBank:DB04840,keggCompound:C13650,pubChemCompound:2966,pubChemSubstance:46507664,pubChemSubstance:7846928','c1ccc2c(c1)CCN(C2)C(=N)N'),('PA452618','opioids','','','Drug Class','',''),('PA452619','heroin','Smack,diacetylmorphine,diamorphine','','Drug/Small Molecule','chebi:27808,chemSpider:4575379,drugBank:DB01452,keggCompound:C06534,pubChemCompound:5462328,pubChemSubstance:46506839,pubChemSubstance:8764,url:http://en.wikipedia.org/wiki/Heroin','CC(=O)Oc1ccc2c3c1O[C@@H]4[C@]35CCN([C@](C2)[C@@H]5C=C[C@@]4OC(=O)C)C'),('PA452620','tegafur','','','Drug/Small Molecule','',''),('PA452621','antineoplastic agents','','','Drug Class','',''),('PA452622','antimetabolites','','','Drug Class','',''),('PA452626','alox5-pathway modifiers','','','Drug Class','',''),('PA452627','flavopiridol','Alvocidib,CPB,Flavo,Flavopiridol hydrochloride,HMR-1275,flavopiridol','','Drug/Small Molecule','bindingDb:5655,drugBank:DB03496,pdb:CPB,pubChemCompound:5287969,pubChemSubstance:11041362,pubChemSubstance:46507266',''),('PA452628','nucleosides and nucleotides excl. reverse transcriptase inhibitors','','','Drug Class','',''),('PA452629','zuclopenthixol','Clopenthixol,Zuclopenthixolum [latin],Zuclopentixol [spanish],zuclopenthixol acetate,zuclopenthixol decanoate,zuclopenthixol dihydrochloride','Acuphase,Clopixol','Drug/Small Molecule','TTD:DAP000845,chebi:51364,chemSpider:4470984,dpd:2230402,drugBank:DB01624,pubChemCompound:5311507,pubChemSubstance:11056550,pubChemSubstance:46507341,url:http://en.wikipedia.org/wiki/Zuclopenthixol',''),('PA452631','thiazolidinediones','thiazolidinedione drugs','','Drug Class','',''),('PA452632','acenocoumarol','Acenocoumarin,Acenocoumarolum [inn-latin],Nicoumalone,Nicumalon,Nitrophenylacetylethyl-4-hydroxycoumarine,Nitrovarfarian,Nitrowarfarin','Ascumar,Mini-sintrom,Neositron,Sincoumar,Sinkumar,','Drug/Small Molecule','TTD:DAP000772,chebi:53766,dpd:10383,drugBank:DB01418,keggDrug:D07064,pubChemCompound:9052,pubChemSubstance:10321722,url:http://en.wikipedia.org/wiki/Acenocoumarol','CC(=O)CC(c1ccc(cc1)N(=O)=O)c2c(c3ccccc3oc2=O)O'),('PA452633','morphine-6-glucoronide','morphine-6-glucuronide','','Drug/Small Molecule','',''),('PA452634','purine analogues','','','Drug Class','',''),('PA452637','hormonal contraceptives for systemic use','','','Drug Class','',''),('PA452638','arsenite','','','Drug/Small Molecule','',''),('PA452639','infliximab','Ig gamma-1 chain C region','Remicade','Drug/Small Molecule','TTD:DAP000107,dpd:2244016,drugBank:DB00065,genBank:J00228,uniProtKb:P01857,url:http://en.wikipedia.org/wiki/Infliximab',''),('PA452640','imidapril','','','Drug/Small Molecule','','CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2[C@@H](CN(C2=O)C)C(=O)O'),('PA452642','podophyllotoxin derivatives','','','Drug Class','',''),('PA7000','sorafenib','Sorafenib tosylate,sorafenib','Nexavar','Drug/Small Molecule','DailyMed:b50667e4-5ebc-4968-a646-d605058dbef0,HET:BAX,TTD:DAP000006,bindingDb:16673,chebi:50924,chemSpider:187440,drugBank:DB00398,ndc:50419-488-58,pdb:BAX,pubChemCompound:216239,pubChemSubstance:46505329,pubChemSubstance:789424,url:http://en.wikipedia.org/wiki/Sorafenib','CNC(=O)c1cc(ccn1)Oc2ccc(cc2)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl'),('PA7001','vatalanib','PTK787','','Drug/Small Molecule','','c1ccc2c(c1)c(nnc2Nc3ccc(cc3)Cl)Cc4ccncc4');
/*!40000 ALTER TABLE `drug_hyperlink` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `drug_response_drugs`
--

DROP TABLE IF EXISTS `drug_response_drugs`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `drug_response_drugs` (
  `RSID` varchar(20) DEFAULT NULL,
  `Alleles` varchar(7) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `Drug` varchar(60) DEFAULT NULL,
  `System` varchar(60) DEFAULT NULL,
  `subSystem` varchar(100) DEFAULT NULL,
  `drugID` varchar(30) DEFAULT NULL,
  `info` text,
  `Level` varchar(10) DEFAULT NULL,
  `Efficacy` varchar(20) DEFAULT NULL,
  `Dosage` varchar(20) DEFAULT NULL,
  `Toxicity` varchar(20) DEFAULT NULL,
  `Genotype` varchar(10) DEFAULT NULL,
  `Sentence` text
) ENGINE=MyISAM DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `drug_response_drugs`
--

LOCK TABLES `drug_response_drugs` WRITE;
/*!40000 ALTER TABLE `drug_response_drugs` DISABLE KEYS */;
INSERT INTO `drug_response_drugs` VALUES ('rs3093726','T > C','LST1','abacavir--PA448004','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB01048','Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. [DrugBank]','Level 4','-','-','decreased','CC','                Patients with the CC genotype may have decreased but not absent risk of hypersensitivity when treated with abacavir as compared to patients with the CT or TT genotypes. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs11209716','T > C','PTGER3','Ace Inhibitors, Plain--PA164712308','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','CC','                Patients with the CC genotype and hypertension who are treated with ACE inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk of cough when treated with ACE inhibitors.'),('rs1799722','C > T','BDKRB2','Ace Inhibitors, Plain--PA164712308','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for cough.'),('rs1799722','C > T','BDKRB2','Ace Inhibitors, Plain--PA164712308','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for cough.'),('rs2016848','G > A','MME','Ace Inhibitors, Plain--PA164712308','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cough with ACE inhibitor treatment. Patients with this genotype were not studied directly.'),('rs2016848','G > A','MME','Ace Inhibitors, Plain--PA164712308','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cough with ACE inhibitor treatment.'),('rs8012552','C > T','BDKRB2','Ace Inhibitors, Plain--PA164712308','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','TT','                Patients with the TT genotype and hypertension who are treated with ACE-inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of cough with ACE-inhibitors.'),('rs1057910','A > C','CYP2C9','acenocoumarol--PA452632','VARIOUS',NULL,NULL,NULL,'Level 2A','-','decreased','-','AC','                Patients with the AC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs1057910','A > C','CYP2C9','acenocoumarol--PA452632','VARIOUS',NULL,NULL,NULL,'Level 2A','-','decreased','-','CC','                Patients with the CC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs2108622','C > T','CYP4F2','acenocoumarol--PA452632','VARIOUS',NULL,NULL,NULL,'Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs2108622','C > T','CYP4F2','acenocoumarol--PA452632','VARIOUS',NULL,NULL,NULL,'Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs4086116','C > T','CYP2C9','acenocoumarol--PA452632','VARIOUS',NULL,NULL,NULL,'Level 3','-','decreased','-','CT','                Patients with the CT genotype may require a lower dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs4086116','C > T','CYP2C9','acenocoumarol--PA452632','VARIOUS',NULL,NULL,NULL,'Level 3','-','decreased','-','TT','                Patients with the TT genotype may require the lowest dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs9934438','G > A','VKORC1','acenocoumarol--PA452632','VARIOUS',NULL,NULL,NULL,'Level 1B','-','decreased','-','AG','                Patients with the AG genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs9934438','G > A','VKORC1','acenocoumarol--PA452632','VARIOUS',NULL,NULL,NULL,'Level 1B','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs1800629','G > A','TNF','adalimumab--PA10004','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and rheumatoid arthritis who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype or may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to anti-TNF therapy.'),('rs1800629','G > A','TNF','adalimumab--PA10004','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype and rheumatoid arthritis who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to anti-TNF therapy.'),('rs1544410','C > T','VDR','alendronate--PA448082','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00630','Alendronate is a nitrogen-containing, second generation bisphosphonate. Bisphosphonates were first used to treat Pagets disease in 1971. This class of medications is comprised of inorganic pyrophosphate analogues that contain non-hydrolyzable P-C-P bonds. Similar to other bisphosphonates, alendronate has a high affinity for bone mineral and is taken up during osteoclast resorption. Alendronate inhibits farnesyl pyrophosphate synthetase, one of the enzymes in the mevalonic acid pathway involved in producing isoprenoid compounds that are essential for post-translational modification of small guanosine triphosphate (GTP)-binding proteins, such as Rho, Ras and Rab. Inhibition of this process interferes with osteoclast function and survival. Alendronate is used for the treatment of osteoporosis and Pagets disease','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with bisphosphonates may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to bisphosphonates.'),('rs2297480','T > G','FDPS','alendronate--PA448082','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00630','Alendronate is a nitrogen-containing, second generation bisphosphonate. Bisphosphonates were first used to treat Pagets disease in 1971. This class of medications is comprised of inorganic pyrophosphate analogues that contain non-hydrolyzable P-C-P bonds. Similar to other bisphosphonates, alendronate has a high affinity for bone mineral and is taken up during osteoclast resorption. Alendronate inhibits farnesyl pyrophosphate synthetase, one of the enzymes in the mevalonic acid pathway involved in producing isoprenoid compounds that are essential for post-translational modification of small guanosine triphosphate (GTP)-binding proteins, such as Rho, Ras and Rab. Inhibition of this process interferes with osteoclast function and survival. Alendronate is used for the treatment of osteoporosis and Pagets disease','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs712829','G > T','EGFR','Alkylating Agents--PA164712331','VARIOUS',NULL,NULL,NULL,'Level 4','decreased','-','-','GT','                Cancer cells with the GT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.'),('rs712829','G > T','EGFR','Alkylating Agents--PA164712331','VARIOUS',NULL,NULL,NULL,'Level 4','decreased','-','-','TT','                Cancer cells with the TT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.'),('rs9263726','G > A','CCHCR1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','AG','                Patients with the AG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. This allele was in complete LD with HLA-B*5801 in the Japanese population. Evidence for the HLA-B*5801 allele and risk for SJS/TEN is stronger. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263726','G > A','CCHCR1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','AA','                Patients with the AA genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. This is a very rare allele and the AA homozygote was not observed in the supporting study. This allele was in complete LD with HLA-B*5801 in the Japanese population. Evidence for the HLA-B*5801 allele and risk for SJS/TEN is stronger. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263733','C > T','CCHCR1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263733','C > T','CCHCR1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DurgBank]','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263745','G > A','CCHCR1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','AG','                Patients with the AG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263745','G > A','CCHCR1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','AA','                Patients with the AA genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263781','T > C','CCHCR1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263781','T > C','CCHCR1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263785','T > G','CCHCR1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','GT','                Patients with the GT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263785','T > G','CCHCR1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','GG','                Patients with the GG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263794','A > G','CCHCR1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','AG','                Patients with the AG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263794','A > G','CCHCR1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','GG','                Patients with the GG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263796','C > T','CCHCR1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263796','C > T','CCHCR1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263800','G > A','CCHCR1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','AG','                Patients with the AG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263800','G > A','CCHCR1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','AA','                Patients with the AA genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263827','C > T','POU5F1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263827','C > T','POU5F1','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9267445','G > C','MICB','allopurinol--PA448320','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','decreased','CC','                Patients with the CC genotype may have decreased but not absent risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs12720441','G > A','KCNH2','amiodarone--PA448383','CARDIOVASCULAR SYSTEM','CARDIAC THERAPY','DB01118','An antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance. [DrugBank]','Level 4','-','-','increased','AG','                Patients with the AG genotype may have increased risk for Torsades de Point when treated with amiodarone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs12720441','G > A','KCNH2','amiodarone--PA448383','CARDIOVASCULAR SYSTEM','CARDIAC THERAPY','DB01118','An antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance. [DrugBank]','Level 4','-','-','increased','AA','                Patients with the AA genotype may have increased risk for Torsades de Point when treated with amiodarone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs5065','A > G','NPPA','amlodipine--PA448388','CARDIOVASCULAR SYSTEM','CARDIAC THERAPY','DB01118','An antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance. [DrugBank]','Level 4','increased','-','-','AG','                Patients with Hypertension and the AG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.'),('rs5065','A > G','NPPA','amlodipine--PA448388','CARDIOVASCULAR SYSTEM','CARDIAC THERAPY','DB01118','An antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance. [DrugBank]','Level 4','increased','-','-','GG','                Patients with Hypertension and the GG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.'),('rs10509681','T > C','CYP2C8','amodiaquine--PA448404','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS','ANTIPROTOZOALS','DB00613','A 4-aminoquinoquinoline compound with anti-inflammatory properties. [DrugBank]','Level 4','-','-','increased','CT','                Patients with the CT genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs10509681','T > C','CYP2C8','amodiaquine--PA448404','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS','ANTIPROTOZOALS','DB00613','A 4-aminoquinoquinoline compound with anti-inflammatory properties. [DrugBank]','Level 4','-','-','increased','CC','                Patients with the CC genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs11572080','C > T','CYP2C8','amodiaquine--PA448404','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS','ANTIPROTOZOALS','DB00613','A 4-aminoquinoquinoline compound with anti-inflammatory properties. [DrugBank]','Level 4','-','-','increased','CT','                Patients with the CT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs11572080','C > T','CYP2C8','amodiaquine--PA448404','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS','ANTIPROTOZOALS','DB00613','A 4-aminoquinoquinoline compound with anti-inflammatory properties. [DrugBank]','Level 4','-','-','increased','TT','                Patients with the TT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs9274407','A > T','HLA-DQB1','amoxicillin--PA448406','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIBACTERIALS FOR SYSTEMIC USE','DB01060','A broad-spectrum semisynthetic antibiotic similar to ampicillin except that its resistance to gastric acid permits higher serum levels with oral administration. Amoxicillin is commonly prescribed with clauvanic acid (a beta lactamase inhibitor) as it is susceptible to beta-lacatamase degradation. [DrugBank]','Level 3','-','-','decreased','TT','                Patients with the TT genotype may have decreased but not absent risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk for drug induced liver injury.'),('rs2070995','T > C','KCNJ6','Analgesics--PA164712362','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the TC genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance for requiring a rescue analgesic.'),('rs2070995','T > C','KCNJ6','Analgesics--PA164712362','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance for requiring a rescue analgesic.'),('rs1045642','A > G','ABCB1','anthracyclines and related substances--PA130620651','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','anthracyclines and related substances--PA130620651','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1056892','G > A','CBR3','anthracyclines and related substances--PA130620651','VARIOUS',NULL,NULL,NULL,'Level 2B','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs10836235','C > T','CAT','anthracyclines and related substances--PA130620651','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','CT','                Patients with the CT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the CT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs10836235','C > T','CAT','anthracyclines and related substances--PA130620651','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','TT','                Patients with the TT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the TT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs2032582','A > C','ABCB1','anthracyclines and related substances--PA130620651','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','AC','                Patients with the CA genotype and cancer who are treated with anthracyclines: 1) may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype 2) may have increased overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to anthracyclines.'),('rs2032582','A > C','ABCB1','anthracyclines and related substances--PA130620651','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC, CT or TT genotype and cancer who are treated with anthracyclines 1) may have an increased risk of resistance as compared to patients with the AC and AA genotype 2) may have decreased overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to anthracyclines.'),('rs9024','G > A','CBR1','anthracyclines and related substances--PA130620651','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','AG','                Patients with the AG genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of drug-induced Cardiomyopathies.'),('rs9024','G > A','CBR1','anthracyclines and related substances--PA130620651','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of drug-induced Cardiomyopathies.'),('rs9514091','G > A','SLC10A2','anthracyclines and related substances--PA130620651','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','AG','                Patients with the AG genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for cardiotoxicity.'),('rs9514091','G > A','SLC10A2','anthracyclines and related substances--PA130620651','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for cardiotoxicity.'),('rs10879346','C > T','TPH2','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with antidepressants may have less improvement in symptoms as compared to patients with the CT and CC genotype.'),('rs1360780','T > C','FKBP5','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with the CC genotype may 1) have decreased response to antidepressants 2) have decreased suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1799889','G > GG','SERPINE1','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs1799889','G > GG','SERPINE1','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs2032583','A > G','ABCB1','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs2032583','A > G','ABCB1','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs2227631','A > G','SERPINE1','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs2227631','A > G','SERPINE1','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs2235015','C > A','ABCB1','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AC','                Patients with the AC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs2235015','C > A','ABCB1','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs3800373','C > A','FKBP5','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','decreased','-','-','AA','                Patients with the AA genotype and depression who are treated with antidepressants may be less likely to have improvement in symptoms as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs61888800','G > T','BDNF','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GT','                Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.'),('rs61888800','G > T','BDNF','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype with major depressive disorder may experience a  lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.'),('rs6295','C > G','HTR1A','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CG','                Patients with the CG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs6295','C > G','HTR1A','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs7569963','G > A','CREB1','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs7569963','G > A','CREB1','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs7997012','A > G','HTR2A','antidepressants--PA452229','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1045642','A > G','ABCB1','antiepileptics--PA143485705','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Genotype AG may be associated with increased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype GG. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. Theres also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patients response to antiepileptics.'),('rs1045642','A > G','ABCB1','antiepileptics--PA143485705','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Genotype GG genotype  may be associated with decreased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype AA. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. Theres also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patients response to antiepileptics.'),('rs2032582','A > C','ABCB1','antiepileptics--PA143485705','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','decreased','-','CC','                Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patients response to carbamazepine.'),('rs2032582','A > C','ABCB1','antiepileptics--PA143485705','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 4','decreased','-','-','CC','                Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patients response to antiepileptics.'),('rs2273697','G > A','ABCC2','antiepileptics--PA143485705','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype and epilepsy who are treated with carbamazepine 1) may have an increased risk for neurological adverse events 2) may have increased likelihood of response to antiepileptic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs2273697','G > A','ABCC2','antiepileptics--PA143485705','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype and epilepsy who are treated with carbamazepine 1) may have an increased risk for neurological adverse events 2) may have increased likelihood of response to antiepileptic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs3740066','C > T','ABCC2','antiepileptics--PA143485705','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. This association was not found in all studies. Other genetic and clinical factors may also influence a patients response to antiepileptics.'),('rs3740066','C > T','ABCC2','antiepileptics--PA143485705','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. This association was not found in all studies. Other genetic and clinical factors may also influence a patients response to antiepileptics.'),('rs717620','C > T','ABCC2','antiepileptics--PA143485705','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antiepileptics.'),('rs717620','C > T','ABCC2','antiepileptics--PA143485705','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antiepileptics.'),('rs2070744','C > T','NOS3','Antihypertensives And Diuretics In Combination--PA164712446','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the CT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for resistance.'),('rs2070744','C > T','NOS3','Antihypertensives And Diuretics In Combination--PA164712446','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for resistance.'),('rs2070744','C > T','NOS3','Antihypertensives And Diuretics In Combination--PA164712446','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the CT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antihypertensives.'),('rs2070744','C > T','NOS3','Antihypertensives And Diuretics In Combination--PA164712446','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antihypertensives.'),('rs1801252','A > G','ADRB1','Antihypertensives--PA164712445','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype may 1) experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) not require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients likelihood of response, in particular ADRB1 Arg389 (rs1801253).'),('rs1801252','A > G','ADRB1','Antihypertensives--PA164712445','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                People with the GG genotype may 1) not experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) not require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients likelihood of response, in particular ADRB1 Arg389 (rs1801253).'),('rs2070744','C > T','NOS3','Antihypertensives--PA164712445','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the CT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antihypertensives.'),('rs2070744','C > T','NOS3','Antihypertensives--PA164712445','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antihypertensives.'),('rs1057910','A > C','CYP2C9','Antiinflammatory agents, non-steroids--PA164712462','VARIOUS',NULL,NULL,NULL,'Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','Antiinflammatory agents, non-steroids--PA164712462','VARIOUS',NULL,NULL,NULL,'Level 2A','-','-','increased','CC','                Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs943580','G > A','AGT','Antiinflammatory agents, non-steroids--PA164712462','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.'),('rs943580','G > A','AGT','Antiinflammatory agents, non-steroids--PA164712462','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype may have an increased risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.'),('rs1042522','G > C','TP53','antineoplastic agents--PA452621','VARIOUS',NULL,NULL,NULL,'Level 2B','increased','-','-','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1042522','G > C','TP53','antineoplastic agents--PA452621','VARIOUS',NULL,NULL,NULL,'Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1079598','A > G','DRD2','antipsychotics--PA452233','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1079598','A > G','DRD2','antipsychotics--PA452233','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1414334','C > G','HTR2C','antipsychotics--PA452233','VARIOUS',NULL,NULL,NULL,'Level 1B','-','-','decreased','GG','                Patients with the GG genotype who are treated with antipsychotics may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patients risk for developing metabolic syndrome.'),('rs1799732','- > G','DRD2','antipsychotics--PA452233','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1800497','G > A','ANKK1','antipsychotics--PA452233','VARIOUS',NULL,NULL,NULL,'Level 1B','-','-','decreased','AA','                Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk for tardive dyskinesia as compared to patients with the GA and GG genotype. Other genetic and clinical factors may also influence a patients risk for tardive dyskinesia when taking antipsychotics.'),('rs1800497','G > A','ANKK1','antipsychotics--PA452233','VARIOUS',NULL,NULL,NULL,'Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1800497','G > A','ANKK1','antipsychotics--PA452233','VARIOUS',NULL,NULL,NULL,'Level 2B','-','-','increased','AA','                Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1801133','G > A','CLCN6','antipsychotics--PA452233','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1801133','G > A','CLCN6','antipsychotics--PA452233','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs2069514','G > A','CYP1A2','antipsychotics--PA452233','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Schizophrenia patients with the AG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AG is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patients risk for adverse events to antipsychotics.'),('rs2069514','G > A','CYP1A2','antipsychotics--PA452233','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Schizophrenia patients with the AA genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AA is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patients risk for adverse events to antipsychotics.'),('rs4680','G > A','COMT','antipsychotics--PA452233','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','AG','                Patients with the AG genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for tardive dyskinesia.'),('rs4680','G > A','COMT','antipsychotics--PA452233','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for tardive dyskinesia.'),('rs6277','G > A','DRD2','antipsychotics--PA452233','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased, but not absent risk, for weight gain when treated with clozapine or olanzepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs951439','C > T','RGS4','antipsychotics--PA452233','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs951439','C > T','RGS4','antipsychotics--PA452233','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may have increased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs429358','T > C','APOC1','Antivirals for treatment of HIV infections, combinations--PA','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE',NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patients risk for adverse events with ritonavir treatment.'),('rs429358','T > C','APOC1','Antivirals for treatment of HIV infections, combinations--PA','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE',NULL,NULL,'Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patients risk for adverse events with ritonavir treatment.'),('rs7412','C > T','APOE','Antivirals for treatment of HIV infections, combinations--PA','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE',NULL,NULL,'Level 4','-','-','increased','CT','                Patients with the CT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype or may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients triglyceride levels.'),('rs7412','C > T','APOE','Antivirals for treatment of HIV infections, combinations--PA','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE',NULL,NULL,'Level 4','-','-','increased','TT','                Patients with the TT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients triglyceride levels.'),('rs1799732','- > G','DRD2','aripiprazole--PA10026','NERVOUS SYSTEM','PSYCHOLEPTICS','DB01238','Aripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.[DrugBank]','Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1799732','- > G','DRD2','aripiprazole--PA10026','NERVOUS SYSTEM','PSYCHOLEPTICS','DB01238','Aripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.[DrugBank]','Level 3','increased','-','-','G/del','                Patients with the G/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with these alleles and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1050828','C > T','G6PD','artesunate--PA165111697','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Pediatric patients with the CT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs1050828','C > T','G6PD','artesunate--PA165111697','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Pediatric patients with the TT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs20417','C > G','PTGS2','aspirin--PA448497','ALIMENTARY TRACT AND METABOLISM','STOMATOLOGICAL PREPARATIONS','DB00945','The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. [DrugBank]','Level 3','increased','-','-','CG','                Patients with the CG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patients response to aspirin.'),('rs20417','C > G','PTGS2','aspirin--PA448497','ALIMENTARY TRACT AND METABOLISM','STOMATOLOGICAL PREPARATIONS','DB00945','The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. [DrugBank]','Level 3','increased','-','-','GG','                Patients with the GG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patients response to aspirin.'),('rs730012','A > C','LTC4S','aspirin--PA448497','ALIMENTARY TRACT AND METABOLISM','STOMATOLOGICAL PREPARATIONS','DB00945','The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. [DrugBank]','Level 3','-','-','increased','AC','                Patients with the AC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for urticaria.'),('rs730012','A > C','LTC4S','aspirin--PA448497','ALIMENTARY TRACT AND METABOLISM','STOMATOLOGICAL PREPARATIONS','DB00945','The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. [DrugBank]','Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for urticaria.'),('rs1051375','G > A','CACNA1C','atenolol--PA448499','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00335','A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. [DrugBank]','Level 3','increased','-','-','AA','                Patients with the AA genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with verapamil compared to treatment with atenolol. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs1801252','A > G','ADRB1','atenolol--PA448499','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00335','A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. [DrugBank]','Level 3','decreased','-','-','GG','                People with the GG genotype may 1) not experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) not require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients likelihood of response, in particular ADRB1 Arg389 (rs1801253).'),('rs1801253','G > C','ADRB1','atenolol--PA448499','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00335','A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. [DrugBank]','Level 3','increased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','atenolol--PA448499','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00335','A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. [DrugBank]','Level 3','increased','-','-','CC','                Patients with the CC genotype 1) may have an increased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have a decreased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs688','C > T','LDLR','atenolol--PA448499','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00335','A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. [DrugBank]','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have less effective lowering of systolic blood pressure with atenolol as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patients likelihood of response.'),('rs17238540','T > G','HMGCR','atorvastatin--PA448500','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 3','decreased','-','-','GT','                Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17238540','T > G','HMGCR','atorvastatin--PA448500','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 3','decreased','-','-','GG','                Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs1935349','C > T','HTR7','atorvastatin--PA448500','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for statin-related myalgia as compared to patients with the CC genotypes, or may have a decreased risk for statin-related myalgia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs1935349','C > T','HTR7','atorvastatin--PA448500','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for statin-related myalgia as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs2276307','A > G','HTR3B','atorvastatin--PA448500','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for myalgia.'),('rs2276307','A > G','HTR3B','atorvastatin--PA448500','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 3','-','-','increased','GG','                Patients with the GG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patients risk for myalgia.'),('rs4693075','G > C','COQ2','atorvastatin--PA448500','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 2B','-','-','decreased','CC','                Patients with the CC genotype may have decreased risk of statin-related muscle symptoms as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence a patients risk of toxicity.'),('rs5443','C > T','GNB3','atorvastatin--PA448500','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 4','increased','-','-','CT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs5443','C > T','GNB3','atorvastatin--PA448500','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 4','increased','-','-','TT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs1127354','C > A','DDRGK1','azathioprine--PA448515','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 3','increased','-','-','AC','                Patients with the AC genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1127354','C > A','DDRGK1','azathioprine--PA448515','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 3','increased','-','-','AA','                Patients with the AA genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AA genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1127354','C > A','DDRGK1','azathioprine--PA448515','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 3','decreased','-','-','AC','                Patients with the AC genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1127354','C > A','DDRGK1','azathioprine--PA448515','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 3','decreased','-','-','AA','                Patients with the AA genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1142345','T > C','TPMT','azathioprine--PA448515','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CT','                Patients with the CT genotype  1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1142345','T > C','TPMT','azathioprine--PA448515','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','azathioprine--PA448515','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','azathioprine--PA448515','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','azathioprine--PA448515','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CG','                Patients with the CG genotype (e.g. TPMT*1/*2): may have increased deactivation of thiopurines and a decreased, but not absent, risk for toxicity with thiopurine drugs as compared to patients with the GG genotype (TPMT*2/*2) or may have decreased deactivation of thiopurines and an increased risk for toxicity with thiopurine drugs as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','azathioprine--PA448515','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs17098707','A > T','GRK5','Beta Blocking Agents--PA164712535','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 4','decreased','-','-','AT','                Patients with the AT genotype and heart failure may have lower, but not absent, risk for death as compared to patients with the AA genotype and may benefit more from beta blocker treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse cardiovascular events.'),('rs17098707','A > T','GRK5','Beta Blocking Agents--PA164712535','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 4','decreased','-','-','TT','                Patients with the TT genotype and heart failure may have lower, but not absent, risk for death as compared to patients with the AA genotype regardless of beta blocker.'),('rs1801252','A > G','ADRB1','Beta Blocking Agents--PA164712535','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                People with the GG genotype may 1) not experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) not require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients likelihood of response, in particular ADRB1 Arg389 (rs1801253).'),('rs1801253','G > C','ADRB1','Beta Blocking Agents--PA164712535','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','Beta Blocking Agents--PA164712535','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype 1) may have an increased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have a decreased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs4253778','G > C','PPARA','Beta Blocking Agents--PA164712535','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CG','                Patients with the CG genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for rehospitalization.'),('rs4253778','G > C','PPARA','Beta Blocking Agents--PA164712535','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for rehospitalization.'),('rs1801252','A > G','ADRB1','bisoprolol--PA448641','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                People with the GG genotype may 1) not experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) not require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients likelihood of response, in particular ADRB1 Arg389 (rs1801253).'),('rs1544410','C > T','VDR','Bisphosphonates--PA164712563','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with bisphosphonates may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to bisphosphonates.'),('rs16944','A > G','IL1B','Bisphosphonates--PA164712563','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and Pagets disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs16944','A > G','IL1B','Bisphosphonates--PA164712563','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs1934951','C > T','CYP2C8','Bisphosphonates--PA164712563','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','CT','                Patients with the CT genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.'),('rs1934951','C > T','CYP2C8','Bisphosphonates--PA164712563','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.'),('rs2297480','T > G','FDPS','Bisphosphonates--PA164712563','VARIOUS',NULL,NULL,NULL,'Level 2B','increased','-','-','GT','                Patients with the GT genotype may have an increased chance of response to bisphosphonate treatment as compared to patients with the GG genotype. Patients with the GT genotype may still be at risk for non-response to bisphosphonate treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs2297480','T > G','FDPS','Bisphosphonates--PA164712563','VARIOUS',NULL,NULL,NULL,'Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1799732','- > G','DRD2','Bromperidol--PA165282097','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1801253','G > C','ADRB1','bucindolol--PA165945764','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','bucindolol--PA165945764','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype 1) may have an increased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have a decreased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs37973','G > A','GLCCI1','budesonide--PA448681','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype may have intermediate increased risk of poor response to inhaled glucocorticoids in asthma patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patients response to glucocorticoids. The G allele is associated with decrease in the expression of GLCCI1 gene and cells with heterozygous AG genotype has an intermediate GLCC1 expression value.'),('rs37973','G > A','GLCCI1','budesonide--PA448681','VARIOUS',NULL,NULL,NULL,'Level 3','Efficacy','-','-','AA','                Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patients response to glucocorticoids.'),('rs165599','G > A','ARVCF','bupropion--PA448687','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AG genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs165599','G > A','ARVCF','bupropion--PA448687','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1800497','G > A','ANKK1','bupropion--PA448687','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 1B','decreased','-','-','AG','                Patients with the AG genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients chance for quitting smoking.'),('rs1800497','G > A','ANKK1','bupropion--PA448687','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 1B','decreased','-','-','AA','                Patients with the AA genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients chance for quitting smoking.'),('rs2298383','C > T','ADORA2A','caffeine--PA448710','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00201','A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine\'s most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes smooth muscle, stimulates cardiac muscle, stimulates diuresis, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide phosphodiesterases, antagonism of adenosine receptors, and modulation of intracellular calcium handling. [DrugBank]','Level 2B','-','-','decreased','CT','                Patients with the CT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.'),('rs2298383','C > T','ADORA2A','caffeine--PA448710','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','-','decreased','TT','                Patients with the TT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.'),('rs5751876','T > C','ADORA2A','caffeine--PA448710','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','decreased','-','CT','                Individuals with the CT genotype 1) may be less sensitive to caffeine and less likely to experience anxiety 2) may consume more caffeine as compared to individuals with the TT genotype. Please note contradictory results have been reported. Other genetic and clinical factors may also influence an individuals response to caffeine.'),('rs5751876','T > C','ADORA2A','caffeine--PA448710','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','decreased','-','CC','                Individuals with the CC genotype 1) may be less sensitive to caffeine and less likely to experience anxiety 2) may consume more caffeine as compared to individuals with the TT genotype. Please note contradictory results have been reported. Other genetic and clinical factors may also influence an individuals response to caffeine.'),('rs762551','C > A','CYP1A2','caffeine--PA448710','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AC','                Patients with the AC genotype may have an increased risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of myocardial infarction.'),('rs762551','C > A','CYP1A2','caffeine--PA448710','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype may have a decreased, but not absent, risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patients risk of myocardial infarction.'),('rs1544410','C > T','VDR','Calcium--PA164712582','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with bisphosphonates may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to bisphosphonates.'),('rs1045642','A > G','ABCB1','capecitabine--PA448771','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with AG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.'),('rs1045642','A > G','ABCB1','capecitabine--PA448771','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.'),('rs1801131','T > G','MTHFR','capecitabine--PA448771','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','increased','-','-','GT','                Patients with the  GT genotype may have 1) increased response, 2) increased risk of Drug Toxicity in people with Colorectal Neoplasms treated with oxaliplatin, capecitabine, fluorouracil, leucovorin as compared to patients with TT genotype. Other genetic and clinical factors may influence a patients response to these drugs.'),('rs1801131','T > G','MTHFR','capecitabine--PA448771','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','increased','-','-','GG','                Patients with the  GG genotype may have 1) increased response, 2) increased risk of Drug Toxicity in people with Colorectal Neoplasms treated with oxaliplatin, capecitabine, fluorouracil, leucovorin as compared to patients with TT genotype. Other genetic and clinical factors may influence a patients response to these drugs.'),('rs1801131','T > G','MTHFR','capecitabine--PA448771','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','-','increased','GT','                Patients with the GT genotype may have increased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to capecitabine.'),('rs1801131','T > G','MTHFR','capecitabine--PA448771','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','-','increased','GG','                Patients with the GG genotype may have increased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to capecitabine.'),('rs2297595','T > C','DPYD','capecitabine--PA448771','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','-','increased','CT','                Patients with the CT genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs2297595','T > C','DPYD','capecitabine--PA448771','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1045642','A > G','ABCB1','carbamazepine--PA448785','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 4','-','increased','-','AG','                Patient with genotype AG may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine.'),('rs1045642','A > G','ABCB1','carbamazepine--PA448785','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 4','-','decreased','-','GG','                Patient with genotype GG may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine...'),('rs1051740','T > C','EPHX1','carbamazepine--PA448785','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','increased','-','CT','                Patients with the CT genotype and Epilepsy who are treated with carbamazepine may have an increased dose of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to carbamazepine.'),('rs1051740','T > C','EPHX1','carbamazepine--PA448785','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','increased','-','CC','                Patients with the CC genotype and Epilepsy who are treated with carbamazepine may have an increased dose of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to carbamazepine.'),('rs1800629','G > A','LST1','carbamazepine--PA448785','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients chance of adverse response.'),('rs2032582','A > C','ABCB1','carbamazepine--PA448785','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','decreased','-','CC','                Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patients response to carbamazepine.'),('rs2227956','G > A','HSPA1A','carbamazepine--PA448785','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients chance of adverse response.'),('rs2234922','A > G','EPHX1','carbamazepine--PA448785','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','increased','-','AG','                Patients with the AG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of carbamazepine.'),('rs2234922','A > G','EPHX1','carbamazepine--PA448785','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','increased','-','GG','                Patients with the GG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of carbamazepine.'),('rs2273697','G > A','ABCC2','carbamazepine--PA448785','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype and epilepsy who are treated with carbamazepine 1) may have an increased risk for neurological adverse events 2) may have increased likelihood of response to antiepileptic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs2273697','G > A','ABCC2','carbamazepine--PA448785','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype and epilepsy who are treated with carbamazepine 1) may have an increased risk for neurological adverse events 2) may have increased likelihood of response to antiepileptic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs2844682','G > A','MUC21','carbamazepine--PA448785','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased but not absent risk of Stevens-Johnson syndrome when treated with carbamazepine as compared to patients with the AG or GG genotypes. This variant is a tagging SNP for HLA-B*1502, for which there is greater evidence of association with carbamazepine associated Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs3812718','C > T','SCN1A','carbamazepine--PA448785','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','increased','-','CT','                Patients with the CT genotype who are treated with carbamazepine may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine.'),('rs3812718','C > T','SCN1A','carbamazepine--PA448785','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','increased','-','TT','                Patients with the TT genotype who are treated with carbamazepine may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine.'),('rs3909184','G > C','FLOT1','carbamazepine--PA448785','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 1B','-','-','decreased','CC','                Patients with the CC genotype (non-carriers of the HLA-B*1502 allele) who are treated with carbamazapine may have a decreased risk of Stevens-Johnson Syndrome as compared to patients with the GG or CG genotype (patients who carry the HLA-B*1502 allele). Please note, this SNP is used as a tagging SNP for the HLA-B*1502 allele, and the genotyping method used to determine the HLA-B*1502 allele was not described. Other genetic and clinical factors may also influence a patients risk for adverse drug reactions when treated with carbamazapine.'),('rs750332','C > T','BAT2','carbamazepine--PA448785','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','decreased','TT','                Patients with the TT genotype who are treated with carbamazepine may have a decreased, but not absent, risk of Stevens-Johnson syndrome as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients risk for Stevens-Johnson syndrome with carbamazepine treatment.'),('rs11615','A > G','ERCC1','carboplatin--PA448803','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','AG','                Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs11615','A > G','ERCC1','carboplatin--PA448803','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','GG','                Patients with the GG genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs1801133','G > A','CLCN6','carboplatin--PA448803','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','increased','-','-','AA','                Patients with AA genotype may have 1) increased likelihood of response 2) increased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patients response to carboplatin.'),('rs25487','T > C','XRCC1','carboplatin--PA448803','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs9981861','T > C','DSCAM','carboplatin--PA448803','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.'),('rs9981861','T > C','DSCAM','carboplatin--PA448803','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.'),('rs1042714','G > C','ADRB2','carvedilol--PA448817','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with the CC genotype and heart failure may be less likely to have improved left ventricular ejection fraction after carvedilol treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1801253','G > C','ADRB1','carvedilol--PA448817','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','carvedilol--PA448817','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype 1) may have an increased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have a decreased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1057910','A > C','CYP2C9','celecoxib--PA448871','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','celecoxib--PA448871','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','-','increased','CC','                Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','celecoxib--PA448871','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','decreased','-','AC','                Patients with the AC genotype may have reduced metabolism of celecoxib and may require dose reduction when starting celecoxib therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1057910','A > C','CYP2C9','celecoxib--PA448871','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','decreased','-','CC','                Patients with the CC genotype may have greatly reduced metabolism of celecoxib and may require dose reduction (50% of standard starting dose) when starting celecoxib therapy or alternative management in juvenile rheumatoid arthritis patients who carry this genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1799853','C > T','CYP2C9','celecoxib--PA448871','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the CT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1799853','C > T','CYP2C9','celecoxib--PA448871','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs2819742','A > G','RYR2','cerivastatin--PA448897','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype may have an increased risk of cerivastatin-associated rhabdomyolysis as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patients risk of toxicity. '),('rs4149056','T > C','SLCO1B1','cerivastatin--PA448897','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 2A','-','-','increased','CT','                Patients with the CT genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.'),('rs4149056','T > C','SLCO1B1','cerivastatin--PA448897','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 2A','-','-','decreased','CC','                Patients with the CC genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.'),('rs2227983','G > A','EGFR','cetuximab--PA10040','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','AG','                Patients with the AG genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2227983','G > A','EGFR','cetuximab--PA10040','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs396991','A > C','FCGR3A','cetuximab--PA10040','VARIOUS',NULL,NULL,NULL,'Level 2B','decreased','-','-','CC','                Patients with the CC genotype with Colorectal Cancer who are treated with cetuximab may have poorer response and treatment outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to therapy.'),('rs4444903','A > G','EGF','cetuximab--PA10040','VARIOUS',NULL,NULL,NULL,'Level 2B','decreased','-','-','GG','                Patients with the GG genotype who are treated with cetuximab may have a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to cetuximab treatment.'),('rs9344','G > A','CCND1','cetuximab--PA10040','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype may have increased survival when treated with cetuximab as compared to patients with the AG or GG genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.'),('rs1799732','- > G','DRD2','chlorpromazine--PA448964','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1799732','- > G','DRD2','chlorpromazine--PA448964','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','G/del','                Patients with the G/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with these alleles and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs5065','A > G','NPPA','chlorthalidone--PA448970','VARIOUS',NULL,NULL,NULL,'Level 4','increased','-','-','AG','                Patients with Hypertension and the AG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.'),('rs5065','A > G','NPPA','chlorthalidone--PA448970','VARIOUS',NULL,NULL,NULL,'Level 4','increased','-','-','GG','                Patients with Hypertension and the GG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.'),('rs1042522','G > C','TP53','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1042522','G > C','TP53','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype may have better response (decreased risk of lymph node metastases and increased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1045642','A > G','ABCB1','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1142345','T > C','TPMT','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the TC genotype who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1142345','T > C','TPMT','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs11615','A > G','ERCC1','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','AG','                Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs11615','A > G','ERCC1','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','GG','                Patients with the GG genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs11615','A > G','ERCC1','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the AG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients risk for adverse events with cisplatin and cyclophosphamide treatment.'),('rs12201199','A > T','TPMT','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AT','                Patients with the AT genotype may have increased risk for hearing loss with cisplatin treatment compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs12201199','A > T','TPMT','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for hearing loss with cisplatin treatment compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs13181','T > G','ERCC2','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with platinum compounds as compared to patients with the GT or TT genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.'),('rs1695','A > G','GSTP1','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1695','A > G','GSTP1','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1799793','C > T','ERCC2','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of overall survival  as compared to patients with the CC genotype. Genotype CT is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide. Both findings have been contradicted in another studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1799793','C > T','ERCC2','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Genotype TT is not associated with increased risk of Drug Toxicity or decreased progression-free or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.'),('rs1799793','C > T','ERCC2','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype may have 1) increased survival and 2) increased risk for hematological toxicity with cisplatin regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to cisplatin regimens.'),('rs1799793','C > T','ERCC2','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype may have increased survival with cisplatin regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to cisplatin regimens.'),('rs1800460','C > T','TPMT','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the TC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1800460','C > T','TPMT','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1801133','G > A','MTHFR','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype may have: 1) increased likelihood of response to chemotherapy, 2) increased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotypes AG or GG. Other genetic and clinical factors may also influence a patients response to cisplatin.'),('rs1805087','A > G','MTR','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype may have increased likelihood of Drug Toxicity when treated with cisplatin in people with Osteosarcoma as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence a patients risk for toxicity to cisplatin.'),('rs2075252','T > C','LRP2','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','CC','                Patients with the CC genotype treated with cisplatin may have a reduced but not non-existent risk for hearing loss as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs2228001','G > T','XPC','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 1B','-','-','decreased','TT','                Patients with the TT genotype may have a decreased but not non-existent risk for toxicity with cisplatin treatment as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs25487','T > C','XRCC1','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs316019','A > C','SLC22A2','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs3212986','C > A','ERCC1','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk for nephrotoxicity with platinum-based regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs3957357','A > G','GSTA1','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.'),('rs4646316','C > T','COMT','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 1B','-','-','decreased','TT','                Patients with the TT genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk of hearing loss as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs9332377','C > T','COMT','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 1B','-','-','increased','CT','                Patients with the CT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs9332377','C > T','COMT','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 1B','-','-','increased','TT','                Patients with the TT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs9597','C > G','BAIAP3','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CG','                Patients with the CG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to cisplatin and irinotecan treatment.'),('rs9597','C > G','BAIAP3','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype, although the GG genotype was not observed in the supporting study. Other genetic and clinical factors may also influence a patients response to cisplatin and irinotecan treatment.'),('rs9679162','G > T','GALNT14','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype may have increased response, including increased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs1799889','G > GG','SERPINE1','citalopram--PA449015','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs1799889','G > GG','SERPINE1','citalopram--PA449015','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs1954787','T > C','GRIK4','citalopram--PA449015','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 1B','increased','-','-','CT','                Patients with the CT genotype may have an increased chance of response to citalopram treatment as compared to patients with the TT genotype. Patients with the CT genotype may still be at risk for non-response to citalopram treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1954787','T > C','GRIK4','citalopram--PA449015','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 1B','increased','-','-','CC','                Patients with the CC genotype may have an increased chance of response to citalopram treatment as compared to patients with the TT genotype. Patients with the CC genotype may still be at risk for non-response to citalopram treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs2227631','A > G','SERPINE1','citalopram--PA449015','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs2227631','A > G','SERPINE1','citalopram--PA449015','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs334558','A > G','GSK3B','citalopram--PA449015','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have more improvement in symptoms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients response to fluoxetine and citalopram.'),('rs7569963','G > A','CREB1','citalopram--PA449015','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs7569963','G > A','CREB1','citalopram--PA449015','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs7997012','A > G','HTR2A','citalopram--PA449015','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs9274407','A > T','HLA-DQB1','clavulanate--PA164742987','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','TT','                Patients with the TT genotype may have decreased but not absent risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk for drug induced liver injury.'),('rs1544410','C > T','VDR','clodronate--PA10239','MUSCULO-SKELETAL SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with bisphosphonates may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to bisphosphonates.'),('rs16944','A > G','IL1B','clodronate--PA10239','MUSCULO-SKELETAL SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs731236','A > G','VDR','clodronate--PA10239','MUSCULO-SKELETAL SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased likelihood of resistance when treated with clodronate compared to patients with genotype AA. Other genetic and clinical factors may also influence resistance to clodronate.'),('rs1360780','T > C','FKBP5','clomipramine--PA449048','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','decreased','CC','                Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to paroxetine, venlafaxine, clomipramine or nefazodone.'),('rs1045642','A > G','ABCB1','clopidogrel--PA449053','BLOOD AND BLOOD FORMING ORGANS',NULL,NULL,NULL,'Level 2A','-','-','decreased','GG','                People with GG  genotype may have decreased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Other genetic and clinical factors may also impact the response to clopidogrel.'),('rs4244285','G > A','CYP2C19','clopidogrel--PA449053','BLOOD AND BLOOD FORMING ORGANS',NULL,NULL,NULL,'Level 1A','increased','-','-','AG','                Patients with the AG genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for secondary cardiovascular events and response to clopidogrel.'),('rs4244285','G > A','CYP2C19','clopidogrel--PA449053','BLOOD AND BLOOD FORMING ORGANS',NULL,NULL,NULL,'Level 1A','increased','-','-','AA','                Patients with the AA genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for secondary cardiovascular events and response to clopidogrel.'),('rs4986893','G > A','CYP2C19','clopidogrel--PA449053','BLOOD AND BLOOD FORMING ORGANS',NULL,NULL,NULL,'Level 1A','increased','-','-','AG','                Patients with the AG genotype 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patients risk for secondary cardiovascular events and response to clopidogrel.'),('rs4986893','G > A','CYP2C19','clopidogrel--PA449053','BLOOD AND BLOOD FORMING ORGANS',NULL,NULL,NULL,'Level 1A','increased','-','-','AA','                Patients with the AA genotype 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patients risk for secondary cardiovascular events and response to clopidogrel.'),('rs662','T > C','PON1','clopidogrel--PA449053','BLOOD AND BLOOD FORMING ORGANS',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype who are treated with clopidogrel 1) may have lower levels of active metabolite, resulting in decreased platelet inhibition and decreased response 2) may have an increased risk for stent thrombosis, target vessel revascularization, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CC genotype. This association has not been found in more studies than the number of studies the association was shown. Other genetic and clinical factors may also influence a patients response to clopidogrel.'),('rs662','T > C','PON1','clopidogrel--PA449053','BLOOD AND BLOOD FORMING ORGANS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype who are treated with clopidogrel 1) may have higher levels of active metabolite, resulting in increased platelet inhibition and better response 2) may have a decreased, but not absent, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CT or TT genotype. This association has not been found in more studies than the number of studies the association was shown. Other genetic and clinical factors may also influence a patients response to clopidogrel.'),('rs1079598','A > G','DRD2','clozapine--PA449061','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1079598','A > G','DRD2','clozapine--PA449061','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1414334','C > G','HTR2C','clozapine--PA449061','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 1B','-','-','decreased','GG','                Patients with the GG genotype who are treated with antipsychotics may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patients risk for developing metabolic syndrome.'),('rs1799732','- > G','DRD2','clozapine--PA449061','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1799732','- > G','DRD2','clozapine--PA449061','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','G/del','                Patients with the G/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with these alleles and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1800497','G > A','ANKK1','clozapine--PA449061','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1800497','G > A','ANKK1','clozapine--PA449061','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','-','increased','AA','                Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs6277','G > A','DRD2','clozapine--PA449061','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased, but not absent risk, for weight gain when treated with clozapine or olanzepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs6280','C > T','DRD3','clozapine--PA449061','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a better response to treatment as compared to patients with the CC or CT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patients response to clozapine treatment.'),('rs742105','C > T','DTNBP1','clozapine--PA449061','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients response to clozapine.'),('rs742105','C > T','DTNBP1','clozapine--PA449061','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients response to clozapine.'),('rs9282861','C > T','SULT1A1','conjugated estrogens--PA164754789','GENITO URINARY SYSTEM AND SEX HORMONES',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse responses to hormone replacement therapy.'),('rs9282861','C > T','SULT1A1','conjugated estrogens--PA164754789','GENITO URINARY SYSTEM AND SEX HORMONES',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse responses to hormone replacement therapy.'),('rs9340799','A > G','ESR1','conjugated estrogens--PA164754789','GENITO URINARY SYSTEM AND SEX HORMONES',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density.'),('rs9340799','A > G','ESR1','conjugated estrogens--PA164754789','GENITO URINARY SYSTEM AND SEX HORMONES',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype may experience 1) greater increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) smaller decreases in spine bone mineral density when untreated, as compared to patient with the AA genotype. Other genetic and clinical factors may also influence spine bone mineral density.'),('rs1801131','T > G','MTHFR','cyanocobalamin--PA451892','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','GT','                Genotype GT may be associated with overall survival and progression free survival  in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patients response to pemetrexed.'),('rs1801131','T > G','MTHFR','cyanocobalamin--PA451892','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Genotype GG may be associated with overall survival and progression free survival  in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patients response to pemetrexed.'),('rs1042522','G > C','TP53','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1042522','G > C','TP53','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs11615','A > G','ERCC1','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSVARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the AG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients risk for adverse events with cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','increased','-','-','AG','                Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1695','A > G','GSTP1','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','increased','-','-','GG','                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1695','A > G','GSTP1','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1695','A > G','GSTP1','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1799793','C > T','ERCC2','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of overall survival  as compared to patients with the CC genotype. Genotype CT is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide. Both findings have been contradicted in another studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1799793','C > T','ERCC2','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Genotype TT is not associated with increased risk of Drug Toxicity or decreased progression-free or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.'),('rs1799983','T > G','NOS3','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GT','                Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs1799983','T > G','NOS3','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs1801133','G > A','MTHFR','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','-','increased','AA','                Patients with the AA genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to cyclophosphamide.'),('rs2032582','A > C','ABCB1','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CT or TT. Other genetic and clinical factors may also influence a patients response to cyclophosphamide and doxorubicin.'),('rs2279343','A > G','CYP2B6','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype who have received a  hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for oral mucositis.'),('rs2279343','A > G','CYP2B6','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype who have received a  hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for oral mucositis.'),('rs25487','T > C','XRCC1','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CT or TT genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.'),('rs2740574','C > T','CYP3A4','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','TT','                Premenopausal patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have a shorter period of time before chemotherapy-induced ovarian failure compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.'),('rs3745274','G > T','CYP2B6','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','decreased','-','GT','                Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs3745274','G > T','CYP2B6','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','decreased','-','TT','                Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs3745274','G > T','CYP2B6','cyclophosphamide--PA449165','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','GT','                Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patients risk for venoocclusive disease of the liver.'),('rs3745274','G > T','CYP2B6','cyclophosphamide--PA449165','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','TT','                Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the TT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patients risk for venoocclusive disease of the liver.'),('rs3957357','A > G','GSTA1','cyclophosphamide--PA449165','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.'),('rs4244285','G > A','CYP2C19','cyclophosphamide--PA449165','VARIOUS',NULL,NULL,NULL,'Level 4','-','-','decreased','AG','                Female patients with the AG genotype and Systemic Lupus Erythematosus who are treated with a high cumulative dose of cyclophosphamide (= or >23.75 g) may have a decreased risk of ovarian toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cyclophosphamide-induced ovarian toxicity.'),('rs4244285','G > A','CYP2C19','cyclophosphamide--PA449165','VARIOUS',NULL,NULL,NULL,'Level 4','-','-','decreased','AA','                Female patients with the AA genotype and Systemic Lupus Erythematosus who are treated with a high cumulative dose of cyclophosphamide (= or >23.75 g) may have a decreased risk of ovarian toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cyclophosphamide-induced ovarian toxicity.'),('rs4244285','G > A','CYP2C19','cyclophosphamide--PA449165','VARIOUS',NULL,NULL,NULL,'Level 4','increased','-','-','AA','                Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs4880','A > G','SOD2','cyclophosphamide--PA449165','VARIOUS',NULL,NULL,NULL,'Level 2B','decreased','-','-','GG','                Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients survival when treated with cyclophosphamide.'),('rs8192709','C > T','CYP2B6','cyclophosphamide--PA449165','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Recipients of HLA-identical hematopoietic stem cell transplantation with the CT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hemorrhagic cystitis.'),('rs8192709','C > T','CYP2B6','cyclophosphamide--PA449165','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Recipients of HLA-identical hematopoietic stem cell transplantation with the TT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hemorrhagic cystitis.'),('rs9561778','G > T','ABCC4','cyclophosphamide--PA449165','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','GT','                Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse events with cyclophosphamide treatment.'),('rs9561778','G > T','ABCC4','cyclophosphamide--PA449165','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events with cyclophosphamide treatment.'),('rs9561778','G > T','ABCC4','cyclophosphamide--PA449165','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','GT','                Patients with the GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for ADRs.'),('rs9561778','G > T','ABCC4','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for ADRs.'),('rs1045642','A > G','ABCB1','cyclosporine--PA449167','VARIOUS',NULL,NULL,NULL,'Level 3','-','increased','-','AG','                Patients with genotype AG may have increased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.'),('rs1045642','A > G','ABCB1','cyclosporine--PA449167','VARIOUS',NULL,NULL,NULL,'Level 3','-','decreased','-','GG','                Patients with genotype GG may have decreased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype AA or AG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.'),('rs1128503','A > G','ABCB1','cyclosporine--PA449167','VARIOUS',NULL,NULL,NULL,'Level 3','-','increased','-','GG','                Patients with the GG genotype and Myasthenia Gravis may have increased clearance of cyclosporine and therefore may require an increased dose of cyclosporine, compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.'),('rs2032582','A > C','ABCB1','cyclosporine--PA449167','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','AC','                Patients with the AC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of resistance to cyclosporine.'),('rs2032582','A > C','ABCB1','cyclosporine--PA449167','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with the CC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of resistance to cyclosporine.'),('rs2032582','A > C','ABCB1','cyclosporine--PA449167','VARIOUS',NULL,NULL,NULL,'Level 3','-','decreased','-','CC','                Patients with the CC genotype may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.'),('rs776746','C > T','CYP3A5','cyclosporine--PA449167','VARIOUS',NULL,NULL,NULL,'Level 3','-','increased','-','CT','                Patients with the TC genotype may require an increased dose of cyclosporine to reach target blood concentration as compared to patients with the CC genotype, although some studies find no association with dosage. Other genetic and clinical factors may also influence dose of cyclosporine.'),('rs776746','C > T','CYP3A5','cyclosporine--PA449167','VARIOUS',NULL,NULL,NULL,'Level 3','-','increased','-','TT','                Patients with the TT genotype may require an increased dose of cyclosporine to reach target blood concentration as compared to patients with the CC genotype,  although some studies find no association with dosage. Other genetic and clinical factors may also influence dose of cyclosporine.'),('rs1045642','A > G','ABCB1','cytarabine--PA449177','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','cytarabine--PA449177','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs2072671','A > C','CDA','cytarabine--PA449177','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AC','                Patients with the AC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs2072671','A > C','CDA','cytarabine--PA449177','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs532545','C > T','CDA','cytarabine--PA449177','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the genotype CT and Myeloid Leukemia who are treated with cytarabine may have a decreased survival time and an increased risk for death as compared to patients with the CC genotype, or may have an increased survival time and a decreased risk for death as compared to patients with the TT genotype, though this may not be statistically significant. Other genetic and clinical factors may also influence a patients survival when treated with cytarabine.'),('rs532545','C > T','CDA','cytarabine--PA449177','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the genotype TT and Myeloid Leukemia who are treated with cytarabine 1) may have a decreased survival time 2) may have an increased risk for death, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients survival when treated with cytarabine.'),('rs532545','C > T','CDA','cytarabine--PA449177','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','-','increased','CT','                Patients with the CT genotype who are treated with cytarabine may have an increased risk of toxicity compared to patients with the CC genotype. Other genetic and clinical factors may also influence cytarabine toxicity.'),('rs532545','C > T','CDA','cytarabine--PA449177','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','-','increased','TT','                Patients with the TT genotype who are treated with cytarabine may have an increased risk of toxicity compared to patients with the CC genotype. Other genetic and clinical factors may also influence cytarabine toxicity.'),('rs602950','A > G','CDA','cytarabine--PA449177','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','-','increased','AG','                Patients with the AG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for cytarabine-induced toxicity.'),('rs602950','A > G','CDA','cytarabine--PA449177','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','-','increased','GG','                Patients with the GG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for cytarabine-induced toxicity.'),('rs61888800','G > T','BDNF','desipramine--PA449233','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GT','                Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.'),('rs61888800','G > T','BDNF','desipramine--PA449233','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype with major depressive disorder may experience a  lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.'),('rs1045642','A > G','ABCB1','dexamethasone--PA449247','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs2032582','A > C','ABCB1','dexamethasone--PA449247','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patients response to the therapy.'),('rs1057910','A > C','CYP2C9','diclofenac--PA449293','SENSORY ORGANS',NULL,NULL,NULL,'Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','diclofenac--PA449293','SENSORY ORGANS',NULL,NULL,NULL,'Level 2A','-','-','increased','CC','                Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs2070744','C > T','NOS3','diuretics--PA151249535','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the CT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antihypertensives.'),('rs2070744','C > T','NOS3','diuretics--PA151249535','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antihypertensives.'),('rs4961','G > T','ADD1','diuretics--PA151249535','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GT','                Patients with the GT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patients response to diuretics.'),('rs4961','G > T','ADD1','diuretics--PA151249535','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patients response to diuretics.'),('rs1056836','C > G','CYP1B1','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with taxanes may have longer disease-free progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs11045585','A > G','SLCO1B3','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to docetaxel.'),('rs11045585','A > G','SLCO1B3','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to docetaxel.'),('rs12418','G > A','CHST3','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs12418','G > A','CHST3','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs12960','G > A','RPL13','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs1382368','C > T','XRCC4','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','increased','-','CT','                Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the CC genotype, or decreased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.'),('rs1382368','C > T','XRCC4','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','increased','-','TT','                Patients with the TT genotype may have increased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.'),('rs1402467','C > G','SULT1C4','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CG','                Patients with the CG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs1402467','C > G','SULT1C4','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs1799931','G > A','NAT2','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs1871450','G > A','CHST3','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs1871450','G > A','CHST3','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs1883322','C > T','PPARD','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2016520','C > T','PPARD','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2227291','G > C','ATP7A','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','CC','                Patients with the CC genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2234922','A > G','EPHX1','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','decreased','-','AG','                Patients with the AG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.'),('rs2234922','A > G','EPHX1','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','decreased','-','GG','                Patients with the GG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.'),('rs2238472','C > T','ABCC6','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','TT','                Patients with the TT genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2292954','A > G','SPG7','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2301159','G > A','SLC10A2','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs2301159','G > A','SLC10A2','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs2740574','C > T','CYP3A','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','decreased','-','TT','                Patients with the TT genotype may have decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of docetaxel.'),('rs3734254','C > T','PPARD','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs3734254','C > T','PPARD','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs4148943','C > T','CHST3','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4148945','C > T','CHST3','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4148947','T > C','CHST3','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4148950','G > A','CHST3','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs4148950','G > A','CHST3','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs4646487','C > T','CYP4B1','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4646487','C > T','CYP4B1','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs518329','T > C','PRDX4','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','increased','-','CT','                Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.'),('rs518329','T > C','PRDX4','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','increased','-','CC','                Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.'),('rs6922548','A > G','PPARD','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs6922548','A > G','PPARD','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs730720','C > T','CHST3','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs7769719','G > A','PPARD','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs870995','C > A','PIK3CA','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','decreased','-','AA','                Patients with the AA genotype may have decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.'),('rs1045642','A > G','ABCB1','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs1045642','A > G','ABCB1','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs13058338','T > A','RAC2','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin  may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the TT genotype. Please note, the risk allele reported in the study has been complemented to the positive chromosomal strand here. Other genetic and clinical factors may also influence a patients risk for cardiotoxicity.'),('rs17222723','T > A','ABCC2','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AT','                Patients with the AT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for cardiotoxicity.'),('rs17222723','T > A','ABCC2','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for cardiotoxicity.'),('rs1799983','T > G','NOS3','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GT','                Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs1799983','T > G','NOS3','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs1883112','G > A','NCF4','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patients risk for cardiotoxicity.'),('rs2032582','A > C','ABCB1','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patients response to the therapy.'),('rs2032582','A > C','ABCB1','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CT or TT. Other genetic and clinical factors may also influence a patients response to cyclophosphamide and doxorubicin.'),('rs20572','C > T','CBR1','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','increased','-','CT','                Patients with the CT genotype may have 1) decreased clearance of doxorubicin 2) increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with CC genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.'),('rs2070744','C > T','NOS3','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs2070744','C > T','NOS3','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence disease-free survival.'),('rs3745274','G > T','CYP2B6','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','increased','-','TT','                Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs4244285','G > A','CYP2C19','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','increased','-','-','AA','                Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs45511401','G > T','ABCC1','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','GT','                Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxocity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for cardiotoxicity.'),('rs45511401','G > T','ABCC1','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cardiotoxicity.'),('rs4673','A > G','CYBA','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','GG','                Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for cardiotoxicity.'),('rs8133052','G > A','CBR3','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype, or 1) may have increased metabolism of doxorubicin 2) may have less tumor reduction 3) may have decreased severity of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to doxorubicin treatment and risk of toxicity.'),('rs8133052','G > A','CBR3','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients response to doxorubicin treatment and risk of toxicity.'),('rs8187710','G > A','ABCC2','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of cardiotoxicity.'),('rs8187710','G > A','ABCC2','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of cardiotoxicity.'),('rs9561778','G > T','ABCC4','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','GT','                Patients with the GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for ADRs.'),('rs9561778','G > T','ABCC4','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for ADRs.'),('rs20572','C > T','CBR1','doxorubicinol--PA165291922','VARIOUS',NULL,NULL,NULL,'Level 4','-','increased','-','CT','                Patients with the CT genotype may have 1) decreased clearance of doxorubicin 2) increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with CC genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.'),('rs16969968','G > A','CHRNA3','Drugs used in nicotine dependence--PA164712720','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with AG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the AG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Finding are based on haplotype analysis of rs16969968 and rs680244. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs16969968','G > A','CHRNA3','Drugs used in nicotine dependence--PA164712720','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the GG genotype. However, contradictory findings have been reported, with the AA genotype may be associated with a decreased likelihood of smoking cessation compared to GG genotype. Finding are based on haplotype analysis of rs16969968 and rs680244. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs1799971','A > G','OPRM1','Drugs used in nicotine dependence--PA164712720','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with AG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the AG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs1799971','A > G','OPRM1','Drugs used in nicotine dependence--PA164712720','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the GG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs1800497','G > A','ANKK1','Drugs used in nicotine dependence--PA164712720','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with AG genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs1800497','G > A','ANKK1','Drugs used in nicotine dependence--PA164712720','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs963468','G > A','DRD3','duloxetine--PA10066','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to duloxetine treatment.'),('rs963468','G > A','DRD3','duloxetine--PA10066','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to duloxetine treatment.'),('rs1045642','A > G','ABCB1','efavirenz--PA449441','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.'),('rs2032582','A > C','ABCB1','efavirenz--PA449441','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype may have increased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the AA genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz'),('rs3745274','G > T','CYP2A7P1','efavirenz--PA449441','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 2A','-','increased','-','TT','                Patients with the TT genotype may have increased plasma concentration of efavirenz in people with HIV as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients exposure to efavirenz.'),('rs3745274','G > T','CYP2A7P1','efavirenz--PA449441','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 2A','-','-','increased','GT','                Patients with the GT genotype may have an increased risk of efavirenz-induced side effects (central nervous symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs3745274','G > T','CYP2A7P1','efavirenz--PA449441','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 2A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for efavirenz-induced side effects (central nervous symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2227983','G > A','EGFR','egfr inhibitors--PA153561371','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','AG','                Patients with the AG genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2227983','G > A','EGFR','egfr inhibitors--PA153561371','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1045642','A > G','ABCB1','epirubicin--PA449476','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','epirubicin--PA449476','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1695','A > G','GSTP1','epirubicin--PA449476','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','increased','-','-','AG','                Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1695','A > G','GSTP1','epirubicin--PA449476','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','increased','-','-','GG','                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs2227983','G > A','EGFR','erlotinib--PA134687924','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','AG','                Patients with the AG genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2227983','G > A','EGFR','erlotinib--PA134687924','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs712829','G > T','EGFR','erlotinib--PA134687924','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','GT','                Patients with the GT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.'),('rs712829','G > T','EGFR','erlotinib--PA134687924','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','TT','                Patients with the TT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.'),('rs712829','G > T','EGFR','erlotinib--PA134687924','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','increased','-','-','GT','                Patients with the GT genotype may be more sensitive to treatment with erlotinib  compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.'),('rs712829','G > T','EGFR','erlotinib--PA134687924','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','increased','-','-','TT','                Patients with the TT genotype may be more sensitive to treatment with erlotinib  compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.'),('rs11188072','C > T','CYP2C19','escitalopram--PA10074','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with escitalopram may require an increased dose  as compared to patients with the CT or CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs4795541','G > GG','SLC6A4','escitalopram--PA10074','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AGATGCTGGG','                Patients with the insert/del (Long/ Short) genotype who are treated with escitalopram: 1) who have experienced one or more Stressful Life Event in the 6 months pretreatment may have increased response compared to patients with the del/del genotype. Patients who have not experienced one or more Stressful Life Event in the 6 months pretreatment may have a similar response compared to patients with the del/del genotype. 2) may have an increased risk of side effects, including headache, compared to patients with the insert/insert genotype. Other genetic and clinical factors may also influence response to escitalopram and side effects induced by escitalopram.'),('rs4795541','G > GG','SLC6A4','escitalopram--PA10074','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AGATGCTGGG','                Patients with the insert/insert (Long/ Long) genotype who are treated with treated with escitalopram: 1) who have experienced one or more Stressful Life Event in the 6 months pretreatment may have increased response when treated with escitalopram compared to patients with the del/del genotype. Patients who have not experienced one or more Stressful Life Event in the 6 months pretreatment may have a similar response compared to patients with the del/del genotype. 2) may have a decreased risk of side effects, including headache, compared to patients with the insert/del or del/del genotype. Other genetic and clinical factors may also influence  response to escitalopram and side effects induced by escitalopram.'),('rs9316233','C > G','HTR2A','escitalopram--PA10074','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased antidepressant response to escitalopram as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to escitalopram.'),('rs1800629','G > A','TNF','etanercept--PA449515','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and rheumatoid arthritis who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype or may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to anti-TNF therapy.'),('rs1800629','G > A','TNF','etanercept--PA449515','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype and rheumatoid arthritis who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to anti-TNF therapy.'),('rs1799971','A > G','OPRM1','ethanol--PA448073','VARIOUS',NULL,NULL,NULL,'Level 2B','-','-','increased','AG','                Patients with the AG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients ethanol response.'),('rs1799971','A > G','OPRM1','ethanol--PA448073','VARIOUS',NULL,NULL,NULL,'Level 2B','-','-','increased','GG','                Patients with the GG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients ethanol response.'),('rs1800497','G > A','ANKK1','ethanol--PA448073','VARIOUS',NULL,NULL,NULL,'Level 2B','-','-','increased','AG','                Patients with AG genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patients risk for alcohol dependency.'),('rs1800497','G > A','ANKK1','ethanol--PA448073','VARIOUS',NULL,NULL,NULL,'Level 2B','-','-','increased','AA','                Patients with AA genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patients risk for alcohol dependency.'),('rs1544410','C > T','VDR','etidronic acid--PA449548','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with bisphosphonates may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to bisphosphonates.'),('rs16944','A > G','IL1B','etidronic acid--PA449548','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and Pagets disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs16944','A > G','IL1B','etidronic acid--PA449548','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs2784917','A > G','SLIT1','etoposide--PA449552','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','-','increased','AG','                Patients with the AG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2784917','A > G','SLIT1','etoposide--PA449552','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','-','increased','GG','                Patients with the GG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs6539870','A > G','','etoposide--PA449552','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','-','increased','GG','                Patients with the GG genotype may have increased risk of toxicity with etoposide compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1045642','A > G','ABCB1','fexofenadine--PA449621','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 3','-','increased','-','AG','                Healthy individuals with the AG genotype who are treated with fexofenadine may have higher plasma drug levels as compared to healthy individuals with the AA genotype.  Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.'),('rs1045642','A > G','ABCB1','fexofenadine--PA449621','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 3','-','increased','-','GG','                Healthy individuals with the GG genotype who are treated with fexofenadine may have higher plasma drug levels as compared with healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.'),('rs37973','G > A','GLCCI1','flunisolide--PA449661','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patients response to glucocorticoids.'),('rs1042522','G > C','TP53','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1042522','G > C','TP53','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype may have better response (decreased risk of lymph node metastases and increased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1045642','A > G','ABCB1','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1045642','A > G','ABCB1','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','GG','                Patients with GG genotype may have decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also impact a patients response to fluorouracil.'),('rs13181','T > G','ERCC2','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GT','                Patients with the GT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity as compared to patients with the TT genotype 2) an increased risk of early relapse as compared to patients with the TT genotype. However, a trend of an association is found for the GT genotype with increased progression free survival compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil, leucovorin and oxaliplatin.'),('rs13181','T > G','ERCC2','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity 2) an increased risk of early relapse and 3) decreased progression free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil, leucovorin and oxaliplatin.'),('rs1695','A > G','GSTP1','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','increased','-','-','GG','                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.'),('rs1695','A > G','GSTP1','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','AG','                Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for hematological toxicity when exposed to fluorouracil.'),('rs1695','A > G','GSTP1','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','GG','                Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hematological toxicity when exposed to flourouracil.'),('rs1799983','T > G','NOS3','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GT','                Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs1799983','T > G','NOS3','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs1801019','G > C','UMPS','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','-','-','increased','CG','                Patients with CG genotype and cancer may have a decreased, but not absent, risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and  leucovorin as compared to patients with the CC genotype. However, contradictory findings have been reported that show the CG genotype may be associated with increased risk for grade 3 to 4 diarrhea when treated with fluorouracil and leucovorin compared to the GG genotype.Other genetic and clinical factors may also influence response to leucovorin, tegafur and fluorouracil.'),('rs1801019','G > C','UMPS','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','-','-','increased','CC','                Patients with CC genotype and cancer may have an increased risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and  leucovorin as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to leucovorin, tegafur and fluorouracil.'),('rs1801131','T > G','MTHFR','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','increased','-','-','GT','                Patients with the  GT genotype may have 1) increased response, 2) increased risk of Drug Toxicity in people with Colorectal Neoplasms treated with oxaliplatin, capecitabine, fluorouracil, leucovorin as compared to patients with TT genotype. Other genetic and clinical factors may influence a patients response to these drugs.'),('rs1801131','T > G','MTHFR','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','increased','-','-','GG','                Patients with the  GG genotype may have 1) increased response, 2) increased risk of Drug Toxicity in people with Colorectal Neoplasms treated with oxaliplatin, capecitabine, fluorouracil, leucovorin as compared to patients with TT genotype. Other genetic and clinical factors may influence a patients response to these drugs.'),('rs1801131','T > G','MTHFR','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','GT','                Patients with the GT genotype may have decreased risk of Drug Toxicity when treated with fluorouracil and radiotherapy in people with Rectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1801131','T > G','MTHFR','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk of Drug Toxicity when treated with fluorouracil and radiotherapy in people with Rectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1801133','G > A','MTHFR','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','-','increased','AG','                Patients with the AG genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1801133','G > A','MTHFR','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','-','increased','AA','                Patients with the AA genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the GG genotype. However, conflicting finding of no-association for this genotype has also been reported. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1801158','C > T','DPYD','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype may have an increased risk of fluorouracil-related toxicity in cancer patients as compared to patients with the CC genotype. Genotype CT is also associated with decreased DPYD activity. Other genetic and clinical factors may also influence a patients risk of fluorouracil-related toxicity.'),('rs1801158','C > T','DPYD','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk of fluorouracil-related toxicity in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of fluorouracil-related toxicity.'),('rs1801159','T > C','DPYD','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased likelihood of middle-severe nausea,  vomiting and white blood cell decreases in cancer patients treated with fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk of fluorouracil  related adverse events.'),('rs1801159','T > C','DPYD','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased likelihood of middle-severe nausea,  vomiting and white blood cell decreases in cancer patients treated with fluorouracil as compared to patients with the TT genotype. Genotype CC is also associated with decreased clearance of fluorouracil. Other genetic and clinical factors may also influence a patients risk of fluorouracil  related adverse events.'),('rs1801265','G > A','DPYD','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased likelihood of middle-severe nausea and vomiting in Asian cancer patients treated with fluorouracil as as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patients risk for fluorouracil-related toxicity.'),('rs2070744','C > T','NOS3','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs2070744','C > T','NOS3','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence disease-free survival.'),('rs2297595','T > C','DPYD','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','-','increased','CT','                Patients with the CT genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs2297595','T > C','DPYD','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs25487','T > C','XRCC1','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype may have increased response to fluorouracil-containing chemotherapy regimens as compared to patients with the CT or TT genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.'),('rs67376798','T > A','DPYD','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','-','increased','AT','                Patients with the AT genotype and Cancer who are treated with fluorouracil-containing regimens 1) may have decreased clearance of the drug 2) may have an increased risk and severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for fluorouracil-induced toxicity.'),('rs67376798','T > A','DPYD','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','-','increased','AA','                Patients with the AA genotype were not reported, however, patients with the AT genotype and Cancer who are treated with fluorouracil-containing regimens 1) may have decreased clearance of the drug 2) may have an increased risk and severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for fluorouracil-induced toxicity.'),('rs9561778','G > T','ABCC4','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','GT','                Patients with the GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for ADRs.'),('rs9561778','G > T','ABCC4','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for ADRs.'),('rs9679162','G > T','GALNT14','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype may have increased response, including increased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs1799889','G > GG','SERPINE1','fluoxetine--PA449673','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs1799889','G > GG','SERPINE1','fluoxetine--PA449673','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs2227631','A > G','SERPINE1','fluoxetine--PA449673','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs2227631','A > G','SERPINE1','fluoxetine--PA449673','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs25531','T > C','SLC6A4','fluoxetine--PA449673','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 4','decreased','-','-','CT','                Patients with the CT genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT.  Other genetic and clinical factors may also influence a patients response.'),('rs25531','T > C','SLC6A4','fluoxetine--PA449673','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 4','decreased','-','-','CC','                Patients with the CC genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT.  Other genetic and clinical factors may also influence a patients response.'),('rs334558','A > G','GSK3B','fluoxetine--PA449673','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have more improvement in symptoms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients response to fluoxetine and citalopram.'),('rs61888800','G > T','BDNF','fluoxetine--PA449673','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GT','                Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.'),('rs61888800','G > T','BDNF','fluoxetine--PA449673','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype with major depressive disorder may experience a  lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.'),('rs37973','G > A','GLCCI1','fluticasone propionate--PA449686','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patients response to glucocorticoids.'),('rs11045819','C > A','SLCO1B1','fluvastatin--PA449688','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AC','                Patients with the AC genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to fluvastatin.'),('rs11045819','C > A','SLCO1B1','fluvastatin--PA449688','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patients response to fluvastatin.'),('rs17238540','T > G','HMGCR','fluvastatin--PA449688','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GT','                Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17238540','T > G','HMGCR','fluvastatin--PA449688','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17244841','A > T','HMGCR','fluvastatin--PA449688','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs5443','C > T','GNB3','fluvastatin--PA449688','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 4','increased','-','-','CT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs5443','C > T','GNB3','fluvastatin--PA449688','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 4','increased','-','-','TT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs10042486','C > T','HTR1A','fluvoxamine--PA449690','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs10042486','C > T','HTR1A','fluvoxamine--PA449690','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment  as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs6295','C > G','HTR1A','fluvoxamine--PA449690','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CG','                Patients with the CG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs6295','C > G','HTR1A','fluvoxamine--PA449690','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs1801131','T > G','MTHFR','folic acid--PA449692','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','GT','                Genotype GT may be associated with overall survival and progression free survival  in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patients response to pemetrexed.'),('rs1801131','T > G','MTHFR','folic acid--PA449692','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Genotype GG may be associated with overall survival and progression free survival  in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patients response to pemetrexed.'),('rs4961','G > T','ADD1','furosemide--PA449719','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 2B','decreased','-','-','GT','                Patients with the GT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to diuretics.'),('rs4961','G > T','ADD1','furosemide--PA449719','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 2B','decreased','-','-','TT','                Patients with the TT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to diuretics.'),('rs712829','G > T','EGFR','gefitinib--PA131301952','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GT','                Patients with the GT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs712829','G > T','EGFR','gefitinib--PA131301952','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs712829','G > T','EGFR','geldanamycin--PA152031327','VARIOUS',NULL,NULL,NULL,'Level 4','decreased','-','-','GT','                Patients with the genotype GT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patients response.'),('rs712829','G > T','EGFR','geldanamycin--PA152031327','VARIOUS',NULL,NULL,NULL,'Level 4','decreased','-','-','TT','                Patients with the genotype TT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patients response.'),('rs2072671','A > C','CDA','gemcitabine--PA449748','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AC','                Patients with the AC genotype who are treated with gemcitabine may have an increased risk of hematological toxicity as compared to patients with the the CC genotype and an increased risk of gastrointestinal toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs2072671','A > C','CDA','gemcitabine--PA449748','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with gemcitabine may have an increased risk of gastrointestinal toxicity and decreased risk of hematological toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs60369023','G > A','CDA','gemcitabine--PA449748','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity Neutropenia as compared to patients with the GG genotype, or 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.'),('rs60369023','G > A','CDA','gemcitabine--PA449748','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity of Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.'),('rs9937','A > G','RRM1','gemcitabine--PA449748','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','-','decreased','AG','                Patients with the AG genotype and the A allele of rs1042858 with advanced breast cancer who are treated with gemcitabine 1) may be less likely to experience toxicity such as neutropenia 2) may have a tendency, though not a statistically significant one, towards poorer progression-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of toxicity and response to gemcitabine.'),('rs9937','A > G','RRM1','gemcitabine--PA449748','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','-','decreased','GG','                Patients with the GG genotype and the A allele of rs1042858 with advanced breast cancer who are treated with gemcitabine 1) may be less likely to experience toxicity such as neutropenia 2) may have a tendency, though not a statistically significant one, towards poorer progression-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of toxicity and response to gemcitabine.'),('rs5219','T > C','KCNJ11','gliclazide--PA10892','ALIMENTARY TRACT AND METABOLISM',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with CC genotype may have poorer response (higher decrease in HbA1c) to 6-month treatment of sulfonylureas in people with Type 2 diabetes as compared to patients with genotype CT or TT. Other genetic or clinical factors may also influence a patients response to sulfonylureas.'),('rs37973','G > A','GLCCI1','glucocorticoids--PA452347','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype may have intermediate increased risk of poor response to inhaled glucocorticoids in asthma patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patients response to glucocorticoids. The G allele is associated with decrease in the expression of GLCCI1 gene and cells with heterozygous AG genotype has an intermediate GLCC1 expression value.'),('rs37973','G > A','GLCCI1','glucocorticoids--PA452347','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patients response to glucocorticoids.'),('rs909706','T > C','DTNBP1','haloperidol--PA449841','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 4','decreased','-','-','CC','                Patients with the CC genotype and Schizophrenia may have a reduced response to haloperidol as compared to patients with the CT genotype. Results were suggestive of an association. Other genetic and clinical factors may also influence a patients response to haloperidol.'),('rs17238540','T > G','HMGCR','hmg coa reductase inhibitors--PA133950441','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','GT','                Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17238540','T > G','HMGCR','hmg coa reductase inhibitors--PA133950441','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17244841','A > T','HMGCR','hmg coa reductase inhibitors--PA133950441','VARIOUS',NULL,NULL,NULL,'Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs1935349','C > T','HTR7','hmg coa reductase inhibitors--PA133950441','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for statin-related myalgia as compared to patients with the CC genotypes, or may have a decreased risk for statin-related myalgia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs1935349','C > T','HTR7','hmg coa reductase inhibitors--PA133950441','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for statin-related myalgia as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs4149056','T > C','SLCO1B1','hmg coa reductase inhibitors--PA133950441','VARIOUS',NULL,NULL,NULL,'Level 2A','-','-','increased','CT','                Patients with the CT genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patients metabolism and response to statins.'),('rs4149056','T > C','SLCO1B1','hmg coa reductase inhibitors--PA133950441','VARIOUS',NULL,NULL,NULL,'Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patients metabolism and response to statins.'),('rs4693075','G > C','COQ2','hmg coa reductase inhibitors--PA133950441','VARIOUS',NULL,NULL,NULL,'Level 2B','-','-','decreased','CC','                Patients with the CC genotype may have decreased risk of statin-related muscle symptoms as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence a patients risk of toxicity.'),('rs5443','C > T','GNB3','hmg coa reductase inhibitors--PA133950441','VARIOUS',NULL,NULL,NULL,'Level 4','decreased','-','-','CT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs5443','C > T','GNB3','hmg coa reductase inhibitors--PA133950441','VARIOUS',NULL,NULL,NULL,'Level 4','decreased','-','-','TT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs4149601','G > A','NEDD4L','hydrochlorothiazide--PA449899','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype and Hypertension who are treated with hydrochlorothiazide may have a better response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to hydrochlorothiazide treatment.'),('rs4149601','G > A','NEDD4L','hydrochlorothiazide--PA449899','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype and Hypertension who are treated with hydrochlorothiazide may have a better response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to hydrochlorothiazide treatment.'),('rs4961','G > T','ADD1','hydrochlorothiazide--PA449899','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GT','                Patients with the GT genotype may have a better response to hydrochlorothiazide treatment as compared to patients with the GG genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patients response to hydrochlorothiazide treatment.'),('rs4961','G > T','ADD1','hydrochlorothiazide--PA449899','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype may have a better response to hydrochlorothiazide treatment as compared to patients with the GG genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patients response to hydrochlorothiazide treatment.'),('rs7297610','C > T','YEATS4','hydrochlorothiazide--PA449899','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 2B','decreased','-','-','CT','                Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to hydrochlorothiazide.'),('rs7297610','C > T','YEATS4','hydrochlorothiazide--PA449899','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 2B','decreased','-','-','TT','                Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to hydrochlorothiazide.'),('rs20417','C > G','PTGS2','ibuprofen--PA449957','GENITO URINARY SYSTEM AND SEX HORMONES',NULL,NULL,NULL,'Level 3','increased','-','-','CG','                Patients with the CG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to ibuprofen.'),('rs20417','C > G','PTGS2','ibuprofen--PA449957','GENITO URINARY SYSTEM AND SEX HORMONES',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to ibuprofen.'),('rs1045642','A > G','ABCB1','idarubicin--PA449961','GENITO URINARY SYSTEM AND SEX HORMONES',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','idarubicin--PA449961','GENITO URINARY SYSTEM AND SEX HORMONES',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs4799915','C > T','CELF4','iloperidone--PA161199368','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs4799915','C > T','CELF4','iloperidone--PA161199368','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs4933824','T > G','NRG3','iloperidone--PA161199368','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the TT or GT genotype.  Other genetic and clinical factors may also influence a patients response.'),('rs7142881','G > A','NUBPL','iloperidone--PA161199368','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs7142881','G > A','NUBPL','iloperidone--PA161199368','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs993648','C > T','CERKL','iloperidone--PA161199368','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patients response.'),('rs1800629','G > A','TNF','infliximab--PA452639','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and rheumatoid arthritis who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype or may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to anti-TNF therapy.'),('rs1800629','G > A','TNF','infliximab--PA452639','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype and rheumatoid arthritis who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to anti-TNF therapy.'),('rs9657182','C > T','IDO1','interferon alfa-2a, recombinant--PA164779048','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','CT','                Patients with the CT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patients risk for drug side effects.'),('rs9657182','C > T','IDO1','interferon alfa-2a, recombinant--PA164779048','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','TT','                Patients with the TT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patients risk for drug side effects.'),('rs1127354','C > A','ITPA','interferon alfa-2b, recombinant--PA164783990','VARIOUS',NULL,NULL,NULL,'Level 2B','-','decreased','-','AC','                Patients with the AC genotype and Hepatitis C, Chronic may have a decreased, but not absent, risk of 1) dose reduction of ribavirin, 2) rapid decrease in hemoglobin levels when treated with interferon alfa-2b, recombinant and ribavirin or interferon alfa-2b, recombinant and ribavirin, and telaprevir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for response to ribavirin.'),('rs1127354','C > A','ITPA','interferon alfa-2b, recombinant--PA164783990','VARIOUS',NULL,NULL,NULL,'Level 2B','-','decreased','-','AA','                Patients with the AA genotype and Hepatitis C, Chronic may have a decreased, but not absent, risk of 1) dose reduction of ribavirin, 2) rapid decrease in hemoglobin levels when treated with interferon alfa-2b, recombinant and ribavirin or interferon alfa-2b, recombinant and ribavirin, and telaprevir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for response to ribavirin.'),('rs9272105','G > A','HLA-DQA1','interferon beta-1a--PA450037','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype may have decreased but not absent risk for developing neutralizing anti-IFN-beta antibodies (i.e. decreased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to interferon-beta therapy.'),('rs9272105','G > A','HLA-DQA1','interferon beta-1b--PA450039','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype may have decreased but not absent risk for developing neutralizing anti-IFN-beta antibodies (i.e. decreased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to interferon-beta therapy.'),('rs1367117','G > A','APOB','irbesartan--PA450084','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype who are treated with irbesartan may be less likely to respond than patients with the AG or the GG genotype.  Other genetic and clinical factors may also influence a patients response.'),('rs4124874','T > G','UGT1A1','irinotecan--PA450085','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','GT','                Patients with the GT genotype and Cancer who are treated with irinotecan may have an increased risk of Neutropenia as compared to patients with the TT genotype, or may have a decreased risk of Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs4124874','T > G','UGT1A1','irinotecan--PA450085','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype and Cancer who are treated with irinotecan may have an increased risk of Neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs9597','C > G','BAIAP3','irinotecan--PA450085','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CG','                Patients with the CG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to cisplatin and irinotecan treatment.'),('rs9597','C > G','BAIAP3','irinotecan--PA450085','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype, although the GG genotype was not observed in the supporting study. Other genetic and clinical factors may also influence a patients response to cisplatin and irinotecan treatment.'),('rs3213422','A > C','ATP5A1P3','leflunomide--PA450192','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','increased','-','-','CC','                Patients with the CC genotype who are treated with leflunomide may be more likely to respond compared to patients with the AA genotype.  Other genetic and clinical factors may also influence a patients response.'),('rs762551','C > A','CYP1A2','leflunomide--PA450192','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','AC','                Patients with the AC genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity with leflunomide treatment.'),('rs762551','C > A','CYP1A2','leflunomide--PA450192','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity with leflunomide treatment.'),('rs9340799','A > G','ESR1','leflunomide--PA450192','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype may experience decreased response to leflunomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693.'),('rs4646','A > C','CYP19A1','letrozole--PA450196','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with the CC genotype who are treated with letrozole may have decreased treatment efficacy compared to patients with the AA or AC genotype.  Other genetic and clinical factors may also influence a patients response.'),('rs1051266','T > C','SLC19A1','leucovorin--PA450198','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) decreased, but not absent, risk of Toxic liver disease 2) increased risk of Drug Toxicity 3) increased likelihood of treatment interruptions as compared to patients with the CC genotype. Further, patients with the CT genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patients response to leucovorin, mercaptopurine and methotrexate.'),('rs1051266','T > C','SLC19A1','leucovorin--PA450198','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) increased likelihood of Toxic liver disease 2) decreased, but not absent, risk of Drug Toxicity 3) decreased likelihood of treatment interruptions as compared to patients with the CT and TT genotype. Further, patients with the CC genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patients response to leucovorin, mercaptopurine and methotrexate.'),('rs13181','T > G','ERCC2','leucovorin--PA450198','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','GT','                Patients with the GT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity as compared to patients with the TT genotype 2) an increased risk of early relapse as compared to patients with the TT genotype. However, a trend of an association is found for the GT genotype with increased progression free survival compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil, leucovorin and oxaliplatin.'),('rs13181','T > G','ERCC2','leucovorin--PA450198','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity 2) an increased risk of early relapse and 3) decreased progression free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil, leucovorin and oxaliplatin.'),('rs1801019','G > C','UMPS','leucovorin--PA450198','VARIOUS',NULL,NULL,NULL,'Level 2B','-','-','increased','CG','                Patients with CG genotype and cancer may have a decreased, but not absent, risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and  leucovorin as compared to patients with the CC genotype. However, contradictory findings have been reported that show the CG genotype may be associated with increased risk for grade 3 to 4 diarrhea when treated with fluorouracil and leucovorin compared to the GG genotype.Other genetic and clinical factors may also influence response to leucovorin, tegafur and fluorouracil.'),('rs1801019','G > C','UMPS','leucovorin--PA450198','VARIOUS',NULL,NULL,NULL,'Level 2B','-','-','increased','CC','                Patients with CC genotype and cancer may have an increased risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and  leucovorin as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to leucovorin, tegafur and fluorouracil.'),('rs1801131','T > G','MTHFR','leucovorin--PA450198','VARIOUS',NULL,NULL,NULL,'Level 2A','increased','-','-','GT','                Patients with the  GT genotype may have 1) increased response, 2) increased risk of Drug Toxicity in people with Colorectal Neoplasms treated with oxaliplatin, capecitabine, fluorouracil, leucovorin as compared to patients with TT genotype. Other genetic and clinical factors may influence a patients response to these drugs.'),('rs1801131','T > G','MTHFR','leucovorin--PA450198','VARIOUS',NULL,NULL,NULL,'Level 2A','increased','-','-','GG','                Patients with the  GG genotype may have 1) increased response, 2) increased risk of Drug Toxicity in people with Colorectal Neoplasms treated with oxaliplatin, capecitabine, fluorouracil, leucovorin as compared to patients with TT genotype. Other genetic and clinical factors may influence a patients response to these drugs.'),('rs1801133','G > A','MTHFR','leucovorin--PA450198','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype may have increased risk of Drug Toxicity in cancer patients treated with leucovorin, oxaliplatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to leucovorin.'),('rs1801133','G > A','MTHFR','leucovorin--PA450198','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype may have increased risk of Drug Toxicity in cancer patients treated with leucovorin, oxaliplatin as compared to patients with the GG genotype. However, conflicting finding of no-association for this genotype has also been reported. Other genetic and clinical factors may also influence a patients risk of toxicity to leucovorin.'),('rs67376798','T > A','DPYD','leucovorin--PA450198','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AT','                Patients with the AT genotype and Cancer who are treated with regimens containing leucovorin may have increased severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs67376798','T > A','DPYD','leucovorin--PA450198','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype were not reported, however patients with the AT genotype and Cancer who are treated with regimens containing leucovorin may have increased severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs2284017','T > C','CACNG2','Lithium--PA164712869','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype and bipolar disorder who are treated with lithium may be more likely to have a reduction in symptoms as compared to patients with the TT genotype or may be less likely to have a reduction in symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to lithium.'),('rs2284017','T > C','CACNG2','Lithium--PA164712869','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype and bipolar disorder who are treated with lithium may be more likely to have a reduction in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to lithium.'),('rs2284017','T > C','CACNG2','lithium--PA450243','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs2284017','T > C','CACNG2','lithium--PA450243','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs7439366','T > C','UGT2B7','lorazepam--PA450267','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Healthy individuals with the CT genotype who are treated with valproic acid and lorazepam may have poorer responses in psychocognitive function tests as compared to those with the TT genotype or may have better responses in psychocognitive function tests as compared to patients with the CC genotype. Other genetic and clinical factors may also influence an individuals response to valproic acid and lorazepam treatment.'),('rs7439366','T > C','UGT2B7','lorazepam--PA450267','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Healthy individuals with the CC genotype who are treated with valproic acid and lorazepam may have poorer responses in psychocognitive function tests as compared to those with the TT genotype. Other genetic and clinical factors may also influence an individuals response to valproic acid and lorazepam treatment.'),('rs1057910','A > C','CYP2C9','losartan--PA450268','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AC','                Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.'),('rs1057910','A > C','CYP2C9','losartan--PA450268','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Subjects with the CC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.'),('rs17238540','T > G','HMGCR','lovastatin--PA450272','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GT','                Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17238540','T > G','HMGCR','lovastatin--PA450272','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs5443','C > T','GNB3','lovastatin--PA450272','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 4','increased','-','-','CT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs5443','C > T','GNB3','lovastatin--PA450272','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 4','increased','-','-','TT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs3775291','C > T','TLR3','Measles vaccines--PA164712887','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Children with the TT genotype may have an increased response to measles vaccination as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to measles vaccination.'),('rs9340799','A > G','ESR1','medroxyprogesterone--PA450344','GENITO URINARY SYSTEM AND SEX HORMONES',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density.'),('rs9340799','A > G','ESR1','medroxyprogesterone--PA450344','GENITO URINARY SYSTEM AND SEX HORMONES',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype may experience 1) greater increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) smaller decreases in spine bone mineral density when untreated, as compared to patient with the AA genotype. Other genetic and clinical factors may also influence spine bone mineral density.'),('rs11188072','C > T','CYP2C19','mephenytoin--PA450373','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs1051266','T > C','SLC19A1','mercaptopurine--PA450379','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) decreased, but not absent, risk of Toxic liver disease 2) increased risk of Drug Toxicity 3) increased likelihood of treatment interruptions as compared to patients with the CC genotype. Further, patients with the CT genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patients response to leucovorin, mercaptopurine and methotrexate.'),('rs1051266','T > C','SLC19A1','mercaptopurine--PA450379','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) increased likelihood of Toxic liver disease 2) decreased, but not absent, risk of Drug Toxicity 3) decreased likelihood of treatment interruptions as compared to patients with the CT and TT genotype. Further, patients with the CC genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patients response to leucovorin, mercaptopurine and methotrexate.'),('rs1142345','T > C','TPMT','mercaptopurine--PA450379','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 1A','-','-','increased','CT','                Patients with the CT genotype  1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1142345','T > C','TPMT','mercaptopurine--PA450379','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','mercaptopurine--PA450379','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','mercaptopurine--PA450379','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','mercaptopurine--PA450379','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 1A','-','-','increased','CG','                Patients with the CG genotype (e.g. TPMT*1/*2): may have increased deactivation of thiopurines and a decreased, but not absent, risk for toxicity with thiopurine drugs as compared to patients with the GG genotype (TPMT*2/*2) or may have decreased deactivation of thiopurines and an increased risk for toxicity with thiopurine drugs as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','mercaptopurine--PA450379','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800584','C > T','TPMT','mercaptopurine--PA450379','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 1A','-','-','increased','CT','                Patients with the CT genotype who are treated with standard doses of mercaptopurine   may be at  increased risk for life-threatening myelosuppression as compared to patients with the CC genotype.   Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1800584','C > T','TPMT','mercaptopurine--PA450379','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 1A','-','-','increased','TT','                Patients with the TT genotype who are treated with standard doses of mercaptopurine may be at  increased risk for life-threatening myelosuppression as compared to patients with the CC genotype.   Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1801133','G > A','MTHFR','mercaptopurine--PA450379','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patients risk for toxicity to mercaptopurine.'),('rs1801133','G > A','MTHFR','mercaptopurine--PA450379','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patients risk for toxicity to mercaptopurine.'),('rs5219','T > C','KCNJ11','metformin--PA450395','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with the CC genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs622342','C > A','SLC22A1','metformin--PA450395','ALIMENTARY TRACT AND METABOLISM',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype and the GG genotype at rs2289669 who have diabetes may have a better response to metformin, as measured by a larger reduction in HbA1c levels, as compared to patients with the CC genotype and the GG genotype at rs2289669. This association is not significant when compared to patients with the CC genotype and the AG or AA genotype at rs2289699. Other genetic and clinical factors may also influence a patients reduction in HbA1c levels with metformin treatment.'),('rs6275','A > G','DRD2','methadone--PA450401','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','increased','-','AG','                Patients with the AG genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the GG genotype or may require an increased dose of methadone as compared to patients with the AA genotype. This was seen in Asian patients - the opposite association was seen in a different study with White patients. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs6275','A > G','DRD2','methadone--PA450401','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','increased','-','GG','                Patients with the GG genotype and Heroin Dependence may require an increased dose of methadone as compared to patients with the AA genotype. This was seen in Asian patients - the opposite association was seen in a different study with White patients. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs6275','A > G','DRD2','methadone--PA450401','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','decreased','-','GG','                Patients with the GG genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the AA genotype. This was seen in White patients - the opposite association was seen in a different study with Asian patients. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs2076369','T > G','PICK1','methamphetamine--PA450403','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','GG','                Patients with the GG genotype who are methamphetamine abusers may have a decreased, but not absent, risk for spontaneous relapse of psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for spontaneous relapse of psychosis with methamphetamine abuse.'),('rs2619538','A > T','DTNBP1','methamphetamine--PA450403','VARIOUS',NULL,NULL,NULL,'Level 4','-','-','decreased','TT','                Patients with the TT genotype may have a decreased risk for methamphetamine psychosis compared to patients with the AT genotype. Please note this association did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patients risk to methamphetamine psychosis.'),('rs3213207','T > C','DTNBP1','methamphetamine--PA450403','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype who are exposed to methamphetamine may have an increased risk for psychosis as compared to patients with the TT genotype.  Other genetic and clinical factors may also influence a patients risk for psychosis with methamphetamine exposure.'),('rs1045642','A > G','ABCB1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','increased','-','-','AG','                Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have an increased risk of adverse drug events (please note this association was not significant after correcting for multiple variables) 2) may have an increased risk of not responding to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse drug events and responsiveness when treated with methotrexate.'),('rs1045642','A > G','ABCB1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','increased','-','-','GG','                Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have a decreased risk of adverse drug events (please note this association was not significant after correcting for multiple variables) 2) may have increased likelihood of responding to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse drug events and responsiveness when treated with methotrexate.'),('rs1051266','T > C','SLC19A1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) decreased, but not absent, risk of Toxic liver disease 2) increased risk of Drug Toxicity 3) increased likelihood of treatment interruptions as compared to patients with the CC genotype. Further, patients with the CT genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patients response to leucovorin, mercaptopurine and methotrexate.'),('rs1051266','T > C','SLC19A1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) increased likelihood of Toxic liver disease 2) decreased, but not absent, risk of Drug Toxicity 3) decreased likelihood of treatment interruptions as compared to patients with the CT and TT genotype. Further, patients with the CC genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patients response to leucovorin, mercaptopurine and methotrexate.'),('rs1051266','T > C','SLC19A1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','CC','                Patients with the CC genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk of hepatotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for hepatoxicity.'),('rs1051266','T > C','SLC19A1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the TC genotype and Rheumatoid Arthritis who are treated with methotrexate may have less symptom improvement as compared to patients with the TT genotype or may have more symptom improvement as compared to patients with the CC genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patients response to methotrexate therapy.'),('rs1051266','T > C','SLC19A1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have less symptom improvement as compared to patients with the TT genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patients response to methotrexate therapy.'),('rs11045879','T > C','SLCO1B1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','CC','                Patients with the CC genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate as compared to patients with the CT or TT genotype 2)  may have a decreased, but not absent, risk for GI toxicity (mucositis) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for GI toxicity when treated with methotrexate.'),('rs1127354','C > A','ITPA','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AC','                Patients with the AC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that show the AC genotype may have an increased response to methotrexate as compared to patients with the CC genotype or or show no association of the allele with response to methotrexate. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs1127354','C > A','ITPA','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that show the AA genotype may have an increased response to methotrexate as compared to patients with the CC genotype or or show no association of the allele with response to methotrexate. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs11545078','G > A','GGH','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.'),('rs11545078','G > A','GGH','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.'),('rs13120400','T > C','ABCG2','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs1544105','C > T','FPGS','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the TC genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs1544105','C > T','FPGS','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs1695','A > G','GSTP1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased likelihood of Drug Toxicity as compared to patients with the AG and AA genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patients level of methotrexate induced toxicity.'),('rs17602729','G > A','AMPD1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of CNS adverse events as compared to patients with the GG genotype. Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patients response to methotrexate and risk of CNS adverse events.'),('rs17602729','G > A','AMPD1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs17731538','G > A','ABCG2','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area or severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs1799983','T > G','NOS3','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GT','                Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs1799983','T > G','NOS3','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs1800909','A > G','GGH','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may have better improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to methotrexate therapy.'),('rs1800909','A > G','GGH','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have better improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to methotrexate therapy.'),('rs1801131','T > G','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype and non-Hodgkin lymphoma who are treated with methotrexate may have an increased risk of mucositis as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients risk for mucositis when treated with methotrexate.'),('rs1801131','T > G','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GT','                Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of clinical response but may have a decreased response base on Disease Activity Score in 44 joints improvement at 6 months as compared to patients with the TT genotype. This association has been contradicted in other studies including a larger meta-analysis that found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs1801131','T > G','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of clinical response but may have a decreased response base on Disease Activity Score in 44 joints improvement at 6 months as compared to patients with the TT genotype. This association has been contradicted in other studies including a larger meta-analysis that found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs1801131','T > G','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','GT','                Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype or may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype.  This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs1801131','T > G','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 1B','-','-','increased','AA','                Patients with the AA genotype with Leukemia or Lymphoma who are treated with methotrexate regimens may have an increased risk and increased severity of mucositis, as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patients risk of oral mucositis.'),('rs1801133','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype and Rheumatoid Arthritis may be more at risk of alopecia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of alopecia.'),('rs1801133','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse events as compared to patients with the AA genotype (though this association has not been found in all studies). There does not seem to be an association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype (though this association has not been found in all studies). There does not seem to be an association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype and non-Hodgkin lymphoma who are treated with methotrexate may have an increased risk of mucositis, thrombocytopenia and hepatic toxicity as compared to patients with the GG genotype. This association was not found in pediatric patients with non-Hodgkin lymphoma who were treated with methotrexate. Other genetic and clinical factors may also influence a patients risk for methotrexate-induced toxicity.'),('rs1801133','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype with non-hodgkin lymphoma who are treated with methotrexate may be less likely to have event free survival at 5 years as compared to patients with the GG genotype. This genotype was not associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the GG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype with non-hodgkin lymphoma who are treated with methotrexate may be less likely to have event free survival at 5 years as compared to patients with the GG genotype. This genotype was not associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the GG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','increased','-','AG','                Patients with the AG genotype and Leukemia who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate as compared to patients with the GG genotype or may be at decreased risk of toxicity as compared to patients with the AA genotype. This association has been contradicted or not found in several studies. Other genetic and clinical factors may also influence a patients risk for toxicity and response with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','increased','-','AA','                Patients with the AA genotype and Leukemia who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate as compared to patients with the GG genotype. This association has been contradicted or not found in several studies. Other genetic and clinical factors may also influence a patients risk for toxicity and response with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk Graft vs Host disease and efficacy of methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk Graft vs Host disease and efficacy of methotrexate treatment.'),('rs1801394','A > G','MTRR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','-','-','increased','AG','                Pediatric ALL patients with AG genotypes may have increased likelihood of methotrexate induced toxicity (oral mucositis), increased speed of platelet recovery and increased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the AA genotype. Allele G is not associated with decreased IQ in pediatric ALL patients treated with methotrexate. Other genetic and clinical factors may also influence response to methotrexate.'),('rs1801394','A > G','MTRR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','-','-','increased','GG','                Pediatric ALL patients with GG genotypes may have  increased likelihood of methotrexate induced toxicity (oral mucositis) and increased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the AA genotype. Allele G is not associated with decreased IQ in pediatric ALL patients treated with methotrexate. Other genetic and clinical factors may also influence response to methotrexate.'),('rs1805087','A > G','MTR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype may have: 1) decreased likelihood of Drug Toxicity, 2) increased response when treated with methotrexate as compared to patients with genotypes GG. However, contradictory findings have also been reported. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs1805087','A > G','MTR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype may have: 1) increased likelihood of Drug Toxicity, 2) decreased response when treated with methotrexate as compared to patients with genotypes AA or AG. However, contradictory findings have also been reported. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs1979277','G > A','SHMT1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Pediatric patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased catalytic activity of TYMS as compared to pediatric patients with the AG and GG genotype. Patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased likelihood of Toxic liver disease as compared to patients with the AG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs2070744','C > T','NOS3','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs2070744','C > T','NOS3','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence disease-free survival.'),('rs2236225','G > A','MTHFD1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for response to therapy.'),('rs2236225','G > A','MTHFD1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for response to therapy.'),('rs2236624','T > C','ADORA2A','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','CC','                Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for an adverse event as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for an adverse event.'),('rs2238476','G > A','ABCC1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent, risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate and risk of toxicity.'),('rs2238476','G > A','ABCC1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate and risk of toxicity.'),('rs2267076','T > C','ADORA2A','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','CC','                Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse events when treated with methotrexate.'),('rs2298383','C > T','ADORA2A','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype or may have an increased risk for adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse events when treated with methotrexate.'),('rs2298383','C > T','ADORA2A','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse events when treated with methotrexate.'),('rs2372536','C > G','ATIC','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','CG','                Patients with the CG genotype and rheumatoid arthritis who are treated with methotrexate may be less likely to have symptom improvement as compared to patients with the GG genotype.'),('rs2372536','C > G','ATIC','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have symptom improvement  as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs246240','A > G','ABCC1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','AG','                Patients with the AG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity to methotrexate.'),('rs246240','A > G','ABCC1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','GG','                Patients with the GG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity to methotrexate.'),('rs28364006','A > G','ABCC1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs2853539','A > G','TYMS','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have improvement in disease activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs2853539','A > G','TYMS','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have improvement in disease activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs35592','T > C','ABCC1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs35592','T > C','ABCC1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with the CC genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs3758149','G > A','GGH','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have decreased conversion of the drug to active polyglutamates 2) may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.'),('rs3761422','T > C','ADORA2A','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','CC','                Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse events when treated with methotrexate.'),('rs4149081','G > A','SLCO1B1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate as compared to patients with the AG or GG genotype 2) may have a decreased, but not absent, risk of GI toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients risk of GI toxicity.'),('rs4673993','T > C','ATIC','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','CT','                Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype or may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs4673993','T > C','ATIC','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','CC','                Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs4846051','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a higher drug toxicity score as compared to patients with the AA genotype or may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients level of methotrexate induced toxicity.'),('rs4846051','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients level of methotrexate induced toxicity.'),('rs4888024','A > G','','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.'),('rs4888024','A > G','','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.'),('rs5760410','G > A','ADORA2A','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype who are treated with methotrexate may have a decreased, but not absent, risk of adverse events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs9344','G > A','CCND1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype may have 1) decreased but not absent risk for drug toxicity 2) decreased event free survival when treated with methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patients response to methotrexate, particularly rs34743033.'),('rs9345389','A > G','','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.'),('rs9345389','A > G','','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.'),('rs9895420','T > A','ABCC3','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AT','                Patients with the AT genotype may have 1) decreased event free survival 2) increased risk of central nervous system relapse 3) decreased risk of thrombocytopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs9895420','T > A','ABCC3','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype may have 1) decreased event free survival 2) increased risk of central nervous system relapse 3) decreased risk of thrombocytopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs1801253','G > C','ADRB1','metoprolol--PA450480','metoprolol',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the  CC (Arg389) genotype may have a stronger DBP response to metoprolol with a significantly greater reduction in 24-hour and daytime DBP than was found in carriers of a G(Gly389) allele. Other genetic and clinical factors may also influence the patients response to metoprolol.'),('rs1801253','G > C','ADRB1','metoprolol--PA450480','metoprolol',NULL,NULL,NULL,'Level 3','increased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','metoprolol--PA450480','metoprolol',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype 1) may have an increased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have a decreased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs3892097','C > T','CYP2D6','metoprolol--PA450480','metoprolol',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with CT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patients response to metoprolol. Please check other variants for PM phenotype.'),('rs3892097','C > T','CYP2D6','metoprolol--PA450480','metoprolol',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with TT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with CC genotype.  Other genetic and clinical factors may also influence a patients response to metoprolol. Please check other variants for PM phenotype.'),('rs10042486','C > T','HTR1A','milnacipran--PA164752812','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs10042486','C > T','HTR1A','milnacipran--PA164752812','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment  as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs10879346','C > T','TPH2','mirtazapine--PA450522','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with antidepressants may have less improvement in symptoms as compared to patients with the CT and CC genotype.'),('rs1487278','T > C','TPH2','mirtazapine--PA450522','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to antidepressant. (The frequency for CC allele is very low, homozygous minor allele carriers were pooled together with the heterozygous samples and compared with the homozygous major allele (T) carrier.)'),('rs9679162','G > T','GALNT14','mitoxantrone--PA450526','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype may have increased response, including increased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs119774','C > T','ABCC1','montelukast--PA450546','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to montelukast.'),('rs119774','C > T','ABCC1','montelukast--PA450546','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype were not studied. But patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to montelukast.'),('rs2115819','A > G','ALOX5','montelukast--PA450546','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to montelukast.'),('rs2115819','A > G','ALOX5','montelukast--PA450546','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment,  compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patients response to montelukast.'),('rs2660845','G > A','LTA4H','montelukast--PA450546','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype and asthma who are treated with montelukast  may have an increased risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of asthma exacerbations with montelukast treatment.'),('rs2660845','G > A','LTA4H','montelukast--PA450546','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype and asthma who are treated with montelukast  may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patients risk of asthma exacerbations with montelukast treatment.'),('rs730012','A > C','LTC4S','montelukast--PA450546','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AC','                Patients with the AC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of asthma exacerbations with montelukast treatment.'),('rs730012','A > C','LTC4S','montelukast--PA450546','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with the CC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. However, this difference was not statistically significant. This may be related to the relatively low frequency of CC homozygotes (11%) in the study. Other genetic and clinical factors may also influence a patients risk of asthma exacerbations with montelukast treatment.'),('rs1799971','A > G','OPRM1','morphine--PA450550','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 2B','-','increased','-','AG','                Patients with the AG genotype who are treated with morphine: 1) may require a higher dose as compared to patients with the AA genotype 2) may be less likely to have an increased pain relief as compared to patients the AA genotype and neoplasms. Other genetic and clinical factors may also influence a patients response when treated with morphine.'),('rs1799971','A > G','OPRM1','morphine--PA450550','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 2B','-','increased','-','GG','                Patients with the GG genotype who are treated with morphine: 1) may require the highest dose as compared to patients with the AG and AA genotype  2) may be less likely to have an increased pain relief as compared to patients the AA genotype and neoplasms. Other genetic and clinical factors may also influence a patients response when treated with morphine.'),('rs4680','G > A','COMT','morphine--PA450550','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 3','-','decreased','-','AA','                Patients with the AA genotype who are treated with morphine may require the lowest dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients response when treated with morphine.'),('rs1801253','G > C','ADRB1','muraglitazar--PA162356187','VARIOUS',NULL,NULL,NULL,'Level 4','-','-','decreased','CC','                Patients with the CC genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patients risk for edema with muraglitazar treatment.'),('rs2368564','C > T','REN','muraglitazar--PA162356187','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','CT','                No conclusive results were found for patients with the CT genotype. But patients with the TT genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for edema when treated with muraglitazar.'),('rs2368564','C > T','REN','muraglitazar--PA162356187','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','TT','                Patients with the TT genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for edema when treated with muraglitazar.'),('rs5370','G > T','EDN1','muraglitazar--PA162356187','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','GT','                No conclusive results were found for patients with the GT genotype. But patients with the TT genotype and type 2 diabetes who are treated with muarglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of edema with muraglitazar treatment.'),('rs5370','G > T','EDN1','muraglitazar--PA162356187','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype and type 2 diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of edema with muraglitazar treatment.'),('rs2278293','C > T','IMPDH1','mycophenolate mofetil--PA450566','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','CT','                Patients with the CT genotype may have a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the CC genotype  but the CT genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patients risk for acute rejection after transplantation.'),('rs2278293','C > T','IMPDH1','mycophenolate mofetil--PA450566','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','TT','                Patients with the TT genotype may have a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the CC genotype but the TT genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patients risk for acute rejection after transplantation.'),('rs2278294','C > T','IMPDH1','mycophenolate mofetil--PA450566','VARIOUS',NULL,NULL,NULL,'Level 2B','decreased','-','-','CT','                Patients with the CT genotype may have decreased but not absent risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs2278294','C > T','IMPDH1','mycophenolate mofetil--PA450566','VARIOUS',NULL,NULL,NULL,'Level 2B','decreased','-','-','TT','                Patients with the TT genotype may have decreased but not absent risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs2278294','C > T','IMPDH1','mycophenolate mofetil--PA450566','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs2278294','C > T','IMPDH1','mycophenolate mofetil--PA450566','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs4149117','T > G','SLCO1B3','mycophenolate mofetil--PA450566','VARIOUS',NULL,NULL,NULL,'Level 4','-','increased','-','GT','                Patients with the GT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype, or 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity and exposure to mycophenolic acid.'),('rs4149117','T > G','SLCO1B3','mycophenolate mofetil--PA450566','VARIOUS',NULL,NULL,NULL,'Level 4','-','increased','-','GG','                Patients with the GG genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity and exposure to mycophenolic acid.'),('rs1799971','A > G','OPRM1','naloxone--PA450586','VARIOUS',NULL,NULL,NULL,'Level 2B','increased','-','-','AG','                Patients with the AG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype.'),('rs1799971','A > G','OPRM1','naloxone--PA450586','VARIOUS',NULL,NULL,NULL,'Level 2B','increased','-','-','GG','                Patients with the GG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to naloxone.'),('rs1799971','A > G','OPRM1','naltrexone--PA450588','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype who are treated with naltrexone may have an increased 1) response to naltrexone, 2) blunting of alcohol craving, 3) severity of intoxication when exposed to ethanol and naltrexone as compared to patients with the AA genotype. The association with naltrexone response has been contradicted in other studies. Other genetic and clinical factors may also influence a patients response to naltrexone.'),('rs1799971','A > G','OPRM1','naltrexone--PA450588','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with naltrexone may have an increased 1) response to naltrexone, 2) blunting of alcohol craving, 3) severity of intoxication when exposed to ethanol and naltrexone as compared to patients with the AA genotype. The association with naltrexone response has been contradicted in other studies. Other genetic and clinical factors may also influence a patients response to naltrexone.'),('rs37973','G > A','GLCCI1','nedocromil--PA450601','RESPIRATORY SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patients response to glucocorticoids.'),('rs1360780','T > C','FKBP5','nefazodone--PA450603','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','decreased','CC','                Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to paroxetine, venlafaxine, clomipramine or nefazodone.'),('rs1045642','A > G','ABCB1','nelfinavir--PA450606','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.'),('rs1799732','- > G','DRD2','nemonapride--PA151186253','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1799732','- > G','DRD2','nemonapride--PA151186253','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','G/del','                Patients with the G/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with these alleles and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1800497','G > A','ANKK1','nemonapride--PA151186253','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Female patients with the AG genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patients response to nemonapride.'),('rs1800497','G > A','ANKK1','nemonapride--PA151186253','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Female patients with the AA genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patients response to nemonapride.'),('rs1045642','A > G','ABCB1','nevirapine--PA450616','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 2A','-','-','increased','GG','                Patients with the GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hepatotoxicity with nevirapine treatment.'),('rs16969968','G > A','CHRNA5','nicotine--PA450626','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with AG genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype. Findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patients risk for nicotine dependency.'),('rs16969968','G > A','CHRNA5','nicotine--PA450626','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with AA genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype. Findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patients risk for nicotine dependency.'),('rs1799971','A > G','OPRM1','nicotine--PA450626','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with AG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the AG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs1799971','A > G','OPRM1','nicotine--PA450626','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the GG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs1800497','G > A','ANKK1','nicotine--PA450626','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with AG genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs1800497','G > A','ANKK1','nicotine--PA450626','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs4680','G > A','COMT','nicotine--PA450626','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2A','increased','-','-','AG','                Patients with the AG genotype who are treated with nicotine replacement therapy may have a decreased likelihood of smoking cessation and increased risk of relapse as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to nicotine replacement therapy.'),('rs4680','G > A','COMT','nicotine--PA450626','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2A','increased','-','-','AA','                Patients with the AA genotype who are treated with nicotine replacement therapy may have an increased likelihood of smoking cessation and decreased risk of relapse as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to nicotine replacement therapy.'),('rs1801131','T > G','MTHFR','nitrous oxide--PA450645','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype may have higher homocysteine levels after nitrous oxide anesthesia as compared to patients with the TG and TT genotype.Other genetic and clinical factors may also influence a patients homocysteine levels after nitrous oxide exposure.'),('rs1801133','G > A','MTHFR','nitrous oxide--PA450645','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the GA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients homocysteine levels after nitrous oxide anesthesia.'),('rs1801133','G > A','MTHFR','nitrous oxide--PA450645',NULL,NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients homocysteine levels after nitrous oxide anesthesia.'),('rs1045642','A > G','ABCB1','nortriptyline--PA450657','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','decreased','AG','                Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for postural hypotension with nortriptyline treatment.'),('rs1045642','A > G','ABCB1','nortriptyline--PA450657','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','decreased','GG','                Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for postural hypotension with nortriptyline treatment.'),('rs1079598','A > G','DRD2','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1079598','A > G','DRD2','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1799732','- > G','DRD2','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1799732','- > G','DRD2','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','G/del','                Patients with the G/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with these alleles and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1800497','G > A','ANKK1','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1800497','G > A','ANKK1','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','-','increased','AA','                Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs2842030','G > T','RGS4','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients response to perphanazine.'),('rs3813929','C > T','HTR2C','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','-','decreased','CT','                Patients with the CT genotype and psychiatric disorders or schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for weight gain with olanzapine treatment.'),('rs3813929','C > T','HTR2C','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','-','decreased','TT','                Patients with the TT genotype and psychiatric disorders or schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for weight gain with olanzapine treatment.'),('rs4731426','G > C','LEP','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','decreased','CG','                Patients with the CG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of extreme weight gain with olanzapine treatment.'),('rs4731426','G > C','LEP','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','decreased','CC','                Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of extreme weight gain with olanzapine treatment.'),('rs4994','A > G','ADRB3','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for weight gain with olanzapine treatment.'),('rs518147','G > C','HTR2C','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','-','decreased','CC','                Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of weight gain with olanzapine treatment.'),('rs5443','C > T','GNB3','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of weight gain with olanzapine.'),('rs5443','C > T','GNB3','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of weight gain with olanzapine.'),('rs6277','G > A','DRD2','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased, but not absent risk, for weight gain when treated with clozapine or olanzepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs6280','C > T','DRD3','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the CT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patients response to olanzapine.'),('rs6280','C > T','DRD3','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patients response to olanzapine.'),('rs6313','G > A','HTR2A','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the GA genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for weight gain with olanzapine treatment.'),('rs6313','G > A','HTR2A','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for weight gain with olanzapine treatment.'),('rs6313','G > A','HTR2A','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.'),('rs6313','G > A','HTR2A','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.'),('rs6318','G > C','HTR2C','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 4','-','-','increased','CG','                Patients with the CG genotype and schizophrenia, treated with olanzapine, may have an increased (but not statistically significant) likelihood for tendency of olanzapine-induced weight as compared to patients the genotype GG. Other genetic and clinical factors may also influence a patients risk for olanzapine-induced weight gain.'),('rs6318','G > C','HTR2C','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 4','-','-','increased','CC','                Patients with the CC genotype and schizophrenia, treated with olanzapine, may have an increased (but not statistically significant) likelihood for tendency of olanzapine-induced weight as compared to patients the genotype GG. Other genetic and clinical factors may also influence a patients risk for olanzapine-induced weight gain.'),('rs762551','C > A','CYP1A2','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have decreased response to olanzapine based on decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patients response to olanzapine.'),('rs7997012','A > G','HTR2A','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','decreased','AG','                Patients with the AG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for side effects with olanzapine treatment.'),('rs7997012','A > G','HTR2A','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','decreased','GG','                Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for side effects with olanzapine treatment.'),('rs951439','C > T','RGS4','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs951439','C > T','RGS4','olanzapine--PA450688','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may have increased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs11188072','C > T','CYP2C19','omeprazole--PA450704','ALIMENTARY TRACT AND METABOLISM',NULL,NULL,NULL,'Level 2A','-','increased','-','TT','                Adult patients, but not pediatric patients, with the TT genotype who are treated with omeprazole may require an increased dose as compared to patients with the CT or CC genotype.  Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration. This might not be applicable to pediatric patients.'),('rs2032583','A > G','ABCB1','Other antidepressants--PA164713016','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs2032583','A > G','ABCB1','Other antidepressants--PA164713016','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs2235015','C > A','ABCB1','Other antidepressants--PA164713016','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AC','                Patients with the AC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs2235015','C > A','ABCB1','Other antidepressants--PA164713016','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs11615','A > G','ERCC1','oxaliplatin--PA131285527','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','AG','                Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs11615','A > G','ERCC1','oxaliplatin--PA131285527','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','GG','                Patients with the GG genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs13181','T > G','ERCC2','oxaliplatin--PA131285527','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GT','                Patients with the GT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity as compared to patients with the TT genotype 2) an increased risk of early relapse as compared to patients with the TT genotype. However, a trend of an association is found for the GT genotype with increased progression free survival compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil, leucovorin and oxaliplatin.'),('rs13181','T > G','ERCC2','oxaliplatin--PA131285527','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity 2) an increased risk of early relapse and 3) decreased progression free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil, leucovorin and oxaliplatin.'),('rs13181','T > G','ERCC2','oxaliplatin--PA131285527','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with platinum compounds as compared to patients with the GT or TT genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.'),('rs1695','A > G','GSTP1','oxaliplatin--PA131285527','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','increased','-','-','GG','                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.'),('rs1695','A > G','GSTP1','oxaliplatin--PA131285527','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1695','A > G','GSTP1','oxaliplatin--PA131285527','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1801131','T > G','MTHFR','oxaliplatin--PA131285527','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','increased','-','-','GT','                Patients with the  GT genotype may have 1) increased response, 2) increased risk of Drug Toxicity in people with Colorectal Neoplasms treated with oxaliplatin, capecitabine, fluorouracil, leucovorin as compared to patients with TT genotype. Other genetic and clinical factors may influence a patients response to these drugs.'),('rs1801131','T > G','MTHFR','oxaliplatin--PA131285527','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','increased','-','-','GG','                Patients with the  GG genotype may have 1) increased response, 2) increased risk of Drug Toxicity in people with Colorectal Neoplasms treated with oxaliplatin, capecitabine, fluorouracil, leucovorin as compared to patients with TT genotype. Other genetic and clinical factors may influence a patients response to these drugs.'),('rs1801133','G > A','MTHFR','oxaliplatin--PA131285527','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype may have increased risk of Drug Toxicity in cancer patients treated with leucovorin, oxaliplatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to leucovorin.'),('rs1801133','G > A','MTHFR','oxaliplatin--PA131285527','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype may have increased risk of Drug Toxicity in cancer patients treated with leucovorin, oxaliplatin as compared to patients with the GG genotype. However, conflicting finding of no-association for this genotype has also been reported. Other genetic and clinical factors may also influence a patients risk of toxicity to leucovorin.'),('rs25487','T > C','XRCC1','oxaliplatin--PA131285527','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs1042522','G > C','TP53','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1042522','G > C','TP53','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.'),('rs1045642','A > G','ABCB1','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Genotype GG may be associated with increased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype AG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.'),('rs1056836','C > G','CYP1B1','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with taxanes may have longer disease-free progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs1113129','G > C','CYP2C8','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','CC','                Patients with the CC genotype may have  increased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CG or GG genotype.  Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs11572080','C > T','CYP2C8','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype may be at decreased, but not absent, risk of neurotoxicity when treated with paclitaxel compared to patients with the TT genotype or may be at increased risk of neurotoxicity  when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of neurotoxicity.'),('rs11572080','C > T','CYP2C8','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype may be at increased risk of neurotoxicity  when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of neurotoxicity.'),('rs11572103','T > A','CYP2C8','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','decreased','-','AT','                Patients with the AT genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.'),('rs11572103','T > A','CYP2C8','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 4','-','decreased','-','AA','                Patients with the AA genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.'),('rs12721627','G > C','CYP3A','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','decreased','-','CG','                Patients with the CG genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.'),('rs12721627','G > C','CYP3A','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','decreased','-','CC','                Patients with the CC genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.'),('rs2032582','A > C','ABCB1','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the CT genotype may have decreased, but not absent, risk for resistance to taxanes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to taxanes.'),('rs776746','C > T','CYP3A','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk of neurotoxicity when treated with paclitaxel as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.'),('rs9981861','T > C','DSCAM','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.'),('rs9981861','T > C','DSCAM','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.'),('rs1934951','C > T','CYP2C8','pamidronate--PA450767','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.'),('rs11188072','C > T','CYP2C19','pantoprazole--PA450774','VARIOUS',NULL,NULL,NULL,'Level 3','-','increased','-','CT','                Patients with the CT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs11188072','C > T','CYP2C19','pantoprazole--PA450774','VARIOUS',NULL,NULL,NULL,'Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs10042486','C > T','HTR1A','paroxetine--PA450801','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs10042486','C > T','HTR1A','paroxetine--PA450801','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment  as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs11042725','C > A','ADM','paroxetine--PA450801','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AC','                Patients with the AC genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to paroxetine.'),('rs11042725','C > A','ADM','paroxetine--PA450801','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to paroxetine.'),('rs1360780','T > C','FKBP5','paroxetine--PA450801','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','decreased','CC','                Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to paroxetine, venlafaxine, clomipramine or nefazodone.'),('rs6295','C > G','HTR1A','paroxetine--PA450801','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CG','                Patients with the CG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs6295','C > G','HTR1A','paroxetine--PA450801','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs12979860','C > T','IL28B','peginterferon alfa-2a--PA164749390','VARIOUS',NULL,NULL,NULL,'Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs12979860','C > T','IL28B','peginterferon alfa-2a--PA164749390','VARIOUS',NULL,NULL,NULL,'Level 1A','decreased','-','-','TT','                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2a--PA164749390','VARIOUS',NULL,NULL,NULL,'Level 1B','decreased','-','-','GT','                Patients with the  GT genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs8099917','T > G','IL28B','peginterferon alfa-2a--PA164749390','VARIOUS',NULL,NULL,NULL,'Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs12979860','C > T','IL28B','peginterferon alfa-2b--PA164784024','VARIOUS',NULL,NULL,NULL,'Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs12979860','C > T','IL28B','peginterferon alfa-2b--PA164784024','VARIOUS',NULL,NULL,NULL,'Level 1A','decreased','-','-','TT','                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2b--PA164784024','VARIOUS',NULL,NULL,NULL,'Level 1B','decreased','-','-','GT','                Patients with the  GT genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs8099917','T > G','IL28B','peginterferon alfa-2b--PA164784024','VARIOUS',NULL,NULL,NULL,'Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs9657182','C > T','IDO1','peginterferon alfa-2b--PA164784024','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','CT','                Patients with the CT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patients risk for drug side effects.'),('rs9657182','C > T','IDO1','peginterferon alfa-2b--PA164784024','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','TT','                Patients with the TT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patients risk for drug side effects.'),('rs12050217','A > G','BDKRB1','perindopril--PA450877','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk  for cardiac events when taking perindopril.'),('rs12050217','A > G','BDKRB1','perindopril--PA450877','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk  for cardiac events when taking perindopril.'),('rs275651','T > A','AGTR1','perindopril--PA450877','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AT','                Patients with the TA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for cardiac events when treated with perindopril.'),('rs275651','T > A','AGTR1','perindopril--PA450877','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for cardiac events when treated with perindopril.'),('rs5182','C > T','AGTR1','perindopril--PA450877','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 4','decreased','-','-','TT','                Patients with the TT genotype may have reduced risk for cardiac events when treated with perindopril as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patients response.'),('rs2842030','G > T','RGS4','perphenazine--PA450882','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients response to perphanazine.'),('rs951439','C > T','RGS4','perphenazine--PA450882','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs951439','C > T','RGS4','perphenazine--PA450882','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may have increased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs2108622','C > T','CYP4F2','phenprocoumon--PA450921','BLOOD AND BLOOD FORMING ORGANS',NULL,NULL,NULL,'Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs2108622','C > T','CYP4F2','phenprocoumon--PA450921','BLOOD AND BLOOD FORMING ORGANS',NULL,NULL,NULL,'Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1045642','A > G','ABCB1','phenytoin--PA450947','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','increased','-','AG','                Patients with genotype AG may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patients dose of phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin--PA450947','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','increased','-','GG','                Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patients dose of phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin--PA450947','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with genotype AG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians. Other genetic or clinical factors may influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin--PA450947','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with genotype GG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians.  Other genetic or clinical factors may influence a patients response to phenytoin.'),('rs1051740','T > C','EPHX1','phenytoin--PA450947','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','CC','                Patients with the CC genotype who use phenytoin during the first trimester of pregnancy may be less likely to have a child with a craniofacial abnormality as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk of having a child with a craniofacial abnormality.'),('rs1057910','A > C','CYP2C9','phenytoin--PA450947','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1057910','A > C','CYP2C9','phenytoin--PA450947','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','CC','                Patients with the CC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1799853','C > T','CYP2C9','phenytoin--PA450947','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1799853','C > T','CYP2C9','phenytoin--PA450947','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs2234922','A > G','EPHX1','phenytoin--PA450947','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2234922','A > G','EPHX1','phenytoin--PA450947','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs3812718','C > T','SCN1A','phenytoin--PA450947','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','increased','-','CT','                Patients with the CT genotype who are treated with phenytoin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.'),('rs3812718','C > T','SCN1A','phenytoin--PA450947','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','increased','-','TT','                Patients with the TT genotype who are treated with phenytoin may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.'),('rs11615','A > G','ERCC1','Platinum compounds--PA164713176','VARIOUS',NULL,NULL,NULL,'Level 2B','increased','-','-','AG','                Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs11615','A > G','ERCC1','Platinum compounds--PA164713176','VARIOUS',NULL,NULL,NULL,'Level 2B','increased','-','-','GG','                Patients with the GG genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs13181','T > G','ERCC2','Platinum compounds--PA164713176','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with platinum compounds as compared to patients with the GT or TT genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.'),('rs1695','A > G','GSTP1','Platinum compounds--PA164713176','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1695','A > G','GSTP1','Platinum compounds--PA164713176','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs2032582','A > C','ABCB1','Platinum compounds--PA164713176','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','CC','                Patients with the CC genotype may have decreased but not non-existent risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CA, CT, AA or TT genotypes. Other genetic and clinical factors may also influence a patients risk for gastrointestinal toxicity with taxane and platinum regimens.'),('rs25487','T > C','XRCC1','Platinum compounds--PA164713176','VARIOUS',NULL,NULL,NULL,'Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs3212986','C > A','ERCC1','Platinum compounds--PA164713176','VARIOUS',NULL,NULL,NULL,'Level 2B','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk for nephrotoxicity with platinum-based regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs3212986','C > A','CD3EAP','Platinum compounds--PA164713176','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','AC','                Patients with the AC genotype may have better overall survival rate when treated with platinum in people with Non-Small-Cell Lung Carcinoma as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patients response to Platinum compounds.'),('rs3212986','C > A','CD3EAP','Platinum compounds--PA164713176','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype may have better overall survival rate when treated with platinum in people with Non-Small-Cell Lung Carcinoma as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patients response to Platinum compounds.'),('rs3212986','C > A','CD3EAP','Platinum compounds--PA164713176','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','AC','                Patients with the CA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients survival with platinum compounds.'),('rs3212986','C > A','CD3EAP','Platinum compounds--PA164713176','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients survival with platinum compounds.'),('rs11615','A > G','ERCC1','platinum--PA150595617','VARIOUS',NULL,NULL,NULL,'Level 2B','increased','-','-','AG','                Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs11615','A > G','ERCC1','platinum--PA150595617','VARIOUS',NULL,NULL,NULL,'Level 2B','increased','-','-','GG','                Patients with the GG genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs13181','T > G','ERCC2','platinum--PA150595617','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with platinum compounds as compared to patients with the GT or TT genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.'),('rs25487','T > C','XRCC1','platinum--PA150595617','VARIOUS',NULL,NULL,NULL,'Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs3212986','C > A','ERCC1','platinum--PA150595617','VARIOUS',NULL,NULL,NULL,'Level 2B','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk for nephrotoxicity with platinum-based regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs6280','C > T','DRD3','pramipexole--PA164742949','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype may have better therapeutic efficacy (response rate = 60%)of pramipexole in Chinese patients with Parkinsons disease compared to patiens carrying the C allele (response rate =13%). Other genetic and clinical factors may also influence a patients response.'),('rs17238540','T > G','HMGCR','pravastatin--PA451089','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GT','                Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17238540','T > G','HMGCR','pravastatin--PA451089','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17244841','A > T','HMGCR','pravastatin--PA451089','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs1935349','C > T','HTR7','pravastatin--PA451089','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for statin-related myalgia as compared to patients with the CC genotypes, or may have a decreased risk for statin-related myalgia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs1935349','C > T','HTR7','pravastatin--PA451089','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for statin-related myalgia as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs20455','A > G','KIF6','pravastatin--PA451089','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 2B','increased','-','-','AG','                Patients with the AG genotype may have an increased risk for adverse cardiovascular events (myocardial infarction and coronary heart diseases) as compared to patients with the AA genotype. Pravastatin treatment substantially reduced that risk. Other genetic and clinical factors may also influence a patients risk for adverse cardiovascular events.'),('rs20455','A > G','KIF6','pravastatin--PA451089','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 2B','increased','-','-','GG','                Patients with the GG genotype may have an increased risk for adverse cardiovascular events (myocardial infarction and coronary heart diseases) as compared to patients with the AA genotype. Pravastatin treatment substantially reduced that risk. Other genetic and clinical factors may also influence a patients risk for adverse cardiovascular events.'),('rs2276307','A > G','HTR3B','pravastatin--PA451089','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for myalgia.'),('rs2276307','A > G','HTR3B','pravastatin--PA451089','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patients risk for myalgia.'),('rs2306283','A > G','SLCO1B1','pravastatin--PA451089','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype may have decreased plasma AUC of pravastatin as compared to patients with the AA genotype.'),('rs2306283','A > G','SLCO1B1','pravastatin--PA451089','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased plasma AUC of pravastatin as compared to patients with the AA genotype.'),('rs4149015','G > A','SLCO1B1','pravastatin--PA451089','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 2A','increased','-','-','AG','                Patients carrying the AG genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs4149015','G > A','SLCO1B1','pravastatin--PA451089','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 2A','increased','-','-','AA','                Patients carrying the AA genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. This variant is part of the SLCO1B1*17 haplotype. Other genetic and clinical factors may also influence a patients response.'),('rs5443','C > T','GNB3','pravastatin--PA451089','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 4','increased','-','-','CT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs5443','C > T','GNB3','pravastatin--PA451089','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 4','increased','-','-','TT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs1050828','C > T','G6PD','primaquine--PA451103','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Pediatric patients with the CT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs1050828','C > T','G6PD','primaquine--PA451103','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Pediatric patients with the TT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs58597806','G > A','UGT1A9','propofol--PA451141','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 4','-','-','increased','AG','                Patients with the AG genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.'),('rs58597806','G > A','UGT1A9','propofol--PA451141','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 4','-','-','increased','AA','                Patients with the AA genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.'),('rs1142345','T > C','TPMT','purine analogues--PA452634','VARIOUS',NULL,NULL,NULL,'Level 1A','-','-','increased','CT','                Patients with the CT genotype  1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1142345','T > C','TPMT','purine analogues--PA452634','VARIOUS',NULL,NULL,NULL,'Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','purine analogues--PA452634','VARIOUS',NULL,NULL,NULL,'Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','purine analogues--PA452634','VARIOUS',NULL,NULL,NULL,'Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','purine analogues--PA452634','VARIOUS',NULL,NULL,NULL,'Level 1A','-','-','increased','CG','                Patients with the CG genotype (e.g. TPMT*1/*2): may have increased deactivation of thiopurines and a decreased, but not absent, risk for toxicity with thiopurine drugs as compared to patients with the GG genotype (TPMT*2/*2) or may have decreased deactivation of thiopurines and an increased risk for toxicity with thiopurine drugs as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','purine analogues--PA452634','VARIOUS',NULL,NULL,NULL,'Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1050828','C > T','G6PD','pyrimethamine--PA451193','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Pediatric patients with the CT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs1050828','C > T','G6PD','pyrimethamine--PA451193','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Pediatric patients with the TT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs951439','C > T','RGS4','quetiapine--PA451201','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs951439','C > T','RGS4','quetiapine--PA451201','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may have increased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs1544410','C > T','VDR','raloxifene--PA451221','GENITO URINARY SYSTEM AND SEX HORMONES',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with bisphosphonates may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to bisphosphonates.'),('rs290487','C > T','TCF7L2','repaglinide--PA451234','GENITO URINARY SYSTEM AND SEX HORMONES',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype may have better response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patients repsonse.'),('rs4149056','T > C','SLCO1B1','repaglinide--PA451234','GENITO URINARY SYSTEM AND SEX HORMONES',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype may have increased mean plasma AUC of repaglinide and greater blood glucose-lowering effect in response to repaglinide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients response.'),('rs5219','T > C','ABCC8','repaglinide--PA451234','GENITO URINARY SYSTEM AND SEX HORMONES',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with the CC genotype are less likely to respond to repaglinide  than patients with the CT or TT genotype in T2DM patients. Other genetic and clinical factors may also influence a patients response.'),('rs1127354','C > A','ITPA','ribavirin--PA451241','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 2B','-','decreased','-','AC','                Patients with the AC genotype and Hepatitis C, Chronic may have a decreased, but not absent, risk of 1) dose reduction of ribavirin, 2) rapid decrease in hemoglobin levels when treated with interferon alfa-2b, recombinant and ribavirin or interferon alfa-2b, recombinant and ribavirin, and telaprevir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for response to ribavirin.'),('rs1127354','C > A','ITPA','ribavirin--PA451241','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 2B','-','decreased','-','AA','                Patients with the AA genotype and Hepatitis C, Chronic may have a decreased, but not absent, risk of 1) dose reduction of ribavirin, 2) rapid decrease in hemoglobin levels when treated with interferon alfa-2b, recombinant and ribavirin or interferon alfa-2b, recombinant and ribavirin, and telaprevir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for response to ribavirin.'),('rs12979860','C > T','IL28B','ribavirin--PA451241','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs12979860','C > T','IL28B','ribavirin--PA451241','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 1A','decreased','-','-','TT','                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','ribavirin--PA451241','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 1B','decreased','-','-','GT','                Patients with the  GT genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs8099917','T > G','IL28B','ribavirin--PA451241','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs16944','A > G','IL1B','risedronate--PA451255','MUSCULO-SKELETAL SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and Pagets disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs16944','A > G','IL1B','risedronate--PA451255','MUSCULO-SKELETAL SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs2297480','T > G','FDPS','risedronate--PA451255','MUSCULO-SKELETAL SYSTEM',NULL,NULL,NULL,'Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1128503','A > G','ABCB1','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patients response.'),('rs1128503','A > G','ABCB1','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype may have poorer response to risperidone in Children with Autism, than patients with AG or GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs1414334','C > G','HTR2C','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 1B','-','-','decreased','GG','                Patients with the GG genotype who are treated with antipsychotics may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patients risk for developing metabolic syndrome.'),('rs165599','G > A','COMT','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs165599','G > A','COMT','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs167771','G > A','DRD3','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AG or GG genotype. Patients with the AA genotype may still be at risk for toxicity when taking risperidone. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1799732','- > G','DRD2','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1799978','T > C','DRD2','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2A','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the TC And TT genotype.'),('rs1799978','T > C','DRD2','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1799978','T > C','DRD2','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800497','G > A','ANKK1','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1800497','G > A','ANKK1','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 2B','-','-','increased','AA','                Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1800497','G > A','ANKK1','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the GG genotype or may have less improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs1800497','G > A','ANKK1','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs2494732','T > C','AKT1','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the CT genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs2494732','T > C','AKT1','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs2661319','T > C','RGS4','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs2842030','G > T','RGS4','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 4','decreased','-','-','GT','                Patients with the GT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs2842030','G > T','RGS4','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 4','decreased','-','-','TT','                Patients with the TT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs3803300','T > C','AKT1','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 4','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the CT or GG genotype. Please note this did not reach statistical significance. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs3813928','G > A','HTR2C','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patients response.'),('rs3813928','G > A','HTR2C','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','AA','                Patients with the AA genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patients response.'),('rs6280','C > T','DRD3','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the CT genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patients response.'),('rs6280','C > T','DRD3','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype may have smaller reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating poorer response to risperidone in Children with Autism, than TT homozygotes compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patients response.'),('rs6311','C > T','HTR2A','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Patients with the CT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs6311','C > T','HTR2A','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs6313','G > A','HTR2A','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.'),('rs6313','G > A','HTR2A','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.'),('rs724226','A > G','GRM3','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs724226','A > G','GRM3','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs7799039','G > A','LEP','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype may have excessive risperidone-associated weight gain in youths as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs7799039','G > A','LEP','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype may have excessive risperidone-associated weight gain in youths as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs951439','C > T','RGS4','risperidone--PA451257','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype may have increased chance of response to risperidone as compared to patients with CC or CT genotypes. Other genetic and clinical factors may also influence a patients chance of response to risperidone.'),('rs2854116','C > T','APOA4','ritonavir--PA451260','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype and HIV who are treated with ritonavir may have increased severity of triglyceride elevation as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients triglyceride levels.'),('rs2854117','T > C','APOA4','ritonavir--PA451260','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 3','-','-','decreased','CC','                Patients with the CC genotype and HIV who are treated with ritonavir may have lower triglyceride levels (lower risk of Hypertriglyceridemia) as compared to patients with the TC or TT genotype. Patients with the CC genotype may still be at risk for toxicity when taking ritonavir. Other genetic and clinical factors may also influence a patients triglyceride levels.'),('rs429358','T > C','APOC1','ritonavir--PA451260','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patients risk for adverse events with ritonavir treatment.'),('rs429358','T > C','APOC1','ritonavir--PA451260','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patients risk for adverse events with ritonavir treatment.'),('rs5128','G > C','APOC3','ritonavir--PA451260','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 3','-','-','increased','CC','                Patients with the CC genotype and HIV who are treated with ritonavir may have an increased risk of triglyceride elevation as compared to patients with the CG or GG genotype.'),('rs7412','C > T','APOC1','ritonavir--PA451260','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs7412','C > T','APOC1','ritonavir--PA451260','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs7412','C > T','APOE','ritonavir--PA451260','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 4','-','-','increased','CT','                Patients with the CT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype or may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients triglyceride levels.'),('rs7412','C > T','APOE','ritonavir--PA451260','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 4','-','-','increased','TT','                Patients with the TT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients triglyceride levels.'),('rs396991','A > C','FCGR3A','rituximab--PA451261','VARIOUS',NULL,NULL,NULL,'Level 2B','increased','-','-','AC','                Lymphoma patients with the AC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to rituximab.'),('rs396991','A > C','FCGR3A','rituximab--PA451261','VARIOUS',NULL,NULL,NULL,'Level 2B','increased','-','-','CC','                Lymphoma patients with the CC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to rituximab.'),('rs20417','C > G','PTGS2','rofecoxib--PA451268','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','CG','                Patients with the CG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to rofecoxib.'),('rs20417','C > G','PTGS2','rofecoxib--PA451268','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to rofecoxib.'),('rs10192566','C > G','LPIN1','rosiglitazone--PA451283','ALIMENTARY TRACT AND METABOLISM',NULL,NULL,NULL,'Level 3','decreased','-','-','CG','                Patients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to rosiglitazone.'),('rs10192566','C > G','LPIN1','rosiglitazone--PA451283','ALIMENTARY TRACT AND METABOLISM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype and type 2 diabetes who are treated with rosiglitazone may have the largest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patients response to rosiglitazone.'),('rs10509681','T > C','CYP2C8','rosiglitazone--PA451283','ALIMENTARY TRACT AND METABOLISM',NULL,NULL,NULL,'Level 3','-','increased','-','CT','                Patients with the CT (CYP2C8*3/*1) genotype may have increased metabolism of rosiglitazone compared to patients with the TT genotype (CYP2C8*1/*1), or may have decreased metabolism of rosiglitazone compared to patients with the CC genotype (CYP2C8*3/*3). This is not associated with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of rosiglitazone and blood glucose levels.'),('rs10509681','T > C','CYP2C8','rosiglitazone--PA451283','rosiglitazone',NULL,NULL,NULL,'Level 3','-','increased','-','CC','                Patients with the CC genotype (CYP2C8*3/*3) may have increased metabolism of rosiglitazone compared to patients with the TT genotype (CYP2C8*1/*1), but this is not associated with differences in blood glucose lowering efficacy compared to patients with the TT genotype. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of rosiglitazone and blood glucose levels.'),('rs2231142','G > T','ABCG2','rosuvastatin--PA134308647','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 2B','increased','-','-','GT','                Patients with the GT genotype who are treated with rosuvastatin may be more likely to reach target LDL levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to rosuvastatin.'),('rs2231142','G > T','ABCG2','rosuvastatin--PA134308647','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 2B','increased','-','-','TT','                Patients with the TT genotype may have increased response to rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to rosuvastatin.'),('rs4693075','G > C','COQ2','rosuvastatin--PA134308647','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 2B','-','-','decreased','CC','                Patients with the CC genotype may have decreased risk of statin-related muscle symptoms as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence a patients risk of toxicity.'),('rs5443','C > T','GNB3','rosuvastatin--PA134308647','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 4','decreased','-','-','CT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs5443','C > T','GNB3','rosuvastatin--PA134308647','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 4','decreased','-','-','TT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs2267715','G > A','CRHR2','salbutamol--PA448068','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compare to patients with the GG genotype. However, contradictory finding has been reported. No conclusive results regarding the association between this variant and bronchodilator response.'),('rs7793837','A > T','CRHR2','salbutamol--PA448068','VARIOUS',NULL,NULL,NULL,'Level 2B','decreased','-','-','TT','                Patients with the TT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to short-acting beta2-antagonists.'),('rs2267715','G > A','CRHR2','selective beta-2-adrenoreceptor agonists--PA134687887','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compare to patients with the GG genotype. However, contradictory finding has been reported. No conclusive results regarding the association between this variant and bronchodilator response.'),('rs2781659','A > G','ARG1','selective beta-2-adrenoreceptor agonists--PA134687887','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have decreased improvement in forced expiratory volume (FEV) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to beta-2-adenoreceptor agonist treatment.'),('rs7793837','A > T','CRHR2','selective beta-2-adrenoreceptor agonists--PA134687887','VARIOUS',NULL,NULL,NULL,'Level 2B','decreased','-','-','TT','                Patients with the TT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to short-acting beta2-antagonists.'),('rs6295','C > G','HTR1A','Selective serotonin reuptake inhibitors--PA164713257','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','CG','                Patients with the CG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs6295','C > G','HTR1A','Selective serotonin reuptake inhibitors--PA164713257','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs7997012','A > G','HTR2A','Selective serotonin reuptake inhibitors--PA164713257','VARIOUS',NULL,NULL,NULL,'Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs4343','G > A','ACE','sildenafil--PA451346','GENITO URINARY SYSTEM AND SEX HORMONES',NULL,NULL,NULL,'Level 3','decreased','-','-','AG','                Patients with the AG genotype and erectile dysfunction who are treated with sildenafil may have a decreased chance of positive erectile response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to sildenafil.'),('rs4343','G > A','ACE','sildenafil--PA451346','GENITO URINARY SYSTEM AND SEX HORMONES',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype and erectile dysfunction who are treated with sildenafil may have an increased chance of positive erectile response as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients response to sildenafil.'),('rs5443','C > T','GNB3','sildenafil--PA451346','GENITO URINARY SYSTEM AND SEX HORMONES',NULL,NULL,NULL,'Level 2B','increased','-','-','TT','                Patients with the TT genotype and erectile dysfunction who are treated with sildenafilthan may be more likely to have positive erectile response as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients response to sildenafil.'),('rs17238540','T > G','HMGCR','simvastatin--PA451363','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GT','                Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17238540','T > G','HMGCR','simvastatin--PA451363','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','decreased','-','-','GG','                Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17244841','A > T','HMGCR','simvastatin--PA451363','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs1935349','C > T','HTR7','simvastatin--PA451363','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for statin-related myalgia as compared to patients with the CC genotypes, or may have a decreased risk for statin-related myalgia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs1935349','C > T','HTR7','simvastatin--PA451363','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for statin-related myalgia as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs2276307','A > G','HTR3B','simvastatin--PA451363','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for myalgia.'),('rs2276307','A > G','HTR3B','simvastatin--PA451363','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 3','-','-','increased','GG','                Patients with the GG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patients risk for myalgia.'),('rs4149056','T > C','SLCO1B1','simvastatin--PA451363','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 1A','-','-','increased','CT','                Patients with the CT genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs4149056','T > C','SLCO1B1','simvastatin--PA451363','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 1A','-','-','increased','CC','                Patients with the CC genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs5443','C > T','GNB3','simvastatin--PA451363','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 4','increased','-','-','CT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs5443','C > T','GNB3','simvastatin--PA451363','CARDIOVASCULAR SYSTEM',NULL,NULL,NULL,'Level 4','increased','-','-','TT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs2740574','C > T','CYP3A','sirolimus--PA451365','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','decreased','-','TT','                Patients with the TT genotype may require a decreased dose of tacrolimus or sirolimus as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs776746','C > T','CYP3A5','sirolimus--PA451365','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','increased','-','CT','                Patients with the CT genotype (*1/*3) and who are recipients of transplants may have increased metabolism of sirolimus and require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients sirolimus dose requirements.'),('rs776746','C > T','CYP3A5','sirolimus--PA451365','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','-','increased','-','TT','                Patients with the TT genotype (*1/*1) and who are recipients of transplants may have increased metabolism of sirolimus and require a higher dose as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patients sirolimus dose requirements.'),('rs4343','G > A','ACE','spironolactone--PA451483','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype is associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs4343','G > A','ACE','spironolactone--PA451483','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype is associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs4961','G > T','ADD1','spironolactone--PA451483','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','decreased','-','-','GT','                Patients with the GT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to diuretics.'),('rs4961','G > T','ADD1','spironolactone--PA451483','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2B','decreased','-','-','TT','                Patients with the TT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to diuretics.'),('rs1050828','C > T','G6PD','sulfadoxine--PA451540','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','CT','                Pediatric patients with the CT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs1050828','C > T','G6PD','sulfadoxine--PA451540','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','TT','                Pediatric patients with the TT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs1057910','A > C','CYP2C9','sulfonamides, urea derivatives--PA10390','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype who are treated with sulfonylurea: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the AA genotype 2) May be less likely to have failure of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to sulfonylurea therapy.'),('rs12255372','G > T','TCF7L2','sulfonamides, urea derivatives--PA10390','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','GT','                Patients with the GT genotype and type II diabetes who are treated with sulfonylureas may be less likely to achieve a target HbA1c level of <7% as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs12255372','G > T','TCF7L2','sulfonamides, urea derivatives--PA10390','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype and type II diabetes who are treated with sulfonylureas may be less likely to achieve a target HbA1c level of <7% as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs1799853','C > T','CYP2C9','sulfonamides, urea derivatives--PA10390','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype and type II diabetes who are treated with sulfonylureas: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the CC genotype 2) May be less likely to experience treatment failure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to sulfonylureas.'),('rs5219','T > C','KCNJ11','sulfonamides, urea derivatives--PA10390','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with the CC genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs5219','T > C','KCNJ11','sulfonamides, urea derivatives--PA10390','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with CC genotype may have poorer response (higher decrease in HbA1c) to 6-month treatment of sulfonylureas in people with Type 2 diabetes as compared to patients with genotype CT or TT. Other genetic or clinical factors may also influence a patients response to sulfonylureas.'),('rs5443','C > T','GNB3','sumatriptan--PA451566','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to sumatriptan.'),('rs5443','C > T','GNB3','sumatriptan--PA451566','NERVOUS SYSTEM',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype. However, patients with this genotype were not studied directly. Other genetic and clinical factors may also influence a patients response to sumatriptan.'),('rs2032582','A > C','ABCB1','tacrolimus--PA451578','DERMATOLOGICALS',NULL,NULL,NULL,'Level 3','decreased','-','-','AC','                Patients with AC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with Colitis, Ulcerative as compared to patients with the AA genotype. Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C. Other genetic or clinical factors may influence response and dose of tacrolimus.'),('rs2032582','A > C','ABCB1','tacrolimus--PA451578','DERMATOLOGICALS',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Patients with CC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with Colitis, Ulcerative as compared to patients with the AA genotype. Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C. Other genetic or clinical factors may influence response and dose of tacrolimus.'),('rs2740574','C > T','CYP3A','tacrolimus--PA451578','DERMATOLOGICALS',NULL,NULL,NULL,'Level 2A','-','decreased','-','TT','                Patients with the TT genotype may require a decreased dose of tacrolimus or sirolimus as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs776746','C > T','CYP3A5','tacrolimus--PA451578','DERMATOLOGICALS',NULL,NULL,NULL,'Level 1B','-','increased','-','CT','                Patients with the CT genotype who are treated with tacrolimus may have increased clearance of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients tacrolimus dose requirement.'),('rs776746','C > T','CYP3A5','tacrolimus--PA451578','DERMATOLOGICALS',NULL,NULL,NULL,'Level 1B','-','increased','-','TT','                Patients with the TT genotype who are treated with tacrolimus may have increased clearance of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients tacrolimus dose requirement.'),('rs776746','C > T','CYP3A5','tacrolimus--PA451578','DERMATOLOGICALS',NULL,NULL,NULL,'Level 2A','-','-','increased','CT','                Patients with the CT genotype (*1/*3) and are recipients of Kidney Transplant who are treated with tacrolimus may have an increased risk of nephrotoxicity as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patients risk for drug-induced nephrotoxicity.'),('rs776746','C > T','CYP3A5','tacrolimus--PA451578','DERMATOLOGICALS',NULL,NULL,NULL,'Level 2A','-','-','increased','TT','                Patients with the TT (*1/*1) genotype and are recipients of Kidney Transplant who are treated with tacrolimus may have an increased risk of nephrotoxicity as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patients risk for drug-induced nephrotoxicity.'),('rs776746','C > T','CYP3A5','tacrolimus--PA451578','DERMATOLOGICALS',NULL,NULL,NULL,'Level 3','increased','-','-','CT','                Patients with the CT genotype (*1/*3) and recipients of Kidney Transplant who are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patients response to tacrolimus treatment and risk of transplant rejection.'),('rs776746','C > T','CYP3A5','tacrolimus--PA451578','DERMATOLOGICALS',NULL,NULL,NULL,'Level 3','increased','-','-','TT','                Patients with the TT (*1/*1) genotype and recipients of Kidney Transplant who are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patients response to tacrolimus treatment and risk of transplant rejection.'),('rs776746','C > T','CYP3A5','tacrolimus--PA451578','DERMATOLOGICALS',NULL,NULL,NULL,'Level 3','-','-','decreased','CT','                Patients with the CT genotype and recipients of Kidney Transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hyperlipidemia.'),('rs776746','C > T','CYP3A5','tacrolimus--PA451578','DERMATOLOGICALS',NULL,NULL,NULL,'Level 3','-','-','decreased','TT','                Patients with the TT genotype and recipients of Kidney Transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hyperlipidemia.'),('rs3892097','C > T','CYP2D6','tamoxifen--PA451581','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','increased','-','-','CT','                Patients with the CT genotype who are treated with tamoxifen: 1) may have a decreased, but not absent, risk of relapse as compared to patients with the TT genotype 2) may have an increased severity in hot flashes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk of relapse.'),('rs3892097','C > T','CYP2D6','tamoxifen--PA451581','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 2A','increased','-','-','TT','                Patients with the TT genotype who are treated with tamoxifen: 1) may have an increased risk of relapse as compared to patients with the CT or CC genotype 2) may have a decreased severity in hot flashes as compared to patients with the CT or CC genotype.'),('rs4986938','C > T','ESR2','tamoxifen--PA451581','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','CT','                Patients with the CT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the  CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.'),('rs4986938','C > T','ESR2','tamoxifen--PA451581','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','TT','                Patients with the TT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the  CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.'),('rs9340799','A > G','ESR1','tamoxifen--PA451581','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','GG','                The GG genotype carriers had larger tamoxifen-induced decrease in total cholesterol in postmenopausal woman compared to GA/AA genotypes (P=0.03; GG vs GA/AA) and tamoxifen-induced increase in triglycerides (P=0.002; gene-dose effect) and decrease in high density lipoprotein (P=0.004; gene-dose effect) in premenopausal women.'),('rs1056836','C > G','CYP1B1','taxanes--PA150481189','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with taxanes may have longer disease-free progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs2032582','A > C','ABCB1','taxanes--PA150481189','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','decreased','CC','                Patients with the CC genotype may have decreased but not non-existent risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CA, CT, AA or TT genotypes. Other genetic and clinical factors may also influence a patients risk for gastrointestinal toxicity with taxane and platinum regimens.'),('rs2032582','A > C','ABCB1','taxanes--PA150481189','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Patients with the CC genotype may have 1) increased risk for resistance 2) decreased response to taxanes as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence a patients response to taxanes.'),('rs1801019','G > C','UMPS','tegafur--PA452620','VARIOUS',NULL,NULL,NULL,'Level 2B','-','-','increased','CG','                Patients with CG genotype and cancer may have a decreased, but not absent, risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and  leucovorin as compared to patients with the CC genotype. However, contradictory findings have been reported that show the CG genotype may be associated with increased risk for grade 3 to 4 diarrhea when treated with fluorouracil and leucovorin compared to the GG genotype.Other genetic and clinical factors may also influence response to leucovorin, tegafur and fluorouracil.'),('rs1801019','G > C','UMPS','tegafur--PA452620','VARIOUS',NULL,NULL,NULL,'Level 2B','-','-','increased','CC','                Patients with CC genotype and cancer may have an increased risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and  leucovorin as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to leucovorin, tegafur and fluorouracil.'),('rs17222723','T > A','ABCC2','tenofovir--PA10204','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 3','-','-','decreased','AT','                Patients with the AT genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patients risk for adverse events with tenofovir treatment.'),('rs17222723','T > A','ABCC2','tenofovir--PA10204','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patients risk for adverse events with tenofovir treatment.'),('rs2273697','G > A','ABCC2','tenofovir--PA10204','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype may have increased risk of renal proximal tubulopathy when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs2273697','G > A','ABCC2','tenofovir--PA10204','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 3','-','-','increased','AA','                Patients with the AA genotype may have increased risk of renal proximal tubulopathy when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs717620','C > T','ABCC2','tenofovir--PA10204','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 3','-','-','decreased','CT','                Patients with the CT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced kidney tubular dysfunction.'),('rs717620','C > T','ABCC2','tenofovir--PA10204','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 3','-','-','decreased','TT','                Patients with the TT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced kidney tubular dysfunction.'),('rs9349256','G > A','ABCC10','tenofovir--PA10204','ANTIINFECTIVES FOR SYSTEMIC USE',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased but not absent risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs12418','G > A','CHST3','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs12418','G > A','CHST3','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs12960','G > A','RPL13','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs1402467','C > G','SULT1C4','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','CG','                Patients with the CG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs1402467','C > G','SULT1C4','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs1799931','G > A','NAT2','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs1871450','G > A','CHST3','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AG','                Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs1871450','G > A','CHST3','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','increased','-','-','AA','                Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs1883322','C > T','PPARD','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2016520','C > T','PPARD','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2227291','G > C','ATP7A','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS',NULL,NULL,NULL,'Level 3','-','-','decreased','CC','                Patients with the CC genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2238472','C > T','ABCC6','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','-','-','decreased','TT','                Patients with the TT genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2292954','A > G','SPG7','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2301159','G > A','SLC10A2','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs2301159','G > A','SLC10A2','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','-','-','increased','AA','                Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs3734254','C > T','PPARD','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs3734254','C > T','PPARD','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','increased','-','-','TT','                Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs4148943','C > T','CHST3','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4148945','C > T','CHST3','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4148947','T > C','CHST3','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','decreased','-','-','CC','                Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4148950','G > A','CHST3','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs4148950','G > A','CHST3','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','increased','-','-','AA','                Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs4646487','C > T','CYP4B1','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4646487','C > T','CYP4B1','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs6922548','A > G','PPARD','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs6922548','A > G','PPARD','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','increased','-','-','GG','                Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs730720','C > T','CHST3','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs7769719','G > A','PPARD','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','decreased','-','-','AA','                Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs1142345','T > C','TPMT','thioguanine--PA451663','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CT','                Patients with the CT genotype  1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1142345','T > C','TPMT','thioguanine--PA451663','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','thioguanine--PA451663','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','thioguanine--PA451663','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','thioguanine--PA451663','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CG','                Patients with the CG genotype (e.g. TPMT*1/*2): may have increased deactivation of thiopurines and a decreased, but not absent, risk for toxicity with thiopurine drugs as compared to patients with the GG genotype (TPMT*2/*2) or may have decreased deactivation of thiopurines and an increased risk for toxicity with thiopurine drugs as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','thioguanine--PA451663','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs16944','A > G','IL1B','tiludronate--PA451688','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB01133','Tiludronate is a bisphosphonate characterized by a (4-chlorophenylthio) group on the carbon atom of the basic P-C-P structure common to all bisphosphonates.','Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs712829','G > T','EGFR','topoisomerase I inhibitors--PA150481186','VARIOUS',NULL,NULL,NULL,'Level 4','decreased','-','-','GT','                Cancer patients with genotype GT may be less likely to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patients response.'),('rs712829','G > T','EGFR','topoisomerase I inhibitors--PA150481186','VARIOUS',NULL,NULL,NULL,'Level 4','decreased','-','-','TT','                Cancer patients with genotype TT may be less likely  to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patients response.'),('rs1136201','A > G','ERBB2','trastuzumab--PA451743','VARIOUS',NULL,NULL,NULL,'Level 3','-','-','increased','AG','                Patients with the AG genotype may have increased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of toxicity.'),('rs37973','G > A','GLCCI1','triamcinolone--PA451749','ALIMENTARY TRACT AND METABOLISM','STOMATOLOGICAL PREPARATIONS','DB00620','A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated','Level 3','increased','-','-','AA','                Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patients response to glucocorticoids.'),('rs10811661','T > C','','troglitazone--PA451799','ALIMENTARY TRACT AND METABOLISM','DRUGS USED IN DIABETES','DB00197','Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.','Level 3','increased','-','-','CT','                Patients with the CT genotype and at high risk for type II diabetes who are treated with troglitazone may have increased beta call function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to troglitazone.'),('rs10811661','T > C','','troglitazone--PA451799','ALIMENTARY TRACT AND METABOLISM','DRUGS USED IN DIABETES','DB00197','Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.','Level 3','increased','-','-','CC','                Patients with the CC genotype and at high-risk for type II diabetes who are treated with troglitazone may have increased beta cell function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response.'),('rs2814707','C > T','MOBKL2B','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patients response.'),('rs2814707','C > T','MOBKL2B','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Rheumatoid Arthritis patients with the TT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patients response.'),('rs3849942','T > C','C9orf72','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 4','increased','-','-','CC','                Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patients response.'),('rs437943','T > C','','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 4','decreased','-','-','CT','                Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to a patient with genotype TT.'),('rs437943','T > C','','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 4','decreased','-','-','CC','                Rheumatoid Arthritis patients with the CC genotype may be less likely to respond to TNF inhibitors compared to a patient with genotype TT.'),('rs6028945','G > T','','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','GT','                Rheumatoid Arthritis patients with the genotype GT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs6028945','G > T','','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Rheumatoid Arthritis patients with the genotype TT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs6071980','T > C','','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Rheumatoid Arthritis patients with the genotype CT may be less likely to respond to TNF inhibitors compared with a patient with the genotype TT . Other genetic and clinical factors may also influence a patients response.'),('rs6071980','T > C','','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Rheumatoid Arthritis patients with the genotype CC may be less likely to respond to TNF inhibitors compared with a patient with the genotype TT . Other genetic and clinical factors may also influence a patients response.'),('rs6138150','T > C','','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Rheumatoid Arthritis patients with the genotype CC may be more likely to respond to TNF inhibitors compared with patients with genotypes TT or CT .  Other genetic and clinical factors may also influence a patients response.'),('rs7046653','A > G','MOBKL2B','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG. Other genetic and clinical factors may also influence a patients response.'),('rs774359','T > C','C9orf72','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','CT','                Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patients response.'),('rs774359','T > C','C9orf72','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','CC','                Rheumatoid Arthritis patients with the CC genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patients response.'),('rs854547','G > A','PON1','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 4','decreased','-','-','AG','                Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs854547','G > A','PON1','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 4','decreased','-','-','AA','                Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs854548','A > G','PON1','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 4','increased','-','-','GG','                Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG.  Other genetic and clinical factors may also influence a patients response.'),('rs854555','A > C','PON1','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','CC','                Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AC.  Other genetic and clinical factors may also influence a patients response.'),('rs868856','A > G','MOBKL2B','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 3','increased','-','-','GG','                Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AG. Other genetic and clinical factors may also influence a patients response.'),('rs928655','G > A','GBP6','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 4','decreased','-','-','AG','                Rheumatoid Arthritis patients with genotype AG may be less likely to respond to TNF inhibitors compared to patients with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs928655','G > A','GBP6','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 4','decreased','-','-','AA','                Rheumatoid Arthritis patients with genotype AA may be less likely to respond to TNF inhibitors compared to patients with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs983332','G > T','','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','GT','                Rheumatoid Arthritis patients with genotype GT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs983332','G > T','','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','VARIOUS',NULL,NULL,NULL,'Level 3','decreased','-','-','TT','                Rheumatoid Arthritis patients with genotype TT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs1057910','A > C','CYP2C9','valproic acid--PA451846','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs1057910','A > C','CYP2C9','valproic acid--PA451846','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','-','increased','CC','                Patients with the CC genotype were not studied. However, patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs1105879','A > C','UGT1A6','valproic acid--PA451846','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','AC','                Patients with the AC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs1105879','A > C','UGT1A6','valproic acid--PA451846','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','CC','                Patients with the CC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs2070959','A > G','UGT1A10','valproic acid--PA451846','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','AG','                Patients with the AG genotype may require an increased dose of valproic acid compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs2070959','A > G','UGT1A10','valproic acid--PA451846','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','GG','                Patients with the GG genotype may require an increased dose of valproic acid compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs6759892','T > G','UGT1A10','valproic acid--PA451846','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','GT','                Patients with the GT genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients valproic acid dose requirement.'),('rs6759892','T > G','UGT1A10','valproic acid--PA451846','NERVOUS SYSTEM',NULL,'A fatty acid with anticonvulsa',NULL,'Level 3','-','increased','-','GG','                Patients with the GG genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT and GT genotype. Other genetic and clinical factors may also influence a patients valproic acid dose requirement.'),('rs7439366','T > C','UGT2B7','valproic acid--PA451846','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','decreased','-','-','CT','                Healthy individuals with the CT genotype who are treated with valproic acid and lorazepam may have poorer responses in psychocognitive function tests as compared to those with the TT genotype or may have better responses in psychocognitive function tests as compared to patients with the CC genotype. Other genetic and clinical factors may also influence an individuals response to valproic acid and lorazepam treatment.'),('rs7439366','T > C','UGT2B7','valproic acid--PA451846','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','decreased','-','-','CC','                Healthy individuals with the CC genotype who are treated with valproic acid and lorazepam may have poorer responses in psychocognitive function tests as compared to those with the TT genotype. Other genetic and clinical factors may also influence an individuals response to valproic acid and lorazepam treatment.'),('rs10879346','C > T','TPH2','venlafaxine--PA451866','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with antidepressants may have less improvement in symptoms as compared to patients with the CT and CC genotype.'),('rs1360780','T > C','FKBP5','venlafaxine--PA451866','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to paroxetine, venlafaxine, clomipramine or nefazodone.'),('rs1487278','T > C','TPH2','venlafaxine--PA451866','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','increased','-','-','CT','                Patients with the CT genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to antidepressant.'),('rs1487278','T > C','TPH2','venlafaxine--PA451866','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','increased','-','-','CC','                Patients with the CC genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to antidepressant. (The frequency for CC allele is very low, homozygous minor allele carriers were pooled together with the heterozygous samples and compared with the homozygous major allele (T) carrier.)'),('rs3892097','C > T','CYP2D6','venlafaxine--PA451866','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','-','-','increased','CT','                Patients with the CT genotype who are treated with venlafaxine may have an increased risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to venlafaxine.'),('rs3892097','C > T','CYP2D6','venlafaxine--PA451866','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','-','-','increased','TT','                Patients with the TT genotype who are treated with venlafaxine may have an increased risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to venlafaxine.'),('rs10494366','G > T','NOS1AP','verapamil--PA451868','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 3','-','-','decreased','TT','                Patients with the TT genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients QTc prolongation risk.'),('rs1051375','G > A','CACNA1C','verapamil--PA451868','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 3','increased','-','-','AA','                Patients with the AA genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with verapamil compared to treatment with atenolol. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs10918594','C > G','NOS1AP','verapamil--PA451868','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 4','-','-','increased','CG','                While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype, it was not shown conclusively if heterzygous (GC) individuals are affected. Other genetic and clinical factors may also influence a patients QTc prolongation risk.'),('rs10918594','C > G','NOS1AP','verapamil--PA451868','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 4','-','-','increased','GG','                Patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients QTc prolongation risk.'),('rs11739136','C > T','KCNIP1','verapamil--PA451868','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 3','decreased','-','-','CT','                Patients with the CT genotype: 1) may have decreased blood pressure, 2) decreased risk for hypertension and 3) faster control of blood pressure when treated with verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients blood pressure and response to antihypertensives.'),('rs11739136','C > T','KCNIP1','verapamil--PA451868','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 3','decreased','-','-','TT','                Patients with the CT genotype: 1) may have decreased blood pressure, 2) decreased risk for hypertension and 3) faster control of blood pressure when treated with verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients blood pressure and response to antihypertensives.'),('rs1801252','A > G','ADRB1','verapamil--PA451868','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 4','decreased','-','-','GG','                Patients with the GG genotype who have Coronary Artery Disease may have a decreased risk for death when treated with verapamil as compared to patients with the AA or AG genotype and the rs1801253 allele C. Other genetic and clinical factors may also influence risk of death.'),('rs1801253','G > C','ADRB1','verapamil--PA451868','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 3','decreased','-','-','CC','                Patients with the CC genotype and Atrial Fibrillation may have a decreased response to verapamil treatment compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to verapamil.'),('rs1045642','A > G','ABCB1','vincristine--PA451879','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00541','Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkins disease, acute erythraemia, and acute panmyelosis.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs2032582','A > C','ABCB1','vincristine--PA451879','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTITHROMBOTIC AGENTS','DB00541','Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkins disease, acute erythraemia, and acute panmyelosis.','Level 3','decreased','-','-','CC','                Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patients response to the therapy.'),('rs1057910','A > C','CYP2C9','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','increased','-','AC','                Patients with the AC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.'),('rs1057910','A > C','CYP2C9','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','increased','-','CC','                Patients with the CC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.'),('rs10871454','C > T','STX4','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype.'),('rs10871454','C > T','STX4','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','TT','                Patients with the TT genotype who are treated with warfarin may require the lowest dose as compared to patients with the CT or CC genotype.'),('rs12714145','C > T','GGCX','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','increased','-','TT','                Genotype TT may be associated with increased dose of warfarin as compared to genotype GG. However, contradictory findings (no association) have been reported. Other genetic and clinical factors may influence a patients dose of warfain.'),('rs17708472','G > A','VKORC1','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','increased','-','AG','                Patients with the AG genotype: 1) may require a higher dose of warfarin as compared to patients with the GG genotype 2) may have an increased risk of warfarin resistance as compared to patients with the GG genotype.'),('rs17708472','G > A','VKORC1','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','increased','-','AA','                Patients with the AA genotype: 1) may require a higher dose of warfarin as compared to patients with the GG genotype 2) may have an increased risk of warfarin resistance as compared to patients with the GG genotype.'),('rs1799853','C > T','CYP2C9','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients dose of warfarin.'),('rs1799853','C > T','CYP2C9','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','-','TT','                Patients with the TT genotype who are treated with warfarin may require a lower dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients dose of warfarin.'),('rs2108622','C > T','CYP4F2','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs2108622','C > T','CYP4F2','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs2292566','G > A','EPHX1','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','AG','                Patients with the AG genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.'),('rs2292566','G > A','EPHX1','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','AA','                Patients with the AA genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.'),('rs2359612','A > G','PRSS53','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTSANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','increased','-','GG','                Patients with the GG genotype who are treated with warfarin may require a higher dose as compared to patients with the AG or AA genotype.'),('rs28371685','C > T','CYP2C9','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a decreased dose as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin.'),('rs28371685','C > T','CYP2C9','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','TT','                Patients with the TT genotype who are treated with warfarin may require the lowest does as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin.'),('rs28371686','C > G','CYP2C9','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 2A','-','decreased','-','CG','                Patients with the CG genotype who are treated with warfarin may require a decreased dose as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin.'),('rs28371686','C > G','CYP2C9','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 2A','-','decreased','-','GG','                Patients with the GG genotype who are treated with warfarin may require the lowest does as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin.'),('rs339097','A > G','CALU','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 2B','-','increased','-','AG','                Patients with the AG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients warfarin dose.'),('rs339097','A > G','CALU','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 2B','-','increased','-','GG','                Patients with the GG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients warfarin dose.'),('rs7294','C > T','VKORC1','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.'),('rs7294','C > T','VKORC1','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.'),('rs7900194','G > A','CYP2C9','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','AG','                Patients with the AG genotype who are treated with warfarin may require a lower maintenance dose as compared to patients with the GG genotype.'),('rs7900194','G > A','CYP2C9','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin may require the lowest maintenance dose as compared to patients with the AG or GG genotype.'),('rs8050894','C > G','PRSS53','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','CG','                Patients with the CG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype.'),('rs8050894','C > G','PRSS53','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','GG','                Patients with the GG genotype who are treated with warfarin may require the lowest dose as compared to patients with the CG or CC genotype.'),('rs9934438','G > A','VKORC1','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','decreased','-','AG','                Patients with the AG genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs9934438','G > A','VKORC1','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs951439','C > T','RGS4','ziprasidone--PA451974','BLOOD AND BLOOD FORMING ORGANS','PSYCHOLEPTICS','DB00246','Ziprasidone (marketed as Geodon, Zeldox) was the fifth atypical antipsychotic to gain FDA approval (February 2001). Ziprasidone is Food and Drug Administration (FDA) approved for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients. Ziprasidone has also received approval for acute treatment of mania associated with bipolar disorder','Level 3','increased','-','-','CT','                Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs951439','C > T','RGS4','ziprasidone--PA451974','BLOOD AND BLOOD FORMING ORGANS','PSYCHOLEPTICS','DB00246','Ziprasidone (marketed as Geodon, Zeldox) was the fifth atypical antipsychotic to gain FDA approval (February 2001). Ziprasidone is Food and Drug Administration (FDA) approved for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients. Ziprasidone has also received approval for acute treatment of mania associated with bipolar disorder','Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may have increased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs1934951','C > T','CYP2C8','zoledronate--PA10235','BLOOD AND BLOOD FORMING ORGANS','DRUGS FOR TREATMENT OF BONE DISEASES','DB00399','Zoledronate (zoledronic acid, marketed by Novartis under the trade names Zometa and Reclast) is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases.\n\nAn annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture.\n\nZoledronate is a single 5 mg infusion for the treatment of Pagets disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.');
/*!40000 ALTER TABLE `drug_response_drugs` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `drug_rs`
--

DROP TABLE IF EXISTS `drug_rs`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `drug_rs` (
  `RSID` varchar(20) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `Drug` varchar(60) DEFAULT NULL,
  `Efficacy` varchar(20) DEFAULT NULL,
  `Dosage` varchar(20) DEFAULT NULL,
  `Toxicity` varchar(20) DEFAULT NULL
) ENGINE=MyISAM DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `drug_rs`
--

LOCK TABLES `drug_rs` WRITE;
/*!40000 ALTER TABLE `drug_rs` DISABLE KEYS */;
INSERT INTO `drug_rs` VALUES ('rs3093726','LST1','abacavir--PA448004','-','-','decreased'),('rs11209716','PTGER3','Ace Inhibitors, Plain--PA164712308','-','-','decreased'),('rs8012552','BDKRB2','Ace Inhibitors, Plain--PA164712308','-','-','decreased'),('rs1799722','BDKRB2','Ace Inhibitors, Plain--PA164712308','-','-','increased'),('rs2016848','MME','Ace Inhibitors, Plain--PA164712308','-','-','increased'),('rs1057910','CYP2C9','acenocoumarol--PA452632','-','decreased','-'),('rs4086116','CYP2C9','acenocoumarol--PA452632','-','decreased','-'),('rs9934438','VKORC1','acenocoumarol--PA452632','-','decreased','-'),('rs2108622','CYP4F2','acenocoumarol--PA452632','-','increased','-'),('rs1800629','TNF','adalimumab--PA10004','decreased','-','-'),('rs1544410','VDR','alendronate--PA448082','decreased','-','-'),('rs2297480','FDPS','alendronate--PA448082','decreased','-','-'),('rs712829','EGFR','Alkylating Agents--PA164712331','decreased','-','-'),('rs9267445','MICB','allopurinol--PA448320','-','-','decreased'),('rs9263726','CCHCR1','allopurinol--PA448320','-','-','increased'),('rs9263733','CCHCR1','allopurinol--PA448320','-','-','increased'),('rs9263745','CCHCR1','allopurinol--PA448320','-','-','increased'),('rs9263781','CCHCR1','allopurinol--PA448320','-','-','increased'),('rs9263785','CCHCR1','allopurinol--PA448320','-','-','increased'),('rs9263794','CCHCR1','allopurinol--PA448320','-','-','increased'),('rs9263796','CCHCR1','allopurinol--PA448320','-','-','increased'),('rs9263800','CCHCR1','allopurinol--PA448320','-','-','increased'),('rs9263827','POU5F1','allopurinol--PA448320','-','-','increased'),('rs12720441','KCNH2','amiodarone--PA448383','-','-','increased'),('rs5065','NPPA','amlodipine--PA448388','increased','-','-'),('rs10509681','CYP2C8','amodiaquine--PA448404','-','-','increased'),('rs11572080','CYP2C8','amodiaquine--PA448404','-','-','increased'),('rs9274407','HLA-DQB1','amoxicillin--PA448406','-','-','decreased'),('rs2070995','KCNJ6','Analgesics--PA164712362','increased','-','-'),('rs1056892','CBR3','anthracyclines and related substances--PA130620651','-','-','decreased'),('rs10836235','CAT','anthracyclines and related substances--PA130620651','-','-','decreased'),('rs9024','CBR1','anthracyclines and related substances--PA130620651','-','-','decreased'),('rs9514091','SLC10A2','anthracyclines and related substances--PA130620651','-','-','decreased'),('rs1045642','ABCB1','anthracyclines and related substances--PA130620651','decreased','-','-'),('rs2032582','ABCB1','anthracyclines and related substances--PA130620651','increased','-','-'),('rs10879346','TPH2','antidepressants--PA452229','decreased','-','-'),('rs1360780','FKBP5','antidepressants--PA452229','decreased','-','-'),('rs1799889','SERPINE1','antidepressants--PA452229','decreased','-','-'),('rs2227631','SERPINE1','antidepressants--PA452229','decreased','-','-'),('rs3800373','FKBP5','antidepressants--PA452229','decreased','-','-'),('rs61888800','BDNF','antidepressants--PA452229','decreased','-','-'),('rs7569963','CREB1','antidepressants--PA452229','decreased','-','-'),('rs7997012','HTR2A','antidepressants--PA452229','decreased','-','-'),('rs2032583','ABCB1','antidepressants--PA452229','increased','-','-'),('rs2235015','ABCB1','antidepressants--PA452229','increased','-','-'),('rs6295','HTR1A','antidepressants--PA452229','increased','-','-'),('rs2032582','ABCB1','antiepileptics--PA143485705','-','decreased','-'),('rs2032582','ABCB1','antiepileptics--PA143485705','decreased','-','-'),('rs2273697','ABCC2','antiepileptics--PA143485705','-','-','increased'),('rs1045642','ABCB1','antiepileptics--PA143485705','increased','-','-'),('rs3740066','ABCC2','antiepileptics--PA143485705','increased','-','-'),('rs717620','ABCC2','antiepileptics--PA143485705','increased','-','-'),('rs2070744','NOS3','Antihypertensives And Diuretics In Combination--PA164712446','decreased','-','-'),('rs2070744','NOS3','Antihypertensives--PA164712445','decreased','-','-'),('rs1801252','ADRB1','Antihypertensives--PA164712445','increased','-','-'),('rs1057910','CYP2C9','Antiinflammatory agents, non-steroids--PA164712462','-','-','increased'),('rs943580','AGT','Antiinflammatory agents, non-steroids--PA164712462','-','-','increased'),('rs1042522','TP53','antineoplastic agents--PA452621','increased','-','-'),('rs1414334','HTR2C','antipsychotics--PA452233','-','-','decreased'),('rs1800497','ANKK1','antipsychotics--PA452233','-','-','decreased'),('rs4680','COMT','antipsychotics--PA452233','-','-','decreased'),('rs6277','DRD2','antipsychotics--PA452233','-','-','decreased'),('rs1079598','DRD2','antipsychotics--PA452233','-','-','increased'),('rs1800497','ANKK1','antipsychotics--PA452233','-','-','increased'),('rs1801133','CLCN6','antipsychotics--PA452233','-','-','increased'),('rs2069514','CYP1A2','antipsychotics--PA452233','-','-','increased'),('rs1799732','DRD2','antipsychotics--PA452233','increased','-','-'),('rs951439','RGS4','antipsychotics--PA452233','increased','-','-'),('rs429358','APOC1','Antivirals for treatment of HIV infections, combinations--PA','-','-','increased'),('rs7412','APOE','Antivirals for treatment of HIV infections, combinations--PA','-','-','increased'),('rs1799732','DRD2','aripiprazole--PA10026','increased','-','-'),('rs1050828','G6PD','artesunate--PA165111697','-','-','increased'),('rs730012','LTC4S','aspirin--PA448497','-','-','increased'),('rs20417','PTGS2','aspirin--PA448497','increased','-','-'),('rs1801252','ADRB1','atenolol--PA448499','decreased','-','-'),('rs688','LDLR','atenolol--PA448499','decreased','-','-'),('rs1051375','CACNA1C','atenolol--PA448499','increased','-','-'),('rs1801253','ADRB1','atenolol--PA448499','increased','-','-'),('rs4693075','COQ2','atorvastatin--PA448500','-','-','decreased'),('rs17238540','HMGCR','atorvastatin--PA448500','decreased','-','-'),('rs1935349','HTR7','atorvastatin--PA448500','-','-','increased'),('rs2276307','HTR3B','atorvastatin--PA448500','-','-','increased'),('rs5443','GNB3','atorvastatin--PA448500','increased','-','-'),('rs1127354','DDRGK1','azathioprine--PA448515','decreased','-','-'),('rs1142345','TPMT','azathioprine--PA448515','-','-','increased'),('rs1800460','TPMT','azathioprine--PA448515','-','-','increased'),('rs1800462','TPMT','azathioprine--PA448515','-','-','increased'),('rs1127354','DDRGK1','azathioprine--PA448515','increased','-','-'),('rs17098707','GRK5','Beta Blocking Agents--PA164712535','decreased','-','-'),('rs1801252','ADRB1','Beta Blocking Agents--PA164712535','decreased','-','-'),('rs1801253','ADRB1','Beta Blocking Agents--PA164712535','increased','-','-'),('rs4253778','PPARA','Beta Blocking Agents--PA164712535','increased','-','-'),('rs1801252','ADRB1','bisoprolol--PA448641','decreased','-','-'),('rs1934951','CYP2C8','Bisphosphonates--PA164712563','-','-','decreased'),('rs1544410','VDR','Bisphosphonates--PA164712563','decreased','-','-'),('rs16944','IL1B','Bisphosphonates--PA164712563','decreased','-','-'),('rs2297480','FDPS','Bisphosphonates--PA164712563','decreased','-','-'),('rs1934951','CYP2C8','Bisphosphonates--PA164712563','-','-','increased'),('rs16944','IL1B','Bisphosphonates--PA164712563','increased','-','-'),('rs2297480','FDPS','Bisphosphonates--PA164712563','increased','-','-'),('rs1799732','DRD2','Bromperidol--PA165282097','increased','-','-'),('rs1801253','ADRB1','bucindolol--PA165945764','increased','-','-'),('rs37973','GLCCI1','budesonide--PA448681','Efficacy','-','-'),('rs37973','GLCCI1','budesonide--PA448681','increased','-','-'),('rs1800497','ANKK1','bupropion--PA448687','decreased','-','-'),('rs165599','ARVCF','bupropion--PA448687','increased','-','-'),('rs2298383','ADORA2A','caffeine--PA448710','-','-','decreased'),('rs5751876','ADORA2A','caffeine--PA448710','-','decreased','-'),('rs762551','CYP1A2','caffeine--PA448710','-','-','increased'),('rs1544410','VDR','Calcium--PA164712582','decreased','-','-'),('rs1045642','ABCB1','capecitabine--PA448771','-','-','increased'),('rs1801131','MTHFR','capecitabine--PA448771','-','-','increased'),('rs2297595','DPYD','capecitabine--PA448771','-','-','increased'),('rs1801131','MTHFR','capecitabine--PA448771','increased','-','-'),('rs2844682','MUC21','carbamazepine--PA448785','-','-','decreased'),('rs3909184','FLOT1','carbamazepine--PA448785','-','-','decreased'),('rs750332','BAT2','carbamazepine--PA448785','-','-','decreased'),('rs1045642','ABCB1','carbamazepine--PA448785','-','decreased','-'),('rs2032582','ABCB1','carbamazepine--PA448785','-','decreased','-'),('rs1800629','LST1','carbamazepine--PA448785','-','-','increased'),('rs2227956','HSPA1A','carbamazepine--PA448785','-','-','increased'),('rs2273697','ABCC2','carbamazepine--PA448785','-','-','increased'),('rs1045642','ABCB1','carbamazepine--PA448785','-','increased','-'),('rs1051740','EPHX1','carbamazepine--PA448785','-','increased','-'),('rs2234922','EPHX1','carbamazepine--PA448785','-','increased','-'),('rs3812718','SCN1A','carbamazepine--PA448785','-','increased','-'),('rs11615','ERCC1','carboplatin--PA448803','increased','-','-'),('rs1801133','CLCN6','carboplatin--PA448803','increased','-','-'),('rs25487','XRCC1','carboplatin--PA448803','increased','-','-'),('rs9981861','DSCAM','carboplatin--PA448803','increased','-','-'),('rs1042714','ADRB2','carvedilol--PA448817','decreased','-','-'),('rs1801253','ADRB1','carvedilol--PA448817','increased','-','-'),('rs1057910','CYP2C9','celecoxib--PA448871','-','decreased','-'),('rs1799853','CYP2C9','celecoxib--PA448871','decreased','-','-'),('rs1057910','CYP2C9','celecoxib--PA448871','-','-','increased'),('rs4149056','SLCO1B1','cerivastatin--PA448897','-','-','decreased'),('rs2819742','RYR2','cerivastatin--PA448897','-','-','increased'),('rs4149056','SLCO1B1','cerivastatin--PA448897','-','-','increased'),('rs2227983','EGFR','cetuximab--PA10040','-','-','decreased'),('rs396991','FCGR3A','cetuximab--PA10040','decreased','-','-'),('rs4444903','EGF','cetuximab--PA10040','decreased','-','-'),('rs9344','CCND1','cetuximab--PA10040','increased','-','-'),('rs1799732','DRD2','chlorpromazine--PA448964','increased','-','-'),('rs5065','NPPA','chlorthalidone--PA448970','increased','-','-'),('rs11615','ERCC1','cisplatin--PA449014','-','-','decreased'),('rs2075252','LRP2','cisplatin--PA449014','-','-','decreased'),('rs2228001','XPC','cisplatin--PA449014','-','-','decreased'),('rs3212986','ERCC1','cisplatin--PA449014','-','-','decreased'),('rs3957357','GSTA1','cisplatin--PA449014','-','-','decreased'),('rs4646316','COMT','cisplatin--PA449014','-','-','decreased'),('rs13181','ERCC2','cisplatin--PA449014','decreased','-','-'),('rs1695','GSTP1','cisplatin--PA449014','decreased','-','-'),('rs1142345','TPMT','cisplatin--PA449014','-','-','increased'),('rs12201199','TPMT','cisplatin--PA449014','-','-','increased'),('rs1800460','TPMT','cisplatin--PA449014','-','-','increased'),('rs1805087','MTR','cisplatin--PA449014','-','-','increased'),('rs316019','SLC22A2','cisplatin--PA449014','-','-','increased'),('rs9332377','COMT','cisplatin--PA449014','-','-','increased'),('rs1042522','TP53','cisplatin--PA449014','increased','-','-'),('rs1045642','ABCB1','cisplatin--PA449014','increased','-','-'),('rs11615','ERCC1','cisplatin--PA449014','increased','-','-'),('rs1799793','ERCC2','cisplatin--PA449014','increased','-','-'),('rs1801133','MTHFR','cisplatin--PA449014','increased','-','-'),('rs25487','XRCC1','cisplatin--PA449014','increased','-','-'),('rs9597','BAIAP3','cisplatin--PA449014','increased','-','-'),('rs9679162','GALNT14','cisplatin--PA449014','increased','-','-'),('rs1799889','SERPINE1','citalopram--PA449015','decreased','-','-'),('rs2227631','SERPINE1','citalopram--PA449015','decreased','-','-'),('rs7569963','CREB1','citalopram--PA449015','decreased','-','-'),('rs7997012','HTR2A','citalopram--PA449015','decreased','-','-'),('rs1954787','GRIK4','citalopram--PA449015','increased','-','-'),('rs334558','GSK3B','citalopram--PA449015','increased','-','-'),('rs9274407','HLA-DQB1','clavulanate--PA164742987','-','-','decreased'),('rs1544410','VDR','clodronate--PA10239','decreased','-','-'),('rs731236','VDR','clodronate--PA10239','decreased','-','-'),('rs16944','IL1B','clodronate--PA10239','increased','-','-'),('rs1360780','FKBP5','clomipramine--PA449048','-','-','decreased'),('rs1045642','ABCB1','clopidogrel--PA449053','-','-','decreased'),('rs4244285','CYP2C19','clopidogrel--PA449053','increased','-','-'),('rs4986893','CYP2C19','clopidogrel--PA449053','increased','-','-'),('rs662','PON1','clopidogrel--PA449053','increased','-','-'),('rs1414334','HTR2C','clozapine--PA449061','-','-','decreased'),('rs6277','DRD2','clozapine--PA449061','-','-','decreased'),('rs1079598','DRD2','clozapine--PA449061','-','-','increased'),('rs1800497','ANKK1','clozapine--PA449061','-','-','increased'),('rs1799732','DRD2','clozapine--PA449061','increased','-','-'),('rs6280','DRD3','clozapine--PA449061','increased','-','-'),('rs742105','DTNBP1','clozapine--PA449061','increased','-','-'),('rs9282861','SULT1A1','conjugated estrogens--PA164754789','-','-','increased'),('rs9340799','ESR1','conjugated estrogens--PA164754789','increased','-','-'),('rs1801131','MTHFR','cyanocobalamin--PA451892','increased','-','-'),('rs11615','ERCC1','cyclophosphamide--PA449165','-','-','decreased'),('rs2740574','CYP3A4','cyclophosphamide--PA449165','-','-','decreased'),('rs3745274','CYP2B6','cyclophosphamide--PA449165','-','-','decreased'),('rs3957357','GSTA1','cyclophosphamide--PA449165','-','-','decreased'),('rs4244285','CYP2C19','cyclophosphamide--PA449165','-','-','decreased'),('rs3745274','CYP2B6','cyclophosphamide--PA449165','-','decreased','-'),('rs1695','GSTP1','cyclophosphamide--PA449165','decreased','-','-'),('rs4880','SOD2','cyclophosphamide--PA449165','decreased','-','-'),('rs1801133','MTHFR','cyclophosphamide--PA449165','-','-','increased'),('rs2279343','CYP2B6','cyclophosphamide--PA449165','-','-','increased'),('rs8192709','CYP2B6','cyclophosphamide--PA449165','-','-','increased'),('rs9561778','ABCC4','cyclophosphamide--PA449165','-','-','increased'),('rs1042522','TP53','cyclophosphamide--PA449165','increased','-','-'),('rs1695','GSTP1','cyclophosphamide--PA449165','increased','-','-'),('rs1799793','ERCC2','cyclophosphamide--PA449165','increased','-','-'),('rs1799983','NOS3','cyclophosphamide--PA449165','increased','-','-'),('rs2032582','ABCB1','cyclophosphamide--PA449165','increased','-','-'),('rs25487','XRCC1','cyclophosphamide--PA449165','increased','-','-'),('rs4244285','CYP2C19','cyclophosphamide--PA449165','increased','-','-'),('rs1045642','ABCB1','cyclosporine--PA449167','-','decreased','-'),('rs2032582','ABCB1','cyclosporine--PA449167','-','decreased','-'),('rs2032582','ABCB1','cyclosporine--PA449167','decreased','-','-'),('rs1045642','ABCB1','cyclosporine--PA449167','-','increased','-'),('rs1128503','ABCB1','cyclosporine--PA449167','-','increased','-'),('rs776746','CYP3A5','cyclosporine--PA449167','-','increased','-'),('rs1045642','ABCB1','cytarabine--PA449177','decreased','-','-'),('rs2072671','CDA','cytarabine--PA449177','-','-','increased'),('rs532545','CDA','cytarabine--PA449177','-','-','increased'),('rs602950','CDA','cytarabine--PA449177','-','-','increased'),('rs532545','CDA','cytarabine--PA449177','increased','-','-'),('rs61888800','BDNF','desipramine--PA449233','decreased','-','-'),('rs1045642','ABCB1','dexamethasone--PA449247','decreased','-','-'),('rs2032582','ABCB1','dexamethasone--PA449247','decreased','-','-'),('rs1057910','CYP2C9','diclofenac--PA449293','-','-','increased'),('rs2070744','NOS3','diuretics--PA151249535','decreased','-','-'),('rs4961','ADD1','diuretics--PA151249535','decreased','-','-'),('rs12960','RPL13','docetaxel--PA449383','-','-','decreased'),('rs1799931','NAT2','docetaxel--PA449383','-','-','decreased'),('rs2227291','ATP7A','docetaxel--PA449383','-','-','decreased'),('rs2238472','ABCC6','docetaxel--PA449383','-','-','decreased'),('rs2292954','SPG7','docetaxel--PA449383','-','-','decreased'),('rs2234922','EPHX1','docetaxel--PA449383','-','decreased','-'),('rs2740574','CYP3A','docetaxel--PA449383','-','decreased','-'),('rs870995','PIK3CA','docetaxel--PA449383','-','decreased','-'),('rs1883322','PPARD','docetaxel--PA449383','decreased','-','-'),('rs2016520','PPARD','docetaxel--PA449383','decreased','-','-'),('rs4148943','CHST3','docetaxel--PA449383','decreased','-','-'),('rs4148945','CHST3','docetaxel--PA449383','decreased','-','-'),('rs4148947','CHST3','docetaxel--PA449383','decreased','-','-'),('rs730720','CHST3','docetaxel--PA449383','decreased','-','-'),('rs7769719','PPARD','docetaxel--PA449383','decreased','-','-'),('rs11045585','SLCO1B3','docetaxel--PA449383','-','-','increased'),('rs2301159','SLC10A2','docetaxel--PA449383','-','-','increased'),('rs4646487','CYP4B1','docetaxel--PA449383','-','-','increased'),('rs1382368','XRCC4','docetaxel--PA449383','-','increased','-'),('rs518329','PRDX4','docetaxel--PA449383','-','increased','-'),('rs1056836','CYP1B1','docetaxel--PA449383','increased','-','-'),('rs12418','CHST3','docetaxel--PA449383','increased','-','-'),('rs1402467','SULT1C4','docetaxel--PA449383','increased','-','-'),('rs1871450','CHST3','docetaxel--PA449383','increased','-','-'),('rs3734254','PPARD','docetaxel--PA449383','increased','-','-'),('rs4148950','CHST3','docetaxel--PA449383','increased','-','-'),('rs6922548','PPARD','docetaxel--PA449383','increased','-','-'),('rs20572','CBR1','doxorubicinol--PA165291922','-','increased','-'),('rs13058338','RAC2','doxorubicin--PA449412','-','-','decreased'),('rs4673','CYBA','doxorubicin--PA449412','-','-','decreased'),('rs1045642','ABCB1','doxorubicin--PA449412','decreased','-','-'),('rs2032582','ABCB1','doxorubicin--PA449412','decreased','-','-'),('rs2070744','NOS3','doxorubicin--PA449412','decreased','-','-'),('rs17222723','ABCC2','doxorubicin--PA449412','-','-','increased'),('rs1883112','NCF4','doxorubicin--PA449412','-','-','increased'),('rs45511401','ABCC1','doxorubicin--PA449412','-','-','increased'),('rs8187710','ABCC2','doxorubicin--PA449412','-','-','increased'),('rs9561778','ABCC4','doxorubicin--PA449412','-','-','increased'),('rs20572','CBR1','doxorubicin--PA449412','-','increased','-'),('rs3745274','CYP2B6','doxorubicin--PA449412','-','increased','-'),('rs1799983','NOS3','doxorubicin--PA449412','increased','-','-'),('rs2032582','ABCB1','doxorubicin--PA449412','increased','-','-'),('rs4244285','CYP2C19','doxorubicin--PA449412','increased','-','-'),('rs8133052','CBR3','doxorubicin--PA449412','increased','-','-'),('rs16969968','CHRNA3','Drugs used in nicotine dependence--PA164712720','increased','-','-'),('rs1799971','OPRM1','Drugs used in nicotine dependence--PA164712720','increased','-','-'),('rs1800497','ANKK1','Drugs used in nicotine dependence--PA164712720','increased','-','-'),('rs963468','DRD3','duloxetine--PA10066','increased','-','-'),('rs3745274','CYP2A7P1','efavirenz--PA449441','-','-','increased'),('rs3745274','CYP2A7P1','efavirenz--PA449441','-','increased','-'),('rs1045642','ABCB1','efavirenz--PA449441','increased','-','-'),('rs2032582','ABCB1','efavirenz--PA449441','increased','-','-'),('rs2227983','EGFR','egfr inhibitors--PA153561371','-','-','decreased'),('rs1045642','ABCB1','epirubicin--PA449476','decreased','-','-'),('rs1695','GSTP1','epirubicin--PA449476','increased','-','-'),('rs2227983','EGFR','erlotinib--PA134687924','-','-','decreased'),('rs712829','EGFR','erlotinib--PA134687924','-','-','decreased'),('rs712829','EGFR','erlotinib--PA134687924','increased','-','-'),('rs9316233','HTR2A','escitalopram--PA10074','decreased','-','-'),('rs11188072','CYP2C19','escitalopram--PA10074','-','increased','-'),('rs4795541','SLC6A4','escitalopram--PA10074','increased','-','-'),('rs1800629','TNF','etanercept--PA449515','decreased','-','-'),('rs1799971','OPRM1','ethanol--PA448073','-','-','increased'),('rs1800497','ANKK1','ethanol--PA448073','-','-','increased'),('rs1544410','VDR','etidronic acid--PA449548','decreased','-','-'),('rs16944','IL1B','etidronic acid--PA449548','decreased','-','-'),('rs16944','IL1B','etidronic acid--PA449548','increased','-','-'),('rs2784917','SLIT1','etoposide--PA449552','-','-','increased'),('rs1045642','ABCB1','fexofenadine--PA449621','-','increased','-'),('rs37973','GLCCI1','flunisolide--PA449661','decreased','-','-'),('rs1045642','ABCB1','fluorouracil--PA128406956','-','-','decreased'),('rs1695','GSTP1','fluorouracil--PA128406956','-','-','decreased'),('rs1801131','MTHFR','fluorouracil--PA128406956','-','-','decreased'),('rs1801265','DPYD','fluorouracil--PA128406956','-','-','decreased'),('rs2070744','NOS3','fluorouracil--PA128406956','decreased','-','-'),('rs1801019','UMPS','fluorouracil--PA128406956','-','-','increased'),('rs1801133','MTHFR','fluorouracil--PA128406956','-','-','increased'),('rs1801158','DPYD','fluorouracil--PA128406956','-','-','increased'),('rs1801159','DPYD','fluorouracil--PA128406956','-','-','increased'),('rs2297595','DPYD','fluorouracil--PA128406956','-','-','increased'),('rs67376798','DPYD','fluorouracil--PA128406956','-','-','increased'),('rs9561778','ABCC4','fluorouracil--PA128406956','-','-','increased'),('rs1042522','TP53','fluorouracil--PA128406956','increased','-','-'),('rs1045642','ABCB1','fluorouracil--PA128406956','increased','-','-'),('rs13181','ERCC2','fluorouracil--PA128406956','increased','-','-'),('rs1695','GSTP1','fluorouracil--PA128406956','increased','-','-'),('rs1799983','NOS3','fluorouracil--PA128406956','increased','-','-'),('rs1801131','MTHFR','fluorouracil--PA128406956','increased','-','-'),('rs25487','XRCC1','fluorouracil--PA128406956','increased','-','-'),('rs9679162','GALNT14','fluorouracil--PA128406956','increased','-','-'),('rs1799889','SERPINE1','fluoxetine--PA449673','decreased','-','-'),('rs2227631','SERPINE1','fluoxetine--PA449673','decreased','-','-'),('rs25531','SLC6A4','fluoxetine--PA449673','decreased','-','-'),('rs61888800','BDNF','fluoxetine--PA449673','decreased','-','-'),('rs334558','GSK3B','fluoxetine--PA449673','increased','-','-'),('rs37973','GLCCI1','fluticasone propionate--PA449686','decreased','-','-'),('rs17238540','HMGCR','fluvastatin--PA449688','decreased','-','-'),('rs17244841','HMGCR','fluvastatin--PA449688','decreased','-','-'),('rs11045819','SLCO1B1','fluvastatin--PA449688','increased','-','-'),('rs5443','GNB3','fluvastatin--PA449688','increased','-','-'),('rs10042486','HTR1A','fluvoxamine--PA449690','decreased','-','-'),('rs6295','HTR1A','fluvoxamine--PA449690','increased','-','-'),('rs1801131','MTHFR','folic acid--PA449692','increased','-','-'),('rs4961','ADD1','furosemide--PA449719','decreased','-','-'),('rs712829','EGFR','gefitinib--PA131301952','increased','-','-'),('rs712829','EGFR','geldanamycin--PA152031327','decreased','-','-'),('rs9937','RRM1','gemcitabine--PA449748','-','-','decreased'),('rs2072671','CDA','gemcitabine--PA449748','-','-','increased'),('rs60369023','CDA','gemcitabine--PA449748','-','-','increased'),('rs5219','KCNJ11','gliclazide--PA10892','decreased','-','-'),('rs37973','GLCCI1','glucocorticoids--PA452347','increased','-','-'),('rs909706','DTNBP1','haloperidol--PA449841','decreased','-','-'),('rs4693075','COQ2','hmg coa reductase inhibitors--PA133950441','-','-','decreased'),('rs17238540','HMGCR','hmg coa reductase inhibitors--PA133950441','decreased','-','-'),('rs17244841','HMGCR','hmg coa reductase inhibitors--PA133950441','decreased','-','-'),('rs5443','GNB3','hmg coa reductase inhibitors--PA133950441','decreased','-','-'),('rs1935349','HTR7','hmg coa reductase inhibitors--PA133950441','-','-','increased'),('rs4149056','SLCO1B1','hmg coa reductase inhibitors--PA133950441','-','-','increased'),('rs7297610','YEATS4','hydrochlorothiazide--PA449899','decreased','-','-'),('rs4149601','NEDD4L','hydrochlorothiazide--PA449899','increased','-','-'),('rs4961','ADD1','hydrochlorothiazide--PA449899','increased','-','-'),('rs20417','PTGS2','ibuprofen--PA449957','increased','-','-'),('rs1045642','ABCB1','idarubicin--PA449961','decreased','-','-'),('rs4799915','CELF4','iloperidone--PA161199368','-','-','increased'),('rs4933824','NRG3','iloperidone--PA161199368','-','-','increased'),('rs7142881','NUBPL','iloperidone--PA161199368','-','-','increased'),('rs993648','CERKL','iloperidone--PA161199368','-','-','increased'),('rs4888024','','methotrexate--PA450428','-','-','increased'),('rs6539870','','etoposide--PA449552','-','-','increased'),('rs9345389','','methotrexate--PA450428','-','-','increased'),('rs10811661','','troglitazone--PA451799','increased','-','-'),('rs1800629','TNF','infliximab--PA452639','decreased','-','-'),('rs9657182','IDO1','interferon alfa-2a, recombinant--PA164779048','-','-','decreased'),('rs1127354','ITPA','interferon alfa-2b, recombinant--PA164783990','-','decreased','-'),('rs9272105','HLA-DQA1','interferon beta-1a--PA450037','decreased','-','-'),('rs9272105','HLA-DQA1','interferon beta-1b--PA450039','decreased','-','-'),('rs1367117','APOB','irbesartan--PA450084','decreased','-','-'),('rs4124874','UGT1A1','irinotecan--PA450085','-','-','increased'),('rs9597','BAIAP3','irinotecan--PA450085','increased','-','-'),('rs762551','CYP1A2','leflunomide--PA450192','-','-','decreased'),('rs9340799','ESR1','leflunomide--PA450192','decreased','-','-'),('rs3213422','ATP5A1P3','leflunomide--PA450192','increased','-','-'),('rs4646','CYP19A1','letrozole--PA450196','decreased','-','-'),('rs1801019','UMPS','leucovorin--PA450198','-','-','increased'),('rs1801133','MTHFR','leucovorin--PA450198','-','-','increased'),('rs67376798','DPYD','leucovorin--PA450198','-','-','increased'),('rs1051266','SLC19A1','leucovorin--PA450198','increased','-','-'),('rs13181','ERCC2','leucovorin--PA450198','increased','-','-'),('rs1801131','MTHFR','leucovorin--PA450198','increased','-','-'),('rs2284017','CACNG2','Lithium--PA164712869','increased','-','-'),('rs2284017','CACNG2','lithium--PA450243','increased','-','-'),('rs7439366','UGT2B7','lorazepam--PA450267','decreased','-','-'),('rs1057910','CYP2C9','losartan--PA450268','decreased','-','-'),('rs17238540','HMGCR','lovastatin--PA450272','decreased','-','-'),('rs5443','GNB3','lovastatin--PA450272','increased','-','-'),('rs3775291','TLR3','Measles vaccines--PA164712887','increased','-','-'),('rs9340799','ESR1','medroxyprogesterone--PA450344','increased','-','-'),('rs11188072','CYP2C19','mephenytoin--PA450373','-','increased','-'),('rs1142345','TPMT','mercaptopurine--PA450379','-','-','increased'),('rs1800460','TPMT','mercaptopurine--PA450379','-','-','increased'),('rs1800462','TPMT','mercaptopurine--PA450379','-','-','increased'),('rs1800584','TPMT','mercaptopurine--PA450379','-','-','increased'),('rs1801133','MTHFR','mercaptopurine--PA450379','-','-','increased'),('rs1051266','SLC19A1','mercaptopurine--PA450379','increased','-','-'),('rs5219','KCNJ11','metformin--PA450395','decreased','-','-'),('rs622342','SLC22A1','metformin--PA450395','increased','-','-'),('rs6275','DRD2','methadone--PA450401','-','decreased','-'),('rs6275','DRD2','methadone--PA450401','-','increased','-'),('rs2076369','PICK1','methamphetamine--PA450403','-','-','decreased'),('rs2619538','DTNBP1','methamphetamine--PA450403','-','-','decreased'),('rs3213207','DTNBP1','methamphetamine--PA450403','-','-','increased'),('rs1051266','SLC19A1','methotrexate--PA450428','-','-','decreased'),('rs11045879','SLCO1B1','methotrexate--PA450428','-','-','decreased'),('rs2236624','ADORA2A','methotrexate--PA450428','-','-','decreased'),('rs2267076','ADORA2A','methotrexate--PA450428','-','-','decreased'),('rs246240','ABCC1','methotrexate--PA450428','-','-','decreased'),('rs3761422','ADORA2A','methotrexate--PA450428','-','-','decreased'),('rs4149081','SLCO1B1','methotrexate--PA450428','-','-','decreased'),('rs5760410','ADORA2A','methotrexate--PA450428','-','-','decreased'),('rs1051266','SLC19A1','methotrexate--PA450428','decreased','-','-'),('rs1544105','FPGS','methotrexate--PA450428','decreased','-','-'),('rs17731538','ABCG2','methotrexate--PA450428','decreased','-','-'),('rs1801133','MTHFR','methotrexate--PA450428','decreased','-','-'),('rs2070744','NOS3','methotrexate--PA450428','decreased','-','-'),('rs2236225','MTHFD1','methotrexate--PA450428','decreased','-','-'),('rs2238476','ABCC1','methotrexate--PA450428','decreased','-','-'),('rs2372536','ATIC','methotrexate--PA450428','decreased','-','-'),('rs35592','ABCC1','methotrexate--PA450428','decreased','-','-'),('rs3758149','GGH','methotrexate--PA450428','decreased','-','-'),('rs9344','CCND1','methotrexate--PA450428','decreased','-','-'),('rs11545078','GGH','methotrexate--PA450428','-','-','increased'),('rs1695','GSTP1','methotrexate--PA450428','-','-','increased'),('rs1801131','MTHFR','methotrexate--PA450428','-','-','increased'),('rs1801133','MTHFR','methotrexate--PA450428','-','-','increased'),('rs1801394','MTRR','methotrexate--PA450428','-','-','increased'),('rs1979277','SHMT1','methotrexate--PA450428','-','-','increased'),('rs2298383','ADORA2A','methotrexate--PA450428','-','-','increased'),('rs4846051','MTHFR','methotrexate--PA450428','-','-','increased'),('rs1801133','MTHFR','methotrexate--PA450428','-','increased','-'),('rs1045642','ABCB1','methotrexate--PA450428','increased','-','-'),('rs1051266','SLC19A1','methotrexate--PA450428','increased','-','-'),('rs1127354','ITPA','methotrexate--PA450428','increased','-','-'),('rs13120400','ABCG2','methotrexate--PA450428','increased','-','-'),('rs17602729','AMPD1','methotrexate--PA450428','increased','-','-'),('rs1799983','NOS3','methotrexate--PA450428','increased','-','-'),('rs1800909','GGH','methotrexate--PA450428','increased','-','-'),('rs1801131','MTHFR','methotrexate--PA450428','increased','-','-'),('rs1805087','MTR','methotrexate--PA450428','increased','-','-'),('rs28364006','ABCC1','methotrexate--PA450428','increased','-','-'),('rs2853539','TYMS','methotrexate--PA450428','increased','-','-'),('rs4673993','ATIC','methotrexate--PA450428','increased','-','-'),('rs9895420','ABCC3','methotrexate--PA450428','increased','-','-'),('rs1801253','ADRB1','metoprolol--PA450480','increased','-','-'),('rs3892097','CYP2D6','metoprolol--PA450480','increased','-','-'),('rs10042486','HTR1A','milnacipran--PA164752812','decreased','-','-'),('rs10879346','TPH2','mirtazapine--PA450522','decreased','-','-'),('rs1487278','TPH2','mirtazapine--PA450522','increased','-','-'),('rs9679162','GALNT14','mitoxantrone--PA450526','increased','-','-'),('rs2660845','LTA4H','montelukast--PA450546','decreased','-','-'),('rs730012','LTC4S','montelukast--PA450546','decreased','-','-'),('rs119774','ABCC1','montelukast--PA450546','increased','-','-'),('rs2115819','ALOX5','montelukast--PA450546','increased','-','-'),('rs2660845','LTA4H','montelukast--PA450546','increased','-','-'),('rs4680','COMT','morphine--PA450550','-','decreased','-'),('rs1799971','OPRM1','morphine--PA450550','-','increased','-'),('rs1801253','ADRB1','muraglitazar--PA162356187','-','-','decreased'),('rs2368564','REN','muraglitazar--PA162356187','-','-','decreased'),('rs5370','EDN1','muraglitazar--PA162356187','-','-','increased'),('rs2278293','IMPDH1','mycophenolate mofetil--PA450566','-','-','decreased'),('rs2278294','IMPDH1','mycophenolate mofetil--PA450566','decreased','-','-'),('rs2278294','IMPDH1','mycophenolate mofetil--PA450566','-','-','increased'),('rs4149117','SLCO1B3','mycophenolate mofetil--PA450566','-','increased','-'),('rs1799971','OPRM1','naloxone--PA450586','increased','-','-'),('rs1799971','OPRM1','naltrexone--PA450588','increased','-','-'),('rs437943','','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','decreased','-','-'),('rs6028945','','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','decreased','-','-'),('rs6071980','','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','decreased','-','-'),('rs983332','','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','decreased','-','-'),('rs6138150','','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','increased','-','-'),('rs37973','GLCCI1','nedocromil--PA450601','increased','-','-'),('rs1360780','FKBP5','nefazodone--PA450603','-','-','decreased'),('rs1045642','ABCB1','nelfinavir--PA450606','increased','-','-'),('rs1800497','ANKK1','nemonapride--PA151186253','-','-','increased'),('rs1799732','DRD2','nemonapride--PA151186253','increased','-','-'),('rs1045642','ABCB1','nevirapine--PA450616','-','-','increased'),('rs16969968','CHRNA5','nicotine--PA450626','-','-','increased'),('rs1799971','OPRM1','nicotine--PA450626','increased','-','-'),('rs1800497','ANKK1','nicotine--PA450626','increased','-','-'),('rs4680','COMT','nicotine--PA450626','increased','-','-'),('rs1801131','MTHFR','nitrous oxide--PA450645','-','-','increased'),('rs1801133','MTHFR','nitrous oxide--PA450645','-','-','increased'),('rs1045642','ABCB1','nortriptyline--PA450657','-','-','decreased'),('rs3813929','HTR2C','olanzapine--PA450688','-','-','decreased'),('rs4731426','LEP','olanzapine--PA450688','-','-','decreased'),('rs518147','HTR2C','olanzapine--PA450688','-','-','decreased'),('rs6277','DRD2','olanzapine--PA450688','-','-','decreased'),('rs7997012','HTR2A','olanzapine--PA450688','-','-','decreased'),('rs6280','DRD3','olanzapine--PA450688','decreased','-','-'),('rs762551','CYP1A2','olanzapine--PA450688','decreased','-','-'),('rs1079598','DRD2','olanzapine--PA450688','-','-','increased'),('rs1800497','ANKK1','olanzapine--PA450688','-','-','increased'),('rs4994','ADRB3','olanzapine--PA450688','-','-','increased'),('rs5443','GNB3','olanzapine--PA450688','-','-','increased'),('rs6313','HTR2A','olanzapine--PA450688','-','-','increased'),('rs6318','HTR2C','olanzapine--PA450688','-','-','increased'),('rs1799732','DRD2','olanzapine--PA450688','increased','-','-'),('rs2842030','RGS4','olanzapine--PA450688','increased','-','-'),('rs6313','HTR2A','olanzapine--PA450688','increased','-','-'),('rs951439','RGS4','olanzapine--PA450688','increased','-','-'),('rs11188072','CYP2C19','omeprazole--PA450704','-','increased','-'),('rs2032583','ABCB1','Other antidepressants--PA164713016','increased','-','-'),('rs2235015','ABCB1','Other antidepressants--PA164713016','increased','-','-'),('rs13181','ERCC2','oxaliplatin--PA131285527','decreased','-','-'),('rs1695','GSTP1','oxaliplatin--PA131285527','-','-','increased'),('rs1801133','MTHFR','oxaliplatin--PA131285527','-','-','increased'),('rs11615','ERCC1','oxaliplatin--PA131285527','increased','-','-'),('rs13181','ERCC2','oxaliplatin--PA131285527','increased','-','-'),('rs1695','GSTP1','oxaliplatin--PA131285527','increased','-','-'),('rs1801131','MTHFR','oxaliplatin--PA131285527','increased','-','-'),('rs25487','XRCC1','oxaliplatin--PA131285527','increased','-','-'),('rs1045642','ABCB1','paclitaxel--PA450761','-','-','decreased'),('rs11572103','CYP2C8','paclitaxel--PA450761','-','decreased','-'),('rs12721627','CYP3A','paclitaxel--PA450761','-','decreased','-'),('rs2032582','ABCB1','paclitaxel--PA450761','decreased','-','-'),('rs1113129','CYP2C8','paclitaxel--PA450761','-','-','increased'),('rs11572080','CYP2C8','paclitaxel--PA450761','-','-','increased'),('rs776746','CYP3A','paclitaxel--PA450761','-','-','increased'),('rs1042522','TP53','paclitaxel--PA450761','increased','-','-'),('rs1045642','ABCB1','paclitaxel--PA450761','increased','-','-'),('rs1056836','CYP1B1','paclitaxel--PA450761','increased','-','-'),('rs9981861','DSCAM','paclitaxel--PA450761','increased','-','-'),('rs1934951','CYP2C8','pamidronate--PA450767','-','-','increased'),('rs11188072','CYP2C19','pantoprazole--PA450774','-','increased','-'),('rs1360780','FKBP5','paroxetine--PA450801','-','-','decreased'),('rs10042486','HTR1A','paroxetine--PA450801','decreased','-','-'),('rs11042725','ADM','paroxetine--PA450801','increased','-','-'),('rs6295','HTR1A','paroxetine--PA450801','increased','-','-'),('rs12979860','IL28B','peginterferon alfa-2a--PA164749390','decreased','-','-'),('rs8099917','IL28B','peginterferon alfa-2a--PA164749390','decreased','-','-'),('rs9657182','IDO1','peginterferon alfa-2b--PA164784024','-','-','decreased'),('rs12979860','IL28B','peginterferon alfa-2b--PA164784024','decreased','-','-'),('rs8099917','IL28B','peginterferon alfa-2b--PA164784024','decreased','-','-'),('rs5182','AGTR1','perindopril--PA450877','decreased','-','-'),('rs12050217','BDKRB1','perindopril--PA450877','increased','-','-'),('rs275651','AGTR1','perindopril--PA450877','increased','-','-'),('rs2842030','RGS4','perphenazine--PA450882','increased','-','-'),('rs951439','RGS4','perphenazine--PA450882','increased','-','-'),('rs2108622','CYP4F2','phenprocoumon--PA450921','-','increased','-'),('rs1051740','EPHX1','phenytoin--PA450947','-','-','increased'),('rs1057910','CYP2C9','phenytoin--PA450947','-','-','increased'),('rs2234922','EPHX1','phenytoin--PA450947','-','-','increased'),('rs1045642','ABCB1','phenytoin--PA450947','-','increased','-'),('rs3812718','SCN1A','phenytoin--PA450947','-','increased','-'),('rs1045642','ABCB1','phenytoin--PA450947','increased','-','-'),('rs1799853','CYP2C9','phenytoin--PA450947','increased','-','-'),('rs2032582','ABCB1','Platinum compounds--PA164713176','-','-','decreased'),('rs3212986','ERCC1','Platinum compounds--PA164713176','-','-','decreased'),('rs13181','ERCC2','Platinum compounds--PA164713176','decreased','-','-'),('rs3212986','CD3EAP','Platinum compounds--PA164713176','decreased','-','-'),('rs1695','GSTP1','Platinum compounds--PA164713176','-','-','increased'),('rs11615','ERCC1','Platinum compounds--PA164713176','increased','-','-'),('rs25487','XRCC1','Platinum compounds--PA164713176','increased','-','-'),('rs3212986','CD3EAP','Platinum compounds--PA164713176','increased','-','-'),('rs3212986','ERCC1','platinum--PA150595617','-','-','decreased'),('rs13181','ERCC2','platinum--PA150595617','decreased','-','-'),('rs11615','ERCC1','platinum--PA150595617','increased','-','-'),('rs25487','XRCC1','platinum--PA150595617','increased','-','-'),('rs6280','DRD3','pramipexole--PA164742949','increased','-','-'),('rs17238540','HMGCR','pravastatin--PA451089','decreased','-','-'),('rs17244841','HMGCR','pravastatin--PA451089','decreased','-','-'),('rs2306283','SLCO1B1','pravastatin--PA451089','decreased','-','-'),('rs1935349','HTR7','pravastatin--PA451089','-','-','increased'),('rs2276307','HTR3B','pravastatin--PA451089','-','-','increased'),('rs20455','KIF6','pravastatin--PA451089','increased','-','-'),('rs4149015','SLCO1B1','pravastatin--PA451089','increased','-','-'),('rs5443','GNB3','pravastatin--PA451089','increased','-','-'),('rs1050828','G6PD','primaquine--PA451103','-','-','increased'),('rs58597806','UGT1A9','propofol--PA451141','-','-','increased'),('rs1142345','TPMT','purine analogues--PA452634','-','-','increased'),('rs1800460','TPMT','purine analogues--PA452634','-','-','increased'),('rs1800462','TPMT','purine analogues--PA452634','-','-','increased'),('rs1050828','G6PD','pyrimethamine--PA451193','-','-','increased'),('rs951439','RGS4','quetiapine--PA451201','increased','-','-'),('rs1544410','VDR','raloxifene--PA451221','decreased','-','-'),('rs5219','ABCC8','repaglinide--PA451234','decreased','-','-'),('rs290487','TCF7L2','repaglinide--PA451234','increased','-','-'),('rs4149056','SLCO1B1','repaglinide--PA451234','increased','-','-'),('rs1127354','ITPA','ribavirin--PA451241','-','decreased','-'),('rs12979860','IL28B','ribavirin--PA451241','decreased','-','-'),('rs8099917','IL28B','ribavirin--PA451241','decreased','-','-'),('rs16944','IL1B','risedronate--PA451255','decreased','-','-'),('rs2297480','FDPS','risedronate--PA451255','decreased','-','-'),('rs16944','IL1B','risedronate--PA451255','increased','-','-'),('rs1414334','HTR2C','risperidone--PA451257','-','-','decreased'),('rs167771','DRD3','risperidone--PA451257','-','-','decreased'),('rs1128503','ABCB1','risperidone--PA451257','decreased','-','-'),('rs165599','COMT','risperidone--PA451257','decreased','-','-'),('rs1799978','DRD2','risperidone--PA451257','decreased','-','-'),('rs2494732','AKT1','risperidone--PA451257','decreased','-','-'),('rs2661319','RGS4','risperidone--PA451257','decreased','-','-'),('rs2842030','RGS4','risperidone--PA451257','decreased','-','-'),('rs3803300','AKT1','risperidone--PA451257','decreased','-','-'),('rs3813928','HTR2C','risperidone--PA451257','decreased','-','-'),('rs6280','DRD3','risperidone--PA451257','decreased','-','-'),('rs6311','HTR2A','risperidone--PA451257','decreased','-','-'),('rs1799978','DRD2','risperidone--PA451257','-','-','increased'),('rs1800497','ANKK1','risperidone--PA451257','-','-','increased'),('rs7799039','LEP','risperidone--PA451257','-','-','increased'),('rs1799732','DRD2','risperidone--PA451257','increased','-','-'),('rs1800497','ANKK1','risperidone--PA451257','increased','-','-'),('rs6313','HTR2A','risperidone--PA451257','increased','-','-'),('rs724226','GRM3','risperidone--PA451257','increased','-','-'),('rs951439','RGS4','risperidone--PA451257','increased','-','-'),('rs2854117','APOA4','ritonavir--PA451260','-','-','decreased'),('rs2854116','APOA4','ritonavir--PA451260','-','-','increased'),('rs429358','APOC1','ritonavir--PA451260','-','-','increased'),('rs5128','APOC3','ritonavir--PA451260','-','-','increased'),('rs7412','APOC1','ritonavir--PA451260','-','-','increased'),('rs7412','APOE','ritonavir--PA451260','-','-','increased'),('rs396991','FCGR3A','rituximab--PA451261','increased','-','-'),('rs20417','PTGS2','rofecoxib--PA451268','decreased','-','-'),('rs10192566','LPIN1','rosiglitazone--PA451283','decreased','-','-'),('rs10509681','CYP2C8','rosiglitazone--PA451283','-','increased','-'),('rs4693075','COQ2','rosuvastatin--PA134308647','-','-','decreased'),('rs5443','GNB3','rosuvastatin--PA134308647','decreased','-','-'),('rs2231142','ABCG2','rosuvastatin--PA134308647','increased','-','-'),('rs7793837','CRHR2','salbutamol--PA448068','decreased','-','-'),('rs2267715','CRHR2','salbutamol--PA448068','increased','-','-'),('rs2781659','ARG1','selective beta-2-adrenoreceptor agonists--PA134687887','decreased','-','-'),('rs7793837','CRHR2','selective beta-2-adrenoreceptor agonists--PA134687887','decreased','-','-'),('rs2267715','CRHR2','selective beta-2-adrenoreceptor agonists--PA134687887','increased','-','-'),('rs7997012','HTR2A','Selective serotonin reuptake inhibitors--PA164713257','decreased','-','-'),('rs6295','HTR1A','Selective serotonin reuptake inhibitors--PA164713257','increased','-','-'),('rs4343','ACE','sildenafil--PA451346','decreased','-','-'),('rs4343','ACE','sildenafil--PA451346','increased','-','-'),('rs5443','GNB3','sildenafil--PA451346','increased','-','-'),('rs17238540','HMGCR','simvastatin--PA451363','decreased','-','-'),('rs17244841','HMGCR','simvastatin--PA451363','decreased','-','-'),('rs1935349','HTR7','simvastatin--PA451363','-','-','increased'),('rs2276307','HTR3B','simvastatin--PA451363','-','-','increased'),('rs4149056','SLCO1B1','simvastatin--PA451363','-','-','increased'),('rs5443','GNB3','simvastatin--PA451363','increased','-','-'),('rs2740574','CYP3A','sirolimus--PA451365','-','decreased','-'),('rs776746','CYP3A5','sirolimus--PA451365','-','increased','-'),('rs4961','ADD1','spironolactone--PA451483','decreased','-','-'),('rs4343','ACE','spironolactone--PA451483','increased','-','-'),('rs1050828','G6PD','sulfadoxine--PA451540','-','-','increased'),('rs12255372','TCF7L2','sulfonamides, urea derivatives--PA10390','decreased','-','-'),('rs5219','KCNJ11','sulfonamides, urea derivatives--PA10390','decreased','-','-'),('rs1057910','CYP2C9','sulfonamides, urea derivatives--PA10390','increased','-','-'),('rs1799853','CYP2C9','sulfonamides, urea derivatives--PA10390','increased','-','-'),('rs5443','GNB3','sumatriptan--PA451566','increased','-','-'),('rs776746','CYP3A5','tacrolimus--PA451578','-','-','decreased'),('rs2740574','CYP3A','tacrolimus--PA451578','-','decreased','-'),('rs2032582','ABCB1','tacrolimus--PA451578','decreased','-','-'),('rs776746','CYP3A5','tacrolimus--PA451578','-','-','increased'),('rs776746','CYP3A5','tacrolimus--PA451578','-','increased','-'),('rs776746','CYP3A5','tacrolimus--PA451578','increased','-','-'),('rs4986938','ESR2','tamoxifen--PA451581','-','-','decreased'),('rs9340799','ESR1','tamoxifen--PA451581','-','-','decreased'),('rs3892097','CYP2D6','tamoxifen--PA451581','increased','-','-'),('rs2032582','ABCB1','taxanes--PA150481189','-','-','decreased'),('rs1056836','CYP1B1','taxanes--PA150481189','increased','-','-'),('rs2032582','ABCB1','taxanes--PA150481189','increased','-','-'),('rs1801019','UMPS','tegafur--PA452620','-','-','increased'),('rs17222723','ABCC2','tenofovir--PA10204','-','-','decreased'),('rs717620','ABCC2','tenofovir--PA10204','-','-','decreased'),('rs9349256','ABCC10','tenofovir--PA10204','-','-','decreased'),('rs2273697','ABCC2','tenofovir--PA10204','-','-','increased'),('rs12960','RPL13','thalidomide--PA451644','-','-','decreased'),('rs1799931','NAT2','thalidomide--PA451644','-','-','decreased'),('rs2227291','ATP7A','thalidomide--PA451644','-','-','decreased'),('rs2238472','ABCC6','thalidomide--PA451644','-','-','decreased'),('rs2292954','SPG7','thalidomide--PA451644','-','-','decreased'),('rs1883322','PPARD','thalidomide--PA451644','decreased','-','-'),('rs2016520','PPARD','thalidomide--PA451644','decreased','-','-'),('rs4148943','CHST3','thalidomide--PA451644','decreased','-','-'),('rs4148945','CHST3','thalidomide--PA451644','decreased','-','-'),('rs4148947','CHST3','thalidomide--PA451644','decreased','-','-'),('rs730720','CHST3','thalidomide--PA451644','decreased','-','-'),('rs7769719','PPARD','thalidomide--PA451644','decreased','-','-'),('rs2301159','SLC10A2','thalidomide--PA451644','-','-','increased'),('rs4646487','CYP4B1','thalidomide--PA451644','-','-','increased'),('rs12418','CHST3','thalidomide--PA451644','increased','-','-'),('rs1402467','SULT1C4','thalidomide--PA451644','increased','-','-'),('rs1871450','CHST3','thalidomide--PA451644','increased','-','-'),('rs3734254','PPARD','thalidomide--PA451644','increased','-','-'),('rs4148950','CHST3','thalidomide--PA451644','increased','-','-'),('rs6922548','PPARD','thalidomide--PA451644','increased','-','-'),('rs1142345','TPMT','thioguanine--PA451663','-','-','increased'),('rs1800460','TPMT','thioguanine--PA451663','-','-','increased'),('rs1800462','TPMT','thioguanine--PA451663','-','-','increased'),('rs16944','IL1B','tiludronate--PA451688','increased','-','-'),('rs712829','EGFR','topoisomerase I inhibitors--PA150481186','decreased','-','-'),('rs1136201','ERBB2','trastuzumab--PA451743','-','-','increased'),('rs37973','GLCCI1','triamcinolone--PA451749','increased','-','-'),('rs2814707','MOBKL2B','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','decreased','-','-'),('rs774359','C9orf72','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','decreased','-','-'),('rs854547','PON1','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','decreased','-','-'),('rs928655','GBP6','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','decreased','-','-'),('rs3849942','C9orf72','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','increased','-','-'),('rs7046653','MOBKL2B','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','increased','-','-'),('rs854548','PON1','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','increased','-','-'),('rs854555','PON1','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','increased','-','-'),('rs868856','MOBKL2B','Tumor necrosis factor alpha (TNF-alpha) inhibitors--PA164713','increased','-','-'),('rs7439366','UGT2B7','valproic acid--PA451846','decreased','-','-'),('rs1057910','CYP2C9','valproic acid--PA451846','-','-','increased'),('rs1105879','UGT1A6','valproic acid--PA451846','-','increased','-'),('rs2070959','UGT1A10','valproic acid--PA451846','-','increased','-'),('rs6759892','UGT1A10','valproic acid--PA451846','-','increased','-'),('rs1360780','FKBP5','venlafaxine--PA451866','-','-','decreased'),('rs10879346','TPH2','venlafaxine--PA451866','decreased','-','-'),('rs3892097','CYP2D6','venlafaxine--PA451866','-','-','increased'),('rs1487278','TPH2','venlafaxine--PA451866','increased','-','-'),('rs10494366','NOS1AP','verapamil--PA451868','-','-','decreased'),('rs11739136','KCNIP1','verapamil--PA451868','decreased','-','-'),('rs1801252','ADRB1','verapamil--PA451868','decreased','-','-'),('rs1801253','ADRB1','verapamil--PA451868','decreased','-','-'),('rs10918594','NOS1AP','verapamil--PA451868','-','-','increased'),('rs1051375','CACNA1C','verapamil--PA451868','increased','-','-'),('rs1045642','ABCB1','vincristine--PA451879','decreased','-','-'),('rs2032582','ABCB1','vincristine--PA451879','decreased','-','-'),('rs10871454','STX4','warfarin--PA451906','-','decreased','-'),('rs1799853','CYP2C9','warfarin--PA451906','-','decreased','-'),('rs2292566','EPHX1','warfarin--PA451906','-','decreased','-'),('rs28371685','CYP2C9','warfarin--PA451906','-','decreased','-'),('rs28371686','CYP2C9','warfarin--PA451906','-','decreased','-'),('rs7900194','CYP2C9','warfarin--PA451906','-','decreased','-'),('rs8050894','PRSS53','warfarin--PA451906','-','decreased','-'),('rs9934438','VKORC1','warfarin--PA451906','-','decreased','-'),('rs1057910','CYP2C9','warfarin--PA451906','-','increased','-'),('rs12714145','GGCX','warfarin--PA451906','-','increased','-'),('rs17708472','VKORC1','warfarin--PA451906','-','increased','-'),('rs2108622','CYP4F2','warfarin--PA451906','-','increased','-'),('rs2359612','PRSS53','warfarin--PA451906','-','increased','-'),('rs339097','CALU','warfarin--PA451906','-','increased','-'),('rs7294','VKORC1','warfarin--PA451906','-','increased','-'),('rs951439','RGS4','ziprasidone--PA451974','increased','-','-'),('rs1934951','CYP2C8','zoledronate--PA10235','-','-','increased');
/*!40000 ALTER TABLE `drug_rs` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `example`
--

DROP TABLE IF EXISTS `example`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `example` (
  `RSID` varchar(20) DEFAULT NULL,
  `Alleles` varchar(7) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `Drug` varchar(60) DEFAULT NULL,
  `System` varchar(60) DEFAULT NULL,
  `subSystem` text,
  `drugID` varchar(60) DEFAULT NULL,
  `info` text,
  `Level` varchar(10) DEFAULT NULL,
  `Efficacy` varchar(20) DEFAULT NULL,
  `Dosage` varchar(20) DEFAULT NULL,
  `Toxicity` varchar(20) DEFAULT NULL,
  `Genotype` varchar(10) DEFAULT NULL,
  `Sentence` text
) ENGINE=InnoDB DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `example`
--

LOCK TABLES `example` WRITE;
/*!40000 ALTER TABLE `example` DISABLE KEYS */;
INSERT INTO `example` VALUES ('rs2016848','G > A','MME','Ace Inhibitors, Plain--PA164712308','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','increased','AG','                Patients with the AG genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cough with ACE inhibitor treatment. Patients with this genotype were not studied directly.'),('rs1799722','C > T','BDKRB2','Ace Inhibitors, Plain--PA164712308','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','increased','CT','                Patients with the CT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for cough.'),('rs9934438','G > A','VKORC1','acenocoumarol--PA452632','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs2108622','C > T','CYP4F2','acenocoumarol--PA452632','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs4086116','C > T','CYP2C9','acenocoumarol--PA452632','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 3','-','decreased','-','CT','                Patients with the CT genotype may require a lower dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs2297480','T > G','FDPS','alendronate--PA448082','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00630','Alendronate is a nitrogen-containing, second generation bisphosphonate. Bisphosphonates were first used to treat Pageta?s disease in 1971. This class of medications is comprised of inorganic pyrophosphate analogues that contain non-hydrolyzable P-C-P bonds. Similar to other bisphosphonates, alendronate has a high affinity for bone mineral and is taken up during osteoclast resorption. Alendronate inhibits farnesyl pyrophosphate synthetase, one of the enzymes in the mevalonic acid pathway involved in producing isoprenoid compounds that are essential for post-translational modification of small guanosine triphosphate (GTP)-binding proteins, such as Rho, Ras and Rab. Inhibition of this process interferes with osteoclast function and survival. Alendronate is used for the treatment of osteoporosis and Pageta?s disease','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs712829','G > T','EGFR','Alkylating Agents--PA164712331','VARIOUS','','','An alkylating antineoplastic agent is an alkylating agent used in cancer treatment that attaches an alkyl group to DNA.','Level 4','decreased','-','-','GT','                Cancer cells with the GT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.'),('rs2070995','T > C','KCNJ6','Analgesics--PA164712362','NERVOUS SYSTEM','ANALGESICS','','An analgesic, or painkiller, is any member of the group of drugs used to achieve analgesia  relief from pain.','Level 3','increased','-','-','CT','                Patients with the TC genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance for requiring a rescue analgesic.'),('rs10836235','C > T','CAT','anthracyclines and related substances--PA130620651','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','-','-','decreased','TT','                Patients with the TT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the TT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs2227631','A > G','SERPINE1','antidepressants--PA452229','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs6295','C > G','HTR1A','antidepressants--PA452229','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs2070744','C > T','NOS3','Antihypertensives And Diuretics In Combination--PA164712446','CARDIOVASCULAR SYSTEM','','','Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure)','Level 3','-','-','-','TT','                Patients with the TT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for resistance.'),('rs2070744','C > T','NOS3','Antihypertensives And Diuretics In Combination--PA164712446','CARDIOVASCULAR SYSTEM','','','Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure)','Level 3','-','-','-','TT','                Patients with the TT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antihypertensives.'),('rs2070744','C > T','NOS3','Antihypertensives--PA164712445','CARDIOVASCULAR SYSTEM','ANTIHYPERTENSIVES','','Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure)','Level 3','-','-','-','TT','                Patients with the TT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antihypertensives.'),('rs1042522','C > G','TP53','antineoplastic agents--PA452621','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','','Inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells','Level 2B','-','-','decreased','CC','                Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1079598','A > G','DRD2','antipsychotics--PA452233','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs4680','G > A','COMT','antipsychotics--PA452233','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','decreased','AG','                Patients with the AG genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for tardive dyskinesia.'),('rs1801133','G > A','CLCN6','antipsychotics--PA452233','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','increased','AG','                Patients with the AG genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1800497','G > A','ANKK1','antipsychotics--PA452233','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs20417','C > G','PTGS2','aspirin--PA448497','ALIMENTARY TRACT AND METABOLISM','STOMATOLOGICAL PREPARATIONS','DB00945','The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. [DrugBank]','Level 3','increased','-','-','CG','                Patients with the CG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patients response to aspirin.'),('rs1801253','G > C','ADRB1','atenolol--PA448499','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00335','A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. [DrugBank]','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','atenolol--PA448499','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00335','A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. [DrugBank]','Level 3','decreased','-','increased','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs2276307','A > G','HTR3B','atorvastatin--PA448500','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for myalgia.'),('rs1801253','G > C','ADRB1','Beta Blocking Agents--PA164712535','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','','Beta blockers are a class of drugs that target the beta receptor. Beta receptors are found on cells of the heart muscles, smooth muscles, airways, arteries, kidneys, and other tissues that are part of the sympathetic nervous system and lead to stress responses, especially when they are stimulated by epinephrine (adrenaline).','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','Beta Blocking Agents--PA164712535','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','','Beta blockers are a class of drugs that target the beta receptor. Beta receptors are found on cells of the heart muscles, smooth muscles, airways, arteries, kidneys, and other tissues that are part of the sympathetic nervous system and lead to stress responses, especially when they are stimulated by epinephrine (adrenaline).','Level 3','decreased','-','increased','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs16944','A > G','IL1B','Bisphosphonates--PA164712563','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Pagets disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs2297480','T > G','FDPS','Bisphosphonates--PA164712563','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1934951','C > T','CYP2C8','Bisphosphonates--PA164712563','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 3','-','-','decreased','CT','                Patients with the CT genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.'),('rs1801253','G > C','ADRB1','bucindolol--PA165945764','VARIOUS','','','Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity.[1][2] It was under review by the FDA in the United States for the treatment of heart failure in 2009 ','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','bucindolol--PA165945764','VARIOUS','','','Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity.[1][2] It was under review by the FDA in the United States for the treatment of heart failure in 2009 ','Level 3','decreased','-','increased','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs165599','G > A','ARVCF','bupropion--PA448687','NERVOUS SYSTEM','','','Bupropion is a drug primarily used as an atypical antidepressant and smoking cessation aid. Marketed as Wellbutrin, Budeprion, Prexaton, Elontril, Aplenzin, or other trade names, it is one of the most frequently prescribed antidepressants in the United States. Marketed in lower-dose formulations as Zyban, Voxra, or other names, it is also widely used to reduce nicotine cravings by people who are trying to quit smoking. It is taken in the form of pills, and in the United States is available only by prescription.','Level 3','increased','-','-','AA','                Patients with the AA genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1800497','G > A','ANKK1','bupropion--PA448687','NERVOUS SYSTEM','','','Bupropion is a drug primarily used as an atypical antidepressant and smoking cessation aid. Marketed as Wellbutrin, Budeprion, Prexaton, Elontril, Aplenzin, or other trade names, it is one of the most frequently prescribed antidepressants in the United States. Marketed in lower-dose formulations as Zyban, Voxra, or other names, it is also widely used to reduce nicotine cravings by people who are trying to quit smoking. It is taken in the form of pills, and in the United States is available only by prescription.','Level 1B','decreased','-','-','AG','                Patients with the AG genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients chance for quitting smoking.'),('rs1801131','T > G','MTHFR','capecitabine--PA448771','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','GT','                Patients with the GT genotype may have increased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to capecitabine.'),('rs3812718','C > T','SCN1A','carbamazepine--PA448785','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 2B','-','increased','-','TT','                Patients with the TT genotype who are treated with carbamazepine may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine.'),('rs1051740','T > C','EPHX1','carbamazepine--PA448785','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 2B','-','increased','-','CT','                Patients with the CT genotype and Epilepsy who are treated with carbamazepine may have an increased dose of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to carbamazepine.'),('rs750332','C > T','BAT2','carbamazepine--PA448785','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 3','-','-','decreased','TT','                Patients with the TT genotype who are treated with carbamazepine may have a decreased, but not absent, risk of Stevens-Johnson syndrome as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients risk for Stevens-Johnson syndrome with carbamazepine treatment.'),('rs25487','T > C','XRCC1','carboplatin--PA448803','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00958 ','An organoplatinum compound that possesses antineoplastic activity.','Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs11615','A > G','ERCC1','carboplatin--PA448803','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00958 ','An organoplatinum compound that possesses antineoplastic activity.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs9981861','T > C','DSCAM','carboplatin--PA448803','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00958 ','An organoplatinum compound that possesses antineoplastic activity.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.'),('rs1042714','G > C','ADRB2','carvedilol--PA448817','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB01136','Carvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-1 adrenergic receptors.','Level 3','decreased','-','-','CC','                Patients with the CC genotype and heart failure may be less likely to have improved left ventricular ejection fraction after carvedilol treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1801253','G > C','ADRB1','carvedilol--PA448817','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB01136','Carvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-2 adrenergic receptors.','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','carvedilol--PA448817','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB01136','Carvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-4 adrenergic receptors.','Level 3','decreased','-','increased','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs2819742','A > G','RYR2','cerivastatin--PA448897','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00439','On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.','Level 3','-','-','increased','GG','                Patients with the GG genotype may have an increased risk of cerivastatin-associated rhabdomyolysis as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patients risk of toxicity. '),('rs25487','T > C','XRCC1','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','increased','-','increased','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs1042522','C > G','TP53','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','increased','-','decreased','CC','                Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs316019','A > C','SLC22A2','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs3957357','A > G','GSTA1','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.'),('rs11615','A > G','ERCC1','cisplatin--PA449014','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs2227631','A > G','SERPINE1','citalopram--PA449015','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs334558','A > G','GSK3B','citalopram--PA449015','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','increased','-','-','GG','                Patients with the GG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have more improvement in symptoms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients response to fluoxetine and citalopram.'),('rs1954787','T > C','GRIK4','citalopram--PA449015','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 1B','increased','-','-','CC','                Patients with the CC genotype may have an increased chance of response to citalopram treatment as compared to patients with the TT genotype. Patients with the CC genotype may still be at risk for non-response to citalopram treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs6280','C > T','DRD3','clozapine--PA449061','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','increased','-','-','TT','                Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a better response to treatment as compared to patients with the CC or CT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patients response to clozapine treatment.'),('rs1079598','A > G','DRD2','clozapine--PA449061','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1800497','G > A','ANKK1','clozapine--PA449061','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs25487','T > C','XRCC1','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','increased','-','-','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CT or TT genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.'),('rs1042522','C > G','TP53','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','-','-','decreased','CC','                Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs3957357','A > G','GSTA1','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.'),('rs2740574','C > T','CYP3A4','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','TT','                Premenopausal patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have a shorter period of time before chemotherapy-induced ovarian failure compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.'),('rs9561778','G > T','ABCC4','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','increased','GT','                Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse events with cyclophosphamide treatment.'),('rs9561778','G > T','ABCC4','cyclophosphamide--PA449165','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','increased','GT','                Patients with the GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for ADRs.'),('rs776746','C > T','CYP3A5','cyclosporine--PA449167','VARIOUS','','','Cyclosporine is available in its original form and as another product that has been modified (changed) so that the medication can be better absorbed in the body. Original cyclosporine and cyclosporine (modified) are absorbed by the body in different amounts, so they cannot be substituted for one another. Take only the type of cyclosporine that was prescribed by your doctor. When your doctor gives you a written prescription, check to be sure that he or she has specified the type of cyclosporine you should receive. Each time you have your prescription filled, look at the brand name printed on your prescription label to be sure that you have received the same type of cyclosporine. Talk to your pharmacist if the brand name is unfamiliar or you are not sure you have received the right type of cyclosporine.','Level 3','-','increased','-','CT','                Patients with the TC genotype may require an increased dose of cyclosporine to reach target blood concentration as compared to patients with the CC genotype, although some studies find no association with dosage. Other genetic and clinical factors may also influence dose of cyclosporine.'),('rs2070744','C > T','NOS3','diuretics--PA151249535','CARDIOVASCULAR SYSTEM','DIURETICS','','A diuretic is any substance that promotes the production of urine. This includes forced diuresis. There are several categories of diuretics. All diuretics increase the excretion of water from bodies, although each class does so in a distinct way. Alternatively, an antidiuretic such as vasopressin is an agent or drug which reduces the excretion of water in urine.','Level 3','-','-','-','TT','                Patients with the TT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antihypertensives.'),('rs4961','G > T','ADD1','diuretics--PA151249535','CARDIOVASCULAR SYSTEM','DIURETICS','','A diuretic is any substance that promotes the production of urine. This includes forced diuresis. There are several categories of diuretics. All diuretics increase the excretion of water from bodies, although each class does so in a distinct way. Alternatively, an antidiuretic such as vasopressin is an agent or drug which reduces the excretion of water in urine.','Level 3','-','-','-','GT','                Patients with the GT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patients response to diuretics.'),('rs11045585','A > G','SLCO1B3','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to docetaxel.'),('rs2301159','G > A','SLC10A2','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','increased','AA','                Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs3734254','C > T','PPARD','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs4646487','C > T','CYP4B1','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2740574','C > T','CYP3A','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','-','TT','                Patients with the TT genotype may have decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of docetaxel.'),('rs1056836','C > G','CYP1B1','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with taxanes may have longer disease-free progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs12418','G > A','CHST3','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs4148950','G > A','CHST3','docetaxel--PA449383','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','increased','AG','                Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs2070744','C > T','NOS3','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','-','TT','                Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence disease-free survival.'),('rs1883112','G > A','NCF4','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','increased','AA','                Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patients risk for cardiotoxicity.'),('rs4673','A > G','CYBA','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for cardiotoxicity.'),('rs8133052','G > A','CBR3','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','increased','-','-','AA','                Patients with the AA genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients response to doxorubicin treatment and risk of toxicity.'),('rs9561778','G > T','ABCC4','doxorubicin--PA449412','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','increased','GT','                Patients with the GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for ADRs.'),('rs16969968','G > A','CHRNA3','Drugs used in nicotine dependence--PA164712720','NERVOUS SYSTEM','','','','Level 3','increased','-','-','AG','                Patients with AG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the AG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Finding are based on haplotype analysis of rs16969968 and rs680244. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs1800497','G > A','ANKK1','Drugs used in nicotine dependence--PA164712720','NERVOUS SYSTEM','','','','Level 3','increased','-','-','AG','                Patients with AG genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs712829','G > T','EGFR','erlotinib--PA134687924','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00530 ','Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.','Level 3','-','-','decreased','GT','                Patients with the GT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.'),('rs712829','G > T','EGFR','erlotinib--PA134687924','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00530 ','Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.','Level 4','increased','-','-','GT','                Patients with the GT genotype may be more sensitive to treatment with erlotinib  compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.'),('rs1800497','G > A','ANKK1','ethanol--PA448073','VARIOUS','','','Ethanol is a psychoactive drug and is one of the oldest recreational drugs still used by humans. Ethanol can cause alcohol intoxication when consumed. Best known as the type of alcohol found in alcoholic beverages, it is also used in thermometers, as a solvent, and as a fuel. In common usage, it is often referred to simply as alcohol or spirits.','Level 2B','-','-','increased','AG','                Patients with AG genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patients risk for alcohol dependency.'),('rs16944','A > G','IL1B','etidronic acid--PA449548','VARIOUS','','Etidronic acid is a chelating ','Etidronic acid is a chelating agent and may be added to bind or, to some extent, counter the effects of substances, such as calcium, iron or other metal ions, which may be discharged as a component of grey wastewater and could conceivably contaminate groundwater supplies. As a phosphonate it has corrosion inhibiting properties on unnalloyed steel. Etidronic acid also acts to retard rancidification and oxidation of fatty acids.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Pagets disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs25487','T > C','XRCC1','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','CC','                Patients with the CC genotype may have increased response to fluorouracil-containing chemotherapy regimens as compared to patients with the CT or TT genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.'),('rs1042522','C > G','TP53','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','decreased','CC','                Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs2070744','C > T','NOS3','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','-','TT','                Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence disease-free survival.'),('rs1801131','T > G','MTHFR','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GT','                Patients with the GT genotype may have decreased risk of Drug Toxicity when treated with fluorouracil and radiotherapy in people with Rectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1801133','G > A','MTHFR','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','AG','                Patients with the AG genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1801265','G > A','DPYD','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased likelihood of middle-severe nausea and vomiting in Asian cancer patients treated with fluorouracil as as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patients risk for fluorouracil-related toxicity.'),('rs9561778','G > T','ABCC4','fluorouracil--PA128406956','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','GT','                Patients with the GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for ADRs.'),('rs25531','T > C','SLC6A4','fluoxetine--PA449673','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 4','decreased','-','-','CC','                Patients with the CC genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT.  Other genetic and clinical factors may also influence a patients response.'),('rs2227631','A > G','SERPINE1','fluoxetine--PA449673','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs334558','A > G','GSK3B','fluoxetine--PA449673','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 3','increased','-','-','GG','                Patients with the GG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have more improvement in symptoms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients response to fluoxetine and citalopram.'),('rs10042486','C > T','HTR1A','fluvoxamine--PA449690','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00176 ','Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.','Level 3','decreased','-','-','CT','                Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs6295','C > G','HTR1A','fluvoxamine--PA449690','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00176 ','Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs4961','G > T','ADD1','furosemide--PA449719','CARDIOVASCULAR SYSTEM','DIURETICS','DB00695 ','A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. [PubChem]','Level 2B','decreased','-','-','GT','                Patients with the GT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to diuretics.'),('rs712829','G > T','EGFR','gefitinib--PA131301952','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00317 ','Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells.','Level 3','increased','-','-','GT','                Patients with the GT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs712829','G > T','EGFR','geldanamycin--PA152031327','VARIOUS','','','Geldanamycin is a benzoquinone ansamycin antibiotic that inhibits the function of Hsp90 (Heat Shock Protein 90) by binding to the unusual ADP/ATP-binding pocket of the protein.[1] HSP90 client proteins play important roles in the regulation of the cell cycle, cell growth, cell survival, apoptosis, angiogenesis and oncogenesis.','Level 4','decreased','-','-','GT','                Patients with the genotype GT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patients response.'),('rs9937','A > G','RRM1','gemcitabine--PA449748','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00441 ','Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar? by Eli Lilly and Company. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication.','Level 4','-','-','decreased','AG','                Patients with the AG genotype and the A allele of rs1042858 with advanced breast cancer who are treated with gemcitabine 1) may be less likely to experience toxicity such as neutropenia 2) may have a tendency, though not a statistically significant one, towards poorer progression-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of toxicity and response to gemcitabine.'),('rs4961','G > T','ADD1','hydrochlorothiazide--PA449899','CARDIOVASCULAR SYSTEM','DIURETICS','DB00999 ','A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium.','Level 3','increased','-','-','GT','                Patients with the GT genotype may have a better response to hydrochlorothiazide treatment as compared to patients with the GG genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patients response to hydrochlorothiazide treatment.'),('rs20417','C > G','PTGS2','ibuprofen--PA449957','GENITO URINARY SYSTEM AND SEX HORMONES','OTHER GYNECOLOGICALS','DB01050','Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to ibuprofen.'),('rs7142881','G > A','NUBPL','iloperidone--PA161199368','VARIOUS','','','Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.','Level 3','-','-','increased','AG','                Patients with the AG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs4799915','C > T','CELF4','iloperidone--PA161199368','VARIOUS','','','Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.','Level 3','-','-','increased','TT','                Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs2284017','T > C','CACNG2','lithium--PA450243','VARIOUS','','','Lithium and its compounds have several industrial applications, including heat-resistant glass and ceramics, high strength-to-weight alloys used in aircraft, lithium batteries and lithium-ion batteries. These uses consume more than half of lithium production.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs1801133','G > A','MTHFR','mercaptopurine--PA450379','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 3','-','-','-','AG','                Patients with the AG genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patients risk for toxicity to mercaptopurine.'),('rs622342','C > A','SLC22A1','metformin--PA450395','ALIMENTARY TRACT AND METABOLISM','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 3','increased','-','-','AA','                Patients with the AA genotype and the GG genotype at rs2289669 who have diabetes may have a better response to metformin, as measured by a larger reduction in HbA1c levels, as compared to patients with the CC genotype and the GG genotype at rs2289669. This association is not significant when compared to patients with the CC genotype and the AG or AA genotype at rs2289699. Other genetic and clinical factors may also influence a patients reduction in HbA1c levels with metformin treatment.'),('rs2076369','T > G','PICK1','methamphetamine--PA450403','VARIOUS','','','In low doses, methamphetamine can cause an elevated mood and increase alertness, concentration, and energy in fatigued individuals. At higher doses, it can induce psychosis, rhabdomyolysis and cerebral hemorrhage. Methamphetamine is known to have a high potential for abuse and addiction. Recreational use of methamphetamine may result in psychosis or lead to post-withdrawal syndrome, a withdrawal syndrome that can persist for months beyond the typical withdrawal period. Unlike amphetamine and cocaine, methamphetamine is neurotoxic to humans, damaging both dopamine and serotonin neurons in the CNS. Entirely opposite to the long-term use of amphetamine, there is evidence that methamphetamine causes brain damage from long-term use in humans; this damage includes adverse changes in brain structure and function, such as reductions in gray matter volume in several brain regions and adverse changes in markers of metabolic integrity.','Level 3','-','-','decreased','GG','                Patients with the GG genotype who are methamphetamine abusers may have a decreased, but not absent, risk for spontaneous relapse of psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for spontaneous relapse of psychosis with methamphetamine abuse.'),('rs2070744','C > T','NOS3','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','-','TT','                Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence disease-free survival.'),('rs1801131','T > G','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','GT','                Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of clinical response but may have a decreased response base on Disease Activity Score in 44 joints improvement at 6 months as compared to patients with the TT genotype. This association has been contradicted in other studies including a larger meta-analysis that found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs1801131','T > G','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','-','GT','                Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype or may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype.  This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Rheumatoid Arthritis may be more at risk of alopecia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of alopecia.'),('rs1801133','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse events as compared to patients with the AA genotype (though this association has not been found in all studies). There does not seem to be an association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','AG','                Patients with the AG genotype with non-hodgkin lymphoma who are treated with methotrexate may be less likely to have event free survival at 5 years as compared to patients with the GG genotype. This genotype was not associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the GG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','decreased','increased','AG','                Patients with the AG genotype and Leukemia who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate as compared to patients with the GG genotype or may be at decreased risk of toxicity as compared to patients with the AA genotype. This association has been contradicted or not found in several studies. Other genetic and clinical factors may also influence a patients risk for toxicity and response with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk Graft vs Host disease and efficacy of methotrexate treatment.'),('rs4846051','G > A','MTHFR','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','AA','                Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients level of methotrexate induced toxicity.'),('rs1544105','C > T','FPGS','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','TT','                Patients with the TT genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs2372536','C > G','ATIC','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','CG','                Patients with the CG genotype and rheumatoid arthritis who are treated with methotrexate may be less likely to have symptom improvement as compared to patients with the GG genotype.'),('rs2298383','C > T','ADORA2A','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','-','CT','                Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype or may have an increased risk for adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse events when treated with methotrexate.'),('rs246240','A > G','ABCC1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity to methotrexate.'),('rs35592','T > C','ABCC1','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','CT','                Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs4888024','A > G','Not available','methotrexate--PA450428','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','-','GG','                Patients with the GG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.'),('rs1801253','G > C','ADRB1','metoprolol--PA450480','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','metoprolol--PA450480','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','metoprolol--PA450480','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','decreased','-','increased','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs10042486','C > T','HTR1A','milnacipran--PA164752812','VARIOUS','','','Milnacipran (Ixel, Savella, Dalcipran, Toledomin) is a serotonin','Level 3','decreased','-','-','CT','                Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs2660845','G > A','LTA4H','montelukast--PA450546','RESPIRATORY SYSTEM','DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES','DB00471 ','Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it.','Level 3','-','-','increased','AG','                Patients with the AG genotype and asthma who are treated with montelukast  may have an increased risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of asthma exacerbations with montelukast treatment.'),('rs2115819','A > G','ALOX5','montelukast--PA450546','RESPIRATORY SYSTEM','DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES','DB00471 ','Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it.','Level 3','increased','-','-','GG','                Patients with the GG genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment,  compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patients response to montelukast.'),('rs4149117','T > G','SLCO1B3','mycophenolate mofetil--PA450566','VARIOUS','','DB00688 ','Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent, inosine monophosphate dehydrogenase (IMPDH) inhibitor.','Level 4','-','-','-','GT','                Patients with the GT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype, or 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity and exposure to mycophenolic acid.'),('rs2278294','C > T','IMPDH1','mycophenolate mofetil--PA450566','VARIOUS','','DB00688 ','Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent, inosine monophosphate dehydrogenase (IMPDH) inhibitor.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1800497','G > A','ANKK1','nemonapride--PA151186253','VARIOUS','','','Nemonapride (Emilace) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in 1991. ','Level 3','-','-','increased','AG','                Female patients with the AG genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patients response to nemonapride.'),('rs16969968','G > A','CHRNA5','nicotine--PA450626','NERVOUS SYSTEM','OTHER NERVOUS SYSTEM DRUGS','DB00184','Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. [PubChem]','Level 3','-','-','increased','AG','                Patients with AG genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype. Findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patients risk for nicotine dependency.'),('rs1800497','G > A','ANKK1','nicotine--PA450626','NERVOUS SYSTEM','OTHER NERVOUS SYSTEM DRUGS','DB00184','Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. [PubChem]','Level 3','increased','-','-','AG','                Patients with AG genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs1801133','G > A','MTHFR','nitrous oxide--PA450645','VARIOUS','','','Nitrous oxide, commonly known as laughing gas, nitrous, nitro, or NOS[1] is a chemical compound','Level 3','-','-','-','AG','                Patients with the GA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients homocysteine levels after nitrous oxide anesthesia.'),('rs2842030','G > T','RGS4','olanzapine--PA450688','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients response to perphanazine.'),('rs4731426','G > C','LEP','olanzapine--PA450688','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of extreme weight gain with olanzapine treatment.'),('rs7997012','A > G','HTR2A','olanzapine--PA450688','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for side effects with olanzapine treatment.'),('rs6280','C > T','DRD3','olanzapine--PA450688','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','decreased','-','-','TT','                Patients with the TT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patients response to olanzapine.'),('rs1079598','A > G','DRD2','olanzapine--PA450688','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1800497','G > A','ANKK1','olanzapine--PA450688','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs25487','T > C','XRCC1','oxaliplatin--PA131285527','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs11615','A > G','ERCC1','oxaliplatin--PA131285527','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs1042522','C > G','TP53','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 2B','-','-','decreased','CC','                Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs9981861','T > C','DSCAM','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.'),('rs1056836','C > G','CYP1B1','paclitaxel--PA450761','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with taxanes may have longer disease-free progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs10042486','C > T','HTR1A','paroxetine--PA450801','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00726 ','Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]','Level 3','decreased','-','-','CT','                Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs11042725','C > A','ADM','paroxetine--PA450801','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00726 ','Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]','Level 3','increased','-','-','AC','                Patients with the AC genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to paroxetine.'),('rs2842030','G > T','RGS4','perphenazine--PA450882','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00850 ','An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. [PubChem]','Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients response to perphanazine.'),('rs2108622','C > T','CYP4F2','phenprocoumon--PA450921','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00946','Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs3812718','C > T','SCN1A','phenytoin--PA450947','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 2B','-','increased','-','TT','                Patients with the TT genotype who are treated with phenytoin may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.'),('rs25487','T > C','XRCC1','Platinum compounds--PA164713176','VARIOUS','','','','Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs11615','A > G','ERCC1','Platinum compounds--PA164713176','VARIOUS','','','','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs25487','T > C','XRCC1','platinum--PA150595617','VARIOUS','','','','Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs11615','A > G','ERCC1','platinum--PA150595617','VARIOUS','','','','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs6280','C > T','DRD3','pramipexole--PA164742949','NERVOUS SYSTEM','ANTI-PARKINSON DRUGS','DB00413 ','Pramipexole is a medication indicated for treating Parkinson??s disease and restless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache or to counteract the problems with low libido experienced by some users of SSRI antidepressant drugs.','Level 3','increased','-','-','TT','                Patients with the TT genotype may have better therapeutic efficacy (response rate = 60%)of pramipexole in Chinese patients with Parkinsons disease compared to patiens carrying the C allele (response rate =13%). Other genetic and clinical factors may also influence a patients response.'),('rs2306283','A > G','SLCO1B1','pravastatin--PA451089','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased plasma AUC of pravastatin as compared to patients with the AA genotype.'),('rs20455','A > G','KIF6','pravastatin--PA451089','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 2B','-','-','increased','GG','                Patients with the GG genotype may have an increased risk for adverse cardiovascular events (myocardial infarction and coronary heart diseases) as compared to patients with the AA genotype. Pravastatin treatment substantially reduced that risk. Other genetic and clinical factors may also influence a patients risk for adverse cardiovascular events.'),('rs2276307','A > G','HTR3B','pravastatin--PA451089','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for myalgia.'),('rs290487','C > T','TCF7L2','repaglinide--PA451234','GENITO URINARY SYSTEM AND SEX HORMONES','DRUGS USED IN DIABETES','DB00912 ','Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to |? cells of the pancreas to stimulate insulin release.','Level 3','increased','-','-','TT','                Patients with the TT genotype may have better response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patients repsonse.'),('rs5219','T > C','ABCC8','repaglinide--PA451234','GENITO URINARY SYSTEM AND SEX HORMONES','DRUGS USED IN DIABETES','DB00912 ','Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to |? cells of the pancreas to stimulate insulin release.','Level 3','decreased','-','-','CC','                Patients with the CC genotype are less likely to respond to repaglinide  than patients with the CT or TT genotype in T2DM patients. Other genetic and clinical factors may also influence a patients response.'),('rs16944','A > G','IL1B','risedronate--PA451255','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00884 ','Risedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Pagets disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs2297480','T > G','FDPS','risedronate--PA451255','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00884 ','Risedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs2661319','T > C','RGS4','risperidone--PA451257','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs2842030','G > T','RGS4','risperidone--PA451257','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 4','decreased','-','-','TT','                Patients with the TT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs7799039','G > A','LEP','risperidone--PA451257','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','increased','AA','                Patients with the AA genotype may have excessive risperidone-associated weight gain in youths as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs724226','A > G','GRM3','risperidone--PA451257','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','AG','                Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs167771','G > A','DRD3','risperidone--PA451257','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AG or GG genotype. Patients with the AA genotype may still be at risk for toxicity when taking risperidone. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs6280','C > T','DRD3','risperidone--PA451257','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have smaller reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating poorer response to risperidone in Children with Autism, than TT homozygotes compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patients response.'),('rs1799978','T > C','DRD2','risperidone--PA451257','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs165599','G > A','COMT','risperidone--PA451257','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','AA','                Patients with the AA genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs1800497','G > A','ANKK1','risperidone--PA451257','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1800497','G > A','ANKK1','risperidone--PA451257','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','AG','                Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the GG genotype or may have less improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs2494732','T > C','AKT1','risperidone--PA451257','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs5128','G > C','APOC3','ritonavir--PA451260','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00503 ','An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. [PubChem]','Level 3','-','-','increased','CC','                Patients with the CC genotype and HIV who are treated with ritonavir may have an increased risk of triglyceride elevation as compared to patients with the CG or GG genotype.'),('rs2854116','C > T','APOA4','ritonavir--PA451260','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00503 ','An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. [PubChem]','Level 3','-','-','increased','TT','                Patients with the TT genotype and HIV who are treated with ritonavir may have increased severity of triglyceride elevation as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients triglyceride levels.'),('rs2854117','T > C','APOA4','ritonavir--PA451260','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00503 ','An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. [PubChem]','Level 3','-','-','decreased','CC','                Patients with the CC genotype and HIV who are treated with ritonavir may have lower triglyceride levels (lower risk of Hypertriglyceridemia) as compared to patients with the TC or TT genotype. Patients with the CC genotype may still be at risk for toxicity when taking ritonavir. Other genetic and clinical factors may also influence a patients triglyceride levels.'),('rs20417','C > G','PTGS2','rofecoxib--PA451268','VARIOUS','','','Rituximab (trade names Rituxan, MabThera and Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.','Level 3','decreased','-','-','CG','                Patients with the CG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to rofecoxib.'),('rs2267715','G > A','CRHR2','salbutamol--PA448068','VARIOUS','','DB01001 ','Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart.','Level 3','increased','-','-','AA','                Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compare to patients with the GG genotype. However, contradictory finding has been reported. No conclusive results regarding the association between this variant and bronchodilator response.'),('rs2267715','G > A','CRHR2','selective beta-2-adrenoreceptor agonists--PA134687887','VARIOUS','','','Selective beta-2-adrenoreceptor agonists are a class of drugs that act on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation, resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin.They are primarily used to treat asthma and other pulmonary disorders.','Level 3','increased','-','-','AA','                Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compare to patients with the GG genotype. However, contradictory finding has been reported. No conclusive results regarding the association between this variant and bronchodilator response.'),('rs6295','C > G','HTR1A','Selective serotonin reuptake inhibitors--PA164713257','VARIOUS','','','Selective beta-2-adrenoreceptor agonists are a class of drugs that act on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation, resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin.They are primarily used to treat asthma and other pulmonary disorders.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs4343','G > A','ACE','sildenafil--PA451346','GENITO URINARY SYSTEM AND SEX HORMONES','UROLOGICALS','DB00203 ','Sildenfail is a vasoactive agent used to treat erectile dysfunction and reduce symptoms in patients with pulmonary arterial hypertension (PAH). Sildenafil elevates levels of the second messenger, cGMP, by inhibiting its breakdown via phosphodiesterase type 5 (PDE5).','Level 3','increased','-','-','AA','                Patients with the AA genotype and erectile dysfunction who are treated with sildenafil may have an increased chance of positive erectile response as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients response to sildenafil.'),('rs2276307','A > G','HTR3B','simvastatin--PA451363','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for myalgia.'),('rs776746','C > T','CYP3A5','sirolimus--PA451365','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00877 ','A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production.','Level 2A','-','increased','-','CT','                Patients with the CT genotype (*1/*3) and who are recipients of transplants may have increased metabolism of sirolimus and require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients sirolimus dose requirements.'),('rs2740574','C > T','CYP3A','sirolimus--PA451365','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00877 ','A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production.','Level 2A','-','decreased','-','TT','                Patients with the TT genotype may require a decreased dose of tacrolimus or sirolimus as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs4961','G > T','ADD1','spironolactone--PA451483','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','DIURETICS','DB00421 ','A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis.','Level 2B','decreased','-','-','GT','                Patients with the GT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to diuretics.'),('rs4343','G > A','ACE','spironolactone--PA451483','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','DIURETICS','DB00421 ','A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis.','Level 3','increased','-','-','AA','                Patients with the AA genotype is associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs5219','T > C','KCNJ11','sulfonamides, urea derivatives--PA10390','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','increased','-','-','CC','                Patients with the CC genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs5219','T > C','KCNJ11','sulfonamides, urea derivatives--PA10390','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','-','-','-','CC','                Patients with CC genotype may have poorer response (higher decrease in HbA1c) to 6-month treatment of sulfonylureas in people with Type 2 diabetes as compared to patients with genotype CT or TT. Other genetic or clinical factors may also influence a patients response to sulfonylureas.'),('rs5219','T > C','KCNJ11','sulfonamides, urea derivatives--PA10390','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','-','-','-','CC','                Patients with the CC genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs5219','T > C','KCNJ11','sulfonamides, urea derivatives--PA10390','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','decreased','-','-','CC','                Patients with CC genotype may have poorer response (higher decrease in HbA1c) to 6-month treatment of sulfonylureas in people with Type 2 diabetes as compared to patients with genotype CT or TT. Other genetic or clinical factors may also influence a patients response to sulfonylureas.'),('rs776746','C > T','CYP3A5','tacrolimus--PA451578','DERMATOLOGICALS','OTHER DERMATOLOGICAL PREPARATIONS','DB00864 ','Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient??s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. ','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are treated with tacrolimus may have increased clearance of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients tacrolimus dose requirement.'),('rs776746','C > T','CYP3A5','tacrolimus--PA451578','DERMATOLOGICALS','OTHER DERMATOLOGICAL PREPARATIONS','DB00864 ','Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient??s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. ','Level 2A','-','-','increased','CT','                Patients with the CT genotype (*1/*3) and are recipients of Kidney Transplant who are treated with tacrolimus may have an increased risk of nephrotoxicity as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patients risk for drug-induced nephrotoxicity.'),('rs776746','C > T','CYP3A5','tacrolimus--PA451578','DERMATOLOGICALS','OTHER DERMATOLOGICAL PREPARATIONS','DB00864 ','Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient??s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. ','Level 3','-','-','-','CT','                Patients with the CT genotype (*1/*3) and recipients of Kidney Transplant who are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patients response to tacrolimus treatment and risk of transplant rejection.'),('rs776746','C > T','CYP3A5','tacrolimus--PA451578','DERMATOLOGICALS','OTHER DERMATOLOGICAL PREPARATIONS','DB00864 ','Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient??s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. ','Level 3','-','-','decreased','CT','                Patients with the CT genotype and recipients of Kidney Transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hyperlipidemia.'),('rs2740574','C > T','CYP3A','tacrolimus--PA451578','DERMATOLOGICALS','OTHER DERMATOLOGICAL PREPARATIONS','DB00864 ','Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient??s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. ','Level 2A','-','decreased','-','TT','                Patients with the TT genotype may require a decreased dose of tacrolimus or sirolimus as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs1056836','C > G','CYP1B1','taxanes--PA150481189','VARIOUS','','','Taxanes are diterpenes produced by the plants of the genus Taxus (yews), and are widely used as chemotherapy agents.[1] Taxane agents include paclitaxel (Taxol) and docetaxel (Taxotere).Taxanes present difficulties in formulation as medicines because they are poorly soluble in water.','Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with taxanes may have longer disease-free progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs2301159','G > A','SLC10A2','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','-','-','increased','AA','                Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs3734254','C > T','PPARD','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs4646487','C > T','CYP4B1','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs12418','G > A','CHST3','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs1871450','G > A','CHST3','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','increased','-','-','AG','                Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs4148950','G > A','CHST3','thalidomide--PA451644','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','increased','-','increased','AG','                Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs712829','G > T','EGFR','topoisomerase I inhibitors--PA150481186','VARIOUS','','','Topoisomerase inhibitors are agents designed to interfere with the action of topoisomerase enzymes[1] (topoisomerase I and II), which are enzymes that control the changes in DNA structure[2] by catalyzing the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle.','Level 4','decreased','-','-','GT','                Cancer patients with genotype GT may be less likely to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patients response.'),('rs10811661','T > C','Not available','troglitazone--PA451799','ALIMENTARY TRACT AND METABOLISM','DRUGS USED IN DIABETES','DB00197','Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.','Level 3','increased','-','-','CT','                Patients with the CT genotype and at high risk for type II diabetes who are treated with troglitazone may have increased beta call function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to troglitazone.'),('rs10494366','G > T','NOS1AP','verapamil--PA451868','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 3','-','-','decreased','TT','                Patients with the TT genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients QTc prolongation risk.'),('rs10918594','C > G','NOS1AP','verapamil--PA451868','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 4','-','-','increased','CG','                While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype, it was not shown conclusively if heterzygous (GC) individuals are affected. Other genetic and clinical factors may also influence a patients QTc prolongation risk.'),('rs9934438','G > A','VKORC1','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs10871454','C > T','STX4','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','TT','                Patients with the TT genotype who are treated with warfarin may require the lowest dose as compared to patients with the CT or CC genotype.'),('rs8050894','C > G','PRSS53','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','GG','                Patients with the GG genotype who are treated with warfarin may require the lowest dose as compared to patients with the CG or CC genotype.'),('rs12714145','C > T','GGCX','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','increased','-','TT','                Genotype TT may be associated with increased dose of warfarin as compared to genotype GG. However, contradictory findings (no association) have been reported. Other genetic and clinical factors may influence a patients dose of warfain.'),('rs2292566','G > A','EPHX1','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','AG','                Patients with the AG genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.'),('rs2108622','C > T','CYP4F2','warfarin--PA451906','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.');
/*!40000 ALTER TABLE `example` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `fda_drug`
--

DROP TABLE IF EXISTS `fda_drug`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `fda_drug` (
  `Drug` varchar(255) CHARACTER SET utf8 DEFAULT NULL,
  `Area` varchar(255) CHARACTER SET utf8 DEFAULT NULL,
  `Gene` varchar(255) CHARACTER SET utf8 DEFAULT NULL,
  `Ref` varchar(255) CHARACTER SET utf8 DEFAULT NULL,
  `Label` varchar(255) CHARACTER SET utf8 DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=latin1 ROW_FORMAT=COMPACT;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `fda_drug`
--

LOCK TABLES `fda_drug` WRITE;
/*!40000 ALTER TABLE `fda_drug` DISABLE KEYS */;
INSERT INTO `fda_drug` VALUES ('Abacavir','Infectious Diseases','HLA-B','HLA-B*5701 allele carriers','Boxed Warning, Contraindications, Warnings and Precautions'),('Ado-Trastuzumab Emtansine','Oncology','ERBB2','HER2 protein overexpression or gene amplification positive','Indications and Usage, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies'),('Afatinib','Oncology','EGFR','EGFR exon 19 deletion or exon 21 substitution (L858R)positive','Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies'),('Amitriptyline','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Precautions'),('Anastrozole','Oncology','ESR1, PGR','Hormone receptor-positive','Indications and Usage, Adverse Reactions, Drug Interactions, Clinical Studies'),('Arformoterol','Pulmonary','UGT1A1','UGT1A1 poor metabolizers','Clinical Pharmacology'),('Arformoterol','Pulmonary','CYP2D6','CYP2D6 intermediate or poor metabolizers','Clinical Pharmacology'),('Aripiprazole','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Dosage and Administration, Clinical Pharmacology'),('Arsenic Trioxide','Oncology','PML-RARA','PML-RAR translocation positive','Clinical Pharmacology, Indications and Usage'),('Atomoxetine','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Dosage and Administration, Warnings and Precautions, Drug Interactions, Clinical Pharmacology'),('Azathioprine','Rheumatology','TPMT','TPMT intermediate or poor metabolizers','Clinical Pharmacology, Warnings, Precautions Drug Interactions, Adverse Reactions, Dosage and Administration'),('Boceprevir','Infectious Diseases','IFNL3','IL28B rs12979860 T allele carriers (C/T and T/T genotype)','Clinical Pharmacology'),('Bosutinib','Oncology','BCR/ABL1','Philadelphia chromosome positive','Indications and Usage Adverse Reactions, Use in Specific Populations, Clinical Studies'),('Busulfan','Oncology','BCR-ABL1','Philadelphia chromosome negative','Clinical Studies'),('Capecitabine','Oncology','DPYD','DPD deficient','Contraindications, Warnings and Precautions, Patient Information'),('Carbamazepine','Neurology','HLA-B','HLA-B*1502 allele carriers','Boxed Warning, Warnings, Precautions'),('Carbamazepine','Neurology','HLA-A','HLA-A*3101 allele carriers','Warnings'),('Carglumic Acid','Inborn Errors of Metabolism','NAGS','N-acetylglutamate synthase deficient','Indications and Usage, Warnings and Precautions, Use in Specific Populations Clinical Pharmacology Clinical Studies'),('Carisoprodol','Rheumatology','CYP2C19','CYP2C19 poor metabolizers','Use in Specific Populations, Clinical Pharmacology'),('Carvedilol','Cardiology','CYP2D6','CYP2D6 poor metabolizers','Drug Interactions, Clinical Pharmacology'),('Celecoxib','Rheumatology','CYP2C9','CYP2C9 poor metabolizers','Dosage and Administration, Use in Specific Populations, Clinical Pharmacology'),('Ceritinib','Oncology','ALK','ALK gene rearrangement positive','Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies'),('Cetuximab','Oncology','EGFR','EGFR protein expression positive','Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies'),('Cetuximab','Oncology','KRAS','KRAS codon 12 and 13 mutation negative','Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies'),('Cevimeline','Dental','CYP2D6','CYP2D6 poor metabolizers','Precautions'),('Chloroquine','Infectious Diseases','G6PD','G6PD deficient','Precautions'),('Chlorpropamide','Endocrinology','G6PD','G6PD deficient','Precautions'),('Cisplatin','Oncology','TPMT','TPMT intermediate or poor metabolizers','Clinical Pharmacology, Warnings, Precautions, Adverse Reactions'),('Citalopram','Psychiatry','CYP2C19','CYP2C19 poor metabolizers','Clinical Pharmacology, Warnings, Dosage and Administration'),('Citalopram','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Clinical Pharmacology'),('Clobazam','Neurology','CYP2C19','CYP2C19 poor metabolizers','Dosage and Administration, Use in Specific Populations, Clinical Pharmacology'),('Clomipramine','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Precautions'),('Clopidogrel','Cardiology','CYP2C19','CYP2C19 intermediate or poor metabolizers','Boxed Warning, Dosage and Administration, Warnings and Precautions, Clinical Pharmacology'),('Clozapine','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Dosage and Administration, Use in Specific Populations, Clinical Pharmacology'),('Codeine','Anesthesiology','CYP2D6','CYP2D6 ultra-rapid metabolizers','Boxed Warnings, Warnings and Precautions, Use in Specific Populations, Patient Counseling Information'),('Crizotinib','Oncology','ALK','ALK gene rearrangement positive','Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies'),('Dabrafenib','Oncology','BRAF','BRAF V600E/K mutation positive','Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies, Patient Counseling Information'),('Dabrafenib','Oncology','G6PD','G6PD deficient','Warnings and Precautions, Adverse Reactions, Patient Counseling Information'),('Dapsone','Dermatology','G6PD','G6PD deficient','Warnings and Precautions, Use in Specific Populations, Patient Counseling Information'),('Dapsone','Infectious Diseases','G6PD','G6PD deficient','Precautions, Adverse Reactions, Overdosage'),('Dasatinib','Oncology','BCR/ABL1','Philadelphia chromosome positive;, T315I mutation-positive','Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies'),('Denileukin Diftitox','Oncology','IL2RA','CD25 antigen positive','Indications and Usage, Warnings and Precautions, Clinical Studies'),('Desipramine','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Precautions'),('Dexlansoprazole','Gastroenterology','CYP2C19','CYP2C19 poor metabolizers','Drug Interactions, Clinical Pharmacology'),('Dextromethorphan and Quinidine','Neurology','CYP2D6','CYP2D6 poor metabolizers','Warnings and Precautions, Clinical Pharmacology'),('Diazepam','Psychiatry','CYP2C19','CYP2C19 poor metabolizers','Clinical Pharmacology'),('Divalproex','Neurology','POLG','POLG mutation positive','Boxed Warning, Contraindications, Warnings and Precautions'),('Doxepin','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Clinical Pharmacology'),('Doxepin','Psychiatry','CYP2C19','CYP2D6 poor metabolizers','Clinical Pharmacology'),('Drospirenone and Ethinyl Estradiol','Gynecology, Dermatology','CYP2C19','CYP2C19 intermediate metabolizers','Clinical Pharmacology'),('Eliglustat','Inborn Errors of Metabolism','CYP2D6','CYP2D6 ultrarapid, intermediate or poor metabolizers','Indications and Usage, Dosage and Administration, Contraindications, Warnings and Precautions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies'),('Eltrombopag','Hematology','F5','Factor V Leiden carriers','Warnings and Precautions'),('Eltrombopag','Hematology','SERPINC1','Antithrombin III deficient','Warnings and Precautions'),('Erlotinib','Oncology','EGFR','EGFR protein expression positive','Clinical Studies'),('Erlotinib','Oncology','EGFR','EGFR exon 19 deletion or exon 21 substitution (L858R) positive','Indications and Usage Dosage and Administration, Adverse Reactions, Clinical Pharmacology Clinical Studies'),('Esomeprazole','Gastroenterology','CYP2C19','CYP2C19 poor metabolizers','Drug Interactions, Clinical Pharmacology'),('Everolimus','Oncology','ERBB2','HER2 protein overexpression negative','Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies'),('Everolimus','Oncology','ESR1','Estrogen receptor positive','Clinical Studies'),('Exemestane','Oncology','ESR1','Estrogen receptor positive','Indications and Usage, Dosage and Administration, Clinical Studies'),('Exemestane','Oncology','PGR','Progesterone receptor positive','Clinical Studies'),('Fluorouracil','Dermatology','DPYD','DPD deficient','Contraindications, Warnings, Patient Information'),('Fluorouracil','Oncology','DPYD','DPD deficient','Warnings'),('Fluoxetine','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Clinical Pharmacology, Warnings, Precautions'),('Flurbiprofen','Rheumatology','CYP2C9','CYP2C9 poor metabolizers','Clinical Pharmacology'),('Fluvoxamine','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Drug Interactions'),('Fulvestrant','Oncology','ESR1, PGR','Hormone receptor positive','Indications and Usage, Clinical Pharmacology, Clinical Studies'),('Galantamine','Neurology','CYP2D6','CYP2D6 poor metabolizers','Clinical Pharmacology'),('Glimepiride','Endocrinology','G6PD','G6PD deficient','Warning and Precautions, Adverse Reactions'),('Glipizide','Endocrinology','G6PD','G6PD deficient','Precautions'),('Glyburide','Endocrinology','G6PD','G6PD deficient','Precautions'),('Ibrutinib','Oncology','del (17p)','Chromosome 17p deletion positive','Indications and Usage, Clinical Studies'),('Iloperidone','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Dosage and Administration, Warnings and Precautions,Drug Interactions, Clinical Pharmacology'),('Imatinib','Oncology','KIT','KIT protein expression positive, c-KIT D816V mutation negative','Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies'),('Imatinib','Oncology','BCR-ABL1','Philadelphia chromosome positive','Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies'),('Imatinib','Oncology','PDGFRB','PDGFR gene rearrangement positive','Indications and Usage, Dosage and Administration, Clincal Studies'),('Imatinib','Oncology','FIP1L1-PDGFRA','FIP1L1-PDGFR fusion kinase (or CHIC2 deletion) positive','Indications and Usage, Dosage and Administration, Clinical Studies'),('Imipramine','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Precautions'),('Indacaterol','Pulmonary','UGT1A1','UGT1A1-*28 allele homozygotes','Clinical Pharmacology'),('Irinotecan','Oncology','UGT1A1','UGT1A1*28 allele carriers','Dosage and Administration, Warnings and Precautions, Clinical Pharmacology'),('Isosorbide and Hydralazine','Cardiology','NAT1-2','Slow acetylators','Clinical Pharmacology'),('Ivacaftor','Pulmonary','CFTR','CFTR G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R mutation carriers, F508del mutation homozygotes','Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies'),('Lansoprazole','Gastroenterology','CYP2C19','CYP2C19 intermediate or poor metabolizers','Drug Interactions'),('Lapatinib','Oncology','ERBB2','HER2 protein overexpression positive','Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies'),('Lapatinib','Oncology','HLA-DQA1, HLA-DRB1','HLA-DQA1*0201 or -DRB1*0701 allele carriers','Clinical Pharmacology'),('Lenalidomide','Hematology','del (5q)','Chromosome 5q deletion positive','Boxed Warning, Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies'),('Letrozole','Oncology','ESR1, PGR','Hormone receptor positive','Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies'),('Lomitapide','Endocrinology','LDLR','LDLR mutation homozygotes (homozygous familial hypercholesterolemia)','Indication and Usage, Warnings and Precautions, Adverse Reactions, Clinical Studies'),('Mafenide','Infectious Diseases','G6PD','G6PD deficient','Warnings, Adverse Reactions'),('Mercaptopurine','Oncology','TPMT','TPMT intermediate or poor metabolizers','Clinical Pharmacology, Warnings, Precautions, Adverse Reactions, Dosage and Administration'),('Methylene Blue','Hematology','G6PD','G6PD deficient','Precautions'),('Metoclopramide','Gastroentrology','CYB5R1-4','NADH cytochrome b5 reductase deficient','Precautions'),('Metoprolol','Cardiology','CYP2D6','CYP2D6 poor metabolizers','Clinical Pharmacology'),('Mipomersen','Endocrinology','LDLR','LDLR mutation heterozygotes and homozygotes (heterozygous and homozygous familial hypercholesterolemia)','Boxed Warning, Indications and Usage, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies'),('Modafinil','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Clinical Pharmacology, Precautions'),('Mycophenolic Acid','Transplantation','HPRT1','HGPRT deficient','Warnings and Precautions'),('Nalidixic Acid','Infectious Diseases','G6PD','G6PD deficient','Precautions, Adverse Reactions'),('Nefazodone','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Precautions'),('Nilotinib','Oncology','BCR-ABL','Philadelphia chromosome positive','Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specififc Populations, Clinical Pharmacology, Clinical Studies'),('Nilotinib','Oncology','UGT1A1','UGT1A1*28 allele homozygotes','Clinical Pharmacology'),('Nitrofurantoin','Infectious Diseases','G6PD','G6PD deficient','Warnings, Adverse Reactions'),('Nortriptyline','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Precautions'),('Obinutuzumab','Oncology','MS4A1','CD20 antigen positive','Clinical Studies'),('Omacetaxine','Oncology','BCR-ABL1','Philadelphia chromosome positive','Clinical Pharmacology, Clinical Studies'),('Omeprazole','Gastroenterology','CYP2C19','CYP2C19 poor metabolizers','Drug Interactions'),('Panitumumab','Oncology','EGFR','EGFR protein expression positive','Clinical Pharmacology, Clinical Studies'),('Panitumumab','Oncology','KRAS','KRAS codon 12 and 13 mutation negative','Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies'),('Pantoprazole','Gastroenterology','CYP2C19','CYP2C19 extensive metabolizers','Clinical Pharmacology'),('Paroxetine','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Clinical Pharmacology, Drug Interactions'),('Pazopanib','Oncology','UGT1A1','(TA)7/(TA)7 genotype (UGT1A1*28/*28)','Clinical Pharmacology, Warnings and Precautions'),('PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid','Gastroenterology','G6PD','G6PD deficient','Warnings and Precautions'),('Peginterferon alfa-2b','Infectious Diseases','IFNL3','IL28B rs12979860 T allele carriers','Clinical Pharmacology'),('Pegloticase','Rheumatology','G6PD','G6PD deficient','Contraindications, Patient Counseling Information'),('Perphenazine','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Clinical Pharmacology, Drug Interactions'),('Pertuzumab','Oncology','ERBB2','HER2 protein overexpression positive','Indications and Usage, Warnings and Precautions, Adverse Reactions, Clinical Studies, Clinical Pharmacology'),('Phenytoin','Neurology','HLA-B','HLA-B*1502 allele carriers','Warnings'),('Pimozide','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Warnings, Precautions, Contraindications, Dosage and Administration'),('Ponatinib','Oncology','BCR ?ABL T315I','BCR ?ABL T315I mutation','Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies'),('Prasugrel','Cardiology','CYP2C19','CYP2C19 poor metabolizers','Use in Specific Populations, Clinical Pharmacology, Clinical Studies'),('Pravastatin','Endocrinology','LDLR','LDLR mutation heterozygotes and homozygotes (heterozygous and homozygous familial hypercholesterolemia)','Indications and Usage, Use in Specific Populations, Clinical Studies'),('Primaquine','Infectious Diseases','G6PD','G6PD deficient','Warnings and Precautions, Adverse Reactions'),('Propafenone','Cardiology','CYP2D6','CYP2D6 poor metabolizers','Dosage and Administration, Warnings and Precautions, Clinical Pharmacology'),('Propranolol','Cardiology','CYP2D6','CYP2D6 poor metabolizers','Clinical Pharmacology'),('Protriptyline','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Precautions'),('Quinidine','Cardiology','CYP2D6','CYP2D6 poor metabolizers','Precautions'),('Quinine Sulfate','Infectious Diseases','G6PD','G6PD deficient','Contraindications'),('Quinine Sulfate','Infectious Diseases','CYP2D6','CYP2D6 poor metabolizers','Drug Interactions'),('Rabeprazole','Gastroenterology','CYP2C19','CYP2C19 poor metabolizers','Drug Interactions, Clinical Pharmacology'),('Rasburicase','Oncology','G6PD','G6PD deficient','Boxed Warning, Contraindications, Warnings and Precautions'),('Rasburicase','Oncology','CYB5R1-4','NADH cytochrome b5 reductase deficient','Warnings and Precautions'),('Rifampin, Isoniazid, and Pyrazinamide','Infectious Diseases','NAT1-2','Slow acetylators (inactivators)','Clinical Pharmacology, Adverse Reactions'),('Risperidone','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Clinical Pharmacology'),('Rituximab','Oncology','MS4A1','CD20 antigen positive','Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies'),('Simeprevir','Infectious Diseases','IFNL3','IL28B rs12979860 T allele carriers','Clinical Pharmacology, Clinical Studies'),('Sodium Nitrite','Toxicology','G6PD','G6PD deficient','Warnings and Precautions'),('Sodium phenylacetate and Sodium Benzoate','Inborn Errors of Metabolism','NAGS, CPS1, ASS1, OTC, ASL, ABL2','Urea cycle enzyme deficient','Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Drug Interactions, Use in Specific Populations, Overdosage, Clinical Pharmacology, Clinical Studies'),('Sofosbuvir','Infectious Diseases','IFNL3','IL28B rs12979860 T allele carriers (non-C/C genotype)IL28B','Clinical Studies'),('Succimer','Hematology','G6PD','G6PD deficient','Clinical Pharmacology'),('Sulfamethoxazole and Trimethoprim','Infectious Diseases','G6PD','G6PD deficient','Precautions'),('Tamoxifen','Oncology','ESR1, PGR','Hormone receptor positive','Clinical Pharmacology, Indications and Usage, Precautions, Adverse Reactions, Medication Guide'),('Tamoxifen','Oncology','F5','Factor V Leiden carriers','Warnings'),('Tamoxifen','Oncology','F2','Prothrombin 20210A allele positive','Warnings'),('Telaprevir','Infectious Diseases','IFNL3','IL28B rs12979860 T allele carriers (C/T and T/T genotype)','Clinical Pharmacology, Clinical Studies'),('Terbinafine','Infectious Diseases','CYP2D6','CYP2D6 poor metabolizers','Drug Interactions'),('Tetrabenazine','Neurology','CYP2D6','CYP2D6 poor metabolizers','Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology'),('Thioguanine','Oncology','TPMT','TPMT intermediate or poor metabolizers (deficient)','Warnings, Precautions, Dosage and Administration'),('Thioridazine','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Contraindications, Warnings, Precautions'),('Ticagrelor','Cardiology','CYP2C19','CYP2C19 poor metabolizers','Clinical Studies'),('Tolterodine','Genitourinary','CYP2D6','CYP2D6 poor metabolizers','Warnings and Precautions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology'),('Tositumomab','Oncology','MS4A1','CD20 antigen positive','Indications and Usage, Clinical Pharmacology'),('Tramadol','Analgesic','CYP2D6','CYP2D6 poor metabolizers','Clinical Pharmacology'),('Trametinib','Oncology','BRAF','BRAF V600E/K mutation positive','Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies, Patient Counseling Information'),('Trastuzumab','Oncology','ERBB2','HER2 protein overexpression positive','Indications and Usage, Warnings and Precautions, Clinical Pharmacology, Clinical Studies'),('Tretinoin','Oncology','PML/RARA','PML/RAR translocation positive','Clinical Pharmacology, Indications and Usage, Warnings'),('Trimipramine','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Precautions'),('Valproic Acid','Neurology','POLG','POLG mutation positive','Boxed Warning, Contraindications, Warnings and Precautions'),('Valproic Acid','Neurology','NAGS, CPS1, ASS1, OTC, ASL, ABL2','Urea cycle enzyme deficient','Contraindications, Warnings and Precautions'),('Vemurafenib','Oncology','BRAF','BRAF V600E mutation positive','Indications and Usage, Dosage and Administration, Warning and Precautions, Clinical Pharmacology, Clinical Studies, Patient Counseling Information'),('Venlafaxine','Psychiatry','CYP2D6','CYP2D6 poor metabolizers','Precautions'),('Voriconazole','Infectious Diseases','CYP2C19','CYP2C19 intermediate or poor metabolizers','Clinical Pharmacology'),('Vortioxetine','Neurology','CYP2D6','CYP2D6 poor metabolizers','Dosage and Administration, Clinical Pharmacology'),('Warfarin','Cardiology or Hematology','CYP2C9','CYP2C9 intermediate or poor metabolizers','Dosage and Administration, Drug Interactions, Clinical Pharmacology'),('Warfarin','Cardiology or Hematology','VKORC1','VKORC1 A allele carriers','Dosage and Administration, Clinical Pharmacology'),('Warfarin','Cardiology, Hematology','PROS','Protein S deficient','Warnings and Precautions'),('Warfarin','Cardiology, Hematology','PROC','Protein C deficient','Warnings and Precautions');
/*!40000 ALTER TABLE `fda_drug` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `fda_table`
--

DROP TABLE IF EXISTS `fda_table`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `fda_table` (
  `RSID` varchar(20) DEFAULT NULL,
  `Alleles` varchar(7) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `Drug` varchar(60) DEFAULT NULL,
  `System` varchar(100) DEFAULT NULL,
  `subSystem` varchar(100) DEFAULT NULL,
  `drugID` varchar(30) DEFAULT NULL,
  `info` text CHARACTER SET utf8,
  `Level` varchar(10) DEFAULT NULL,
  `Efficacy` varchar(20) DEFAULT NULL,
  `Dosage` varchar(20) DEFAULT NULL,
  `Toxicity` varchar(20) DEFAULT NULL,
  `Genotype` varchar(10) DEFAULT NULL,
  `Sentence` text
) ENGINE=MyISAM DEFAULT CHARSET=latin1 ROW_FORMAT=DYNAMIC;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `fda_table`
--

LOCK TABLES `fda_table` WRITE;
/*!40000 ALTER TABLE `fda_table` DISABLE KEYS */;
INSERT INTO `fda_table` VALUES ('rs1799732','- > G','DRD2','aripiprazole','NERVOUS SYSTEM','PSYCHOLEPTICS','DB01238','Aripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.[DrugBank]','Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1799732','- > G','DRD2','aripiprazole','NERVOUS SYSTEM','PSYCHOLEPTICS','DB01238','Aripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.[DrugBank]','Level 3','increased','-','-','G/del','                Patients with the G/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with these alleles and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1142345','T > C','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CT','                Patients with the CT genotype  1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1142345','T > C','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CG','                Patients with the CG genotype (e.g. TPMT*1/*2): may have increased deactivation of thiopurines and a decreased, but not absent, risk for toxicity with thiopurine drugs as compared to patients with the GG genotype (TPMT*2/*2) or may have decreased deactivation of thiopurines and an increased risk for toxicity with thiopurine drugs as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1127354','C > A','DDRGK1','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 3','increased','-','-','AC','                Patients with the AC genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1127354','C > A','DDRGK1','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 3','increased','-','-','AA','                Patients with the AA genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AA genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1127354','C > A','DDRGK1','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 3','decreased','-','-','AC','                Patients with the AC genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1127354','C > A','DDRGK1','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 3','decreased','-','-','AA','                Patients with the AA genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1801131','T > G','MTHFR','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','GT','                Patients with the GT genotype may have increased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to capecitabine.'),('rs1801131','T > G','MTHFR','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','GG','                Patients with the GG genotype may have increased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to capecitabine.'),('rs2297595','T > C','DPYD','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','CT','                Patients with the CT genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs2297595','T > C','DPYD','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1045642','A > G','ABCB1','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 3','-','-','increased','AG','                Patients with AG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.'),('rs1045642','A > G','ABCB1','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 3','-','-','increased','GG','                Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.'),('rs3812718','C > T','SCN1A','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 2B','-','increased','-','CT','                Patients with the CT genotype who are treated with carbamazepine may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine.'),('rs3812718','C > T','SCN1A','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 2B','-','increased','-','TT','                Patients with the TT genotype who are treated with carbamazepine may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine.'),('rs2844682','G > A','MUC21','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased but not absent risk of Stevens-Johnson syndrome when treated with carbamazepine as compared to patients with the AG or GG genotypes. This variant is a tagging SNP for HLA-B*1502, for which there is greater evidence of association with carbamazepine associated Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1800629','G > A','LST1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 3','-','-','increased','AA','                Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients chance of adverse response.'),('rs2227956','G > A','HSPA1A','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 3','-','-','increased','AA','                Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients chance of adverse response.'),('rs3909184','G > C','FLOT1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 1B','-','-','decreased','CC','                Patients with the CC genotype (non-carriers of the HLA-B*1502 allele) who are treated with carbamazapine may have a decreased risk of Stevens-Johnson Syndrome as compared to patients with the GG or CG genotype (patients who carry the HLA-B*1502 allele). Please note, this SNP is used as a tagging SNP for the HLA-B*1502 allele, and the genotyping method used to determine the HLA-B*1502 allele was not described. Other genetic and clinical factors may also influence a patients risk for adverse drug reactions when treated with carbamazapine.'),('rs1051740','T > C','EPHX1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 2B','-','increased','-','CT','                Patients with the CT genotype and Epilepsy who are treated with carbamazepine may have an increased dose of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to carbamazepine.'),('rs1051740','T > C','EPHX1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 2B','-','increased','-','CC','                Patients with the CC genotype and Epilepsy who are treated with carbamazepine may have an increased dose of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to carbamazepine.'),('rs2234922','A > G','EPHX1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 2B','-','increased','-','AG','                Patients with the AG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of carbamazepine.'),('rs2234922','A > G','EPHX1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 2B','-','increased','-','GG','                Patients with the GG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of carbamazepine.'),('rs750332','C > T','BAT2','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 3','-','-','decreased','TT','                Patients with the TT genotype who are treated with carbamazepine may have a decreased, but not absent, risk of Stevens-Johnson syndrome as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients risk for Stevens-Johnson syndrome with carbamazepine treatment.'),('rs2273697','G > A','ABCC2','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 3','-','-','increased','AG','                Patients with the AG genotype and epilepsy who are treated with carbamazepine 1) may have an increased risk for neurological adverse events 2) may have increased likelihood of response to antiepileptic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs2273697','G > A','ABCC2','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 3','-','-','increased','AA','                Patients with the AA genotype and epilepsy who are treated with carbamazepine 1) may have an increased risk for neurological adverse events 2) may have increased likelihood of response to antiepileptic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs1045642','A > G','ABCB1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 4','-','increased','-','AG','                Patient with genotype AG may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine.'),('rs1045642','A > G','ABCB1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 4','-','decreased','-','GG','                Patient with genotype GG may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine...'),('rs2032582','A > C','ABCB1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 3','increased','-','-','CC','                Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patients response to carbamazepine.'),('rs1042714','G > C','ADRB2','carvedilol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB01136','Carvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-1 adrenergic receptors.','Level 3','decreased','-','-','CC','                Patients with the CC genotype and heart failure may be less likely to have improved left ventricular ejection fraction after carvedilol treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1801253','G > C','ADRB1','carvedilol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB01136','Carvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-2 adrenergic receptors.','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','carvedilol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB01136','Carvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-3 adrenergic receptors.','Level 3','increased','-','-','CC','                Patients with the CC genotype 1) may have an increased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have a decreased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','carvedilol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB01136','Carvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-4 adrenergic receptors.','Level 3','decreased','-','increased','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','-','increased','CC','                Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','decreased','-','AC','                Patients with the AC genotype may have reduced metabolism of celecoxib and may require dose reduction when starting celecoxib therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','decreased','-','CC','                Patients with the CC genotype may have greatly reduced metabolism of celecoxib and may require dose reduction (50% of standard starting dose) when starting celecoxib therapy or alternative management in juvenile rheumatoid arthritis patients who carry this genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1799853','C > T','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 3','decreased','-','-','CT','                Patients with the CT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1799853','C > T','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs396991','A > C','FCGR3A','cetuximab','VARIOUS','','','Cetuximab (Erbitux) is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is manufactured and distributed in the United States by the drug companies Bristol-Myers Squibb and Eli Lilly and Company and in Europe by the drug company Merck KGaA.','Level 2B','decreased','-','-','CC','                Patients with the CC genotype with Colorectal Cancer who are treated with cetuximab may have poorer response and treatment outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to therapy.'),('rs2227983','G > A','EGFR','cetuximab','VARIOUS','','','Cetuximab (Erbitux) is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is manufactured and distributed in the United States by the drug companies Bristol-Myers Squibb and Eli Lilly and Company and in Europe by the drug company Merck KGaA.','Level 3','-','-','decreased','AG','                Patients with the AG genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2227983','G > A','EGFR','cetuximab','VARIOUS','','','Cetuximab (Erbitux) is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is manufactured and distributed in the United States by the drug companies Bristol-Myers Squibb and Eli Lilly and Company and in Europe by the drug company Merck KGaA.','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs4444903','A > G','EGF','cetuximab','VARIOUS','','','Cetuximab (Erbitux) is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is manufactured and distributed in the United States by the drug companies Bristol-Myers Squibb and Eli Lilly and Company and in Europe by the drug company Merck KGaA.','Level 2B','increased','-','-','GG','                Patients with the GG genotype who are treated with cetuximab may have a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to cetuximab treatment.'),('rs25487','T > C','XRCC1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','increased','-','increased','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs2228001','G > T','XPC','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','decreased','TT','                Patients with the TT genotype may have a decreased but not non-existent risk for toxicity with cisplatin treatment as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1142345','T > C','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CT','                Patients with the TC genotype who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1142345','T > C','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs12201199','A > T','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','AT','                Patients with the AT genotype may have increased risk for hearing loss with cisplatin treatment compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs12201199','A > T','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for hearing loss with cisplatin treatment compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CT','                Patients with the TC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1800460','C > T','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','TT','                Patients with the TT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1042522','C > G','TP53','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1042522','C > G','TP53','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','increased','-','decreased','CC','                Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs316019','A > C','SLC22A2','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1805087','A > G','MTR','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','GG','                Patients with the GG genotype may have increased likelihood of Drug Toxicity when treated with cisplatin in people with Osteosarcoma as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence a patients risk for toxicity to cisplatin.'),('rs1801133','G > A','MTHFR','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','increased','AA','                Patients with the AA genotype may have: 1) increased likelihood of response to chemotherapy, 2) increased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotypes AG or GG. Other genetic and clinical factors may also influence a patients response to cisplatin.'),('rs2075252','T > C','LRP2','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','decreased','CC','                Patients with the CC genotype treated with cisplatin may have a reduced but not non-existent risk for hearing loss as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs3957357','A > G','GSTA1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.'),('rs9679162','G > T','GALNT14','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','TT','                Patients with the TT genotype may have increased response, including increased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs13181','T > G','ERCC2','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with platinum compounds as compared to patients with the GT or TT genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.'),('rs1799793','C > T','ERCC2','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','CT','                Patients with the CT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of overall survival  as compared to patients with the CC genotype. Genotype CT is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide. Both findings have been contradicted in another studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1799793','C > T','ERCC2','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','TT','                Genotype TT is not associated with increased risk of Drug Toxicity or decreased progression-free or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.'),('rs1799793','C > T','ERCC2','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have 1) increased survival and 2) increased risk for hematological toxicity with cisplatin regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to cisplatin regimens.'),('rs1799793','C > T','ERCC2','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','TT','                Patients with the TT genotype may have increased survival with cisplatin regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to cisplatin regimens.'),('rs3212986','C > A','ERCC1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk for nephrotoxicity with platinum-based regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs11615','A > G','ERCC1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs11615','A > G','ERCC1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','decreased','GG','                Patients with the GG genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs11615','A > G','ERCC1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the AG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients risk for adverse events with cisplatin and cyclophosphamide treatment.'),('rs4646316','C > T','COMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','decreased','TT','                Patients with the TT genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk of hearing loss as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs9332377','C > T','COMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','increased','CT','                Patients with the CT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs9332377','C > T','COMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','increased','TT','                Patients with the TT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs9597','C > G','BAIAP3','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to cisplatin and irinotecan treatment.'),('rs9597','C > G','BAIAP3','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','GG','                Patients with the GG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype, although the GG genotype was not observed in the supporting study. Other genetic and clinical factors may also influence a patients response to cisplatin and irinotecan treatment.'),('rs1045642','A > G','ABCB1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1045642','A > G','ABCB1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have better response (decreased risk of lymph node metastases and increased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs2227631','A > G','SERPINE1','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs2227631','A > G','SERPINE1','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs1799889','A > G','SERPINE1','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs1799889','A > G','SERPINE1','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs7997012','A > G','HTR2A','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs334558','A > G','GSK3B','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','increased','-','-','GG','                Patients with the GG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have more improvement in symptoms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients response to fluoxetine and citalopram.'),('rs1954787','T > C','GRIK4','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 1B','increased','-','-','CT','                Patients with the CT genotype may have an increased chance of response to citalopram treatment as compared to patients with the TT genotype. Patients with the CT genotype may still be at risk for non-response to citalopram treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1954787','T > C','GRIK4','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 1B','increased','-','-','CC','                Patients with the CC genotype may have an increased chance of response to citalopram treatment as compared to patients with the TT genotype. Patients with the CC genotype may still be at risk for non-response to citalopram treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs7569963','G > A','CREB1','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs7569963','G > A','CREB1','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','decreased','-','-','AA','                Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1360780','T > C','FKBP5','clomipramine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01242 ','Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. ','Level 3','-','-','decreased','CC','                Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to paroxetine, venlafaxine, clomipramine or nefazodone.'),('rs662','T > C','PON1','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 3','increased','-','-','CC','                Patients with the CC genotype who are treated with clopidogrel 1) may have higher levels of active metabolite, resulting in increased platelet inhibition and better response 2) may have a decreased, but not absent, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CT or TT genotype. This association has not been found in more studies than the number of studies the association was shown. Other genetic and clinical factors may also influence a patients response to clopidogrel.'),('rs4244285','G > A','CYP2C19','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 1A','decreased','-','-','AG','                Patients with the AG genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for secondary cardiovascular events and response to clopidogrel.'),('rs4244285','G > A','CYP2C19','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 1A','decreased','-','-','AA','                Patients with the AA genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for secondary cardiovascular events and response to clopidogrel.'),('rs1045642','A > G','ABCB1','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 2A','increased','-','-','GG','                People with GG  genotype may have decreased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Other genetic and clinical factors may also impact the response to clopidogrel.'),('rs1414334','C > G','HTR2C','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 1B','-','-','decreased','GG','                Patients with the GG genotype who are treated with antipsychotics may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patients risk for developing metabolic syndrome.'),('rs742105','C > T','DTNBP1','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','increased','-','-','CT','                Patients with the CT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients response to clozapine.'),('rs742105','C > T','DTNBP1','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','increased','-','-','TT','                Patients with the TT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients response to clozapine.'),('rs6280','C > T','DRD3','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','increased','-','-','TT','                Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a better response to treatment as compared to patients with the CC or CT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patients response to clozapine treatment.'),('rs1079598','A > G','DRD2','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1079598','A > G','DRD2','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','-','-','increased','GG','                Patients with the GG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1799732','- > G','DRD2','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1799732','- > G','DRD2','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','increased','-','-','G/del','                Patients with the G/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with these alleles and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs6277','G > A','DRD2','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased, but not absent risk, for weight gain when treated with clozapine or olanzepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1800497','G > A','ANKK1','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1800497','G > A','ANKK1','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 2B','-','-','increased','AA','                Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs61888800','G > T','BDNF','desipramine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01151 ','Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation.','Level 3','decreased','-','-','GT','                Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.'),('rs61888800','G > T','BDNF','desipramine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01151 ','Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation.','Level 3','decreased','-','-','TT','                Patients with the TT genotype with major depressive disorder may experience a  lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.'),('rs2227983','G > A','EGFR','erlotinib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00530 ','Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.','Level 3','-','-','decreased','AG','                Patients with the AG genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2227983','G > A','EGFR','erlotinib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00530 ','Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs712829','G > T','EGFR','erlotinib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00530 ','Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.','Level 3','-','-','decreased','GT','                Patients with the GT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.'),('rs712829','G > T','EGFR','erlotinib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00530 ','Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.','Level 3','-','-','decreased','TT','                Patients with the TT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.'),('rs712829','G > T','EGFR','erlotinib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00530 ','Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.','Level 4','increased','-','-','GT','                Patients with the GT genotype may be more sensitive to treatment with erlotinib  compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.'),('rs712829','G > T','EGFR','erlotinib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00530 ','Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.','Level 4','increased','-','-','TT','                Patients with the TT genotype may be more sensitive to treatment with erlotinib  compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.'),('rs25487','T > C','XRCC1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','CC','                Patients with the CC genotype may have increased response to fluorouracil-containing chemotherapy regimens as compared to patients with the CT or TT genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.'),('rs1801019','G > C','UMPS','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','increased','CC','                Patients with CC genotype and cancer may have an increased risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and  leucovorin as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to leucovorin, tegafur and fluorouracil.'),('rs1042522','C > G','TP53','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1042522','C > G','TP53','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','decreased','CC','                Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1799983','T > G','NOS3','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','GT','                Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs1799983','T > G','NOS3','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs2070744','C > T','NOS3','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','-','CT','                Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs2070744','C > T','NOS3','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','-','TT','                Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence disease-free survival.'),('rs1801131','T > G','MTHFR','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GT','                Patients with the GT genotype may have decreased risk of Drug Toxicity when treated with fluorouracil and radiotherapy in people with Rectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1801131','T > G','MTHFR','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk of Drug Toxicity when treated with fluorouracil and radiotherapy in people with Rectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1801133','G > A','MTHFR','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','AG','                Patients with the AG genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1801133','G > A','MTHFR','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','AA','                Patients with the AA genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the GG genotype. However, conflicting finding of no-association for this genotype has also been reported. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','increased','-','-','GG','                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','AG','                Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for hematological toxicity when exposed to fluorouracil.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hematological toxicity when exposed to flourouracil.'),('rs9679162','G > T','GALNT14','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','TT','                Patients with the TT genotype may have increased response, including increased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs13181','T > G','ERCC2','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','GT','                Patients with the GT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity as compared to patients with the TT genotype 2) an increased risk of early relapse as compared to patients with the TT genotype. However, a trend of an association is found for the GT genotype with increased progression free survival compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil, leucovorin and oxaliplatin.'),('rs13181','T > G','ERCC2','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','GG','                Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity 2) an increased risk of early relapse and 3) decreased progression free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil, leucovorin and oxaliplatin.'),('rs1801158','C > T','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','CT','                Patients with the CT genotype may have an increased risk of fluorouracil-related toxicity in cancer patients as compared to patients with the CC genotype. Genotype CT is also associated with decreased DPYD activity. Other genetic and clinical factors may also influence a patients risk of fluorouracil-related toxicity.'),('rs1801158','C > T','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk of fluorouracil-related toxicity in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of fluorouracil-related toxicity.'),('rs1801159','T > C','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased likelihood of middle-severe nausea,  vomiting and white blood cell decreases in cancer patients treated with fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk of fluorouracil  related adverse events.'),('rs1801159','T > C','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased likelihood of middle-severe nausea,  vomiting and white blood cell decreases in cancer patients treated with fluorouracil as compared to patients with the TT genotype. Genotype CC is also associated with decreased clearance of fluorouracil. Other genetic and clinical factors may also influence a patients risk of fluorouracil  related adverse events.'),('rs1801265','G > A','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased likelihood of middle-severe nausea and vomiting in Asian cancer patients treated with fluorouracil as as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patients risk for fluorouracil-related toxicity.'),('rs2297595','T > C','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','CT','                Patients with the CT genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs2297595','T > C','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs67376798','T > A','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','AT','                Patients with the AT genotype and Cancer who are treated with fluorouracil-containing regimens 1) may have decreased clearance of the drug 2) may have an increased risk and severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for fluorouracil-induced toxicity.'),('rs67376798','T > A','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','AA','                Patients with the AA genotype were not reported, however, patients with the AT genotype and Cancer who are treated with fluorouracil-containing regimens 1) may have decreased clearance of the drug 2) may have an increased risk and severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for fluorouracil-induced toxicity.'),('rs9561778','G > T','ABCC4','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','GT','                Patients with the GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for ADRs.'),('rs9561778','G > T','ABCC4','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for ADRs.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','AG','                Patients with the AG genotype may have better response (decreased risk of lymph node metastases and increased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with GG genotype may have decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also impact a patients response to fluorouracil.'),('rs25531','T > C','SLC6A4','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 4','decreased','-','-','CT','                Patients with the CT genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT.  Other genetic and clinical factors may also influence a patients response.'),('rs25531','T > C','SLC6A4','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 4','decreased','-','-','CC','                Patients with the CC genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT.  Other genetic and clinical factors may also influence a patients response.'),('rs2227631','A > G','SERPINE1','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs2227631','A > G','SERPINE1','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs1799889','A > G','SERPINE1','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs1799889','A > G','SERPINE1','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs334558','A > G','GSK3B','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 3','increased','-','-','GG','                Patients with the GG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have more improvement in symptoms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients response to fluoxetine and citalopram.'),('rs61888800','G > T','BDNF','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 3','decreased','-','-','GT','                Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.'),('rs61888800','G > T','BDNF','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 3','decreased','-','-','TT','                Patients with the TT genotype with major depressive disorder may experience a  lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.'),('rs10042486','C > T','HTR1A','fluvoxamine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00176 ','Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.','Level 3','decreased','-','-','CT','                Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs10042486','C > T','HTR1A','fluvoxamine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00176 ','Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.','Level 3','decreased','-','-','TT','                Patients with the TT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment  as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs6295','C > G','HTR1A','fluvoxamine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00176 ','Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs6295','C > G','HTR1A','fluvoxamine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00176 ','Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.','Level 3','increased','-','-','GG','                Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs7142881','G > A','NUBPL','iloperidone','VARIOUS','','','Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.','Level 3','-','-','increased','AG','                Patients with the AG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs7142881','G > A','NUBPL','iloperidone','VARIOUS','','','Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.','Level 3','-','-','increased','AA','                Patients with the AA genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs4933824','T > G','NRG3','iloperidone','VARIOUS','','','Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.','Level 3','-','-','increased','GG','                Patients with the GG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the TT or GT genotype.  Other genetic and clinical factors may also influence a patients response.'),('rs4799915','C > T','CELF4','iloperidone','VARIOUS','','','Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.','Level 3','-','-','increased','CT','                Patients with the CT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs4799915','C > T','CELF4','iloperidone','VARIOUS','','','Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.','Level 3','-','-','increased','TT','                Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs4124874','T > G','UGT1A1','irinotecan','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00762 ','Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I.','Level 3','-','-','increased','GT','                Patients with the GT genotype and Cancer who are treated with irinotecan may have an increased risk of Neutropenia as compared to patients with the TT genotype, or may have a decreased risk of Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs4124874','T > G','UGT1A1','irinotecan','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00762 ','Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I.','Level 3','-','-','increased','GG','                Patients with the GG genotype and Cancer who are treated with irinotecan may have an increased risk of Neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs9597','C > G','BAIAP3','irinotecan','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00762 ','Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to cisplatin and irinotecan treatment.'),('rs9597','C > G','BAIAP3','irinotecan','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00762 ','Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I.','Level 3','increased','-','-','GG','                Patients with the GG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype, although the GG genotype was not observed in the supporting study. Other genetic and clinical factors may also influence a patients response to cisplatin and irinotecan treatment.'),('rs4646','A > C','CYP19A1','letrozole','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00762 ','Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I.','Level 3','decreased','-','-','CC','                Patients with the CC genotype who are treated with letrozole may have decreased treatment efficacy compared to patients with the AA or AC genotype.  Other genetic and clinical factors may also influence a patients response.'),('rs1142345','T > C','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CT','                Patients with the CT genotype  1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1142345','T > C','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CG','                Patients with the CG genotype (e.g. TPMT*1/*2): may have increased deactivation of thiopurines and a decreased, but not absent, risk for toxicity with thiopurine drugs as compared to patients with the GG genotype (TPMT*2/*2) or may have decreased deactivation of thiopurines and an increased risk for toxicity with thiopurine drugs as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800584','C > T','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CT','                Patients with the CT genotype who are treated with standard doses of mercaptopurine   may be at  increased risk for life-threatening myelosuppression as compared to patients with the CC genotype.   Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1800584','C > T','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','TT','                Patients with the TT genotype who are treated with standard doses of mercaptopurine may be at  increased risk for life-threatening myelosuppression as compared to patients with the CC genotype.   Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1051266','T > C','SLC19A1','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 3','increased','-','-','CC','                Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) increased likelihood of Toxic liver disease 2) decreased, but not absent, risk of Drug Toxicity 3) decreased likelihood of treatment interruptions as compared to patients with the CT and TT genotype. Further, patients with the CC genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patients response to leucovorin, mercaptopurine and methotrexate.'),('rs1051266','T > C','SLC19A1','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 3','-','-','increased','CT','                Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) decreased, but not absent, risk of Toxic liver disease 2) increased risk of Drug Toxicity 3) increased likelihood of treatment interruptions as compared to patients with the CC genotype. Further, patients with the CT genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patients response to leucovorin, mercaptopurine and methotrexate.'),('rs1801133','G > A','MTHFR','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 3','-','-','-','AG','                Patients with the AG genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patients risk for toxicity to mercaptopurine.'),('rs1801133','G > A','MTHFR','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 3','-','-','-','AA','                Patients with the AA genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patients risk for toxicity to mercaptopurine.'),('rs3892097','C > T','CYP2D6','metoprolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','increased','-','-','CT','                Patients with CT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patients response to metoprolol. Please check other variants for PM phenotype.'),('rs3892097','C > T','CYP2D6','metoprolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','increased','-','-','TT','                Patients with TT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with CC genotype.  Other genetic and clinical factors may also influence a patients response to metoprolol. Please check other variants for PM phenotype.'),('rs1801253','G > C','ADRB1','metoprolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','metoprolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','metoprolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','increased','-','-','CC','                Patients with the CC genotype 1) may have an increased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have a decreased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','metoprolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','decreased','-','increased','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1360780','T > C','FKBP5','nefazodone','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01149 ','Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to paroxetine, venlafaxine, clomipramine or nefazodone.'),('rs1045642','A > G','ABCB1','nortriptyline','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00540 ','Nortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for postural hypotension with nortriptyline treatment.'),('rs1045642','A > G','ABCB1','nortriptyline','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00540 ','Nortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for postural hypotension with nortriptyline treatment.'),('rs11188072','C > T','CYP2C19','omeprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00338 ','A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles','Level 2A','-','increased','-','TT','                Adult patients, but not pediatric patients, with the TT genotype who are treated with omeprazole may require an increased dose as compared to patients with the CT or CC genotype.  Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration. This might not be applicable to pediatric patients.'),('rs11188072','C > T','CYP2C19','pantoprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00213 ','Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.','Level 3','-','increased','-','CT','                Patients with the CT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs11188072','C > T','CYP2C19','pantoprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00213 ','Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs10042486','C > T','HTR1A','paroxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00726 ','Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]','Level 3','decreased','-','-','CT','                Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs10042486','C > T','HTR1A','paroxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00726 ','Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]','Level 3','decreased','-','-','TT','                Patients with the TT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment  as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs6295','C > G','HTR1A','paroxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00726 ','Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs1360780','T > C','FKBP5','paroxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00726 ','Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]','Level 3','-','-','decreased','CC','                Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to paroxetine, venlafaxine, clomipramine or nefazodone.'),('rs11042725','C > A','ADM','paroxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00726 ','Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]','Level 3','increased','-','-','AC','                Patients with the AC genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to paroxetine.'),('rs11042725','C > A','ADM','paroxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00726 ','Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]','Level 3','increased','-','-','AA','                Patients with the AA genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to paroxetine.'),('rs12979860','C > T','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs12979860','C > T','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','TT','                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GT','                Patients with the  GT genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs8099917','T > G','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs9657182','C > T','IDO1','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 3','-','-','decreased','CT','                Patients with the CT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patients risk for drug side effects.'),('rs9657182','C > T','IDO1','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 3','-','-','decreased','TT','                Patients with the TT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patients risk for drug side effects.'),('rs2842030','G > T','RGS4','perphenazine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00850 ','An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. [PubChem]','Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients response to perphanazine.'),('rs951439','C > T','RGS4','perphenazine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00850 ','An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. [PubChem]','Level 3','increased','-','-','CT','                Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs951439','C > T','RGS4','perphenazine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00850 ','An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. [PubChem]','Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may have increased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs3812718','C > T','SCN1A','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 2B','-','increased','-','CT','                Patients with the CT genotype who are treated with phenytoin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.'),('rs3812718','C > T','SCN1A','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 2B','-','increased','-','TT','                Patients with the TT genotype who are treated with phenytoin may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.'),('rs1051740','T > C','EPHX1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','decreased','CC','                Patients with the CC genotype who use phenytoin during the first trimester of pregnancy may be less likely to have a child with a craniofacial abnormality as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk of having a child with a craniofacial abnormality.'),('rs2234922','A > G','EPHX1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','AG','                Patients with the AG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2234922','A > G','EPHX1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','GG','                Patients with the GG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1057910','A > C','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1057910','A > C','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','CC','                Patients with the CC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1799853','C > T','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','CT','                Patients with the CT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1799853','C > T','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','TT','                Patients with the TT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','-','AG','                Patients with genotype AG may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patients dose of phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','decreased','-','-','AG','                Patients with genotype AG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians. Other genetic or clinical factors may influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','decreased','-','-','GG','                Patients with genotype GG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians.  Other genetic or clinical factors may influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','increased','-','GG','                Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patients dose of phenytoin.'),('rs2306283','A > G','SLCO1B1','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have decreased plasma AUC of pravastatin as compared to patients with the AA genotype.'),('rs2306283','A > G','SLCO1B1','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased plasma AUC of pravastatin as compared to patients with the AA genotype.'),('rs4149015','G > A','SLCO1B1','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 2A','decreased','-','-','AG','                Patients carrying the AG genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs4149015','G > A','SLCO1B1','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 2A','decreased','-','-','AA','                Patients carrying the AA genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. This variant is part of the SLCO1B1*17 haplotype. Other genetic and clinical factors may also influence a patients response.'),('rs20455','A > G','KIF6','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have an increased risk for adverse cardiovascular events (myocardial infarction and coronary heart diseases) as compared to patients with the AA genotype. Pravastatin treatment substantially reduced that risk. Other genetic and clinical factors may also influence a patients risk for adverse cardiovascular events.'),('rs20455','A > G','KIF6','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 2B','-','-','increased','GG','                Patients with the GG genotype may have an increased risk for adverse cardiovascular events (myocardial infarction and coronary heart diseases) as compared to patients with the AA genotype. Pravastatin treatment substantially reduced that risk. Other genetic and clinical factors may also influence a patients risk for adverse cardiovascular events.'),('rs1935349','C > T','HTR7','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for statin-related myalgia as compared to patients with the CC genotypes, or may have a decreased risk for statin-related myalgia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs1935349','C > T','HTR7','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for statin-related myalgia as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs2276307','A > G','HTR3B','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for myalgia.'),('rs2276307','A > G','HTR3B','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','-','-','increased','GG','                Patients with the GG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patients risk for myalgia.'),('rs17238540','T > G','HMGCR','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','decreased','-','-','GT','                Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17238540','T > G','HMGCR','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','decreased','-','-','GG','                Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17244841','A > T','HMGCR','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs5443','C > T','GNB3','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 4','increased','-','-','CT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs5443','C > T','GNB3','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 4','increased','-','-','TT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs1050828','C > T','G6PD','primaquine','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS','ANTIPROTOZOALS','DB01087 ','An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide','Level 3','-','-','increased','CT','                Pediatric patients with the CT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs1050828','C > T','G6PD','primaquine','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS','ANTIPROTOZOALS','DB01087 ','An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide','Level 3','-','-','increased','TT','                Pediatric patients with the TT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs2661319','T > C','RGS4','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs2842030','G > T','RGS4','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 4','decreased','-','-','GT','                Patients with the GT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs2842030','G > T','RGS4','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 4','decreased','-','-','TT','                Patients with the TT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs951439','C > T','RGS4','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','TT','                Patients with the TT genotype may have increased chance of response to risperidone as compared to patients with CC or CT genotypes. Other genetic and clinical factors may also influence a patients chance of response to risperidone.'),('rs7799039','G > A','LEP','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','increased','AG','                Patients with the AG genotype may have excessive risperidone-associated weight gain in youths as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs7799039','G > A','LEP','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','increased','AA','                Patients with the AA genotype may have excessive risperidone-associated weight gain in youths as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1414334','C > G','HTR2C','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 1B','-','-','decreased','GG','                Patients with the GG genotype who are treated with antipsychotics may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patients risk for developing metabolic syndrome.'),('rs3813928','G > A','HTR2C','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patients response.'),('rs3813928','G > A','HTR2C','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','AA','                Patients with the AA genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patients response.'),('rs6311','C > T','HTR2A','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs6311','C > T','HTR2A','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs6313','G > A','HTR2A','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.'),('rs6313','G > A','HTR2A','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','AA','                Patients with the AA genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.'),('rs724226','A > G','GRM3','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','AG','                Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs724226','A > G','GRM3','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','GG','                Patients with the GG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs167771','G > A','DRD3','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AG or GG genotype. Patients with the AA genotype may still be at risk for toxicity when taking risperidone. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs6280','C > T','DRD3','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patients response.'),('rs6280','C > T','DRD3','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have smaller reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating poorer response to risperidone in Children with Autism, than TT homozygotes compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patients response.'),('rs1799732','- > G','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 2A','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the TC And TT genotype.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs165599','G > A','COMT','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs165599','G > A','COMT','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','AA','                Patients with the AA genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs1800497','G > A','ANKK1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1800497','G > A','ANKK1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 2B','-','-','increased','AA','                Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1800497','G > A','ANKK1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','AG','                Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the GG genotype or may have less improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs1800497','G > A','ANKK1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','AA','                Patients with the AA genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs2494732','T > C','AKT1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','CT','                Patients with the CT genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs2494732','T > C','AKT1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs3803300','T > C','AKT1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 4','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the CT or GG genotype. Please note this did not reach statistical significance. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs1128503','A > G','ABCB1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patients response.'),('rs1128503','A > G','ABCB1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have poorer response to risperidone in Children with Autism, than patients with AG or GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs396991','A > C','FCGR3A','rituximab','VARIOUS','','','Rituximab (trade names Rituxan, MabThera and Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.','Level 2B','increased','-','-','AC','                Lymphoma patients with the AC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to rituximab.'),('rs396991','A > C','FCGR3A','rituximab','VARIOUS','','','Rituximab (trade names Rituxan, MabThera and Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.','Level 2B','increased','-','-','CC','                Lymphoma patients with the CC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to rituximab.'),('rs4986938','C > T','ESR2','tamoxifen','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ENDOCRINE THERAPY','DB00675','One of the selective estrogen receptor modulators (SERM) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer.','Level 3','-','-','-','CT','                Patients with the CT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the  CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.'),('rs4986938','C > T','ESR2','tamoxifen','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ENDOCRINE THERAPY','DB00675','One of the selective estrogen receptor modulators (SERM) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer.','Level 3','-','-','-','TT','                Patients with the TT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the  CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.'),('rs9340799','A > G','ESR1','tamoxifen','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ENDOCRINE THERAPY','DB00675','One of the selective estrogen receptor modulators (SERM) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer.','Level 3','-','-','-','GG','                The GG genotype carriers had larger tamoxifen-induced decrease in total cholesterol in postmenopausal woman compared to GA/AA genotypes (P=0.03; GG vs GA/AA) and tamoxifen-induced increase in triglycerides (P=0.002; gene-dose effect) and decrease in high density lipoprotein (P=0.004; gene-dose effect) in premenopausal women.'),('rs1142345','T > C','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CT','                Patients with the CT genotype  1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1142345','T > C','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CG','                Patients with the CG genotype (e.g. TPMT*1/*2): may have increased deactivation of thiopurines and a decreased, but not absent, risk for toxicity with thiopurine drugs as compared to patients with the GG genotype (TPMT*2/*2) or may have decreased deactivation of thiopurines and an increased risk for toxicity with thiopurine drugs as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1136201','A > G','ERBB2','trastuzumab','VARIOUS','','','Topoisomerase inhibitors are agents designed to interfere with the action of topoisomerase enzymes[1] (topoisomerase I and II), which are enzymes that control the changes in DNA structure[2] by catalyzing the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle.','Level 3','-','-','increased','AG','                Patients with the AG genotype may have increased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of toxicity.'),('rs7439366','T > C','UGT2B7','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','decreased','-','-','CT','                Healthy individuals with the CT genotype who are treated with valproic acid and lorazepam may have poorer responses in psychocognitive function tests as compared to those with the TT genotype or may have better responses in psychocognitive function tests as compared to patients with the CC genotype. Other genetic and clinical factors may also influence an individuals response to valproic acid and lorazepam treatment.'),('rs7439366','T > C','UGT2B7','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','decreased','-','-','CC','                Healthy individuals with the CC genotype who are treated with valproic acid and lorazepam may have poorer responses in psychocognitive function tests as compared to those with the TT genotype. Other genetic and clinical factors may also influence an individuals response to valproic acid and lorazepam treatment.'),('rs1105879','A > C','UGT1A6','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','AC','                Patients with the AC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs1105879','A > C','UGT1A6','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','CC','                Patients with the CC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs2070959','A > G','UGT1A10','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','AG','                Patients with the AG genotype may require an increased dose of valproic acid compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs2070959','A > G','UGT1A10','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','GG','                Patients with the GG genotype may require an increased dose of valproic acid compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs6759892','T > G','UGT1A10','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','GT','                Patients with the GT genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients valproic acid dose requirement.'),('rs6759892','T > G','UGT1A10','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsa','Level 3','-','increased','-','GG','                Patients with the GG genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT and GT genotype. Other genetic and clinical factors may also influence a patients valproic acid dose requirement.'),('rs1057910','A > C','CYP2C9','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs1057910','A > C','CYP2C9','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','-','increased','CC','                Patients with the CC genotype were not studied. However, patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs10879346','C > T','TPH2','venlafaxine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with antidepressants may have less improvement in symptoms as compared to patients with the CT and CC genotype.'),('rs1487278','T > C','TPH2','venlafaxine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','increased','-','-','CT','                Patients with the CT genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to antidepressant.'),('rs1487278','T > C','TPH2','venlafaxine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','increased','-','-','CC','                Patients with the CC genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to antidepressant. (The frequency for CC allele is very low, homozygous minor allele carriers were pooled together with the heterozygous samples and compared with the homozygous major allele (T) carrier.)'),('rs1360780','T > C','FKBP5','venlafaxine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to paroxetine, venlafaxine, clomipramine or nefazodone.'),('rs3892097','C > T','CYP2D6','venlafaxine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','-','-','increased','CT','                Patients with the CT genotype who are treated with venlafaxine may have an increased risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to venlafaxine.'),('rs3892097','C > T','CYP2D6','venlafaxine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','-','-','increased','TT','                Patients with the TT genotype who are treated with venlafaxine may have an increased risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to venlafaxine.'),('rs17708472','G > A','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','increased','-','AG','                Patients with the AG genotype: 1) may require a higher dose of warfarin as compared to patients with the GG genotype 2) may have an increased risk of warfarin resistance as compared to patients with the GG genotype.'),('rs17708472','G > A','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','increased','-','AA','                Patients with the AA genotype: 1) may require a higher dose of warfarin as compared to patients with the GG genotype 2) may have an increased risk of warfarin resistance as compared to patients with the GG genotype.'),('rs7294','C > T','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.'),('rs7294','C > T','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.'),('rs9934438','G > A','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','decreased','-','AG','                Patients with the AG genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs9934438','G > A','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs10871454','C > T','STX4','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype.'),('rs10871454','C > T','STX4','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','TT','                Patients with the TT genotype who are treated with warfarin may require the lowest dose as compared to patients with the CT or CC genotype.'),('rs2359612','A > G','PRSS53','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTSANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','increased','-','GG','                Patients with the GG genotype who are treated with warfarin may require a higher dose as compared to patients with the AG or AA genotype.'),('rs8050894','C > G','PRSS53','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','CG','                Patients with the CG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype.'),('rs8050894','C > G','PRSS53','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','GG','                Patients with the GG genotype who are treated with warfarin may require the lowest dose as compared to patients with the CG or CC genotype.'),('rs12714145','C > T','GGCX','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','increased','-','TT','                Genotype TT may be associated with increased dose of warfarin as compared to genotype GG. However, contradictory findings (no association) have been reported. Other genetic and clinical factors may influence a patients dose of warfain.'),('rs2292566','G > A','EPHX1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','AG','                Patients with the AG genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.'),('rs2292566','G > A','EPHX1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','AA','                Patients with the AA genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.'),('rs2108622','C > T','CYP4F2','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs2108622','C > T','CYP4F2','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1799853','C > T','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients dose of warfarin.'),('rs1799853','C > T','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','-','TT','                Patients with the TT genotype who are treated with warfarin may require a lower dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients dose of warfarin.'),('rs28371685','C > T','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a decreased dose as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin.'),('rs28371685','C > T','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','TT','                Patients with the TT genotype who are treated with warfarin may require the lowest does as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin.'),('rs28371686','C > G','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 2A','-','decreased','-','CG','                Patients with the CG genotype who are treated with warfarin may require a decreased dose as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin.'),('rs28371686','C > G','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 2A','-','decreased','-','GG','                Patients with the GG genotype who are treated with warfarin may require the lowest does as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin.'),('rs7900194','G > A','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','AG','                Patients with the AG genotype who are treated with warfarin may require a lower maintenance dose as compared to patients with the GG genotype.'),('rs7900194','G > A','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin may require the lowest maintenance dose as compared to patients with the AG or GG genotype.'),('rs1057910','A > C','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','increased','AC','                Patients with the AC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.'),('rs1057910','A > C','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','increased','CC','                Patients with the CC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.'),('rs339097','A > G','CALU','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 2B','-','increased','-','AG','                Patients with the AG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients warfarin dose.'),('rs339097','A > G','CALU','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 2B','-','increased','-','GG','                Patients with the GG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients warfarin dose.');
/*!40000 ALTER TABLE `fda_table` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `k8masw5vv36x`
--

DROP TABLE IF EXISTS `k8masw5vv36x`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `k8masw5vv36x` (
  `RSID` varchar(20) DEFAULT NULL,
  `Alleles` varchar(7) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `Drug` varchar(60) DEFAULT NULL,
  `System` varchar(60) DEFAULT NULL,
  `subSystem` text,
  `drugID` varchar(60) DEFAULT NULL,
  `info` text,
  `Level` varchar(10) DEFAULT NULL,
  `Efficacy` varchar(20) DEFAULT NULL,
  `Dosage` varchar(20) DEFAULT NULL,
  `Toxicity` varchar(20) DEFAULT NULL,
  `Genotype` varchar(10) DEFAULT NULL,
  `Sentence` text
) ENGINE=InnoDB DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `k8masw5vv36x`
--

LOCK TABLES `k8masw5vv36x` WRITE;
/*!40000 ALTER TABLE `k8masw5vv36x` DISABLE KEYS */;
INSERT INTO `k8masw5vv36x` VALUES ('rs11209716','T > C','PTGER3','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and hypertension who are treated with ACE inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk of cough when treated with ACE inhibitors.'),('rs2016848','G > A','MME','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','increased','AA','                Patients with the AA genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cough with ACE inhibitor treatment.'),('rs8012552','C > T','BDKRB2','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','decreased','TT','                Patients with the TT genotype and hypertension who are treated with ACE-inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of cough with ACE-inhibitors.'),('rs9934438','G > A','VKORC1','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs2108622','C > T','CYP4F2','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 2A','-','decreased','-','CC','                Patients with the CC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs2297480','T > G','FDPS','alendronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00630','Alendronate is a nitrogen-containing, second generation bisphosphonate. Bisphosphonates were first used to treat Pageta?s disease in 1971. This class of medications is comprised of inorganic pyrophosphate analogues that contain non-hydrolyzable P-C-P bonds. Similar to other bisphosphonates, alendronate has a high affinity for bone mineral and is taken up during osteoclast resorption. Alendronate inhibits farnesyl pyrophosphate synthetase, one of the enzymes in the mevalonic acid pathway involved in producing isoprenoid compounds that are essential for post-translational modification of small guanosine triphosphate (GTP)-binding proteins, such as Rho, Ras and Rab. Inhibition of this process interferes with osteoclast function and survival. Alendronate is used for the treatment of osteoporosis and Pageta?s disease','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1056892','G > A','CBR3','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 2B','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1045642','A > G','ABCB1','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs7997012','A > G','HTR2A','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs3800373','C > A','FKBP5','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 2B','decreased','-','-','AA','                Patients with the AA genotype and depression who are treated with antidepressants may be less likely to have improvement in symptoms as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1045642','A > G','ABCB1','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','increased','-','-','GG','                Genotype GG genotype  may be associated with decreased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype AA. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. Theres also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patients response to antiepileptics.'),('rs1057910','A > C','CYP2C9','Antiinflammatory agents, non-steroids','VARIOUS','','','The term nonsteroidal distinguishes these drugs from steroids, which, among a broad range of other effects, have a similar eicosanoid-depressing, anti-inflammatory action. As analgesics, NSAIDs are unusual in that they are non-narcotic and thus are used as a non-addictive alternative to narcotics.','Level 2A','-','-','increased','CC','                Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1042522','C > G','TP53','antineoplastic agents','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','','Inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1801133','G > A','CLCN6','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','increased','AA','                Patients with the AA genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1142345','T > C','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2297480','T > G','FDPS','Bisphosphonates','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs2297595','T > C','DPYD','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1045642','A > G','ABCB1','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 3','-','-','increased','GG','                Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.'),('rs1045642','A > G','ABCB1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 4','-','decreased','-','GG','                Patient with genotype GG may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine...'),('rs1801133','G > A','CLCN6','carboplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00958 ','An organoplatinum compound that possesses antineoplastic activity.','Level 2A','increased','-','increased','AA','                Patients with AA genotype may have 1) increased likelihood of response 2) increased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patients response to carboplatin.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','-','increased','CC','                Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','decreased','-','CC','                Patients with the CC genotype may have greatly reduced metabolism of celecoxib and may require dose reduction (50% of standard starting dose) when starting celecoxib therapy or alternative management in juvenile rheumatoid arthritis patients who carry this genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1799853','C > T','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs4149056','T > C','SLCO1B1','cerivastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00439','On August 8, 2002 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.'),('rs2228001','G > T','XPC','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','decreased','TT','                Patients with the TT genotype may have a decreased but not non-existent risk for toxicity with cisplatin treatment as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1142345','T > C','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1800460','C > T','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','TT','                Patients with the TT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1042522','C > G','TP53','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1801133','G > A','MTHFR','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','increased','AA','                Patients with the AA genotype may have: 1) increased likelihood of response to chemotherapy, 2) increased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotypes AG or GG. Other genetic and clinical factors may also influence a patients response to cisplatin.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs9332377','C > T','COMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','increased','TT','                Patients with the TT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1045642','A > G','ABCB1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs7997012','A > G','HTR2A','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1954787','T > C','GRIK4','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 1B','increased','-','-','CC','                Patients with the CC genotype may have an increased chance of response to citalopram treatment as compared to patients with the TT genotype. Patients with the CC genotype may still be at risk for non-response to citalopram treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs4244285','G > A','CYP2C19','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 1A','decreased','-','-','AA','                Patients with the AA genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for secondary cardiovascular events and response to clopidogrel.'),('rs1045642','A > G','ABCB1','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 2A','increased','-','-','GG','                People with GG  genotype may have decreased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Other genetic and clinical factors may also impact the response to clopidogrel.'),('rs1042522','C > G','TP53','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1801133','G > A','MTHFR','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2A','-','-','increased','AA','                Patients with the AA genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to cyclophosphamide.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2A','decreased','-','increased','GG','                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs4244285','G > A','CYP2C19','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 4','-','-','decreased','AA','                Female patients with the AA genotype and Systemic Lupus Erythematosus who are treated with a high cumulative dose of cyclophosphamide (= or >23.75 g) may have a decreased risk of ovarian toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cyclophosphamide-induced ovarian toxicity.'),('rs4244285','G > A','CYP2C19','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 4','decreased','-','-','AA','                Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','decreased','TT','                Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the TT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patients risk for venoocclusive disease of the liver.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','decreased','-','TT','                Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs1045642','A > G','ABCB1','cyclosporine','VARIOUS','','','Cyclosporine is available in its original form and as another product that has been modified (changed) so that the medication can be better absorbed in the body. Original cyclosporine and cyclosporine (modified) are absorbed by the body in different amounts, so they cannot be substituted for one another. Take only the type of cyclosporine that was prescribed by your doctor. When your doctor gives you a written prescription, check to be sure that he or she has specified the type of cyclosporine you should receive. Each time you have your prescription filled, look at the brand name printed on your prescription label to be sure that you have received the same type of cyclosporine. Talk to your pharmacist if the brand name is unfamiliar or you are not sure you have received the right type of cyclosporine.','Level 3','-','decreased','-','GG','                Patients with genotype GG may have decreased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype AA or AG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.'),('rs1045642','A > G','ABCB1','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','dexamethasone','RESPIRATORY SYSTEM','','','Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant effects. It is 25 times more potent than cortisol in its glucocorticoid effect, while having minimal mineralocorticoid effect.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs1057910','A > C','CYP2C9','diclofenac','SENSORY ORGANS','OPHTHALMOLOGICALS','DB00586 ','A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. [PubChem]','Level 2A','-','-','increased','CC','                Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs4244285','G > A','CYP2C19','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 4','decreased','-','-','AA','                Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs3745274','G > T','CYP2B6','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','-','TT','                Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs3745274','G > T','CYP2A7P1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 2A','-','increased','-','TT','                Patients with the TT genotype may have increased plasma concentration of efavirenz in people with HIV as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients exposure to efavirenz.'),('rs3745274','G > T','CYP2A7P1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 2A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for efavirenz-induced side effects (central nervous symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1045642','A > G','ABCB1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.'),('rs1695','A > G','GSTP1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 2A','decreased','-','increased','GG','                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1045642','A > G','ABCB1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs11188072','C > T','CYP2C19','escitalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01175 ','Escitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity.','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with escitalopram may require an increased dose  as compared to patients with the CT or CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs1045642','A > G','ABCB1','fexofenadine','RESPIRATORY SYSTEM','ANTIHISTAMINES FOR SYSTEMIC USE','DB00950','Fexofenadine hydrochloride (Allegra) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine.','Level 3','-','-','-','GG','                Healthy individuals with the GG genotype who are treated with fexofenadine may have higher plasma drug levels as compared with healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.'),('rs1042522','C > G','TP53','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1801133','G > A','MTHFR','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','AA','                Patients with the AA genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the GG genotype. However, conflicting finding of no-association for this genotype has also been reported. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','increased','-','-','GG','                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hematological toxicity when exposed to flourouracil.'),('rs2297595','T > C','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with GG genotype may have decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also impact a patients response to fluorouracil.'),('rs4149056','T > C','SLCO1B1','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patients metabolism and response to statins.'),('rs1045642','A > G','ABCB1','idarubicin','GENITO URINARY SYSTEM AND SEX HORMONES','OTHER GYNECOLOGICALS','DB01050','Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1057910','A > C','CYP2C9','losartan','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00678 ','Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. ','Level 3','decreased','-','-','CC','                Subjects with the CC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.'),('rs11188072','C > T','CYP2C19','mephenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00532 ','Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. It is generally reserved for treatment of individuals refractory to less toxic agents. ','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs1142345','T > C','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1801133','G > A','MTHFR','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 3','-','-','-','AA','                Patients with the AA genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patients risk for toxicity to mercaptopurine.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 1B','-','-','increased','AA','                Patients with the AA genotype with Leukemia or Lymphoma who are treated with methotrexate regimens may have an increased risk and increased severity of mucositis, as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patients risk of oral mucositis.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AA','                Patients with the AA genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype (though this association has not been found in all studies). There does not seem to be an association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AA','                Patients with the AA genotype and non-Hodgkin lymphoma who are treated with methotrexate may have an increased risk of mucositis, thrombocytopenia and hepatic toxicity as compared to patients with the GG genotype. This association was not found in pediatric patients with non-Hodgkin lymphoma who were treated with methotrexate. Other genetic and clinical factors may also influence a patients risk for methotrexate-induced toxicity.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','AA','                Patients with the AA genotype with non-hodgkin lymphoma who are treated with methotrexate may be less likely to have event free survival at 5 years as compared to patients with the GG genotype. This genotype was not associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the GG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','decreased','increased','AA','                Patients with the AA genotype and Leukemia who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate as compared to patients with the GG genotype. This association has been contradicted or not found in several studies. Other genetic and clinical factors may also influence a patients risk for toxicity and response with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','AA','                Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk Graft vs Host disease and efficacy of methotrexate treatment.'),('rs1695','A > G','GSTP1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','GG','                Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased likelihood of Drug Toxicity as compared to patients with the AG and AA genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patients level of methotrexate induced toxicity.'),('rs1045642','A > G','ABCB1','nelfinavir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00220 ','A potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.','Level 3','-','-','-','GG','                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.'),('rs1045642','A > G','ABCB1','nevirapine','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00238 ','A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. [PubChem]','Level 2A','-','-','increased','GG','                Patients with the GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hepatotoxicity with nevirapine treatment.'),('rs1801133','G > A','MTHFR','nitrous oxide','VARIOUS','','','Nitrous oxide, commonly known as laughing gas, nitrous, nitro, or NOS[1] is a chemical compound','Level 3','-','-','-','AA','                Patients with the AA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients homocysteine levels after nitrous oxide anesthesia.'),('rs1045642','A > G','ABCB1','nortriptyline','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00540 ','Nortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for postural hypotension with nortriptyline treatment.'),('rs7997012','A > G','HTR2A','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for side effects with olanzapine treatment.'),('rs11188072','C > T','CYP2C19','omeprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00338 ','A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles','Level 2A','-','increased','-','TT','                Adult patients, but not pediatric patients, with the TT genotype who are treated with omeprazole may require an increased dose as compared to patients with the CT or CC genotype.  Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration. This might not be applicable to pediatric patients.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 2A','increased','-','-','GG','                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 3','-','-','increased','GG','                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1042522','C > G','TP53','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.'),('rs1045642','A > G','ABCB1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','increased','-','-','GG','                Genotype GG may be associated with increased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype AG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.'),('rs11188072','C > T','CYP2C19','pantoprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00213 ','Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs12979860','C > T','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','TT','                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs12979860','C > T','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','TT','                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs2108622','C > T','CYP4F2','phenprocoumon','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00946','Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','CC','                Patients with the CC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1799853','C > T','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','TT','                Patients with the TT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','decreased','-','-','GG','                Patients with genotype GG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians.  Other genetic or clinical factors may influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','increased','-','GG','                Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patients dose of phenytoin.'),('rs1695','A > G','GSTP1','Platinum compounds','VARIOUS','','','','Level 3','-','-','increased','GG','                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1142345','T > C','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs4149056','T > C','SLCO1B1','repaglinide','GENITO URINARY SYSTEM AND SEX HORMONES','DRUGS USED IN DIABETES','DB00912 ','Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to |? cells of the pancreas to stimulate insulin release.','Level 3','-','-','-','CC','                Patients with the CC genotype may have increased mean plasma AUC of repaglinide and greater blood glucose-lowering effect in response to repaglinide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients response.'),('rs12979860','C > T','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1A','decreased','-','-','TT','                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs2297480','T > G','FDPS','risedronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00884 ','Risedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 2A','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the TC And TT genotype.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs7997012','A > G','HTR2A','Selective serotonin reuptake inhibitors','VARIOUS','','','Selective beta-2-adrenoreceptor agonists are a class of drugs that act on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation, resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin.They are primarily used to treat asthma and other pulmonary disorders.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs4149056','T > C','SLCO1B1','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 1A','-','-','increased','CC','                Patients with the CC genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1057910','A > C','CYP2C9','sulfonamides, urea derivatives','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','increased','-','-','CC','                Patients with the CC genotype who are treated with sulfonylurea: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the AA genotype 2) May be less likely to have failure of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to sulfonylurea therapy.'),('rs1799853','C > T','CYP2C9','sulfonamides, urea derivatives','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','increased','-','-','TT','                Patients with the TT genotype and type II diabetes who are treated with sulfonylureas: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the CC genotype 2) May be less likely to experience treatment failure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to sulfonylureas.'),('rs1142345','T > C','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1057910','A > C','CYP2C9','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','-','increased','CC','                Patients with the CC genotype were not studied. However, patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs1045642','A > G','ABCB1','vincristine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00541','Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkina?s disease, acute erythraemia, and acute panmyelosis.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs7294','C > T','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.'),('rs9934438','G > A','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs2108622','C > T','CYP4F2','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1799853','C > T','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','-','TT','                Patients with the TT genotype who are treated with warfarin may require a lower dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients dose of warfarin.'),('rs1057910','A > C','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','increased','CC','                Patients with the CC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.'),('rs11209716','T > C','PTGER3','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and hypertension who are treated with ACE inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk of cough when treated with ACE inhibitors.'),('rs2016848','G > A','MME','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','increased','AA','                Patients with the AA genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cough with ACE inhibitor treatment.'),('rs8012552','C > T','BDKRB2','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','decreased','TT','                Patients with the TT genotype and hypertension who are treated with ACE-inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of cough with ACE-inhibitors.'),('rs9934438','G > A','VKORC1','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs2108622','C > T','CYP4F2','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 2A','-','decreased','-','CC','                Patients with the CC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs2297480','T > G','FDPS','alendronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00630','Alendronate is a nitrogen-containing, second generation bisphosphonate. Bisphosphonates were first used to treat Pageta?s disease in 1971. This class of medications is comprised of inorganic pyrophosphate analogues that contain non-hydrolyzable P-C-P bonds. Similar to other bisphosphonates, alendronate has a high affinity for bone mineral and is taken up during osteoclast resorption. Alendronate inhibits farnesyl pyrophosphate synthetase, one of the enzymes in the mevalonic acid pathway involved in producing isoprenoid compounds that are essential for post-translational modification of small guanosine triphosphate (GTP)-binding proteins, such as Rho, Ras and Rab. Inhibition of this process interferes with osteoclast function and survival. Alendronate is used for the treatment of osteoporosis and Pageta?s disease','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1056892','G > A','CBR3','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 2B','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1045642','A > G','ABCB1','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs7997012','A > G','HTR2A','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs3800373','C > A','FKBP5','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 2B','decreased','-','-','AA','                Patients with the AA genotype and depression who are treated with antidepressants may be less likely to have improvement in symptoms as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1045642','A > G','ABCB1','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','increased','-','-','GG','                Genotype GG genotype  may be associated with decreased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype AA. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. Theres also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patients response to antiepileptics.'),('rs1057910','A > C','CYP2C9','Antiinflammatory agents, non-steroids','VARIOUS','','','The term nonsteroidal distinguishes these drugs from steroids, which, among a broad range of other effects, have a similar eicosanoid-depressing, anti-inflammatory action. As analgesics, NSAIDs are unusual in that they are non-narcotic and thus are used as a non-addictive alternative to narcotics.','Level 2A','-','-','increased','CC','                Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1042522','C > G','TP53','antineoplastic agents','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','','Inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1801133','G > A','CLCN6','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','increased','AA','                Patients with the AA genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1142345','T > C','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2297480','T > G','FDPS','Bisphosphonates','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs2297595','T > C','DPYD','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1045642','A > G','ABCB1','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 3','-','-','increased','GG','                Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.'),('rs1045642','A > G','ABCB1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 4','-','decreased','-','GG','                Patient with genotype GG may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine...'),('rs1801133','G > A','CLCN6','carboplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00958 ','An organoplatinum compound that possesses antineoplastic activity.','Level 2A','increased','-','increased','AA','                Patients with AA genotype may have 1) increased likelihood of response 2) increased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patients response to carboplatin.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','-','increased','CC','                Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','decreased','-','CC','                Patients with the CC genotype may have greatly reduced metabolism of celecoxib and may require dose reduction (50% of standard starting dose) when starting celecoxib therapy or alternative management in juvenile rheumatoid arthritis patients who carry this genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1799853','C > T','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs4149056','T > C','SLCO1B1','cerivastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00439','On August 8, 2002 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.'),('rs2228001','G > T','XPC','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','decreased','TT','                Patients with the TT genotype may have a decreased but not non-existent risk for toxicity with cisplatin treatment as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1142345','T > C','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1800460','C > T','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','TT','                Patients with the TT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1042522','C > G','TP53','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1801133','G > A','MTHFR','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','increased','AA','                Patients with the AA genotype may have: 1) increased likelihood of response to chemotherapy, 2) increased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotypes AG or GG. Other genetic and clinical factors may also influence a patients response to cisplatin.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs9332377','C > T','COMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','increased','TT','                Patients with the TT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1045642','A > G','ABCB1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs7997012','A > G','HTR2A','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1954787','T > C','GRIK4','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 1B','increased','-','-','CC','                Patients with the CC genotype may have an increased chance of response to citalopram treatment as compared to patients with the TT genotype. Patients with the CC genotype may still be at risk for non-response to citalopram treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs4244285','G > A','CYP2C19','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 1A','decreased','-','-','AA','                Patients with the AA genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for secondary cardiovascular events and response to clopidogrel.'),('rs1045642','A > G','ABCB1','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 2A','increased','-','-','GG','                People with GG  genotype may have decreased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Other genetic and clinical factors may also impact the response to clopidogrel.'),('rs1042522','C > G','TP53','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1801133','G > A','MTHFR','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2A','-','-','increased','AA','                Patients with the AA genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to cyclophosphamide.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2A','decreased','-','increased','GG','                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs4244285','G > A','CYP2C19','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 4','-','-','decreased','AA','                Female patients with the AA genotype and Systemic Lupus Erythematosus who are treated with a high cumulative dose of cyclophosphamide (= or >23.75 g) may have a decreased risk of ovarian toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cyclophosphamide-induced ovarian toxicity.'),('rs4244285','G > A','CYP2C19','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 4','decreased','-','-','AA','                Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','decreased','TT','                Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the TT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patients risk for venoocclusive disease of the liver.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','decreased','-','TT','                Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs1045642','A > G','ABCB1','cyclosporine','VARIOUS','','','Cyclosporine is available in its original form and as another product that has been modified (changed) so that the medication can be better absorbed in the body. Original cyclosporine and cyclosporine (modified) are absorbed by the body in different amounts, so they cannot be substituted for one another. Take only the type of cyclosporine that was prescribed by your doctor. When your doctor gives you a written prescription, check to be sure that he or she has specified the type of cyclosporine you should receive. Each time you have your prescription filled, look at the brand name printed on your prescription label to be sure that you have received the same type of cyclosporine. Talk to your pharmacist if the brand name is unfamiliar or you are not sure you have received the right type of cyclosporine.','Level 3','-','decreased','-','GG','                Patients with genotype GG may have decreased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype AA or AG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.'),('rs1045642','A > G','ABCB1','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','dexamethasone','RESPIRATORY SYSTEM','','','Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant effects. It is 25 times more potent than cortisol in its glucocorticoid effect, while having minimal mineralocorticoid effect.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs1057910','A > C','CYP2C9','diclofenac','SENSORY ORGANS','OPHTHALMOLOGICALS','DB00586 ','A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. [PubChem]','Level 2A','-','-','increased','CC','                Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs4244285','G > A','CYP2C19','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 4','decreased','-','-','AA','                Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs3745274','G > T','CYP2B6','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','-','TT','                Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs3745274','G > T','CYP2A7P1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 2A','-','increased','-','TT','                Patients with the TT genotype may have increased plasma concentration of efavirenz in people with HIV as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients exposure to efavirenz.'),('rs3745274','G > T','CYP2A7P1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 2A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for efavirenz-induced side effects (central nervous symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1045642','A > G','ABCB1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.'),('rs1695','A > G','GSTP1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 2A','decreased','-','increased','GG','                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1045642','A > G','ABCB1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs11188072','C > T','CYP2C19','escitalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01175 ','Escitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity.','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with escitalopram may require an increased dose  as compared to patients with the CT or CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs1045642','A > G','ABCB1','fexofenadine','RESPIRATORY SYSTEM','ANTIHISTAMINES FOR SYSTEMIC USE','DB00950','Fexofenadine hydrochloride (Allegra) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine.','Level 3','-','-','-','GG','                Healthy individuals with the GG genotype who are treated with fexofenadine may have higher plasma drug levels as compared with healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.'),('rs1042522','C > G','TP53','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1801133','G > A','MTHFR','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','AA','                Patients with the AA genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the GG genotype. However, conflicting finding of no-association for this genotype has also been reported. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','increased','-','-','GG','                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hematological toxicity when exposed to flourouracil.'),('rs2297595','T > C','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with GG genotype may have decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also impact a patients response to fluorouracil.'),('rs4149056','T > C','SLCO1B1','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patients metabolism and response to statins.'),('rs1045642','A > G','ABCB1','idarubicin','GENITO URINARY SYSTEM AND SEX HORMONES','OTHER GYNECOLOGICALS','DB01050','Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1057910','A > C','CYP2C9','losartan','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00678 ','Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. ','Level 3','decreased','-','-','CC','                Subjects with the CC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.'),('rs11188072','C > T','CYP2C19','mephenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00532 ','Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. It is generally reserved for treatment of individuals refractory to less toxic agents. ','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs1142345','T > C','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1801133','G > A','MTHFR','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 3','-','-','-','AA','                Patients with the AA genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patients risk for toxicity to mercaptopurine.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 1B','-','-','increased','AA','                Patients with the AA genotype with Leukemia or Lymphoma who are treated with methotrexate regimens may have an increased risk and increased severity of mucositis, as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patients risk of oral mucositis.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AA','                Patients with the AA genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype (though this association has not been found in all studies). There does not seem to be an association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AA','                Patients with the AA genotype and non-Hodgkin lymphoma who are treated with methotrexate may have an increased risk of mucositis, thrombocytopenia and hepatic toxicity as compared to patients with the GG genotype. This association was not found in pediatric patients with non-Hodgkin lymphoma who were treated with methotrexate. Other genetic and clinical factors may also influence a patients risk for methotrexate-induced toxicity.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','AA','                Patients with the AA genotype with non-hodgkin lymphoma who are treated with methotrexate may be less likely to have event free survival at 5 years as compared to patients with the GG genotype. This genotype was not associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the GG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','decreased','increased','AA','                Patients with the AA genotype and Leukemia who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate as compared to patients with the GG genotype. This association has been contradicted or not found in several studies. Other genetic and clinical factors may also influence a patients risk for toxicity and response with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','AA','                Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk Graft vs Host disease and efficacy of methotrexate treatment.'),('rs1695','A > G','GSTP1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','GG','                Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased likelihood of Drug Toxicity as compared to patients with the AG and AA genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patients level of methotrexate induced toxicity.'),('rs1045642','A > G','ABCB1','nelfinavir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00220 ','A potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.','Level 3','-','-','-','GG','                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.'),('rs1045642','A > G','ABCB1','nevirapine','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00238 ','A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. [PubChem]','Level 2A','-','-','increased','GG','                Patients with the GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hepatotoxicity with nevirapine treatment.'),('rs1801133','G > A','MTHFR','nitrous oxide','VARIOUS','','','Nitrous oxide, commonly known as laughing gas, nitrous, nitro, or NOS[1] is a chemical compound','Level 3','-','-','-','AA','                Patients with the AA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients homocysteine levels after nitrous oxide anesthesia.'),('rs1045642','A > G','ABCB1','nortriptyline','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00540 ','Nortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for postural hypotension with nortriptyline treatment.'),('rs7997012','A > G','HTR2A','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for side effects with olanzapine treatment.'),('rs11188072','C > T','CYP2C19','omeprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00338 ','A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles','Level 2A','-','increased','-','TT','                Adult patients, but not pediatric patients, with the TT genotype who are treated with omeprazole may require an increased dose as compared to patients with the CT or CC genotype.  Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration. This might not be applicable to pediatric patients.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 2A','increased','-','-','GG','                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 3','-','-','increased','GG','                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1042522','C > G','TP53','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.'),('rs1045642','A > G','ABCB1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','increased','-','-','GG','                Genotype GG may be associated with increased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype AG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.'),('rs11188072','C > T','CYP2C19','pantoprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00213 ','Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs12979860','C > T','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','TT','                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs12979860','C > T','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','TT','                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs2108622','C > T','CYP4F2','phenprocoumon','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00946','Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','CC','                Patients with the CC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1799853','C > T','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','TT','                Patients with the TT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','decreased','-','-','GG','                Patients with genotype GG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians.  Other genetic or clinical factors may influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','increased','-','GG','                Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patients dose of phenytoin.'),('rs1695','A > G','GSTP1','Platinum compounds','VARIOUS','','','','Level 3','-','-','increased','GG','                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1142345','T > C','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs4149056','T > C','SLCO1B1','repaglinide','GENITO URINARY SYSTEM AND SEX HORMONES','DRUGS USED IN DIABETES','DB00912 ','Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to |? cells of the pancreas to stimulate insulin release.','Level 3','-','-','-','CC','                Patients with the CC genotype may have increased mean plasma AUC of repaglinide and greater blood glucose-lowering effect in response to repaglinide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients response.'),('rs12979860','C > T','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1A','decreased','-','-','TT','                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs2297480','T > G','FDPS','risedronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00884 ','Risedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 2A','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the TC And TT genotype.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs7997012','A > G','HTR2A','Selective serotonin reuptake inhibitors','VARIOUS','','','Selective beta-2-adrenoreceptor agonists are a class of drugs that act on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation, resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin.They are primarily used to treat asthma and other pulmonary disorders.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs4149056','T > C','SLCO1B1','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 1A','-','-','increased','CC','                Patients with the CC genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1057910','A > C','CYP2C9','sulfonamides, urea derivatives','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','increased','-','-','CC','                Patients with the CC genotype who are treated with sulfonylurea: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the AA genotype 2) May be less likely to have failure of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to sulfonylurea therapy.'),('rs1799853','C > T','CYP2C9','sulfonamides, urea derivatives','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','increased','-','-','TT','                Patients with the TT genotype and type II diabetes who are treated with sulfonylureas: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the CC genotype 2) May be less likely to experience treatment failure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to sulfonylureas.'),('rs1142345','T > C','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1057910','A > C','CYP2C9','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','-','increased','CC','                Patients with the CC genotype were not studied. However, patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs1045642','A > G','ABCB1','vincristine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00541','Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkina?s disease, acute erythraemia, and acute panmyelosis.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs7294','C > T','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.'),('rs9934438','G > A','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs2108622','C > T','CYP4F2','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1799853','C > T','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','-','TT','                Patients with the TT genotype who are treated with warfarin may require a lower dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients dose of warfarin.'),('rs1057910','A > C','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','increased','CC','                Patients with the CC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.');
/*!40000 ALTER TABLE `k8masw5vv36x` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `sample1`
--

DROP TABLE IF EXISTS `sample1`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `sample1` (
  `RSID` varchar(20) DEFAULT NULL,
  `Alleles` varchar(7) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `Drug` varchar(60) DEFAULT NULL,
  `System` varchar(60) DEFAULT NULL,
  `subSystem` text,
  `drugID` varchar(60) DEFAULT NULL,
  `info` text,
  `Level` varchar(10) DEFAULT NULL,
  `Efficacy` varchar(20) DEFAULT NULL,
  `Dosage` varchar(20) DEFAULT NULL,
  `Toxicity` varchar(20) DEFAULT NULL,
  `Genotype` varchar(10) DEFAULT NULL,
  `Sentence` text
) ENGINE=InnoDB DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `sample1`
--

LOCK TABLES `sample1` WRITE;
/*!40000 ALTER TABLE `sample1` DISABLE KEYS */;
INSERT INTO `sample1` VALUES ('rs11209716','T > C','PTGER3','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and hypertension who are treated with ACE inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk of cough when treated with ACE inhibitors.'),('rs2016848','G > A','MME','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','increased','AA','                Patients with the AA genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cough with ACE inhibitor treatment.'),('rs2108622','C > T','CYP4F2','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1056892','G > A','CBR3','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 2B','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1042522','C > G','TP53','antineoplastic agents','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','','Inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1801133','G > A','CLCN6','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','increased','AA','                Patients with the AA genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1800460','C > T','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2297595','T > C','DPYD','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1801133','G > A','CLCN6','carboplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00958 ','An organoplatinum compound that possesses antineoplastic activity.','Level 2A','increased','-','increased','AA','                Patients with AA genotype may have 1) increased likelihood of response 2) increased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patients response to carboplatin.'),('rs1799853','C > T','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 3','decreased','-','-','CT','                Patients with the CT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs2228001','G > T','XPC','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','decreased','TT','                Patients with the TT genotype may have a decreased but not non-existent risk for toxicity with cisplatin treatment as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CT','                Patients with the TC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1042522','C > G','TP53','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1801133','G > A','MTHFR','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','increased','AA','                Patients with the AA genotype may have: 1) increased likelihood of response to chemotherapy, 2) increased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotypes AG or GG. Other genetic and clinical factors may also influence a patients response to cisplatin.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs9332377','C > T','COMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','increased','CT','                Patients with the CT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1042522','C > G','TP53','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1801133','G > A','MTHFR','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2A','-','-','increased','AA','                Patients with the AA genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to cyclophosphamide.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2A','increased','-','-','AG','                Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','decreased','GT','                Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patients risk for venoocclusive disease of the liver.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','decreased','-','GT','                Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs3745274','G > T','CYP2A7P1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 2A','-','-','increased','GT','                Patients with the GT genotype may have an increased risk of efavirenz-induced side effects (central nervous symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1695','A > G','GSTP1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 2A','increased','-','-','AG','                Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1042522','C > G','TP53','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1801133','G > A','MTHFR','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','AA','                Patients with the AA genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the GG genotype. However, conflicting finding of no-association for this genotype has also been reported. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','AG','                Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for hematological toxicity when exposed to fluorouracil.'),('rs2297595','T > C','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1800460','C > T','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1801133','G > A','MTHFR','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 3','-','-','-','AA','                Patients with the AA genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patients risk for toxicity to mercaptopurine.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 1B','-','-','increased','AA','                Patients with the AA genotype with Leukemia or Lymphoma who are treated with methotrexate regimens may have an increased risk and increased severity of mucositis, as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patients risk of oral mucositis.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AA','                Patients with the AA genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype (though this association has not been found in all studies). There does not seem to be an association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AA','                Patients with the AA genotype and non-Hodgkin lymphoma who are treated with methotrexate may have an increased risk of mucositis, thrombocytopenia and hepatic toxicity as compared to patients with the GG genotype. This association was not found in pediatric patients with non-Hodgkin lymphoma who were treated with methotrexate. Other genetic and clinical factors may also influence a patients risk for methotrexate-induced toxicity.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','AA','                Patients with the AA genotype with non-hodgkin lymphoma who are treated with methotrexate may be less likely to have event free survival at 5 years as compared to patients with the GG genotype. This genotype was not associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the GG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','decreased','increased','AA','                Patients with the AA genotype and Leukemia who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate as compared to patients with the GG genotype. This association has been contradicted or not found in several studies. Other genetic and clinical factors may also influence a patients risk for toxicity and response with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','AA','                Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk Graft vs Host disease and efficacy of methotrexate treatment.'),('rs1801133','G > A','MTHFR','nitrous oxide','VARIOUS','','','Nitrous oxide, commonly known as laughing gas, nitrous, nitro, or NOS[1] is a chemical compound','Level 3','-','-','-','AA','                Patients with the AA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients homocysteine levels after nitrous oxide anesthesia.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 3','-','-','increased','AG','                Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1042522','C > G','TP53','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs12979860','C > T','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','TT','                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs12979860','C > T','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','TT','                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs2108622','C > T','CYP4F2','phenprocoumon','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00946','Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1799853','C > T','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','CT','                Patients with the CT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1695','A > G','GSTP1','Platinum compounds','VARIOUS','','','','Level 3','-','-','increased','AG','                Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1800460','C > T','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs12979860','C > T','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1A','decreased','-','-','TT','                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs1800460','C > T','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs7294','C > T','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.'),('rs2108622','C > T','CYP4F2','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1799853','C > T','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients dose of warfarin.');
/*!40000 ALTER TABLE `sample1` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `sample10`
--

DROP TABLE IF EXISTS `sample10`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `sample10` (
  `RSID` varchar(20) DEFAULT NULL,
  `Alleles` varchar(7) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `Drug` varchar(60) DEFAULT NULL,
  `System` varchar(60) DEFAULT NULL,
  `subSystem` text,
  `drugID` varchar(60) DEFAULT NULL,
  `info` text,
  `Level` varchar(10) DEFAULT NULL,
  `Efficacy` varchar(20) DEFAULT NULL,
  `Dosage` varchar(20) DEFAULT NULL,
  `Toxicity` varchar(20) DEFAULT NULL,
  `Genotype` varchar(10) DEFAULT NULL,
  `Sentence` text
) ENGINE=InnoDB DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `sample10`
--

LOCK TABLES `sample10` WRITE;
/*!40000 ALTER TABLE `sample10` DISABLE KEYS */;
INSERT INTO `sample10` VALUES ('rs2108622','C > T','CYP4F2','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs2108622','C > T','CYP4F2','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 2A','-','decreased','-','AC','                Patients with the AC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs1056892','G > A','CBR3','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 2B','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1045642','A > G','ABCB1','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','increased','-','-','GG','                Genotype GG genotype  may be associated with decreased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype AA. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. Theres also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patients response to antiepileptics.'),('rs1057910','A > C','CYP2C9','Antiinflammatory agents, non-steroids','VARIOUS','','','The term nonsteroidal distinguishes these drugs from steroids, which, among a broad range of other effects, have a similar eicosanoid-depressing, anti-inflammatory action. As analgesics, NSAIDs are unusual in that they are non-narcotic and thus are used as a non-addictive alternative to narcotics.','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1042522','C > G','TP53','antineoplastic agents','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','','Inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1800460','C > T','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1045642','A > G','ABCB1','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 3','-','-','increased','GG','                Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.'),('rs1045642','A > G','ABCB1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 4','-','decreased','-','GG','                Patient with genotype GG may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine...'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','decreased','-','AC','                Patients with the AC genotype may have reduced metabolism of celecoxib and may require dose reduction when starting celecoxib therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1799853','C > T','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 3','decreased','-','-','CT','                Patients with the CT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs4149056','T > C','SLCO1B1','cerivastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00439','On August 8, 2002 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.'),('rs1800460','C > T','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CT','                Patients with the TC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1042522','C > G','TP53','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs9332377','C > T','COMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','increased','TT','                Patients with the TT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1045642','A > G','ABCB1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs4244285','G > A','CYP2C19','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 1A','decreased','-','-','AA','                Patients with the AA genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for secondary cardiovascular events and response to clopidogrel.'),('rs1045642','A > G','ABCB1','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 2A','increased','-','-','GG','                People with GG  genotype may have decreased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Other genetic and clinical factors may also impact the response to clopidogrel.'),('rs1042522','C > G','TP53','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2A','decreased','-','increased','GG','                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs4244285','G > A','CYP2C19','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 4','-','-','decreased','AA','                Female patients with the AA genotype and Systemic Lupus Erythematosus who are treated with a high cumulative dose of cyclophosphamide (= or >23.75 g) may have a decreased risk of ovarian toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cyclophosphamide-induced ovarian toxicity.'),('rs4244285','G > A','CYP2C19','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 4','decreased','-','-','AA','                Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','decreased','GT','                Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patients risk for venoocclusive disease of the liver.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','decreased','-','GT','                Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs1045642','A > G','ABCB1','cyclosporine','VARIOUS','','','Cyclosporine is available in its original form and as another product that has been modified (changed) so that the medication can be better absorbed in the body. Original cyclosporine and cyclosporine (modified) are absorbed by the body in different amounts, so they cannot be substituted for one another. Take only the type of cyclosporine that was prescribed by your doctor. When your doctor gives you a written prescription, check to be sure that he or she has specified the type of cyclosporine you should receive. Each time you have your prescription filled, look at the brand name printed on your prescription label to be sure that you have received the same type of cyclosporine. Talk to your pharmacist if the brand name is unfamiliar or you are not sure you have received the right type of cyclosporine.','Level 3','-','decreased','-','GG','                Patients with genotype GG may have decreased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype AA or AG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.'),('rs1045642','A > G','ABCB1','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','dexamethasone','RESPIRATORY SYSTEM','','','Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant effects. It is 25 times more potent than cortisol in its glucocorticoid effect, while having minimal mineralocorticoid effect.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs1057910','A > C','CYP2C9','diclofenac','SENSORY ORGANS','OPHTHALMOLOGICALS','DB00586 ','A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. [PubChem]','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs4244285','G > A','CYP2C19','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 4','decreased','-','-','AA','                Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs3745274','G > T','CYP2A7P1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 2A','-','-','increased','GT','                Patients with the GT genotype may have an increased risk of efavirenz-induced side effects (central nervous symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1045642','A > G','ABCB1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.'),('rs1695','A > G','GSTP1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 2A','decreased','-','increased','GG','                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1045642','A > G','ABCB1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','fexofenadine','RESPIRATORY SYSTEM','ANTIHISTAMINES FOR SYSTEMIC USE','DB00950','Fexofenadine hydrochloride (Allegra) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine.','Level 3','-','-','-','GG','                Healthy individuals with the GG genotype who are treated with fexofenadine may have higher plasma drug levels as compared with healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.'),('rs1042522','C > G','TP53','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','increased','-','-','GG','                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hematological toxicity when exposed to flourouracil.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with GG genotype may have decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also impact a patients response to fluorouracil.'),('rs17244841','A > T','HMGCR','fluvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01095 ','Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs4149056','T > C','SLCO1B1','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patients metabolism and response to statins.'),('rs17244841','A > T','HMGCR','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs1045642','A > G','ABCB1','idarubicin','GENITO URINARY SYSTEM AND SEX HORMONES','OTHER GYNECOLOGICALS','DB01050','Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1057910','A > C','CYP2C9','losartan','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00678 ','Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. ','Level 3','decreased','-','-','AC','                Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.'),('rs1800460','C > T','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1695','A > G','GSTP1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','GG','                Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased likelihood of Drug Toxicity as compared to patients with the AG and AA genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patients level of methotrexate induced toxicity.'),('rs1045642','A > G','ABCB1','nelfinavir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00220 ','A potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.','Level 3','-','-','-','GG','                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.'),('rs1045642','A > G','ABCB1','nevirapine','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00238 ','A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. [PubChem]','Level 2A','-','-','increased','GG','                Patients with the GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hepatotoxicity with nevirapine treatment.'),('rs1045642','A > G','ABCB1','nortriptyline','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00540 ','Nortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for postural hypotension with nortriptyline treatment.'),('rs7997012','A > G','HTR2A','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for side effects with olanzapine treatment.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 2A','increased','-','-','GG','                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 3','-','-','increased','GG','                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1042522','C > G','TP53','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.'),('rs1045642','A > G','ABCB1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','increased','-','-','GG','                Genotype GG may be associated with increased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype AG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.'),('rs11188072','C > T','CYP2C19','pantoprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00213 ','Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.','Level 3','-','increased','-','CT','                Patients with the CT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs12979860','C > T','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs12979860','C > T','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs2108622','C > T','CYP4F2','phenprocoumon','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00946','Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs2108622','C > T','CYP4F2','phenprocoumon','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00946','Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1799853','C > T','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','CT','                Patients with the CT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','decreased','-','-','GG','                Patients with genotype GG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians.  Other genetic or clinical factors may influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','increased','-','GG','                Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patients dose of phenytoin.'),('rs1695','A > G','GSTP1','Platinum compounds','VARIOUS','','','','Level 3','-','-','increased','GG','                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs17244841','A > T','HMGCR','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs1800460','C > T','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs4149056','T > C','SLCO1B1','repaglinide','GENITO URINARY SYSTEM AND SEX HORMONES','DRUGS USED IN DIABETES','DB00912 ','Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to |? cells of the pancreas to stimulate insulin release.','Level 3','-','-','-','CC','                Patients with the CC genotype may have increased mean plasma AUC of repaglinide and greater blood glucose-lowering effect in response to repaglinide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients response.'),('rs12979860','C > T','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs4149056','T > C','SLCO1B1','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 1A','-','-','increased','CC','                Patients with the CC genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs17244841','A > T','HMGCR','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs1800460','C > T','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1057910','A > C','CYP2C9','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs1045642','A > G','ABCB1','vincristine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00541','Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkina?s disease, acute erythraemia, and acute panmyelosis.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs7294','C > T','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.'),('rs2108622','C > T','CYP4F2','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs2108622','C > T','CYP4F2','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1799853','C > T','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients dose of warfarin.'),('rs1057910','A > C','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','increased','AC','                Patients with the AC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.');
/*!40000 ALTER TABLE `sample10` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `sample2`
--

DROP TABLE IF EXISTS `sample2`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `sample2` (
  `RSID` varchar(20) DEFAULT NULL,
  `Alleles` varchar(7) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `Drug` varchar(60) DEFAULT NULL,
  `System` varchar(60) DEFAULT NULL,
  `subSystem` text,
  `drugID` varchar(60) DEFAULT NULL,
  `info` text,
  `Level` varchar(10) DEFAULT NULL,
  `Efficacy` varchar(20) DEFAULT NULL,
  `Dosage` varchar(20) DEFAULT NULL,
  `Toxicity` varchar(20) DEFAULT NULL,
  `Genotype` varchar(10) DEFAULT NULL,
  `Sentence` text
) ENGINE=InnoDB DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `sample2`
--

LOCK TABLES `sample2` WRITE;
/*!40000 ALTER TABLE `sample2` DISABLE KEYS */;
INSERT INTO `sample2` VALUES ('rs2108622','C > T','CYP4F2','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 2A','-','decreased','-','AC','                Patients with the AC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs1045642','A > G','ABCB1','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','increased','-','-','AG','                Genotype AG may be associated with increased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype GG. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. Theres also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patients response to antiepileptics.'),('rs1057910','A > C','CYP2C9','Antiinflammatory agents, non-steroids','VARIOUS','','','The term nonsteroidal distinguishes these drugs from steroids, which, among a broad range of other effects, have a similar eicosanoid-depressing, anti-inflammatory action. As analgesics, NSAIDs are unusual in that they are non-narcotic and thus are used as a non-addictive alternative to narcotics.','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1042522','C > G','TP53','antineoplastic agents','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','','Inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 3','-','-','increased','AG','                Patients with AG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.'),('rs1045642','A > G','ABCB1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 4','-','increased','-','AG','                Patient with genotype AG may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','decreased','-','AC','                Patients with the AC genotype may have reduced metabolism of celecoxib and may require dose reduction when starting celecoxib therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs4149056','T > C','SLCO1B1','cerivastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00439','On August 8, 2002 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.'),('rs1042522','C > G','TP53','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1045642','A > G','ABCB1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have better response (decreased risk of lymph node metastases and increased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1042522','C > G','TP53','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2A','decreased','-','increased','GG','                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','decreased','TT','                Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the TT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patients risk for venoocclusive disease of the liver.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','decreased','-','TT','                Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs1045642','A > G','ABCB1','cyclosporine','VARIOUS','','','Cyclosporine is available in its original form and as another product that has been modified (changed) so that the medication can be better absorbed in the body. Original cyclosporine and cyclosporine (modified) are absorbed by the body in different amounts, so they cannot be substituted for one another. Take only the type of cyclosporine that was prescribed by your doctor. When your doctor gives you a written prescription, check to be sure that he or she has specified the type of cyclosporine you should receive. Each time you have your prescription filled, look at the brand name printed on your prescription label to be sure that you have received the same type of cyclosporine. Talk to your pharmacist if the brand name is unfamiliar or you are not sure you have received the right type of cyclosporine.','Level 3','-','increased','-','AG','                Patients with genotype AG may have increased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.'),('rs1045642','A > G','ABCB1','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1057910','A > C','CYP2C9','diclofenac','SENSORY ORGANS','OPHTHALMOLOGICALS','DB00586 ','A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. [PubChem]','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs3745274','G > T','CYP2B6','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','-','TT','                Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs3745274','G > T','CYP2A7P1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 2A','-','increased','-','TT','                Patients with the TT genotype may have increased plasma concentration of efavirenz in people with HIV as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients exposure to efavirenz.'),('rs3745274','G > T','CYP2A7P1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 2A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for efavirenz-induced side effects (central nervous symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1695','A > G','GSTP1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 2A','decreased','-','increased','GG','                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1045642','A > G','ABCB1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','fexofenadine','RESPIRATORY SYSTEM','ANTIHISTAMINES FOR SYSTEMIC USE','DB00950','Fexofenadine hydrochloride (Allegra) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine.','Level 3','-','-','-','AG','                Healthy individuals with the AG genotype who are treated with fexofenadine may have higher plasma drug levels as compared to healthy individuals with the AA genotype.  Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.'),('rs1042522','C > G','TP53','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','increased','-','-','GG','                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hematological toxicity when exposed to flourouracil.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','AG','                Patients with the AG genotype may have better response (decreased risk of lymph node metastases and increased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs17244841','A > T','HMGCR','fluvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01095 ','Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs4149056','T > C','SLCO1B1','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patients metabolism and response to statins.'),('rs17244841','A > T','HMGCR','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs1045642','A > G','ABCB1','idarubicin','GENITO URINARY SYSTEM AND SEX HORMONES','OTHER GYNECOLOGICALS','DB01050','Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1057910','A > C','CYP2C9','losartan','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00678 ','Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. ','Level 3','decreased','-','-','AC','                Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.'),('rs1695','A > G','GSTP1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','GG','                Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased likelihood of Drug Toxicity as compared to patients with the AG and AA genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patients level of methotrexate induced toxicity.'),('rs1045642','A > G','ABCB1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 4','-','-','increased','AG','                Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have an increased risk of adverse drug events (please note this association was not significant after correcting for multiple variables) 2) may have an increased risk of not responding to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse drug events and responsiveness when treated with methotrexate.'),('rs1045642','A > G','ABCB1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 4','decreased','-','-','AG','                Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have an increased risk of adverse drug events (please note this association was not significant after correcting for multiple variables) 2) may have an increased risk of not responding to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse drug events and responsiveness when treated with methotrexate.'),('rs1045642','A > G','ABCB1','nortriptyline','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00540 ','Nortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for postural hypotension with nortriptyline treatment.'),('rs7997012','A > G','HTR2A','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for side effects with olanzapine treatment.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 2A','increased','-','-','GG','                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 3','-','-','increased','GG','                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1042522','C > G','TP53','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs2108622','C > T','CYP4F2','phenprocoumon','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00946','Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','-','AG','                Patients with genotype AG may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patients dose of phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','decreased','-','-','AG','                Patients with genotype AG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians. Other genetic or clinical factors may influence a patients response to phenytoin.'),('rs1695','A > G','GSTP1','Platinum compounds','VARIOUS','','','','Level 3','-','-','increased','GG','                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs17244841','A > T','HMGCR','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs4149056','T > C','SLCO1B1','repaglinide','GENITO URINARY SYSTEM AND SEX HORMONES','DRUGS USED IN DIABETES','DB00912 ','Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to |? cells of the pancreas to stimulate insulin release.','Level 3','-','-','-','CC','                Patients with the CC genotype may have increased mean plasma AUC of repaglinide and greater blood glucose-lowering effect in response to repaglinide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients response.'),('rs4149056','T > C','SLCO1B1','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 1A','-','-','increased','CC','                Patients with the CC genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs17244841','A > T','HMGCR','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs1057910','A > C','CYP2C9','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs2108622','C > T','CYP4F2','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','increased','AC','                Patients with the AC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.');
/*!40000 ALTER TABLE `sample2` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `sample3`
--

DROP TABLE IF EXISTS `sample3`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `sample3` (
  `RSID` varchar(20) DEFAULT NULL,
  `Alleles` varchar(7) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `Drug` varchar(60) DEFAULT NULL,
  `System` varchar(60) DEFAULT NULL,
  `subSystem` text,
  `drugID` varchar(60) DEFAULT NULL,
  `info` text,
  `Level` varchar(10) DEFAULT NULL,
  `Efficacy` varchar(20) DEFAULT NULL,
  `Dosage` varchar(20) DEFAULT NULL,
  `Toxicity` varchar(20) DEFAULT NULL,
  `Genotype` varchar(10) DEFAULT NULL,
  `Sentence` text
) ENGINE=InnoDB DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `sample3`
--

LOCK TABLES `sample3` WRITE;
/*!40000 ALTER TABLE `sample3` DISABLE KEYS */;
INSERT INTO `sample3` VALUES ('rs1045642','A > G','ABCB1','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','increased','-','-','AG','                Genotype AG may be associated with increased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype GG. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. Theres also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patients response to antiepileptics.'),('rs1042522','C > G','TP53','antineoplastic agents','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','','Inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 3','-','-','increased','AG','                Patients with AG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.'),('rs1045642','A > G','ABCB1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 4','-','increased','-','AG','                Patient with genotype AG may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine.'),('rs1042522','C > G','TP53','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have better response (decreased risk of lymph node metastases and increased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1042522','C > G','TP53','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','cyclosporine','VARIOUS','','','Cyclosporine is available in its original form and as another product that has been modified (changed) so that the medication can be better absorbed in the body. Original cyclosporine and cyclosporine (modified) are absorbed by the body in different amounts, so they cannot be substituted for one another. Take only the type of cyclosporine that was prescribed by your doctor. When your doctor gives you a written prescription, check to be sure that he or she has specified the type of cyclosporine you should receive. Each time you have your prescription filled, look at the brand name printed on your prescription label to be sure that you have received the same type of cyclosporine. Talk to your pharmacist if the brand name is unfamiliar or you are not sure you have received the right type of cyclosporine.','Level 3','-','increased','-','AG','                Patients with genotype AG may have increased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.'),('rs1045642','A > G','ABCB1','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs11188072','C > T','CYP2C19','escitalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01175 ','Escitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity.','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with escitalopram may require an increased dose  as compared to patients with the CT or CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs1045642','A > G','ABCB1','fexofenadine','RESPIRATORY SYSTEM','ANTIHISTAMINES FOR SYSTEMIC USE','DB00950','Fexofenadine hydrochloride (Allegra) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine.','Level 3','-','-','-','AG','                Healthy individuals with the AG genotype who are treated with fexofenadine may have higher plasma drug levels as compared to healthy individuals with the AA genotype.  Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.'),('rs1042522','C > G','TP53','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','AG','                Patients with the AG genotype may have better response (decreased risk of lymph node metastases and increased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs17244841','A > T','HMGCR','fluvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01095 ','Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17244841','A > T','HMGCR','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs1045642','A > G','ABCB1','idarubicin','GENITO URINARY SYSTEM AND SEX HORMONES','OTHER GYNECOLOGICALS','DB01050','Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs11188072','C > T','CYP2C19','mephenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00532 ','Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. It is generally reserved for treatment of individuals refractory to less toxic agents. ','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs1045642','A > G','ABCB1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 4','-','-','increased','AG','                Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have an increased risk of adverse drug events (please note this association was not significant after correcting for multiple variables) 2) may have an increased risk of not responding to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse drug events and responsiveness when treated with methotrexate.'),('rs1045642','A > G','ABCB1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 4','decreased','-','-','AG','                Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have an increased risk of adverse drug events (please note this association was not significant after correcting for multiple variables) 2) may have an increased risk of not responding to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse drug events and responsiveness when treated with methotrexate.'),('rs1045642','A > G','ABCB1','nortriptyline','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00540 ','Nortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for postural hypotension with nortriptyline treatment.'),('rs11188072','C > T','CYP2C19','omeprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00338 ','A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles','Level 2A','-','increased','-','TT','                Adult patients, but not pediatric patients, with the TT genotype who are treated with omeprazole may require an increased dose as compared to patients with the CT or CC genotype.  Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration. This might not be applicable to pediatric patients.'),('rs1042522','C > G','TP53','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs11188072','C > T','CYP2C19','pantoprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00213 ','Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','-','AG','                Patients with genotype AG may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patients dose of phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','decreased','-','-','AG','                Patients with genotype AG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians. Other genetic or clinical factors may influence a patients response to phenytoin.'),('rs17244841','A > T','HMGCR','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17244841','A > T','HMGCR','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.');
/*!40000 ALTER TABLE `sample3` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `sample4`
--

DROP TABLE IF EXISTS `sample4`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `sample4` (
  `RSID` varchar(20) DEFAULT NULL,
  `Alleles` varchar(7) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `Drug` varchar(60) DEFAULT NULL,
  `System` varchar(60) DEFAULT NULL,
  `subSystem` text,
  `drugID` varchar(60) DEFAULT NULL,
  `info` text,
  `Level` varchar(10) DEFAULT NULL,
  `Efficacy` varchar(20) DEFAULT NULL,
  `Dosage` varchar(20) DEFAULT NULL,
  `Toxicity` varchar(20) DEFAULT NULL,
  `Genotype` varchar(10) DEFAULT NULL,
  `Sentence` text
) ENGINE=InnoDB DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `sample4`
--

LOCK TABLES `sample4` WRITE;
/*!40000 ALTER TABLE `sample4` DISABLE KEYS */;
INSERT INTO `sample4` VALUES ('rs2108622','C > T','CYP4F2','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 2A','-','decreased','-','AC','                Patients with the AC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs1057910','A > C','CYP2C9','Antiinflammatory agents, non-steroids','VARIOUS','','','The term nonsteroidal distinguishes these drugs from steroids, which, among a broad range of other effects, have a similar eicosanoid-depressing, anti-inflammatory action. As analgesics, NSAIDs are unusual in that they are non-narcotic and thus are used as a non-addictive alternative to narcotics.','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1042522','C > G','TP53','antineoplastic agents','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','','Inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','decreased','-','AC','                Patients with the AC genotype may have reduced metabolism of celecoxib and may require dose reduction when starting celecoxib therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1042522','C > G','TP53','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1042522','C > G','TP53','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1057910','A > C','CYP2C9','diclofenac','SENSORY ORGANS','OPHTHALMOLOGICALS','DB00586 ','A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. [PubChem]','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1042522','C > G','TP53','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1057910','A > C','CYP2C9','losartan','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00678 ','Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. ','Level 3','decreased','-','-','AC','                Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.'),('rs1042522','C > G','TP53','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs2108622','C > T','CYP4F2','phenprocoumon','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00946','Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 2A','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the TC And TT genotype.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1057910','A > C','CYP2C9','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs7294','C > T','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.'),('rs2108622','C > T','CYP4F2','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','increased','AC','                Patients with the AC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.');
/*!40000 ALTER TABLE `sample4` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `sample5`
--

DROP TABLE IF EXISTS `sample5`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `sample5` (
  `RSID` varchar(20) DEFAULT NULL,
  `Alleles` varchar(7) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `Drug` varchar(60) DEFAULT NULL,
  `System` varchar(60) DEFAULT NULL,
  `subSystem` text,
  `drugID` varchar(60) DEFAULT NULL,
  `info` text,
  `Level` varchar(10) DEFAULT NULL,
  `Efficacy` varchar(20) DEFAULT NULL,
  `Dosage` varchar(20) DEFAULT NULL,
  `Toxicity` varchar(20) DEFAULT NULL,
  `Genotype` varchar(10) DEFAULT NULL,
  `Sentence` text
) ENGINE=InnoDB DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `sample5`
--

LOCK TABLES `sample5` WRITE;
/*!40000 ALTER TABLE `sample5` DISABLE KEYS */;
INSERT INTO `sample5` VALUES ('rs1045642','A > G','ABCB1','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','increased','-','-','AG','                Genotype AG may be associated with increased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype GG. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. Theres also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patients response to antiepileptics.'),('rs1042522','C > G','TP53','antineoplastic agents','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','','Inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 3','-','-','increased','AG','                Patients with AG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.'),('rs1045642','A > G','ABCB1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 4','-','increased','-','AG','                Patient with genotype AG may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine.'),('rs1042522','C > G','TP53','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have better response (decreased risk of lymph node metastases and increased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1042522','C > G','TP53','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','cyclosporine','VARIOUS','','','Cyclosporine is available in its original form and as another product that has been modified (changed) so that the medication can be better absorbed in the body. Original cyclosporine and cyclosporine (modified) are absorbed by the body in different amounts, so they cannot be substituted for one another. Take only the type of cyclosporine that was prescribed by your doctor. When your doctor gives you a written prescription, check to be sure that he or she has specified the type of cyclosporine you should receive. Each time you have your prescription filled, look at the brand name printed on your prescription label to be sure that you have received the same type of cyclosporine. Talk to your pharmacist if the brand name is unfamiliar or you are not sure you have received the right type of cyclosporine.','Level 3','-','increased','-','AG','                Patients with genotype AG may have increased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.'),('rs1045642','A > G','ABCB1','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs11188072','C > T','CYP2C19','escitalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01175 ','Escitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity.','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with escitalopram may require an increased dose  as compared to patients with the CT or CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs1045642','A > G','ABCB1','fexofenadine','RESPIRATORY SYSTEM','ANTIHISTAMINES FOR SYSTEMIC USE','DB00950','Fexofenadine hydrochloride (Allegra) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine.','Level 3','-','-','-','AG','                Healthy individuals with the AG genotype who are treated with fexofenadine may have higher plasma drug levels as compared to healthy individuals with the AA genotype.  Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.'),('rs1042522','C > G','TP53','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','AG','                Patients with the AG genotype may have better response (decreased risk of lymph node metastases and increased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs17244841','A > T','HMGCR','fluvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01095 ','Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17244841','A > T','HMGCR','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs1045642','A > G','ABCB1','idarubicin','GENITO URINARY SYSTEM AND SEX HORMONES','OTHER GYNECOLOGICALS','DB01050','Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs11188072','C > T','CYP2C19','mephenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00532 ','Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. It is generally reserved for treatment of individuals refractory to less toxic agents. ','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs1045642','A > G','ABCB1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 4','-','-','increased','AG','                Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have an increased risk of adverse drug events (please note this association was not significant after correcting for multiple variables) 2) may have an increased risk of not responding to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse drug events and responsiveness when treated with methotrexate.'),('rs1045642','A > G','ABCB1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 4','decreased','-','-','AG','                Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have an increased risk of adverse drug events (please note this association was not significant after correcting for multiple variables) 2) may have an increased risk of not responding to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse drug events and responsiveness when treated with methotrexate.'),('rs1045642','A > G','ABCB1','nortriptyline','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00540 ','Nortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for postural hypotension with nortriptyline treatment.'),('rs11188072','C > T','CYP2C19','omeprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00338 ','A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles','Level 2A','-','increased','-','TT','                Adult patients, but not pediatric patients, with the TT genotype who are treated with omeprazole may require an increased dose as compared to patients with the CT or CC genotype.  Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration. This might not be applicable to pediatric patients.'),('rs1042522','C > G','TP53','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs11188072','C > T','CYP2C19','pantoprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00213 ','Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','-','AG','                Patients with genotype AG may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patients dose of phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','decreased','-','-','AG','                Patients with genotype AG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians. Other genetic or clinical factors may influence a patients response to phenytoin.'),('rs17244841','A > T','HMGCR','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 2A','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the TC And TT genotype.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs17244841','A > T','HMGCR','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.');
/*!40000 ALTER TABLE `sample5` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `sample6`
--

DROP TABLE IF EXISTS `sample6`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `sample6` (
  `RSID` varchar(20) DEFAULT NULL,
  `Alleles` varchar(7) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `Drug` varchar(60) DEFAULT NULL,
  `System` varchar(60) DEFAULT NULL,
  `subSystem` text,
  `drugID` varchar(60) DEFAULT NULL,
  `info` text,
  `Level` varchar(10) DEFAULT NULL,
  `Efficacy` varchar(20) DEFAULT NULL,
  `Dosage` varchar(20) DEFAULT NULL,
  `Toxicity` varchar(20) DEFAULT NULL,
  `Genotype` varchar(10) DEFAULT NULL,
  `Sentence` text
) ENGINE=InnoDB DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `sample6`
--

LOCK TABLES `sample6` WRITE;
/*!40000 ALTER TABLE `sample6` DISABLE KEYS */;
INSERT INTO `sample6` VALUES ('rs8012552','C > T','BDKRB2','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','decreased','TT','                Patients with the TT genotype and hypertension who are treated with ACE-inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of cough with ACE-inhibitors.'),('rs2108622','C > T','CYP4F2','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 2A','-','decreased','-','AC','                Patients with the AC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs2297480','T > G','FDPS','alendronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00630','Alendronate is a nitrogen-containing, second generation bisphosphonate. Bisphosphonates were first used to treat Pageta?s disease in 1971. This class of medications is comprised of inorganic pyrophosphate analogues that contain non-hydrolyzable P-C-P bonds. Similar to other bisphosphonates, alendronate has a high affinity for bone mineral and is taken up during osteoclast resorption. Alendronate inhibits farnesyl pyrophosphate synthetase, one of the enzymes in the mevalonic acid pathway involved in producing isoprenoid compounds that are essential for post-translational modification of small guanosine triphosphate (GTP)-binding proteins, such as Rho, Ras and Rab. Inhibition of this process interferes with osteoclast function and survival. Alendronate is used for the treatment of osteoporosis and Pageta?s disease','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1056892','G > A','CBR3','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 2B','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs7997012','A > G','HTR2A','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs3800373','C > A','FKBP5','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 2B','decreased','-','-','AA','                Patients with the AA genotype and depression who are treated with antidepressants may be less likely to have improvement in symptoms as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1057910','A > C','CYP2C9','Antiinflammatory agents, non-steroids','VARIOUS','','','The term nonsteroidal distinguishes these drugs from steroids, which, among a broad range of other effects, have a similar eicosanoid-depressing, anti-inflammatory action. As analgesics, NSAIDs are unusual in that they are non-narcotic and thus are used as a non-addictive alternative to narcotics.','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1042522','C > G','TP53','antineoplastic agents','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','','Inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1142345','T > C','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2297480','T > G','FDPS','Bisphosphonates','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','decreased','-','AC','                Patients with the AC genotype may have reduced metabolism of celecoxib and may require dose reduction when starting celecoxib therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1142345','T > C','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1042522','C > G','TP53','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs9332377','C > T','COMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','increased','TT','                Patients with the TT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs7997012','A > G','HTR2A','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1042522','C > G','TP53','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1057910','A > C','CYP2C9','diclofenac','SENSORY ORGANS','OPHTHALMOLOGICALS','DB00586 ','A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. [PubChem]','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs11188072','C > T','CYP2C19','escitalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01175 ','Escitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity.','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with escitalopram may require an increased dose  as compared to patients with the CT or CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs1042522','C > G','TP53','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1057910','A > C','CYP2C9','losartan','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00678 ','Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. ','Level 3','decreased','-','-','AC','                Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.'),('rs11188072','C > T','CYP2C19','mephenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00532 ','Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. It is generally reserved for treatment of individuals refractory to less toxic agents. ','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs1142345','T > C','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs7997012','A > G','HTR2A','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for side effects with olanzapine treatment.'),('rs11188072','C > T','CYP2C19','omeprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00338 ','A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles','Level 2A','-','increased','-','TT','                Adult patients, but not pediatric patients, with the TT genotype who are treated with omeprazole may require an increased dose as compared to patients with the CT or CC genotype.  Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration. This might not be applicable to pediatric patients.'),('rs1042522','C > G','TP53','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs11188072','C > T','CYP2C19','pantoprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00213 ','Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs2108622','C > T','CYP4F2','phenprocoumon','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00946','Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1142345','T > C','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2297480','T > G','FDPS','risedronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00884 ','Risedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 2A','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the TC And TT genotype.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs7997012','A > G','HTR2A','Selective serotonin reuptake inhibitors','VARIOUS','','','Selective beta-2-adrenoreceptor agonists are a class of drugs that act on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation, resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin.They are primarily used to treat asthma and other pulmonary disorders.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1142345','T > C','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1057910','A > C','CYP2C9','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs2108622','C > T','CYP4F2','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','increased','AC','                Patients with the AC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.');
/*!40000 ALTER TABLE `sample6` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `sample7`
--

DROP TABLE IF EXISTS `sample7`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `sample7` (
  `RSID` varchar(20) DEFAULT NULL,
  `Alleles` varchar(7) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `Drug` varchar(60) DEFAULT NULL,
  `System` varchar(60) DEFAULT NULL,
  `subSystem` text,
  `drugID` varchar(60) DEFAULT NULL,
  `info` text,
  `Level` varchar(10) DEFAULT NULL,
  `Efficacy` varchar(20) DEFAULT NULL,
  `Dosage` varchar(20) DEFAULT NULL,
  `Toxicity` varchar(20) DEFAULT NULL,
  `Genotype` varchar(10) DEFAULT NULL,
  `Sentence` text
) ENGINE=InnoDB DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `sample7`
--

LOCK TABLES `sample7` WRITE;
/*!40000 ALTER TABLE `sample7` DISABLE KEYS */;
INSERT INTO `sample7` VALUES ('rs2016848','G > A','MME','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','increased','AA','                Patients with the AA genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cough with ACE inhibitor treatment.'),('rs8012552','C > T','BDKRB2','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','decreased','TT','                Patients with the TT genotype and hypertension who are treated with ACE-inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of cough with ACE-inhibitors.'),('rs9934438','G > A','VKORC1','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs2108622','C > T','CYP4F2','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs2108622','C > T','CYP4F2','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 2A','-','decreased','-','CC','                Patients with the CC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs2297480','T > G','FDPS','alendronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00630','Alendronate is a nitrogen-containing, second generation bisphosphonate. Bisphosphonates were first used to treat Pageta?s disease in 1971. This class of medications is comprised of inorganic pyrophosphate analogues that contain non-hydrolyzable P-C-P bonds. Similar to other bisphosphonates, alendronate has a high affinity for bone mineral and is taken up during osteoclast resorption. Alendronate inhibits farnesyl pyrophosphate synthetase, one of the enzymes in the mevalonic acid pathway involved in producing isoprenoid compounds that are essential for post-translational modification of small guanosine triphosphate (GTP)-binding proteins, such as Rho, Ras and Rab. Inhibition of this process interferes with osteoclast function and survival. Alendronate is used for the treatment of osteoporosis and Pageta?s disease','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1045642','A > G','ABCB1','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs7997012','A > G','HTR2A','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs3800373','C > A','FKBP5','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 2B','decreased','-','-','AA','                Patients with the AA genotype and depression who are treated with antidepressants may be less likely to have improvement in symptoms as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1045642','A > G','ABCB1','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','increased','-','-','GG','                Genotype GG genotype  may be associated with decreased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype AA. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. Theres also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patients response to antiepileptics.'),('rs1057910','A > C','CYP2C9','Antiinflammatory agents, non-steroids','VARIOUS','','','The term nonsteroidal distinguishes these drugs from steroids, which, among a broad range of other effects, have a similar eicosanoid-depressing, anti-inflammatory action. As analgesics, NSAIDs are unusual in that they are non-narcotic and thus are used as a non-addictive alternative to narcotics.','Level 2A','-','-','increased','CC','                Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1042522','C > G','TP53','antineoplastic agents','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','','Inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1142345','T > C','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2297480','T > G','FDPS','Bisphosphonates','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs2297595','T > C','DPYD','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1045642','A > G','ABCB1','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 3','-','-','increased','GG','                Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.'),('rs1045642','A > G','ABCB1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 4','-','decreased','-','GG','                Patient with genotype GG may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine...'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','-','increased','CC','                Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','decreased','-','CC','                Patients with the CC genotype may have greatly reduced metabolism of celecoxib and may require dose reduction (50% of standard starting dose) when starting celecoxib therapy or alternative management in juvenile rheumatoid arthritis patients who carry this genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1799853','C > T','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 3','decreased','-','-','CT','                Patients with the CT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs4149056','T > C','SLCO1B1','cerivastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00439','On August 8, 2002 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.'),('rs1142345','T > C','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1800460','C > T','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CT','                Patients with the TC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1042522','C > G','TP53','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs9332377','C > T','COMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','increased','TT','                Patients with the TT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1045642','A > G','ABCB1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs7997012','A > G','HTR2A','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs4244285','G > A','CYP2C19','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 1A','decreased','-','-','AA','                Patients with the AA genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for secondary cardiovascular events and response to clopidogrel.'),('rs1045642','A > G','ABCB1','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 2A','increased','-','-','GG','                People with GG  genotype may have decreased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Other genetic and clinical factors may also impact the response to clopidogrel.'),('rs1042522','C > G','TP53','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2A','increased','-','-','AG','                Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs4244285','G > A','CYP2C19','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 4','-','-','decreased','AA','                Female patients with the AA genotype and Systemic Lupus Erythematosus who are treated with a high cumulative dose of cyclophosphamide (= or >23.75 g) may have a decreased risk of ovarian toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cyclophosphamide-induced ovarian toxicity.'),('rs4244285','G > A','CYP2C19','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 4','decreased','-','-','AA','                Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','decreased','TT','                Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the TT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patients risk for venoocclusive disease of the liver.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','decreased','-','TT','                Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs1045642','A > G','ABCB1','cyclosporine','VARIOUS','','','Cyclosporine is available in its original form and as another product that has been modified (changed) so that the medication can be better absorbed in the body. Original cyclosporine and cyclosporine (modified) are absorbed by the body in different amounts, so they cannot be substituted for one another. Take only the type of cyclosporine that was prescribed by your doctor. When your doctor gives you a written prescription, check to be sure that he or she has specified the type of cyclosporine you should receive. Each time you have your prescription filled, look at the brand name printed on your prescription label to be sure that you have received the same type of cyclosporine. Talk to your pharmacist if the brand name is unfamiliar or you are not sure you have received the right type of cyclosporine.','Level 3','-','decreased','-','GG','                Patients with genotype GG may have decreased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype AA or AG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.'),('rs1045642','A > G','ABCB1','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','dexamethasone','RESPIRATORY SYSTEM','','','Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant effects. It is 25 times more potent than cortisol in its glucocorticoid effect, while having minimal mineralocorticoid effect.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs1057910','A > C','CYP2C9','diclofenac','SENSORY ORGANS','OPHTHALMOLOGICALS','DB00586 ','A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. [PubChem]','Level 2A','-','-','increased','CC','                Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs4244285','G > A','CYP2C19','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 4','decreased','-','-','AA','                Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs3745274','G > T','CYP2B6','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','-','TT','                Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs3745274','G > T','CYP2A7P1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 2A','-','increased','-','TT','                Patients with the TT genotype may have increased plasma concentration of efavirenz in people with HIV as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients exposure to efavirenz.'),('rs3745274','G > T','CYP2A7P1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 2A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for efavirenz-induced side effects (central nervous symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1045642','A > G','ABCB1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.'),('rs1695','A > G','GSTP1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 2A','increased','-','-','AG','                Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1045642','A > G','ABCB1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','fexofenadine','RESPIRATORY SYSTEM','ANTIHISTAMINES FOR SYSTEMIC USE','DB00950','Fexofenadine hydrochloride (Allegra) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine.','Level 3','-','-','-','GG','                Healthy individuals with the GG genotype who are treated with fexofenadine may have higher plasma drug levels as compared with healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.'),('rs1042522','C > G','TP53','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','AG','                Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for hematological toxicity when exposed to fluorouracil.'),('rs2297595','T > C','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with GG genotype may have decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also impact a patients response to fluorouracil.'),('rs4149056','T > C','SLCO1B1','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patients metabolism and response to statins.'),('rs1045642','A > G','ABCB1','idarubicin','GENITO URINARY SYSTEM AND SEX HORMONES','OTHER GYNECOLOGICALS','DB01050','Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1057910','A > C','CYP2C9','losartan','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00678 ','Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. ','Level 3','decreased','-','-','CC','                Subjects with the CC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.'),('rs1142345','T > C','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1045642','A > G','ABCB1','nelfinavir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00220 ','A potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.','Level 3','-','-','-','GG','                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.'),('rs1045642','A > G','ABCB1','nevirapine','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00238 ','A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. [PubChem]','Level 2A','-','-','increased','GG','                Patients with the GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hepatotoxicity with nevirapine treatment.'),('rs1045642','A > G','ABCB1','nortriptyline','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00540 ','Nortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for postural hypotension with nortriptyline treatment.'),('rs7997012','A > G','HTR2A','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for side effects with olanzapine treatment.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 3','-','-','increased','AG','                Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1042522','C > G','TP53','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.'),('rs1045642','A > G','ABCB1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','increased','-','-','GG','                Genotype GG may be associated with increased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype AG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.'),('rs11188072','C > T','CYP2C19','pantoprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00213 ','Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.','Level 3','-','increased','-','CT','                Patients with the CT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs12979860','C > T','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs12979860','C > T','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs2108622','C > T','CYP4F2','phenprocoumon','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00946','Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs2108622','C > T','CYP4F2','phenprocoumon','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00946','Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','CC','                Patients with the CC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1799853','C > T','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','CT','                Patients with the CT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','decreased','-','-','GG','                Patients with genotype GG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians.  Other genetic or clinical factors may influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','increased','-','GG','                Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patients dose of phenytoin.'),('rs1695','A > G','GSTP1','Platinum compounds','VARIOUS','','','','Level 3','-','-','increased','AG','                Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1142345','T > C','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs4149056','T > C','SLCO1B1','repaglinide','GENITO URINARY SYSTEM AND SEX HORMONES','DRUGS USED IN DIABETES','DB00912 ','Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to |? cells of the pancreas to stimulate insulin release.','Level 3','-','-','-','CC','                Patients with the CC genotype may have increased mean plasma AUC of repaglinide and greater blood glucose-lowering effect in response to repaglinide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients response.'),('rs12979860','C > T','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs2297480','T > G','FDPS','risedronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00884 ','Risedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs7997012','A > G','HTR2A','Selective serotonin reuptake inhibitors','VARIOUS','','','Selective beta-2-adrenoreceptor agonists are a class of drugs that act on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation, resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin.They are primarily used to treat asthma and other pulmonary disorders.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs4149056','T > C','SLCO1B1','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 1A','-','-','increased','CC','                Patients with the CC genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1057910','A > C','CYP2C9','sulfonamides, urea derivatives','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','increased','-','-','CC','                Patients with the CC genotype who are treated with sulfonylurea: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the AA genotype 2) May be less likely to have failure of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to sulfonylurea therapy.'),('rs1142345','T > C','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1057910','A > C','CYP2C9','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','-','increased','CC','                Patients with the CC genotype were not studied. However, patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs1045642','A > G','ABCB1','vincristine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00541','Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkina?s disease, acute erythraemia, and acute panmyelosis.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs7294','C > T','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.'),('rs9934438','G > A','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs2108622','C > T','CYP4F2','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs2108622','C > T','CYP4F2','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1799853','C > T','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients dose of warfarin.'),('rs1057910','A > C','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','increased','CC','                Patients with the CC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.');
/*!40000 ALTER TABLE `sample7` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `sample8`
--

DROP TABLE IF EXISTS `sample8`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `sample8` (
  `RSID` varchar(20) DEFAULT NULL,
  `Alleles` varchar(7) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `Drug` varchar(60) DEFAULT NULL,
  `System` varchar(60) DEFAULT NULL,
  `subSystem` text,
  `drugID` varchar(60) DEFAULT NULL,
  `info` text,
  `Level` varchar(10) DEFAULT NULL,
  `Efficacy` varchar(20) DEFAULT NULL,
  `Dosage` varchar(20) DEFAULT NULL,
  `Toxicity` varchar(20) DEFAULT NULL,
  `Genotype` varchar(10) DEFAULT NULL,
  `Sentence` text
) ENGINE=InnoDB DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `sample8`
--

LOCK TABLES `sample8` WRITE;
/*!40000 ALTER TABLE `sample8` DISABLE KEYS */;
INSERT INTO `sample8` VALUES ('rs8012552','C > T','BDKRB2','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','decreased','TT','                Patients with the TT genotype and hypertension who are treated with ACE-inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of cough with ACE-inhibitors.'),('rs2108622','C > T','CYP4F2','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs2108622','C > T','CYP4F2','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 2A','-','decreased','-','AC','                Patients with the AC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs1056892','G > A','CBR3','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 2B','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1045642','A > G','ABCB1','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs7997012','A > G','HTR2A','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1045642','A > G','ABCB1','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','increased','-','-','GG','                Genotype GG genotype  may be associated with decreased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype AA. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. Theres also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patients response to antiepileptics.'),('rs1057910','A > C','CYP2C9','Antiinflammatory agents, non-steroids','VARIOUS','','','The term nonsteroidal distinguishes these drugs from steroids, which, among a broad range of other effects, have a similar eicosanoid-depressing, anti-inflammatory action. As analgesics, NSAIDs are unusual in that they are non-narcotic and thus are used as a non-addictive alternative to narcotics.','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1042522','C > G','TP53','antineoplastic agents','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','','Inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1142345','T > C','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2297595','T > C','DPYD','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1045642','A > G','ABCB1','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 3','-','-','increased','GG','                Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.'),('rs1045642','A > G','ABCB1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 4','-','decreased','-','GG','                Patient with genotype GG may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine...'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','decreased','-','AC','                Patients with the AC genotype may have reduced metabolism of celecoxib and may require dose reduction when starting celecoxib therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1799853','C > T','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs2228001','G > T','XPC','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','decreased','TT','                Patients with the TT genotype may have a decreased but not non-existent risk for toxicity with cisplatin treatment as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1142345','T > C','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1800460','C > T','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CT','                Patients with the TC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1042522','C > G','TP53','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs9332377','C > T','COMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','increased','CT','                Patients with the CT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1045642','A > G','ABCB1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs7997012','A > G','HTR2A','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1954787','T > C','GRIK4','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 1B','increased','-','-','CC','                Patients with the CC genotype may have an increased chance of response to citalopram treatment as compared to patients with the TT genotype. Patients with the CC genotype may still be at risk for non-response to citalopram treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1045642','A > G','ABCB1','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 2A','increased','-','-','GG','                People with GG  genotype may have decreased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Other genetic and clinical factors may also impact the response to clopidogrel.'),('rs1042522','C > G','TP53','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2A','decreased','-','increased','GG','                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','decreased','GT','                Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patients risk for venoocclusive disease of the liver.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','decreased','-','GT','                Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs1045642','A > G','ABCB1','cyclosporine','VARIOUS','','','Cyclosporine is available in its original form and as another product that has been modified (changed) so that the medication can be better absorbed in the body. Original cyclosporine and cyclosporine (modified) are absorbed by the body in different amounts, so they cannot be substituted for one another. Take only the type of cyclosporine that was prescribed by your doctor. When your doctor gives you a written prescription, check to be sure that he or she has specified the type of cyclosporine you should receive. Each time you have your prescription filled, look at the brand name printed on your prescription label to be sure that you have received the same type of cyclosporine. Talk to your pharmacist if the brand name is unfamiliar or you are not sure you have received the right type of cyclosporine.','Level 3','-','decreased','-','GG','                Patients with genotype GG may have decreased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype AA or AG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.'),('rs1045642','A > G','ABCB1','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','dexamethasone','RESPIRATORY SYSTEM','','','Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant effects. It is 25 times more potent than cortisol in its glucocorticoid effect, while having minimal mineralocorticoid effect.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs1057910','A > C','CYP2C9','diclofenac','SENSORY ORGANS','OPHTHALMOLOGICALS','DB00586 ','A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. [PubChem]','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs3745274','G > T','CYP2A7P1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 2A','-','-','increased','GT','                Patients with the GT genotype may have an increased risk of efavirenz-induced side effects (central nervous symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1045642','A > G','ABCB1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.'),('rs1695','A > G','GSTP1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 2A','decreased','-','increased','GG','                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1045642','A > G','ABCB1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','fexofenadine','RESPIRATORY SYSTEM','ANTIHISTAMINES FOR SYSTEMIC USE','DB00950','Fexofenadine hydrochloride (Allegra) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine.','Level 3','-','-','-','GG','                Healthy individuals with the GG genotype who are treated with fexofenadine may have higher plasma drug levels as compared with healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.'),('rs1042522','C > G','TP53','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','increased','-','-','GG','                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hematological toxicity when exposed to flourouracil.'),('rs2297595','T > C','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with GG genotype may have decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also impact a patients response to fluorouracil.'),('rs1045642','A > G','ABCB1','idarubicin','GENITO URINARY SYSTEM AND SEX HORMONES','OTHER GYNECOLOGICALS','DB01050','Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1057910','A > C','CYP2C9','losartan','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00678 ','Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. ','Level 3','decreased','-','-','AC','                Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.'),('rs1142345','T > C','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1695','A > G','GSTP1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','GG','                Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased likelihood of Drug Toxicity as compared to patients with the AG and AA genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patients level of methotrexate induced toxicity.'),('rs1045642','A > G','ABCB1','nelfinavir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00220 ','A potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.','Level 3','-','-','-','GG','                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.'),('rs1045642','A > G','ABCB1','nevirapine','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00238 ','A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. [PubChem]','Level 2A','-','-','increased','GG','                Patients with the GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hepatotoxicity with nevirapine treatment.'),('rs1045642','A > G','ABCB1','nortriptyline','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00540 ','Nortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for postural hypotension with nortriptyline treatment.'),('rs7997012','A > G','HTR2A','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for side effects with olanzapine treatment.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 2A','increased','-','-','GG','                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 3','-','-','increased','GG','                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1042522','C > G','TP53','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.'),('rs1045642','A > G','ABCB1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','increased','-','-','GG','                Genotype GG may be associated with increased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype AG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.'),('rs11188072','C > T','CYP2C19','pantoprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00213 ','Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.','Level 3','-','increased','-','CT','                Patients with the CT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs12979860','C > T','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs12979860','C > T','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs2108622','C > T','CYP4F2','phenprocoumon','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00946','Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs2108622','C > T','CYP4F2','phenprocoumon','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00946','Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1799853','C > T','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','TT','                Patients with the TT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','decreased','-','-','GG','                Patients with genotype GG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians.  Other genetic or clinical factors may influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','increased','-','GG','                Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patients dose of phenytoin.'),('rs1695','A > G','GSTP1','Platinum compounds','VARIOUS','','','','Level 3','-','-','increased','GG','                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1142345','T > C','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs12979860','C > T','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 2A','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the TC And TT genotype.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs7997012','A > G','HTR2A','Selective serotonin reuptake inhibitors','VARIOUS','','','Selective beta-2-adrenoreceptor agonists are a class of drugs that act on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation, resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin.They are primarily used to treat asthma and other pulmonary disorders.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1799853','C > T','CYP2C9','sulfonamides, urea derivatives','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','increased','-','-','TT','                Patients with the TT genotype and type II diabetes who are treated with sulfonylureas: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the CC genotype 2) May be less likely to experience treatment failure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to sulfonylureas.'),('rs1142345','T > C','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1057910','A > C','CYP2C9','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs1045642','A > G','ABCB1','vincristine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00541','Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkina?s disease, acute erythraemia, and acute panmyelosis.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs7294','C > T','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.'),('rs2108622','C > T','CYP4F2','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs2108622','C > T','CYP4F2','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1799853','C > T','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','-','TT','                Patients with the TT genotype who are treated with warfarin may require a lower dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients dose of warfarin.'),('rs1057910','A > C','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','increased','AC','                Patients with the AC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.');
/*!40000 ALTER TABLE `sample8` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `sample9`
--

DROP TABLE IF EXISTS `sample9`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `sample9` (
  `RSID` varchar(20) DEFAULT NULL,
  `Alleles` varchar(7) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `Drug` varchar(60) DEFAULT NULL,
  `System` varchar(60) DEFAULT NULL,
  `subSystem` text,
  `drugID` varchar(60) DEFAULT NULL,
  `info` text,
  `Level` varchar(10) DEFAULT NULL,
  `Efficacy` varchar(20) DEFAULT NULL,
  `Dosage` varchar(20) DEFAULT NULL,
  `Toxicity` varchar(20) DEFAULT NULL,
  `Genotype` varchar(10) DEFAULT NULL,
  `Sentence` text
) ENGINE=InnoDB DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `sample9`
--

LOCK TABLES `sample9` WRITE;
/*!40000 ALTER TABLE `sample9` DISABLE KEYS */;
INSERT INTO `sample9` VALUES ('rs8012552','C > T','BDKRB2','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','decreased','TT','                Patients with the TT genotype and hypertension who are treated with ACE-inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of cough with ACE-inhibitors.'),('rs9934438','G > A','VKORC1','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs2108622','C > T','CYP4F2','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 2A','-','decreased','-','AC','                Patients with the AC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs2297480','T > G','FDPS','alendronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00630','Alendronate is a nitrogen-containing, second generation bisphosphonate. Bisphosphonates were first used to treat Pageta?s disease in 1971. This class of medications is comprised of inorganic pyrophosphate analogues that contain non-hydrolyzable P-C-P bonds. Similar to other bisphosphonates, alendronate has a high affinity for bone mineral and is taken up during osteoclast resorption. Alendronate inhibits farnesyl pyrophosphate synthetase, one of the enzymes in the mevalonic acid pathway involved in producing isoprenoid compounds that are essential for post-translational modification of small guanosine triphosphate (GTP)-binding proteins, such as Rho, Ras and Rab. Inhibition of this process interferes with osteoclast function and survival. Alendronate is used for the treatment of osteoporosis and Pageta?s disease','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1045642','A > G','ABCB1','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs7997012','A > G','HTR2A','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs3800373','C > A','FKBP5','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 2B','decreased','-','-','AA','                Patients with the AA genotype and depression who are treated with antidepressants may be less likely to have improvement in symptoms as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1045642','A > G','ABCB1','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','increased','-','-','GG','                Genotype GG genotype  may be associated with decreased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype AA. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. Theres also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patients response to antiepileptics.'),('rs1057910','A > C','CYP2C9','Antiinflammatory agents, non-steroids','VARIOUS','','','The term nonsteroidal distinguishes these drugs from steroids, which, among a broad range of other effects, have a similar eicosanoid-depressing, anti-inflammatory action. As analgesics, NSAIDs are unusual in that they are non-narcotic and thus are used as a non-addictive alternative to narcotics.','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1042522','C > G','TP53','antineoplastic agents','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','','Inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1800460','C > T','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2297480','T > G','FDPS','Bisphosphonates','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1045642','A > G','ABCB1','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 3','-','-','increased','GG','                Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.'),('rs1045642','A > G','ABCB1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 4','-','decreased','-','GG','                Patient with genotype GG may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine...'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','decreased','-','AC','                Patients with the AC genotype may have reduced metabolism of celecoxib and may require dose reduction when starting celecoxib therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1799853','C > T','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1800460','C > T','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','TT','                Patients with the TT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1042522','C > G','TP53','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs9332377','C > T','COMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','increased','TT','                Patients with the TT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1045642','A > G','ABCB1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs7997012','A > G','HTR2A','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs1045642','A > G','ABCB1','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 2A','increased','-','-','GG','                People with GG  genotype may have decreased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Other genetic and clinical factors may also impact the response to clopidogrel.'),('rs1042522','C > G','TP53','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2A','decreased','-','increased','GG','                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','decreased','GT','                Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patients risk for venoocclusive disease of the liver.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','decreased','-','GT','                Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs1045642','A > G','ABCB1','cyclosporine','VARIOUS','','','Cyclosporine is available in its original form and as another product that has been modified (changed) so that the medication can be better absorbed in the body. Original cyclosporine and cyclosporine (modified) are absorbed by the body in different amounts, so they cannot be substituted for one another. Take only the type of cyclosporine that was prescribed by your doctor. When your doctor gives you a written prescription, check to be sure that he or she has specified the type of cyclosporine you should receive. Each time you have your prescription filled, look at the brand name printed on your prescription label to be sure that you have received the same type of cyclosporine. Talk to your pharmacist if the brand name is unfamiliar or you are not sure you have received the right type of cyclosporine.','Level 3','-','decreased','-','GG','                Patients with genotype GG may have decreased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype AA or AG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.'),('rs1045642','A > G','ABCB1','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','dexamethasone','RESPIRATORY SYSTEM','','','Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant effects. It is 25 times more potent than cortisol in its glucocorticoid effect, while having minimal mineralocorticoid effect.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs1057910','A > C','CYP2C9','diclofenac','SENSORY ORGANS','OPHTHALMOLOGICALS','DB00586 ','A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. [PubChem]','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs3745274','G > T','CYP2A7P1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 2A','-','-','increased','GT','                Patients with the GT genotype may have an increased risk of efavirenz-induced side effects (central nervous symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1045642','A > G','ABCB1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.'),('rs1695','A > G','GSTP1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 2A','decreased','-','increased','GG','                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1045642','A > G','ABCB1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','fexofenadine','RESPIRATORY SYSTEM','ANTIHISTAMINES FOR SYSTEMIC USE','DB00950','Fexofenadine hydrochloride (Allegra) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine.','Level 3','-','-','-','GG','                Healthy individuals with the GG genotype who are treated with fexofenadine may have higher plasma drug levels as compared with healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.'),('rs1042522','C > G','TP53','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','increased','-','-','GG','                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hematological toxicity when exposed to flourouracil.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with GG genotype may have decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also impact a patients response to fluorouracil.'),('rs17244841','A > T','HMGCR','fluvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01095 ','Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17244841','A > T','HMGCR','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs1045642','A > G','ABCB1','idarubicin','GENITO URINARY SYSTEM AND SEX HORMONES','OTHER GYNECOLOGICALS','DB01050','Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1057910','A > C','CYP2C9','losartan','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00678 ','Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. ','Level 3','decreased','-','-','AC','                Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.'),('rs1800460','C > T','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1695','A > G','GSTP1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','GG','                Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased likelihood of Drug Toxicity as compared to patients with the AG and AA genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patients level of methotrexate induced toxicity.'),('rs1045642','A > G','ABCB1','nelfinavir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00220 ','A potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.','Level 3','-','-','-','GG','                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.'),('rs1045642','A > G','ABCB1','nevirapine','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00238 ','A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. [PubChem]','Level 2A','-','-','increased','GG','                Patients with the GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hepatotoxicity with nevirapine treatment.'),('rs1045642','A > G','ABCB1','nortriptyline','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00540 ','Nortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for postural hypotension with nortriptyline treatment.'),('rs7997012','A > G','HTR2A','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for side effects with olanzapine treatment.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 2A','increased','-','-','GG','                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 3','-','-','increased','GG','                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1042522','C > G','TP53','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1045642','A > G','ABCB1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.'),('rs1045642','A > G','ABCB1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','increased','-','-','GG','                Genotype GG may be associated with increased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype AG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.'),('rs11188072','C > T','CYP2C19','pantoprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00213 ','Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.','Level 3','-','increased','-','CT','                Patients with the CT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs12979860','C > T','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs12979860','C > T','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs2108622','C > T','CYP4F2','phenprocoumon','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00946','Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1799853','C > T','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','TT','                Patients with the TT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','decreased','-','-','GG','                Patients with genotype GG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians.  Other genetic or clinical factors may influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','increased','-','GG','                Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patients dose of phenytoin.'),('rs1695','A > G','GSTP1','Platinum compounds','VARIOUS','','','','Level 3','-','-','increased','GG','                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs17244841','A > T','HMGCR','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs1800460','C > T','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs12979860','C > T','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs2297480','T > G','FDPS','risedronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00884 ','Risedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs7997012','A > G','HTR2A','Selective serotonin reuptake inhibitors','VARIOUS','','','Selective beta-2-adrenoreceptor agonists are a class of drugs that act on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation, resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin.They are primarily used to treat asthma and other pulmonary disorders.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs17244841','A > T','HMGCR','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs1799853','C > T','CYP2C9','sulfonamides, urea derivatives','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','increased','-','-','TT','                Patients with the TT genotype and type II diabetes who are treated with sulfonylureas: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the CC genotype 2) May be less likely to experience treatment failure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to sulfonylureas.'),('rs1800460','C > T','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1057910','A > C','CYP2C9','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs1045642','A > G','ABCB1','vincristine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00541','Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkina?s disease, acute erythraemia, and acute panmyelosis.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs7294','C > T','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.'),('rs9934438','G > A','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs2108622','C > T','CYP4F2','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1799853','C > T','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','-','TT','                Patients with the TT genotype who are treated with warfarin may require a lower dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients dose of warfarin.'),('rs1057910','A > C','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','increased','AC','                Patients with the AC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.');
/*!40000 ALTER TABLE `sample9` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `statistics_report`
--

DROP TABLE IF EXISTS `statistics_report`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `statistics_report` (
  `RSID` varchar(255) DEFAULT NULL,
  `Genotype` varchar(255) DEFAULT NULL,
  `Drug` varchar(255) DEFAULT NULL,
  `Gene` varchar(255) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8 ROW_FORMAT=COMPACT;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `statistics_report`
--

LOCK TABLES `statistics_report` WRITE;
/*!40000 ALTER TABLE `statistics_report` DISABLE KEYS */;
INSERT INTO `statistics_report` VALUES ('rs11209716','CC','Ace Inhibitors, Plain','PTGER3'),('rs2016848','AA','Ace Inhibitors, Plain','MME'),('rs2108622','TT','acenocoumarol','CYP4F2'),('rs1056892','AA','anthracyclines and related substances','CBR3'),('rs1042522','CG','antineoplastic agents','TP53'),('rs1801133','AA','antipsychotics','CLCN6'),('rs1800460','CT','azathioprine','TPMT'),('rs1800462','GG','azathioprine','TPMT'),('rs2297595','CC','capecitabine','DPYD'),('rs1801133','AA','carboplatin','CLCN6'),('rs1799853','CT','celecoxib','CYP2C9'),('rs2228001','TT','cisplatin','XPC'),('rs1800460','CT','cisplatin','TPMT'),('rs1042522','CG','cisplatin','TP53'),('rs1801133','AA','cisplatin','MTHFR'),('rs1695','AG','cisplatin','GSTP1'),('rs9332377','CT','cisplatin','COMT'),('rs1042522','CG','cyclophosphamide','TP53'),('rs1801133','AA','cyclophosphamide','MTHFR'),('rs1695','AG','cyclophosphamide','GSTP1'),('rs3745274','GT','cyclophosphamide','CYP2B6'),('rs3745274','GT','efavirenz','CYP2A7P1'),('rs1695','AG','epirubicin','GSTP1'),('rs1042522','CG','fluorouracil','TP53'),('rs1801133','AA','fluorouracil','MTHFR'),('rs1695','AG','fluorouracil','GSTP1'),('rs2297595','CC','fluorouracil','DPYD'),('rs1800460','CT','mercaptopurine','TPMT'),('rs1800462','GG','mercaptopurine','TPMT'),('rs1801133','AA','mercaptopurine','MTHFR'),('rs1801133','AA','methotrexate','MTHFR'),('rs1801133','AA','nitrous oxide','MTHFR'),('rs1695','AG','oxaliplatin','GSTP1'),('rs1042522','CG','paclitaxel','TP53'),('rs12979860','TT','peginterferon alfa-2a','IL28B'),('rs8099917','GG','peginterferon alfa-2a','IL28B'),('rs12979860','TT','peginterferon alfa-2b','IL28B'),('rs8099917','GG','peginterferon alfa-2b','IL28B'),('rs2108622','TT','phenprocoumon','CYP4F2'),('rs1799853','CT','phenytoin','CYP2C9'),('rs1695','AG','Platinum compounds','GSTP1'),('rs1800460','CT','purine analogues','TPMT'),('rs1800462','GG','purine analogues','TPMT'),('rs12979860','TT','ribavirin','IL28B'),('rs8099917','GG','ribavirin','IL28B'),('rs1800460','CT','thioguanine','TPMT'),('rs1800462','GG','thioguanine','TPMT'),('rs7294','CT','warfarin','VKORC1'),('rs2108622','TT','warfarin','CYP4F2'),('rs1799853','CT','warfarin','CYP2C9'),('rs2108622','CT','acenocoumarol','CYP4F2'),('rs2108622','TT','acenocoumarol','CYP4F2'),('rs1057910','AC','acenocoumarol','CYP2C9'),('rs1056892','AA','anthracyclines and related substances','CBR3'),('rs1045642','GG','anthracyclines and related substances','ABCB1'),('rs1045642','GG','antiepileptics','ABCB1'),('rs1057910','AC','Antiinflammatory agents, non-steroids','CYP2C9'),('rs1042522','CG','antineoplastic agents','TP53'),('rs1800460','CT','azathioprine','TPMT'),('rs1800462','GG','azathioprine','TPMT'),('rs1045642','GG','capecitabine','ABCB1'),('rs1045642','GG','carbamazepine','ABCB1'),('rs1057910','AC','celecoxib','CYP2C9'),('rs1799853','CT','celecoxib','CYP2C9'),('rs4149056','CC','cerivastatin','SLCO1B1'),('rs1800460','CT','cisplatin','TPMT'),('rs1042522','CG','cisplatin','TP53'),('rs1695','GG','cisplatin','GSTP1'),('rs9332377','TT','cisplatin','COMT'),('rs1045642','GG','cisplatin','ABCB1'),('rs4244285','AA','clopidogrel','CYP2C19'),('rs1045642','GG','clopidogrel','ABCB1'),('rs1042522','CG','cyclophosphamide','TP53'),('rs1695','GG','cyclophosphamide','GSTP1'),('rs4244285','AA','cyclophosphamide','CYP2C19'),('rs3745274','GT','cyclophosphamide','CYP2B6'),('rs1045642','GG','cyclosporine','ABCB1'),('rs1045642','GG','cytarabine','ABCB1'),('rs1045642','GG','dexamethasone','ABCB1'),('rs1057910','AC','diclofenac','CYP2C9'),('rs4244285','AA','doxorubicin','CYP2C19'),('rs1045642','GG','doxorubicin','ABCB1'),('rs3745274','GT','efavirenz','CYP2A7P1'),('rs1045642','GG','efavirenz','ABCB1'),('rs1695','GG','epirubicin','GSTP1'),('rs1045642','GG','epirubicin','ABCB1'),('rs1045642','GG','fexofenadine','ABCB1'),('rs1042522','CG','fluorouracil','TP53'),('rs1695','GG','fluorouracil','GSTP1'),('rs1045642','GG','fluorouracil','ABCB1'),('rs17244841','AT','fluvastatin','HMGCR'),('rs4149056','CC','hmg coa reductase inhibitors','SLCO1B1'),('rs17244841','AT','hmg coa reductase inhibitors','HMGCR'),('rs1045642','GG','idarubicin','ABCB1'),('rs1057910','AC','losartan','CYP2C9'),('rs1800460','CT','mercaptopurine','TPMT'),('rs1800462','GG','mercaptopurine','TPMT'),('rs1695','GG','methotrexate','GSTP1'),('rs1045642','GG','nelfinavir','ABCB1'),('rs1045642','GG','nevirapine','ABCB1'),('rs1045642','GG','nortriptyline','ABCB1'),('rs7997012','AG','olanzapine','HTR2A'),('rs1695','GG','oxaliplatin','GSTP1'),('rs1042522','CG','paclitaxel','TP53'),('rs1045642','GG','paclitaxel','ABCB1'),('rs11188072','CT','pantoprazole','CYP2C19'),('rs12979860','CT','peginterferon alfa-2a','IL28B'),('rs8099917','GG','peginterferon alfa-2a','IL28B'),('rs12979860','CT','peginterferon alfa-2b','IL28B'),('rs8099917','GG','peginterferon alfa-2b','IL28B'),('rs2108622','CT','phenprocoumon','CYP4F2'),('rs2108622','TT','phenprocoumon','CYP4F2'),('rs1057910','AC','phenytoin','CYP2C9'),('rs1799853','CT','phenytoin','CYP2C9'),('rs1045642','GG','phenytoin','ABCB1'),('rs1695','GG','Platinum compounds','GSTP1'),('rs17244841','AT','pravastatin','HMGCR'),('rs1800460','CT','purine analogues','TPMT'),('rs1800462','GG','purine analogues','TPMT'),('rs4149056','CC','repaglinide','SLCO1B1'),('rs12979860','CT','ribavirin','IL28B'),('rs8099917','GG','ribavirin','IL28B'),('rs4149056','CC','simvastatin','SLCO1B1'),('rs17244841','AT','simvastatin','HMGCR'),('rs1800460','CT','thioguanine','TPMT'),('rs1800462','GG','thioguanine','TPMT'),('rs1057910','AC','valproic acid','CYP2C9'),('rs1045642','GG','vincristine','ABCB1'),('rs7294','CT','warfarin','VKORC1'),('rs2108622','CT','warfarin','CYP4F2'),('rs2108622','TT','warfarin','CYP4F2'),('rs1799853','CT','warfarin','CYP2C9'),('rs1057910','AC','warfarin','CYP2C9'),('rs2108622','CT','acenocoumarol','CYP4F2'),('rs1057910','AC','acenocoumarol','CYP2C9'),('rs1045642','AG','anthracyclines and related substances','ABCB1'),('rs1045642','AG','antiepileptics','ABCB1'),('rs1057910','AC','Antiinflammatory agents, non-steroids','CYP2C9'),('rs1042522','CG','antineoplastic agents','TP53'),('rs1045642','AG','capecitabine','ABCB1'),('rs1045642','AG','carbamazepine','ABCB1'),('rs1057910','AC','celecoxib','CYP2C9'),('rs4149056','CC','cerivastatin','SLCO1B1'),('rs1042522','CG','cisplatin','TP53'),('rs1695','GG','cisplatin','GSTP1'),('rs1045642','AG','cisplatin','ABCB1'),('rs1042522','CG','cyclophosphamide','TP53'),('rs1695','GG','cyclophosphamide','GSTP1'),('rs3745274','TT','cyclophosphamide','CYP2B6'),('rs1045642','AG','cyclosporine','ABCB1'),('rs1045642','AG','cytarabine','ABCB1'),('rs1057910','AC','diclofenac','CYP2C9'),('rs3745274','TT','doxorubicin','CYP2B6'),('rs1045642','AG','doxorubicin','ABCB1'),('rs3745274','TT','efavirenz','CYP2A7P1'),('rs1695','GG','epirubicin','GSTP1'),('rs1045642','AG','epirubicin','ABCB1'),('rs1045642','AG','fexofenadine','ABCB1'),('rs1042522','CG','fluorouracil','TP53'),('rs1695','GG','fluorouracil','GSTP1'),('rs1045642','AG','fluorouracil','ABCB1'),('rs17244841','AT','fluvastatin','HMGCR'),('rs4149056','CC','hmg coa reductase inhibitors','SLCO1B1'),('rs17244841','AT','hmg coa reductase inhibitors','HMGCR'),('rs1045642','AG','idarubicin','ABCB1'),('rs1057910','AC','losartan','CYP2C9'),('rs1695','GG','methotrexate','GSTP1'),('rs1045642','AG','methotrexate','ABCB1'),('rs1045642','AG','nortriptyline','ABCB1'),('rs7997012','AG','olanzapine','HTR2A'),('rs1695','GG','oxaliplatin','GSTP1'),('rs1042522','CG','paclitaxel','TP53'),('rs2108622','CT','phenprocoumon','CYP4F2'),('rs1057910','AC','phenytoin','CYP2C9'),('rs1045642','AG','phenytoin','ABCB1'),('rs1695','GG','Platinum compounds','GSTP1'),('rs17244841','AT','pravastatin','HMGCR'),('rs4149056','CC','repaglinide','SLCO1B1'),('rs4149056','CC','simvastatin','SLCO1B1'),('rs17244841','AT','simvastatin','HMGCR'),('rs1057910','AC','valproic acid','CYP2C9'),('rs2108622','CT','warfarin','CYP4F2'),('rs1057910','AC','warfarin','CYP2C9'),('rs1045642','AG','anthracyclines and related substances','ABCB1'),('rs1045642','AG','antiepileptics','ABCB1'),('rs1042522','CG','antineoplastic agents','TP53'),('rs1045642','AG','capecitabine','ABCB1'),('rs1045642','AG','carbamazepine','ABCB1'),('rs1042522','CG','cisplatin','TP53'),('rs1045642','AG','cisplatin','ABCB1'),('rs1042522','CG','cyclophosphamide','TP53'),('rs1045642','AG','cyclosporine','ABCB1'),('rs1045642','AG','cytarabine','ABCB1'),('rs1045642','AG','doxorubicin','ABCB1'),('rs1045642','AG','epirubicin','ABCB1'),('rs11188072','TT','escitalopram','CYP2C19'),('rs1045642','AG','fexofenadine','ABCB1'),('rs1042522','CG','fluorouracil','TP53'),('rs1045642','AG','fluorouracil','ABCB1'),('rs17244841','AT','fluvastatin','HMGCR'),('rs17244841','AT','hmg coa reductase inhibitors','HMGCR'),('rs1045642','AG','idarubicin','ABCB1'),('rs11188072','TT','mephenytoin','CYP2C19'),('rs1045642','AG','methotrexate','ABCB1'),('rs1045642','AG','nortriptyline','ABCB1'),('rs11188072','TT','omeprazole','CYP2C19'),('rs1042522','CG','paclitaxel','TP53'),('rs11188072','TT','pantoprazole','CYP2C19'),('rs1045642','AG','phenytoin','ABCB1'),('rs17244841','AT','pravastatin','HMGCR'),('rs17244841','AT','simvastatin','HMGCR'),('rs2108622','CT','acenocoumarol','CYP4F2'),('rs1057910','AC','acenocoumarol','CYP2C9'),('rs1057910','AC','Antiinflammatory agents, non-steroids','CYP2C9'),('rs1042522','CG','antineoplastic agents','TP53'),('rs1057910','AC','celecoxib','CYP2C9'),('rs1042522','CG','cisplatin','TP53'),('rs1042522','CG','cyclophosphamide','TP53'),('rs1057910','AC','diclofenac','CYP2C9'),('rs1042522','CG','fluorouracil','TP53'),('rs1057910','AC','losartan','CYP2C9'),('rs1042522','CG','paclitaxel','TP53'),('rs2108622','CT','phenprocoumon','CYP4F2'),('rs1057910','AC','phenytoin','CYP2C9'),('rs1799978','CC','risperidone','DRD2'),('rs1057910','AC','valproic acid','CYP2C9'),('rs7294','CT','warfarin','VKORC1'),('rs2108622','CT','warfarin','CYP4F2'),('rs1057910','AC','warfarin','CYP2C9'),('rs1045642','AG','anthracyclines and related substances','ABCB1'),('rs1045642','AG','antiepileptics','ABCB1'),('rs1042522','CG','antineoplastic agents','TP53'),('rs1045642','AG','capecitabine','ABCB1'),('rs1045642','AG','carbamazepine','ABCB1'),('rs1042522','CG','cisplatin','TP53'),('rs1045642','AG','cisplatin','ABCB1'),('rs1042522','CG','cyclophosphamide','TP53'),('rs1045642','AG','cyclosporine','ABCB1'),('rs1045642','AG','cytarabine','ABCB1'),('rs1045642','AG','doxorubicin','ABCB1'),('rs1045642','AG','epirubicin','ABCB1'),('rs11188072','TT','escitalopram','CYP2C19'),('rs1045642','AG','fexofenadine','ABCB1'),('rs1042522','CG','fluorouracil','TP53'),('rs1045642','AG','fluorouracil','ABCB1'),('rs17244841','AT','fluvastatin','HMGCR'),('rs17244841','AT','hmg coa reductase inhibitors','HMGCR'),('rs1045642','AG','idarubicin','ABCB1'),('rs11188072','TT','mephenytoin','CYP2C19'),('rs1045642','AG','methotrexate','ABCB1'),('rs1045642','AG','nortriptyline','ABCB1'),('rs11188072','TT','omeprazole','CYP2C19'),('rs1042522','CG','paclitaxel','TP53'),('rs11188072','TT','pantoprazole','CYP2C19'),('rs1045642','AG','phenytoin','ABCB1'),('rs17244841','AT','pravastatin','HMGCR'),('rs1799978','CC','risperidone','DRD2'),('rs17244841','AT','simvastatin','HMGCR'),('rs8012552','TT','Ace Inhibitors, Plain','BDKRB2'),('rs2108622','CT','acenocoumarol','CYP4F2'),('rs1057910','AC','acenocoumarol','CYP2C9'),('rs2297480','GG','alendronate','FDPS'),('rs1056892','AA','anthracyclines and related substances','CBR3'),('rs7997012','GG','antidepressants','HTR2A'),('rs3800373','AA','antidepressants','FKBP5'),('rs1057910','AC','Antiinflammatory agents, non-steroids','CYP2C9'),('rs1042522','CG','antineoplastic agents','TP53'),('rs1142345','CC','azathioprine','TPMT'),('rs2297480','GG','Bisphosphonates','FDPS'),('rs1057910','AC','celecoxib','CYP2C9'),('rs1142345','CC','cisplatin','TPMT'),('rs1042522','CG','cisplatin','TP53'),('rs9332377','TT','cisplatin','COMT'),('rs7997012','GG','citalopram','HTR2A'),('rs1042522','CG','cyclophosphamide','TP53'),('rs1057910','AC','diclofenac','CYP2C9'),('rs11188072','TT','escitalopram','CYP2C19'),('rs1042522','CG','fluorouracil','TP53'),('rs1057910','AC','losartan','CYP2C9'),('rs11188072','TT','mephenytoin','CYP2C19'),('rs1142345','CC','mercaptopurine','TPMT'),('rs7997012','GG','olanzapine','HTR2A'),('rs11188072','TT','omeprazole','CYP2C19'),('rs1042522','CG','paclitaxel','TP53'),('rs11188072','TT','pantoprazole','CYP2C19'),('rs2108622','CT','phenprocoumon','CYP4F2'),('rs1057910','AC','phenytoin','CYP2C9'),('rs1142345','CC','purine analogues','TPMT'),('rs2297480','GG','risedronate','FDPS'),('rs1799978','CC','risperidone','DRD2'),('rs7997012','GG','Selective serotonin reuptake inhibitors','HTR2A'),('rs1142345','CC','thioguanine','TPMT'),('rs1057910','AC','valproic acid','CYP2C9'),('rs2108622','CT','warfarin','CYP4F2'),('rs1057910','AC','warfarin','CYP2C9'),('rs2016848','AA','Ace Inhibitors, Plain','MME'),('rs8012552','TT','Ace Inhibitors, Plain','BDKRB2'),('rs9934438','AA','acenocoumarol','VKORC1'),('rs2108622','CT','acenocoumarol','CYP4F2'),('rs2108622','TT','acenocoumarol','CYP4F2'),('rs1057910','CC','acenocoumarol','CYP2C9'),('rs2297480','GG','alendronate','FDPS'),('rs1045642','GG','anthracyclines and related substances','ABCB1'),('rs7997012','GG','antidepressants','HTR2A'),('rs3800373','AA','antidepressants','FKBP5'),('rs1045642','GG','antiepileptics','ABCB1'),('rs1057910','CC','Antiinflammatory agents, non-steroids','CYP2C9'),('rs1042522','CG','antineoplastic agents','TP53'),('rs1142345','CC','azathioprine','TPMT'),('rs1800460','CT','azathioprine','TPMT'),('rs1800462','GG','azathioprine','TPMT'),('rs2297480','GG','Bisphosphonates','FDPS'),('rs2297595','CC','capecitabine','DPYD'),('rs1045642','GG','capecitabine','ABCB1'),('rs1045642','GG','carbamazepine','ABCB1'),('rs1057910','CC','celecoxib','CYP2C9'),('rs1799853','CT','celecoxib','CYP2C9'),('rs4149056','CC','cerivastatin','SLCO1B1'),('rs1142345','CC','cisplatin','TPMT'),('rs1800460','CT','cisplatin','TPMT'),('rs1042522','CG','cisplatin','TP53'),('rs1695','AG','cisplatin','GSTP1'),('rs9332377','TT','cisplatin','COMT'),('rs1045642','GG','cisplatin','ABCB1'),('rs7997012','GG','citalopram','HTR2A'),('rs4244285','AA','clopidogrel','CYP2C19'),('rs1045642','GG','clopidogrel','ABCB1'),('rs1042522','CG','cyclophosphamide','TP53'),('rs1695','AG','cyclophosphamide','GSTP1'),('rs4244285','AA','cyclophosphamide','CYP2C19'),('rs3745274','TT','cyclophosphamide','CYP2B6'),('rs1045642','GG','cyclosporine','ABCB1'),('rs1045642','GG','cytarabine','ABCB1'),('rs1045642','GG','dexamethasone','ABCB1'),('rs1057910','CC','diclofenac','CYP2C9'),('rs4244285','AA','doxorubicin','CYP2C19'),('rs3745274','TT','doxorubicin','CYP2B6'),('rs1045642','GG','doxorubicin','ABCB1'),('rs3745274','TT','efavirenz','CYP2A7P1'),('rs1045642','GG','efavirenz','ABCB1'),('rs1695','AG','epirubicin','GSTP1'),('rs1045642','GG','epirubicin','ABCB1'),('rs1045642','GG','fexofenadine','ABCB1'),('rs1042522','CG','fluorouracil','TP53'),('rs1695','AG','fluorouracil','GSTP1'),('rs2297595','CC','fluorouracil','DPYD'),('rs1045642','GG','fluorouracil','ABCB1'),('rs4149056','CC','hmg coa reductase inhibitors','SLCO1B1'),('rs1045642','GG','idarubicin','ABCB1'),('rs1057910','CC','losartan','CYP2C9'),('rs1142345','CC','mercaptopurine','TPMT'),('rs1800460','CT','mercaptopurine','TPMT'),('rs1800462','GG','mercaptopurine','TPMT'),('rs1045642','GG','nelfinavir','ABCB1'),('rs1045642','GG','nevirapine','ABCB1'),('rs1045642','GG','nortriptyline','ABCB1'),('rs7997012','GG','olanzapine','HTR2A'),('rs1695','AG','oxaliplatin','GSTP1'),('rs1042522','CG','paclitaxel','TP53'),('rs1045642','GG','paclitaxel','ABCB1'),('rs11188072','CT','pantoprazole','CYP2C19'),('rs12979860','CT','peginterferon alfa-2a','IL28B'),('rs8099917','GG','peginterferon alfa-2a','IL28B'),('rs12979860','CT','peginterferon alfa-2b','IL28B'),('rs8099917','GG','peginterferon alfa-2b','IL28B'),('rs2108622','CT','phenprocoumon','CYP4F2'),('rs2108622','TT','phenprocoumon','CYP4F2'),('rs1057910','CC','phenytoin','CYP2C9'),('rs1799853','CT','phenytoin','CYP2C9'),('rs1045642','GG','phenytoin','ABCB1'),('rs1695','AG','Platinum compounds','GSTP1'),('rs1142345','CC','purine analogues','TPMT'),('rs1800460','CT','purine analogues','TPMT'),('rs1800462','GG','purine analogues','TPMT'),('rs4149056','CC','repaglinide','SLCO1B1'),('rs12979860','CT','ribavirin','IL28B'),('rs8099917','GG','ribavirin','IL28B'),('rs2297480','GG','risedronate','FDPS'),('rs7997012','GG','Selective serotonin reuptake inhibitors','HTR2A'),('rs4149056','CC','simvastatin','SLCO1B1'),('rs1057910','CC','sulfonamides, urea derivatives','CYP2C9'),('rs1142345','CC','thioguanine','TPMT'),('rs1800460','CT','thioguanine','TPMT'),('rs1800462','GG','thioguanine','TPMT'),('rs1057910','CC','valproic acid','CYP2C9'),('rs1045642','GG','vincristine','ABCB1'),('rs7294','CT','warfarin','VKORC1'),('rs9934438','AA','warfarin','VKORC1'),('rs2108622','CT','warfarin','CYP4F2'),('rs2108622','TT','warfarin','CYP4F2'),('rs1799853','CT','warfarin','CYP2C9'),('rs1057910','CC','warfarin','CYP2C9'),('rs8012552','TT','Ace Inhibitors, Plain','BDKRB2'),('rs2108622','CT','acenocoumarol','CYP4F2'),('rs2108622','TT','acenocoumarol','CYP4F2'),('rs1057910','AC','acenocoumarol','CYP2C9'),('rs1056892','AA','anthracyclines and related substances','CBR3'),('rs1045642','GG','anthracyclines and related substances','ABCB1'),('rs7997012','GG','antidepressants','HTR2A'),('rs1045642','GG','antiepileptics','ABCB1'),('rs1057910','AC','Antiinflammatory agents, non-steroids','CYP2C9'),('rs1042522','CG','antineoplastic agents','TP53'),('rs1142345','CC','azathioprine','TPMT'),('rs1800460','CT','azathioprine','TPMT'),('rs1800462','GG','azathioprine','TPMT'),('rs2297595','CC','capecitabine','DPYD'),('rs1045642','GG','capecitabine','ABCB1'),('rs1045642','GG','carbamazepine','ABCB1'),('rs1057910','AC','celecoxib','CYP2C9'),('rs1799853','TT','celecoxib','CYP2C9'),('rs2228001','TT','cisplatin','XPC'),('rs1142345','CC','cisplatin','TPMT'),('rs1800460','CT','cisplatin','TPMT'),('rs1042522','CG','cisplatin','TP53'),('rs1695','GG','cisplatin','GSTP1'),('rs9332377','CT','cisplatin','COMT'),('rs1045642','GG','cisplatin','ABCB1'),('rs7997012','GG','citalopram','HTR2A'),('rs1954787','CC','citalopram','GRIK4'),('rs1045642','GG','clopidogrel','ABCB1'),('rs1042522','CG','cyclophosphamide','TP53'),('rs1695','GG','cyclophosphamide','GSTP1'),('rs3745274','GT','cyclophosphamide','CYP2B6'),('rs1045642','GG','cyclosporine','ABCB1'),('rs1045642','GG','cytarabine','ABCB1'),('rs1045642','GG','dexamethasone','ABCB1'),('rs1057910','AC','diclofenac','CYP2C9'),('rs1045642','GG','doxorubicin','ABCB1'),('rs3745274','GT','efavirenz','CYP2A7P1'),('rs1045642','GG','efavirenz','ABCB1'),('rs1695','GG','epirubicin','GSTP1'),('rs1045642','GG','epirubicin','ABCB1'),('rs1045642','GG','fexofenadine','ABCB1'),('rs1042522','CG','fluorouracil','TP53'),('rs1695','GG','fluorouracil','GSTP1'),('rs2297595','CC','fluorouracil','DPYD'),('rs1045642','GG','fluorouracil','ABCB1'),('rs1045642','GG','idarubicin','ABCB1'),('rs1057910','AC','losartan','CYP2C9'),('rs1142345','CC','mercaptopurine','TPMT'),('rs1800460','CT','mercaptopurine','TPMT'),('rs1800462','GG','mercaptopurine','TPMT'),('rs1695','GG','methotrexate','GSTP1'),('rs1045642','GG','nelfinavir','ABCB1'),('rs1045642','GG','nevirapine','ABCB1'),('rs1045642','GG','nortriptyline','ABCB1'),('rs7997012','GG','olanzapine','HTR2A'),('rs1695','GG','oxaliplatin','GSTP1'),('rs1042522','CG','paclitaxel','TP53'),('rs1045642','GG','paclitaxel','ABCB1'),('rs11188072','CT','pantoprazole','CYP2C19'),('rs12979860','CT','peginterferon alfa-2a','IL28B'),('rs8099917','GG','peginterferon alfa-2a','IL28B'),('rs12979860','CT','peginterferon alfa-2b','IL28B'),('rs8099917','GG','peginterferon alfa-2b','IL28B'),('rs2108622','CT','phenprocoumon','CYP4F2'),('rs2108622','TT','phenprocoumon','CYP4F2'),('rs1057910','AC','phenytoin','CYP2C9'),('rs1799853','TT','phenytoin','CYP2C9'),('rs1045642','GG','phenytoin','ABCB1'),('rs1695','GG','Platinum compounds','GSTP1'),('rs1142345','CC','purine analogues','TPMT'),('rs1800460','CT','purine analogues','TPMT'),('rs1800462','GG','purine analogues','TPMT'),('rs12979860','CT','ribavirin','IL28B'),('rs8099917','GG','ribavirin','IL28B'),('rs1799978','CC','risperidone','DRD2'),('rs7997012','GG','Selective serotonin reuptake inhibitors','HTR2A'),('rs1799853','TT','sulfonamides, urea derivatives','CYP2C9'),('rs1142345','CC','thioguanine','TPMT'),('rs1800460','CT','thioguanine','TPMT'),('rs1800462','GG','thioguanine','TPMT'),('rs1057910','AC','valproic acid','CYP2C9'),('rs1045642','GG','vincristine','ABCB1'),('rs7294','TT','warfarin','VKORC1'),('rs2108622','CT','warfarin','CYP4F2'),('rs2108622','TT','warfarin','CYP4F2'),('rs1799853','TT','warfarin','CYP2C9'),('rs1057910','AC','warfarin','CYP2C9'),('rs8012552','TT','Ace Inhibitors, Plain','BDKRB2'),('rs9934438','AA','acenocoumarol','VKORC1'),('rs2108622','CT','acenocoumarol','CYP4F2'),('rs1057910','AC','acenocoumarol','CYP2C9'),('rs2297480','GG','alendronate','FDPS'),('rs1045642','GG','anthracyclines and related substances','ABCB1'),('rs7997012','GG','antidepressants','HTR2A'),('rs3800373','AA','antidepressants','FKBP5'),('rs1045642','GG','antiepileptics','ABCB1'),('rs1057910','AC','Antiinflammatory agents, non-steroids','CYP2C9'),('rs1042522','CG','antineoplastic agents','TP53'),('rs1800460','TT','azathioprine','TPMT'),('rs1800462','GG','azathioprine','TPMT'),('rs2297480','GG','Bisphosphonates','FDPS'),('rs1045642','GG','capecitabine','ABCB1'),('rs1045642','GG','carbamazepine','ABCB1'),('rs1057910','AC','celecoxib','CYP2C9'),('rs1799853','TT','celecoxib','CYP2C9'),('rs1800460','TT','cisplatin','TPMT'),('rs1042522','CG','cisplatin','TP53'),('rs1695','GG','cisplatin','GSTP1'),('rs9332377','TT','cisplatin','COMT'),('rs1045642','GG','cisplatin','ABCB1'),('rs7997012','GG','citalopram','HTR2A'),('rs1045642','GG','clopidogrel','ABCB1'),('rs1042522','CG','cyclophosphamide','TP53'),('rs1695','GG','cyclophosphamide','GSTP1'),('rs3745274','GT','cyclophosphamide','CYP2B6'),('rs1045642','GG','cyclosporine','ABCB1'),('rs1045642','GG','cytarabine','ABCB1'),('rs1045642','GG','dexamethasone','ABCB1'),('rs1057910','AC','diclofenac','CYP2C9'),('rs1045642','GG','doxorubicin','ABCB1'),('rs3745274','GT','efavirenz','CYP2A7P1'),('rs1045642','GG','efavirenz','ABCB1'),('rs1695','GG','epirubicin','GSTP1'),('rs1045642','GG','epirubicin','ABCB1'),('rs1045642','GG','fexofenadine','ABCB1'),('rs1042522','CG','fluorouracil','TP53'),('rs1695','GG','fluorouracil','GSTP1'),('rs1045642','GG','fluorouracil','ABCB1'),('rs17244841','AT','fluvastatin','HMGCR'),('rs17244841','AT','hmg coa reductase inhibitors','HMGCR'),('rs1045642','GG','idarubicin','ABCB1'),('rs1057910','AC','losartan','CYP2C9'),('rs1800460','TT','mercaptopurine','TPMT'),('rs1800462','GG','mercaptopurine','TPMT'),('rs1695','GG','methotrexate','GSTP1'),('rs1045642','GG','nelfinavir','ABCB1'),('rs1045642','GG','nevirapine','ABCB1'),('rs1045642','GG','nortriptyline','ABCB1'),('rs7997012','GG','olanzapine','HTR2A'),('rs1695','GG','oxaliplatin','GSTP1'),('rs1042522','CG','paclitaxel','TP53'),('rs1045642','GG','paclitaxel','ABCB1'),('rs11188072','CT','pantoprazole','CYP2C19'),('rs12979860','CT','peginterferon alfa-2a','IL28B'),('rs8099917','GG','peginterferon alfa-2a','IL28B'),('rs12979860','CT','peginterferon alfa-2b','IL28B'),('rs8099917','GG','peginterferon alfa-2b','IL28B'),('rs2108622','CT','phenprocoumon','CYP4F2'),('rs1057910','AC','phenytoin','CYP2C9'),('rs1799853','TT','phenytoin','CYP2C9'),('rs1045642','GG','phenytoin','ABCB1'),('rs1695','GG','Platinum compounds','GSTP1'),('rs17244841','AT','pravastatin','HMGCR'),('rs1800460','TT','purine analogues','TPMT'),('rs1800462','GG','purine analogues','TPMT'),('rs12979860','CT','ribavirin','IL28B'),('rs8099917','GG','ribavirin','IL28B'),('rs2297480','GG','risedronate','FDPS'),('rs7997012','GG','Selective serotonin reuptake inhibitors','HTR2A'),('rs17244841','AT','simvastatin','HMGCR'),('rs1799853','TT','sulfonamides, urea derivatives','CYP2C9'),('rs1800460','TT','thioguanine','TPMT'),('rs1800462','GG','thioguanine','TPMT'),('rs1057910','AC','valproic acid','CYP2C9'),('rs1045642','GG','vincristine','ABCB1'),('rs7294','CT','warfarin','VKORC1'),('rs9934438','AA','warfarin','VKORC1'),('rs2108622','CT','warfarin','CYP4F2'),('rs1799853','TT','warfarin','CYP2C9'),('rs1057910','AC','warfarin','CYP2C9');
/*!40000 ALTER TABLE `statistics_report` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `system_list`
--

DROP TABLE IF EXISTS `system_list`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `system_list` (
  `System` text
) ENGINE=MyISAM DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `system_list`
--

LOCK TABLES `system_list` WRITE;
/*!40000 ALTER TABLE `system_list` DISABLE KEYS */;
INSERT INTO `system_list` VALUES ('ALIMENTARY TRACT AND METABOLISM'),('BLOOD AND BLOOD FORMING ORGANS'),('CARDIOVASCULAR SYSTEM'),('DERMATOLOGICALS'),('GENITO URINARY SYSTEM AND SEX HORMONES'),('SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS'),('ANTIINFECTIVES FOR SYSTEMIC USE'),('ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS'),('MUSCULO-SKELETAL SYSTEM'),('NERVOUS SYSTEM'),('ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS'),('RESPIRATORY SYSTEM'),('SENSORY ORGANS'),('VARIOUS');
/*!40000 ALTER TABLE `system_list` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `test`
--

DROP TABLE IF EXISTS `test`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `test` (
  `RSID` varchar(20) DEFAULT NULL,
  `Alleles` varchar(7) DEFAULT NULL,
  `Gene` varchar(50) DEFAULT NULL,
  `Drug` varchar(60) DEFAULT NULL,
  `System` varchar(100) DEFAULT NULL,
  `subSystem` varchar(100) DEFAULT NULL,
  `drugID` varchar(30) DEFAULT NULL,
  `info` text CHARACTER SET utf8,
  `Level` varchar(10) DEFAULT NULL,
  `Efficacy` varchar(20) DEFAULT NULL,
  `Dosage` varchar(20) DEFAULT NULL,
  `Toxicity` varchar(20) DEFAULT NULL,
  `Genotype` varchar(10) DEFAULT NULL,
  `Sentence` text
) ENGINE=MyISAM DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `test`
--

LOCK TABLES `test` WRITE;
/*!40000 ALTER TABLE `test` DISABLE KEYS */;
INSERT INTO `test` VALUES ('rs11209716','T > C','PTGER3','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and hypertension who are treated with ACE inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk of cough when treated with ACE inhibitors.'),('rs2016848','G > A','MME','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','increased','AG','                Patients with the AG genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cough with ACE inhibitor treatment. Patients with this genotype were not studied directly.'),('rs2016848','G > A','MME','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','increased','AA','                Patients with the AA genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cough with ACE inhibitor treatment.'),('rs1799722','C > T','BDKRB2','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','increased','CT','                Patients with the CT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for cough.'),('rs1799722','C > T','BDKRB2','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','increased','TT','                Patients with the TT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for cough.'),('rs8012552','C > T','BDKRB2','Ace Inhibitors, Plain','VARIOUS','','','An ACE inhibitor (or angiotensin-converting-enzyme inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.','Level 3','-','-','decreased','TT','                Patients with the TT genotype and hypertension who are treated with ACE-inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of cough with ACE-inhibitors.'),('rs9934438','G > A','VKORC1','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','decreased','-','AG','                Patients with the AG genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs9934438','G > A','VKORC1','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs2108622','C > T','CYP4F2','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs2108622','C > T','CYP4F2','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1057910','A > C','CYP2C9','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 2A','-','decreased','-','AC','                Patients with the AC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs1057910','A > C','CYP2C9','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 2A','-','decreased','-','CC','                Patients with the CC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs4086116','C > T','CYP2C9','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 3','-','decreased','-','CT','                Patients with the CT genotype may require a lower dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs4086116','C > T','CYP2C9','acenocoumarol','VARIOUS','','','Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome.','Level 3','-','decreased','-','TT','                Patients with the TT genotype may require the lowest dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.'),('rs1800629','G > A','TNF','adalimumab','VARIOUS','','','Adalimumab, trade name Humira, is a TNF inhibiting anti-inflammatory drug.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and rheumatoid arthritis who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype or may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to anti-TNF therapy.'),('rs1800629','G > A','TNF','adalimumab','VARIOUS','','','Adalimumab, trade name Humira, is a TNF inhibiting anti-inflammatory drug.','Level 3','decreased','-','-','AA','                Patients with the AA genotype and rheumatoid arthritis who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to anti-TNF therapy.'),('rs1544410','C > T','VDR','alendronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00630','Alendronate is a nitrogen-containing, second generation bisphosphonate. Bisphosphonates were first used to treat Pageta?s disease in 1971. This class of medications is comprised of inorganic pyrophosphate analogues that contain non-hydrolyzable P-C-P bonds. Similar to other bisphosphonates, alendronate has a high affinity for bone mineral and is taken up during osteoclast resorption. Alendronate inhibits farnesyl pyrophosphate synthetase, one of the enzymes in the mevalonic acid pathway involved in producing isoprenoid compounds that are essential for post-translational modification of small guanosine triphosphate (GTP)-binding proteins, such as Rho, Ras and Rab. Inhibition of this process interferes with osteoclast function and survival. Alendronate is used for the treatment of osteoporosis and Pageta?s disease','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with bisphosphonates may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to bisphosphonates.'),('rs2297480','T > G','FDPS','alendronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00630','Alendronate is a nitrogen-containing, second generation bisphosphonate. Bisphosphonates were first used to treat Pageta?s disease in 1971. This class of medications is comprised of inorganic pyrophosphate analogues that contain non-hydrolyzable P-C-P bonds. Similar to other bisphosphonates, alendronate has a high affinity for bone mineral and is taken up during osteoclast resorption. Alendronate inhibits farnesyl pyrophosphate synthetase, one of the enzymes in the mevalonic acid pathway involved in producing isoprenoid compounds that are essential for post-translational modification of small guanosine triphosphate (GTP)-binding proteins, such as Rho, Ras and Rab. Inhibition of this process interferes with osteoclast function and survival. Alendronate is used for the treatment of osteoporosis and Pageta?s disease','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs712829','G > T','EGFR','Alkylating Agents','VARIOUS','','','An alkylating antineoplastic agent is an alkylating agent used in cancer treatment that attaches an alkyl group to DNA.','Level 4','decreased','-','-','GT','                Cancer cells with the GT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.'),('rs712829','G > T','EGFR','Alkylating Agents','VARIOUS','','','An alkylating antineoplastic agent is an alkylating agent used in cancer treatment that attaches an alkyl group to DNA.','Level 4','decreased','-','-','TT','                Cancer cells with the TT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.'),('rs9263827','C > T','POU5F1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263827','C > T','POU5F1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9267445','G > C','MICB','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','decreased','CC','                Patients with the CC genotype may have decreased but not absent risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263726','G > A','CCHCR1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','AG','                Patients with the AG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. This allele was in complete LD with HLA-B*5801 in the Japanese population. Evidence for the HLA-B*5801 allele and risk for SJS/TEN is stronger. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263726','G > A','CCHCR1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','AA','                Patients with the AA genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. This is a very rare allele and the AA homozygote was not observed in the supporting study. This allele was in complete LD with HLA-B*5801 in the Japanese population. Evidence for the HLA-B*5801 allele and risk for SJS/TEN is stronger. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263733','C > T','CCHCR1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263733','C > T','CCHCR1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DurgBank]','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263745','G > A','CCHCR1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','AG','                Patients with the AG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263745','G > A','CCHCR1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','AA','                Patients with the AA genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263781','T > C','CCHCR1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263781','T > C','CCHCR1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263785','T > G','CCHCR1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','GT','                Patients with the GT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263785','T > G','CCHCR1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','GG','                Patients with the GG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263794','A > G','CCHCR1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','AG','                Patients with the AG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263794','A > G','CCHCR1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','GG','                Patients with the GG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263796','C > T','CCHCR1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263796','C > T','CCHCR1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263800','G > A','CCHCR1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','AG','                Patients with the AG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs9263800','G > A','CCHCR1','allopurinol','MUSCULO-SKELETAL SYSTEM','ANTIGOUT PREPARATIONS','DB00437','A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [DrugBank]','Level 3','-','-','increased','AA','                Patients with the AA genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.'),('rs12720441','G > A','KCNH2','amiodarone','CARDIOVASCULAR SYSTEM','CARDIAC THERAPY','DB01118','An antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance. [DrugBank]','Level 4','-','-','increased','AG','                Patients with the AG genotype may have increased risk for Torsades de Point when treated with amiodarone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs12720441','G > A','KCNH2','amiodarone','CARDIOVASCULAR SYSTEM','CARDIAC THERAPY','DB01118','An antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance. [DrugBank]','Level 4','-','-','increased','AA','                Patients with the AA genotype may have increased risk for Torsades de Point when treated with amiodarone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs5065','A > G','NPPA','amlodipine','CARDIOVASCULAR SYSTEM','CARDIAC THERAPY','DB01118','An antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance. [DrugBank]','Level 4','increased','-','-','AG','                Patients with Hypertension and the AG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.'),('rs5065','A > G','NPPA','amlodipine','CARDIOVASCULAR SYSTEM','CARDIAC THERAPY','DB01118','An antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance. [DrugBank]','Level 4','increased','-','-','GG','                Patients with Hypertension and the GG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.'),('rs10509681','T > C','CYP2C8','amodiaquine','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS','ANTIPROTOZOALS','DB00613','A 4-aminoquinoquinoline compound with anti-inflammatory properties. [DrugBank]','Level 4','-','-','increased','CT','                Patients with the CT genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs10509681','T > C','CYP2C8','amodiaquine','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS','ANTIPROTOZOALS','DB00613','A 4-aminoquinoquinoline compound with anti-inflammatory properties. [DrugBank]','Level 4','-','-','increased','CC','                Patients with the CC genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs11572080','C > T','CYP2C8','amodiaquine','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS','ANTIPROTOZOALS','DB00613','A 4-aminoquinoquinoline compound with anti-inflammatory properties. [DrugBank]','Level 4','-','-','increased','CT','                Patients with the CT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs11572080','C > T','CYP2C8','amodiaquine','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS','ANTIPROTOZOALS','DB00613','A 4-aminoquinoquinoline compound with anti-inflammatory properties. [DrugBank]','Level 4','-','-','increased','TT','                Patients with the TT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs9274407','A > T','HLA-DQB1','amoxicillin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIBACTERIALS FOR SYSTEMIC USE','DB01060','A broad-spectrum semisynthetic antibiotic similar to ampicillin except that its resistance to gastric acid permits higher serum levels with oral administration. Amoxicillin is commonly prescribed with clauvanic acid (a beta lactamase inhibitor) as it is susceptible to beta-lacatamase degradation. [DrugBank]','Level 3','-','-','decreased','TT','                Patients with the TT genotype may have decreased but not absent risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk for drug induced liver injury.'),('rs2070995','T > C','KCNJ6','Analgesics','NERVOUS SYSTEM','ANALGESICS','','An analgesic, or painkiller, is any member of the group of drugs used to achieve analgesia  relief from pain.','Level 3','increased','-','-','CT','                Patients with the TC genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance for requiring a rescue analgesic.'),('rs2070995','T > C','KCNJ6','Analgesics','NERVOUS SYSTEM','ANALGESICS','','An analgesic, or painkiller, is any member of the group of drugs used to achieve analgesia  relief from pain.','Level 3','increased','-','-','CC','                Patients with the CC genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance for requiring a rescue analgesic.'),('rs9514091','G > A','SLC10A2','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','-','-','decreased','AG','                Patients with the AG genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for cardiotoxicity.'),('rs9514091','G > A','SLC10A2','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for cardiotoxicity.'),('rs1056892','G > A','CBR3','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 2B','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs9024','G > A','CBR1','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of drug-induced Cardiomyopathies.'),('rs9024','G > A','CBR1','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','-','-','decreased','AA','                Patients with the AA genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of drug-induced Cardiomyopathies.'),('rs10836235','C > T','CAT','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','-','-','decreased','CT','                Patients with the CT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the CT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs10836235','C > T','CAT','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','-','-','decreased','TT','                Patients with the TT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the TT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1045642','A > G','ABCB1','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs2032582','A > C','ABCB1','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','increased','-','-','AC','                Patients with the CA genotype and cancer who are treated with anthracyclines: 1) may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype 2) may have increased overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to anthracyclines.'),('rs2032582','A > C','ABCB1','anthracyclines and related substances','VARIOUS','','','These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers.','Level 3','decreased','-','-','CC','                Patients with the CC, CT or TT genotype and cancer who are treated with anthracyclines 1) may have an increased risk of resistance as compared to patients with the AC and AA genotype 2) may have decreased overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to anthracyclines.'),('rs10879346','C > T','TPH2','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with antidepressants may have less improvement in symptoms as compared to patients with the CT and CC genotype.'),('rs2227631','A > G','SERPINE1','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs2227631','A > G','SERPINE1','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs1799889','A > G','SERPINE1','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs1799889','A > G','SERPINE1','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs7997012','A > G','HTR2A','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs6295','C > G','HTR1A','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs6295','C > G','HTR1A','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','increased','-','-','GG','                Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs1360780','T > C','FKBP5','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','CC','                Patients with the CC genotype may 1) have decreased response to antidepressants 2) have decreased suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs3800373','C > A','FKBP5','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 2B','decreased','-','-','AA','                Patients with the AA genotype and depression who are treated with antidepressants may be less likely to have improvement in symptoms as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs7569963','G > A','CREB1','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs7569963','G > A','CREB1','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','AA','                Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs61888800','G > T','BDNF','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','GT','                Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.'),('rs61888800','G > T','BDNF','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','TT','                Patients with the TT genotype with major depressive disorder may experience a  lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.'),('rs2032583','A > G','ABCB1','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','increased','-','-','AG','                Patients with the AG genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs2032583','A > G','ABCB1','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','increased','-','-','GG','                Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs2235015','C > A','ABCB1','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','AC','                Patients with the AC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs2235015','C > A','ABCB1','antidepressants','NERVOUS SYSTEM','','','Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraines, attention-deficit hyperactivity disorder (ADHD), substance abuse and sleep disorders. They can be used alone or in combination with other medications.','Level 3','decreased','-','-','AA','                Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs2273697','G > A','ABCC2','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','-','-','increased','AG','                Patients with the AG genotype and epilepsy who are treated with carbamazepine 1) may have an increased risk for neurological adverse events 2) may have increased likelihood of response to antiepileptic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs2273697','G > A','ABCC2','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','-','-','increased','AA','                Patients with the AA genotype and epilepsy who are treated with carbamazepine 1) may have an increased risk for neurological adverse events 2) may have increased likelihood of response to antiepileptic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs3740066','C > T','ABCC2','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','decreased','-','-','CT','                Patients with the CT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. This association was not found in all studies. Other genetic and clinical factors may also influence a patients response to antiepileptics.'),('rs3740066','C > T','ABCC2','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','decreased','-','-','TT','                Patients with the TT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. This association was not found in all studies. Other genetic and clinical factors may also influence a patients response to antiepileptics.'),('rs717620','C > T','ABCC2','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','decreased','-','-','CT','                Patients with the CT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antiepileptics.'),('rs717620','C > T','ABCC2','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','decreased','-','-','TT','                Patients with the TT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antiepileptics.'),('rs1045642','A > G','ABCB1','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','increased','-','-','AG','                Genotype AG may be associated with increased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype GG. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. Theres also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patients response to antiepileptics.'),('rs1045642','A > G','ABCB1','antiepileptics','NERVOUS SYSTEM','ANTIEPILEPTICS','','Antiepileptics are a class of drugs that try and prevent rapid, repetitive, stimulation of the brain that causes seizure activity such as in epilepsy. Members of this class of drugs include carbamazepine, valproate, lamotrigine, oxcarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin, acetazolamide and sulthiame','Level 3','increased','-','-','GG','                Genotype GG genotype  may be associated with decreased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype AA. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. Theres also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patients response to antiepileptics.'),('rs2070744','C > T','NOS3','Antihypertensives And Diuretics In Combination','CARDIOVASCULAR SYSTEM','','','Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure)','Level 3','-','-','-','CT','                Patients with the CT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for resistance.'),('rs2070744','C > T','NOS3','Antihypertensives And Diuretics In Combination','CARDIOVASCULAR SYSTEM','','','Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure)','Level 3','-','-','-','TT','                Patients with the TT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for resistance.'),('rs2070744','C > T','NOS3','Antihypertensives And Diuretics In Combination','CARDIOVASCULAR SYSTEM','','','Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure)','Level 3','-','-','-','CT','                Patients with the CT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antihypertensives.'),('rs2070744','C > T','NOS3','Antihypertensives And Diuretics In Combination','CARDIOVASCULAR SYSTEM','','','Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure)','Level 3','-','-','-','TT','                Patients with the TT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antihypertensives.'),('rs2070744','C > T','NOS3','Antihypertensives','CARDIOVASCULAR SYSTEM','ANTIHYPERTENSIVES','','Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure)','Level 3','-','-','-','CT','                Patients with the CT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antihypertensives.'),('rs2070744','C > T','NOS3','Antihypertensives','CARDIOVASCULAR SYSTEM','ANTIHYPERTENSIVES','','Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure)','Level 3','-','-','-','TT','                Patients with the TT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antihypertensives.'),('rs1801252','A > G','ADRB1','Antihypertensives','CARDIOVASCULAR SYSTEM','ANTIHYPERTENSIVES','','Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure)','Level 3','increased','-','-','AG','                Patients with the AG genotype may 1) experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) not require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients likelihood of response, in particular ADRB1 Arg389 (rs1801253).'),('rs1801252','A > G','ADRB1','Antihypertensives','CARDIOVASCULAR SYSTEM','ANTIHYPERTENSIVES','','Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure)','Level 3','increased','-','-','GG','                People with the GG genotype may 1) not experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) not require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients likelihood of response, in particular ADRB1 Arg389 (rs1801253).'),('rs1057910','A > C','CYP2C9','Antiinflammatory agents, non-steroids','VARIOUS','','','The term nonsteroidal distinguishes these drugs from steroids, which, among a broad range of other effects, have a similar eicosanoid-depressing, anti-inflammatory action. As analgesics, NSAIDs are unusual in that they are non-narcotic and thus are used as a non-addictive alternative to narcotics.','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','Antiinflammatory agents, non-steroids','VARIOUS','','','The term nonsteroidal distinguishes these drugs from steroids, which, among a broad range of other effects, have a similar eicosanoid-depressing, anti-inflammatory action. As analgesics, NSAIDs are unusual in that they are non-narcotic and thus are used as a non-addictive alternative to narcotics.','Level 2A','-','-','increased','CC','                Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1042522','C > G','TP53','antineoplastic agents','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','','Inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1042522','C > G','TP53','antineoplastic agents','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','','Inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells','Level 2B','-','-','decreased','CC','                Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs951439','C > T','RGS4','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','increased','-','-','CT','                Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs951439','C > T','RGS4','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may have increased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs1414334','C > G','HTR2C','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 1B','-','-','decreased','GG','                Patients with the GG genotype who are treated with antipsychotics may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patients risk for developing metabolic syndrome.'),('rs1079598','A > G','DRD2','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1079598','A > G','DRD2','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','increased','GG','                Patients with the GG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1799732','- > G','DRD2','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs6277','G > A','DRD2','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased, but not absent risk, for weight gain when treated with clozapine or olanzepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs2069514','G > A','CYP1A2','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','increased','AG','                Schizophrenia patients with the AG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AG is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patients risk for adverse events to antipsychotics.'),('rs2069514','G > A','CYP1A2','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','increased','AA','                Schizophrenia patients with the AA genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AA is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patients risk for adverse events to antipsychotics.'),('rs4680','G > A','COMT','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','decreased','AG','                Patients with the AG genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for tardive dyskinesia.'),('rs4680','G > A','COMT','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','decreased','AA','                Patients with the AA genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for tardive dyskinesia.'),('rs1801133','G > A','CLCN6','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','increased','AG','                Patients with the AG genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1801133','G > A','CLCN6','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 3','-','-','increased','AA','                Patients with the AA genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1800497','G > A','ANKK1','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 1B','-','-','decreased','AA','                Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk for tardive dyskinesia as compared to patients with the GA and GG genotype. Other genetic and clinical factors may also influence a patients risk for tardive dyskinesia when taking antipsychotics.'),('rs1800497','G > A','ANKK1','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1800497','G > A','ANKK1','antipsychotics','VARIOUS','','','Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), in particular in schizophrenia and bipolar disorder, and is increasingly being used in the management of non-psychotic disorders (ATC code N05A).','Level 2B','-','-','increased','AA','                Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs7412','C > T','APOE','Antivirals for treatment of HIV infections, combinations','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','','','Level 4','-','-','increased','CT','                Patients with the CT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype or may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients triglyceride levels.'),('rs7412','C > T','APOE','Antivirals for treatment of HIV infections, combinations','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','','','Level 4','-','-','increased','TT','                Patients with the TT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients triglyceride levels.'),('rs429358','T > C','APOC1','Antivirals for treatment of HIV infections, combinations','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','','','Level 3','-','-','increased','CT','                Patients with the CT genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patients risk for adverse events with ritonavir treatment.'),('rs429358','T > C','APOC1','Antivirals for treatment of HIV infections, combinations','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','','','Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patients risk for adverse events with ritonavir treatment.'),('rs1799732','- > G','DRD2','aripiprazole','NERVOUS SYSTEM','PSYCHOLEPTICS','DB01238','Aripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.[DrugBank]','Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1799732','- > G','DRD2','aripiprazole','NERVOUS SYSTEM','PSYCHOLEPTICS','DB01238','Aripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.[DrugBank]','Level 3','increased','-','-','G/del','                Patients with the G/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with these alleles and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1050828','C > T','G6PD','artesunate','VARIOUS','','','Artesunate (INN) is part of the artemisinin group of drugs that treat malaria. It is a semi-synthetic derivative of artemisinin that is water-soluble and may therefore be given by injection. It is sometimes abbreviated AS.','Level 3','-','-','increased','CT','                Pediatric patients with the CT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs1050828','C > T','G6PD','artesunate','VARIOUS','','','Artesunate (INN) is part of the artemisinin group of drugs that treat malaria. It is a semi-synthetic derivative of artemisinin that is water-soluble and may therefore be given by injection. It is sometimes abbreviated AS.','Level 3','-','-','increased','TT','                Pediatric patients with the TT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs20417','C > G','PTGS2','aspirin','ALIMENTARY TRACT AND METABOLISM','STOMATOLOGICAL PREPARATIONS','DB00945','The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. [DrugBank]','Level 3','increased','-','-','CG','                Patients with the CG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patients response to aspirin.'),('rs20417','C > G','PTGS2','aspirin','ALIMENTARY TRACT AND METABOLISM','STOMATOLOGICAL PREPARATIONS','DB00945','The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. [DrugBank]','Level 3','increased','-','-','GG','                Patients with the GG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patients response to aspirin.'),('rs730012','A > C','LTC4S','aspirin','ALIMENTARY TRACT AND METABOLISM','STOMATOLOGICAL PREPARATIONS','DB00945','The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. [DrugBank]','Level 3','-','-','increased','AC','                Patients with the AC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for urticaria.'),('rs730012','A > C','LTC4S','aspirin','ALIMENTARY TRACT AND METABOLISM','STOMATOLOGICAL PREPARATIONS','DB00945','The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. [DrugBank]','Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for urticaria.'),('rs688','C > T','LDLR','atenolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00335','A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. [DrugBank]','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have less effective lowering of systolic blood pressure with atenolol as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patients likelihood of response.'),('rs1051375','G > A','CACNA1C','atenolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00335','A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. [DrugBank]','Level 3','increased','-','-','AA','                Patients with the AA genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with verapamil compared to treatment with atenolol. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs1801252','A > G','ADRB1','atenolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00335','A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. [DrugBank]','Level 3','-','-','-','GG','                People with the GG genotype may 1) not experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) not require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients likelihood of response, in particular ADRB1 Arg389 (rs1801253).'),('rs1801253','G > C','ADRB1','atenolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00335','A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. [DrugBank]','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','atenolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00335','A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. [DrugBank]','Level 3','increased','-','-','CC','                Patients with the CC genotype 1) may have an increased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have a decreased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','atenolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00335','A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. [DrugBank]','Level 3','decreased','-','increased','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1935349','C > T','HTR7','atorvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for statin-related myalgia as compared to patients with the CC genotypes, or may have a decreased risk for statin-related myalgia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs1935349','C > T','HTR7','atorvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for statin-related myalgia as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs2276307','A > G','HTR3B','atorvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for myalgia.'),('rs2276307','A > G','HTR3B','atorvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 3','-','-','increased','GG','                Patients with the GG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patients risk for myalgia.'),('rs17238540','T > G','HMGCR','atorvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 3','decreased','-','-','GT','                Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17238540','T > G','HMGCR','atorvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 3','decreased','-','-','GG','                Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs5443','C > T','GNB3','atorvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 4','increased','-','-','CT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs5443','C > T','GNB3','atorvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 4','increased','-','-','TT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs4693075','G > C','COQ2','atorvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01076','Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.','Level 2B','-','-','decreased','CC','                Patients with the CC genotype may have decreased risk of statin-related muscle symptoms as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence a patients risk of toxicity.'),('rs1142345','T > C','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CT','                Patients with the CT genotype  1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1142345','T > C','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','CG','                Patients with the CG genotype (e.g. TPMT*1/*2): may have increased deactivation of thiopurines and a decreased, but not absent, risk for toxicity with thiopurine drugs as compared to patients with the GG genotype (TPMT*2/*2) or may have decreased deactivation of thiopurines and an increased risk for toxicity with thiopurine drugs as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993 ','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1127354','C > A','DDRGK1','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 3','increased','-','-','AC','                Patients with the AC genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1127354','C > A','DDRGK1','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 3','increased','-','-','AA','                Patients with the AA genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AA genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1127354','C > A','DDRGK1','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 3','decreased','-','-','AC','                Patients with the AC genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1127354','C > A','DDRGK1','azathioprine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00993','An immunosuppressive pro-drug. It is converted into 6-mercaptopurine in the body where it blocks purine metabolism and DNA synthesis.','Level 3','decreased','-','-','AA','                Patients with the AA genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs4253778','G > C','PPARA','Beta Blocking Agents','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','','Beta blockers are a class of drugs that target the beta receptor. Beta receptors are found on cells of the heart muscles, smooth muscles, airways, arteries, kidneys, and other tissues that are part of the sympathetic nervous system and lead to stress responses, especially when they are stimulated by epinephrine (adrenaline).','Level 3','decreased','-','-','CG','                Patients with the CG genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for rehospitalization.'),('rs4253778','G > C','PPARA','Beta Blocking Agents','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','','Beta blockers are a class of drugs that target the beta receptor. Beta receptors are found on cells of the heart muscles, smooth muscles, airways, arteries, kidneys, and other tissues that are part of the sympathetic nervous system and lead to stress responses, especially when they are stimulated by epinephrine (adrenaline).','Level 3','decreased','-','-','CC','                Patients with the CC genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for rehospitalization.'),('rs17098707','A > T','GRK5','Beta Blocking Agents','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','','Beta blockers are a class of drugs that target the beta receptor. Beta receptors are found on cells of the heart muscles, smooth muscles, airways, arteries, kidneys, and other tissues that are part of the sympathetic nervous system and lead to stress responses, especially when they are stimulated by epinephrine (adrenaline).','Level 4','decreased','-','-','AT','                Patients with the AT genotype and heart failure may have lower, but not absent, risk for death as compared to patients with the AA genotype and may benefit more from beta blocker treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse cardiovascular events.'),('rs17098707','A > T','GRK5','Beta Blocking Agents','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','','Beta blockers are a class of drugs that target the beta receptor. Beta receptors are found on cells of the heart muscles, smooth muscles, airways, arteries, kidneys, and other tissues that are part of the sympathetic nervous system and lead to stress responses, especially when they are stimulated by epinephrine (adrenaline).','Level 4','decreased','-','-','TT','                Patients with the TT genotype and heart failure may have lower, but not absent, risk for death as compared to patients with the AA genotype regardless of beta blocker.'),('rs1801252','A > G','ADRB1','Beta Blocking Agents','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','','Beta blockers are a class of drugs that target the beta receptor. Beta receptors are found on cells of the heart muscles, smooth muscles, airways, arteries, kidneys, and other tissues that are part of the sympathetic nervous system and lead to stress responses, especially when they are stimulated by epinephrine (adrenaline).','Level 3','-','-','-','GG','                People with the GG genotype may 1) not experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) not require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients likelihood of response, in particular ADRB1 Arg389 (rs1801253).'),('rs1801253','G > C','ADRB1','Beta Blocking Agents','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','','Beta blockers are a class of drugs that target the beta receptor. Beta receptors are found on cells of the heart muscles, smooth muscles, airways, arteries, kidneys, and other tissues that are part of the sympathetic nervous system and lead to stress responses, especially when they are stimulated by epinephrine (adrenaline).','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','Beta Blocking Agents','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','','Beta blockers are a class of drugs that target the beta receptor. Beta receptors are found on cells of the heart muscles, smooth muscles, airways, arteries, kidneys, and other tissues that are part of the sympathetic nervous system and lead to stress responses, especially when they are stimulated by epinephrine (adrenaline).','Level 3','increased','-','-','CC','                Patients with the CC genotype 1) may have an increased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have a decreased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','Beta Blocking Agents','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','','Beta blockers are a class of drugs that target the beta receptor. Beta receptors are found on cells of the heart muscles, smooth muscles, airways, arteries, kidneys, and other tissues that are part of the sympathetic nervous system and lead to stress responses, especially when they are stimulated by epinephrine (adrenaline).','Level 3','decreased','-','increased','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801252','A > G','ADRB1','bisoprolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00612','Bisoprolol is a cardioselective beta1-adrenergic blocking agent used for secondary prevention of myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension. Bisoprolol is structurally similar to metoprolol, acebutolol and atenolol in that it has two substituents in the para position of the benzene ring. The beta1-selectivity of these agents is thought to be due in part to the large substituents in the para position. At lower doses (less than 20 mg daily), bisoprolol selectively blocks cardiac beta1-adrenergic receptors with little activity against beta2-adrenergic receptors of the lungs and vascular smooth muscle. Receptor selectivity decreases with daily doses of 20 mg or greater. Unlike propranolol and pindolol, bisoprolol does not exhibit membrane-stabilizing or sympathomimetic activity. Bisoprolol possesses a single chiral centre and is administered as a racemic mixture. Only l-bisoprolol exhibits significant beta-blocking activity.','Level 3','-','-','-','GG','                People with the GG genotype may 1) not experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) not require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients likelihood of response, in particular ADRB1 Arg389 (rs1801253).'),('rs1544410','C > T','VDR','Bisphosphonates','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with bisphosphonates may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to bisphosphonates.'),('rs16944','A > G','IL1B','Bisphosphonates','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Pagets disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs16944','A > G','IL1B','Bisphosphonates','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs2297480','T > G','FDPS','Bisphosphonates','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 2B','increased','-','-','GT','                Patients with the GT genotype may have an increased chance of response to bisphosphonate treatment as compared to patients with the GG genotype. Patients with the GT genotype may still be at risk for non-response to bisphosphonate treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs2297480','T > G','FDPS','Bisphosphonates','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1934951','C > T','CYP2C8','Bisphosphonates','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 3','-','-','decreased','CT','                Patients with the CT genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.'),('rs1934951','C > T','CYP2C8','Bisphosphonates','VARIOUS','','','Bisphosphonates (also called diphosphonates) are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.'),('rs1799732','- > G','DRD2','Bromperidol','VARIOUS','','','Bromperidol (marketed as Bromidol, Bromodol) is a drug which is a butyrophenone derivative. It is a potent and long-acting neuroleptic, used as an antipsychotic in the treatment of schizophrenia. It was discovered at Janssen Pharmaceutica in 1966.','Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1801253','G > C','ADRB1','bucindolol','VARIOUS','','','Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity.[1][2] It was under review by the FDA in the United States for the treatment of heart failure in 2009 ','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','bucindolol','VARIOUS','','','Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity.[1][2] It was under review by the FDA in the United States for the treatment of heart failure in 2009 ','Level 3','increased','-','-','CC','                Patients with the CC genotype 1) may have an increased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have a decreased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','bucindolol','VARIOUS','','','Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity.[1][2] It was under review by the FDA in the United States for the treatment of heart failure in 2009 ','Level 3','decreased','-','increased','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs37973','G > A','GLCCI1','budesonide','VARIOUS','','','Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity.[1][2] It was under review by the FDA in the United States for the treatment of heart failure in 2009 ','Level 3','Efficacy','-','-','AA','                Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patients response to glucocorticoids.'),('rs165599','G > A','ARVCF','bupropion','NERVOUS SYSTEM','','','Bupropion is a drug primarily used as an atypical antidepressant and smoking cessation aid. Marketed as Wellbutrin, Budeprion, Prexaton, Elontril, Aplenzin, or other trade names, it is one of the most frequently prescribed antidepressants in the United States. Marketed in lower-dose formulations as Zyban, Voxra, or other names, it is also widely used to reduce nicotine cravings by people who are trying to quit smoking. It is taken in the form of pills, and in the United States is available only by prescription.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AG genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs165599','G > A','ARVCF','bupropion','NERVOUS SYSTEM','','','Bupropion is a drug primarily used as an atypical antidepressant and smoking cessation aid. Marketed as Wellbutrin, Budeprion, Prexaton, Elontril, Aplenzin, or other trade names, it is one of the most frequently prescribed antidepressants in the United States. Marketed in lower-dose formulations as Zyban, Voxra, or other names, it is also widely used to reduce nicotine cravings by people who are trying to quit smoking. It is taken in the form of pills, and in the United States is available only by prescription.','Level 3','increased','-','-','AA','                Patients with the AA genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1800497','G > A','ANKK1','bupropion','NERVOUS SYSTEM','','','Bupropion is a drug primarily used as an atypical antidepressant and smoking cessation aid. Marketed as Wellbutrin, Budeprion, Prexaton, Elontril, Aplenzin, or other trade names, it is one of the most frequently prescribed antidepressants in the United States. Marketed in lower-dose formulations as Zyban, Voxra, or other names, it is also widely used to reduce nicotine cravings by people who are trying to quit smoking. It is taken in the form of pills, and in the United States is available only by prescription.','Level 1B','decreased','-','-','AG','                Patients with the AG genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients chance for quitting smoking.'),('rs1800497','G > A','ANKK1','bupropion','NERVOUS SYSTEM','','','Bupropion is a drug primarily used as an atypical antidepressant and smoking cessation aid. Marketed as Wellbutrin, Budeprion, Prexaton, Elontril, Aplenzin, or other trade names, it is one of the most frequently prescribed antidepressants in the United States. Marketed in lower-dose formulations as Zyban, Voxra, or other names, it is also widely used to reduce nicotine cravings by people who are trying to quit smoking. It is taken in the form of pills, and in the United States is available only by prescription.','Level 1B','decreased','-','-','AA','                Patients with the AA genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients chance for quitting smoking.'),('rs762551','C > A','CYP1A2','caffeine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00201','A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine\'s most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes smooth muscle, stimulates cardiac muscle, stimulates diuresis, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide phosphodiesterases, antagonism of adenosine receptors, and modulation of intracellular calcium handling. [DrugBank]','Level 3','-','-','-','AA','                Patients with the AA genotype may have a decreased, but not absent, risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patients risk of myocardial infarction.'),('rs2298383','C > T','ADORA2A','caffeine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00201','A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine\'s most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes smooth muscle, stimulates cardiac muscle, stimulates diuresis, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide phosphodiesterases, antagonism of adenosine receptors, and modulation of intracellular calcium handling. [DrugBank]','Level 2B','-','-','decreased','CT','                Patients with the CT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.'),('rs2298383','C > T','ADORA2A','caffeine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00201','A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine\'s most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes smooth muscle, stimulates cardiac muscle, stimulates diuresis, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide phosphodiesterases, antagonism of adenosine receptors, and modulation of intracellular calcium handling. [DrugBank]','Level 2B','-','-','decreased','TT','                Patients with the TT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.'),('rs5751876','T > C','ADORA2A','caffeine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00201','A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine\'s most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes smooth muscle, stimulates cardiac muscle, stimulates diuresis, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide phosphodiesterases, antagonism of adenosine receptors, and modulation of intracellular calcium handling. [DrugBank]','Level 3','-','-','-','CT','                Individuals with the CT genotype 1) may be less sensitive to caffeine and less likely to experience anxiety 2) may consume more caffeine as compared to individuals with the TT genotype. Please note contradictory results have been reported. Other genetic and clinical factors may also influence an individuals response to caffeine.'),('rs5751876','T > C','ADORA2A','caffeine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00201','A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine\'s most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes smooth muscle, stimulates cardiac muscle, stimulates diuresis, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide phosphodiesterases, antagonism of adenosine receptors, and modulation of intracellular calcium handling. [DrugBank]','Level 3','-','-','-','CC','                Individuals with the CC genotype 1) may be less sensitive to caffeine and less likely to experience anxiety 2) may consume more caffeine as compared to individuals with the TT genotype. Please note contradictory results have been reported. Other genetic and clinical factors may also influence an individuals response to caffeine.'),('rs1544410','C > T','VDR','Calcium','VARIOUS','','','Calcium is essential for living organisms, in particular in cell physiology, where movement of the calcium ion into and out of the cytoplasm functions as a signal for many cellular processes. As a major material used in mineralization of bone, teeth and shells, calcium is the most abundant metal by mass in many animals.','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with bisphosphonates may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to bisphosphonates.'),('rs1801131','T > G','MTHFR','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','GT','                Patients with the GT genotype may have increased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to capecitabine.'),('rs1801131','T > G','MTHFR','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','GG','                Patients with the GG genotype may have increased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to capecitabine.'),('rs2297595','T > C','DPYD','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','CT','                Patients with the CT genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs2297595','T > C','DPYD','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1045642','A > G','ABCB1','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 3','-','-','increased','AG','                Patients with AG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.'),('rs1045642','A > G','ABCB1','capecitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01101 ?','Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.','Level 3','-','-','increased','GG','                Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.'),('rs3812718','C > T','SCN1A','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 2B','-','increased','-','CT','                Patients with the CT genotype who are treated with carbamazepine may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine.'),('rs3812718','C > T','SCN1A','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 2B','-','increased','-','TT','                Patients with the TT genotype who are treated with carbamazepine may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine.'),('rs2844682','G > A','MUC21','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased but not absent risk of Stevens-Johnson syndrome when treated with carbamazepine as compared to patients with the AG or GG genotypes. This variant is a tagging SNP for HLA-B*1502, for which there is greater evidence of association with carbamazepine associated Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1800629','G > A','LST1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 3','-','-','increased','AA','                Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients chance of adverse response.'),('rs2227956','G > A','HSPA1A','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 3','-','-','increased','AA','                Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients chance of adverse response.'),('rs3909184','G > C','FLOT1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 1B','-','-','decreased','CC','                Patients with the CC genotype (non-carriers of the HLA-B*1502 allele) who are treated with carbamazapine may have a decreased risk of Stevens-Johnson Syndrome as compared to patients with the GG or CG genotype (patients who carry the HLA-B*1502 allele). Please note, this SNP is used as a tagging SNP for the HLA-B*1502 allele, and the genotyping method used to determine the HLA-B*1502 allele was not described. Other genetic and clinical factors may also influence a patients risk for adverse drug reactions when treated with carbamazapine.'),('rs1051740','T > C','EPHX1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 2B','-','increased','-','CT','                Patients with the CT genotype and Epilepsy who are treated with carbamazepine may have an increased dose of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to carbamazepine.'),('rs1051740','T > C','EPHX1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 2B','-','increased','-','CC','                Patients with the CC genotype and Epilepsy who are treated with carbamazepine may have an increased dose of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to carbamazepine.'),('rs2234922','A > G','EPHX1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 2B','-','increased','-','AG','                Patients with the AG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of carbamazepine.'),('rs2234922','A > G','EPHX1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 2B','-','increased','-','GG','                Patients with the GG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of carbamazepine.'),('rs750332','C > T','BAT2','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 3','-','-','decreased','TT','                Patients with the TT genotype who are treated with carbamazepine may have a decreased, but not absent, risk of Stevens-Johnson syndrome as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients risk for Stevens-Johnson syndrome with carbamazepine treatment.'),('rs2273697','G > A','ABCC2','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 3','-','-','increased','AG','                Patients with the AG genotype and epilepsy who are treated with carbamazepine 1) may have an increased risk for neurological adverse events 2) may have increased likelihood of response to antiepileptic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs2273697','G > A','ABCC2','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 3','-','-','increased','AA','                Patients with the AA genotype and epilepsy who are treated with carbamazepine 1) may have an increased risk for neurological adverse events 2) may have increased likelihood of response to antiepileptic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs1045642','A > G','ABCB1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 4','-','increased','-','AG','                Patient with genotype AG may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine.'),('rs1045642','A > G','ABCB1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 4','-','decreased','-','GG','                Patient with genotype GG may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine...'),('rs2032582','A > C','ABCB1','carbamazepine','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00564','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. ','Level 3','increased','-','-','CC','                Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patients response to carbamazepine.'),('rs25487','T > C','XRCC1','carboplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00958 ','An organoplatinum compound that possesses antineoplastic activity.','Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs11615','A > G','ERCC1','carboplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00958 ','An organoplatinum compound that possesses antineoplastic activity.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs11615','A > G','ERCC1','carboplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00958 ','An organoplatinum compound that possesses antineoplastic activity.','Level 2B','-','-','decreased','GG','                Patients with the GG genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs9981861','T > C','DSCAM','carboplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00958 ','An organoplatinum compound that possesses antineoplastic activity.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.'),('rs9981861','T > C','DSCAM','carboplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00958 ','An organoplatinum compound that possesses antineoplastic activity.','Level 3','increased','-','-','CC','                Patients with the CC genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.'),('rs1801133','G > A','CLCN6','carboplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00958 ','An organoplatinum compound that possesses antineoplastic activity.','Level 2A','increased','-','increased','AA','                Patients with AA genotype may have 1) increased likelihood of response 2) increased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patients response to carboplatin.'),('rs1042714','G > C','ADRB2','carvedilol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB01136','Carvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-1 adrenergic receptors.','Level 3','decreased','-','-','CC','                Patients with the CC genotype and heart failure may be less likely to have improved left ventricular ejection fraction after carvedilol treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1801253','G > C','ADRB1','carvedilol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB01136','Carvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-2 adrenergic receptors.','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','carvedilol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB01136','Carvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-3 adrenergic receptors.','Level 3','increased','-','-','CC','                Patients with the CC genotype 1) may have an increased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have a decreased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','carvedilol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB01136','Carvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-4 adrenergic receptors.','Level 3','decreased','-','increased','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','-','increased','CC','                Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','decreased','-','AC','                Patients with the AC genotype may have reduced metabolism of celecoxib and may require dose reduction when starting celecoxib therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1057910','A > C','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 2A','-','decreased','-','CC','                Patients with the CC genotype may have greatly reduced metabolism of celecoxib and may require dose reduction (50% of standard starting dose) when starting celecoxib therapy or alternative management in juvenile rheumatoid arthritis patients who carry this genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1799853','C > T','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 3','decreased','-','-','CT','                Patients with the CT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs1799853','C > T','CYP2C9','celecoxib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00482 ','Celecoxib is a non-steroidal anti-inflammatory drug','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to celecoxib.'),('rs4149056','T > C','SLCO1B1','cerivastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00439','On August 8, 2002 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.'),('rs4149056','T > C','SLCO1B1','cerivastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00439','On August 8, 2003 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.','Level 2A','-','-','increased','CT','                Patients with the CT genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.'),('rs2819742','A > G','RYR2','cerivastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00439','On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.','Level 3','-','-','increased','GG','                Patients with the GG genotype may have an increased risk of cerivastatin-associated rhabdomyolysis as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patients risk of toxicity. '),('rs396991','A > C','FCGR3A','cetuximab','VARIOUS','','','Cetuximab (Erbitux) is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is manufactured and distributed in the United States by the drug companies Bristol-Myers Squibb and Eli Lilly and Company and in Europe by the drug company Merck KGaA.','Level 2B','decreased','-','-','CC','                Patients with the CC genotype with Colorectal Cancer who are treated with cetuximab may have poorer response and treatment outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to therapy.'),('rs2227983','G > A','EGFR','cetuximab','VARIOUS','','','Cetuximab (Erbitux) is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is manufactured and distributed in the United States by the drug companies Bristol-Myers Squibb and Eli Lilly and Company and in Europe by the drug company Merck KGaA.','Level 3','-','-','decreased','AG','                Patients with the AG genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2227983','G > A','EGFR','cetuximab','VARIOUS','','','Cetuximab (Erbitux) is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is manufactured and distributed in the United States by the drug companies Bristol-Myers Squibb and Eli Lilly and Company and in Europe by the drug company Merck KGaA.','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs4444903','A > G','EGF','cetuximab','VARIOUS','','','Cetuximab (Erbitux) is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is manufactured and distributed in the United States by the drug companies Bristol-Myers Squibb and Eli Lilly and Company and in Europe by the drug company Merck KGaA.','Level 2B','increased','-','-','GG','                Patients with the GG genotype who are treated with cetuximab may have a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to cetuximab treatment.'),('rs1799732','- > G','DRD2','chlorpromazine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00477 ','The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine?s antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem]','Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1799732','- > G','DRD2','chlorpromazine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00478','The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine?s antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem]','Level 3','increased','-','-','G/del','                Patients with the G/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with these alleles and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs5065','A > G','NPPA','chlorthalidone','VARIOUS','','DB00310 ','A benzenesulfonamide-phthalimidine that tautomerizes to a benzophenones form. It is considered a thiazide-like diuretic. [PubChem]','Level 4','increased','-','-','AG','                Patients with Hypertension and the AG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.'),('rs5065','A > G','NPPA','chlorthalidone','VARIOUS','','DB00310 ','A benzenesulfonamide-phthalimidine that tautomerizes to a benzophenones form. It is considered a thiazide-like diuretic. [PubChem]','Level 4','increased','-','-','GG','                Patients with Hypertension and the GG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.'),('rs25487','T > C','XRCC1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','increased','-','increased','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs2228001','G > T','XPC','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','decreased','TT','                Patients with the TT genotype may have a decreased but not non-existent risk for toxicity with cisplatin treatment as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1142345','T > C','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CT','                Patients with the TC genotype who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1142345','T > C','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs12201199','A > T','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','AT','                Patients with the AT genotype may have increased risk for hearing loss with cisplatin treatment compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs12201199','A > T','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for hearing loss with cisplatin treatment compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CT','                Patients with the TC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1800460','C > T','TPMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','TT','                Patients with the TT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs1042522','C > G','TP53','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1042522','C > G','TP53','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','increased','-','decreased','CC','                Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs316019','A > C','SLC22A2','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1805087','A > G','MTR','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','increased','GG','                Patients with the GG genotype may have increased likelihood of Drug Toxicity when treated with cisplatin in people with Osteosarcoma as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence a patients risk for toxicity to cisplatin.'),('rs1801133','G > A','MTHFR','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','increased','AA','                Patients with the AA genotype may have: 1) increased likelihood of response to chemotherapy, 2) increased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotypes AG or GG. Other genetic and clinical factors may also influence a patients response to cisplatin.'),('rs2075252','T > C','LRP2','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','decreased','CC','                Patients with the CC genotype treated with cisplatin may have a reduced but not non-existent risk for hearing loss as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1695','A > G','GSTP1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs3957357','A > G','GSTA1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.'),('rs9679162','G > T','GALNT14','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','TT','                Patients with the TT genotype may have increased response, including increased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs13181','T > G','ERCC2','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with platinum compounds as compared to patients with the GT or TT genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.'),('rs1799793','C > T','ERCC2','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','CT','                Patients with the CT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of overall survival  as compared to patients with the CC genotype. Genotype CT is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide. Both findings have been contradicted in another studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1799793','C > T','ERCC2','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','TT','                Genotype TT is not associated with increased risk of Drug Toxicity or decreased progression-free or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.'),('rs1799793','C > T','ERCC2','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have 1) increased survival and 2) increased risk for hematological toxicity with cisplatin regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to cisplatin regimens.'),('rs1799793','C > T','ERCC2','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','TT','                Patients with the TT genotype may have increased survival with cisplatin regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to cisplatin regimens.'),('rs3212986','C > A','ERCC1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk for nephrotoxicity with platinum-based regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs11615','A > G','ERCC1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs11615','A > G','ERCC1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 2B','-','-','decreased','GG','                Patients with the GG genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs11615','A > G','ERCC1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the AG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients risk for adverse events with cisplatin and cyclophosphamide treatment.'),('rs4646316','C > T','COMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','decreased','TT','                Patients with the TT genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk of hearing loss as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs9332377','C > T','COMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','increased','CT','                Patients with the CT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs9332377','C > T','COMT','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 1B','-','-','increased','TT','                Patients with the TT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.'),('rs9597','C > G','BAIAP3','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to cisplatin and irinotecan treatment.'),('rs9597','C > G','BAIAP3','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','GG','                Patients with the GG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype, although the GG genotype was not observed in the supporting study. Other genetic and clinical factors may also influence a patients response to cisplatin and irinotecan treatment.'),('rs1045642','A > G','ABCB1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1045642','A > G','ABCB1','cisplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00515 ','Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have better response (decreased risk of lymph node metastases and increased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs2227631','A > G','SERPINE1','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs2227631','A > G','SERPINE1','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs1799889','A > G','SERPINE1','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs1799889','A > G','SERPINE1','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs7997012','A > G','HTR2A','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs334558','A > G','GSK3B','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','increased','-','-','GG','                Patients with the GG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have more improvement in symptoms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients response to fluoxetine and citalopram.'),('rs1954787','T > C','GRIK4','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 1B','increased','-','-','CT','                Patients with the CT genotype may have an increased chance of response to citalopram treatment as compared to patients with the TT genotype. Patients with the CT genotype may still be at risk for non-response to citalopram treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs1954787','T > C','GRIK4','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 1B','increased','-','-','CC','                Patients with the CC genotype may have an increased chance of response to citalopram treatment as compared to patients with the TT genotype. Patients with the CC genotype may still be at risk for non-response to citalopram treatment based on their genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs7569963','G > A','CREB1','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs7569963','G > A','CREB1','citalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00215 ','Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs)','Level 3','decreased','-','-','AA','                Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs9274407','A > T','HLA-DQB1','clavulanate','VARIOUS','','DB00766 ','Clavulanic acid and its salts and esters. The acid is a suicide inhibitor of bacterial beta-lactamase enzymes from Streptomyces clavuligerus. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with beta-lactam antibiotics prevents antibiotic inactivation by microbial lactamase. [PubChem]','Level 3','-','-','decreased','TT','                Patients with the TT genotype may have decreased but not absent risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk for drug induced liver injury.'),('rs1544410','C > T','VDR','clodronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00720 ','A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification. [PubChem]','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with bisphosphonates may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to bisphosphonates.'),('rs731236','A > G','VDR','clodronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00720 ','A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype may have decreased likelihood of resistance when treated with clodronate compared to patients with genotype AA. Other genetic and clinical factors may also influence resistance to clodronate.'),('rs16944','A > G','IL1B','clodronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00720 ','A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs1360780','T > C','FKBP5','clomipramine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01242 ','Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. ','Level 3','-','-','decreased','CC','                Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to paroxetine, venlafaxine, clomipramine or nefazodone.'),('rs662','T > C','PON1','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 3','increased','-','-','CC','                Patients with the CC genotype who are treated with clopidogrel 1) may have higher levels of active metabolite, resulting in increased platelet inhibition and better response 2) may have a decreased, but not absent, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CT or TT genotype. This association has not been found in more studies than the number of studies the association was shown. Other genetic and clinical factors may also influence a patients response to clopidogrel.'),('rs4244285','G > A','CYP2C19','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 1A','decreased','-','-','AG','                Patients with the AG genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for secondary cardiovascular events and response to clopidogrel.'),('rs4244285','G > A','CYP2C19','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 1A','decreased','-','-','AA','                Patients with the AA genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for secondary cardiovascular events and response to clopidogrel.'),('rs1045642','A > G','ABCB1','clopidogrel','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00758 ','Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.','Level 2A','increased','-','-','GG','                People with GG  genotype may have decreased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Other genetic and clinical factors may also impact the response to clopidogrel.'),('rs1414334','C > G','HTR2C','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 1B','-','-','decreased','GG','                Patients with the GG genotype who are treated with antipsychotics may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patients risk for developing metabolic syndrome.'),('rs742105','C > T','DTNBP1','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','increased','-','-','CT','                Patients with the CT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients response to clozapine.'),('rs742105','C > T','DTNBP1','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','increased','-','-','TT','                Patients with the TT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients response to clozapine.'),('rs6280','C > T','DRD3','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','increased','-','-','TT','                Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a better response to treatment as compared to patients with the CC or CT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patients response to clozapine treatment.'),('rs1079598','A > G','DRD2','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1079598','A > G','DRD2','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','-','-','increased','GG','                Patients with the GG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1799732','- > G','DRD2','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1799732','- > G','DRD2','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','increased','-','-','G/del','                Patients with the G/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with these alleles and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs6277','G > A','DRD2','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased, but not absent risk, for weight gain when treated with clozapine or olanzepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1800497','G > A','ANKK1','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1800497','G > A','ANKK1','clozapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00363 ','A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.','Level 2B','-','-','increased','AA','                Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs9282861','C > T','SULT1A1','conjugated estrogens','GENITO URINARY SYSTEM AND SEX HORMONES','SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM','DB00286 ','Conjugated estrogens, a mixture of the water-soluble salts of sulfate esters from estrone','Level 3','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse responses to hormone replacement therapy.'),('rs9282861','C > T','SULT1A1','conjugated estrogens','GENITO URINARY SYSTEM AND SEX HORMONES','SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM','DB00287','Conjugated estrogens, a mixture of the water-soluble salts of sulfate esters from estrone','Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse responses to hormone replacement therapy.'),('rs9340799','A > G','ESR1','conjugated estrogens','GENITO URINARY SYSTEM AND SEX HORMONES','SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM','DB00288','Conjugated estrogens, a mixture of the water-soluble salts of sulfate esters from estrone','Level 3','-','-','-','AG','                Patients with the AG genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density.'),('rs9340799','A > G','ESR1','conjugated estrogens','GENITO URINARY SYSTEM AND SEX HORMONES','SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM','DB00289','Conjugated estrogens, a mixture of the water-soluble salts of sulfate esters from estrone','Level 3','-','-','-','GG','                Patients with the GG genotype may experience 1) greater increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) smaller decreases in spine bone mineral density when untreated, as compared to patient with the AA genotype. Other genetic and clinical factors may also influence spine bone mineral density.'),('rs25487','T > C','XRCC1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','increased','-','-','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CT or TT genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.'),('rs1042522','C > G','TP53','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1042522','C > G','TP53','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','-','-','decreased','CC','                Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs4880','A > G','SOD2','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients survival when treated with cyclophosphamide.'),('rs1799983','T > G','NOS3','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','increased','-','-','GT','                Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs1799983','T > G','NOS3','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs1801133','G > A','MTHFR','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2A','-','-','increased','AA','                Patients with the AA genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to cyclophosphamide.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2A','increased','-','-','AG','                Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1695','A > G','GSTP1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 2A','decreased','-','increased','GG','                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs3957357','A > G','GSTA1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.'),('rs1799793','C > T','ERCC2','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','increased','-','-','CT','                Patients with the CT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of overall survival  as compared to patients with the CC genotype. Genotype CT is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide. Both findings have been contradicted in another studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.'),('rs1799793','C > T','ERCC2','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','increased','-','-','TT','                Genotype TT is not associated with increased risk of Drug Toxicity or decreased progression-free or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.'),('rs11615','A > G','ERCC1','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSVARIOUS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','decreased','GG','                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the AG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients risk for adverse events with cisplatin and cyclophosphamide treatment.'),('rs2740574','C > T','CYP3A4','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','decreased','-','-','TT','                Premenopausal patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have a shorter period of time before chemotherapy-induced ovarian failure compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.'),('rs4244285','G > A','CYP2C19','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 4','-','-','decreased','AG','                Female patients with the AG genotype and Systemic Lupus Erythematosus who are treated with a high cumulative dose of cyclophosphamide (= or >23.75 g) may have a decreased risk of ovarian toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cyclophosphamide-induced ovarian toxicity.'),('rs4244285','G > A','CYP2C19','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 4','-','-','decreased','AA','                Female patients with the AA genotype and Systemic Lupus Erythematosus who are treated with a high cumulative dose of cyclophosphamide (= or >23.75 g) may have a decreased risk of ovarian toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cyclophosphamide-induced ovarian toxicity.'),('rs4244285','G > A','CYP2C19','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 4','decreased','-','-','AA','                Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','decreased','GT','                Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patients risk for venoocclusive disease of the liver.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','decreased','TT','                Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the TT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patients risk for venoocclusive disease of the liver.'),('rs8192709','C > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','increased','CT','                Recipients of HLA-identical hematopoietic stem cell transplantation with the CT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hemorrhagic cystitis.'),('rs8192709','C > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','increased','TT','                Recipients of HLA-identical hematopoietic stem cell transplantation with the TT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hemorrhagic cystitis.'),('rs2279343','A > G','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','increased','AG','                Patients with the AG genotype who have received a  hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for oral mucositis.'),('rs2279343','A > G','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','increased','GG','                Patients with the GG genotype who have received a  hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for oral mucositis.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','decreased','-','GT','                Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs3745274','G > T','CYP2B6','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','decreased','-','TT','                Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs9561778','G > T','ABCC4','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','increased','GT','                Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse events with cyclophosphamide treatment.'),('rs9561778','G > T','ABCC4','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','increased','TT','                Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events with cyclophosphamide treatment.'),('rs9561778','G > T','ABCC4','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','increased','GT','                Patients with the GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for ADRs.'),('rs9561778','G > T','ABCC4','cyclophosphamide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00531 ','Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]','Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for ADRs.'),('rs776746','C > T','CYP3A5','cyclosporine','VARIOUS','','','Cyclosporine is available in its original form and as another product that has been modified (changed) so that the medication can be better absorbed in the body. Original cyclosporine and cyclosporine (modified) are absorbed by the body in different amounts, so they cannot be substituted for one another. Take only the type of cyclosporine that was prescribed by your doctor. When your doctor gives you a written prescription, check to be sure that he or she has specified the type of cyclosporine you should receive. Each time you have your prescription filled, look at the brand name printed on your prescription label to be sure that you have received the same type of cyclosporine. Talk to your pharmacist if the brand name is unfamiliar or you are not sure you have received the right type of cyclosporine.','Level 3','-','increased','-','CT','                Patients with the TC genotype may require an increased dose of cyclosporine to reach target blood concentration as compared to patients with the CC genotype, although some studies find no association with dosage. Other genetic and clinical factors may also influence dose of cyclosporine.'),('rs776746','C > T','CYP3A5','cyclosporine','VARIOUS','','','Cyclosporine is available in its original form and as another product that has been modified (changed) so that the medication can be better absorbed in the body. Original cyclosporine and cyclosporine (modified) are absorbed by the body in different amounts, so they cannot be substituted for one another. Take only the type of cyclosporine that was prescribed by your doctor. When your doctor gives you a written prescription, check to be sure that he or she has specified the type of cyclosporine you should receive. Each time you have your prescription filled, look at the brand name printed on your prescription label to be sure that you have received the same type of cyclosporine. Talk to your pharmacist if the brand name is unfamiliar or you are not sure you have received the right type of cyclosporine.','Level 3','-','increased','-','TT','                Patients with the TT genotype may require an increased dose of cyclosporine to reach target blood concentration as compared to patients with the CC genotype,  although some studies find no association with dosage. Other genetic and clinical factors may also influence dose of cyclosporine.'),('rs1045642','A > G','ABCB1','cyclosporine','VARIOUS','','','Cyclosporine is available in its original form and as another product that has been modified (changed) so that the medication can be better absorbed in the body. Original cyclosporine and cyclosporine (modified) are absorbed by the body in different amounts, so they cannot be substituted for one another. Take only the type of cyclosporine that was prescribed by your doctor. When your doctor gives you a written prescription, check to be sure that he or she has specified the type of cyclosporine you should receive. Each time you have your prescription filled, look at the brand name printed on your prescription label to be sure that you have received the same type of cyclosporine. Talk to your pharmacist if the brand name is unfamiliar or you are not sure you have received the right type of cyclosporine.','Level 3','-','increased','-','AG','                Patients with genotype AG may have increased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.'),('rs1045642','A > G','ABCB1','cyclosporine','VARIOUS','','','Cyclosporine is available in its original form and as another product that has been modified (changed) so that the medication can be better absorbed in the body. Original cyclosporine and cyclosporine (modified) are absorbed by the body in different amounts, so they cannot be substituted for one another. Take only the type of cyclosporine that was prescribed by your doctor. When your doctor gives you a written prescription, check to be sure that he or she has specified the type of cyclosporine you should receive. Each time you have your prescription filled, look at the brand name printed on your prescription label to be sure that you have received the same type of cyclosporine. Talk to your pharmacist if the brand name is unfamiliar or you are not sure you have received the right type of cyclosporine.','Level 3','-','decreased','-','GG','                Patients with genotype GG may have decreased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype AA or AG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.'),('rs1128503','A > G','ABCB1','cyclosporine','VARIOUS','','','Cyclosporine is available in its original form and as another product that has been modified (changed) so that the medication can be better absorbed in the body. Original cyclosporine and cyclosporine (modified) are absorbed by the body in different amounts, so they cannot be substituted for one another. Take only the type of cyclosporine that was prescribed by your doctor. When your doctor gives you a written prescription, check to be sure that he or she has specified the type of cyclosporine you should receive. Each time you have your prescription filled, look at the brand name printed on your prescription label to be sure that you have received the same type of cyclosporine. Talk to your pharmacist if the brand name is unfamiliar or you are not sure you have received the right type of cyclosporine.','Level 3','-','increased','-','GG','                Patients with the GG genotype and Myasthenia Gravis may have increased clearance of cyclosporine and therefore may require an increased dose of cyclosporine, compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.'),('rs2072671','A > C','CDA','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 3','-','-','increased','AC','                Patients with the AC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs2072671','A > C','CDA','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs532545','C > T','CDA','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 3','decreased','-','-','CT','                Patients with the genotype CT and Myeloid Leukemia who are treated with cytarabine may have a decreased survival time and an increased risk for death as compared to patients with the CC genotype, or may have an increased survival time and a decreased risk for death as compared to patients with the TT genotype, though this may not be statistically significant. Other genetic and clinical factors may also influence a patients survival when treated with cytarabine.'),('rs532545','C > T','CDA','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 3','decreased','-','-','TT','                Patients with the genotype TT and Myeloid Leukemia who are treated with cytarabine 1) may have a decreased survival time 2) may have an increased risk for death, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients survival when treated with cytarabine.'),('rs602950','A > G','CDA','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 4','-','-','increased','AG','                Patients with the AG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for cytarabine-induced toxicity.'),('rs602950','A > G','CDA','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 4','-','-','increased','GG','                Patients with the GG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for cytarabine-induced toxicity.'),('rs1045642','A > G','ABCB1','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','cytarabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00987 ','A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs61888800','G > T','BDNF','desipramine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01151 ','Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation.','Level 3','decreased','-','-','GT','                Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.'),('rs61888800','G > T','BDNF','desipramine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01151 ','Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation.','Level 3','decreased','-','-','TT','                Patients with the TT genotype with major depressive disorder may experience a  lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.'),('rs1045642','A > G','ABCB1','dexamethasone','RESPIRATORY SYSTEM','','','Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant effects. It is 25 times more potent than cortisol in its glucocorticoid effect, while having minimal mineralocorticoid effect.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs2032582','A > C','ABCB1','dexamethasone','RESPIRATORY SYSTEM','','','Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant effects. It is 25 times more potent than cortisol in its glucocorticoid effect, while having minimal mineralocorticoid effect.','Level 3','decreased','-','-','CC','                Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patients response to the therapy.'),('rs1057910','A > C','CYP2C9','diclofenac','SENSORY ORGANS','OPHTHALMOLOGICALS','DB00586 ','A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. [PubChem]','Level 2A','-','-','increased','AC','                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs1057910','A > C','CYP2C9','diclofenac','SENSORY ORGANS','OPHTHALMOLOGICALS','DB00586 ','A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. [PubChem]','Level 2A','-','-','increased','CC','                Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.'),('rs2070744','C > T','NOS3','diuretics','CARDIOVASCULAR SYSTEM','DIURETICS','','A diuretic is any substance that promotes the production of urine. This includes forced diuresis. There are several categories of diuretics. All diuretics increase the excretion of water from bodies, although each class does so in a distinct way. Alternatively, an antidiuretic such as vasopressin is an agent or drug which reduces the excretion of water in urine.','Level 3','-','-','-','CT','                Patients with the CT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antihypertensives.'),('rs2070744','C > T','NOS3','diuretics','CARDIOVASCULAR SYSTEM','DIURETICS','','A diuretic is any substance that promotes the production of urine. This includes forced diuresis. There are several categories of diuretics. All diuretics increase the excretion of water from bodies, although each class does so in a distinct way. Alternatively, an antidiuretic such as vasopressin is an agent or drug which reduces the excretion of water in urine.','Level 3','-','-','-','TT','                Patients with the TT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antihypertensives.'),('rs4961','G > T','ADD1','diuretics','CARDIOVASCULAR SYSTEM','DIURETICS','','A diuretic is any substance that promotes the production of urine. This includes forced diuresis. There are several categories of diuretics. All diuretics increase the excretion of water from bodies, although each class does so in a distinct way. Alternatively, an antidiuretic such as vasopressin is an agent or drug which reduces the excretion of water in urine.','Level 3','-','-','-','GT','                Patients with the GT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patients response to diuretics.'),('rs4961','G > T','ADD1','diuretics','CARDIOVASCULAR SYSTEM','DIURETICS','','A diuretic is any substance that promotes the production of urine. This includes forced diuresis. There are several categories of diuretics. All diuretics increase the excretion of water from bodies, although each class does so in a distinct way. Alternatively, an antidiuretic such as vasopressin is an agent or drug which reduces the excretion of water in urine.','Level 3','-','-','-','TT','                Patients with the TT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patients response to diuretics.'),('rs1382368','C > T','XRCC4','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 4','-','increased','-','CT','                Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the CC genotype, or decreased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.'),('rs1382368','C > T','XRCC4','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 4','-','increased','-','TT','                Patients with the TT genotype may have increased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.'),('rs1402467','C > G','SULT1C4','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs1402467','C > G','SULT1C4','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','GG','                Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs2292954','A > G','SPG7','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs11045585','A > G','SLCO1B3','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to docetaxel.'),('rs11045585','A > G','SLCO1B3','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','increased','GG','                Patients with the GG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to docetaxel.'),('rs2301159','G > A','SLC10A2','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs2301159','G > A','SLC10A2','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','increased','AA','                Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs12960','G > A','RPL13','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs518329','T > C','PRDX4','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 4','-','-','-','CT','                Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.'),('rs518329','T > C','PRDX4','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 4','-','-','-','CC','                Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.'),('rs1883322','C > T','PPARD','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2016520','C > T','PPARD','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs3734254','C > T','PPARD','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs3734254','C > T','PPARD','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','TT','                Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs6922548','A > G','PPARD','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs6922548','A > G','PPARD','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','GG','                Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs7769719','G > A','PPARD','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','decreased','-','-','AA','                Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs870995','C > A','PIK3CA','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 4','-','-','-','AA','                Patients with the AA genotype may have decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.'),('rs1799931','G > A','NAT2','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2234922','A > G','EPHX1','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 4','-','decreased','-','AG','                Patients with the AG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.'),('rs2234922','A > G','EPHX1','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 4','-','decreased','-','GG','                Patients with the GG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.'),('rs4646487','C > T','CYP4B1','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4646487','C > T','CYP4B1','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2740574','C > T','CYP3A','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','-','TT','                Patients with the TT genotype may have decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of docetaxel.'),('rs1056836','C > G','CYP1B1','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with taxanes may have longer disease-free progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs12418','G > A','CHST3','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs12418','G > A','CHST3','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','-','AA','                Patients with the AA genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs4148943','C > T','CHST3','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4148945','C > T','CHST3','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','decreased','-','decreased','TT','                Patients with the TT genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4148947','T > C','CHST3','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','decreased','-','-','CC','                Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4148950','G > A','CHST3','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','increased','AG','                Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs4148950','G > A','CHST3','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','increased','-','increased','AA','                Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs730720','C > T','CHST3','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2238472','C > T','ABCC6','docetaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01248','Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.','Level 3','-','-','decreased','TT','                Patients with the TT genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs20572','C > T','CBR1','doxorubicinol','VARIOUS','','','','Level 4','-','-','-','CT','                Patients with the CT genotype may have 1) decreased clearance of doxorubicin 2) increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with CC genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.'),('rs13058338','T > A','RAC2','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','decreased','AA','                Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin  may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the TT genotype. Please note, the risk allele reported in the study has been complemented to the positive chromosomal strand here. Other genetic and clinical factors may also influence a patients risk for cardiotoxicity.'),('rs1799983','T > G','NOS3','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','increased','-','-','GT','                Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs1799983','T > G','NOS3','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','increased','-','-','GG','                Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs2070744','C > T','NOS3','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','-','CT','                Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs2070744','C > T','NOS3','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','-','TT','                Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence disease-free survival.'),('rs1883112','G > A','NCF4','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','increased','AA','                Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patients risk for cardiotoxicity.'),('rs4244285','G > A','CYP2C19','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 4','decreased','-','-','AA','                Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs3745274','G > T','CYP2B6','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','-','TT','                Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs4673','A > G','CYBA','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for cardiotoxicity.'),('rs8133052','G > A','CBR3','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','increased','-','-','AG','                Patients with the AG genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype, or 1) may have increased metabolism of doxorubicin 2) may have less tumor reduction 3) may have decreased severity of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to doxorubicin treatment and risk of toxicity.'),('rs8133052','G > A','CBR3','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','increased','-','-','AA','                Patients with the AA genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients response to doxorubicin treatment and risk of toxicity.'),('rs20572','C > T','CBR1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 4','-','-','-','CT','                Patients with the CT genotype may have 1) decreased clearance of doxorubicin 2) increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with CC genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.'),('rs9561778','G > T','ABCC4','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','increased','GT','                Patients with the GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for ADRs.'),('rs9561778','G > T','ABCC4','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for ADRs.'),('rs17222723','T > A','ABCC2','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','increased','AT','                Patients with the AT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for cardiotoxicity.'),('rs17222723','T > A','ABCC2','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','increased','AA','                Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for cardiotoxicity.'),('rs8187710','G > A','ABCC2','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','increased','AG','                Patients with the AG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of cardiotoxicity.'),('rs8187710','G > A','ABCC2','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','increased','AA','                Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of cardiotoxicity.'),('rs45511401','G > T','ABCC1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','increased','GT','                Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxocity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for cardiotoxicity.'),('rs45511401','G > T','ABCC1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','-','-','increased','TT','                Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cardiotoxicity.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs1045642','A > G','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs2032582','A > C','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','decreased','-','-','CC','                Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patients response to the therapy.'),('rs2032582','A > C','ABCB1','doxorubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00997 ','Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.','Level 3','increased','-','-','CC','                Patients with the CC genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CT or TT. Other genetic and clinical factors may also influence a patients response to cyclophosphamide and doxorubicin.'),('rs16969968','G > A','CHRNA3','Drugs used in nicotine dependence','NERVOUS SYSTEM','','','','Level 3','increased','-','-','AG','                Patients with AG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the AG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Finding are based on haplotype analysis of rs16969968 and rs680244. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs16969968','G > A','CHRNA3','Drugs used in nicotine dependence','NERVOUS SYSTEM','','','','Level 3','increased','-','-','AA','                Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the GG genotype. However, contradictory findings have been reported, with the AA genotype may be associated with a decreased likelihood of smoking cessation compared to GG genotype. Finding are based on haplotype analysis of rs16969968 and rs680244. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs1800497','G > A','ANKK1','Drugs used in nicotine dependence','NERVOUS SYSTEM','','','','Level 3','increased','-','-','AG','                Patients with AG genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs1800497','G > A','ANKK1','Drugs used in nicotine dependence','NERVOUS SYSTEM','','','','Level 3','increased','-','-','AA','                Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs963468','G > A','DRD3','duloxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00476 ','Duloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is a drug which primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), pain related to diabetic peripheral neuropathy and in some countries stress urinary incontinence (SUI). It is manufactured and marketed by Eli Lilly and Company.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to duloxetine treatment.'),('rs963468','G > A','DRD3','duloxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00476 ','Duloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is a drug which primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), pain related to diabetic peripheral neuropathy and in some countries stress urinary incontinence (SUI). It is manufactured and marketed by Eli Lilly and Company.','Level 3','increased','-','-','AA','                Patients with the AA genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to duloxetine treatment.'),('rs3745274','G > T','CYP2A7P1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 2A','-','increased','-','TT','                Patients with the TT genotype may have increased plasma concentration of efavirenz in people with HIV as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients exposure to efavirenz.'),('rs3745274','G > T','CYP2A7P1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 2A','-','-','increased','GT','                Patients with the GT genotype may have an increased risk of efavirenz-induced side effects (central nervous symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs3745274','G > T','CYP2A7P1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 2A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for efavirenz-induced side effects (central nervous symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1045642','A > G','ABCB1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.'),('rs2032582','A > C','ABCB1','efavirenz','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00625 ','For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.','Level 3','decreased','-','-','CC','                Patients with the CC genotype may have increased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the AA genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz'),('rs2227983','G > A','EGFR','egfr inhibitors','VARIOUS','','','The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands.','Level 3','-','-','decreased','AG','                Patients with the AG genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2227983','G > A','EGFR','egfr inhibitors','VARIOUS','','','The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands.','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1695','A > G','GSTP1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 2A','increased','-','-','AG','                Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1695','A > G','GSTP1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 2A','decreased','-','increased','GG','                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.'),('rs1045642','A > G','ABCB1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','epirubicin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00445','The compound exerts its antitumor effects by interference with the synthesis and function of DNA.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs2227983','G > A','EGFR','erlotinib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00530 ','Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.','Level 3','-','-','decreased','AG','                Patients with the AG genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2227983','G > A','EGFR','erlotinib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00530 ','Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs712829','G > T','EGFR','erlotinib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00530 ','Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.','Level 3','-','-','decreased','GT','                Patients with the GT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.'),('rs712829','G > T','EGFR','erlotinib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00530 ','Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.','Level 3','-','-','decreased','TT','                Patients with the TT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.'),('rs712829','G > T','EGFR','erlotinib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00530 ','Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.','Level 4','increased','-','-','GT','                Patients with the GT genotype may be more sensitive to treatment with erlotinib  compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.'),('rs712829','G > T','EGFR','erlotinib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00530 ','Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.','Level 4','increased','-','-','TT','                Patients with the TT genotype may be more sensitive to treatment with erlotinib  compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.'),('rs4795541','G > GG','SLC6A4','escitalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01175 ','Escitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity.','Level 3','-','-','-','AGATGCTGGG','                Patients with the insert/del (Long/ Short) genotype who are treated with escitalopram: 1) who have experienced one or more Stressful Life Event in the 6 months pretreatment may have increased response compared to patients with the del/del genotype. Patients who have not experienced one or more Stressful Life Event in the 6 months pretreatment may have a similar response compared to patients with the del/del genotype. 2) may have an increased risk of side effects, including headache, compared to patients with the insert/insert genotype. Other genetic and clinical factors may also influence response to escitalopram and side effects induced by escitalopram.'),('rs4795541','G > GG','SLC6A4','escitalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01175 ','Escitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity.','Level 3','-','-','-','AGATGCTGGG','                Patients with the insert/insert (Long/ Long) genotype who are treated with treated with escitalopram: 1) who have experienced one or more Stressful Life Event in the 6 months pretreatment may have increased response when treated with escitalopram compared to patients with the del/del genotype. Patients who have not experienced one or more Stressful Life Event in the 6 months pretreatment may have a similar response compared to patients with the del/del genotype. 2) may have a decreased risk of side effects, including headache, compared to patients with the insert/del or del/del genotype. Other genetic and clinical factors may also influence  response to escitalopram and side effects induced by escitalopram.'),('rs9316233','C > G','HTR2A','escitalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01175 ','Escitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased antidepressant response to escitalopram as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to escitalopram.'),('rs11188072','C > T','CYP2C19','escitalopram','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01175 ','Escitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity.','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with escitalopram may require an increased dose  as compared to patients with the CT or CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs1800629','G > A','TNF','etanercept','VARIOUS','','','Etanercept (trade name Enbrel) is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF; a soluble inflammatory cytokine) by acting as a TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and rheumatoid arthritis who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype or may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to anti-TNF therapy.'),('rs1800629','G > A','TNF','etanercept','VARIOUS','','','Etanercept (trade name Enbrel) is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF; a soluble inflammatory cytokine) by acting as a TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis.','Level 3','decreased','-','-','AA','                Patients with the AA genotype and rheumatoid arthritis who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to anti-TNF therapy.'),('rs1799971','A > G','OPRM1','ethanol','VARIOUS','','','Ethanol is a psychoactive drug and is one of the oldest recreational drugs still used by humans. Ethanol can cause alcohol intoxication when consumed. Best known as the type of alcohol found in alcoholic beverages, it is also used in thermometers, as a solvent, and as a fuel. In common usage, it is often referred to simply as alcohol or spirits.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients ethanol response.'),('rs1799971','A > G','OPRM1','ethanol','VARIOUS','','','Ethanol is a psychoactive drug and is one of the oldest recreational drugs still used by humans. Ethanol can cause alcohol intoxication when consumed. Best known as the type of alcohol found in alcoholic beverages, it is also used in thermometers, as a solvent, and as a fuel. In common usage, it is often referred to simply as alcohol or spirits.','Level 2B','-','-','increased','GG','                Patients with the GG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients ethanol response.'),('rs1800497','G > A','ANKK1','ethanol','VARIOUS','','','Ethanol is a psychoactive drug and is one of the oldest recreational drugs still used by humans. Ethanol can cause alcohol intoxication when consumed. Best known as the type of alcohol found in alcoholic beverages, it is also used in thermometers, as a solvent, and as a fuel. In common usage, it is often referred to simply as alcohol or spirits.','Level 2B','-','-','increased','AG','                Patients with AG genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patients risk for alcohol dependency.'),('rs1800497','G > A','ANKK1','ethanol','VARIOUS','','','Ethanol is a psychoactive drug and is one of the oldest recreational drugs still used by humans. Ethanol can cause alcohol intoxication when consumed. Best known as the type of alcohol found in alcoholic beverages, it is also used in thermometers, as a solvent, and as a fuel. In common usage, it is often referred to simply as alcohol or spirits.','Level 2B','-','-','increased','AA','                Patients with AA genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patients risk for alcohol dependency.'),('rs1544410','C > T','VDR','etidronic acid','VARIOUS','','Etidronic acid is a chelating ','Etidronic acid is a chelating agent and may be added to bind or, to some extent, counter the effects of substances, such as calcium, iron or other metal ions, which may be discharged as a component of grey wastewater and could conceivably contaminate groundwater supplies. As a phosphonate it has corrosion inhibiting properties on unnalloyed steel. Etidronic acid also acts to retard rancidification and oxidation of fatty acids.','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with bisphosphonates may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to bisphosphonates.'),('rs16944','A > G','IL1B','etidronic acid','VARIOUS','','Etidronic acid is a chelating ','Etidronic acid is a chelating agent and may be added to bind or, to some extent, counter the effects of substances, such as calcium, iron or other metal ions, which may be discharged as a component of grey wastewater and could conceivably contaminate groundwater supplies. As a phosphonate it has corrosion inhibiting properties on unnalloyed steel. Etidronic acid also acts to retard rancidification and oxidation of fatty acids.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Pagets disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs16944','A > G','IL1B','etidronic acid','VARIOUS','','Etidronic acid is a chelating ','Etidronic acid is a chelating agent and may be added to bind or, to some extent, counter the effects of substances, such as calcium, iron or other metal ions, which may be discharged as a component of grey wastewater and could conceivably contaminate groundwater supplies. As a phosphonate it has corrosion inhibiting properties on unnalloyed steel. Etidronic acid also acts to retard rancidification and oxidation of fatty acids.','Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs2784917','A > G','SLIT1','etoposide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','Etidronic acid is a chelating ','A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding.','Level 4','-','-','decreased','AG','                Patients with the AG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2784917','A > G','SLIT1','etoposide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00773 ','A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding.','Level 4','-','-','decreased','GG','                Patients with the GG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs6539870','A > G','Not available','etoposide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00773 ','A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding.','Level 4','-','-','increased','GG','                Patients with the GG genotype may have increased risk of toxicity with etoposide compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1045642','A > G','ABCB1','fexofenadine','RESPIRATORY SYSTEM','ANTIHISTAMINES FOR SYSTEMIC USE','DB00950','Fexofenadine hydrochloride (Allegra) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine.','Level 3','-','-','-','AG','                Healthy individuals with the AG genotype who are treated with fexofenadine may have higher plasma drug levels as compared to healthy individuals with the AA genotype.  Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.'),('rs1045642','A > G','ABCB1','fexofenadine','RESPIRATORY SYSTEM','ANTIHISTAMINES FOR SYSTEMIC USE','DB00950','Fexofenadine hydrochloride (Allegra) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine.','Level 3','-','-','-','GG','                Healthy individuals with the GG genotype who are treated with fexofenadine may have higher plasma drug levels as compared with healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.'),('rs37973','G > A','GLCCI1','flunisolide','RESPIRATORY SYSTEM','NASAL PREPARATIONS','DB00180','Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid often prescribed as treatment for allergic rhinitis.','Level 3','increased','-','-','AA','                Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patients response to glucocorticoids.'),('rs25487','T > C','XRCC1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','CC','                Patients with the CC genotype may have increased response to fluorouracil-containing chemotherapy regimens as compared to patients with the CT or TT genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.'),('rs1801019','G > C','UMPS','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','increased','CC','                Patients with CC genotype and cancer may have an increased risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and  leucovorin as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to leucovorin, tegafur and fluorouracil.'),('rs1042522','C > G','TP53','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1042522','C > G','TP53','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2B','-','-','decreased','CC','                Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1799983','T > G','NOS3','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','GT','                Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs1799983','T > G','NOS3','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs2070744','C > T','NOS3','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','-','CT','                Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs2070744','C > T','NOS3','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','-','TT','                Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence disease-free survival.'),('rs1801131','T > G','MTHFR','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GT','                Patients with the GT genotype may have decreased risk of Drug Toxicity when treated with fluorouracil and radiotherapy in people with Rectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1801131','T > G','MTHFR','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk of Drug Toxicity when treated with fluorouracil and radiotherapy in people with Rectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1801133','G > A','MTHFR','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','AG','                Patients with the AG genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1801133','G > A','MTHFR','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','AA','                Patients with the AA genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the GG genotype. However, conflicting finding of no-association for this genotype has also been reported. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','increased','-','-','GG','                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','AG','                Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for hematological toxicity when exposed to fluorouracil.'),('rs1695','A > G','GSTP1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hematological toxicity when exposed to flourouracil.'),('rs9679162','G > T','GALNT14','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','TT','                Patients with the TT genotype may have increased response, including increased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs13181','T > G','ERCC2','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','GT','                Patients with the GT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity as compared to patients with the TT genotype 2) an increased risk of early relapse as compared to patients with the TT genotype. However, a trend of an association is found for the GT genotype with increased progression free survival compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil, leucovorin and oxaliplatin.'),('rs13181','T > G','ERCC2','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','GG','                Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity 2) an increased risk of early relapse and 3) decreased progression free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil, leucovorin and oxaliplatin.'),('rs1801158','C > T','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','CT','                Patients with the CT genotype may have an increased risk of fluorouracil-related toxicity in cancer patients as compared to patients with the CC genotype. Genotype CT is also associated with decreased DPYD activity. Other genetic and clinical factors may also influence a patients risk of fluorouracil-related toxicity.'),('rs1801158','C > T','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk of fluorouracil-related toxicity in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of fluorouracil-related toxicity.'),('rs1801159','T > C','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased likelihood of middle-severe nausea,  vomiting and white blood cell decreases in cancer patients treated with fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk of fluorouracil  related adverse events.'),('rs1801159','T > C','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased likelihood of middle-severe nausea,  vomiting and white blood cell decreases in cancer patients treated with fluorouracil as compared to patients with the TT genotype. Genotype CC is also associated with decreased clearance of fluorouracil. Other genetic and clinical factors may also influence a patients risk of fluorouracil  related adverse events.'),('rs1801265','G > A','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased likelihood of middle-severe nausea and vomiting in Asian cancer patients treated with fluorouracil as as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patients risk for fluorouracil-related toxicity.'),('rs2297595','T > C','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','CT','                Patients with the CT genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs2297595','T > C','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.'),('rs67376798','T > A','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','AT','                Patients with the AT genotype and Cancer who are treated with fluorouracil-containing regimens 1) may have decreased clearance of the drug 2) may have an increased risk and severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for fluorouracil-induced toxicity.'),('rs67376798','T > A','DPYD','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 2A','-','-','increased','AA','                Patients with the AA genotype were not reported, however, patients with the AT genotype and Cancer who are treated with fluorouracil-containing regimens 1) may have decreased clearance of the drug 2) may have an increased risk and severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for fluorouracil-induced toxicity.'),('rs9561778','G > T','ABCC4','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','GT','                Patients with the GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for ADRs.'),('rs9561778','G > T','ABCC4','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for ADRs.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','AG','                Patients with the AG genotype may have better response (decreased risk of lymph node metastases and increased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.'),('rs1045642','A > G','ABCB1','fluorouracil','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00544 ','A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]','Level 3','-','-','decreased','GG','                Patients with GG genotype may have decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also impact a patients response to fluorouracil.'),('rs25531','T > C','SLC6A4','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 4','decreased','-','-','CT','                Patients with the CT genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT.  Other genetic and clinical factors may also influence a patients response.'),('rs25531','T > C','SLC6A4','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 4','decreased','-','-','CC','                Patients with the CC genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT.  Other genetic and clinical factors may also influence a patients response.'),('rs2227631','A > G','SERPINE1','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs2227631','A > G','SERPINE1','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs1799889','A > G','SERPINE1','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 3','decreased','-','-','AG','                Patients with the AG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs1799889','A > G','SERPINE1','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 3','decreased','-','-','GG','                Patients with the GG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for non-response to antidepressants.'),('rs334558','A > G','GSK3B','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 3','increased','-','-','GG','                Patients with the GG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have more improvement in symptoms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients response to fluoxetine and citalopram.'),('rs61888800','G > T','BDNF','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 3','decreased','-','-','GT','                Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.'),('rs61888800','G > T','BDNF','fluoxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00472 ','Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs).','Level 3','decreased','-','-','TT','                Patients with the TT genotype with major depressive disorder may experience a  lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.'),('rs37973','G > A','GLCCI1','fluticasone propionate','RESPIRATORY SYSTEM','CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS','DB00588 ','Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma.','Level 3','increased','-','-','AA','                Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patients response to glucocorticoids.'),('rs11045819','C > A','SLCO1B1','fluvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01095 ','Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.','Level 3','increased','-','-','AC','                Patients with the AC genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to fluvastatin.'),('rs11045819','C > A','SLCO1B1','fluvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01095 ','Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.','Level 3','increased','-','-','AA','                Patients with the AA genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patients response to fluvastatin.'),('rs17238540','T > G','HMGCR','fluvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01095 ','Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.','Level 3','decreased','-','-','GT','                Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17238540','T > G','HMGCR','fluvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01095 ','Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.','Level 3','decreased','-','-','GG','                Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17244841','A > T','HMGCR','fluvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01095 ','Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs5443','C > T','GNB3','fluvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01095 ','Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.','Level 4','increased','-','-','CT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs5443','C > T','GNB3','fluvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01095 ','Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.','Level 4','increased','-','-','TT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs10042486','C > T','HTR1A','fluvoxamine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00176 ','Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.','Level 3','decreased','-','-','CT','                Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs10042486','C > T','HTR1A','fluvoxamine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00176 ','Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.','Level 3','decreased','-','-','TT','                Patients with the TT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment  as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs6295','C > G','HTR1A','fluvoxamine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00176 ','Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs6295','C > G','HTR1A','fluvoxamine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00176 ','Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.','Level 3','increased','-','-','GG','                Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs4961','G > T','ADD1','furosemide','CARDIOVASCULAR SYSTEM','DIURETICS','DB00695 ','A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. [PubChem]','Level 2B','decreased','-','-','GT','                Patients with the GT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to diuretics.'),('rs4961','G > T','ADD1','furosemide','CARDIOVASCULAR SYSTEM','DIURETICS','DB00695 ','A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. [PubChem]','Level 2B','decreased','-','-','TT','                Patients with the TT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to diuretics.'),('rs712829','G > T','EGFR','gefitinib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00317 ','Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells.','Level 3','increased','-','-','GT','                Patients with the GT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs712829','G > T','EGFR','gefitinib','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00317 ','Gefitinib (originally coded ZD1840) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells.','Level 3','increased','-','-','TT','                Patients with the TT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs712829','G > T','EGFR','geldanamycin','VARIOUS','','','Geldanamycin is a benzoquinone ansamycin antibiotic that inhibits the function of Hsp90 (Heat Shock Protein 90) by binding to the unusual ADP/ATP-binding pocket of the protein.[1] HSP90 client proteins play important roles in the regulation of the cell cycle, cell growth, cell survival, apoptosis, angiogenesis and oncogenesis.','Level 4','decreased','-','-','GT','                Patients with the genotype GT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patients response.'),('rs712829','G > T','EGFR','geldanamycin','VARIOUS','','','Geldanamycin is a benzoquinone ansamycin antibiotic that inhibits the function of Hsp90 (Heat Shock Protein 90) by binding to the unusual ADP/ATP-binding pocket of the protein.[1] HSP90 client proteins play important roles in the regulation of the cell cycle, cell growth, cell survival, apoptosis, angiogenesis and oncogenesis.','Level 4','decreased','-','-','TT','                Patients with the genotype TT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patients response.'),('rs9937','A > G','RRM1','gemcitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00441 ','Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar? by Eli Lilly and Company. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication.','Level 4','-','-','decreased','AG','                Patients with the AG genotype and the A allele of rs1042858 with advanced breast cancer who are treated with gemcitabine 1) may be less likely to experience toxicity such as neutropenia 2) may have a tendency, though not a statistically significant one, towards poorer progression-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of toxicity and response to gemcitabine.'),('rs9937','A > G','RRM1','gemcitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00441 ','Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar? by Eli Lilly and Company. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication.','Level 4','-','-','decreased','GG','                Patients with the GG genotype and the A allele of rs1042858 with advanced breast cancer who are treated with gemcitabine 1) may be less likely to experience toxicity such as neutropenia 2) may have a tendency, though not a statistically significant one, towards poorer progression-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of toxicity and response to gemcitabine.'),('rs2072671','A > C','CDA','gemcitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00441 ','Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar? by Eli Lilly and Company. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication.','Level 3','-','-','increased','AC','                Patients with the AC genotype who are treated with gemcitabine may have an increased risk of hematological toxicity as compared to patients with the the CC genotype and an increased risk of gastrointestinal toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs2072671','A > C','CDA','gemcitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00441 ','Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar? by Eli Lilly and Company. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication.','Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with gemcitabine may have an increased risk of gastrointestinal toxicity and decreased risk of hematological toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs60369023','G > A','CDA','gemcitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00441 ','Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar? by Eli Lilly and Company. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication.','Level 3','-','-','-','AG','                Patients with the AG genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity Neutropenia as compared to patients with the GG genotype, or 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.'),('rs60369023','G > A','CDA','gemcitabine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00441 ','Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar? by Eli Lilly and Company. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication.','Level 3','-','-','-','AA','                Patients with the AA genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity of Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.'),('rs37973','G > A','GLCCI1','glucocorticoids','VARIOUS','','','Glucocorticoids (GCs) are a class of steroid hormones that bind to the glucocorticoid receptor (GR), which is present in almost every vertebrate animal cell. The name glucocorticoid (glucose + cortex + steroid) derives from its role in the regulation of the metabolism of glucose, its synthesis in the adrenal cortex, and its steroidal structure','Level 3','increased','-','-','AA','                Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patients response to glucocorticoids.'),('rs909706','T > C','DTNBP1','haloperidol','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00502 ','A phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of huntington disease.','Level 4','decreased','-','-','CC','                Patients with the CC genotype and Schizophrenia may have a reduced response to haloperidol as compared to patients with the CT genotype. Results were suggestive of an association. Other genetic and clinical factors may also influence a patients response to haloperidol.'),('rs4149056','T > C','SLCO1B1','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 2A','-','-','increased','CT','                Patients with the CT genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patients metabolism and response to statins.'),('rs4149056','T > C','SLCO1B1','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 2A','-','-','increased','CC','                Patients with the CC genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patients metabolism and response to statins.'),('rs1935349','C > T','HTR7','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for statin-related myalgia as compared to patients with the CC genotypes, or may have a decreased risk for statin-related myalgia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs1935349','C > T','HTR7','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for statin-related myalgia as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs17238540','T > G','HMGCR','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 3','decreased','-','-','GT','                Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17238540','T > G','HMGCR','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 3','decreased','-','-','GG','                Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17244841','A > T','HMGCR','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs5443','C > T','GNB3','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 4','increased','-','-','CT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs5443','C > T','GNB3','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 4','increased','-','-','TT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs4693075','G > C','COQ2','hmg coa reductase inhibitors','VARIOUS','','','In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.','Level 2B','-','-','decreased','CC','                Patients with the CC genotype may have decreased risk of statin-related muscle symptoms as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence a patients risk of toxicity.'),('rs7297610','C > T','YEATS4','hydrochlorothiazide','CARDIOVASCULAR SYSTEM','DIURETICS','DB00999 ','A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium.','Level 2B','decreased','-','-','CT','                Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to hydrochlorothiazide.'),('rs7297610','C > T','YEATS4','hydrochlorothiazide','CARDIOVASCULAR SYSTEM','DIURETICS','DB00999 ','A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium.','Level 2B','decreased','-','-','TT','                Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to hydrochlorothiazide.'),('rs4149601','G > A','NEDD4L','hydrochlorothiazide','CARDIOVASCULAR SYSTEM','DIURETICS','DB00999 ','A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium.','Level 3','increased','-','-','AA','                Patients with the AA genotype and Hypertension who are treated with hydrochlorothiazide may have a better response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to hydrochlorothiazide treatment.'),('rs4961','G > T','ADD1','hydrochlorothiazide','CARDIOVASCULAR SYSTEM','DIURETICS','DB00999 ','A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium.','Level 3','increased','-','-','GT','                Patients with the GT genotype may have a better response to hydrochlorothiazide treatment as compared to patients with the GG genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patients response to hydrochlorothiazide treatment.'),('rs4961','G > T','ADD1','hydrochlorothiazide','CARDIOVASCULAR SYSTEM','DIURETICS','DB00999 ','A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium.','Level 3','increased','-','-','TT','                Patients with the TT genotype may have a better response to hydrochlorothiazide treatment as compared to patients with the GG genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patients response to hydrochlorothiazide treatment.'),('rs20417','C > G','PTGS2','ibuprofen','GENITO URINARY SYSTEM AND SEX HORMONES','OTHER GYNECOLOGICALS','DB01050','Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to ibuprofen.'),('rs20417','C > G','PTGS2','ibuprofen','GENITO URINARY SYSTEM AND SEX HORMONES','OTHER GYNECOLOGICALS','DB01050','Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.','Level 3','increased','-','-','GG','                Patients with the GG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to ibuprofen.'),('rs1045642','A > G','ABCB1','idarubicin','GENITO URINARY SYSTEM AND SEX HORMONES','OTHER GYNECOLOGICALS','DB01050','Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs1045642','A > G','ABCB1','idarubicin','GENITO URINARY SYSTEM AND SEX HORMONES','OTHER GYNECOLOGICALS','DB01050','Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.'),('rs7142881','G > A','NUBPL','iloperidone','VARIOUS','','','Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.','Level 3','-','-','increased','AG','                Patients with the AG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs7142881','G > A','NUBPL','iloperidone','VARIOUS','','','Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.','Level 3','-','-','increased','AA','                Patients with the AA genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs4933824','T > G','NRG3','iloperidone','VARIOUS','','','Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.','Level 3','-','-','increased','GG','                Patients with the GG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the TT or GT genotype.  Other genetic and clinical factors may also influence a patients response.'),('rs4799915','C > T','CELF4','iloperidone','VARIOUS','','','Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.','Level 3','-','-','increased','CT','                Patients with the CT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs4799915','C > T','CELF4','iloperidone','VARIOUS','','','Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.','Level 3','-','-','increased','TT','                Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs1800629','G > A','TNF','infliximab','VARIOUS','','','Infliximab was approved by the U.S. Food and Drug Administration (FDA) for the treatment of psoriasis, Crohn\'s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab won its initial approval by the FDA for the treatment of Crohn\'s disease in August 1998','Level 3','decreased','-','-','AG','                Patients with the AG genotype and rheumatoid arthritis who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype or may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to anti-TNF therapy.'),('rs1800629','G > A','TNF','infliximab','VARIOUS','','','Infliximab was approved by the U.S. Food and Drug Administration (FDA) for the treatment of psoriasis, Crohn\'s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab won its initial approval by the FDA for the treatment of Crohn\'s disease in August 1998','Level 3','decreased','-','-','AA','                Patients with the AA genotype and rheumatoid arthritis who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to anti-TNF therapy.'),('rs9657182','C > T','IDO1','interferon alfa-2a, recombinant','VARIOUS','','','Alpha-interferons, including Interferon alfa-2a, cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping Interferon alfa-2a therapy','Level 3','-','-','decreased','CT','                Patients with the CT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patients risk for drug side effects.'),('rs9657182','C > T','IDO1','interferon alfa-2a, recombinant','VARIOUS','','','Alpha-interferons, including Interferon alfa-2a, cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping Interferon alfa-2a therapy','Level 3','-','-','decreased','TT','                Patients with the TT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patients risk for drug side effects.'),('rs1127354','C > A','ITPA','interferon alfa-2b, recombinant','VARIOUS','','','Alpha-interferons, including Interferon alfa-2a, cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping Interferon alfa-2a therapy','Level 2B','-','decreased','-','AC','                Patients with the AC genotype and Hepatitis C, Chronic may have a decreased, but not absent, risk of 1) dose reduction of ribavirin, 2) rapid decrease in hemoglobin levels when treated with interferon alfa-2b, recombinant and ribavirin or interferon alfa-2b, recombinant and ribavirin, and telaprevir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for response to ribavirin.'),('rs1127354','C > A','ITPA','interferon alfa-2b, recombinant','VARIOUS','','','Alpha-interferons, including Interferon alfa-2a, cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping Interferon alfa-2a therapy','Level 2B','-','decreased','-','AA','                Patients with the AA genotype and Hepatitis C, Chronic may have a decreased, but not absent, risk of 1) dose reduction of ribavirin, 2) rapid decrease in hemoglobin levels when treated with interferon alfa-2b, recombinant and ribavirin or interferon alfa-2b, recombinant and ribavirin, and telaprevir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for response to ribavirin.'),('rs9272105','G > A','HLA-DQA1','interferon beta-1a','VARIOUS','','','Alpha-interferons, including Interferon alfa-2a, cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping Interferon alfa-2a therapy','Level 3','increased','-','-','AA','                Patients with the AA genotype may have decreased but not absent risk for developing neutralizing anti-IFN-beta antibodies (i.e. decreased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to interferon-beta therapy.'),('rs9272105','G > A','HLA-DQA1','interferon beta-1b','VARIOUS','','','Alpha-interferons, including Interferon alfa-2a, cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping Interferon alfa-2a therapy','Level 3','increased','-','-','AA','                Patients with the AA genotype may have decreased but not absent risk for developing neutralizing anti-IFN-beta antibodies (i.e. decreased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to interferon-beta therapy.'),('rs1367117','G > A','APOB','irbesartan','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB01029','Irbesartan is an angiotensin receptor blocker (ARB) used mainly for the treatment of hypertension. It competes with angiotensin II for binding at the AT1 receptor subtype. ','Level 3','decreased','-','-','AA','                Patients with the AA genotype who are treated with irbesartan may be less likely to respond than patients with the AG or the GG genotype.  Other genetic and clinical factors may also influence a patients response.'),('rs4124874','T > G','UGT1A1','irinotecan','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00762 ','Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I.','Level 3','-','-','increased','GT','                Patients with the GT genotype and Cancer who are treated with irinotecan may have an increased risk of Neutropenia as compared to patients with the TT genotype, or may have a decreased risk of Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs4124874','T > G','UGT1A1','irinotecan','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00762 ','Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I.','Level 3','-','-','increased','GG','                Patients with the GG genotype and Cancer who are treated with irinotecan may have an increased risk of Neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs9597','C > G','BAIAP3','irinotecan','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00762 ','Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to cisplatin and irinotecan treatment.'),('rs9597','C > G','BAIAP3','irinotecan','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00762 ','Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I.','Level 3','increased','-','-','GG','                Patients with the GG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype, although the GG genotype was not observed in the supporting study. Other genetic and clinical factors may also influence a patients response to cisplatin and irinotecan treatment.'),('rs9340799','A > G','ESR1','leflunomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00762 ','Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may experience decreased response to leflunomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693.'),('rs762551','C > A','CYP1A2','leflunomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00762 ','Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I.','Level 3','-','-','decreased','AC','                Patients with the AC genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity with leflunomide treatment.'),('rs762551','C > A','CYP1A2','leflunomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00762 ','Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I.','Level 3','-','-','decreased','AA','                Patients with the AA genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity with leflunomide treatment.'),('rs3213422','A > C','ATP5A1P3','leflunomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00762 ','Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I.','Level 4','increased','-','-','CC','                Patients with the CC genotype who are treated with leflunomide may be more likely to respond compared to patients with the AA genotype.  Other genetic and clinical factors may also influence a patients response.'),('rs4646','A > C','CYP19A1','letrozole','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00762 ','Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I.','Level 3','decreased','-','-','CC','                Patients with the CC genotype who are treated with letrozole may have decreased treatment efficacy compared to patients with the AA or AC genotype.  Other genetic and clinical factors may also influence a patients response.'),('rs1801019','G > C','UMPS','leucovorin','VARIOUS','','','Folinic acid (INN) or leucovorin (USAN), generally administered as calcium or sodium folinate (or leucovorin calcium/sodium), is an adjuvant used in cancer chemotherapy involving the drug methotrexate.[1] It is also used in synergistic combination with the chemotherapy agent 5-fluorouracil.','Level 2B','-','-','increased','CC','                Patients with CC genotype and cancer may have an increased risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and  leucovorin as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to leucovorin, tegafur and fluorouracil.'),('rs1051266','T > C','SLC19A1','leucovorin','VARIOUS','','','Folinic acid (INN) or leucovorin (USAN), generally administered as calcium or sodium folinate (or leucovorin calcium/sodium), is an adjuvant used in cancer chemotherapy involving the drug methotrexate.[1] It is also used in synergistic combination with the chemotherapy agent 5-fluorouracil.','Level 3','increased','-','-','CC','                Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) increased likelihood of Toxic liver disease 2) decreased, but not absent, risk of Drug Toxicity 3) decreased likelihood of treatment interruptions as compared to patients with the CT and TT genotype. Further, patients with the CC genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patients response to leucovorin, mercaptopurine and methotrexate.'),('rs1051266','T > C','SLC19A1','leucovorin','VARIOUS','','','Folinic acid (INN) or leucovorin (USAN), generally administered as calcium or sodium folinate (or leucovorin calcium/sodium), is an adjuvant used in cancer chemotherapy involving the drug methotrexate.[1] It is also used in synergistic combination with the chemotherapy agent 5-fluorouracil.','Level 3','-','-','increased','CT','                Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) decreased, but not absent, risk of Toxic liver disease 2) increased risk of Drug Toxicity 3) increased likelihood of treatment interruptions as compared to patients with the CC genotype. Further, patients with the CT genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patients response to leucovorin, mercaptopurine and methotrexate.'),('rs13181','T > G','ERCC2','leucovorin','VARIOUS','','','Folinic acid (INN) or leucovorin (USAN), generally administered as calcium or sodium folinate (or leucovorin calcium/sodium), is an adjuvant used in cancer chemotherapy involving the drug methotrexate.[1] It is also used in synergistic combination with the chemotherapy agent 5-fluorouracil.','Level 3','-','-','increased','GT','                Patients with the GT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity as compared to patients with the TT genotype 2) an increased risk of early relapse as compared to patients with the TT genotype. However, a trend of an association is found for the GT genotype with increased progression free survival compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil, leucovorin and oxaliplatin.'),('rs13181','T > G','ERCC2','leucovorin','VARIOUS','','','Folinic acid (INN) or leucovorin (USAN), generally administered as calcium or sodium folinate (or leucovorin calcium/sodium), is an adjuvant used in cancer chemotherapy involving the drug methotrexate.[1] It is also used in synergistic combination with the chemotherapy agent 5-fluorouracil.','Level 3','-','-','increased','GG','                Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity 2) an increased risk of early relapse and 3) decreased progression free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil, leucovorin and oxaliplatin.'),('rs67376798','T > A','DPYD','leucovorin','VARIOUS','','','Folinic acid (INN) or leucovorin (USAN), generally administered as calcium or sodium folinate (or leucovorin calcium/sodium), is an adjuvant used in cancer chemotherapy involving the drug methotrexate.[1] It is also used in synergistic combination with the chemotherapy agent 5-fluorouracil.','Level 3','-','-','increased','AT','                Patients with the AT genotype and Cancer who are treated with regimens containing leucovorin may have increased severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs67376798','T > A','DPYD','leucovorin','VARIOUS','','','Folinic acid (INN) or leucovorin (USAN), generally administered as calcium or sodium folinate (or leucovorin calcium/sodium), is an adjuvant used in cancer chemotherapy involving the drug methotrexate.[1] It is also used in synergistic combination with the chemotherapy agent 5-fluorouracil.','Level 3','-','-','increased','AA','                Patients with the AA genotype were not reported, however patients with the AT genotype and Cancer who are treated with regimens containing leucovorin may have increased severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity.'),('rs2284017','T > C','CACNG2','lithium','VARIOUS','','','Lithium and its compounds have several industrial applications, including heat-resistant glass and ceramics, high strength-to-weight alloys used in aircraft, lithium batteries and lithium-ion batteries. These uses consume more than half of lithium production.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs2284017','T > C','CACNG2','lithium','VARIOUS','','','Lithium and its compounds have several industrial applications, including heat-resistant glass and ceramics, high strength-to-weight alloys used in aircraft, lithium batteries and lithium-ion batteries. These uses consume more than half of lithium production.','Level 3','increased','-','-','CC','                Patients with the CC genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs7439366','T > C','UGT2B7','lorazepam','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00186 ','A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.','Level 3','decreased','-','-','CT','                Healthy individuals with the CT genotype who are treated with valproic acid and lorazepam may have poorer responses in psychocognitive function tests as compared to those with the TT genotype or may have better responses in psychocognitive function tests as compared to patients with the CC genotype. Other genetic and clinical factors may also influence an individuals response to valproic acid and lorazepam treatment.'),('rs7439366','T > C','UGT2B7','lorazepam','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00186 ','A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.','Level 3','decreased','-','-','CC','                Healthy individuals with the CC genotype who are treated with valproic acid and lorazepam may have poorer responses in psychocognitive function tests as compared to those with the TT genotype. Other genetic and clinical factors may also influence an individuals response to valproic acid and lorazepam treatment.'),('rs1057910','A > C','CYP2C9','losartan','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00678 ','Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. ','Level 3','decreased','-','-','AC','                Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.'),('rs1057910','A > C','CYP2C9','losartan','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00678 ','Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. ','Level 3','decreased','-','-','CC','                Subjects with the CC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.'),('rs17238540','T > G','HMGCR','lovastatin','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00678 ','Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. ','Level 3','decreased','-','-','GT','                Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17238540','T > G','HMGCR','lovastatin','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00678 ','Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. ','Level 3','decreased','-','-','GG','                Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs5443','C > T','GNB3','lovastatin','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00678 ','Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. ','Level 4','increased','-','-','CT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs5443','C > T','GNB3','lovastatin','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00678 ','Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. ','Level 4','increased','-','-','TT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs9340799','A > G','ESR1','medroxyprogesterone','GENITO URINARY SYSTEM AND SEX HORMONES','SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM','DB00603 ','(6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione. A synthetic progestational hormone used in veterinary practice as an estrus regulator. [PubChem]','Level 3','-','-','-','AG','                Patients with the AG genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density.'),('rs9340799','A > G','ESR1','medroxyprogesterone','GENITO URINARY SYSTEM AND SEX HORMONES','SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM','DB00603 ','(6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione. A synthetic progestational hormone used in veterinary practice as an estrus regulator. [PubChem]','Level 3','-','-','-','GG','                Patients with the GG genotype may experience 1) greater increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) smaller decreases in spine bone mineral density when untreated, as compared to patient with the AA genotype. Other genetic and clinical factors may also influence spine bone mineral density.'),('rs11188072','C > T','CYP2C19','mephenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00532 ','Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. It is generally reserved for treatment of individuals refractory to less toxic agents. ','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs1142345','T > C','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CT','                Patients with the CT genotype  1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1142345','T > C','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CG','                Patients with the CG genotype (e.g. TPMT*1/*2): may have increased deactivation of thiopurines and a decreased, but not absent, risk for toxicity with thiopurine drugs as compared to patients with the GG genotype (TPMT*2/*2) or may have decreased deactivation of thiopurines and an increased risk for toxicity with thiopurine drugs as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800584','C > T','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','CT','                Patients with the CT genotype who are treated with standard doses of mercaptopurine   may be at  increased risk for life-threatening myelosuppression as compared to patients with the CC genotype.   Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1800584','C > T','TPMT','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 1A','-','-','increased','TT','                Patients with the TT genotype who are treated with standard doses of mercaptopurine may be at  increased risk for life-threatening myelosuppression as compared to patients with the CC genotype.   Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1051266','T > C','SLC19A1','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 3','increased','-','-','CC','                Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) increased likelihood of Toxic liver disease 2) decreased, but not absent, risk of Drug Toxicity 3) decreased likelihood of treatment interruptions as compared to patients with the CT and TT genotype. Further, patients with the CC genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patients response to leucovorin, mercaptopurine and methotrexate.'),('rs1051266','T > C','SLC19A1','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 3','-','-','increased','CT','                Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) decreased, but not absent, risk of Toxic liver disease 2) increased risk of Drug Toxicity 3) increased likelihood of treatment interruptions as compared to patients with the CC genotype. Further, patients with the CT genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patients response to leucovorin, mercaptopurine and methotrexate.'),('rs1801133','G > A','MTHFR','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 3','-','-','-','AG','                Patients with the AG genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patients risk for toxicity to mercaptopurine.'),('rs1801133','G > A','MTHFR','mercaptopurine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 3','-','-','-','AA','                Patients with the AA genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patients risk for toxicity to mercaptopurine.'),('rs622342','C > A','SLC22A1','metformin','ALIMENTARY TRACT AND METABOLISM','ANTINEOPLASTIC AGENTS','DB01033 ','An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]','Level 3','increased','-','-','AA','                Patients with the AA genotype and the GG genotype at rs2289669 who have diabetes may have a better response to metformin, as measured by a larger reduction in HbA1c levels, as compared to patients with the CC genotype and the GG genotype at rs2289669. This association is not significant when compared to patients with the CC genotype and the AG or AA genotype at rs2289699. Other genetic and clinical factors may also influence a patients reduction in HbA1c levels with metformin treatment.'),('rs6275','A > G','DRD2','methadone','NERVOUS SYSTEM','ANALGESICS','DB00333 ','A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist.','Level 3','-','decreased','-','GG','                Patients with the GG genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the AA genotype. This was seen in White patients - the opposite association was seen in a different study with Asian patients. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs2076369','T > G','PICK1','methamphetamine','VARIOUS','','','In low doses, methamphetamine can cause an elevated mood and increase alertness, concentration, and energy in fatigued individuals. At higher doses, it can induce psychosis, rhabdomyolysis and cerebral hemorrhage. Methamphetamine is known to have a high potential for abuse and addiction. Recreational use of methamphetamine may result in psychosis or lead to post-withdrawal syndrome, a withdrawal syndrome that can persist for months beyond the typical withdrawal period. Unlike amphetamine and cocaine, methamphetamine is neurotoxic to humans, damaging both dopamine and serotonin neurons in the CNS. Entirely opposite to the long-term use of amphetamine, there is evidence that methamphetamine causes brain damage from long-term use in humans; this damage includes adverse changes in brain structure and function, such as reductions in gray matter volume in several brain regions and adverse changes in markers of metabolic integrity.','Level 3','-','-','decreased','GG','                Patients with the GG genotype who are methamphetamine abusers may have a decreased, but not absent, risk for spontaneous relapse of psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for spontaneous relapse of psychosis with methamphetamine abuse.'),('rs2619538','A > T','DTNBP1','methamphetamine','VARIOUS','','','In low doses, methamphetamine can cause an elevated mood and increase alertness, concentration, and energy in fatigued individuals. At higher doses, it can induce psychosis, rhabdomyolysis and cerebral hemorrhage. Methamphetamine is known to have a high potential for abuse and addiction. Recreational use of methamphetamine may result in psychosis or lead to post-withdrawal syndrome, a withdrawal syndrome that can persist for months beyond the typical withdrawal period. Unlike amphetamine and cocaine, methamphetamine is neurotoxic to humans, damaging both dopamine and serotonin neurons in the CNS. Entirely opposite to the long-term use of amphetamine, there is evidence that methamphetamine causes brain damage from long-term use in humans; this damage includes adverse changes in brain structure and function, such as reductions in gray matter volume in several brain regions and adverse changes in markers of metabolic integrity.','Level 4','-','-','decreased','TT','                Patients with the TT genotype may have a decreased risk for methamphetamine psychosis compared to patients with the AT genotype. Please note this association did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patients risk to methamphetamine psychosis.'),('rs2853539','A > G','TYMS','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','AG','                Patients with the AG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have improvement in disease activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs2853539','A > G','TYMS','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','GG','                Patients with the GG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have improvement in disease activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs11045879','T > C','SLCO1B1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate as compared to patients with the CT or TT genotype 2)  may have a decreased, but not absent, risk for GI toxicity (mucositis) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for GI toxicity when treated with methotrexate.'),('rs4149081','G > A','SLCO1B1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','AA','                Patients with the AA genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate as compared to patients with the AG or GG genotype 2) may have a decreased, but not absent, risk of GI toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients risk of GI toxicity.'),('rs1051266','T > C','SLC19A1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','CC','                Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) increased likelihood of Toxic liver disease 2) decreased, but not absent, risk of Drug Toxicity 3) decreased likelihood of treatment interruptions as compared to patients with the CT and TT genotype. Further, patients with the CC genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patients response to leucovorin, mercaptopurine and methotrexate.'),('rs1051266','T > C','SLC19A1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk of hepatotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for hepatoxicity.'),('rs1051266','T > C','SLC19A1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','CT','                Patients with the TC genotype and Rheumatoid Arthritis who are treated with methotrexate may have less symptom improvement as compared to patients with the TT genotype or may have more symptom improvement as compared to patients with the CC genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patients response to methotrexate therapy.'),('rs1051266','T > C','SLC19A1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','CC','                Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have less symptom improvement as compared to patients with the TT genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patients response to methotrexate therapy.'),('rs1051266','T > C','SLC19A1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','CT','                Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) decreased, but not absent, risk of Toxic liver disease 2) increased risk of Drug Toxicity 3) increased likelihood of treatment interruptions as compared to patients with the CC genotype. Further, patients with the CT genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patients response to leucovorin, mercaptopurine and methotrexate.'),('rs1799983','T > G','NOS3','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','GT','                Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs1799983','T > G','NOS3','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','GG','                Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs2070744','C > T','NOS3','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','-','CT','                Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.'),('rs2070744','C > T','NOS3','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','-','TT','                Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence disease-free survival.'),('rs1801394','A > G','MTRR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 2B','-','-','increased','AG','                Pediatric ALL patients with AG genotypes may have increased likelihood of methotrexate induced toxicity (oral mucositis), increased speed of platelet recovery and increased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the AA genotype. Allele G is not associated with decreased IQ in pediatric ALL patients treated with methotrexate. Other genetic and clinical factors may also influence response to methotrexate.'),('rs1801394','A > G','MTRR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 2B','-','-','increased','GG','                Pediatric ALL patients with GG genotypes may have  increased likelihood of methotrexate induced toxicity (oral mucositis) and increased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the AA genotype. Allele G is not associated with decreased IQ in pediatric ALL patients treated with methotrexate. Other genetic and clinical factors may also influence response to methotrexate.'),('rs1805087','A > G','MTR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','increased','GG','                Patients with the GG genotype may have: 1) increased likelihood of Drug Toxicity, 2) decreased response when treated with methotrexate as compared to patients with genotypes AA or AG. However, contradictory findings have also been reported. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs1801131','T > G','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','GG','                Patients with the GG genotype and non-Hodgkin lymphoma who are treated with methotrexate may have an increased risk of mucositis as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients risk for mucositis when treated with methotrexate.'),('rs1801131','T > G','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','GT','                Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of clinical response but may have a decreased response base on Disease Activity Score in 44 joints improvement at 6 months as compared to patients with the TT genotype. This association has been contradicted in other studies including a larger meta-analysis that found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs1801131','T > G','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','GG','                Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of clinical response but may have a decreased response base on Disease Activity Score in 44 joints improvement at 6 months as compared to patients with the TT genotype. This association has been contradicted in other studies including a larger meta-analysis that found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs1801131','T > G','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','-','GT','                Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype or may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype.  This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs1801131','T > G','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','-','GG','                Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 1B','-','-','increased','AA','                Patients with the AA genotype with Leukemia or Lymphoma who are treated with methotrexate regimens may have an increased risk and increased severity of mucositis, as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patients risk of oral mucositis.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Rheumatoid Arthritis may be more at risk of alopecia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of alopecia.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse events as compared to patients with the AA genotype (though this association has not been found in all studies). There does not seem to be an association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AA','                Patients with the AA genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype (though this association has not been found in all studies). There does not seem to be an association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AA','                Patients with the AA genotype and non-Hodgkin lymphoma who are treated with methotrexate may have an increased risk of mucositis, thrombocytopenia and hepatic toxicity as compared to patients with the GG genotype. This association was not found in pediatric patients with non-Hodgkin lymphoma who were treated with methotrexate. Other genetic and clinical factors may also influence a patients risk for methotrexate-induced toxicity.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','AG','                Patients with the AG genotype with non-hodgkin lymphoma who are treated with methotrexate may be less likely to have event free survival at 5 years as compared to patients with the GG genotype. This genotype was not associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the GG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','AA','                Patients with the AA genotype with non-hodgkin lymphoma who are treated with methotrexate may be less likely to have event free survival at 5 years as compared to patients with the GG genotype. This genotype was not associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the GG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','decreased','increased','AG','                Patients with the AG genotype and Leukemia who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate as compared to patients with the GG genotype or may be at decreased risk of toxicity as compared to patients with the AA genotype. This association has been contradicted or not found in several studies. Other genetic and clinical factors may also influence a patients risk for toxicity and response with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','decreased','increased','AA','                Patients with the AA genotype and Leukemia who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate as compared to patients with the GG genotype. This association has been contradicted or not found in several studies. Other genetic and clinical factors may also influence a patients risk for toxicity and response with methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk Graft vs Host disease and efficacy of methotrexate treatment.'),('rs1801133','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','AA','                Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk Graft vs Host disease and efficacy of methotrexate treatment.'),('rs4846051','G > A','MTHFR','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','AA','                Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients level of methotrexate induced toxicity.'),('rs2236225','G > A','MTHFD1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for response to therapy.'),('rs2236225','G > A','MTHFD1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','AA','                Patients with the AA genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for response to therapy.'),('rs1127354','C > A','ITPA','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','increased','AC','                Patients with the AC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that show the AC genotype may have an increased response to methotrexate as compared to patients with the CC genotype or or show no association of the allele with response to methotrexate. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs1127354','C > A','ITPA','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','increased','AA','                Patients with the AA genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that show the AA genotype may have an increased response to methotrexate as compared to patients with the CC genotype or or show no association of the allele with response to methotrexate. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs1695','A > G','GSTP1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','GG','                Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased likelihood of Drug Toxicity as compared to patients with the AG and AA genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patients level of methotrexate induced toxicity.'),('rs11545078','G > A','GGH','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AG','                Patients with the AG genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.'),('rs11545078','G > A','GGH','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','AA','                Patients with the AA genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.'),('rs1800909','A > G','GGH','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','AG','                Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may have better improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to methotrexate therapy.'),('rs1800909','A > G','GGH','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','GG','                Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have better improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to methotrexate therapy.'),('rs3758149','G > A','GGH','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','AA','                Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have decreased conversion of the drug to active polyglutamates 2) may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.'),('rs1544105','C > T','FPGS','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','CT','                Patients with the TC genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs1544105','C > T','FPGS','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','TT','                Patients with the TT genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs2372536','C > G','ATIC','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','CG','                Patients with the CG genotype and rheumatoid arthritis who are treated with methotrexate may be less likely to have symptom improvement as compared to patients with the GG genotype.'),('rs2372536','C > G','ATIC','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','GG','                Patients with the GG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have symptom improvement  as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs4673993','T > C','ATIC','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 2B','increased','-','-','CT','                Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype or may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs4673993','T > C','ATIC','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 2B','increased','-','-','CC','                Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.'),('rs17602729','G > A','AMPD1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','AG','                Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of CNS adverse events as compared to patients with the GG genotype. Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patients response to methotrexate and risk of CNS adverse events.'),('rs17602729','G > A','AMPD1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','AA','                Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs2236624','T > C','ADORA2A','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for an adverse event as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for an adverse event.'),('rs2267076','T > C','ADORA2A','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse events when treated with methotrexate.'),('rs2298383','C > T','ADORA2A','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','-','CT','                Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype or may have an increased risk for adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse events when treated with methotrexate.'),('rs2298383','C > T','ADORA2A','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','increased','TT','                Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse events when treated with methotrexate.'),('rs3761422','T > C','ADORA2A','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse events when treated with methotrexate.'),('rs5760410','G > A','ADORA2A','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','AA','                Patients with the AA genotype who are treated with methotrexate may have a decreased, but not absent, risk of adverse events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.'),('rs13120400','T > C','ABCG2','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','CC','                Patients with the CC genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs17731538','G > A','ABCG2','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area or severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs9895420','T > A','ABCC3','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','AT','                Patients with the AT genotype may have 1) decreased event free survival 2) increased risk of central nervous system relapse 3) decreased risk of thrombocytopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs9895420','T > A','ABCC3','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','AA','                Patients with the AA genotype may have 1) decreased event free survival 2) increased risk of central nervous system relapse 3) decreased risk of thrombocytopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs2238476','G > A','ABCC1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','decreased','AG','                Patients with the AG genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent, risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate and risk of toxicity.'),('rs2238476','G > A','ABCC1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','decreased','AA','                Patients with the AA genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate and risk of toxicity.'),('rs246240','A > G','ABCC1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity to methotrexate.'),('rs246240','A > G','ABCC1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity to methotrexate.'),('rs28364006','A > G','ABCC1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','increased','-','-','GG','                Patients with the GG genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs35592','T > C','ABCC1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','CT','                Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs35592','T > C','ABCC1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','CC','                Patients with the CC genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to methotrexate.'),('rs1045642','A > G','ABCB1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 4','-','-','increased','AG','                Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have an increased risk of adverse drug events (please note this association was not significant after correcting for multiple variables) 2) may have an increased risk of not responding to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse drug events and responsiveness when treated with methotrexate.'),('rs1045642','A > G','ABCB1','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 4','decreased','-','-','AG','                Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have an increased risk of adverse drug events (please note this association was not significant after correcting for multiple variables) 2) may have an increased risk of not responding to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse drug events and responsiveness when treated with methotrexate.'),('rs4888024','A > G','Not available','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','-','AG','                Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.'),('rs4888024','A > G','Not available','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','-','-','-','GG','                Patients with the GG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.'),('rs9345389','A > G','Not available','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.'),('rs9345389','A > G','Not available','methotrexate','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00563','An antineoplastic antimetabolite with immunosuppressant properties.','Level 3','decreased','-','-','GG','                Patients with the GG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.'),('rs3892097','C > T','CYP2D6','metoprolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','increased','-','-','CT','                Patients with CT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patients response to metoprolol. Please check other variants for PM phenotype.'),('rs3892097','C > T','CYP2D6','metoprolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','increased','-','-','TT','                Patients with TT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with CC genotype.  Other genetic and clinical factors may also influence a patients response to metoprolol. Please check other variants for PM phenotype.'),('rs1801253','G > C','ADRB1','metoprolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','metoprolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','decreased','-','-','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','metoprolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','increased','-','-','CC','                Patients with the CC genotype 1) may have an increased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have a decreased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs1801253','G > C','ADRB1','metoprolol','CARDIOVASCULAR SYSTEM','BETA BLOCKING AGENTS','DB00264 ','Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension.','Level 3','decreased','-','increased','CG','                Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to Beta Blocking Agents.'),('rs10042486','C > T','HTR1A','milnacipran','VARIOUS','','','Milnacipran (Ixel, Savella, Dalcipran, Toledomin) is a serotonin','Level 3','decreased','-','-','CT','                Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs10042486','C > T','HTR1A','milnacipran','VARIOUS','','','Milnacipran (Ixel, Savella, Dalcipran, Toledomin) is a serotonin','Level 3','decreased','-','-','TT','                Patients with the TT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment  as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs10879346','C > T','TPH2','mirtazapine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00370 ','Mirtazapine is an antidepressant introduced by Organon International in 1996 used for the treatment of moderate to severe depression.','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with antidepressants may have less improvement in symptoms as compared to patients with the CT and CC genotype.'),('rs1487278','T > C','TPH2','mirtazapine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00370 ','Mirtazapine is an antidepressant introduced by Organon International in 1996 used for the treatment of moderate to severe depression.','Level 3','increased','-','-','CC','                Patients with the CC genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to antidepressant. (The frequency for CC allele is very low, homozygous minor allele carriers were pooled together with the heterozygous samples and compared with the homozygous major allele (T) carrier.)'),('rs9679162','G > T','GALNT14','mitoxantrone','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01204 ','An anthracenedione-derived antineoplastic agent. [PubChem]','Level 3','increased','-','-','TT','                Patients with the TT genotype may have increased response, including increased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs730012','A > C','LTC4S','montelukast','RESPIRATORY SYSTEM','DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES','DB00471 ','Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it.','Level 3','increased','-','-','AC','                Patients with the AC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of asthma exacerbations with montelukast treatment.'),('rs730012','A > C','LTC4S','montelukast','RESPIRATORY SYSTEM','DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES','DB00471 ','Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it.','Level 3','increased','-','-','CC','                Patients with the CC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. However, this difference was not statistically significant. This may be related to the relatively low frequency of CC homozygotes (11%) in the study. Other genetic and clinical factors may also influence a patients risk of asthma exacerbations with montelukast treatment.'),('rs2660845','G > A','LTA4H','montelukast','RESPIRATORY SYSTEM','DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES','DB00471 ','Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it.','Level 3','-','-','increased','AG','                Patients with the AG genotype and asthma who are treated with montelukast  may have an increased risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of asthma exacerbations with montelukast treatment.'),('rs2660845','G > A','LTA4H','montelukast','RESPIRATORY SYSTEM','DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES','DB00471 ','Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it.','Level 3','-','-','decreased','AA','                Patients with the AA genotype and asthma who are treated with montelukast  may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patients risk of asthma exacerbations with montelukast treatment.'),('rs2115819','A > G','ALOX5','montelukast','RESPIRATORY SYSTEM','DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES','DB00471 ','Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it.','Level 3','increased','-','-','AG','                Patients with the AG genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to montelukast.'),('rs2115819','A > G','ALOX5','montelukast','RESPIRATORY SYSTEM','DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES','DB00471 ','Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it.','Level 3','increased','-','-','GG','                Patients with the GG genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment,  compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patients response to montelukast.'),('rs119774','C > T','ABCC1','montelukast','RESPIRATORY SYSTEM','DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES','DB00471 ','Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it.','Level 3','increased','-','-','CT','                Patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to montelukast.'),('rs119774','C > T','ABCC1','montelukast','RESPIRATORY SYSTEM','DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES','DB00471 ','Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it.','Level 3','increased','-','-','TT','                Patients with the TT genotype were not studied. But patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to montelukast.'),('rs1799971','A > G','OPRM1','morphine','RESPIRATORY SYSTEM','DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES','DB00471 ','Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it.','Level 2B','-','increased','-','AG','                Patients with the AG genotype who are treated with morphine: 1) may require a higher dose as compared to patients with the AA genotype 2) may be less likely to have an increased pain relief as compared to patients the AA genotype and neoplasms. Other genetic and clinical factors may also influence a patients response when treated with morphine.'),('rs1799971','A > G','OPRM1','morphine','RESPIRATORY SYSTEM','DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES','DB00471 ','Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it.','Level 2B','-','increased','-','GG','                Patients with the GG genotype who are treated with morphine: 1) may require the highest dose as compared to patients with the AG and AA genotype  2) may be less likely to have an increased pain relief as compared to patients the AA genotype and neoplasms. Other genetic and clinical factors may also influence a patients response when treated with morphine.'),('rs4680','G > A','COMT','morphine','RESPIRATORY SYSTEM','DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES','DB00471 ','Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it.','Level 3','-','decreased','-','AA','                Patients with the AA genotype who are treated with morphine may require the lowest dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients response when treated with morphine.'),('rs2368564','C > T','REN','muraglitazar','VARIOUS','','','Data on muraglitazar is relatively less due to the recent introduction of this agent. One double-blind randomized clinical trial[2] comparing muraglitazar and pioglitazone found that the effects of the former were favourable in terms of HDL-C increase, decrease in total cholesterol, apolipoprotein B, triglycerides and a greater reduction in HbA1c (P<0.0001 for all comparisons).','Level 3','-','-','decreased','CT','                No conclusive results were found for patients with the CT genotype. But patients with the TT genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for edema when treated with muraglitazar.'),('rs2368564','C > T','REN','muraglitazar','VARIOUS','','','Data on muraglitazar is relatively less due to the recent introduction of this agent. One double-blind randomized clinical trial[2] comparing muraglitazar and pioglitazone found that the effects of the former were favourable in terms of HDL-C increase, decrease in total cholesterol, apolipoprotein B, triglycerides and a greater reduction in HbA1c (P<0.0001 for all comparisons).','Level 3','-','-','decreased','TT','                Patients with the TT genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for edema when treated with muraglitazar.'),('rs5370','G > T','EDN1','muraglitazar','VARIOUS','','','Data on muraglitazar is relatively less due to the recent introduction of this agent. One double-blind randomized clinical trial[2] comparing muraglitazar and pioglitazone found that the effects of the former were favourable in terms of HDL-C increase, decrease in total cholesterol, apolipoprotein B, triglycerides and a greater reduction in HbA1c (P<0.0001 for all comparisons).','Level 3','-','-','-','GT','                No conclusive results were found for patients with the GT genotype. But patients with the TT genotype and type 2 diabetes who are treated with muarglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of edema with muraglitazar treatment.'),('rs5370','G > T','EDN1','muraglitazar','VARIOUS','','','Data on muraglitazar is relatively less due to the recent introduction of this agent. One double-blind randomized clinical trial[2] comparing muraglitazar and pioglitazone found that the effects of the former were favourable in terms of HDL-C increase, decrease in total cholesterol, apolipoprotein B, triglycerides and a greater reduction in HbA1c (P<0.0001 for all comparisons).','Level 3','-','-','increased','TT','                Patients with the TT genotype and type 2 diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of edema with muraglitazar treatment.'),('rs1801253','G > C','ADRB1','muraglitazar','VARIOUS','','','Data on muraglitazar is relatively less due to the recent introduction of this agent. One double-blind randomized clinical trial[2] comparing muraglitazar and pioglitazone found that the effects of the former were favourable in terms of HDL-C increase, decrease in total cholesterol, apolipoprotein B, triglycerides and a greater reduction in HbA1c (P<0.0001 for all comparisons).','Level 4','-','-','decreased','CC','                Patients with the CC genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patients risk for edema with muraglitazar treatment.'),('rs4149117','T > G','SLCO1B3','mycophenolate mofetil','VARIOUS','','DB00688 ','Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent, inosine monophosphate dehydrogenase (IMPDH) inhibitor.','Level 4','-','-','-','GT','                Patients with the GT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype, or 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity and exposure to mycophenolic acid.'),('rs4149117','T > G','SLCO1B3','mycophenolate mofetil','VARIOUS','','DB00688 ','Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent, inosine monophosphate dehydrogenase (IMPDH) inhibitor.','Level 4','-','-','-','GG','                Patients with the GG genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced toxicity and exposure to mycophenolic acid.'),('rs2278294','C > T','IMPDH1','mycophenolate mofetil','VARIOUS','','DB00688 ','Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent, inosine monophosphate dehydrogenase (IMPDH) inhibitor.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs2278294','C > T','IMPDH1','mycophenolate mofetil','VARIOUS','','DB00688 ','Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent, inosine monophosphate dehydrogenase (IMPDH) inhibitor.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1799971','A > G','OPRM1','naloxone','VARIOUS','ALL OTHER THERAPEUTIC PRODUCTS','DB01183 ','A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. [PubChem]','Level 2B','increased','-','-','AG','                Patients with the AG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype.'),('rs1799971','A > G','OPRM1','naloxone','VARIOUS','ALL OTHER THERAPEUTIC PRODUCTS','DB01183 ','A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. [PubChem]','Level 2B','increased','-','-','GG','                Patients with the GG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to naloxone.'),('rs1799971','A > G','OPRM1','naltrexone','VARIOUS','ALL OTHER THERAPEUTIC PRODUCTS','DB01183 ','A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. [PubChem]','Level 3','increased','-','-','AG','                Patients with the AG genotype who are treated with naltrexone may have an increased 1) response to naltrexone, 2) blunting of alcohol craving, 3) severity of intoxication when exposed to ethanol and naltrexone as compared to patients with the AA genotype. The association with naltrexone response has been contradicted in other studies. Other genetic and clinical factors may also influence a patients response to naltrexone.'),('rs1799971','A > G','OPRM1','naltrexone','VARIOUS','ALL OTHER THERAPEUTIC PRODUCTS','DB01183 ','A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with naltrexone may have an increased 1) response to naltrexone, 2) blunting of alcohol craving, 3) severity of intoxication when exposed to ethanol and naltrexone as compared to patients with the AA genotype. The association with naltrexone response has been contradicted in other studies. Other genetic and clinical factors may also influence a patients response to naltrexone.'),('rs37973','G > A','GLCCI1','nedocromil','RESPIRATORY SYSTEM','NASAL PREPARATIONS','DB00716 ','A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets. [PubChem]','Level 3','increased','-','-','AA','                Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patients response to glucocorticoids.'),('rs1360780','T > C','FKBP5','nefazodone','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB01149 ','Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to paroxetine, venlafaxine, clomipramine or nefazodone.'),('rs1045642','A > G','ABCB1','nelfinavir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00220 ','A potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.','Level 3','-','-','-','GG','                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.'),('rs1799732','- > G','DRD2','nemonapride','VARIOUS','','','Nemonapride (Emilace) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in 1991. ','Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1799732','- > G','DRD2','nemonapride','VARIOUS','','','Nemonapride (Emilace) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in 1991. ','Level 3','increased','-','-','G/del','                Patients with the G/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with these alleles and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1800497','G > A','ANKK1','nemonapride','VARIOUS','','','Nemonapride (Emilace) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in 1991. ','Level 3','-','-','increased','AG','                Female patients with the AG genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patients response to nemonapride.'),('rs1800497','G > A','ANKK1','nemonapride','VARIOUS','','','Nemonapride (Emilace) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in 1991. ','Level 3','-','-','increased','AA','                Female patients with the AA genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patients response to nemonapride.'),('rs1045642','A > G','ABCB1','nevirapine','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00238 ','A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. [PubChem]','Level 2A','-','-','increased','GG','                Patients with the GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hepatotoxicity with nevirapine treatment.'),('rs16969968','G > A','CHRNA5','nicotine','NERVOUS SYSTEM','OTHER NERVOUS SYSTEM DRUGS','DB00184','Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. [PubChem]','Level 3','-','-','increased','AG','                Patients with AG genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype. Findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patients risk for nicotine dependency.'),('rs16969968','G > A','CHRNA5','nicotine','NERVOUS SYSTEM','OTHER NERVOUS SYSTEM DRUGS','DB00184','Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. [PubChem]','Level 3','-','-','increased','AA','                Patients with AA genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype. Findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patients risk for nicotine dependency.'),('rs1800497','G > A','ANKK1','nicotine','NERVOUS SYSTEM','OTHER NERVOUS SYSTEM DRUGS','DB00184','Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. [PubChem]','Level 3','increased','-','-','AG','                Patients with AG genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs1800497','G > A','ANKK1','nicotine','NERVOUS SYSTEM','OTHER NERVOUS SYSTEM DRUGS','DB00184','Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. [PubChem]','Level 3','increased','-','-','AA','                Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patients likelihood of smoking cessation.'),('rs1801133','G > A','MTHFR','nitrous oxide','VARIOUS','','','Nitrous oxide, commonly known as laughing gas, nitrous, nitro, or NOS[1] is a chemical compound','Level 3','-','-','-','AG','                Patients with the GA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients homocysteine levels after nitrous oxide anesthesia.'),('rs1801133','G > A','MTHFR','nitrous oxide','VARIOUS','','','Nitrous oxide, commonly known as laughing gas, nitrous, nitro, or NOS[1] is a chemical compound','Level 3','-','-','-','AA','                Patients with the AA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients homocysteine levels after nitrous oxide anesthesia.'),('rs1801131','T > G','MTHFR','nitrous oxide','VARIOUS','','','Nitrous oxide, commonly known as laughing gas, nitrous, nitro, or NOS[1] is a chemical compound','Level 3','-','-','-','GG','                Patients with the GG genotype may have higher homocysteine levels after nitrous oxide anesthesia as compared to patients with the TG and TT genotype.Other genetic and clinical factors may also influence a patients homocysteine levels after nitrous oxide exposure.'),('rs1045642','A > G','ABCB1','nortriptyline','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00540 ','Nortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for postural hypotension with nortriptyline treatment.'),('rs1045642','A > G','ABCB1','nortriptyline','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00540 ','Nortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for postural hypotension with nortriptyline treatment.'),('rs2842030','G > T','RGS4','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients response to perphanazine.'),('rs951439','C > T','RGS4','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','increased','-','-','CT','                Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs951439','C > T','RGS4','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may have increased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs4731426','G > C','LEP','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','decreased','CG','                Patients with the CG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of extreme weight gain with olanzapine treatment.'),('rs4731426','G > C','LEP','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of extreme weight gain with olanzapine treatment.'),('rs3813929','C > T','HTR2C','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 2B','-','-','decreased','CT','                Patients with the CT genotype and psychiatric disorders or schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for weight gain with olanzapine treatment.'),('rs3813929','C > T','HTR2C','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 2B','-','-','decreased','TT','                Patients with the TT genotype and psychiatric disorders or schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for weight gain with olanzapine treatment.'),('rs518147','G > C','HTR2C','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 2B','-','-','decreased','CC','                Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of weight gain with olanzapine treatment.'),('rs6318','G > C','HTR2C','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 4','-','-','increased','CG','                Patients with the CG genotype and schizophrenia, treated with olanzapine, may have an increased (but not statistically significant) likelihood for tendency of olanzapine-induced weight as compared to patients the genotype GG. Other genetic and clinical factors may also influence a patients risk for olanzapine-induced weight gain.'),('rs6318','G > C','HTR2C','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 4','-','-','increased','CC','                Patients with the CC genotype and schizophrenia, treated with olanzapine, may have an increased (but not statistically significant) likelihood for tendency of olanzapine-induced weight as compared to patients the genotype GG. Other genetic and clinical factors may also influence a patients risk for olanzapine-induced weight gain.'),('rs6313','G > A','HTR2A','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.'),('rs6313','G > A','HTR2A','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','decreased','-','-','AA','                Patients with the AA genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.'),('rs6313','G > A','HTR2A','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.'),('rs6313','G > A','HTR2A','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','decreased','-','-','AA','                Patients with the AA genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.'),('rs7997012','A > G','HTR2A','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','decreased','AG','                Patients with the AG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for side effects with olanzapine treatment.'),('rs7997012','A > G','HTR2A','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','decreased','GG','                Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for side effects with olanzapine treatment.'),('rs5443','C > T','GNB3','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','increased','CT','                Patients with the CT genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of weight gain with olanzapine.'),('rs5443','C > T','GNB3','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','increased','TT','                Patients with the TT genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of weight gain with olanzapine.'),('rs6280','C > T','DRD3','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','decreased','-','-','CT','                Patients with the CT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patients response to olanzapine.'),('rs6280','C > T','DRD3','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','decreased','-','-','TT','                Patients with the TT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patients response to olanzapine.'),('rs1079598','A > G','DRD2','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1079598','A > G','DRD2','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','increased','GG','                Patients with the GG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs1799732','- > G','DRD2','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1799732','- > G','DRD2','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','increased','-','-','G/del','                Patients with the G/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with these alleles and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs6277','G > A','DRD2','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased, but not absent risk, for weight gain when treated with clozapine or olanzepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients risk of side-effects.'),('rs762551','C > A','CYP1A2','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','decreased','-','-','AA','                Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have decreased response to olanzapine based on decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patients response to olanzapine.'),('rs1800497','G > A','ANKK1','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1800497','G > A','ANKK1','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 2B','-','-','increased','AA','                Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs4994','A > G','ADRB3','olanzapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00334 ','Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.','Level 3','-','-','increased','GG','                Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for weight gain with olanzapine treatment.'),('rs11188072','C > T','CYP2C19','omeprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00338 ','A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles','Level 2A','-','increased','-','TT','                Adult patients, but not pediatric patients, with the TT genotype who are treated with omeprazole may require an increased dose as compared to patients with the CT or CC genotype.  Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration. This might not be applicable to pediatric patients.'),('rs2032583','A > G','ABCB1','Other antidepressants','NERVOUS SYSTEM','','','','Level 3','increased','-','-','AG','                Patients with the AG genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs2032583','A > G','ABCB1','Other antidepressants','NERVOUS SYSTEM','','','','Level 3','increased','-','-','GG','                Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs2235015','C > A','ABCB1','Other antidepressants','NERVOUS SYSTEM','','','','Level 3','decreased','-','-','AC','                Patients with the AC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs2235015','C > A','ABCB1','Other antidepressants','NERVOUS SYSTEM','','','','Level 3','decreased','-','-','AA','                Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients chance for remission.'),('rs25487','T > C','XRCC1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 2A','increased','-','-','GG','                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 3','-','-','increased','AG','                Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1695','A > G','GSTP1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 3','-','-','increased','GG','                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs13181','T > G','ERCC2','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 3','-','-','increased','GT','                Patients with the GT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity as compared to patients with the TT genotype 2) an increased risk of early relapse as compared to patients with the TT genotype. However, a trend of an association is found for the GT genotype with increased progression free survival compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil, leucovorin and oxaliplatin.'),('rs13181','T > G','ERCC2','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 3','-','-','increased','GG','                Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity 2) an increased risk of early relapse and 3) decreased progression free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil, leucovorin and oxaliplatin.'),('rs13181','T > G','ERCC2','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 3','-','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with platinum compounds as compared to patients with the GT or TT genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.'),('rs11615','A > G','ERCC1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs11615','A > G','ERCC1','oxaliplatin','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00526 ','Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity.','Level 2B','-','-','decreased','GG','                Patients with the GG genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs1042522','C > G','TP53','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 2B','-','-','increased','CG','                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs1042522','C > G','TP53','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 2B','-','-','decreased','CC','                Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.'),('rs9981861','T > C','DSCAM','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.'),('rs9981861','T > C','DSCAM','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','increased','-','-','CC','                Patients with the CC genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.'),('rs12721627','G > C','CYP3A','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','-','decreased','-','CG','                Patients with the CG genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.'),('rs12721627','G > C','CYP3A','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','-','decreased','-','CC','                Patients with the CC genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.'),('rs776746','C > T','CYP3A','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk of neurotoxicity when treated with paclitaxel as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.'),('rs1113129','G > C','CYP2C8','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','-','-','increased','CC','                Patients with the CC genotype may have  increased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CG or GG genotype.  Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs11572080','C > T','CYP2C8','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','-','-','increased','CT','                Patients with the CT genotype may be at decreased, but not absent, risk of neurotoxicity when treated with paclitaxel compared to patients with the TT genotype or may be at increased risk of neurotoxicity  when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of neurotoxicity.'),('rs11572080','C > T','CYP2C8','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','-','-','increased','TT','                Patients with the TT genotype may be at increased risk of neurotoxicity  when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of neurotoxicity.'),('rs11572103','T > A','CYP2C8','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 4','-','decreased','-','AT','                Patients with the AT genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.'),('rs11572103','T > A','CYP2C8','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 4','-','decreased','-','AA','                Patients with the AA genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.'),('rs1056836','C > G','CYP1B1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with taxanes may have longer disease-free progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs1045642','A > G','ABCB1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.'),('rs1045642','A > G','ABCB1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','increased','-','-','GG','                Genotype GG may be associated with increased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype AG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.'),('rs2032582','A > C','ABCB1','paclitaxel','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB01229 ','A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have decreased, but not absent, risk for resistance to taxanes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to taxanes.'),('rs1934951','C > T','CYP2C8','pamidronate','VARIOUS','','DB00282 ','Pamidronic acid (INN) or pamidronate disodium (USAN), marketed as pamidronate disodium pentahydrate under the brand name Aredia, is a bisphosphonate. [Wikipedia]','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.'),('rs11188072','C > T','CYP2C19','pantoprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00213 ','Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.','Level 3','-','increased','-','CT','                Patients with the CT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs11188072','C > T','CYP2C19','pantoprazole','ALIMENTARY TRACT AND METABOLISM','DRUGS FOR ACID RELATED DISORDERS','DB00213 ','Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.','Level 3','-','increased','-','TT','                Patients with the TT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.'),('rs10042486','C > T','HTR1A','paroxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00726 ','Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]','Level 3','decreased','-','-','CT','                Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs10042486','C > T','HTR1A','paroxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00726 ','Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]','Level 3','decreased','-','-','TT','                Patients with the TT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment  as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs6295','C > G','HTR1A','paroxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00726 ','Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]','Level 3','increased','-','-','GG','                Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs1360780','T > C','FKBP5','paroxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00726 ','Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]','Level 3','-','-','decreased','CC','                Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to paroxetine, venlafaxine, clomipramine or nefazodone.'),('rs11042725','C > A','ADM','paroxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00726 ','Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]','Level 3','increased','-','-','AC','                Patients with the AC genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to paroxetine.'),('rs11042725','C > A','ADM','paroxetine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00726 ','Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]','Level 3','increased','-','-','AA','                Patients with the AA genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to paroxetine.'),('rs12979860','C > T','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs12979860','C > T','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','TT','                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GT','                Patients with the  GT genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs8099917','T > G','IL28B','peginterferon alfa-2a','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs12979860','C > T','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs12979860','C > T','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1A','decreased','-','-','TT','                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GT','                Patients with the  GT genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs8099917','T > G','IL28B','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs9657182','C > T','IDO1','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 3','-','-','decreased','CT','                Patients with the CT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patients risk for drug side effects.'),('rs9657182','C > T','IDO1','peginterferon alfa-2b','VARIOUS','','','Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.','Level 3','-','-','decreased','TT','                Patients with the TT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patients risk for drug side effects.'),('rs12050217','A > G','BDKRB1','perindopril','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00790 ','Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. ','Level 3','increased','-','-','AG','                Patients with the AG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk  for cardiac events when taking perindopril.'),('rs12050217','A > G','BDKRB1','perindopril','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00790 ','Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. ','Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk  for cardiac events when taking perindopril.'),('rs275651','T > A','AGTR1','perindopril','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00790 ','Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. ','Level 3','-','-','increased','AT','                Patients with the TA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for cardiac events when treated with perindopril.'),('rs275651','T > A','AGTR1','perindopril','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00790 ','Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. ','Level 3','-','-','increased','AA','                Patients with the AA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for cardiac events when treated with perindopril.'),('rs5182','C > T','AGTR1','perindopril','CARDIOVASCULAR SYSTEM','AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM','DB00790 ','Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. ','Level 4','increased','-','-','TT','                Patients with the TT genotype may have reduced risk for cardiac events when treated with perindopril as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patients response.'),('rs2842030','G > T','RGS4','perphenazine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00850 ','An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. [PubChem]','Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patients response to perphanazine.'),('rs951439','C > T','RGS4','perphenazine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00850 ','An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. [PubChem]','Level 3','increased','-','-','CT','                Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs951439','C > T','RGS4','perphenazine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00850 ','An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. [PubChem]','Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may have increased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs2108622','C > T','CYP4F2','phenprocoumon','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00946','Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs2108622','C > T','CYP4F2','phenprocoumon','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00946','Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs3812718','C > T','SCN1A','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 2B','-','increased','-','CT','                Patients with the CT genotype who are treated with phenytoin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.'),('rs3812718','C > T','SCN1A','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 2B','-','increased','-','TT','                Patients with the TT genotype who are treated with phenytoin may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.'),('rs1051740','T > C','EPHX1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','decreased','CC','                Patients with the CC genotype who use phenytoin during the first trimester of pregnancy may be less likely to have a child with a craniofacial abnormality as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk of having a child with a craniofacial abnormality.'),('rs2234922','A > G','EPHX1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','AG','                Patients with the AG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2234922','A > G','EPHX1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','GG','                Patients with the GG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1057910','A > C','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1057910','A > C','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','CC','                Patients with the CC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1799853','C > T','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','CT','                Patients with the CT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1799853','C > T','CYP2C9','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','increased','TT','                Patients with the TT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','-','-','AG','                Patients with genotype AG may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patients dose of phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','decreased','-','-','AG','                Patients with genotype AG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians. Other genetic or clinical factors may influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','decreased','-','-','GG','                Patients with genotype GG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians.  Other genetic or clinical factors may influence a patients response to phenytoin.'),('rs1045642','A > G','ABCB1','phenytoin','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00252 ','An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization.','Level 3','-','increased','-','GG','                Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patients dose of phenytoin.'),('rs25487','T > C','XRCC1','Platinum compounds','VARIOUS','','','','Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs1695','A > G','GSTP1','Platinum compounds','VARIOUS','','','','Level 3','-','-','increased','AG','                Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs1695','A > G','GSTP1','Platinum compounds','VARIOUS','','','','Level 3','-','-','increased','GG','                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.'),('rs13181','T > G','ERCC2','Platinum compounds','VARIOUS','','','','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with platinum compounds as compared to patients with the GT or TT genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.'),('rs3212986','C > A','ERCC1','Platinum compounds','VARIOUS','','','','Level 2B','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk for nephrotoxicity with platinum-based regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs11615','A > G','ERCC1','Platinum compounds','VARIOUS','','','','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs11615','A > G','ERCC1','Platinum compounds','VARIOUS','','','','Level 2B','-','-','decreased','GG','                Patients with the GG genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs3212986','C > A','CD3EAP','Platinum compounds','VARIOUS','','','','Level 3','increased','-','-','AC','                Patients with the AC genotype may have better overall survival rate when treated with platinum in people with Non-Small-Cell Lung Carcinoma as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patients response to Platinum compounds.'),('rs3212986','C > A','CD3EAP','Platinum compounds','VARIOUS','','','','Level 3','increased','-','-','AA','                Patients with the AA genotype may have better overall survival rate when treated with platinum in people with Non-Small-Cell Lung Carcinoma as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patients response to Platinum compounds.'),('rs3212986','C > A','CD3EAP','Platinum compounds','VARIOUS','','','','Level 3','decreased','-','-','AC','                Patients with the CA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients survival with platinum compounds.'),('rs3212986','C > A','CD3EAP','Platinum compounds','VARIOUS','','','','Level 3','decreased','-','-','AA','                Patients with the AA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients survival with platinum compounds.'),('rs2032582','A > C','ABCB1','Platinum compounds','VARIOUS','','','','Level 3','-','-','decreased','CC','                Patients with the CC genotype may have decreased but not non-existent risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CA, CT, AA or TT genotypes. Other genetic and clinical factors may also influence a patients risk for gastrointestinal toxicity with taxane and platinum regimens.'),('rs25487','T > C','XRCC1','platinum','VARIOUS','','','','Level 2B','increased','-','-','CC','                Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs13181','T > G','ERCC2','platinum','VARIOUS','','','','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with platinum compounds as compared to patients with the GT or TT genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.'),('rs3212986','C > A','ERCC1','platinum','VARIOUS','','','','Level 2B','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk for nephrotoxicity with platinum-based regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.'),('rs11615','A > G','ERCC1','platinum','VARIOUS','','','','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs11615','A > G','ERCC1','platinum','VARIOUS','','','','Level 2B','-','-','decreased','GG','                Patients with the GG genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to platinum compounds.'),('rs6280','C > T','DRD3','pramipexole','NERVOUS SYSTEM','ANTI-PARKINSON DRUGS','DB00413 ','Pramipexole is a medication indicated for treating Parkinson?s disease and restless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache or to counteract the problems with low libido experienced by some users of SSRI antidepressant drugs.','Level 3','increased','-','-','TT','                Patients with the TT genotype may have better therapeutic efficacy (response rate = 60%)of pramipexole in Chinese patients with Parkinsons disease compared to patiens carrying the C allele (response rate =13%). Other genetic and clinical factors may also influence a patients response.'),('rs2306283','A > G','SLCO1B1','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have decreased plasma AUC of pravastatin as compared to patients with the AA genotype.'),('rs2306283','A > G','SLCO1B1','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased plasma AUC of pravastatin as compared to patients with the AA genotype.'),('rs4149015','G > A','SLCO1B1','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 2A','decreased','-','-','AG','                Patients carrying the AG genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs4149015','G > A','SLCO1B1','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 2A','decreased','-','-','AA','                Patients carrying the AA genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. This variant is part of the SLCO1B1*17 haplotype. Other genetic and clinical factors may also influence a patients response.'),('rs20455','A > G','KIF6','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have an increased risk for adverse cardiovascular events (myocardial infarction and coronary heart diseases) as compared to patients with the AA genotype. Pravastatin treatment substantially reduced that risk. Other genetic and clinical factors may also influence a patients risk for adverse cardiovascular events.'),('rs20455','A > G','KIF6','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 2B','-','-','increased','GG','                Patients with the GG genotype may have an increased risk for adverse cardiovascular events (myocardial infarction and coronary heart diseases) as compared to patients with the AA genotype. Pravastatin treatment substantially reduced that risk. Other genetic and clinical factors may also influence a patients risk for adverse cardiovascular events.'),('rs1935349','C > T','HTR7','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for statin-related myalgia as compared to patients with the CC genotypes, or may have a decreased risk for statin-related myalgia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs1935349','C > T','HTR7','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for statin-related myalgia as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs2276307','A > G','HTR3B','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for myalgia.'),('rs2276307','A > G','HTR3B','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','-','-','increased','GG','                Patients with the GG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patients risk for myalgia.'),('rs17238540','T > G','HMGCR','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','decreased','-','-','GT','                Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17238540','T > G','HMGCR','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 3','decreased','-','-','GG','                Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17244841','A > T','HMGCR','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs5443','C > T','GNB3','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 4','increased','-','-','CT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs5443','C > T','GNB3','pravastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB00175 ','Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered.','Level 4','increased','-','-','TT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs1050828','C > T','G6PD','primaquine','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS','ANTIPROTOZOALS','DB01087 ','An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide','Level 3','-','-','increased','CT','                Pediatric patients with the CT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs1050828','C > T','G6PD','primaquine','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS','ANTIPROTOZOALS','DB01087 ','An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide','Level 3','-','-','increased','TT','                Pediatric patients with the TT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs58597806','G > A','UGT1A9','propofol','NERVOUS SYSTEM','ANESTHETICS','DB00818 ','Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects ','Level 4','-','-','increased','AG','                Patients with the AG genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.'),('rs58597806','G > A','UGT1A9','propofol','NERVOUS SYSTEM','ANESTHETICS','DB00818 ','Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects ','Level 4','-','-','increased','AA','                Patients with the AA genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.'),('rs1142345','T > C','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','CT','                Patients with the CT genotype  1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1142345','T > C','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','CG','                Patients with the CG genotype (e.g. TPMT*1/*2): may have increased deactivation of thiopurines and a decreased, but not absent, risk for toxicity with thiopurine drugs as compared to patients with the GG genotype (TPMT*2/*2) or may have decreased deactivation of thiopurines and an increased risk for toxicity with thiopurine drugs as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','purine analogues','VARIOUS','','','Purine analogues are antimetabolites that mimic the structure of metabolic purines. Including Mercaptopurine, Thioguanine, Fludarabine','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1050828','C > T','G6PD','pyrimethamine','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS','ANTIPROTOZOALS','DB00205 ','One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis. [PubChem]','Level 3','-','-','increased','CT','                Pediatric patients with the CT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs1050828','C > T','G6PD','pyrimethamine','ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS','ANTIPROTOZOALS','DB00205 ','One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis. [PubChem]','Level 3','-','-','increased','TT','                Pediatric patients with the TT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs951439','C > T','RGS4','quetiapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB01224 ','Quetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder.','Level 3','increased','-','-','CT','                Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs951439','C > T','RGS4','quetiapine','NERVOUS SYSTEM','PSYCHOLEPTICS','DB01224 ','Quetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder.','Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may have increased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs1544410','C > T','VDR','raloxifene','GENITO URINARY SYSTEM AND SEX HORMONES','SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM','DB00481 ','A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women.','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with bisphosphonates may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to bisphosphonates.'),('rs290487','C > T','TCF7L2','repaglinide','GENITO URINARY SYSTEM AND SEX HORMONES','DRUGS USED IN DIABETES','DB00912 ','Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to |? cells of the pancreas to stimulate insulin release.','Level 3','increased','-','-','TT','                Patients with the TT genotype may have better response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patients repsonse.'),('rs4149056','T > C','SLCO1B1','repaglinide','GENITO URINARY SYSTEM AND SEX HORMONES','DRUGS USED IN DIABETES','DB00912 ','Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to |? cells of the pancreas to stimulate insulin release.','Level 3','-','-','-','CC','                Patients with the CC genotype may have increased mean plasma AUC of repaglinide and greater blood glucose-lowering effect in response to repaglinide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients response.'),('rs5219','T > C','ABCC8','repaglinide','GENITO URINARY SYSTEM AND SEX HORMONES','DRUGS USED IN DIABETES','DB00912 ','Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to |? cells of the pancreas to stimulate insulin release.','Level 3','decreased','-','-','CC','                Patients with the CC genotype are less likely to respond to repaglinide  than patients with the CT or TT genotype in T2DM patients. Other genetic and clinical factors may also influence a patients response.'),('rs1127354','C > A','ITPA','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 2B','-','decreased','-','AC','                Patients with the AC genotype and Hepatitis C, Chronic may have a decreased, but not absent, risk of 1) dose reduction of ribavirin, 2) rapid decrease in hemoglobin levels when treated with interferon alfa-2b, recombinant and ribavirin or interferon alfa-2b, recombinant and ribavirin, and telaprevir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for response to ribavirin.'),('rs1127354','C > A','ITPA','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 2B','-','decreased','-','AA','                Patients with the AA genotype and Hepatitis C, Chronic may have a decreased, but not absent, risk of 1) dose reduction of ribavirin, 2) rapid decrease in hemoglobin levels when treated with interferon alfa-2b, recombinant and ribavirin or interferon alfa-2b, recombinant and ribavirin, and telaprevir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for response to ribavirin.'),('rs12979860','C > T','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1A','decreased','-','-','CT','                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs12979860','C > T','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1A','decreased','-','-','TT','                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.'),('rs8099917','T > G','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1B','decreased','-','-','GT','                Patients with the  GT genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs8099917','T > G','IL28B','ribavirin','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00811 ','A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]','Level 1B','decreased','-','-','GG','                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.'),('rs16944','A > G','IL1B','risedronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00884 ','Risedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Pagets disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs16944','A > G','IL1B','risedronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00884 ','Risedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis','Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs2297480','T > G','FDPS','risedronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB00884 ','Risedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis','Level 2B','decreased','-','-','GG','                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.'),('rs2661319','T > C','RGS4','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs2842030','G > T','RGS4','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 4','decreased','-','-','GT','                Patients with the GT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs2842030','G > T','RGS4','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 4','decreased','-','-','TT','                Patients with the TT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs951439','C > T','RGS4','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','TT','                Patients with the TT genotype may have increased chance of response to risperidone as compared to patients with CC or CT genotypes. Other genetic and clinical factors may also influence a patients chance of response to risperidone.'),('rs7799039','G > A','LEP','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','increased','AG','                Patients with the AG genotype may have excessive risperidone-associated weight gain in youths as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs7799039','G > A','LEP','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','increased','AA','                Patients with the AA genotype may have excessive risperidone-associated weight gain in youths as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1414334','C > G','HTR2C','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 1B','-','-','decreased','GG','                Patients with the GG genotype who are treated with antipsychotics may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patients risk for developing metabolic syndrome.'),('rs3813928','G > A','HTR2C','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patients response.'),('rs3813928','G > A','HTR2C','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','AA','                Patients with the AA genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patients response.'),('rs6311','C > T','HTR2A','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs6311','C > T','HTR2A','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs6313','G > A','HTR2A','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.'),('rs6313','G > A','HTR2A','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','AA','                Patients with the AA genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.'),('rs724226','A > G','GRM3','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','AG','                Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs724226','A > G','GRM3','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','GG','                Patients with the GG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs167771','G > A','DRD3','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AG or GG genotype. Patients with the AA genotype may still be at risk for toxicity when taking risperidone. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs6280','C > T','DRD3','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patients response.'),('rs6280','C > T','DRD3','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have smaller reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating poorer response to risperidone in Children with Autism, than TT homozygotes compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patients response.'),('rs1799732','- > G','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','GG','                Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patients response to antipsychotics.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 2A','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the TC And TT genotype.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1799978','T > C','DRD2','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','-','-','increased','CC','                Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs165599','G > A','COMT','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','AG','                Patients with the AG genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs165599','G > A','COMT','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','AA','                Patients with the AA genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs1800497','G > A','ANKK1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 2B','-','-','increased','AG','                Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1800497','G > A','ANKK1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 2B','-','-','increased','AA','                Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for side effects.'),('rs1800497','G > A','ANKK1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','AG','                Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the GG genotype or may have less improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs1800497','G > A','ANKK1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','increased','-','-','AA','                Patients with the AA genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs2494732','T > C','AKT1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','CT','                Patients with the CT genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs2494732','T > C','AKT1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs3803300','T > C','AKT1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 4','decreased','-','-','CC','                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the CT or GG genotype. Please note this did not reach statistical significance. Other genetic and clinical factors may also influence a patients response to risperidone.'),('rs1128503','A > G','ABCB1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','AG','                Patients with the AG genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patients response.'),('rs1128503','A > G','ABCB1','risperidone','NERVOUS SYSTEM','PSYCHOLEPTICS','DB00734 ','Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have poorer response to risperidone in Children with Autism, than patients with AG or GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs7412','C > T','APOE','ritonavir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00503 ','An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. [PubChem]','Level 4','-','-','increased','CT','                Patients with the CT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype or may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients triglyceride levels.'),('rs7412','C > T','APOE','ritonavir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00503 ','An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. [PubChem]','Level 4','-','-','increased','TT','                Patients with the TT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients triglyceride levels.'),('rs5128','G > C','APOC3','ritonavir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00503 ','An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. [PubChem]','Level 3','-','-','increased','CC','                Patients with the CC genotype and HIV who are treated with ritonavir may have an increased risk of triglyceride elevation as compared to patients with the CG or GG genotype.'),('rs429358','T > C','APOC1','ritonavir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00503 ','An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. [PubChem]','Level 3','-','-','increased','CT','                Patients with the CT genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patients risk for adverse events with ritonavir treatment.'),('rs429358','T > C','APOC1','ritonavir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00503 ','An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. [PubChem]','Level 3','-','-','increased','CC','                Patients with the CC genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patients risk for adverse events with ritonavir treatment.'),('rs7412','C > T','APOC1','ritonavir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00503 ','An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. [PubChem]','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs7412','C > T','APOC1','ritonavir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00503 ','An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. [PubChem]','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs2854116','C > T','APOA4','ritonavir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00503 ','An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. [PubChem]','Level 3','-','-','increased','TT','                Patients with the TT genotype and HIV who are treated with ritonavir may have increased severity of triglyceride elevation as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients triglyceride levels.'),('rs2854117','T > C','APOA4','ritonavir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00503 ','An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. [PubChem]','Level 3','-','-','decreased','CC','                Patients with the CC genotype and HIV who are treated with ritonavir may have lower triglyceride levels (lower risk of Hypertriglyceridemia) as compared to patients with the TC or TT genotype. Patients with the CC genotype may still be at risk for toxicity when taking ritonavir. Other genetic and clinical factors may also influence a patients triglyceride levels.'),('rs396991','A > C','FCGR3A','rituximab','VARIOUS','','','Rituximab (trade names Rituxan, MabThera and Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.','Level 2B','increased','-','-','AC','                Lymphoma patients with the AC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to rituximab.'),('rs396991','A > C','FCGR3A','rituximab','VARIOUS','','','Rituximab (trade names Rituxan, MabThera and Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.','Level 2B','increased','-','-','CC','                Lymphoma patients with the CC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to rituximab.'),('rs20417','C > G','PTGS2','rofecoxib','VARIOUS','','','Rituximab (trade names Rituxan, MabThera and Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.','Level 3','decreased','-','-','CG','                Patients with the CG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to rofecoxib.'),('rs20417','C > G','PTGS2','rofecoxib','VARIOUS','','','Rituximab (trade names Rituxan, MabThera and Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to rofecoxib.'),('rs10192566','C > G','LPIN1','rosiglitazone','ALIMENTARY TRACT AND METABOLISM','DRUGS USED IN DIABETES','DB00412 ','Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl).','Level 3','-','-','-','CG','                Patients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to rosiglitazone.'),('rs10192566','C > G','LPIN1','rosiglitazone','ALIMENTARY TRACT AND METABOLISM','DRUGS USED IN DIABETES','DB00412 ','Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl).','Level 3','-','-','-','GG','                Patients with the GG genotype and type 2 diabetes who are treated with rosiglitazone may have the largest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patients response to rosiglitazone.'),('rs10509681','T > C','CYP2C8','rosiglitazone','ALIMENTARY TRACT AND METABOLISM','DRUGS USED IN DIABETES','DB00412 ','Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl).','Level 3','-','increased','-','CC','                Patients with the CC genotype (CYP2C8*3/*3) may have increased metabolism of rosiglitazone compared to patients with the TT genotype (CYP2C8*1/*1), but this is not associated with differences in blood glucose lowering efficacy compared to patients with the TT genotype. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of rosiglitazone and blood glucose levels.'),('rs10509681','T > C','CYP2C8','rosiglitazone','ALIMENTARY TRACT AND METABOLISM','DRUGS USED IN DIABETES','DB00412 ','Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl).','Level 3','-','increased','-','CT','                Patients with the CT (CYP2C8*3/*1) genotype may have increased metabolism of rosiglitazone compared to patients with the TT genotype (CYP2C8*1/*1), or may have decreased metabolism of rosiglitazone compared to patients with the CC genotype (CYP2C8*3/*3). This is not associated with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of rosiglitazone and blood glucose levels.'),('rs5443','C > T','GNB3','rosuvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01098 ','Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.','Level 4','increased','-','-','CT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs5443','C > T','GNB3','rosuvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01098 ','Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.','Level 4','increased','-','-','TT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs4693075','G > C','COQ2','rosuvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01098 ','Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.','Level 2B','-','-','decreased','CC','                Patients with the CC genotype may have decreased risk of statin-related muscle symptoms as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence a patients risk of toxicity.'),('rs2231142','G > T','ABCG2','rosuvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01098 ','Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.','Level 2B','increased','-','-','GT','                Patients with the GT genotype who are treated with rosuvastatin may be more likely to reach target LDL levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to rosuvastatin.'),('rs2231142','G > T','ABCG2','rosuvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','DB01098 ','Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.','Level 2B','increased','-','-','TT','                Patients with the TT genotype may have increased response to rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to rosuvastatin.'),('rs2267715','G > A','CRHR2','salbutamol','VARIOUS','','DB01001 ','Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart.','Level 3','increased','-','-','AA','                Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compare to patients with the GG genotype. However, contradictory finding has been reported. No conclusive results regarding the association between this variant and bronchodilator response.'),('rs7793837','A > T','CRHR2','salbutamol','VARIOUS','','DB01001 ','Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart.','Level 2B','decreased','-','-','TT','                Patients with the TT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to short-acting beta2-antagonists.'),('rs2267715','G > A','CRHR2','selective beta-2-adrenoreceptor agonists','VARIOUS','','','Selective beta-2-adrenoreceptor agonists are a class of drugs that act on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation, resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin.They are primarily used to treat asthma and other pulmonary disorders.','Level 3','increased','-','-','AA','                Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compare to patients with the GG genotype. However, contradictory finding has been reported. No conclusive results regarding the association between this variant and bronchodilator response.'),('rs7793837','A > T','CRHR2','selective beta-2-adrenoreceptor agonists','VARIOUS','','','Selective beta-2-adrenoreceptor agonists are a class of drugs that act on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation, resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin.They are primarily used to treat asthma and other pulmonary disorders.','Level 2B','decreased','-','-','TT','                Patients with the TT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to short-acting beta2-antagonists.'),('rs2781659','A > G','ARG1','selective beta-2-adrenoreceptor agonists','VARIOUS','','','Selective beta-2-adrenoreceptor agonists are a class of drugs that act on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation, resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin.They are primarily used to treat asthma and other pulmonary disorders.','Level 3','increased','-','-','GG','                Patients with the GG genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have decreased improvement in forced expiratory volume (FEV) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to beta-2-adenoreceptor agonist treatment.'),('rs7997012','A > G','HTR2A','Selective serotonin reuptake inhibitors','VARIOUS','','','Selective beta-2-adrenoreceptor agonists are a class of drugs that act on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation, resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin.They are primarily used to treat asthma and other pulmonary disorders.','Level 2B','decreased','-','-','GG','                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.'),('rs6295','C > G','HTR1A','Selective serotonin reuptake inhibitors','VARIOUS','','','Selective beta-2-adrenoreceptor agonists are a class of drugs that act on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation, resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin.They are primarily used to treat asthma and other pulmonary disorders.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs6295','C > G','HTR1A','Selective serotonin reuptake inhibitors','VARIOUS','','','Selective beta-2-adrenoreceptor agonists are a class of drugs that act on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation, resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin.They are primarily used to treat asthma and other pulmonary disorders.','Level 3','increased','-','-','GG','                Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.'),('rs5443','C > T','GNB3','sildenafil','GENITO URINARY SYSTEM AND SEX HORMONES','UROLOGICALS','DB00203 ','Sildenfail is a vasoactive agent used to treat erectile dysfunction and reduce symptoms in patients with pulmonary arterial hypertension (PAH). Sildenafil elevates levels of the second messenger, cGMP, by inhibiting its breakdown via phosphodiesterase type 5 (PDE5).','Level 2B','increased','-','-','TT','                Patients with the TT genotype and erectile dysfunction who are treated with sildenafilthan may be more likely to have positive erectile response as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients response to sildenafil.'),('rs4343','G > A','ACE','sildenafil','GENITO URINARY SYSTEM AND SEX HORMONES','UROLOGICALS','DB00203 ','Sildenfail is a vasoactive agent used to treat erectile dysfunction and reduce symptoms in patients with pulmonary arterial hypertension (PAH). Sildenafil elevates levels of the second messenger, cGMP, by inhibiting its breakdown via phosphodiesterase type 5 (PDE5).','Level 3','decreased','-','-','AG','                Patients with the AG genotype and erectile dysfunction who are treated with sildenafil may have a decreased chance of positive erectile response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to sildenafil.'),('rs4343','G > A','ACE','sildenafil','GENITO URINARY SYSTEM AND SEX HORMONES','UROLOGICALS','DB00203 ','Sildenfail is a vasoactive agent used to treat erectile dysfunction and reduce symptoms in patients with pulmonary arterial hypertension (PAH). Sildenafil elevates levels of the second messenger, cGMP, by inhibiting its breakdown via phosphodiesterase type 5 (PDE5).','Level 3','increased','-','-','AA','                Patients with the AA genotype and erectile dysfunction who are treated with sildenafil may have an increased chance of positive erectile response as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients response to sildenafil.'),('rs4149056','T > C','SLCO1B1','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs4149056','T > C','SLCO1B1','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 1A','-','-','increased','CC','                Patients with the CC genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1935349','C > T','HTR7','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have increased risk for statin-related myalgia as compared to patients with the CC genotypes, or may have a decreased risk for statin-related myalgia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs1935349','C > T','HTR7','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for statin-related myalgia as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patients risk for adverse responses to statins.'),('rs2276307','A > G','HTR3B','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 3','-','-','increased','AG','                Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for myalgia.'),('rs2276307','A > G','HTR3B','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 3','-','-','increased','GG','                Patients with the GG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patients risk for myalgia.'),('rs17238540','T > G','HMGCR','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 3','decreased','-','-','GT','                Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17238540','T > G','HMGCR','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 3','decreased','-','-','GG','                Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs17244841','A > T','HMGCR','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 2A','decreased','-','-','AT','                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.'),('rs5443','C > T','GNB3','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 4','increased','-','-','CT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs5443','C > T','GNB3','simvastatin','CARDIOVASCULAR SYSTEM','LIPID MODIFYING AGENTS','Simvastatin','Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis.','Level 4','increased','-','-','TT','                Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.'),('rs776746','C > T','CYP3A5','sirolimus','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00877 ','A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production.','Level 2A','-','increased','-','CT','                Patients with the CT genotype (*1/*3) and who are recipients of transplants may have increased metabolism of sirolimus and require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients sirolimus dose requirements.'),('rs776746','C > T','CYP3A5','sirolimus','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00877 ','A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production.','Level 2A','-','increased','-','TT','                Patients with the TT genotype (*1/*1) and who are recipients of transplants may have increased metabolism of sirolimus and require a higher dose as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patients sirolimus dose requirements.'),('rs2740574','C > T','CYP3A','sirolimus','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB00877 ','A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production.','Level 2A','-','decreased','-','TT','                Patients with the TT genotype may require a decreased dose of tacrolimus or sirolimus as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs4961','G > T','ADD1','spironolactone','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','DIURETICS','DB00421 ','A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis.','Level 2B','decreased','-','-','GT','                Patients with the GT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to diuretics.'),('rs4961','G > T','ADD1','spironolactone','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','DIURETICS','DB00421 ','A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis.','Level 2B','decreased','-','-','TT','                Patients with the TT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to diuretics.'),('rs4343','G > A','ACE','spironolactone','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','DIURETICS','DB00421 ','A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis.','Level 3','increased','-','-','AG','                Patients with the AG genotype is associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs4343','G > A','ACE','spironolactone','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','DIURETICS','DB00421 ','A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis.','Level 3','increased','-','-','AA','                Patients with the AA genotype is associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs1050828','C > T','G6PD','sulfadoxine','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','-','-','increased','CT','                Pediatric patients with the CT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs1050828','C > T','G6PD','sulfadoxine','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','-','-','increased','TT','                Pediatric patients with the TT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.'),('rs12255372','G > T','TCF7L2','sulfonamides, urea derivatives','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','decreased','-','-','GT','                Patients with the GT genotype and type II diabetes who are treated with sulfonylureas may be less likely to achieve a target HbA1c level of <7% as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs12255372','G > T','TCF7L2','sulfonamides, urea derivatives','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','decreased','-','-','TT','                Patients with the TT genotype and type II diabetes who are treated with sulfonylureas may be less likely to achieve a target HbA1c level of <7% as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response.'),('rs5219','T > C','KCNJ11','sulfonamides, urea derivatives','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','increased','-','-','CC','                Patients with the CC genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs5219','T > C','KCNJ11','sulfonamides, urea derivatives','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','-','-','-','CC','                Patients with CC genotype may have poorer response (higher decrease in HbA1c) to 6-month treatment of sulfonylureas in people with Type 2 diabetes as compared to patients with genotype CT or TT. Other genetic or clinical factors may also influence a patients response to sulfonylureas.'),('rs5219','T > C','KCNJ11','sulfonamides, urea derivatives','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','-','-','-','CC','                Patients with the CC genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs5219','T > C','KCNJ11','sulfonamides, urea derivatives','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','decreased','-','-','CC','                Patients with CC genotype may have poorer response (higher decrease in HbA1c) to 6-month treatment of sulfonylureas in people with Type 2 diabetes as compared to patients with genotype CT or TT. Other genetic or clinical factors may also influence a patients response to sulfonylureas.'),('rs1057910','A > C','CYP2C9','sulfonamides, urea derivatives','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','increased','-','-','CC','                Patients with the CC genotype who are treated with sulfonylurea: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the AA genotype 2) May be less likely to have failure of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to sulfonylurea therapy.'),('rs1799853','C > T','CYP2C9','sulfonamides, urea derivatives','VARIOUS','','','Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.[1] It is also used, usually in combination with other drugs, to treat or prevent various infections in livestock.[2]','Level 3','increased','-','-','TT','                Patients with the TT genotype and type II diabetes who are treated with sulfonylureas: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the CC genotype 2) May be less likely to experience treatment failure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to sulfonylureas.'),('rs5443','C > T','GNB3','sumatriptan','NERVOUS SYSTEM','ANALGESICS','DB00669','A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of migraine disorders. A transdermal patch version of sumatriptan is currently in phase I trials in the U.S. under the code name NP101 (NuPathe).','Level 3','increased','-','-','CT','                Patients with the CT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to sumatriptan.'),('rs5443','C > T','GNB3','sumatriptan','NERVOUS SYSTEM','ANALGESICS','DB00669','A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of migraine disorders. A transdermal patch version of sumatriptan is currently in phase I trials in the U.S. under the code name NP101 (NuPathe).','Level 3','increased','-','-','TT','                Patients with the TT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype. However, patients with this genotype were not studied directly. Other genetic and clinical factors may also influence a patients response to sumatriptan.'),('rs776746','C > T','CYP3A5','tacrolimus','DERMATOLOGICALS','OTHER DERMATOLOGICAL PREPARATIONS','DB00864 ','Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient?s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. ','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are treated with tacrolimus may have increased clearance of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients tacrolimus dose requirement.'),('rs776746','C > T','CYP3A5','tacrolimus','DERMATOLOGICALS','OTHER DERMATOLOGICAL PREPARATIONS','DB00864 ','Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient?s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. ','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are treated with tacrolimus may have increased clearance of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients tacrolimus dose requirement.'),('rs776746','C > T','CYP3A5','tacrolimus','DERMATOLOGICALS','OTHER DERMATOLOGICAL PREPARATIONS','DB00864 ','Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient?s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. ','Level 2A','-','-','increased','CT','                Patients with the CT genotype (*1/*3) and are recipients of Kidney Transplant who are treated with tacrolimus may have an increased risk of nephrotoxicity as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patients risk for drug-induced nephrotoxicity.'),('rs776746','C > T','CYP3A5','tacrolimus','DERMATOLOGICALS','OTHER DERMATOLOGICAL PREPARATIONS','DB00864 ','Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient?s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. ','Level 2A','-','-','increased','TT','                Patients with the TT (*1/*1) genotype and are recipients of Kidney Transplant who are treated with tacrolimus may have an increased risk of nephrotoxicity as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patients risk for drug-induced nephrotoxicity.'),('rs776746','C > T','CYP3A5','tacrolimus','DERMATOLOGICALS','OTHER DERMATOLOGICAL PREPARATIONS','DB00864 ','Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient?s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. ','Level 3','-','-','-','CT','                Patients with the CT genotype (*1/*3) and recipients of Kidney Transplant who are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patients response to tacrolimus treatment and risk of transplant rejection.'),('rs776746','C > T','CYP3A5','tacrolimus','DERMATOLOGICALS','OTHER DERMATOLOGICAL PREPARATIONS','DB00864 ','Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient?s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. ','Level 3','-','-','-','TT','                Patients with the TT (*1/*1) genotype and recipients of Kidney Transplant who are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patients response to tacrolimus treatment and risk of transplant rejection.'),('rs776746','C > T','CYP3A5','tacrolimus','DERMATOLOGICALS','OTHER DERMATOLOGICAL PREPARATIONS','DB00864 ','Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient?s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. ','Level 3','-','-','decreased','CT','                Patients with the CT genotype and recipients of Kidney Transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hyperlipidemia.'),('rs776746','C > T','CYP3A5','tacrolimus','DERMATOLOGICALS','OTHER DERMATOLOGICAL PREPARATIONS','DB00864 ','Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient?s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. ','Level 3','-','-','decreased','TT','                Patients with the TT genotype and recipients of Kidney Transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hyperlipidemia.'),('rs2740574','C > T','CYP3A','tacrolimus','DERMATOLOGICALS','OTHER DERMATOLOGICAL PREPARATIONS','DB00864 ','Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient?s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. ','Level 2A','-','decreased','-','TT','                Patients with the TT genotype may require a decreased dose of tacrolimus or sirolimus as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs2032582','A > C','ABCB1','tacrolimus','DERMATOLOGICALS','OTHER DERMATOLOGICAL PREPARATIONS','DB00864 ','Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient?s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. ','Level 3','-','-','-','AC','                Patients with AC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with Colitis, Ulcerative as compared to patients with the AA genotype. Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C. Other genetic or clinical factors may influence response and dose of tacrolimus.'),('rs2032582','A > C','ABCB1','tacrolimus','DERMATOLOGICALS','OTHER DERMATOLOGICAL PREPARATIONS','DB00864 ','Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient?s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. ','Level 3','-','-','-','CC','                Patients with CC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with Colitis, Ulcerative as compared to patients with the AA genotype. Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C. Other genetic or clinical factors may influence response and dose of tacrolimus.'),('rs4986938','C > T','ESR2','tamoxifen','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ENDOCRINE THERAPY','DB00675','One of the selective estrogen receptor modulators (SERM) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer.','Level 3','-','-','-','CT','                Patients with the CT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the  CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.'),('rs4986938','C > T','ESR2','tamoxifen','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ENDOCRINE THERAPY','DB00675','One of the selective estrogen receptor modulators (SERM) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer.','Level 3','-','-','-','TT','                Patients with the TT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the  CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.'),('rs9340799','A > G','ESR1','tamoxifen','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ENDOCRINE THERAPY','DB00675','One of the selective estrogen receptor modulators (SERM) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer.','Level 3','-','-','-','GG','                The GG genotype carriers had larger tamoxifen-induced decrease in total cholesterol in postmenopausal woman compared to GA/AA genotypes (P=0.03; GG vs GA/AA) and tamoxifen-induced increase in triglycerides (P=0.002; gene-dose effect) and decrease in high density lipoprotein (P=0.004; gene-dose effect) in premenopausal women.'),('rs1056836','C > G','CYP1B1','taxanes','VARIOUS','','','Taxanes are diterpenes produced by the plants of the genus Taxus (yews), and are widely used as chemotherapy agents.[1] Taxane agents include paclitaxel (Taxol) and docetaxel (Taxotere).Taxanes present difficulties in formulation as medicines because they are poorly soluble in water.','Level 3','increased','-','-','GG','                Patients with the GG genotype who are treated with taxanes may have longer disease-free progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response.'),('rs2032582','A > C','ABCB1','taxanes','VARIOUS','','','Taxanes are diterpenes produced by the plants of the genus Taxus (yews), and are widely used as chemotherapy agents.[1] Taxane agents include paclitaxel (Taxol) and docetaxel (Taxotere).Taxanes present difficulties in formulation as medicines because they are poorly soluble in water.','Level 3','-','-','decreased','CC','                Patients with the CC genotype may have decreased but not non-existent risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CA, CT, AA or TT genotypes. Other genetic and clinical factors may also influence a patients risk for gastrointestinal toxicity with taxane and platinum regimens.'),('rs2032582','A > C','ABCB1','taxanes','VARIOUS','','','Taxanes are diterpenes produced by the plants of the genus Taxus (yews), and are widely used as chemotherapy agents.[1] Taxane agents include paclitaxel (Taxol) and docetaxel (Taxotere).Taxanes present difficulties in formulation as medicines because they are poorly soluble in water.','Level 3','decreased','-','-','CC','                Patients with the CC genotype may have 1) increased risk for resistance 2) decreased response to taxanes as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence a patients response to taxanes.'),('rs1801019','G > C','UMPS','tegafur','VARIOUS','','','Taxanes are diterpenes produced by the plants of the genus Taxus (yews), and are widely used as chemotherapy agents.[1] Taxane agents include paclitaxel (Taxol) and docetaxel (Taxotere).Taxanes present difficulties in formulation as medicines because they are poorly soluble in water.','Level 2B','-','-','increased','CC','                Patients with CC genotype and cancer may have an increased risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and  leucovorin as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to leucovorin, tegafur and fluorouracil.'),('rs17222723','T > A','ABCC2','tenofovir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00300 ','Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread','Level 3','-','-','decreased','AT','                Patients with the AT genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patients risk for adverse events with tenofovir treatment.'),('rs17222723','T > A','ABCC2','tenofovir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00300 ','Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread','Level 3','-','-','decreased','AA','                Patients with the AA genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patients risk for adverse events with tenofovir treatment.'),('rs2273697','G > A','ABCC2','tenofovir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00300 ','Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread','Level 3','-','-','increased','AG','                Patients with the AG genotype may have increased risk of renal proximal tubulopathy when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs2273697','G > A','ABCC2','tenofovir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00300 ','Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread','Level 3','-','-','increased','AA','                Patients with the AA genotype may have increased risk of renal proximal tubulopathy when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs717620','C > T','ABCC2','tenofovir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00300 ','Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread','Level 3','-','-','decreased','CT','                Patients with the CT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced kidney tubular dysfunction.'),('rs717620','C > T','ABCC2','tenofovir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00300 ','Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread','Level 3','-','-','decreased','TT','                Patients with the TT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for drug-induced kidney tubular dysfunction.'),('rs9349256','G > A','ABCC10','tenofovir','ANTIINFECTIVES FOR SYSTEMIC USE','ANTIVIRALS FOR SYSTEMIC USE','DB00300 ','Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased but not absent risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patients risk for adverse events.'),('rs1402467','C > G','SULT1C4','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','increased','-','-','CG','                Patients with the CG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs1402467','C > G','SULT1C4','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','increased','-','-','GG','                Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs2292954','A > G','SPG7','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','-','-','decreased','GG','                Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2301159','G > A','SLC10A2','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','-','-','increased','AG','                Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs2301159','G > A','SLC10A2','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','-','-','increased','AA','                Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs12960','G > A','RPL13','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs1883322','C > T','PPARD','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2016520','C > T','PPARD','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs3734254','C > T','PPARD','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','increased','-','-','CT','                Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs3734254','C > T','PPARD','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','increased','-','-','TT','                Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.'),('rs6922548','A > G','PPARD','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs6922548','A > G','PPARD','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','increased','-','-','GG','                Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs7769719','G > A','PPARD','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','decreased','-','-','AA','                Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs1799931','G > A','NAT2','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','-','-','decreased','AA','                Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4646487','C > T','CYP4B1','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','-','-','increased','CT','                Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4646487','C > T','CYP4B1','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs12418','G > A','CHST3','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','increased','-','-','AG','                Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs12418','G > A','CHST3','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','increased','-','-','AA','                Patients with the AA genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs1871450','G > A','CHST3','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','increased','-','-','AG','                Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs1871450','G > A','CHST3','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','increased','-','increased','AA','                Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs4148943','C > T','CHST3','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4148945','C > T','CHST3','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','decreased','-','decreased','TT','                Patients with the TT genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4148947','T > C','CHST3','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','decreased','-','-','CC','                Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs4148950','G > A','CHST3','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','increased','-','increased','AG','                Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs4148950','G > A','CHST3','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','increased','-','increased','AA','                Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.'),('rs730720','C > T','CHST3','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','decreased','-','-','TT','                Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2227291','G > C','ATP7A','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders.','Level 3','-','-','decreased','CC','                Patients with the CC genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs2238472','C > T','ABCC6','thalidomide','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','IMMUNOSUPPRESSIVE AGENTS','DB01041','A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.','Level 3','-','-','decreased','TT','                Patients with the TT genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.'),('rs1142345','T > C','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CT','                Patients with the CT genotype  1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1142345','T > C','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CC','                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CT','                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800460','C > T','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','TT','                Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','CG','                Patients with the CG genotype (e.g. TPMT*1/*2): may have increased deactivation of thiopurines and a decreased, but not absent, risk for toxicity with thiopurine drugs as compared to patients with the GG genotype (TPMT*2/*2) or may have decreased deactivation of thiopurines and an increased risk for toxicity with thiopurine drugs as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs1800462','C > G','TPMT','thioguanine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00352','An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. ','Level 1A','-','-','increased','GG','                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.'),('rs16944','A > G','IL1B','tiludronate','MUSCULO-SKELETAL SYSTEM','DRUGS FOR TREATMENT OF BONE DISEASES','DB01133','Tiludronate is a bisphosphonate characterized by a (4-chlorophenylthio) group on the carbon atom of the basic P-C-P structure common to all bisphosphonates.','Level 3','increased','-','-','GG','                Patients with the GG genotype and Pagets disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patients risk for resistance to bisphosphonates.'),('rs712829','G > T','EGFR','topoisomerase I inhibitors','VARIOUS','','','Topoisomerase inhibitors are agents designed to interfere with the action of topoisomerase enzymes[1] (topoisomerase I and II), which are enzymes that control the changes in DNA structure[2] by catalyzing the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle.','Level 4','decreased','-','-','GT','                Cancer patients with genotype GT may be less likely to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patients response.'),('rs712829','G > T','EGFR','topoisomerase I inhibitors','VARIOUS','','','Topoisomerase inhibitors are agents designed to interfere with the action of topoisomerase enzymes[1] (topoisomerase I and II), which are enzymes that control the changes in DNA structure[2] by catalyzing the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle.','Level 4','decreased','-','-','TT','                Cancer patients with genotype TT may be less likely  to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patients response.'),('rs1136201','A > G','ERBB2','trastuzumab','VARIOUS','','','Topoisomerase inhibitors are agents designed to interfere with the action of topoisomerase enzymes[1] (topoisomerase I and II), which are enzymes that control the changes in DNA structure[2] by catalyzing the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle.','Level 3','-','-','increased','AG','                Patients with the AG genotype may have increased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk of toxicity.'),('rs37973','G > A','GLCCI1','triamcinolone','ALIMENTARY TRACT AND METABOLISM','STOMATOLOGICAL PREPARATIONS','DB00620','A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated','Level 3','increased','-','-','AA','                Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patients response to glucocorticoids.'),('rs10811661','T > C','Not available','troglitazone','ALIMENTARY TRACT AND METABOLISM','DRUGS USED IN DIABETES','DB00197','Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.','Level 3','increased','-','-','CT','                Patients with the CT genotype and at high risk for type II diabetes who are treated with troglitazone may have increased beta call function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to troglitazone.'),('rs10811661','T > C','Not available','troglitazone','ALIMENTARY TRACT AND METABOLISM','DRUGS USED IN DIABETES','DB00197','Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.','Level 3','increased','-','-','CC','                Patients with the CC genotype and at high-risk for type II diabetes who are treated with troglitazone may have increased beta cell function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response.'),('rs854547','G > A','PON1','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 4','decreased','-','-','AG','                Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs854547','G > A','PON1','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 4','decreased','-','-','AA','                Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs854548','A > G','PON1','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 4','increased','-','-','GG','                Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG.  Other genetic and clinical factors may also influence a patients response.'),('rs854555','A > C','PON1','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 3','increased','-','-','CC','                Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AC.  Other genetic and clinical factors may also influence a patients response.'),('rs2814707','C > T','MOBKL2B','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 3','decreased','-','-','CT','                Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patients response.'),('rs2814707','C > T','MOBKL2B','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 3','decreased','-','-','TT','                Rheumatoid Arthritis patients with the TT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patients response.'),('rs7046653','A > G','MOBKL2B','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 3','increased','-','-','GG','                Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG. Other genetic and clinical factors may also influence a patients response.'),('rs868856','A > G','MOBKL2B','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 3','increased','-','-','GG','                Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AG. Other genetic and clinical factors may also influence a patients response.'),('rs928655','G > A','GBP6','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 4','decreased','-','-','AG','                Rheumatoid Arthritis patients with genotype AG may be less likely to respond to TNF inhibitors compared to patients with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs928655','G > A','GBP6','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 4','decreased','-','-','AA','                Rheumatoid Arthritis patients with genotype AA may be less likely to respond to TNF inhibitors compared to patients with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs3849942','T > C','C9orf72','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 4','increased','-','-','CC','                Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patients response.'),('rs774359','T > C','C9orf72','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 3','decreased','-','-','CT','                Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patients response.'),('rs774359','T > C','C9orf72','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 3','decreased','-','-','CC','                Rheumatoid Arthritis patients with the CC genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patients response.'),('rs983332','G > T','Not available','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 3','decreased','-','-','TT','                Rheumatoid Arthritis patients with genotype TT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs437943','T > C','Not available','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 4','decreased','-','-','CT','                Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to a patient with genotype TT.'),('rs437943','T > C','Not available','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 4','decreased','-','-','CC','                Rheumatoid Arthritis patients with the CC genotype may be less likely to respond to TNF inhibitors compared to a patient with genotype TT.'),('rs6028945','G > T','Not available','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 3','decreased','-','-','GT','                Rheumatoid Arthritis patients with the genotype GT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs6028945','G > T','Not available','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 3','decreased','-','-','TT','                Rheumatoid Arthritis patients with the genotype TT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs6071980','T > C','Not available','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 3','decreased','-','-','CT','                Rheumatoid Arthritis patients with the genotype CT may be less likely to respond to TNF inhibitors compared with a patient with the genotype TT . Other genetic and clinical factors may also influence a patients response.'),('rs6071980','T > C','Not available','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 3','decreased','-','-','CC','                Rheumatoid Arthritis patients with the genotype CC may be less likely to respond to TNF inhibitors compared with a patient with the genotype TT . Other genetic and clinical factors may also influence a patients response.'),('rs6138150','T > C','Not available','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 3','increased','-','-','CC','                Rheumatoid Arthritis patients with the genotype CC may be more likely to respond to TNF inhibitors compared with patients with genotypes TT or CT .  Other genetic and clinical factors may also influence a patients response.'),('rs983332','G > T','Not available','Tumor necrosis factor alpha (TNF-alpha) inhibitors','VARIOUS','','','A TNF inhibitor is a pharmaceutical drug that suppresses response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, psoriasis, hidradenitis suppurativa and refractory asthma, so a TNF inhibitor may be used in their treatment. The important side effects that have been most extensively related to TNF inhibitors include: lymphoma, infections (especially - Tuberculosis reactivation), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]','Level 3','decreased','-','-','GT','                Rheumatoid Arthritis patients with genotype GT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patients response.'),('rs7439366','T > C','UGT2B7','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','decreased','-','-','CT','                Healthy individuals with the CT genotype who are treated with valproic acid and lorazepam may have poorer responses in psychocognitive function tests as compared to those with the TT genotype or may have better responses in psychocognitive function tests as compared to patients with the CC genotype. Other genetic and clinical factors may also influence an individuals response to valproic acid and lorazepam treatment.'),('rs7439366','T > C','UGT2B7','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','decreased','-','-','CC','                Healthy individuals with the CC genotype who are treated with valproic acid and lorazepam may have poorer responses in psychocognitive function tests as compared to those with the TT genotype. Other genetic and clinical factors may also influence an individuals response to valproic acid and lorazepam treatment.'),('rs1105879','A > C','UGT1A6','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','AC','                Patients with the AC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs1105879','A > C','UGT1A6','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','CC','                Patients with the CC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs2070959','A > G','UGT1A10','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','AG','                Patients with the AG genotype may require an increased dose of valproic acid compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs2070959','A > G','UGT1A10','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','GG','                Patients with the GG genotype may require an increased dose of valproic acid compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patients dose requirements.'),('rs6759892','T > G','UGT1A10','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','increased','-','GT','                Patients with the GT genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients valproic acid dose requirement.'),('rs6759892','T > G','UGT1A10','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsa','Level 3','-','increased','-','GG','                Patients with the GG genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT and GT genotype. Other genetic and clinical factors may also influence a patients valproic acid dose requirement.'),('rs1057910','A > C','CYP2C9','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','-','increased','AC','                Patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs1057910','A > C','CYP2C9','valproic acid','NERVOUS SYSTEM','ANTIEPILEPTICS','DB00313','A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.','Level 3','-','-','increased','CC','                Patients with the CC genotype were not studied. However, patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.'),('rs10879346','C > T','TPH2','venlafaxine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','decreased','-','-','TT','                Patients with the TT genotype who are treated with antidepressants may have less improvement in symptoms as compared to patients with the CT and CC genotype.'),('rs1487278','T > C','TPH2','venlafaxine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','increased','-','-','CT','                Patients with the CT genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to antidepressant.'),('rs1487278','T > C','TPH2','venlafaxine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','increased','-','-','CC','                Patients with the CC genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to antidepressant. (The frequency for CC allele is very low, homozygous minor allele carriers were pooled together with the heterozygous samples and compared with the homozygous major allele (T) carrier.)'),('rs1360780','T > C','FKBP5','venlafaxine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','-','-','decreased','CC','                Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients response to paroxetine, venlafaxine, clomipramine or nefazodone.'),('rs3892097','C > T','CYP2D6','venlafaxine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','-','-','increased','CT','                Patients with the CT genotype who are treated with venlafaxine may have an increased risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to venlafaxine.'),('rs3892097','C > T','CYP2D6','venlafaxine','NERVOUS SYSTEM','PSYCHOANALEPTICS','DB00285','Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006.','Level 3','-','-','increased','TT','                Patients with the TT genotype who are treated with venlafaxine may have an increased risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to venlafaxine.'),('rs10494366','G > T','NOS1AP','verapamil','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 3','-','-','decreased','TT','                Patients with the TT genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients QTc prolongation risk.'),('rs10918594','C > G','NOS1AP','verapamil','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 4','-','-','increased','CG','                While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype, it was not shown conclusively if heterzygous (GC) individuals are affected. Other genetic and clinical factors may also influence a patients QTc prolongation risk.'),('rs10918594','C > G','NOS1AP','verapamil','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 4','-','-','increased','GG','                Patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients QTc prolongation risk.'),('rs11739136','C > T','KCNIP1','verapamil','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 3','increased','-','-','CT','                Patients with the CT genotype: 1) may have decreased blood pressure, 2) decreased risk for hypertension and 3) faster control of blood pressure when treated with verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients blood pressure and response to antihypertensives.'),('rs11739136','C > T','KCNIP1','verapamil','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 3','increased','-','-','TT','                Patients with the CT genotype: 1) may have decreased blood pressure, 2) decreased risk for hypertension and 3) faster control of blood pressure when treated with verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients blood pressure and response to antihypertensives.'),('rs1051375','G > A','CACNA1C','verapamil','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 3','increased','-','-','AA','                Patients with the AA genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with verapamil compared to treatment with atenolol. Other genetic and clinical factors may also influence a patients response to treatment.'),('rs1801252','A > G','ADRB1','verapamil','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 4','decreased','-','-','GG','                Patients with the GG genotype who have Coronary Artery Disease may have a decreased risk for death when treated with verapamil as compared to patients with the AA or AG genotype and the rs1801253 allele C. Other genetic and clinical factors may also influence risk of death.'),('rs1801253','G > C','ADRB1','verapamil','CARDIOVASCULAR SYSTEM','CALCIUM CHANNEL BLOCKERS','DB00661','A calcium channel blocker that is a class IV anti-arrhythmia agent','Level 3','decreased','-','-','CC','                Patients with the CC genotype and Atrial Fibrillation may have a decreased response to verapamil treatment compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patients response to verapamil.'),('rs1045642','A > G','ABCB1','vincristine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTINEOPLASTIC AGENTS','DB00541','Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkina?s disease, acute erythraemia, and acute panmyelosis.','Level 3','decreased','-','-','GG','                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.'),('rs2032582','A > C','ABCB1','vincristine','ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS','ANTITHROMBOTIC AGENTS','DB00541','Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkina?s disease, acute erythraemia, and acute panmyelosis.','Level 3','decreased','-','-','CC','                Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patients response to the therapy.'),('rs17708472','G > A','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','increased','-','AG','                Patients with the AG genotype: 1) may require a higher dose of warfarin as compared to patients with the GG genotype 2) may have an increased risk of warfarin resistance as compared to patients with the GG genotype.'),('rs17708472','G > A','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','increased','-','AA','                Patients with the AA genotype: 1) may require a higher dose of warfarin as compared to patients with the GG genotype 2) may have an increased risk of warfarin resistance as compared to patients with the GG genotype.'),('rs7294','C > T','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.'),('rs7294','C > T','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.'),('rs9934438','G > A','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','decreased','-','AG','                Patients with the AG genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs9934438','G > A','VKORC1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin or acenocoumarol.'),('rs10871454','C > T','STX4','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype.'),('rs10871454','C > T','STX4','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','TT','                Patients with the TT genotype who are treated with warfarin may require the lowest dose as compared to patients with the CT or CC genotype.'),('rs2359612','A > G','PRSS53','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTSANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','increased','-','GG','                Patients with the GG genotype who are treated with warfarin may require a higher dose as compared to patients with the AG or AA genotype.'),('rs8050894','C > G','PRSS53','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','CG','                Patients with the CG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype.'),('rs8050894','C > G','PRSS53','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','GG','                Patients with the GG genotype who are treated with warfarin may require the lowest dose as compared to patients with the CG or CC genotype.'),('rs12714145','C > T','GGCX','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','increased','-','TT','                Genotype TT may be associated with increased dose of warfarin as compared to genotype GG. However, contradictory findings (no association) have been reported. Other genetic and clinical factors may influence a patients dose of warfain.'),('rs2292566','G > A','EPHX1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','AG','                Patients with the AG genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.'),('rs2292566','G > A','EPHX1','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','AA','                Patients with the AA genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.'),('rs2108622','C > T','CYP4F2','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','CT','                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs2108622','C > T','CYP4F2','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1B','-','increased','-','TT','                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.'),('rs1799853','C > T','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients dose of warfarin.'),('rs1799853','C > T','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','-','TT','                Patients with the TT genotype who are treated with warfarin may require a lower dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients dose of warfarin.'),('rs28371685','C > T','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','CT','                Patients with the CT genotype who are treated with warfarin may require a decreased dose as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin.'),('rs28371685','C > T','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','TT','                Patients with the TT genotype who are treated with warfarin may require the lowest does as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin.'),('rs28371686','C > G','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 2A','-','decreased','-','CG','                Patients with the CG genotype who are treated with warfarin may require a decreased dose as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin.'),('rs28371686','C > G','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 2A','-','decreased','-','GG','                Patients with the GG genotype who are treated with warfarin may require the lowest does as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patients required dose of warfarin.'),('rs7900194','G > A','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','AG','                Patients with the AG genotype who are treated with warfarin may require a lower maintenance dose as compared to patients with the GG genotype.'),('rs7900194','G > A','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 3','-','decreased','-','AA','                Patients with the AA genotype who are treated with warfarin may require the lowest maintenance dose as compared to patients with the AG or GG genotype.'),('rs1057910','A > C','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','increased','AC','                Patients with the AC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.'),('rs1057910','A > C','CYP2C9','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 1A','-','decreased','increased','CC','                Patients with the CC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.'),('rs339097','A > G','CALU','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 2B','-','increased','-','AG','                Patients with the AG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients warfarin dose.'),('rs339097','A > G','CALU','warfarin','BLOOD AND BLOOD FORMING ORGANS','ANTITHROMBOTIC AGENTS','DB00682','Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.','Level 2B','-','increased','-','GG','                Patients with the GG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients warfarin dose.'),('rs951439','C > T','RGS4','ziprasidone','BLOOD AND BLOOD FORMING ORGANS','PSYCHOLEPTICS','DB00246','Ziprasidone (marketed as Geodon, Zeldox) was the fifth atypical antipsychotic to gain FDA approval (February 2001). Ziprasidone is Food and Drug Administration (FDA) approved for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients. Ziprasidone has also received approval for acute treatment of mania associated with bipolar disorder','Level 3','increased','-','-','CT','                Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs951439','C > T','RGS4','ziprasidone','BLOOD AND BLOOD FORMING ORGANS','PSYCHOLEPTICS','DB00246','Ziprasidone (marketed as Geodon, Zeldox) was the fifth atypical antipsychotic to gain FDA approval (February 2001). Ziprasidone is Food and Drug Administration (FDA) approved for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients. Ziprasidone has also received approval for acute treatment of mania associated with bipolar disorder','Level 3','increased','-','-','TT','                Patients with the TT genotype and schizophrenia may have increased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.'),('rs1934951','C > T','CYP2C8','zoledronate','BLOOD AND BLOOD FORMING ORGANS','DRUGS FOR TREATMENT OF BONE DISEASES','DB00399','Zoledronate (zoledronic acid, marketed by Novartis under the trade names Zometa and Reclast) is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases.An annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture.Zoledronate is a single 5 mg infusion for the treatment of disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis.','Level 3','-','-','increased','TT','                Patients with the TT genotype may have increased risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.');
/*!40000 ALTER TABLE `test` ENABLE KEYS */;
UNLOCK TABLES;
/*!40103 SET TIME_ZONE=@OLD_TIME_ZONE */;

/*!40101 SET SQL_MODE=@OLD_SQL_MODE */;
/*!40014 SET FOREIGN_KEY_CHECKS=@OLD_FOREIGN_KEY_CHECKS */;
/*!40014 SET UNIQUE_CHECKS=@OLD_UNIQUE_CHECKS */;
/*!40101 SET CHARACTER_SET_CLIENT=@OLD_CHARACTER_SET_CLIENT */;
/*!40101 SET CHARACTER_SET_RESULTS=@OLD_CHARACTER_SET_RESULTS */;
/*!40101 SET COLLATION_CONNECTION=@OLD_COLLATION_CONNECTION */;
/*!40111 SET SQL_NOTES=@OLD_SQL_NOTES */;

-- Dump completed on 2015-05-09  3:31:51
